PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Miyamoto, H; Rahman, M; Takatera, H; Kang, HY; Yeh, S; Chang, HC; Nishimura, K; Fujimoto, N; Chang, CS				Miyamoto, H; Rahman, M; Takatera, H; Kang, HY; Yeh, S; Chang, HC; Nishimura, K; Fujimoto, N; Chang, CS			A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION FUNCTION AF-2; TRANSCRIPTIONAL COACTIVATOR; NUCLEAR RECEPTORS; HORMONE; PROTEIN; CLONING; GENE; TRANSACTIVATION; ANTIANDROGENS; EPIDEMIOLOGY	The ligand-bound androgen receptor (AR) regulates target genes via a mechanism involving coregulators such as androgen receptor-associated 54 (ARA54). We investigated whether the interruption of the AR coregulator function could lead to down-regulation of AR activity. Using in vitro mutagenesis and a yeast two-hybrid screening assay, we have isolated a mutant ARA54 (mt-ARA54) carrying a point mutation at amino acid 472 changing a glutamic acid to lysine, which acts as a dominant-negative inhibitor of AR transactivation. In transient transfection assays of prostate cancer cell lines, the mt-ARA54 suppressed endogenous mutated AR-mediated and exogenous wild-type AR-mediated transactivation in LNCaP and PC-3 cells, respectively. In DU145 cells, the mt-ARA54 suppressed exogenous ARA54 but not other coregulators, such as ARA55-enhanced or SRC-1-enhanced AR transactivation. In the LNCaP cells stably transfected with the plasmids encoding the mt-ARA54 under the doxycycline inducible system, the overexpression of the mt-ARA54 inhibited cell growth and endogenous expression of prostate-specific antigen. Mammalian two-hybrid assays further demonstrated that the mt-ARA54 can disrupt the interaction between wild-type ARA54 molecules, suggesting that ARA54 dimerization or oligomerization may play an essential role in the enhancement of AR transactivation. Together, our results demonstrate that a dominant-negative AR coregulator can suppress AR transactivation and cell proliferation in prostate cancer cells. Further studies may provide a new therapeutic approach for blocking AR-mediated prostate cancer growth.	Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	chang@urmc.rochester.edu	Kang, Hong-Yo/W-9031-2019	Kang, Hong-Yo/0000-0003-0626-5037; Miyamoto, Hiroshi/0000-0001-7610-7769; CHANG, HONG-CHIANG/0000-0001-5411-6680; Chang, Chawnshang/0000-0001-8510-3516	NCI NIH HHS [CA71570] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 2000, NEW ENGL J MED, V343, P856, DOI 10.1056/NEJM200009213431205; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chang HC, 1999, P NATL ACAD SCI USA, V96, P11173, DOI 10.1073/pnas.96.20.11173; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Di Croce Luciano, 1999, EMBO (European Molecular Biology Organization) Journal, V18, P6201, DOI 10.1093/emboj/18.22.6201; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Goktas S, 1999, SEMIN ONCOL, V26, P162; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hrouda D, 1999, SEMIN ONCOL, V26, P455; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Jenster G, 1999, SEMIN ONCOL, V26, P407; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kelly WK, 1997, UROL CLIN N AM, V24, P421, DOI 10.1016/S0094-0143(05)70389-X; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P11083, DOI 10.1073/pnas.95.19.11083; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Miyamoto H, 2000, INT J UROL, V7, P32; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; MONTIE JE, 1994, UROLOGY, V43, P892, DOI 10.1016/0090-4295(94)90163-5; Narusaka Y, 1999, J BIOL CHEM, V274, P23270, DOI 10.1074/jbc.274.33.23270; ONATE SA, 1995, SCIENCE, V270, P1354; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Ruijter E, 1999, ENDOCR REV, V20, P22, DOI 10.1210/er.20.1.22; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Verrier CS, 1997, MOL ENDOCRINOL, V11, P1009, DOI 10.1210/me.11.8.1009; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yeh SY, 1999, ENDOCRINE, V11, P195, DOI 10.1385/ENDO:11:2:195; Yeh SY, 1997, LANCET, V349, P852, DOI 10.1016/S0140-6736(05)61756-4; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527	44	53	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4609	4617		10.1074/jbc.M108312200	http://dx.doi.org/10.1074/jbc.M108312200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11673464	hybrid			2022-12-25	WOS:000173962900010
J	Cho, HDD; Tomita, K; Suzuki, T; Weiner, AM				Cho, HDD; Tomita, K; Suzuki, T; Weiner, AM			U2 small nuclear RNA is a substrate for the CCA-adding enzyme (tRNA nucleotidyltransferase)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION PARTICLE RNA; COMPLETE GENOME SEQUENCE; 3' END FORMATION; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; U1 SNRNA; SPLICING FACTOR; COILED BODIES; VIRAL RNAS; IN-VIVO	The CCA-adding enzyme builds and repairs the 3'-terminus of tRNA. Approximately 65% of mature human U2 small nuclear RNA (snRNA) ends in T-terminal CCA, as do all mature tRNAs; the other 35% ends in 3' CC or possibly 3' C. The 3'-terminal A of U2 snRNA cannot be encoded because the 3' end of the U2 snRNA coding region is CC/CC, where the slash indicates the last encoded nucleotide. The first detectable U2 snRNA precursor contains 10-16 extra 3' nucleotides that are removed by one or more 3' exonucleases. Thus, if 3' exonuclease activity removes the encoded 3' CC during U2 snRNA maturation, as appears to be the case in vitro, the cell may need to build or rebuild the 3'-terminal A, CA, or CCA of U2 snRNA. We asked whether homologous and heterologous class I and class II CCA-adding enzymes could add 3'-terminal A, CA, or CCA to human U2 snRNA lacking 3'-terminal A, CA, or CCA. The naked U2 snRNAs were good substrates for the human CCA-adding enzyme but were inactive with the Escherichia coli enzyme; activity was also observed on native U2 SnRNPs. We suggest that the 3' stem/loop of U2 snRNA resembles a tRNA minihelix, the smallest efficient substrate for class I and Il CCA-adding enzymes, and that CCA addition to U2 snRNA may take place in vivo after snRNP assembly has begun.	Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan	University of Washington; University of Washington Seattle; University of Tokyo	Weiner, AM (corresponding author), Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA.		Tomita, Kozo/E-9390-2017; Suzuki, Tsutomu/J-1776-2015; Tomita, Kozo/J-5746-2013	Tomita, Kozo/0000-0002-7374-3898; Suzuki, Tsutomu/0000-0002-9731-1731; 				ACH RA, 1987, MOL CELL BIOL, V7, P2070, DOI 10.1128/MCB.7.6.2070; Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; BARTSCH I, 1987, MOL CELL BIOL, V7, P2521, DOI 10.1128/MCB.7.7.2521; BEHRENS SE, 1993, P NATL ACAD SCI USA, V90, P8229, DOI 10.1073/pnas.90.17.8229; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P455, DOI 10.1093/nar/19.3.455; Booth BL, 1997, J BIOL CHEM, V272, P984, DOI 10.1074/jbc.272.2.984; Boyd DC, 2000, GENE, V247, P33, DOI 10.1016/S0378-1119(00)00134-7; BROSI R, 1993, J BIOL CHEM, V268, P17640; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; Chen YH, 2000, RNA, V6, P1277, DOI 10.1017/S1355838200000285; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; Cuello P, 1999, EMBO J, V18, P2867, DOI 10.1093/emboj/18.10.2867; Deutscher M P, 1974, Methods Enzymol, V29, P706; DEUTSCHER MP, 1990, METHOD ENZYMOL, V181, P434; DEUTSCHER MP, 1982, ENZYMES, V15, P183, DOI DOI 10.1016/S1874-6047(08)60279-6; DEVEGVAR HEN, 1986, CELL, V47, P259; DOLAPCHIEV LB, 1974, BIOCHEM BIOPH RES CO, V61, P273, DOI 10.1016/0006-291X(74)90563-4; Dominski Z, 2001, MOL CELL BIOL, V21, P2008, DOI 10.1128/MCB.21.6.2008-2017.2001; ELICEIRI GL, 1976, BIOCHEM BIOPH RES CO, V72, P507, DOI 10.1016/S0006-291X(76)80070-8; Fechter P, 2001, J MOL BIOL, V309, P387, DOI 10.1006/jmbi.2001.4654; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; GESTELAND RF, 1993, MONOGRAPH, V24; GESTELAND RF, 1999, MONOGRAPH, V37; Giege R, 1996, P NATL ACAD SCI USA, V93, P12078, DOI 10.1073/pnas.93.22.12078; HANLEY BA, 1991, NUCLEIC ACIDS RES, V19, P1861, DOI 10.1093/nar/19.8.1861; HANLEY BA, 1991, NUCLEIC ACIDS RES, V19, P6319, DOI 10.1093/nar/19.22.6319; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; HERNANDEZ N, 1986, CELL, V47, P249, DOI 10.1016/0092-8674(86)90447-2; HERNANDEZ N, 1985, EMBO J, V4, P1827, DOI 10.1002/j.1460-2075.1985.tb03857.x; HO NWY, 1973, BIOCHIM BIOPHYS ACTA, V308, P53, DOI 10.1016/0005-2787(73)90121-4; Hopper AK, 1998, SCIENCE, V282, P2003, DOI 10.1126/science.282.5396.2003; Huang Q, 1999, NUCLEIC ACIDS RES, V27, P1025, DOI 10.1093/nar/27.4.1025; Huang Q, 1997, MOL CELL BIOL, V17, P7178, DOI 10.1128/MCB.17.12.7178; Jakab G, 1997, BIOCHIMIE, V79, P387, DOI 10.1016/S0300-9084(97)86148-2; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KLEINSCHMIDT AM, 1989, NUCLEIC ACIDS RES, V17, P4817, DOI 10.1093/nar/17.12.4817; KLEINSCHMIDT AM, 1987, MOL CELL BIOL, V7, P3131, DOI 10.1128/MCB.7.9.3131; Li ZJ, 1997, BIOCHEM J, V327, P847, DOI 10.1042/bj3270847; Li ZW, 1998, P NATL ACAD SCI USA, V95, P2856, DOI 10.1073/pnas.95.6.2856; LI ZW, 1994, J BIOL CHEM, V269, P6064; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Ma B, 2001, J BIOL CHEM, V276, P5027, DOI 10.1074/jbc.M009301200; MAIZELS N, 1999, RNA WORLD, V2, P79; MANS RMW, 1990, NUCLEIC ACIDS RES, V18, P3479, DOI 10.1093/nar/18.12.3479; Matera AG, 1999, TRENDS CELL BIOL, V9, P302, DOI 10.1016/S0962-8924(99)01606-2; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Nagaike T, 2001, J BIOL CHEM, V276, P40041, DOI 10.1074/jbc.M106202200; Narayanan A, 1999, MOL BIOL CELL, V10, P2131, DOI 10.1091/mbc.10.7.2131; OH BK, 1994, NUCLEIC ACIDS RES, V22, P4087, DOI 10.1093/nar/22.20.4087; ORUM H, 1991, J MOL BIOL, V222, P219, DOI 10.1016/0022-2836(91)90208-N; PAVELITZ T, 1995, EMBO J, V14, P169, DOI 10.1002/j.1460-2075.1995.tb06987.x; PEDERSON T, 1990, MOL BIOL REP, V14, P179, DOI 10.1007/BF00360466; Perumal K, 2001, J BIOL CHEM, V276, P21791, DOI 10.1074/jbc.M101905200; Perumal K, 2000, MOL CELL BIOCHEM, V208, P99, DOI 10.1023/A:1007098122583; PHILIPPS GR, 1975, H-S Z PHYSIOL CHEM, V356, P1085, DOI 10.1515/bchm2.1975.356.2.1085; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; RAO ALN, 1989, P NATL ACAD SCI USA, V86, P5335, DOI 10.1073/pnas.86.14.5335; REDDY R, 1981, NUCLEIC ACIDS RES, V9, P5645, DOI 10.1093/nar/9.21.5645; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Shi PY, 1998, RNA, V4, P276; SHIBATA H, 1974, MOL CELL BIOCHEM, V4, P3, DOI 10.1007/BF01731099; Sinha KM, 1998, J BIOL CHEM, V273, P6853, DOI 10.1074/jbc.273.12.6853; Sleeman JE, 1999, CURR BIOL, V9, P1065, DOI 10.1016/S0960-9822(99)80475-8; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Sprinzl M, 1979, Prog Nucleic Acid Res Mol Biol, V22, P1, DOI 10.1016/S0079-6603(08)60798-9; STROKE IL, 1985, J MOL BIOL, V184, P183, DOI 10.1016/0022-2836(85)90372-9; Tomari Y, 2000, GENES CELLS, V5, P689, DOI 10.1046/j.1365-2443.2000.00360.x; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WEINBERG RA, 1968, J MOL BIOL, V38, P289, DOI 10.1016/0022-2836(68)90387-2; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; WELLS SE, 1994, MOL CELL BIOL, V14, P6337, DOI 10.1128/MCB.14.9.6337; WENDELBURG BJ, 1992, MOL CELL BIOL, V12, P4132, DOI 10.1128/MCB.12.9.4132; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Williams MA, 2000, NUCLEIC ACIDS RES, V28, P4444, DOI 10.1093/nar/28.22.4444; Wolfe CL, 1996, J BIOL CHEM, V271, P4679; Yu YT, 1998, EMBO J, V17, P5783, DOI 10.1093/emboj/17.19.5783; Yu YT, 2001, J CELL BIOL, V152, P1279, DOI 10.1083/jcb.152.6.1279; YU YT, 1999, RNA WORLD, V2, P487; Yue DX, 1996, RNA, V2, P895; YUO CY, 1985, CELL, V42, P193, DOI 10.1016/S0092-8674(85)80115-X; Zhao XY, 2001, MOL CELL, V7, P539, DOI 10.1016/S1097-2765(01)00201-5; ZHU LQ, 1987, EMBO J, V6, P2473, DOI 10.1002/j.1460-2075.1987.tb02528.x; ZIEVE GW, 1988, J MOL BIOL, V199, P259, DOI 10.1016/0022-2836(88)90312-9	89	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3447	3455		10.1074/jbc.M109559200	http://dx.doi.org/10.1074/jbc.M109559200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11700323	hybrid			2022-12-25	WOS:000173688000053
J	Leemhuis, H; Uitdehaag, JCM; Rozeboom, HJ; Dijkstra, BW; Dijkhuizen, L				Leemhuis, H; Uitdehaag, JCM; Rozeboom, HJ; Dijkstra, BW; Dijkhuizen, L			The remote substrate binding subsite-6 in cyclodextrin-glycosyltransferase controls the transferase activity of the enzyme via an induced-fit mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CIRCULANS STRAIN-251; THERMOANAEROBACTERIUM THERMOSULFURIGENES EM1; ALPHA-AMYLASE FAMILY; X-RAY STRUCTURE; PRODUCT SPECIFICITY; 1.8-ANGSTROM RESOLUTION; ANGSTROM RESOLUTION; NUCLEOTIDE-SEQUENCE; BETA-CYCLODEXTRIN; GLUCANOTRANSFERASE	Cyclodextrin-glycosyltransferase (CGTase) catalyzes the formation of alpha-, beta-, and gamma-cyclodextrins (cyclic alpha-(1,4)-linked oligosaccharides of 6, 7, or 8 glucose residues, respectively) from starch. Nine substrate binding subsites were observed in an x-ray structure of the CGTase from Bacillus circulans strain 251 complexed with a maltononaose substrate. Subsite -6 is conserved in CGTases, suggesting its importance for the reactions catalyzed by the enzyme. To investigate this in detail, we made six mutant CGTases (Y167F, G179L, G180L, N193G, N193L, and G179L/G180L). All subsite -6 mutants had decreased k(cat) values for beta-cyclodextrin formation, as well as for the disproportionation and coupling reactions, but not for hydrolysis. Especially G179L, G180L, and G179L/G180L affected the transglycosylation activities, most prominently for the coupling reactions. The results demonstrate that (i) subsite -6 is important for all three CGTase-catalyzed transglycosylation reactions, (ii) Gly-180 is conserved because of its importance for the circularization of the linear substrates, (iii) it is possible to independently change cyclization and coupling activities, and (iv) substrate interactions at subsite -6 activate the enzyme in catalysis via an induced-fit mechanism. This article provides for the first time definite biochemical evidence for such an induced-fit mechanism in the alpha-amylase family.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; Univ Groningen, BIOSON Res Inst, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Biophys Chem Lab, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Dijkhuizen, L (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Dijkhuizen, Lubbert/E-9454-2014; Dijkhuizen, Lubbert/K-3539-2019; Dijkstra, Bauke W./H-4308-2019	Dijkhuizen, Lubbert/0000-0003-2312-7162; Dijkstra, Bauke W./0000-0001-9731-6586; Rozeboom, Henriette/0000-0002-1656-6477				BENDER H, 1990, CARBOHYD RES, V206, P257, DOI 10.1016/0008-6215(90)80065-B; BRON S, 1990, MODERN MICROBIOLOGIC, P146; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; FRENCH D, 1965, ARCH BIOCHEM BIOPHYS, V111, P153, DOI 10.1016/0003-9861(65)90334-6; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harata K, 1996, ACTA CRYSTALLOGR D, V52, P1136, DOI 10.1107/S0907444996008438; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Janecek S, 1997, PROG BIOPHYS MOL BIO, V67, P67, DOI 10.1016/S0079-6107(97)00015-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kim YH, 1997, BIOCHEM MOL BIOL INT, V41, P227; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; Knegtel RMA, 1996, J MOL BIOL, V256, P611, DOI 10.1006/jmbi.1996.0113; KNEGTEL RMK, 1995, J BIOL CHEM, V270, P29256, DOI 10.1074/jbc.270.49.29256; Kubota M., 1991, DENPUN KAGAKU, V38, P141; LAWSON CL, 1994, J MOL BIOL, V236, P590, DOI 10.1006/jmbi.1994.1168; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; Mosi R, 1997, BIOCHEMISTRY-US, V36, P9927, DOI 10.1021/bi970618u; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; NAKAMURA A, 1994, FEBS LETT, V337, P66, DOI 10.1016/0014-5793(94)80631-4; NAKAMURA A, 1993, BIOCHEMISTRY-US, V32, P6624, DOI 10.1021/bi00077a015; NAKAMURA A, 1994, BIOCHEMISTRY-US, V33, P9929, DOI 10.1021/bi00199a015; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Parsiegla G, 1998, EUR J BIOCHEM, V255, P710, DOI 10.1046/j.1432-1327.1998.2550710.x; Penninga D, 1996, J BIOL CHEM, V271, P32777, DOI 10.1074/jbc.271.51.32777; PENNINGA D, 1995, BIOCHEMISTRY-US, V34, P3368, DOI 10.1021/bi00010a028; Schmidt AK, 1998, BIOCHEMISTRY-US, V37, P5909, DOI 10.1021/bi9729918; SMITH H, 1988, GENE, V70, P351, DOI 10.1016/0378-1119(88)90207-7; Strokopytov B, 1996, BIOCHEMISTRY-US, V35, P4241, DOI 10.1021/bi952339h; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; Terada Y, 1997, J BIOL CHEM, V272, P15729, DOI 10.1074/jbc.272.25.15729; Uitdehaag JCM, 1999, J BIOL CHEM, V274, P34868, DOI 10.1074/jbc.274.49.34868; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; Uitdehaag JCM, 2001, PROTEINS, V43, P327, DOI 10.1002/prot.1044; Uitdehaag JCM, 2000, BIOCHEMISTRY-US, V39, P7772, DOI 10.1021/bi000340x; van der Veen BA, 2000, J MOL BIOL, V296, P1027, DOI 10.1006/jmbi.2000.3528; van der Veen BA, 2000, EUR J BIOCHEM, V267, P658, DOI 10.1046/j.1432-1327.2000.01031.x; van der Veen BA, 2000, BBA-PROTEIN STRUCT M, V1543, P336, DOI 10.1016/S0167-4838(00)00233-8; van der Veen BA, 2001, J BIOL CHEM, V276, P44557, DOI 10.1074/jbc.M107533200; Wind RD, 1998, J BIOL CHEM, V273, P5771, DOI 10.1074/jbc.273.10.5771	41	44	45	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1113	1119		10.1074/jbc.M106667200	http://dx.doi.org/10.1074/jbc.M106667200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11696539	hybrid, Green Published			2022-12-25	WOS:000173166800032
J	Mosser, VA; Amana, IJ; Schimerlik, MI				Mosser, VA; Amana, IJ; Schimerlik, MI			Kinetic analysis of M-2 muscarinic receptor activation of G(i) in Sf9 insect cell membranes.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; SITE-DIRECTED MUTAGENESIS; ACETYLCHOLINE-RECEPTOR; COUPLING SELECTIVITY; D-2S RECEPTOR; RECONSTITUTION; DISAGGREGATION; NUCLEOTIDES; TRANSDUCIN; MODULATION	A steady-state kinetic mechanism describing the interaction of M-2 muscarinic acetylcholine receptors and the guanine nucleotide-binding protein G(i)alpha(2)beta(1)gamma(3) are presented. Data are consistent with two parallel pathways of agonist-promoted GTPase activity arising from receptor coupled to a single or multiple guanine nucleotide-binding proteins. An aspartate 103 to asparagine receptor mutation resulted in a receptor lacking the ability to catalyze the binding of guanosine-5'-O-(3-thiotriphosphate) or guanosine triphosphate hydrolysis by the G protein. An aspartate 69 to asparagine receptor mutant was able to catalyze agonist-specific guanine nucleotide exchange and GTPase activity. A threonine 187 to alanine receptor mutation resulted in a receptor that catalyzed guanine nucleotide exchange comparable with wild-type receptors but had reduced ability to stimulate GTP hydrolysis. A tyrosine 403 to phenylalanine receptor mutation resulted in an increase in agonist-promoted GTPAse activity compared with wild type. The observation that the threonine 187 and tyrosine 403 mutants promote guanine nucleotide exchange similarly to wild type but alter GTPase activity compared with wild type suggests that the effects of the mutations arise downstream from guanine nucleotide exchange and may result from changes in receptor-G protein dissociation.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Oregon State Univ, Environm Hlth Sci Ctr, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Schimerlik, MI (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.			Amanna, Ian/0000-0001-7545-4013	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23632] Funding Source: Medline; NIEHS NIH HHS [ES00210] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barr AJ, 1997, J BIOL CHEM, V272, P2223; BENNETT N, 1985, J BIOL CHEM, V260, P4156; CHA S, 1968, J BIOL CHEM, V243, P820; COULTER S, 1992, P NATL ACAD SCI USA, V89, P5842, DOI 10.1073/pnas.89.13.5842; FRASER CM, 1989, MOL PHARMACOL, V36, P840; Grunewald S, 1996, BIOCHEMISTRY-US, V35, P15149, DOI 10.1021/bi9607564; Grunewald S, 1996, BIOCHEMISTRY-US, V35, P15162, DOI 10.1021/bi960757w; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HEITZ F, 1995, J RECEPT SIGNAL TR R, V15, P55, DOI 10.3109/10799899509045207; Hermans E, 1997, BRIT J PHARMACOL, V121, P1817, DOI 10.1038/sj.bjp.0701334; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; JAHANGEER S, 1993, P NATL ACAD SCI USA, V90, P8782, DOI 10.1073/pnas.90.19.8782; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; January B, 1997, J BIOL CHEM, V272, P23871, DOI 10.1074/jbc.272.38.23871; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; Koller KJ, 1997, ANAL BIOCHEM, V250, P51, DOI 10.1006/abio.1997.2190; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Miyamoto A, 1997, J BIOL CHEM, V272, P19601, DOI 10.1074/jbc.272.31.19601; NAKAMURA S, 1990, P NATL ACAD SCI USA, V87, P6413, DOI 10.1073/pnas.87.16.6413; NAKAMURA SI, 1991, P NATL ACAD SCI USA, V88, P7150, DOI 10.1073/pnas.88.16.7150; PASSONEAU J, 1962, BIOCHEM BIOPH RES CO, V7, P10, DOI 10.1016/0006-291X(62)90134-1; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PETERSON GL, 1995, J BIOL CHEM, V270, P17808, DOI 10.1074/jbc.270.30.17808; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; RINKEN A, 1994, BIOCHEM PHARMACOL, V48, P1245, DOI 10.1016/0006-2952(94)90162-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; TOTA MR, 1987, BIOCHEMISTRY-US, V26, P8175, DOI 10.1021/bi00399a023; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; VANHOLDE KE, 1998, PRINCIPLS PHYSICAL B, P217; Vogel WK, 1999, ARCH BIOCHEM BIOPHYS, V361, P283, DOI 10.1006/abbi.1998.0985; Vogel WK, 1997, MOL PHARMACOL, V52, P1087, DOI 10.1124/mol.52.6.1087; Wess J, 1997, LIFE SCI, V60, P1007, DOI 10.1016/S0024-3205(97)00041-6; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371	37	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					922	931		10.1074/jbc.M104210200	http://dx.doi.org/10.1074/jbc.M104210200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11689554	hybrid			2022-12-25	WOS:000173166800009
J	Paing, MM; Stutts, AB; Kohout, TA; Lefkowitz, RJ; Trejo, J				Paing, MM; Stutts, AB; Kohout, TA; Lefkowitz, RJ; Trejo, J			beta-arrestins regulate protease-activated receptor-1 desensitization but not internalization or down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; THROMBIN-RECEPTOR; COUPLED RECEPTOR; MEDIATED ENDOCYTOSIS; ENDOTHELIAL-CELLS; CLATHRIN ADAPTER; PLASMA-MEMBRANE; DYNAMIN; TRAFFICKING; MECHANISM	The widely expressed beta-arrestin isoforms 1 and 2 bind phosphorylated G protein-coupled receptors (GPCRs) and mediate desensitization and internalization. Phosphorylation of protease-activated receptor-1 (PAR1), a GPCR for thrombin, is important for desensitization and internalization, however, the role of beta-arrestins in signaling and trafficking of PAR1 remains unknown. To assess beta-arrestin function we examined signaling and trafficking of PAR1 in mouse embryonic fibroblasts (MEFs) derived from beta-arrestin (betaarr) knockouts. Desensitization of PAR1 signaling was markedly impaired in MEFs lacking both betaarr1 and 13arr2 isoforms compared with wild-type cells. Strikingly, in cells lacking only betaarr1 PAR1 desensitization was also significantly impaired compared with betaarr2-lacking or wild-type cells. In wild-type MEFs, activated PAR1 was internalized through a dynamin- and clathrin-dependent pathway and degraded. Surprisingly, in cells lacking both betaarr1 and betaarr2 activated PAR1 was similarly internalized through a dynamin- and clathrin-dependent pathway and degraded, whereas the beta(2)-adrenergic receptor (beta(2)-AR) failed to internalize. A PAR1 cytoplasmic tail mutant defective in agonist-induced phosphorylation failed to internalize in both wild-type and beta-arrestin knockout cells. Thus, PAR1 appears to utilize a distinct phosphorylation-dependent but beta-arrestin-independent pathway for internalization through clathrin-coated pits. Together, these findings strongly suggest that the individual beta-arrestin isoforms can differentially regulate GPCR desensitization and further reveal a novel mechanism by which GPCRs can internalize through a dynamin- and clathrin-dependent pathway that is in independent of arrestins.	Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Trejo, J (corresponding author), Univ N Carolina, Dept Pharmacol, Sch Med, 1106 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.		Lefkowitz, Robert/AAW-2649-2021	TREJO, JOANN/0000-0003-4405-6228	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, K01HL067697, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037, HL67697] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACTON SL, 1990, J CELL BIOL, V111, P1419, DOI 10.1083/jcb.111.4.1419; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; CHEN J, 1994, J BIOL CHEM, V269, P16041; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P2486, DOI 10.1021/bi982527i; HEIN L, 1994, J BIOL CHEM, V269, P27719; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1994, J BIOL CHEM, V269, P1125; KATOH S, 1994, BIOL PHARM BULL, V17, P1003; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shapiro MJ, 1998, J BIOL CHEM, V273, P29009, DOI 10.1074/jbc.273.44.29009; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; Trejo J, 2000, J BIOL CHEM, V275, P31255, DOI 10.1074/jbc.M003770200; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; VON ZM, 1992, J BIOL CHEM, V267, P3530; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868	42	166	174	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1292	1300		10.1074/jbc.M109160200	http://dx.doi.org/10.1074/jbc.M109160200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694535	hybrid, Green Published			2022-12-25	WOS:000173166800056
J	Soundararajan, M; Chang, ZY; Morgan, RD; Heslop, P; Connolly, BA				Soundararajan, M; Chang, ZY; Morgan, RD; Heslop, P; Connolly, BA			DNA binding and recognition by the IIs restriction endonuclease MboII.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T7 EXPRESSION SYSTEM; STEADY-STATE; ECORV ENDONUCLEASE; SINGLE-TURNOVER; CALCIUM-IONS; CLEAVAGE; FOKI; SPECIFICITY; KINETICS; ENZYMES	The type Its restriction endonuclease MboII recognizes nonsymmetrical GAAGA sites, cutting 8 (top strand) and 7 (bottom strand) bases to the right. Gel retardation showed that MboII bound specifically to GAAGA sequences, producing two distinct complexes each containing one MboII and one DNA molecule. Interference analysis indicated that the initial species formed, named complex 1, comprised an interaction between the enzyme and the GAAGA target. Complex 2 involved interaction of the protein with both the GAAGA and the cutting sites. Only in the presence of divalent metal ions such as Ca2+ is the conversion of complex 1 to 2 rapid. Additionally, a very retarded complex was seen with Ca2+, possibly a (MboII)(2)-(DNA)(2) complex. Plasmids containing a single GAAGA site were hydrolyzed slowly by MboII. Plasmids containing two sites were cut far more rapidly, suggesting that the enzyme requires two recognition sites in the same DNA molecule for efficient hydrolysis. MboII appears to have a mechanism similar to the best characterized type Its enzyme, FokI. Both enzymes initially bind DNA as monomers, followed by dimerization to give an (enzyme)(2)(DNA)(2) complex. Dimerization is efficient only when the two target sites are located in the same DNA molecule and requires divalent metal ions.	Newcastle Univ, Dept Biochem & Mol Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; New England Biolabs Inc, Beverly, MA 01915 USA	Newcastle University - UK	Connolly, BA (corresponding author), Newcastle Univ, Dept Biochem & Mol Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	b.a.connolly@ncl.ac.uk		Soundararajan, Meera/0000-0003-4687-0151				BALDWIN GS, 1995, BIOCHEMISTRY-US, V34, P705, DOI 10.1021/bi00002a038; BATH AJ, 2002, IN PRESS J BIOL CHEM, V277; Bilcock DT, 1999, J BIOL CHEM, V274, P36379, DOI 10.1074/jbc.274.51.36379; Bitinaite J, 1998, P NATL ACAD SCI USA, V95, P10570, DOI 10.1073/pnas.95.18.10570; BOCKLAGE H, 1991, NUCLEIC ACIDS RES, V19, P1007, DOI 10.1093/nar/19.5.1007; BROWN NL, 1980, J MOL BIOL, V140, P143, DOI 10.1016/0022-2836(80)90360-5; Colandene JD, 2000, BIOCHEMISTRY-US, V39, P13703, DOI 10.1021/bi001812a; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; Embleton ML, 1999, J MOL BIOL, V289, P785, DOI 10.1006/jmbi.1999.2822; Engler LE, 2001, J MOL BIOL, V307, P619, DOI 10.1006/jmbi.2000.4428; Gormley NA, 2000, J BIOL CHEM, V275, P6928, DOI 10.1074/jbc.275.10.6928; HALFORD SE, 1994, DNA PROTEIN INTERACT, P385; HENSLEY P, 1990, J BIOL CHEM, V265, P15300; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KACZOROWSKI T, 1989, GENE, V80, P209, DOI 10.1016/0378-1119(89)90285-0; Kovall RA, 1999, CURR OPIN CHEM BIOL, V3, P578, DOI 10.1016/S1367-5931(99)00012-5; Lagunavicius A, 1997, BIOCHEMISTRY-US, V36, P11093, DOI 10.1021/bi963126a; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LI L, 1993, GENE, V133, P79, DOI 10.1016/0378-1119(93)90227-T; Martin AM, 1999, BIOCHEMISTRY-US, V38, P8430, DOI 10.1021/bi9905359; MCLURE W, 1980, P NATL ACAD SCI USA, V77, P5634; *MICR SCI SOFTW, 1995, SCI; Nastri HG, 1997, J BIOL CHEM, V272, P25761, DOI 10.1074/jbc.272.41.25761; Petrauskene OV, 1998, FEBS LETT, V425, P29, DOI 10.1016/S0014-5793(98)00184-7; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Roberts RJ, 2001, NUCLEIC ACIDS RES, V29, P268, DOI 10.1093/nar/29.1.268; Sam MD, 1999, J AM CHEM SOC, V121, P1444, DOI 10.1021/ja983787q; Sambrook J., 1989, MOL CLONING, pA1; Sapranauskas R, 2000, J BIOL CHEM, V275, P30878, DOI 10.1074/jbc.M003350200; Sasnauskas G, 1999, BIOCHEMISTRY-US, V38, P4028, DOI 10.1021/bi982456n; SEKTAS M, 1992, NUCLEIC ACIDS RES, V20, P433, DOI 10.1093/nar/20.3.433; SEKTAS M, 1995, GENE, V157, P181, DOI 10.1016/0378-1119(94)00742-B; SHAW PE, 2001, DNA PROTEIN INTERACT, P221; Siksnys V, 1999, J MOL BIOL, V291, P1105, DOI 10.1006/jmbi.1999.2977; Skirgaila R, 1998, BIOL CHEM, V379, P595; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; SZYBALSKI W, 1991, GENE, V100, P13, DOI 10.1016/0378-1119(91)90345-C; TUCHOLSKI J, 1995, GENE, V157, P87, DOI 10.1016/0378-1119(94)00787-S; Vanamee ES, 2001, J MOL BIOL, V309, P69, DOI 10.1006/jmbi.2001.4635; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; Wah DA, 1998, P NATL ACAD SCI USA, V95, P10564, DOI 10.1073/pnas.95.18.10564; WENTZELL LM, 1995, J MOL BIOL, V248, P581, DOI 10.1006/jmbi.1995.0244; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZEBALA JA, 1992, J BIOL CHEM, V267, P8097	48	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					887	895		10.1074/jbc.M109100200	http://dx.doi.org/10.1074/jbc.M109100200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11606594	hybrid			2022-12-25	WOS:000173166800005
J	Sun, YB; Wenger, L; Brinckerhoff, CE; Misra, RR; Cheung, HS				Sun, YB; Wenger, L; Brinckerhoff, CE; Misra, RR; Cheung, HS			Basic calcium phosphate crystals induce matrix metalloproteinase-1 through the Ras/Mitogen-activated protein Kinase/c-Fos/AP-1/metalloproteinase 1 pathway - Involvement of transcription factor binding sites AP-1 and PEA-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SERUM RESPONSE FACTOR; KINASE-C; MOLECULAR MECHANISM; HUMAN FIBROBLASTS; COLLAGENASE GENE; GROWTH-FACTOR; MAP KINASE; EXPRESSION; PROMOTER	Synovial fluid basic calcium phosphate (BCP) crystals are common in osteoarthritis and are associated with severe degenerative arthropathy. Besides stimulating synovial fibroblast-like cells to proliferate, BCP crystals are a potent inducer of human matrix metalloproteinases (hMMPs), which can speed up the articular joint tissue degeneration of osteoarthritis patients. Here, we report that transfections with hMMP1 luciferase reporter plasmids in fibroblast-like synoviocytes revealed that the induction of hMMP1 promoter by BCP crystals was mainly mediated through the -72AP-1 element. Elimination of the -72AP-1 element either by mutation or deletion abolished the induction of hMMP1 promoter activity by BCP crystals almost completely. Interestingly, a mutation at the -88PEA-3 site also abolished the induction of hMMP1 promoter. Further mutation at the -181AP-1 site resumed the induction, indicating that the -181AP-1 element had an effect opposite to the -72AP-1 element. The effect of -181AP-1 could be inactivated either by a mutation at this -181AP-1 site or by the -88PEA-3 element. In addition, dominant negative Ras, Raf, and MEK1/2 could block the induction of hMMP1, and a MEK1/2-specific inhibitor (UO126) could block the induction of hMMP1 and c-Fos by BCP crystals. Taken together, these data indicate that multiple elements, including at least AP-1 and PEA-3, are involved in the induction of hMMP1 gene expression by BCP crystals and that the induction follows the Ras/MAPK/c-Fos/AP-1/MMP1 signaling pathway.	Univ Miami, Sch Med, Dept Med, Arthrit Div D26, Miami, FL 33101 USA; Dartmouth Coll Sch Med, Dept Med, Hanover, NH 03755 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Dept Vet Affairs Med Ctr, Res Serv, Miami, FL 33125 USA; Dept Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Miami, FL 33125 USA; Univ Miami, Dept Biomed Engn, Coral Gables, FL 33146 USA	University of Miami; Dartmouth College; Medical College of Wisconsin; Geriatric Research Education & Clinical Center; University of Miami	Cheung, HS (corresponding author), Univ Miami, Sch Med, Dept Med, Arthrit Div D26, POB 016960, Miami, FL 33101 USA.	hcheung@med.miami.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038421, R37AR026599, R01AR026599] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR26599, AR38421] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BRINCKERHOFF C E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P145; Brogley MA, 1999, J CELL PHYSIOL, V180, P215, DOI 10.1002/(SICI)1097-4652(199908)180:2<215::AID-JCP9>3.0.CO;2-J; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CARROLL GJ, 1991, J RHEUMATOL, V18, P861; CHEUNG HS, 1984, ARTHRITIS RHEUM-US, V27, P668, DOI 10.1002/art.1780270610; Cheung HS, 1996, BBA-MOL BASIS DIS, V1315, P105, DOI 10.1016/0925-4439(95)00106-9; Cheung HS, 1997, OSTEOARTHR CARTILAGE, V5, P145, DOI 10.1016/S1063-4584(97)80009-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; Ellerbroek SM, 2001, CANCER RES, V61, P1855; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HALVERSON PB, 1986, ANN RHEUM DIS, V45, P603, DOI 10.1136/ard.45.7.603; HALVERSON PB, 1997, ARTHRITIS ALLIED CON, P2127; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HARRIS VK, 2000, J BIOL CHEM, V276, P10801; HATA A, 1993, J BIOL CHEM, V268, P9122; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; LENGYEL E, 1995, BBA-MOL CELL RES, V1268, P65, DOI 10.1016/0167-4889(95)00050-3; Malemud Charles J., 1999, Frontiers in Bioscience, V4, pd762; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; McCarthy GM, 1998, J BIOL CHEM, V273, P35161, DOI 10.1074/jbc.273.52.35161; MCCARTHY GM, 1991, ARTHRITIS RHEUM-US, V34, P1021, DOI 10.1002/art.1780340812; MCCARTHY GM, 1992, J CELL PHYSIOL, V153, P140, DOI 10.1002/jcp.1041530118; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MITCHELL PG, 1989, J BIOL CHEM, V264, P14071; Nair D, 1997, J BIOL CHEM, V272, P18920, DOI 10.1074/jbc.272.30.18920; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Reuben PM, 2001, CONNECT TISSUE RES, V42, P1, DOI 10.3109/03008200109014244; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; RYAN LM, 1997, ARTHRITIS ALLIED CON, P2103; Shlopov BV, 1997, ARTHRITIS RHEUM-US, V40, P2065, DOI 10.1002/art.1780401120; Su ZZ, 2000, ONCOGENE, V19, P3411, DOI 10.1038/sj.onc.1203666; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; White LA, 1995, MATRIX BIOL, V14, P715, DOI 10.1016/S0945-053X(05)80014-9; WOESSNER JF, 1991, J RHEUMATOL, V18, P99	56	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1544	1552		10.1074/jbc.M100567200	http://dx.doi.org/10.1074/jbc.M100567200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11682465	hybrid			2022-12-25	WOS:000173166800088
J	Ju, TZ; Cummings, RD; Canfield, WM				Ju, TZ; Cummings, RD; Canfield, WM			Purification, characterization, and subunit structure of rat core 1 beta 1,3-galactosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED GLYCOSYLATION; N-ACETYLGLUCOSAMINYLTRANSFERASE-I; GLYCAN BRANCH FORMATION; DISULFIDE-BONDED DIMER; MOLECULAR-CLONING; IGA NEPHROPATHY; MUCIN SYNTHESIS; TN-SYNDROME; GAL BETA-3-N-ACETYLGLUCOSAMINYLTRANSFERASE; R BETA-3-GALACTOSYLTRANSFERASE	The O-linked oligosaccharides (O-glycans) in mammalian glycoproteins are classified according to their core structures. Among the most common is the core I disaccharide structure consisting of Galbeta1-->3GalNAcalpha1-->Ser/ Thr, which is also the precursor for many extended O-glycan structures. The key enzyme for biosynthesis of core 1 O-glycan from the precursor GalNAc-alpha-Ser/Thr is UDP-Gal:GalNAc-alpha-Ser/Thr beta3-galactosyltransferase (core1 beta3-Gal-T). Core 1 beta3-Gal-T activity, which requires Mn2+, was solubilized from rat liver membranes and purified 71,034-fold to apparent homogeneity (>90% purity) in 5.7% yield by ion exchange chromatography on SP-Sepharose, affinity chromatography on immobilized asialo-bovine submaxillary mucin, and gel filtration chromatography on Superose 12. The purified enzyme is free of contaminating glycosyltransferases. Two peaks of core 1 beta3-Gal-T activity were identified in the final step on Superose 12. One peak of activity contained protein bands on non-reducing SDS-PAGE of similar to84- and similar to86-kDa disulfide-linked dimers, whereas the second peak of activity contained monomers of similar to43-kDa. Reducing SDS-PAGE of these proteins gave similar to42- and similar to43-kDa monomers. Both the 84/86-kDa dimers and the 42/43-kDa monomers have the same novel N-terminal sequence. The purified enzyme, which is remarkably stable, has an apparent K-m for UDP-Gal of 630 mum and an apparent V-max of 206 mumol/mg/h protein using GalNAcalpha1-O-phenyl as the acceptor. The reaction product was generated using asialo-bovine submaxillary mucin as an acceptor; treatment with O-glycosidase generated the expected disaccharide Galbeta1-->3GalNAc. These studies demonstrate that activity of the core 1 beta1,3-Gal-T from rat liver is contained within a single, novel, disulfide-bonded, dimeric enzyme.	Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, W K Warren Med Res Inst, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Canfield, WM (corresponding author), Novazyme Pharmaceut Inc, 800 Res Pkwy,Ste 200, Oklahoma City, OK 73104 USA.			Ju, Tongzhong/0000-0002-4429-1976	NIAID NIH HHS [R01 AI48075-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048075] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen AC, 1997, NEPHROL DIAL TRANSPL, V12, P701, DOI 10.1093/ndt/12.4.701; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Barreaud JP, 2000, GLYCOBIOLOGY, V10, P611, DOI 10.1093/glycob/10.6.611; Berger EG, 1999, BBA-MOL BASIS DIS, V1455, P255, DOI 10.1016/S0925-4439(99)00069-1; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; BROCKHAUSEN I, 1983, CAN J BIOCHEM CELL B, V61, P1322, DOI 10.1139/o83-169; Brockhausen I, 1998, GLYCOCONJUGATE J, V15, P595, DOI 10.1023/A:1006967910803; BROCKHAUSEN I, 1984, CAN J BIOCHEM CELL B, V62, P1081, DOI 10.1139/o84-140; BROCKHAUSEN I, 1992, BIOCHEM CELL BIOL, V70, P99, DOI 10.1139/o92-015; Brockhausen I, 1998, ACTA ANAT, V161, P36; BROCKHAUSEN I, 1990, BIOCHEMISTRY-US, V29, P10206, DOI 10.1021/bi00496a008; BROCKHAUSEN I, 1995, GLYCOPROTEINS A, V29, P201; Brockhausen I., 1997, GLYCOSCIENCES STATUS, P79; BROCKHAUSEN I, 1997, GLYCOPROTEINS HUMAN, P13; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; ELHAMMER A, 1984, J CELL BIOL, V99, P327, DOI 10.1083/jcb.99.1.327; ENDO Y, 1976, J BIOCHEM-TOKYO, V80, P1; EPPENBERGERCASTORI S, 1989, GLYCOCONJUGATE J, V6, P101, DOI 10.1007/BF01047893; Felner KM, 1998, BBA-MOL BASIS DIS, V1406, P115; FURUKAWA K, 1985, BIOCHEM J, V227, P573, DOI 10.1042/bj2270573; HarduinLepers A, 1995, GLYCOBIOLOGY, V5, P741, DOI 10.1093/glycob/5.8.741; HENDRICKS LC, 1991, J BIOL CHEM, V266, P17559; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; Jaskiewicz E, 1996, J BIOL CHEM, V271, P26395, DOI 10.1074/jbc.271.42.26395; Ju TZ, 2002, J BIOL CHEM, V277, P178, DOI 10.1074/jbc.M109060200; Kanie Y, 1998, ANAL BIOCHEM, V263, P240, DOI 10.1006/abio.1998.2762; Kingsley PD, 2000, GLYCOBIOLOGY, V10, P1317, DOI 10.1093/glycob/10.12.1317; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; Malissard M, 1996, EUR J BIOCHEM, V239, P340, DOI 10.1111/j.1432-1033.1996.0340u.x; MENDICINO J, 1982, J BIOL CHEM, V257, P3987; MESTECKY J, 1993, CONTRIB NEPHROL, V104, P172; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; Miege C, 1999, EUR J BIOCHEM, V265, P990, DOI 10.1046/j.1432-1327.1999.00801.x; Miyoshi E, 1999, BBA-GEN SUBJECTS, V1473, P9, DOI 10.1016/S0304-4165(99)00166-X; NAKAZAWA K, 1991, EUR J BIOCHEM, V196, P363, DOI 10.1111/j.1432-1033.1991.tb15825.x; NAVARATNAM N, 1988, EUR J BIOCHEM, V171, P623, DOI 10.1111/j.1432-1033.1988.tb13833.x; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; PILLER V, 1990, J BIOL CHEM, V265, P9264; Priatel JJ, 1997, GLYCOBIOLOGY, V7, P45, DOI 10.1093/glycob/7.1.45; Rottger S, 1998, J CELL SCI, V111, P45; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; Seko A, 1998, FEBS LETT, V440, P307, DOI 10.1016/S0014-5793(98)01458-6; Springer GF, 1997, J MOL MED, V75, P594, DOI 10.1007/s001090050144; THURNHER M, 1993, J CLIN INVEST, V91, P2103, DOI 10.1172/JCI116434; TOMANA M, 1995, ADV EXP MED BIOL, V376, P221; Tomana M, 1997, KIDNEY INT, V52, P509, DOI 10.1038/ki.1997.361; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Zhu GF, 1997, GLYCOBIOLOGY, V7, P987, DOI 10.1093/glycob/7.7.987	61	90	98	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					169	177		10.1074/jbc.M109056200	http://dx.doi.org/10.1074/jbc.M109056200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11673471	hybrid			2022-12-25	WOS:000173087900024
J	Pursglove, SE; Mulhern, TD; Mackay, JP; Hinds, MG; Booker, GW				Pursglove, SE; Mulhern, TD; Mackay, JP; Hinds, MG; Booker, GW			The solution structure and intramolecular associations of the Tec kinase Src homology 3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; X-LINKED AGAMMAGLOBULINEMIA; SH3 DOMAIN; CRYSTAL-STRUCTURE; BINDING; FAMILY; GENE; BTK; ACTIVATION; INSIGHTS	Tec is the prototypic member of a family of intracellular tyrosine kinases that includes Txk, Bmx, Itk, and Btk. Tee family kinases share similarities in domain structure with Src family kinases, but one of the features that differentiates them is a proline-rich region (PRR) preceding their Src homology (SH) 3 domain. Evidence that the PRR of Itk can bind in an intramolecular fashion to its SH3 domain and the lack of a regulatory tyrosine in the C terminus indicates that Tee kinases must be regulated by a different set of intramolecular interactions to the Src kinases. We have determined the solution structure of the Tee SH3 domain and have investigated interactions with its PRR, which contains two SH3-binding sites. We demonstrate that in vitro, the Tee PRR can bind in an intramolecular fashion to the SH3. However, the affinity is lower than that for dimerization via reciprocal PRR-SH3 association. Using site-directed mutagenesis we show that both sites can bind the Tee SH3 domain; site 1 ((155)KTLPPAP(161)) binds intramolecularly, while site 2 ((KRRPPPPIPP174)-K-165) cannot and binds in an intermolecular fashion. These distinct roles for the SH3 binding sites in Tee family kinases could be important for protein targeting and enzyme activation.	Univ Adelaide, Dept Mol Biosci, Adelaide, SA 5005, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; Univ Sydney, Dept Biochem, Sydney, NSW 2000, Australia; Biomol Res Inst, Parkville, Vic 3052, Australia	University of Adelaide; University of Melbourne; University of Sydney	Booker, GW (corresponding author), Univ Adelaide, Dept Mol Biosci, Adelaide, SA 5005, Australia.		Hinds, Mark Gavin/AAD-3653-2020; Mulhern, Terrence/A-1206-2007; Mackay, Joel/D-6834-2011	Hinds, Mark Gavin/0000-0002-2856-5375; Mackay, Joel/0000-0001-7508-8033; Mulhern, Terrence/0000-0002-1609-7498				ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Brazin KN, 2000, J MOL BIOL, V302, P607, DOI 10.1006/jmbi.2000.4091; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; Hansson H, 2001, FEBS LETT, V489, P67, DOI 10.1016/S0014-5793(00)02438-8; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kang SW, 2001, EMBO J, V20, P5692, DOI 10.1093/emboj/20.20.5692; KAWAKAMI Y, 1996, IMMUNOL LETT, V54, P133; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; MANO H, 1994, ONCOGENE, V9, P3205; MANO H, 1993, ONCOGENE, V8, P417; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Merkel AL, 1999, CYTOGENET CELL GENET, V84, P132, DOI 10.1159/000015240; Morrogh LM, 1999, EUR J IMMUNOL, V29, P2269; Morton CJ, 1996, STRUCTURE, V4, P705, DOI 10.1016/S0969-2126(96)00076-7; Mulhern TD, 1997, STRUCTURE, V5, P1313, DOI 10.1016/S0969-2126(97)00283-9; Mulhern TD, 2000, J MOL BIOL, V297, P989, DOI 10.1006/jmbi.2000.3610; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Patel HV, 1997, PROTEINS, V29, P545, DOI 10.1002/(SICI)1097-0134(199712)29:4<545::AID-PROT13>3.0.CO;2-M; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Pursglove SE, 1998, J BIOMOL NMR, V12, P461, DOI 10.1023/A:1008307417981; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIDERAS P, 1994, J IMMUNOL, V153, P5607; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SOMMERS CL, 1995, ONCOGENE, V11, P245; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; VIHINEN M, 1994, BIOCHEM BIOPH RES CO, V205, P1270, DOI 10.1006/bbrc.1994.2802; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Wishart DS, 1998, J BIOMOL NMR, V11, P329, DOI 10.1023/A:1008202230140; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamashita Y, 1996, JPN J CANCER RES, V87, P1106, DOI 10.1111/j.1349-7006.1996.tb03118.x; ZHU QL, 1994, J EXP MED, V180, P461, DOI 10.1084/jem.180.2.461	39	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					755	762		10.1074/jbc.M108318200	http://dx.doi.org/10.1074/jbc.M108318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11684687	hybrid			2022-12-25	WOS:000173087900098
J	Ren, DT; Yang, HP; Zhang, SQ				Ren, DT; Yang, HP; Zhang, SQ			Cell death mediated by MAPK is associated with hydrogen peroxide production in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DISEASE RESISTANCE; SIGNAL-TRANSDUCTION; OXIDATIVE BURST; HYPERSENSITIVE RESPONSE; FUNCTIONAL-ANALYSIS; DEFENSE RESPONSES; PATHOGEN DEFENSE; GENE; STRESS	Rapid and localized programmed cell death, known as the hypersensitive response (HR) is frequently associated with plant disease resistance. In contrast to our knowledge about the regulation and execution of apoptosis in animal system, information about plant HR is limited. Recent studies implicated the mitogen-activated protein kinase (MAPK) cascade in regulating plant HR cell death as well as several other defense responses during incompatible interactions between plants and pathogens. Here, we report the generation of transgenic Arabidopsis plants that express the active mutants of AtMEK4 and AtMEK5, two closely related MAPK kinases under the control of a steroid-inducible promoter. Induction of the transgene expression by the application of dexamethasone, a steroid, leads to HR-like cell death, which is preceded by the activation of endogenous MAPKs and the generation of hydrogen peroxide. Both prolonged MAPK activation and reactive oxygen species generation have been implicated in the regulation of HR cell death induced by incompatible pathogens. As a result, we speculate that the prolonged activation of the MAPK pathway in cells could disrupt the redox balance, which leads to the generation of reactive oxygen species and eventually HR cell death.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Zhang, SQ (corresponding author), Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA.	zhangsh@missouri.edu	Zhang, Shuqun/X-6343-2019					Adam AL, 1997, PLANT PHYSIOL, V115, P853, DOI 10.1104/pp.115.2.853; Allan AC, 1997, PLANT CELL, V9, P1559, DOI 10.1105/tpc.9.9.1559; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; Bolwell GP, 1999, CURR OPIN PLANT BIOL, V2, P287, DOI 10.1016/S1369-5266(99)80051-X; Caffrey DR, 1999, J MOL EVOL, V49, P567, DOI 10.1007/PL00006578; Cardinale F, 2000, J BIOL CHEM, V275, P36734, DOI 10.1074/jbc.M007418200; Chandra S, 1996, P NATL ACAD SCI USA, V93, P13393, DOI 10.1073/pnas.93.23.13393; Clough SJ, 2000, P NATL ACAD SCI USA, V97, P9323, DOI 10.1073/pnas.150005697; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Corpas FJ, 2001, TRENDS PLANT SCI, V6, P145, DOI 10.1016/S1360-1385(01)01898-2; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Desikan R, 2001, PLANT PHYSIOL, V126, P1579, DOI 10.1104/pp.126.4.1579; Ditt RF, 2001, P NATL ACAD SCI USA, V98, P10954, DOI 10.1073/pnas.191383498; Dong XN, 1998, CURR OPIN PLANT BIOL, V1, P316, DOI 10.1016/1369-5266(88)80053-0; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; GALLIE DR, 1987, NUCLEIC ACIDS RES, V15, P3257, DOI 10.1093/nar/15.8.3257; Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8; GOODMAN RN, 1995, HYPERSENSITIVE DEFEN; Grant JJ, 2000, PLANT PHYSIOL, V124, P21, DOI 10.1104/pp.124.1.21; HE SY, 1994, MOL PLANT MICROBE IN, V7, P289, DOI 10.1094/MPMI-7-0289; Hoyos ME, 2000, PLANT PHYSIOL, V122, P1355, DOI 10.1104/pp.122.4.1355; Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853; Jonak C, 1996, P NATL ACAD SCI USA, V93, P11274, DOI 10.1073/pnas.93.20.11274; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lam E, 2001, NATURE, V411, P848, DOI 10.1038/35081184; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Ligterink W, 1997, SCIENCE, V276, P2054, DOI 10.1126/science.276.5321.2054; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martin GB, 1999, CURR OPIN PLANT BIOL, V2, P273, DOI 10.1016/S1369-5266(99)80049-1; McDowell JM, 2000, TRENDS BIOCHEM SCI, V25, P79, DOI 10.1016/S0968-0004(99)01532-7; Mizoguchi T, 1997, TRENDS BIOTECHNOL, V15, P15, DOI 10.1016/S0167-7799(96)10074-3; Mizoguchi T, 1996, P NATL ACAD SCI USA, V93, P765, DOI 10.1073/pnas.93.2.765; Munnik T, 1999, PLANT J, V20, P381, DOI 10.1046/j.1365-313x.1999.00610.x; Nuhse TS, 2000, J BIOL CHEM, V275, P7521, DOI 10.1074/jbc.275.11.7521; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; Petersen M, 2000, CELL, V103, P1111, DOI 10.1016/S0092-8674(00)00213-0; Rajasekhar VK, 1999, PLANT PHYSIOL, V120, P1137, DOI 10.1104/pp.120.4.1137; Richberg MH, 1998, CURR OPIN PLANT BIOL, V1, P480, DOI 10.1016/S1369-5266(98)80039-3; Romeis T, 2001, CURR OPIN PLANT BIOL, V4, P407, DOI 10.1016/S1369-5266(00)00193-X; Romeis T, 1999, PLANT CELL, V11, P273, DOI 10.1105/tpc.11.2.273; Scheel D, 1998, CURR OPIN PLANT BIOL, V1, P305, DOI 10.1016/1369-5266(88)80051-7; SEO S, 1995, SCIENCE, V270, P1988, DOI 10.1126/science.270.5244.1988; Somssich IE, 1998, TRENDS PLANT SCI, V3, P86, DOI 10.1016/S1360-1385(98)01199-6; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; Suzuki K, 1999, PLANT PHYSIOL, V119, P1465, DOI 10.1104/pp.119.4.1465; Tena G, 2001, CURR OPIN PLANT BIOL, V4, P392, DOI 10.1016/S1369-5266(00)00191-6; ThordalChristensen H, 1997, PLANT J, V11, P1187, DOI 10.1046/j.1365-313X.1997.11061187.x; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yang KY, 2001, P NATL ACAD SCI USA, V98, P741, DOI 10.1073/pnas.98.2.741; Zhang SQ, 1998, PLANT CELL, V10, P435, DOI 10.1105/tpc.10.3.435; Zhang SQ, 2001, TRENDS PLANT SCI, V6, P520, DOI 10.1016/S1360-1385(01)02103-3; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7433, DOI 10.1073/pnas.95.13.7433; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7225, DOI 10.1073/pnas.95.12.7225; Zhang SQ, 2001, PLANT CELL, V13, P1877, DOI 10.1105/tpc.13.8.1877; Zhang SQ, 1997, PLANT CELL, V9, P809, DOI 10.1105/tpc.9.5.809; Zhang SQ, 2000, PLANT J, V23, P339, DOI 10.1046/j.1365-313x.2000.00780.x	64	331	360	5	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					559	565		10.1074/jbc.M109495200	http://dx.doi.org/10.1074/jbc.M109495200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11687590	hybrid			2022-12-25	WOS:000173087900074
J	Liden, M; Romert, A; Tryggvason, K; Persson, B; Eriksson, U				Liden, M; Romert, A; Tryggvason, K; Persson, B; Eriksson, U			Biochemical defects in 11-cis-retinol dehydrogenase mutants associated with fundus albipunctatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							11-CIS RETINOL DEHYDROGENASE; RDH5 GENE; MEMBRANE TOPOLOGY; JAPANESE PATIENTS; EXPRESSION; MUTATIONS; IDENTIFICATION; LOCALIZATION; TRANSPORT; RHODOPSIN	Mutations in the gene encoding 11-cis-retinol dehydrogenase (RDH5; EC 1.1.1.105) are associated with fundus albipunctatus, an autosomal recessive eye disease characterized by stationary night blindness and accumulation of white spots in the retina. In addition, some mutated alleles are associated with development of cone dystrophy, especially in elderly patients. The numbers of identified RDH5 mutations linked to fundus albipunctatus have increased considerably during recent years. In this work, we have characterized the biochemical and cell biological properties of 11 mutants of RDH5 to understand the molecular pathology of the disease. All RDH5 mutants showed decreased protein stability and subcellular mislocalization and, in most cases, loss of enzymatic activity in vitro and in vivo. Surprisingly, mutant A294P displays significant enzymatic activity. Cross-linking studies and molecular modeling showed that RDH5 is dimeric, and co-expression analyses of wild-type and mutated alleles showed that the mutated enzymes, in a transdominant-negative manner, influenced the in vivo enzymatic properties of functional variants of the enzyme, particularly the A294P mutant. Thus, under certain conditions, nonfunctional alleles act in a dominant-negative way on functional but relatively unstable mutated alleles. However, in heterozygous individuals carrying one wild-type allele, the disease is recessive, probably due to the stability of the wild-type enzyme.	Karolinska Inst, Stockholm Branch, Ludwig Inst Canc Res, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Karolinska Inst, Stockholm Bioinformat Ctr, S-17177 Stockholm, Sweden	Karolinska Institutet; Ludwig Institute for Cancer Research; Karolinska Institutet; Karolinska Institutet	Eriksson, U (corresponding author), Karolinska Inst, Stockholm Branch, Ludwig Inst Canc Res, Box 240, S-17177 Stockholm, Sweden.	ueri@licr.ki.se						Cideciyan AV, 2000, VISUAL NEUROSCI, V17, P667, DOI 10.1017/S0952523800175029; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Driessen CAGG, 2001, OPHTHALMOLOGY, V108, P1479, DOI 10.1016/S0161-6420(01)00640-6; Dryja TP, 2000, AM J OPHTHALMOL, V130, P547, DOI 10.1016/S0002-9394(00)00737-6; GHOSH D, 1995, STRUCTURE, V3, P503, DOI 10.1016/S0969-2126(01)00183-6; Gonzalez-Fernandez F, 1999, MOL VIS, V5, pU1; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Hirose E, 2000, INVEST OPHTH VIS SCI, V41, P3933; Kallberg Y, 1999, BIOINFORMATICS, V15, P260, DOI 10.1093/bioinformatics/15.3.260; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kuroiwa S, 2000, AM J OPHTHALMOL, V130, P672, DOI 10.1016/S0002-9394(00)00765-0; Li TS, 1996, P NATL ACAD SCI USA, V93, P14176, DOI 10.1073/pnas.93.24.14176; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; Moreno A, 1996, FEBS LETT, V395, P99, DOI 10.1016/0014-5793(96)01009-5; Nakamura M, 2000, INVEST OPHTH VIS SCI, V41, P3925; Nilsson I, 1998, J MOL BIOL, V284, P1185, DOI 10.1006/jmbi.1998.2219; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Romert A, 2000, EXP CELL RES, V256, P338, DOI 10.1006/excr.2000.4817; Romert A, 1998, P NATL ACAD SCI USA, V95, P4404, DOI 10.1073/pnas.95.8.4404; Saari JC, 2000, METHOD ENZYMOL, V316, P359; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Simon A, 1996, GENOMICS, V36, P424, DOI 10.1006/geno.1996.0487; Simon A, 1999, J CELL SCI, V112, P549; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tryggvason K, 2001, J BIOL CHEM, V276, P19253, DOI 10.1074/jbc.M100215200; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Wada Y, 2000, INVEST OPHTH VIS SCI, V41, P1894; Wang J, 1999, BIOCHEM J, V338, P23, DOI 10.1042/0264-6021:3380023; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707	31	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49251	49257		10.1074/jbc.M107337200	http://dx.doi.org/10.1074/jbc.M107337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11675386	hybrid			2022-12-25	WOS:000173922100083
J	Cartwright, IJ; Higgins, JA				Cartwright, IJ; Higgins, JA			Direct evidence for a two-step assembly of ApoB48-containing lipoproteins in the lumen of the smooth endoplasmic reticulum of rabbit enterocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEIN; APOLIPOPROTEIN-B; FAT-ABSORPTION; MODEL; RAT; CHYLOMICRONS; DEGRADATION; APOPROTEIN; SECRETION	The aim of this study was to investigate the types and characteristics of chylomicron precursors in the lumen of the secretory compartment of rabbit enterocytes. Luminal contents were separated into density subfractions in two continuous self-generating gradients of different density profiles. In enterocytes from rabbits fed a low fat diet, newly synthesized and immunodetectable apoB48 was only in the subfraction of density similar to high density lipoprotein (dense particles); the luminal triacylglycerol (TAG) content was low and only in the subfraction of density similar to that of chylomicrons/very low density lipoproteins (light particles). After feeding fat, newly synthesized, and immunodetectable apoB48 was in both dense (phospholipid-rich) and light (TAG-rich) particles. Luminal TAG mass and synthesis increased after fat feeding and was only in light particles. Pulse-chase experiments showed that the luminal-radiolabeled apoB48 lost from the dense particles was recovered in the light particles and the secreted chylomicrons. All of the light particle lipids (mass and newly synthesized) co-immunoprecipitated with apoB48. However, in the dense particles, there was a preferential co-precipitation of the preexisting rather than newly synthesized phospholipid. Assembly of apoB48-containing TAG-enriched lipoproteins is therefore a two-step process. The first step produces dense apoB48 phospholipid-rich particles, which accumulate in the smooth endoplasmic reticulum lumen. In the second step, these dense particles rapidly acquire the bulk of the TAG and additional phospholipid in a single and rapid step.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Higgins, JA (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	J.Higgins@sheffield.ac.uk						ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; Carraway M, 2000, BIOCHEMISTRY-US, V39, P9737, DOI 10.1021/bi000791h; Cartwright IJ, 1999, J LIPID RES, V40, P1357; Cartwright IJ, 1996, BIOCHEM J, V314, P977, DOI 10.1042/bj3140977; Cartwright IJ, 1999, J LIPID RES, V40, P1858; Cartwright IJ, 1997, J LIPID RES, V38, P531; Cartwright IJ, 2000, J LIPID RES, V41, P1728; CARTWRIGHT IJ, 1993, J BIOL CHEM, V268, P20937; CARTWRIGHT IJ, 1995, BIOCHEM J, V310, P977; CHRISTENSEN NJ, 1983, J LIPID RES, V24, P1229; Davidson Nicholas O., 1994, P1909; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Erickson S.K., 1995, INT CONGR SER, P414; FORD T, 1985, IODINATED DENSITY GR, P23; GLICKMAN RM, 1986, P NATL ACAD SCI USA, V83, P5296, DOI 10.1073/pnas.83.14.5296; Hamilton RL, 1998, J LIPID RES, V39, P1543; HIGGINS JA, 2000, ATHEROSCLEROSIS, P37; Hirano K, 1996, J BIOL CHEM, V271, P9887, DOI 10.1074/jbc.271.17.9887; Hussain MM, 2000, ATHEROSCLEROSIS, V148, P1; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Hussain MM, 1996, BBA-LIPID LIPID MET, V1300, P151, DOI 10.1016/0005-2760(96)00041-0; JONES AL, 1971, J LIPID RES, V12, P580; Kendrick JS, 1999, J LIPID RES, V40, P504; Kendrick JS, 2001, BIOCHEM J, V356, P821, DOI 10.1042/0264-6021:3560821; Kumar NS, 1997, AM J PHYSIOL-GASTR L, V273, pG18, DOI 10.1152/ajpgi.1997.273.1.G18; KUMAR SN, 1999, AM J PHYSIOL, V275, pG378; LIN MCM, 1994, J BIOL CHEM, V269, P29138; Luchoomun J, 1999, J BIOL CHEM, V274, P19565, DOI 10.1074/jbc.274.28.19565; Mansbach CM, 1998, J LIPID RES, V39, P963; Morrison JR, 1996, P NATL ACAD SCI USA, V93, P7154, DOI 10.1073/pnas.93.14.7154; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; ROY CC, 1987, GASTROENTEROLOGY, V92, P390, DOI 10.1016/0016-5085(87)90133-8; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; Rustaeus S, 1999, J NUTR, V129, p463S, DOI 10.1093/jn/129.2.463S; SMALL DM, 1984, J LIPID RES, V25, P1490; STRAUSS EW, 1966, J LIPID RES, V7, P307; Tso Patrick, 1994, P1867; WILKINSON J, 1993, J LIPID RES, V34, P815; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365	41	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48048	48057		10.1074/jbc.M104229200	http://dx.doi.org/10.1074/jbc.M104229200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11675380	hybrid			2022-12-25	WOS:000172927000044
J	Lim, D; Kyozuka, K; Gragnaniello, G; Carafoli, E; Santella, L				Lim, D; Kyozuka, K; Gragnaniello, G; Carafoli, E; Santella, L			NAADP(+) initiates the Ca2+ response during fertilization of starfish oocytes	FASEB JOURNAL			English	Article						Ca2+ response at fertilization; nicotinic acid adenine nucleotide phosphate; inositol 1,4,5-trisphosphate; starfish oocytes	SEA-URCHIN EGGS; ADENINE-DINUCLEOTIDE PHOSPHATE; CYCLIC ADP-RIBOSE; INDUCED CALCIUM OSCILLATIONS; GTP-BINDING PROTEIN; BETA-GAMMA-SUBUNIT; INOSITOL TRISPHOSPHATE; ASCIDIAN OOCYTES; 1-METHYLADENINE-INDUCED MATURATION; MEIOSIS REINITIATION	We have explored the role of the recently discovered second messenger nicotinic acid adenine nucleotide phosphate (NAADP(+)) in Ca2+ swings that accompany the fertilization process in starfish oocytes. The injection of NAADP(+) deep into the cytoplasm of oocytes matured by the hormone 1-methyladenine (1-MA), mobilized Ca2+ exclusively in the cortical layer, showing that the NAADP(+)-sensitive Ca2+ pool is restricted to the subplasma membrane region of the cell. At variance with this, InsP(3) initiated the liberation of Ca2+ next to the point of injection in the center of the cell. The initial cortical Ca2+ liberation induced by NAADP(+) was followed by a spreading of the Ca2+ wave to the remainder of the cell and by a massive cortical granule exocytosis similar to that routinely observed on injection of InsP(3). A striking difference in the responses to NAADP(+) and InsP(3) was revealed by the removal of the nucleus from immature oocytes, i.e., from oocytes not treated with 1-MA. Whereas the Ca2+ response and the cortical granule exocytosis induced by NAADP(+) were unaffected by the removal of the nucleus, the Ca2+ response promoted by InsP(3) was significantly slowed. In addition, the cortical granule exocytosis was completely abolished. When enucleated oocytes were fertilized, the spermatozoon still promoted the Ca2+ wave and normal cortical exocytosis, strongly suggesting that the Ca2+ response was mediated by NAADP(+) and not by InsP(3). InsP(3)-sensitive Ca2+ stores may mediate the propagation of the wave initiated by NAADP(+) since its spreading was strongly affected by removal of the nucleus.	Staz Zool Anton Dohrn, Cell Biol Lab, I-80121 Naples, Italy; Asamushi Marine Biol Stn, Asamushi, Aomori 0393501, Japan; Univ Padua, Dept Biochem, I-35121 Padua, Italy	Stazione Zoologica Anton Dohrn di Napoli; University of Padua	Santella, L (corresponding author), Staz Zool Anton Dohrn, Cell Biol Lab, Villa Comunale, I-80121 Naples, Italy.	santella@alpha.szn.it	Lim, Dmitry/H-9101-2012; Carafoli, Ernesto/K-5192-2016; Santella, Luigia/AAM-3524-2020	Carafoli, Ernesto/0000-0002-7826-0094; Santella, Luigia/0000-0001-7159-0499				Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; Auld A, 2000, BBA-MOL CELL RES, V1497, P11, DOI 10.1016/S0167-4889(00)00045-8; Calakos N, 1996, PHYSIOL REV, V76, P1; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; CHIBA K, 1989, DEV GROWTH DIFFER, V31, P447; CHIBA K, 1990, DEV BIOL, V140, P300, DOI 10.1016/0012-1606(90)90080-3; CHIBA K, 1993, MOL BIOL CELL, V4, P1027, DOI 10.1091/mbc.4.10.1027; Ciapa B, 2000, BIOL CELL, V92, P215, DOI 10.1016/S0248-4900(00)01065-0; CRETON R, 1995, DEV GROWTH DIFFER, V37, P703; DALE B, 1991, EXP CELL RES, V192, P302, DOI 10.1016/0014-4827(91)90190-6; Deguchi R, 1996, DEVELOPMENT, V122, P3651; Deng MQ, 2000, BIOL REPROD, V62, P873, DOI 10.1095/biolreprod62.4.873; Flament S, 2000, ZYGOTE, V8, P3, DOI 10.1017/S0967199400000770; Galione A, 2000, BIOL CELL, V92, P197, DOI 10.1016/S0248-4900(00)01070-4; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; Genazzani AA, 1997, TRENDS PHARMACOL SCI, V18, P108, DOI 10.1016/S0165-6147(96)01036-X; Genazzani AA, 1997, BRIT J PHARMACOL, V121, P1489, DOI 10.1038/sj.bjp.0701295; Gillo B, 1996, J PHOTOCH PHOTOBIO B, V35, P77, DOI 10.1016/1011-1344(96)07303-4; Giusti AF, 1999, DEV BIOL, V208, P189, DOI 10.1006/dbio.1998.9187; HAGIWARA S, 1975, J GEN PHYSIOL, V65, P617, DOI 10.1085/jgp.65.5.617; Halabisky B, 2000, J NEUROSCI, V20, P5124; HIRAI S, 1971, EXP CELL RES, V68, P137, DOI 10.1016/0014-4827(71)90595-7; JAFFE LA, 1993, J CELL BIOL, V121, P775, DOI 10.1083/jcb.121.4.775; JAFFE LA, 1993, DEV BIOL, V156, P556; JAFFE LF, 1990, MECH FERTILIZATION, V3, P127; Jones KT, 1998, INT J DEV BIOL, V42, P1; KANATANI H, 1969, NATURE, V221, P273, DOI 10.1038/221273a0; KINOSITA K JR, 1977, Proceedings of the National Academy of Sciences of the United States of America, V74, P1923, DOI 10.1073/pnas.74.5.1923; Kishimoto T, 1999, DEV BIOL, V214, P1, DOI 10.1006/dbio.1999.9393; Kyozuka K, 1998, DEVELOPMENT, V125, P4099; Leclerc C, 2000, BIOL CELL, V92, P285, DOI 10.1016/S0248-4900(00)01069-8; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 2000, J CELL SCI, V113, P4413; Levasseur M, 2000, DEVELOPMENT, V127, P631; Leveque C, 2000, J NEUROCHEM, V74, P367, DOI 10.1046/j.1471-4159.2000.0740367.x; LONGO FJ, 1995, ZYGOTE, V3, P225, DOI 10.1017/S0967199400002628; MCDOUGALL A, 1995, CURR BIOL, V5, P318, DOI 10.1016/S0960-9822(95)00062-5; McDougall A, 1998, DEVELOPMENT, V125, P4451; McDougall Alex, 1993, Zygote, V1, P35; McGuinness OM, 1996, DEVELOPMENT, V122, P2199; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MIYAZAKI S, 1979, DEV BIOL, V70, P327, DOI 10.1016/0012-1606(79)90031-9; MOHRI T, 1995, DEV BIOL, V172, P139, DOI 10.1006/dbio.1995.0011; PAREKH AB, 1995, PFLUG ARCH EUR J PHY, V430, P954, DOI 10.1007/BF01837409; PerezTerzic CM, 1995, BIOCHEM J, V312, P955, DOI 10.1042/bj3120955; PETERSEN CC, 1996, BIOCHEM J, V307, P663; RIDGWAY EB, 1977, P NATL ACAD SCI USA, V74, P623, DOI 10.1073/pnas.74.2.623; ROSSIGNOL DP, 1983, BIOCHIM BIOPHYS ACTA, V763, P346, DOI 10.1016/0167-4889(83)90096-4; Runft LL, 2000, DEVELOPMENT, V127, P3227; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; Santella L, 1997, CELL CALCIUM, V22, P11, DOI 10.1016/S0143-4160(97)90085-3; Santella L, 1999, EXP CELL RES, V248, P567, DOI 10.1006/excr.1999.4425; SCHMIDT T, 1982, DEV BIOL, V90, P284, DOI 10.1016/0012-1606(82)90377-3; SHILLING F, 1989, DEV BIOL, V133, P605, DOI 10.1016/0012-1606(89)90063-8; STEINHARDT R, 1977, DEV BIOL, V58, P185, DOI 10.1016/0012-1606(77)90084-7; STEVENS M, 1970, EXP CELL RES, V59, P482, DOI 10.1016/0014-4827(70)90658-0; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; Stricker SA, 1999, MICROSC RES TECHNIQ, V46, P356, DOI 10.1002/(SICI)1097-0029(19990915)46:6<356::AID-JEMT4>3.0.CO;2-6; Stricker SA, 1998, DEV BIOL, V203, P305, DOI 10.1006/dbio.1998.9058; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TURNER PR, 1986, J CELL BIOL, V102, P70, DOI 10.1083/jcb.102.1.70; Vogel SS, 1999, P NATL ACAD SCI USA, V96, P5019, DOI 10.1073/pnas.96.9.5019; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0	64	84	85	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2257	2267		10.1096/fj.01-0157com	http://dx.doi.org/10.1096/fj.01-0157com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641253				2022-12-25	WOS:000171920400038
J	Kim, WH; Hong, F; Jaruga, B; Hu, ZY; Fan, SJ; Liang, TJ; Gao, B				Kim, WH; Hong, F; Jaruga, B; Hu, ZY; Fan, SJ; Liang, TJ; Gao, B			Additive activation of hepatic NF-kappa B by ethanol and HBX or HCV core protein: involvement of TNF-alpha receptor I-independent and -dependent mechanisms	FASEB JOURNAL			English	Article						CYP2E1; ethanol metabolism; hepatitis; nuclear factor-kappa B; liver	C VIRUS-INFECTION; NECROSIS-FACTOR-ALPHA; SIGNAL-TRANSDUCTION PATHWAY; ALCOHOLIC LIVER-DISEASE; TRANSCRIPTION FACTORS; INTERFERON THERAPY; X PROTEIN; DNA-BINDING; ACETALDEHYDE; EXPRESSION	Alcohol consumption and viral hepatitis infection synergistically accelerate liver injury, but the underlying mechanism is not fully understood. Here we have examined the effects of ethanol on hepatitis B protein X (HBX)- or hepatitis C core protein (HCV core protein)- mediated activation of NF-kappaB, a critical signal in hepatic injury, regeneration, and tumor transformation. Acute ethanol or acetaldehyde exposure potentiates HBX or HCV core protein activation of NF-kappaB in primary mouse hepatocytes. Such potentiation can be abolished by blocking ethanol metabolism or overexpression of dominant negative NF-kappaB inducing kinase (NIK), I kappaB kinase (IKK), or I kappaB. Moreover, pertussis toxin attenuates NF-kappaB activation induced by acetaldehyde but not by HBX or HCV core protein, whereas HBX or HCV core protein-mediated activation of NF-kappaB is abolished completely in tumor necrosis factor receptor 1 (TNFR1) (-/-) hepatocytes. Finally, chronic ethanol consumption induces hepatic CYP2E1 protein expression and potentiates HBX or HCV core protein activation of NF-kappaB in the liver. These findings suggest that ethanol activates hepatic NF-kappaB via its metabolism and that HBX or HCV core protein activates hepatic NF-kappaB via TNFR1. With the essential role of TNFR1 in alcoholic liver injury, targeting TNFR1 by hepatitis viral proteins could contribute to cooperative effects of alcohol consumption and viral hepatitis on liver disease.	NIAAA, Sect Liver Biol, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA; NIDDKD, Liver Dis Sect, NIH, Bethesda, MD 20892 USA; Long Isl Jewish Med Ctr, Albert Einstein Coll Med, New Hyde Pk, NY 11042 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Northwell Health; Yeshiva University	Gao, B (corresponding author), NIAAA, Sect Liver Biol, Lab Physiol Studies, NIH, Pk Bldg,Room 120,12420 Parklawn Dr,MSC 8115, Bethesda, MD 20892 USA.	bgao@mail.nih.gov		Kim, Won-Ho/0000-0002-4849-472X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054501, ZIADK054500, Z01DK054500, Z01DK054502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000367] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Anania FA, 1999, ALCOHOL CLIN EXP RES, V23, P279; Andrisani OM, 1999, INT J ONCOL, V15, P373; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Banerjee R, 2000, HEPATOLOGY, V32, P367, DOI 10.1053/jhep.2000.9197; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BRECHOT C, 1982, NEW ENGL J MED, V306, P1384, DOI 10.1056/NEJM198206103062302; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CLEMENS DL, 1995, ARCH BIOCHEM BIOPHYS, V321, P311, DOI 10.1006/abbi.1995.1400; Cook RT, 1998, ALCOHOL CLIN EXP RES, V22, P1927, DOI 10.1097/00000374-199812000-00007; Corrao G, 1998, HEPATOLOGY, V27, P914, DOI 10.1002/hep.510270404; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; Dai Y, 1995, J PHARMACOL EXP THER, V275, P1614; Di Bisceglie AM, 1998, LANCET, V351, P351, DOI 10.1016/S0140-6736(97)07361-3; DIEHL AM, 1990, GASTROENTEROLOGY, V99, P1105, DOI 10.1016/0016-5085(90)90631-A; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; FORKERT PG, 1991, CARCINOGENESIS, V12, P2259, DOI 10.1093/carcin/12.12.2259; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GAO B, 1995, J BIOL CHEM, V270, P5614, DOI 10.1074/jbc.270.10.5614; Gao B, 1996, MOL CELL BIOL, V16, P5997; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; Hoek JB, 1999, HEPATOLOGY, V29, P1602, DOI 10.1002/hep.510290536; Hong F, 2001, FASEB J, V15, P1595, DOI 10.1096/fj.00-0908fje; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Iimuro Y, 1997, HEPATOLOGY, V26, P1530; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; Kawamura T, 1997, HEPATOLOGY, V25, P1014, DOI 10.1002/hep.510250437; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KEKULE AS, 1992, ARCH VIROL, P63; Khan KN, 2000, ALCOHOL ALCOHOLISM, V35, P286, DOI 10.1093/alcalc/35.3.286; Kondili LA, 1998, EPIDEMIOL INFECT, V121, P391, DOI 10.1017/S0950268898001216; Lai MMC, 2000, HEPATOLOGY, V32, P427, DOI 10.1053/jhep.2000.9856; LAUER U, 1994, HEPATOLOGY, V19, P23, DOI 10.1002/hep.1840190106; LOBOALFONSO J, 1997, FOCUS, V17, P6; MAUCH TJ, 1986, HEPATOLOGY, V6, P263, DOI 10.1002/hep.1840060218; MENDENHALL CL, 1993, AM J GASTROENTEROL, V88, P1022; Mochida S, 1996, ALCOHOL CLIN EXP RES, V20, pA371, DOI 10.1111/j.1530-0277.1996.tb01811.x; Nalpas B, 1998, ALCOHOL ALCOHOLISM, V33, P202; Nanji AA, 1999, HEPATOLOGY, V30, P934, DOI 10.1002/hep.510300402; Nevins CL, 1999, DIGEST DIS SCI, V44, P1236, DOI 10.1023/A:1026605130185; Nguyen VAT, 2000, BIOCHEM J, V349, P427, DOI 10.1042/0264-6021:3490427; NICHOLLS RM, 1994, ALCOHOL ALCOHOLISM, V29, P149; NIEMELA O, 1991, J CLIN INVEST, V87, P1367, DOI 10.1172/JCI115141; Niemela O, 1998, ALCOHOL CLIN EXP RES, V22, P2118, DOI 10.1111/j.1530-0277.1998.tb05925.x; NIEMELA O, 1994, LAB INVEST, V70, P537; Ohnishi K, 1996, AM J GASTROENTEROL, V91, P1374; Ohta S, 1998, PREV MED, V27, P461, DOI 10.1006/pmed.1998.0298; OKAZAKI T, 1994, SCAND J GASTROENTERO, V29, P1039, DOI 10.3109/00365529409094883; OSHITA M, 1994, HEPATOLOGY, V20, P1115; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Regev A, 1999, ALCOHOL CLIN EXP RES, V23, P1543, DOI 10.1111/j.1530-0277.1999.tb04679.x; Roman J, 1999, HEPATOLOGY, V30, P1473, DOI 10.1002/hep.510300623; Roman J, 2000, J BIOL CHEM, V275, P14684, DOI 10.1074/jbc.275.19.14684; Rosman AS, 1996, AM J GASTROENTEROL, V91, P498; SAWADA M, 1993, ALCOHOL ALCOHOLISM, V28, P85, DOI 10.1093/alcalc/28.Supplement_1B.85; SCHENKER S, 1995, ALCOHOL CLIN EXP RES, V19, P1364, DOI 10.1111/j.1530-0277.1995.tb01626.x; Schiff Eugene R., 1999, American Journal of Medicine, V107, p95S; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; WATSON RR, 1994, ALCOHOL ALCOHOLISM, V29, P131; Weil R, 1999, MOL CELL BIOL, V19, P6345; Wheeler MD, 2000, HEPATOLOGY, V32, P1050, DOI 10.1053/jhep.2000.19339; Wiley TE, 1998, HEPATOLOGY, V28, P805, DOI 10.1002/hep.510280330; Wu Jian, 1999, Frontiers in Bioscience, V4, pd520; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9; You LR, 1999, J VIROL, V73, P1672, DOI 10.1128/JVI.73.2.1672-1681.1999; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	76	66	70	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2551	+		10.1096/fj.01-0217	http://dx.doi.org/10.1096/fj.01-0217			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641261	Bronze			2022-12-25	WOS:000171372700023
J	Antollini, SS; Barrantes, FJ				Antollini, SS; Barrantes, FJ			Unique effects of different fatty acid species on the physical properties of the Torpedo acetylcholine receptor membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANES; GENERALIZED POLARIZATION; LAURDAN FLUORESCENCE; SECONDARY STRUCTURE; LIPID-COMPOSITION; ARACHIDONIC-ACID; CHOLESTEROL; PROTEIN; PHOSPHOLIPIDS; CALIFORNICA	To study the effects produced by free fatty acids (FFA) on the biophysical properties of Torpedo marmorata nicotinic acetylcholine receptor-rich native membranes and to investigate the topology of their binding site(s), fluorescence measurements were carried out using the fluorescent probe Laurdan (6-dodecanoyl-2-(dimethylamino) naphthalene) and ADIFAB, an Acrylodan-derivatized intestinal fatty acid-binding protein. The generalized polarization (GP) of the former probe was used to learn about the physical state of the membrane upon FFA binding. Saturated FFA induced a slight increase in GP, whereas cis-unsaturated fatty acids decreased GP. Double bond isomerism could also be distinguished; oleic acid (18:1cis) induced a net disordering effect, whereas elaidic acid (18:1trans) produced no changes in GP. The changes in the efficiency of the Forster energy transfer from the protein to Laurdan brought about by addition of FFA, together with the distances involved in this process, indicate that all FFA studied share a common site at the lipid-protein interface. However, despite being located at the same site, each class of FFA differs in its effect on the physical properties of the membrane. These data lead us to suggest that it is the direct action of FFA at the lipid-protein interface, displacing essential lipids from their sites rather than changes in bulk properties such as membrane fluidity that accounts for the effect of FFA on the acetylcholine receptor membrane.	Inst Invest Bioquim Bahia Blanca, Bahia Blanca, Argentina; UNESCO, Chair Biophys & Mol Neurobiol, Bahia Blanca, Argentina		Barrantes, FJ (corresponding author), Inst Invest Bioquim Bahia Blanca, B8000FWB, Bahia Blanca, Argentina.		Barrantes, Francisco J./HCH-0258-2022	Barrantes, Francisco J./0000-0002-4745-681X	FOGARTY INTERNATIONAL CENTER [R03TW001225] Funding Source: NIH RePORTER; FIC NIH HHS [1RO3-TW01225-01] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Addona GH, 1998, BBA-BIOMEMBRANES, V1370, P299, DOI 10.1016/S0005-2736(97)00280-0; ANDREASEN TJ, 1980, BIOCHEMISTRY-US, V19, P4719, DOI 10.1021/bi00561a027; ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; Antollini SS, 1996, BIOPHYS J, V70, P1275, DOI 10.1016/S0006-3495(96)79684-4; Antollini SS, 1998, BIOCHEMISTRY-US, V37, P16653, DOI 10.1021/bi9808215; ANTOLLINI SS, 1999, BIOPHYS J, V76, P370; Baenziger JE, 1999, BIOCHEMISTRY-US, V38, P4905, DOI 10.1021/bi990181l; Baenziger JE, 2000, J BIOL CHEM, V275, P777, DOI 10.1074/jbc.275.2.777; BARRANTES FJ, 1993, FASEB J, V7, P1460, DOI 10.1096/fasebj.7.15.8262330; Barrantes FJ, 2000, KIDNEY INT, V57, P1382, DOI 10.1046/j.1523-1755.2000.00979.x; BARRANTES FJ, 1982, NEURORECEPTORS, P315; BARRY MA, 1993, MICROSC RES TECHNIQ, V26, P231, DOI 10.1002/jemt.1070260306; BHUSHAN A, 1993, BIOPHYS J, V64, P716, DOI 10.1016/S0006-3495(93)81431-0; BHUSHAN A, 1990, BIOCHIM BIOPHYS ACTA, V1027, P93, DOI 10.1016/0005-2736(90)90053-Q; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BOUZAT CB, 1993, RECEPTOR CHANNEL, V1, P251; Corbin J, 1998, BBA-BIOMEMBRANES, V1414, P65, DOI 10.1016/S0005-2736(98)00153-9; CRIADO M, 1982, BIOCHEMISTRY-US, V21, P3622, DOI 10.1021/bi00258a015; CRIADO M, 1984, J BIOL CHEM, V259, P9188; Dreger M, 1997, BIOCHEMISTRY-US, V36, P839, DOI 10.1021/bi960666z; FERNANDEZBALLESTER G, 1994, BIOCHEM SOC T, V22, P776, DOI 10.1042/bst0220776; FONG TM, 1987, BIOCHEMISTRY-US, V26, P3871, DOI 10.1021/bi00387a020; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GIRAUDAT J, 1985, BIOCHEMISTRY-US, V24, P3121, DOI 10.1021/bi00334a008; GUTIERREZMERINO C, 1995, BIOCHEMISTRY-US, V34, P4846, DOI 10.1021/bi00014a042; HARTIG PR, 1979, BIOCHEMISTRY-US, V18, P1146, DOI 10.1021/bi00574a004; JONES OT, 1988, BIOCHEMISTRY-US, V27, P2364, DOI 10.1021/bi00407a018; MARSH D, 1978, P NATL ACAD SCI USA, V75, P4329, DOI 10.1073/pnas.75.9.4329; MARSH D, 1981, BIOCHIM BIOPHYS ACTA, V645, P97, DOI 10.1016/0005-2736(81)90516-2; MCCARTHY MP, 1992, J BIOL CHEM, V267, P7655; Minota S, 1997, J NEUROPHYSIOL, V78, P2396, DOI 10.1152/jn.1997.78.5.2396; NARAYANASWAMI V, 1993, BIOCHEMISTRY-US, V32, P12420, DOI 10.1021/bi00097a021; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; PARASASSI T, 1990, BIOPHYS J, V57, P1179, DOI 10.1016/S0006-3495(90)82637-0; PRASAD R, 1996, MANUAL MEMBRANE LIPI, P1; Rankin SE, 1997, BIOPHYS J, V73, P2446, DOI 10.1016/S0006-3495(97)78273-0; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; Ryan SE, 1996, J BIOL CHEM, V271, P24590, DOI 10.1074/jbc.271.40.24590; SUNSHINE C, 1992, BIOCHIM BIOPHYS ACTA, V1108, P240, DOI 10.1016/0005-2736(92)90031-G; SUNSHINE C, 1994, BBA-BIOMEMBRANES, V1191, P59, DOI 10.1016/0005-2736(94)90233-X; VIJAYARAGHAVAN S, 1995, J NEUROSCI, V15, P3679; VILLAR MT, 1988, BIOCHIM BIOPHYS ACTA, V938, P35, DOI 10.1016/0005-2736(88)90119-8	44	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1249	1254		10.1074/jbc.M106618200	http://dx.doi.org/10.1074/jbc.M106618200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11682474	Green Published, hybrid			2022-12-25	WOS:000173166800050
J	Kozhukh, GV; Hagihara, Y; Kawakami, T; Hasegawa, K; Naiki, H; Goto, Y				Kozhukh, GV; Hagihara, Y; Kawakami, T; Hasegawa, K; Naiki, H; Goto, Y			Investigation of a peptide responsible for amyloid fibril formation of beta(2)-microglobulin by Achromobacter protease I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-MICROGLOBULIN; APOLIPOPROTEIN-E; KINETIC-ANALYSIS; HEMODIALYSIS; AGGREGATION; FRAGMENT; MODEL	To obtain insight into the mechanism of amyloid fibril formation from beta(2)-microglobulin (beta2-m), we prepared a series of peptide fragments using a lysine-specific protease from Achromobacter lyticus and examined their ability to form amyloid fibrils at pH 2.5. Among the nine peptides prepared by the digestion, the peptide Ser(20)-Lys(41) (K3) spontaneously formed amyloid fibrils, confirmed by thioflavin T binding and electron microscopy. The fibrils composed of K3 peptide induced fibril formation of intact beta2-m with a lag phase, distinct from the extension reaction without a lag phase observed for intact beta2-m seeds. Fibril formation of K3 peptide with intact 132-m seeds also exhibited a lag phase. On the other hand, the extension reaction of K3 peptide with the K3 seeds occurred without a lag phase. At neutral pH, the fibrils composed of either intact beta2-m or K3 peptide spontaneously depolymerized. Intriguingly, the depolymerization of K3 fibrils was faster than that of intact beta2-m fibrils. These results indicated that, although K3 peptide can form fibrils by itself more readily than intact beta2-m, the K3 fibrils are less stable than the intact beta2-m fibrils, suggesting a close relation between the free energy barrier of amyloid fibril formation and its stability.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Natl Inst Adv Ind Sci & Technol, Special Div Human Life Technol, Ikeda, Osaka 5638577, Japan; Fukui Med Univ, Dept Pathol, Matsuoka, Fukui 9101193, Japan	Osaka University; National Institute of Advanced Industrial Science & Technology (AIST); University of Fukui	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	HAGIHARA, Yoshihisa/K-4996-2016; Naiki, Hironobu/G-5599-2014	HAGIHARA, Yoshihisa/0000-0002-5980-1764; Kozhukh, Genadiy/0000-0003-4624-269X				AKHREM AA, 1989, ANAL BIOCHEM, V179, P86, DOI 10.1016/0003-2697(89)90205-4; Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Brange J, 1997, J PHARM SCI, V86, P517, DOI 10.1021/js960297s; CASEY TT, 1986, HUM PATHOL, V17, P731, DOI 10.1016/S0046-8177(86)80183-6; Chien P, 2001, NATURE, V410, P223, DOI 10.1038/35065632; Chiti F, 2001, J MOL BIOL, V307, P379, DOI 10.1006/jmbi.2000.4478; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Gejyo F, 1990, Contrib Nephrol, V78, P47; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; Gillmore JD, 1997, BRIT J HAEMATOL, V99, P245, DOI 10.1046/j.1365-2141.1997.303194.x; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Haggqvist B, 1999, P NATL ACAD SCI USA, V96, P8669, DOI 10.1073/pnas.96.15.8669; Hasegawa K, 1999, BIOCHEMISTRY-US, V38, P15514, DOI 10.1021/bi991161m; Hoshino M, 2000, J MOL BIOL, V304, P927, DOI 10.1006/jmbi.2000.4243; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; KOCH KM, 1992, KIDNEY INT, V41, P1416, DOI 10.1038/ki.1992.207; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MacPhee CE, 2000, J MOL BIOL, V297, P1203, DOI 10.1006/jmbi.2000.3600; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Morgan CJ, 2001, J MOL BIOL, V309, P339, DOI 10.1006/jmbi.2001.4661; Naiki H, 1998, BIOCHEMISTRY-US, V37, P17882, DOI 10.1021/bi980550y; Naiki H, 1999, METHOD ENZYMOL, V309, P305; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Naiki H, 1996, LAB INVEST, V74, P374; NAIKI H, 1991, LAB INVEST, V65, P104; Ohnishi S, 2000, J MOL BIOL, V301, P477, DOI 10.1006/jmbi.2000.3980; OKON M, 1992, BIOCHEMISTRY-US, V31, P8906, DOI 10.1021/bi00152a030; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; Yamaguchi I, 2001, BIOCHEMISTRY-US, V40, P8499, DOI 10.1021/bi0027128	34	113	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1310	1315		10.1074/jbc.M108753200	http://dx.doi.org/10.1074/jbc.M108753200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11687582	hybrid			2022-12-25	WOS:000173166800058
J	Gilbert, M; Karwaski, MF; Bernatchez, S; Young, NM; Taboada, E; Michniewicz, J; Cunningham, AM; Wakarchuk, WW				Gilbert, M; Karwaski, MF; Bernatchez, S; Young, NM; Taboada, E; Michniewicz, J; Cunningham, AM; Wakarchuk, WW			The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni - Biosynthesis of sialylated ganglioside mimics in the core oligosaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUILLAIN-BARRE-SYNDROME; CAPSULAR POLYSACCHARIDE; NEISSERIA-MENINGITIDIS; CHEMICAL STRUCTURES; MOLECULAR MIMICRY; PHASE VARIATION; LIPOPOLYSACCHARIDE; IDENTIFICATION; REGIONS; COLI	We have compared the lipo-oligosaccharide (LOS) biosynthesis loci from 11 Campylobacter jejuni strains expressing a total of 8 different ganglioside mimics in their LOS outer cores. Based on the organization of the genes, the 11 corresponding loci could be classified into three classes, with one of them being clearly an intermediate evolutionary step between the other two. Comparative genomics and expression of specific glycosyltransferases combined with in vitro activity assays allowed us to identify at least five distinct mechanisms that allow C. jejuni to vary the structure of the LOS outer core as follows: 1) different gene complements; 2) phase variation because of homopolymeric tracts; 3) gene inactivation by the deletion or insertion of a single base (without phase variation); 4) single mutation leading to the inactivation of a glycosyltransferase; and 5) single or multiple mutations leading to "allelic" glycosyltransferases with different acceptor specificities. The differences in the LOS outer core structures expressed by the 11 C. jejuni strains examined can be explained by one or more of the five mechanisms described in this work.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Gilbert, M (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	michel.gilbert@nrc.ca	Taboada, Eduardo N/Y-4854-2018; Wakarchuk, Warren/AAO-2774-2020; Wakarchuk, Warren/Q-9514-2017	Taboada, Eduardo N/0000-0001-8373-3653; Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Gilbert, Michel/0000-0002-0204-4408				Allos BM, 2001, CLIN INFECT DIS, V32, P1201, DOI 10.1086/319760; ASPINALL GO, 1993, EUR J BIOCHEM, V213, P1029, DOI 10.1111/j.1432-1033.1993.tb17850.x; ASPINALL GO, 1995, EUR J BIOCHEM, V231, P570, DOI 10.1111/j.1432-1033.1995.0570d.x; ASPINALL GO, 1993, EUR J BIOCHEM, V213, P1017, DOI 10.1111/j.1432-1033.1993.tb17849.x; ASPINALL GO, 1994, INFECT IMMUN, V62, P2122, DOI 10.1128/IAI.62.5.2122-2125.1994; ASPINALL GO, 1994, BIOCHEMISTRY-US, V33, P241, DOI 10.1021/bi00167a032; Bacon DJ, 2001, MOL MICROBIOL, V40, P769, DOI 10.1046/j.1365-2958.2001.02431.x; Castric P, 2001, J BIOL CHEM, V276, P26479, DOI 10.1074/jbc.M102685200; Dingle KE, 2001, J CLIN MICROBIOL, V39, P14, DOI 10.1128/JCM.39.1.14-23.2001; Filiatrault MJ, 2000, INFECT IMMUN, V68, P3352, DOI 10.1128/IAI.68.6.3352-3361.2000; Gilbert M, 1996, J BIOL CHEM, V271, P28271, DOI 10.1074/jbc.271.45.28271; Gilbert M, 2000, J BIOL CHEM, V275, P3896, DOI 10.1074/jbc.275.6.3896; Guerry P, 2000, INFECT IMMUN, V68, P6656, DOI 10.1128/IAI.68.12.6656-6662.2000; GUERRY P, 2002, IN PRESS INFECT IMMU; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; Jacobs BC, 1998, NEUROLOGY, V51, P1110, DOI 10.1212/WNL.51.4.1110; Jennings MP, 1999, MICROBIOL-UK, V145, P3013, DOI 10.1099/00221287-145-11-3013; Jiang SM, 2001, INFECT IMMUN, V69, P1244, DOI 10.1128/IAI.69.3.1244-1255.2001; Karlyshev AV, 2000, MOL MICROBIOL, V35, P529, DOI 10.1046/j.1365-2958.2000.01717.x; Klena JD, 1998, GENE, V222, P177, DOI 10.1016/S0378-1119(98)00501-0; Linton D, 2000, MOL MICROBIOL, V35, P1120, DOI 10.1046/j.1365-2958.2000.01780.x; Linton D, 2000, MOL MICROBIOL, V37, P501, DOI 10.1046/j.1365-2958.2000.02020.x; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; Moran AP, 1999, J APPL MICROBIOL, V86, P361, DOI 10.1046/j.1365-2672.1999.00713.x; Morona JK, 1999, J BACTERIOL, V181, P5355, DOI 10.1128/JB.181.17.5355-5364.1999; MOXON ER, 1990, CURR TOP MICROBIOL, V150, P65; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; PENNER JL, 1983, EUR J CLIN MICROBIOL, V2, P378, DOI 10.1007/BF02019474; Prendergast MM, 2000, J ENDOTOXIN RES, V6, P341, DOI 10.1179/096805100101532270; Preston A, 1996, CRIT REV MICROBIOL, V22, P139, DOI 10.3109/10408419609106458; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; Shin JEN, 1997, CARBOHYD RES, V305, P223; Suerbaum S, 2001, J BACTERIOL, V183, P2553, DOI 10.1128/JB.183.8.2553-2559.2001; van Belkum A, 2001, NAT MED, V7, P752, DOI 10.1038/89831; Wakarchuk W, 1996, J BIOL CHEM, V271, P19166, DOI 10.1074/jbc.271.32.19166; YUKI N, 1992, BIOMED RES-TOKYO, V13, P451, DOI 10.2220/biomedres.13.451	36	233	246	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					327	337		10.1074/jbc.M108452200	http://dx.doi.org/10.1074/jbc.M108452200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11689567	hybrid			2022-12-25	WOS:000173087900044
J	Lu, XH; Lin, S; Chang, CCY; Chang, TY				Lu, XH; Lin, S; Chang, CCY; Chang, TY			Mutant acyl-coenzyme A : cholesterol acyltransferase 1 devoid of cysteine residues remains catalytically active	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BACTERIORHODOPSIN MUTANTS; TRANSMEMBRANE PROTEINS; LACTOSE PERMEASE; ESCHERICHIA-COLI; HUMAN LIVER; COA; ACAT-1; CELLS; IDENTIFICATION	Acyl-coenzyme A:cholesterol acyltransferase (ACAT) plays important roles in cellular cholesterol homeostasis and in the early stages of atherosclerosis. ACAT1 is an integral membrane protein with multiple transmembrane domains. Human ACAT1 contains nine cysteine residues; its activity is severely inhibited by various thiol-specific modification reagents including p-chloromercuribenzene sulfonic acid, suggesting that certain cysteine residue(s) might be near or at the active site. We constructed various ACAT1 mutants that contained either single cysteine to alanine substitution at various positions, contained a reduced number of cysteines, or contained no cysteine at all. Each of these mutants retained 20% or more of the wild-type ACAT activity. Therefore, cysteine is not essential for ACAT catalysis. For the cysteine-free enzyme, its basic kinetic properties and intracellular localization in Chinese hamster ovary cells were shown to be very similar to those of the wild-type enzyme. The availability of the cysteine-free ACAT1 will facilitate future ACAT structure function studies. Additional studies show that Cys(467) is one of the major target sites that leads to p-chloromercuribenzene sulfonic acid-mediated ACAT1 inactivation, suggesting that Cys(467) may be near the ACAT active site(s).	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Chang, TY (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.			Chang, Ta-Yuan/0000-0002-3249-0468	NHLBI NIH HHS [HL60306] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060306] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; Bhatnagar RS, 1998, NAT STRUCT BIOL, V5, P1091, DOI 10.1038/4202; BISHOP JE, 1980, ANAL BIOCHEM, V106, P344, DOI 10.1016/0003-2697(80)90531-X; Buhman KF, 2000, BBA-MOL CELL BIOL L, V1529, P142, DOI 10.1016/S1388-1981(00)00144-X; Cao GQ, 1996, J BIOL CHEM, V271, P14642, DOI 10.1074/jbc.271.24.14642; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Chang CCY, 2000, J BIOL CHEM, V275, P28083; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; Chang TY, 2001, CURR OPIN LIPIDOL, V12, P289, DOI 10.1097/00041433-200106000-00008; CHANG TY, IN PRESS J LIPID RES, V42; Chen JCH, 1998, BIOCHEMISTRY-US, V37, P5107, DOI 10.1021/bi972989g; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; FLITSCH SL, 1989, BIOCHEMISTRY-US, V28, P7800, DOI 10.1021/bi00445a041; Guo ZM, 2001, J LIPID RES, V42, P1282; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Joyce CW, 2000, MOL BIOL CELL, V11, P3675, DOI 10.1091/mbc.11.11.3675; KINNUNEN PM, 1988, BIOCHEMISTRY-US, V27, P7351, DOI 10.1021/bi00419a026; KINNUNEN PM, 1988, BIOCHEMISTRY-US, V27, P7344, DOI 10.1021/bi00419a025; Krause B.R., 1995, INFLAMMATION MEDIATO, P173; Lee O, 1998, J LIPID RES, V39, P1722; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; Marmorstein R, 2001, CELL MOL LIFE SCI, V58, P693, DOI 10.1007/PL00000893; Olsen JG, 1999, FEBS LETT, V460, P46, DOI 10.1016/S0014-5793(99)01303-4; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P141; Peelman F, 1998, PROTEIN SCI, V7, P587, DOI 10.1002/pro.5560070307; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rudel LL, 2001, CURR OPIN LIPIDOL, V12, P121, DOI 10.1097/00041433-200104000-00005; Sakashita N, 2000, AM J PATHOL, V156, P227, DOI 10.1016/S0002-9440(10)64723-2; STRYER L, 1995, BIOCHEMISTRY-US, P158; Venkatesan P, 2000, BIOCHEMISTRY-US, V39, P10641, DOI 10.1021/bi000438b; Venkatesan P, 2000, BIOCHEMISTRY-US, V39, P10649, DOI 10.1021/bi0004394; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Weston SA, 1998, NAT STRUCT BIOL, V5, P213, DOI 10.1038/nsb0398-213; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; Yu CJ, 1999, J BIOL CHEM, V274, P36139, DOI 10.1074/jbc.274.51.36139	40	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					711	718		10.1074/jbc.M109427200	http://dx.doi.org/10.1074/jbc.M109427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11684695	hybrid			2022-12-25	WOS:000173087900093
J	Quattrocchi, CC; Wannenes, F; Persico, AM; Ciafre, SA; D'Arcangelo, G; Farace, MG; Keller, F				Quattrocchi, CC; Wannenes, F; Persico, AM; Ciafre, SA; D'Arcangelo, G; Farace, MG; Keller, F			Reelin is a serine protease of the extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL MIGRATION; LIPOPROTEIN RECEPTORS; INTEGRIN RECEPTORS; VLDL RECEPTOR; CELL-ADHESION; MICE LACKING; MUTANT MICE; EXPRESSION; PROTEINS; MOUSE	Reelin is an extracellular matrix protein that plays a pivotal role in development of the central nervous system. Reelin is also expressed in the adult brain, notably in the cerebral cortex, where it might play a role in synaptic plasticity. The mechanism of action of reelin at the molecular level has been the subject of several hypotheses. Here we show that reelin is a serine protease and that proteolytic activity is relevant to its function, since (i) Reelin expression in HEK 293T cells impairs their ability to adhere to fibronectin-coated surfaces, and adhesion to fibronectin is restored by micromolar concentrations of diisopropyl phosphorofluoridate, a serine hydrolase inhibitor; (ii) purified Reelin binds FP-Peg-biotin, a trap probe which irreversibly binds to serine residues located in active catalytic sites of serine hydrolases; (iii) purified Reelin rapidly degrades fibronectin and laminin, while collagen IV is degraded at a much slower rate; fibronectin degradation is inhibited by inhibitors of serine proteases, and by monoclonal antibody CR-50, an antibody known to block the function of Reelin both in vitro and in vivo. The proteolytic activity of Reelin on adhesion molecules of the extracellular matrix and/or receptors on neurons may explain how Reelin regulates neuronal migration and synaptic plasticity.	Neurosci Lab, Dept Physiol & Neurosci, I-00155 Rome, Italy; Univ Brescia, Fac Med, Program Neurosci, I-25123 Brescia, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Internal Med, I-00133 Rome, Italy; Baylor Coll Med, Cain Fdn Labs, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	University of Brescia; University of Rome Tor Vergata; University of Rome Tor Vergata; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Keller, F (corresponding author), Neurosci Lab, Dept Physiol & Neurosci, Univ Campus Biomed,Via Longoni 83, I-00155 Rome, Italy.	f.keller@unicampus.it	Persico, Antonio/AAB-9504-2022; ciafrè, silvia anna/G-1783-2012	ciafrè, silvia anna/0000-0001-6467-8396; Quattrocchi, Carlo Cosimo/0000-0001-6823-7707; D'Arcangelo, Gabriella/0000-0003-1575-1010; Keller, Flavio/0000-0002-6449-6960; Persico, Antonio/0000-0001-8910-4479				Abraham DG, 1997, MOL PHARMACOL, V52, P227, DOI 10.1124/mol.52.2.227; Alcantara S, 1998, J NEUROSCI, V18, P7779; Anton ES, 1999, NEURON, V22, P277, DOI 10.1016/S0896-6273(00)81089-2; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper JA, 1999, CELL, V97, P671, DOI 10.1016/S0092-8674(00)80778-3; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; de Bergeyck V, 1998, J NEUROSCI METH, V82, P17, DOI 10.1016/S0165-0270(98)00024-7; de Rouvroit CL, 1999, EXP NEUROL, V156, P214, DOI 10.1006/exnr.1998.7007; DeSilva U, 1997, GENOME RES, V7, P157, DOI 10.1101/gr.7.2.157; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; Gliemann J, 1998, BIOL CHEM, V379, P951; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; Guidotti A, 2000, ARCH GEN PSYCHIAT, V57, P1061, DOI 10.1001/archpsyc.57.11.1061; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; HOFFARTH RM, 1995, J NEUROSCI, V15, P4838; Hong SE, 2000, NAT GENET, V26, P93, DOI 10.1038/79246; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; KINOSHITA H, 1989, FEBS LETT, V250, P411, DOI 10.1016/0014-5793(89)80766-5; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KUSUMOTO H, 1988, P NATL ACAD SCI USA, V85, P7307, DOI 10.1073/pnas.85.19.7307; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu WS, 2001, P NATL ACAD SCI USA, V98, P3477, DOI 10.1073/pnas.051614698; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Miyamoto S, 1998, ANN NY ACAD SCI, V857, P119, DOI 10.1111/j.1749-6632.1998.tb10112.x; Nakagami Y, 2000, J NEUROSCI, V20, P2003; Persico AM, 2001, MOL PSYCHIATR, V6, P150, DOI 10.1038/sj.mp.4000850; Pesold C, 1999, P NATL ACAD SCI USA, V96, P3217, DOI 10.1073/pnas.96.6.3217; Pesold C, 1998, P NATL ACAD SCI USA, V95, P3221, DOI 10.1073/pnas.95.6.3221; PINTOLORD MC, 1982, DEV BRAIN RES, V4, P379, DOI 10.1016/0165-3806(82)90181-X; Rodriguez MA, 2000, P NATL ACAD SCI USA, V97, P3550, DOI 10.1073/pnas.050589797; Seeds NW, 1999, P NATL ACAD SCI USA, V96, P14118, DOI 10.1073/pnas.96.24.14118; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; SHEPPARD AM, 1991, J NEUROSCI, V11, P3928; Smalheiser NR, 2000, P NATL ACAD SCI USA, V97, P1281, DOI 10.1073/pnas.97.3.1281; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Tueting P, 1999, NEUROREPORT, V10, P1329, DOI 10.1097/00001756-199904260-00032; Utsunomiya-Tate N, 2000, P NATL ACAD SCI USA, V97, P9729, DOI 10.1073/pnas.160272497	40	119	127	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					303	309		10.1074/jbc.M106996200	http://dx.doi.org/10.1074/jbc.M106996200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11689558	hybrid			2022-12-25	WOS:000173087900041
J	Sasaki, Y; Ishida, S; Morimoto, I; Yamashita, T; Kojima, T; Kihara, C; Tanaka, T; Imai, K; Nakamura, Y; Tokino, T				Sasaki, Y; Ishida, S; Morimoto, I; Yamashita, T; Kojima, T; Kihara, C; Tanaka, T; Imai, K; Nakamura, Y; Tokino, T			The p53 family member genes are involved in the notch signal pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-ANALYSIS; SPONTANEOUS TUMORS; DROSOPHILA NOTCH; DELTA-HOMOLOG; CANCER-CELLS; P73; P63; MUTATIONS; LIGAND; NEUROBLASTOMA	The p53 tumor suppressor is a transcription factor that regulates cell growth and death in response to environmental stimuli such as DNA damage. p63/p51 and p73 were recently identified as members of the p53 gene family. In contrast to p53 however, p63 and p73 are rarely mutated in human cancers. Mice that lack p53 are developmentally normal, while p63 and p73 appear to play critical roles in normal development. To determine how p63 and p73 are involved in normal development, we attempted to identify target genes that are specifically regulated by p63 and/or p73 but not by p53. We found that the Jagged1 (JAG1) and Jagged2 (JAG2) genes, encoding ligands for the Notch receptors, are up-regulated by p63 and p73. Furthermore, we identified a p63-binding site in the second intron of the JAG1 gene, which can directly interact with the p63 protein in vivo, as assessed by a chromatin immunoprecipitation assay. A heterologous reporter assay revealed that this p63-binding site is a functional response element and is specific for p63. We also found a target of Notch signaling, HES-1 was up-regulated in Jurkat cells, in which Notch1 is highly expressed, when co-cultured with p63-transfected cells, suggesting that p63 can trigger the Notch signal pathway in neighboring cells. Our findings show an association between the p53 family genes and Notch signaling and suggest a potential molecular mechanism for the involvement of the p53 family genes in normal development.	Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Mol Biol,Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Univ Tokyo, Inst Med Sci, Human Genome Ctr, Lab Mol Med,Minato Ku, Tokyo 1088639, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; University of Tokyo	Tokino, T (corresponding author), Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Mol Biol,Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	tokino@sapmed.ac.jp	Sasaki, Yasushi/AAA-3079-2019; Tokino, Takashi/AAI-9887-2021; Tanaka, Toshihiro/J-9310-2014	Sasaki, Yasushi/0000-0002-3500-8059; Tanaka, Toshihiro/0000-0001-6201-9784				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Bash J, 1999, EMBO J, V18, P2803, DOI 10.1093/emboj/18.10.2803; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Levrero M, 2000, J CELL SCI, V113, P1661; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Mai M, 1998, GENOMICS, V51, P359, DOI 10.1006/geno.1998.5387; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Morrissette JJD, 2001, HUM MOL GENET, V10, P405, DOI 10.1093/hmg/10.4.405; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Okabe H, 2001, CANCER RES, V61, P2129; Ono K, 2000, CANCER RES, V60, P5007; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Prabhu NS, 1998, INT J ONCOL, V13, P5; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; Shimada A, 1999, CANCER RES, V59, P2781; Shutter JR, 2000, GENE DEV, V14, P1313; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zheng XJ, 2001, FEBS LETT, V489, P4, DOI 10.1016/S0014-5793(00)02437-6; Zhu JH, 1998, CANCER RES, V58, P5061	51	163	172	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					719	724		10.1074/jbc.M108080200	http://dx.doi.org/10.1074/jbc.M108080200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11641404	hybrid			2022-12-25	WOS:000173087900094
J	Schneider, C; Boeglin, WE; Prusakiewicz, JJ; Rowlinson, SW; Marnett, LJ; Samel, N; Brash, AR				Schneider, C; Boeglin, WE; Prusakiewicz, JJ; Rowlinson, SW; Marnett, LJ; Samel, N; Brash, AR			Control of prostaglandin stereochemistry at the 15-carbon by cyclooxygenases-1 and -2 - A critical role for serine 530 and valine 349	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE H SYNTHASE-1; ARACHIDONIC-ACID; ACTIVE-SITE; ASPIRIN ACETYLATION; PLEXAURA-HOMOMALLA; NSAID BINDING; OXYGENATION; INHIBITION; CORAL; COX-2	Prostaglandin synthesis by cyclooxygenases-1 and -2 (COX-1 and COX-2) involves an initial oxygenation of arachidonic acid at C-11, followed by endoperoxide and cyclopentane ring formation, and then a second reaction with molecular oxygen in the S configuration at C-15. The resulting 15S-hydroxyl group of prostaglandins is crucial for their bioactivity. Using human COX-1 and human and murine COX-2, we have identified two amino acids located in the oxygenase active site that control the stereochemistry at C-15. The most crucial determinant is Ser-530, the residue that is acetylated by aspirin. In COX-2, site-directed mutagenesis of Ser-530 to methionine, threonine, or valine produced highly active enzymes that formed 82-95% 15R-configuration prostaglandins; these have the opposite stereochemistry at C-15 to the natural products. In COX-1, the corresponding Ser-530 mutations inactivated the enzyme. The second residue, Val-349, exerts a more subtle influence. When Val-349 was replaced by isoleucine, the mutant COX-1 and COX-2 enzymes formed 41 and 65% 15R-prostaglandins, respectively. This change was highly specific for isoleucine, as mutations of Val-349 to alanine, leucine, asparagine, or threonine did not alter or only slightly altered (less than or equal to13%) the S-configuration at C-15. These results establish a previously unrecognized role for Ser-530 and Val-349 in maintaining the correct S stereochemistry of the carbon-15 hydroxyl group during prostaglandin synthesis. The findings may also explain the absolute conservation of Ser-530, the target of aspirin, throughout the families of cyclooxygenase enzymes.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Tallinn Univ Technol, Inst Chem, Dept Bioorgan Chem, EE-12618 Tallinn, Estonia	Vanderbilt University; Vanderbilt University; Vanderbilt University; Tallinn University of Technology	Brash, AR (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 23rd Ave Pierce, Nashville, TN 37232 USA.	alan.brash@mcmail.vanderbilt.edu	Samel, Nigulas/A-1420-2019		FIC NIH HHS [TW-00404] Funding Source: Medline; NCI NIH HHS [CA89450] Funding Source: Medline; NIGMS NIH HHS [GM-53638] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089450] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Kiefer JR, 2000, NATURE, V405, P97, DOI 10.1038/35011103; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; MANCINI JA, 1994, FEBS LETT, V342, P33, DOI 10.1016/0014-5793(94)80579-2; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; NAKANO J, 1972, BRIT J PHARMACOL, V44, P63, DOI 10.1111/j.1476-5381.1972.tb07238.x; PEERS KE, 1983, CHEM PHYS LIPIDS, V32, P49, DOI 10.1016/0009-3084(83)90069-5; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; POWELL WS, 1982, METHOD ENZYMOL, V86, P467; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; Schneider C, 2000, ANAL BIOCHEM, V287, P186, DOI 10.1006/abio.2000.4847; Schneider C, 2000, J BIOL CHEM, V275, P4743, DOI 10.1074/jbc.275.7.4743; Schneider C, 2001, ARCH BIOCHEM BIOPHYS, V386, P268, DOI 10.1006/abbi.2000.2217; SCHNEIDER WP, 1977, J AM CHEM SOC, V99, P6062, DOI 10.1021/ja00460a037; Selinsky BS, 2001, BIOCHEMISTRY-US, V40, P5172, DOI 10.1021/bi010045s; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SPRAGGINS RL, 1972, TETRAHEDRON LETT, P4343; Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501; Thuresson ED, 2001, J BIOL CHEM, V276, P10347, DOI 10.1074/jbc.M009377200; Valmsen K, 2001, P NATL ACAD SCI USA, V98, P7700, DOI 10.1073/pnas.131022398; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u	31	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					478	485		10.1074/jbc.M107471200	http://dx.doi.org/10.1074/jbc.M107471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11677234	hybrid			2022-12-25	WOS:000173087900064
J	Cheng, ZJ; Miller, LJ				Cheng, ZJ; Miller, LJ			Agonist-dependent dissociation of oligomeric complexes of G protein-coupled cholecystokinin receptors demonstrated in living cells using bioluminescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TRANSFER BRET; DIMERIZATION; INTERNALIZATION; COEXPRESSION; BINDING; IDENTIFICATION; RECONSTITUTION; MECHANISM; RESIDUES	Dimerization of some G protein-coupled receptors has recently been demonstrated, but how widespread this phenomenon might be and its functional implications are not yet clear. We have utilized biophysical and biochemical techniques to evaluate whether the type A cholecystokinin (CCK) receptor can form oligomeric complexes in the plasma membrane and the impact of ligand binding and signaling on such complexes. We investigated the possibility of bioluminescence resonance energy transfer (BRET) between receptor constructs that included carboxyl-terminal tags of Renilla luciferase or yellow fluorescent protein. Indeed, co-expression of these constructs in COS cells resulted in the constitutive presence of a significant BRET signal above that in a series of controls, with this signal reduced by co-expression of competing non-tagged CCK receptors. The presence of an oligomeric complex of CCK receptor molecules was confirmed in co-immunoprecipitation experiments. Occupation of CCK receptors with agonist ligands (CCK or gastrin-4) resulted in the rapid reduction in BRET signal in contrast to the enhancement of such a signal reported after agonist occupation of the beta (2)-adrenergic receptor. These effects on CCK receptor oligomerization were concentration-dependent, correlating with the potencies of the agonists. A smaller effect was observed for a partial agonist, and no effect was observed for antagonist occupation of this receptor. Agonist-induced reduction in BRET signal was also observed for pairs of CCK receptors with a donor-acceptor pair situated in other positions within the receptor. Manipulation of the phosphorylation state of CCK receptor using protein kinase C activation with phorbol ester or inhibition with staurosporine had no effect on the basal level or agonist effect on CCK receptor oligomerization. This provides the first evidence for CCK receptor oligomerization in living cells, with insights that the active conformation of this receptor dissociates these complexes in a phosphorylation-independent manner.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Biochem Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Miller, LJ (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Med, Guggenheim 17, Rochester, MN 55905 USA.				NIDDK NIH HHS [DK32878] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032878, R01DK032878] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Ding XQ, 2001, J BIOL CHEM, V276, P4236, DOI 10.1074/jbc.M003798200; Dong MQ, 2000, J BIOL CHEM, V275, P26032, DOI 10.1074/jbc.M000612200; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Go WY, 1998, AM J PHYSIOL-GASTR L, V275, pG56, DOI 10.1152/ajpgi.1998.275.1.G56; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hadac EM, 1999, J MED CHEM, V42, P2105, DOI 10.1021/jm980732q; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Heim HK, 1995, J PHYSIOL PHARMACOL, V46, P489; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUTT V, 1980, GASTROINTESTINAL HOR, P169; ONDETTI MA, 1970, AM J DIG DIS, V15, P149, DOI 10.1007/BF02235646; OZCELEBI F, 1995, J BIOL CHEM, V270, P3435, DOI 10.1074/jbc.270.7.3435; Ozcelebi F, 1996, J BIOL CHEM, V271, P3750; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Roettger BF, 1997, MOL PHARMACOL, V51, P357; ULRICH CD, 1993, BIOCHEM BIOPH RES CO, V193, P204, DOI 10.1006/bbrc.1993.1610; Weiss JM, 1996, J THEOR BIOL, V178, P151, DOI 10.1006/jtbi.1996.0014; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Yesilaltay A, 2000, MOL BIOL CELL, V11, P2873, DOI 10.1091/mbc.11.9.2873; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	40	111	117	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48040	48047		10.1074/jbc.M105668200	http://dx.doi.org/10.1074/jbc.M105668200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11673456	hybrid			2022-12-25	WOS:000172927000043
J	Deryabina, YI; Bazhenova, EN; Saris, NEL; Zvyagilskaya, RA				Deryabina, YI; Bazhenova, EN; Saris, NEL; Zvyagilskaya, RA			Ca2+ efflux in mitochondria from the yeast Endomyces magnusii.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CA-2+ EFFLUX; CALCIUM-TRANSPORT; OXIDATIVE-PHOSPHORYLATION; PERMEABILITY TRANSITION; POLYAMINES; INHIBITION; SYSTEM; HOMEOSTASIS; MOVEMENTS	Calcium release pathways in Ca2+-preloaded mitochondria from the yeast Endomyces magnusii were studied. In the presence of phosphate as a permeant anion, Ca2+ was released from respiring mitochondria only after massive cation loading at the onset of anaerobiosis. Ca2+ release was not affected by cyclosporin A, an inhibitor of the mitochondrial permeability transition. Aeration of the mitochondrial suspension inhibited the efflux of Ca2+ and induced its re-uptake. With acetate as the permeant anion, a spontaneous net Ca2+ efflux set in after uptake of similar to 150 nmol of Ca2+/mg of protein. The rate of this efflux was proportional to the Ca2+ load and insensitive to aeration, protonophorous uncouplers, and Na+ ions. Ca2+ efflux was inhibited by La3+, Mn2+, Mg2+, tetraphenylphosphonium, inorganic phosphate, and nigericin and stimulated by hypotonicity, spermine, and valinomycin in the presence of 4 mM KCl. Atractyloside and t-butyl hydroperoxide were without effect. Ca2+ efflux was associated with contraction, but not with mitochondrial swelling. We conclude that the permeability transition pore is not involved in Ca2+ efflux in preloaded E. magnusii mitochondria. The efflux occurs via an Na+-independent pathway, in many ways similar to the one in mammalian mitochondria.	Univ Helsinki, Bioctr Viikki 1, Dept Appl Chem & Microbiol, FIN-00014 Helsinki, Finland; Russian Acad Sci, AN Bach Inst Biochem, HRU-117071 Moscow, Russia	University of Helsinki; Russian Academy of Sciences	Saris, NEL (corresponding author), Univ Helsinki, Bioctr Viikki 1, Dept Appl Chem & Microbiol, POB 56, FIN-00014 Helsinki, Finland.	nils-erik.saris@helsinki.fi						AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; ALLSHIRE A, 1985, BIOCHIM BIOPHYS ACTA, V807, P202, DOI 10.1016/0005-2728(85)90123-9; BALCAVAG.WX, 1973, BIOCHIM BIOPHYS ACTA, V305, P41, DOI 10.1016/0005-2728(73)90229-6; Bazhenova EN, 1998, BBA-BIOMEMBRANES, V1371, P96, DOI 10.1016/S0005-2736(98)00004-2; Bazhenova EN, 1998, J BIOL CHEM, V273, P4372, DOI 10.1074/jbc.273.8.4372; BAZHENOVA EN, 1997, DOKL AKAD NAUK SSSR, V353, P1; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1983, EUR J BIOCHEM, V134, P377, DOI 10.1111/j.1432-1033.1983.tb07578.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANCE B, 1955, NATURE, V175, P1120, DOI 10.1038/1751120a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CROMPTON M, 1977, EUR J BIOCHEM, V79, P549, DOI 10.1111/j.1432-1033.1977.tb11839.x; Deryabina YI, 1996, BIOCHEMISTRY-MOSCOW+, V61, P1206; Forster C, 2000, J BIOL CHEM, V275, P38245, DOI 10.1074/jbc.M006650200; FULCERI R, 1993, BIOCHEM J, V289, P299, DOI 10.1042/bj2890299; Gavin CE, 1999, NEUROTOXICOLOGY, V20, P445; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; JENSEN JR, 1987, J NEUROCHEM, V48, P765, DOI 10.1111/j.1471-4159.1987.tb05583.x; Jung DW, 1997, J BIOL CHEM, V272, P21104, DOI 10.1074/jbc.272.34.21104; KARADJOV JS, 1988, BIOFIZIKA+, V33, P1001; Kavanagh NI, 2000, BBA-BIOENERGETICS, V1457, P57, DOI 10.1016/S0005-2728(00)00054-2; LEHNINGER AL, 1967, ADV ENZYMOL RAMB, V29, P259; LEIKIN YN, 1987, BIOKHIMIYA, V52, P676; LUKACS GL, 1985, BIOCHIM BIOPHYS ACTA, V809, P160, DOI 10.1016/0005-2728(85)90058-1; MCCORMACK JG, 1993, BIOCHEM SOC T, V21, P793, DOI 10.1042/bst0210793; MOORE CL, 1971, BIOCHEM BIOPH RES CO, V42, P298, DOI 10.1016/0006-291X(71)90102-1; Mooren FC, 1998, BBA-MOL BASIS DIS, V1406, P127, DOI 10.1016/S0925-4439(98)00006-4; NICCHITTA CV, 1984, J BIOL CHEM, V259, P2978; NOVGORODOV SA, 1985, FEBS LETT, V183, P47, DOI 10.1016/0014-5793(85)80951-0; Pozzan T, 2000, EUR J BIOCHEM, V267, P5269, DOI 10.1046/j.1432-1327.2000.01567.x; REED KC, 1974, BIOCHEM J, V140, P143, DOI 10.1042/bj1400143; RIZZUTO R, 1987, BIOCHEM J, V246, P271, DOI 10.1042/bj2460271; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1016, P77, DOI 10.1016/0005-2728(90)90009-S; ROTTENBERG H, 1990, FEBS LETT, V274, P65, DOI 10.1016/0014-5793(90)81330-Q; Rustenbeck I, 1996, BIOCHEM MOL BIOL INT, V38, P1003; Saris N.E., 1963, SOC SCI FENN COMMENT, V28, P1; Saris NEL, 2000, CLIN CHIM ACTA, V294, P1, DOI 10.1016/S0009-8981(99)00258-2; SARIS NEL, 1983, BIOCHIM BIOPHYS ACTA, V725, P19, DOI 10.1016/0005-2728(83)90219-0; SARIS NEL, 1969, FEBS S, V17, P363; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; VOTYAKOVA TV, 1990, FEBS LETT, V261, P139, DOI 10.1016/0014-5793(90)80655-3; VOTYAKOVA TV, 1993, J BIOENERG BIOMEMBR, V25, P569, DOI 10.1007/BF01108413; ZOCCARATO F, 1982, EUR J BIOCHEM, V127, P333, DOI 10.1111/j.1432-1033.1982.tb06875.x; ZVIAGILSKAIA RA, 1983, DOKL AKAD NAUK SSSR+, V269, P1238; ZVIAGILSKAIA RA, 1982, DOKL AKAD NAUK SSSR+, V263, P491; ZVYAGIL'SKAYA R A, 1987, Mikrobiologiya, V56, P543; ZVYAGIL'SKAYA R A, 1981, Biokhimiya, V46, P3	49	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47801	47806		10.1074/jbc.M103685200	http://dx.doi.org/10.1074/jbc.M103685200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11673451	hybrid			2022-12-25	WOS:000172927000011
J	Wang, BL; Xiong, QH; Shi, Q; Le, XD; Xie, KP				Wang, BL; Xiong, QH; Shi, Q; Le, XD; Xie, KP			Genetic disruption of host interferon-gamma drastically enhances the metastasis of pancreatic adenocarcinoma through impaired expression of inducible nitric oxide synthase	ONCOGENE			English	Article						interferon-gamma; knockout; nitric oxide; metastasis; pancreas	CELL-LINES; CANCER; TUMORS; REGRESSION; THERAPY; MICE; MECHANISMS; BETA; P53	Synergistic induction of the inducible nitric oxide synthase (NOS II) gene requires a combination of interferon-gamma (IFN-gamma) and lipopolysaccharide (LPS). In this study, we determined whether the induction of IFN-gamma was required for NOS U-mediated antitumor activity in viro. Highly metastatic H7 murine pancreatic adenocarcinoma cells were implanted into the subcutis, footpad, and pancreas of syngeneic IFN-gamma (+/+) and IFN-gamma (-/-) mice. These cells grew and produced metastases and ascites in IFN-gamma (+/+) mice. In sharp contrast, the same tumor cells grew much more aggressively, metastasized more extensively, and produced a larger amount of malignant ascites in IFN-gamma (-/-) mice. Also, induction of IFN-gamma correlated with NOS II gene expression and NO production in IFN-gamma (+/+) injected with the tumor cells but not in IFN-gamma (-/-) mice or IFN-gamma (+/+) mice without tumor challenge. In vitro, only LPS plus IFN-gamma induced a high level of NO production and cytotoxicity against H7 cells. These data suggested that the tumor cells stimulated IFN-gamma secretion from host cells, which in turn stimulated NO production by host cells and suppressed tumor growth and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Xie, KP (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA 16672-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambs S, 1997, FASEB J, V11, P443, DOI 10.1096/fasebj.11.6.9194524; Chinje EC, 1997, ESSAYS BIOCHEM, V32, P61; CORBETT TH, 1984, CANCER RES, V44, P717; Einhorn S, 1996, J INTERF CYTOK RES, V16, P275, DOI 10.1089/jir.1996.16.275; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; JOHNS TG, 1992, J NATL CANCER I, V84, P1185, DOI 10.1093/jnci/84.15.1185; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KROWN SE, 1988, J NATL CANCER I, V80, P306, DOI 10.1093/jnci/80.5.306; Kundu N, 1998, INT J CANCER, V76, P713, DOI 10.1002/(SICI)1097-0215(19980529)76:5<713::AID-IJC17>3.0.CO;2-4; LOKSHIN A, 1995, JNCI-J NATL CANCER I, V87, P206, DOI 10.1093/jnci/87.3.206; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Onier N, 1999, INT J CANCER, V81, P755, DOI 10.1002/(SICI)1097-0215(19990531)81:5<755::AID-IJC15>3.0.CO;2-3; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Shi Q, 2000, INT J ONCOL, V17, P217; Shi Q, 1999, CANCER RES, V59, P2072; SHI Q, 2000, CANCER RES, V60, P2645; Tannenbaum CS, 2000, SEMIN CANCER BIOL, V10, P113, DOI 10.1006/scbi.2000.0314; THOMAS H, 1991, PHARMACOL THERAPEUT, V52, P307, DOI 10.1016/0163-7258(91)90030-P; Tozer G M, 1997, Clin Oncol (R Coll Radiol), V9, P357, DOI 10.1016/S0936-6555(97)80128-8; Wang BL, 2001, INT J CANCER, V91, P607, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1109>3.0.CO;2-D; Wang BL, 2001, CANCER RES, V61, P71; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; XIE K, 1997, CLIN CANCER RES, V3, P2189; XIE KP, 1995, CANCER RES, V55, P3123; Xie KP, 1998, CANCER METAST REV, V17, P55, DOI 10.1023/A:1005956721457; Zhang JF, 1996, P NATL ACAD SCI USA, V93, P4513, DOI 10.1073/pnas.93.9.4513	31	19	21	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6930	6937		10.1038/sj.onc.1204871	http://dx.doi.org/10.1038/sj.onc.1204871			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687972				2022-12-25	WOS:000171641000014
J	Botchkarev, VA; Botchkareva, NV; Nakamura, M; Huber, O; Funa, K; Lauster, R; Paus, R; Gilchrest, BA				Botchkarev, VA; Botchkareva, NV; Nakamura, M; Huber, O; Funa, K; Lauster, R; Paus, R; Gilchrest, BA			Noggin is required for induction of the hair follicle growth phase in postnatal skin	FASEB JOURNAL			English	Article						hair cycle; bone morphogenetic protein; telogen; anagen; sonic hedgehog	BASAL-CELL CARCINOMAS; NEUROTROPHIC FACTOR; SIGNALING PATHWAYS; SONIC-HEDGEHOG; BETA-CATENIN; STEM-CELLS; ANAGEN; EXPRESSION; MORPHOGENESIS; INVOLVEMENT	During postnatal development, the hair follicle (HF) shows cyclic activity with periods of relative resting, active growth (anagen), and regression. We demonstrate that similar to the HF induction in embryonic skin, initiation of a new hair growth phase in postnatal skin requires neutralization of the inhibitory activity of bone morphogenetic protein 4 (BMP4) by the BMP antagonist noggin. In the resting HF, BMP4 mRNA predominates over noggin in the epithelium and mesenchyme, and the BMP receptor IA is prominently expressed in the follicular germ. Anagen development is accompanied by down-regulation of the BMP4 and increased noggin mRNA in the HF. Furthermore, administration of noggin protein induces new hair growth phase in postnatal telogen skin in vivo. In contrast, BMP4 induces selective arrest of anagen development in the non-tylotrich (secondary) HF. As a hair growth inducer, noggin increases Shh mRNA in the HF whereas BMP4 down-regulates Shh. This suggests that modulation of BMP4 signaling by noggin is essential for hair growth phase induction in postnatal skin and that the hair growth-inducing effect of noggin is mediated, at least in part, by Shh.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA; Univ Hamburg, Univ Hosp Eppendorf, Dept Dermatol, Hamburg, Germany; Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Clin Chem & Pathobiochem, D-1000 Berlin, Germany; Univ Gothenburg, Dept Anat & Cell Biol, Gothenburg, Sweden; Deutsch Rheumaforschungszentrum, Berlin, Germany	Boston University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Gothenburg; Deutsches Rheuma-Forschungszentrum (DRFZ)	Botchkarev, VA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.	vladbotc@bu.edu	Huber, Otmar/AAA-4548-2021; Paus, Ralf/F-6243-2011	Huber, Otmar/0000-0003-4359-1747; Botchkarev, Vladimir/0000-0002-5212-5353	NIAMS NIH HHS [1RO3 AR47414-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR047414] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Botchkarev V. A., 2000, Journal of Investigative Dermatology, V114, P754; Botchkarev VA, 2000, CANCER RES, V60, P5002; Botchkarev VA, 2000, FASEB J, V14, P1931, DOI 10.1096/fj.99-0930com; Botchkarev VA, 1999, NAT CELL BIOL, V1, P158, DOI 10.1038/11078; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkarev VA, 1999, FASEB J, V13, P395, DOI 10.1096/fasebj.13.2.395; Botchkarev VA, 1999, LAB INVEST, V79, P557; Botchkareva NV, 2001, FASEB J, V15, P645, DOI 10.1096/fj.00-0368com; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Cotsarelis G, 1999, EXP DERMATOL, V8, P80, DOI 10.1111/j.1600-0625.1999.tb00351.x; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; HANDJISKI BK, 1994, BRIT J DERMATOL, V131, P303, DOI 10.1111/j.1365-2133.1994.tb08515.x; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Jung HS, 1998, DEV BIOL, V196, P11, DOI 10.1006/dbio.1998.8850; Koch PJ, 1998, J CELL SCI, V111, P2529; Kulessa H, 2000, EMBO J, V19, P6664, DOI 10.1093/emboj/19.24.6664; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LAVKER RM, 1999, DERMATOLOGY GEN MED, P230; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Mecklenburg L, 2000, J INVEST DERMATOL, V114, P909, DOI 10.1046/j.1523-1747.2000.00954.x; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; NAGORCKA BN, 1985, J THEOR BIOL, V114, P243, DOI 10.1016/S0022-5193(85)80106-5; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; Nifuji A, 1999, J CELL BIOCHEM, V73, P437, DOI 10.1002/(SICI)1097-4644(19990615)73:4<437::AID-JCB2>3.3.CO;2-2; Noramly S, 1998, DEVELOPMENT, V125, P3775; Oh HS, 1996, P NATL ACAD SCI USA, V93, P12525, DOI 10.1073/pnas.93.22.12525; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; PAUS R, 1989, LAB INVEST, V60, P365; PAUS R, 1994, DEV BIOL, V163, P230, DOI 10.1006/dbio.1994.1139; PAUS R, 1994, LAB INVEST, V71, P134; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; Philpott M, 1998, MOL BASIS EPITHELIAL, P75; Price VH, 1999, NEW ENGL J MED, V341, P964, DOI 10.1056/NEJM199909233411307; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; Sano S, 2000, P NATL ACAD SCI USA, V97, P13824, DOI 10.1073/pnas.240303097; Sato N, 1999, J CLIN INVEST, V104, P855, DOI 10.1172/JCI7691; SLOMINSKI A, 1994, J INVEST DERMATOL, V102, P862, DOI 10.1111/1523-1747.ep12382606; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; SLOMINSKI A, 1991, J INVEST DERMATOL, V96, P172, DOI 10.1111/1523-1747.ep12460956; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Stenn K., 1998, MOL BASIS EPITHELIAL, P111; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Tobin DJ, 1999, J INVEST DERM SYMP P, V4, P323, DOI 10.1038/sj.jidsp.5640239; Tucker AS, 2000, DEVELOPMENT, V127, P4691; Vielkind U, 1996, ACTA ANAT, V157, P183; Wang LC, 2000, J INVEST DERMATOL, V114, P901, DOI 10.1046/j.1523-1747.2000.00951.x; WILSON C, 1994, DIFFERENTIATION, V55, P127, DOI 10.1046/j.1432-0436.1994.5520127.x; Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317; Zhang YD, 2000, DEVELOPMENT, V127, P1431; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	68	164	181	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2205	2214		10.1096/fj.01-0207com	http://dx.doi.org/10.1096/fj.01-0207com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641247				2022-12-25	WOS:000171920400032
J	Ganglberger, E; Sponer, B; Scholl, I; Wiedermann, U; Baumann, S; Hafner, C; Breiteneder, H; Suter, M; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E				Ganglberger, E; Sponer, B; Scholl, I; Wiedermann, U; Baumann, S; Hafner, C; Breiteneder, H; Suter, M; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E			Monovalent fusion proteins of immunoglobulin E mimotopes are safe for therapy of type I allergy	FASEB JOURNAL			English	Article						Bet v 1; IgE epitope; ABP-fusion protein; blocking IgG	BIRCH POLLEN ALLERGEN; BET V 1; IGG MONOCLONAL-ANTIBODIES; PHAGE-DISPLAYED PEPTIDES; B-CELL EPITOPES; MOLECULAR CHARACTERIZATION; DISCONTINUOUS EPITOPES; IMMUNE-RESPONSE; BINDING; SELECTION	By screening phage display random peptide libraries with purified immunoglobulin E (IgE) from birch pollen-allergic patients, we previously defined peptides mimicking natural IgE epitopes (mimotopes) of the major birch pollen allergen Bet v 1. The present study aimed to define a monovalent carrier for the IgE mimotopes to induce protective antibodies directed to the IgE epitopes, suitable for mimotope-specific therapy. We expressed the selected mimotopes as fusion proteins together with streptococcal albumin binding protein (ABP). The fusion proteins were recognized specifically by anti-Bet v 1 human IgE, which demonstrated that the mimotopes fused to ABP resemble the natural IgE epitope. Bet v 1-specific IgG was induced by immunization of BALB/c mice with fusion proteins. These IgG antibodies could inhibit IgE binding to Bet v 1. Skin testing of Bet v 1 allergic mice showed that the ABP mimotope constructs did not elicit type I skin reactions, although they possess IgE binding structures. Our data suggest that IgE mimotopes are safe for epitope-specific immunotherapy of sensitized individuals, when presented in a monovalent form. Therefore, ABP-fused mimotopes are promising candidates for a new type of immunotherapy based on the precise induction of blocking antibodies.	Univ Vienna, Sch Med, Dept Pathophysiol, A-1090 Vienna, Austria; Univ Zurich, Dept Virol, CH-8057 Zurich, Switzerland	University of Vienna; University of Zurich	Jensen-Jarolim, E (corresponding author), Univ Vienna, Sch Med, Dept Pathophysiol, AKH-3Q,Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	erika.jensen-jarolim@akh-wien.ac.at	Jensen-Jarolim, Erika/C-5120-2018	Jensen-Jarolim, Erika/0000-0003-4019-5765; Wiedermann, Ursula/0000-0002-1302-3223				Ball T, 1999, FASEB J, V13, P1277, DOI 10.1096/fasebj.13.11.1277; BARBAS CF, 1991, METHODS COMPANION ME, V2, P119; Bauer L, 1997, CLIN EXP IMMUNOL, V107, P536, DOI 10.1046/j.1365-2249.1997.d01-953.x; Baumann S, 1998, J IMMUNOL METHODS, V221, P95, DOI 10.1016/S0022-1759(98)00168-9; Denepoux S, 2000, FEBS LETT, V465, P39, DOI 10.1016/S0014-5793(99)01703-2; FELICI F, 1993, GENE, V128, P21, DOI 10.1016/0378-1119(93)90148-V; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; Focke M, 2001, INT ARCH ALLERGY IMM, V124, P398, DOI 10.1159/000053769; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Ganglberger E, 2000, FASEB J, V14, P2177, DOI 10.1096/fj.99-1000com; Grabowska AM, 2000, VIROLOGY, V269, P47, DOI 10.1006/viro.2000.0185; Helm BA, 1997, ALLERGY, V52, P1155, DOI 10.1111/j.1398-9995.1997.tb02518.x; JAROLIM E, 1990, J ALLERGY CLIN IMMUN, V85, P996, DOI 10.1016/0091-6749(90)90043-4; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; Jensen-Jarolim E, 1999, FASEB J, V13, P1586, DOI 10.1096/fasebj.13.12.1586; Jensen-Jarolim E, 1998, FASEB J, V12, P1635, DOI 10.1096/fasebj.12.15.1635; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; Laffer S, 1996, J IMMUNOL, V157, P4953; Lebecque S, 1997, J ALLERGY CLIN IMMUN, V99, P374, DOI 10.1016/S0091-6749(97)70056-3; Leitner A, 1998, EUR J IMMUNOL, V28, P2921, DOI 10.1002/(SICI)1521-4141(199809)28:09<2921::AID-IMMU2921>3.0.CO;2-D; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MEOLA A, 1995, J IMMUNOL, V154, P3162; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Simon Gary L., 1995, P53; Srivastava N, 2000, HYBRIDOMA, V19, P23, DOI 10.1089/027245700315761; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Visco V, 1996, J IMMUNOL, V157, P956; VOGEL M, 1994, EUR J IMMUNOL, V24, P1200, DOI 10.1002/eji.1830240529; Wiedermann U, 1998, CLIN EXP IMMUNOL, V111, P144; Zuercher AW, 2000, EUR J IMMUNOL, V30, P128, DOI 10.1002/1521-4141(200001)30:1<128::AID-IMMU128>3.3.CO;2-O; ZURCHER AW, 1995, IMMUNOL LETT, V46, P49, DOI 10.1016/0165-2478(95)00014-V	34	25	28	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2524	+		10.1096/fj.00-0888fje	http://dx.doi.org/10.1096/fj.00-0888fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641259				2022-12-25	WOS:000171372700016
J	Langedijk, JPM				Langedijk, JPM			Translocation activity of C-terminal domain of pestivirus E-rns and ribotoxin L3 loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWINE FEVER VIRUS; VIRAL DIARRHEA VIRUS; PROTEIN ALPHA-SARCIN; HOG-CHOLERA VIRUS; ANTENNAPEDIA HOMEODOMAIN; MEMBRANE INTERACTION; NUCLEOTIDE-SEQUENCE; GLYCOPROTEIN E2; 3RD HELIX; RIBONUCLEASE	The pestivirus envelope glycoprotein E-rns has RNase activity and therefore was suspected to enter cells to cleave RNA. The protein contains an RNase domain with a C-terminal extension, which shows homology with a membrane-active peptide. The modular architecture and the C-terminal homology suggested that the C terminus could be responsible for the presumed translocation. Peptides corresponding to the C-terminal domain of E-rns and also the homologous L3 loop of ribotoxin II were indeed able to translocate across the eukaryotic cell membrane and were targeted to the nucleoli. The entire E-rns protein was also able to translocate into the cell. Furthermore, other labeled proteins and even active enzymes could be transported inside the cell when they were attached to the C-terminal E-rns peptide. Translocation was energy-independent and not mediated by a protein receptor. The peptides showed no specificity for cell type or species.	Inst Anim Sci & Hlth ID Lelystad, Dept Mammalian Virol, NL-8200 AB Lelystad, Netherlands; Pepscan Syst Inc, NL-8203 AB Lelystad, Netherlands	Pepscan Therapeutics B.V.	Langedijk, JPM (corresponding author), Inst Anim Sci & Hlth ID Lelystad, Dept Mammalian Virol, Edelhertweg 15,POB 65, NL-8200 AB Lelystad, Netherlands.							Bellet-Amalric E, 2000, BBA-BIOMEMBRANES, V1467, P131, DOI 10.1016/S0005-2736(00)00218-2; Bruschke CJM, 1997, VACCINE, V15, P1940, DOI 10.1016/S0264-410X(97)00125-4; COLETT M. S., 1998, VIROLOGY, V165, P191; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; FIELDS C G, 1991, Peptide Research, V4, P95; Francis T, 1991, Thyroid, V1, P223, DOI 10.1089/thy.1991.1.223; FRANKLIN AL, 1981, STAIN TECHNOL, V56, P343, DOI 10.3109/10520298109067341; Gasset M., 1994, CURR TOP PEPT PROTEI, V1, P99; HORIUCHI H, 1988, J BIOCHEM-TOKYO, V103, P408, DOI 10.1093/oxfordjournals.jbchem.a122284; Hulst MM, 2000, J VIROL, V74, P9553, DOI 10.1128/JVI.74.20.9553-9561.2000; Hulst MM, 1997, J GEN VIROL, V78, P2779, DOI 10.1099/0022-1317-78-11-2779; HULST MM, 1994, VIROLOGY, V200, P558, DOI 10.1006/viro.1994.1218; Iqbal M, 2000, J GEN VIROL, V81, P451, DOI 10.1099/0022-1317-81-2-451; KONIG M, 1995, J VIROL, V69, P6479; LAMY B, 1991, NUCLEIC ACIDS RES, V19, P1001, DOI 10.1093/nar/19.5.1001; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; MANCHENO JM, 1995, BIOPHYS J, V68, P2387, DOI 10.1016/S0006-3495(95)80421-2; MANCHENO JM, 1995, J THEOR BIOL, V172, P259, DOI 10.1006/jtbi.1995.0022; Matsuzaki K, 1998, BBA-REV BIOMEMBRANES, V1376, P391, DOI 10.1016/S0304-4157(98)00014-8; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; MOORMANN RJM, 1990, VIROLOGY, V177, P184, DOI 10.1016/0042-6822(90)90472-4; PATON DJ, 1992, VET REC, V131, P185, DOI 10.1136/vr.131.9.185; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; RUGGLI N, 1995, VIRUS GENES, V10, P115, DOI 10.1007/BF01702592; RUMENAPF T, 1993, J VIROL, V67, P3288; SCHINDLER DG, 1977, NUCLEIC ACIDS RES, V4, P1097, DOI 10.1093/nar/4.4.1097; SCHNEIDER R, 1993, SCIENCE, V261, P1169, DOI 10.1126/science.8356450; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; THIEL HJ, 1991, J VIROL, V65, P4705, DOI 10.1128/JVI.65.9.4705-4712.1991; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WENGLER G, 1995, FLAVIVIRIDAE VIRUS T; Yang XJ, 1996, STRUCTURE, V4, P837, DOI 10.1016/S0969-2126(96)00090-1; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	34	54	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5308	5314		10.1074/jbc.M104147200	http://dx.doi.org/10.1074/jbc.M104147200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11673454	hybrid			2022-12-25	WOS:000173962900097
J	Sampaleanu, LM; Yu, BMN; Howell, PL				Sampaleanu, LM; Yu, BMN; Howell, PL			Mutational analysis of duck delta 2 crystallin and the structure of an inactive mutant with bound substrate provide insight into the enzymatic mechanism of argininosuccinate lyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BIOCHEMICAL-CHARACTERIZATION; ADENYLOSUCCINATE LYASE; STRUCTURE REFINEMENT; SEQUENCE-ANALYSIS; LENS CRYSTALLINS; II CRYSTALLIN; ACTIVE-SITE; FUMARASE-C; EXPRESSION	The major soluble avian eye lens protein, 5 crystallin, is highly homologous to the housekeeping enzyme argininosuccinate lyase (ASL). ASL is part of the urea and arginine-citrulline cycles and catalyzes the reversible breakdown of argininosuccinate to arginine and fumarate. In duck lenses, there are two 5 crystallin isoforms that are 94% identical in amino acid sequence. Only the 52 isoform has maintained ASL activity and has been used to investigate the enzymatic mechanism of ASL. The role of the active site residues Ser-29, Asp-33, Asp-89, Asn-116, Thr-161, His-162, Arg-238, Thr-281, Ser283, Asn-291, Asp-293, Glu-296, Lys-325, Asp-330, and Lys331 have been investigated by site-directed mutagenesis, and the structure of the inactive duck 52 crystallin (ddeltac2) mutant S283A with bound argininosuccinate was determined at 1.96 Angstrom resolution. The S283A mutation does not interfere with substrate binding, because the 280's loop (residues 270-290) is in the open conformation and Ala-283 is more than 7 A from the substrate. The substrate is bound in a different conformation to that observed previously indicating a large degree of conformational flexibility in the fumarate moiety when the 280's loop is in the open conformation. The structure of the S283A ddeltac2 mutant and mutagenesis results reveal that a complex network of interactions of both protein residues and water molecules are involved in substrate binding and specificity. Small changes even to residues not involved directly in anchoring the argininosuccinate have a significant effect on catalysis. The results suggest that either His-162 or Thr-161 are responsible for proton abstraction and reinforce the putative role of Ser-283 as the catalytic acid, although we cannot eliminate the possibility that arginine is released in an uncharged form, with the solvent providing the required proton. A detailed enzymatic mechanism of ASL/ddeltac2 is presented.	Hosp Sick Children, Struct Biol & Biochem Program, Inst Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Howell, PL (corresponding author), Hosp Sick Children, Struct Biol & Biochem Program, Inst Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							AbuAbed M, 1997, BIOCHEMISTRY-US, V36, P14012, DOI 10.1021/bi971407s; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BARBOSA P, 1991, J BIOL CHEM, V266, P22319; Brunger AT, 1998, CURR OPIN STRUC BIOL, V8, P606, DOI 10.1016/S0959-440X(98)80152-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chakraborty AR, 1999, BIOCHEMISTRY-US, V38, P2435, DOI 10.1021/bi982150g; CHIOU SH, 1992, BIOCHIM BIOPHYS ACTA, V1160, P317, DOI 10.1016/0167-4838(92)90094-T; CHIOU SH, 1991, BIOCHEM INT, V25, P705; GARRARD LJ, 1985, J BIOL CHEM, V260, P5548; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KLEYWEGT GJ, 1995, CCP4 ESF EACBM NEWSL, P45; KONDOH H, 1991, GENE, V99, P267, DOI 10.1016/0378-1119(91)90137-Z; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE HJ, 1993, BIOCHEM J, V293, P537, DOI 10.1042/bj2930537; LEE HJ, 1992, BIOCHEM J, V283, P597, DOI 10.1042/bj2830597; MORI M, 1990, PROG CLIN BIOL RES, V344, P683; NICHOLAS KB, 1997, EMBNEW NEWS, P4; OBRIEN WE, 1986, P NATL ACAD SCI USA, V83, P7211, DOI 10.1073/pnas.83.19.7211; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1998, ACTA CRYSTALLOGR D, V54, P1285, DOI 10.1107/S0907444998004119; PATEJUNAS G, 1995, EXP EYE RES, V61, P151, DOI 10.1016/S0014-4835(05)80034-X; PIATIGORSKY J, 1994, EXS, V71, P241; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; PIATIGORSKY J, 1989, FASEB J, V3, P1933, DOI 10.1096/fasebj.3.8.2656357; RAUSHEL FM, 1984, BIOCHEMISTRY-US, V23, P1791, DOI 10.1021/bi00303a032; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; ROUSSEL A, 1991, TURBO FRODO SILICON; Sampaleanu LM, 1999, PROTEIN SCI, V8, P529; Sampaleanu LM, 2001, BIOCHEMISTRY-US, V40, P15570, DOI 10.1021/bi011525m; Sampaleanu LM, 2001, BIOCHEMISTRY-US, V40, P2732, DOI 10.1021/bi002272k; SARIBAS AS, 1994, J BIOL CHEM, V269, P6313; SIMPSON A, 1994, NAT STRUCT BIOL, V1, P724, DOI 10.1038/nsb1094-724; STONE RL, 1993, J BIOL CHEM, V268, P19710; Toth EA, 2000, STRUCT FOLD DES, V8, P163, DOI 10.1016/S0969-2126(00)00092-7; Turner MA, 1997, P NATL ACAD SCI USA, V94, P9063, DOI 10.1073/pnas.94.17.9063; Vallee F, 1999, BIOCHEMISTRY-US, V38, P2425, DOI 10.1021/bi982149h; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Weaver T, 1996, BIOCHEMISTRY-US, V35, P13955, DOI 10.1021/bi9614702; Weaver T, 1997, PROTEIN SCI, V6, P834; Weaver T, 1998, J MOL BIOL, V280, P431, DOI 10.1006/jmbi.1998.1862; WEAVER TM, 1995, NAT STRUCT BIOL, V2, P654, DOI 10.1038/nsb0895-654; WILLIAMS SE, 1992, BIOCHEMISTRY-US, V31, P9768, DOI 10.1021/bi00155a033; WOODS SA, 1986, BIOCHEM J, V237, P547, DOI 10.1042/bj2370547; WOODS SA, 1988, BIOCHIM BIOPHYS ACTA, V954, P14, DOI 10.1016/0167-4838(88)90050-7; Wu CY, 1998, BIOCHEM J, V333, P327, DOI 10.1042/bj3330327	47	29	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4166	4175		10.1074/jbc.M107465200	http://dx.doi.org/10.1074/jbc.M107465200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11698398	hybrid			2022-12-25	WOS:000173813900052
J	Kimchi-Sarfaty, C; Kasir, J; Ambudkar, SV; Rahamimoff, H				Kimchi-Sarfaty, C; Kasir, J; Ambudkar, SV; Rahamimoff, H			Transport activity and surface expression of the Na+-Ca2+ exchanger NCX1 are inhibited by the immunosuppressive agent cyclosporin A and by the nonimmunosuppressive agent PSC833	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM TOXICITY; MAMMALIAN-CELL LINES; FUNCTIONAL EXPRESSION; MULTIDRUG-RESISTANCE; SDZ PSC-833; RNA-POLYMERASE; HELA-CELLS; CLONING; TRANSPLANTATION; PROTEIN	Cyclosporin A (CsA) treatment of HEK 293 cells expressing the rat heart RHE-1 (NCX1.1, EMBL accession number X68191) or the rat brain RBE-2 (NCX1.5, GenBank(TM) accession number X68813) Na+-Ca2+ exchanger inhibited their transport activity in a concentration-dependent manner. The inhibition was detectable at 2 mum CsA, and exposure of the cells to 20 mum CsA resulted in a decrease of the Na+-dependent Ca2+ uptake to about 20% relative to that of untreated cells. Determination of the surface expression of the exchanger protein revealed a parallel concentration-dependent reduction in the amount of the immunoreactive protein. No reduction was detected in the amount of total immunoreactive exchanger protein in CsA-treated cells relative to untreated ones. Among the different drugs tested, only PSC833, an analog of cyclosporin D, mimicked the effects of CsA. Exposure of the transfected cells to the chemically related cyclosporin D and macrolide drugs (FK506 or rapamycin) had no effect on the transport activity or the surface expression of the Na+-Ca2+ exchanger. Co-expression of the human multidrug transporter P-glycoprotein (of which both drugs are modulators) with the cloned Na+-Ca2+ exchanger revealed that transport activity and surface expression of each transporter in the co-transfected system were similar to those of each transporter alone in both the presence and absence of CsA or PSC833. CsA and PSC833 inhibited the surface expression of the NCX1 protein but did not alter the surface expression of P-glycoprotein. Unlike some P-glycoprotein endoplasmic reticulum-retained mutants (Loo, T. W., and Clarke, D. M. (1997) J. Biol. Chem. 272, 709-712), CsA did not rescue RBE-2/F913-->Stop, an endoplasmic reticulum-retained function-competent mutant of the Na+-Ca2+ exchanger (Kasir, J., Ren, X., Furman, L, and Rahamimoff, H. (1999) J. Biot Chem. 274, 24873-24880) and did not induce its kinesis to the surface membrane, further demonstrating molecular differences between P-glycoprotein and NCX1 mutants for interaction with CsA.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel; NCI, Cell Biol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rahamimoff, H (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.		Ambudkar, Suresh V/L-1317-2016; Ambudkar, Suresh V/B-5964-2008	Kimchi-Sarfaty, Chava/0000-0002-9355-8585				ArchinalMattheis A, 1995, ONCOL RES, V7, P603; BERDEN JHM, 1985, LANCET, V1, P219; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; BOESCH D, 1991, CANCER RES, V51, P4226; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; CARAFOLI E, 1999, CALCIUM CELLULAR REG, V1; Chen H, 1998, FEBS LETT, V422, P307, DOI 10.1016/S0014-5793(98)00028-3; Cook O, 1998, BBA-BIOMEMBRANES, V1371, P40, DOI 10.1016/S0005-2736(97)00272-1; Cruz F, 2001, BIOCHEM PHARMACOL, V62, P129, DOI 10.1016/S0006-2952(01)00642-6; DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404; Frapier JM, 2001, FEBS LETT, V493, P57, DOI 10.1016/S0014-5793(01)02269-4; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FURMAN I, 1995, J BIOL CHEM, V270, P19120, DOI 10.1074/jbc.270.32.19120; FURMAN I, 1993, FEBS LETT, V319, P105, DOI 10.1016/0014-5793(93)80046-W; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Hariharan S, 2000, NEW ENGL J MED, V342, P605, DOI 10.1056/NEJM200003023420901; Harlow E., 1988, ANTIBODIES LAB MANUA; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; Helekar SA, 1997, P NATL ACAD SCI USA, V94, P5432, DOI 10.1073/pnas.94.10.5432; Holt DW, 2000, CLIN CHEM, V46, P872; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; Kasir J, 1999, J BIOL CHEM, V274, P24873, DOI 10.1074/jbc.274.35.24873; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lemaire M, 1996, CANCER CHEMOTH PHARM, V38, P481, DOI 10.1007/s002800050515; Li L, 2000, J BIOL CHEM, V275, P20903, DOI 10.1074/jbc.M000995200; LI ZP, 1994, J BIOL CHEM, V269, P17434; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; LOW W, 1993, FEBS LETT, V316, P63, DOI 10.1016/0014-5793(93)81737-K; Lush RM, 1997, J CLIN PHARMACOL, V37, P123, DOI 10.1002/j.1552-4604.1997.tb04770.x; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; OELLERICH M, 1995, THER DRUG MONIT, V17, P642, DOI 10.1097/00007691-199512000-00017; Ren XY, 2001, J BIOL CHEM, V276, P9572, DOI 10.1074/jbc.M007823200; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; Rund D, 1998, HUM GENE THER, V9, P649, DOI 10.1089/hum.1998.9.5-649; SADEG N, 1993, IMMUNOPHARM IMMUNOT, V15, P163, DOI 10.3109/08923979309025992; SCHERRER U, 1990, NEW ENGL J MED, V323, P693, DOI 10.1056/NEJM199009133231101; Schiene-Fischer C, 2001, FEBS LETT, V495, P1, DOI 10.1016/S0014-5793(01)02326-2; Shiraishi S, 2000, NEUROSCI LETT, V293, P211, DOI 10.1016/S0304-3940(00)01513-5; Shiraishi S, 2001, J PHARMACOL EXP THER, V297, P657; Smith AJ, 1998, J NATL CANCER I, V90, P1161, DOI 10.1093/jnci/90.15.1161; Sonneveld P, 1996, LEUKEMIA, V10, P1741; Tran TT, 2000, J BIOL CHEM, V275, P35708, DOI 10.1074/jbc.M005636200; Zhou Y, 1999, MOL PHARMACOL, V56, P997, DOI 10.1124/mol.56.5.997	49	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2505	2510		10.1074/jbc.M109154200	http://dx.doi.org/10.1074/jbc.M109154200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11700317	hybrid			2022-12-25	WOS:000173421500019
J	Arrigo, CJ; Singh, K; Modak, MJ				Arrigo, CJ; Singh, K; Modak, MJ			DNA polymerase I of Mycobacterium tuberculosis - Functional role of a conserved aspartate in the hinge joining the M and N helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; KLENOW FRAGMENT; ESCHERICHIA-COLI; CRYSTAL-STRUCTURES; DEOXYNUCLEOSIDE TRIPHOSPHATE; ACTIVE-SITE; O-HELIX; COMPLEX; RESIDUES; BINDING	The highly conserved GXD sequence present in the Mycobacterium tuberculosis DNA polymerase I corresponds to a hinge region in the finger subdomain connecting M and N helices of Escherichia coli pol I. An examination of the crystal structures of pol I family polymerases reveals that the invariant aspartate of the hinge forms a salt bridge with the conserved arginine of the O-helix and an H-bond with Gln-708. To clarify the role of this region, we generated and characterized conserved and nonconserved mutant derivatives of this aspartate, the preceding glutamate and the GIn in TB pol I. For comparison, D732A mutein of pol I was also included. The muteins representing conserved aspartate (Asp-707 of TB pol I or Asp-732 of pol I) showed a strong K-m(dNTP) effect and minor alteration in K-d(DNA), with about 10-20-fold decrease in overall catalytic efficiency. The TB muteins, E706A and Q683A, have less pronounced deviations from the wild-type enzyme. Further examination of D707A of TB pol I showed no alteration in the processivity or the dideoxynucleotide sensitivity patterns. However, both TB pol D707A and homologous E. coli D732A failed to form a stable E-DNA-dNTP ternary complex. These results suggest that the aspartate in the hinge region is catalytically important and is required for dNTP binding and in the formation of a prepolymerase ternary complex.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Modak, MJ (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.				NIGMS NIH HHS [GM-36307] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Dzantiev L, 1999, J BIOL CHEM, V274, P3279, DOI 10.1074/jbc.274.6.3279; Gangurde R, 2000, J BIOL CHEM, V275, P19685, DOI 10.1074/jbc.M002307200; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P7256, DOI 10.1021/bi960537i; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; Li Y, 1998, PROTEIN SCI, V7, P1116, DOI 10.1002/pro.5560070505; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; Mizrahi V, 1996, NUCLEIC ACIDS RES, V24, P4845, DOI 10.1093/nar/24.24.4845; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; SINGH K, 1998, TRENDS BIOCHEM SCI, V21, P186; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; Tong WJ, 1997, BIOCHEMISTRY-US, V36, P5749, DOI 10.1021/bi962410z; Tuske S, 2000, J BIOL CHEM, V275, P23759, DOI 10.1074/jbc.M001804200	25	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1653	1661		10.1074/jbc.M108536200	http://dx.doi.org/10.1074/jbc.M108536200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11677239	hybrid			2022-12-25	WOS:000173421300007
J	Bathgate, RAD; Samuel, CS; Burazin, TCD; Layfield, S; Claasz, AA; Reytomas, IGT; Dawson, NF; Zhao, CX; Bond, C; Summers, RJ; Parry, LJ; Wade, JD; Tregear, GW				Bathgate, RAD; Samuel, CS; Burazin, TCD; Layfield, S; Claasz, AA; Reytomas, IGT; Dawson, NF; Zhao, CX; Bond, C; Summers, RJ; Parry, LJ; Wade, JD; Tregear, GW			Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene - Novel members of the relaxin peptide family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-LIKE PEPTIDE; RAT-BRAIN; EXPRESSION; BINDING; IDENTIFICATION; SUPERFAMILY; FIBROBLASTS; RECEPTORS; PREGNANCY; SECRETION	We have identified a novel human relaxin gene, designated H3 relaxin, and an equivalent relaxin gene in the mouse from the Celera Genomics data base. Both genes encode a putative prohormone sequence incorporating the classic two-chain, three cysteine-bonded structure of the relaxin/insulin family and, importantly, contain the RXXXRXX(I/V) motif in the B-chain that is essential for relaxin receptor binding. A peptide derived from the likely proteolytic processing of the H3 relaxin prohormone sequence was synthesized and found to possess relaxin activity in bioassays utilizing the human monocytic cell line, THP-1, that expresses the relaxin receptor. The expression of this novel relaxin gene was studied in mouse tissues using RT-PCR, where transcripts were identified with a pattern of expression distinct from that of the previously characterized mouse relaxin. The highest levels of expression were found in the brain, whereas significant expression was also observed in the spleen, thymus, lung, and ovary. Northern blotting demonstrated an similar to1.2-kb transcript present in mouse brain poly(A) RNA but not in other tissues. These data, together with the localization of transcripts in the pars ventromedialis of the dorsal tegmental nucleus of C57BLK6J mouse brain by in situ hybridization histochemistry, suggest a new role for relaxin in neuropeptide signaling processes. Together, these studies describe a third member of the human relaxin family and its equivalent in the mouse.	Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia; Monash Univ, Dept Pharmacol, Clayton, Vic 3800, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne; Monash University	Bathgate, RAD (corresponding author), Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia.		Summers, Roger J/F-6351-2011; Bathgate, Ross/ABE-6471-2020	Summers, Roger J/0000-0002-8367-4056; Bathgate, Ross/0000-0001-6301-861X; Wade, John/0000-0002-1352-6568; Parry, Laura/0000-0002-6883-3418				ADHAM IM, 1993, J BIOL CHEM, V268, P26668; Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; Bathgate R, 1999, BIOL REPROD, V61, P1090, DOI 10.1095/biolreprod61.4.1090; Bullesbach EE, 2000, J BIOL CHEM, V275, P35276, DOI 10.1074/jbc.M005728200; BULLESBACH EE, 1995, INT J PEPT PROT RES, V46, P238; BULLESBACH EE, 1991, J BIOL CHEM, V266, P10754; Bullesbach EE, 1999, J BIOL CHEM, V274, P22354, DOI 10.1074/jbc.274.32.22354; Bullesbach EE, 1995, PROGRESS IN RELAXIN RESEARCH, P145; Burazin TCD, 2001, J NEUROENDOCRINOL, V13, P358, DOI 10.1046/j.1365-2826.2001.00640.x; CLAASZ AA, 2001, RELAXIN 2000; Conklin D, 1999, GENOMICS, V60, P50, DOI 10.1006/geno.1999.5899; Dawson NF, 1999, J PEPT RES, V53, P542, DOI 10.1034/j.1399-3011.1999.00060.x; De Rienzo G, 2001, ENDOCRINOLOGY, V142, P3231, DOI 10.1210/en.142.7.3231; EVANS BA, 1993, J MOL ENDOCRINOL, V10, P15, DOI 10.1677/jme.0.0100015; Gunnersen JM, 1996, MOL CELL ENDOCRINOL, V118, P85, DOI 10.1016/0303-7207(96)03770-7; HANSELL DJ, 1991, J CLIN ENDOCR METAB, V72, P899, DOI 10.1210/jcem-72-4-899; HERRERO MT, 1991, NEUROSCI LETT, V123, P144, DOI 10.1016/0304-3940(91)90916-H; HORNSBY DJ, 2001, P 3 INT C REL REL PE; Hsu SY, 1999, MOL ENDOCRINOL, V13, P2163, DOI 10.1210/me.13.12.2163; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; IVELL R, 1989, MOL CELL ENDOCRINOL, V66, P251, DOI 10.1016/0303-7207(89)90037-3; Ivell R, 1997, Rev Reprod, V2, P133, DOI 10.1530/ror.0.0020133; LIU R, 1984, BRAIN RES, V310, P123, DOI 10.1016/0006-8993(84)90015-5; LUCAS C, 1989, J ENDOCRINOL, V120, P449, DOI 10.1677/joe.0.1200449; MARUYAMA K, 1992, J PROTEIN CHEM, V11, P1, DOI 10.1007/BF01025086; MEESSEN H, 1949, CYTOARCHITECTONIC AT; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OSHEROFF PL, 1991, P NATL ACAD SCI USA, V88, P6413, DOI 10.1073/pnas.88.15.6413; Palejwala S, 1998, ENDOCRINOLOGY, V139, P1208, DOI 10.1210/en.139.3.1208; PARRY LJ, 1990, J NEUROENDOCRINOL, V2, P53, DOI 10.1111/j.1365-2826.1990.tb00392.x; Parsell DA, 1996, J BIOL CHEM, V271, P27936, DOI 10.1074/jbc.271.44.27936; PEAKER M, 1989, ENDOCRINOLOGY, V125, P693, DOI 10.1210/endo-125-2-693; Qiao ZS, 2001, BIOCHEMISTRY-US, V40, P2662, DOI 10.1021/bi001613r; Sambrook J., 2002, MOL CLONING LAB MANU; Sherwood O. David, 1994, P861; Sinnayah P, 1999, ENDOCRINOLOGY, V140, P5082, DOI 10.1210/en.140.11.5082; Stewart DR, 1999, HUM REPROD, V14, P338, DOI 10.1093/humrep/14.2.338; Summerlee AJS, 1998, ENDOCRINOLOGY, V139, P2322, DOI 10.1210/en.139.5.2322; Tan YY, 1998, BRIT J PHARMACOL, V123, P762, DOI 10.1038/sj.bjp.0701659; Tan YY, 1999, BRIT J PHARMACOL, V127, P91, DOI 10.1038/sj.bjp.0702517; TAN YY, 2001, RELAXIN 2000; UNEMORI EN, 1990, J BIOL CHEM, V265, P10681; Wade J D, 1996, Biomed Pept Proteins Nucleic Acids, V2, P27; Wade J D, 1996, Biomed Pept Proteins Nucleic Acids, V2, P89; WADE JD, 1994, J PROTEIN CHEM, V13, P315, DOI 10.1007/BF01901564; WILSON PM, 1985, BRAIN RES REV, V10, P85, DOI 10.1016/0165-0173(85)90001-3; WINSLOW JW, 1992, ENDOCRINOLOGY, V130, P2660, DOI 10.1210/en.130.5.2660; Wisden W, 1994, SITU HYBRIDIZATION P, P9	50	308	318	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1148	1157		10.1074/jbc.M107882200	http://dx.doi.org/10.1074/jbc.M107882200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11689565	hybrid			2022-12-25	WOS:000173166800036
J	Gutierrez-Cirlos, EB; Trumpower, BL				Gutierrez-Cirlos, EB; Trumpower, BL			Inhibitory analogs of ubiquinol act anti-cooperatively on the yeast cytochrome bc(1) complex - Evidence for an alternating, half-of-the-sites mechanism of ubiquinol oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; STEADY-STATE KINETICS; IRON-SULFUR PROTEIN; C REDUCTASE; SACCHAROMYCES-CEREVISIAE; ELECTRON-TRANSFER; RESPIRATORY-CHAIN; BINDING; OXIDOREDUCTASE; PURIFICATION	The cytochrome bc(1) complex is a dimeric enzyme that links electron transfer from ubiquinol to cytochrome c by a protonmotive Q cycle mechanism in which ubiquinol is oxidized at one center in the enzyme, referred to as center P, and ubiquinone is re-reduced at a second center, referred to as center N. To understand better the mechanism of ubiquinol oxidation, we have examined the interaction of several inhibitory analogs of ubiquinol with the yeast cytochrome bc(1) complex. Stigmatellin and methoxyacrylate stilbene, two inhibitors that block ubiquinol oxidation at center P, inhibit the yeast enzyme with a stoichiometry of 0.5 per bc(1) complex, indicating that one molecule of inhibitor is sufficient to fully inhibit the dimeric enzyme. This stoichiometry was obtained when the inhibitors were titrated in cytochrome c reductase assays and in reactions of quinol with enzyme in which the inhibitors block pre-steady state reduction of cytochrome b. As an independent measure of inhibitor binding, we titrated the red shift in the optical spectrum of ferrocytochrome b with methoxyacrylate stilbene and thus confirmed the results of the inhibition of activity titrations. The titration curves also indicate that the binding is anti-cooperative, in that a second molecule of inhibitor binds with much lower affinity to a dimer in which an inhibitor molecule is already bound. Because these inhibitors bind to the ubiquinol oxidation site in the bc(1) complex, we propose that the yeast cytochrome bc(1) complex oxidizes ubiquinol by an alternating, half-of-the-sites mechanism.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Trumpower, BL (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	Trumpower@Dartmouth.edu	Gutierrez Cirlos, Emma Berta/D-4463-2011; Gutiérrez, Emma/AAG-5191-2021	Gutierrez Cirlos, Emma Berta/0000-0002-6672-1711	NIGMS NIH HHS [GM20379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020379, R37GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY MN, 1992, J BIOL CHEM, V267, P4128; Berry EA, 1999, J BIOENERG BIOMEMBR, V31, P177, DOI 10.1023/A:1005459426843; BRANDT U, 1988, EUR J BIOCHEM, V173, P499, DOI 10.1111/j.1432-1033.1988.tb14026.x; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; CAVAZZONI M, 1993, ARCH BIOCHEM BIOPHYS, V303, P246, DOI 10.1006/abbi.1993.1279; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; Do TQ, 2001, J BIOL CHEM, V276, P18161, DOI 10.1074/jbc.M100952200; FERNANDEZVALESCO J, 1991, BIOCHEM SOC T, V19, P588, DOI 10.1042/bst0190588; Gopta OA, 1998, FEBS LETT, V431, P291, DOI 10.1016/S0014-5793(98)00768-6; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KSENZENKO M, 1983, FEBS LETT, V155, P19, DOI 10.1016/0014-5793(83)80200-2; KUBOTA T, 1992, J BIOCHEM-TOKYO, V111, P91, DOI 10.1093/oxfordjournals.jbchem.a123725; LINK TA, 1993, J BIOENERG BIOMEMBR, V25, P221, DOI 10.1007/BF00762584; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; Margoliash E, 1967, METHOD ENZYMOL, V10, P339; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Nett JH, 2000, EUR J BIOCHEM, V267, P5777, DOI 10.1046/j.1432-1327.2000.01650.x; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; THIERBACH G, 1984, BIOCHIM BIOPHYS ACTA, V765, P227, DOI 10.1016/0005-2728(84)90017-3; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TSAI AL, 1985, BIOCHIM BIOPHYS ACTA, V806, P418, DOI 10.1016/0005-2728(85)90249-X; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	31	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1195	1202		10.1074/jbc.M109097200	http://dx.doi.org/10.1074/jbc.M109097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11700316	hybrid			2022-12-25	WOS:000173166800042
J	Poy, MN; Ruch, RJ; Fernstrom, MA; Okabayashi, Y; Najjar, SM				Poy, MN; Ruch, RJ; Fernstrom, MA; Okabayashi, Y; Najjar, SM			Shc and CEACAM1 interact to regulate the mitogenic action of insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; CELL-ADHESION MOLECULE; BILIARY GLYCOPROTEIN; RECEPTOR SUBSTRATE-1; INDUCED PHOSPHORYLATION; ENDOGENOUS SUBSTRATE; JUXTAMEMBRANE DOMAIN; TYROSINE KINASE; PROTEIN; BINDING	CEACAM1, a tumor suppressor (previously known as pp120), is a plasma membrane protein that undergoes phosphorylation on Tyr(488) in its cytoplasmic tail by the insulin receptor tyrosine kinase. Co-expression of CEACAM1 with insulin receptors decreased cell growth in response to insulin. Co-immunoprecipitation experiments in intact NIH 3T3 cells and glutathione S-transferase pull-down assays revealed that phosphorylated Tyr488 in CEACAM1 binds to the SH2 domain of She, another substrate of the insulin receptor. Overexpressing She SH2 domain relieved endogenous She from binding to CEACAM1 and restored MAP kinase activity, growth of cells in response to insulin, and their colonization in soft agar. Thus, by binding to She, CEACAM1 sequesters this major coupler of Grb2 to the insulin receptor and down-regulates the Ras/MAP kinase mitogenesis pathway. Additionally, CEACAM1 binding to She enhances its ability to compete with IRS-1 for phosphorylation by the insulin receptor. This leads to a decrease in IRS-1 binding to phosphoinositide W-kinase and to the down-regulation of the phosphoinositide 3'-kinase/Akt pathway that mediates cell proliferation and survival. Thus, binding to She appears to constitute a major mechanism for the down-regulatory effect of CEACAM1 on cell proliferation.	Med Coll Ohio, Dept Pharmacol & Therapeut, Toledo, OH 43614 USA; Med Coll Ohio, Dept Pathol, Toledo, OH 43614 USA; Kobe Univ, Sch Med, Dept Internal Med 2, Kobe, Hyogo 650, Japan	Kobe University	Najjar, SM (corresponding author), Med Coll Ohio, Dept Pharmacol & Therapeut, HSci Bldg,Rm 270,3035 Arlington Ave, Toledo, OH 43614 USA.	snajjar@mco.edu	Najjar, Sonia M/GXW-2217-2022; Poy, Matthew/F-6914-2017	Poy, Matthew/0000-0002-4904-2426	NATIONAL CANCER INSTITUTE [T32CA079450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK057497, R01DK054254] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA79450] Funding Source: Medline; NIDDK NIH HHS [DK57497, DK54254] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bone H, 2000, CELL SIGNAL, V12, P183, DOI 10.1016/S0898-6568(99)00088-1; Choice CV, 1998, J BIOL CHEM, V273, P22194, DOI 10.1074/jbc.273.35.22194; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; EDLUND M, 1993, FEBS LETT, V327, P90, DOI 10.1016/0014-5793(93)81046-3; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Ishihara H, 1997, J BIOL CHEM, V272, P9581; Ishihara H, 1999, BIOCHEM BIOPH RES CO, V260, P265, DOI 10.1006/bbrc.1999.0888; JHUN BH, 1994, J BIOL CHEM, V269, P5699; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KasusJacobi A, 1997, J BIOL CHEM, V272, P17166, DOI 10.1074/jbc.272.27.17166; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kimura M, 1997, EUR J PHARMACOL, V327, P87, DOI 10.1016/S0014-2999(97)89682-3; LiCalzi S, 1997, AM J PHYSIOL-ENDOC M, V273, pE801, DOI 10.1152/ajpendo.1997.273.4.E801; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Luo WP, 1998, ONCOGENE, V16, P1141, DOI 10.1038/sj.onc.1201619; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; Najjar SM, 1998, J BIOL CHEM, V273, P12923, DOI 10.1074/jbc.273.21.12923; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; Najjar SM, 1997, BIOCHEMISTRY-US, V36, P6827, DOI 10.1021/bi962634h; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RUCH RJ, 1988, CANCER RES, V48, P2519; Sadekova S, 2000, MOL BIOL CELL, V11, P65, DOI 10.1091/mbc.11.1.65; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Soni P, 2000, MOL CELL BIOL, V20, P3896, DOI 10.1128/MCB.20.11.3896-3905.2000; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; THOMPSON NL, 1994, PATHOBIOLOGY, V62, P209, DOI 10.1159/000163912; Turbide C, 1997, CANCER RES, V57, P2781; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; XIAO S, 1994, J BIOL CHEM, V269, P21244; Xu YR, 1999, J CELL BIOCHEM, V75, P264; Xu YR, 1997, J BIOL CHEM, V272, P13463, DOI 10.1074/jbc.272.21.13463; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	61	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1076	1084		10.1074/jbc.M108415200	http://dx.doi.org/10.1074/jbc.M108415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694516	hybrid			2022-12-25	WOS:000173166800027
J	Fallon, L; Moreau, F; Croft, BG; Labib, N; Gu, WJ; Fon, EA				Fallon, L; Moreau, F; Croft, BG; Labib, N; Gu, WJ; Fon, EA			Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; ALPHA-SYNUCLEIN; NMDA RECEPTOR; LEWY BODIES; MEMBRANE; DISEASE; GENE; COMPLEX; DOMAINS; FAMILY	Mutations in the gene encoding parkin cause an autosomal recessive juvenile-onset form of Parkinson's disease. Parkin functions as a RING-type E3 ubiquitin-ligase, coordinating the transfer of ubiquitin to substrate proteins and thereby targeting them for degradation by the proteasome. We now report that the extreme C terminus of parkin, which is selectively truncated by a Parkinson's disease-causing mutation, functions as a class II PDZ-binding motif that binds CASK the mammalian homolog of Caenorhabditis elegans Lin-2, but not other PDZ proteins in brain extracts. Importantly, parkin co-localizes with CASK at synapses in cultured cortical neurons as well as in postsynaptic densities and lipid rafts in brain. Further, parkin associates not only with CASK but also with other postsynaptic proteins in the N-methyl D-aspartate (NMDA) receptor-signaling complex, in rat brain in vivo. Finally, despite exhibiting E2-dependent ubiquitin ligase activity, rat brain parkin does not ubiquitinate CASK, suggesting that CASK may function in targeting or scaffolding parkin within the postsynaptic complex rather than as a direct substrate for parkin-mediated ubiquitination. These data implicate for the first time a PDZ-mediated interaction between parkin and CASK in neurodegeneration and possibly in ubiquitination of proteins involved in synaptic transmission and plasticity.	McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada; Hop La Pitie Salpetriere, INSERM, U289, Paris, France	McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Fon, EA (corresponding author), McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.							Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Gu WJ, 2000, J NEUROCHEM, V74, P1773, DOI 10.1046/j.1471-4159.2000.0741773.x; Hata Y, 1996, J NEUROSCI, V16, P2488; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Mueller HT, 2000, J BIOL CHEM, V275, P39302, DOI 10.1074/jbc.M008453200; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; Perez AS, 1998, NEUROSCI LETT, V258, P121, DOI 10.1016/S0304-3940(98)00846-5; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; SI SK, 2001, J NEUROCHEM, V78, P42; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	36	148	150	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					486	491		10.1074/jbc.M109806200	http://dx.doi.org/10.1074/jbc.M109806200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11679592	hybrid			2022-12-25	WOS:000173087900065
J	Schmitz, C; Hilpert, J; Jacobsen, C; Boensch, C; Christensen, EI; Luft, FC; Willnow, TE				Schmitz, C; Hilpert, J; Jacobsen, C; Boensch, C; Christensen, EI; Luft, FC; Willnow, TE			Megalin deficiency offers protection from renal aminoglycoside accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENTAMICIN UPTAKE; MEMBRANE-BINDING; PROXIMAL TUBULE; NEPHROTOXICITY; RECEPTOR; CALCIUM; KIDNEY; GP330; RATS; LOCALIZATION	Aminoglycosides are antibiotics commonly used to treat life-threatening Gram-negative bacterial infections. However, their use is hampered by their severe nephrotoxicity due to accumulation in renal proximal tubules. Several pathways have been implicated in the renal uptake of aminoglycosides including megalin, an endocytic receptor in proximal tubular cells. Here, we have used mouse models with genetic or functional megalin deficiency to explore the contribution of megalin and other pathways to renal aminoglycoside uptake in vivo. We demonstrate that the uptake of aminoglycosides into the kidney directly correlates with renal megalin activity and is completely eliminated in mice lacking the receptor. Thus, our studies provide unequivocal evidence that megalin is the only major pathway responsible for renal aminoglycoside accumulation and that the receptor represents a unique drug target to prevent aminoglycoside-induced nephrotoxicity in patients.	Max Delbrueck Ctr Mol Med, D-13125 Berlin, Germany; Free Univ Berlin, Med Fac, D-13125 Berlin, Germany; Humboldt Univ, Fac Med, Franz Volhard Clin, D-13125 Berlin, Germany; Aarhus Univ, Dept Biochem Med, DK-8000 Aarhus, Denmark; Aarhus Univ, Dept Cell Biol, DK-8000 Aarhus, Denmark	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Franz-Volhard Clinical Research Center; Humboldt University of Berlin; Aarhus University; Aarhus University	Willnow, TE (corresponding author), Max Delbrueck Ctr Mol Med, Robert Roessle Str 10, D-13125 Berlin, Germany.	willnow@mdc-berlin.de		Willnow, Thomas/0000-0001-9515-7921; Luft, Friedrich/0000-0002-8635-1199				BEGG EJ, 1995, BRIT J CLIN PHARMACO, V39, P605, DOI 10.1111/j.1365-2125.1995.tb05719.x; Birn H, 2000, J AM SOC NEPHROL, V11, P191, DOI 10.1681/ASN.V112191; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; Christensen EI, 1999, J AM SOC NEPHROL, V10, P685; Christensen EI, 1998, INT REV CYTOL, V180, P237; Christensen EI, 1999, J AM SOC NEPHROL, V10, P2224; Davey P., 1991, Reviews in Medical Microbiology, V2, P22; Decorti G, 1999, LIFE SCI, V65, P1115, DOI 10.1016/S0024-3205(99)00345-8; DEGROOT JCMJ, 1990, HEARING RES, V50, P35, DOI 10.1016/0378-5955(90)90031-J; EISENBERG JM, 1987, ANN INTERN MED, V107, P900, DOI 10.7326/0003-4819-107-6-900; FARQUHAR MG, 1995, J CLIN INVEST, V96, P1184, DOI 10.1172/JCI118149; FORD DM, 1994, AM J PHYSIOL, V266, pC52, DOI 10.1152/ajpcell.1994.266.1.C52; GIULIANO RA, 1986, J PHARMACOL EXP THER, V236, P470; Hitt CM, 1997, PHARMACOTHERAPY, V17, P810; HOLOHAN PD, 1988, J PHARMACOL EXP THER, V247, P349; HUY PTB, 1986, J CLIN INVEST, V77, P1492, DOI 10.1172/JCI112463; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; Leheste JR, 1999, AM J PATHOL, V155, P1361, DOI 10.1016/S0002-9440(10)65238-8; LUFT FC, 1974, J INFECT DIS, V130, P656, DOI 10.1093/infdis/130.6.656; MATHEWS A, 1987, J CLIN PHARM THER, V12, P273, DOI 10.1111/j.1365-2710.1987.tb00539.x; Mingeot-Leclercq MP, 1999, ANTIMICROB AGENTS CH, V43, P1003, DOI 10.1128/AAC.43.5.1003; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; Molitoris BA, 1997, CURR OPIN NEPHROL HY, V6, P384; Nagai J, 2001, AM J PHYSIOL-RENAL, V281, pF337, DOI 10.1152/ajprenal.2001.281.2.F337; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; Orlando RA, 1998, J AM SOC NEPHROL, V9, P1759; QUARUM ML, 1984, J LAB CLIN MED, V103, P104; SCHACHT J, 1993, OTOLARYNG CLIN N AM, V26, P845; SILVERBLATT FJ, 1979, KIDNEY INT, V15, P335, DOI 10.1038/ki.1979.45; Sousa MM, 2000, J BIOL CHEM, V275, P38176, DOI 10.1074/jbc.M002886200; Sundin DP, 2001, J AM SOC NEPHROL, V12, P114, DOI 10.1681/ASN.V121114; SUZUKI S, 1994, COMP BIOCHEM PHYS C, V109, P77, DOI 10.1016/1367-8280(94)00037-9; SUZUKI S, 1995, COMP BIOCHEM PHYS C, V112, P15, DOI 10.1016/0742-8413(95)00075-5; WEINBERG JM, 1985, BIOCHEM PHARMACOL, V34, P1779, DOI 10.1016/0006-2952(85)90649-5; WILLIAMS PD, 1987, ANTIMICROB AGENTS CH, V31, P570, DOI 10.1128/AAC.31.4.570; WILLIAMS PD, 1985, RES COMMUN CHEM PATH, V47, P317; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x	38	151	158	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					618	622		10.1074/jbc.M109959200	http://dx.doi.org/10.1074/jbc.M109959200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11700326	hybrid			2022-12-25	WOS:000173087900081
J	Park, KH; Suk, JE; Jacobsen, R; Gray, WR; McIntosh, JM; Han, KH				Park, KH; Suk, JE; Jacobsen, R; Gray, WR; McIntosh, JM; Han, KH			Solution conformation of alpha-conotoxin EI, a neuromuscular toxin specific for the alpha(1)/delta subunit interface of Torpedo nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL SOLUTION STRUCTURE; 1.1 ANGSTROM RESOLUTION; NMR SOLUTION STRUCTURE; CRYSTAL-STRUCTURE; PROTEIN CONFORMATIONS; PAIRWISE INTERACTIONS; H-1-NMR SPECTROSCOPY; MOLECULAR-DYNAMICS; DISTANCE GEOMETRY	A high resolution structure of alpha-conotoxin EI has been determined by H-1 NMR spectroscopy and molecular modeling. alpha-Conotoxin EI has the same disulfide framework as alpha4/7 conotoxins targeting neuronal nicotinic acetylcholine receptors but antagonizes the neuromuscular receptor as do the alpha3/5 and alphaA conotoxins. The unique binding preference of alpha-conotoxin El to the alpha(1)/delta subunit interface of Torpedo neuromuscular receptor makes it a valuable structural template for superposition of various alpha-conotoxins possessing distinct receptor subtype specificities. Structural comparison of alpha-conotoxin EI with the gamma-subunit favoring a-conotoxin GI suggests that the Torpedo delta-subunit preference of the former originates from its second loop. Superposition of three-dimensional structures of seven alpha-conotoxins reveals that the estimated size of the toxin-binding pocket in nicotinic acetylcholine receptor is similar to20 Angstrom (height) x 20 Angstrom (width) x 15 Angstrom (thickness).	Korea Res Inst Biosci & Biotechnol, Prot Engn Lab, Taejon, South Korea; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Han, KH (corresponding author), Korea Res Inst Biosci & Biotechnol, Prot Engn Lab, Yusong PO Box 115, Taejon, South Korea.				NIGMS NIH HHS [GM48677] Funding Source: Medline; NIMH NIH HHS [MH53631] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053631, R29MH053631] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BEHLING RW, 1988, P NATL ACAD SCI USA, V85, P6721, DOI 10.1073/pnas.85.18.6721; BILLETER M, 1982, J MOL BIOL, V155, P321, DOI 10.1016/0022-2836(82)90008-0; BORGIAS BA, 1988, J MAGN RESON, V79, P493, DOI 10.1016/0022-2364(88)90085-6; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Bren N, 2000, J BIOL CHEM, V275, P12692, DOI 10.1074/jbc.275.17.12692; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Cho JH, 2000, J BIOL CHEM, V275, P8680, DOI 10.1074/jbc.275.12.8680; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P1732, DOI 10.1021/bi00380a037; EISENHABER F, 1995, J COMPUT CHEM, V16, P273, DOI 10.1002/jcc.540160303; FAINZILBER M, 1994, BIOCHEMISTRY-US, V33, P9523, DOI 10.1021/bi00198a018; Favreau P, 1999, BIOCHEMISTRY-US, V38, P6317, DOI 10.1021/bi982817z; Fraenkel Y, 1996, CRIT REV BIOCHEM MOL, V31, P273, DOI 10.3109/10409239609106586; FRAENKEL Y, 1994, BIOCHEMISTRY-US, V33, P644, DOI 10.1021/bi00169a004; Franco A, 1999, LETT PEPT SCI, V6, P199, DOI 10.1023/A:1008826505893; Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701; Gouda H, 1997, BBA-PROTEIN STRUCT M, V1343, P327, DOI 10.1016/S0167-4838(97)00140-4; GRAY WR, 1981, J BIOL CHEM, V256, P4734; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Guddat LW, 1996, BIOCHEMISTRY-US, V35, P11329, DOI 10.1021/bi960820h; Han KH, 1997, BIOCHEMISTRY-US, V36, P1669, DOI 10.1021/bi962301k; HANN RM, 1994, BIOCHEMISTRY-US, V33, P14058, DOI 10.1021/bi00251a014; Hill JM, 1998, BIOCHEMISTRY-US, V37, P15621, DOI 10.1021/bi981535w; HOPKINS C, 1995, J BIOL CHEM, V270, P22361, DOI 10.1074/jbc.270.38.22361; Hu SH, 1996, STRUCTURE, V4, P417, DOI 10.1016/S0969-2126(96)00047-0; Hu SH, 1997, BIOCHEMISTRY-US, V36, P11323, DOI 10.1021/bi9713052; Hu SH, 1998, BIOCHEMISTRY-US, V37, P11425, DOI 10.1021/bi9806549; Jacobsen R, 1997, J BIOL CHEM, V272, P22531, DOI 10.1074/jbc.272.36.22531; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KOBAYASHI Y, 1989, BIOCHEMISTRY-US, V28, P4853, DOI 10.1021/bi00437a050; Lamthanh H, 1999, FEBS LETT, V454, P293, DOI 10.1016/S0014-5793(99)00831-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu H, 1995, J BIOMOL NMR, V6, P390; Loughnan M, 1998, J BIOL CHEM, V273, P15667, DOI 10.1074/jbc.273.25.15667; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; Luo S, 1999, BIOCHEMISTRY-US, V38, P14542, DOI 10.1021/bi991252j; Luo SQ, 1998, J NEUROSCI, V18, P8571; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MARTINEZ JS, 1995, BIOCHEMISTRY-US, V34, P14519, DOI 10.1021/bi00044a030; Maslennikov IV, 1999, FEBS LETT, V444, P275, DOI 10.1016/S0014-5793(99)00069-1; Maslennikov IV, 1998, EUR J BIOCHEM, V254, P238, DOI 10.1046/j.1432-1327.1998.2540238.x; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Mok KH, 1999, BIOCHEMISTRY-US, V38, P11895, DOI 10.1021/bi990558n; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PARDI A, 1989, BIOCHEMISTRY-US, V28, P5494, DOI 10.1021/bi00439a026; Quiram PA, 2000, J BIOL CHEM, V275, P4889, DOI 10.1074/jbc.275.7.4889; Rogers JP, 1999, BIOCHEMISTRY-US, V38, P3874, DOI 10.1021/bi9826254; Rosenthal JA, 1999, BIOCHEMISTRY-US, V38, P7847, DOI 10.1021/bi990045g; Saez-Briones P, 1999, EUR J BIOCHEM, V265, P902, DOI 10.1046/j.1432-1327.1999.00787.x; Shon KJ, 1997, BIOCHEMISTRY-US, V36, P15693, DOI 10.1021/bi971443r; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; THOMAS PD, 1991, P NATL ACAD SCI USA, V88, P1237, DOI 10.1073/pnas.88.4.1237; Unwin N, 1996, J MOL BIOL, V257, P586, DOI 10.1006/jmbi.1996.0187; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P122; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065	61	32	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49028	49033		10.1074/jbc.M107798200	http://dx.doi.org/10.1074/jbc.M107798200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11641403	hybrid			2022-12-25	WOS:000173922100055
J	Lin, JL; Chen, HC; Fang, HI; Robinson, D; Kung, HJ; Shih, HM				Lin, JL; Chen, HC; Fang, HI; Robinson, D; Kung, HJ; Shih, HM			MST4, a new Ste20-related kinase that mediates cell growth and transformation via modulating ERK pathway	ONCOGENE			English	Article						Ste20 kinase; cell transformation; kinase signaling	N-TERMINAL KINASE; STE20-LIKE PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; SIGNALING COMPONENTS; ADAPTER PROTEINS; CARCINOMA-CELLS; FAMILY MEMBERS; OXIDANT STRESS; ACTIVATION; APOPTOSIS	In this study, we report the cloning and characterization of a novel human Ste20-related kinase that we designated MST4 (accession number AF231012). The 416 amino acid full-length MST4 contains an aminoterminal kinase domain, which is highly homologous to MST3 and SOK, and a unique carboxy-terminal domain. Northern blot analysis indicated that MST4 is highly expressed in placenta, thymus, and peripheral blood leukocytes. Wild-type but not kinase-dead MST4 can phosphorylate myelin basic protein in an in vitro kinase assay. MST4 specifically activates ERK but not JNK or p38 MAPK in transient transfected cells or in stable cell lines. Overexpression of dominant negative MEK1 or treatment with PD98059 abolishes MST4-induced ERK activity, whereas dominant-negative Ras or c-Raf-1 mutants failed to do so, indicating MST4 activates MEK1/ERK via a Ras/Raf-1 independent pathway. HeLa and Phoenix cell lines overexpressing wild-type, but not kinase-dead, MST4 exhibit increased growth rate and form aggressive soft-agar colonies. These phenotypes can be inhibited by PD98059. These results provide the first evidence that MST4 is biologically active in the activation of MEK/ERK pathway and in mediating cell growth and transformation.	Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	National Health Research Institutes - Taiwan; National Defense Medical Center; University of California System; University of California Davis	Shih, HM (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 128,Sec2,Yen Chiu Yuan RD, Taipei 11529, Taiwan.	shihh@nhri.org.tw	Kung, Hsing-Jien/C-7651-2013; Shih, Hsiu-Ming/S-7023-2018					ARNOLD R, 2001, J BIOL CHEM, V29, P29; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BRUNET A, 1994, ONCOGENE, V9, P3379; Chen HC, 1998, J BIOMED SCI, V5, P86, DOI 10.1007/BF02258361; Chen Y. R., 1999, GENE THER MOL BIOL, V4, P83; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; Dan I, 2000, FEBS LETT, V469, P19, DOI 10.1016/S0014-5793(00)01247-3; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Endo J, 2000, FEBS LETT, V468, P234, DOI 10.1016/S0014-5793(00)01219-9; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; GRAVES JD, 2001, J BIOL CHEM, V13, P13; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Greulich H, 1996, ONCOGENE, V12, P1689; HANKS SK, 1991, METHOD ENZYMOL, V200, P525; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Johnston AM, 2000, ONCOGENE, V19, P4290, DOI 10.1038/sj.onc.1203784; Kakeya H, 1998, CANCER RES, V58, P4888; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; LEE KK, 2001, J BIOL CHEM, V7, P7; LING P, 2001, J BIOL CHEM, V13, P13; Ljungdahl S, 1998, CELL GROWTH DIFFER, V9, P565; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; Nakano K, 2000, J BIOL CHEM, V275, P20533, DOI 10.1074/jbc.M001009200; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Osada S, 1997, FEBS LETT, V404, P227, DOI 10.1016/S0014-5793(97)00139-7; Plattner R, 1999, ONCOGENE, V18, P1807, DOI 10.1038/sj.onc.1202482; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; QIAN Z, 2001, J BIOL CHEM, V16, P16; Raitt DC, 2000, EMBO J, V19, P4623, DOI 10.1093/emboj/19.17.4623; Rimerman RA, 2000, J BIOL CHEM, V275, P14736, DOI 10.1074/jbc.M910241199; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Schramek H, 1997, J BIOL CHEM, V272, P11426; Schrick K, 1997, GENETICS, V147, P19; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Shi CS, 2000, BLOOD, V95, P776, DOI 10.1182/blood.V95.3.776.003k23_776_782; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tassi E, 1999, J BIOL CHEM, V274, P33287, DOI 10.1074/jbc.274.47.33287; Tsutsumi T, 2000, J BIOL CHEM, V275, P9157, DOI 10.1074/jbc.275.13.9157; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Verheijen MHG, 1999, J BIOL CHEM, V274, P1487, DOI 10.1074/jbc.274.3.1487; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yustein JT, 2000, ONCOGENE, V19, P710, DOI 10.1038/sj.onc.1203342; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133; Zhou TH, 2000, J BIOL CHEM, V275, P2513, DOI 10.1074/jbc.275.4.2513	65	84	87	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6559	6569		10.1038/sj.onc.1204818	http://dx.doi.org/10.1038/sj.onc.1204818			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641781				2022-12-25	WOS:000171404200009
J	Arck, PC; Handjiski, B; Hagen, E; Joachim, R; Klapp, BF; Paus, R				Arck, PC; Handjiski, B; Hagen, E; Joachim, R; Klapp, BF; Paus, R			Indications for a brain-hair follicle axis: inhibition of keratinocyte proliferation and up-regulation of keratinocyte apoptosis in telogen hair follicles by stress and substance P	FASEB JOURNAL			English	Article						sonic stress; activated macrophages; apoptosis; hair follicle; mast cells	CORTICOTROPIN-RELEASING HORMONE; MAST-CELL DEGRANULATION; MURINE SKIN; MODULATION; RECEPTOR; INVOLVEMENT; NEUROPEPTIDES; MACROPHAGES; ENDOCRINE; BIOLOGY	It has long been suspected that stress can cause hair loss, although convincing evidence of this has been unavailable. Here, we show that in mice sonic stress significantly increased the number of hair follicles containing apoptotic cells and inhibited intrafollicular keratinocyte proliferation in situ. Sonic stress also significantly increased the number of activated perifollicular macrophage clusters and the number of degranulated mast cells, whereas it down-regulated the number of intraepithelial gamma delta T lymphocytes. These stress-induced immune changes could be mimicked by injection of the neuropeptide substance P in nonstressed mice and were abrogated by a selective substance P receptor antagonist in stressed mice. We conclude that stress can indeed inhibit hair growth in vivo, probably via a substance P-dependent activation of macrophages and/or mast cells in the context of a brain-hair follicle axis.	Humboldt Univ, Dept Internal Med, Charite, Berlin, Germany; Univ Hamburg, Univ Hosp eppendorf, Dept Dermatol, Hamburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf	Arck, PC (corresponding author), Biomed Forschungszentrum, Med Klin, Charite, Campus Virchow Klinikum,Raum 2-0549,Augustenburge, D-13353 Berlin, Germany.	petra.arck@charite.de	Paus, Ralf/F-6243-2011; Arck, Petra C/D-7094-2013	Arck, Petra/0000-0002-2932-926X				ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7; ARCK PC, 1995, BIOL REPROD, V53, P814, DOI 10.1095/biolreprod53.4.814; Arck PC, 1997, AM J REPROD IMMUNOL, V37, P87; Berman AS, 1996, NEUROIMMUNOMODULAT, V3, P141, DOI 10.1159/000097239; BIENENSTOCK J, 1988, MONOGR ALLERGY, V24, P134; BLALOCK JE, 1994, IMMUNOL TODAY, V15, P504, DOI 10.1016/0167-5699(94)90205-4; Botchkarev VA, 1999, J INVEST DERMATOL, V113, P878, DOI 10.1046/j.1523-1747.1999.00791.x; CAMACHO F, 1997, TRICHOLOGY; ChancellorFreeland C, 1995, ANN NY ACAD SCI, V771, P472, DOI 10.1111/j.1749-6632.1995.tb44703.x; CHASE HB, 1953, BIOL HAIR GROWTH, P435; Chrousos GP, 1998, ANN NY ACAD SCI, V851, P311, DOI 10.1111/j.1749-6632.1998.tb09006.x; Conti B, 2000, NEUROIMMUNOMODULAT, V8, P1, DOI 10.1159/000026445; Csermely P, 1998, CELL STRESS CHAPERON, V3, P1, DOI 10.1379/1466-1268(1998)003<0001:MBOSRI>2.3.CO;2; Dawber R., 1997, DIS HAIR SCALP; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; Eichmuller S, 1998, J HISTOCHEM CYTOCHEM, V46, P361, DOI 10.1177/002215549804600310; Ericson M, 1999, Exp Dermatol, V8, P344; Farooqi IS, 2000, J CLIN ENDOCR METAB, V85, P2644, DOI 10.1210/jc.85.8.2644; Farrell AM, 1997, BRIT J DERMATOL, V136, P802, DOI 10.1111/j.1365-2133.1997.tb03685.x; Foitzik K, 2000, FASEB J, V14, P752, DOI 10.1096/fasebj.14.5.752; Garcia-Hernandez Maria Jose, 1999, Journal of Dermatology (Tokyo), V26, P625; GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; GERDES J, 1984, J IMMUNOL, V133, P1710; Hordinsky M K, 1999, Exp Dermatol, V8, P314; Jessop D S, 2000, Stress, V3, P209, DOI 10.3109/10253890009001125; JOACHIM RA, IN PRESS AM J REPROD; KAWATE R, 1994, PHYSIOL BEHAV, V55, P921, DOI 10.1016/0031-9384(94)90080-9; KOBLENZER CS, 1983, ARCH DERMATOL, V119, P501, DOI 10.1001/archderm.119.6.501; Lindner G, 1997, AM J PATHOL, V151, P1601; Maurer M, 1997, LAB INVEST, V77, P319; Maurer M, 1995, Exp Dermatol, V4, P266, DOI 10.1111/j.1600-0625.1995.tb00256.x; MAZELIS AG, 1987, DIABETES RES CLIN EX, V6, P195; McCann BS, 1999, ANN BEHAV MED, V21, P103, DOI 10.1007/BF02908290; McCormack RJ, 1996, NEUROIMMUNOMODULAT, V3, P35, DOI 10.1159/000097225; McEwen BS, 1997, BRAIN RES REV, V23, P79, DOI 10.1016/S0165-0173(96)00012-4; NAKAMURA K, 1990, J NEUROIMMUNOL, V30, P23, DOI 10.1016/0165-5728(90)90049-S; NIO DA, 1993, J IMMUNOL, V150, P5281; Paus R, 1999, ANN NY ACAD SCI, V885, P350; PAUS R, 1995, ARCH DERMATOL RES, V287, P500, DOI 10.1007/BF00373436; PAUS R, 1994, DEV BIOL, V163, P230, DOI 10.1006/dbio.1994.1139; PAUS R, 1994, LAB INVEST, V71, P134; PAUS R, 1994, BRIT J DERMATOL, V130, P281, DOI 10.1111/j.1365-2133.1994.tb02922.x; Paus R, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P61, DOI 10.1038/jidsymp.1997.13; Paus R, 1999, J INVEST DERM SYMP P, V4, P226, DOI 10.1038/sj.jidsp.5640217; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, IN PRESS J ALLERGY; QUI BS, 1999, NAT MED, V5, P1178; RUCKERT R, IN PRESS BR J DERMAT; Rupniak NMJ, 1999, TRENDS PHARMACOL SCI, V20, P485, DOI 10.1016/S0165-6147(99)01396-6; RYDER M. L., 1958, BIOLOGY HAIR GROWTH, P305; SCHMIDT JB, 1994, SKIN PHARMACOL, V7, P61; Sheridan JF, 1998, ANN NY ACAD SCI, V840, P803, DOI 10.1111/j.1749-6632.1998.tb09618.x; Sinclair R, 1999, INT J DERMATOL, V38, P8, DOI 10.1046/j.1365-4362.1999.00003.x; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; STENN KS, 1994, J DERMATOL SCI, V14, P109; STENN KS, IN PRESS PHYSL REV; Suzuki R, 1999, J IMMUNOL, V163, P2410; Suzuki S, 1998, J INVEST DERMATOL, V111, P963, DOI 10.1046/j.1523-1747.1998.00427.x; Takashima A, 1996, Semin Immunol, V8, P333, DOI 10.1006/smim.1996.0044; Theoharides TC, 1998, ENDOCRINOLOGY, V139, P403, DOI 10.1210/en.139.1.403; Venencie PY, 1999, BRIT J DERMATOL, V141, P438; Webster EL, 1998, ANN NY ACAD SCI, V840, P21, DOI 10.1111/j.1749-6632.1998.tb09545.x; WHITE SE, 1976, ARCTIC ALPINE RES, V8, P1; WILLIAMS RM, 1995, CHEM IMMUNOL, V61, P208; York J, 1998, PSYCHOL REP, V82, P1044; Zhu GF, 1996, J NEUROSCI, V16, P3745	67	95	100	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2536	+		10.1096/fj.00-0699fje	http://dx.doi.org/10.1096/fj.00-0699fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641256				2022-12-25	WOS:000171372700019
J	Clark, SW; Fee, BE; Cleveland, JL				Clark, SW; Fee, BE; Cleveland, JL			Misexpression of the eyes absent family triggers the apoptotic program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; CELL-DEATH; DROSOPHILA EYE; SINE-OCULIS; HEMATOPOIETIC-CELLS; SKI PROTOONCOGENE; VISUAL-SYSTEM; EYELESS GENE; MICE LACKING; C-MYC	Genetic studies in Drosophila and mice have shown that eyes absent (eya) is an important and conserved transcriptional regulator of development. Along with eyeless/Pax6, sine oculis, and dachshund, eya genes function as master regulators in eye development and can induce ectopic eye formation. Furthermore, the loss-of-function mutants of these genes in the fly causes partial or complete loss of the compound eye, and this is associated with inappropriate apoptosis. Conversely, ectopic eyeless expression in the context of eyes absent or sine oculis mutations results in apoptosis, suggesting that the proper ratio of these factors regulates apoptosis. Here we report that enforced expression of fly eya or of one of its mammalian homologs, Eya2, triggers rapid apoptosis in interleukin-3-dependent 32D.3 murine myeloid cells, which express Eya family members but not Pax6. Eya-induced cell death overrides survival factors and has many features typical of apoptosis, including plasma and mitochondrial membrane changes and caspase activation. Eya-induced apoptosis is blocked by Bcl-2 overexpression but not by the broad-spectrum caspase inhibitor z-VAD.fmk, suggesting that mitochondria are a major target in Eya-induced apoptosis. These results support the concept that inappropriate changes in the steady state levels of Eya proteins may trigger programmed cell deaths during development.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Cleveland, JL (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale, Memphis, TN 38105 USA.	john.cleveland@stjude.org			NCI NIH HHS [CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; Bonini NM, 1998, DEV BIOL, V196, P42, DOI 10.1006/dbio.1997.8845; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; Bonini NM, 1997, DEVELOPMENT, V124, P4819; BONINI NM, 1995, CURR OPIN GENET DEV, V5, P507, DOI 10.1016/0959-437X(95)90056-M; Bonini NM, 1999, BIOESSAYS, V21, P991, DOI 10.1002/(SICI)1521-1878(199912)22:1&lt;991::AID-BIES3&gt;3.0.CO;2-3; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Borsani G, 1999, HUM MOL GENET, V8, P11, DOI 10.1093/hmg/8.1.11; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Cory S, 1998, P NATL ACAD SCI USA, V95, P12077, DOI 10.1073/pnas.95.21.12077; Curtiss J, 2000, DEVELOPMENT, V127, P1325; Dai HQ, 1999, CANCER RES, V59, P4944; Duncan MK, 1997, MAMM GENOME, V8, P479, DOI 10.1007/s003359900480; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Halder G, 1998, DEVELOPMENT, V125, P2181; Hammond KL, 1998, MECH DEVELOP, V74, P121, DOI 10.1016/S0925-4773(98)00071-9; Hazelett DJ, 1998, DEVELOPMENT, V125, P3741; Hensey C, 1998, DEV BIOL, V203, P36, DOI 10.1006/dbio.1998.9028; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; MARDON G, 1994, DEVELOPMENT, V120, P3473; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Oliver G, 1997, TRENDS NEUROSCI, V20, P415, DOI 10.1016/S0166-2236(97)01082-5; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Plaza S, 1999, ONCOGENE, V18, P1041, DOI 10.1038/sj.onc.1202406; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; SERIKAKU MA, 1994, GENETICS, V138, P1137; Shen WP, 1997, DEVELOPMENT, V124, P45; THORNBERY NA, 1997, SCIENCE, V281, P1312; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Xu PX, 1997, P NATL ACAD SCI USA, V94, P11974, DOI 10.1073/pnas.94.22.11974; Xu PX, 1999, NAT GENET, V23, P113, DOI 10.1038/12722; Xu PX, 1997, DEVELOPMENT, V124, P219; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; Zimmerman JE, 1997, GENOME RES, V7, P128, DOI 10.1101/gr.7.2.128	55	35	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3560	3567		10.1074/jbc.M108410200	http://dx.doi.org/10.1074/jbc.M108410200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11700312	hybrid			2022-12-25	WOS:000173688000067
J	Poon, E; Howman, EV; Newey, SE; Davies, KE				Poon, E; Howman, EV; Newey, SE; Davies, KE			Association of syncoilin and desmin - Linking intermediate filament proteins to the dystrophin-associated protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN COMPLEX; AVIAN ERYTHROCYTES; NUCLEAR-ENVELOPE; PLASMA-MEMBRANE; SKELETAL-MUSCLE; WILD-TYPE; VIMENTIN; MYOPATHY; MICE; PLECTIN	We recently identified a novel protein called syncoilin, a putative intermediate filament protein that interacts with a-dystrobrevin, a member of the dystrophin-associated protein complex. Syncoilin is found at the neuromuscular junction, sarcolemma, and Z-Iines and is thought to be important for muscle fiber integrity. Based on the similar protein structure and cellular localization of syncoilin and desmin, we proposed that these proteins interact in vivo. The data presented confirm an interaction between syncoilin and desmin and demonstrate their co-localization in skeletal muscle. Intriguingly, whereas these proteins interact, COS-7 cell expression studies show that desmin and syncoilin do not assemble into heterofilaments. Furthermore, fractionation assay and immunofluorescence study of H2K myoblasts and myotubes suggest that, unlike typical intermediate filament proteins, syncoilin does not participate in filament formation with any protein. However, it is possible that syncoilin is involved in the anchoring of the desmin intermediate filament network at the sarcolemma and the neuromuscular junction. This interaction is likely to be important for maintaining muscle fiber integrity and may also link the dystrophin-associated protein complex to the cytoskeleton. The dysfunction or absence of syncoilin may result in the disruption of the intermediate filament network leading to muscle necrosis. Syncoilin is therefore an ideal candidate gene for muscular dystrophies and desmin-related myopathies.	Univ Oxford, Dept Human Anat & Genet, MRC, Funct Genet Unit, Oxford OX1 3QX, England	University of Oxford	Davies, KE (corresponding author), Univ Oxford, Dept Human Anat & Genet, MRC, Funct Genet Unit, S Parks Rd, Oxford OX1 3QX, England.		Poon, Ellen/ABD-6962-2020	Poon, Ellen/0000-0002-9280-3681				Bellin RM, 1999, J BIOL CHEM, V274, P29493, DOI 10.1074/jbc.274.41.29493; Bellin RM, 2001, J BIOL CHEM, V276, P32330, DOI 10.1074/jbc.M104005200; Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; Carlsson L, 2000, HISTOCHEM CELL BIOL, V114, P39; Cheng TJ, 2000, J CELL BIOCHEM, V79, P126, DOI 10.1002/1097-4644(2000)79:1<126::AID-JCB120>3.3.CO;2-Q; Deconinck AE, 1997, J CELL BIOL, V136, P883, DOI 10.1083/jcb.136.4.883; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GEORGATOS SD, 1987, P NATL ACAD SCI USA, V84, P6780, DOI 10.1073/pnas.84.19.6780; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; GOEBEL HH, 1994, REV NEUROL, V150, P452; Goebel HH, 1997, CURR OPIN NEUROL, V10, P426, DOI 10.1097/00019052-199710000-00012; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; GRANGER BL, 1979, CELL, V18, P1053, DOI 10.1016/0092-8674(79)90218-6; HELLIWELL TR, 1994, J NEUROL SCI, V124, P174, DOI 10.1016/0022-510X(94)90324-7; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Li ZL, 1997, J CELL BIOL, V139, P129, DOI 10.1083/jcb.139.1.129; Mitsui T, 2000, J CELL BIOCHEM, V77, P584, DOI 10.1002/(SICI)1097-4644(20000615)77:4<584::AID-JCB6>3.0.CO;2-U; Mizuno Y, 2001, P NATL ACAD SCI USA, V98, P6156, DOI 10.1073/pnas.111153298; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Newey SE, 2001, J BIOL CHEM, V276, P6645, DOI 10.1074/jbc.M008305200; Sam M, 2000, AM J PHYSIOL-CELL PH, V279, pC1116, DOI 10.1152/ajpcell.2000.279.4.C1116; Schweitzer SC, 2001, J CELL SCI, V114, P1079; SEALOCK R, 1989, SYNAPSE, V3, P315, DOI 10.1002/syn.890030404; Steinbock FA, 2000, J CELL SCI, V113, P483; Steinbock FA, 1999, BIOL CHEM, V380, P151, DOI 10.1515/BC.1999.023; TOKUYASU KT, 1983, J CELL BIOL, V96, P1727, DOI 10.1083/jcb.96.6.1727; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Vicart P, 1996, HUM GENET, V98, P422, DOI 10.1007/s004390050233; WICHE G, 1993, J CELL BIOL, V121, P607, DOI 10.1083/jcb.121.3.607; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	36	62	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3433	3439		10.1074/jbc.M105273200	http://dx.doi.org/10.1074/jbc.M105273200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11694502	hybrid			2022-12-25	WOS:000173688000051
J	Burns, JM; Dairaghi, DJ; Deitz, M; Tsang, M; Schall, TJ				Burns, JM; Dairaghi, DJ; Deitz, M; Tsang, M; Schall, TJ			Comprehensive mapping of poxvirus vCCI chemokine-binding protein - Expanded range of ligand interactions and unusual dissociation kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CHEMOKINE; MOLLUSCUM CONTAGIOSUM; RECEPTOR (CCR)8; T1/35KDA FAMILY; TRUNCATED FORM; VIRUS; IDENTIFICATION; HERPESVIRUS; CK-BETA-8; AGONIST	In compiling a comprehensive map of the ligand binding capacity of elements within the chemokine system, we have determined the spectrum of chemokines capable of interacting with the poxvirus-encoded viral CC chemokine inhibitor, vCCI. More than 80 chemokines were tested in parallel for their ability to displace radiolabeled signature chemokines from vCCI. Of these chemokines, 26 showed potential high affinity interactions. These interactions revealed an expanded spectrum of binding capacity for vCCI to now include molecules such as human myeloid progenitor inhibitory factor-1 as ligands. In addition, high affinity viral protein-protein interactions were revealed. For example, binding between poxvirus vCCI and the herpesvirus vMIP-II from HHV8 occurs with IC50 similar to10-50 nm. Unusual dissociation kinetics were observed between certain chemokines and vCCI. Notably, many ligands displayed a precipitous displacement profile, suggesting marked positive cooperativity of binding. Finally, heterologous competition provided evidence for overlapping but distinct binding sites for the many chemokines that bind to vCCI. The determination of the binding fingerprint and unusual binding interactions of vCCI with a large number of chemokines suggest a finely honed evolutionary strategy of chemokine sequestration during viral infection.	ChemoCentryx, Div Discovery Biol, San Carlos, CA 94070 USA; ChemoCentryx, Div Mol Pharmacol, San Carlos, CA 94070 USA; R&D Syst, Minneapolis, MN 55413 USA		Schall, TJ (corresponding author), ChemoCentryx, Div Discovery Biol, 1539 Ind Rd, San Carlos, CA 94070 USA.							Alcami A, 1998, J IMMUNOL, V160, P624; Baird JW, 1999, J BIOL CHEM, V274, P33496, DOI 10.1074/jbc.274.47.33496; Berkhout TA, 2000, BIOCHEM PHARMACOL, V59, P591, DOI 10.1016/S0006-2952(99)00354-8; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; Carfi A, 1999, P NATL ACAD SCI USA, V96, P12379, DOI 10.1073/pnas.96.22.12379; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; Damon I, 1998, P NATL ACAD SCI USA, V95, P6403, DOI 10.1073/pnas.95.11.6403; Endres MJ, 1999, J EXP MED, V189, P1993, DOI 10.1084/jem.189.12.1993; Fleming P, 1999, J VIROL, V73, P6800, DOI 10.1128/JVI.73.8.6800-6809.1999; Gosling J, 2000, J IMMUNOL, V164, P2851, DOI 10.4049/jimmunol.164.6.2851; Graham KA, 1997, VIROLOGY, V229, P12, DOI 10.1006/viro.1996.8423; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Krathwohl MD, 1997, P NATL ACAD SCI USA, V94, P9875, DOI 10.1073/pnas.94.18.9875; Lalani AS, 1998, VIROLOGY, V250, P173, DOI 10.1006/viro.1998.9340; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Macphee CH, 1998, J IMMUNOL, V161, P6273; Penfold MET, 1999, P NATL ACAD SCI USA, V96, P9839, DOI 10.1073/pnas.96.17.9839; Saederup N, 1999, P NATL ACAD SCI USA, V96, P10881, DOI 10.1073/pnas.96.19.10881; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Smith CA, 1997, VIROLOGY, V236, P316, DOI 10.1006/viro.1997.8730; Sozzani S, 1998, BLOOD, V92, P4036, DOI 10.1182/blood.V92.11.4036.423k17_4036_4039; Tanaka Y, 1999, EUR J IMMUNOL, V29, P633, DOI 10.1002/(SICI)1521-4141(199902)29:02<633::AID-IMMU633>3.0.CO;2-I; Van Damme J, 1999, Chem Immunol, V72, P42, DOI 10.1159/000058725; Youn BS, 1998, BLOOD, V91, P3118, DOI 10.1182/blood.V91.9.3118.3118_3118_3126; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zou P, 1999, J VIROL, V73, P5926, DOI 10.1128/JVI.73.7.5926-5933.1999	26	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2785	2789		10.1074/jbc.M109884200	http://dx.doi.org/10.1074/jbc.M109884200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11696549	hybrid			2022-12-25	WOS:000173421500055
J	Ward, SDC; Hamdan, FF; Bloodworth, LM; Wess, J				Ward, SDC; Hamdan, FF; Bloodworth, LM; Wess, J			Conformational changes that occur during M-3 muscarinic acetylcholine receptor activation probed by the use of an in situ disulfide cross-linking strategy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTORS; ALANINE-SCANNING MUTAGENESIS; TRANSMEMBRANE DOMAIN; AMINO-ACID; CONSTITUTIVE ACTIVATION; SENSORY RECEPTOR; CYTOPLASMIC SIDE; G ALPHA(Q); RHODOPSIN	The structural changes involved in ligand-dependent activation of G protein-coupled receptors are not well understood at present. To address this issue, we developed an in situ disulfide cross-linking strategy using the rat M-3 muscarinic receptor, a prototypical G(q)-coupled receptor, as a model system. It is known that a tyrosine residue (Tyr(254)) located at the C terminus of transmembrane domain (TM) V and several primarily hydrophobic amino acids present within the cytoplasmic portion of TM VI play key roles in determining the G protein coupling selectivity of the M-3 receptor subtype. To examine whether M-3 receptor activation involves changes in the relative orientations of these functionally critical residues, pairs of cysteine residues were substituted into a modified version of the M. receptor that contained a factor Xa cleavage site within the third intracellular loop and lacked most endogenous cysteine residues. All analyzed mutant receptors contained a Y254C point mutation and a second cysteine substitution within the segment Lys(484)-Ser(493) at the intracellular end of TM VI. Following their transient expression in COS-7 cells, mutant receptors present in their native membrane environment (in situ) were subjected to mild oxidizing conditions, either in the absence or in the presence of the muscarinic agonist, carbachol. The successful formation of disulfide cross-links was monitored by studying changes in the electrophoretic mobility of oxidized, factor Xa-treated receptors on SDS gels. The observed cross-linking patterns indicated that M-3 receptor activation leads to structural changes that allow the cytoplasmic ends of TM V and TM VI to move closer to each other and that also appear to involve a major change in secondary structure at the cytoplasmic end of TM VI. This is the first study employing aninsitudisulfidecross-linkingstrategytoexamineagonistdependent dynamic structural changes in a G protein-coupled receptor.	NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05, Bethesda, MD 20892 USA.	jwess@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BLUML K, 1994, J BIOL CHEM, V269, P402; BLUML K, 1994, J BIOL CHEM, V269, P11537; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Burstein ES, 1996, J BIOL CHEM, V271, P2882, DOI 10.1074/jbc.271.6.2882; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; Cai K, 1999, BIOCHEMISTRY-US, V38, P12893, DOI 10.1021/bi9912443; Cai KW, 1997, P NATL ACAD SCI USA, V94, P14267, DOI 10.1073/pnas.94.26.14267; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; HOGGER P, 1995, J BIOL CHEM, V270, P7405; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Kostenis E, 1997, J BIOL CHEM, V272, P19107, DOI 10.1074/jbc.272.31.19107; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LAZARENO S, 1993, LIFE SCI, V52, P449, DOI 10.1016/0024-3205(93)90301-I; LEE GF, 1994, J BIOL CHEM, V269, P29920; Lee NH, 1996, MOL PHARMACOL, V50, P140; Lim WK, 2001, BIOCHEM J, V354, P337, DOI 10.1042/0264-6021:3540337; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; Lu ZL, 1999, J BIOL CHEM, V274, P7309, DOI 10.1074/jbc.274.11.7309; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P1444; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Ward SDC, 1999, MOL PHARMACOL, V56, P1031, DOI 10.1124/mol.56.5.1031; WATSON S, 1994, G PROTEIN LINKED REC, P1; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u; Yu HB, 1999, BIOCHEMISTRY-US, V38, P12028, DOI 10.1021/bi990948+; Yu HB, 1999, BIOCHEMISTRY-US, V38, P12033, DOI 10.1021/bi9909492; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zeng FY, 1999, J NEUROCHEM, V72, P2404, DOI 10.1046/j.1471-4159.1999.0722404.x; Zeng FY, 1999, J BIOL CHEM, V274, P16629, DOI 10.1074/jbc.274.23.16629	58	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2247	2257		10.1074/jbc.M107647200	http://dx.doi.org/10.1074/jbc.M107647200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11698401	hybrid			2022-12-25	WOS:000173421300085
J	Williamson, D; Pikovski, I; Cranmer, SL; Mangin, P; Mistry, N; Domagala, T; Chehab, S; Lanza, F; Salem, HH; Jackson, SP				Williamson, D; Pikovski, I; Cranmer, SL; Mangin, P; Mistry, N; Domagala, T; Chehab, S; Lanza, F; Salem, HH; Jackson, SP			Interaction between platelet glycoprotein Ib alpha and filamin-1 is essential for glycoprotein Ib/IX receptor anchorage at high shear	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; BERNARD-SOULIER-SYNDROME; ASIALO-VONWILLEBRAND-FACTOR; ACTIN-BINDING PROTEIN; CYTOPLASMIC DOMAIN; IX COMPLEX; INTEGRIN ALPHA(IIB)BETA(3); TRANSFECTED CELLS; AGGREGATION; ADHESION	The interaction of the glycoprotein (GP) Ilb-V-IX receptor complex with the membrane skeleton of platelets is dependent on a specific interaction between the cytoplasmic tail of GPIbalpha and filamin-1. This interaction has been proposed to regulate key aspects of platelet function, including the ligand binding of GPIb-V-IX and the ability of the cells to sustain adhesion to von Willebrand factor (vWf) under high shear. In this study we have examined sequences in the GPIba intracellular domain necessary for interaction of the receptor with filamin-1. We have identified two adjacent sequences involving amino acids 557-568 and 569-579 of the GPIbalpha cytoplasmic domain that are critical for normal association between the receptor complex and filamin-1. Under flow conditions, Chinese hamster ovary (CHO) cells expressing these two mutant receptors exhibited an increase in translocation velocity that was associated with increased cell detachment from the vWf matrix at high shear. The shear-dependent acceleration in velocity of mutant Delta557-568 and Delta569-579 CHO cells was associated with a critical defect in receptor anchorage, evident from significant extraction of GPIb-IX from the CHO cell membrane at high shear. These studies define a critical role for amino acids within the 557-579 sequence of GPIbalpha for interaction with filamin-1.	Box Hill Hosp, Monash Med Sch, Dept Med, Australian Ctr Blood Dis, Box Hill, Vic 3128, Australia; EFS Alsace, INSERM U 311, F-67065 Strasbourg, France	Box Hill Hospital; Monash University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Jackson, SP (corresponding author), Box Hill Hosp, Monash Med Sch, Dept Med, Australian Ctr Blood Dis, Arnold St, Box Hill, Vic 3128, Australia.		Lanza, Francois/H-9252-2016; Mangin, Pierre/H-9354-2016	Lanza, Francois/0000-0002-5802-4748; Jackson, Shaun/0000-0002-4750-1991				Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; Dong JF, 1997, BIOCHEMISTRY-US, V36, P12421, DOI 10.1021/bi970636b; DU XP, 1994, J BIOL CHEM, V269, P18287; Englund GD, 2001, J BIOL CHEM, V276, P16952, DOI 10.1074/jbc.M008048200; Feng SJ, 2000, BLOOD, V95, P551, DOI 10.1182/blood.V95.2.551; GRALNICK HR, 1985, J CLIN INVEST, V75, P19; Gu MY, 1999, J CELL BIOL, V147, P1085, DOI 10.1083/jcb.147.5.1085; JAKOBSEN E, 1974, THROMB RES, V4, P499, DOI 10.1016/0049-3848(74)90227-8; Kulkarni S, 2000, J CLIN INVEST, V105, P783, DOI 10.1172/JCI7569; Lopez JA, 1998, BLOOD, V91, P4397, DOI 10.1182/blood.V91.12.4397.412k42_4397_4418; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; Mistry N, 2000, BLOOD, V96, P3480; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; Ruggeri ZM, 1997, THROMB HAEMOSTASIS, V78, P611; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; TSCHOPP TB, 1974, J LAB CLIN MED, V83, P296; Ware J, 2000, P NATL ACAD SCI USA, V97, P2803, DOI 10.1073/pnas.050582097; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847; Yuan YP, 1999, J BIOL CHEM, V274, P36241, DOI 10.1074/jbc.274.51.36241	26	55	56	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2151	2159		10.1074/jbc.M109384200	http://dx.doi.org/10.1074/jbc.M109384200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11700320	hybrid			2022-12-25	WOS:000173421300074
J	Ng, KKS; Cherney, MM; Vazquez, AL; Machin, A; Alonso, JMM; Parra, F; James, MNG				Ng, KKS; Cherney, MM; Vazquez, AL; Machin, A; Alonso, JMM; Parra, F; James, MNG			Crystal structures of active and inactive conformations of a caliciviral RNA-dependent RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMORRHAGIC-DISEASE; REVERSE-TRANSCRIPTASE; COMPLEX; MOLSCRIPT	The structure of the RNA-dependent RNA polymerase (RdRP) from the rabbit hemorrhagic disease virus has been determined by x-ray crystallography to a 2.5-Angstrom resolution. The overall structure resembles a "right hand," as seen before in other polymerases, including the RdRP`s of polio virus and hepatitis C virus. Two copies of the polymerase are present in the asymmetric unit of the crystal, revealing active and inactive conformations within the same crystal form. The fingers and palm domains form a relatively rigid unit, but the thumb domain can adopt either "closed" or "open" conformations differing by a rigid body rotation of similar to8 degrees. Metal ions bind at different positions in the two conformations and suggest how structural changes may be important to enzymatic function in RdRP`s. Comparisons between the structures of the alternate conformational states of rabbit hemorrhagic disease virus RdRP and the structures of RdRPs from hepatitis C virus and polio virus suggest novel structure-function relationships in this medically important class of enzymes.	Univ Alberta, Dept Biochem, Canadian Inst Hlth, Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada; Univ Oviedo, CSIC, Inst Univ Biotecnol Asturias, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	University of Alberta; Consejo Superior de Investigaciones Cientificas (CSIC); University of Oviedo	James, MNG (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth, Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada.	Michael.James@ualberta.ca	Parra, Francisco/D-5401-2009; Martin Alonso, Jose Manuel/C-7763-2013	Parra, Francisco/0000-0002-1885-9521; Martin Alonso, Jose Manuel/0000-0003-1725-6216; Ng, Kenneth K.S./0000-0001-7280-8445	NCRR NIH HHS [RR07707] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Andino R, 1999, TRENDS MICROBIOL, V7, P76, DOI 10.1016/S0966-842X(98)01446-2; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cowtan K, 1999, ACTA CRYSTALLOGR D, V55, P1555, DOI 10.1107/S0907444999007416; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; Dzantiev L, 2001, BIOCHEMISTRY-US, V40, P3215, DOI 10.1021/bi002569i; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Gohara DW, 2000, J BIOL CHEM, V275, P25523, DOI 10.1074/jbc.M002671200; Green KY, 2000, J INFECT DIS, V181, pS322, DOI 10.1086/315591; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Jager Joachim, 1999, Current Opinion in Structural Biology, V9, P21, DOI 10.1016/S0959-440X(99)80004-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kensch O, 2000, J MOL BIOL, V301, P1029, DOI 10.1006/jmbi.2000.3998; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Machin A, 2001, J BIOL CHEM, V276, P27787, DOI 10.1074/jbc.M100707200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moyle G, 2001, DRUGS, V61, P19, DOI 10.2165/00003495-200161010-00003; O'Reilly EK, 1998, VIROLOGY, V252, P287, DOI 10.1006/viro.1998.9463; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARRA F, 1990, J VIROL, V64, P4013, DOI 10.1128/JVI.64.8.4013-4015.1990; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Sluis-Cremer N, 2000, BIOCHEM J, V348, P77, DOI 10.1042/0264-6021:3480077; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thiel HJ, 1999, VET MICROBIOL, V69, P55, DOI 10.1016/S0378-1135(99)00088-7; Vazquez AL, 2000, J VIROL, V74, P3888, DOI 10.1128/JVI.74.8.3888-3891.2000; Vazquez AL, 2001, ARCH VIROL, V146, P59, DOI 10.1007/s007050170191; Vazquez AL, 1998, J VIROL, V72, P2999; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	38	140	150	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1381	1387		10.1074/jbc.M109261200	http://dx.doi.org/10.1074/jbc.M109261200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11677245	hybrid			2022-12-25	WOS:000173166800068
J	Badea, T; Niculescu, F; Soane, L; Fosbrink, M; Sorana, H; Rus, V; Shin, ML; Rus, H				Badea, T; Niculescu, F; Soane, L; Fosbrink, M; Sorana, H; Rus, V; Shin, ML; Rus, H			RGC-32 increases p34(CDC2) kinase activity and entry of aortic smooth muscle cells into S-phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL COMPLEMENT COMPLEXES; ACTIVATED PROTEIN-KINASE; DNA-REPLICATION; CYCLE PROGRESSION; MEMBRANE ATTACK; CDC2; OLIGODENDROCYTES; PHOSPHORYLATION; EXPRESSION; INHIBITION	Proliferation of aortic smooth muscle cells contributes to atherogenesis and neointima formation. Sublytic activation of complement, particularly C5b-9, induces cell cycle progression in aortic smooth muscle cells. RGC-32 is a novel protein that may promote cell cycle progression in response to complement activation. We cloned human RGC-32 cDNA from a human fetal brain cDNA library. The human RGC-32 cDNA encodes a 117-amino acid protein with 92% similarity to the rat and mouse protein. Human RGC-32 maps to chromosome 13 and is expressed in most tissues. Sublytic complement activation enhanced RGC-32 mRNA expression in human aortic smooth muscle cells and induced nuclear translocation of the protein. RGC-32 was physically associated with cyclin-dependent kinase p34(CDC2) and increased the kinase activity in vivo and in vitro. In addition, RGC-32 was phosphorylated by p34(CDC2)-cyclin B1 in vitro. Mutation of RGC-32 protein at Thr-91 prevented the p34(CDC2)-mediated phosphorylation and resulted in loss of p34(CDC2) kinase enhancing activity. Overexpression of RGC-32 induced quiescent aortic smooth muscle cells to enter S-phase. These data indicate that cell cycle activation by C5b-9 may involve p34(CDC2) activity through RGC-32. RGC-32 appears to be a cell cycle regulatory factor that mediates cell proliferation, both as an activator and substrate of p34(CDC2).	Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Div Clin Immunol & Rheumatol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Rus, H (corresponding author), Univ Maryland, Sch Med, Dept Pathol, 10 S Pine St, Baltimore, MD 21201 USA.		Rus, Horea/AAF-2583-2020; Badea, Tudor Constantin/B-1654-2018	Badea, Tudor Constantin/0000-0003-3086-6713	NIAID NIH HHS [R0-1 AI19006] Funding Source: Medline; NINDS NIH HHS [R0-1 NS 199006] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Badea TC, 1998, J BIOL CHEM, V273, P26977, DOI 10.1074/jbc.273.41.26977; BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985; CARNEY DF, 1990, J IMMUNOL, V145, P623; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; DAHIELL SM, 1998, GLIA, V30, P187; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418; IMAGAWA DK, 1986, J IMMUNOL, V136, P4637; KITAGAWA M, 1994, ONCOGENE, V9, P2549; Komatsu R, 1998, CIRCULATION, V98, P224, DOI 10.1161/01.CIR.98.3.224; KOSKI CL, 1983, P NATL ACAD SCI-BIOL, V80, P3816, DOI 10.1073/pnas.80.12.3816; Lang TJ, 1997, J NEUROCHEM, V68, P1581; LIANG P, 1997, DIFFERENTIAL DISPLAY, P3; LOYER P, 1994, J BIOL CHEM, V269, P2491; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; MAYER MM, 1972, P NATL ACAD SCI USA, V69, P2954, DOI 10.1073/pnas.69.10.2954; MORGAN BP, 1987, J IMMUNOL, V138, P246; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; NICULESCU F, 1994, J BIOL CHEM, V269, P4417; NICULESCU F, 1993, J IMMUNOL, V150, P214; Niculescu F, 1997, J IMMUNOL, V158, P4405; Niculescu F, 1999, ATHEROSCLEROSIS, V142, P47, DOI 10.1016/S0021-9150(98)00185-3; Niculescu FI., 1996, BIOMEMBR, V4, P123; Nigg E A, 1991, Semin Cell Biol, V2, P261; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; Roberts BT, 1999, P NATL ACAD SCI USA, V96, P2800, DOI 10.1073/pnas.96.6.2800; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rus HG, 1996, J IMMUNOL, V156, P4892; RUS HG, 1997, CLIN EXP IMMUNOGENET, V14, P85; SHIRAZI Y, 1993, J IMMUNOL, V150, P4581; Sriram V, 2001, CIRCULATION, V103, P2414; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Uren A, 1997, J BIOL CHEM, V272, P21669, DOI 10.1074/jbc.272.35.21669; WIEDMER T, 1987, J BIOL CHEM, V262, P13674; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200	39	97	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					502	508		10.1074/jbc.M109354200	http://dx.doi.org/10.1074/jbc.M109354200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11687586	hybrid			2022-12-25	WOS:000173087900067
J	Jaumot, M; Yan, J; Clyde-Smith, J; Sluimer, J; Hancock, JF				Jaumot, M; Yan, J; Clyde-Smith, J; Sluimer, J; Hancock, JF			The linker domain of the Ha-Ras hypervariable region regulates interactions with exchange factors, Raf-1 and phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PLASMA-MEMBRANE; K-RAS; N-RAS; POLYBASIC DOMAIN; CAAX MOTIF; C-TERMINUS; PALMITOYLATION; P21RAS; TRANSFORMATION	Ha-Ras and Ki-Ras have different distributions across plasma membrane microdomains. The Ras C-terminal anchors are primarily responsible for membrane microlocalization, but recent work has shown that the interaction of Ha-Ras with lipid rafts is modulated by GTP loading via a mechanism that requires the hypervariable region (HVR). We have now identified two regions in the HVR linker domain that regulate Ha-Ras raft association. Release of activated Ha-Ras from lipid rafts is blocked by deleting amino acids 173-179 or 166-172. Alanine replacement of amino acids 173-179 but not 166-172 restores wild type micro-localization, indicating that specific N-terminal sequences of the linker domain operate in concert with a more C-terminal spacer domain to regulate Ha-Ras raft association. Mutations in the linker domain that confine activated Ha-RasG12V to lipid rafts abrogate Raf-1, phosphoinositide 3-kinase, and Akt activation and inhibit PC 12 cell differentiation. N-Myristoylation also prevents the release of activated Ha-Ras from lipid rafts and inhibits Raf-1 activation. These results demonstrate that the correct modulation of Ha-Ras lateral segregation is critical for downstream signaling. Mutations in the linker domain also suppress the dominant negative phenotype of Ha-RasS17N, indicating that HVR sequences are essential for efficient interaction of Ha-Ras with exchange factors in intact cells.	Univ Queensland, Sch Med, Dept Pathol, Expt Oncol Lab, Herston, Qld 4006, Australia	University of Queensland	Hancock, JF (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Expt Oncol Lab, Herston Rd, Herston, Qld 4006, Australia.	j.hancock@mailbox.uq.edu.au	Clyde-Smith, Jodi/R-8910-2016; Jaumot, Montserrat/F-2640-2016; Sluimer, Judith c/D-5277-2012; Yan, Jun/F-1224-2010	Clyde-Smith, Jodi/0000-0001-9798-9924; Sluimer, Judith c/0000-0002-0269-4582; Hancock, John/0000-0003-0542-4710; Yan, Jun/0000-0001-9617-0335; Jaumot, Montserrat/0000-0003-2864-357X				Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Booden MA, 2000, J BIOL CHEM, V275, P23559, DOI 10.1074/jbc.M001368200; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Chen JM, 1999, J PROTEIN CHEM, V18, P867, DOI 10.1023/A:1020631313180; Chen X, 2001, J BIOL CHEM, V276, P34617, DOI 10.1074/jbc.M103995200; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Coats SG, 1999, BIOCHEMISTRY-US, V38, P12926, DOI 10.1021/bi9909290; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; Prior IA, 2001, J CELL SCI, V114, P1603; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rizzo MA, 2001, J BIOL CHEM, V276, P34928, DOI 10.1074/jbc.M105918200; Roy MO, 2000, BIOCHEMISTRY-US, V39, P8298, DOI 10.1021/bi000512q; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Welman A, 2000, ONCOGENE, V19, P4582, DOI 10.1038/sj.onc.1203818; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	38	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					272	278		10.1074/jbc.M108423200	http://dx.doi.org/10.1074/jbc.M108423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11689566	hybrid			2022-12-25	WOS:000173087900037
J	Yagi, K; Furuhashi, M; Aoki, H; Goto, D; Kuwano, H; Sugamura, K; Miyazono, K; Kato, M				Yagi, K; Furuhashi, M; Aoki, H; Goto, D; Kuwano, H; Sugamura, K; Miyazono, K; Kato, M			c-myc is a downstream target of the Smad pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; GENE-EXPRESSION; E2F SITE; TRANSCRIPTIONAL REPRESSION; TGF-BETA-1 INHIBITION; REGULATED REPRESSION; ESSENTIAL COFACTOR	c-Myc is one of the most potent regulators of cell cycle progression in higher eukaryotes. Down-regulation of c-Myc is a critical event for growth inhibition induced by transforming growth factor-beta (TGF-beta) and is frequently impaired in cancer cells. We determined a Smad-responsive element in the c-myc promoter. This element is a complex of the TGF-beta1 inhibitory element (TIE) originally identified in the transin/stromelysin promoter and an E2F site responsible for transcriptional activation of the c-myc promoter. Smad3 and E2F-4 directly bound to the element (TIE/E2F), and substitution of two nucleotides in TIE/E2F impaired binding of both Smad3 and E2F-4 as well as serum-induced activation and TGF-beta-induced suppression of the c-myc promoter activity. Smads bound TIE/E2F within 1 h after stimulation with TGF-beta, before the suppression of c-myc transcription, whereas binding of p130 to TIE/E2F became augmented later than 12 h. TGF-beta signaling did not compete with E2F-4 for binding to TIE/E2F, but reduced p300 co-immunoprecipitating with E2F-4. Therefore, TGF-beta signaling may suppress c-myc promoter activity by dissociating p300 from E2F-4.	Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Japan Soc Promot Sci, Res Future Program, Toshima Ku, Tokyo 1708455, Japan; Gunma Univ, Sch Med, Dept Surg 1, Maebashi, Gumma 3718511, Japan; Tohoku Univ, Sch Med, Dept Microbiol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Tokyo 1130033, Japan	Japanese Foundation for Cancer Research; Japan Society for the Promotion of Science; Gunma University; Tohoku University; University of Tokyo	Kato, M (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.							ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; BirchenallRoberts MC, 1996, ONCOGENE, V13, P1499; Carlberg AL, 1999, INT J ONCOL, V15, P121; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FERNANDEZPOL JA, 1987, BIOCHEM BIOPH RES CO, V144, P1197, DOI 10.1016/0006-291X(87)91438-0; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERZINGER T, 1995, ONCOGENE, V10, P2079; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Iavarone A, 1999, MOL CELL BIOL, V19, P916; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Malliri A, 1996, CELL GROWTH DIFFER, V7, P1291; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; MULDER KM, 1990, CANCER RES, V50, P7581; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; PATERSON IC, 1995, BRIT J CANCER, V72, P922, DOI 10.1038/bjc.1995.434; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Ritter SJ, 1998, J BIOL CHEM, V273, P12798, DOI 10.1074/jbc.273.21.12798; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; USA T, 1994, ENDOCRINOLOGY, V135, P1378, DOI 10.1210/en.135.4.1378; Veal E, 1998, MOL CELL BIOL, V18, P5032, DOI 10.1128/MCB.18.9.5032; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	61	197	211	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					854	861		10.1074/jbc.M104170200	http://dx.doi.org/10.1074/jbc.M104170200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11689553	hybrid			2022-12-25	WOS:000173087900109
J	Bernocco, S; Finet, S; Ebel, C; Eichenberger, D; Mazzorana, M; Farjanel, J; Hulmes, DJS				Bernocco, S; Finet, S; Ebel, C; Eichenberger, D; Mazzorana, M; Farjanel, J; Hulmes, DJS			Biophysical characterization of the C-propeptide trimer from human procollagen III reveals a tri-lobed structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL PROPEPTIDE; BONE MORPHOGENETIC PROTEIN-1; SMALL-ANGLE SCATTERING; I PROCOLLAGEN; EXTRACELLULAR-MATRIX; OSTEOGENESIS IMPERFECTA; SEDIMENTATION ANALYSIS; MOLECULAR RECOGNITION; FRAMESHIFT MUTATION; GENETIC ALGORITHM	Procollagen C-propeptide domains direct chain association during intracellular assembly of procollagen molecules. In addition, they control collagen solubility during extracellular proteolytic processing and fibril formation and interact with cell surface receptors and extracellular matrix components involved in feedback inhibition, mineralization, cell growth arrest, and chemotaxis. At present, three-dimensional structural information for the C-propeptides, which would help to understand the underlying molecular mechanisms, is lacking. Here we have carried out a biophysical study of the recombinant C-propeptide trimer from human procollagen III using laser light scattering, analytical ultracentrifugation, and small angle x-ray scattering. The results show that the trimer is an elongated molecule, which by modeling of the x-ray scattering data appears to be cruciform in shape with three large lobes and one minor lobe. We speculate that each of the major lobes corresponds to one of the three component polypeptide chains, which come together in a junction region to connect to the rest of the procollagen molecule.	Univ Lyon 1, CNRS UMR 5086, Inst Biol Chim Prot, F-69367 Lyon 07, France; CEA, UJF, CNRS, UMR 5075,Inst Biol Struct, F-38027 Grenoble, France; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; European Synchrotron Radiation Facility (ESRF)	Hulmes, DJS (corresponding author), Univ Lyon 1, CNRS UMR 5086, Inst Biol Chim Prot, 7 Passage Vercors, F-69367 Lyon 07, France.			Hulmes, David/0000-0002-0651-1317; Ebel, Christine/0000-0002-6912-500X; MAZZORANA, Marlene/0000-0002-3956-4319				Alvares K, 1999, BIOCHEMISTRY-US, V38, P5401, DOI 10.1021/bi9821824; Bhattacharyya-Pakrasi M, 1998, MATRIX BIOL, V17, P223; Bottomley MJ, 2001, CURR BIOL, V11, P1114, DOI 10.1016/S0960-9822(01)00317-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burchardt ER, 1998, MATRIX BIOL, V17, P673, DOI 10.1016/S0945-053X(98)90118-4; Campbell BG, 2001, J BONE MINER RES, V16, P1147, DOI 10.1359/jbmr.2001.16.6.1147; Cantor C.R., 1980, BIOPHYSICAL CHEM 2; Chacon P, 2000, J MOL BIOL, V299, P1289, DOI 10.1006/jmbi.2000.3784; Chacon P, 1998, BIOPHYS J, V74, P2760, DOI 10.1016/S0006-3495(98)77984-6; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; CHOGLAY AA, 1993, J BIOL CHEM, V268, P6107; Davies D, 1997, EUR J BIOCHEM, V246, P274, DOI 10.1111/j.1432-1033.1997.t01-1-00274.x; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; Doyle SA, 1998, J CELL BIOCHEM, V71, P233; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; Guinier A., 1955, SMALL ANGLE SCATTERI; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Jarvis DL, 1998, CURR OPIN BIOTECH, V9, P528, DOI 10.1016/S0958-1669(98)80041-4; KADLER K, 1995, PROTEIN PROFILE, V2, P491; KATAYAMA K, 1991, BIOCHEMISTRY-US, V30, P7097, DOI 10.1021/bi00243a009; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KIRSCH T, 1992, FEBS LETT, V310, P143, DOI 10.1016/0014-5793(92)81316-E; Kofford MW, 1997, J BIOL CHEM, V272, P7127, DOI 10.1074/jbc.272.11.7127; KOIVU J, 1987, FEBS LETT, V212, P229, DOI 10.1016/0014-5793(87)81350-9; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamande SR, 1999, SEMIN CELL DEV BIOL, V10, P455, DOI 10.1006/scdb.1999.0317; Lee ER, 1996, J HISTOCHEM CYTOCHEM, V44, P433, DOI 10.1177/44.5.8627001; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Lim AL, 1998, J CELL BIOCHEM, V71, P216, DOI 10.1002/(SICI)1097-4644(19981101)71:2<216::AID-JCB7>3.3.CO;2-K; Martin R, 2000, J MOL BIOL, V301, P11, DOI 10.1006/jmbi.2000.3855; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Mizuno M, 2000, FEBS LETT, V479, P123, DOI 10.1016/S0014-5793(00)01900-1; Moschcovich L, 2001, EUR J BIOCHEM, V268, P2991, DOI 10.1046/j.1432-1327.2001.02189.x; MOULD AP, 1990, J MOL BIOL, V211, P581, DOI 10.1016/0022-2836(90)90267-P; MOULD AP, 1987, J MOL BIOL, V195, P543, DOI 10.1016/0022-2836(87)90182-3; Nakata K, 1996, ANN NY ACAD SCI, V785, P307, DOI 10.1111/j.1749-6632.1996.tb56292.x; Narayanan T, 2001, NUCL INSTRUM METH A, V467, P1005, DOI 10.1016/S0168-9002(01)00553-8; Olsen DR, 2001, J BIOL CHEM, V276, P24038, DOI 10.1074/jbc.M101613200; Orgel JP, 2000, STRUCT FOLD DES, V8, P137, DOI 10.1016/S0969-2126(00)00089-7; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pace JM, 2001, J MED GENET, V38, P443, DOI 10.1136/jmg.38.7.443; Palmieri D, 2000, J BIOL CHEM, V275, P32658, DOI 10.1074/jbc.M002698200; PIHLAJANIEMI T, 1984, J BIOL CHEM, V259, P2941; PORORD G, 1982, SMALL ANGLE XRAY SCA; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; Ricard-Blum S, 2000, UNCONVENTIONAL COLLA; Rushton JA, 1999, J NEUROCHEM, V73, P1816; Schuck P, 1999, BIOPHYS J, V76, P2288, DOI 10.1016/S0006-3495(99)77384-4; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 1996, ACTA CRYSTALLOGR A, V52, P419, DOI 10.1107/S0108767396000177; Thielens NM, 1999, J BIOL CHEM, V274, P9149, DOI 10.1074/jbc.274.14.9149; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLING MC, 1990, J CLIN INVEST, V85, P282, DOI 10.1172/JCI114424; WU CH, 1991, J BIOL CHEM, V266, P2983; Zafarullah K, 1997, MATRIX BIOL, V16, P201, DOI 10.1016/S0945-053X(97)90009-3; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	61	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48930	48936		10.1074/jbc.M108611200	http://dx.doi.org/10.1074/jbc.M108611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11684689	hybrid			2022-12-25	WOS:000173922100041
J	Voets, T; Prenen, J; Fleig, A; Vennekens, R; Watanabe, H; Hoenderop, JGJ; Bindels, RJM; Droogmans, G; Penner, R; Nilius, B				Voets, T; Prenen, J; Fleig, A; Vennekens, R; Watanabe, H; Hoenderop, JGJ; Bindels, RJM; Droogmans, G; Penner, R; Nilius, B			CaT1 and the calcium release-activated calcium channel manifest distinct pore properties.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCENTRATION-DEPENDENCE; ION PERMEATION; CA2+ CHANNELS; TRP; VOLTAGE; ENTRY; BLOCK; SELECTIVITY; EXPRESSION; DEPLETION	The calcium release-activated calcium channel (CRAC) is a highly Ca2+-selective ion channel that is activated on depletion of inositol triphosphate (IP3)-sensitive intracellular Ca2+ stores. It was recently reported that CaT1, a member of the TRP family of cation channels, exhibits the unique biophysical properties of CRAC, which led to the conclusion that CaT1 comprises all or part of the CRAC pore (Yue, L., Peng, J. B., Hediger, M. A., and Clapham, D. E. (2001) Nature 410, 705-709). Here, we directly compare endogenous CRAC with heterologously expressed CaT1 and show that they manifest several clearly distinct properties. CaT1 can be distinguished from CRAC in the following features: sensitivity to store-depleting agents; inward rectification in the absence of divalent cations; relative permeability to Na+ and Cs+; effect of 2-aminoethoxydiphenyl borate (2-APB). Moreover, CaT1 displays a mode of voltage-dependent gating that is fully absent in CRAC and originates from the voltage-dependent binding(unbinding of Mg2+ inside the channel pore. Our results imply that the pores of CaT1 and CRAC are not identical and indicate that CaT1 is a Mg2+-gated channel not directly related to CRAC.	Catholic Univ Louvain, Physiol Lab, B-3000 Louvain, Belgium; Univ Hawaii, Queens Med Ctr, Ctr Biomed Res, Lab Cell & Mol Signalling, Honolulu, HI 96813 USA; Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96813 USA; Univ Nijmegen, Med Ctr, Inst Cellular Signalling, Dept Cell Physiol, Nijmegen, Netherlands	Universite Catholique Louvain; The Queen's Medical Center; University of Hawaii System; University of Hawaii System; Radboud University Nijmegen		Thomas.Voets@med.kuleuven.ac.be	Voets, Thomas/E-2466-2012; Vennekens, Rudi/AAQ-1664-2020; Voets, Thomas/AAD-4389-2019; Hoenderop, Joost G.J./H-8047-2014; Bindels, René JM/B-9824-2013	Voets, Thomas/0000-0001-5526-5821; Vennekens, Rudi/0000-0002-2564-5150; Voets, Thomas/0000-0001-5526-5821; Hoenderop, Joost G.J./0000-0002-1816-8544; Bindels, René JM/0000-0003-1167-1339; Fleig, Andrea/0000-0001-8396-7249; Penner, Reinhold/0000-0002-5366-1537				Bakowski D, 2001, J PHYSIOL-LONDON, V532, P55, DOI 10.1111/j.1469-7793.2001.0055g.x; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; CARBONE E, 1987, J PHYSIOL-LONDON, V386, P571, DOI 10.1113/jphysiol.1987.sp016552; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HESS P, 1986, J GEN PHYSIOL, V88, P293, DOI 10.1085/jgp.88.3.293; Hille B., 1992, IONIC CHANNELS EXCIT; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Kerschbaum HH, 1998, J GEN PHYSIOL, V111, P521, DOI 10.1085/jgp.111.4.521; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kukkonen JP, 2001, CELL CALCIUM, V30, P117, DOI 10.1054/ceca.2001.0219; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Petersen OH, 2001, CURR BIOL, V11, pR520, DOI 10.1016/S0960-9822(01)00309-8; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney JW, 2001, NATURE, V410, P648, DOI 10.1038/35070704; Trouet D, 1997, PFLUG ARCH EUR J PHY, V434, P632, DOI 10.1007/s004240050445; Vennekens R, 2001, J PHYSIOL-LONDON, V530, P183, DOI 10.1111/j.1469-7793.2001.0183l.x; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	34	187	202	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47767	47770		10.1074/jbc.C100607200	http://dx.doi.org/10.1074/jbc.C100607200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11687570	Green Published, hybrid			2022-12-25	WOS:000172927000006
J	Ye, KQ; Zhou, J; Landen, JW; Bradbury, EM; Joshi, HC				Ye, KQ; Zhou, J; Landen, JW; Bradbury, EM; Joshi, HC			Sustained activation of p34(cdc2) is required for noscapine-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAXOL-INDUCED APOPTOSIS; DEPENDENT PROTEIN-KINASES; CELL-CYCLE; MITOTIC BLOCK; DEATH; BCL-2; PHOSPHORYLATION; PATHWAY; PACLITAXEL; G(2)/M	Mitotic arrest and subsequent apoptosis has been observed in many types of cells treated with anti-microtubule agents. However, the molecular mechanisms underlying the two events as well as their relationship are not well understood; on the contrary, there has been increasing evidence indicating that anti-microtubule agents might induce apoptosis via signaling pathways independent of mitosis. In this study, we found that apoptosis induced by noscapine, an anti-microtubule drug previously shown to cause both mitotic arrest and apoptotic cell death, was blocked by inhibiting p34(cdc2) activity with olomoucine in FM3A murine mammary carcinoma cells or by reducing the level and activity of p34(cdc2) in a mutant cell line FT210 derived from FM3A. Furthermore, transfection of the mutant FT210 cells with wild-type p34(cdc2) restored their ability to undergo mitotic arrest and then apoptosis in response to noscapine. Thus, we conclude that sustained activation of the p34(cdc2) kinase during mitotic arrest is required for subsequent apoptosis induced by noscapine, establishing a link between the two events.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA; Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA	Emory University; University of California System; University of California Davis	Joshi, HC (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, 1648 Pierce Dr, Atlanta, GA 30322 USA.	joshi@cellbio.emory.edu						ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; BHALLA K, 1993, LEUKEMIA, V7, P563; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BONFOCO E, 1995, EXP CELL RES, V218, P189, DOI 10.1006/excr.1995.1147; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; Fan W., 1996, Cellular Pharmacology, V3, P343; Fan W., 1996, Cellular Pharmacology, V3, P435; FAN W, 1998, MICROSC MICROANAL, V4, P1042; Fang GF, 1998, CANCER RES, V58, P3202; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Joshi HC, 1998, CURR OPIN CELL BIOL, V10, P35, DOI 10.1016/S0955-0674(98)80084-7; Kawamura KI, 1996, BRIT J CANCER, V73, P183, DOI 10.1038/bjc.1996.33; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; Kruyt FAE, 1997, CANCER RES, V57, P2244; Lieu CH, 1997, BIOCHEM PHARMACOL, V53, P1587, DOI 10.1016/S0006-2952(97)82450-1; LONG BH, 1994, CANCER RES, V54, P4355; LOTEM J, 1992, BLOOD, V80, P1750; MARTIN SJ, 1995, SCIENCE, V269, P106, DOI 10.1126/science.7604270; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Miller MC, 1999, CANCER CHEMOTH PHARM, V44, P444, DOI 10.1007/s002800051117; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Paulson JR, 1996, J CELL SCI, V109, P1437; Roth W, 1998, BRIT J CANCER, V77, P404, DOI 10.1038/bjc.1998.64; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; Torres K. E., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P530; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yao SL, 1996, CANCER RES, V56, P4551; Ye KQ, 1998, P NATL ACAD SCI USA, V95, P1601, DOI 10.1073/pnas.95.4.1601; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4	38	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46697	46700		10.1074/jbc.C100550200	http://dx.doi.org/10.1074/jbc.C100550200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11679575	hybrid			2022-12-25	WOS:000172768500004
J	Deng, WG; Ruan, KH; Du, M; Saunders, MA; Wu, KK				Deng, WG; Ruan, KH; Du, M; Saunders, MA; Wu, KK			Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its ATPase activity in human fibroblasts	FASEB JOURNAL			English	Article						salicylate binding protein; SA; COX-2; acetylsalicylic acid	SYSTEMIC ACQUIRED-RESISTANCE; NF-KAPPA-B; SODIUM-SALICYLATE; CHAPERONE BIP; ACID; SPECIFICITY; KINASE; CYCLOOXYGENASE-2; TRANSCRIPTION; INFLAMMATION	Salicylic acid (SA), an endogenous signaling molecule of plants, possesses anti-inflammatory and anti-neoplastic actions in human. Its derivative, aspirin, is the most commonly used anti-inflammatory and analgesic drug. Aspirin and sodium salicylate (salicylates) have been reported to have multiple pharmacological actions. However, it is unclear whether they bind to a cellular protein. Here, we report for the first time the purification from human fibroblasts of a similar to 78 kDa salicylate binding protein with sequence identity to immunoglobulin heavy chain binding protein (BiP). The K-d values of SA binding to crude extract and to recombinant BiP were 45.2 and 54.6 muM, respectively. BiP is a chaperone protein containing a polypeptide binding site recognizing specific heptapeptide sequence and an ATP binding site. A heptapeptide with the specific sequence displaced SA binding in a concentration-dependent manner whereas a control heptapeptide did not. Salicylates inhibited ATPase activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression. These results indicate that salicylates bind specifically to the polypeptide binding site of BiP in human cells that may interfere with folding and transport of proteins important in inflammation.	Univ Texas, Sch Med, Dept Internal Med, Vasc Biol Res Ctr, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Internal Med, Div Hematol, Houston, TX 77030 USA	University of Texas System; University of Texas System	Wu, KK (corresponding author), Univ Texas, Sch Med, Dept Internal Med, Vasc Biol Res Ctr, 6431 Fannin MSB 5-016, Houston, TX 77030 USA.	Kenneth.K.Wu.@uth.tmc.edu	Wu, Kenneth Kun-Yu/B-1070-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50675] Funding Source: Medline; NINDS NIH HHS [NS-23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SB, 1991, BIOCHEM PHARMACOL, V41, P1567, DOI 10.1016/0006-2952(91)90155-X; AMIN AR, 1995, P NATL ACAD SCI USA, V92, P7626; Bellosillo B, 1998, BLOOD, V92, P1406, DOI 10.1182/blood.V92.4.1406.416k17_1406_1414; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BROT N, 1994, P NATL ACAD SCI USA, V91, P12120, DOI 10.1073/pnas.91.25.12120; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CHEN ZX, 1991, P NATL ACAD SCI USA, V88, P8179, DOI 10.1073/pnas.88.18.8179; CHEN ZX, 1993, P NATL ACAD SCI USA, V90, P9533, DOI 10.1073/pnas.90.20.9533; Cronstein BN, 1999, P NATL ACAD SCI USA, V96, P6377, DOI 10.1073/pnas.96.11.6377; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; HIGGS GA, 1987, P NATL ACAD SCI USA, V84, P1417, DOI 10.1073/pnas.84.5.1417; Klampfer L, 1999, BLOOD, V93, P2386, DOI 10.1182/blood.V93.7.2386.407k15_2386_2394; Knarr G, 1999, J BIOL CHEM, V274, P29850, DOI 10.1074/jbc.274.42.29850; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Law BK, 2000, J BIOL CHEM, V275, P38261, DOI 10.1074/jbc.M005545200; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; Mitchell JA, 1997, MOL PHARMACOL, V51, P907, DOI 10.1124/mol.51.6.907; Ruffer M, 1995, FEBS LETT, V377, P175, DOI 10.1016/0014-5793(95)01334-2; SAUNDERS MA, IN PRESS J BIOL CHEM; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SPOHN M, 1980, BIOCHIM BIOPHYS ACTA, V608, P409, DOI 10.1016/0005-2787(80)90186-0; THUN MJ, 1993, CANCER RES, V53, P122; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	36	30	35	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2463	2470		10.1096/fj.01-0259com	http://dx.doi.org/10.1096/fj.01-0259com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689471				2022-12-25	WOS:000172420500016
J	Baisden, JM; Gatesman, AS; Cherezova, L; Jiang, BH; Flynn, DC				Baisden, JM; Gatesman, AS; Cherezova, L; Jiang, BH; Flynn, DC			The intrinsic ability of AFAP-110 to alter actin filament integrity is linked with its ability to also activate cellular tyrosine kinases	ONCOGENE			English	Article						AFAP-110; Src; actin filaments	PP60C-SRC PROTEIN-KINASE; TRANSFORMED FIBROBLASTS; STABLE ASSOCIATION; STRESS FIBERS; SH3 DOMAINS; V-SRC; C-SRC; COMPLEX; PP60SRC; MOTIF	The actin filament-associated protein of 110 kDa (AFAP-110) is a Src binding partner that represents a potential modulator of actin filament integrity in response to cellular signals. Previous reports have demonstrated that AFAP-110 is capable of directly binding and altering actin filaments. Deletion of the leucine zipper motif of AFAP-110 (AFAP-110(Delta lzip)) has been shown to induce a phenotype which resembles Src-transformed cells, by repositioning actin filaments into rosettes. This deletion also mimics a conformational change in AFAP-110 that is detected in Src-transformed cells. The results presented here indicate that unlike AFAP-110, AFAP-110 Delta lzip is capable of activating cellular tyrosine kinases, including Src family members, and that AFAP-110 Delta lzip itself is hyperphosphorylated. The newly tyrosine phosphorylated proteins and activated Src-family members appear to be associated with actin-rich lamellipodia. A point mutation that alters the SH3-binding motif of AFAP-110 Delta lzip prevents it from activating tyrosine kinases and altering actin filament integrity. In addition, a deletion within a pleckstrin homology (PH) domain of AFAP-110 Delta lzip will also revert its effects upon actin filaments. Lastly, dominant-positive RhoA(V14) will block the ability of AFAP-110(Delta lzip) from inducing actin filament rosettes, but does not inhibit Src activation. Thus, conformational changes in AFAP-110 enable it to activate cellular kinases in a mechanism requiring SH3 and/or PH domain interactions. We hypothesize that cellular signals which alter AFAP-110 conformation, enable it to activate cellular kinases such as cSrc, which then direct changes in actin filament integrity in a Rho-dependent fashion.	W Virginia Univ, Dept Microbiol & Immunol, Morgantown, WV 26506 USA	West Virginia University	Flynn, DC (corresponding author), W Virginia Univ, Dept Microbiol & Immunol, 2822 MBRCC, Morgantown, WV 26506 USA.	dflynn@hsc.wvu.edu	Baisden, Joseph/AAN-7747-2021	Baisden, Joseph/0000-0002-8986-407X; Jiang, Bing-Hua/0000-0003-4526-2031	NATIONAL CANCER INSTITUTE [R01CA060731, R29CA060731] Funding Source: NIH RePORTER; NCI NIH HHS [CA60731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAISDEN JM, 2001, IN PRESS ONCOGENE; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; Fincham VJ, 1999, J CELL SCI, V112, P947; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; He H, 2000, CANCER J, V6, P243; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Qian Y, 1999, HYBRIDOMA, V18, P167, DOI 10.1089/hyb.1999.18.167; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000	30	42	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6607	6616		10.1038/sj.onc.1204802	http://dx.doi.org/10.1038/sj.onc.1204802			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641786				2022-12-25	WOS:000171404200014
J	Toyofuku, K; Wada, I; Valencia, JC; Kushimoto, T; Ferrans, VJ; Hearing, VJ				Toyofuku, K; Wada, I; Valencia, JC; Kushimoto, T; Ferrans, VJ; Hearing, VJ			Oculocutaneous albinism types 1 and 3 are ER retention diseases: mutation of tyrosinase or Tyrp1 can affect the processing of both mutant and wild-type proteins	FASEB JOURNAL			English	Article						albinism; chaperones; pigmentation; melanogenesis	DHICA OXIDASE ACTIVITY; ENDOPLASMIC-RETICULUM; MAMMALIAN TYROSINASE; ULTRASTRUCTURAL-LOCALIZATION; BINDING-SPECIFICITY; MELANOGENIC COMPLEX; MEMBRANE-PROTEINS; MELANIN FORMATION; MOLECULAR-BASIS; B-16 MELANOMA	Various types of oculocutaneous albinism (OCA) are associated with reduced pigmentation in the skin, hair, and eyes that results from mutations in genes involved in melanin synthesis. Immortal mouse melanocyte lines (melan-a, melan-b, and melan-c) provide opportune models with which to investigate the etiology of two different types of OCA (types I and III), which arise from mutations in Tyr and Tyrp1, respectively. We compared intracellular processing, sorting, and degradation of tyrosinase and Tyrp1, and the effects on their catalytic function and melanin synthesis, in these wild-type and mutant melanocytes. A mutation in either Tyr or Tyrp1 increased the time of association of tyrosinase and Tyrp1 with calnexin and Bip, which in turn resulted in the retention of these mutant products in the ER. A mutation in either gene selectively enhanced the duration and efficiency of chaperone interactions (even with the wild-type protein in the mutant melanocytes) and markedly slowed their transport to melanosomes. These results show that OCA1 and OCA3 are (in some cases, at least) ER retention diseases wherein a mutation in one melanogenic protein affects the maturation and stability of the other in the melanogenic pathway.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Sapporo Med Univ, Dept Biochem, Sapporo, Hokkaido, Japan; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sapporo Medical University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Room 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov		Wada, Ikuo/0000-0001-5668-6994				Allen S, 2000, BLOOD, V96, P560; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Boissy RE, 1996, AM J HUM GENET, V58, P1145; Boissy RE, 1998, EXP DERMATOL, V7, P198, DOI 10.1111/j.1600-0625.1998.tb00324.x; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; Branza-Nichita N, 1999, BIOCHEM BIOPH RES CO, V261, P720, DOI 10.1006/bbrc.1999.1030; DAKOUR J, 1993, EXP CELL RES, V209, P288, DOI 10.1006/excr.1993.1313; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; DOOLITTLE DP, 1996, GENETIC VARIANTS STR, P17; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Furumura M, 1998, BIOCHEM BIOPH RES CO, V242, P579, DOI 10.1006/bbrc.1997.8007; GIEBEL LB, 1991, J CLIN INVEST, V87, P1119, DOI 10.1172/JCI115075; GIEBEL LB, 1991, AM J HUM GENET, V48, P1159; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; HEARING VJ, 1978, BIOCHIM BIOPHYS ACTA, V522, P327, DOI 10.1016/0005-2744(78)90067-0; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; Jackson IJ, 1997, HUM MOL GENET, V6, P1613, DOI 10.1093/hmg/6.10.1613; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; Jimenez-Cervantes C, 1998, BIOCHEM BIOPH RES CO, V253, P761, DOI 10.1006/bbrc.1998.9817; JIMENEZCERVANTES C, 1994, J BIOL CHEM, V269, P17993; JOHNSON R, 1992, NAT GENET, V1, P226, DOI 10.1038/ng0692-226; Kikuchi A, 1996, BRIT J DERMATOL, V135, P400, DOI 10.1111/j.1365-2133.1996.tb01503.x; KING RA, 1991, J CLIN INVEST, V87, P1046, DOI 10.1172/JCI115064; KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x; KOBAYASHI T, 1994, PIGM CELL RES, V7, P227, DOI 10.1111/j.1600-0749.1994.tb00054.x; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; Kobayashi T, 1998, J BIOL CHEM, V273, P31801, DOI 10.1074/jbc.273.48.31801; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LEUSTEK T, 1992, CELL MOL BIOL, V38, P1; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Manga P, 1997, AM J HUM GENET, V61, P1095, DOI 10.1086/301603; Manga P, 2001, EXP EYE RES, V72, P695, DOI 10.1006/exer.2001.1006; Negroiu G, 2000, J BIOL CHEM, V275, P32200, DOI 10.1074/jbc.M005186200; Oetting WS, 2000, PIGM CELL RES, V13, P320, DOI 10.1034/j.1600-0749.2000.130503.x; Oetting WS, 1999, HUM MUTAT, V13, P99, DOI 10.1002/(SICI)1098-1004(1999)13:2<99::AID-HUMU2>3.3.CO;2-3; OETTING WS, 1994, J INVEST DERMATOL, V103, pS131, DOI 10.1111/1523-1747.ep12399447; OETTING WS, 1994, PIGM CELL RES, V7, P285, DOI 10.1111/j.1600-0749.1994.tb00629.x; ORLOW SJ, 1994, J INVEST DERMATOL, V103, P196, DOI 10.1111/1523-1747.ep12392743; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; SCHAUMBURGLEVER G, 1991, J CUTAN PATHOL, V18, P432, DOI 10.1111/j.1600-0560.1991.tb01380.x; Setaluri V, 2000, PIGM CELL RES, V13, P128, DOI 10.1034/j.1600-0749.2000.130302.x; SIEGRIST W, 1986, ANAL BIOCHEM, V159, P191, DOI 10.1016/0003-2697(86)90327-1; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; SPRITZ RA, 1994, ADV HUM GENET, V22, P1; Spritz RA, 1997, J INVEST DERMATOL, V109, P207, DOI 10.1111/1523-1747.ep12319351; SPRITZ RA, 1990, NEW ENGL J MED, V322, P1724, DOI 10.1056/NEJM199006143222407; SPRITZ RA, 1994, HUM MOL GENET, V3, P1469, DOI 10.1093/hmg/3.suppl_1.1469; Spritz RA, 1997, HUM MUTAT, V10, P171, DOI 10.1002/(SICI)1098-1004(1997)10:2<171::AID-HUMU11>3.3.CO;2-9; Tomita Y, 1999, J BIOCHEM-TOKYO, V126, P1090, DOI 10.1093/oxfordjournals.jbchem.a022554; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; Toyofuku K, 2001, BIOCHEM J, V355, P259, DOI 10.1042/0264-6021:3550259; TRIPATHI RK, 1991, GENE EXPRESSION, V1, P103; TRIPATHI RK, 1992, J BIOL CHEM, V267, P23707; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; URABE K, 1994, BBA-MOL CELL RES, V1221, P272, DOI 10.1016/0167-4889(94)90250-X; Wang Y, 2000, BIOCHEM BIOPH RES CO, V271, P22, DOI 10.1006/bbrc.2000.2577; WINDER A, 1994, CELL MOL BIOL RES, V40, P613	66	111	117	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2149	2161		10.1096/fj.01-0216com	http://dx.doi.org/10.1096/fj.01-0216com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641241				2022-12-25	WOS:000171920400026
J	Cieslak, M; Niewiarowska, J; Nawrot, M; Koziolkiewicz, M; Stec, WJ; Cierniewski, CS				Cieslak, M; Niewiarowska, J; Nawrot, M; Koziolkiewicz, M; Stec, WJ; Cierniewski, CS			DNAzymes to beta(1) and beta(3) mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ANTISENSE OLIGODEOXYRIBONUCLEOTIDES; BREAST-CANCER; ANGIOGENESIS; ALPHA(V)BETA(3); RECEPTOR; VITRONECTIN; MECHANISMS; MIGRATION; SUBUNIT	A novel approach based on DNA-cleaving deoxyribozymes (DNAzymes) was developed to control expression of beta(1) and beta(3) integrins in endothelial cells. To engineer a specific cleavage site in mRNA, the flanking domains of DNAzymes were derived from oligodeoxynucleotides complementary to sequences corresponding to 1053-1070 and 1243-1267 in beta(1) and beta(3) mRNA, respectively. Phosphorothioate analogues of these antisense oligodeoxynucleotides, designated beta1-1053 and beta3-1243, significantly inhibited expression of beta(1) and beta(3) integrin subunits in endothelial and K562 cells at the level of mRNA and protein synthesis. They also specifically decreased the cell surface expression of corresponding subunits in endothelial cells and K562 cells, as measured by flow cytometry. In functional tests, beta1-1053 and beta3-1243 markedly reduced adhesion of cells to fibronectin and vitronectin, respectively. We designed DNAzymes to beta(1) and beta(3) mRNAs containing a 15-deoxynucleotide catalytic domain that was flanked by two substrate recognition segments of 8 and 10 deoxynucleotides for beta(1) and beta(3) DNAzymes, respectively. Both DNAzymes in the presence of Mg2+ specifically cleaved their substrates, synthetic beta(1) and beta(3) mRNA fragments. Although DNAzymes were partially modified with phosphorothioate and with 2'-O-methyl groups at both the 5' and 3' ends indicated similar kinetic parameters, they were significantly more potent than the unmodified DNAzymes because of their much higher resistance to nuclease degradation. Similar to the antisense oligonucleotides, DNAzymes abolished microvascular endothelial cell capillary tube formation in fibrin and Matrigel. In conclusion, DNAzymes to beta(1) and beta(3) mRNAs with 2'-O-methyl modifications are potentially useful as gene-inactivating agents and may ultimately provide a therapeutic means to inhibit angiogenesis in vivo.	Med Univ Lodz, Dept Biophys, PL-90131 Lodz, Poland; Polish Acad Sci, Ctr Mol & Macromol Res, PL-90363 Lodz, Poland; Polish Acad Sci, Ctr Microbiol & Virol, PL-93232 Lodz, Poland	Medical University Lodz; Polish Academy of Sciences; Polish Academy of Sciences	Cierniewski, CS (corresponding author), Med Univ Lodz, Dept Biophys, 3 Lendley St, PL-90131 Lodz, Poland.		Cieslak, Marcin/ABF-2494-2020; Koziolkiewicz, Maria/P-2983-2019	Cieslak, Marcin/0000-0002-9628-214X; Koziolkiewicz, Maria/0000-0003-4628-4566; Niewiarowska, Jolanta/0000-0003-0561-7766; Wiktorska, Magdalena/0000-0001-7346-0380				Bach TL, 1998, J BIOL CHEM, V273, P30719, DOI 10.1074/jbc.273.46.30719; Bayless KJ, 2000, AM J PATHOL, V156, P1673, DOI 10.1016/S0002-9440(10)65038-9; Bello L, 2000, NEUROSURGERY, V47, P1185, DOI 10.1097/00006123-200011000-00035; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Breaker RR, 2000, SCIENCE, V290, P2095, DOI 10.1126/science.290.5499.2095; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHALUPOWICZ DG, 1995, J CELL BIOL, V130, P207, DOI 10.1083/jcb.130.1.207; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Cheresh DA, 1998, NAT MED, V4, P395, DOI 10.1038/nm0498-395; Dallabrida SM, 2000, J BIOL CHEM, V275, P32281, DOI 10.1074/jbc.M001446200; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Eliceiri BP, 2000, CANCER J, V6, pS245; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAFFE EA, 1976, J EXP MED, V144, P9; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Kobylanska A, 1999, ACTA BIOCHIM POL, V46, P679; KOIVISTO L, 1994, BIOCHEM J, V300, P771, DOI 10.1042/bj3000771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; NEHLS V, 1994, MICROVASC RES, V48, P349, DOI 10.1006/mvre.1994.1061; OBRIEN ER, 1994, AM J PATHOL, V145, P883; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; PYTELA R, 1994, METHOD ENZYMOL, V245, P420; Razandi M, 2000, J BIOL CHEM, V275, P38540, DOI 10.1074/jbc.M007555200; RIEBER AJ, 1993, THROMB HAEMOSTASIS, V69, P476; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SAELMAN EUM, 1995, J CELL SCI, V108, P3531; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Vaerman JL, 1997, BLOOD, V90, P331; Warashina M, 1999, CHEM BIOL, V6, P237, DOI 10.1016/S1074-5521(99)80039-8; WILLIAMS S, 1993, LAB INVEST, V69, P491; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841; ZUTTER MM, 1992, J BIOL CHEM, V267, P20233	47	47	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					6779	6787		10.1074/jbc.M102325200	http://dx.doi.org/10.1074/jbc.M102325200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11675378	hybrid			2022-12-25	WOS:000174104300006
J	Cristillo, AD; Bierer, BE				Cristillo, AD; Bierer, BE			Identification of novel targets of immunosuppressive agents by cDNA-based microarray analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL PROLIFERATION; SIGNAL-TRANSDUCTION; CYCLOSPORINE-A; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; TRANSCRIPTION FACTORS; PROTEIN PHOSPHATASE; GENE-EXPRESSION; STAT PROTEINS; GROWTH-FACTOR	The immunosuppressive agents cyclosporin A (C A) and tacrolimus (FK506) bind to unrelated intracellular immunophilin receptors, cyclophilin (CyP) and FK506-binding protein (FKBP), respectively. The complexes of CsA.CyP and of FK506-FKBP both bind to and inhibit the activity of the calcium/calmodulin-dependent serine/ threonine phosphatase calcineurin. We used cDNA microarray analysis to characterize early human peripheral blood T cell transcriptional responses following antigen receptor stimulation in the absence or presence of CsA or FK506, hoping to identify novel targets dependent upon calcineurin or immunophilins or, perhaps, specific targets of either CyP or FKBP inhibitable by one drug alone. The array data failed to identify genes uniquely sensitive to only one drug, suggesting that transcriptionally regulated, immunophilin-dependent but calcineurin-independent targets fell below the limits of detection in this system. In contrast, transcript profiling identified and mRNA and protein analysis confirmed novel as well as known genes reproducibly induced or inhibited by both immunosuppressive agents. In this context, we show that transcriptional activation of Stat5a and repression of the cytokine interleukin-16 are regulated by T cell receptor engagement and dependent upon drug-immunophilin complexes and, presumably, calcineurin activity.	NHLBI, Lab Lymphocyte Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Bierer, BE (corresponding author), NHLBI, Lab Lymphocyte Biol, NIH, Bldg 10,Rm 6C208,10 Ctr Dr, Bethesda, MD 20892 USA.			Bierer, Barbara/0000-0001-6448-8170				ABRAHAM RT, 1988, MOL CELL BIOL, V8, P5448, DOI 10.1128/MCB.8.12.5448; BALER M, 1995, NATURE, V378, P563; BIERER BE, 1993, CURR OPIN IMMUNOL, V5, P763, DOI 10.1016/0952-7915(93)90135-F; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; BUNJES D, 1981, EUR J IMMUNOL, V11, P657, DOI 10.1002/eji.1830110812; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Chupp GL, 1998, J IMMUNOL, V161, P3114; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Cristillo AD, 1997, DNA CELL BIOL, V16, P1449, DOI 10.1089/dna.1997.16.1449; CRUIKSHANK WW, 1987, J IMMUNOL, V138, P3817; Cruikshank WW, 2000, J LEUKOCYTE BIOL, V67, P757, DOI 10.1002/jlb.67.6.757; ESPEVIK T, 1987, J EXP MED, V166, P571, DOI 10.1084/jem.166.2.571; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; FRANTZ B, 1994, EMBO J, V13; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JUNE CH, 1990, J IMMUNOL, V144, P1591; Kagami S, 2000, BLOOD, V95, P1370, DOI 10.1182/blood.V95.4.1370.004k29_1370_1377; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KALDJIAN EP, 1995, J IMMUNOL, V154, P4351; Kirken RA, 1997, J BIOL CHEM, V272, P15459, DOI 10.1074/jbc.272.24.15459; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Laberge S, 1996, J IMMUNOL, V156, P310; Lechner O, 2001, CURR BIOL, V11, P587, DOI 10.1016/S0960-9822(01)00160-9; Liebecq C, 1992, BIOCH NOMENCLATURE R; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Luo C, 1996, MOL CELL BIOL, V16, P3955; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; Maciaszek JW, 1997, J IMMUNOL, V158, P5; Majka M, 2000, BLOOD, V96, P4142, DOI 10.1182/blood.V96.13.4142.h8004142_4142_4151; Mathy NL, 2000, J IMMUNOL, V164, P4429, DOI 10.4049/jimmunol.164.9.4429; Matsuda S, 2000, EMBO REP, V1, P428, DOI 10.1093/embo-reports/kvd090; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Nakamura N, 1999, ONCOGENE, V18, P2667, DOI 10.1038/sj.onc.1202608; Nelson BH, 1997, P NATL ACAD SCI USA, V94, P1878, DOI 10.1073/pnas.94.5.1878; Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; REEM GH, 1983, SCIENCE, V221, P63, DOI 10.1126/science.6407112; Rengarajan J, 2000, IMMUNITY, V12, P293, DOI 10.1016/S1074-7613(00)80182-X; Rogge L, 2000, NAT GENET, V25, P96, DOI 10.1038/75671; Rosenthal LA, 1997, CELL IMMUNOL, V181, P172, DOI 10.1006/cimm.1997.1208; Rumsaeng V, 1997, J IMMUNOL, V158, P1353; SASAKI T, 1985, BIOCHEM J, V227, P971, DOI 10.1042/bj2270971; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; Teague TK, 1999, P NATL ACAD SCI USA, V96, P12691, DOI 10.1073/pnas.96.22.12691; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; Walker J, 2000, J IMMUNOL METHODS, V239, P167, DOI 10.1016/S0022-1759(00)00181-2; WANG RL, 1996, IMMUNITY, V5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1984, J IMMUNOL, V133, P123; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Welte T, 1999, SCIENCE, V283, P222, DOI 10.1126/science.283.5399.222; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Wu DMH, 1999, J IMMUNOL, V162, P1287; Yamashita M, 2000, J EXP MED, V191, P1869, DOI 10.1084/jem.191.11.1869; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; YOSHIMURA N, 1985, TRANSPLANTATION, V40, P661, DOI 10.1097/00007890-198512000-00018; Yu CL, 1997, J IMMUNOL, V159, P5206; Yu CR, 1998, J LEUKOCYTE BIOL, V64, P245, DOI 10.1002/jlb.64.2.245; Zhang YJ, 2001, J BIOL CHEM, V276, P1299, DOI 10.1074/jbc.M008513200	76	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4465	4476		10.1074/jbc.M108598200	http://dx.doi.org/10.1074/jbc.M108598200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11694517	hybrid			2022-12-25	WOS:000173813900089
J	Sliva, D; Rizzo, MT; English, D				Sliva, D; Rizzo, MT; English, D			Phosphatidylinositol 3-kinase and NF-kappa B regulate motility of invasive MDA-AM-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PHOSPHOINOSITIDE 3-KINASE; LIPID PRODUCTS; CONSTITUTIVE ACTIVATION; PHOSPHATIDIC-ACID; HUMAN NEUTROPHILS; EPITHELIAL-CELLS; PROTEIN-KINASE; UP-REGULATION; RECEPTOR	Cell migration is a fundamental aspect of the neoplastic cell metastasis. Here, we show that phosphatidylinositol (PI) 3-kinase is constitutively active and controls cell motility of highly invasive breast cancer cells by the activation of transcription factor, NF-kappaB. The urokinase-type plasminogen activator (uPA) promoter contains an NF-kappaB binding site, and uPA expression in MDA-MB-231 cells is induced by the constitutively active NF-kappaB. Thus, motility was inhibited by overexpression of a dominant negative p85alpha regulatory subunit of PI 3-kinase (p85DN), as well as by pretreatment of cells with specific inhibitors of the p110 catalytic subunit of PI 3-kinase, wortmannin and LY294002. The involvement of gene transcription in cell motility was suggested because treatment with actinomycin D and cycloheximide, which inhibit transcription and new protein synthesis, respectively, abolished endogenous migration of MDA-MB-231 cells. Although wortmannin, Ly294002, or overexpression of p85DN did not significantly reduce DNA binding activity of NF-kappaB in nuclear extracts, wortmannin, Ly294002, and the overexpression of p85DN or IkappaBalpha inhibited constitutive activation of NF-kappaB in a reporter gene assay. Highly invasive MDA-MB-231 cells constitutively secreted uPA in amounts significantly higher than poorly invasive MCF-7 cells. Furthermore, inhibition of NF-kappaB markedly attenuated endogenous migration, and inhibition of PI 3-kinase and NF-kappaB reduced secretion of uPA. Our data suggest a link between constitutively active PI 3-kinase, NF-kappaB, and secretion of uPA, which is responsible for the migration of highly invasive breast cancer cells. Thus, constitutively active PI 3-kinase controls cell motility by the regulation of expression of uPA through the activation of NF-kappaB.	Clarian Hlth Partners Inc, Methodist Res Inst, Canc Res Lab, Indianapolis, IN 46202 USA; Clarian Hlth Partners Inc, Methodist Res Inst, Signal Transduct Lab, Indianapolis, IN 46202 USA; Clarian Hlth Partners Inc, Methodist Res Inst, Expt Cell Res Program, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Sch Allied Hlth Sci, Indianapolis, IN 46202 USA	Indiana University System; Indiana University System; Indiana University System; Indiana University System; Indiana University-Purdue University Indianapolis	Sliva, D (corresponding author), Clarian Hlth Partners Inc, Methodist Res Inst, Canc Res Lab, 1633 N Capitol Ave,MT 350, Indianapolis, IN 46202 USA.	dsliva@clarian.org	Rizzo, Maria/HGD-6576-2022		NHLBI NIH HHS [P01 HL 58064, R01 HL 61751] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061751, P01HL058064] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Ausubel FA, 1990, CURRENT PROTOCOLS MO; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; Bond M, 1999, BIOCHEM BIOPH RES CO, V264, P561, DOI 10.1006/bbrc.1999.1551; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Brostjan C, 1997, J IMMUNOL, V158, P3836; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Derman MP, 1996, J BIOL CHEM, V271, P4251; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; Farina AR, 1998, INT J CANCER, V75, P721; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; Hill K, 2000, J BIOL CHEM, V275, P3741, DOI 10.1074/jbc.275.6.3741; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; JANICKE F, 1989, LANCET, V2, P1049; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Min W, 1996, MOL CELL BIOL, V16, P359; Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199; MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x; NAKANISHI S, 1995, CELL SIGNAL, V7, P545, DOI 10.1016/0898-6568(95)00033-L; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; RIZZO MT, 1994, CANCER RES, V54, P2611; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SCHMITT M, 1992, BIOL CHEM H-S, V373, P611, DOI 10.1515/bchm3.1992.373.2.611; SHATTUCKBRANDT RL, 1977, CANCER RES, V57, P3032; SHEELA S, 1982, CARCINOGENESIS, V3, P363, DOI 10.1093/carcin/3.4.363; Siddiqui RA, 2000, BBA-MOL CELL BIOL L, V1483, P161, DOI 10.1016/S1388-1981(99)00172-9; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sliva D, 2000, BIOCHEM BIOPH RES CO, V268, P471, DOI 10.1006/bbrc.2000.2111; SLIVA D, 1994, J BIOL CHEM, V269, P26208; Sliva D, 1999, BIOCHEM BIOPH RES CO, V263, P149, DOI 10.1006/bbrc.1999.1083; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Theodorescu D, 1998, CELL GROWTH DIFFER, V9, P919; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yu SM, 1997, BIOCHEM J, V328, P363	59	126	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3150	3157		10.1074/jbc.M109579200	http://dx.doi.org/10.1074/jbc.M109579200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11689575	hybrid			2022-12-25	WOS:000173688000014
J	Cai, Y; Lechner, MS; Nihalani, D; Prindle, MJ; Holzman, LB; Dressler, GR				Cai, Y; Lechner, MS; Nihalani, D; Prindle, MJ; Holzman, LB; Dressler, GR			Phosphorylation of Pax2 by the c-jun N-terminal kinase and enhanced Pax2-dependent transcription activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL-TRANSDUCTION; KIDNEY DEVELOPMENT; MAMMALIAN-CELLS; WILMS-TUMOR; DOMAINS; PATHWAYS; LOCALIZATION; EXPRESSION; MESENCHYME	The Pax gene family encodes DNA-binding proteins that can both activate and repress transcription of specific target genes during embryonic development. Pax proteins are required for pattern formation and cell differentiation in a broad spectrum of developing tissues. Consistent with its expression in the intermediate mesoderm, the optic cup and stalk, and the otic vesicle, Pax2, a member of the Pax2/5/8 subfamily, is essential for the development of the renal epithelia, the optic cup, and the inner ear. In addition to a DNA binding domain, the Pax2 protein contains a carboxyl-terminal transactivation domain rich in serine, threonine, and tyrosine. In this report, we demonstrate that the Pax2 transactivation domain is phosphorylated by the c-Jun N-terminal kinase, but not the ERK1/2 or p38 AMP kinases and that phosphorylation is coincident with increased transactivation of a Pax2-dependent reporter gene. Activation of JNK by either upstream kinase MEKK1 or DLK or by expression of Wnt signaling proteins significantly enhances Pax2 phosphorylation in cells. In vitro kinase assays using immunoprecipitated JNK or constitutively active, recombinant JNK show phosphorylation of GST-Pax2 fusion proteins. In transfected cells, phosphorylation of Pax2 correlates with increased transactivation of a Pax2-dependent reporter gene, suggesting that serine/threonine phosphorylation of the transactivation domain is important for Pax2 activity. Pax2 can form a complex with the JNK scaffolding protein JIP1, and this interaction is enhanced by activation of the JNK signaling module with the upstream kinase DLK. The data demonstrate that Pax2 is a new target for the JNK signaling module and point to a novel mechanism for mediating Pax-dependent transcription regulation.	Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dressler, GR (corresponding author), MSRB1,4510,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		nihalani, deepak/AAK-9453-2020	Holzman, Lawrence/0000-0002-8961-234X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054723, R01DK054740] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54740, DK54723] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bouchard M, 2000, DEVELOPMENT, V127, P3703; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Brophy PD, 2001, DEVELOPMENT, V128, P4747; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dehbi M, 1996, ONCOGENE, V13, P447; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lechner MS, 1996, J BIOL CHEM, V271, P21088, DOI 10.1074/jbc.271.35.21088; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Mikkola I, 1999, J BIOL CHEM, V274, P15115, DOI 10.1074/jbc.274.21.15115; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mlodzik M, 1999, EMBO J, V18, P6873, DOI 10.1093/emboj/18.24.6873; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; Pfeffer PL, 2000, DEVELOPMENT, V127, P1017; Poleev A, 1997, EUR J BIOCHEM, V247, P860, DOI 10.1111/j.1432-1033.1997.00860.x; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; RYAN G, 1995, DEVELOPMENT, V121, P867; Schwarz M, 1999, MECH DEVELOP, V82, P29, DOI 10.1016/S0925-4773(99)00005-2; Song DL, 1996, DEVELOPMENT, V122, P627; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Torres M, 1995, DEVELOPMENT, V121, P4057; Torres MA, 1996, DEVELOPMENT, V122, P3381; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	32	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1217	1222		10.1074/jbc.M109663200	http://dx.doi.org/10.1074/jbc.M109663200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11700324	hybrid			2022-12-25	WOS:000173166800045
J	Nikolopoulos, SN; Turner, CE				Nikolopoulos, SN; Turner, CE			Molecular dissection of actopaxin-integrin-linked kinase-paxillin interactions and their role in subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION LOCALIZATION; CELL-ADHESION; PROTEIN-KINASE; CAENORHABDITIS-ELEGANS; GROWTH; MUSCLE; MOTIF; B/AKT; ILK	Paxillin is a focal adhesion adapter protein involved in integrin signaling. We have recently reported that the paxillin LD1 motif acts as a binding interface for both the actin-binding protein actopaxin and the serine/threonine integrin-linked kinase (ILK). In this report we demonstrate the direct association between actopaxin and ILK and dissect the role of the respective interactions in their subcellular localization. Co-immunoprecipitation experiments were employed to map the binding sites on ILK and actopaxin. ILK binds to the CH2 domain of actopaxin. However, an actopaxin CH2 domain mutant defective for paxillin binding (paxillin binding subdomain mutant) retains the capacity to bind ILK, indicating that paxillin and ILK binding sites on actopaxin are distinct. Actopaxin binds to the C terminus of ILK. Despite the direct binding between actopaxin and ILK, mutation analysis confirmed a primary role for paxillin in their localization to focal adhesions. Interestingly, an ILK mutant (E359K) that was previously reported to act as dominant negative for ILK function was unable to bind actopaxin or paxillin and failed to localize to focal adhesions. This mutant also exhibited in vitro kinase activity comparable with wild-type ILK. Taken together, these data suggest that normal ILK signaling is dependent on efficient localization involving multiple protein interactions.	SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Turner, CE (corresponding author), SUNY Upstate Med Univ, Dept Cell & Dev Biol, 750 E Adams St, Syracuse, NY 13210 USA.				NIGMS NIH HHS [GM47607, R01 GM047607] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607, R29GM047607] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; GETTNER SN, 1995, J CELL BIOL, V129, P1127, DOI 10.1083/jcb.129.4.1127; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hobert O, 1999, J CELL BIOL, V144, P45, DOI 10.1083/jcb.144.1.45; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Li FG, 1999, J CELL SCI, V112, P4589; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Olski TM, 2001, J CELL SCI, V114, P525; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; TURNER CE, 1991, EXP CELL RES, V192, P651, DOI 10.1016/0014-4827(91)90090-H; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Wheeler GN, 2001, GENE, V262, P291, DOI 10.1016/S0378-1119(00)00512-6; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007	30	114	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1568	1575		10.1074/jbc.M108612200	http://dx.doi.org/10.1074/jbc.M108612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694518	hybrid			2022-12-25	WOS:000173166800091
J	Santamaria, B; Estevez, AM; Martinez-Costa, OH; Aragon, JJ				Santamaria, B; Estevez, AM; Martinez-Costa, OH; Aragon, JJ			Creation of an allosteric phosphofructokinase starting with a nonallosteric enzyme - The case of Dictyostelium discoideum phosphofructokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PHOSPHOFRUCTOKINASE; RABBIT MUSCLE PHOSPHOFRUCTOKINASE; ASCARIS-SUUM PHOSPHOFRUCTOKINASE; YEAST PHOSPHOFRUCTOKINASE; FRUCTOSE 2,6-BISPHOSPHATE; ESCHERICHIA-COLI; BEHAVIOR; DESENSITIZATION; INACTIVATION; PURIFICATION	An allosteric phosphofructokinase (PFK) was created by sequence manipulation of the nonallosteric enzyme from the slime mold Dictyostelium discoideum (DdPFK). Most amino acid residues proposed as important for catalytic and allosteric sites are conserved in DdPFK except for a few of them, and their reversion did not modify its kinetic behavior. However, deletions at the unique C-terminal extension of this PFK produced a markedly allosteric enzyme. Thus, a mutant lacking the last 26 C-terminal residues exhibited hysteresis in the time course, intense cooperativity (n(H) = 3.8), and a 200-fold decrease in the apparent affinity for fructose 6-phosphate (S-0.5 = 4500 muM), strong activation by fructose 2,6-bisphosphate (K-act = 0.1 mum) and fructose 1,6-bisphosphate (K-act = 40 muM), dependence on enzyme concentration, proton inhibition, and subunit association-dissociation in response to fructose 6-phosphate versus the nonhysteretic and hyperbolic wild-type enzyme (n(H) = 1.0; K-m = 22 mum) that remained as a stable tetramer. Systematic deletions and point mutations at the C-tail region of DdPFK identified the last C-terminal residue, Leu(834), as critical to produce a nonallosteric enzyme. All allosteric mutants were practically insensitive to MgATP inhibition, suggesting that this effect does not involve the same allosteric transition as that responsible for fructose 6-phosphate cooperativity and fructose bisphosphate activation.	Univ Autonoma Madrid, Fac Med, Dept Bioquim, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Med, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain	Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Aragon, JJ (corresponding author), Univ Autonoma Madrid, Fac Med, Dept Bioquim, Arzobispo Morcillo 4, E-28029 Madrid, Spain.		Estevez, Antonio M/K-7835-2014; Martinez-Costa, Oscar/B-7275-2014	Estevez, Antonio M/0000-0002-8272-5405; Martinez-Costa, Oscar/0000-0003-4893-2205				ARAGON JJ, 1991, FASEB J, V5, P2945, DOI 10.1096/fasebj.5.14.1752361; ARAGON JJ, 1985, BIOCHEM BIOPH RES CO, V131, P849, DOI 10.1016/0006-291X(85)91317-8; ATKINSON DE, 1965, BIOCHEM BIOPH RES CO, V18, P1, DOI 10.1016/0006-291X(65)90872-7; AUZAT I, 1995, BIOCHEMISTRY-US, V34, P7062, DOI 10.1021/bi00021a018; Auzat I, 1997, J MOL BIOL, V267, P476, DOI 10.1006/jmbi.1997.0883; BAR J, 1986, EUR J BIOCHEM, V156, P311, DOI 10.1111/j.1432-1033.1986.tb09584.x; BARTRONS R, 1982, FEBS LETT, V143, P137, DOI 10.1016/0014-5793(82)80290-1; BOCK PE, 1976, J BIOL CHEM, V251, P5630; BOCK PE, 1976, J BIOL CHEM, V251, P5637; BOSCA L, 1985, J BIOL CHEM, V260, P2100; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLOMBO G, 1975, J BIOL CHEM, V250, P9404; COOK PF, 1987, J BIOL CHEM, V262, P14063; EMERK K, 1975, ARCH BIOCHEM BIOPHYS, V168, P210, DOI 10.1016/0003-9861(75)90243-X; Estevez AM, 1997, EUR J BIOCHEM, V243, P442, DOI 10.1111/j.1432-1033.1997.0442a.x; ESTEVEZ AM, 1995, FEBS LETT, V374, P100, DOI 10.1016/0014-5793(95)01085-S; FRIEDEN C, 1976, J BIOL CHEM, V251, P5644; FRIEDEN C, 1970, J BIOL CHEM, V245, P5788; Harlow E., 1988, ANTIBODIES LAB MANUA, P553; Heinisch JJ, 1996, J BIOL CHEM, V271, P15928, DOI 10.1074/jbc.271.27.15928; HESTERBERG LK, 1980, BIOCHEMISTRY-US, V19, P2030, DOI 10.1021/bi00551a004; HILL DE, 1975, BIOCHEMISTRY-US, V14, P203, DOI 10.1021/bi00673a003; KEMP RG, 1983, MOL CELL BIOCHEM, V57, P147, DOI 10.1007/BF00849191; KEMP RG, 1969, BIOCHEMISTRY-US, V8, P3162, DOI 10.1021/bi00836a005; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LI JY, 1993, J BIOL CHEM, V268, P24599; Li YL, 1999, BIOCHEMISTRY-US, V38, P16407, DOI 10.1021/bi991761l; LUTHER MA, 1985, BIOCHEMISTRY-US, V24, P2463, DOI 10.1021/bi00331a011; MARTINEZCOSTA OH, 1994, EUR J BIOCHEM, V226, P1007, DOI 10.1111/j.1432-1033.1994.01007.x; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Neet K E, 1980, Methods Enzymol, V64, P139; PETTIGREW DW, 1979, J BIOL CHEM, V254, P1887; Pham AS, 2001, BIOCHEMISTRY-US, V40, P4150, DOI 10.1021/bi001769r; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; RAMAIAH A, 1973, EUR J BIOCHEM, V39, P183, DOI 10.1111/j.1432-1033.1973.tb03116.x; RAO GSJ, 1987, J BIOL CHEM, V262, P14068; Rao GSJ, 1999, ARCH BIOCHEM BIOPHYS, V365, P335, DOI 10.1006/abbi.1999.1183; REINHART GD, 1980, BIOCHEMISTRY-US, V19, P1484, DOI 10.1021/bi00548a035; REINHART GD, 1980, J BIOL CHEM, V255, P576; REINHART GD, 1987, ARCH BIOCHEM BIOPHYS, V258, P65, DOI 10.1016/0003-9861(87)90323-7; REINHART GD, 1980, BIOCHEMISTRY-US, V19, P1491, DOI 10.1021/bi00548a036; REINHART GD, 1980, BIOCHEMISTRY-US, V19, P1477, DOI 10.1021/bi00548a034; Rodicio R, 2000, J BIOL CHEM, V275, P40952, DOI 10.1074/jbc.M007131200; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sanchez-Martinez C, 2000, BIOCHEM BIOPH RES CO, V271, P635, DOI 10.1006/bbrc.2000.2681; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SETLOW B, 1970, J BIOL CHEM, V245, P5524; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SOLS A, 1981, CURR TOP CELL REGUL, V19, P77; UYEDA K, 1965, J BIOL CHEM, V240, P4682; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; VALAITIS AP, 1987, J BIOL CHEM, V262, P5044; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315	53	23	23	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1210	1216		10.1074/jbc.M109480200	http://dx.doi.org/10.1074/jbc.M109480200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11700322	hybrid			2022-12-25	WOS:000173166800044
J	Yamamoto, T; Rodriguez, J; Ikemoto, N				Yamamoto, T; Rodriguez, J; Ikemoto, N			Ca2+-dependent dual functions of peptide C. The peptide corresponding to the Glu(724)-Pro(760) region (the so-called determinant of excitation-contraction coupling) of the dihydropyridine receptor alpha 1 subunit II-III loop.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL RYANODINE RECEPTORS; JUNCTIONAL FOOT PROTEIN; CA2+ RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; MUSCLE-FIBERS; CONFORMATIONAL-CHANGES; ACTIVATION; DEPOLARIZATION; SEQUENCE	Both in vivo and in vitro studies suggest that the Glu(724)-Pro(760) (peptide C) region of the dihydropyridine receptor alpha1 II-III loop is important for excitation-contraction coupling, although its actual function has not yet been elucidated. According to our recent studies, peptide C inhibits Ca2+ release induced by T-tubule depolarization or peptide A. Here we report that peptide C has Ca2+-dependent dual functions on the skeletal muscle ryanodine receptor. Thus, at above-threshold [Ca2+]s (greater than or equal to0.1 muM) peptide C blocked peptide A-induced activation of the ryanodine receptor (ryanodine binding and Ca2+ release); peptide C also blocked T-tubule depolarization-induced Ca2+ release. However, at sub-threshold [Ca2+]s (<0.1 muM), peptide C enhanced ryanodine binding and induced Ca2+ release. If peptide A was present, together with peptide C, both peptides produced additive activation effects. Neither peptide A nor peptide C produced any appreciable effect on the cardiac muscle ryanodine receptor at both high (1.0 muM) and low (0.01 muM) Ca2+ concentrations. These results suggest the possibility that the in vivo counterpart of peptide C retains both activating and blocking functions of the skeletal muscle-type excitation-contraction coupling.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Cambridge, MA 02138 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Harvard University	Ikemoto, N (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	ikemoto@bbri.org			NIAMS NIH HHS [AR16922] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016922] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahern CA, 2001, P NATL ACAD SCI USA, V98, P6935, DOI 10.1073/pnas.111001898; ASHLEY CC, 1991, Q REV BIOPHYS, V24, P1, DOI 10.1017/S0033583500003267; Casarotto MG, 2000, J BIOL CHEM, V275, P11631, DOI 10.1074/jbc.275.16.11631; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P15634, DOI 10.1074/jbc.270.26.15634; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; IKEMOTO N, 1994, BIOCHEMISTRY-US, V33, P10961, DOI 10.1021/bi00202a015; Ikemoto N, 1998, ADV EXP MED BIOL, V453, P199; IKEMOTO N, 1988, METHOD ENZYMOL, V157, P469; KANG JJ, 1992, BIOCHEMISTRY-US, V31, P3288, DOI 10.1021/bi00127a034; Lamb GD, 2000, AM J PHYSIOL-CELL PH, V279, pC891, DOI 10.1152/ajpcell.2000.279.4.C891; Lamb GD, 2000, CLIN EXP PHARMACOL P, V27, P216, DOI 10.1046/j.1440-1681.2000.03224.x; LAMB GD, 1990, J PHYSIOL-LONDON, V423, P495, DOI 10.1113/jphysiol.1990.sp018036; Lu Xiangyang, 1995, Biophysical Journal, V68, pA372; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; Proenza C, 2000, J BIOL CHEM, V275, P29935, DOI 10.1074/jbc.C000464200; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; Saiki Y, 1999, J BIOL CHEM, V274, P7825, DOI 10.1074/jbc.274.12.7825; Stange M, 2001, BIOPHYS J, V81, P1419, DOI 10.1016/S0006-3495(01)75797-9; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Wilkens CM, 2001, P NATL ACAD SCI USA, V98, P5892, DOI 10.1073/pnas.101618098; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; YANO M, 1995, J BIOL CHEM, V270, P3017, DOI 10.1074/jbc.270.7.3017; Zhu XS, 1999, FEBS LETT, V450, P221, DOI 10.1016/S0014-5793(99)00496-2	31	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					993	1001		10.1074/jbc.M105837200	http://dx.doi.org/10.1074/jbc.M105837200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11682472	hybrid			2022-12-25	WOS:000173166800018
J	Kim, J; Huang, WP; Stromhaug, PE; Klionsky, DJ				Kim, J; Huang, WP; Stromhaug, PE; Klionsky, DJ			Convergence of multiple autophagy and cytoplasm to vacuole targeting components to a perivacuolar membrane compartment prior to de novo vesicle formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SORTING RECEPTOR; AMINOPEPTIDASE-I; PROTEIN-KINASE; YEAST VACUOLE; PATHWAY; TRANSPORT; MUTANTS; COMPLEX; GENE	Under starvation conditions, the majority of intracellular degradation occurs at the lysosome or vacuole by the autophagy pathway. The cytoplasmic substrates destined for degradation are packaged inside unique double-membrane transport vesicles called autophagosomes and are targeted to the lysosome/vacuole for subsequent breakdown and recycling. Genetic analyses of yeast autophagy mutants, apg and aut, have begun to identify the molecular machinery as well as indicate a substantial overlap with the biosynthetic cytoplasm to vacuole targeting (Cvt) pathway. Transport vesicle formation is a key regulatory step of both pathways. In this study, we characterize the putative compartment from which both autophagosomes and the analogous Cvt vesicles may originate. Microscopy analyses identified a perivacuolar membrane as the resident compartment for both the Apg1-Cvt9 signaling complex, which mediates the switching between autophagic and Cvt transport, and the autophagy/Cvt-specific phosphatidylinositol 3-kinase complex. Furthermore, the perivacuolar compartment designates the initial site of membrane binding by the Apg/Cvt vesicle component Aut7, the Cvt cargo receptor Cvt19, and the Apg conjugation machinery, which functions in the de novo formation of vesicles. Biochemical isolation of the vesicle component Aut7 and density gradient analyses recapitulate the microscopy findings although also supporting the paradigm that components required for vesicle formation and packaging concentrate at subdomains within the donor membrane compartment.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Klionsky, DJ (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.		Klionsky, Daniel J./ABD-5189-2021	Klionsky, Daniel J./0000-0002-7828-8118; HUANG, WEI-PANG/0000-0001-8410-6555	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM053396-12, R01 GM053396, R01 GM053396-13, GM53396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2001, MICROBIOL MOL BIOL R, V65, P463, DOI 10.1128/MMBR.65.3.463-479.2001; Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; Cavallini G, 2001, EXP GERONTOL, V36, P497, DOI 10.1016/S0531-5565(00)00224-2; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; Gerhardt B, 1998, J BIOL CHEM, V273, P15818, DOI 10.1074/jbc.273.25.15818; Glick BS, 2000, CURR OPIN CELL BIOL, V12, P450, DOI 10.1016/S0955-0674(00)00116-2; Guan J, 2001, MOL BIOL CELL, V12, P3821, DOI 10.1091/mbc.12.12.3821; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; Labbe S, 1999, METHOD ENZYMOL, V306, P145; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; Paglin S, 2001, CANCER RES, V61, P439; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Saftig P, 2001, TRENDS MOL MED, V7, P37, DOI 10.1016/S1471-4914(00)01868-2; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 2001, MOL CELL, V7, P1131, DOI 10.1016/S1097-2765(01)00263-5; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; Straub M, 1997, J BACTERIOL, V179, P3875, DOI 10.1128/jb.179.12.3875-3883.1997; Stromhaug PE, 2001, TRAFFIC, V2, P524, DOI 10.1034/j.1600-0854.2001.20802.x; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wang CW, 2001, J BIOL CHEM, V276, P30442, DOI 10.1074/jbc.M102342200; Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	60	225	234	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					763	773		10.1074/jbc.M109134200	http://dx.doi.org/10.1074/jbc.M109134200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11675395	hybrid, Green Accepted			2022-12-25	WOS:000173087900099
J	Sawhney, RS; Zhou, GHK; Humphrey, LE; Ghosh, P; Kreisberg, JI; Brattain, MG				Sawhney, RS; Zhou, GHK; Humphrey, LE; Ghosh, P; Kreisberg, JI; Brattain, MG			Differences in sensitivity of biological functions mediated by epidermal growth factor receptor activation with respect to endogenous and exogenous ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA-CELLS; MAMMALIAN-CELLS; TISSUE-CULTURE; ALPHA-2-BETA-1 INTEGRINS; EGF RECEPTOR; FACTOR-ALPHA; EXPRESSION; MIGRATION; ADHESION; LINES	Despite constitutive expression of autocrine transforming growth factor-alpha (TGF-alpha) in growth factor-independent colon carcinoma cells, the epidermal growth factor receptor (EGFr) is not saturated and can be further activated by exogenous EGFr ligand. Given that the activation of EGFr by exogenous growth factor has no further effect on DNA synthesis, the question arises as to what function this additional EGFr activation might have. We report that EGF induces integrin alpha(2) expression, integrin-mediated adhesion, and micromotility of HCT116 cells. The stimulatory effect of ligand on these biological functions is abrogated by treatment with AG1478- and EGFr-blocking monoclonal antibody. This provides evidence that the biological responses are EGFr-mediated and EGFr is located upstream of integrin a, expression. Therefore, although exogenous EGF has no effect on DNA synthesis beyond that induced by autocrine TGF-alpha (at subsaturating levels of EGFr occupation) exogenous growth factor does induce integrin a2 expression, cell adhesion, and micromotion. An important finding revealed by this study is the documentation of biological responses of EGFr-mediated functions, including DNA synthesis, cell adhesion, and micromotion, which differ in sensitivity with respect to different degrees of EGFr activation at the basal state and in response to exogenous ligand.	Roswell Pk Canc Inst, Dept Therapeut & Pharmacol, Buffalo, NY 14263 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Roswell Park Cancer Institute; University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine	Brattain, MG (corresponding author), Roswell Pk Canc Inst, Dept Therapeut & Pharmacol, Buffalo, NY 14263 USA.				NATIONAL CANCER INSTITUTE [R01CA050457, R01CA054807, R01CA034432] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34432, CA 50457, CA 54807] Funding Source: Medline; NHLBI NIH HHS [HL07446] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BELLAS RE, 1991, J BIOL CHEM, V266, P12008; BOYD DD, 1988, CANCER RES, V48, P2469; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHANTRET I, 1988, CANCER RES, V48, P1936; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DUBAND JL, 1986, J CELL BIOL, V102, P160, DOI 10.1083/jcb.102.1.160; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FUJII K, 1995, EXP CELL RES, V216, P261, DOI 10.1006/excr.1995.1032; GIAEVER I, 1989, PHYSICA D, V38, P128, DOI 10.1016/0167-2789(89)90182-6; GIAEVER I, 1984, P NATL ACAD SCI-BIOL, V81, P3761, DOI 10.1073/pnas.81.12.3761; GIAEVER I, 1993, NATURE, V366, P591, DOI 10.1038/366591a0; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gong JG, 1997, CELL GROWTH DIFFER, V8, P83; GREGORIOU M, 1984, EMBO J, V3, P929, DOI 10.1002/j.1460-2075.1984.tb01910.x; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Ho WC, 1997, MOL BIOL CELL, V8, P1863, DOI 10.1091/mbc.8.10.1863; HOWELL GM, 1995, J CELL PHYSIOL, V162, P256, DOI 10.1002/jcp.1041620211; Howell GM, 1998, MOL CELL BIOL, V18, P303, DOI 10.1128/MCB.18.1.303; Howell GM, 1998, J BIOL CHEM, V273, P9214, DOI 10.1074/jbc.273.15.9214; Jakus J, 1996, ONCOGENE, V12, P2369; Jiang DH, 1998, J CELL PHYSIOL, V175, P174, DOI 10.1002/(SICI)1097-4652(199805)175:2<174::AID-JCP7>3.3.CO;2-E; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li J, 1999, J BIOL CHEM, V274, P11209, DOI 10.1074/jbc.274.16.11209; LO CM, 1993, EXP CELL RES, V204, P102, DOI 10.1006/excr.1993.1014; LOTZ MM, 1990, CELL REGUL, V1, P249, DOI 10.1091/mbc.1.3.249; MITRA P, 1991, BIOTECHNIQUES, V11, P504; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; PALACEK SP, 1997, NATURE, V385, P537; Pasqualini R, 1996, NAT MED, V2, P1197, DOI 10.1038/nm1196-1197; Reddy L, 1998, EXP CELL RES, V245, P360, DOI 10.1006/excr.1998.4273; SAWHNEY RS, 1991, J BIOL CHEM, V266, P9231; SCHLECHTE W, 1990, CANCER COMMUN, V2, P173; Solic N, 1997, EXP CELL RES, V234, P465, DOI 10.1006/excr.1997.3635; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WAN CW, 1988, CANCER LETT, V43, P139, DOI 10.1016/0304-3835(88)90226-1; Wang DH, 1999, J BIOL CHEM, V274, P12840, DOI 10.1074/jbc.274.18.12840; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154; Ware MF, 1998, J CELL SCI, V111, P2423; Yang HS, 2000, ONCOGENE, V19, P1901, DOI 10.1038/sj.onc.1203513	48	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					75	86		10.1074/jbc.M103268200	http://dx.doi.org/10.1074/jbc.M103268200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11684674	hybrid			2022-12-25	WOS:000173087900012
J	Winter, J; Klappa, P; Freedman, RB; Lilie, H; Rudolph, R				Winter, J; Klappa, P; Freedman, RB; Lilie, H; Rudolph, R			Catalytic activity and chaperone function of human protein-disulfide isomerase are required for the efficient refolding of proinsulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; ESCHERICHIA-COLI; PEPTIDE-BINDING; FOLDING PATHWAY; THIOREDOXIN; INSULIN; VITRO; SITE; AGGREGATION; MOLECULE	Protein-disulfide isomerase (PDI) catalyzes the formation, rearrangement, and breakage of disulfide bonds and is capable of binding peptides and unfolded proteins in a chaperone-like manner. In this study we examined which of these functions are required to facilitate efficient refolding of denatured and reduced proinsulin. In our model system, PDI and also a PDI mutant having only one active site increased the rate of oxidative folding when present in catalytic amounts. PDI variants that are completely devoid of isomerase activity are not able to accelerate proinsulin folding, but can increase the yield of refolding, indicating that they act as a chaperone. Maximum refolding yields, however, are only achieved with wild-type PDI. Using genistein, an inhibitor for the peptide-binding site, the ability of PDI to prevent aggregation of folding proinsulin was significantly suppressed. The present results suggest that PDI is acting both as an isomerase and as a chaperone during folding and disulfide bond formation of proinsulin.	Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle An Der Saale, Germany; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	Martin Luther University Halle Wittenberg; University of Kent	Rudolph, R (corresponding author), Univ Halle Wittenberg, Inst Biotechnol, Kurt Mothes Str 3, D-06120 Halle An Der Saale, Germany.	Rudolph@biochemtech.uni-halle.de						CAI H, 1994, J BIOL CHEM, V269, P24550; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; EKLUND H, 1984, EMBO J, V3, P1443, DOI 10.1002/j.1460-2075.1984.tb01994.x; FREEDMAN RB, 1999, MOL CHAPERONES PROTE, P437; Ganesh C, 2001, PROTEIN SCI, V10, P1635, DOI 10.1110/ps.8101; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; HEJNAES KR, 1992, PROTEIN ENG, V5, P797, DOI 10.1093/protein/5.8.797; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; Katiyar S, 2001, BBA-PROTEIN STRUCT M, V1548, P47, DOI 10.1016/S0167-4838(01)00214-X; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; KEMMLER W, 1971, J BIOL CHEM, V246, P6786; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; Klappa P, 2000, J BIOL CHEM, V275, P13213, DOI 10.1074/jbc.275.18.13213; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Klappa P, 2001, BIOCHEM J, V354, P553, DOI 10.1042/0264-6021:3540553; Li WK, 1997, EUR J BIOCHEM, V246, P127, DOI 10.1111/j.1432-1033.1997.t01-1-00127.x; LILIE H, 1994, J BIOL CHEM, V269, P14290; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; Mayer M, 2000, J BIOL CHEM, V275, P29421, DOI 10.1074/jbc.M002655200; MCCLELLAND DA, 1995, BIOCHEM J, V311, P133, DOI 10.1042/bj3110133; Milner SJ, 1999, BIOTECHNOL BIOENG, V62, P693; Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319; PUIG A, 1994, J BIOL CHEM, V269, P7764; Qiao ZS, 2001, BIOCHEMISTRY-US, V40, P2662, DOI 10.1021/bi001613r; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; Rosenfeld RD, 1997, ARCH BIOCHEM BIOPHYS, V342, P298, DOI 10.1006/abbi.1997.9996; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; TANG B, 1994, BIOCHEM J, V301, P17, DOI 10.1042/bj3010017; TANG JG, 1988, BIOCHEM J, V255, P451, DOI 10.1042/bj2550451; TSIBRIS JCM, 1989, J BIOL CHEM, V264, P13967; van den Berg P, 1999, EMBO J, V18, P4794, DOI 10.1093/emboj/18.17.4794; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Wang CC, 1998, BIOCHEMISTRY-MOSCOW+, V63, P407; WANG CC, 1991, TRENDS BIOCHEM SCI, V16, P279, DOI 10.1016/0968-0004(91)90114-B; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; Winter J, 2000, J BIOTECHNOL, V84, P175, DOI 10.1016/S0168-1656(00)00356-4; Yang Y, 1999, J BIOL CHEM, V274, P37598, DOI 10.1074/jbc.274.53.37598; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651; Zhang FL, 2000, PLANT CELL REP, V19, P569, DOI 10.1007/s002990050775; Zheng J, 2001, J BIOL CHEM, V276, P15747, DOI 10.1074/jbc.M011444200; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	44	82	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					310	317		10.1074/jbc.M107832200	http://dx.doi.org/10.1074/jbc.M107832200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11694508	hybrid			2022-12-25	WOS:000173087900042
J	Zhang, YJ; Guo, LD; Chen, K; Wu, CY				Zhang, YJ; Guo, LD; Chen, K; Wu, CY			A critical role of the PINCH-integrin-linked kinase interaction in the regulation of cell shape change and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED FIBROBLASTS; MYOGENIC DIFFERENTIATION; MATRIX ADHESIONS; ADAPTER PROTEIN; FOCAL ADHESIONS; FIBRONECTIN; DOMAIN; GROWTH; SRC; PHOSPHORYLATION	The interaction of cells with extracellular matrix recruits multiple proteins to cell-matrix contact sites (e.g. focal and fibrillar adhesions), which connect the extracellular matrix to the actin cytoskeleton. and regulate cell shape change, migration, and other cellular processes. We previously identified PINCH, an adaptor protein comprising primarily five LIM domains, as a binding protein for integrin-linked kinase (ILK). In this study, we show that PINCH co-localizes with ILK in both focal adhesions and fibrillar adhesions. Furthermore, we have investigated the molecular basis underlying the targeting of PINCH to the cell-matrix contact sites and the functional significance of the PINCH-ILK interaction. We have found that the N-terminal LIM1 domain, which mediates the ILK binding, is required for the targeting of PINCH to the cell-matrix contact sites. The C-terminal LIM domains, although not absolutely required, play an important regulatory role in the localization of PINCH to cell-matrix contact sites. Inhibition of the PINCH-ILK interaction, either by overexpression of a PINCH N-terminal fragment containing the ILK-binding LIM1 domain or by overexpression of an ILK N-terminal fragment containing the PINCH-binding ankyrin domain, retarded cell spreading, and reduced cell motility. These results suggest that PINCH, through its interaction with ILK, is crucially involved in the regulation of cell shape change and motility.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wu, CY (corresponding author), Univ Pittsburgh, Dept Pathol, 707B Scaire Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.				NIDDK NIH HHS [DK54639] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054639] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Braverman LE, 1999, J BIOL CHEM, V274, P5542, DOI 10.1074/jbc.274.9.5542; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Chen M, 1998, J BIOL CHEM, V273, P25171, DOI 10.1074/jbc.273.39.25171; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN WT, 1982, J CELL BIOL, V95, P205, DOI 10.1083/jcb.95.1.205; CHEN WT, 1985, J CELL BIOL, V100, P1103, DOI 10.1083/jcb.100.4.1103; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Guo LD, 2001, AM J PATHOL, V159, P1735, DOI 10.1016/S0002-9440(10)63020-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hobert O, 1999, J CELL BIOL, V144, P45, DOI 10.1083/jcb.144.1.45; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; HYNES RO, 1978, CELL, V15, P875, DOI 10.1016/0092-8674(78)90272-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; Li FG, 1999, J CELL SCI, V112, P4589; Li J, 1999, J CELL BIOL, V147, P1391, DOI 10.1083/jcb.147.7.1391; Lin XY, 2000, MOL BIOL CELL, V11, p515A; Mackinnon AC, 2000, MOL BIOL CELL, V11, p515A; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Olski TM, 2001, J CELL SCI, V114, P525; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Tu YZ, 2001, FEBS LETT, V491, P193, DOI 10.1016/S0014-5793(01)02195-0; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Velyvis A, 2001, J BIOL CHEM, V276, P4932, DOI 10.1074/jbc.M007632200; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Wu CY, 2001, J CELL SCI, V114, P2549; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zamir E, 1999, J CELL SCI, V112, P1655; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007	45	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					318	326		10.1074/jbc.M108257200	http://dx.doi.org/10.1074/jbc.M108257200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11694512	hybrid			2022-12-25	WOS:000173087900043
J	Babenko, AP; Bryan, J				Babenko, AP; Bryan, J			A conserved inhibitory and differential stimulatory action of nucleotides on K(IR)6.0/SUR complexes is essential for excitation-metabolism coupling by K-ATP channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; RAT VENTRICULAR MYOCYTES; PANCREATIC BETA-CELLS; SULFONYLUREA RECEPTOR; INSULIN-SECRETION; BINDING-PROPERTIES; C-TERMINUS; MEMBRANE; KIR6.2; ACTIVATION	The mechanism by which ubiquitous adenine nucleotide-gated K(IR)6.0(4)/SUR4 channels link membrane excitability with cellular metabolism is controversial. Is a decreased sensitivity to inhibitory ATP required, or is the Mg-ADP/ATP-dependent stimulatory action of the ATPase, sulfonylurea receptor (SUR), on K-IR sufficient to elicit a physiologically significant open channel probability? To evaluate the roles of nucleotide inhibition versus stimulation, we compared K(IR)6.1-based K-NDP channels with K(IR)6.2-based K-ATP channels and all possible K(IR)6.1/6.2 hybrids. Although K-NDP channels are thought to be poorly sensitive to inhibitory ATP and to require Mg-nucleotide diphosphates for activity, we demonstrate that, like K-ATP, and hybrid channels, they are inhibited with an IC50(ATP) 100-fold lower than [ATP](i). K(IR)6.1 is, however, more efficiently stimulated by SUR than K(IR)6.2, thus providing a mechanism for differential nucleotide regulation, in addition to the known differential interactions of Mg-nucleotides with SUR isoforms. The on-cell and spontaneous activities of K-NDP, K-ATP, and hybrid channels identified in native cells, are different; thus, their similar IC50(ATP) values argue the regulatory "beta" SUR subunits play a preeminent role in coupling excitation to metabolism and pose questions about the physiologic significance of models, which assume the ATP insensitivity of open K(IR)s.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Babenko, AP (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.							Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ammala C, 1996, J PHYSIOL-LONDON, V494, P709, DOI 10.1113/jphysiol.1996.sp021526; ASHCROFT FM, 1989, J PHYSIOL-LONDON, V416, P349, DOI 10.1113/jphysiol.1989.sp017765; Babenko A, 1997, CIRC RES, V80, P589, DOI 10.1161/01.RES.80.4.589; Babenko AP, 2000, J BIOL CHEM, V275, P31563, DOI 10.1074/jbc.C000553200; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; BABENKO AP, 1992, FEBS LETT, V313, P148, DOI 10.1016/0014-5793(92)81432-L; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; Babenko AP, 1999, FEBS LETT, V445, P131, DOI 10.1016/S0014-5793(99)00102-7; Babenko AP, 1998, CIRC RES, V83, P1132, DOI 10.1161/01.RES.83.11.1132; Babenko AP, 1999, BIOCHEM BIOPH RES CO, V255, P231, DOI 10.1006/bbrc.1999.0172; Babenko AP, 2000, J BIOL CHEM, V275, P717, DOI 10.1074/jbc.275.2.717; Babenko AP, 1999, FEBS LETT, V459, P367, DOI 10.1016/S0014-5793(99)01215-6; Babenko AP, 1998, BIOPHYS J, V74, pA114; BABENKO AP, 1991, BASIC APPL MYOL, V2, P316; Baron A, 1999, CIRC RES, V85, P707, DOI 10.1161/01.RES.85.8.707; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BEECH DJ, 1993, BRIT J PHARMACOL, V110, P573, DOI 10.1111/j.1476-5381.1993.tb13849.x; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; Cui Y, 2001, P NATL ACAD SCI USA, V98, P729, DOI 10.1073/pnas.011370498; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; FAIVRE JF, 1990, BIOCHIM BIOPHYS ACTA, V1029, P167, DOI 10.1016/0005-2736(90)90450-3; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FINDLAY I, 1991, FEBS LETT, V279, P95, DOI 10.1016/0014-5793(91)80259-6; FINDLAY I, 1988, PFLUG ARCH EUR J PHY, V412, P37, DOI 10.1007/BF00583729; FINDLAY I, 1987, J PHYSIOL-LONDON, V391, P611, DOI 10.1113/jphysiol.1987.sp016759; Han X, 1996, J PHYSIOL-LONDON, V490, P337, DOI 10.1113/jphysiol.1996.sp021148; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; KORICHNEVA I, 1995, CIRC RES, V77, P556, DOI 10.1161/01.RES.77.3.556; Koster JC, 2000, CELL, V100, P645, DOI 10.1016/S0092-8674(00)80701-1; Light PE, 1999, CARDIOVASC RES, V44, P356, DOI 10.1016/S0008-6363(99)00218-7; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Satoh E, 1998, J PHYSIOL-LONDON, V511, P663, DOI 10.1111/j.1469-7793.1998.663bg.x; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Seharaseyon J, 2000, J BIOL CHEM, V275, P17561, DOI 10.1074/jbc.275.23.17561; Shyng SL, 2000, P NATL ACAD SCI USA, V97, P937, DOI 10.1073/pnas.97.2.937; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Suzuki M, 2001, CIRC RES, V88, P570, DOI 10.1161/01.RES.88.6.570; Tanabe K, 2000, BIOCHEM BIOPH RES CO, V272, P316, DOI 10.1006/bbrc.2000.2780; Tanabe K, 1999, J BIOL CHEM, V274, P3931, DOI 10.1074/jbc.274.7.3931; TRUBE G, 1984, PFLUG ARCH EUR J PHY, V401, P178, DOI 10.1007/BF00583879; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	56	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49083	49092		10.1074/jbc.M108763200	http://dx.doi.org/10.1074/jbc.M108763200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11673467	hybrid			2022-12-25	WOS:000173922100062
J	Takeda, K; Ichiki, T; Tokunou, T; Iino, N; Takeshita, A				Takeda, K; Ichiki, T; Tokunou, T; Iino, N; Takeshita, A			15-deoxy-Delta(12,14)-prostaglandin J(2) and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II TYPE-1 RECEPTOR; ANGIOTENSIN-II; PROTEIN-KINASE; PPAR-GAMMA; GENE-TRANSCRIPTION; SIGNALING CASCADE; MESANGIAL CELLS; DOWN-REGULATION; NITRIC-OXIDE; RAT	Peroxisome proliferator-activated receptor (PPAR) gamma belongs to the nuclear receptor superfamily of ligand-dependent transcription factors. Recent results have shown that the ligands for nuclear receptors have rapid effects so called "nongenomic" effects, which are observed within minutes after stimulation. We examined whether 15-deoxy-Delta 12,14-prostaglandin J(2), (15-d-PGJ2) had rapid effects on cultured vascular smooth muscle cells. Phosphorylation of ERK and c-fos mRNA expression were determined by Western and Northern blot analyses, respectively. PPARgamma agonists 15-d-PGJ2 and thiazolidinediones such as pioglitazone and troglitazone elicited rapid activation of ERK within 15 min and induced c-fos mRNA expression within 30 min, whereas the PPARalpha agonist bezafibrate failed to activate ERK. 15-d-PGJ2-induced expression of c-fos m-RNA was blocked by PD98059 or U0126, two ERK kinase inhibitors, suggesting that the MEK/ERK pathway mediates 15-d-PGJ2-induced c-fos gene expression. Furthermore, pretreatment with wortmannin, an inhibitor of phosphatidylinositol 3 (PI3)-kinase, inhibited 15-d-PGJ2-induced ERK activation and c-fos mRNA expression, suggesting that PI3-kinase is involved in the process. An electrophoretic mobility shift assay showed that 15-d-PGJ2 enhanced AP-1 binding activity to AP-1 consensus sequence in a time-dependent manner. 15-d-PGJ2 increased thymidine incorporation in a PI3-kinase-dependent manner. Taken together, our findings show that 15-d-PGJ2 and thiazolidinediones activate the MEK/ERK pathway through PI3-kinase and lead to c-fos mRNA expression and DNA synthesis. These findings indicate a novel regulatory mechanism of gene expression by 15-d-PGJ2 and thiazolidinediones.	Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Ichiki, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	ichiki@cardiol.med.kyushu-u.ac.jp	Tokunou, Tomotake/AAG-3403-2019					Bokemeyer D, 1998, HYPERTENSION, V32, P661, DOI 10.1161/01.HYP.32.4.661; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; CaulinGlaser T, 1997, CIRC RES, V81, P885; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Funakoshi Y, 1999, HYPERTENSION, V34, P118, DOI 10.1161/01.HYP.34.1.118; Goetze S, 2000, J CARDIOVASC PHARM, V35, P749, DOI 10.1097/00005344-200005000-00011; Graf K, 1997, FEBS LETT, V400, P119, DOI 10.1016/S0014-5793(96)01371-3; Haneda M, 1997, DIABETES, V46, P847, DOI 10.2337/diabetes.46.5.847; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Ichiki T, 1998, HYPERTENSION, V31, P342, DOI 10.1161/01.HYP.31.1.342; Iijima K, 1998, BIOCHEM BIOPH RES CO, V247, P353, DOI 10.1006/bbrc.1998.8794; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Miura K, 2000, BLOOD, V96, P2199, DOI 10.1182/blood.V96.6.2199.h8002199_2199_2205; Neugarten J, 1999, AM J PHYSIOL-RENAL, V277, pF875, DOI 10.1152/ajprenal.1999.277.6.F875; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Pandey SK, 1999, BIOCHEMISTRY-US, V38, P14667, DOI 10.1021/bi9911886; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rokos CL, 1997, J BIOL CHEM, V272, P13452, DOI 10.1074/jbc.272.20.13452; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Schmidt BMW, 2000, FRONT NEUROENDOCRIN, V21, P57, DOI 10.1006/frne.1999.0189; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Silbiger S, 1999, KIDNEY INT, V55, P1268, DOI 10.1046/j.1523-1755.1999.00376.x; SILBIGER SR, 1995, AM J KIDNEY DIS, V25, P515, DOI 10.1016/0272-6386(95)90119-1; Singh M, 1999, J NEUROSCI, V19, P1179; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Takeda K, 2000, HYPERTENSION, V35, P297, DOI 10.1161/01.HYP.35.1.297; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	34	125	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48950	48955		10.1074/jbc.M108722200	http://dx.doi.org/10.1074/jbc.M108722200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11687581	hybrid			2022-12-25	WOS:000173922100044
J	Wang, JH; Guan, E; Roderiquez, G; Calvert, V; Alvarez, R; Norcross, MA				Wang, JH; Guan, E; Roderiquez, G; Calvert, V; Alvarez, R; Norcross, MA			Role of tyrosine phosphorylation in ligand-independent sequestration of CXCR4 in human primary monocytes-macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; FOCAL ADHESION KINASE; HEMATOPOIETIC PROGENITOR CELLS; CHEMOKINE RECEPTOR CXCR4; HUMAN T-LYMPHOCYTES; SIGNAL-TRANSDUCTION; HIV-1 INFECTION; CCR5 EXPRESSION; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR	The chemokine stromal cell-derived factor (SDF)-1 and its receptor, CXCR4, play important roles in human immunodeficiency virus type 1 (HIV-1) pathophysiology, leukocyte trafficking, inflammation, hematopoiesis, embryogenesis, angiogenesis, and cancer metastasis. The effects of cytokines on the regulation of CXCR4 function were investigated in human primary monocytes-macrophages. The expression of functional CXCR4 on the cell surface was demonstrated by the detection of ligand-in-induced Ca2+ mobilization, chemotaxis, and ligand-induced receptor endocytosis. Surface CXCR4 expression was down-regulated by cytokines interleukin-4 (IL-4), IL-13, and granulocyte-macrophage colony-stimulating factor (GM-CSF) and up-regulated by IL-10 and transforming growth factor-beta1. Down-regulation was mediated post-translationally, in the absence of protein degradation, through an endocytotic mechanism. In contrast to SDF-1alpha-induced CXCR4 endocytosis, cytokine-induced endocytosis of this receptor was independent of actin filament polymerization. GM-CSF increased the expression of G protein-coupled receptor kinase 3 (GRK3), beta-arrestin-1, Pyk2, and focal adhesion kinase (FAK). Cytokine treatment also increased the total and tyrosine-specific phosphorylation of CXCR4 as well as the phosphorylation of FAK on tyrosine 397. It also induced the formation of GRK3.CXCR4 or FAK.CXCR4 complexes. Infection of macrophages by primary R5X4 and X4 isolates of HIV-1 was inhibited by IL-4, IL-13, and GM-CSF, an effect that was associated with down-regulation of surface CXCR4 expression. These data indicate that ligand-dependent and ligand-independent endocytoses of CXCR4 are mediated by different mechanisms. Cytokine-induced endocytosis of chemokine receptors may be of therapeutic value in HIV-1 infection, inflammation, tumor metastasis, and defective hematopoiesis.	US FDA, Ctr Biol Evaluat & Res, Div Therapeut Prot, Lab Gene Regulat, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Norcross, MA (corresponding author), US FDA, NIH,Ctr Biol Evaluat & Res, Div Therapeut Prot, Lab Gene Regulat, Bldg 29B,Rm 4E12,8800 Rockville Pike, Bethesda, MD 20892 USA.							Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Aragay AM, 1998, FEBS LETT, V430, P37, DOI 10.1016/S0014-5793(98)00495-5; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; Bailer RT, 2000, EUR J IMMUNOL, V30, P1340, DOI 10.1002/(SICI)1521-4141(200005)30:5<1340::AID-IMMU1340>3.0.CO;2-L; Bjorndal A, 1997, J VIROL, V71, P7478; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Brelot A, 1999, J VIROL, V73, P2576, DOI 10.1128/JVI.73.4.2576-2586.1999; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Cicala C, 1999, J IMMUNOL, V163, P420; Coughlan CM, 2000, NEUROSCIENCE, V97, P591, DOI 10.1016/S0306-4522(00)00024-5; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deichmann M, 1997, BLOOD, V89, P3522, DOI 10.1182/blood.V89.10.3522.3522_3522_3528; Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Hariharan D, 1999, BLOOD, V93, P1137, DOI 10.1182/blood.V93.4.1137.404a35_1137_1144; Iyengar S, 1998, J VIROL, V72, P5251, DOI 10.1128/JVI.72.6.5251-5255.1998; Jourdan P, 1998, J IMMUNOL, V160, P4153; Kawabata T, 1999, P NATL ACAD SCI USA, V96, P5663, DOI 10.1073/pnas.96.10.5663; Kinter A, 2000, IMMUNOL REV, V177, P88, DOI 10.1034/j.1600-065X.2000.17708.x; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Kume A, 1997, BLOOD, V89, P3434, DOI 10.1182/blood.V89.9.3434; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Maples CJ, 1997, J BIOL CHEM, V272, P6741, DOI 10.1074/jbc.272.10.6741; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Moriuchi M, 1998, J CLIN INVEST, V102, P1540, DOI 10.1172/JCI4151; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murdoch C, 2000, IMMUNOL REV, V177, P175, DOI 10.1034/j.1600-065X.2000.17715.x; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Ott DE, 2000, VIROLOGY, V266, P42, DOI 10.1006/viro.1999.0075; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Perrin-Tricaud C, 1999, VIROLOGY, V255, P20, DOI 10.1006/viro.1998.9573; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Signoret N, 1998, J CELL SCI, V111, P2819; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simmons G, 1998, J VIROL, V72, P8453, DOI 10.1128/JVI.72.10.8453-8457.1998; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tarasova NI, 1998, J BIOL CHEM, V273, P15883, DOI 10.1074/jbc.273.26.15883; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Wang JF, 2000, BLOOD, V95, P2505, DOI 10.1182/blood.V95.8.2505.008k24_2505_2513; Wang JH, 1999, J IMMUNOL, V163, P5763; Wang JH, 2001, J IMMUNOL, V167, P3360, DOI 10.4049/jimmunol.167.6.3360; Wang JH, 1998, J VIROL, V72, P7642, DOI 10.1128/JVI.72.9.7642-7647.1998; Watson JM, 2001, J BIOL CHEM, V276, P3536, DOI 10.1074/jbc.M006916200; Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	67	68	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49236	49243		10.1074/jbc.M108523200	http://dx.doi.org/10.1074/jbc.M108523200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11668182	hybrid			2022-12-25	WOS:000173922100081
J	Criss, AK; Silva, M; Casanova, JE; McCormick, BA				Criss, AK; Silva, M; Casanova, JE; McCormick, BA			Regulation of Salmonella-induced neutrophil transmigration by epithelial ADP-ribosylation factor 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; PROTEIN-KINASE-C; PLASMA-MEMBRANE; INTESTINAL EPITHELIA; ACTIN CYTOSKELETON; PHOSPHATIDIC-ACID; MAMMALIAN-CELLS; FACTOR ARNO; TYPHIMURIUM; ARF6	Salmonella typhimurium elicits an acute inflammatory response in the host intestinal epithelium, characterized by the movement of polymorphonuclear leukocytes (PMN) across the epithelial monolayer to the intestinal lumen. It was recently shown that SipA, a protein secreted by S. typhimurium, is necessary and sufficient to drive PMN transmigration across model intestinal epithelia (Lee, C. A., Silva, M., Siber, A. M., Kelly, A. J., Galyov, E., and McCormick, B. A (2000) Proc. Natl. Acad Sci. USA 97, 12283-12288). However, the epithelial factors responsible for this process have not been identified. Here, for the first time, we demonstrate that S. typhimurium-induced PMN transmigration across Madin-Darby canine kidney-polarized monolayers is regulated by the GTPase ARF6. Apically added S. typhimurium promoted the translocation of ARF6 and its exchange factor ARNO to the apical surface. Overexpression of a dominant-negative mutant of ARF6 inhibited Salmonella-induced PMN transmigration, which was due to a reduction in apical release of the PMN chemoattractant PEEC (pathogen-elicited epithelial chemoattractant), without affecting bacterial internalization. Furthermore, ARF6 and its effector phospholipase D (PLD) were both required for bacteria-induced translocation of protein kinase C (PKC) to membranes. These results describe a novel signal transduction pathway, in which Salmonella initiates an ARF6- and PLD-dependent lipid signaling cascade that, in turn, directs activation of PKC, release of PEEC, and subsequent transepithelial PMN movement.	Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA; Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA; Massachusetts Gen Hosp, Combined Program Pediat Gastroenterol & Nutr, Charlestown, MA 02129 USA	University of Virginia; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Casanova, JE (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Box 800732, Charlottesville, VA 22908 USA.	jec9e@virginia.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032991, R01AI032991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058536, R01DK056754, P01DK033506] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-32991] Funding Source: Medline; NIDDK NIH HHS [DK-56754, DK-33506, DK-58536] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Criss AK, 2001, J CELL SCI, V114, P1331; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Dana RR, 2000, J BIOL CHEM, V275, P32566, DOI 10.1074/jbc.M005406200; Darwin KH, 1999, CLIN MICROBIOL REV, V12, P405, DOI 10.1128/CMR.12.3.405; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Ferro T, 2000, AM J PHYSIOL-LUNG C, V278, pL1107, DOI 10.1152/ajplung.2000.278.6.L1107; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; Gewirtz AT, 1999, INFECT IMMUN, V67, P608, DOI 10.1128/IAI.67.2.608-617.1999; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; HUECK CJ, 1995, MOL MICROBIOL, V18, P479, DOI 10.1111/j.1365-2958.1995.mmi_18030479.x; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Lee CA, 2000, P NATL ACAD SCI USA, V97, P12283, DOI 10.1073/pnas.97.22.12283; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; Londono I, 1999, KIDNEY INT, V55, P1407, DOI 10.1046/j.1523-1755.1999.00365.x; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Manifava M, 2001, J BIOL CHEM, V276, P8987, DOI 10.1074/jbc.M010308200; Maranda B, 2001, J BIOL CHEM, V276, P18540, DOI 10.1074/jbc.M011577200; MCCORMICK BA, 1995, J CELL BIOL, V131, P1599, DOI 10.1083/jcb.131.6.1599; MCCORMICK BA, 1995, INFECT IMMUN, V63, P2302, DOI 10.1128/IAI.63.6.2302-2309.1995; MCCORMICK BA, 1993, J CELL BIOL, V123, P895, DOI 10.1083/jcb.123.4.895; McCormick BA, 1998, J IMMUNOL, V160, P455; Melendez AJ, 2001, CURR BIOL, V11, P869, DOI 10.1016/S0960-9822(01)00260-3; Meresse S, 1999, EMBO J, V18, P4394, DOI 10.1093/emboj/18.16.4394; Millar CA, 1999, J BIOL CHEM, V274, P17619, DOI 10.1074/jbc.274.25.17619; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; Mukherjee K, 2001, J BIOL CHEM, V276, P23607, DOI 10.1074/jbc.M101034200; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Radhakrishna H, 1999, J CELL SCI, V112, P855; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Santy LC, 1999, CURR BIOL, V9, P1173, DOI 10.1016/S0960-9822(00)80019-6; Shome K, 1998, J BIOL CHEM, V273, P30836, DOI 10.1074/jbc.273.46.30836; Stender S, 2000, MOL MICROBIOL, V36, P1206, DOI 10.1046/j.1365-2958.2000.01933.x; Turner JR, 1999, AM J PHYSIOL-CELL PH, V277, pC554, DOI 10.1152/ajpcell.1999.277.3.C554; Venkateswarlu K, 2000, BIOCHEM J, V345, P719, DOI 10.1042/0264-6021:3450719; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Wakelam MJO, 1998, BBA-MOL CELL BIOL L, V1436, P117, DOI 10.1016/S0005-2760(98)00123-4; WELSH CF, 1994, MOL CELL BIOCHEM, V138, P157, DOI 10.1007/BF00928458; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977	61	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48431	48439		10.1074/jbc.M106969200	http://dx.doi.org/10.1074/jbc.M106969200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11641400	hybrid			2022-12-25	WOS:000172927000095
J	Killick, R; Pollard, CC; Asuni, AA; Mudher, AK; Richardson, JC; Rupniak, HT; Sheppard, PW; Varndell, IM; Brion, JP; Levey, AI; Levy, OA; Vestling, M; Cowburn, R; Lovestone, S; Anderton, BH				Killick, R; Pollard, CC; Asuni, AA; Mudher, AK; Richardson, JC; Rupniak, HT; Sheppard, PW; Varndell, IM; Brion, JP; Levey, AI; Levy, OA; Vestling, M; Cowburn, R; Lovestone, S; Anderton, BH			Presenilin 1 independently regulates beta-catenin stability and transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE ACTIVITY; IN-VIVO; AXIN; MUTATIONS; DROSOPHILA; ARMADILLO; CLEAVAGE	Presenilin 1 (PS1) regulates beta -catenin stability; however, published data regarding the direction of the effect are contradictory. We examined the effects of wildtype and mutant forms of PSI on the membrane, cytoplasmic, nuclear, and signaling pools of endogenous and exogenous beta -catenin by immunofluorescence microscopy, subcellular fractionation, and in a transcription assay. We found that PSI destabilizes the cytoplasmic and nuclear pools of beta -catenin when stabilized by Wnt or Dvl but not when stabilized at lower levels of the Wnt pathway. The PSI mutants examined were less able to reduce the stability of beta -catenin. PSI also inhibited the transcriptional activity of endogenous beta -catenin, and the PSI mutants were again less inhibitory at the level of Dvl but showed a different pattern of inhibition toward transcription below Dvl. The transcriptional activity of exogenously expressed wild-type beta -catenin and two mutants, Delta N89 beta -catenin and Delta ST beta -catenin, were also inhibited by wild-type and mutant PSI. We conclude that PSI negatively regulates the stability and transcriptional activity of beta -catenin at different levels in the Writ pathway, that the effect on transcriptional activity appears to be independent of the GSK-3 beta mediated degradation of beta -catenin, and that mutations in PSI differentially affect the stability and transcriptional activity of beta -catenin.	Kings Coll London, Inst Psychiat, Dept Neurosci, London SE5 8AF, England; GlaxoSmithKline Neurol Ctr Excellence Drug Discov, Dept Neurodegenerat Res, Harlow CM19 5AW, Essex, England; Affiniti Res Prod Ltd, Exeter EX6 8HD, Devon, England; Free Univ Brussels, Fac Med, B-1070 Brussels, Belgium; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA; Karolinska Inst, Dept Geriatr Med, S-14186 Huddinge, Sweden	University of London; King's College London; GlaxoSmithKline; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Emory University; Karolinska Institutet	Killick, R (corresponding author), Kings Coll London, Inst Psychiat, Dept Neurosci, De Crespigny Pk, London SE5 8AF, England.	r.killick@iop.kcl.ac.uk	Asuni, Ayodeji/F-4285-2011; Brion, Jean-Pierre/C-6467-2009; Lovestone, Simon/E-8725-2010; Levey, Allan/F-2104-2011	Asuni, Ayodeji/0000-0003-3488-6893; Brion, Jean-Pierre/0000-0002-1917-775X; Levey, Allan/0000-0002-3153-502X; Killick, Richard/0000-0002-8815-3436; Richardson, Jill/0000-0001-6564-3187; Lovestone, Simon/0000-0003-0473-4565				Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cox RT, 2000, GENETICS, V155, P1725; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Haass C, 1999, EUR ARCH PSY CLIN N, V249, P23; Kang DE, 1999, J NEUROSCI, V19, P4229; Kawamura Y, 2001, EUR J BIOCHEM, V268, P3036, DOI 10.1046/j.1432-1327.2001.02197.x; Kesavapany S, 2001, EUR J NEUROSCI, V13, P241, DOI 10.1046/j.1460-9568.2001.01376.x; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kirschenbaum F, 2001, J BIOL CHEM, V276, P7366, DOI 10.1074/jbc.M004697200; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Krylova O, 2000, J CELL BIOL, V151, P83, DOI 10.1083/jcb.151.1.83; Kwon YT, 2000, CURR BIOL, V10, P363, DOI 10.1016/S0960-9822(00)00411-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; Mudher A, 2001, J NEUROSCI, V21, P4987, DOI 10.1523/JNEUROSCI.21-14-04987.2001; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Noll E, 2000, DEV BIOL, V227, P450, DOI 10.1006/dbio.2000.9925; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	47	35	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48554	48561		10.1074/jbc.M108332200	http://dx.doi.org/10.1074/jbc.M108332200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606587	hybrid			2022-12-25	WOS:000172927000110
J	Lu, W; Strohecker, A; Ou, JH				Lu, W; Strohecker, A; Ou, JH			Post-translational modification of the hepatitis C virus core protein by tissue transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-LOCALIZATION; NUCLEAR-LOCALIZATION; CELL-DEATH; GENE; IDENTIFICATION; EXPRESSION; SIGNAL; RNA; CENTRIFUGATION; SUPPRESSION	The hepatitis C virus (HCV) core protein is a structural protein that packages the viral genomic RNA. In this study, we demonstrate that a stable core protein dimer could be produced in liver cells. The production of this protein could be enhanced by calphostin C and serum deprivation. This protein was determined to be the core protein dimer because of its reactivity with the anti-core antibody, its similar electrophoretic mobility compared with that of the core protein dimer generated by cross-linking with glutaraldehyde, and its increase in size by a hemagglutinin tag fused to the core protein sequence. This core protein dimer was highly stable and resistant to SDS and beta -mercaptoethanol. The enzyme that mediated the formation of this stable core protein dimer was determined to be the tissue transglutaminase (tTG) because, first, tTG could be activated by calphostin C and serum deprivation; second, the formation of this dimer was suppressed by monodansylcadaverine, a tTG inhibitor; and third, the core protein could be crosslinked by tTG in vitro. Thus, the HCV core protein represents the first known viral structural protein substrate of tTG. The post-translational modification by tTG reduced the RNA binding activity of the core protein, raising the possibility that tTG may regulate the biological functions of the HCV core protein.	Univ So Calif, Dept Mol Microbiol & Immunol, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California	Ou, JH (corresponding author), Univ So Calif, Dept Mol Microbiol & Immunol, Keck Sch Med, 2011 Zonal Ave,HMR-401, Los Angeles, CA 90033 USA.	jamesou@hsc.usc.edu			NIAID NIH HHS [AI40038] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI040038] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi T, 1996, HEPATOLOGY, V23, P1244; Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; CHANG SC, 1994, BIOCHEM BIOPH RES CO, V205, P1284, DOI 10.1006/bbrc.1994.2804; Choi J., 2001, Recent Research Developments in Virology, V3, P105; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; DE L, 1995, J CLIN MICROBIOL, V33, P562, DOI 10.1128/JCM.33.3.562-571.1995; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Echarri A, 1996, J MOL BIOL, V262, P640, DOI 10.1006/jmbi.1996.0542; Fesus L, 1996, EXPERIENTIA, V52, P942, DOI 10.1007/BF01920102; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hebert SS, 2000, J BIOL CHEM, V275, P32482, DOI 10.1074/jbc.M006528200; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1993, J VIROL, V67, P1953, DOI 10.1128/JVI.67.4.1953-1958.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; KANTO T, 1994, HEPATOLOGY, V19, P296; Katoh S, 1996, BIOCHEM J, V313, P305, DOI 10.1042/bj3130305; Kuncio GS, 1998, AM J PHYSIOL-GASTR L, V274, pG240, DOI 10.1152/ajpgi.1998.274.2.G240; Kunkel M, 2001, J VIROL, V75, P2119, DOI 10.1128/JVI.75.5.2119-2129.2001; LABBE M, 1994, J GEN VIROL, V75, P3423, DOI 10.1099/0022-1317-75-12-3423; LANFORD RE, 1993, VIROLOGY, V197, P225, DOI 10.1006/viro.1993.1583; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; LIAO W, 1995, J VIROL, V69, P1025, DOI 10.1128/JVI.69.2.1025-1029.1995; Liu QY, 1997, J VIROL, V71, P657, DOI 10.1128/JVI.71.1.657-662.1997; LO SY, 1995, VIROLOGY, V213, P455, DOI 10.1006/viro.1995.0018; LO SY, 1998, METH MOLEC MED, V19, P325; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Marcellin P, 1999, J HEPATOL, V31, P9, DOI 10.1016/S0168-8278(99)80368-7; Matsumoto M, 1996, VIROLOGY, V218, P43, DOI 10.1006/viro.1996.0164; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; Nolandt O, 1997, J GEN VIROL, V78, P1331, DOI 10.1099/0022-1317-78-6-1331; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Schuppan D, 2000, GASTROENTEROLOGY, V119, P234, DOI 10.1053/gast.2000.8521; SELBY MJ, 1993, J GEN VIROL, V74, P1103, DOI 10.1099/0022-1317-74-6-1103; SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995; Shimoike T, 1999, J VIROL, V73, P9718, DOI 10.1128/JVI.73.12.9718-9725.1999; TAKAHASHI K, 1992, VIROLOGY, V191, P431, DOI 10.1016/0042-6822(92)90204-3; Wang TH, 2000, J VIROL, V74, P11347, DOI 10.1128/JVI.74.23.11347-11358.2000; WILLIAMS J, 1999, AM J MED, V107, pS2; Wu J, 2000, J BIOL CHEM, V275, P22213, DOI 10.1074/jbc.M000091200; Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998	46	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47993	47999		10.1074/jbc.M109674200	http://dx.doi.org/10.1074/jbc.M109674200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606596	hybrid			2022-12-25	WOS:000172927000037
J	Poetsch, A; Molday, LL; Molday, RS				Poetsch, A; Molday, LL; Molday, RS			The cGMP-gated channel and related glutamic acid-rich proteins interact with peripherin-2 at the rim region of rod photoreceptor disc membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA/CA-K EXCHANGER; BLUE NATIVE ELECTROPHORESIS; OUTER SEGMENT DISKS; PLASMA-MEMBRANE; CATION CHANNEL; RETINAL RODS; BETA-SUBUNIT; LOCALIZATION; ROM-1; CELLS	The rod cGMP-gated channel is localized in the plasma membrane of rod photoreceptor outer segments, where it plays a central role in phototransduction. It consists of alpha- and beta -subunits that assemble into a heterotetrameric protein. Each subunit contains structural features characteristic of nucleotide-gated channels, including a cGMP-binding domain, multiple membrane-spanning segments, and a pore region. In addition, the beta -subunit has a large glutamic acid- and proline-rich region called GARP that is also expressed as two soluble protein variants. Using monoclonal antibodies in conjunction with immunoprecipitation, cross-linking, and electrophoretic techniques, we show that the cGMP-gated channel associates with the Na/Ca-K exchanger in the rod outer segment plasma membrane. This complex and soluble GARP proteins also interact with peripherin-2 oligomers in the rim region of outer segment disc membranes. These results suggest that channel/peripherin protein interactions mediated by the GARP part of the channel beta -subunit play a role in connecting the rim region of discs to the plasma membrane and in anchoring the channel-exchanger complex in the rod outer segment plasma membrane.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Ophthalmol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	molday@interchange.ubc.ca	Poetsch, Ansgar/A-1862-2013	Poetsch, Ansgar/0000-0002-7540-3475	NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARDELL MD, 1995, GENOMICS, V28, P32, DOI 10.1006/geno.1995.1102; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; BAUER PJ, 1992, J PHYSIOL-LONDON, V451, P109, DOI 10.1113/jphysiol.1992.sp019156; Boesze-Battaglia K, 1998, BIOCHEMISTRY-US, V37, P9477, DOI 10.1021/bi980173p; CHEN TY, 1994, P NATL ACAD SCI USA, V91, P11757, DOI 10.1073/pnas.91.24.11757; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; Colville CA, 1996, J BIOL CHEM, V271, P32968, DOI 10.1074/jbc.271.51.32968; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; COOK NJ, 1989, J BIOL CHEM, V264, P6996; Goldberg AFX, 1996, BIOCHEMISTRY-US, V35, P6144, DOI 10.1021/bi960259n; HSU SC, 1991, J BIOL CHEM, V266, P21745; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; KARPEN JW, 1992, J PHYSIOL-LONDON, V448, P257, DOI 10.1113/jphysiol.1992.sp019040; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Kim TSY, 1998, J BIOL CHEM, V273, P16561, DOI 10.1074/jbc.273.26.16561; Korschen HG, 1999, NATURE, V400, P761, DOI 10.1038/23468; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; Loewen CJR, 2000, J BIOL CHEM, V275, P5370, DOI 10.1074/jbc.275.8.5370; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MOLDAY RS, 1991, J BIOL CHEM, V266, P21917; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; Molday RS, 1998, VISION RES, V38, P1315, DOI 10.1016/S0042-6989(97)00409-4; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; Moritz OL, 1996, INVEST OPHTH VIS SCI, V37, P352; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; REID DM, 1990, BIOCHEMISTRY-US, V29, P1601, DOI 10.1021/bi00458a035; ROOF DJ, 1982, J CELL BIOL, V95, P487, DOI 10.1083/jcb.95.2.487; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schwarzer A, 1997, BIOCHEMISTRY-US, V36, P13667, DOI 10.1021/bi9710232; Schwarzer A, 2000, J BIOL CHEM, V275, P13448, DOI 10.1074/jbc.275.18.13448; SUGIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P3116, DOI 10.1073/pnas.88.8.3116; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USUKURA J, 1981, BIOMED RES-TOKYO, V2, P177, DOI 10.2220/biomedres.2.177; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; ZIMMERMAN AL, 1988, BIOPHYS J, V54, P351, DOI 10.1016/S0006-3495(88)82966-7	39	147	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48009	48016		10.1074/jbc.M108941200	http://dx.doi.org/10.1074/jbc.M108941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11641407	hybrid			2022-12-25	WOS:000172927000039
J	Pugliese, G; Pricci, F; Iacobini, C; Leto, G; Amadio, L; Barsotti, P; Frigeri, L; Hsu, DK; Vlassara, H; Liu, FT; Di Mario, U				Pugliese, G; Pricci, F; Iacobini, C; Leto, G; Amadio, L; Barsotti, P; Frigeri, L; Hsu, DK; Vlassara, H; Liu, FT; Di Mario, U			Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice	FASEB JOURNAL			English	Article						diabetic nephropathy; advanced glycation end products; advanced glycation end product receptors extracellular matrix	GLYCATION END-PRODUCTS; GENE-EXPRESSION; BINDING-PROTEIN; COMPETITIVE PCR; GROWTH-FACTOR; MATRIX; AGE; ACTIVATION; CELLS; IDENTIFICATION	Several molecules were shown to bind advanced glycation end products (AGEs) in vitro, but it is not known whether they all serve as AGE receptors and which functional role they play in vivo. We investigated the role of galectin-3, a multifunctional lectin with (anti) adhesive and growth-regulating properties, as an AGE receptor and its contribution to the development of diabetic glomerular disease, using a knockout mouse model. Galectin-3 knockout mice obtained by gene ablation and the corresponding wild-type mice were rendered diabetic with streptozotocin and killed 4 months later, together with age-matched nondiabetic controls. Despite a comparable degree of metabolic derangement, galectin-3-deficient mice developed accelerated glomerulopathy vs. the wild-type animals, as evidenced by the more pronounced increase in proteinuria, extracellular matrix gene expression, and mesangial expansion. This was associated with a more marked renal/glomerular AGE accumulation, indicating it was attributable to the lack of galectin-3 AGE receptor function. The galectin-3-deficient genotype was associated with reduced expression of receptors implicated in AGE removal (macrophage scavenger receptor A and AGE-R1) and increased expression of those mediating cell activation (RAGE and AGE-R2). These results show that the galectin-3-regulated AGE receptor pathway is operating in vivo and protects toward AGE-induced tissue injury in contrast to that through RAGE.	Univ Roma La Sapienza, Dept Clin Sci, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Ist Super Sanita, Lab Metab & Biochem Pathol, I-00161 Rome, Italy; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA	Sapienza University Rome; Sapienza University Rome; Istituto Superiore di Sanita (ISS); Scripps Research Institute; La Jolla Institute for Immunology; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Pugliese, G (corresponding author), Dipartimento Sci Clin Endocrinol, Viale Policlin 155, I-00161 Rome, Italy.	giuseppe.pugliese@uniroma1.it	Liu, FU-TONG/A-5749-2019; Pugliese, Giuseppe/G-8776-2012; Pricci, Flavia/K-7739-2016	Liu, FU-TONG/0000-0002-3354-1001; Pricci, Flavia/0000-0002-1877-4376; Pugliese, Giuseppe/0000-0003-1574-0397	Telethon [D.066] Funding Source: Medline	Telethon(Fondazione Telethon)		Bierhaus A, 1997, DIABETES, V46, P1481, DOI 10.2337/diabetes.46.9.1481; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; FUKUI M, 1992, DIABETES, V41, P1520, DOI 10.2337/diabetes.41.12.1520; GAMBARO G, 1994, KIDNEY INT, V46, P797, DOI 10.1038/ki.1994.335; He CJ, 2000, KIDNEY INT, V58, P1931, DOI 10.1046/j.1523-1755.2000.00365.x; HORIUCHI S, 1996, DIABETES S3, V45, P73; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; HSU DK, 1992, J BIOL CHEM, V267, P14167; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; KOTHS K, 1993, J BIOL CHEM, V268, P14245; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; Lougheed M, 1997, J BIOL CHEM, V272, P12938, DOI 10.1074/jbc.272.20.12938; Mazzucco G, 1997, CONTRIB NEPHROL, V122, P129; Mitsuhashi T, 1997, J IMMUNOL METHODS, V207, P79, DOI 10.1016/S0022-1759(97)00110-5; Mitsuhashi T, 1997, J CLIN INVEST, V100, P847, DOI 10.1172/JCI119600; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Ochieng J, 1998, BIOCHEM BIOPH RES CO, V246, P788, DOI 10.1006/bbrc.1998.8708; PETEN EP, 1993, KIDNEY INT, V43, pS55; PETEN EP, 1992, AM J PHYSIOL, V263, pF951, DOI 10.1152/ajprenal.1992.263.5.F951; Pricci F, 2000, KIDNEY INT, V58, pS31, DOI 10.1046/j.1523-1755.2000.07706.x; Pugliese G, 1997, DIABETES, V46, P1881, DOI 10.2337/diabetes.46.11.1881; Pugliese G, 1997, DIABETES, V46, P1198, DOI 10.2337/diabetes.46.7.1198; Pugliese G, 2000, DIABETES, V49, P1249, DOI 10.2337/diabetes.49.7.1249; Sasaki N, 2001, BRAIN RES, V888, P256, DOI 10.1016/S0006-8993(00)03075-4; STEFFES MW, 1989, DIABETES, V38, P1077, DOI 10.2337/diabetes.38.9.1077; Stitt AW, 2000, FASEB J, V14, P2390; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; VLASSARA H, 1996, KIDNEY INT, V49, P1785; YANG CW, 1994, P NATL ACAD SCI USA, V91, P9436, DOI 10.1073/pnas.91.20.9436; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Zhang WP, 1997, BIOCHEM MOL MED, V61, P58, DOI 10.1006/bmme.1997.2592; Zhu WQ, 2001, BIOCHEM BIOPH RES CO, V280, P1183, DOI 10.1006/bbrc.2001.4256	35	151	153	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2471	2479		10.1096/fj.01-0006com	http://dx.doi.org/10.1096/fj.01-0006com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689472	Green Submitted			2022-12-25	WOS:000172420500017
J	Jazaeri, AA; Nunes, KJ; Dalton, MS; Xu, MH; Shupnik, MA; Rice, LW				Jazaeri, AA; Nunes, KJ; Dalton, MS; Xu, MH; Shupnik, MA; Rice, LW			Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression	ONCOGENE			English	Article						ER-alpha; ER-beta; PR; PR-B; endometrial cancer; MMMT	ESTROGEN-RECEPTOR-BETA; PROGESTERONE-RECEPTOR; GENE-EXPRESSION; DOWN-REGULATION; MESSENGER-RNAS; CANCER-CELLS; ALPHA; ACTIVATION; REGULATOR	Both the estrogen receptor (ER) and the progesterone receptor (PR) have two subtypes: ER-alpha and beta, and PR-A and -B, respectively. These subtypes differ in function and expression, and recent reports have correlated changes in the normal proportions of these isoforms with neoplastic states. We investigated ER and PR isoform expression in normal pre- and post-menopausal endometrium, well-differentiated endometrial adenocarcinoma, and poorly differentiated malignant mixed mullerian tumors (MMMTs). Semi-quantitative RT-PCR and immunoblotting were used to measure receptor mRNA and protein expression. Estrogen receptor-alpha/beta mRNA ratios were significantly higher in postmenopausal (27.3) compared to premenopausal endometrium (4.9) mainly as a result of lower ER-beta expression in the former. Compared to age-matched postmenopausal controls, the ER-alpha/beta ratio was reduced in both grade I adenocarcinoma and MMMT specimens (3.3 and 6.8, respectively), due to a selective loss of ER-alpha. The relative abundance of PR-A and PR-B mRNA remained unchanged between all tissue subtypes. Total PR protein, however, was significantly reduced in MMMTs compared to all other groups. Thus, sex steroid receptor expression is significantly and differentially altered in well-differentiated and poorly-differentiated endometrial cancers. Both cancers exhibit decreased ER-alpha expression and the MMMTs also demonstrate a significant loss of PR protein.	Univ Virginia, Hlth Sci Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Charlottesville, VA 22906 USA; Univ Virginia, Hlth Sci Ctr, Div Endocrinol, Charlottesville, VA 22906 USA	University of Virginia; University of Virginia	Rice, LW (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Box 800712, Charlottesville, VA 22906 USA.	Lwr9y@virginia.edu	Jazaeri, Amir/I-3458-2015; Jazaeri, Amir/A-2400-2008	Jazaeri, Amir/0000-0003-4335-4151; 	NCI NIH HHS [K08 CA73668-01] Funding Source: Medline; NICHD NIH HHS [U54 HD 28934] Funding Source: Medline; NIDDK NIH HHS [R01 DK57082] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K08CA073668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057082] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; ANTUNES CMF, 1979, NEW ENGL J MED, V300, P9, DOI 10.1056/NEJM197901043000103; Brandenberger AW, 1998, J CLIN ENDOCR METAB, V83, P1025, DOI 10.1210/jc.83.3.1025; COSTA MJ, 1994, MODERN PATHOL, V7, P619; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FECHNER RE, 1974, CANCER-AM CANCER SOC, V34, P444, DOI 10.1002/1097-0142(197408)34:2<444::AID-CNCR2820340232>3.0.CO;2-J; Foley EF, 2000, CANCER RES, V60, P245; Graham JD, 1996, J STEROID BIOCHEM, V56, P93; Gray L A Sr, 1977, Obstet Gynecol Surv, V32, P619, DOI 10.1097/00006254-197709000-00023; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GUSBERG SB, 1971, AM J OBSTET GYNECOL, V111, P633, DOI 10.1016/0002-9378(71)90965-3; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Ing NH, 1996, BIOL REPROD, V54, P591, DOI 10.1095/biolreprod54.3.591; Jazaeri O, 1999, GYNECOL ONCOL, V74, P38, DOI 10.1006/gyno.1999.5404; Kumar NS, 1998, CANCER RES, V58, P1860; Matsuzaki S, 1999, MOL HUM REPROD, V5, P559, DOI 10.1093/molehr/5.6.559; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PERSSON I, 1989, BRIT MED J, V298, P147, DOI 10.1136/bmj.298.6667.147; Pettersson K, 2000, ONCOGENE, V19, P4970, DOI 10.1038/sj.onc.1203828; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; Pujol P, 1998, CANCER RES, V58, P5367; Rutherford T, 2000, OBSTET GYNECOL, V96, P417, DOI 10.1016/S0029-7844(00)00917-0; Sherman ME, 2000, MODERN PATHOL, V13, P295, DOI 10.1038/modpathol.3880051; SOPER JT, 1984, AM J OBSTET GYNECOL, V150, P342, DOI 10.1016/S0002-9378(84)80135-0; SUTTON GP, 1986, OBSTET GYNECOL, V68, P709; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Yeap BB, 1999, ENDOCRINOLOGY, V140, P3282, DOI 10.1210/en.140.7.3282; Zelmanowicz A, 1998, GYNECOL ONCOL, V69, P253, DOI 10.1006/gyno.1998.4941	31	51	55	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6965	6969		10.1038/sj.onc.1204809	http://dx.doi.org/10.1038/sj.onc.1204809			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687977				2022-12-25	WOS:000171641000019
J	Boldrini, L; Faviana, P; Pistolesi, F; Gisfredi, S; Di Quirico, D; Lucchi, M; Mussi, A; Angeletti, CA; Baldinotti, F; Fogli, A; Simi, P; Basolo, F; Fontanini, G				Boldrini, L; Faviana, P; Pistolesi, F; Gisfredi, S; Di Quirico, D; Lucchi, M; Mussi, A; Angeletti, CA; Baldinotti, F; Fogli, A; Simi, P; Basolo, F; Fontanini, G			Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer	ONCOGENE			English	Article						NSCLC; Fas (CD95/APO-1); p53; mutations	TUMOR-NECROSIS-FACTOR; LIGAND EXPRESSION; IN-VIVO; P53-MEDIATED APOPTOSIS; MEDIATED APOPTOSIS; IMMUNE PRIVILEGE; GROWTH-FACTOR; RECEPTOR; ANTIGEN; ADENOCARCINOMAS	The Fas (APO-1/CD95) system regulates a number of physiological and pathological processes of cell death. The ligand for Fas induces apoptosis by interacting with a transmembrane cell surface Fas receptor. The key role of the Fas system has been studied mostly in the immune system, but Fas mutations, one of the possible mechanisms for resistance to apoptosis signaling, may be involved in the pathogenesis of non-lymphoid malignancies as well. To better understand the potential involvement of Fas system in non-small cell lung cancer (NSCLC) we evaluated Fas and Fas-ligand mRNA expression by polymerase chain reaction in 102 tumor samples and in 44 normal surrounding tissues. Although over 60% of the human NSCLC analysed expressed both genes, they seem to be unable to induce apoptosis in vivo by autocrine suicide. In this regard, we investigated in 79 cases, the promoter and the entire coding region of the Fas gene by polymerase chain reaction, single strand conformation polymorphism and DNA sequencing for detecting putative alterations. Sixteen tumors (20.25%) were found to have Fas alterations, in promoter and/or exon region. In all cases samples carried heterozygous alterations and mostly showed simultaneous mutations of p53 gene. Moreover, the quantitative analysis of Fas mRNA expression showed high levels of Fas messenger associated with p53 wild-type status alone. Taken together, these findings point to an involvement of Fas/Fas-ligand system in the development of NSCLC, suggesting that the loss of its apoptotic function might be linked to p53 alterations which contribute to the self-maintenance of cancer cells.	Univ Pisa, Dept Oncol Transplants & Adv Technol Med, Pisa, Italy; Univ Pisa, Dept Cardiothorac Surg, Pisa, Italy; UO Cytogenet & Mol Genet, Dept Oncol, I-56100 Pisa, Italy	University of Pisa; University of Pisa	Fontanini, G (corresponding author), Dept Oncol, Div Pathol, Via Roma 57, I-56126 Pisa, Italy.		Faviana, Pinuccia/ABA-8436-2021; Basolo, Fulvio/AAC-2727-2019; Fontanini, Gabriella/O-7636-2015; Faviana, Pinuccia/L-5620-2019; FAVIANA, PINUCCIA/R-7928-2017; Lucchi, Marco/K-2140-2019	Faviana, Pinuccia/0000-0003-4283-1083; Basolo, Fulvio/0000-0003-1657-5020; Fontanini, Gabriella/0000-0003-1957-2052; FAVIANA, PINUCCIA/0000-0003-4283-1083; Boldrini, Laura/0000-0001-5904-3708; LUCCHI, MARCO/0000-0001-9909-6820				Beltinger C, 1998, BLOOD, V91, P3943; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bennett MW, 1998, J IMMUNOL, V160, P5669; Boldrini L, 1999, INT J ONCOL, V14, P161; Boussaud V, 1998, EUR RESPIR J, V12, P926, DOI 10.1183/09031936.98.12040926; Butler LM, 2000, BRIT J CANCER, V82, P131; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIRESTEIN GS, 1995, J CLIN INVEST, V96, P1631, DOI 10.1172/JCI118202; Fontanini G, 1999, CLIN CANCER RES, V5, P155; GRATAS C, 1997, BRAIN PATHOL, V7, P853; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; ITOH N, 1993, J BIOL CHEM, V268, P10932; Kashii Y, 1999, J IMMUNOL, V163, P5358; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lee SH, 1999, CANCER RES, V59, P3068; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LICHTER P, 1992, GENOMICS, V14, P179, DOI 10.1016/S0888-7543(05)80302-7; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Midis GP, 1996, CANCER RES, V56, P3870; Mitra D, 1996, IMMUNOLOGY, V87, P581, DOI 10.1046/j.1365-2567.1996.510589.x; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; MUNKER R, 1995, ANN HEMATOL, V70, P15, DOI 10.1007/BF01715376; Munker R, 1996, LEUKEMIA, V10, P1531; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nambu Y, 1998, J CLIN INVEST, V101, P1102, DOI 10.1172/JCI1692; Niehans GA, 1997, CANCER RES, V57, P1007; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OConnell J, 1997, MOL MED, V3, P294, DOI 10.1007/BF03401808; Rakkar ANS, 1999, CELL DEATH DIFFER, V6, P326, DOI 10.1038/sj.cdd.4400498; RHIN KJ, 2000, J INVEST DERMATOL, V114, P122; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Ungefroren H, 1998, CANCER RES, V58, P1741; Uramoto H, 1999, EUR J CANCER, V35, P1462, DOI 10.1016/S0959-8049(99)00157-4; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	39	24	25	2	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6632	6637		10.1038/sj.onc.1204727	http://dx.doi.org/10.1038/sj.onc.1204727			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641789				2022-12-25	WOS:000171404200017
J	Kim, SW; Kim, HJ; Jung, DJ; Lee, SK; Kim, YS; Kim, JH; Kim, TS; Lee, JW				Kim, SW; Kim, HJ; Jung, DJ; Lee, SK; Kim, YS; Kim, JH; Kim, TS; Lee, JW			Retinoid-dependent antagonism of serum response factor transactivation mediated by transcriptional coactivator proteins	ONCOGENE			English	Article						SRF; retinoids; transcription; coactivator; nuclear receptors	NUCLEAR HORMONE-RECEPTOR; THYROID-HORMONE; BINDING DOMAIN; CO-REPRESSOR; EXPRESSION; ELEMENT; GENE; ACTIVATION; INTERACTS; PROMOTER	Transcriptional coactivators SRC-1 and p300 specifically interact with liganded-nuclear receptors and also modulate other transcription factors, including serum response factor (SRF). Here, we report that retinoids repress transactivation by SRF and specific interactions exist between the DNA binding domains of SRF and retinoic acid and retinoid X receptors. We further demonstrate that the repression may involve retinoid-dependent competition for a limiting amount of SRC-I and p300 between SRF and retinoid receptors. We propose that the well-defined anti-proliferative action of retinoids could, at least in part, result from this novel transrepressive action on the mitogenic transcription factor SRF.	Pohang Univ Sci & Technol, Ctr Ligand & Transcript, Pohang 790784, South Korea; Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 506303, South Korea	Pohang University of Science & Technology (POSTECH); Chonnam National University; Salk Institute; Gwangju Institute of Science & Technology (GIST)	Lee, JW (corresponding author), Pohang Univ Sci & Technol, Ctr Ligand & Transcript, Pohang 790784, South Korea.		Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208; Kim, Seung-Whan/0000-0001-6983-0481				Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; BUSHEL P, 1995, ONCOGENE, V10, P1361; CATALA F, 1995, MOL CELL BIOL, V15, P4585; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; KIM JH, 1994, J BIOL CHEM, V269, P13740; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; LEE JW, 1992, MOL ENDOCRINOL, V6, P1867, DOI 10.1210/me.6.11.1867; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Moore DD, 1995, GLOB MOB SURV; Poser S, 2000, EMBO J, V19, P4955, DOI 10.1093/emboj/19.18.4955; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Slack J L, 1999, Curr Opin Hematol, V6, P236, DOI 10.1097/00062752-199907000-00007; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	27	12	12	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6638	6642		10.1038/sj.onc.1204695	http://dx.doi.org/10.1038/sj.onc.1204695			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641790				2022-12-25	WOS:000171404200018
J	Condorelli, G; Aycock, JK; Frati, G; Napoli, C				Condorelli, G; Aycock, JK; Frati, G; Napoli, C			Mutated p21/WAF/CIP transgene overexpression reduces smooth muscle cell proliferation, macrophage deposition, oxidation-sensitive mechanisms, and restenosis in hypercholesterolemic apolipoprotein E knockout mice	FASEB JOURNAL			English	Article						gene therapy; apoptosis; cell cycle; apo E knockout	E-DEFICIENT MICE; MEDIATED GENE-TRANSFER; HERITABLE HYPERLIPIDEMIC RABBITS; EXPERIMENTAL BALLOON ANGIOPLASTY; DEPENDENT KINASE INHIBITOR; ARTERIAL INJURY; CAROTID ARTERIES; VESSEL WALL; NEOINTIMAL HYPERPLASIA; CORONARY ANGIOPLASTY	We have investigated whether by introducing a mutated p21 cyclin-dependent kinase inhibitor through a standard type 5 adenovirus (Ad), it would be possible to interfere with restenosis in hypercholesterolemic apolipoprotein E knockout mice. Restenosis is a clinically relevant, undesired effect of percutaneous transluminal coronary angioplasty (PTCA). A critical event underlying restenosis is smooth muscle cell (SMC) proliferation leading to neointimal formation and vessel reocclusion. Recent data demonstrated that it is possible to reduce restenosis by introducing various genes blocking the cell cycle through Ad vectors. Nonetheless, most experiments were conducted in the healthy carotid artery of rat, which is far from the condition of human disease. Therefore, we investigated whether antiproliferative or proapoptotic genes affect restenosis in a model of atherosclerosis closer to clinical settings. Ad-mutated(m)-p21WAF/CIP1 transgene overexpression induces a significant reduction of restenosis in hypercholesterolemic apolipoprotein E knockout mice subjected to injury of common carotid artery. This was associated with reduced SMC density and proliferation, macrophage deposition, and oxidation-sensitive mechanisms. Treatment with p21/WAF also enhanced TUNEL positivity of arterial cells. We show that in an experimental model of atherosclerosis, braking the cell proliferation through increased vascular apoptosis and reduced oxidation-sensitive signal transduction and macrophage accumulation can significantly ameliorate the deleterious effects of vascular injuries similar to those that occur during PTCA and related procedures.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Roma La Sapienza, IRCCS Neuromed, Fac Med 2, Rome, Italy; Univ Naples Federico II, Dept Med, Naples, Italy; Univ Calif San Diego, Dept Med 0682, La Jolla, CA 92093 USA	Jefferson University; IRCCS Neuromed; Sapienza University Rome; University of Naples Federico II; University of California System; University of California San Diego	Condorelli, G (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, TJU 233 S 10th St, Philadelphia, PA 19107 USA.	gianluigi.condorelli@mail.tju.edu	Frati, Giacomo/ABI-7410-2020; Condorelli, Gianluigi/Q-6736-2017	Napoli, Claudio/0000-0002-5455-555X; Condorelli, Gianluigi/0000-0003-0481-6843; Frati, Giacomo/0000-0003-2703-3761				AMELI S, 1994, CIRCULATION, V90, P1935, DOI 10.1161/01.CIR.90.4.1935; Bauriedel G, 1998, ARTERIOSCL THROM VAS, V18, P1132, DOI 10.1161/01.ATV.18.7.1132; Bult H, 2000, TRENDS PHARMACOL SCI, V21, P274, DOI 10.1016/S0165-6147(00)01505-4; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; Claudio PP, 1999, CIRC RES, V85, P1032; Condorelli G, 1999, CIRCULATION, V99, P3071, DOI 10.1161/01.CIR.99.23.3071; de Nigris F, 2000, CIRCULATION, V102, P2111, DOI 10.1161/01.CIR.102.17.2111; Feldman MD, 2000, J LONG-TERM EFF MED, V10, P47; Gurlek A, 1995, J Cardiovasc Risk, V2, P51; HANKE H, 1994, EUR HEART J, V15, P691, DOI 10.1093/oxfordjournals.eurheartj.a060569; Johnson GJ, 1999, THROMB HAEMOSTASIS, V81, P835; Kanemitsu S, 1998, Ther Apher, V2, P65, DOI 10.1111/j.1744-9987.1998.tb00075.x; Kibbe MR, 2000, CIRC RES, V86, P829, DOI 10.1161/01.RES.86.8.829; Komatsu R, 1998, CIRCULATION, V98, P224, DOI 10.1161/01.CIR.98.3.224; LAFONT AM, 1995, J CLIN INVEST, V95, P1018, DOI 10.1172/JCI117746; Laitinen M, 2000, HUM GENE THER, V11, P263, DOI 10.1089/10430340050016003; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; Le Tourneau T, 1999, J AM COLL CARDIOL, V33, P876, DOI 10.1016/S0735-1097(98)00621-4; Lee DP, 1999, VASC MED, V4, P257; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Lund DD, 1999, STROKE, V30, P120, DOI 10.1161/01.STR.30.1.120; Lundgren C, 1996, JPN HEART J, V37, P119; Manka DR, 2000, J MAGN RESON IMAGING, V12, P790, DOI 10.1002/1522-2586(200011)12:5<790::AID-JMRI19>3.0.CO;2-6; Manka DR, 1999, J VASC RES, V36, P372, DOI 10.1159/000025676; Marra DE, 2000, CIRCULATION, V102, P2124, DOI 10.1161/01.CIR.102.17.2124; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Monahan PE, 2000, GENE THER, V7, P24, DOI 10.1038/sj.gt.3301109; Moreno PR, 1999, AM J CARDIOL, V84, P462, DOI 10.1016/S0002-9149(99)00334-3; Moreno PR, 1996, CIRCULATION, V94, P3098, DOI 10.1161/01.CIR.94.12.3098; Morsy MA, 1998, P NATL ACAD SCI USA, V95, P7866, DOI 10.1073/pnas.95.14.7866; Napoli C, 1999, CIRCULATION, V99, P2003, DOI 10.1161/01.CIR.99.15.2003; Napoli C, 2000, P NATL ACAD SCI USA, V97, P3678, DOI 10.1073/pnas.97.7.3678; Napoli C, 2001, P NATL ACAD SCI USA, V98, P2860, DOI 10.1073/pnas.041602898; Niebauer J, 1999, CIRCULATION, V100, P1830, DOI 10.1161/01.CIR.100.17.1830; Ooboshi H, 1997, ARTERIOSCL THROM VAS, V17, P1786, DOI 10.1161/01.ATV.17.9.1786; Palasis M, 2000, HUM GENE THER, V11, P237, DOI 10.1089/10430340050015987; PALINSKI W, 2000, CONT CARDIOLOGY VASC, P149; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; RAPP JH, 1987, SURGERY, V101, P277; Reis ED, 2000, P NATL ACAD SCI USA, V97, P12764, DOI 10.1073/pnas.210394497; Rekhter MD, 1998, CIRC RES, V82, P1243, DOI 10.1161/01.RES.82.12.1243; Rouis M, 1999, CIRCULATION, V100, P533, DOI 10.1161/01.CIR.100.5.533; Sakai A, 1996, HEART VESSELS, V11, P255, DOI 10.1007/BF01746206; Sata M, 2000, J MOL CELL CARDIOL, V32, P2097, DOI 10.1006/jmcc.2000.1238; SCHULICK AH, 1995, CIRCULATION, V91, P2407, DOI 10.1161/01.CIR.91.9.2407; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith RC, 1997, CIRCULATION, V96, P1899, DOI 10.1161/01.CIR.96.6.1899; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; VIOLARIS AG, 1994, CIRCULATION, V90, P2267, DOI 10.1161/01.CIR.90.5.2267; Walsh K, 2000, CARDIOVASC RES, V45, P756, DOI 10.1016/S0008-6363(99)00270-9; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; YHAHERTTUALA S, 2000, LANCET, V355, P213	53	49	50	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2162	2170		10.1096/fj.01-0032com	http://dx.doi.org/10.1096/fj.01-0032com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641242				2022-12-25	WOS:000171920400027
J	Hartlapp, I; Abe, R; Saeed, RW; Peng, T; Voelter, W; Bucala, R; Metz, CN				Hartlapp, I; Abe, R; Saeed, RW; Peng, T; Voelter, W; Bucala, R; Metz, CN			Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo	FASEB JOURNAL			English	Article						fibroblast; antigen; MMP-9; wound healing; neovascularization	FIBROBLAST-GROWTH-FACTOR; PERIPHERAL-BLOOD FIBROCYTES; MATRIX METALLOPROTEINASES; TUMOR ANGIOGENESIS; BASEMENT-MEMBRANE; DOWN-REGULATION; IN-VITRO; EXPRESSION; INTERFERON; INVITRO	Angiogenesis is an ordered process requiring the inter-play of numerous cellular and humoral factors. Studies over the past 20 years have identified several growth factors, cytokines, and enzymes that promote blood vessel formation. Most have revealed how individual factors promote an angiogenic phenotype in endothelial cells in vitro or contribute to blood vessel formation in vivo. However, the fundamental question that remains unanswered is how the cellular microenvironment contributes to angiogenesis. Fibrocytes are a recently characterized mesenchymal cell type isolated from peripheral blood that rapidly enter subcutaneously implanted wound chambers and sites of tissue injury. Here we describe the induction of an angiogenic phenotype in microvascular endothelial cells in vitro and promotion of angiogenesis in vivo by cultured fibrocytes. Fibrocytes constitutively secrete extracellular matrix-degrading enzymes, primarily matrix metalloproteinase 9, which promotes endothelial cell invasion. In addition, fibrocytes secrete several proangiogenic factors including VEGF, bFGF, IL-8, PDGF, and hematopoietic growth factors that promote endothelial cell migration, proliferation, and/or tube formation. By contrast, they do not produce representative antiangiogenic factors. Finally, both autologous fibrocytes and fibrocyte-conditioned media were found to induce blood vessel formation in vivo using the Matrigel angiogenesis model.	Picower Inst Med Res, Lab Vasc Biol, Manhasset, NY 11030 USA; Univ Tubingen, Tubingen, Germany	Northwell Health; Eberhard Karls University of Tubingen	Metz, CN (corresponding author), Picower Inst Med Res, Lab Vasc Biol, 350 Community Dr, Manhasset, NY 11030 USA.	cmetz@picower.edu	Abe, Riichiro/A-5450-2012	Christine, Metz/0000-0002-1013-1691				Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556; AGREN MS, 1994, BRIT J DERMATOL, V131, P634, DOI 10.1111/j.1365-2133.1994.tb04974.x; Baatout S, 1996, Rom J Intern Med, V34, P263; Baatout S, 1997, ANTICANCER RES, V17, P451; Brown KJ, 1996, LAB INVEST, V75, P539; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; BUSSOLINO F, 1991, J CLIN INVEST, V87, P986, DOI 10.1172/JCI115107; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; Chesney J, 1997, P NATL ACAD SCI USA, V94, P6307, DOI 10.1073/pnas.94.12.6307; Chesney J, 1998, J IMMUNOL, V160, P419; DAVIDSON JM, 1992, INFLAMMATION BASIC P, P809; Dentelli P, 1999, J IMMUNOL, V163, P2151; Dinney CPN, 1998, CANCER RES, V58, P808; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Gebauer G, 1998, ANTICANCER RES, V18, P1191; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; Goke M, 1998, AM J PHYSIOL-GASTR L, V274, pG809, DOI 10.1152/ajpgi.1998.274.5.G809; Grab DJ, 1999, MOL MED, V5, P46, DOI 10.1007/BF03402138; Harris SR, 1998, IN VIVO, V12, P563; HEYNS AD, 1985, EXP CELL RES, V161, P297, DOI 10.1016/0014-4827(85)90087-4; Ito Y, 1996, INT J CANCER, V67, P148, DOI 10.1002/(SICI)1097-0215(19960703)67:1<148::AID-IJC24>3.3.CO;2-6; Kahari VM, 1997, EXP DERMATOL, V6, P199, DOI 10.1111/j.1600-0625.1997.tb00164.x; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; Kumar R, 1998, INT J ONCOL, V12, P749; Madlener M, 1998, ARCH DERMATOL RES, V290, pS24, DOI 10.1007/PL00007450; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; Nilsen EM, 1998, GUT, V42, P635, DOI 10.1136/gut.42.5.635; PASSANITI A, 1992, LAB INVEST, V67, P519; PETZELBAUER P, 1995, CYTOKINE, V7, P267, DOI 10.1006/cyto.1995.0031; Riedel F, 2000, HEAD NECK-J SCI SPEC, V22, P183, DOI 10.1002/(SICI)1097-0347(200003)22:2<183::AID-HED11>3.0.CO;2-R; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; SALO T, 1994, LAB INVEST, V70, P176; SATO N, 1990, J INVEST DERMATOL, V95, pS85, DOI 10.1111/1523-1747.ep12874809; Sigounas G, 1997, ANGIOLOGY, V48, P141, DOI 10.1177/000331979704800207; Slaton JW, 1999, CLIN CANCER RES, V5, P2726; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410	36	204	228	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2215	2224		10.1096/fj.01-0049com	http://dx.doi.org/10.1096/fj.01-0049com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641248				2022-12-25	WOS:000171920400033
J	Im, SH; Barchan, D; Maiti, PK; Raveh, L; Souroujon, MC; Fuchs, S				Im, SH; Barchan, D; Maiti, PK; Raveh, L; Souroujon, MC; Fuchs, S			Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18	FASEB JOURNAL			English	Article						autoimmunity; interleukin 18; cytokines and costimulatory factors; immunotherapy; MG	INTERLEUKIN-1-BETA CONVERTING-ENZYME; ALKALINE-PHOSPHATASE ACTIVITY; ACETYLCHOLINE-RECEPTOR; IFN-GAMMA; CD40 LIGAND; INTERFERON-GAMMA; MONOCLONAL-ANTIBODIES; RECOMBINANT FRAGMENT; NASAL TOLERANCE; EXPRESSION	Interleukin-18 (IL-18) is a pleiotropic proinflammatory cytokine that plays an important role in interferon gamma (IFN-gamma) production and IL-12-driven Th1 phenotype polarization. Increased expression of IL-18 has been observed in several autoimmune diseases. In this study we have analyzed the role of IL-18 in an antibody-mediated autoimmune disease and elucidated the mechanisms involved in disease suppression mediated by blockade of IL-18, using experimental autoimmune myasthenia gravis (EAMG) as a model. EAMG is a T cell-regulated, antibody-mediated autoimmune disease in which the nicotinic acetylcholine receptor (AChR) is the major autoantigen. Th1- and Th2-type responses are both implicated in EAMG development. We show that treatment by anti-IL-18 during ongoing EAMG suppresses disease progression. The protective effect can be adoptively transferred to naive recipients and is mediated by increased levels of the immunosuppressive Th3-type cytokine TGF-beta and decreased AChR-specific Th1-type cellular responses. Suppression of EAMG is accompanied by down-regulation of the costimulatory factor CD40L and up-regulation of CTLA-4, a key negative immunomodulator. Our results suggest that IL-18 blockade may potentially be applied for immunointervention in myasthenia gravis.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Open Univ, IL-61392 Tel Aviv, Israel; Israel Inst Biol Res, IL-74100 Ness Ziona, Israel	Weizmann Institute of Science; Open University Israel	Fuchs, S (corresponding author), Weizmann Inst Sci, Dept Immunol, Wolfson Bldg,Room 404, IL-76100 Rehovot, Israel.	sara.fuchs@weizmann.ac.il	Im, Sin-Hyeog/E-6811-2013; Im, Sin-Hyeog/AAM-9586-2021	Im, Sin-Hyeog/0000-0002-3173-1856; Im, Sin-Hyeog/0000-0002-3173-1856				AHARONOV A, 1977, IMMUNOCHEMISTRY, V14, P129, DOI 10.1016/0019-2791(77)90291-9; Andre-Schmutz I, 1999, EUR J IMMUNOL, V29, P245, DOI 10.1002/(SICI)1521-4141(199901)29:01<245::AID-IMMU245>3.3.CO;2-F; Balasa B, 1997, J EXP MED, V186, P385, DOI 10.1084/jem.186.3.385; Barchan D, 1999, P NATL ACAD SCI USA, V96, P8086, DOI 10.1073/pnas.96.14.8086; Bright JJ, 1998, J IMMUNOL, V161, P1772; Christadoss P, 2000, CLIN IMMUNOL, V94, P75, DOI 10.1006/clim.1999.4807; Dinarello CA, 1999, METHODS, V19, P121, DOI 10.1006/meth.1999.0837; Grewal IS, 1996, IMMUNOL REV, V153, P85, DOI 10.1111/j.1600-065X.1996.tb00921.x; GU DL, 1995, J EXP MED, V181, P547, DOI 10.1084/jem.181.2.547; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; HASHIMOTO N, 1986, J IMMUNOL METHODS, V90, P97; Im SH, 2000, J NEUROIMMUNOL, V111, P161, DOI 10.1016/S0165-5728(00)00395-7; Im SH, 2000, J IMMUNOL, V165, P3599, DOI 10.4049/jimmunol.165.7.3599; Im SH, 1999, J CLIN INVEST, V104, P1723, DOI 10.1172/JCI8121; Im SH, 2001, J IMMUNOL, V166, P6893, DOI 10.4049/jimmunol.166.11.6893; Jander S, 1998, J NEUROIMMUNOL, V91, P93, DOI 10.1016/S0165-5728(98)00162-3; Karachunski PI, 2000, J IMMUNOL, V164, P5236, DOI 10.4049/jimmunol.164.10.5236; KASYAPA CS, 1992, IMMUNOL LETT, V33, P3151; KASYAPA CSS, 1992, IMMUNOL LETT, V31, P111, DOI 10.1016/0165-2478(92)90136-C; King C, 1998, IMMUNITY, V8, P601, DOI 10.1016/S1074-7613(00)80565-8; Kohka H, 1998, J LEUKOCYTE BIOL, V64, P519, DOI 10.1002/jlb.64.4.519; Lebel-Binay S, 2000, EUR CYTOKINE NETW, V11, P15; Moller B, 2001, RHEUMATOLOGY, V40, P302, DOI 10.1093/rheumatology/40.3.302; Monteleone G, 1999, J IMMUNOL, V163, P143; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; Perez VL, 1997, IMMUNITY, V6, P411, DOI 10.1016/S1074-7613(00)80284-8; Schultze JL, 1999, J EXP MED, V189, P1, DOI 10.1084/jem.189.1.1; Shi FD, 2000, NAT IMMUNOL, V1, P245, DOI 10.1038/79792; Shi FD, 1998, EUR J IMMUNOL, V28, P3587, DOI 10.1002/(SICI)1521-4141(199811)28:11<3587::AID-IMMU3587>3.3.CO;2-P; Shi FD, 1998, CLIN EXP IMMUNOL, V111, P506; SOUROUJON MC, 1983, MUSCLE NERVE, V6, P303, DOI 10.1002/mus.880060410; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Taniguchi M, 1997, J IMMUNOL METHODS, V206, P107, DOI 10.1016/S0022-1759(97)00094-X; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wildbaum G, 1998, J IMMUNOL, V161, P6368; Yin DL, 1999, J IMMUNOL, V163, P4328; Yoshimoto T, 1998, J IMMUNOL, V161, P3400; Zhang GX, 1999, J IMMUNOL, V162, P3775	40	41	51	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2140	2148		10.1096/fj.01-0072com	http://dx.doi.org/10.1096/fj.01-0072com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641240				2022-12-25	WOS:000171920400025
J	Tucker, PC; Sack, GH				Tucker, PC; Sack, GH			Expression of serum amyloid A genes in mouse brain: unprecedented response to inflammatory mediators	FASEB JOURNAL			English	Article						inflammation; neuroimmunology; acute-phase reactants; gene regulation; SAA	ACUTE-PHASE RESPONSE; ALZHEIMERS-DISEASE BRAIN; CEREBROSPINAL-FLUID; PROTEIN; CELLS; INTERLEUKIN-1; INDUCTION; MICROGLIA; SAA; IMMUNOREACTIVITY	Serum amyloid A (SAA) proteins were originally identified as prominent acute-phase serum proteins synthesized predominantly by hepatocytes. These small proteins are remarkably lipophilic, and we have sought evidence for their synthesis in mouse brain. RT-PCR showed constitutive expression of the murine SAA(1) gene in the brains of normal BALB/cJ mice. After intracerebral inoculation with Sindbis virus, these mice predictably increase brain expression of tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1 beta), and IL-6. However, brain SAA(1) expression fell after injecting either virus or control saline and remained low despite increases in TNF-alpha and IL-6, which are known to induce its expression in hepatocytes. Our data thus show that expression of the murine SAA(1) gene has different, unprecedented control in mouse brain, suggesting that the protein itself may have a different physiological role there.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Sack, GH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	gsack@jhmi.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029234] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01070-02] Funding Source: Medline; NINDS NIH HHS [NS29234] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AISEN PS, 1994, AM J PSYCHIAT, V151, P1105; Artl A, 2000, ARTERIOSCL THROM VAS, V20, P763, DOI 10.1161/01.ATV.20.3.763; Bartolak-Suki E, 2000, AMYLOID, V7, P111, DOI 10.3109/13506120009146247; BAUSSERMAN LL, 1983, J BIOL CHEM, V258, P681; BENDITT EP, 1971, FEBS LETT, V19, P169, DOI 10.1016/0014-5793(71)80506-9; BENDITT EP, 1977, P NATL ACAD SCI USA, V74, P4025, DOI 10.1073/pnas.74.9.4025; BETTS JC, 1993, J BIOL CHEM, V268, P25624; BRINCKERHOFF CE, 1989, SCIENCE, V243, P655, DOI 10.1126/science.2536953; Cabana VG, 1999, J LIPID RES, V40, P1090; Chung TF, 2000, AMYLOID, V7, P105, DOI 10.3109/13506120009146246; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; Finch CE, 1996, NEUROBIOL AGING, V17, P809; GANAPATHI MK, 1988, BIOCHEM BIOPH RES CO, V157, P271, DOI 10.1016/S0006-291X(88)80043-3; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GRIFFIN DE, 1986, J IMMUNOL, V136, P1841; GRIFFIN DE, 1994, ARCH VIROL, P31; GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Hardardottir I, 1997, BBA-LIPID LIPID MET, V1344, P210, DOI 10.1016/S0005-2760(96)00143-9; HUSBY G, 1994, AMYLOID, V1, P119, DOI 10.3109/13506129409148635; HUSBY G, 1974, J CLIN INVEST, V53, P1054, DOI 10.1172/JCI107642; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; IWAMOTO N, 1994, NEUROSCI LETT, V177, P23, DOI 10.1016/0304-3940(94)90035-3; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; Liang JS, 1997, NEUROSCI LETT, V225, P73, DOI 10.1016/S0304-3940(97)00196-1; LIANG JS, 1995, J LIPID RES, V36, P37; Liang JS, 1996, J LIPID RES, V37, P2109; LOWELL CA, 1986, J BIOL CHEM, V261, P8442; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; MACKENZIE IRA, 1995, NEUROBIOL AGING, V16, P797, DOI 10.1016/0197-4580(95)00092-S; MCGEER PL, 1992, RES IMMUNOL, V143, P621, DOI 10.1016/0923-2494(92)80045-M; Meeker AK, 1998, PROTEINS, V30, P381, DOI 10.1002/(SICI)1097-0134(19980301)30:4<381::AID-PROT5>3.0.CO;2-M; MOENCH TR, 1984, J EXP MED, V159, P77, DOI 10.1084/jem.159.1.77; MORROW JF, 1981, P NATL ACAD SCI-BIOL, V78, P4718, DOI 10.1073/pnas.78.8.4718; RAYNES JG, 1991, CLIN EXP IMMUNOL, V83, P488; RIENHOFF HY, 1990, MOL BIOL MED, V7, P287; SACK GH, 1992, AM J PATHOL, V141, P525; SACK GH, 1989, GENE, V84, P509, DOI 10.1016/0378-1119(89)90528-3; SEGREST JP, 1976, BIOCHEMISTRY-US, V15, P3187, DOI 10.1021/bi00660a005; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Urieli-Shoval S, 1998, J HISTOCHEM CYTOCHEM, V46, P1377, DOI 10.1177/002215549804601206; WESSELINGH SL, 1994, J IMMUNOL, V152, P1289	43	11	11	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2241	2246		10.1096/fj.01-0133com	http://dx.doi.org/10.1096/fj.01-0133com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641251				2022-12-25	WOS:000171920400036
J	Abid, MR; Tsai, JC; Spokes, KC; Deshpande, SS; Irani, K; Aird, WC				Abid, MR; Tsai, JC; Spokes, KC; Deshpande, SS; Irani, K; Aird, WC			Vascular endothelial growth factor induces manganese-superoxide dismutase expression in endothelial cells by a Rac1-regulated NADPH oxidase-dependent mechanism	FASEB JOURNAL			English	Article						gene regulation; cell signaling; endothelial cell migration; reactive oxygen species; vascular endothelial growth factor	SMOOTH-MUSCLE CELLS; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; NITRIC-OXIDE; ANGIOTENSIN-II; SIGNAL-TRANSDUCTION; IN-VIVO; CRITICAL COMPONENT; OXIDATIVE STRESS; NAD(P)H OXIDASE	Vascular endothelial growth factor (VEGF) is a potent vascular endothelial cell-specific mitogen that modulates endothelial cell function. In the present study, we show that VEGF induces manganese-superoxide dismutase (MnSOD) mRNA and protein in human coronary artery endothelial cells (HCAEC) and pulmonary artery endothelial cells. VEGF-mediated induction of MnSOD mRNA was inhibited by pretreatment with the NADPH oxidase inhibitors, diphenyleneiodonium (DPI), and 4-(2-aminoethyl)-benzenesulfonyl fluoride, but not with the nitric oxide synthase inhibitor L-NAME (N-monomethyl-L-arginine) or the xanthine oxidase inhibitor allopurinol. VEGF stimulation of MnSOD was also inhibited by adenoviral-mediated overexpression of catalase Cu, Zn-SOD and a dominant-negative form of the small GTPase component of NADPH oxidase Rac1 (Rac1N17). Treatment of HCAEC with VEGF resulted in a transient increase in ROS production at 20 min, as measured by 2',7'-dichlorodihydrofluorescein oxidation. This effect was abrogated by expression of Rac1N17. Taken together, these findings suggest that VEGF induces MnSOD by an NADPH oxidase-dependent mechanism and that VEGF signaling in the endothelium is coupled to the redox state of the cell.	Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Mol Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Johns Hopkins University	Aird, WC (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, RW-663,330 Brookline Ave, Boston, MA 02215 USA.	waird@caregroup.harvard.edu		Irani, Kaikobad/0000-0001-9194-7387				Abid MR, 2000, FEBS LETT, V486, P252, DOI 10.1016/S0014-5793(00)02305-X; AKASHI M, 1995, J BIOL CHEM, V270, P15864, DOI 10.1074/jbc.270.26.15864; Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960; Bates DO, 1999, MICROCIRCULATION, V6, P83, DOI 10.1038/sj.mn.7300054; Bauersachs J, 1999, CIRCULATION, V100, P292, DOI 10.1161/01.CIR.100.3.292; Bayraktutan U, 1998, CARDIOVASC RES, V38, P256, DOI 10.1016/S0008-6363(98)00003-0; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; Cominacini L, 2000, J BIOL CHEM, V275, P12633, DOI 10.1074/jbc.275.17.12633; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; Deng L, 2001, J BIOL CHEM, V276, P413, DOI 10.1074/jbc.M004551200; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; Howard AB, 1997, AM J PHYSIOL-CELL PH, V272, pC421, DOI 10.1152/ajpcell.1997.272.2.C421; Huang TT, 1999, ANN NY ACAD SCI, V893, P95, DOI 10.1111/j.1749-6632.1999.tb07820.x; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; Kiningham KK, 1999, FASEB J, V13, P1601, DOI 10.1096/fasebj.13.12.1601; Kunsch C, 1999, CIRC RES, V85, P753, DOI 10.1161/01.RES.85.8.753; Kuroda M, 2000, ANTICANCER RES, V20, P7; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LAURINDO FRM, 1994, CIRC RES, V74, P700, DOI 10.1161/01.RES.74.4.700; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MALTERUD KE, 1993, PHARMACOLOGY, V47, P77, DOI 10.1159/000139846; Marumo T, 1997, CIRCULATION, V96, P2361; Marumo T, 1999, J VASC RES, V36, P510, DOI 10.1159/000025694; Meeson AP, 1999, DEVELOPMENT, V126, P1407; Mitchell J, 1996, J CELL PHYSIOL, V169, P333, DOI 10.1002/(SICI)1097-4652(199611)169:2<333::AID-JCP12>3.0.CO;2-A; MOHAZZABH KM, 1994, AM J PHYSIOL, V266, pH2568, DOI 10.1152/ajpheart.1994.266.6.H2568; MUGGE A, 1991, AM J PHYSIOL, V260, P219; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; NIU XF, 1994, CIRC RES, V74, P1133, DOI 10.1161/01.RES.74.6.1133; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Rahman A, 1998, AM J PHYSIOL-LUNG C, V275, pL533, DOI 10.1152/ajplung.1998.275.3.L533; Robinson BH, 1998, J INHERIT METAB DIS, V21, P598, DOI 10.1023/A:1005427323835; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tsai JC, 2000, AM J PHYSIOL-CELL PH, V279, pC1414, DOI 10.1152/ajpcell.2000.279.5.C1414; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Van Gelder CM, 1999, J TRAUMA, V47, P885, DOI 10.1097/00005373-199911000-00012; Veikkola T, 2000, CANCER RES, V60, P203; VISNER GA, 1990, J BIOL CHEM, V265, P2856; Vlahopoulos S, 1999, BLOOD, V94, P1878, DOI 10.1182/blood.V94.6.1878; Warner BB, 1996, AM J PHYSIOL-LUNG C, V271, pL150, DOI 10.1152/ajplung.1996.271.1.L150; WEBER C, 1994, ARTERIOSCLER THROMB, V14, P1665, DOI 10.1161/01.ATV.14.10.1665; Wei ZH, 1999, CIRC RES, V85, P682, DOI 10.1161/01.RES.85.8.682; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Xie YW, 1998, CIRC RES, V82, P891; Yeh LH, 1999, AM J PHYSIOL-CELL PH, V276, pC838, DOI 10.1152/ajpcell.1999.276.4.C838; Zachary I, 1998, EXP NEPHROL, V6, P480; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488; Zhao GC, 1997, AM J PHYSIOL-LUNG C, V273, pL1112, DOI 10.1152/ajplung.1997.273.6.L1112; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	73	133	135	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					2548	+		10.1096/fj.01-0338fje	http://dx.doi.org/10.1096/fj.01-0338fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641265				2022-12-25	WOS:000171372700026
J	Sata, M; Nishimatsu, H; Suzuki, E; Sugiura, S; Yoshizumi, M; Ouchi, Y; Hirata, Y; Nagai, R				Sata, M; Nishimatsu, H; Suzuki, E; Sugiura, S; Yoshizumi, M; Ouchi, Y; Hirata, Y; Nagai, R			Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia	FASEB JOURNAL			English	Article						angiogenesis; cholesterol; statins; vasodilatation	THERAPEUTIC ANGIOGENESIS; GENE-TRANSFER; UP-REGULATION; PRAVASTATIN; SIMVASTATIN; AKT; ADRENOMEDULLIN; MYOCARDIUM; ACTIVATION; CELLS	HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors, or statins, are prescribed widely to lower cholesterol. Accumulating evidence indicates that statins have various effects on vascular cells, which are independent of their lipid-lowering effect. Here, we tested the hypothesis that statins may augment collateral flow to ischemic tissues. We induced hind-limb ischemia in wild-type mice and treated them with either saline or cerivastatin. Cerivastatin enhanced the blood flow recovery dramatically as determined by Laser Doppler imaging. The mice treated with saline displayed frequent autoamputation of the ischemic toe, which was prevented completely by cerivastatin. Anti-CD31 immunostaining revealed that cerivastatin significantly increased the capillary density. Endothelial nitric oxide synthase (eNOS) activity was enhanced markedly in the mice treated with cerivastatin. The angiogenic effect of cerivastatin was abrogated in eNOS deficient (eNOS-/-) mice. These results indicate that eNOS is essential for cerivastatin to promote collateral growth in response to ischemia.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Nephrol & Endocrinol, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo	Sata, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	sata-2im@h.u-tokyo.ac.jp						Aikawa M, 2001, CIRCULATION, V103, P276; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Davignon J, 1999, CURR OPIN LIPIDOL, V10, P543, DOI 10.1097/00041433-199912000-00010; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Freedman SB, 2001, J MOL CELL CARDIOL, V33, P379, DOI 10.1006/jmcc.2000.1329; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Hayakawa H, 1999, HYPERTENSION, V33, P689, DOI 10.1161/01.HYP.33.2.689; Hernandez-Perera O, 1998, J CLIN INVEST, V101, P2711, DOI 10.1172/JCI1500; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Isner JM, 1999, CIRCULATION, V99, P1653, DOI 10.1161/01.CIR.99.13.1653; Kawata S, 2001, BRIT J CANCER, V84, P886, DOI 10.1054/bjoc.2000.1716; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Lee RJ, 2000, CIRCULATION, V102, P898; Lefer AM, 1999, CIRCULATION, V100, P178, DOI 10.1161/01.CIR.100.2.178; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Maron DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207; Matoba T, 2000, J CLIN INVEST, V106, P1521, DOI 10.1172/JCI10506; Murohara T, 1999, ARTERIOSCL THROM VAS, V19, P1156, DOI 10.1161/01.ATV.19.5.1156; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Parenti A, 2001, FASEB J, V15, P1487, DOI 10.1096/fj.00-0503fje; PEDERSEN TR, 1994, LANCET, V344, P1383; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Sata M, 2000, HYPERTENSION, V36, P83, DOI 10.1161/01.HYP.36.1.83; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Simons M, 2000, NAT MED, V6, P965, DOI 10.1038/79646; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Ueda Y, 1999, J AM COLL CARDIOL, V34, P2120, DOI 10.1016/S0735-1097(99)00440-4; Vale PR, 2000, CIRCULATION, V102, P965, DOI 10.1161/01.CIR.102.9.965; Vale PR, 2001, CIRCULATION, V103, P2138; van Royen N, 2001, CARDIOVASC RES, V49, P543, DOI 10.1016/S0008-6363(00)00206-6; Vasa M, 2001, CIRCULATION, V103, P2885, DOI 10.1161/hc2401.092816; Vincent L, 2001, FEBS LETT, V495, P159, DOI 10.1016/S0014-5793(01)02337-7; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Ziche M, 2000, J NEURO-ONCOL, V50, P139, DOI 10.1023/A:1006431309841	42	95	111	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2530	+		10.1096/fj.01-0415fje	http://dx.doi.org/10.1096/fj.01-0415fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641268				2022-12-25	WOS:000171372700017
J	Mohan, R; Chintala, SK; Jung, JC; Villar, WVL; McCabe, F; Russo, LA; Lee, Y; McCarthy, BE; Wollenberg, KR; Jester, JV; Wang, M; Welgus, HG; Shipley, JM; Senior, RM; Fini, ME				Mohan, R; Chintala, SK; Jung, JC; Villar, WVL; McCabe, F; Russo, LA; Lee, Y; McCarthy, BE; Wollenberg, KR; Jester, JV; Wang, M; Welgus, HG; Shipley, JM; Senior, RM; Fini, ME			Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER PHOTOREFRACTIVE KERATECTOMY; BASEMENT-MEMBRANE COMPONENTS; EPIDERMAL-GROWTH-FACTOR; TGF-BETA; CELL-MIGRATION; COLLAGENASE SYNTHESIS; WOUND REPAIR; CORNEAL; FIBRONECTIN; PROTEIN	We studied the role of the matrix metalloproteinase gelatinase B (geIB; MMP-9) in epithelial regeneration using the geIB-deficient mouse. We report the novel finding that, in contrast to other MMPs expressed at the front of the advancing epithelial sheet in wounds of cornea, skin, or trachea, gelB acts to inhibit the rate of wound closure. We determined this to be due to control of cell replication, a novel capacity for MMP's not previously described. We also found that gelB delays the inflammatory response. Acceleration of these processes in gelB-deficient mice is correlated with a delay in signal transduction through Smad2, a transcription factor that inhibits cell proliferation, and in accumulation of epithelial-associated interieukin-1alpha, a cytokine that inhibits Smad2 signaling and promotes the inflammatory response. GelB-deficient mice also reveal defects in remodeling of extracellular matrix at the epithelial basement membrane zone, in particular, failure to effectively remove the fibrin(ogen) provisional matrix. We conclude that gelB coordinates and effects multiple events involved in the process of epithelial regeneration.	Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA; Tufts Ctr Vis Res, Boston, MA 02111 USA; Univ Texas, SW Med Ctr, Dept Ophthalmol, Dallas, TX 75390 USA; Washington Univ, Sch Med Barnes Jewish Hosp, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med Barnes Jewish Hosp, Div Dermatol, St Louis, MO 63110 USA	Tufts University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	Fini, ME (corresponding author), Tufts Univ, Sch Med, New England Eye Ctr, 750 Washington St,Box 450, Boston, MA 02111 USA.	efini@lifespan.org		Jester, James/0000-0002-9246-0981	NATIONAL EYE INSTITUTE [R01EY012651, P30EY013078, R01EY007348] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042981] Funding Source: NIH RePORTER; NEI NIH HHS [EY13078, EY07348, EY12651] Funding Source: Medline; NHLBI NIH HHS [HL47328] Funding Source: Medline; NIAMS NIH HHS [AR42981] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Azar DT, 1998, ARCH OPHTHALMOL-CHIC, V116, P1206, DOI 10.1001/archopht.116.9.1206; Betsuyaku T, 2000, AM J PATHOL, V157, P525, DOI 10.1016/S0002-9440(10)64563-4; Betsuyaku T, 1999, AM J RESP CELL MOL, V20, P1303, DOI 10.1165/ajrcmb.20.6.3558; Bitzer M, 2000, GENE DEV, V14, P187; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Chin JR, 1997, DEVELOPMENT, V124, P1519; Chung EH, 1999, INVEST OPHTH VIS SCI, V40, P1952; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; Davidson JM, 1999, CURR TOPICS PATHOL, V93, P111; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; Drew AF, 2000, INVEST OPHTH VIS SCI, V41, P67; FALANGA V, 1994, J INVEST DERMATOL, V102, P125, DOI 10.1111/1523-1747.ep12371745; FALANGA V, 1993, LANCET, V341, P1006, DOI 10.1016/0140-6736(93)91085-Z; FINI ME, 1991, INVEST OPHTH VIS SCI, V32, P2997; Fini ME, 1999, PROG RETIN EYE RES, V18, P529, DOI 10.1016/S1350-9462(98)00033-0; Fini ME, 1998, BIOL EXTRAC, P299; Fini ME, 1996, AM J PATHOL, V149, P1287; Fini ME, 1998, ARCH DERMATOL RES, V290, pS12, DOI 10.1007/PL00007449; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUJIKAWA LS, 1981, LAB INVEST, V45, P120; FUJIKAWA LS, 1984, J CELL BIOL, V98, P128, DOI 10.1083/jcb.98.1.128; GARTRY DS, 1992, OPHTHALMOLOGY, V99, P1209; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gipson I K, 1995, Curr Opin Ophthalmol, V6, P3; GIPSON IK, 1989, INVEST OPHTH VIS SCI, V30, P425; GIPSON IK, 1982, DEV BIOL, V92, P259, DOI 10.1016/0012-1606(82)90170-1; GIPSON IK, 1988, DEV BIOL, V126, P253, DOI 10.1016/0012-1606(88)90136-4; GROBELNY D, 1992, BIOCHEMISTRY-US, V31, P7152, DOI 10.1021/bi00146a017; GUO M, 1989, J INVEST DERMATOL, V93, P372, DOI 10.1111/1523-1747.ep12280275; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hunt T K, 2000, Adv Skin Wound Care, V13, P6; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Jester JV, 1999, J CELL SCI, V112, P613; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Legrand C, 1999, J CELL BIOL, V146, P517, DOI 10.1083/jcb.146.2.517; Lelongt B, 2001, J EXP MED, V193, P793, DOI 10.1084/jem.193.7.793; LEPPERT D, 1995, J IMMUNOL, V154, P4379; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; MAGUEN E, 1994, OPHTHALMOLOGY, V101, P1548; MATSUBARA M, 1991, INVEST OPHTH VIS SCI, V32, P3221; MATSUBARA M, 1991, DEV BIOL, V147, P425, DOI 10.1016/0012-1606(91)90300-R; NISHIDA T, 1982, JPN J OPHTHALMOL, V26, P410; Okada S, 1997, AM J RESP CELL MOL, V17, P519, DOI 10.1165/ajrcmb.17.4.2877; Parks WC, 1998, BIOL EXTRAC, P263; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; PHAN TMM, 1989, INVEST OPHTH VIS SCI, V30, P377; Phillips T J, 1992, Epithelial Cell Biol, V1, P39; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; PIERCE GF, 1995, ANNU REV MED, V46, P467; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Ravanti L, 2000, INT J MOL MED, V6, P391; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Schaffer CJ, 1996, INT REV CYTOL, V169, P151, DOI 10.1016/S0074-7696(08)61986-5; Schallhorn SC, 1996, OPHTHALMOLOGY, V103, P5, DOI 10.1016/S0161-6420(96)30733-1; Schonbeck U, 1998, J IMMUNOL, V161, P3340; SCHULTZ G, 1994, EYE, V8, P184, DOI 10.1038/eye.1994.43; SEILER T, 1994, OPHTHALMOLOGY, V101, P153; SHER NA, 1994, OPHTHALMOLOGY, V101, P1575; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; STRISSEL KJ, 1995, INVEST OPHTH VIS SCI, V36, P151; Strissel KJ, 1997, INVEST OPHTH VIS SCI, V38, P546; SUDA T, 1982, CURR EYE RES, V1, P553, DOI 10.3109/02713688109069181; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; VU TH, 1998, GELATINASE B; Wang M, 1999, P NATL ACAD SCI USA, V96, P6885, DOI 10.1073/pnas.96.12.6885; WATT FM, 1991, J CELL SCI, V99, P397; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; Wilson AJ, 1999, CLIN SCI, V97, P385, DOI 10.1042/CS19980351; WILSON SE, 1994, EXP EYE RES, V59, P63, DOI 10.1006/exer.1994.1081; Woessner JF, 1998, BIOL EXTRAC, P1; WOODLEY DT, 1985, J AM ACAD DERMATOL, V12, P420, DOI 10.1016/S0190-9622(85)80005-0; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yu Q, 2000, GENE DEV, V14, P163; Zagon IS, 2000, BRAIN RES, V882, P169, DOI 10.1016/S0006-8993(00)02864-X; Zieske JD, 2000, INVEST OPHTH VIS SCI, V41, P1346	81	208	218	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2065	2072		10.1074/jbc.M107611200	http://dx.doi.org/10.1074/jbc.M107611200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11689563	hybrid			2022-12-25	WOS:000173421300062
J	Hourcade, DE; Mitchell, L; Kuttner-Kondo, LA; Atkinson, JP; Medof, ME				Hourcade, DE; Mitchell, L; Kuttner-Kondo, LA; Atkinson, JP; Medof, ME			Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACQUIRED IMMUNE-RESPONSE; CATION-BINDING SITE; PROTEIN INTERFACES; CRYSTAL-STRUCTURE; HOT-SPOTS; MUTAGENESIS; CD11B/CD18; PATHWAY; INNATE; CD35	The AP C3 convertase, C3bBb(Mg2+), is subject to irreversible dissociation (decay acceleration) by three proteins: DAF, CR1, and factor H. We have begun to map the factor B (fB) sites critical to these interactions. We generated a panel of fB mutations, focusing on the type A domain because it carries divalent cation and C3b-binding elements. C3bBb complexes were assembled with the mutants and subjected to decay acceleration. Two critical fB sites were identified with a structural model. 1) Several mutations centered at adjacent alpha helices 4 and 5 (Gln-335, Tyr-338, Ser-339, Asp-382) caused substantial resistance to DAF and CR1-mediated decay acceleration but not factor H. 2) Several mutations centered at the alpha I helix and adjoining loops (especially D254G) caused resistance to decay acceleration mediated by all three regulators and also increased C3b-binding affinity and C3bBb stability. In the simplest interpretation of these results, DAF and CRI directly interact with C3bBb at alpha 4/5; factor H likely interacts at some other location, possibly on the C3b subunit. Mutations at the C3b.Bb interface interfere with the normal dissociation of C3b from Bb, whether it is spontaneous or promoted by DAF, CR1, or factor H.	Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA; Case Western Reserve Univ, Dept Pathol & Med, Cleveland, OH 44106 USA	Washington University (WUSTL); Case Western Reserve University	Hourcade, DE (corresponding author), Washington Univ, Sch Med, Dept Med, Div Rheumatol, Campus Box 8045,660 S Euclid Ave, St Louis, MO 63110 USA.			Atkinson, John/0000-0002-2514-3441				Ahearn JM, 1998, HUMAN COMPLEMENT SYS, P167; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Brodbeck WG, 1996, J IMMUNOL, V156, P2528; Brodbeck WG, 2000, IMMUNOLOGY, V101, P104, DOI 10.1046/j.1365-2567.2000.00086.x; Carroll MC, 1998, CURR OPIN IMMUNOL, V10, P36; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Hinshelwood J, 1999, J MOL BIOL, V294, P587, DOI 10.1006/jmbi.1999.3223; Hinshelwood J, 2000, J MOL BIOL, V298, P135, DOI 10.1006/jmbi.2000.3632; HOURCADE D, 1996, MOL IMMUNOL, V33, P57; HOURCADE D, 1989, PROG IMMUNOL, V7, P171; Hourcade DE, 1999, J IMMUNOL, V162, P2906; HOURCADE DE, 1995, J BIOL CHEM, V270, P19716, DOI 10.1074/jbc.270.34.19716; Hourcade DE, 1998, J BIOL CHEM, V273, P25996, DOI 10.1074/jbc.273.40.25996; Hu ZJ, 2000, PROTEINS, V39, P331, DOI 10.1002/(SICI)1097-0134(20000601)39:4<331::AID-PROT60>3.0.CO;2-A; KRYCH M, 1994, J BIOL CHEM, V269, P13273; KRYCH M, 1996, MOL IMMUNOL, V33; Krych-Goldberg M, 1999, J BIOL CHEM, V274, P31160, DOI 10.1074/jbc.274.44.31160; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; Kuttner-Kondo LA, 2001, J IMMUNOL, V167, P2164, DOI 10.4049/jimmunol.167.4.2164; KuttnerKondo L, 1996, PROTEIN ENG, V9, P1143, DOI 10.1093/protein/9.12.1143; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Liszewski M.K., 1998, HUMAN COMPLEMENT SYS, P149; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOLE JE, 1984, J BIOL CHEM, V259, P3407; Nielsen CH, 2000, IMMUNOLOGY, V100, P4, DOI 10.1046/j.1365-2567.2000.00009.x; PANGBURN MK, 1986, J IMMUNOL, V136, P2216; Perkins SJ, 1999, BIOCHEM SOC T, V27, P815, DOI 10.1042/bst0270815; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Tuckwell DS, 1997, BIOCHEMISTRY-US, V36, P6605, DOI 10.1021/bi963155l; Volanakis JE, 1998, HUMAN COMPLEMENT SYS, V20, P9, DOI DOI 10.1201/B14212-3	32	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1107	1112		10.1074/jbc.M109322200	http://dx.doi.org/10.1074/jbc.M109322200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694537	hybrid			2022-12-25	WOS:000173166800031
J	Samso, M; Wagenknecht, T				Samso, M; Wagenknecht, T			Apocalmodulin and Ca2+-calmodulin bind to neighboring locations on the ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; DIHYDROPYRIDINE RECEPTOR; CRYOELECTRON MICROSCOPY; ELECTRON-MICROSCOPY; CALMODULIN-BINDING; TARGET RECOGNITION; PEPTIDE COMPLEX; CA2+	Calmodulin (CaM) binds to the ryanodine receptor/ calcium release channel of skeletal muscle (RyR1), both in the absence and presence of Ca2+, and regulates the activity of the channel activity by activating and inhibiting it, respectively. Using cryo-electron microscopy and three-dimensional reconstruction, we found that one apoCaM binds per RyR1 subunit along the sides of the cytoplasmic assembly of the receptor. This location is distinct from but close to the location found for Ca2+-CaM, providing a structural basis for efficient switching of CaM between these two positions with the oscillating intracellular Ca2+ concentration that generates muscle relaxation/contraction cycles. The locations of apoCaM and Ca2+-CaM at a critical region for RYR1-dihydropyridine receptor interaction are suggestive of a direct role for CaM in the mechanism of excitation-contraction coupling.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Samso, M (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Empire State Plaza, Albany, NY 12201 USA.			Samso, Montserrat/0000-0002-2788-3283	NCRR NIH HHS [RR01219-19] Funding Source: Medline; NIAMS NIH HHS [AR 40615] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARMITAGE P, 1994, STAT METHODS MED RES, P99; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BURATTI R, 1995, BIOCHEM BIOPH RES CO, V213, P1082, DOI 10.1006/bbrc.1995.2238; Chavis P, 1996, NATURE, V382, P719, DOI 10.1038/382719a0; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Fruen BR, 2000, AM J PHYSIOL-CELL PH, V279, pC724, DOI 10.1152/ajpcell.2000.279.3.C724; FUENTES O, 1994, CELL CALCIUM, V15, P305, DOI 10.1016/0143-4160(94)90070-1; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; Houdusse A, 1996, STRUCTURE, V4, P1475, DOI 10.1016/S0969-2126(96)00154-2; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; Leong P, 1998, J BIOL CHEM, V273, P29958, DOI 10.1074/jbc.273.45.29958; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; LU XY, 1994, J BIOL CHEM, V269, P6511; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Martin C, 1998, NEUROSCIENCE, V85, P205, DOI 10.1016/S0306-4522(97)00612-X; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; Meissner G, 1995, BIOSCIENCE REP, V15, P399, DOI 10.1007/BF01788371; MENEGAZZI P, 1994, BIOCHEMISTRY-US, V33, P9078, DOI 10.1021/bi00197a008; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; PORTER MC, 1999, J BIOL CHEM, V274, P36831; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Rodney GG, 2000, BIOCHEMISTRY-US, V39, P7807, DOI 10.1021/bi0005660; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; Samso M, 1999, J CELL BIOL, V146, P493, DOI 10.1083/jcb.146.2.493; Samso M, 1998, J STRUCT BIOL, V121, P172, DOI 10.1006/jsbi.1997.3955; Samso M, 2000, BIOPHYS J, V78, p149A; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; Sharma MR, 1998, J BIOL CHEM, V273, P18429, DOI 10.1074/jbc.273.29.18429; Shoshan-Barmatz V, 1998, INT REV CYTOL, V183, P185, DOI 10.1016/S0074-7696(08)60145-X; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; WAGENKNECHT T, 1994, BIOPHYS J, V67, P2286, DOI 10.1016/S0006-3495(94)80714-3; Yamaguchi N, 2001, J BIOL CHEM, V276, P22579, DOI 10.1074/jbc.M102729200; YANG HC, 1994, BIOCHEMISTRY-US, V33, P518, DOI 10.1021/bi00168a017; Zhang MJ, 1998, BIOCHEM CELL BIOL, V76, P313, DOI 10.1139/bcb-76-2-3-313; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	57	113	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1349	1353		10.1074/jbc.M109196200	http://dx.doi.org/10.1074/jbc.M109196200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694536	hybrid			2022-12-25	WOS:000173166800063
J	Alvarez, J; Vinas, J; Alonso, JMM; Albar, JP; Ashman, K; Dominguez, P				Alvarez, J; Vinas, J; Alonso, JMM; Albar, JP; Ashman, K; Dominguez, P			Characterization and cloning of two isoforms of heteroglobin, a novel heterodimeric glycoprotein of the secretoglobin-uteroglobin family showing tissue-specific and sex differential expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-BINDING-PROTEIN; HAMSTER HARDERIAN-GLAND; RAT VENTRAL PROSTATE; POLYACRYLAMIDE-GEL ELECTROPHORESIS; AMINO-ACID-SEQUENCE; MESSENGER-RNAS; GENE FAMILY; C-3 GENES; PURIFICATION; IDENTIFICATION	Heteroglobin (HGB) is a 39-kDa heterodimeric protein detected under non-reducing conditions in harderian, parotid, and submaxillary glands and saliva of the Syrian hamster with antiserum raised against the carboxyl end deduced from the female harderian gland cDNA FHG22 (Dominguez, P. (1995) FEBS Lett. 376, 257-261). After reduction, only one 5.6-kDa polypeptide, named HGB.A, was immunodetected and identified by sequencing as the mature FHG22 product. Tissue-specific expression of HGBA and HGB mimics that of FHG22 mRNA, with sex differences in submaxillary and harderian glands. Purification of HGB revealed it consists of HGB.A disulfide bonded to HGB.B, a 33.5-kDa N-glycosylated subunit that yields a 9-kDa core polypeptide after deglycosylation. Two highly homologous (96.2%) eDNA clones (HGB.B1 and HGB.B2) encoding 94 amino acid-long isoforms were identified by screening a female harderian gland library with an HGB.B probe. The corresponding mature polypeptides are 78 amino acids long with 12 differences, but 3 putative N-glycosylation sites are maintained. The expression of HGB.B mRNAs is parallel to that of HGB and HGB.A, but no HGB.132 mRNA was detected in submaxillary glands. Homology studies indicate that HGB.A and HGB.B1/HGB.B2 belong to different subfamilies of the secretoglobin-uteroglobin family and form heterodimers as previously described.	Univ Oviedo, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Samuel Lunenfeld Res Inst, Toronto, ON MSG 1X5, Canada	University of Oviedo; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Dominguez, P (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Edificio Santiago Gascon, E-33006 Oviedo, Spain.		Ashman, Keith/G-2328-2011; Martin Alonso, Jose Manuel/C-7763-2013; Dominguez, Pedro/A-8266-2012	Martin Alonso, Jose Manuel/0000-0003-1725-6216; Dominguez, Pedro/0000-0003-4788-1071				ANDERSSON O, 1991, AM J RESP CELL MOL, V5, P6, DOI 10.1165/ajrcmb/5.1.6; ANDERSSON O, 1994, J BIOL CHEM, V269, P19081; Atherton E., 1987, PEPTIDES ANAL SYNTHE, V9, P1; AUMULLER G, 1995, CELL TISSUE RES, V280, P171, DOI 10.1007/BF00304522; AUSTEN BM, 1979, FEBS LETT, V103, P308, DOI 10.1016/0014-5793(79)81351-4; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAKER ME, 1983, BIOCHEM BIOPH RES CO, V114, P325, DOI 10.1016/0006-291X(83)91631-5; Barnes HJ, 1996, J MOL BIOL, V256, P392, DOI 10.1006/jmbi.1996.0094; BEATO M, 1976, J STEROID BIOCHEM, V7, P327, DOI 10.1016/0022-4731(76)90091-1; Becker RM, 1998, GENOMICS, V54, P70, DOI 10.1006/geno.1998.5539; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Callebaut I, 2000, ANN NY ACAD SCI, V923, P90; Colpitts TL, 2000, ANN NY ACAD SCI, V923, P312; DEHARO MSL, 1994, FEBS LETT, V349, P249, DOI 10.1016/0014-5793(94)00678-4; DOMINGUEZ P, 1994, MOL CELL ENDOCRINOL, V106, P81, DOI 10.1016/0303-7207(94)90189-9; DOMINGUEZ P, 1995, FEBS LETT, V376, P257, DOI 10.1016/0014-5793(95)01294-4; Dominguez P, 1996, MICROSC RES TECHNIQ, V34, P111, DOI 10.1002/(SICI)1097-0029(19960601)34:2<111::AID-JEMT3>3.3.CO;2-M; GIRGIS SI, 1988, NUCLEIC ACIDS RES, V16, P10371, DOI 10.1093/nar/16.21.10371; GONZALEZ KD, 1995, FEBS LETT, V361, P255, DOI 10.1016/0014-5793(95)00167-8; Hames BD., 1990, GEL ELECTROPHORESIS, P1; HEYNS W, 1978, EUR J BIOCHEM, V89, P181, DOI 10.1111/j.1432-1033.1978.tb20910.x; HURST HC, 1983, EMBO J, V2, P769, DOI 10.1002/j.1460-2075.1983.tb01498.x; KARN RC, 1994, BIOCHEM GENET, V32, P271, DOI 10.1007/BF00555830; Klug J, 2000, ANN NY ACAD SCI, V923, P348; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; Kristensen AK, 1997, BIOL CHEM, V378, P899; Kundu GC, 1996, P NATL ACAD SCI USA, V93, P2915, DOI 10.1073/pnas.93.7.2915; Kundu GC, 1998, J BIOL CHEM, V273, P22819, DOI 10.1074/jbc.273.35.22819; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEA OA, 1979, J BIOL CHEM, V254, P6196; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; Lehrer RI, 1998, FEBS LETT, V432, P163, DOI 10.1016/S0014-5793(98)00852-7; Lehrer RI, 2000, ANN NY ACAD SCI, V923, P59; Lima P. H., 1997, Investigative Ophthalmology and Visual Science, V38, pS148; MARSHALL RD, 1974, BIOCH SOC S, V40, P7; MCMASTERS KM, 1984, BIOL REPROD, V31, P579, DOI 10.1095/biolreprod31.3.579; MIELE L, 1994, J ENDOCRINOL INVEST, V17, P679, DOI 10.1007/BF03349687; Molloy MP, 1997, ELECTROPHORESIS, V18, P2811, DOI 10.1002/elps.1150181516; Mukherjee AB, 1999, CELL MOL LIFE SCI, V55, P771, DOI 10.1007/s000180050331; Ni J, 2000, ANN NY ACAD SCI, V923, P25; OLCESE J, 1989, COMP BIOCHEM PHYS A, V93, P655, DOI 10.1016/0300-9629(89)90480-5; PARKER M, 1982, NATURE, V298, P92, DOI 10.1038/298092a0; PARKER MG, 1983, J BIOL CHEM, V258, P12; Payne AP, 1996, MICROSC RES TECHNIQ, V34, P123, DOI 10.1002/(SICI)1097-0029(19960601)34:2<123::AID-JEMT5>3.0.CO;2-T; PAYNE AP, 1994, J ANAT, V185, P1; PEETERS BL, 1980, J BIOL CHEM, V255, P7017; Ploubidou A, 2000, EMBO J, V19, P3932, DOI 10.1093/emboj/19.15.3932; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; SCHUBERT D, 1970, J MOL BIOL, V51, P287, DOI 10.1016/0022-2836(70)90143-9; Singh G, 2000, ANN NY ACAD SCI, V923, P43; SINGH G, 1993, EXP LUNG RES, V19, P67, DOI 10.3109/01902149309071081; Stripp BR, 1996, AM J PHYSIOL-LUNG C, V271, pL656, DOI 10.1152/ajplung.1996.271.4.L656; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMLAND TC, 1994, NAT STRUCT BIOL, V1, P538, DOI 10.1038/nsb0894-538; Varriale B, 1996, MOL CELL ENDOCRINOL, V124, P87, DOI 10.1016/S0303-7207(96)03932-9; Vercaeren I, 1996, ENDOCRINOLOGY, V137, P4713, DOI 10.1210/en.137.11.4713; Watson MA, 1996, CANCER RES, V56, P860; ZHANG YL, 1985, MOL CELL ENDOCRINOL, V43, P151, DOI 10.1016/0303-7207(85)90078-4; Zhang ZJ, 1997, SCIENCE, V276, P1408, DOI 10.1126/science.276.5317.1408; Zhao CQ, 1999, BIOCHEM BIOPH RES CO, V256, P147, DOI 10.1006/bbrc.1999.0274; Zheng F, 1999, NAT MED, V5, P1018, DOI 10.1038/12458	66	9	9	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					233	242		10.1074/jbc.M106678200	http://dx.doi.org/10.1074/jbc.M106678200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11684684	hybrid			2022-12-25	WOS:000173087900032
J	Kelly, BS; Antholine, WE; Griffith, OW				Kelly, BS; Antholine, WE; Griffith, OW			Escherichia coli gamma-glutamylcysteine synthetase - Two active site metal ions affect substrate and inhibitor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNADENYLYLATED GLUTAMINE-SYNTHETASE; ELECTRON-PARAMAGNETIC RESONANCE; GLUTATHIONE BIOSYNTHESIS; DEFICIENT MUTANTS; SULFOXIMINE; PURIFICATION; METABOLISM; RADIATION; MECHANISM; BACTERIA	gamma-Glutamylcysteine synthetase (gamma-GCS, glutamate-cysteine ligase), which catalyzes the first and rate-limiting step in glutathione biosynthesis, is present in many prokaryotes and in virtually all eukaryotes. Although all eukaryotic gamma-GCS isoforms examined to date are rapidly inhibited by buthionine sulfoximine (BSO), most reports indicate that bacterial gamma-GCS is resistant to BSO. We have confirmed the latter finding with Escherichia coli, gamma-GCS under standard assay conditions, showing both decreased initial binding affinity for BSO and a reduced rate of BSO-mediated inactivation compared with mammalian isoforms. We also find that substitution of Mn2+ for Mg2+ in assay mixtures increases both the initial binding affinity of BSO and the rate at which BSO causes mechanism-based inactivation. Similarly, the specificity of E. coli gamma-GCS for its amino acid substrates is broadened in the presence of Mn2+, and the rate of reaction for some very poor substrates is improved. These results suggest that divalent metal ions have a role in amino acid binding to E. coli gamma-GCS. Electron paramagnetic resonance (EPR) studies carried out with Mn2+ show that E. coli gamma-GCS binds two divalent metal ions; K-d values for Mn2+ are 1.1 mum and 82 mum, respectively. Binding of L-glutamate or L-BSO to the two Mn2+/ gamma-GCS species produces additional upfield and down-field X-band EPR hyperfine lines at 45 G intervals, a result indicating that the two Mn2+ are spin-coupled and thus apparently separated by 5 A or less in the active site. Additional EPR studies in which Cu2+ replaced Mg2+ or Mn2+ suggest that Cu2+ is bound by one N and three O ligands in the gamma-GCS active site. The results are discussed in the context of the catalytic mechanism of gamma-GCS and its relationship to the more fully characterized glutamine synthetase reaction.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Inst Biophys, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Griffith, OW (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.				NATIONAL CANCER INSTITUTE [R01CA077233] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NCI NIH HHS [CA77233] Funding Source: Medline; NCRR NIH HHS [RR01008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abbott JJ, 2001, J BIOL CHEM, V276, P42099, DOI 10.1074/jbc.M104672200; ALONSOMORAGA A, 1987, MOL CELL BIOCHEM, V73, P61; ARRICK BA, 1981, J EXP MED, V153, P720, DOI 10.1084/jem.153.3.720; BALAKRISHNAN MS, 1978, BIOCHEMISTRY-US, V17, P3531, DOI 10.1021/bi00610a017; BIAGLOW JE, 1983, RADIAT RES, V95, P437, DOI 10.2307/3576092; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYGRAVE FL, 1966, BIOCHEM J, V101, P488, DOI 10.1042/bj1010488; CAMPBELL EB, 1991, ANAL BIOCHEM, V194, P268, DOI 10.1016/0003-2697(91)90229-M; COHN M, 1954, NATURE, V173, P1090, DOI 10.1038/1731090b0; DAHL TA, 1989, J BACTERIOL, V171, P2188, DOI 10.1128/jb.171.4.2188-2194.1989; EADS CD, 1985, BIOCHEMISTRY-US, V24, P1221, DOI 10.1021/bi00326a025; Ferguson GP, 1998, ARCH MICROBIOL, V170, P209, DOI 10.1007/s002030050635; FRONCISZ W, 1982, J MAGN RESON, V47, P515, DOI 10.1016/0022-2364(82)90221-9; FUCHS JA, 1995, METHOD ENZYMOL, V252, P83; GIBBS EJ, 1984, BIOCHEM BIOPH RES CO, V120, P939, DOI 10.1016/S0006-291X(84)80197-7; GILAV E, 1980, J AM CHEM SOC, V102, P5115, DOI 10.1021/ja00535a059; GILL HS, 2000, BIOCHIM BIOPHYS ACTA, V1477, P122; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; GRIFFITH OW, 1977, P NATL ACAD SCI USA, V74, P3330, DOI 10.1073/pnas.74.8.3330; GRIFFITH OW, 1979, J BIOL CHEM, V254, P1205; GRIFFITH OW, 1991, SYNERGISM ANTAGONISM, P245; HARROP HA, 1991, INT J RADIAT BIOL, V59, P1237, DOI 10.1080/09553009114551111; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HUANG CS, 1988, P NATL ACAD SCI USA, V85, P2464, DOI 10.1073/pnas.85.8.2464; HUNT JB, 1980, J BIOL CHEM, V255, P590; IRVING H, 1953, J CHEM SOC, P3192, DOI 10.1039/jr9530003192; LIAW SH, 1994, BIOCHEMISTRY-US, V33, P675, DOI 10.1021/bi00169a007; MANNING JM, 1969, BIOCHEMISTRY-US, V8, P2681, DOI 10.1021/bi00834a066; MEISTER A, 1985, METHOD ENZYMOL, V113, P185; MEISTER A, 1995, METHOD ENZYMOL, V252, P26; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1994, CANCER RES, V54, pS1969; Misra I, 1998, PROTEIN EXPRES PURIF, V13, P268, DOI 10.1006/prep.1998.0897; MOORE WR, 1987, ANAL BIOCHEM, V161, P487, DOI 10.1016/0003-2697(87)90478-7; MOORE WR, 1989, P NATL ACAD SCI USA, V86, P1461, DOI 10.1073/pnas.86.5.1461; MURATA K, 1982, APPL ENVIRON MICROB, V44, P1444, DOI 10.1128/AEM.44.6.1444-1448.1982; MURATA K, 1982, J GEN MICROBIOL, V128, P1047; Murata K, 1994, Bioprocess Technol, V19, P159; MURATA K, 1980, J GEN MICROBIOL, V120, P545; NEWTON GL, 1990, GLUTATHIONE METABOLI, P69; ORLOWSKI M, 1971, J BIOL CHEM, V246, P7095; OWENS RA, 1986, ENVIRON MUTAGEN, V8, P659, DOI 10.1002/em.2860080503; PEISACH J, 1974, ARCH BIOCHEM BIOPHYS, V165, P691, DOI 10.1016/0003-9861(74)90298-7; RATHBUN WB, 1967, ARCH BIOCHEM BIOPHYS, V122, P73, DOI 10.1016/0003-9861(67)90125-7; Reed G., 1984, BIOL MAGN RESON, V6, P73; RICHMAN PG, 1973, J BIOL CHEM, V248, P6684; ROMERO MJM, 1991, TOXICOL APPL PHARM, V111, P485, DOI 10.1016/0041-008X(91)90252-A; ROSS RT, 1965, J CHEM PHYS, V42, P3919, DOI 10.1063/1.1695859; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; SEKURA R, 1977, J BIOL CHEM, V252, P2599; SMITH J, 1979, COMP BIOCHEM PHYS B, V63, P39, DOI 10.1016/0305-0491(79)90231-1; SUNDQUIST AR, 1989, J MOL EVOL, V29, P429, DOI 10.1007/BF02602913; VILLAFRANCA JJ, 1985, CURR TOP CELL REGUL, V26, P207; VILLAFRANCA JJ, 1976, BIOCHEMISTRY-US, V15, P544, DOI 10.1021/bi00648a014; VILLAFRANCA JJ, 1976, BIOCHEMISTRY-US, V15, P1536; WALSH C, 1979, ENZYMATIC REACTION M, P88; WATANABE K, 1986, AGR BIOL CHEM TOKYO, V50, P1925, DOI 10.1080/00021369.1986.10867700	59	50	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					50	58		10.1074/jbc.M107961200	http://dx.doi.org/10.1074/jbc.M107961200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11675389	hybrid			2022-12-25	WOS:000173087900009
J	Kondejewski, LH; Lee, DL; Jelokhani-Niaraki, M; Farmer, SW; Hancock, REW; Hodges, RS				Kondejewski, LH; Lee, DL; Jelokhani-Niaraki, M; Farmer, SW; Hancock, REW; Hodges, RS			Optimization of microbial specificity in cyclic peptides by modulation of hydrophobicity within a defined structural framework	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; CRAB TACHYPLEUS-TRIDENTATUS; NUCLEAR MAGNETIC-RESONANCE; GRAMICIDIN-S; ANTIMICROBIAL PEPTIDE; PSEUDOMONAS-AERUGINOSA; HEMOLYTIC ACTIVITIES; OUTER-MEMBRANE; POLYPHEMUSIN-I; CDNA SEQUENCE	In the present study we have utilized the structural framework of the analog GS14K4 (cyclo(VKLd-K-Vd-YPL KVKLd-YP, where d denotes a D-amino acid)), to examine the role of hydrophobicity in microbial activity and specificity. The hydrophobicity of GS14K4 was systematically altered by residue replacements in the hydrophobic sites of the molecule to produce a series of analogs that were either less or more hydrophobic than the parent compound. Circular dichroism spectroscopy and reversed-phase high performance liquid chromatography analysis showed that the molecules were structurally similar and only differed in overall hydrophobicity. The hydrophobicity of GS14K4 was found to be the midpoint for hemolytic activity, with more hydrophobic analogs exhibiting increased hemolytic activity and less hydrophobic analogs showing decreased hemolytic activity. For antimicrobial activity there were differences between the hydrophobicity requirements against Gram-positive and Gram-negative microorganisms. The hydrophobicity of GS14K4 was sufficient for maximum activity against Gram-negative microorganisms and yeast, with no further increases in activity occurring with increasing hydrophobicity. With Gram-positive microorganisms significant increases in activity with increasing hydrophobicity were seen in three of the six microorganisms tested. A therapeutic index (calculated as a measure of specificity of the peptides for the microorganisms over human erythrocytes) served to define the boundaries of a therapeutic window within which lay the optimum peptide hydrophobicity for each microorganism. The therapeutic window was found to be at a lower hydrophobicity level for Gram-negative microorganisms than for Gram-positive microorganisms, although the limits were more variable for the latter. Our results show that the balance between activity and specificity in the present cyclic peptides can be optimized for each microorganism by systematic modulation of hydrophobicity.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ British Columbia, Canadian Bacterial Dis Network, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Microbiol, Vancouver, BC V6T 1Z3, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2S2, Canada	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of British Columbia; University of British Columbia; University of Alberta; University of Alberta	Hodges, RS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave,B121, Denver, CO 80262 USA.	robert.hodges@uchsc.edu	Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503; Farmer, Susan/0000-0002-6712-7810	NIGMS NIH HHS [R01GM61855] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061855] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; BAZZO R, 1988, EUR J BIOCHEM, V173, P139, DOI 10.1111/j.1432-1033.1988.tb13977.x; BECHINGER B, 1992, BIOPHYS J, V62, P12, DOI 10.1016/S0006-3495(92)81763-0; Dathe M, 1997, FEBS LETT, V403, P208, DOI 10.1016/S0014-5793(97)00055-0; Gibbs AC, 1998, NAT STRUCT BIOL, V5, P284, DOI 10.1038/nsb0498-284; GUO DC, 1986, J CHROMATOGR, V359, P499, DOI 10.1016/0021-9673(86)80102-9; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; HANCOCK REW, 1981, J ANTIMICROB CHEMOTH, V8, P429, DOI 10.1093/jac/8.6.429; HANCOCK REW, 1993, ANTIMICROB AGENTS CH, V37, P453, DOI 10.1128/AAC.37.3.453; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Harwig S S, 1995, J Pept Sci, V1, P207, DOI 10.1002/psc.310010308; Hetru C, 2000, BIOCHEM J, V345, P653, DOI 10.1042/0264-6021:3450653; Hirota N, 1998, J MOL BIOL, V275, P365, DOI 10.1006/jmbi.1997.1468; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P7620, DOI 10.1021/bi00420a008; IZUMIYA N, 1979, SYNTHETIC ASPECTS BI, P49; Jelokhani-Niaraki M, 2000, BIOCHEM J, V349, P747, DOI 10.1042/bj3490747; Juvvadi P, 1996, J PEPT SCI, V2, P223, DOI 10.1002/psc.63; KAWANO K, 1990, J BIOL CHEM, V265, P15365; KHALED MA, 1978, BIOCHEMISTRY-US, V17, P2490; Kondejewski LH, 1999, J BIOL CHEM, V274, P13181, DOI 10.1074/jbc.274.19.13181; Kondejewski LH, 1996, J BIOL CHEM, V271, P25261, DOI 10.1074/jbc.271.41.25261; Kondejewski LH, 1996, INT J PEPT PROT RES, V47, P460; Krause E, 1996, INT J PEPT PROT RES, V48, P559; KUO MC, 1980, BIOPHYS J, V32, P807, DOI 10.1016/S0006-3495(80)85018-1; Lavigne P, 1998, J MOL BIOL, V281, P165, DOI 10.1006/jmbi.1998.1914; LOH B, 1984, ANTIMICROB AGENTS CH, V26, P546, DOI 10.1128/AAC.26.4.546; Mant CT, 1998, J CHROMATOGR A, V816, P79, DOI 10.1016/S0021-9673(98)00508-1; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; McInnes C, 2000, J BIOL CHEM, V275, P14287, DOI 10.1074/jbc.275.19.14287; MIYATA T, 1989, J BIOCHEM, V106, P663, DOI 10.1093/oxfordjournals.jbchem.a122913; MOORE RA, 1986, ANTIMICROB AGENTS CH, V29, P496, DOI 10.1128/AAC.29.3.496; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; NICAS TI, 1983, J GEN MICROBIOL, V129, P509; ONO S, 1987, FEBS LETT, V220, P332, DOI 10.1016/0014-5793(87)80841-4; Oren Ziv, 2001, P183; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; PATHAK N, 1995, PROTEINS, V22, P182, DOI 10.1002/prot.340220210; Prenner EJ, 1999, BBA-BIOMEMBRANES, V1417, P211, DOI 10.1016/S0005-2736(99)00004-8; Prenner EJ, 2001, BBA-BIOMEMBRANES, V1510, P83, DOI 10.1016/S0005-2736(00)00337-0; Rothemund S, 1996, PEPTIDE RES, V9, P79; SEREDA TJ, 1994, J CHROMATOGR A, V676, P139, DOI 10.1016/0021-9673(94)00371-8; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1363, DOI 10.1006/bbrc.1993.2403; van 't Hof W, 2001, BIOL CHEM, V382, P597, DOI 10.1515/BC.2001.072; Wieprecht T, 1997, BIOCHEMISTRY-US, V36, P6124, DOI 10.1021/bi9619987; Wishart DS, 1996, LETT PEPT SCI, V3, P53, DOI 10.1007/BF00131086; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; Zhang LJ, 2000, BIOCHEMISTRY-US, V39, P14504, DOI 10.1021/bi0011173; Zhang LJ, 2000, ANTIMICROB AGENTS CH, V44, P3317, DOI 10.1128/AAC.44.12.3317-3321.2000; ZHOU N E, 1990, Peptide Research, V3, P8	50	64	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					67	74		10.1074/jbc.M107825200	http://dx.doi.org/10.1074/jbc.M107825200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11682479	hybrid			2022-12-25	WOS:000173087900011
J	McMillan, DR; Kayes-Wandover, KM; Richardson, JA; White, PC				McMillan, DR; Kayes-Wandover, KM; Richardson, JA; White, PC			Very large G protein-coupled receptor-1, the largest known cell surface protein, is highly expressed in the developing central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; ALPHA-LATROTOXIN; GENOMIC DNA; FLAMINGO; SEQUENCE; FAMILY; GENE	We previously identified a member of the G protein-coupled receptor family, very large G protein-coupled receptor-1 (VLGR1). VLGR1 has a large ectodomain containing multiple calcium exchanger beta repeats that resemble regulatory domains of sodium-calcium exchanger proteins. Similar repeats are found in the extracellular aggregation factor of marine sponges, which mediates species-specific cell aggregation. We now report that the protein encoded by the originally described human cDNA (now termed VILGR1a) is, in fact, at 1967 amino acids, the smallest of three expressed human isoforms. It is encoded by an alternative transcript that begins within intron 64 of the VLGR1 gene. The longest gene product, VLGR1b, is 6307 amino acids (6298 amino acids in mice) due to a much larger ectodomain containing 35 calcium exchanger beta repeats and a pentraxin homology domain. VLGR1b is apparently the largest known cell surface protein. The VLGR1 gene comprises 90 exons and is >600 kb long. In situ hybridization studies with mouse embryo sections show that high level expression of VLGR1 is restricted to the developing central nervous system and eye. Strong expression in the ventricular zone, home of neural progenitor cells during embryonal neurogenesis, suggests a fundamental role for VLGR1 in the development of the central nervous system.	Univ Texas, SW Med Ctr, Div Pediat Endocrinol, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol & Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	White, PC (corresponding author), Univ Texas, SW Med Ctr, Div Pediat Endocrinol, Dept Pediat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Perrin.White@UTSouthwestern.edu						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; FernandezBusquets X, 1997, J BIOL CHEM, V272, P27839, DOI 10.1074/jbc.272.44.27839; Gao FB, 2000, NEURON, V28, P91, DOI 10.1016/S0896-6273(00)00088-X; HODGKIN J, 1995, SCIENCE, V270, P410, DOI 10.1126/science.270.5235.410; Jarchow J, 1998, CELL ADHES COMMUN, V6, P405, DOI 10.3109/15419069809109149; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KELLER CS, 1995, CURR OPIN CELL BIOL, V7, P32, DOI 10.1016/0955-0674(95)80042-5; Kirkpatrick LL, 2000, J BIOL CHEM, V275, P17786, DOI 10.1074/jbc.M002254200; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Levers TE, 2001, J NEUROBIOL, V48, P265, DOI 10.1002/neu.1056; Long MY, 1998, P NATL ACAD SCI USA, V95, P219, DOI 10.1073/pnas.95.1.219; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; Morris SC, 2000, P NATL ACAD SCI USA, V97, P4426, DOI 10.1073/pnas.97.9.4426; Nikkila H, 2000, MOL ENDOCRINOL, V14, P1351, DOI 10.1210/me.14.9.1351; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Shelton JM, 2000, J LIPID RES, V41, P532; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; Skradski SL, 2001, NEURON, V31, P537, DOI 10.1016/S0896-6273(01)00397-X; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Sudhof TC, 2001, ANNU REV NEUROSCI, V24, P933, DOI 10.1146/annurev.neuro.24.1.933; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; Young P, 2001, J CELL BIOL, V154, P123, DOI 10.1083/jcb.200102110	31	110	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					785	792		10.1074/jbc.M108929200	http://dx.doi.org/10.1074/jbc.M108929200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11606593	hybrid			2022-12-25	WOS:000173087900101
J	Rager, N; Ben Mamoun, C; Carter, NS; Goldberg, DE; Ullman, B				Rager, N; Ben Mamoun, C; Carter, NS; Goldberg, DE; Ullman, B			Localization of the Plasmodium falciparum PfNT1 nucleoside transporter to the parasite plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2C; INFECTED ERYTHROCYTES; IDENTIFICATION; QUANTITATION; CLONING; TARGET; ASSAY	Nutrient transporters play critical roles in parasite metabolism, but the membranes in which they reside have not been clearly defined. The transport of purine nutrients is crucial to the survival of the malaria parasite Plasmodium falciparum, and nucleoside transport activity has been associated with a number of different membrane components within the parasitized erythrocyte. To determine the location of the PfNT1 nucleoside transporter, the first component of the nucleoside permeation pathway to be studied at the molecular level in P. falciparum (Carter, N. S., Ben Mamoun, C., Liu, W., Silva, E. O., Landfear, S. M., Goldberg, D. E., and Ullman, B. (2000) J. Biol. Chem. 275, 10683-10691), polyclonal antisera against the NH2-terminal 36 amino acids of PfNT1 were raised in rabbits. Western blot analysis of parasite lysates revealed that the antibodies were specific for PfNT1 and that the level of PfNT1 protein in the infected erythrocyte is regulated in a stage-specific fashion. The amount of PfNT1 polypeptide increases dramatically during the early trophozoite stage and reaches its maximal level in the late trophozoite and schizont stages. Deconvolution and immunoelectron microscopy using these monospecific antibodies revealed that PfNT1 localizes predominantly, if not exclusively, to the plasma membrane of the parasite and not to the parasitophorous vacuolar or erythrocyte membranes.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Connecticut, Sch Med, Ctr Microbial Pathogenesis, Farmington, CT 06030 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Oregon Health & Science University; University of Connecticut; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Ullman, B (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	ullmanb@ohsu.edu			NIAID NIH HHS [AI44138, AI23682] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044138, R01AI023682, R37AI023682] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARD DA, 2001, METHOD CELL BIOL, V30, P353; Ben Mamoun C, 2001, MOL MICROBIOL, V39, P973, DOI 10.1046/j.1365-2958.2001.02289.x; Ben Mamoun C, 1998, J BIOL CHEM, V273, P11241, DOI 10.1074/jbc.273.18.11241; Beresford RM, 1995, P NZ PLAN P, V48, P89, DOI 10.30843/nzpp.1995.48.11498; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carter NS, 2000, J BIOL CHEM, V275, P10683, DOI 10.1074/jbc.275.14.10683; Desai SA, 2000, NATURE, V406, P1001, DOI 10.1038/35023000; ENGVALL E, 1972, J IMMUNOL, V109, P129; GERO AM, 1988, MOL BIOCHEM PARASIT, V27, P159, DOI 10.1016/0166-6851(88)90035-7; GERO AM, 1990, BLOOD CELLS, V16, P467; GERO AM, 1994, ADV EXP MED BIOL, V370, P493; Gero AM, 1999, NUCLEOS NUCLEOT, V18, P885, DOI 10.1080/15257779908041593; GERO AM, 1994, PARASITOL TODAY, V10, P395, DOI 10.1016/0169-4758(94)90231-3; GINSBURG H, 1998, MALARIA PARASITE BIO, P219; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HALDAR K, 1994, PARASITOL TODAY, V10, P393, DOI 10.1016/0169-4758(94)90230-5; JAY D, 1986, ANNU REV BIOCHEM, V55, P511, DOI 10.1146/annurev.bi.55.070186.002455; Kirk K, 2001, PHYSIOL REV, V81, P495, DOI 10.1152/physrev.2001.81.2.495; KIRK K, 1995, BIOCHEM J, V311, P761, DOI 10.1042/bj3110761; KIRK K, 1994, J BIOL CHEM, V269, P3339; Kirk K, 1999, PARASITOL TODAY, V15, P355, DOI 10.1016/S0169-4758(99)01495-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Lauer SA, 1997, SCIENCE, V276, P1122, DOI 10.1126/science.276.5315.1122; Mamoun CB, 2001, MOL MICROBIOL, V39, P26, DOI 10.1046/j.1365-2958.2001.02222.x; Parker MD, 2000, BIOCHEM J, V349, P67, DOI 10.1042/0264-6021:3490067; Ringwald P, 1999, J CLIN MICROBIOL, V37, P700, DOI 10.1128/JCM.37.3.700-705.1999; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; UPSTON JM, 1995, BBA-BIOMEMBRANES, V1236, P249, DOI 10.1016/0005-2736(95)00055-8; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; WHO Expert Committee on Malaria, 2000, WHO TECH REP SER, V892, P1; Woodrow CJ, 1999, J BIOL CHEM, V274, P7272, DOI 10.1074/jbc.274.11.7272; [No title captured]	36	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41095	41099		10.1074/jbc.M107037200	http://dx.doi.org/10.1074/jbc.M107037200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11682491	hybrid			2022-12-25	WOS:000171925600097
J	Romano, M; Catalano, A; Nutini, M; D'Urbano, E; Crescenzi, C; Claria, J; Libner, R; Davi, G; Procopio, A				Romano, M; Catalano, A; Nutini, M; D'Urbano, E; Crescenzi, C; Claria, J; Libner, R; Davi, G; Procopio, A			5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor	FASEB JOURNAL			English	Article						mesothelioma; arachidonic acid; apoptosis; angiogenesis; eicosanoids	IN-VITRO; CANCER-CELLS; COLON-CANCER; ANTISENSE OLIGONUCLEOTIDES; EXPRESSION; INHIBITION; 12-LIPOXYGENASE; TRANSFORMATION; LIPOXYGENASES; ANGIOGENESIS	Evidence indicates that lipoxygenases (LO) may play a role in cancer cell survival. We show that human malignant pleural mesothelial (MM) cells, but not normal mesothelial (NM) cells, express a catalytically active 5-LO. Pharmacological or genetic inhibition of MM cell 5-LO determined nucleosome formation and induced a DNA fragmentation pattern typical of apoptosis. This was completely reversed by exogenously added 5(S)-HETE but not by 12(S)-, 15(S) HETE, or leukotriene (LT)B(4). A 5-LO antisense oligonucleotide potently and time-dependently reduced vascular endothelial growth factor (VEGF) mRNA and constitutive VEGF accumulation in the conditioned media of MM cells. When NM cells were transfected with a 5-LO cDNA, basal and arachidonic acid-induced VEGF formation increased consistently by 6- and 12-fold, respectively. This was associated with a significant increase in DNA synthesis that was counteracted by a specific anti-VEGF antibody. Arachidonic acid and 5(S) HETE also potently stimulated the activity of a VEGF promoter construct. Thus, 5-LO is a key regulator of MM cell proliferation and survival via a VEGF-related circuit.	Univ Messina, Dept Human Pathol, Messina, Italy; Univ Ancona, Inst Expt Pathol, I-60128 Ancona, Italy; Univ G DAnnunzio, Dept Med & Aging, Chieti, Italy; Hosp Clin Barcelona, DNA Unit, Barcelona, Spain; City Hosp, Dept Pathol, Alessandria, Italy	University of Messina; Marche Polytechnic University; G d'Annunzio University of Chieti-Pescara; University of Barcelona; Hospital Clinic de Barcelona	Romano, M (corresponding author), Univ G DAnnunzio, Cattedra Ematol, Dipartimento Med & Sci Invecchiamento, Via Vestini 31, I-66013 Chieti, Italy.	mromano@unich.it	Procopio, Antonio Domenico/AAB-2451-2021; Claria, Joan/M-7772-2019; Romano, Mario/I-7986-2012	Procopio, Antonio Domenico/0000-0001-6897-8724; Romano, Mario/0000-0001-8512-1458; Claria, Joan/0000-0003-4333-7749				Attanoos RL, 1997, HISTOPATHOLOGY, V30, P403, DOI 10.1046/j.1365-2559.1997.5460776.x; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581; Ding XZ, 1999, BIOCHEM BIOPH RES CO, V261, P218, DOI 10.1006/bbrc.1999.1012; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Froom P, 2000, J OCCUP ENVIRON MED, V42, P19, DOI 10.1097/00043764-200001000-00007; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; Ho L, 2001, Cancer Treat Res, V105, P327; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; Kumar-Singh S, 1999, J PATHOL, V189, P72, DOI 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Langerak AW, 1996, J PATHOL, V178, P151; LEE TC, 1993, CANCER RES, V53, P2858; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; MANNING LS, 1991, CLIN EXP IMMUNOL, V83, P85; Marrogi A, 2000, CANCER RES, V60, P3696; Marzo AL, 1997, CANCER RES, V57, P3200; Masferrer JL, 2000, CANCER RES, V60, P1306; Natarajan R, 1997, AM J PHYSIOL-HEART C, V273, pH2224, DOI 10.1152/ajpheart.1997.273.5.H2224; Nie DT, 2000, BLOOD, V95, P2304, DOI 10.1182/blood.V95.7.2304.007k23_2304_2311; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Park S, 1998, CANCER LETT, V127, P23, DOI 10.1016/S0304-3835(97)00543-0; ROMANO M, 1992, BIOCHEMISTRY-US, V31, P8269, DOI 10.1021/bi00150a021; ROMANO M, 1993, BIOCHEM J, V296, P127, DOI 10.1042/bj2960127; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; Testa JR, 1998, CANCER RES, V58, P4505; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; Zebrowski BK, 1999, CLIN CANCER RES, V5, P3364	39	101	105	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2326	2336		10.1096/fj.01-0150com	http://dx.doi.org/10.1096/fj.01-0150com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689458				2022-12-25	WOS:000172420500003
J	Clarke, P; Meintzer, SM; Spalding, AC; Johnson, GL; Tyler, KL				Clarke, P; Meintzer, SM; Spalding, AC; Johnson, GL; Tyler, KL			Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection	ONCOGENE			English	Article						apoptosis; TRAIL; reovirus; caspase 8; chemotherapy	INFLUENZA-VIRUS INFECTION; NECROSIS-FACTOR-ALPHA; TUMORICIDAL ACTIVITY; SIGNALING PATHWAY; DEATH RECEPTORS; MOLECULAR-BASIS; LIGAND; EXPRESSION; ACTIVATION; MODULATION	TRAIL (TNF-related apoptosis-inducing ligand) induces apoptosis in susceptible cells by binding to death receptors 4 (DR4) and 5 (DR5). TRAIL preferentially induces apoptosis in transformed cells and the identification of mechanisms by which TRAIL-induced apoptosis can be enhanced may lead to novel cancer chemotherapeutic strategies. Here we show that reovirus infection induces apoptosis in cancer cell lines derived from human breast, lung and cervical cancers. Reovirus-induced apoptosis is mediated by TRAIL and is associated with the release of TRAIL from infected cells. Reovirus infection synergistically and specifically sensitizes cancer cell lines to killing by exogenous TRAIL. This sensitization both enhances the susceptibility of previously resistant cell lines to TRAIL-induced apoptosis and reduces the amount of TRAIL needed to kill already sensitive lines. Sensitization is not associated with a detectable change in the expression of TRAIL. receptors in reovirus-infected cells. Sensitization is associated with an increase in the activity of the death receptor-associated initiator caspase. caspase 8, and is inhibited by the peptide IETD-fmk, suggesting that reovirus sensitizes cancer cells to TRAIL-induced apoptosis in a caspase 8-dependent manner. Reovirus-induced sensitization of cells to TRAIL is also associated with increased cleavage of PARP, a substrate of the effector caspases 3 and 7.	Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med Microbiol & Immunol, Denver, CO 80262 USA; Denver Vet Affairs Med Ctr, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Tyler, KL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Neurol B 182, 4200 E 9th Ave, Denver, CO 80262 USA.		Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014071] Funding Source: NIH RePORTER; NIA NIH HHS [1RO1AG14071] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Conaldi PG, 1998, J CLIN INVEST, V102, P2041, DOI 10.1172/JCI3480; Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000; Cuello M, 2001, GYNECOL ONCOL, V81, P380, DOI 10.1006/gyno.2001.6194; DeBiasi RL, 2001, J VIROL, V75, P351, DOI 10.1128/JVI.75.1.351-361.2001; Debiasi RL, 1999, J VIROL, V73, P695, DOI 10.1128/JVI.73.1.695-701.1999; DUKE RC, 1992, CURRENT PROTOCOLS IM; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Jelachich ML, 2001, J VIROL, V75, P5930, DOI 10.1128/JVI.75.13.5930-5938.2001; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kaplan D, 1998, J VIROL, V72, P6279, DOI 10.1128/JVI.72.8.6279-6282.1998; Keane MM, 1999, CANCER RES, V59, P734; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Oberhaus SM, 1997, J VIROL, V71, P2100, DOI 10.1128/JVI.71.3.2100-2106.1997; OBERHAUS SM, 1998, CURRENT TOPICS MICRO, V233; Ozoren N, 2000, CANCER RES, V60, P6259; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rayet B, 1998, J VIROL, V72, P8893, DOI 10.1128/JVI.72.11.8893-8903.1998; Sedger LM, 1999, J IMMUNOL, V163, P920; Sieg S, 1996, J VIROL, V70, P8747, DOI 10.1128/JVI.70.12.8747-8751.1996; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; TAKIZAWA T, 1995, VIROLOGY, V209, P288, DOI 10.1006/viro.1995.1260; TAKIZAWA T, 1993, J GEN VIROL, V74, P2347, DOI 10.1099/0022-1317-74-11-2347; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; TYLER KL, 1985, NEUROLOGY, V35, P88, DOI 10.1212/WNL.35.1.88; Tyler KL, 1996, J VIROL, V70, P7984, DOI 10.1128/JVI.70.11.7984-7991.1996; TYLER KL, 1995, J VIROL, V69, P6972, DOI 10.1128/JVI.69.11.6972-6979.1995; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang GH, 1997, J VIROL, V71, P8928, DOI 10.1128/JVI.71.11.8928-8932.1997; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yu R, 2000, CANCER RES, V60, P2384; Zhang XD, 1999, CANCER RES, V59, P2747	43	51	54	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6910	6919		10.1038/sj.onc.1204842	http://dx.doi.org/10.1038/sj.onc.1204842			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687970				2022-12-25	WOS:000171641000012
J	Tarapore, P; Tokuyama, Y; Horn, HF; Fukasawa, K				Tarapore, P; Tokuyama, Y; Horn, HF; Fukasawa, K			Difference in the centrosome duplication regulatory activity among p53 'hot spot' mutants: potential role of Ser 315 phosphorylation-dependent centrosome binding of p53	ONCOGENE			English	Article						centrosome duplication; cancer; p53; CDK2; phosphorylation	TRANSCRIPTIONAL ACTIVATION; GENOMIC INSTABILITY; EMBRYO FIBROBLASTS; CYCLIN-E; HYPERAMPLIFICATION; MUTATIONS; CANCER; MICE; CDK2; P21	The p53 tumor suppressor protein regulates centrosome duplication through multiple pathways, and p21(Waf1/Cip1) (Waf1), a major target of p53's transactivation function, has been shown to be one of the effectors. However, it had been unclear whether the p53's Waf1-independent centrosome duplication regulatory pathways require its transactivation function. In human cancers, specific residues of p53 are mutated at a high frequency. These 'hot spot' mutations abrogate p53's transactivation function. If p53 regulates centrosome duplication in a transactivation-independent manner, different 'hot spot' mutants may regulate centrosome duplication differently. To test this, we examined the effect of two 'hot spot' mutants (R175H and R249S) for their centrosome duplication regulatory activities. We found that R175H lost the ability to regulate centrosome duplication, while R249S partially retained it. Moreover, R249S associates with both unduplicated and duplicated centrosomes similar to wild-type p53, while R175H only associates with duplicated, but not unduplicated centrosomes. Since cyclin-dependent kinase 2 (CDK2) triggers initiation of centrosome duplication, and p53 is phosphorylated on Ser 315 by CDK2, we examined the p53 mutants with a replacement of Ser 315 to Ala (A) and Asp (D), both of which retain the transactivation function. We found that S315D retained a complete centrosome duplication activity, while S315A only partially retained it. Moreover, S315D associates with both unduplicated and duplicated centrosomes, while S315A associates with only duplicated, but not unduplicated centrosomes. Thus, p53 controls the centrosome duplication cycle both in transactivation-dependent and transactivation-independent manners, and the ability to bind to unduplicated centrosomes, which is controlled by phosphorylation on Ser 315, may be important for the overall p53-mediated regulation of centrosome duplication.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.	Kenji.Fukasawa@uc.edu	Tarapore, Pheruza/A-8876-2013	Tarapore, Pheruza/0000-0003-0911-3661; Horn, Henning/0000-0002-5885-8996	NCI NIH HHS [CA90522] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090522] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; AHNEN DJ, 1992, J CELL BIOCHEM, P143; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bates S, 1999, MOL CARCINOGEN, V24, P7, DOI 10.1002/(SICI)1098-2744(199901)24:1<7::AID-MC2>3.0.CO;2-5; BORNENS M, 1992, KALNINS, V6, P2; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge RM, 1998, BREAST CANCER RES TR, V52, P79, DOI 10.1023/A:1006163101948; FUCHS B, 1995, ONCOGENE, V10, P789; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KIKUCHIYANOSHITA R, 1995, ONCOGENE, V11, P1339; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lange BMH, 2000, CURR TOP DEV BIOL, V49, P235; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MAZIA D, 1987, INT REV CYTOL, V100, P49; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mowat MRA, 1998, ADV CANCER RES, V74, P25, DOI 10.1016/S0065-230X(08)60764-2; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nylander K, 2000, J ORAL PATHOL MED, V29, P413, DOI 10.1034/j.1600-0714.2000.290901.x; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ozen H, 2000, CURR OPIN ONCOL, V12, P255, DOI 10.1097/00001622-200005000-00012; PRICE BD, 1995, ONCOGENE, V11, P73; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sluder G, 2000, CURR TOP DEV BIOL, V49, P267; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Urbani L, 1999, CURR BIOL, V9, pR315, DOI 10.1016/S0960-9822(99)80201-2; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; VET JAM, 1994, WORLD J UROL, V12, P84; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; WILLIAMS NN, 1990, SURG GYNECOL OBSTET, V171, P257; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	59	44	45	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6851	6863		10.1038/sj.onc.1204848	http://dx.doi.org/10.1038/sj.onc.1204848			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687964				2022-12-25	WOS:000171641000006
J	Wallin, R; Hutson, SM; Cain, D; Sweatt, A; Sane, DC				Wallin, R; Hutson, SM; Cain, D; Sweatt, A; Sane, DC			A molecular mechanism for genetic warfarin resistance in the rat	FASEB JOURNAL			English	Article						vitamin K; warfarin; vitamin K-dependent proteins	K-DEPENDENT CARBOXYLASE; EPOXIDE REDUCTASE; BINDING-PROTEIN; 2,3-EPOXIDE REDUCTASE; SECRETORY PATHWAY; HUMAN-LIVER; VITAMIN; METABOLISM; PROTHROMBIN; CALUMENIN	Warfarin targets vitamin K 2,3-epoxide reductase (VKOR), the enzyme that produces reduced vitamin K, a required cofactor for gamma -carboxylation of vitamin K-dependent proteins. To identify VKOR, we used 4'-azido-warfarin-H-3-alcohol as an affinity label. When added to a partially purified preparation of VKOR, two proteins were identified by mass spectrometry as calumenin and cytochrome B-5. Rat calumenin was cloned and sequenced and the recombinant protein was produced. When added to an in vitro test system, the 47 kDa recombinant protein was found to inhibit VKOR activity and to protect the enzyme from warfarin inhibition. Calumenin was also shown to inhibit the overall activity of the complete vitamin K-dependent gamma -carboxylation system. The results were repeated in COS-1 cells overexpressing recombinant calumenin. By comparing calumenin mRNA levels in various tissues from normal rats and warfarin-resistant rats, only the livers from resistant rats were different from normal rats by showing increased levels. Partially purified VKOR from resistant and normal rat livers showed no differences in Km-values, specific activity, and sensitivity to warfarin. A novel model for genetic warfarin resistance in the rat is proposed, whereby the concentration of calumenin in liver determines resistance.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Wallin, R (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rwallin@wfubmc.edu						ALMONDHIRY H, 1989, THROMB HAEMOSTASIS, V62, P661; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Begent LA, 2001, J PHARM PHARMACOL, V53, P481, DOI 10.1211/0022357011775776; Cain D, 1998, THROMB HAEMOSTASIS, V80, P128, DOI 10.1055/s-0037-1615151; CAIN D, 1998, J BIOL CHEM, V273, P4982; DEBOERVANDENBERG MAG, 1986, BIOCHIM BIOPHYS ACTA, V884, P150, DOI 10.1016/0304-4165(86)90238-2; Dockal M, 2000, PROTEIN SCI, V9, P1455, DOI 10.1110/ps.9.8.1455; DODDS D, 1995, J NEUROCHEM, V64, P2339; DOWD P, 1995, SCIENCE, V269, P1684, DOI 10.1126/science.7569894; FASCO MJ, 1983, BIOCHEMISTRY-US, V22, P5655, DOI 10.1021/bi00293a031; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HERMODSON MA, 1969, AM J PHYSIOL, V217, P1316, DOI 10.1152/ajplegacy.1969.217.5.1316; HILDEBRANDT EF, 1982, BIOCHEMISTRY-US, V21, P2406, DOI 10.1021/bi00539a020; Honore B, 2000, FEBS LETT, V466, P11, DOI 10.1016/S0014-5793(99)01780-9; Imai T, 1997, BIOCHEM BIOPH RES CO, V233, P765, DOI 10.1006/bbrc.1997.6531; Kaminsky LS, 1997, PHARMACOL THERAPEUT, V73, P67, DOI 10.1016/S0163-7258(96)00140-4; Kohn MH, 2000, BLOOD, V96, P1996, DOI 10.1182/blood.V96.5.1996.h8001996_1996_1998; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JJ, 1985, BIOCHEMISTRY-US, V24, P7063, DOI 10.1021/bi00346a007; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MYSZKA DG, 1991, J BIOL CHEM, V266, P20725; OBACH RS, 1992, ARCH BIOCHEM BIOPHYS, V294, P215, DOI 10.1016/0003-9861(92)90160-X; OREILLY RA, 1970, NEW ENGL J MED, V282, P1448, DOI 10.1056/NEJM197006252822602; PARK BK, 1988, BIOCHEM PHARMACOL, V37, P19, DOI 10.1016/0006-2952(88)90750-2; SILVERMAN RB, 1988, BIOCHEM BIOPH RES CO, V155, P1248, DOI 10.1016/S0006-291X(88)81274-9; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUTCLIFFE FA, 1990, CHEM-BIOL INTERACT, V75, P171, DOI 10.1016/0009-2797(90)90116-5; Suttie J W, 1987, Adv Exp Med Biol, V214, P3; Suttie J. W., 1978, Handbook of lipid research. Volume 2. The fat-soluble vitamins, P211; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; Taube J, 2000, BLOOD, V96, P1816, DOI 10.1182/blood.V96.5.1816.h8001816_1816_1819; THIJSSEN HHW, 1989, BIOCHEM PHARMACOL, V38, P1115, DOI 10.1016/0006-2952(89)90257-8; THIJSSEN HHW, 1991, BIOCHEM PHARMACOL, V42, P2181, DOI 10.1016/0006-2952(91)90354-8; Vorum H, 2000, FEBS LETT, V465, P129, DOI 10.1016/S0014-5793(99)01734-2; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; VORUM H, 1998, BIOCHIM BIOPHYS ACTA, V1368, P121; WALLACE ME, 1976, J HYG-CAMBRIDGE, V76, P173, DOI 10.1017/S0022172400055078; WALLIN R, 1985, J CLIN INVEST, V76, P1879, DOI 10.1172/JCI112182; WALLIN R, 1993, BIOCHEM J, V291, P723, DOI 10.1042/bj2910723; WALLIN R, 1990, BIOCHEM J, V272, P473, DOI 10.1042/bj2720473; WALLIN R, 1991, THROMB RES, V62, P235, DOI 10.1016/0049-3848(91)90144-L; WALLIN R, 1987, INT J BIOCHEM, V19, P1063, DOI 10.1016/0020-711X(87)90307-7; Wallin R, 1997, METHOD ENZYMOL, V282, P395; WALLIN R, 1987, BIOCHEM J, V241, P389, DOI 10.1042/bj2410389; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yabe D, 1997, J BIOL CHEM, V272, P18232, DOI 10.1074/jbc.272.29.18232	50	73	79	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2542	+		10.1096/fj.01-0337fje	http://dx.doi.org/10.1096/fj.01-0337fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641264				2022-12-25	WOS:000171372700024
J	Chen, EI; Kridel, SJ; Howard, EW; Li, WZ; Godzik, A; Smith, JW				Chen, EI; Kridel, SJ; Howard, EW; Li, WZ; Godzik, A; Smith, JW			A unique substrate recognition profile for matrix metalloproteinase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST COLLAGENASE; SEQUENCE SPECIFICITIES; CATALYTIC DOMAIN; TISSUE INHIBITOR; TERMINAL DOMAIN; TYROSINE KINASE; DRUG DESIGN; ACTIVATION; SITE; LOCALIZATION	The catalytic domains of the matrix metalloproteinases (MMPs) are structurally homologous, raising questions as to the degree of distinction, or overlap, in substrate recognition. The primary objective of the present study was to define the substrate recognition profile of MMP-2, a protease that was historically referred to as gelatinase A. By cleaving a phage peptide library with recombinant MMP-2, four distinct sets of substrates were identified. The first set is structurally related to substrates previously reported for other MMPs These substrates contain the PXX down arrow X-Hy consensus motif (where X-Hy is a hydrophobic residue) and are not generally selective for MMP-2 over the other MMPs tested. Two other groups of substrates were selected from the phage library with similar frequency. Substrates in group II contain the L/IXX down arrow X-Hy consensus motif. Substrates in group III contain a consensus motif with a sequence of XHySX down arrow L, and the fourth set of substrates contain the HXX down arrow X-Hy sequence. Substrates in Group II, III, and IV were found to be 8- to almost 200-fold more selective for MMP-2 over MMP-9. To gain an understanding of the structural basis for substrate selectivity, individual residues within substrates were mutated, revealing that the P-2 residue is a key element in conferring selectivity. These findings indicate that MMP-2 and MMP-9 exhibit different substrate recognition profiles and point to the P-2 subsite as a primary determinant in substrate distinction.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA	Sanford Burnham Prebys Medical Discovery Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center	Smith, JW (corresponding author), Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA.		Godzik, Adam/A-7279-2009; Godzik, Adam/AAW-1467-2020; Li, Weizhong/A-9735-2008	Godzik, Adam/0000-0002-2425-852X; Godzik, Adam/0000-0002-2425-852X; Li, Weizhong/0000-0003-1804-9403	NCI NIH HHS [CA82713, CA69306, CA30199] Funding Source: Medline; NIAMS NIH HHS [AR42750] Funding Source: Medline; NIGMS NIH HHS [GM60049] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA082713, P30CA030199, R01CA069306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060049] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Brown PD, 1995, ANN ONCOL, V6, P967, DOI 10.1093/oxfordjournals.annonc.a059091; Coombs GS, 1998, CHEM BIOL, V5, P475, DOI 10.1016/S1074-5521(98)90004-7; Deng SJ, 2000, J BIOL CHEM, V275, P31422, DOI 10.1074/jbc.M004538200; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; Fernandez-Patron C, 1999, THROMB HAEMOSTASIS, V82, P1730, DOI 10.1055/s-0037-1614906; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749-6632.1994.tb24746.x; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; GREENWALD RA, 1999, ANN NY ACAD SCI, V878; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Itoh T, 1998, CANCER RES, V58, P1048; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; Massova I, 1997, J MOL MODEL, V3, P17, DOI 10.1007/s008940050021; MCGEEHAN GM, 1995, METHOD ENZYMOL, V248, P35; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Nemunaitis J, 1998, CLIN CANCER RES, V4, P1101; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; PARKS CW, 1998, MATRIX METALLOPROTEI; Parsons SL, 1997, EUR J SURG ONCOL, V23, P526, DOI 10.1016/S0748-7983(97)93077-8; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; STOCKER W, 1995, PROTEIN SCI, V4, P823; TANG XX, 1995, GENOMICS, V29, P426, DOI 10.1006/geno.1995.9985; Zhang BH, 1999, PROTEIN SCI, V8, P1104, DOI 10.1110/ps.8.5.1104	40	97	114	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4485	4491		10.1074/jbc.M109469200	http://dx.doi.org/10.1074/jbc.M109469200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11694539	hybrid			2022-12-25	WOS:000173813900091
J	Liu, CH; Martin, CT				Liu, CH; Martin, CT			Promoter clearance by T7 RNA polymerase - Initial bubble collapse and transcript dissociation monitored by base analog fluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION COMPLEX; ENERGY-TRANSFER; DNA HYBRID; BACTERIOPHAGE-T7; 2-AMINOPURINE; TRANSITIONS; STABILITY; BINDING	Footprinting, fluorescence, and x-ray structural information from the initial, promoter-bound complex of T7 RNA polymerasc describes the very beginning of the initiation of transcription, whereas recent fluorescence and biochemical studies paint a preliminary picture of an elongation complex. The current work focuses on the transition from an initially transcribing, promoter-bound complex to an elongation complex clear of the promoter. Fluorescence quenching is used to follow the melted state of the DNA bubble, and a novel approach using a locally mismatched fluorescent base analog reports on the local structure of the heteroduplex. Fluorescent base analogs placed at positions -2 and -1 of the promoter indicate that this initially melted, non-transcribed region remains melted as the polymerase translocates through to position +8. In progressing to position +9, this region of the DNA bubble begins to collapse. Probes placed at positions +1 and +2 of the template strand indicate that the 5' end of the RNA remains in a heteroduplex as the complex translocates to position +10. Subsequent translocation leads to sequential dissociation of the first 2 bases of the RNA. These results show that the initially transcribing complex bubble can reach a size of up to 13 base pairs and a maximal heteroduplex length of 10 base pairs. They further indicate that initial bubble collapse precedes dissociation of the 5' end of the RNA.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Martin, CT (corresponding author), Univ Massachusetts, Dept Chem, 710 N Pleasant St, Amherst, MA 01003 USA.		Martin, Craig T/L-3596-2013	Martin, Craig T/0000-0003-1029-5239	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055002] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01GM55002] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bandwar RP, 2001, J BIOL CHEM, V276, P14075, DOI 10.1074/jbc.M011289200; BIERZYNSKI A, 1977, BIOPHYS CHEM, V6, P223, DOI 10.1016/0301-4622(77)85003-5; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Ebright RH, 2000, J MOL BIOL, V304, P687, DOI 10.1006/jmbi.2000.4309; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; Kireeva ML, 2000, J BIOL CHEM, V275, P6530, DOI 10.1074/jbc.275.9.6530; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Liu CH, 2001, J MOL BIOL, V308, P465, DOI 10.1006/jmbi.2001.4601; Mentesana PE, 2000, J MOL BIOL, V302, P1049, DOI 10.1006/jmbi.2000.4114; NORDLUND TM, 1993, BIOCHEMISTRY-US, V32, P12090, DOI 10.1021/bi00096a020; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P946, DOI 10.1021/bi001664o; SCHICK C, 1993, BIOCHEMISTRY-US, V32, P4275, DOI 10.1021/bi00067a016; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; Sullivan JJ, 1997, BIOCHEMISTRY-US, V36, P8005, DOI 10.1021/bi970363k; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; Ujvari A, 1996, BIOCHEMISTRY-US, V35, P14574, DOI 10.1021/bi961165g; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; XU DG, 1994, BIOCHEMISTRY-US, V33, P9592, DOI 10.1021/bi00198a027; Xu DG, 2000, BIOPHYS J, V78, P1042, DOI 10.1016/S0006-3495(00)76663-X; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	32	96	97	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2725	2731		10.1074/jbc.M108856200	http://dx.doi.org/10.1074/jbc.M108856200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11694519	hybrid			2022-12-25	WOS:000173421500047
J	Dowell, P; Cooke, DW				Dowell, P; Cooke, DW			Olf-1/Early B cell factor is a regulator of glut4 gene expression in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE TRANSPORTER; TRANSCRIPTION FACTOR; MESSENGER-RNA; INSULIN-RESISTANCE; ADIPOSE-TISSUE; MEDIATES REPRESSION; TRANSGENIC MICE; FUNCTIONAL-CHARACTERIZATION; NEURONAL DEVELOPMENT; MOLECULAR-CLONING	A negative regulatory element in the 5'-flanking region of the murine glut4 gene mediates chronic insulin and cAMP-induced repression in 3T3-L1 adipocytes. Previous work demonstrated that members of the nuclear factor 1 (NF1) family of transcription factors and an unidentified factor bind to and mediate repression from this regulatory element. By using a yeast one-hybrid screen, Olf-1/Early B cell factor (O/E-1) was isolated as a candidate for this unidentified factor. A protein complex from 3T3-L1 adipocyte nuclear extract that bound the negative regulatory element was recognized by O/E-specific antiserum, and binding activity was competed effectively by distinct O/E-binding sequences. O/E binding activity was also detected in nuclear extracts from insulin-responsive, GLUT4-expressing tissues including adipose, skeletal muscle, and heart. Mutations within the negative regulatory element that abolish binding of O/E proteins concomitantly blocked insulin-induced repression in reporter gene assays. These results suggest that one or more members of the O/E transcription factor family function as important regulators of glut4 gene expression and therefore may play a heretofore unanticipated role in glucose homeostasis and insulin signaling.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Cooke, DW (corresponding author), Dept Pediat, Pk 211,600 N Wolfe St, Baltimore, MD 21287 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055831, R01DK038418, F32DK009894] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55831, DK09894, DK38418] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Alquier T, 2001, NEUROSCI LETT, V308, P75, DOI 10.1016/S0304-3940(01)01936-X; ASSIMACOPOULOSJEANNET F, 1995, METABOLISM, V44, P228, DOI 10.1016/0026-0495(95)90270-8; Bally-Cuif L, 1998, MECH DEVELOP, V77, P85, DOI 10.1016/S0925-4773(98)00144-0; Baumeister H, 1999, MOL BRAIN RES, V72, P65, DOI 10.1016/S0169-328X(99)00210-7; Behrens M, 2000, EUR J NEUROSCI, V12, P1372, DOI 10.1046/j.1460-9568.2000.00032.x; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; Brachmann CB, 1998, YEAST, V14, P115; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Cooke DW, 1999, J BIOL CHEM, V274, P12917, DOI 10.1074/jbc.274.18.12917; Cooke DW, 1999, BIOCHEM BIOPH RES CO, V260, P600, DOI 10.1006/bbrc.1999.0959; Cooke DW, 1998, J BIOL CHEM, V273, P6210, DOI 10.1074/jbc.273.11.6210; Crozatier M, 1996, CURR BIOL, V6, P707, DOI 10.1016/S0960-9822(09)00452-7; CUSIN I, 1990, ENDOCRINOLOGY, V127, P3246, DOI 10.1210/endo-127-6-3246; Davis JA, 1996, J NEUROSCI, V16, P5082; Dubois L, 1998, CURR BIOL, V8, P199, DOI 10.1016/S0960-9822(98)70084-3; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1992, DIABETES, V41, P465, DOI 10.2337/diabetes.41.4.465; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; HAGMAN J, 1995, EMBO J, V14, P2907, DOI 10.1002/j.1460-2075.1995.tb07290.x; HELDERMAN JH, 1978, EUR J IMMUNOL, V8, P589, DOI 10.1002/eji.1830080810; HELDERMAN JH, 1978, NATURE, V274, P62, DOI 10.1038/274062a0; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; Kassam A, 1998, MOL CELL ENDOCRINOL, V141, P153, DOI 10.1016/S0303-7207(98)00085-9; KRUG U, 1972, P NATL ACAD SCI USA, V69, P2604, DOI 10.1073/pnas.69.9.2604; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Marcus Sandra L., 1995, Gene Expression, V4, P227; MARKS HERBERT H., 1960, BULL NEW YORK ACAD MED, V36, P296; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Oshel KM, 2000, J BIOL CHEM, V275, P23666, DOI 10.1074/jbc.M001452200; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; Pozzoli O, 2001, DEV BIOL, V233, P495, DOI 10.1006/dbio.2001.0230; Prasad BC, 1998, DEVELOPMENT, V125, P1561; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; SIVITZ WI, 1990, MOL ENDOCRINOL, V4, P583, DOI 10.1210/mend-4-4-583; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TANAKA S, 1993, INT J OBESITY, V17, P631; Thomson MJ, 1997, J BIOL CHEM, V272, P7759, DOI 10.1074/jbc.272.12.7759; TRAVIS A, 1993, MOL CELL BIOL, V13, P3392, DOI 10.1128/MCB.13.6.3392; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Tsunoda N, 1997, BIOCHEM BIOPH RES CO, V239, P503, DOI 10.1006/bbrc.1997.7516; Unger JW, 1998, HISTOL HISTOPATHOL, V13, P1215, DOI 10.14670/HH-13.1215; Vannucci SJ, 1998, BRAIN RES, V797, P1, DOI 10.1016/S0006-8993(98)00103-6; Vannucci SJ, 1997, GLIA, V21, P2, DOI 10.1002/(SICI)1098-1136(199709)21:1<2::AID-GLIA2>3.0.CO;2-C; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Wang SS, 1997, J NEUROSCI, V17, P4149; Wang Y, 1997, J MOL ENDOCRINOL, V19, P241, DOI 10.1677/jme.0.0190241	57	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1712	1718		10.1074/jbc.M108589200	http://dx.doi.org/10.1074/jbc.M108589200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11696544	hybrid			2022-12-25	WOS:000173421300014
J	Kwon, SH; Ahn, SH; Kim, YK; Bae, GU; Yoon, JW; Hong, S; Lee, HY; Lee, YW; Lee, HW; Han, JW				Kwon, SH; Ahn, SH; Kim, YK; Bae, GU; Yoon, JW; Hong, S; Lee, HY; Lee, YW; Lee, HW; Han, JW			Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE ACTIVITY; CYTOCHROME-C; DEATH; PROTEIN; BAX; P21(WAF1/CIP1); TRANSCRIPTION; ACETYLATION; CHROMATIN; CLEAVAGE	We previously reported that apicidin arrested human cancer cell growth through selective induction of p21(WAF1/Cip1). In this study, the apoptotic potential of apicidin and its mechanism in HL60 cells was investigated. Treatment of HL60 cells with apicidin caused a decrease in viable cell number in a dose-dependent manner and an increase in DNA fragmentation, nuclear morphological change, and apoptotic body formation, concomitant with progressive accumulation of hyper-acetylated histone H4. In addition, apicidin converted the procaspase-3 form to catalytically active effector protease, resulting in subsequent cleavages of poly(ADP-ribose) polymerase and p21(WAF1/Cip1). Incubation of HL60 cells with z-DEVD-fmk, a caspase-3 inhibitor, almost completely abrogated apicidin-induced activation of caspase-3, DNA fragmentation, and cleavages of poly(ADP-ribose) polymerase and p21(WAF1/Cip1). Moreover, these effects were preceded by an increase in translocation of Bax into the mitochondria, resulting in the release of cytochrome c and cleavage of procaspase-9. The addition of cycloheximide greatly inhibited activation of caspase-3 by apicidin by interfering with cleavage of procaspase-3 and DNA fragmentation, suggesting that apicidin-induced apoptosis was dependent on de novo protein synthesis. Consistent with these results, apicidin transiently increased the expressions of both Fas and Fas ligand. Preincubation with NOK-1 monoclonal antibody, which prevents the Fas-Fas ligand interaction and is inhibitory to Fas signaling, interfered with apicidin-induced translocation of Bax, cytochrome c release, cleavage of procaspase-3, and DNA fragmentation. Taken together, the results suggest that apicidin might induce apoptosis through selective induction of Fas/Fas ligand, resulting in the release of cytochrome c from the mitochondria to the cytosol and subsequent activation of caspase-9 and caspase-3.	Sungkyunkwan Univ, Coll Life Sci & Nat Resources, Coll Pharm, Dept Biochem & Mol Biol, Suwon 440746, South Korea; Sungkyunkwan Univ, Coll Life Sci & Nat Resources, Dept Genet, Suwon 440746, South Korea; Konyang Univ, Coll Med, Dept Pharmacol, Nonsan 320711, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea	Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Konyang University; Konyang University Hospital; Seoul National University (SNU)	Han, JW (corresponding author), Sungkyunkwan Univ, Coll Life Sci & Nat Resources, Coll Pharm, Dept Biochem & Mol Biol, Suwon 440746, South Korea.	jhhan@yurim.skku.ac.kr		Ahn, Seong-Hoon/0000-0002-9174-4966				ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cecconi F, 1999, CELL DEATH DIFFER, V6, P1087, DOI 10.1038/sj.cdd.4400602; COUSENS LS, 1979, J BIOL CHEM, V254, P1716; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DarkinRattray SJ, 1996, P NATL ACAD SCI USA, V93, P13143, DOI 10.1073/pnas.93.23.13143; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; Glick RD, 1999, CANCER RES, V59, P4392; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Gurtu V, 1997, ANAL BIOCHEM, V251, P98, DOI 10.1006/abio.1997.2220; Han JW, 2000, CANCER RES, V60, P6068; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Lan L, 1999, FEBS LETT, V444, P90, DOI 10.1016/S0014-5793(99)00032-0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mandal M, 1999, BIOCHEM BIOPH RES CO, V260, P775, DOI 10.1006/bbrc.1999.0966; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Medina V, 1997, CANCER RES, V57, P3697; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Nakamura S, 1999, ANTICANCER RES, V19, P197; NOGUCHI PD, 1978, J HISTOCHEM CYTOCHEM, V26, P761, DOI 10.1177/26.9.361885; Orlinick JR, 1997, J BIOL CHEM, V272, P32221, DOI 10.1074/jbc.272.51.32221; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; Park JS, 1999, APPL ENVIRON MICROB, V65, P126; Pawlowski J, 2000, P NATL ACAD SCI USA, V97, P529, DOI 10.1073/pnas.97.2.529; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; RAKESH D, 1997, J BIOL CHEM, V272, P1965; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Schneider P, 1997, J BIOL CHEM, V272, P18827, DOI 10.1074/jbc.272.30.18827; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Sun SY, 2000, CANCER RES, V60, P6537; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tian RH, 2000, FEBS LETT, V474, P11, DOI 10.1016/S0014-5793(00)01561-1; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang ZL, 1999, CANCER RES, V59, P1259; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; YOSHIDA H, 1992, JPN J CANCER RES, V83, P324, DOI 10.1111/j.1349-7006.1992.tb00109.x; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	51	185	203	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2073	2080		10.1074/jbc.M106699200	http://dx.doi.org/10.1074/jbc.M106699200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11698395	Green Published, hybrid			2022-12-25	WOS:000173421300063
J	Valls, M; Buckle, M; de Lorenzo, V				Valls, M; Buckle, M; de Lorenzo, V			In vivo UV laser footprinting of the Pseudomonas putida sigma(54) Pu promoter reveals that integration host factor couples transcriptional activity to growth phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TOL PLASMID; BINDING-SITES; REGULATOR-XYLR; CROSS-LINKING; PROTEIN; DNA; IHF; ACTIVATION; OPERON	The occupation of the sigma(54) -dependent Pu promoter of Pseudomonas putida by the integration host factor (IHF) under different growth conditions has been monitored in its native state and stoichiometry (i.e. monocopy) with UV laser footprinting technology. We present evidence that an abrupt change in intracellular IHF concentrations occurs when P. putida cells enter stationary phase. This change results in enhanced binding of the factor to the promoter and in the ensuing bending of the target DNA. Since Pu activity depends rigorously on DNA bending, promoter occupation is in turn translated into a much higher transcriptional output when cells leave exponential growth. Inspection of the residual activity of Pu in an IHF- strain reveals that IHF predominantly locks the capacity of the promoter to specific growth stages and also that additional physiological signals are entered in the system through sigma(54)- RNA polymerase. The results substantiate the notion that sigma(54) promoters process metabolic co-regulation signals through factor-induced changes in the architecture of the cognate DNA region. Further, they validate UV laser technology as a suitable tool to visualize nondisruptive alterations of DNA shape in vivo.	Consejo Super Investigac Cientificas, Ctr Nacl Biotecnol, Dept Microbial Biotechnol, Madrid 28049, Spain; CNRS, UMR 8532, Inst Gustave Roussy, F-94805 Villejuif, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	de Lorenzo, V (corresponding author), Consejo Super Investigac Cientificas, Ctr Nacl Biotecnol, Dept Microbial Biotechnol, Campus Cantoblanco, Madrid 28049, Spain.	vdlorenzo@cnb.uam.es	Valls, Marc/I-7285-2015	Valls, Marc/0000-0003-2312-0091; de Lorenzo, Victor/0000-0002-6041-2731				ABRIL MA, 1991, J BIOL CHEM, V266, P15832; Ausubel FM, 1994, CURRENT PROTOCOLS MO; AVIV M, 1994, MOL MICROBIOL, V14, P1021, DOI 10.1111/j.1365-2958.1994.tb01336.x; Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; Bartels F, 2001, J BIOL CHEM, V276, P16641, DOI 10.1074/jbc.M011295200; Bertoni G, 1998, EMBO J, V17, P5120, DOI 10.1093/emboj/17.17.5120; Boccard F, 2000, PRACT APPROACH SER, P201; Buckle M, 2000, PRACT APPROACH SER, P189; BUCKLE M, 1991, NUCLEIC ACIDS RES, V19, P833, DOI 10.1093/nar/19.4.833; Calb R, 1996, J BACTERIOL, V178, P6319, DOI 10.1128/jb.178.21.6319-6326.1996; Carmona M, 1999, MOL MICROBIOL, V31, P261, DOI 10.1046/j.1365-2958.1999.01169.x; Carmona M, 2000, J BACTERIOL, V182, P4711, DOI 10.1128/JB.182.17.4711-4718.2000; Cases I, 1998, CURR OPIN MICROBIOL, V1, P303, DOI 10.1016/S1369-5274(98)80034-9; Cases I, 1999, J BIOL CHEM, V274, P15562, DOI 10.1074/jbc.274.22.15562; Cases I, 1996, MOL MICROBIOL, V19, P7, DOI 10.1046/j.1365-2958.1996.345873.x; Cases I, 2001, EMBO J, V20, P1, DOI 10.1093/emboj/20.1.1; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; DITTO MD, 1994, J BACTERIOL, V176, P3738, DOI 10.1128/JB.176.12.3738-3748.1994; Engelhorn M, 1998, MOL MICROBIOL, V30, P431, DOI 10.1046/j.1365-2958.1998.01078.x; ENGELHORN N, 1995, NUCLEIC ACIDS RES, V23, P2959, DOI 10.1093/nar/23.15.2959; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; Hill SA, 1998, GENE, V215, P303, DOI 10.1016/S0378-1119(98)00285-6; HOCKENSMITH JW, 1993, J BIOL CHEM, V268, P15712; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEE EC, 1991, J BACTERIOL, V173, P609, DOI 10.1128/jb.173.2.609-617.1991; MARQUES S, 1994, J BACTERIOL, V176, P2517; Murtin C, 1998, J MOL BIOL, V284, P949, DOI 10.1006/jmbi.1998.2256; Pemberton IK, 2000, J MOL BIOL, V299, P859, DOI 10.1006/jmbi.2000.3780; PEREZMARTIN J, 1994, J BIOL CHEM, V269, P22657; PerezMartin J, 1997, ANNU REV MICROBIOL, V51, P593, DOI 10.1146/annurev.micro.51.1.593; PEREZMARTIN J, 1995, P NATL ACAD SCI USA, V92, P7277, DOI 10.1073/pnas.92.16.7277; PerezMartin J, 1997, J BACTERIOL, V179, P2757, DOI 10.1128/jb.179.8.2757-2760.1997; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Saier MH, 1998, BIOTECHNOL BIOENG, V58, P170, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<170::AID-BIT9>3.0.CO;2-I; Sze CC, 1999, MOL MICROBIOL, V31, P1217, DOI 10.1046/j.1365-2958.1999.01264.x; Sze CC, 2001, J BACTERIOL, V183, P2842, DOI 10.1128/JB.183.9.2842-2851.2001; Sze CC, 1996, J BACTERIOL, V178, P3727, DOI 10.1128/jb.178.13.3727-3735.1996; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; Weglenska A, 1996, GENE, V181, P85	44	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2169	2175		10.1074/jbc.M108162200	http://dx.doi.org/10.1074/jbc.M108162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11694511	hybrid			2022-12-25	WOS:000173421300076
J	Tillmar, L; Carlsson, C; Welsh, N				Tillmar, L; Carlsson, C; Welsh, N			Control of insulin mRNA stability in rat pancreatic islets - Regulatory role of a 3 '-untranslated region pyrimidine-rich sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; BETA-CELLS; BINDING-PROTEIN; GENE-TRANSCRIPTION; DIABETES-MELLITUS; RIN-5F CELLS; CYCLIC-AMP; GLUCOSE; EXPRESSION; TRACT	Stabilization of insulin mRNA in response to glucose is a significant component of insulin production, but the mechanisms governing this process are unknown. We presently observe that insulin mRNA is a highly abundant messenger and that the content of this mRNA is mainly controlled by changes in messenger stability. We also demonstrate specific binding of the polypyrimidine tract-binding protein to a pyrimidine-rich sequence located in the 3'-untranslated region (3'-UTR) of insulin mRNA. This binding was increased in vitro by dithiothreitol and in vivo by glucose. Inhibition of polypyrimidine tract-binding protein binding to the pyrimidine-rich sequence by mutation of the core binding site resulted in a destabilization of a reporter gene mRNA. Thus, glucose-induced binding of polypyrimidine tract-binding protein to the 3'-UTR of insulin mRNA could be a necessary event in the control of insulin mRNA levels.	Univ Uppsala, Dept Med Cell Biol, S-75123 Uppsala, Sweden	Uppsala University	Welsh, N (corresponding author), Uppsala Univ, Dept Med Cell Biol, Biomedicum, POB 571, SE-75123 Uppsala, Sweden.							ALBERTS B, 1994, MOL BIOL CELL, P369; ANDERSSON A, 1978, DIABETOLOGIA, V14, P397, DOI 10.1007/BF01228134; ASHCROFT SJH, 1978, BIOCHEM J, V174, P517, DOI 10.1042/bj1740517; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; BRUNSTEDT J, 1982, BIOCHEM BIOPH RES CO, V106, P1383, DOI 10.1016/0006-291X(82)91267-0; CHAN SJ, 1979, P NATL ACAD SCI USA, V76, P5036, DOI 10.1073/pnas.76.10.5036; CHEN M, 1993, J BIOL CHEM, V268, P24138; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; EIZIRIK DL, 1993, J CLIN ENDOCR METAB, V76, P399, DOI 10.1210/jc.76.2.399; Field LL, 1996, GENOMICS, V33, P1, DOI 10.1006/geno.1996.0153; GIDDINGS SJ, 1985, DIABETOLOGIA, V28, P343; Grossman JS, 1998, RNA, V4, P613, DOI 10.1017/S1355838298971448; Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; ITOH N, 1978, FEBS LETT, V93, P343, DOI 10.1016/0014-5793(78)81136-3; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; Kim YK, 2000, J MOL BIOL, V304, P119, DOI 10.1006/jmbi.2000.4179; Leibiger B, 2000, J BIOL CHEM, V275, P30153, DOI 10.1074/jbc.M005216200; Leibiger B, 1998, P NATL ACAD SCI USA, V95, P9307, DOI 10.1073/pnas.95.16.9307; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Moreira A, 1998, GENE DEV, V12, P2522, DOI 10.1101/gad.12.16.2522; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; RAIMONDI E, 1995, GENOMICS, V27, P553, DOI 10.1006/geno.1995.1093; ROSENBLUM, 1981, J MED PRIMATOL, V10, P93; ROSENBLUM IY, 1981, J MED PRIMATOL, V10, P93; Saldeen J, 1996, DIABETES, V45, P1197, DOI 10.2337/diabetes.45.9.1197; SEINO S, 1992, MOL BIOL EVOL, V9, P193; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; VALCARCEL J, 1997, CURR BIOL, V7, P705; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; WANG XM, 1995, MOL CELL BIOL, V15, P1769; Webb GC, 2000, P NATL ACAD SCI USA, V97, P5773, DOI 10.1073/pnas.100126597; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; WELSH M, 1985, J BIOL CHEM, V260, P3590; Wicksteed B, 2001, J BIOL CHEM, V276, P22553, DOI 10.1074/jbc.M011214200; Wollerton MC, 2001, RNA, V7, P819, DOI 10.1017/S1355838201010214	41	124	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1099	1106		10.1074/jbc.M108340200	http://dx.doi.org/10.1074/jbc.M108340200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11696543	hybrid			2022-12-25	WOS:000173166800030
J	Wang, BN; Lim, DJ; Han, JH; Kim, YS; Basbaum, CB; Li, JD				Wang, BN; Lim, DJ; Han, JH; Kim, YS; Basbaum, CB; Li, JD			Novel cytoplasmic proteins of nontypeable Haemophilus influenzae up-regulate human MUC5AC mucin transcription via a positive p38 mitogen-activated protein kinase pathway and a negative phosphoinositide 3-kinase-Akt pathway.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MIDDLE-EAR EFFUSIONS; PSEUDOMONAS-AERUGINOSA; OTITIS-MEDIA; HEMOPHILUS-INFLUENZAE; SIGNALING PATHWAYS; RESPIRATORY MUCINS; EPITHELIAL-CELLS; PATHOGENESIS; DISEASE	Nontypeable Haemophilus influenzae (NTHi) is an important human pathogen that causes chronic otitis media with effusion (COME) in children and exacerbation of chronic obstructive pulmonary disease (COPD) in adults. Mucin overproduction, a hallmark of both diseases, has been shown to directly cause conductive hearing loss in COME and airway obstruction in COPD. The molecular mechanisms underlying mucin overproduction in NTHi infections still remain unclear. Here, we show that NTHi strongly up-regulates MUC5AC mucin transcription only after bacterial cell disruption. Maximal up-regulation is induced by heat-stable bacterial cytoplasmic proteins, whereas NTHi surface membrane proteins induce only moderate MUC5AC transcription. These results demonstrate an important role for cytoplasmic molecules from lysed bacteria in the pathogenesis of NTHi infections, and may well explain why many patients still have persistent symptoms such as middle ear effusion in COME after intensive antibiotic treatment. Furthermore, our results indicate that activation of p38 mitogen-activated protein kinase is required for NTHi-induced MUC5AC transcription, whereas activation of phosphoinositide 3-kinase-Akt pathway leads to down-regulation of NTHi-induced MUC5AC transcription via a negative cross-talk with p38 mitogen-activated protein kinase pathway. These studies may bring new insights into molecular pathogenesis of NTHi infections and lead to novel therapeutic intervention for COME and COPD.	House Ear Res Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA 90057 USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA 90057 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Calif San Francisco, Vet Affairs Med Ctr, Gastrointestinal Res Labs, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	House Research Institute; University of Southern California; Scripps Research Institute; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Wang, BN (corresponding author), House Ear Res Inst, Gonda Dept Cell & Mol Biol, 2100 W 3rd St, Los Angeles, CA 90057 USA.		Han, J/G-4671-2010	Li, Jian-Dong/0000-0002-5593-050X; Wang, Beinan/0000-0002-9260-7197	NIDCD NIH HHS [R01-DC04562] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004562] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		APICELLA MA, 1985, INFECT IMMUN, V50, P9, DOI 10.1128/IAI.50.1.9-14.1985; AUSTIN D, 1998, BIOCHIM BIOPHYS ACTA, V1406, P251; BARENKAMP SJ, 1990, PEDIATR INFECT DIS J, V9, P333, DOI 10.1097/00006454-199005000-00006; Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; Bierne H, 2000, CELL MICROBIOL, V2, P465, DOI 10.1046/j.1462-5822.2000.00069.x; Clemans DL, 2000, INFECT IMMUN, V68, P4430, DOI 10.1128/IAI.68.8.4430-4440.2000; DEMARIA TF, 1984, J CLIN MICROBIOL, V20, P15, DOI 10.1128/JCM.20.1.15-17.1984; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Foxwell AR, 1998, MICROBIOL MOL BIOL R, V62, P294, DOI 10.1128/MMBR.62.2.294-308.1998; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; HAUNG S, 1997, IMMUNITY, V6, P739; Hedlund M, 1999, MOL MICROBIOL, V33, P693, DOI 10.1046/j.1365-2958.1999.01513.x; Hovenberg HW, 1996, GLYCOCONJUGATE J, V13, P839, DOI 10.1007/BF00702348; Hutton DA, 1998, GLYCOCONJUGATE J, V15, P283, DOI 10.1023/A:1006901213526; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kim WD, 1997, EUR RESPIR J, V10, P1914, DOI 10.1183/09031936.97.10081914; Kubba H, 2000, CLIN OTOLARYNGOL, V25, P181, DOI 10.1046/j.1365-2273.2000.00350.x; Kubiet M, 2000, INFECT IMMUN, V68, P3362, DOI 10.1128/IAI.68.6.3362-3367.2000; KUKLINSKA D, 1984, EUR J CLIN MICROBIOL, V3, P249, DOI 10.1007/BF02014895; LARIVEE P, 1994, AIRWAY SECRETION PHY, P469; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; Lim D J, 1985, Auris Nasus Larynx, V12 Suppl 1, pS8; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; MAJIMA Y, 1988, ANN OTO RHINOL LARYN, V97, P272, DOI 10.1177/000348948809700311; MNTLE M, 1994, INFECT IMMUN, V62, P1219; MOXON ER, 1986, J ANTIMICROB CHEMOTH, V18, P17, DOI 10.1093/jac/18.Supplement_A.17; MURPHY TF, 1992, AM REV RESPIR DIS, V146, P1067, DOI 10.1164/ajrccm/146.4.1067; Namavar F, 1998, INFECT IMMUN, V66, P444, DOI 10.1128/IAI.66.2.444-447.1998; PHILLIPS NJ, 1992, BIOCHEMISTRY-US, V31, P4515, DOI 10.1021/bi00133a019; ROSEMC, 1992, AM J PHYSL, V263, pL413; Scharfman A, 1996, INFECT IMMUN, V64, P5417, DOI 10.1128/IAI.64.12.5417-5420.1996; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Smirnova MG, 2001, EUR CYTOKINE NETW, V12, P119; STGEME JW, 1993, INFECT AGENT DIS, V2, P1; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Williams SJ, 1999, CANCER RES, V59, P4083; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200	41	104	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					949	957		10.1074/jbc.M107484200	http://dx.doi.org/10.1074/jbc.M107484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11698399	hybrid			2022-12-25	WOS:000173166800013
J	Min, L; Galet, C; Ascoli, M				Min, L; Galet, C; Ascoli, M			The association of arrestin-3 with the human lutropin/choriogonadotropin receptor depends mostly on receptor activation rather than on receptor phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LUTEINIZING-HORMONE RECEPTOR; AGONIST-INDUCED INTERNALIZATION; LIMITED PRECOCIOUS PUBERTY; C-TERMINAL TAIL; BETA(2)-ADRENERGIC RECEPTOR; BETA-ARRESTIN; CHORIOGONADOTROPIN RECEPTOR; WILD-TYPE; CELLS	Although the involvement of the nonvisual arrestins in the agonist-induced internalization of the human lutropin receptor (hLHR) has been documented previously with the use of dominant-negative mutants, a physical association of the nonvisual arrestins with the hLHR in intact cells has not been established. In the studies presented herein, we used a cross-linking/coimmunoprecipitation/immunoblotting approach as well as confocal microscopy to document the association of the hLHR with the nonvisual arrestins in co-transfected 293 cells. We also used this approach to examine the relative importance of receptor activation and receptor phosphorylation in the formation of this complex. Using hLHR mutants that impair phosphorylation, activation, or both, we show that the formation of the hLHR-non-visual arrestin complex depends mostly on the agonist-induced activation of the hLHR rather than on the phosphorylation of the hLHR. These results stand in contrast to those obtained with several other G protein-coupled receptors (i.e. the beta(2)-adrenergic receptor, the m2 muscarinic receptor, rhodopsin, and the type 1A angiotensin receptor) where arrestin binding depends mostly on receptor phosphorylation rather than on receptor activation. We have also examined the association of the nonvisual arrestins with naturally occurring gain-of-function mutations of the hLHR found in boys with Leydig cell hyperplasia or Leydig cell adenomas. Our results show that these mutants associate with the nonvisual arrestins in an agonist-independent fashion.	Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Ascoli, M (corresponding author), Univ Iowa, Dept Pharmacol, 2-319B BSB,51 Newton Rd, Iowa City, IA 52242 USA.		galet, colette/C-4620-2011	galet, colette/0000-0002-5931-2143	NCI NIH HHS [CA-40629] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI M, 1984, J CELL BIOL, V99, P1242, DOI 10.1083/jcb.99.4.1242; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GOODMAN J, 1996, NATURE, V383, P447; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Latronico AC, 1998, J CLIN ENDOCR METAB, V83, P2435, DOI 10.1210/jc.83.7.2435; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li SH, 2001, J BIOL CHEM, V276, P7968, DOI 10.1074/jbc.M010482200; Liu G, 1999, NEW ENGL J MED, V341, P1731, DOI 10.1056/NEJM199912023412304; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Min L, 2000, MOL ENDOCRINOL, V14, P1797, DOI 10.1210/me.14.11.1797; Mukherjee S, 1999, J BIOL CHEM, V274, P12984, DOI 10.1074/jbc.274.19.12984; Muller J, 1998, J MED GENET, V35, P340, DOI 10.1136/jmg.35.4.340; Mundell SJ, 2000, J BIOL CHEM, V275, P12900, DOI 10.1074/jbc.275.17.12900; Nakamura K, 1999, J BIOL CHEM, V274, P25426, DOI 10.1074/jbc.274.36.25426; Nakamura K, 2000, J BIOL CHEM, V275, P241, DOI 10.1074/jbc.275.1.241; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; Qian HW, 2001, MOL ENDOCRINOL, V15, P1706, DOI 10.1210/me.15.10.1706; QUINTANA J, 1993, ENDOCRINOLOGY, V133, P2098, DOI 10.1210/en.133.5.2098; Shinozaki H, 2001, MOL ENDOCRINOL, V15, P972, DOI 10.1210/me.15.6.972; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; Yano K, 1996, BIOCHEM BIOPH RES CO, V220, P1036, DOI 10.1006/bbrc.1996.0528; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999	50	51	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					702	710		10.1074/jbc.M106082200	http://dx.doi.org/10.1074/jbc.M106082200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11696538	hybrid			2022-12-25	WOS:000173087900092
J	Ohkura, N; Yaguchi, H; Tsukada, T; Yamaguchi, K				Ohkura, N; Yaguchi, H; Tsukada, T; Yamaguchi, K			The EWS/NOR1 fusion gene product gains a novel activity affecting pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; POTENT TRANSCRIPTIONAL ACTIVATOR; EWINGS-SARCOMA TRANSLOCATION; EWS GENE; CHROMOSOME-TRANSLOCATION; MESSENGER-RNA; MALIGNANT-MELANOMA; BINDING PROTEIN; SOFT PARTS; RECEPTOR	In extraskeletal myxoid chondrosarcoma, chromosomal translocation creates a gene fusion between EWS and the orphan nuclear receptor NOR1 The resulting fusion gene product, EWS/NOR1, has been believed to lead to malignant transformation by functioning as a transcriptional activator, but an alternative mechanism may also be involved. Here, using a newly developed functional complementation screening in yeast, we found that EWS/NOR1, but not EWS or NOR1, complemented the loss of function of the small nuclear ribonucleoprotein Snu23p, an essential factor for pre-mRNA splicing in yeast. To verify the potential function of EWS/NOR1 in mammalian cells, we next showed that overexpression of EWS/NOR1 caused increased usage of the distal 5'-splice site of pre-mRNA splicing and that EWS/NOR1 interacted with the human splicing protein U1C neither EWS nor NOR1 had the same activity or interaction as EWS/NOR1. Altogether, our findings reveal that EWS/NOR1 gains a novel activity affecting pre-mRNA splicing.	Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Ohkura, N (corresponding author), Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.							Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; BOGENHAGEN DF, 1993, MOL CELL BIOL, V13, P5149, DOI 10.1128/MCB.13.9.5149; CARMOFONSECA M, 1991, EMBO J, V10, P1863, DOI 10.1002/j.1460-2075.1991.tb07712.x; CHANSKY HA, 2001, CANCER RES, V61, P3596; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; Clark J, 1996, ONCOGENE, V12, P229; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Eperon IC, 2000, MOL CELL BIOL, V20, P8303, DOI 10.1128/MCB.20.22.8303-8318.2000; Fujimura Y, 1996, ONCOGENE, V12, P159; Gottschalk A, 1999, EMBO J, V18, P4535, DOI 10.1093/emboj/18.16.4535; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; HEDVAT CV, 1995, MOL ENDOCRINOL, V9, P1692, DOI 10.1210/me.9.12.1692; Hinohara S, 1998, JPN J CANCER RES, V89, P887, DOI 10.1111/j.1349-7006.1998.tb00645.x; Hosokawa Y, 1997, CANCER LETT, V113, P123, DOI 10.1016/S0304-3835(97)04605-3; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; JEON IS, 1995, ONCOGENE, V10, P1229; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; Knoop LL, 2001, J BIOL CHEM, V276, P22317, DOI 10.1074/jbc.M008950200; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; Labelle Y, 1999, ONCOGENE, V18, P3303, DOI 10.1038/sj.onc.1202675; LESSNICK SL, 1995, ONCOGENE, V10, P423; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Misawa K, 2000, P NATL ACAD SCI USA, V97, P3062, DOI 10.1073/pnas.060489597; Nawa G, 1999, BRIT J CANCER, V80, P1185, DOI 10.1038/sj.bjc.6690484; Ohkura N, 1996, BBA-GENE STRUCT EXPR, V1308, P205, DOI 10.1016/0167-4781(96)00101-7; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; Ohkura N, 1999, BBA-GENE STRUCT EXPR, V1444, P69, DOI 10.1016/S0167-4781(98)00247-4; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; Rose MD., 1990, METHODS YEAST GENETI; Rossow KL, 2001, CANCER RES, V61, P2690; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; WANG J, 1995, RNA, V1, P335; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yoshida T, 1999, GENES CELLS, V4, P707, DOI 10.1046/j.1365-2443.1999.00295.x; Zhai G, 2001, BIOCHEMISTRY-US, V40, P2032, DOI 10.1021/bi001941r; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	43	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					535	543		10.1074/jbc.M109018200	http://dx.doi.org/10.1074/jbc.M109018200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11673470	hybrid			2022-12-25	WOS:000173087900071
J	Thomas, KW; Monick, MM; Staber, JM; Yarovinsky, T; Carter, AB; Hunninghake, GW				Thomas, KW; Monick, MM; Staber, JM; Yarovinsky, T; Carter, AB; Hunninghake, GW			Respiratory syncytial virus inhibits apoptosis and induces NF-kappa B activity through a phosphatidylinositol 3-kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; INTERLEUKIN-8 GENE-EXPRESSION; EPITHELIAL-CELL CULTURES; PHOSPHOINOSITIDE 3-KINASE; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; A549 CELLS; MAMMALIAN TARGET; REQUIRES ACTIVATION; AKT PROTOONCOGENE	Respiratory syncytial virus (RSV) infects airway epithelial cells, resulting in cell death and severe inflammation through the induction of NF-kappaB activity and inflammatory cytokine synthesis. Both NF-kappaB activity and apoptosis regulation have been linked to phosphatidylinositol 3-kinase (PI 3-K) and its downstream effector enzymes, AKT and GSK-3. This study evaluates the role of PI 3-K and its downstream mediators in apoptosis and inflammatory gene induction during RSV infection of airway epithelial cells. Whereas RSV infection alone did not produce significant cytotoxicity until 24-48 h following infection, simultaneous RSV infection and exposure to LY294002, a blocker of PI 3-K activity, resulted in cytotoxicity within 12 h. Furthermore, we found that RSV infection during PI 3-K blockade resulted in apoptosis by examining DNA fragmentation, DNA labeling by terminal dUTP nick-end labeling assay, and poly(ADP-ribose) polymerase cleavage by Western blotting. RSV infection produced an increase in the phosphorylation state of AKT, GSK-3, and the p85 regulatory subunit of PI 3-K. The activation of PI 3-K by RSV and its inhibition by LY294002 was confirmed in direct PI 3-K activity assays. Further evidence for the central role of a pathway involving PI 3-K and AKT in preserving cell viability during RSV infection was established by the observation that constitutively active AKT transfected into A549 cells prevented the cytotoxicity and apoptosis of combined RSV and LY294002 treatment. Finally, both PI 3-K inhibition by LY294002 and AKT inhibition by transfection of a dominant negative enzyme blocked RSV-induced NF-kappaB transcriptional activity. These data demonstrate that anti-apoptotic signaling and NF-kappaB-activation by RSV are mediated through activation of PI 3-K-dependent pathways. Blockade of PI 3-K activation resulted in rapid, premature apoptosis and inhibition of RSV-stimulated NF-kappaB-dependent gene transcription.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Thomas, KW (corresponding author), Univ Iowa Hosp & Clin, Div Pulm Crit Care & Occupat Med, C-33 GH, Iowa City, IA 52242 USA.	karl-thomas@uiowa.edu		Staber, Janice/0000-0002-2738-4206	PHS HHS [E509607] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHERNE W, 1970, J CLIN PATHOL, V23, P7, DOI 10.1136/jcp.23.1.7; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bitko V, 1998, J VIROL, V72, P5610, DOI 10.1128/JVI.72.7.5610-5618.1998; Bitko V, 1997, VIROLOGY, V232, P369, DOI 10.1006/viro.1997.8582; BRANDT CD, 1973, AM J EPIDEMIOL, V98, P355, DOI 10.1093/oxfordjournals.aje.a121565; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Carter AB, 1998, AM J RESP CELL MOL, V18, P384, DOI 10.1165/ajrcmb.18.3.2972; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen WZ, 2000, EXP LUNG RES, V26, P13, DOI 10.1080/019021400269934; Chini BA, 1998, J VIROL, V72, P1623, DOI 10.1128/JVI.72.2.1623-1626.1998; Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; D'Addario M, 2000, J MOL BIOL, V298, P765, DOI 10.1006/jmbi.2000.3717; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Denning G, 2001, J BIOL CHEM, V276, P22709, DOI 10.1074/jbc.C100144200; Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456; EVERARD ML, 1994, ARCH DIS CHILD, V71, P428, DOI 10.1136/adc.71.5.428; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; Fiedler MA, 1995, AM J PHYSIOL-LUNG C, V269, pL865, DOI 10.1152/ajplung.1995.269.6.L865; Fiedler MA, 1996, J VIROL, V70, P9079, DOI 10.1128/JVI.70.12.9079-9082.1996; Fiedler MA, 1999, J VIROL, V73, P4502, DOI 10.1128/JVI.73.5.4502-4507.1999; Fiedler MA, 1996, AM J PHYSIOL-LUNG C, V271, pL963, DOI 10.1152/ajplung.1996.271.6.L963; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499; Hogg JC, 1999, AM J RESP CRIT CARE, V160, pS26, DOI 10.1164/ajrccm.160.5.8; Horiuchi M, 1997, J BIOL CHEM, V272, P11952, DOI 10.1074/jbc.272.18.11952; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Krilov LR, 2000, J INFECT DIS, V181, P349, DOI 10.1086/315203; LAMBERT DM, 1988, J GEN VIROL, V69, P313, DOI 10.1099/0022-1317-69-2-313; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; Lazrak A, 2000, AM J PHYSIOL-LUNG C, V278, pL848, DOI 10.1152/ajplung.2000.278.4.L848; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; Mastronarde JG, 1996, J INFECT DIS, V174, P262, DOI 10.1093/infdis/174.2.262; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; Matsushita H, 2000, CIRC RES, V86, P974, DOI 10.1161/01.RES.86.9.974; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; O'Donnell DR, 1999, VIROLOGY, V257, P198, DOI 10.1006/viro.1999.9650; Ozes ON, 1999, NATURE, V401, P82; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; PARROTT RH, 1973, AM J EPIDEMIOL, V98, P289, DOI 10.1093/oxfordjournals.aje.a121558; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Smith GCM, 1999, BIOCHEM SOC SYMP, P91; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; Takeuchi R, 1998, J VIROL, V72, P4498, DOI 10.1128/JVI.72.5.4498-4502.1998; Thomas LH, 1998, J IMMUNOL, V161, P1007; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680	82	116	124	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					492	501		10.1074/jbc.M108107200	http://dx.doi.org/10.1074/jbc.M108107200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11687577	hybrid			2022-12-25	WOS:000173087900066
J	Vilela-Silva, ACES; Castro, MO; Valente, AP; Biermann, CH; Mourao, PAS				Vilela-Silva, ACES; Castro, MO; Valente, AP; Biermann, CH; Mourao, PAS			Sulfated fucans from the egg jellies of the closely related sea urchins Strongylocentrotus droebachiensis and Strongylocentrotus pallidus ensure species-specific fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRANCHED CHONDROITIN SULFATE; PLICATA CHORDATA-TUNICATA; ANTICOAGULANT ACTIVITY; MOLECULAR EVOLUTION; ACROSOME REACTION; L-GALACTOSE; CUCUMBER; POLYSACCHARIDES; ECHINODERMS; ECHINOIDS	Sulfated polysaccharides from egg jelly are the molecules responsible for inducing the sperm acrosome reaction in sea urchins. This is an obligatory event for sperm binding to, and fusion with, the egg. The sulfated polysaccharides from sea urchins have simple, well defined repeating structures, and each species represents a particular pattern of sulfate substitution. Here, we examined the egg jellies of the sea urchin sibling species Strongylocentrotus droebachiensis and Strongylocentrotus pallidus. Surprisingly, females of S. droebachiensis possess eggs containing one of two possible sulfated fucans, which differ in the extent of their 2-O-sulfation. Sulfated fucan I is mostly composed of a regular sequence of four residues ([4-alpha-L-Fucp-2(OSO3)-1-->4-alpha-L-Fucp-2(OSO3)-1-->4-alpha-L-Fucp-1-->4-alpha-L-Fucp-1](n)), whereas sulfated fucan II is a homopolymer of 4-alpha-L-Fucp-2(OSO3)-1 units. Females of S. pallidus contain a single sulfated fucan with the following repeating structure: [3-alpha-L-Fucp-2(OSO3)-1-->3-alpha-L-Fucp-2(OSO3)-1-->3-alpha-L-Fucp4(OSO3)-1-->3-alpha-L-Fucp-4(OSO3)-1](n). The egg jellies of these two species of sea urchins induce the acrosome reaction in homologous (but not heterologous) sperm. Therefore, the fine structure of the sulfated a-fucans from the egg jellies of S. pallidus and S. droebachiensis, which differ in their sulfation patterns and in the position of their glycosidic linkages, ensures species specificity of the sperm acrosome reaction and prevents interspecies crosses. In addition, our observations allow a clear appreciation of the common structural features among the sulfated polysaccharides from sea urchin egg jelly and help to identify structures that confer finer species specificity of recognition in the acrosome reaction.	Fed Univ Rio De Janeiro, Dept Bioquim Med, Ctr Ciencias Saude, BR-21941590 Rio De Janeiro, Brazil; Hosp Univ Clementino Fraga Filho, Lab Tecido Conjuntivo, BR-21941590 Rio De Janeiro, Brazil; Fed Univ Rio De Janeiro, Dept Bioquim Med, Ctr Nacl Ressonancia Nucl Magnet Macromol, BR-21941590 Rio De Janeiro, Brazil; Univ Washington, Friday Harbor Labs, Friday Harbor, WA 98250 USA	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; University of Washington	Mourao, PAS (corresponding author), Fed Univ Rio De Janeiro, Dept Bioquim Med, Ctr Ciencias Saude, Caixa Postal 68041, BR-21941590 Rio De Janeiro, Brazil.		Mourao, Paulo/AAA-5386-2020; Valente, Ana Paula/J-3010-2017	Valente, Ana Paula/0000-0001-7219-1123				ALBANO RM, 1986, J BIOL CHEM, V261, P758; Alves AP, 1997, J BIOL CHEM, V272, P6965, DOI 10.1074/jbc.272.11.6965; Alves AP, 1998, GLYCOBIOLOGY, V8, P939, DOI 10.1093/glycob/8.9.939; Biermann CH, 1998, MOL BIOL EVOL, V15, P1761, DOI 10.1093/oxfordjournals.molbev.a025902; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Darszon A, 1996, CURR TOP DEV BIOL, V34, P117, DOI 10.1016/S0070-2153(08)60710-3; DIETRICH CP, 1977, J CHROMATOGR, V130, P299, DOI 10.1016/S0021-9673(00)89809-X; DISCHE Z, 1948, J BIOL CHEM, V175, P595; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Farias WRL, 2000, J BIOL CHEM, V275, P29299, DOI 10.1074/jbc.M002422200; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; GARBERS DL, 1989, ANNU REV BIOCHEM, V58, P719, DOI 10.1146/annurev.bi.58.070189.003443; KIRCHER HW, 1960, ANAL CHEM, V32, P1103, DOI 10.1021/ac60165a016; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P431, DOI 10.1111/j.1432-1033.1987.tb13534.x; MOURAO PAS, 1991, BIOCHEMISTRY-US, V30, P3458, DOI 10.1021/bi00228a016; MOURAO PAS, 1995, J BIOL CHEM, V270, P3132, DOI 10.1074/jbc.270.7.3132; MULLOY B, 1994, J BIOL CHEM, V269, P22113; NISHINO T, 1991, THROMB RES, V62, P765, DOI 10.1016/0049-3848(91)90380-F; Painter T.J., 1983, POLYSACCHARIDES, P196, DOI DOI 10.1016/B978-0-12-065602-8.50009-1; PATANKAR MS, 1993, J BIOL CHEM, V268, P21770; PAVAO MSG, 1989, J BIOL CHEM, V264, P9972; Percival E., 1967, CHEM ENZYMOLOGY MARI, P157; Pereira MS, 1999, J BIOL CHEM, V274, P7656, DOI 10.1074/jbc.274.12.7656; RIBEIRO AC, 1994, CARBOHYD RES, V255, P225, DOI 10.1016/S0008-6215(00)90981-9; SAITO H, 1968, J BIOL CHEM, V243, P1536; SEGALL GK, 1979, DEV BIOL, V71, P33, DOI 10.1016/0012-1606(79)90080-0; SMITH AB, 1988, MOL BIOL EVOL, V5, P345; SUZUKI N, 1992, COMP BIOCHEM PHYS B, V102, P679, DOI 10.1016/0305-0491(92)90064-X; TAKAHASHI HK, 1981, ANAL BIOCHEM, V116, P451; Vacquier VD, 1997, DEV BIOL, V192, P125, DOI 10.1006/dbio.1997.8729; VACQUIER VD, 1986, TRENDS BIOCHEM SCI, V11, P77, DOI 10.1016/0968-0004(86)90270-7; VIEIRA RP, 1988, J BIOL CHEM, V263, P18176; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; Vilela-Silva ACES, 2001, GLYCOBIOLOGY, V11, P433, DOI 10.1093/glycob/11.6.433; Vilela-Silva ACES, 1999, GLYCOBIOLOGY, V9, P927, DOI 10.1093/glycob/9.9.927; WERNER I, 1952, Acta Soc Med Ups, V57, P230; WRAY GA, 1992, PALEOBIOLOGY, V18, P258, DOI 10.1017/S0094837300010848	37	105	113	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					379	387		10.1074/jbc.M108496200	http://dx.doi.org/10.1074/jbc.M108496200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11687579	hybrid			2022-12-25	WOS:000173087900051
J	Bannwarth, S; Talakoub, L; Letourneur, F; Duarte, M; Purcell, DF; Hiscott, J; Gatignol, A				Bannwarth, S; Talakoub, L; Letourneur, F; Duarte, M; Purcell, DF; Hiscott, J; Gatignol, A			Organization of the human tarbp2 gene reveals two promoters that are repressed in an astrocytic cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEIN; IMMUNODEFICIENCY-VIRUS TYPE-1; DOUBLE-STRANDED-RNA; ESCHERICHIA-COLI; TRBP; KINASE; HIV-1; SEQUENCE; ACTIVATION; EXPRESSION	TRBP1 and TRBP2 are isoforms of a double-stranded RNA-binding protein that differ in their N-terminal end and were each identified by binding to human immunodeficiency virus type 1 (HIV-1) trans-activation-responsive RNA. TRBP1 and TRBP2 also bind and modulate the function of the double-stranded RNA-activated protein kinase, protein kinase R. Both proteins increase long terminal repeat expression in human and murine cells, and their gene has been mapped to human chromosome 12. We have isolated and characterized the complete tarbp2 gene (5493 bp) coding for the two TRBP proteins. Two adjacent promoters initiate transcription of alternative first exons for TRBP1 and TRBP2 mRNAs that are spliced onto common downstream exons. TRBP2 transcription and translation start sites are localized within the first intron of TRBP1. TRBP promoters are TATA-less but have CCAAT boxes, a CpG island, and several potential binding sites for transcriptional factors. Promoter deletion analysis identified two regions from position -1397 to -330 for TRBP1 and from position -330 to +38 for TRBP2 that are important for promoter function. TRBP2 promoter activity was expressed at a higher level compared with TRBP1 promoter. In addition, a specific down-regulation of TRBP1 and TRBP2 promoter activity was identified in human astrocytic cell line U251MG compared with HeLa cells. This minimal TRBP promoter activity may account for minimal HIV-1 replication in astrocytes.	Lady Davis Inst Med Res, Mol Oncol Grp, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; INSERM, Inst Cochin Genet Mol, F-75014 Paris, France; Macfarlane Burnet Ctr Med Res, Fairfield, Vic 3078, Australia; Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia	Lady Davis Institute; McGill University; McGill University; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Melbourne	Gatignol, A (corresponding author), Lady Davis Inst Med Res, Mol Oncol Grp, McGill AIDS Ctr, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	anne.gatignol@mcgill.ca	Purcell, Damian F/G-5068-2011; Gatignol, Anne/AAA-6501-2020	Gatignol, Anne/0000-0002-4553-0836				Abuladze N, 2000, GENE, V251, P109, DOI 10.1016/S0378-1119(00)00204-3; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; BIGNER DD, 1981, J NEUROPATH EXP NEUR, V40, P201, DOI 10.1097/00005072-198105000-00001; Blair Edward D., 1995, Journal of Biomedical Science, V2, P322, DOI 10.1007/BF02255219; Brack-Werner R, 1999, AIDS, V13, P1, DOI 10.1097/00002030-199901140-00003; Chen L, 2000, J BIOL CHEM, V275, P32227, DOI 10.1074/jbc.M002645200; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; Daher A, 2001, J BIOL CHEM, V276, P33899, DOI 10.1074/jbc.M103584200; Daviet L, 2000, EUR J BIOCHEM, V267, P2419, DOI 10.1046/j.1432-1327.2000.01256.x; Di Rienzo AM, 1998, ARCH VIROL, V143, P1599, DOI 10.1007/s007050050401; Duarte M, 2000, J BIOMED SCI, V7, P494; Erard M, 1998, J MOL BIOL, V279, P1085, DOI 10.1006/jmbi.1998.1831; Francois C, 2000, J VIROL, V74, P5587, DOI 10.1128/JVI.74.12.5587-5596.2000; Gatignol A, 1996, GENE EXPRESSION, V5, P217; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; Gorry PR, 1999, J VIROL, V73, P352, DOI 10.1128/JVI.73.1.352-361.1999; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Kandasamy RA, 1996, J BIOL CHEM, V271, P10551, DOI 10.1074/jbc.271.18.10551; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KOZAK CA, 1995, GENOMICS, V25, P66, DOI 10.1016/0888-7543(95)80110-8; KRAUTER K, 1995, NATURE, V377, P321; Lentzen G, 1996, RNA, V2, P244; Ludwig E, 1999, J VIROL, V73, P8279, DOI 10.1128/JVI.73.10.8279-8289.1999; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mount SM, 2000, AM J HUM GENET, V67, P788, DOI 10.1086/303098; NEUMANN M, 1995, J VIROL, V69, P2159, DOI 10.1128/JVI.69.4.2159-2167.1995; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; TROSTER H, 1994, J EXP MED, V180, P2059, DOI 10.1084/jem.180.6.2059; Werner T, 1999, MAMM GENOME, V10, P168, DOI 10.1007/s003359900963; Wickham L, 1999, MOL CELL BIOL, V19, P2220; Zhong J, 1999, NAT GENET, V22, P171, DOI 10.1038/9684; Zhong J, 1998, MAMM GENOME, V9, P413, DOI 10.1007/s003359900786; Zuker M., 1999, V70, P11	45	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48803	48813		10.1074/jbc.M104645200	http://dx.doi.org/10.1074/jbc.M104645200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11641396	hybrid			2022-12-25	WOS:000173922100026
J	Cowper, AE; Caceres, JF; Mayeda, A; Screaton, GR				Cowper, AE; Caceres, JF; Mayeda, A; Screaton, GR			Serine-arginine (SR) protein-like factors that antagonize authentic SR proteins and regulate alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; IN-VITRO; SUBNUCLEAR LOCALIZATION; CAENORHABDITIS-ELEGANS; DROSOPHILA DEVELOPMENT; RECOGNITION MOTIFS; CONSERVED FAMILY; BINDING-PROTEINS; PREMESSENGER RNA; SITE SELECTION	We have characterized two RNA-binding proteins, of apparent molecular masses of similar to40 and 35 kDa, which possess a single N-terminal RNA-recognition motif (RRM) followed by a C-terminal domain rich in serine-arginine dipeptides. Their primary structures resemble the single-RRM serine-arginine (SR) protein, SC35; however their functional effects are quite distinctive. The 40-kDa protein cannot complement SR protein-deficient HeLa cell S100 extract and showed a dominant negative effect in vitro against the authentic SR proteins, SF2/ ASF and SC35. Interestingly, the 40- and 35-kDa proteins antagonize SR proteins and activate the most distal alternative 5' splice site of adenovirus E1A pre-mRNA in vivo, an activity that is similar to that characterized previously for the heterogeneous nuclear ribonucleoprotein particles A/B group of proteins. A series of recombinant chimeric proteins consisting of domains from these proteins and SC35 in various combinations showed that the RRM, but not the C-terminal domain rich in serine-arginine dipeptides, has a dominant role in this activity. Because of the similarity to SR proteins we have named these proteins SRrp40 and SRrp35, respectively, for SR-repressor proteins of similar to40 and similar to35 kDa. Both factors show tissue- and cell type-specific patterns of expression. We propose that these two proteins are SR protein-like alternative splicing regulators that antagonize authentic SR proteins in the modulation of alternative 5' splice site choice.	John Radcliffe Hosp, Weatherall Inst Mol Med, Human Immunol Unit, Oxford OX3 9DU, England; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA	University of Oxford; University of Edinburgh; University of Miami	Screaton, GR (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, Human Immunol Unit, Oxford OX3 9DU, England.	Screaton@molbiol.ox.ac.uk	Caceres, Javier F/D-5260-2013; Mayeda, Akila/ABC-1134-2020	Caceres, Javier F/0000-0001-8025-6169; Mayeda, Akila/0000-0002-9562-550X; Screaton, Gavin/0000-0002-3549-4309	Medical Research Council [MC_U127584479] Funding Source: Medline; MRC [MC_U127584479] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barnard DC, 2000, MOL CELL BIOL, V20, P3049, DOI 10.1128/MCB.20.9.3049-3057.2000; Burge CB, 1999, RNA WORLD, P525; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; CACERES JF, 1997, EUKARYOTIC MRNA PROC, P174; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; Chew SL, 1999, P NATL ACAD SCI USA, V96, P10655, DOI 10.1073/pnas.96.19.10655; Das R, 1999, RNA, V5, P1504, DOI 10.1017/S1355838299991501; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FU XD, 1995, RNA, V1, P663; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Hanamura A, 1998, RNA, V4, P430; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Jumaa H, 1999, CURR BIOL, V9, P899, DOI 10.1016/S0960-9822(99)80394-7; Kawano T, 2000, MECH DEVELOP, V95, P67, DOI 10.1016/S0925-4773(00)00339-7; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Labourier E, 1999, GENE DEV, V13, P740, DOI 10.1101/gad.13.6.740; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Longman D, 2000, EMBO J, V19, P1625, DOI 10.1093/emboj/19.7.1625; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; Mayeda A, 1999, METH MOL B, V118, P315; Mayeda A, 1999, METH MOL B, V118, P309; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Misteli T, 1998, CURR OPIN CELL BIOL, V10, P323, DOI 10.1016/S0955-0674(98)80007-0; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Petersen-Mahrt SK, 1999, EMBO J, V18, P1014, DOI 10.1093/emboj/18.4.1014; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; REED R, 1997, EUKARYOTIC MRNA PROC, P103; RING HJ, 1994, MOL CELL BIOL, V14, P7499, DOI 10.1128/MCB.14.11.7499; ROSCIGNO RF, 1995, RNA, V1, P692; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Soret J, 1998, MOL CELL BIOL, V18, P4924, DOI 10.1128/MCB.18.8.4924; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; van Oordt WVH, 2000, NUCLEIC ACIDS RES, V28, P4822, DOI 10.1093/nar/28.24.4822; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; WANG J, 1995, RNA, V1, P335; WATAKABE A, 1989, NUCLEIC ACIDS RES, V17, P8159, DOI 10.1093/nar/17.20.8159; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; Zhang WJ, 1996, MOL CELL BIOL, V16, P5400; Zhu J, 2000, GENE DEV, V14, P3166, DOI 10.1101/gad.189500; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	68	69	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48908	48914		10.1074/jbc.M103967200	http://dx.doi.org/10.1074/jbc.M103967200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11684676	hybrid			2022-12-25	WOS:000173922100038
J	Poplawski, A; Grabowski, B; Long, SF; Kelman, Z				Poplawski, A; Grabowski, B; Long, SF; Kelman, Z			The zinc finger domain of the archaeal minichromosome maintenance protein is required for helicase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; MCM PROTEINS; S-PHASE; BINDING; COMPLEX; CHROMATIN; PURIFICATION; INITIATION	The minichromosome maintenance (MCM) proteins, a family of six conserved polypeptides found in all eukaryotes, are essential for DNA replication. The archaeon Methanobacterium thermoautotrophicum DeltaH contains a single homologue of MCM with biochemical properties similar to those of the eukaryotic enzyme. The amino acid sequence of the archaeal protein contains a putative zinc-binding domain of the CX2CXnCX2C (C4) type. In this study, the roles of the zinc finger domain in MCM function were examined using recombinant wild-type and mutant proteins expressed and purified from Escherichia coli. The protein with a mutation in the zinc motif forms a dodecameric complex similar to the wild-type enzyme. The mutant enzyme, however, is impaired in DNA-dependent ATPase activity and single-stranded DNA binding, and it does not possess helicase activity. These results illustrate the importance of the zinc-binding domain for archaeal MCM function and suggest a role for zinc binding in the eukaryotic MCM complex as well, since four out of the six eukaryotic MCM proteins contain a similar zinc-binding motif.	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Natl Inst Stand & Technol, Div Analyt Chem, Gaithersburg, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA	Kelman, Z (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.							Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Barns SM, 1996, P NATL ACAD SCI USA, V93, P9188, DOI 10.1073/pnas.93.17.9188; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Biswas N, 1999, J BIOL CHEM, V274, P8068, DOI 10.1074/jbc.274.12.8068; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Edgell DR, 1997, CELL, V89, P995, DOI 10.1016/S0092-8674(00)80285-8; FORSBURG SL, 1994, J CELL SCI, V107, P2779; Grabowski B, 2001, J BACTERIOL, V183, P5459, DOI 10.1128/JB.183.18.5459-5464.2001; HANAS JS, 1983, J BIOL CHEM, V258, P4120; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Kelman Z, 2000, CURR PROTEIN PEPT SC, V1, P139, DOI 10.2174/1389203003381414; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Leon O, 2000, BIOL RES, V33, P21; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAINE GT, 1984, GENETICS, V106, P365; Matsunaga F, 2001, P NATL ACAD SCI USA, V98, P11152, DOI 10.1073/pnas.191387498; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Myllykallio H, 2000, TRENDS MICROBIOL, V8, P537, DOI 10.1016/S0966-842X(00)01881-3; RAMAN CS, 2000, STRUCTURAL THEMES DE, V4; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; van Dinten LC, 2000, J VIROL, V74, P5213, DOI 10.1128/JVI.74.11.5213-5223.2000; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; You ZY, 1999, MOL CELL BIOL, V19, P8003; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	46	57	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49371	49377		10.1074/jbc.M108519200	http://dx.doi.org/10.1074/jbc.M108519200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11606589	hybrid			2022-12-25	WOS:000173922100098
J	Purves, T; Middlemas, A; Agthong, S; Jude, EB; Boulton, AJM; Fernyhough, P; Tomlinson, DR				Purves, T; Middlemas, A; Agthong, S; Jude, EB; Boulton, AJM; Fernyhough, P; Tomlinson, DR			A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy	FASEB JOURNAL			English	Article						diabetes; DRG; MAPK; stress	C-JUN; OXIDATIVE STRESS; ANTIOXIDANT TREATMENT; NERVE DYSFUNCTION; CELLULAR-RESPONSE; SENSORY NEURONS; MAP-KINASES; PHOSPHORYLATION; RATS; GLYCATION	The onset of diabetic neuropathy, a complication of diabetes mellitus, has been linked to poor glycemic control. We tested the hypothesis that the mitogen-activated protein kinases (MAPK) form transducers for the damaging effects of high glucose. In cultures of adult rat sensory neurons, high glucose activated JNK and p38 MAPK but did not result in cell damage. However, oxidative stress activated ERK and p38 MAPKs and resulted in cellular damage. In the dorsal root ganglia of streptozotocin-induced diabetic rats (a model of type I diabetes), ERK and p38 were activated at 8 wk duration, followed by activation of JNK at 12 wk duration. We report activation of JNK and increases in total levels of p38 and JNK in sural nerve of type I and II diabetic patients. These data implicate MAPKs in the etiology of diabetic neuropathy both via direct effects of glucose and via glucose-induced oxidative stress.	Univ Manchester, Sch Biol Sci, Div Neurosci, Manchester M13 9PT, Lancs, England; Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England	University of Manchester; University of Manchester	Tomlinson, DR (corresponding author), Univ Manchester, Sch Biol Sci, Div Neurosci, Stopford Bldg 1-124,Oxford Rd, Manchester M13 9PT, Lancs, England.	david.tomlinson@man.ac.uk	Purves-Tyson, Tertia D/C-9799-2011	Purves-Tyson, Tertia D/0000-0003-2401-4266; Fernyhough, Paul/0000-0002-9507-1201				Awazu M, 1999, J AM SOC NEPHROL, V10, P738; BRAMHALL S, 1969, ANAL BIOCHEM, V31, P146, DOI 10.1016/0003-2697(69)90251-6; BRAVENBOER B, 1992, DIABETOLOGIA, V35, P813, DOI 10.1007/BF00399926; Caldero J, 1998, J NEUROSCI, V18, P356; CAMERON NE, 1993, DIABETOLOGIA, V36, P299, DOI 10.1007/BF00400231; Cantoni O, 1996, FEBS LETT, V389, P285, DOI 10.1016/0014-5793(96)00605-9; Carrington AL, 1999, DIABETES REV, V7, P275; Cohen DM, 1997, COMP BIOCHEM PHYS A, V117, P291, DOI 10.1016/S0300-9629(96)00266-6; Dyck PJ, 1996, J NEUROPATH EXP NEUR, V55, P1181, DOI 10.1097/00005072-199612000-00001; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Fernyhough P, 1999, DIABETES, V48, P881, DOI 10.2337/diabetes.48.4.881; Fernyhough P, 1999, DIABETES REV, V7, P300; FUKINO H, 1986, J TOXICOL ENV HEALTH, V19, P75, DOI 10.1080/15287398609530908; Geilen CC, 1996, J DERMATOL SCI, V12, P255, DOI 10.1016/0923-1811(95)00481-5; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; Haneda M, 1997, DIABETES, V46, P847, DOI 10.2337/diabetes.46.5.847; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Iordanov MS, 1999, J BIOL CHEM, V274, P25801, DOI 10.1074/jbc.274.36.25801; Ito H, 1998, BBA-GENE STRUCT EXPR, V1397, P223, DOI 10.1016/S0167-4781(98)00010-4; KARASU C, 1995, DIABETOLOGIA, V38, P129, DOI 10.1007/s001250050262; Kenney AM, 1998, J NEUROSCI, V18, P1318; Kultz D, 1998, J EXP BIOL, V201, P3015; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Mizisin AP, 1999, J PERIPHER NERV SYST, V4, P211; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NICKANDER KK, 1994, J NEUROL SCI, V126, P6, DOI 10.1016/0022-510X(94)90088-4; Schmidt RE, 1997, J NEUROPATH EXP NEUR, V56, P1028, DOI 10.1097/00005072-199709000-00008; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIDENIUS P, 1980, DIABETES, V29, P182, DOI 10.2337/diabetes.29.3.182; Simm A, 1997, FEBS LETT, V410, P481, DOI 10.1016/S0014-5793(97)00644-3; Thomas PK, 1999, EUR NEUROL, V41, P35, DOI 10.1159/000052078; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; Tomlinson DR, 1999, DIABETOLOGIA, V42, P1271, DOI 10.1007/s001250051439; Veeranna, 1998, J NEUROSCI, V18, P4008; Vinik AI, 2000, DIABETOLOGIA, V43, P957, DOI 10.1007/s001250051477; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YOUNG MJ, 1993, DIABETOLOGIA, V36, P150, DOI 10.1007/BF00400697; Yu R, 1997, J BIOL CHEM, V272, P28962, DOI 10.1074/jbc.272.46.28962; Zochodne DW, 1999, BRAIN PATHOL, V9, P369	44	207	231	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2508	2514		10.1096/fj.01-0253hyp	http://dx.doi.org/10.1096/fj.01-0253hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689477				2022-12-25	WOS:000172420500022
J	Glondu, M; Coopman, P; Laurent-Matha, V; Garcia, M; Rochefort, H; Liaudet-Coopman, E				Glondu, M; Coopman, P; Laurent-Matha, V; Garcia, M; Rochefort, H; Liaudet-Coopman, E			A mutated cathepsin-D devoid of its catalytic activity stimulates the growth of cancer cells	ONCOGENE			English	Article						cathepsin-D; mitogen; mutagenesis; catalytic site	HUMAN IMMUNODEFICIENCY VIRUS; PROCATHEPSIN-D ACTIVATION; BREAST-CANCER; MONOCLONAL-ANTIBODIES; BASEMENT-MEMBRANE; EPITHELIAL-CELLS; MCF7 CELLS; IGF-II; METASTASIS; PROTEASES	Cathepsin-D, a lysosomal aspartyl proteinase, is highly secreted by breast cancer cells and its over-expression by transfection stimulates cancer cell proliferation. The mechanism by which this protease affects proliferation remains, however, unknown. In order to determine whether proteolytic activity is necessary, we abolished its enzymatic activity using site-directed mutagenesis followed by stable transfection in 3Y1-Ad12 cancer cells. Substitution of the aspartic acid residue 231 by an asparagine residue in its catalytic site abrogated the cathepsin-D proteolytic activity but did not affect its expression level, processing or secretion. However, like wild-type cathepsin-D, this mutated catalytically-inactive cathepsin-D retained its capacity to stimulate proliferation of cells embedded in Matrigel or collagen I matrices, colony formation in soft agar and tumor growth in athymic nude mice. Addition on the mock-transfected cells, of either conditioned media containing the wild-ty pe or the mutated pro-cathepsin-D, or of the purified mutated pro-cathepsin-D, partially mimicked the mitogenic activity of the transfected cathepsin-D, indicating a role of the secreted pro-enzyme. Moreover, addition of two anti-cathepsin-D antibodies on the cathepsin-D transfected cells inhibited their proliferation, suggesting an action of the secreted pro-cathepsin-D via an autocrine loop. A synthetic peptide containing the 27-44 residue moiety of the cathepsin-D pro-fragment was, however, not mitogenic suggesting that a receptor for the pro-fragment was not involved. Furthermore, the cathepsin-D mitogenicity was not blocked by inhibiting the interaction of pro-cathepsin-D with the mannose-6-phosphate receptors. Our results altogether demonstrate that a mutated cathepsin-D devoid of catalytic activity is still mitogenic and suggest that it is acting extracellularly by triggering directly or indirectly a yet unidentified cell surface receptor.	Univ Montpellier 1, INSERM, Endocrinol Mol & Cellulaire Canc U540, F-34090 Montpellier, France; Univ Montpellier 2, CNRS, UMR 5539, F-34095 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Rochefort, H (corresponding author), Univ Montpellier 1, INSERM, Endocrinol Mol & Cellulaire Canc U540, 60 Rue Navacelles, F-34090 Montpellier, France.		Coopman, Peter/G-7416-2019; Liaudet-Coopman, Emmanuelle/N-4744-2017	Coopman, Peter/0000-0003-3720-523X; Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Valerie, LAURENT-MATHA/0000-0002-3277-7397				BISSELL MJ, 1999, CANCER RES, V59, P1757; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; CAPONY F, 1987, J CELL BIOL, V104, P253, DOI 10.1083/jcb.104.2.253; CAPONY F, 1989, CANCER RES, V49, P3904; CARNEY DH, 1978, CELL, V15, P1341, DOI 10.1016/0092-8674(78)90059-4; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; DeLeon DD, 1996, ENDOCRINOLOGY, V137, P1851, DOI 10.1210/en.137.5.1851; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; EMERMAN JT, 1977, P NATL ACAD SCI USA, V74, P4466, DOI 10.1073/pnas.74.10.4466; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; FREISS G, 1988, CANCER RES, V48, P3709; FUSEK M, 1994, BIOCHEM J, V303, P775, DOI 10.1042/bj3030775; GARCIA M, 1990, ONCOGENE, V5, P1809; GARCIA M, 1985, CANCER RES, V45, P709; Kane S E, 1990, Semin Cancer Biol, V1, P127; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; Laurent-Matha V, 1998, J CELL SCI, V111, P2539; LIAUDET E, 1995, CELL GROWTH DIFFER, V6, P1045; LIN XL, 1989, J BIOL CHEM, V264, P4482; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; MATHIEU M, 1990, MOL ENDOCRINOL, V4, P1327, DOI 10.1210/mend-4-9-1327; METCALF P, 1993, EMBO J, V12, P1293, DOI 10.1002/j.1460-2075.1993.tb05774.x; MONTCOURRIER P, 1994, J CELL SCI, V107, P2381; Montcourrier P, 1997, CLIN EXP METASTAS, V15, P382, DOI 10.1023/A:1018446104071; Rifkin DB, 1997, FIBRINOLYSIS PROTEOL, V11, P3, DOI 10.1016/S0268-9499(97)80003-3; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; Rochefort H, 1999, APMIS, V107, P86, DOI 10.1111/j.1699-0463.1999.tb01530.x; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612; SLOANE BF, 1984, CANCER METAST REV, V3, P249, DOI 10.1007/BF00048388; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; VEITH FO, 1983, CANCER RES, V43, P1861; Vetvicka V, 1999, BREAST CANCER RES TR, V57, P261, DOI 10.1023/A:1006238003772; VIGNON F, 1992, BREAST CANCER RES TR, V22, P47, DOI 10.1007/BF01833333; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; Wittlin S, 1999, EUR J BIOCHEM, V265, P384, DOI 10.1046/j.1432-1327.1999.00747.x	40	89	94	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6920	6929		10.1038/sj.onc.1204843	http://dx.doi.org/10.1038/sj.onc.1204843			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687971				2022-12-25	WOS:000171641000013
J	Okutani, Y; Kitanaka, A; Tanaka, T; Kamano, H; Ohnishi, H; Kubota, Y; Ishida, T; Takahara, J				Okutani, Y; Kitanaka, A; Tanaka, T; Kamano, H; Ohnishi, H; Kubota, Y; Ishida, T; Takahara, J			Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway	ONCOGENE			English	Article						Src; STAT5; erythropoietin; tyrosine phosphorylation; antisense	COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; ERYTHROID-DIFFERENTIATION; RECEPTOR; EXPRESSION; KINASES; INTERLEUKIN-3; TRANSDUCTION; PROLACTIN; LEUKEMIA	Signal transducers and activators of transcription (STAT) proteins are transcription factors activated by phosphorylation on tyrosine residues after cytokine stimulation. In erythropoietin receptor (EPOR)-mediated signaling, STAT5 is tyrosine-phosphorylated by EPO stimulation. Although Janus Kinase 2 (JAK2) is reported to play a crucial role in EPO-induced activation of STAT5, it is unclear whether JAK2 alone can tyrosine-phosphorylate STAT5 after EPO stimulation. Several studies indicate that STAT activation is caused by members of other families of protein tyrosine kinases such as the Src family. We previously reported that reduction of Src by induction of antisense src RNA expression suppressed EPO-promoted erythroid differentiation in K562 cells. In the present study, we explored the function of Src downstream of the EPOR-initiated signaling. Reduction of Src diminished tyrosine phosphorylation of STAT5 in K562 cells regardless of EPO treatment. The tyrosine phosphorylation level of STAT5 induced by EPO in F-36P cells was reduced in the presence of PPI or PP2 selective Src inhibitor. In addition, the expression of dominant negative Src in F-36P cells reduced the tyrosine phosphorylation of STAT5. When Src and STAT5 were co-expressed in COS7 cells, tyrosine phosphorylation of STAT5 was observed, and tyrosine residue 694 (Tyr 694) of STAT5A was identified as the major phosphorylation site by Src. In vitro kinase assay revealed that GST-STAT5 fusion protein with the conserved C-terminal, but not the C-terminal-truncated mutant which lacks Tyr 694, was tyrosine-phosphorylated by Src. Src can thus directly tyrosine-phosphorylate the activation site of STAT5 (Tyr 694 in STAT5A), and Src may contribute to EPO-induced signal transduction via STAT5.	Kagawa Med Univ, Dept Internal Med 1, Kagawa 7610793, Japan; Kagawa Med Univ, Lab Med, Kagawa 7610793, Japan; Kagawa Univ, Hlth Sci Ctr, Kagawa 7608521, Japan	Kagawa University; Kagawa University; Kagawa University	Tanaka, T (corresponding author), Kagawa Med Univ, Dept Internal Med 1, Kagawa 7610793, Japan.	tanaka@kms.ac.jp						Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; CHIBA S, 1991, BLOOD, V78, P2261; Chin H, 1998, BLOOD, V91, P3734; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kitanaka A, 1999, J IMMUNOL, V162, P1952; KITANAKA A, 1994, BIOCHEM BIOPH RES CO, V201, P1534, DOI 10.1006/bbrc.1994.1878; Kitanaka A, 1998, BLOOD, V91, P940, DOI 10.1182/blood.V91.3.940.940_940_948; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	34	73	80	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6643	6650		10.1038/sj.onc.1204807	http://dx.doi.org/10.1038/sj.onc.1204807			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641791				2022-12-25	WOS:000171404200019
J	Wagner, AH; Schroeter, MR; Hecker, M				Wagner, AH; Schroeter, MR; Hecker, M			17 beta-estradiol inhibition of NADPH oxidase expression in human endothelial cells	FASEB JOURNAL			English	Article						endothelial nitric oxide synthase; estrogen; monocyte chemoattractant protein-1; CD54; superoxide	SUPEROXIDE ANION PRODUCTION; SYNTHASE GENE-EXPRESSION; SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; ESTROGEN-RECEPTOR; POSTMENOPAUSAL WOMEN; ARTERY ENDOTHELIUM; NAD(P)H OXIDASE; ACTIVATION; DISEASE	We investigated the hypothesis that the antiatherosclerotic effect of 17 beta -estradiol (E-2) is due to a shift in the nitric oxide (NO)/superoxide (O-2(-)) balance in the vessel wall, thereby increasing the bioavailability of NO. In human umbilical vein cultured endothelial cells, E-2 (1-100 nmol/l), but not 17 alpha -estradiol, caused a time- and concentration-dependent decrease in expression of the NADPH oxidase subunit gp91phox (up to 60% inhibition at both the mRNA and protein level). This effect was prevented by coincubation with the estrogen receptor antagonists tamoxifen and ICI 182,780 (1 mu mol/l each). Within the same concentration range, E-2 also up-regulated endothelial nitric oxide synthase expression (similar to twofold). Moreover, preincubation of the cells with E-2 or a gp91phox antisense oligonucleotide significantly decreased their capacity to generate O-2(-) on phorbol ester stimulation (i.e., assembly of the active NADPH oxidase complex). Blockade of NO synthase activity, on the other hand, had no effect on phorbol ester-stimulated O-2(-) formation. In addition, E-2 (100 nmol/l) inhibited the increase in adhesion molecule and chemokine expression in cells exposed to cyclic strain. Cyclic strain enhanced endothelial O-2(-) formation, thereby offsetting the inhibitory effect of NO on the expression of these gene products. E-2 thus seems to act as an antioxidant at the genomic level which by improving the NO/O-2(-) balance normalizes expression of proatherosclerotic gene products in endothelial cells.	Univ Gottingen, Dept Cardiovasc Physiol, D-37073 Gottingen, Germany	University of Gottingen	Hecker, M (corresponding author), Univ Gottingen, Dept Cardiovasc Physiol, Humboldtallee 23, D-37073 Gottingen, Germany.	hecker@veg-physiol.med.uni-goettingen.de						Baker VL, 1997, J SOC GYNECOL INVEST, V4, P316, DOI 10.1016/S1071-5576(97)00082-8; Barbacanne MA, 1999, CARDIOVASC RES, V41, P672, DOI 10.1016/S0008-6363(98)00254-5; Bayraktutan U, 2000, ARTERIOSCL THROM VAS, V20, P1903, DOI 10.1161/01.ATV.20.8.1903; Bekesi G, 2000, STEROIDS, V65, P889, DOI 10.1016/S0039-128X(00)00183-5; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; Busse R, 1996, J VASC RES, V33, P181, DOI 10.1159/000159147; Chen YG, 1998, J ASIAN NAT PROD RES, V1, P125, DOI 10.1080/10286029808039854; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; DE CR, 1995, J CLIN INVEST, V96, P60; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Guetta V, 1997, CIRCULATION, V96, P2795, DOI 10.1161/01.CIR.96.9.2795; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; HECKER M, 1994, BIOCHEM J, V299, P247, DOI 10.1042/bj2990247; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Jensen I, 1998, ENDOTHELIUM-NEW YORK, V6, P9, DOI 10.3109/10623329809053401; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; LECABEC V, 1995, J BIOL CHEM, V270, P2067; Liaudet L, 2000, CRIT CARE MED, V28, pN37, DOI 10.1097/00003246-200004001-00005; Lienenluke B, 2000, EUR J IMMUNOL, V30, P2864, DOI 10.1002/1521-4141(200010)30:10<2864::AID-IMMU2864>3.0.CO;2-W; MacRitchie AN, 1997, CIRC RES, V81, P355, DOI 10.1161/01.RES.81.3.355; Meischl C, 1998, SPRINGER SEMIN IMMUN, V19, P417, DOI 10.1007/BF00792600; Mendelsohn ME, 2000, CIRC RES, V87, P956, DOI 10.1161/01.RES.87.11.956; Mendelsohn ME, 2000, J STEROID BIOCHEM, V74, P337, DOI 10.1016/S0960-0760(00)00110-2; Meyer JW, 1999, ENDOTHELIUM-NEW YORK, V7, P11, DOI 10.3109/10623329909165308; Meyer JW, 2000, FEBS LETT, V472, P1, DOI 10.1016/S0014-5793(00)01397-1; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Possel H, 1997, FEBS LETT, V416, P175, DOI 10.1016/S0014-5793(97)01197-6; RIEDEL M, 1993, CLIN INVESTIGATOR, V71, P406; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; Ruschitzka FT, 1997, CARDIOLOGY, V88, P3, DOI 10.1159/000177500; Russell KS, 2000, J BIOL CHEM, V275, P5026, DOI 10.1074/jbc.275.7.5026; Sohn HY, 2000, FREE RADICAL RES, V32, P265, DOI 10.1080/10715760000300271; Spyridopoulos I, 1997, CIRCULATION, V95, P1505; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Swain SD, 1997, J BIOL CHEM, V272, P29502, DOI 10.1074/jbc.272.47.29502; Venkov CD, 1996, CIRCULATION, V94, P727, DOI 10.1161/01.CIR.94.4.727; Virchow R., 1856, GESAMM ABHANDL WISSE, P458; Virdis A, 2000, CIRCULATION, V101, P2258, DOI 10.1161/01.CIR.101.19.2258; Vogel RA, 1997, CLIN CARDIOL, V20, P426, DOI 10.1002/clc.4960200505; Wagner AH, 2000, MOL PHARMACOL, V58, P1333, DOI 10.1124/mol.58.6.1333; Wagner AH, 2000, ARTERIOSCL THROM VAS, V20, P61, DOI 10.1161/01.ATV.20.1.61; Wang XF, 1997, AM J PHYSIOL-HEART C, V273, pH1962, DOI 10.1152/ajpheart.1997.273.4.H1962; Wellman GC, 1996, CLIN EXP PHARMACOL P, V23, P260, DOI 10.1111/j.1440-1681.1996.tb02608.x; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1; Yang SM, 2000, J CARDIOVASC PHARM, V36, P242, DOI 10.1097/00005344-200008000-00015; ZEIHER AM, 1995, CIRC RES, V76, P980, DOI 10.1161/01.RES.76.6.980	52	177	181	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2121	2130		10.1096/fj.01-0123com	http://dx.doi.org/10.1096/fj.01-0123com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641238				2022-12-25	WOS:000171920400023
J	Han, MK; Kim, SJ; Park, YR; Shin, YM; Park, HJ; Park, KJ; Park, KH; Kim, HK; Jang, SI; An, NH; Kim, UH				Han, MK; Kim, SJ; Park, YR; Shin, YM; Park, HJ; Park, KJ; Park, KH; Kim, HK; Jang, SI; An, NH; Kim, UH			Antidiabetic effect of a prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid, through CD38 dimerization and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; RYANODINE RECEPTOR; PANCREATIC-ISLETS; OXIDATIVE STRESS; CELLS; HYDROLYSIS; EXPRESSION; CYCLASE; ACTIVATION; DELIVERY	CD38 is a bifunctional enzyme synthesizing (ADP-ribosyl cyclase) and degrading (cyclic ADP-ribose (cADPR) hydrolase) cADPR, a potent Ca2+ mobilizer from intracellular pools. CD38 internalization has been proposed as a mechanism by which the ectoenzyme produced intracellular cADPR, and thiol compounds have been shown to induce the internalization of CD38. Here, we show that the disulfide bond between Cys-119 and Cys-201 in CD38 may be involved in CD38 dimerization and internalization. We tested the effect of a reducing agent, L-2-oxothiazolidine-4-carboxylic acid (OTC), a prodrug of cysteine, on CD38 internalization in pancreatic islets. OTC enhanced insulin release from isolated islets as well as CD38 internalization and cytoplasmic Ca2+ level. Furthermore, islet cells treated with antisense CD38 oligonucleotide showed inhibition of OTC-induced insulin secretion. Intake of OTC in db/db mice ameliorated glucose tolerance, insulin secretion, and morphology of islets when compared with control mice. These data indicate that OTC improves glucose tolerance by enhancing insulin secretion via CD38/cADPR/Ca2+ signaling machinery. Thus, OTC may represent a novel class of antidiabetic drug.	Chonbuk Natl Univ, Sch Med, Dept Biochem, Chonju 561182, South Korea; Chonbuk Natl Univ, Sch Med, Inst Med Sci, Chonju 561182, South Korea; Adv Biochem Inc, Chonju 561182, South Korea; Wonkwang Univ, Coll Pharm, Iksan 567749, South Korea	Jeonbuk National University; Jeonbuk National University; Wonkwang University	Kim, UH (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Biochem, Chonju 561182, South Korea.	uhkim@moak.chonbuk.ac.kr		Kim, Uh-Hyun/0000-0003-3304-7190; Han, Myung-Kwan/0000-0003-1931-8898				ANDERSON ME, 1987, METHOD ENZYMOL, V143, P313; Bruzzone S, 2001, J BIOL CHEM, V276, P48300, DOI 10.1074/jbc.M107308200; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GUIDA L, 1995, FEBS LETT, V368, P481, DOI 10.1016/0014-5793(95)00715-L; Han MK, 2000, J BIOL CHEM, V275, P20799, DOI 10.1074/jbc.M001189200; HARADA N, 1993, J IMMUNOL, V151, P3111; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; Kaneto H, 1999, DIABETOLOGIA, V42, P1093, DOI 10.1007/s001250051276; Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Marshak S, 1999, DIABETES, V48, P1230, DOI 10.2337/diabetes.48.6.1230; MEISTER A, 1986, J AM COLL NUTR, V5, P137; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; Oiry J, 1999, J MED CHEM, V42, P4733, DOI 10.1021/jm980289j; PORTA P, 1991, J PHARMACOL EXP THER, V257, P331; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; SHIBATA A, 1976, DIABETES, V25, P667, DOI 10.2337/diabetes.25.8.667; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; Suzuki K, 2000, ELECTROPHORESIS, V21, P285, DOI 10.1002/(SICI)1522-2683(20000101)21:2<285::AID-ELPS285>3.0.CO;2-5; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; TOHGO A, 1994, J BIOL CHEM, V269, P28555; Vita JA, 1998, J CLIN INVEST, V101, P1408, DOI 10.1172/JCI1155; WILLIAMSON JM, 1981, P NATL ACAD SCI-BIOL, V78, P936, DOI 10.1073/pnas.78.2.936; York SJ, 1999, J BIOL CHEM, V274, P1164, DOI 10.1074/jbc.274.2.1164; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273	38	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5315	5321		10.1074/jbc.M106439200	http://dx.doi.org/10.1074/jbc.M106439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11679582	hybrid			2022-12-25	WOS:000173962900098
J	Reguera, RM; Balana-Fouce, R; Perez-Pertejo, Y; Fernandez, FJ; Garcia-Estrada, C; Cubria, JC; Ordonez, C; Ordonez, D				Reguera, RM; Balana-Fouce, R; Perez-Pertejo, Y; Fernandez, FJ; Garcia-Estrada, C; Cubria, JC; Ordonez, C; Ordonez, D			Cloning expression and characterization of methionine adenosyltransferase in Leishmania infantum promastigotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; TRYPANOSOMA-BRUCEI; MOLECULAR-CLONING; GENE-EXPRESSION; STRUCTURAL GENE; ACTIVATION; SUBUNIT	Methionine adenosyltransferase (MAT) catalyzes the synthesis of s-adenosylmethionine (AdoMet), a metabolite that plays an important role in a variety of cellular functions, such as methylation, sulfuration, and polyamine synthesis. In this study, genomic DNA from the protozoan parasite Leishmania infantum was cloned and characterized. L infantum NUT, unlike mammalian MAT, is codified by two identical genes in a tandem arrangement and is only weakly regulated by AdoMet. L. infantum MAT mRNA is expressed as a single transcript, with the enzyme forming a homodimer with tripolyphosphatase in addition to MAT activity. Expression of L. infantum MAT in Escherichia coli proves that the MAT and tripolyphosphatase activities are functional in vivo. MAT shows sigmoidal behavior and is weakly inhibited by AdoMet, whereas tripolyphosphatase activity has sigmoidal behavior and is strongly activated by AdoMet. Plasmids containing the regions flanking MAT2 were fused immediately upstream and downstream of the luciferase-coding region and transfected into L. infantum. Subsequent examination of luciferase activity showed that homologous expression in L infantum promastigotes was dramatically dependent on the presence of polypyrimidine tracts and a spliced leader junction site upstream of the luciferase gene, whereas down. stream sequences appeared to have no bearing on expression.	Univ Leon, Fac Vet, Dept Farmacol & Toxicol, E-24071 Leon, Spain; Univ Autonoma Metropolitana Iztapalapa, Dept Biotecnol Ciencias Biol & Salud, Mexico City 09340, DF, Mexico	Universidad de Leon; Universidad Autonoma Metropolitana - Mexico	Ordonez, D (corresponding author), Univ Leon, Fac Vet, Dept Farmacol & Toxicol, Campus Vegazana S-N, E-24071 Leon, Spain.		Fernandez, Francisco/L-3320-2015; Pérez-Pertejo, Yolanda/K-6609-2017; Reguera, Rosa M/K-6027-2017; Garcia-Estrada, Carlos/F-7932-2014; Balana-Fouce, Rafael/AAK-9485-2021; Hu, Ruogu/B-2203-2008; Balana-Fouce, Rafael/K-4890-2014	Fernandez, Francisco/0000-0003-4676-1828; Pérez-Pertejo, Yolanda/0000-0003-2361-3785; Reguera, Rosa M/0000-0001-9148-2997; Garcia-Estrada, Carlos/0000-0001-5617-9669; Balana-Fouce, Rafael/0000-0003-0418-6116; Balana-Fouce, Rafael/0000-0003-0418-6116; Ordonez, Cesar/0000-0002-4685-3901				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALVAREZ L, 1994, BIOCHEM J, V301, P557, DOI 10.1042/bj3010557; BACCHI CJ, 1993, ACTA TROP, V54, P225, DOI 10.1016/0001-706X(93)90095-S; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTONI GL, 1953, J BIOL CHEM, V204, P403; CHIANG PK, 1977, J BIOL CHEM, V252, P4506; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; CORRALES F, 1990, HEPATOLOGY, V11, P216, DOI 10.1002/hep.1840110210; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; DELAROSA J, 1995, J BIOL CHEM, V270, P21860; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; HOBSON AC, 1973, MOL GEN GENET, V126, P7, DOI 10.1007/BF00333477; HORIKAWA S, 1989, EUR J BIOCHEM, V184, P497, DOI 10.1111/j.1432-1033.1989.tb15042.x; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; HORIKAWA S, 1991, BIOCHEM INT, V25, P81; Jimenez-Ruiz A, 1998, EUR J BIOCHEM, V251, P389, DOI 10.1046/j.1432-1327.1998.2510389.x; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; LANGFORD CK, 1994, J BIOL CHEM, V269, P17939; LEBOWITZ JH, 1994, METHOD CELL BIOL, V45, P65; LEBOWITZ JH, 1991, GENE, V103, P119, DOI 10.1016/0378-1119(91)90402-W; LeGros HL, 2000, J BIOL CHEM, V275, P2359, DOI 10.1074/jbc.275.4.2359; Lopez-Vara MC, 2000, PROTEIN EXPRES PURIF, V19, P219, DOI 10.1006/prep.2000.1235; MARKHAM GD, 1984, J BIOL CHEM, V259, P4505; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; MCQUENEY MS, 1995, J BIOL CHEM, V270, P18277, DOI 10.1074/jbc.270.31.18277; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; PAJARES MA, 1992, FEBS LETT, V309, P1, DOI 10.1016/0014-5793(92)80726-W; Quijada L, 1997, J BIOL CHEM, V272, P4493, DOI 10.1074/jbc.272.7.4493; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; SAKATA SF, 1993, J BIOL CHEM, V268, P13978; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATISHCHANDRAN C, 1990, J BACTERIOL, V172, P4489, DOI 10.1128/jb.172.8.4489-4496.1990; SOTO M, 1993, J BIOL CHEM, V268, P21835; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; Takusagawa F, 1996, BIOCHEMISTRY-US, V35, P2586, DOI 10.1021/bi952604z; Teixeira SMR, 1998, BRAZ J MED BIOL RES, V31, P1503, DOI 10.1590/S0100-879X1998001200001; THOMAS D, 1988, MOL CELL BIOL, V8, P5132, DOI 10.1128/MCB.8.12.5132; THOMAS D, 1987, J BIOL CHEM, V262, P16704; YARLETT N, 1993, BIOCHIM BIOPHYS ACTA, V1181, P68, DOI 10.1016/0925-4439(93)90092-F; YARLETT N, 1988, MOL BIOCHEM PARASIT, V27, P1, DOI 10.1016/0166-6851(88)90019-9	44	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3158	3167		10.1074/jbc.M105512200	http://dx.doi.org/10.1074/jbc.M105512200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11698393	hybrid			2022-12-25	WOS:000173688000015
J	Martensson, S; Hammarsten, O				Martensson, S; Hammarsten, O			DNA-dependent protein kinase catalytic subunit - Structural requirements for kinase activation by DNA ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; KU PROTEIN; CELLS DEFICIENT; DAMAGE; REPAIR; PHOSPHORYLATION; AUTOANTIGEN; MECHANISM; BINDING; ATR	DNA-dependent protein kinase (DNA-PK) is a DNA end-activated protein kinase composed of a catalytic subunit, DNA-PKcs, and a DNA binding subunit, Ku, that is involved in repair of DNA double-stranded breaks (DSBs). We have previously shown that DNA-PKcs interacts with single-stranded DNA (ssDNA) ends with a separate ssDNA binding site to be activated for its kinase activity. Here, the properties of the ssDNA binding site were examined by using DNA fragments with modified ssDNA extensions. DNA fragments with a wide range of ssDNA modifictations activated DNA-PKcs, indicating a relaxed specificity for the chemical structure of terminal nucleotides of a DSB. Methyl substitution of the phosphate backbone impaired kinase activation but not binding, indicating that interaction with the DNA backbone was involved in kinase activation. Experiments with RNA and RNA/DNA hybrid fragments suggested that the discrimination between RNA and DNA ends resides in the double-stranded DNA binding function of DNA-PKcs. DNA fragments exposing only one ssDNA end activated DNA-PKcs poorly, suggesting that DNA-PKcs distinguishes between DSBs and ssDNA breaks by simultaneous interaction with two ssDNA ends. These properties potentially explain how DNA-PKcs can be specifically activated by DSBs but still recognize the diverse chemical structures exposed when DSBs are introduced by ionizing radiation.	Gothenburg Univ, Sahlgrens Hosp, Dept Clin Chem, SE-41345 Gothenburg, Sweden	Sahlgrenska University Hospital; University of Gothenburg	Hammarsten, O (corresponding author), Gothenburg Univ, Sahlgrens Hosp, Dept Clin Chem, SE-41345 Gothenburg, Sweden.	ola.hammarsten@clinchem.gu.se	Hammarsten, Ola/A-2791-2012					Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; BLIER PR, 1993, J BIOL CHEM, V268, P7594; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; DARROUDI F, 1990, MUTAT RES, V235, P119, DOI 10.1016/0921-8777(90)90065-D; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; FALZON M, 1993, J BIOL CHEM, V268, P10546; FRANKENBERGSCHWAGER M, 1989, RADIOTHER ONCOL, V14, P307, DOI 10.1016/0167-8140(89)90143-6; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENSI, P20; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Guan J, 2000, NUCLEIC ACIDS RES, V28, P1183, DOI 10.1093/nar/28.5.1183; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; MIMORI T, 1986, J BIOL CHEM, V261, P375; NIAS A, 1998, INTRO RADIOBIOLOGY, P102; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; Ross GM, 1999, ENDOCR-RELAT CANCER, V6, P41, DOI 10.1677/erc.0.0060041; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; Smider V, 1998, MOL CELL BIOL, V18, P6853, DOI 10.1128/MCB.18.11.6853; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Ting NSY, 1999, RADIAT RES, V151, P414, DOI 10.2307/3579828; Turchi JJ, 2000, NUCLEIC ACIDS RES, V28, P4634, DOI 10.1093/nar/28.23.4634; Turchi JJ, 1997, BIOCHEMISTRY-US, V36, P7586, DOI 10.1021/bi963124q; Turchi JJ, 1996, J BIOL CHEM, V271, P13861, DOI 10.1074/jbc.271.23.13861; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang HC, 2001, CANCER RES, V61, P270; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Weinfeld M, 1997, RADIAT RES, V148, P22, DOI 10.2307/3579534; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Yoo S, 1998, BIOCHEMISTRY-US, V37, P1336, DOI 10.1021/bi972100w	48	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					3020	3029		10.1074/jbc.M106711200	http://dx.doi.org/10.1074/jbc.M106711200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11700303	hybrid			2022-12-25	WOS:000173421500085
J	Shimoda, Y; Tajima, Y; Osanai, T; Katsume, A; Kohara, M; Kudo, T; Narimatsu, H; Takashima, N; Ishii, Y; Nakamura, S; Osumi, N; Sanai, Y				Shimoda, Y; Tajima, Y; Osanai, T; Katsume, A; Kohara, M; Kudo, T; Narimatsu, H; Takashima, N; Ishii, Y; Nakamura, S; Osumi, N; Sanai, Y			Pax6 controls the expression of Lewis x epitope in the embryonic forebrain by regulating alpha 1,3-fucosyltransferase IX expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; PROTEIN-TYROSINE-PHOSPHATASE; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; CHONDROITIN SULFATE PROTEOGLYCAN; FUCOSYL-TRANSFERASE GENE; NERVOUS-SYSTEM; SMALL-EYE; CEREBRAL-CORTEX; ANTIGEN SSEA-1; PREIMPLANTATION EMBRYOS	Pax6 is a transcription factor involved in brain patterning and neurogenesis. Expression of Pax6 is specifically observed in the developing cerebral cortex, where Lewis x epitope that is thought to play important roles in cell interactions is colocalized. Here we examined whether Pax6 regulates localization of Lewis x using Pax6 mutant rat embryos. The Lewis x epitope disappeared in the Pax6 mutant cortex, and activity of alpha1,3-fucosyltransferase, which catalyzed the last step of Lewis x biosynthesis, drastically decreased in the mutant cortex as compared with the wild type. Furthermore, expression of a fucosyltransferase gene, FucT-IX, specifically decreased in the mutant, while no change was seen for expression of another fucosyltransferase gene, FucT-IV. These results strongly suggest that Pax6 controls Lewis x expression in the embryonic brain by regulating FucT-IX gene expression.	Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Med Sci, Dept Microbiol & Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Soka Univ, Inst Life Sci, Div Cell Biol, Hachioji, Tokyo 1928577, Japan; Natl Inst Neurosci, Div Biochem & Cellular Biol, Kodaira, Tokyo 1878502, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; Soka University; National Center for Neurology & Psychiatry - Japan	Sanai, Y (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.		Osumi, Noriko/T-2823-2019	Osumi, Noriko/0000-0003-0548-6452				Allendoerfer KL, 1999, DEV BIOL, V211, P208, DOI 10.1006/dbio.1999.9308; ALLENDOERFER KL, 1995, MOL CELL NEUROSCI, V6, P381, DOI 10.1006/mcne.1995.1029; Baboval T, 2000, J NEUROSCI RES, V62, P206, DOI 10.1002/1097-4547(20001015)62:2<206::AID-JNR5>3.0.CO;2-E; Becker DJ, 1999, BBA-MOL BASIS DIS, V1455, P193, DOI 10.1016/S0925-4439(99)00071-X; Caric D, 1997, DEVELOPMENT, V124, P5087; CHALEPAKIS G, 1994, DNA CELL BIOL, V13, P891, DOI 10.1089/dna.1994.13.891; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; Chapouton P, 1999, DEVELOPMENT, V126, P5569; Chou DKH, 1996, GLYCOCONJUGATE J, V13, P295, DOI 10.1007/BF00731504; CHOU DKH, 1994, J NEUROCHEM, V62, P307; CVEKL A, 1995, MOL CELL BIOL, V15, P653; EGGENS I, 1989, J BIOL CHEM, V264, P9476; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; Etzioni A, 1999, BLOOD, V94, P3281, DOI 10.1182/blood.V94.10.3281.422k37_3281_3288; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FOX N, 1981, DEV BIOL, V83, P391, DOI 10.1016/0012-1606(81)90487-5; Fukuda T, 2000, DEV BRAIN RES, V120, P65, DOI 10.1016/S0165-3806(99)00187-X; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; Gotz M, 1996, NEURON, V16, P551, DOI 10.1016/S0896-6273(00)80074-4; Gotz M, 1998, NEURON, V21, P1031, DOI 10.1016/S0896-6273(00)80621-2; Grindley JC, 1997, MECH DEVELOP, V64, P111, DOI 10.1016/S0925-4773(97)00055-5; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HAKOMORI S, 1981, BIOCHEM BIOPH RES CO, V100, P1578, DOI 10.1016/0006-291X(81)90699-9; Heyman I, 1999, PSYCHIATR GENET, V9, P85, DOI 10.1097/00041444-199906000-00006; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Holst BD, 1997, P NATL ACAD SCI USA, V94, P1465, DOI 10.1073/pnas.94.4.1465; HYAFIL F, 1981, CELL, V26, P447, DOI 10.1016/0092-8674(81)90214-2; Inoue T, 2000, DEV BIOL, V219, P373, DOI 10.1006/dbio.2000.9616; Ishii Y, 2000, DEV BRAIN RES, V119, P307, DOI 10.1016/S0165-3806(99)00186-8; Kaneko M, 1999, FEBS LETT, V452, P237, DOI 10.1016/S0014-5793(99)00640-7; Kawano H, 1999, J COMP NEUROL, V408, P147, DOI 10.1002/(SICI)1096-9861(19990531)408:2<147::AID-CNE1>3.0.CO;2-L; KOBATA A, 1969, J BIOL CHEM, V244, P5496; KOJIMA N, 1994, GLYCOCONJUGATE J, V11, P238, DOI 10.1007/BF00731224; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; Kudo T, 1998, J BIOL CHEM, V273, P26729, DOI 10.1074/jbc.273.41.26729; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LAGENAUR C, 1982, NEUROSCI LETT, V31, P181, DOI 10.1016/0304-3940(82)90113-6; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MAI JK, 1992, HISTOCHEM J, V24, P878, DOI 10.1007/BF01046359; MARANI E, 1992, HISTOCHEM J, V24, P852, DOI 10.1007/BF01046357; Mastick GS, 1997, DEVELOPMENT, V124, P1985; Matsunami H, 1995, DEV BIOL, V172, P466, DOI 10.1006/dbio.1995.8029; MATSUO T, 1993, NAT GENET, V3, P299, DOI 10.1038/ng0493-299; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MCCURLEY RS, 1995, GENOMICS, V26, P142, DOI 10.1016/0888-7543(95)80094-3; Meech R, 1999, P NATL ACAD SCI USA, V96, P2420, DOI 10.1073/pnas.96.5.2420; MILEV P, 1995, J BIOL CHEM, V270, P24650, DOI 10.1074/jbc.270.42.24650; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Ohyama K, 1998, DEV BRAIN RES, V107, P219, DOI 10.1016/S0165-3806(97)00220-4; Osanai T, 2001, FEBS LETT, V488, P23, DOI 10.1016/S0014-5793(00)02407-8; Osumi N, 2001, TOHOKU J EXP MED, V193, P163, DOI 10.1620/tjem.193.163; Osumi N, 1997, DEVELOPMENT, V124, P2961; Ozawa M, 1996, J BIOCHEM-TOKYO, V119, P302; Pratt T, 2000, DEVELOPMENT, V127, P5167; RAUCH U, 1991, J BIOL CHEM, V266, P14785; REIFENBERGER G, 1992, HISTOCHEM J, V24, P890, DOI 10.1007/BF01046360; SajdelSulkowska EM, 1997, GLYCOCONJUGATE J, V14, P249, DOI 10.1023/A:1018550023637; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SATOH J, 1994, J NEUROSCI RES, V37, P466, DOI 10.1002/jnr.490370406; SCHMAHL W, 1993, ACTA NEUROPATHOL, V86, P126, DOI 10.1007/BF00334879; Shimoda Y, 1999, J BIOL CHEM, V274, P17115, DOI 10.1074/jbc.274.24.17115; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; Stober G, 1999, BIOL PSYCHIAT, V45, P1585, DOI 10.1016/S0006-3223(99)00024-4; Stoykova A, 2000, J NEUROSCI, V20, P8042; Stoykova A, 1997, DEVELOPMENT, V124, P3765; Stoykova A, 1996, DEVELOPMENT, V122, P3453; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; Takeuchi T, 1999, GASTROENTEROLOGY, V116, P636, DOI 10.1016/S0016-5085(99)70185-X; Toresson H, 2000, DEVELOPMENT, V127, P4361; VESTWEBER D, 1987, DEV BIOL, V124, P451, DOI 10.1016/0012-1606(87)90498-2; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Warren N, 1997, DEVELOPMENT, V124, P1573; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YAMAMOTO M, 1985, P NATL ACAD SCI USA, V82, P3045, DOI 10.1073/pnas.82.9.3045; Yun K, 2001, DEVELOPMENT, V128, P193	83	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2033	2039		10.1074/jbc.M108495200	http://dx.doi.org/10.1074/jbc.M108495200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11675393	hybrid			2022-12-25	WOS:000173421300058
J	Cano, MIN; Blake, JJ; Blackburn, EH; Agabian, N				Cano, MIN; Blake, JJ; Blackburn, EH; Agabian, N			A Trypanosoma brucei protein complex that binds G-overhangs and co-purifies with telomerase activity.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TELOMERASE; ANTIGENIC VARIATION; LENGTH REGULATION; DNA; EST1; IDENTIFICATION; RAP1; RNA; ORGANIZATION; RECOGNITION	The chromosomal ends of Trypanosoma brucei, like those of most eukaryotes, contain conserved 5'-TTAGGG-3' repeated sequences and are maintained by the action of telomerase. Fractionated T. brucei cell extracts with telomerase activity were used as a source of potential regulatory factors or telomerase-associated components that might interact with T. brucei telomeres. Electrophoretic mobility shift assays and UV cross-linking were used to detect possible single-stranded telomeric protein-DNA complexes and to estimate the approximate size of the protein constituents. Three single-stranded telomeric protein-DNA complexes were observed. Complex C3 was highly specific for the G-strand telomeric repeat sequence and shares biochemical characteristics with G-rich, single-stranded telomeric binding proteins and with components of the telomerase holoenzyme described in yeast, ciliates, and humans. Susceptibility to RNase A or chemical nuclease (hydroxyl radical) pre-treatment showed that complex C3 was tightly associated with an RNA component. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry was used to estimate the molecular mass of the peptides obtained by in-gel Lys-C digestion of low abundance C3-associated proteins. The molecular masses of the peptides showed no homologies with other proteins from trypanosomes or with any protein in the data bases screened.	Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Cano, MIN (corresponding author), Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Genet & Evolucao, CP 6109, BR-13083970 Campinas, SP, Brazil.	micano@unicamp.br	Cano, Maria Isabel/M-7691-2019; Cano, Maria Isabel/A-4020-2008	Cano, Maria Isabel/0000-0001-9798-6627; 	NIAID NIH HHS [AI21975] Funding Source: Medline; NIGMS NIH HHS [GM26259] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026259, R37GM026259] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V2; BIENEN EJ, 1981, EXP PARASITOL, V51, P408, DOI 10.1016/0014-4894(81)90128-4; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; BLACKBURN EH, 1984, CELL, V36, P447, DOI 10.1016/0092-8674(84)90238-1; Blasco Maria A., 1999, Genes and Development, V13, P2353, DOI 10.1101/gad.13.18.2353; Borst P, 1996, ARCH MED RES, V27, P379; Bourns BD, 1998, MOL CELL BIOL, V18, P5600, DOI 10.1128/MCB.18.9.5600; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Cano MIN, 1999, P NATL ACAD SCI USA, V96, P3616, DOI 10.1073/pnas.96.7.3616; Cano MIN, 2001, TRENDS PARASITOL, V17, P425, DOI 10.1016/S1471-4922(01)02014-1; Chiurillo MA, 1999, MOL BIOCHEM PARASIT, V100, P173, DOI 10.1016/S0166-6851(99)00047-X; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; Eid JE, 1997, J BIOL CHEM, V272, P14927, DOI 10.1074/jbc.272.23.14927; EID JE, 1995, MOL CELL BIOL, V15, P389, DOI 10.1128/MCB.15.1.389; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Field H, 1996, EXP PARASITOL, V83, P155, DOI 10.1006/expr.1996.0060; Froelich-Ammon SJ, 1998, GENE DEV, V12, P1504, DOI 10.1101/gad.12.10.1504; Gandhi L, 1998, GENE DEV, V12, P721, DOI 10.1101/gad.12.5.721; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HARRINGTON L, 1995, J BIOL CHEM, V270, P8893, DOI 10.1074/jbc.270.15.8893; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; Johnston SD, 1999, MOL CELL BIOL, V19, P923; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; Krauskopf A, 1998, P NATL ACAD SCI USA, V95, P12486, DOI 10.1073/pnas.95.21.12486; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; LANZER M, 1995, MOL BIOCHEM PARASIT, V70, P1, DOI 10.1016/0166-6851(95)00021-R; Le SY, 2000, MOL BIOL CELL, V11, P999, DOI 10.1091/mbc.11.3.999; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; Lu Q, 1998, NUCLEIC ACIDS RES, V26, P1613, DOI 10.1093/nar/26.7.1613; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Morris DK, 1997, CURR BIOL, V7, P969, DOI 10.1016/S0960-9822(06)00416-7; MUNOZJORDAN J, 2001, NATUE, V20, P579; Myler PJ, 2000, BIOCHEM SOC T, V28, P527, DOI 10.1042/bst0280527; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; O'Reilly Marc, 1999, Current Opinion in Structural Biology, V9, P56, DOI 10.1016/S0959-440X(99)80008-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAVERY N, 1996, GENE TRANSCRIPTION D, P1; Shore D, 1997, BIOL CHEM, V378, P591; SHORE D, 1995, TELOMERES, P139; Slijepcevic P, 1998, EXP CELL RES, V244, P268, DOI 10.1006/excr.1998.4185; Smith CD, 1999, J CELL BIOL, V145, P203, DOI 10.1083/jcb.145.2.203; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; VANDERPLOEG LHT, 1984, CELL, V36, P459, DOI 10.1016/0092-8674(84)90239-3; VANDERPLOEG LHT, 1992, MECHANISMS EUKARYOTI, P179; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Zhou JL, 2000, MOL CELL BIOL, V20, P1947, DOI 10.1128/MCB.20.6.1947-1955.2000	56	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					896	906		10.1074/jbc.M104111200	http://dx.doi.org/10.1074/jbc.M104111200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11673453	hybrid			2022-12-25	WOS:000173166800006
J	Gutierrez, S; Javed, A; Tennant, DK; van Rees, M; Montecino, M; Stein, GS; Stein, JL; Lian, JB				Gutierrez, S; Javed, A; Tennant, DK; van Rees, M; Montecino, M; Stein, GS; Stein, JL; Lian, JB			CCAAT/enhancer-binding proteins (C/EBP) beta and delta activate osteocalcin gene transcription and synergize with Runx2 at the C/EBP element to regulate bone-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLASTIC MC3T3-E1 CELLS; IN-VIVO; NUCLEAR-MATRIX; CBF-BETA; CLEIDOCRANIAL DYSPLASIA; PROGRESSIVE DEVELOPMENT; CHROMATIN ORGANIZATION; TARGETED DISRUPTION; RECEPTOR PROMOTER; OC BOX	CCAAT/enhancer-binding proteins (C/EBP) are critical determinants for cellular differentiation and cell type-specific gene expression. Their functional roles in osteoblast development have not been determined. We addressed a key component of the mechanisms by which C/EBP factors regulate transcription of a tissue-specific gene during osteoblast differentiation. Expression of both C/EBPbeta and C/EBPdelta increases from the growth to maturation developmental stages and, like the bone-specific osteocalcin (OC) gene, is also stimulated 3-6-fold by vitamin D(3), a regulator of osteoblast differentiation. We characterized a C/EBP enhancer element in the proximal promoter of the rat osteocalcin gene, which resides in close proximity to a Runx2 (Cbfa1) element, essential for tissue-specific activation. We find that C/EBP and Runx2 factors interact together in a synergistic manner to enhance OC transcription (35-40-fold) in cell culture systems. We show by mutational analysis that this synergism is mediated through the C/EBP-responsive element in the OC promoter and by a direct interaction between Runx2 and C/EBPbeta. Furthermore, we have mapped a domain in Runx2 necessary for this interaction by immunoprecipitation. A Runx2 mutant lacking this interaction domain does not exhibit functional synergism. We conclude that, in addition to Runx2 DNA binding functions, Runx2 can also form a protein complex at C/EBP sites to regulate transcription. Taken together, our findings indicate that C/EBP is a principal transactivator of the OC gene and the synergism with Runx2 suggests that a combinatorial interaction of these factors is a principal mechanism for regulating tissue-specific expression during osteoblast differentiation.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Concepcion, Dept Biol Mol, Concepcion, Chile	University of Massachusetts System; University of Massachusetts Worcester; Universidad de Concepcion	Lian, JB (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	jane.lian@umassmed.edu		Javed, Amjad/0000-0002-0847-8266	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045689, R01AR039588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE012528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012528] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39588, AR45689] Funding Source: Medline; NIDCR NIH HHS [DE12528] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALAM T, 1992, J BIOL CHEM, V267, P5021; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; Armesilla AL, 1996, J BIOL CHEM, V271, P7781, DOI 10.1074/jbc.271.13.7781; Attard FA, 2000, ARCH BIOCHEM BIOPHYS, V378, P57, DOI 10.1006/abbi.2000.1803; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Banerjee C, 1996, ENDOCRINOLOGY, V137, P1991, DOI 10.1210/en.137.5.1991; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; Gabbitas B, 1998, AM J PHYSIOL-ENDOC M, V275, pE222; Graves BJ, 1998, SCIENCE, V279, P1000, DOI 10.1126/science.279.5353.1000; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; Harrison JR, 2000, J BONE MINER RES, V15, P1138, DOI 10.1359/jbmr.2000.15.6.1138; Hoffmann H, 2000, J CELL BIOCHEM, V80, P156; Hoffmann HM, 1996, J CELL BIOCHEM, V61, P310, DOI 10.1002/(SICI)1097-4644(19960501)61:2<310::AID-JCB14>3.0.CO;2-P; Javed A, 1999, MOL CELL BIOL, V19, P7491; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Javed A, 2000, J CELL SCI, V113, P2221; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lian JB, 1999, VITAM HORM, V55, P443; Lian JB, 2001, STEROIDS, V66, P159, DOI 10.1016/S0039-128X(00)00160-4; LopezRodriguez C, 1997, J BIOL CHEM, V272, P29120, DOI 10.1074/jbc.272.46.29120; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; McCarthy TL, 2000, J BIOL CHEM, V275, P21746, DOI 10.1074/jbc.M002291200; Montecino M, 1999, BIOCHEMISTRY-US, V38, P1338, DOI 10.1021/bi982171a; Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s; Montecino M, 1999, J CELL BIOCHEM, V72, P586, DOI 10.1002/(SICI)1097-4644(19990315)72:4<586::AID-JCB13>3.0.CO;2-K; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rosen ED, 2000, GENE DEV, V14, P1293; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Speck NA, 1999, CANCER RES, V59, p1789S; Spiegelman BM, 2000, INT J OBESITY, V24, pS8, DOI 10.1038/sj.ijo.0801492; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Zaiman AL, 1996, J VIROL, V70, P5618, DOI 10.1128/JVI.70.8.5618-5629.1996; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	64	206	209	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1316	1323		10.1074/jbc.M106611200	http://dx.doi.org/10.1074/jbc.M106611200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11668178	hybrid			2022-12-25	WOS:000173166800059
J	Paccani, SR; Boncristiano, M; Ulivieri, C; D'Elios, MM; Del Prete, G; Baldari, CT				Paccani, SR; Boncristiano, M; Ulivieri, C; D'Elios, MM; Del Prete, G; Baldari, CT			Nonsteroidal anti-inflammatory drugs suppress T-cell activation by inhibiting p38 MAPK induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B KINASE; SIGNAL-TRANSDUCTION; ANTIINFLAMMATORY DRUGS; GENE-EXPRESSION; PATHWAYS; CYCLOOXYGENASE-2; INTERLEUKIN-2; SALICYLATE; ASPIRIN; MITOGEN	In addition to antagonizing inflammation by inhibiting the activity of cyclooxygenases (COX), nonsteroidal anti-inflammatory drugs (NSAID) block T-cell activation. The immunosuppressant activity of NSAID correlates with their ability to block transcription factors required for the expression of inducible response genes triggered by T-cell antigen receptor (TCR) engagement. Whereas the inhibition of nuclear factor-kappaB by aspirin and sodium salicylate can be partly accounted for by their binding to IkappaB kinase-beta, the broad range of transcriptional targets of NSAID suggests that the products of COX activity might affect one or more among the early steps in the TCR-signaling cascade. Here we show that the inhibition of NF-AT activation by NSAID correlates with a selective inhibition of p38 MAP kinase induction. The suppression of TCR-dependent p38 activation by NSAID can be fully overcome by prostaglandin E-2, underlining the requirement for COX activity in p38 activation. Furthermore, the inhibition of COX-1 results in defective induction of the COX-2 gene, which behaves as an early TCR responsive gene. The data identify COX-1 and COX-2 as integral and sequential components of TCR signaling to p38 and contribute to elucidate the molecular basis of immunosuppression by NSAID.	Univ Siena, Dept Evolut Biol, I-53100 Siena, Italy; Univ Florence, Dept Internal Med & Immunoallergol, I-50134 Florence, Italy	University of Siena; University of Florence	Baldari, CT (corresponding author), Univ Siena, Dept Evolut Biol, Via Mattioli 4, I-53100 Siena, Italy.		Ulivieri, Cristina/AAH-7543-2020; D'Elios, Mario Milco/Y-9573-2019	D'Elios, Mario Milco/0000-0001-9160-0930; Ulivieri, Cristina/0000-0002-1710-7977; Baldari, Cosima/0000-0002-4414-6744				Baldari CT, 1998, BIOLOGICALS, V26, P1, DOI 10.1006/biol.1997.0116; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; DELAREO G, 2000, J BIOL CHEM, V275, P13871; DeWitt DL, 1999, MOL PHARMACOL, V55, P625; Dong ZG, 1997, J BIOL CHEM, V272, P9962; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; FUTAKI N, 1993, J PHARM PHARMACOL, V45, P753, DOI 10.1111/j.2042-7158.1993.tb07103.x; Hall VC, 1997, J RHEUMATOL, V24, P1467; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Iniguez MA, 1999, J IMMUNOL, V163, P111; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; KAZMI SMI, 1995, J CELL BIOCHEM, V57, P299, DOI 10.1002/jcb.240570214; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Plyte S, 2001, J BIOL CHEM, V276, P14350, DOI 10.1074/jbc.M007854200; Plyte S, 2000, ONCOGENE, V19, P1529, DOI 10.1038/sj.onc.1203451; Pouliot M, 1997, J IMMUNOL, V158, P4930; Rocca B, 1999, J CLIN INVEST, V103, P1469, DOI 10.1172/JCI6400; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Tatla S, 1999, FREE RADICAL BIO MED, V26, P14, DOI 10.1016/S0891-5849(98)00133-6; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	29	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1509	1513		10.1074/jbc.M110676200	http://dx.doi.org/10.1074/jbc.M110676200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11700329	hybrid			2022-12-25	WOS:000173166800083
J	Sabatini, R; Meeuwenoord, N; van Boom, JH; Borst, P				Sabatini, R; Meeuwenoord, N; van Boom, JH; Borst, P			Recognition of base J in duplex DNA by J-binding protein.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSYL-HYDROXYMETHYLURACIL; TRYPANOSOMA-BRUCEI; KINETOPLASTID PROTOZOANS; ENDONUCLEASE; SITES; GLYCOSYLASE; PHOTOLYASE; SEQUENCES	beta-D-Glucosylhydroxymethyluracil, also called base J, is an unusual modified DNA base conserved among Kinetoplastida. Base J is found predominantly in repetitive DNA and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes. We have previously found a J-binding protein (JBP) in Trypanosoma, Leishmania, and Crithidia We have now characterized the binding properties of recombinant JBP from Crithidia using synthetic J-DNA substrates that contain the glycosylated base in various DNA sequences. We find that JBP recognizes base J only when presented in double-stranded DNA but not in single-stranded DNA or in an RNA:DNA duplex. It also fails to interact with free glucose or free base J. JBP is unable to recognize nonmodified DNA or intermediates of J synthesis, suggesting that JBP is not directly involved in J biosynthesis. JBP binds J-DNA with high affinity (K-d = 40-140 nm) but requires at least 5 by flanking the glycosylated base for optimal binding. The nature of the flanking sequence affects binding because J in a telomeric sequence binds JBP with higher affinity than J in another sequence known to contain J in trypanosome DNA. We conclude that JBP is a structure-specific DNA-binding protein. The significance of these results in relation to the biological role and mechanism of action of J modification in kinetoplastids is discussed.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Leiden Inst Chem, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands; Univ Alabama, Div Geog Med, Birmingham, AL 35294 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Leiden University; University of Alabama System; University of Alabama Birmingham	Sabatini, R (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.							BERNARDS A, 1984, NUCLEIC ACIDS RES, V12, P4153, DOI 10.1093/nar/12.10.4153; Blundell PA, 1998, MOL BIOCHEM PARASIT, V93, P115, DOI 10.1016/S0166-6851(98)00030-9; Borst P, 1997, MOL BIOCHEM PARASIT, V90, P1, DOI 10.1016/S0166-6851(97)00170-9; CANN JR, 1989, J BIOL CHEM, V264, P17032; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; Cross M, 1999, EMBO J, V18, P6573, DOI 10.1093/emboj/18.22.6573; Gao YG, 1997, J AM CHEM SOC, V119, P1496, DOI 10.1021/ja963793r; GOMMERSAMPT J, 1991, NUCLEIC ACIDS RES, V19, P1745, DOI 10.1093/nar/19.8.1745; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; Hitomi K, 1997, J BIOL CHEM, V272, P32591, DOI 10.1074/jbc.272.51.32591; HUSAIN I, 1987, NUCLEIC ACIDS RES, V15, P1109; Miao F, 1998, NUCLEIC ACIDS RES, V26, P4034, DOI 10.1093/nar/26.17.4034; OHANDLEY S, 1995, BIOCHEMISTRY-US, V34, P2528, DOI 10.1021/bi00008a017; PAYS E, 1984, NUCLEIC ACIDS RES, V12, P5235, DOI 10.1093/nar/12.13.5235; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; van Leeuwen F, 1998, MOL BIOCHEM PARASIT, V94, P127, DOI 10.1016/S0166-6851(98)00060-7; van Leeuwen F, 1998, MOL CELL BIOL, V18, P5643, DOI 10.1128/MCB.18.10.5643; van Leeuwen F, 1998, P NATL ACAD SCI USA, V95, P2366, DOI 10.1073/pnas.95.5.2366; vanLeeuwen F, 1996, NUCLEIC ACIDS RES, V24, P2476, DOI 10.1093/nar/24.13.2476; vanLeeuwen F, 1997, GENE DEV, V11, P3232, DOI 10.1101/gad.11.23.3232; WIJSMAN ER, 1994, RECL TRAV CHIM PAY B, V113, P337; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933	22	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					958	966		10.1074/jbc.M109000200	http://dx.doi.org/10.1074/jbc.M109000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11700315	hybrid, Green Published			2022-12-25	WOS:000173166800014
J	Solan, NJ; Miyoshi, H; Carmona, EM; Bren, GD; Paya, CV				Solan, NJ; Miyoshi, H; Carmona, EM; Bren, GD; Paya, CV			RelB cellular regulation and transcriptional activity are regulated by p100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NUCLEAR EXPORT SIGNAL; DENDRITIC CELLS; DIFFERENTIAL EXPRESSION; LYMPHOID MALIGNANCIES; DNA-BINDING; IKK-ALPHA; I-REL; PROTEINS; ACTIVATION	RelB mediates the constitutive nuclear pool of NF-KB transcriptional activity in myeloid and lymphoid cells, which is believed to be secondary to its weak interaction with the classical NF-KB inhibitor proteins, the IKBs. In other cell types, RelB is located in the cytosol, thus suggesting that RelB is also regulated by an inhibitory protein(s). In this study, it is demonstrated that RelB is associated in the cytosol with p,100 but not with IKBalpha, IKBbeta, IKBepsilon, nor p105. Its cytosolic control is not affected by stimuli that lead to ReIA nuclear translocation, and RelB nuclear localization is prevented by p100, but not by p105 or IKBa. Structure function analysis p100-ReIB interactions indicates that p100 amino acids 623-900 are required for effective interaction and repression of nuclear translocation and RelB driven NF-KB-dependent transcription. Moreover, this carboxyl-portion of p100 contains a nuclear export signal(s), which is required for effective retrieval of RelB from the nucleus. Finally, overexpression of NF-KB-inducing kinase, a kinase that has recently been shown to induce p100 processing, possibly through IKKalpha activation, causes nuclear translocation of RelB protein. Thus, these studies indicate that p100 is a bone fide inhibitor of RelB and that this transcription factor may be regulated by NF-KB-inducing kinase and/or IKKalpha.	Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Dept Expt Pathol & Lab Med, Rochester, MN 55905 USA; Mayo Clin, Div Infect Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Paya, CV (corresponding author), Mayo Clin, Dept Immunol, 200 1st St SW,Guggenheim 501, Rochester, MN 55905 USA.			MacIver, Nancie/0000-0003-3676-9391	NIAID NIH HHS [R01 AI36076] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036076] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ammon C, 2000, BIOCHEM BIOPH RES CO, V268, P99, DOI 10.1006/bbrc.1999.2083; BEG AA, 1994, ONCOGENE, V9, P1487; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bennett BL, 1996, J BIOL CHEM, V271, P19680, DOI 10.1074/jbc.271.33.19680; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BOURS V, 1994, ONCOGENE, V9, P1699; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; Dejardin E, 1998, ONCOGENE, V16, P3299, DOI 10.1038/sj.onc.1201879; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1995, ONCOGENE, V10, P1003; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; Francis DA, 1998, INT IMMUNOL, V10, P285, DOI 10.1093/intimm/10.3.285; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grossmann M, 1999, INT J BIOCHEM CELL B, V31, P1209, DOI 10.1016/S1357-2725(99)00068-0; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Karin M, 1998, CANCER J SCI AM, V4, pS92; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kistler B, 1998, J IMMUNOL, V160, P2308; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Lin SC, 1998, MOL CELL BIOL, V18, P5523, DOI 10.1128/MCB.18.9.5523; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; NAUMANN M, 1993, ONCOGENE, V8, P2275; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; Neumann M, 1996, J IMMUNOL, V157, P4862; Neumann M, 2000, BLOOD, V95, P277; NISHI K, 1994, J BIOL CHEM, V269, P6320; Olashaw NE, 1996, J BIOL CHEM, V271, P30307; Pettit AR, 1997, J IMMUNOL, V159, P3681; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RYSECK RP, 1995, MOL CELL BIOL, V15, P3100; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; THAKUR S, 1994, ONCOGENE, V9, P2335; Weih F, 1996, J IMMUNOL, V157, P3974; WEIH F, 1994, ONCOGENE, V9, P3289; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Xia YY, 1997, AM J PATHOL, V151, P375; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHANG JD, 1994, ONCOGENE, V9, P1931	64	163	170	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1405	1418		10.1074/jbc.M109619200	http://dx.doi.org/10.1074/jbc.M109619200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11687592	hybrid			2022-12-25	WOS:000173166800071
J	Thapar, N; Griffith, SC; Yeates, TO; Clarke, S				Thapar, N; Griffith, SC; Yeates, TO; Clarke, S			Protein repair methyltransferase from the hyperthermophilic archaeon Pyrococcus furiosus. Unusual methyl-accepting affinity for D-aspartyl and N-succinyl-containing peptides.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ISOASPARTYL METHYLTRANSFERASE; CARBOXYL METHYLTRANSFERASE; CAENORHABDITIS-ELEGANS; ESCHERICHIA-COLI; O-METHYLTRANSFERASE; MEMBRANE-PROTEINS; DAMAGED PROTEINS; RESIDUES; DEAMIDATION; ERYTHROCYTE	Protein L-isoaspartate-(D-aspartate) O-methyltransferases (EC 2.1.1.77), present in a wide variety of prokaryotic and eukaryotic organisms, can initiate the conversion of abnormal L-isoaspartyl residues that arise spontaneously with age to normal L-aspartyl residues. In addition, the mammalian enzyme can recognize spontaneously racemized D-aspartyl residues for conversion to L-aspartyl residues, although no such activity has been seen to date for enzymes from lower animals or prokaryotes. In this work, we characterize the enzyme from the hyperthermophilic archaebacterium Pyrococcus furiosus. Remarkably, this methyltransferase catalyzes both L-isoaspartyl and D-aspartyl methylation reactions in synthetic peptides with affinities that can be significantly higher than those of the human enzyme, previously the most catalytically efficient species known. Analysis of the common features Of L-isoaspartyl and D-aspartyl residues suggested that the basic substrate recognition element for this enzyme may be mimicked by an N-terminal succinyl peptide. We tested this hypothesis with a number of synthetic peptides using both the P. furiosus and the human enzyme. We found that peptides devoid of aspartyl residues but containing the N-succinyl group were in fact methyl esterified by both enzymes. The recent structure determined for the L-isoaspartyl methyltransferase from P. furiosus complexed with an L-isoaspartyl peptide supports this mode of methyl-acceptor recognition. The combination of the thermophilicity and the high affinity binding of methy accepting substrates makes the P. furiosus enzyme useful both as a reagent for detecting isomerized and racemized residues in damaged proteins and for possible human therapeutic use in repairing damaged proteins in extracellular environments where the cytosolic enzyme is not normally found.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, S (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.			Yeates, Todd/0000-0001-5709-9839	NIA NIH HHS [AG18000] Funding Source: Medline; NIGMS NIH HHS [GM26020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018000] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aswad DW, 2000, J PHARMACEUT BIOMED, V21, P1129, DOI 10.1016/S0731-7085(99)00230-7; ASWAD DW, 1984, J BIOL CHEM, V259, P714; BLUMENTALS II, 1990, ANN NY ACAD SCI, V589, P301, DOI 10.1111/j.1749-6632.1990.tb24254.x; BRENNAN TV, 1994, J BIOL CHEM, V269, P24586; CAPASSO S, 1993, J CHEM SOC P2, V2, P679; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FU JC, 1991, J BIOL CHEM, V266, P14562; Fujii N, 1999, BIOCHEM BIOPH RES CO, V265, P746, DOI 10.1006/bbrc.1999.1748; GALLETTI P, 1995, BIOCHEM J, V306, P313, DOI 10.1042/bj3060313; GALLETTI P, 1981, FEBS LETT, V126, P236, DOI 10.1016/0014-5793(81)80250-5; GEIGER T, 1987, J BIOL CHEM, V262, P785; GILBERT JM, 1988, BIOCHEMISTRY-US, V27, P5227, DOI 10.1021/bi00414a042; Griffith SC, 2001, J MOL BIOL, V313, P1103, DOI 10.1006/jmbi.2001.5095; Ichikawa JK, 1998, ARCH BIOCHEM BIOPHYS, V358, P222, DOI 10.1006/abbi.1998.0830; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1993, NEUROCHEM RES, V18, P87, DOI 10.1007/BF00966926; JOHNSON BA, 1991, ANAL BIOCHEM, V192, P384, DOI 10.1016/0003-2697(91)90553-6; JONAS A, 1970, BIOCHEMISTRY-US, V9, P4729, DOI 10.1021/bi00826a016; KAGAN RM, 1995, BIOCHEMISTRY-US, V34, P10794, DOI 10.1021/bi00034a012; Kagan RM, 1997, COMP BIOCHEM PHYS B, V117, P379, DOI 10.1016/S0305-0491(96)00333-1; Kagan RM, 1997, ARCH BIOCHEM BIOPHYS, V348, P320, DOI 10.1006/abbi.1997.0362; Kim E, 1999, J BIOL CHEM, V274, P20671, DOI 10.1074/jbc.274.29.20671; Kumar GNM, 1999, PLANT PHYSIOL, V119, P89, DOI 10.1104/pp.119.1.89; LINDQUIST JA, 1994, J PROTEIN CHEM, V13, P553, DOI 10.1007/BF01901537; LIU DTY, 1992, TRENDS BIOTECHNOL, V10, P364, DOI 10.1016/0167-7799(92)90269-2; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; Lowenson JD, 2001, J BIOL CHEM, V276, P20695, DOI 10.1074/jbc.M100987200; MACLAREN DC, 1995, PROTEIN EXPRES PURIF, V6, P99, DOI 10.1006/prep.1995.1013; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; Mudgett MB, 1997, PLANT PHYSIOL, V115, P1481, DOI 10.1104/pp.115.4.1481; MURRAY ED, 1984, J BIOL CHEM, V259, P722; Niewmierzycka A, 1999, ARCH BIOCHEM BIOPHYS, V364, P209, DOI 10.1006/abbi.1999.1114; OCONNOR CM, 1984, P NATL ACAD SCI-BIOL, V81, P7757, DOI 10.1073/pnas.81.24.7757; OConnor MB, 1997, INSECT BIOCHEM MOLEC, V27, P49, DOI 10.1016/S0965-1748(96)00071-9; PATEL K, 1990, PHARMACEUT RES, V7, P703, DOI 10.1023/A:1015807303766; PEARSON RB, 1986, BIOCHIM BIOPHYS ACTA, V870, P312, DOI 10.1016/0167-4838(86)90235-9; Radkiewicz JL, 2001, J AM CHEM SOC, V123, P3499, DOI 10.1021/ja0026814; Radkiewicz JL, 1996, J AM CHEM SOC, V118, P9148, DOI 10.1021/ja953505b; SHIAO DDF, 1972, EUR J BIOCHEM, V29, P377, DOI 10.1111/j.1432-1033.1972.tb01999.x; Shimizu T, 2000, ARCH BIOCHEM BIOPHYS, V381, P225, DOI 10.1006/abbi.2000.1955; Skinner MM, 2000, STRUCTURE, V8, P1189, DOI 10.1016/S0969-2126(00)00522-0; TAN EW, 1991, J BIOL CHEM, V266, P10719; Thapar N, 2000, PROTEIN EXPRES PURIF, V20, P237, DOI 10.1006/prep.2000.1311; Thapar N, 2001, PLANT PHYSIOL, V125, P1023, DOI 10.1104/pp.125.2.1023; Visick JE, 1998, FEMS MICROBIOL LETT, V167, P19, DOI 10.1111/j.1574-6968.1998.tb13202.x; Visick JE, 1998, J BACTERIOL, V180, P2623, DOI 10.1128/JB.180.10.2623-2629.1998	47	19	19	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1058	1065		10.1074/jbc.M108261200	http://dx.doi.org/10.1074/jbc.M108261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694513	hybrid			2022-12-25	WOS:000173166800025
J	Kottke, TJ; Blajeski, AL; Meng, XW; Svingen, PA; Ruchaud, S; Mesner, PW; Boerner, SA; Samejima, K; Henriquez, NV; Chilcote, TJ; Lord, J; Salmon, M; Earnshaw, WC; Kaufmann, SH				Kottke, TJ; Blajeski, AL; Meng, XW; Svingen, PA; Ruchaud, S; Mesner, PW; Boerner, SA; Samejima, K; Henriquez, NV; Chilcote, TJ; Lord, J; Salmon, M; Earnshaw, WC; Kaufmann, SH			Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INDUCED APOPTOSIS; FAS-MEDIATED APOPTOSIS; DEATH DOMAIN; CYTOCHROME-C; POLY(ADP-RIBOSE) POLYMERASE; MAJOR POLYPEPTIDES; EPITHELIAL-CELLS; CARCINOMA CELLS; LEUKEMIA-CELLS; HL-60 CELLS	MCF-7 human breast cancer cells are widely utilized to study apoptotic processes. Recent studies demonstrated that these cells lack procaspase-3. In the present study, caspase activation and activity were examined in this cell line after treatment with the microtubule poison paclitaxel. When cells were harvested 72 h after the start of a 24-h treatment with 100 nm paclitaxel, 37 +/- 5% of the cells were nonadherent and displayed apoptotic morphological changes. Although mitochondrial cytochrome c release and caspase-9 cleavage were detectable by immunoblotting, assays of cytosol and nuclei prepared from the apoptotic cells failed to demonstrate the presence of activity that cleaved the synthetic caspase substrates LEHD-7-amino-4-trifluoromethylcoumarin (LEHD-AFC), DEVD-AFC, and VEID-AFC. Likewise, the paclitaxel-treated MCF-7 cells failed to cleave a variety of caspase substrates, including lamin A, beta-catenin, gelsolin, protein kinase Cdelta, topoisomerase 1, and procaspases-6, -8, and -10. Transfection of MCF-7 cells with wild type procaspase-3 partially restored cleavage of these polypeptides but did not result in detectable activities that could cleave the synthetic caspase substrates. Immunoblotting revealed that caspase-9, and -3, which were proteolytically cleaved in paclitaxel-treated MCF-7/caspase-3 cells, were sequestered in a salt-resistant sedimentable fraction rather than released to the cytosol. Immunofluorescence indicated large cytoplasmic aggregates containing cleaved caspase-3 in these apoptotic cells. These observations suggest that sequestration of caspases can occur in some model systems, causing tetrapeptide-based activity assays to underestimate the amount of caspase activation that has occurred in situ.	Mayo Clin & Mayo Fdn, Div Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Mol Pharmacol, Rochester, MN 55905 USA; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Birmingham, Div Immun & Infect, Dept Rheumatol, MRC,Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England; Elan Pharmaceut, San Francisco, CA 94080 USA	Mayo Clinic; Mayo Clinic; University of Edinburgh; University of Birmingham	Kaufmann, SH (corresponding author), Mayo Clin & Mayo Fdn, Div Oncol Res, 1301 Guggenheim,200 1st St SW, Rochester, MN 55905 USA.	Kaufmann.Scott@Mayo.edu	Earnshaw, William/AAY-7438-2020; Henriquez, Nico/C-3758-2008; Ruchaud, Sandrine/AAJ-2179-2021	Kaufmann, Scott/0000-0002-4900-7145; Lord, Janet/0000-0003-1030-6786; Boerner, Scott/0000-0003-1388-9665; Earnshaw, William/0000-0002-7191-0621	NCI NIH HHS [R01 CA069008, R01 CA69008] Funding Source: Medline; Wellcome Trust [073915] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARMSTRONG DK, 1994, CANCER RES, V54, P5280; Bible KC, 1999, ANAL BIOCHEM, V267, P217, DOI 10.1006/abio.1998.2980; BLAJESKI AL, 1999, APOPTOSIS PRACTICAL, P215; Blanc C, 2000, CANCER RES, V60, P4386; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Budihardjo II, 1998, CLIN CANCER RES, V4, P117; Burow ME, 1998, CANCER RES, V58, P4940; Burow ME, 1999, CARCINOGENESIS, V20, P2057, DOI 10.1093/carcin/20.11.2057; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; EARNSHAW WC, 1985, CHROMOSOMA, V92, P290, DOI 10.1007/BF00329812; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; FERNANDESALNEMR.T, 1995, CANCER RES, V55, P6405; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Gooch JL, 1999, CANCER LETT, V144, P31, DOI 10.1016/S0304-3835(99)00208-6; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Huang Y, 1997, BREAST CANCER RES TR, V42, P73, DOI 10.1023/A:1005777219997; JAATTELA M, 1995, ONCOGENE, V10, P2297; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532; KAUFMANN SH, 1989, J BIOL CHEM, V264, P13946; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; Kaufmann SH, 2000, BIOESSAYS, V22, P1007, DOI 10.1002/1521-1878(200011)22:11<1007::AID-BIES7>3.3.CO;2-W; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; Kim DK, 2000, EXP CELL RES, V257, P82, DOI 10.1006/excr.2000.4868; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Liu D, 2000, J BIOL CHEM, V275, P9244, DOI 10.1074/jbc.275.13.9244; Liu YY, 1999, EXP CELL RES, V252, P464, DOI 10.1006/excr.1999.4649; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Mathiasen IS, 1999, CANCER RES, V59, P4848; McCloskey DE, 1996, CLIN CANCER RES, V2, P847; McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868; Mesner PW, 1999, J BIOL CHEM, V274, P22635, DOI 10.1074/jbc.274.32.22635; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Perkins C, 1998, CANCER RES, V58, P4561; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sledge GW, 1999, SEMIN ONCOL, V26, P6; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STAUFENBIEL M, 1983, EUR J CELL BIOL, V31, P341; Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665-5679.2000; Svingen PA, 2000, CLIN CANCER RES, V6, P237; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang Q, 2000, CANCER RES, V60, P2040; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang XH, 2001, CANCER RES, V61, P348; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zhang GJ, 1999, CLIN CANCER RES, V5, P2971; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	79	65	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					804	815		10.1074/jbc.M108419200	http://dx.doi.org/10.1074/jbc.M108419200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11677238	hybrid			2022-12-25	WOS:000173087900103
J	Afford, SC; Ahmed-Choudhury, J; Randhawa, S; Russell, C; Youster, J; Crosby, HA; Eliopoulos, A; Hubscher, SG; Young, LS; Adams, DH				Afford, SC; Ahmed-Choudhury, J; Randhawa, S; Russell, C; Youster, J; Crosby, HA; Eliopoulos, A; Hubscher, SG; Young, LS; Adams, DH			CD40 activation-induced, Fas-dependent apoptosis and NF-kappa B/AP-1 signaling in human intrahepatic biliary epithelial cells	FASEB JOURNAL			English	Article						CD40-mediated apoptosis; Fas-mediated apoptosis; primary biliary cirrhosis; NF-kappa B and AP-1 activation	ENDOTHELIAL-CELLS; ALLOGRAFT-REJECTION; KAPPA-B; LIVER; EXPRESSION; LIGAND; DISEASE; DEATH; MICE; CHOLANGIOPATHY	Fas-mediated mechanisms of apoptosis are thought to be involved in the bile duct loss that characterizes diseases such as primary biliary cirrhosis (PBC). We have previously shown that activation of CD40 on hepatocytes can amplify Fas-mediated apoptosis; in the present study, we investigated interactions between CD40 and Fas in biliary epithelial cells (BEC). We report that the bile ducts in PBC liver tissue frequently express increased levels of Fas, Fas ligand (FasL), and CD40 associated with apoptotic BEC. The portal mononuclear infiltrate contains CD40L+ve T cells and macrophages, thereby demonstrating a potential mechanism for CD40 engagement in vivo. Primary cultures of human BEC also expressed Fas, FasL, and CD40 but not CD40L protein or mRNA. Activation of CD40 on BEC using recombinant CD40L increased transcriptional expression of FasL and induced apoptosis, which was inhibited by neutralizing antibodies to either Fas or FasL. Thus, CD40-induced apoptosis of BEC is mediated through Fas/FasL. We then investigated the intracellular signals and transcription factors activated in BEC and found that NF-kappaB and AP-1 were both activated after CD40 ligation. Increased functional NF-kappaB was seen early after CD40 ligation, but returned to baseline levels after 4 h. In contrast, the rapid up-regulation of AP-1 was sustained over 24 h. This study provides further functional evidence of the ability of CD40 to induce Fas/FasL-dependent apoptosis of liver epithelial cells supporting the importance of cross-talk between tumor necrosis factor (TNF) receptor family members as an amplification step in apoptosis induction. Sustained activation of AP-1 in the absence of NF-kappaB signaling may be a critical factor in determining the outcome of CD40 engagement.	Univ Birmingham, MRC, Ctr Immune Regulat, Liver Res Labs, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Dept Pathol, Birmingham B15 2TH, W Midlands, England; Queen Elizabeth Hosp, Inst Clin Sci, CRC, Inst Canc Studies, Birmingham B15 2TH, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham	Afford, SC (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Inst Clin Sci, MRC,Ctr Immune Regulat,Liver Res Labs, Birmingham B15 2TH, W Midlands, England.	s.c.afford@bham.ac.uk	Adams, David H/C-9092-2009; Young, Lawrence S/B-7213-2009	Adams, David H/0000-0001-6776-0336; Young, Lawrence S/0000-0003-3919-4298				ABMAYR SM, 1991, CURRENT PROTOCOLS MO; Afford SC, 1999, J EXP MED, V189, P441, DOI 10.1084/jem.189.2.441; AFFORD SC, 1995, J PATHOL, V176, P373, DOI 10.1002/path.1711760408; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; Eliopoulos AG, 2000, MOL CELL BIOL, V20, P5503, DOI 10.1128/MCB.20.15.5503-5515.2000; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; FLOREANI A, 1989, AUTOIMMUNITY, V2, P311, DOI 10.3109/08916938908997157; Gallop JR, 1995, CERN REPORT, V95, P1; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Harada K, 1997, HEPATOLOGY, V26, P1399; Hayward AR, 1997, J IMMUNOL, V158, P977; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; HUBSCHER SG, 1991, TRANSPLANTATION, V51, P1004, DOI 10.1097/00007890-199105000-00014; JOPLIN R, 1994, GUT, V35, P875, DOI 10.1136/gut.35.7.875; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Krzesz R, 1999, FEBS LETT, V453, P191, DOI 10.1016/S0014-5793(99)00683-3; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; Morland CM, 1997, P ASSOC AM PHYSICIAN, V109, P372; Morland CM, 1996, HEPATOLOGY, V24, P823; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OGASAWARA J, 1993, NATURE, V365, P568, DOI 10.1038/365568a0; SHERLOCK S, 1987, LANCET, V2, P493; Stephens J, 1999, HEPATOLOGY, V30, P27, DOI 10.1002/hep.510300138; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; Ueno Y, 2000, HEPATOLOGY, V31, P966, DOI 10.1053/he.2000.5764; vanKooten C, 1997, KIDNEY INT, V51, P711, DOI 10.1038/ki.1997.102; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; von Leoprechting A, 1999, CANCER RES, V59, P1287; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508	35	100	105	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2345	2354		10.1096/fj.01-0088com	http://dx.doi.org/10.1096/fj.01-0088com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689460				2022-12-25	WOS:000172420500005
J	Laplante, AF; Germain, L; Auger, FA; Moulin, V				Laplante, AF; Germain, L; Auger, FA; Moulin, V			Mechanisms of wound reepithelialization: hints from a tissue-engineered reconstructed skin to long-standing questions	FASEB JOURNAL			English	Article						wound healing; keratinocyte; epithelia; drug screening	HUMAN KERATINOCYTE MIGRATION; EPIDERMAL BASEMENT-MEMBRANE; IN-VITRO; CELL-MIGRATION; EPITHELIAL-CELLS; FULL-THICKNESS; NUDE-MOUSE; EXPRESSION; LAMININ-5; EQUIVALENT	Wound closure of epithelial tissues must occur efficiently to restore rapidly their barrier function. We have developed a tissue-engineered wound-healing model composed of human skin keratinocytes and fibroblasts to better understand the mechanisms of reepithelialization. It allowed us to quantify the reepithelialization rate, which was significantly accelerated in the presence of fibrin or platelet-rich plasma. The reepithelialization of these 6 mm excisional wounds required the contribution of keratinocyte proliferation, migration, stratification, and differentiation. The epidermis regenerated progressively from the surrounding wound margins. After 3 days, the neoepidermis showed a complete spectrum of changes. Near the wound margin, the differentiation of the neoepidermis (keratins 1/10, filaggrin, and loricrin) and regeneration of the dermoepidermal junction (laminin 5 and collagen IV) were more advanced than toward the wound center, where the proliferative index was significantly increased. The spatial distribution of keratinocytes distinguished by particular features suggests two complementary mechanisms of reepithelialization: 1) the passive displacement of the superficial layers near the wound margin that would rapidly regenerate a barrier function and 2) the crawling of keratinocytes over each other at the tip of the progressing neoepidermis. Therefore, this study brings a new perspective to long-standing questions concerning wound reepithelialization.	Univ Laval, Dept Surg, CHA Quebec, Hop St Sacrement,LOEX, Quebec City, PQ G1S 4L8, Canada	Laval University	Moulin, V (corresponding author), Univ Laval, Dept Surg, CHA Quebec, Hop St Sacrement,LOEX, 1050 Ch St Foy, Quebec City, PQ G1S 4L8, Canada.	veronique.moulin@chg.ulaval.ca	Moulin, Veronique J/P-9668-2018	Moulin, Veronique J/0000-0002-2925-2784; Germain, Lucie/0000-0001-8883-6491				AUGER FA, 1993, BRIT J PLAST SURG, V46, P136, DOI 10.1016/0007-1226(93)90145-2; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; BETZ P, 1993, INT J LEGAL MED, V106, P35, DOI 10.1007/BF01225022; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; BUCK RC, 1979, INVEST OPHTH VIS SCI, V18, P767; CAVANI A, 1993, J INVEST DERMATOL, V101, P600, DOI 10.1111/1523-1747.ep12366057; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; COHEN IK, 1994, PRINCIPLES SURG, P279; Coulombe PA, 2000, TRENDS CELL BIOL, V10, P420, DOI 10.1016/S0962-8924(00)01828-6; Dale B. A., 1994, KERATINOCYTE HDB, P323; DEMARCHEZ M, 1986, DEV BIOL, V113, P90, DOI 10.1016/0012-1606(86)90110-7; DEMARCHEZ M, 1987, DEV BIOL, V121, P119, DOI 10.1016/0012-1606(87)90145-X; DONALDSON DJ, 1988, J INVEST DERMATOL, V90, P623, DOI 10.1111/1523-1747.ep12560762; FLEISCHMAJER R, 1993, J HISTOCHEM CYTOCHEM, V41, P1359, DOI 10.1177/41.9.7689083; FUCHS E, 1993, J CELL SCI, P197; GARLICK JA, 1994, LAB INVEST, V70, P916; GERMAIN L, 1995, BURNS, V21, P175, DOI 10.1016/0305-4179(95)80004-8; GERMAIN L, 1993, BURNS, V19, P99, DOI 10.1016/0305-4179(93)90028-7; GERMAIN L, 1995, ENCY HDB BIOMATERIAL, V1, P699; GIBBINS JR, 1978, PATHOLOGY, V10, P207, DOI 10.3109/00313027809063503; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; GRONDAHLHANSEN J, 1988, J INVEST DERMATOL, V90, P790, DOI 10.1111/1523-1747.ep12461511; Holbrook KA, 1987, DERMATOLOGY GENERAL, P93; Jansson K, 1996, IN VITRO CELL DEV-AN, V32, P534; Kainulainen T, 1998, J HISTOCHEM CYTOCHEM, V46, P353, DOI 10.1177/002215549804600309; KIM JP, 1992, J CELL PHYSIOL, V151, P443, DOI 10.1002/jcp.1041510303; KRAWCZYK WS, 1971, J CELL BIOL, V49, P247, DOI 10.1083/jcb.49.2.247; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; L'Heureux N, 2001, FASEB J, V15, P515, DOI 10.1096/fj.00-0283com; Laplante AF, 1998, J HISTOCHEM CYTOCHEM, V46, P1291, DOI 10.1177/002215549804601109; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; MARINKOVICH MP, 1993, DEV DYNAM, V197, P255, DOI 10.1002/aja.1001970404; MARKS R, 1973, BRIT J DERMATOL, V88, P245, DOI 10.1111/j.1365-2133.1973.tb07542.x; MATOLTSY AG, 1976, J INVEST DERMATOL, V67, P20, DOI 10.1111/1523-1747.ep12512473; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; Michel M, 1999, IN VITRO CELL DEV-AN, V35, P318; ODLAND G, 1968, J CELL BIOL, V39, P135, DOI 10.1083/jcb.39.1.135; ORDMAN LJ, 1966, ARCH SURG-CHICAGO, V93, P857; ORTONNE JP, 1981, VIRCHOWS ARCH A, V392, P217, DOI 10.1007/BF00430822; OToole EA, 1997, EXP CELL RES, V233, P330, DOI 10.1006/excr.1997.3586; PANG SC, 1978, AM J ANAT, V153, P177, DOI 10.1002/aja.1001530202; PINKUS H, 1951, J INVEST DERMATOL, V16, P383, DOI 10.1038/jid.1951.45; RADICE GP, 1980, DEV BIOL, V76, P26, DOI 10.1016/0012-1606(80)90360-7; RIGAL C, 1991, J INVEST DERMATOL, V96, P777, DOI 10.1111/1523-1747.ep12471745; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Rovee D.T., 1972, EPIDERMAL WOUND HEAL, P71; ROVEE DT, 1972, EPIDERMAL WOUND HEAL, P159; Sahuc Florent, 1996, Wound Repair and Regeneration, V4, P93, DOI 10.1046/j.1524-475X.1996.40116.x; SCIUBBA JJ, 1977, J PERIODONTAL RES, V12, P204, DOI 10.1111/j.1600-0765.1977.tb00123.x; Smola H, 1998, EXP CELL RES, V239, P399, DOI 10.1006/excr.1997.3910; STANLEY JR, 1981, J INVEST DERMATOL, V77, P240, DOI 10.1111/1523-1747.ep12480082; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P4097, DOI 10.1073/pnas.78.7.4097; Stenn KS., 1992, WOUND HEALING BIOCH, P115; TIDMAN MJ, 1984, J INVEST DERMATOL, V83, P448, DOI 10.1111/1523-1747.ep12273562; VAUGHAN RB, 1966, J CELL SCI, V1, P407; VIZIAM CB, 1964, J INVEST DERMATOL, V43, P499, DOI 10.1038/jid.1964.192; WEISS P, 1960, HARVEY LECT, P13; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580; Xu W, 1996, BURNS, V22, P191, DOI 10.1016/0305-4179(95)00124-7; YAOITA H, 1978, J INVEST DERMATOL, V70, P191, DOI 10.1111/1523-1747.ep12541313; Zacchi V, 1998, J BIOMED MATER RES, V40, P187, DOI 10.1002/(SICI)1097-4636(199805)40:2<187::AID-JBM3>3.0.CO;2-H; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280	63	150	158	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2377	2389		10.1096/fj.01-0250com	http://dx.doi.org/10.1096/fj.01-0250com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689463				2022-12-25	WOS:000172420500008
J	Hu, XT; Zhang, XH; Zhong, Q; Fisher, AB; Bryington, M; Zuckerman, KS				Hu, XT; Zhang, XH; Zhong, Q; Fisher, AB; Bryington, M; Zuckerman, KS			Differential effects of transforming growth factor on cell cycle regulatory molecules in human myeloid leukemia cells	ONCOGENE			English	Article						cell cycle; transforming growth factor; cell line; Rb protein; cdk inhibitor	DEPENDENT-KINASE INHIBITOR; FACTOR-BETA; CDK INHIBITOR; MAMMALIAN-CELLS; TGF-BETA; G1 PHASE; PROTEIN-PHOSPHORYLATION; EPITHELIAL-CELLS; G(1) CYCLINS; P27(KIP1)	In this report we have studied the mechanism by which Transforming Growth Factor beta (TGF beta) inhibits growth of human myeloid leukemia cell lines. TGF beta1 arrested cells in G1 phase and significantly downregulated the expression of cyclin D2, cyclin D3, cdk4, cyclin A, and cdk2. The downregulation of the molecules resulted in approximately 50-90% decrease of the molecule-dependent kinase activity, varying with each molecule. Although treatment of cells with TGF beta1 upregulated accumulation of p27(kip1) in both nucleus and cytoplasm, the association of the p27(kip1) with cdk2, cyclin A, cyclin D2, cyclin D3, and cdk4 was markedly downregulated, suggesting that p27(kip1) is not responsible for the downregulation of the kinase activity. In contrast, TGF beta1 upregulated cyclin E-associated p27(kip1) with no effect on the expression of cyclin E. p27(kip1)-immunodepletion upregulated cyclin E-dependent kinase activity by more than 10-fold in TGF beta1-treated cells but not in proliferating cells; whereas immunodepletion of p27(kip1) from cdk2-immunoprecipitates markedly downregulated cdk2 kinase activity in the lysates extracted from both proliferating and TGF beta -treated cells. Consistent with this observation, TGF beta1 and p27(kip1) antisense cDNA had a synergistic or additive inhibitory effect on cdk2 but not cyclin E-dependent kinase activity. Our data suggest that (1) TGF beta1-mediated growth inhibition is accomplished through multiple pathways and (2) p27(kip1) has opposing effects on cdk2 and cyclin E activity in response to TGF beta1.	Univ S Florida, Hematol Malignancies Program, Interdisciplinary Oncol Program, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Hu, XT (corresponding author), Univ S Florida, Hematol Malignancies Program, Interdisciplinary Oncol Program, MCC 3142,12902 Magnolia Dr, Tampa, FL 33612 USA.	hu@moffitt.usf.edu						ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BATES S, 1994, ONCOGENE, V9, P71; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Drexler HG, 1998, LEUKEMIA RES, V22, P927, DOI 10.1016/S0145-2126(98)00088-5; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FAUTSCH MP, 1995, J CELL BIOCHEM, V58, P517, DOI 10.1002/jcb.240580415; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hu XT, 1999, EXP HEMATOL, V27, P605, DOI 10.1016/S0301-472X(99)00004-1; Hu XT, 2000, BIOCHEM BIOPH RES CO, V276, P930, DOI 10.1006/bbrc.2000.3556; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Singh SP, 1998, CANCER RES, V58, P1730; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; Wang G, 1999, ONCOGENE, V18, P5204, DOI 10.1038/sj.onc.1202912; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	49	14	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6840	6850		10.1038/sj.onc.1204790	http://dx.doi.org/10.1038/sj.onc.1204790			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687963				2022-12-25	WOS:000171641000005
J	Jennings, R; Alsarraj, M; Wright, KL; Munoz-Antonia, T				Jennings, R; Alsarraj, M; Wright, KL; Munoz-Antonia, T			Regulation of the human transforming growth factor beta type II receptor gene promoter by novel Sp1 sites	ONCOGENE			English	Article						transforming growth factor-beta (TGF beta); TGF beta receptors; promoter; Sp1 transcription factor	THYMIDINE KINASE PROMOTER; NF-Y; TRANSCRIPTION FACTORS; CARCINOMA-CELLS; REPRESS TRANSCRIPTION; TUMOR-SUPPRESSOR; SMAD PATHWAY; MCF-7 CELLS; EXPRESSION; BINDING	The transforming growth factor-beta (TGF beta) type II receptor (T betaR-II) is responsible for transducing the growth inhibitory signals of TGF beta. The T betaR-II gene promoter lacks both a TATA box and a CAAT box near the transcription initiation site, and has been shown to contain binding sequences for several transcription factors (Sp1, AP1, NF-Y, Cut and ERT) which are important for T betaR-II gene promoter activity in vitro. However, it is still not clear which interactions are important for the regulation of T betaR-II gene promoter activity in vivo. Using in viro genomic DNA footprinting of normal human epithelial cells (HaCaT), we have identified two novel identical and strongly protected sites (ggggctgg) at positions -59 and - 102 of the T betaR-II gene promoter. Mutation of either site significantly reduced promoter activity in transient transfections. Protein binding to these sites, as determined by electrophoretic mobility shift assays (EMSA), was specifically competed with consensus Sp1 oligonucleotides. Furthermore, anti-Sp1/3 antibodies produced band shifts when incubated with the T betaR-II - 59 and - 102 DNA probes. Importantly, Sp1 protein binding was influenced by the presence of an intact NF-Y binding site at position -83. Our data suggests that both Sp1 and NF-Y may play an important role in regulating T betaR-II gene promoter basal activity in vivo.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Program Immunol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Munoz-Antonia, T (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.							Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; HUMPHRIES DE, 1994, BIOCHEM BIOPH RES CO, V203, P1020, DOI 10.1006/bbrc.1994.2284; Jackson RJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P290, DOI 10.1006/abbi.1999.1459; Ji CH, 1996, J CELL BIOCHEM, V63, P478; Kelly D, 1998, J BIOL CHEM, V273, P21115, DOI 10.1074/jbc.273.33.21115; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu Y, 2000, J BIOL CHEM, V275, P12231, DOI 10.1074/jbc.275.16.12231; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MunozAntonia T, 1996, CANCER RES, V56, P4831; Periyasamy S, 2000, ONCOGENE, V19, P4660, DOI 10.1038/sj.onc.1203822; Roder K, 1999, GENE, V234, P61, DOI 10.1016/S0378-1119(99)00180-8; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sorensen P, 1999, J BIOL CHEM, V274, P30943, DOI 10.1074/jbc.274.43.30943; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Steffen ML, 1999, BIOCHEM J, V340, P425, DOI 10.1042/0264-6021:3400425; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978	39	21	25	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6899	6909		10.1038/sj.onc.1204808	http://dx.doi.org/10.1038/sj.onc.1204808			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687969	Green Published, Green Submitted			2022-12-25	WOS:000171641000011
J	Reddy, KB; McGowen, R; Schuger, L; Visscher, D; Sheng, SJ				Reddy, KB; McGowen, R; Schuger, L; Visscher, D; Sheng, SJ			Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model	ONCOGENE			English	Article						hyperplasia; carcinoma in situ; invasive carcinoma; immunohistochemistry; in situ hybridization	GROWTH-FACTOR-ALPHA; TGF-ALPHA; PLASMINOGEN-ACTIVATOR; MAMMARY; CELL; CANCER; OVEREXPRESSION; HYPERPLASIA; INHIBITION; NEOPLASIA	Maspin is a novel serine protease inhibitor (serpin) with tumor suppressive activity. To date, despite the mounting evidence implicating the potential diagnostic/prognostic and therapeutic value of maspin in breast and prostate carcinoma, the lack of a suitable animal model hampers the in vivo investigation on the role of maspin at different stages of tumor progression. In this study, we used MMTV/TGF-alpha transgenic mouse model to study the expression profile of maspin in mammary tumor progression. Histopathological examinations of MMTV/TGF-alpha transgenic mice revealed TGF-alpha expression leading to hyperproliferation, hyperplasia, and occasional carcinoma in mammary gland. Interestingly, when MMTV/TGF-alpha transgenic mice were breed to homozygocity, they also developed characteristic skin papillomas. Immunohistochemistry analysis of maspin expression in the breast tissues of TGF-oc transgenic mice showed a direct correlation between down-regulation of maspin expression and tumor progression. The loss of maspin expression was concomitant with the critical transition from carcinoma in situ to invasive carcinoma. Subsequent in-situ hybridization analyses suggest that the down-regulation of maspin expression is primarily a transcriptional event. This data is consistent with the tumor suppressive role of maspin. Furthermore, our data suggests that MMTV/TGF-alpha transgenic mouse model is advantageous for in vivo evaluation of both the expression and the biological function of maspin during the slow multi-stage carcinogenesis of mammary gland.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Sheng, SJ (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.	ssheng@med.wayne.edu			NCI NIH HHS [CA 64248, CA 83964, CA69845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064248, R01CA083964, R21CA069845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; McGowen R, 2000, CANCER RES, V60, P4771; REDDY KB, 1994, CELL GROWTH DIFFER, V5, P1275; Rose-Hellekant TA, 2000, ONCOGENE, V19, P1092, DOI 10.1038/sj.onc.1203350; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Wagner M, 2001, GENE DEV, V15, P286, DOI 10.1101/gad.184701; Xia WY, 2000, ONCOGENE, V19, P2398, DOI 10.1038/sj.onc.1203535; Yamada N, 2000, GENE, V241, P267, DOI 10.1016/S0378-1119(99)00484-9; Zhang M, 1997, MOL MED, V3, P49, DOI 10.1007/BF03401667; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	25	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6538	6543		10.1038/sj.onc.1204796	http://dx.doi.org/10.1038/sj.onc.1204796			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641778				2022-12-25	WOS:000171404200006
J	Langevin, HM; Churchill, DL; Cipolla, MJ				Langevin, HM; Churchill, DL; Cipolla, MJ			Mechanical signaling through connective tissue: a mechanism for the therapeutic effect of acupuncture	FASEB JOURNAL			English	Article						collagen; mechanotransduction; meridian	SMOOTH-MUSCLE-CELLS; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; ENDOTHELIAL-CELLS; SHEAR-STRESS; NITRIC-OXIDE; C-FOS; FIBROBLASTS; FORCES; CYTOSKELETON	The mechanism of action of acupuncture remains largely unknown. The reaction to acupuncture needling known as 'de qi', widely viewed as essential to the therapeutic effect of acupuncture, may be a key to understanding its mechanism of action. De qi includes a characteristic needling sensation, perceived by the patient, and 'needle grasp' perceived by the acupuncturist. During needle grasp, the acupuncturist feels pulling and increased resistance to further movement of the inserted needle. We hypothesize that 1) needle grasp is due to mechanical coupling between the needle and connective tissue with winding of tissue around the needle during needle rotation and 2) needle manipulation transmits a mechanical signal to connective tissue cells via mechanotransduction. Such a mechanism may explain local and remote, as well as long-term effects of acupuncture.	Univ Vermont, Coll Med, Dept Neurol, Burlington, VT 05405 USA	University of Vermont	Langevin, HM (corresponding author), Univ Vermont, Coll Med, Dept Neurol, Given C423, Burlington, VT 05405 USA.	hlangevi@zoo.uvm.edu	Cipolla, Marilyn J./B-7098-2009		NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000133, R21AT000300] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01 AT000133-02, R21 AT00300] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		[Anonymous], 1997, NIH CONSENSUS STATEM, V15, P1; APPENZELLER O, 1994, AUTONOMIC NERVOUS SY; Aumailley M, 1998, J MOL MED-JMM, V76, P253, DOI 10.1007/s001090050215; Banes AJ, 1995, BIOCHEM CELL BIOL, V73, P349, DOI 10.1139/o95-043; Bao XP, 2000, AM J PHYSIOL-HEART C, V278, pH1598, DOI 10.1152/ajpheart.2000.278.5.H1598; BESSOU P, 1961, ARCH ITAL BIOL, V99, P293; Brand RA, 1997, ANN MED, V29, P267, DOI 10.3109/07853899708999346; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Cassapakis C., 1995, P 3 S SOC AC RES SEP, P1; Cheng X, 1987, CHINESE ACUPUNCTURE; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Chiquet M, 1999, MATRIX BIOL, V18, P417, DOI 10.1016/S0945-053X(99)00039-6; CHIQUETEHRISMANN R, 1994, J CELL BIOL, V127, P2093, DOI 10.1083/jcb.127.6.2093; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAIFOTIS AG, 1992, J BIOL CHEM, V267, P23455; DARTSCH PC, 1986, EUR J CELL BIOL, V41, P339; DENMEI S, 1990, INTRO MERIDIAN THERA; DESMOULIERE A, 1994, CELL MOTIL CYTOSKEL, V29, P195, DOI 10.1002/cm.970290302; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070; Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8; Gan LM, 2000, FEBS LETT, V477, P89, DOI 10.1016/S0014-5793(00)01788-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Glogauer M, 1997, J CELL SCI, V110, P11; GUNN C C, 1976, American Journal of Chinese Medicine, V4, P183, DOI 10.1142/S0192415X76000238; GUNN CC, 1977, AM J ACUPUNCTURE, V5, P115; Gutierrez JA, 1999, AM J PHYSIOL-GASTR L, V277, pG1074, DOI 10.1152/ajpgi.1999.277.5.G1074; HARRIS AK, 1980, SCIENCE, V208, P177, DOI 10.1126/science.6987736; Heidemann SR, 1999, J CELL BIOL, V145, P109, DOI 10.1083/jcb.145.1.109; HELMES JM, 1995, ACUPUNCTURE ENERGETI; Hibbeler R.C., 1995, ENG MECH STATICS DYN; KIMURA M, 1992, AM J CHINESE MED, V20, P25, DOI 10.1142/S0192415X92000047; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; LANGEVIN HM, 2001, IN PRESS J APPL PHYS; LEVINE JD, 1993, J NEUROSCI, V13, P2273, DOI 10.1523/JNEUROSCI.13-06-02273.1993; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Margolin A, 1998, JAMA-J AM MED ASSOC, V280, P1626, DOI 10.1001/jama.280.18.1626; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; O'Callaghan CJ, 2000, HYPERTENSION, V36, P319, DOI 10.1161/01.HYP.36.3.319; Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591; PIROLA CJ, 1994, ENDOCRINOLOGY, V134, P2230, DOI 10.1210/en.134.5.2230; Pohl U, 1996, PFLUG ARCH EUR J PHY, V432, pR107; Rosenfeldt H, 1998, MOL CELL BIOL, V18, P2659, DOI 10.1128/MCB.18.5.2659; RYAN TJ, 1989, J AM ACAD DERMATOL, V21, P115, DOI 10.1016/S0190-9622(89)70156-0; SAPPINO AP, 1990, LAB INVEST, V63, P144; *SHANGH COLL TRAD, 1987, AC COMPR TEXT; Stoltz JF, 2000, BIORHEOLOGY, V37, P3; Stux G, 1995, BASICS ACUPUNCTURE; SUGIMOTO K, 1991, EXP CELL RES, V196, P353, DOI 10.1016/0014-4827(91)90271-U; SUMPIO BE, 1988, J VASC SURG, V7, P130, DOI 10.1067/mva.1988.avs0070130; TILLMAN LJ, 1992, DYNAMICS HUMAN BIOL, P1; Tyagi SC, 1998, J CELL PHYSIOL, V176, P374, DOI 10.1002/(SICI)1097-4652(199808)176:2<374::AID-JCP16>3.0.CO;2-3; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; van Wamel AJ, 2000, ARCH BIOCHEM BIOPHYS, V381, P67, DOI 10.1006/abbi.2000.1947; VINCENT CA, 1986, PAIN, V24, P1, DOI 10.1016/0304-3959(86)90022-9; WANG KM, 1985, SCI SIN B-CHEM B A M, V28, P963; WANG N, 1993, SCIENCE, V260, P1224; White AR, 1998, ALTERN THER HEALTH M, V4, P66; Williams B, 1998, J HYPERTENS, V16, P1921, DOI 10.1097/00004872-199816121-00011; Willis Jr W. D., 1991, SENSORY MECH SPINAL; Wilson E, 1998, HYPERTENSION, V31, P170, DOI 10.1161/01.HYP.31.1.170; WORSLEY JR, 1982, TRADITIONAL CHINESE, V1; YANG J, 1601, GOLDEN NEEDLE OTHER; Ziegler T, 1998, HYPERTENSION, V32, P351, DOI 10.1161/01.HYP.32.2.351; 1994, COMPLETE TRANSLATION	65	268	311	3	60	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2275	2282		10.1096/fj.01-0015hyp	http://dx.doi.org/10.1096/fj.01-0015hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641255				2022-12-25	WOS:000171920400040
J	Yeung, F; Law, WK; Yeh, CH; Westendorf, JJ; Zhang, Y; Wang, RX; Kao, CH; Chung, LWK				Yeung, F; Law, WK; Yeh, CH; Westendorf, JJ; Zhang, Y; Wang, RX; Kao, CH; Chung, LWK			Regulation of human osteocalcin promoter in hormone independent human prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; TRANSCRIPTION FACTOR; GENE-EXPRESSION; BONE-FORMATION; VITAMIN-D; IN-VIVO; GROWTH; MOUSE; DIFFERENTIATION; OSTEOPONTIN	Osteocalcin (OC) is a small (6 kDa) polypeptide whose expression was thought to be limited to mature osteoblasts. The discovery of OC expression in prostate cancer specimens led us to study the regulation of OC gene in androgen-independent metastatic human prostate PC3 cells. An 800-bp human OC (hOC) promoter-luciferase construct exhibited strong basal and vitamin D-induced activity in OC-positive human prostate and osteosarcoma cell lines. Through deletion analysis of the hOC promoter, the functional hierarchy of the cis-acting elements, OSE1, OSE2, and AP-1/VDRE, was established in PC3 cells (OSE1 > AP-1/VDRE > OSE2). By juxtaposing dimers of these 3 cis-elements, we produced a minimal hOC promoter capable of displaying high tissue specific activity in prostate cancer cells. Our study demonstrated three groups of transcription factors, Runx2, JunD/Fra-2, and Sp1, responsible for the high hOC promoter activity in PC3 cells by binding to the OSE2, AP-1/VDRE, and OSE1 elements, respectively. Among the three groups of transcription factors, the expression levels of Runx2 and Fra-2 are higher in the OC-positive PC3 cells and osteoblasts, compared with the OC-negative LNCaP cells. Interestingly, unlike the mouse OC promoter, the OSE1 site in hOC promoter is regulated by members of Sp1 family instead of the osteoblast-specific factor Osf1. The molecular basis for androgen-independent prostate cancer cells behaving like mature osteoblasts may be explained by the interplay and coordination of these transcription factors under the tight regulation of autocrine and paracrine mediators.	Univ Virginia, Dept Urol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Dept Orthoped Surg, Charlottesville, VA 22908 USA; Univ Minnesota, Ctr Canc, Dept Orthoped Surg, Minneapolis, MN 55455 USA; Emory Univ, Dept Urol, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; Indiana Canc Pavil, Dept Urol, Indianapolis, IN 46202 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Minnesota System; University of Minnesota Twin Cities; Emory University; Emory University	Chung, LWK (corresponding author), Univ Virginia, Dept Urol, Charlottesville, VA 22908 USA.				NCI NIH HHS [CA85555] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA085555] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F., 1999, CURRENT PROTOCOLS MO; Batson OV, 1942, ANN INTERN MED, V16, P38, DOI 10.7326/0003-4819-16-1-38; BROWN LF, 1994, AM J PATHOL, V145, P610; Carey M, 2000, TRANSCRIPTIONAL REGU; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; Chung LWK, 2001, CONT CANC RES, P341; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cooper LF, 1998, J BONE MINER RES, V13, P620, DOI 10.1359/jbmr.1998.13.4.620; CORDER EH, 1993, CANCER EPIDEM BIOMAR, V2, P467; CURATOLO C, 1992, EUR UROL, V21, P105; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; GLEAVE M, 1991, CANCER RES, V51, P3753; GLOWACKI J, 1987, CELL DIFFER DEV, V21, P247, DOI 10.1016/0045-6039(87)90479-9; Goldberg D, 1996, J CELL BIOCHEM, V60, P447; Gollner H, 2001, MECH DEVELOP, V106, P77, DOI 10.1016/S0925-4773(01)00420-8; GUNDBERG CM, 1983, J CLIN ENDOCR METAB, V57, P1221, DOI 10.1210/jcem-57-6-1221; Hsu JY, 2001, CANCER RES, V61, P2852; Izbicka E, 1996, CANCER RES, V56, P633; Jung CY, 2001, GENE, V271, P143, DOI 10.1016/S0378-1119(01)00513-3; KESTERSON RA, 1993, MOL ENDOCRINOL, V7, P462, DOI 10.1210/me.7.3.462; Koeneman KS, 1999, PROSTATE, V39, P246; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lian JB, 1998, J CELL BIOCHEM, P62, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<62::AID-JCB10>3.0.CO;2-S; MACHWATE M, 1995, J CELL BIOCHEM, V57, P62, DOI 10.1002/jcb.240570108; MAHONEN A, 1990, BIOCHIM BIOPHYS ACTA, V1048, P30, DOI 10.1016/0167-4781(90)90018-W; MCCABE LR, 1995, EXP CELL RES, V218, P255, DOI 10.1006/excr.1995.1154; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; Meyer T, 1997, J BIOL CHEM, V272, P30709, DOI 10.1074/jbc.272.49.30709; Meyers S, 1996, ONCOGENE, V13, P303; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NAKASE T, 1994, BONE MINER, V26, P109, DOI 10.1016/S0169-6009(08)80056-6; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Paget S, 1889, LANCET, V133, P571, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447; ROACH HI, 1994, CELL BIOL INT, V18, P617, DOI 10.1006/cbir.1994.1088; SCHEDLICH LJ, 1994, J BONE MINER RES, V9, P143; Schinke T, 1999, J BIOL CHEM, V274, P30182, DOI 10.1074/jbc.274.42.30182; Sims NA, 1997, MOL ENDOCRINOL, V11, P1695, DOI 10.1210/me.11.11.1695; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; Takazawa Y, 2000, J ENDOCRINOL, V165, P579, DOI 10.1677/joe.0.1650579; Tu SM, 2001, LANCET, V357, P336, DOI 10.1016/S0140-6736(00)03639-4; Waltregny D, 1998, J NATL CANCER I, V90, P1000, DOI 10.1093/jnci/90.13.1000; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110	45	94	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2468	2476		10.1074/jbc.M105947200	http://dx.doi.org/10.1074/jbc.M105947200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11684680	hybrid			2022-12-25	WOS:000173421500015
J	Ranalli, TA; DeMott, MS; Bambara, RA				Ranalli, TA; DeMott, MS; Bambara, RA			Mechanism underlying replication protein A stimulation of DNA ligase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; APURINIC-APYRIMIDINIC ENDONUCLEASE; POLYMERASE-ALPHA-PRIMASE; PURIFIED HUMAN PROTEINS; COLI EXONUCLEASE-III; ENZYME APEX NUCLEASE; ESCHERICHIA-COLI; MAMMALIAN-CELLS; FLAP ENDONUCLEASE-1	Replication protein A (RPA) is a heterotrimeric single-stranded DNA-binding protein that participates in multiple DNA transactions that include replication and repair. Base excision repair is a central DNA repair pathway, responsible for the removal of damaged bases. We have shown previously that RPA was able to stimulate long patch base excision repair reconstituted in vitro. Herein we show that human RPA stimulates the activity of the base excision repair component human DNA ligase I by approximately 15-fold. Other analyzed single-stranded binding proteins would not substitute, attesting to the specificity of the stimulation. Conversely, RPA was unable to stimulate the functionally homologous ATP-dependent ligase from T4 bacteriophage. Kinetic analyses suggest that catalysis of ligation is enhanced by RPA, as a 4-fold increase in k(cat) is observed, whereas K-m is not significantly changed. Substrate competition experiments further support the conclusion that RPA does not alter the specificity or rate of substrate binding by DNA ligase I. Additionally, RPA is unable to significantly enhance ligation on substrates containing an unannealed T-upstream primer terminus, suggesting that RPA does not stabilize the nick site to enhance ligase recognition. Furthermore when DNA ligase I is pre-bound to the substrate and limited to a single turnover, RPA is still able to stimulate ligation. Overall, the results support a mechanism of stimulation that involves increasing the rate of catalysis of ligation.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atamna H, 2000, P NATL ACAD SCI USA, V97, P686, DOI 10.1073/pnas.97.2.686; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bhagwat AS, 1999, NUCLEIC ACIDS RES, V27, P4028, DOI 10.1093/nar/27.20.4028; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; BURGERS PMJ, 1988, NUCLEIC ACIDS RES, V16, P6297, DOI 10.1093/nar/16.14.6297; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; Dianov GL, 1999, BIOCHEMISTRY-US, V38, P11021, DOI 10.1021/bi9908890; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; KANE CM, 1981, J BIOL CHEM, V256, P3405; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Krokan HE, 1997, BIOCHEM J, V325, P1; LEHMAN IR, 1974, SCIENCE, V186, P790; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1971, EUR J BIOCHEM, V18, P407, DOI 10.1111/j.1432-1033.1971.tb01257.x; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; MODRICH P, 1973, J BIOL CHEM, V248, P7495; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Nakamura J, 1999, CANCER RES, V59, P2522; Nakamura J, 1998, CANCER RES, V58, P222; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; Podlutsky AJ, 2001, BIOCHEMISTRY-US, V40, P809, DOI 10.1021/bi002064s; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SEKI S, 1991, J BIOL CHEM, V266, P20797; SEKI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P287, DOI 10.1016/0167-4781(92)90027-W; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; TERAOKA H, 1993, J BIOL CHEM, V268, P24156; Timson DJ, 2000, MUTAT RES-DNA REPAIR, V460, P301, DOI 10.1016/S0921-8777(00)00033-1; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; Umezu K, 1998, GENETICS, V148, P989; WAGA S, 1994, J BIOL CHEM, V269, P10923; WEISS B, 1968, J BIOL CHEM, V243, P4543; WEISS B, 1968, J BIOL CHEM, V243, P4530; WEISS B, 1967, J BIOL CHEM, V242, P4270; WEISS B, 1968, J BIOL CHEM, V243, P4556; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	71	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1719	1727		10.1074/jbc.M109053200	http://dx.doi.org/10.1074/jbc.M109053200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11698410	hybrid			2022-12-25	WOS:000173421300015
J	Gemba, T; Valbracht, J; Alsalameh, S; Lotz, M				Gemba, T; Valbracht, J; Alsalameh, S; Lotz, M			Focal adhesion kinase and mitogen-activated protein kinases are involved in chondrocyte activation by the 29-kDa amino-terminal fibronectin fragment.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR CHONDROCYTES; MATRIX-ASSEMBLY RECEPTOR; TYROSINE PHOSPHORYLATION; NITRIC-OXIDE; SIGNAL-TRANSDUCTION; INTEGRIN EXPRESSION; CARTILAGE DAMAGE; SYNOVIAL-FLUID; BINDING; SRC	The 29-kDa amino-terminal fibronectin fragment (FN-f) has a potent chondrolytic effect and is thought to be involved in cartilage degradation in arthritis. However, little is known about signal transduction pathways that are activated by FN-f. Here we demonstrated that FN-f induced nitric oxide (NO) production from human articular chondrocytes. Expression of inducible nitric-oxide synthase (iNOS) mRNA and NO production were observed at 6 and 48 h after FN-f treatment, respectively. Interleukin-1beta (IL-1beta) mRNA up-regulation was stimulated by FN-f in human chondrocytes. To address the possibility that FN-f-induced NO release is mediated by IL-1beta production, the effect of IL-1 receptor antagonist (IL-1ra) was determined. IL-1ra partially inhibited FN-f-induced NO release although it almost completely inhibited IL-1beta-induced NO release. Tyrosine phosphorylation of focal adhesion kinase was induced transiently by FN-f treatment. Blocking antibodies to alpha(5) or beta(1) integrin and Arg-Gly-Asp-containing peptides did not inhibit FN-f-induced NO production. PP2, a Src family kinase inhibitor, or cytochalasin D, which selectively disrupts the network of actin filaments, inhibited both FAK phosphorylation and NO production induced by FN-f, but the phosphatidylinositol 3-kinase inhibitor wortmannin had no effect. Analysis of mitogen-activated protein kinases (MAPK) showed activation of extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase, and p38 MAPK. High concentrations of SB203580, which inhibit both JNK and p38 MAPK, and PD98059 a selective inhibitor of MEK1/2 that blocks ERK activation, inhibited FN-f induced NO production. These data suggest that focal adhesion kinase and MAPK mediate FN-f induced activation of human articular chondrocytes.	Scripps Res Inst, Div Arthrit Res MEM161, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Lotz, M (corresponding author), Scripps Res Inst, Div Arthrit Res MEM161, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mlotz@scripps.edu			NATIONAL INSTITUTE ON AGING [P01AG007996] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR37996] Funding Source: Medline; NIA NIH HHS [AG07996] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Bewsey KE, 1996, BBA-MOL BASIS DIS, V1317, P55, DOI 10.1016/0925-4439(96)00037-3; BLANCO FJ, 1995, AM J PATHOL, V146, P75; BLYSTONE SD, 1992, J BIOL CHEM, V267, P3968; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Homandberg GA, 1998, OSTEOARTHR CARTILAGE, V6, P231, DOI 10.1053/joca.1998.0116; HOMANDBERG GA, 1992, J BIOL CHEM, V267, P3597; Homandberg GA, 1996, ARCH BIOCHEM BIOPHYS, V334, P325, DOI 10.1006/abbi.1996.0461; Homandberg GA, 1997, BIOCHEM J, V321, P751, DOI 10.1042/bj3210751; HOMANDBERG GA, 1993, J RHEUMATOL, V20, P1378; HOMANDBERG GA, 1994, ARCH BIOCHEM BIOPHYS, V310, P40, DOI 10.1006/abbi.1994.1137; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; Lotz M, 1999, RHEUM DIS CLIN N AM, V25, P269, DOI 10.1016/S0889-857X(05)70067-3; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MOON KY, 1994, J BIOL CHEM, V269, P7651; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; SALTER DM, 1992, BRIT J RHEUMATOL, V31, P231; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCOTT DL, 1981, ANN RHEUM DIS, V40, P142, DOI 10.1136/ard.40.2.142; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; Wang ZY, 1999, HYPERTENSION, V34, P1259, DOI 10.1161/01.HYP.34.6.1259; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WOODS VL, 1994, ARTHRITIS RHEUM, V37, P537, DOI 10.1002/art.1780370414; WU CY, 1993, J BIOL CHEM, V268, P21883; WURSTER NB, 1984, BIOCHIM BIOPHYS ACTA, V800, P52, DOI 10.1016/0304-4165(84)90093-X; XIE DL, 1992, J RHEUMATOL, V19, P1448; XIE DL, 1993, BIOCHIM BIOPHYS ACTA, V1182, P189, DOI 10.1016/0925-4439(93)90140-V; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	40	61	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					907	911		10.1074/jbc.M109690200	http://dx.doi.org/10.1074/jbc.M109690200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11677248	hybrid			2022-12-25	WOS:000173166800007
J	Callow, MG; Clairvoyant, F; Zhu, S; Schryver, B; Whyte, DB; Bischoff, JR; Jallal, B; Smeal, T				Callow, MG; Clairvoyant, F; Zhu, S; Schryver, B; Whyte, DB; Bischoff, JR; Jallal, B; Smeal, T			Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P21-ACTIVATED KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; DBL FAMILY; C-JUN; RAS; CDC42; RHO	p2l-activated protein kinase (PAK) serine/threonine kinases are important effectors of Rho family GTPases and have been implicated in the regulation of cell morphology and motility, as well as in cell transformation. To further investigate the possible involvement of PAK kinases in tumorigenesis, we analyzed the expression of several family members in tumor cell lines. Here we demonstrate that PAK4 is frequently overexpressed in human tumor cell lines of various tissue origins. We also have identified serine (Ser-474) as the likely autophosphorylation site in the kinase domain of PAK4 in vivo. Mutation of this serine to glutamic acid (S474E) results in constitutive activation of the kinase. Phosphospecific antibodies directed against serine 474 detect activated PAK4 on the Golgi membrane when PAK4 is co-expressed with activated Cdc42. Furthermore, expression of the active PAK4 (S474E) mutant has transforming potential, leading to anchorage-independent growth of NIH3T3 cells. A kinase-inactive PAK4 (K350A,K351A), on the other hand, efficiently blocks transformation by activated Ras and inhibits anchorage-independent growth of HCT116 colon cancer cells. Taken together, our data strongly implicate PAK4 in oncogenic transformation and suggest that PAK4 activity is required for Ras-driven, anchorage-independent growth.	SUGEN Inc, San Francisco, CA 94080 USA	Pfizer	Smeal, T (corresponding author), SUGEN Inc, 230 E Grand Ave, San Francisco, CA 94080 USA.	tod-smeal@sugen.com						Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CURTIS L, 1988, GENOMICS, V53, P42; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Eby JJ, 1998, CURR BIOL, V8, P967, DOI 10.1016/S0960-9822(98)00398-4; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Howe AK, 2001, J BIOL CHEM, V276, P14541, DOI 10.1074/jbc.C000797200; Huang RY, 1998, MOL CELL BIOL, V18, P7130, DOI 10.1128/MCB.18.12.7130; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Larramendy ML, 1997, AM J PATHOL, V150, P685; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Moskow JJ, 2000, MOL CELL BIOL, V20, P7559, DOI 10.1128/MCB.20.20.7559-7571.2000; Osada S, 1997, FEBS LETT, V404, P227, DOI 10.1016/S0014-5793(97)00139-7; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Tang Y, 1998, P NATL ACAD SCI USA, V95, P5139, DOI 10.1073/pnas.95.9.5139; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Thompson FH, 1996, CANCER GENET CYTOGEN, V87, P55, DOI 10.1016/0165-4608(95)00248-0; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHOA Z, 1998, MOL CELL BIOL, V18, P2153; Zhu KJ, 2001, MOL CELL BIOL, V21, P425, DOI 10.1128/MCB.21.2.425-437.2001	69	217	232	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					550	558		10.1074/jbc.M105732200	http://dx.doi.org/10.1074/jbc.M105732200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11668177	hybrid			2022-12-25	WOS:000173087900073
J	Hao, MM; Lin, SX; Karylowski, OJ; Wustner, D; McGraw, TE; Maxfield, FR				Hao, MM; Lin, SX; Karylowski, OJ; Wustner, D; McGraw, TE; Maxfield, FR			Vesicular and non-vesicular sterol transport in living cells - The endocytic recycling compartment is a major sterol storage organelle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; INTRACELLULAR CHOLESTEROL TRAFFICKING; LOW-DENSITY LIPOPROTEIN; COENZYME-A REDUCTASE; PLASMA-MEMBRANE; CARRIER PROTEIN-2; ENDOPLASMIC-RETICULUM; PHYSICAL-PROPERTIES; STEADY-STATE; PATHWAY	We examined the intracellular transport of sterol in living cells using a naturally fluorescent cholesterol analog, dehydroergosterol (DHE), which has been shown to. mic many of the properties of cholesterol. By using DHE loaded on methyl-beta-cyclodextrin, we followed this cholesterol analog in pulse-chase studies. At steady state, DHE co-localizes extensively with transferrin (Tf), a marker for the endocytic recycling compartment (ERC), and redistributes with Tf in cells with altered ERC morphology. Expression of a dominant-negative mutation of an ERC-associated protein, mRme-1 (G429R), results in the slowing of both DHE and Tf receptor return to the cell surface. [H-3]Cholesterol is found in the same fraction as I-125-Tf on sucrose density gradients, and this fraction can be specifically shifted to a higher density based on the presence of horseradish peroxidase-conjugated Tf in the same organelle. Whereas vesicular transport of Tf and efflux of DHE from the ERC are entirely blocked in energy-depleted cells, delivery of DHE to the ERC from the plasma membrane is only slightly affected. Biochemical studies performed using [H-3]cholesterol show that the energy dependence of cholesterol transport to and from the ERC is similar to DHE transport. We propose that a large portion of intracellular cholesterol is localized in the ERC, and this pool might be important in maintaining cellular cholesterol homeostasis.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA	Cornell University; Cornell University	Maxfield, FR (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.		Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011	Maxfield, Fred/0000-0003-4396-8866; Wustner, Daniel/0000-0003-4995-9709	NIDDK NIH HHS [DK57689, DK27083] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057689, R37DK027083, R01DK027083] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN D, 1993, PROG LIPID RES, V32, P195, DOI 10.1016/0163-7827(93)90015-O; Atshaves BP, 1999, J LIPID RES, V40, P610; BERGERON RJ, 1982, J LIPID RES, V23, P291; Blanchette-Mackie EJ, 2000, BBA-MOL CELL BIOL L, V1486, P171, DOI 10.1016/S1388-1981(00)00055-X; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; COLLES SM, 1995, LIPIDS, V30, P795, DOI 10.1007/BF02533954; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; COXEY RA, 1993, J LIPID RES, V34, P1165; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; EVANS WH, 1985, BIOCHEM J, V232, P33, DOI 10.1042/bj2320033; Frolov A, 1996, J LIPID RES, V37, P1862; Frolov A, 1996, J BIOL CHEM, V271, P16075, DOI 10.1074/jbc.271.27.16075; FUTTER CE, 1989, J CELL SCI, V94, P685; GADELLA TWJ, 1991, BIOCHEMISTRY-US, V30, P5555, DOI 10.1021/bi00236a031; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; HAPALA I, 1994, BIOCHEMISTRY-US, V33, P7682, DOI 10.1021/bi00190a023; Haynes MP, 2000, BIOCHEMISTRY-US, V39, P4508, DOI 10.1021/bi992125q; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Hornick CA, 1997, AM J PHYSIOL-CELL PH, V273, pC1075, DOI 10.1152/ajpcell.1997.273.3.C1075; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; Khelef N, 1998, J BIOL CHEM, V273, P11218, DOI 10.1074/jbc.273.18.11218; Khelef N, 2000, ARTERIOSCL THROM VAS, V20, P1769; Kobayashi T, 1998, SEMIN CELL DEV BIOL, V9, P517, DOI 10.1006/scdb.1998.0257; KOK JW, 1991, J CELL BIOL, V114, P231, DOI 10.1083/jcb.114.2.231; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; LANGE Y, 1992, J LIPID RES, V33, P315; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LANGE Y, 1991, J LIPID RES, V32, P329; Lange Y, 1998, J BIOL CHEM, V273, P18915, DOI 10.1074/jbc.273.30.18915; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; LISCUM L, 1992, J LIPID RES, V33, P1239; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; Schoer JK, 2000, BIOCHEMISTRY-US, V39, P7662, DOI 10.1021/bi992686h; SCHROEDER F, 1991, BIOCHIM BIOPHYS ACTA, V1066, P183, DOI 10.1016/0005-2736(91)90185-B; SCHROEDER F, 1984, PROG LIPID RES, V23, P97, DOI 10.1016/0163-7827(84)90009-2; SCHROEDER F, 1979, J BIOL CHEM, V254, P2456; SCHROEDER F, 1987, BIOCHEMISTRY-US, V26, P2441, DOI 10.1021/bi00383a007; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; SCHROEDER F, 1995, MOL MEMBR BIOL, V12, P113, DOI 10.3109/09687689509038505; SCHROEDER F, 1979, FEBS LETT, V97, P233, DOI 10.1016/0014-5793(79)80091-5; Seedorf U, 2000, BBA-MOL CELL BIOL L, V1486, P45, DOI 10.1016/S1388-1981(00)00047-0; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Skiba PJ, 1996, J BIOL CHEM, V271, P13392, DOI 10.1074/jbc.271.23.13392; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SMITH RJM, 1974, BIOCHEM J, V137, P413, DOI 10.1042/bj1370413; SMUTZER G, 1986, BIOCHIM BIOPHYS ACTA, V862, P361, DOI 10.1016/0005-2736(86)90239-7; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; URBANI L, 1990, J BIOL CHEM, V265, P1919; VANAMERONGEN A, 1989, BIOCHIM BIOPHYS ACTA, V1004, P36, DOI 10.1016/0005-2760(89)90209-9; WARNOCK DE, 1993, J BIOL CHEM, V268, P10145; Wood WG, 1999, LIPIDS, V34, P225, DOI 10.1007/s11745-999-0357-9; WOODFORD JK, 1994, BBA-BIOMEMBRANES, V1189, P52, DOI 10.1016/0005-2736(94)90279-8; WOODFORD JK, 1995, CHEM PHYS LIPIDS, V76, P73, DOI 10.1016/0009-3084(95)02436-M; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	76	242	244	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					609	617		10.1074/jbc.M108861200	http://dx.doi.org/10.1074/jbc.M108861200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11682487	hybrid			2022-12-25	WOS:000173087900080
J	Zubiaur, M; Fernandez, O; Ferrero, E; Salmeron, J; Malissen, B; Malavasi, F; Sancho, J				Zubiaur, M; Fernandez, O; Ferrero, E; Salmeron, J; Malissen, B; Malavasi, F; Sancho, J			CD38 is associated with lipid rafts and upon receptor stimulation leads to Akt/protein kinase B and Erk activation in the absence of the CD3-zeta immune receptor tyrosine-based activation motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; JURKAT T-CELLS; TUMOR-SUPPRESSOR PTEN; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; CHOLESTEROL DEPLETION; SIGNALING PATHWAYS; MEMBRANE DOMAINS; PLASMA-MEMBRANE; ANCHORED PROTEINS	T lymphocytes can be activated via the T cell receptor (TCR) or by triggering through a number of other cell surface structures, including the CD38 co-receptor molecule. Here, we show that in TCR+ T cells that express a CD3-zeta lacking the cytoplasmic domain, cross-linking with CD38- or CD3-specific monoclonal antibodies induces tyrosine phosphorylation of CD3-epsilon, zeta-associated protein-70, linker for activation of T cells, and Shc. Moreover, in these cells, anti-CD38 or anti-CD3 stimulation leads to protein kinase B/Akt and Erk activation, suggesting that the CD3-zeta-immunoreceptor tyrosine-based activation motifs are not required for CD38 signaling in T cells. Interestingly, in unstimulated T cells, lipid rafts are highly enriched in CD38, including the T cells lacking the cytoplasmic tail of CD3-zeta. Moreover, CD38 clustering by extensive cross-linking with an anti-CD38 monoclonal antibody and a secondary antibody leads to an increased resistance of CD38 to detergent solubilization, suggesting that CD38 is constitutively associated with membrane rafts. Consistent with this, cholesterol depletion with methyl-beta-cyclodextrin substantially reduces CD38-mediated Akt activation while enhancing CD38-mediated Erk activation. CD38/raft association may improve the signaling capabilities of CD38 via formation of protein/lipid domains to which signaling-competent molecules, such as immunoreceptor tyrosine-based activation motif-bearing CD3 molecules and protein-tyrosine kinases, are recruited.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain; Hosp Univ San Cecilio, Granada 18012, Spain; CNRS, INSERM, Ctr Immunol, F-13288 Marseille, France; Univ Turin, Sch Med, Immunogenet Lab, I-10126 Turin, Italy	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Hospital Universitario San Cecilio; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Turin	Sancho, J (corresponding author), CSIC, Inst Parasitol & Biomed, Ventanilla 11, Granada 18001, Spain.		Zubiaur, Mercedes/K-9390-2014; Zubiaur, Mercedes/AAC-5792-2021; Sancho, Jaime/K-5989-2019; Sancho, Jaime/O-3228-2013; Malissen, Bernard/AAK-4659-2020	Zubiaur, Mercedes/0000-0002-4127-3027; Zubiaur, Mercedes/0000-0002-4127-3027; Sancho, Jaime/0000-0003-3852-7951; Sancho, Jaime/0000-0003-3852-7951; MALAVASI, Fabio/0000-0002-1844-174X; Malissen, Bernard/0000-0003-1340-9342	Telethon [E.0662] Funding Source: Medline	Telethon(Fondazione Telethon)		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Berthelier V, 1998, BIOCHEM J, V330, P1383, DOI 10.1042/bj3301383; Borgatti P, 1997, EUR J IMMUNOL, V27, P2805, DOI 10.1002/eji.1830271110; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chau LA, 1999, J IMMUNOL, V163, P1853; Cheng PC, 2001, J IMMUNOL, V166, P3693, DOI 10.4049/jimmunol.166.6.3693; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Coffer PJ, 1998, BIOCHEM J, V335, P1; Deaglio S, 1996, J IMMUNOL, V156, P727; Deaglio S, 2000, CHEM IMMUNOL, V75, P99; Deaglio S, 1998, J IMMUNOL, V160, P395; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; deAos I, 1997, J BIOL CHEM, V272, P25310, DOI 10.1074/jbc.272.40.25310; Ebert PJR, 2000, J IMMUNOL, V165, P5435, DOI 10.4049/jimmunol.165.10.5435; EXLEY M, 1994, J BIOL CHEM, V269, P15140; Ferrero E, 2000, CHEM IMMUNOL, V75, P1; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; FUNARO A, 1993, EUR J IMMUNOL, V23, P2407, DOI 10.1002/eji.1830231005; Funaro A, 2000, CHEM IMMUNOL, V75, P256; Genot E, 1998, ONCOGENE, V17, P1731, DOI 10.1038/sj.onc.1202101; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Huby RDJ, 1995, J BIOL CHEM, V270, P30241, DOI 10.1074/jbc.270.51.30241; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; JACKSON DG, 1990, J IMMUNOL, V144, P2811; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; Kitanaka A, 1997, J IMMUNOL, V159, P184; Kosugi A, 1999, INT IMMUNOL, V11, P1395, DOI 10.1093/intimm/11.9.1395; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Millan J, 1999, TISSUE ANTIGENS, V53, P33, DOI 10.1034/j.1399-0039.1999.530104.x; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Morra M, 1998, FASEB J, V12, P581, DOI 10.1096/fasebj.12.7.581; Patel VP, 2001, J IMMUNOL, V166, P754, DOI 10.4049/jimmunol.166.2.754; Petrie RJ, 2000, J IMMUNOL, V165, P1220, DOI 10.4049/jimmunol.165.3.1220; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; SALMERON A, 1995, J IMMUNOL, V154, P1675; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Silvennoinen O, 1996, J IMMUNOL, V156, P100; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; TERHORST C, 1981, CELL, V23, P771, DOI 10.1016/0092-8674(81)90441-4; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; Wang XD, 2000, J IMMUNOL, V164, P1934, DOI 10.4049/jimmunol.164.4.1934; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; Williams BL, 1999, EMBO J, V18, P1832, DOI 10.1093/emboj/18.7.1832; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Yang HL, 2001, J BIOL CHEM, V276, P18775, DOI 10.1074/jbc.M009852200; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zubiaur M, 1999, J BIOL CHEM, V274, P20633, DOI 10.1074/jbc.274.29.20633; Zubiaur M, 1997, J IMMUNOL, V159, P193	68	75	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					13	22		10.1074/jbc.M107474200	http://dx.doi.org/10.1074/jbc.M107474200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11689561	hybrid			2022-12-25	WOS:000173087900004
J	Chen, XA; Zhang, Y; Douglas, L; Zhou, PB				Chen, XA; Zhang, Y; Douglas, L; Zhou, PB			UV-damaged DNA-binding proteins are targets of CUL-4A-mediated ubiquitination and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-E; COMPLEMENTATION GROUP-E; ANAPHASE-PROMOTING COMPLEX; GLOBAL GENOMIC REPAIR; DDB; GENE; P48; SUBUNIT; LIGASE; CELL	Cul-4A, which encodes a member of the cullin family subunit of ubiquitin-protein ligases, is expressed at abnormally high levels in many tumor cells. CLTL-4A can physically associate with the damaged DNA-binding protein (DDB), which is composed of two subunits, p125 and p48. DDB binds specifically to UV-damaged DNA and is believed to play a role in DNA repair. We report here that CLTL-4A stimulates degradation of p48 through the ubiquitin-proteasome pathway, resulting in an overall decrease in UV-damaged DNA binding activity. The R273H mutant of p48 identified from a xeroderma pig-mentosium. (group E) patient is not subjected to CUL-4A-mediated proteolysis, consistent with its inability to bind CLTL-4A. p125 is also an unstable protein, and its ubiquitination is stimulated by CUL-4A. However, the abundance of p125 is not dramatically altered by Cul-4A overexpression. UV irradiation inhibits p125 degradation, which is temporally coupled to the UV-induced translocation of p125 from the cytoplasm into the nucleus. CLTL-4A is localized primarily in the cytoplasm. These findings identify DDB subunits as the first substrates of the CLTL-4A ubiquitination machinery and suggest that abnormal expression of Cul-4A results in reduced p48 levels, thus impairing the ability of DDB in lesion recognition and DNA repair in tumor cells.	Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA	Cornell University; Cornell University	Zhou, PB (corresponding author), Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA.							ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Chen LC, 1998, CANCER RES, V58, P3677; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; Hara R, 2000, MOL CELL BIOL, V20, P9173, DOI 10.1128/MCB.20.24.9173-9181.2000; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Hwang BJ, 1999, METH MOL B, V113, P103; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Krishnamoorthy RR, 1997, BIOCHEMISTRY-US, V36, P960, DOI 10.1021/bi961407c; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin GY, 1998, VIROLOGY, V249, P189, DOI 10.1006/viro.1998.9317; Liu W, 2000, J BIOL CHEM, V275, P21429, DOI 10.1074/jbc.M000961200; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; PAYNE A, 1994, MUTAT RES-FUND MOL M, V310, P89, DOI 10.1016/0027-5107(94)90012-4; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Watanabe T, 1999, J NEUROCHEM, V72, P549, DOI 10.1046/j.1471-4159.1999.0720549.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	50	126	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48175	48182		10.1074/jbc.M106808200	http://dx.doi.org/10.1074/jbc.M106808200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11673459	hybrid			2022-12-25	WOS:000172927000059
J	Kishida, K; Shimomura, I; Nishizawa, H; Maeda, N; Kuriyama, H; Kondo, H; Matsuda, M; Nagaretani, H; Ouchi, N; Hotta, K; Kihara, S; Kadowaki, T; Funahashi, T; Matsuzawa, Y				Kishida, K; Shimomura, I; Nishizawa, H; Maeda, N; Kuriyama, H; Kondo, H; Matsuda, M; Nagaretani, H; Ouchi, N; Hotta, K; Kihara, S; Kadowaki, T; Funahashi, T; Matsuzawa, Y			Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; RESPONSE ELEMENT; HORMONE-RECEPTOR; BINDING DOMAIN; LIGAND; TISSUE; TRANSACTIVATION; ADIPOGENESIS; HETERODIMERS; INDUCTION	The current study demonstrates that aquaporin adipose (AQPap), an adipose-specific glycerol channel (Kishida, K., Kuriyama, H., Funahashi, T., Shimomura, L, Kihara, S., Ouchi, N., Nishida, M., Nishizawa, H., Matsuda, M., Takahashi, M., Hotta, K., Nakamura, T., Yamashita, S., Tochino, Y., and Matsuzawa, Y. (2000) J. Biol. Chem. 275, 20896-20902), is a target gene of peroxisome proliferator-activated receptor (PPAR) gamma. The AQPap mRNA amounts increased following the induction of PPAR gamma in the differentiation of 3T3-L1 adipocytes. The AQPap mRNA in the adipose tissue increased when mice were treated with pioglitazone (PGZ), a synthetic PPAR gamma ligand, and decreased in PPAR gamma (+/-) heterozygous knockout mice. In 3T3-L1 adipocytes, PGZ augmented the AQPap mRNA expression and its promoter activity. Serial deletion of the promoter revealed the putative peroxisome proliferator-activated receptor response element (PPRE) at -93/-77. In 3T3-L1 preadipocytes, the expression of PPAR gamma by transfection and PGZ activated the luciferase activity of the promoter containing the PPRE, whereas the PPRE-deleted mutant was not affected. The gel mobility shift assay showed the direct binding of PPAR gamma -retinoid X receptor a complex to the PPRE. Delta PPAR gamma, which we generated as the dominant negative PPAR gamma lacking the activation function-2 domain, suppressed the promoter activity in 3T3-L1 cells, dose-dependently. We conclude that AQPap is a novel adipose-specific target gene of PPAR gamma through the binding of PPAR gamma -retinoid X receptor complex to the PPRE region in its promoter.	Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan; Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138654, Japan	Osaka University; University of Tokyo	Shimomura, I (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ichi@imed2.med.osaka-u.ac.jp	OUCHI, Noriyuki/I-7306-2014	Hotta, Kikuko/0000-0003-2427-6354; Nisihida, Makoto/0000-0002-0309-7106				Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; BABA H, 1995, NUTRITION, V11, P149; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Castillo G, 1999, EMBO J, V18, P3676, DOI 10.1093/emboj/18.13.3676; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Frohnert BI, 1999, J BIOL CHEM, V274, P3970, DOI 10.1074/jbc.274.7.3970; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Kishida K, 2000, J BIOL CHEM, V275, P20896, DOI 10.1074/jbc.M001119200; Kishida K, 2001, J BIOL CHEM, V276, P36251, DOI 10.1074/jbc.M106040200; KLEIN S, 1990, AM J PHYSIOL, V258, pE32, DOI 10.1152/ajpendo.1990.258.1.E32; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kuriyama H, 1997, BIOCHEM BIOPH RES CO, V241, P53, DOI 10.1006/bbrc.1997.7769; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Man MZ, 1996, MOL ENDOCRINOL, V10, P1021, DOI 10.1210/me.10.8.1021; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; NISHIZAWA H, 2001, J BIOL CHEM; POIRER H, 1999, FEBS LETT, V412, P480; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Ramsay TG, 1996, ENDOCRIN METAB CLIN, V25, P847, DOI 10.1016/S0889-8529(05)70358-3; Ranganathan S, 1998, J BIOL CHEM, V273, P26117, DOI 10.1074/jbc.273.40.26117; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8	41	94	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48572	48579		10.1074/jbc.M108213200	http://dx.doi.org/10.1074/jbc.M108213200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11679588	hybrid			2022-12-25	WOS:000172927000112
J	Taylor, TC; Backlund, A; Bjorhall, K; Spreitzer, RJ; Andersson, I				Taylor, TC; Backlund, A; Bjorhall, K; Spreitzer, RJ; Andersson, I			First crystal structure of rubisco from a green alga, Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE-OXYGENASE; RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; LARGE SUBUNIT; RESOLUTION; ACTIVASE; SPINACH; SPECIFICITY; SUBSTITUTION; REPLACEMENT; HOLOENZYME	The crystal structure of Rubisco (ribulose 1,5-bisphosphate carboxylase/oxygenase) from the unicellular green alga, Chlamydomonas reinhardtii has been determined to 1.4 Angstrom resolution. Overall, the structure shows high similarity to the previously determined structures of L8S8 Rubisco enzymes. The largest difference is found in the loop between beta strands A and B of the small subunit (betaA-betaB loop), which is longer by six amino acid residues than the corresponding region in Rubisco from Spinacia. Mutations of residues in the betaA-betaB loop have been shown to affect holoenzyme stability and catalytic properties. The information contained in the Chlamydomonas structure enables a more reliable analysis of the effect of these mutations. No electron density was observed for the last 13 residues of the small subunit, which are assumed to be disordered in the crystal. Because of the high resolution of the data, some posttranslational modifications are unambiguously apparent in the structure. These include cysteine and N-terminal methylations and proline 4-hydroxylations.	Swedish Univ Agr Sci, Dept Mol Biol, S-75124 Uppsala, Sweden; Univ Uppsala, Dept Med Chem, Div Pharmacognosy, S-75123 Uppsala, Sweden; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	Swedish University of Agricultural Sciences; Uppsala University; University of Nebraska System; University of Nebraska Lincoln	Andersson, I (corresponding author), Swedish Univ Agr Sci, Dept Mol Biol, BMC Box 590, S-75124 Uppsala, Sweden.							ADAM Z, 1995, PHOTOSYNTH RES, V43, P143, DOI 10.1007/BF00042971; Andersson I, 1996, J MOL BIOL, V259, P160, DOI 10.1006/jmbi.1996.0310; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Cleland WW, 1998, CHEM REV, V98, P549, DOI 10.1021/cr970010r; CLONEY LP, 1993, PLANT MOL BIOL, V23, P1285, DOI 10.1007/BF00042362; CURMI PMG, 1992, J BIOL CHEM, V267, P16980; Du YC, 2000, P NATL ACAD SCI USA, V97, P14206, DOI 10.1073/pnas.260503997; Du YC, 2000, J BIOL CHEM, V275, P19844, DOI 10.1074/jbc.M002321200; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FLACHMANN R, 1992, J BIOL CHEM, V267, P10576; Grimm R, 1997, FEBS LETT, V408, P350, DOI 10.1016/S0014-5793(97)00462-6; Hansen S, 1999, J MOL BIOL, V288, P609, DOI 10.1006/jmbi.1999.2701; Hanson TE, 2001, P NATL ACAD SCI USA, V98, P4397, DOI 10.1073/pnas.081610398; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; JORDAN DB, 1981, NATURE, V291, P513, DOI 10.1038/291513a0; Kitano K, 2001, STRUCTURE, V9, P473, DOI 10.1016/S0969-2126(01)00608-6; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; Larson EM, 1997, J BIOL CHEM, V272, P17033, DOI 10.1074/jbc.272.27.17033; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NEWMAN J, 1993, ACTA CRYSTALLOGR D, V49, P548, DOI 10.1107/S090744499300530X; Ott CM, 2000, J BIOL CHEM, V275, P26241, DOI 10.1074/jbc.M004580200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; PORTIS AR, 1995, J EXP BOT, V46, P1285, DOI 10.1093/jxb/46.special_issue.1285; Salvucci ME, 1996, PHOTOSYNTH RES, V47, P1, DOI 10.1007/BF00017748; SCHNEIDER G, 1986, EMBO J, V5, P3409, DOI 10.1002/j.1460-2075.1986.tb04662.x; Spreitzer RJ, 1999, PHOTOSYNTH RES, V60, P29, DOI 10.1023/A:1006240202051; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; Spreitzer RJ, 2001, BIOCHEMISTRY-US, V40, P5615, DOI 10.1021/bi002943e; SPREITZER RJ, 1993, ANNU REV PLANT PHYS, V44, P411, DOI 10.1146/annurev.pp.44.060193.002211; SPREITZER RJ, 1998, MOL BIOL CHLOROPLAST, P515; Sugawara H, 1999, J BIOL CHEM, V274, P15655, DOI 10.1074/jbc.274.22.15655; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; Taylor TC, 1997, BIOCHEMISTRY-US, V36, P4041, DOI 10.1021/bi962818w; Taylor TC, 1996, NAT STRUCT BIOL, V3, P95, DOI 10.1038/nsb0196-95; Taylor TC, 1997, J MOL BIOL, V265, P432, DOI 10.1006/jmbi.1996.0738; Ying ZT, 1999, J BIOL CHEM, V274, P36750, DOI 10.1074/jbc.274.51.36750	43	77	85	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48159	48164		10.1074/jbc.M107765200	http://dx.doi.org/10.1074/jbc.M107765200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11641402	hybrid			2022-12-25	WOS:000172927000057
J	Clay, CE; Atsumi, G; High, KP; Chilton, FH				Clay, CE; Atsumi, G; High, KP; Chilton, FH			Early de novo gene expression is required for 15-deoxy-Delta(12,14)-prostaglandin J(2)-induced apoptosis in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; PROTEIN-KINASE-C; KAPPA-B KINASE; PPAR-GAMMA; CYCLOPENTENONE PROSTAGLANDINS; SIGNALING PATHWAY; CARCINOMA CELLS; J(2); LIGAND; GROWTH	Cyclopentenone prostaglandin derivatives of arachidonic acid are potent inducers of apoptosis in a variety of cancer cell types. Several investigators have shown that the terminal derivative of prostaglandin J(2) (PGJ(2)) metabolism, 15-deoxy-Delta (12,14)-PGJ(2) (15dPGJ(2)), induces apoptosis in breast cancer cells and is a potent activator of the nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPAR gamma), but 15dPGJ(2) effects can be mediated by PPAR gamma -dependent and PPAR gamma -independent mechanisms. Here we report that 15dPGJ(2) regulates early gene expression critical to apoptosis. Specifically, 15dPGJ(2) induces potent and irreversible S phase arrest that is correlated with expression of genes critical to cell cycle arrest and apoptosis, including the cyclin-dependent kinase inhibitor p21(Waf1iCip1) (p21). Inhibition of RNA or protein synthesis abrogates apoptosis induced by 15dPGJ(2) in breast cancer cells but potentiates apoptosis induced by tumor necrosis factor-a or CD95/Fas ligand. Additionally, 15dPGJ(2) induces caspase activation that is blocked by peptide caspase inhibitors. These data show that de novo gene transcription is necessary for 15dPGJ(2)-induced apoptosis in breast cancer cells. Critical candidate genes are likely to be revealed through analysis of differential cDNA array expression.	Wake Forest Univ, Baptist Med Ctr, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Baptist Med Ctr, Sect Pulm Crit Care, Winston Salem, NC 27157 USA; Wake Forest Univ, Baptist Med Ctr, Infect Dis Sect, Winston Salem, NC 27157 USA; Wake Forest Univ, Baptist Med Ctr, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	High, KP (corresponding author), Wake Forest Univ, Sch Med, Infect Dis Sect, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.			Chilton, Floyd/0000-0002-3686-0198	NIAID NIH HHS [R01 AI 42022] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042022] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn SG, 1998, BBA-MOL CELL RES, V1448, P115, DOI 10.1016/S0167-4889(98)00113-X; Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Chang TH, 2000, CANCER RES, V60, P1129; Chattopadhyay N, 2000, J NEUROSCI RES, V61, P67, DOI 10.1002/1097-4547(20000701)61:1<67::AID-JNR8>3.0.CO;2-7; Chen Y, 1999, J BIOL CHEM, V274, P10863, DOI 10.1074/jbc.274.16.10863; Chung SW, 2000, J BIOL CHEM, V275, P32681, DOI 10.1074/jbc.M002577200; Clay CE, 1999, CARCINOGENESIS, V20, P1905, DOI 10.1093/carcin/20.10.1905; Clay CE, 2000, PROSTAG OTH LIPID M, V62, P23, DOI 10.1016/S0090-6980(00)00073-3; Clay CE, 2001, J INVEST MED, V49, P413, DOI 10.2310/6650.2001.33786; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Feng JW, 2000, J LIPID RES, V41, P688; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Freeman ME, 1999, DIGEST DIS, V17, P44, DOI 10.1159/000016902; Freeman WM, 2000, BIOTECHNIQUES, V29, P1042, DOI 10.2144/00295rv01; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Gupta RA, 2001, J BIOL CHEM, V276, P29681, DOI 10.1074/jbc.M103779200; Han SW, 2001, CLIN CANCER RES, V7, P98; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Huang S, 2000, CANCER RES, V60, P5334; Hunter JG, 2001, J BIOL CHEM, V276, P38297; Inoue H, 2000, J BIOL CHEM, V275, P28028; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Joubert AM, 1999, PROSTAG LEUKOTR ESS, V61, P171, DOI 10.1054/plef.1999.0087; Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291; Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li LY, 2001, J BIOL CHEM, V276, P38152; Ma HW, 1998, J BIOL CHEM, V273, P30131, DOI 10.1074/jbc.273.46.30131; Maxey KM, 2000, PROSTAG OTH LIPID M, V62, P15, DOI 10.1016/S0090-6980(00)00072-1; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Mullally JE, 2001, J BIOL CHEM, V276, P30366, DOI 10.1074/jbc.M102198200; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rohn TT, 2001, NEUROREPORT, V12, P839, DOI 10.1097/00001756-200103260-00043; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Sato H, 2000, BRIT J CANCER, V83, P1394, DOI 10.1054/bjoc.2000.1457; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shappell SB, 2001, CANCER RES, V61, P497; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; Trimboli AJ, 1999, CANCER RES, V59, P6171; Vanaja DK, 2000, CANCER RES, V60, P4714; Wu J, 1999, BRIT J CANCER, V79, P1572, DOI 10.1038/sj.bjc.6690250; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116	57	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47131	47135		10.1074/jbc.C100339200	http://dx.doi.org/10.1074/jbc.C100339200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11668172	hybrid			2022-12-25	WOS:000172768500062
J	Chavakis, T; Kanse, SM; Pixley, RA; May, AE; Isordia-Salas, I; Colman, RW; Preissner, KT				Chavakis, T; Kanse, SM; Pixley, RA; May, AE; Isordia-Salas, I; Colman, RW; Preissner, KT			Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen	FASEB JOURNAL			English	Article						HK; monoclonal antibody; leukocyte; Mac-1	CELL-BINDING-SITE; UROKINASE RECEPTOR; LIGHT-CHAIN; FACTOR-X; NEUTROPHIL EMIGRATION; ENDOTHELIAL-CELLS; CD11B/CD18 MAC-1; SURFACE-BINDING; P-SELECTIN; ADHESION	Proteolytic cleavage of single-chain, high molecular weight kininogen (HK) by kallikrein releases the short-lived vasodilator bradykinin and leaves behind a two-chain, high molecular weight kininogen (HKa) reported to bind to the beta2-integrin Mac-1 (CR3, CD11b/CD18, alphaM beta2) on neutrophils and exert antiadhesive properties by binding to the urokinase receptor (uPAR) and vitronectin. We define the molecular mechanisms for the antiadhesive effects of HK related to disruption of beta2-integrin-mediated cellular interactions in vitro and in vivo. In a purified system, HK and HKa inhibited the binding of soluble fibrinogen and ICAM-1 to immobilized Mac-1, but not the binding of ICAM-1 to immobilized LFA-1 (CD11a/CD18, alphaL beta2). This inhibitory effect could be attributed to HK domain 5 and to a lesser degree to HK domain 3, consistent with the requirement of both domains for binding to Mac-1. Accordingly, HK, HKa, and domain 5 inhibited the adhesion of Mac-1 but not LFA-1-transfected K562 human erythroleukemic cells to ICAM-1. Moreover, adhesion of human monocytic cells to fibrinogen and to human endothelial cells was blocked by HK, HKa, and domain 5. By using peptides derived from HK domain 5, the sequences including amino acids H475-G497 (and to a lesser extent, G440-H455) were identified as responsible for the antiadhesive effect, which was independent of uPAR. Finally, administration of domain 5 into mice, followed by induction of thioglycollate-provoked peritonitis, decreased the recruitment of neutrophils by A similar to 70% in this model of acute inflammation. Taken together, HKa (and particularly domain 5) specifically interacts with Mac-1 but not with LFA-1, thereby blocking Mac-1-dependent leukocyte adhesion to fibrinogen and endothelial cells in vitro and in vivo and serving as a novel endogenous regulator of leukocyte recruitment into the inflamed tissue.	Univ Giessen, Fachbereich Humanmed, Inst Biochem, D-35392 Giessen, Germany; Univ Giessen, Dept Internal Med 3, D-35392 Giessen, Germany; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19122 USA; Tech Univ Munich, Deutsch Herzzentrum, D-8000 Munich, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich	Chavakis, T (corresponding author), Univ Giessen, Fachbereich Humanmed, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	triantafyllos.chavakis@innere.med.uni-giessen.de	Chavakis, Triantafyllos/ABE-8845-2020	Kanse, Sandip/0000-0003-0782-9957	NCI NIH HHS [CA63938] Funding Source: Medline; NHLBI NIH HHS [HL56914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1991, J IMMUNOL, V147, P1891; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; Asakura S, 1998, J BIOCHEM-TOKYO, V124, P473, DOI 10.1093/oxfordjournals.jbchem.a022138; ASAKURA S, 1992, J CELL BIOL, V116, P465, DOI 10.1083/jcb.116.2.465; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; CARLOS TM, 1994, BLOOD, V84, P2068; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 1999, BLOOD, V93, P2976; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 2000, BLOOD, V95, P543, DOI 10.1182/blood.V95.2.543; de Gaetano G, 1999, HAEMOSTASIS, V29, P41; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; GUSTAFSON EJ, 1989, J CELL BIOL, V109, P377, DOI 10.1083/jcb.109.1.377; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; HERWALD H, 1995, J BIOL CHEM, V270, P14634; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; Khan MMH, 1998, AM J PHYSIOL-HEART C, V275, pH145, DOI 10.1152/ajpheart.1998.275.1.H145; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; Lin YZ, 1997, BLOOD, V90, P690, DOI 10.1182/blood.V90.2.690.690_690_697; Lu HF, 1997, J CLIN INVEST, V99, P1340, DOI 10.1172/JCI119293; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357; NISHIKAWA K, 1992, BLOOD, V80, P1980; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Plescia J, 1996, BIOCHEM J, V319, P873, DOI 10.1042/bj3190873; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; RAMOS OF, 1988, J IMMUNOL, V140, P1239; REBUCK JW, 1983, AM J CLIN PATHOL, V79, P405, DOI 10.1093/ajcp/79.4.405; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; RETZIOS AD, 1987, J BIOL CHEM, V262, P3074; ROTHLEIN R, 1985, J IMMUNOL, V135, P2668; SCHMAIER AH, 1986, J CLIN INVEST, V77, P1565, DOI 10.1172/JCI112472; Sheng N, 2000, BLOOD, V95, P3788; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; TAIT JF, 1986, J BIOL CHEM, V261, P5396; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; WALDMANN R, 1975, LANCET, V1, P949; WEI Y, 1994, J BIOL CHEM, V269, P32380; WEISEL JW, 1994, J BIOL CHEM, V269, P10100; Yung LYL, 1999, BLOOD, V94, P2716, DOI 10.1182/blood.V94.8.2716.420k32_2716_2724; Zhang JC, 2000, FASEB J, V14, P2589, DOI 10.1096/fj.99-1025com	56	55	56	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2365	2376		10.1096/fj.01-0201com	http://dx.doi.org/10.1096/fj.01-0201com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689462				2022-12-25	WOS:000172420500007
J	Yazawa, H; Yu, ZX; Takeda, K; Le, Y; Gong, WH; Ferrans, VJ; Oppenheim, JJ; Li, CCH; Wang, JM				Yazawa, H; Yu, ZX; Takeda, K; Le, Y; Gong, WH; Ferrans, VJ; Oppenheim, JJ; Li, CCH; Wang, JM			beta amyloid peptide (A beta(42)) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages	FASEB JOURNAL			English	Article						amyloid beta; Alzheimer's disease; internalization; colocalization	NECROSIS-FACTOR-ALPHA; A-BETA; ALZHEIMERS-DISEASE; CHEMOATTRACTANT RECEPTOR; SCAVENGER RECEPTOR; MICROGLIA; NEUROTOXICITY; CELLS; PHAGOCYTOSIS; MONOCYTES	The 42 amino acid form of beta amyloid (A beta (42)) plays a pivotal role in neurotoxicity and the activation of mononuclear phagocytes in Alzheimer's disease (AD). Our recent study revealed that FPRL1, a G-protein-coupled receptor, mediates the chemotactic and activating effect of A beta (42) on mononuclear phagocytes (monocytes and microglia), suggesting that FPRL1 may be involved in the proinflammatory responses in AD. We investigated the role of FPRL1 in cellular uptake and the subsequent fibrillar formation of A beta (42) by using fluorescence confocal microscopy. We found that upon incubation with macrophages or HEK293 cells genetically engineered to express FPRL1, A beta (42) associated with FPRL1 and the A beta (42)/FPRL1 complexes were rapidly internalized into the cytoplasmic compartment. The maximal internalization of A beta (42)/FPRL1 complexes occurred by 30 min after incubation. Removal of free A beta (42) from culture supernatants at 30 min resulted in a progressive recycling of FPRL1 to the cell surface and degradation of the internalized A beta (42). However, persistent exposure of the cells to A beta (42) over 24 h resulted in retention of A beta (42)/FPRL1 complexes in the cytoplasmic compartment and the formation of Congo red positive fibrils in macrophages but not in HEK 293 cell transfected with FPRL1. These results suggest that besides mediating the proinflammatory activity of A beta (42), FPRL1 is also involved in the internalization of A beta (42), which culminates in the formation of fibrils only in macrophages.	NCI, Mol Immunoregulat Lab, SAIC Frederick, Ctr Canc Res, Frederick, MD 21702 USA; NCI, Intramural Res Support Program, SAIC Frederick, Ctr Canc Res, Frederick, MD 21702 USA; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Wang, JM (corresponding author), NCI, Mol Immunoregulat Lab, SAIC Frederick, Ctr Canc Res, Bldg 560,Room 31-40, Frederick, MD 21702 USA.	wangji@mail.ncifcrf.gov	Le, Yingying/L-9785-2017	Le, Yingying/0000-0002-7990-3899	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Antic A, 2000, EXP NEUROL, V161, P96, DOI 10.1006/exnr.1999.7265; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; Combs CK, 1999, J NEUROSCI, V19, P928; DeWitt DA, 1998, EXP NEUROL, V149, P329, DOI 10.1006/exnr.1997.6738; Dzenko KA, 1997, J NEUROIMMUNOL, V80, P6, DOI 10.1016/S0165-5728(97)00128-8; El Khoury J, 1998, NEUROBIOL AGING, V19, pS81, DOI 10.1016/S0197-4580(98)00036-0; ElKhoury J, 1996, NATURE, V382, P716; Ford AL, 1996, J EXP MED, V184, P1737, DOI 10.1084/jem.184.5.1737; Funato H, 1998, AM J PATHOL, V152, P1633; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Heidenreich S, 1997, J IMMUNOL, V159, P3178; Heinzelmann M, 1999, J IMMUNOL, V162, P4240; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; Hull M, 1999, DRUG DISCOV TODAY, V4, P275, DOI 10.1016/S1359-6446(99)01339-2; Kalaria R N, 1999, Curr Opin Hematol, V6, P15, DOI 10.1097/00062752-199901000-00004; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kuo YM, 1999, BIOCHEM BIOPH RES CO, V257, P787, DOI 10.1006/bbrc.1999.0552; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Le YY, 1999, J IMMUNOL, V163, P6777; Le YY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-02-j0003.2001; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; London JA, 1996, P NATL ACAD SCI USA, V93, P4147, DOI 10.1073/pnas.93.9.4147; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lorton D, 2000, NEUROBIOL AGING, V21, P463, DOI 10.1016/S0197-4580(00)00092-0; MACKENZIE IRA, 1995, NEUROBIOL AGING, V16, P797, DOI 10.1016/0197-4580(95)00092-S; MANGAN DF, 1991, J IMMUNOL, V146, P1541; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; McDonald DR, 1998, J NEUROSCI, V18, P4451; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; McGeer PL, 1999, J LEUKOCYTE BIOL, V65, P409, DOI 10.1002/jlb.65.4.409; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Meda L, 1999, J NEUROIMMUNOL, V93, P45, DOI 10.1016/S0165-5728(98)00188-X; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Pachter JS, 1997, MOL PSYCHIATR, V2, P91, DOI 10.1038/sj.mp.4000212; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; Rossi M, 1996, BIOCHEMISTRY-US, V35, P3286, DOI 10.1021/bi950524p; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Seo JK, 1998, CLIN BIOCHEM, V31, P137, DOI 10.1016/S0009-9120(97)00172-0; SHAFFER LM, 1995, NEUROBIOL AGING, V16, P737, DOI 10.1016/0197-4580(95)00055-J; Stalder M, 1999, AM J PATHOL, V154, P1673, DOI 10.1016/S0002-9440(10)65423-5; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Tiffany HL, 2001, J BIOL CHEM, V276, P23645, DOI 10.1074/jbc.M101031200; vanderLaan LJW, 1996, J NEUROIMMUNOL, V70, P145, DOI 10.1016/S0165-5728(96)00110-5; VON ZM, 1992, J BIOL CHEM, V267, P3530; Weltzien RB, 2000, J NEUROSCI RES, V59, P522, DOI 10.1002/(SICI)1097-4547(20000215)59:4<522::AID-JNR7>3.3.CO;2-C; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yates SL, 2000, J NEUROCHEM, V74, P1017, DOI 10.1046/j.1471-4159.2000.0741017.x; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	58	124	144	2	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2454	2462		10.1096/fj.01-0251com	http://dx.doi.org/10.1096/fj.01-0251com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689470				2022-12-25	WOS:000172420500015
J	Hubert, P; Giannini, SL; Vanderplasschen, A; Franzen-Detrooz, E; Jacobs, N; Boniver, J; Delvenne, P				Hubert, P; Giannini, SL; Vanderplasschen, A; Franzen-Detrooz, E; Jacobs, N; Boniver, J; Delvenne, P			Dendritic cells induce the death of human papillomavirus transformed keratinocytes	FASEB JOURNAL			English	Article						cell contact; normal keratinocytes; apoptosis; HPV-transformed keratinocytes	SQUAMOUS INTRAEPITHELIAL LESIONS; NECROSIS-FACTOR-ALPHA; COLONY-STIMULATING FACTOR; ANTIGEN-PRESENTING CELLS; UTERINE CERVIX; LANGERHANS CELLS; FAS-LIGAND; (PRE)NEOPLASTIC LESIONS; PRENEOPLASTIC LESIONS; ORGANOTYPIC CULTURE	Although human papillomavirus (HPV) antigens are expressed in a majority of (pre) neoplastic lesions (squamous intraepithelial lesions; SILs) of the uterine cervix, progression to invasive cancer may occur, which suggests that the presentation of viral antigens to the immune system is deficient in some SILs. To determine whether professional antigen-presenting cells die in SILs, we assayed for the apoptosis of immature dendritic cells (DC) in organotypic cultures of HPV-transformed keratinocytes, which reproduce many features of in vivo observed SILs. Unexpectedly, the infiltration of organotypic cultures by DC specifically induced the apoptosis of HPV+ tumor cells, whereas DC were not affected. In the same conditions and in coculture experiments, apoptosis was not observed in normal keratinocytes. The induction of apoptosis required membrane contacts between DC and HPV-transformed keratinocytes. Although the HPV+ cell lines were sensitive to the effects of TRAIL, soluble TRAILR2-Fc did not block the DC-induced apoptosis. Furthermore, although FasL and Fas were detected on DC and HPV+ cell lines, respectively, functional analysis revealed that this pathway is not responsible for the apoptosis induced by the DC. All together these results suggest that DC may be at the interface between innate and adaptive immunity by inducing the apoptosis of (pre) neoplastic cells.	CHU Sart Tilman, Dept Pathol B35, Univ Hosp Liege, B-4000 Liege, Belgium; Univ Liege, Fac Med Vet, Dept Infect & Parasit Dis, Liege, Belgium	University of Liege; University of Liege	Hubert, P (corresponding author), CHU Sart Tilman, Dept Pathol B35, Univ Hosp Liege, B-4000 Liege, Belgium.	P.Hubert@ulg.ac.be		Jacobs, Nathalie/0000-0002-9895-8465				Al-Saleh W, 1998, J PATHOL, V184, P283, DOI 10.1002/(SICI)1096-9896(199803)184:3<283::AID-PATH25>3.0.CO;2-K; ALSALEH W, 1995, VIRCHOWS ARCH, V427, P41; Andrade W, 1996, J IMMUNOL METHODS, V194, P181, DOI 10.1016/0022-1759(96)00083-X; AUERSPERG N, 1962, J NATL CANCER I, V28, P605; Beaulieu S, 1998, VIROLOGY, V241, P285, DOI 10.1006/viro.1997.8977; BLANTON RA, 1991, AM J PATHOL, V138, P673; Bonham CA, 1997, TRANSPL P, V29, P1116, DOI 10.1016/S0041-1345(96)00458-7; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Chan M, 2000, POPTRONICS, V1, P20; Chaux P, 1997, INT J CANCER, V72, P619, DOI 10.1002/(SICI)1097-0215(19970807)72:4<619::AID-IJC12>3.3.CO;2-Y; COLEMAN N, 1994, AM J CLIN PATHOL, V102, P768, DOI 10.1093/ajcp/102.6.768; DELVENNE P, 1995, AM J PATHOL, V146, P589; Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Freiberg RA, 1996, J BIOL CHEM, V271, P31666, DOI 10.1074/jbc.271.49.31666; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; Giannini SL, 1998, CLIN EXP IMMUNOL, V113, P183; Gilboa E, 1999, CANCER IMMUNOL IMMUN, V48, P382, DOI 10.1007/s002620050590; HERRINGTON CS, 1995, J CLIN PATHOL, V48, P1, DOI 10.1136/jcp.48.1.1; Hirano A, 1999, BLOOD, V93, P2999; Hubert P, 1999, AM J PATHOL, V154, P775, DOI 10.1016/S0002-9440(10)65324-2; Hubert P, 1998, CANCER IMMUNOL IMMUN, V47, P81, DOI 10.1007/s002620050507; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Iwamasa T, 2000, PATHOL RES PRACT, V196, P209, DOI 10.1016/S0344-0338(00)80069-2; Jacobs N, 1998, CLIN EXP IMMUNOL, V111, P219; Jacobs N, 1998, VIRCHOWS ARCH, V432, P323, DOI 10.1007/s004280050173; Kaplan MJ, 2000, J IMMUNOL, V164, P2897, DOI 10.4049/jimmunol.164.6.2897; Kiertscher SM, 2000, J IMMUNOL, V164, P1269, DOI 10.4049/jimmunol.164.3.1269; Kim CH, 2000, INT J ONCOL, V16, P1137; KITABAYASHI A, 1995, INT J HEMATOL, V62, P99; Kobayashi T, 2000, ARTHRITIS RHEUM, V43, P1106, DOI 10.1002/1529-0131(200005)43:5<1106::AID-ANR21>3.0.CO;2-F; Labeur MS, 1999, J IMMUNOL, V162, P168; Lemaire C, 1999, CELL DEATH DIFFER, V6, P813, DOI 10.1038/sj.cdd.4400556; LEWIS GD, 1987, CANCER RES, V47, P5382; Liu YM, 2000, J CELL BIOCHEM, V78, P334, DOI 10.1002/(SICI)1097-4644(20000801)78:2<334::AID-JCB15>3.3.CO;2-6; Nair P, 1999, Pathol Oncol Res, V5, P95, DOI 10.1053/paor.1999.0161; Niehans GA, 1997, CANCER RES, V57, P1007; Nouri-Shirazi M, 2000, J IMMUNOL, V165, P3797, DOI 10.4049/jimmunol.165.7.3797; O'Connell J, 1998, J PATHOL, V186, P240; PATER MM, 1985, VIROLOGY, V145, P313, DOI 10.1016/0042-6822(85)90164-3; Poggi A, 1997, EUR J IMMUNOL, V27, P2965, DOI 10.1002/eji.1830271132; Ramenghi U, 2000, BLOOD, V95, P3176; Reinartz J, 1996, EXP CELL RES, V228, P334, DOI 10.1006/excr.1996.0333; Rosini S, 1996, HUM PATHOL, V27, P834, DOI 10.1016/S0046-8177(96)90458-X; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Subklewe M, 2001, J EXP MED, V193, P405, DOI 10.1084/jem.193.3.405; Sung Kyung Jeh, 1997, Journal of Dermatology (Tokyo), V24, P427; Suss G, 1996, J EXP MED, V183, P1789, DOI 10.1084/jem.183.4.1789; TAZI A, 1993, J CLIN INVEST, V91, P566, DOI 10.1172/JCI116236; Viac J, 1993, In Vivo, V7, P207; VIAC J, 1990, IMMUNOBIOLOGY, V180, P328, DOI 10.1016/S0171-2985(11)80296-2; Vidalain PO, 2000, J VIROL, V74, P556, DOI 10.1128/JVI.74.1.556-559.2000; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Yamamoto K, 1998, CLIN EXP IMMUNOL, V114, P94	55	27	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					2521	+		10.1096/fj.00-0872fje	http://dx.doi.org/10.1096/fj.00-0872fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641258				2022-12-25	WOS:000171372700025
J	Abell, BM; High, S; Moloney, MM				Abell, BM; High, S; Moloney, MM			Membrane protein topology of oleosin is constrained by its long hydrophobic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-ANCHOR PROTEINS; ENDOPLASMIC-RETICULUM; OIL-BODIES; LIPID BODIES; ER MEMBRANE; INSERTION ORIENTATION; HELIANTHUS-ANNUUS; CHARGED RESIDUES; DEVELOPING SEEDS; BODY	Oleosin proteins from Arabidopsis assume a unique endoplasmic reticulum (ER) topology with a membrane-integrated hydrophobic (H) domain of 72 residues, flanked by two cytosolic hydrophilic domains. We have investigated the targeting and topological determinants present within the oleosin polypeptide sequence using ER-derived canine pancreatic microsomes. Our data indicate that oleosins are integrated into membranes by a cotranslational, translocon-mediated pathway. This is supported by the identification of two independent functional signal sequences in the H domain, and by demonstrating the involvement of the SRP receptor in membrane targeting. Oleosin topology was manipulated by the addition of an N-terminal cleavable signal sequence, resulting in translocation of the N terminus to the microsomal lumen. Surprisingly, the C terminus failed to translocate. Inhibition of C-terminal translocation was not dependent on either the sequence of hydrophobic segments in the H domain, the central proline knot motif or charges flanking the H domain. Therefore, the topological constraint results from the length and/or the hydrophobicity of the H domain, implying a general case that long hydrophobic spans are unable to translocate their C terminus to the ER lumen.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Calgary; University of Manchester	Moloney, MM (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.			Abell, Ben/0000-0002-0953-0046; High, Stephen/0000-0002-4532-8152	Biotechnology and Biological Sciences Research Council [SF16973] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Abell BM, 1997, PLANT CELL, V9, P1481, DOI 10.1105/tpc.9.8.1481; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; Beaudoin F, 2000, PLANT J, V23, P159, DOI 10.1046/j.1365-313x.2000.00769.x; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; Facchini PJ, 1996, PLANT PHYSIOL, V112, P1669, DOI 10.1104/pp.112.4.1669; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GEFFEN I, 1993, INT REV CYTOL, V137, P202; Harley CA, 1998, J BIOL CHEM, V273, P24963, DOI 10.1074/jbc.273.38.24963; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; HILLS MJ, 1993, PLANTA, V189, P24, DOI 10.1007/BF00201339; HUANG AHC, 1992, ANNU REV PLANT PHYS, V43, P177, DOI 10.1146/annurev.pp.43.060192.001141; Huang AHC, 1996, PLANT PHYSIOL, V110, P1055, DOI 10.1104/pp.110.4.1055; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; Johnson AE, 1997, TRENDS CELL BIOL, V7, P90, DOI 10.1016/S0962-8924(97)01029-5; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kalies KU, 1996, J BIOL CHEM, V271, P3925; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lacey DJ, 1998, BIOCHEM J, V334, P469, DOI 10.1042/bj3340469; Lacey DJ, 1999, PLANT J, V17, P397, DOI 10.1046/j.1365-313X.1999.00387.x; Lacey DJ, 1996, PLANTA, V199, P545, DOI 10.1007/BF00195185; LI M, 1992, J BIOL CHEM, V267, P8245; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; MURPHY DJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P86, DOI 10.1016/0167-4781(91)90156-G; MURPHY DJ, 1993, PROG LIPID RES, V32, P247, DOI 10.1016/0163-7827(93)90009-L; Napier JA, 1996, PLANT MOL BIOL, V31, P945, DOI 10.1007/BF00040714; Nilsson I, 2000, J BIOL CHEM, V275, P6207, DOI 10.1074/jbc.275.9.6207; Parmenter DL, 1995, PLANT MOL BIOL, V29, P1167, DOI 10.1007/BF00020460; QU R, 1986, BIOCHEM J, V235, P57, DOI 10.1042/bj2350057; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; THOYTS PJE, 1995, PLANT MOL BIOL, V29, P403, DOI 10.1007/BF00043664; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; VANROOIJEN GJH, 1995, PLANT PHYSIOL, V109, P1353, DOI 10.1104/pp.109.4.1353; VANROOIJEN GJH, 1995, BIO-TECHNOL, V13, P72, DOI 10.1038/nbt0195-72; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WANNER G, 1981, PLANTA, V151, P109, DOI 10.1007/BF00387812; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6	41	39	39	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8602	8610		10.1074/jbc.M103712200	http://dx.doi.org/10.1074/jbc.M103712200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11673452	hybrid			2022-12-25	WOS:000174268000125
J	Suzuki, T; Masuda, T; Singh, DP; Tan, FC; Tsuchiya, T; Shimada, H; Ohta, H; Smith, AG; Takamiya, K				Suzuki, T; Masuda, T; Singh, DP; Tan, FC; Tsuchiya, T; Shimada, H; Ohta, H; Smith, AG; Takamiya, K			Two types of Ferrochelatase in photosynthetic and nonphotosynthetic tissues of cucumber - Their difference in phylogeny, gene expression, and localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; HEME-BIOSYNTHESIS; MOLECULAR-CLONING; HIGHER-PLANTS; PROTEINS; CHLOROPLASTS; CHLOROPHYLL; PURIFICATION; BARLEY	Ferrochelatase catalyzes the insertion of Fe2+ into protoporphyrin IX to generate protoheme. In higher plants, there is evidence for two isoforms of this enzyme that fulfill different roles. Here, we describe the isolation of a second ferrochelatase cDNA from cucumber (CsFeC2) that was less similar to a previously isolated isoform (CSFeC1) than it was to some ferrochelatases from other higher plants. In an vitro import experiments, the two cucumber isoforms showed characteristics similar to their respective ferrochelatase counterparts of Arabidopsis thaliana. The C-terminal region of CsFeC2 but not CsFeC1 contained a conserved motif found in light-harvesting chlorophyll proteins, and CsFeC2 belonged to a phylogenetic group of plant ferrochelatases containing this conserved motif. We demonstrate that CsFeC2 was localized predominantly in thylakoid membranes as an intrinsic protein, and forming complexes probably with the C-terminal conserved motif, but a minor portion was also detected in envelope membranes. CsFeC2 mRNA was detected in all tissues and was light-responsive in cotyledons, whereas CsFeC1 mRNA was detected in nonphotosynthetic tissues and was not light-responsive. Interestingly, tissue-, light-, and cycloheximide-dependent expressions of the two isoforms of ferrochelatase were similar to those of two glutamyl-tRNA reductase isoforms involved in the early step of tetrapyrrole biosynthesis, suggesting the existence of distinctly controlled tetrapyrrole biosynthetic pathways in photosynthetic and nonphotosynthetic tissues.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England	Tokyo Institute of Technology; University of Cambridge	Masuda, T (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.		Masuda, Tatsuru/E-7942-2013; Ohta, Hiroyuki/B-1840-2014; Singh, Davinder P/B-4056-2009	Masuda, Tatsuru/0000-0002-1585-5832; Ohta, Hiroyuki/0000-0002-1068-3242; Smith, Alison Gail/0000-0001-6511-5704				ANDERSSON B, 1982, EUR J BIOCHEM, V123, P465, DOI 10.1111/j.1432-1033.1982.tb19790.x; [Anonymous], METHODS CHLOROPLAST; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; Chow KS, 1997, J BIOL CHEM, V272, P27565, DOI 10.1074/jbc.272.44.27565; Chow KS, 1998, PLANT J, V15, P531, DOI 10.1046/j.1365-313X.1998.00235.x; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; ELICH TD, 1989, J BIOL CHEM, V264, P183; Funk C, 1999, BIOCHEMISTRY-US, V38, P9397, DOI 10.1021/bi990545+; Guo RB, 1998, PLANT PHYSIOL, V116, P605, DOI 10.1104/pp.116.2.605; Heddad M, 2000, P NATL ACAD SCI USA, V97, P3741, DOI 10.1073/pnas.050391397; HEIJ HT, 1984, EUR J BIOCHEM, V138, P161; JACOBS JM, 1987, BIOCHEM J, V244, P219, DOI 10.1042/bj2440219; JACOBS JM, 1995, ARCH BIOCHEM BIOPHYS, V323, P274, DOI 10.1006/abbi.1995.9964; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JONES OTG, 1968, BIOCHEM J, V107, P113, DOI 10.1042/bj1070113; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LITTLE HN, 1976, BIOCHEM J, V156, P309, DOI 10.1042/bj1560309; MATRINGE M, 1992, J BIOL CHEM, V267, P4646; MATRINGE M, 1994, J BIOL CHEM, V269, P15010; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; MIYAMOTO K, 1994, PLANT PHYSIOL, V105, P769, DOI 10.1104/pp.105.2.769; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; Nakayama M, 1998, PLANT CELL PHYSIOL, V39, P275, DOI 10.1093/oxfordjournals.pcp.a029368; NISHIMURA M, 1982, PLANT PHYSIOL, V69, P916, DOI 10.1104/pp.69.4.916; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PORRA RJ, 1968, BIOCHEM J, V108, P343, DOI 10.1042/bj1080343; Roper JM, 1997, EUR J BIOCHEM, V246, P32, DOI 10.1111/j.1432-1033.1997.t01-1-00032.x; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SMITH AG, 1994, J BIOL CHEM, V269, P13405; Suzuki T, 2000, PLANT CELL PHYSIOL, V41, P192, DOI 10.1093/pcp/41.2.192; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; Tanaka R, 1996, PLANT PHYSIOL, V110, P1223, DOI 10.1104/pp.110.4.1223; THOMAS J, 1990, PLANT PHYSIOL, V94, P1414, DOI 10.1104/pp.94.3.1414	33	66	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4731	4737		10.1074/jbc.M105613200	http://dx.doi.org/10.1074/jbc.M105613200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11675381	hybrid			2022-12-25	WOS:000173962900025
J	Fernandez, J; Yaman, I; Merrick, WC; Koromilas, A; Wek, RC; Sood, R; Hensold, J; Hatzoglou, M				Fernandez, J; Yaman, I; Merrick, WC; Koromilas, A; Wek, RC; Sood, R; Hensold, J; Hatzoglou, M			Regulation of internal ribosome entry site-mediated translation by eukaryotic initiation factor-2 alpha phosphorylation and translation of a small upstream open reading frame	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE TRANSPORTER CAT-1; GENE-EXPRESSION; MAMMALIAN HOMOLOG; MOLECULAR-BIOLOGY; PROTEIN-SYNTHESIS; MESSENGER-RNA; GCN2; CELLS; VIVO; ACTIVATION	Adaptation to amino acid deficiency is critical for cell survival. In yeast, this adaptation involves phosphorylation of the translation eukaryotic initiation factor (eIF) 2alpha by the kinase GCN2. This leads to the increased translation of the transcription factor GCN4, which in turn increases transcription of amino acid biosynthetic genes, at a time when expression of most genes decreases. Here it is shown that translation of the arginine/lysine transporter cat-1 mRNA increases during amino acid starvation of mammalian cells. This increase requires both GCN2 phosphorylation of eIF2alpha and the translation of a 48-amino acid upstream open reading frame (uORF) present within the 5'-leader of the transporter mRNA. When this 5'-leader was placed in a bicistronic mRNA expression vector, it functioned as an internal ribosomal entry sequence and its regulated activity was dependent on uORF translation. Amino acid starvation also induced translation of monocistronic mRNAs containing the cat-1 5'-leader, in a manner dependent on eIF2alpha phosphorylation and translation of the 48-amino acid uORF. This is the first example of mammalian regulation of internal ribosomal entry sequence-mediated translation by eIF2alpha phosphorylation during amino acid starvation, suggesting that the mechanism of induced Cat-1 protein synthesis is part of the adaptive response of cells to amino acid limitation.	Case Western Reserve Univ, Dept Nutr, Sch Med, Cleveland, Qld 44106, Australia; Case Western Reserve Univ, Dept Biochem, Sch Med, Cleveland, Qld 44106, Australia; Case Western Reserve Univ, Vet Affairs Med Ctr, Sch Med, Cleveland, Qld 44106, Australia; Case Western Reserve Univ, Dept Med, Sch Med, Cleveland, Qld 44106, Australia; McGill Univ, Jewish Gen Hosp, Dept Microbiol, Montreal, PQ H3T 1E2, Canada; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; McGill University; Indiana University System; Indiana University-Purdue University Indianapolis	Hatzoglou, M (corresponding author), Case Western Reserve Univ, Dept Nutr, Sch Med, 10900 Euclid Ave, Cleveland, Qld 44106, Australia.	mxh8@po.cwru.edu	yaman, ibrahim/A-7192-2016	yaman, ibrahim/0000-0002-3987-1984	NIDDK NIH HHS [R01 DK53307-01, 5T32 DK07319] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053307, T32DK007319] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aulak KS, 1999, J BIOL CHEM, V274, P30424, DOI 10.1074/jbc.274.43.30424; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; CAO JH, 1995, J VIROL, V69, P1030, DOI 10.1128/JVI.69.2.1030-1036.1995; CHOI SY, 1992, J BIOL CHEM, V267, P286; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hattori Y, 1999, AM J PHYSIOL-HEART C, V276, pH2020, DOI 10.1152/ajpheart.1999.276.6.H2020; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; HINNEBUSCH AG, 1993, MOL MICROBIOL, V10, P215, DOI 10.1111/j.1365-2958.1993.tb01947.x; HINNEBUSCH AG, 1986, CRC CR REV BIOCH MOL, V21, P277, DOI 10.3109/10409238609113614; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Hyatt SL, 1997, J BIOL CHEM, V272, P19951, DOI 10.1074/jbc.272.32.19951; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Laine RO, 1996, PROG NUCLEIC ACID RE, V53, P219, DOI 10.1016/S0079-6603(08)60146-4; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; Liu J, 1998, AMINO ACIDS, V15, P321, DOI 10.1007/BF01320897; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pilipenko EV, 2000, GENE DEV, V14, P2028; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Qiu HF, 1998, MOL CELL BIOL, V18, P2697, DOI 10.1128/MCB.18.5.2697; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Sood R, 2000, GENETICS, V154, P787; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x	43	84	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2050	2058		10.1074/jbc.M109199200	http://dx.doi.org/10.1074/jbc.M109199200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11684693	hybrid			2022-12-25	WOS:000173421300060
J	Pandit, S; Geissler, W; Harris, G; Sitlani, A				Pandit, S; Geissler, W; Harris, G; Sitlani, A			Allosteric effects of dexamethasone and RU486 on glucocorticoid receptor-DNA interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE ACTIVITY; HEAT-SHOCK-PROTEIN; CHAPERONE MACHINERY; RESPONSE ELEMENTS; STEROID-HORMONE; BINDING DOMAIN; IN-VIVO; GENE; TRANSCRIPTION; DETERMINANTS	The glucocorticoid receptor (GR) is a DNA-binding protein that can regulate the transcription of a large number of genes in a ligand-dependent fashion. Although much progress has been made on the mechanism of transcriptional regulation by GR, a potential allosteric effect of GR-binding ligands on specific GR-DNA interactions is controversial. In this study, gel-shift methods are used to measure the effects of a classical agonist dexamethasone and a prototypical antagonist RU486 on the in vitro interactions of GR with DNA substrates, which contain glucocorticoid response elements (GREs) from promoters of GR-regulated genes. These studies show that cell extracts containing human GR bind specifically and with high affinity to GREs in the absence of ligand. An agonist dexamethasone and antagonist RU486 do not affect the affinity of GR for DNA but subtly alter the electrophoretic mobility of the GR-DNA complex. Importantly, the dissociation rate of GR from DNA increases as a function of the concentration of GRE-containing DNA. At a fixed DNA concentration, dexamethasone-bound GR dissociates from DNA significantly faster than does ligand-free GR or RU486-bound GR. These results are consistent with a model for transcriptional activation in which a dynamic comp ex is formed between agonist-bound GR and DNA.	Merck & Co Inc, Dept Metab Disorders, Rahway, NJ 07065 USA	Merck & Company	Sitlani, A (corresponding author), Merck & Co Inc, Dept Metab Disorders, POB 2000,Mail Code R80Y-300, Rahway, NJ 07065 USA.	ayesha_sitlani@merck.com						Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1993, J STEROID BIOCHEM, V45, P239, DOI 10.1016/0960-0760(93)90338-W; DAHLMANWRIGHT K, 1992, BIOCHEMISTRY-US, V31, P9040, DOI 10.1021/bi00152a047; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; Fletcher TM, 2000, MOL CELL BIOL, V20, P6466, DOI 10.1128/MCB.20.17.6466-6475.2000; Freeman BC, 2000, GENE DEV, V14, P422; Freeman BC, 2001, TRENDS BIOCHEM SCI, V26, P285, DOI 10.1016/S0968-0004(01)01834-5; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; Guido EC, 1996, MOL ENDOCRINOL, V10, P1178, DOI 10.1210/me.10.10.1178; Hager GL, 2000, BIOCHEM SOC T, V28, P405, DOI 10.1042/0300-5127:0280405; Hager GL, 1999, METHOD ENZYMOL, V304, P626; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HUTCHISON KA, 1992, J STEROID BIOCHEM, V41, P715, DOI 10.1016/0960-0760(92)90410-K; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Lieberman BA, 1997, J BIOL CHEM, V272, P1061, DOI 10.1074/jbc.272.2.1061; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; Pearce D, 1998, J BIOL CHEM, V273, P30081, DOI 10.1074/jbc.273.46.30081; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RAJPERT EJ, 1987, J STEROID BIOCHEM, V26, P513, DOI 10.1016/0022-4731(87)90001-X; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; Santoro JC, 2001, ANAL BIOCHEM, V289, P18, DOI 10.1006/abio.2000.4911; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHWEIZERGROYER G, 1988, J STEROID BIOCHEM, V30, P291, DOI 10.1016/0022-4731(88)90109-4; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; van Tilborg MAA, 2000, J MOL BIOL, V301, P947, DOI 10.1006/jmbi.2000.4001; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	46	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1538	1543		10.1074/jbc.M105438200	http://dx.doi.org/10.1074/jbc.M105438200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11682470	hybrid			2022-12-25	WOS:000173166800087
J	Suzuma, I; Suzuma, K; Ueki, K; Hata, Y; Feener, EP; King, GL; Aiello, LP				Suzuma, I; Suzuma, K; Ueki, K; Hata, Y; Feener, EP; King, GL; Aiello, LP			Stretch-induced retinal vascular endothelial growth factor expression is mediated by phosphatidylinositol 3-kinase and protein kinase C (PKC)-zeta but not by stretch-induced ERK1/2, Akt, Ras, or classical/novel PKC pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SMOOTH-MUSCLE-CELLS; DIABETIC-RETINOPATHY; PERMEABILITY FACTOR; SIGNAL-TRANSDUCTION; RISK-FACTORS; MAP KINASE; INSULIN STIMULATION; GLUCOSE-TRANSPORT; MECHANICAL-STRESS; CARDIAC MYOCYTES	Stretch-induced expression of vascular endothelial growth factor (VEGF) is thought to be important in mediating the exacerbation of diabetic retinopathy by systemic hypertension. However, the mechanisms underlying stretch-induced VEGF expression are not fully understood. We present novel findings demonstrating that stretch-induced VEGF expression in retinal capillary pericytes is mediated by phosphatidylinositol (PI) 3-kinase and protein kinase C (PKC)-zeta but is not mediated by ERK1/2, classical/novel isoforms of PKC, Akt, or Ras despite their activation by stretch. Cardiac profile cyclic stretch at 60 cpm increased VEGF mRNA expression in a time- and magnitude-dependent manner without altering mRNA stability. Stretch increased ERK1/2 phosphorylation, PI 3-kinase activity, Akt phosphorylation, and PKC-zeta activity. Signaling pathways were explored using inhibitors of PKC, MEK1/2, and PI 3-kinase; adenovirus-mediated overexpression of ERK, PKC-alpha, PKC-delta, PKC-zeta, and Akt; and dominant negative (DN) mutants of ERK, PKC-zeta, Ras, PI 3-kinase and Akt. Although stretch activated ERK1/2 through a Ras- and PKC classical/novel isoform-dependent pathway, these pathways were not responsible for stretch-induced VEGF expression. Overexpression of DN ERK and Ras had no effect on VEGF expression in these cells. In contrast, DN PI 3-kinase as well as pharmacologic inhibitors of PI 3-kinase blocked stretch-induced VEGF expression. Although stretch-induced PI 3-kinase activation increased both Akt phosphorylation and activity of PKC-zeta, VEGF expression was dependent on PKC-zeta but not Akt. In addition, PKC-zeta did not mediate stretch-induced ERK1/2 activation. These results suggest that stretch-induced expression of VEGF involves a novel mechanism dependent upon PI 3-kinase-mediated activation of PKC-zeta that is independent of stretch-induced activation of ERK1/2, classical/novel PKC isoforms, Ras, or Akt. This mechanism may play a role in the well documented association of concomitant hypertension with clinical exacerbation of neovascularization and vascular permeability.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA; Kyushu Univ, Fac Med, Dept Ophthalmol, Fukuoka 6068507, Japan; Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Joslin Diabetes Center, Inc.; Kyushu University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Aiello, LP (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	lpaiello@joslin.harvard.edu			NATIONAL EYE INSTITUTE [R29EY010827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK048358] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10827, EY-5110] Funding Source: Medline; NIDDK NIH HHS [DK-48358] Funding Source: Medline; PHS HHS [36836] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; Agardh CD, 1997, DIABETES RES CLIN PR, V35, P113, DOI 10.1016/S0168-8227(97)01386-7; Aiello LP, 1998, DIABETES CARE, V21, P143, DOI 10.2337/diacare.21.1.143; AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Amin RH, 1997, INVEST OPHTH VIS SCI, V38, P36; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Bursell SE, 1997, INVEST OPHTH VIS SCI, V38, P2711; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; de Faria JML, 1999, ACTA OPHTHALMOL SCAN, V77, P170; El-Asrar AMA, 1998, INT OPHTHALMOL, V22, P155, DOI 10.1023/A:1006240928938; ENGERMAN R, 1977, DIABETES, V26, P760, DOI 10.2337/diabetes.26.8.760; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032; Gruden G, 1997, P NATL ACAD SCI USA, V94, P12112, DOI 10.1073/pnas.94.22.12112; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6; Hishikawa K, 1997, CIRC RES, V81, P797; Houben AJHM, 1995, J HYPERTENS, V13, P1729; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723; Ishida T, 1997, ANN NY ACAD SCI, V811, P12, DOI 10.1111/j.1749-6632.1997.tb51984.x; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jung YD, 1999, CANCER RES, V59, P4804; King GL, 1997, KIDNEY INT, pS77; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klein R, 1998, OPHTHALMOLOGY, V105, P1801, DOI 10.1016/S0161-6420(98)91020-X; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; LEFLOCH JP, 1990, DIABETES METAB, V16, P26; Lehoux S, 1998, HYPERTENSION, V32, P338, DOI 10.1161/01.HYP.32.2.338; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; Li J, 1997, J CLIN INVEST, V100, P18, DOI 10.1172/JCI119510; Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Mizukami Y, 2000, J BIOL CHEM, V275, P19921, DOI 10.1074/jbc.M907901199; Monick MM, 2000, J IMMUNOL, V165, P4632, DOI 10.4049/jimmunol.165.8.4632; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; *NAT SOC PREV BLIN, 1980, DAT AN VIS PROBL US; *NAT SOC PREV BLIN, 1980, DATA AN VIS PROBL US; NAYAK RC, 1987, J CELL BIOL, V105, P1595; Nazaimoon EMW, 1999, DIABETES RES CLIN PR, V46, P213; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; Okajima E, 2000, BIOCHEM BIOPH RES CO, V270, P108, DOI 10.1006/bbrc.2000.2386; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; Park JM, 1998, AM J PHYSIOL-CELL PH, V275, pC1247, DOI 10.1152/ajpcell.1998.275.5.C1247; Pe'er J, 1998, OPHTHALMOLOGY, V105, P412, DOI 10.1016/S0161-6420(98)93020-2; Pedram A, 1997, J BIOL CHEM, V272, P17097, DOI 10.1074/jbc.272.27.17097; PERSSON K, 1995, AM J PHYSIOL-CELL PH, V269, pC1018, DOI 10.1152/ajpcell.1995.269.4.C1018; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Pourageaud F, 1998, AM J PHYSIOL-HEART C, V274, pH1301, DOI 10.1152/ajpheart.1998.274.4.H1301; RASSAM SMB, 1995, EXP PHYSIOL, V80, P53, DOI 10.1113/expphysiol.1995.sp003834; Riser BL, 1999, KIDNEY INT, V56, P428, DOI 10.1046/j.1523-1755.1999.00600.x; ROSENN B, 1992, AM J OBSTET GYNECOL, V166, P1214, DOI 10.1016/S0002-9378(11)90608-5; Roy MS, 2000, ARCH OPHTHALMOL-CHIC, V118, P105; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SAFAR ME, 1981, CIRCULATION, V63, P393, DOI 10.1161/01.CIR.63.2.393; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Seko Y, 1999, INVEST OPHTH VIS SCI, V40, P3287; Seko Y, 1999, BIOCHEM BIOPH RES CO, V254, P462, DOI 10.1006/bbrc.1998.9969; SENGER DR, 1990, CANCER RES, V50, P1774; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; SIMORREPINATEL V, 1994, INVEST OPHTH VIS SCI, V35, P3393; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; STANTON AV, 1995, J HYPERTENS, V13, P41; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Suzuma I, 2001, DIABETES, V50, P444, DOI 10.2337/diabetes.50.2.444; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Tamura K, 1998, AM J PHYSIOL-REG I, V275, pR1, DOI 10.1152/ajpregu.1998.275.1.R1; TSO MOM, 1982, OPHTHALMOLOGY, V89, P1132; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; UEKI K, 1994, J BIOL CHEM, V269, P15756; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Wellner M, 1999, ARTERIOSCL THROM VAS, V19, P178, DOI 10.1161/01.ATV.19.1.178; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; Ziegler T, 1998, HYPERTENSION, V32, P351, DOI 10.1161/01.HYP.32.2.351	96	68	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1047	1057		10.1074/jbc.M105336200	http://dx.doi.org/10.1074/jbc.M105336200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694503	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000173166800024
J	Choi, KB; Morishige, T; Shitan, N; Yazaki, K; Sato, F				Choi, KB; Morishige, T; Shitan, N; Yazaki, K; Sato, F			Molecular cloning and characterization of coclaurine N-methyltransferase from cultured cells of Coptis japonica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; O-METHYLTRANSFERASES; PURIFICATION; COMMON; BIOSYNTHESIS; EXPRESSION; BERBERINE; GENE	S-Adenosyl-L-methionine:coclaurine N-methyltransferase (CNMT) converts coclaurine to N-methylcoclaurine in isoquinoline alkaloid biosynthesis. The N-terminal amino acid sequence of Coptis CNMT was used to amplify the corresponding cDNA fragment and later to isolate full-length cDNA using 5'- and 3'-rapid amplification of cDNA ends (RACE). The nucleotide sequence and predicted amino acid sequence showed that the cDNA encoded 358 amino acids, which contained a putative S-adenosyl-L-methionine binding domain and showed relatively high homology to tomato phosphoethanolamine-N-methyltransferase. A recombinant protein was expressed in Escherichia coli, and its CNMT activity was confirmed. Recombinant CNMT was purified to homogeneity, and enzymological characterization confirmed that Coptis CNMT has quite broad substrate specificity, i.e. not only for 6-O-methylnorlaudanosoline and norreticuline but also for 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline. The evolution of N-methyltransferases in secondary metabolism is discussed based on sequence similarity.	Kyoto Univ, Div Appl Life Sci, Grad Sch Agr, Kyoto 6068502, Japan; Kyoto Univ, Div Integrated Life Sci, Grad Sch Biostudies, Kyoto 6068502, Japan	Kyoto University; Kyoto University	Sato, F (corresponding author), Kyoto Univ, Div Appl Life Sci, Grad Sch Agr, Kyoto 6068502, Japan.		Sato, Fumihiko/C-1078-2011	Sato, Fumihiko/0000-0001-9497-4452; Shitan, Nobukazu/0000-0001-7760-2745				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRASHEKHAR PJ, 1998, PLANT MOL BIOL, V37, P663; Choi KB, 2001, PHYTOCHEMISTRY, V56, P649, DOI 10.1016/S0031-9422(00)00481-7; FRENZEL T, 1990, PHYTOCHEMISTRY, V29, P3491, DOI 10.1016/0031-9422(90)85263-F; Frick S, 1999, PLANT J, V17, P329, DOI 10.1046/j.1365-313X.1999.00379.x; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HIBI N, 1994, PLANT CELL, V6, P723, DOI 10.1105/tpc.6.5.723; Ibrahim RK, 1998, PLANT MOL BIOL, V36, P1, DOI 10.1023/A:1005939803300; Ibrahim RK, 1997, TRENDS PLANT SCI, V2, P249, DOI 10.1016/S1360-1385(97)86345-5; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; Kato M, 2000, NATURE, V406, P956, DOI 10.1038/35023072; Morishige T, 2000, J BIOL CHEM, V275, P23398, DOI 10.1074/jbc.M002439200; NAKAJIMA K, 1993, P NATL ACAD SCI USA, V90, P9591, DOI 10.1073/pnas.90.20.9591; QUAIFE CJ, 1994, TRANSGENIC RES, V3, P388, DOI 10.1007/BF01976770; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P26; SATO F, 1993, PHYTOCHEMISTRY, V32, P659, DOI 10.1016/S0031-9422(00)95151-3; SATO F, 1994, EUR J BIOCHEM, V225, P125, DOI 10.1111/j.1432-1033.1994.00125.x; SATO F, 1984, PHYTOCHEMISTRY, V23, P281, DOI 10.1016/S0031-9422(00)80318-0; SCOILAS A, 2000, BIOCHEM BIOPH RES CO, V278, P349; STADLER R, 1993, J BIOL CHEM, V268, P823; TAKESHITA N, 1995, PLANT CELL PHYSIOL, V36, P29; WAT CK, 1986, Z NATURFORSCH C, V41, P126; YAMADA Y, 1985, PHYTOCHEMISTRY, V24, P63, DOI 10.1016/S0031-9422(00)80807-9; Ying ZT, 1999, J BIOL CHEM, V274, P36750, DOI 10.1074/jbc.274.51.36750; Zubieta C, 2001, NAT STRUCT BIOL, V8, P271, DOI 10.1038/85029	27	116	131	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					830	835		10.1074/jbc.M106405200	http://dx.doi.org/10.1074/jbc.M106405200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11682473	hybrid			2022-12-25	WOS:000173087900106
J	Lee, RT; Takagahara, I; Lee, YC				Lee, RT; Takagahara, I; Lee, YC			Mapping the binding areas of human C-reactive protein for phosphorylcholine and polycationic compounds - Relationship between the two types of binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM; POLYSACCHARIDE; PHOSPHOCHOLINE; SPECIFICITY; COMPLEMENT; CHROMATIN; ASSAY	We developed a fluorescence-based assay method for determining ligand binding activities of C-reactive protein (CRP) in solution. Using this method, we compared the phosphorylcholine (PC)- and polycation-based binding activities of human CRP. The PC-based binding required calcium, whereas a polycation (e.g. poly-L-lysine) was bound in the presence of either calcium or EDTA, the binding being stronger in the presence of EDTA. The published crystallographic structures of CRP and the CRP-PC complex show it to be a ring-shaped pentamer with a single PC-binding site per subunit facing the same direction. As expected from such a structure, binding affinity of a ligand increased tremendously when multiple PC residues were present on a macromolecular structure. In addition to PC-related structures, certain sugar phosphates (e.g. galactose 6-phosphate) are bound near the PC-binding site, and one of the sugar hydroxyl groups appears to interact with CRP. The best small ligands for the polycationic binding site were Lys-Lys and Lys(4). Because of the presence of multiple Lys-Lys sequences, polylysines have tremendously enhanced affinity. Although PC inhibits both PC- and polycation-based binding, none of the amines that inhibit polylysine binding inhibits PC binding, suggesting that the PC and polycationic binding sites do not overlap.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Oriental Bioserv Kanto Inc, Tsukuba, Ibaraki 3050031, Japan	Johns Hopkins University	Lee, YC (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.				NIDDK NIH HHS [DK09970] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009970, R37DK009970] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES BN, 1960, J BIOL CHEM, V235, P769; AVIGAD G, 1969, CARBOHYD RES, V11, P119, DOI 10.1016/S0008-6215(00)80649-7; Culley FJ, 2000, GLYCOBIOLOGY, V10, P59, DOI 10.1093/glycob/10.1.59; DICAMELLI R, 1980, J IMMUNOL, V125, P1933; DUCLOS TW, 1988, J IMMUNOL, V141, P4266; DYGERT S, 1965, ANAL BIOCHEM, V13, P367, DOI 10.1016/0003-2697(65)90327-1; ELMSLEY J, 1994, NATURE, V367, P338; GEWURZ H, 1995, CURR OPIN IMMUNOL, V7, P54, DOI 10.1016/0952-7915(95)80029-8; HEEGAARD NHH, 1993, J IMMUNOL METHODS, V166, P103, DOI 10.1016/0022-1759(93)90333-3; HEMMILA I, 1984, ANAL BIOCHEM, V137, P335, DOI 10.1016/0003-2697(84)90095-2; HIGGINBOTHAM JD, 1970, P NATL ACAD SCI USA, V67, P138, DOI 10.1073/pnas.67.1.138; KAPLAN M H, 1971, Federation Proceedings, V30, P471; KEMPKA G, 1990, J IMMUNOL, V144, P1004; KILPATRICK JM, 1982, MOL IMMUNOL, V19, P1159, DOI 10.1016/0161-5890(82)90326-1; KILPATRICK JM, 1991, IMMUNOL RES, V10, P43, DOI 10.1007/BF02918166; Lee RT, 2001, BIOCONJUGATE CHEM, V12, P845, DOI 10.1021/bc000112f; LEE RT, 1980, BIOCHEMISTRY-US, V19, P156, DOI 10.1021/bi00542a024; MCKELVY JF, 1969, ARCH BIOCHEM BIOPHYS, V132, P99, DOI 10.1016/0003-9861(69)90341-5; POTEMPA LA, 1981, J IMMUNOL, V127, P1509; ROBEY FA, 1985, J EXP MED, V161, P1344, DOI 10.1084/jem.161.6.1344; ROBEY FA, 1984, J BIOL CHEM, V259, P7311; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STULTS NL, 1987, ANAL BIOCHEM, V161, P567, DOI 10.1016/0003-2697(87)90490-8; Szalai AJ, 1997, IMMUNOL RES, V16, P127, DOI 10.1007/BF02786357; TANAKA T, 1983, J IMMUNOL METHODS, V65, P333, DOI 10.1016/0022-1759(83)90128-X; Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9; VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612; VOLANAKIS JE, 1981, J IMMUNOL, V126, P1820; YING SC, 1989, J IMMUNOL, V143, P221; YOUNG NM, 1978, J IMMUNOL, V121, P1893	31	15	15	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					225	232		10.1074/jbc.M106039200	http://dx.doi.org/10.1074/jbc.M106039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11684681	hybrid			2022-12-25	WOS:000173087900031
J	Matsui, S; Matsumoto, S; Adachi, R; Kusui, K; Hirayama, A; Watanabe, H; Ohashi, K; Mizuno, K; Yamaguchi, T; Kasahara, T; Suzuki, K				Matsui, S; Matsumoto, S; Adachi, R; Kusui, K; Hirayama, A; Watanabe, H; Ohashi, K; Mizuno, K; Yamaguchi, T; Kasahara, T; Suzuki, K			LIM kinase 1 modulates opsonized zymosan-triggered activation of macrophage-like U937 cells - Possible involvement of phosphorylation of cofilin and reorganization of actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; DIFFERENTIATED HL-60 CELLS; PLASMA-MEMBRANES; RAPID DEPHOSPHORYLATION; HUMAN NEUTROPHILS; NADPH OXIDASE; PROTEIN; TRANSLOCATION; DYNAMICS; COMPONENTS	We have previously reported that cofilin, an actin-binding protein, plays an important role in phagocyte functions, such as respiratory burst, phagocytosis, and chemotaxis. On the other hand, it was recently found that LIM motif-containing kinase (LIMR) phosphorylates cofilin. In this work, we investigated the roles of LIMK in activated phagocytes. The results of immunostaining showed that in dormant phagocytes the endogenous LIMK1 was diffusely distributed in the cytosol of macrophage-like U937 cells, and when activated by opsonized zymosan (OZ), it was translocated. to plasma membranes. Green fluorescence protein (GFP)-conjugated LIMK was expressed in the phagocytes, and the GFP-positive cells were isolated by a fluorescence-activated cell sorter. The isolated wild-type LIMK-overexpressing cells produced superoxide at a rate that was 3.2-fold higher than that of only GFP-expressing control cells, whereas the respiratory burst of dominant negative LIMK1(D460A)-expressing cells decreased to 31% of that of the control cells. Phagocytic activity monitored by using Texas Red-labeled OZ was also decreased in the D460A,expressing cells. By immunoblotting using a specific anti-phosphorylated cofilin antibody, it was revealed that in the OZ-activated wild-type LIMK1-GFP-expressing cells, the phosphorylated cofilin increased by 2.3,fold, and that in the OZ-activated D460A-GFP-expressing cells, the phosphorylated cofilin decreased to 47% of that of only GFP-expressing cells (mock control). Furthermore, in the wild-type LIMK1-expressing cells, OZ-evoked increase in filamentous actin was markedly enhanced, whereas in the dominant negative LIMK1-expressing cells, the total level of F-actin was strongly suppressed. These results suggest that LIMK1 regulates the functions of phagocytes through phosphorylation of cofilin and enhances the formation of filamentous actin.	Natl Inst Hlth Sci, Setagaya Ku, Tokyo 158, Japan; Kyoritsu Coll Pharmaceut Sci, Minato Ku, Tokyo 105, Japan; Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan	National Institute of Health Sciences - Japan; Tohoku University	Suzuki, K (corresponding author), Natl Inst Hlth Sci, Setagaya Ku, 18-1 Kamiyoga 1 Chome, Tokyo 158, Japan.		Mizuno, Kensaku/G-8631-2015; Ohashi, Kazumasa/U-7028-2019; Hirayama, Aki/G-7842-2017	Ohashi, Kazumasa/0000-0001-7617-403X; Hirayama, Aki/0000-0001-5777-4208				Adachi R, 2000, INT J IMMUNOPHARMACO, V22, P855, DOI 10.1016/S0192-0561(00)00045-X; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Djafarzadeh S, 1997, EXP CELL RES, V236, P427, DOI 10.1006/excr.1997.3731; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; Grogan A, 1997, J CELL SCI, V110, P3071; Heyworth PG, 1997, HISTOCHEM CELL BIOL, V108, P221, DOI 10.1007/s004180050162; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsui S, 2001, CELL SIGNAL, V13, P17, DOI 10.1016/S0898-6568(00)00124-8; Nagaishi K, 1999, J BIOCHEM-TOKYO, V125, P891, DOI 10.1093/oxfordjournals.jbchem.a022365; Nagaishi K, 1999, J CELL PHYSIOL, V180, P345, DOI 10.1002/(SICI)1097-4652(199909)180:3<345::AID-JCP5>3.0.CO;2-J; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Okada K, 1996, EXP CELL RES, V227, P116, DOI 10.1006/excr.1996.0256; SUZUKI K, 1995, BBA-MOL CELL RES, V1266, P261, DOI 10.1016/0167-4889(95)00029-R; SUZUKI K, 1995, J BIOL CHEM, V270, P19551, DOI 10.1074/jbc.270.33.19551; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	23	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					544	549		10.1074/jbc.M110153200	http://dx.doi.org/10.1074/jbc.M110153200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11694543	hybrid			2022-12-25	WOS:000173087900072
J	Velten, M; Gomez-Vrielynck, N; Chaffotte, A; Ladjimi, MM				Velten, M; Gomez-Vrielynck, N; Chaffotte, A; Ladjimi, MM			Domain structure of the HSC70 cochaperone, HIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE HSC70; BINDING DOMAIN; REACTION CYCLE; PROTEIN PHOSPHATASE-5; LIMITED PROTEOLYSIS; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; SELF-ASSOCIATION; ATP HYDROLYSIS; TPR DOMAIN	The domain structure of the HSC70-interacting protein (HIP), a 43-kDa cytoplasmic cochaperone involved in the regulation of HSC70 chaperone activity and the maturation of progesterone receptor, has been probed by limited proteolysis and biophysical and biochemical approaches. HIP proteolysis by thrombin and chymotrypsin generates essentially two fragments, an NH2-terminal fragment of 25 kDa (N25) and a COOH-terminal fragment of IS kDa (C18) that appear to be well folded and stable as indicated by circular dichroism and recombinant expression in Escherichia coli. NH2-terminal amino acid sequencing of the respective fragments indicates that both proteases cleave HIP within a predicted a-helix following the tetratricopeptide repeat (TPR) region, despite their different specificities and the presence of several potential cleavage sites scattered throughout the sequence, thus suggesting that this region is particularly accessible and may constitute a linker between two structural domains. After size exclusion chromatography, N25 and C18 elute as two distinct and homogeneous species having a Stokes radius of 49 and 24 A, respectively. Equilibrium sedimentation and sedimentation velocity indicate that N25 is a stable dimer, whereas C18 is monomeric in solution, with sedimentation coefficients of 3.2 and 2.3 S and f/f(o) values of 1.5 and 1.1 for N25 and C18, respectively, indicating that the N25 is elongated whereas C18 is globular in shape. Both domains are able to bind to the ATPase domain of HSC70 and,inhibit rhodanese aggregation. Moreover, their effects appear to be additive when used in combination, suggesting a cooperation of these domains in the full-length protein not only for HSC70 binding but also for chaperone activity. Altogether, these results indicate that HIP is made of two structural and functional domains, an NH2-terminal 25-kDa domain, responsible for the dimerization and the overall asymmetry of the molecule, and a COOH-terminal 18-kDa globular domain, both involved in HSC70 and unfolded protein binding.	Univ Paris 06, CNRS, UMR 7631, Lab Biochim Signaux Regulateurs Cellulaires & Mol, Paris, France; Inst Pasteur, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Ladjimi, MM (corresponding author), Univ Paris 06, CNRS, UMR 7631, Lab Biochim Signaux Regulateurs Cellulaires & Mol, 96 Blvd Raspail, Paris, France.	ladjimi@ccr.jussieu.fr						BENAROUDJ N, 1995, BIOCHEMISTRY-US, V34, P15282, DOI 10.1021/bi00046a037; Benaroudj N, 1997, J BIOL CHEM, V272, P8744, DOI 10.1074/jbc.272.13.8744; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Freedman RB, 1998, BIOL CHEM, V379, P321, DOI 10.1515/bchm.1998.379.3.321; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOHFELD J, 1995, CELL, V83, P589; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Irmer H, 1997, J BIOL CHEM, V272, P2230; JANIN J, 1985, METHOD ENZYMOL, V115, P420; Kumar A, 2001, J MOL BIOL, V307, P271, DOI 10.1006/jmbi.2000.4465; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; LEMAIRE M, 1980, ANAL BIOCHEM, V106, P12, DOI 10.1016/0003-2697(80)90112-8; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; Muhlberg AB, 2000, METHODS, V20, P475, DOI 10.1006/meth.2000.0960; Nollen EAA, 2001, J BIOL CHEM, V276, P4677, DOI 10.1074/jbc.M009745200; Nouwen N, 2000, EMBO J, V19, P2229, DOI 10.1093/emboj/19.10.2229; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; Prapapanich V, 1998, MOL CELL BIOL, V18, P944, DOI 10.1128/MCB.18.2.944; Prapapanich V, 1996, MOL CELL BIOL, V16, P6200; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schwartz T, 1999, J BIOL CHEM, V274, P2899, DOI 10.1074/jbc.274.5.2899; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Sinclair C, 1999, J BIOL CHEM, V274, P23666, DOI 10.1074/jbc.274.33.23666; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Velten M, 2000, BIOCHEMISTRY-US, V39, P307, DOI 10.1021/bi9917535; Weiss C, 1999, P NATL ACAD SCI USA, V96, P8890, DOI 10.1073/pnas.96.16.8890; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; Ziegelhoffer T, 1996, CURR BIOL, V6, P272, DOI 10.1016/S0960-9822(02)00476-1	46	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					259	266		10.1074/jbc.M106881200	http://dx.doi.org/10.1074/jbc.M106881200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11687574	hybrid			2022-12-25	WOS:000173087900035
J	Vetterkind, S; Miki, H; Takenawa, T; Klawitz, I; Scheidtmann, KH; Preuss, U				Vetterkind, S; Miki, H; Takenawa, T; Klawitz, I; Scheidtmann, KH; Preuss, U			The rat homologue of Wiskott-Aldrich syndrome protein (WASP)-interacting protein (WIP) associates with actin filaments, recruits N-WASP from the nucleus, and mediates mobilization of actin from stress fibers in favor of filopodia formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARP2/3 COMPLEX; DEPOLYMERIZING PROTEIN; TYROSINE KINASES; CELL-MIGRATION; RHO GTPASES; IDENTIFICATION; POLYMERIZATION; ORGANIZATION; MOTILITY; REGIONS	We cloned and characterized the rat homologue of the Wiskott-Aldrich syndrome protein (WASP)-interacting protein (WIP). Rat WIP shows 86% amino acid sequence identity to human WIP. Northern analyses revealed two major mRNA species of 5.0 and 3.8 kb, which were ubiquitously expressed, though predominantly in spleen and lung. Minor species of 2.4, 1.8, 1.4, and 1.1 kb were also detected in some tissues and cell lines. Thus, WIP is subject to tissue-specific alternative splicing. WIP bound to N-WASP in vivo, as revealed by co-immunoprecipitation. Expression of WIP in rat fibroblasts revealed a clear co-localization with actin stress fibers. However, expression in tumor cells lacking actin cables did not restore these structures. Interestingly, co-expression of WIP and N-WASP resulted in redistribution of N-WASP, abrogating its dominant nuclear expression and leading to co-localization with WIP in the perinuclear area and with actin in membrane protrusions. Moreover, stress fibers and, concomitantly, the associated WIP were largely dissolved. Very similar effects were seen upon epidermal growth factor stimulation of serum-starved cells. Our results suggest that WIP might be involved in transmitting mitogenic signals to cytoskeletal functions, perhaps by modulating the subcellular localization of N-WASP. Interaction of N-WASP with WIP may in turn lead to mobilization of actin from stress fibers and nucleation of new actin filaments in filopodia.	Univ Bonn, Genet Inst, D-53117 Bonn, Germany; Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 108, Japan	University of Bonn; University of Tokyo	Preuss, U (corresponding author), Univ Bonn, Genet Inst, Roemerstr 164, D-53117 Bonn, Germany.							Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Banzai Y, 2000, J BIOL CHEM, V275, P11987, DOI 10.1074/jbc.275.16.11987; Bear JE, 1998, J CELL BIOL, V142, P1325, DOI 10.1083/jcb.142.5.1325; Bear JE, 2001, CURR OPIN CELL BIOL, V13, P158, DOI 10.1016/S0955-0674(00)00193-9; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Field C, 1999, CURR OPIN CELL BIOL, V11, P68, DOI 10.1016/S0955-0674(99)80009-X; Finan PM, 1996, J BIOL CHEM, V271, P26291, DOI 10.1074/jbc.271.42.26291; Fukuoka M, 1997, GENE, V196, P43, DOI 10.1016/S0378-1119(97)00184-4; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; KLAWITZ I, 2001, IN PRESS INT J ONCOL; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; MIKI H, 1994, J BIOL CHEM, V269, P5489; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; OCHS HD, 1980, BLOOD, V55, P243; PINES J, 1995, TRENDS GENET, V11, P326, DOI 10.1016/S0168-9525(00)89092-7; POLLACK R, 1975, P NATL ACAD SCI USA, V72, P994, DOI 10.1073/pnas.72.3.994; Purich DL, 1997, BIOCHEM BIOPH RES CO, V231, P686, DOI 10.1006/bbrc.1997.6158; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Ramesh N, 1999, TRENDS CELL BIOL, V9, P15, DOI 10.1016/S0962-8924(98)01411-1; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sambrook J., 2002, MOL CLONING LAB MANU; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Stewart DM, 1999, J IMMUNOL, V162, P5019; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; Weggen S, 1997, BRAIN PATHOL, V7, P731, DOI 10.1111/j.1750-3639.1997.tb01059.x; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498	40	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					87	95		10.1074/jbc.M104555200	http://dx.doi.org/10.1074/jbc.M104555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11687573	hybrid			2022-12-25	WOS:000173087900013
J	Blake, BL; Wing, MR; Zhou, JY; Lei, Q; Hillmann, JR; Behe, CI; Morris, RA; Harden, TK; Bayliss, DA; Miller, RJ; Siderovski, DP				Blake, BL; Wing, MR; Zhou, JY; Lei, Q; Hillmann, JR; Behe, CI; Morris, RA; Harden, TK; Bayliss, DA; Miller, RJ; Siderovski, DP			G beta association and effector interaction selectivities of the divergent G gamma subunit G gamma(13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNIT; PHOSPHOLIPASE-C BETA; CRYSTAL-STRUCTURE; ACTIVATION; CHANNELS; SEQUENCE; COMBINATIONS; DETERMINANT; INHIBITION; EXPRESSION	Ggamma(13) is a divergent member of the Ggamma subunit family considered to be a component of the gustducin G-protein heterotrimer involved in bitter and sweet taste reception in taste bud cells. Ggamma(13) contains a C-terminal asparagine-proline-tryptophan (NPW) tripeptide, a hallmark of RGS protein Ggamma-like (GGL) domains which dimerize exclusively with Gbeta(5) subunits. In this study, we investigated the functional range of Ggamma(13) assembly with Gbeta subunits using multiple assays of Gbeta association and Gbetagamma effector modulation. Ggamma(13) was observed to associate with all five Gbeta subunits (Gbeta(1-5)) upon co-translation in vitro, as well as function with all five Gbeta subunits in the modulation of Kir3.1/3.4 (GIRK1/4) potassium and N-type (alpha(1B)) calcium channels. Multiple Gbeta/Ggamma(13) pairings were also functional in cellular assays of phospholipase C (PLC) 132 activation and inhibition of Galpha(q)-stimulated PLCbeta1 activity. However, upon cellular co-expression of Ggamma(13) with different Gbeta subunits, only Gbeta(1)/Ggamma(13), Gbeta(3)/Ggamma(13), and Gbeta(4)/Ggamma(13) pairings were found to form stable dimers detectable by co-immunoprecipitation under high-detergent cell lysis conditions. Collectively, these data indicate that Ggamma(13) forms functional Gbetagamma dimers with a range of Gbeta subunits. Coupled with our detection of Ggamma(13) mRNA in mouse and human brain and retina, these results imply that this divergent Ggamma subunit can act in signal transduction pathways other than that dedicated to taste reception in sensory lingual tissue.	Univ N Carolina, Sch Med, Dept Pharmacol, Ctr Neurosci, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Northwestern University; University of Virginia	Siderovski, DP (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Ctr Neurosci, CB 7365,Mary Ellen Jones Bldg,Rm 1106, Chapel Hill, NC 27599 USA.	dsiderov@med.unc.edu	Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029536, R01GM062338, R37GM029536] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039553, P01NS033826] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29536, GM62338] Funding Source: Medline; NIMH NIH HHS [MH001896] Funding Source: Medline; NINDS NIH HHS [NS33826, R01 NS039553, NS39553] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BOYER JL, 1994, J BIOL CHEM, V269, P2814; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Evanko DS, 2001, J BIOL CHEM, V276, P23945, DOI 10.1074/jbc.M101154200; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hildebrandt JD, 1997, BIOCHEM PHARMACOL, V54, P325, DOI 10.1016/S0006-2952(97)00269-4; Huang LQ, 1999, NAT NEUROSCI, V2, P1055, DOI 10.1038/15981; Inoue S, 2000, BIOCHEM BIOPH RES CO, V268, P553, DOI 10.1006/bbrc.2000.2170; Jones MB, 1999, ANAL BIOCHEM, V268, P126, DOI 10.1006/abio.1998.3064; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Matsuda T, 1998, BIOCHEMISTRY-US, V37, P9843, DOI 10.1021/bi973194c; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; PATERSON A, 1995, CELL SIGNAL, V7, P709, DOI 10.1016/0898-6568(95)00039-R; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; Rossler P, 1998, EUR J CELL BIOL, V77, P253; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schulz S, 1999, J BIOL CHEM, V274, P37605, DOI 10.1074/jbc.274.53.37605; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Siderovski DP, 2002, METHOD ENZYMOL, V344, P702; Simen AA, 1998, J NEUROSCI, V18, P3689; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wall MA, 1998, STRUCTURE, V6, P1169, DOI 10.1016/S0969-2126(98)00117-8; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WU DQ, 1992, J BIOL CHEM, V267, P25798; Zhou JY, 2000, J NEUROSCI, V20, P7143	46	30	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49267	49274		10.1074/jbc.M106565200	http://dx.doi.org/10.1074/jbc.M106565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11675383	Green Published, hybrid			2022-12-25	WOS:000173922100085
J	Horn, MP; Pachlopnik, JM; Vogel, M; Dahinden, M; Wurm, F; Stadler, BM; Miescher, SM				Horn, MP; Pachlopnik, JM; Vogel, M; Dahinden, M; Wurm, F; Stadler, BM; Miescher, SM			Conditional autoimmunity mediated by human natural anti-Fc epsilon RI alpha autoantibodies?	FASEB JOURNAL			English	Article						natural autoantibodies; phage display; IgE receptor	AFFINITY IGE RECEPTOR; PASSIVE SENSITIZATION; HISTAMINE-RELEASE; DOWN-REGULATION; HUMAN BASOPHILS; PHAGE DISPLAY; IN-VIVO; ANTIBODIES; EXPRESSION; SYSTEM	Natural antibodies provide an early defense mechanism against pathogens, show a frequent self-reactivity, and are present throughout life. Two questions concern the physiological control of self-reactivity and the pathogenetic link to autoimmune disease. Here we propose a concept of conditional autoimmunity involving natural antibodies against the alpha chain of the high-affinity receptor for IgE (Fc epsilon RI alpha). Like other natural antibodies, anti-Fc epsilon RI alpha antibodies are found in sera of healthy donors. We now report the first human recombinant anti-Fc epsilon RI alpha autoantibodies isolated by repertoire cloning from a human tonsillar IgM library. These high-affinity antibodies recognize Fc epsilon RI alpha on cells and trigger histamine release from freshly isolated blood basophils. However, the latter effect requires IgE removal from the Fc epsilon RI. The same conditional histamine release is seen when using sera from individual normal donors and affinity-purified anti-Fc epsilon RI alpha antibodies isolated from multidonor therapeutic IgG preparations. We propose that such anti-Fc epsilon RI alpha antibodies can become pathogenic and that this is dependent on the state of occupancy of the Fc epsilon RI alpha by its natural ligand IgE. We suggest that an imbalance between Fc epsilon RI alpha occupancy and natural anti-Fc epsilon RI alpha antibodies may be implicated in the pathogenesis of autoimmune urticaria.	Inselspital Bern, Inst Immunol & Allergol, CH-3010 Bern, Switzerland; Ecole Polytech Fed Lausanne, Ctr Biotechnol UNIL EPFL, Lab Cellular Biotechnol, CH-1015 Lausanne, Switzerland; ZLB Bioplasma AG, CH-3022 Bern, Switzerland	University of Bern; University Hospital of Bern; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Miescher, SM (corresponding author), Inselspital Bern, Inst Immunol & Allergol, Sahlihaus 1, CH-3010 Bern, Switzerland.	sylvia.miescher@insel.ch	Pachlopnik Schmid, Jana/N-8018-2018	Pachlopnik Schmid, Jana/0000-0002-6653-9047				BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, 1991, METHODS COMPANION ME, V2, P119; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Horn MP, 1999, EUR J IMMUNOL, V29, P1139, DOI 10.1002/(SICI)1521-4141(199904)29:04<1139::AID-IMMU1139>3.0.CO;2-J; Hurez V, 1997, BLOOD, V90, P4004, DOI 10.1182/blood.V90.10.4004; Kaveri SV, 1998, IMMUNOLOGIST, V6, P227; KNUTTIMULLER JM, 1986, ALLERGY, V41, P457, DOI 10.1111/j.1398-9995.1986.tb00327.x; Lacroix-Desmazes S, 1999, J CLIN IMMUNOL, V19, P26, DOI 10.1023/A:1020510401233; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Miescher S, 1998, VOX SANG, V75, P278, DOI 10.1046/j.1423-0410.1998.7540278.x; Mouthon L, 1996, SCAND J IMMUNOL, V44, P243, DOI 10.1046/j.1365-3083.1996.d01-306.x; Ochsenbein AF, 2000, IMMUNOL TODAY, V21, P624, DOI 10.1016/S0167-5699(00)01754-0; Persic L, 1997, GENE, V187, P9, DOI 10.1016/S0378-1119(96)00628-2; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Rajakulasingam K, 1997, J ALLERGY CLIN IMMUN, V100, P78, DOI 10.1016/S0091-6749(97)70198-2; SABAN R, 1994, J ALLERGY CLIN IMMUN, V94, P836, DOI 10.1016/0091-6749(94)90151-1; Saini SS, 1999, J IMMUNOL, V162, P5624; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Terada N, 1995, J ALLERGY CLIN IMMUN, V96, P1161, DOI 10.1016/S0091-6749(95)70201-6; TOMLINSON IM, 1998, 5 BASE SEQUENCE DIRE; VOGEL M, 1994, EUR J IMMUNOL, V24, P1200, DOI 10.1002/eji.1830240529; ZURCHER AW, 1995, IMMUNOL LETT, V46, P49, DOI 10.1016/0165-2478(95)00014-V	23	41	48	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2268	2274		10.1096/fj.00-0890hyp	http://dx.doi.org/10.1096/fj.00-0890hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641254				2022-12-25	WOS:000171920400039
J	Rubin, C; Xu, G; Judex, S				Rubin, C; Xu, G; Judex, S			The anabolic activity of bone tissue, suppressed by disuse, is normalized by brief exposure to extremely low-magnitude mechanical stimuli	FASEB JOURNAL			English	Article						bone formation; microgravity; bone density; musculoskeletal; sarcopenia; anabolic osteoporosis	STRAIN; HISTOMORPHOMETRY; WEIGHTLESSNESS; UNIFORMITY; MASS	It is generally believed that mechanical signals must be large in order to be anabolic to bone tissue. Recent evidence indicates, however, that extremely low-magnitude (<10 microstrain) mechanical signals readily stimulate bone formation if induced at a high frequency. We examined the ability of extremely low-magnitude, high-frequency mechanical signals to restore anabolic bone cell activity inhibited by disuse. Adult female rats were randomly assigned to six groups: baseline control, age-matched control, mechanically stimulated for 10 min/day, disuse (hind limb suspension), disuse interrupted by 10 min/day of weight bearing, and disuse interrupted by 10 min/day of mechanical stimulation. After a 28 day protocol, bone formation rates (BFR) in the proximal tibia of mechanically stimulated rats increased compared with age-matched control (+97%). Disuse alone reduced BFR (-92%), a suppression only slightly curbed when disuse was interrupted by 10 min of weight bearing (-61%). In contrast, disuse interrupted by 10 min per day of low-level mechanical intervention normalized BFR to values seen in age-matched controls. This work indicates that this noninvasive, extremely low-level stimulus may provide an effective biomechanical intervention for the bone loss that plagues long-term space flight, bed rest, or immobilization caused by paralysis.	SUNY Stony Brook, Dept Biomed Engn, Musculoskeletal Res Lab, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Rubin, C (corresponding author), SUNY Stony Brook, Dept Biomed Engn, Musculoskeletal Res Lab, 3rd Floor, Stony Brook, NY 11794 USA.	clinton.rubin@sunysb.edu						Baldwin KM, 1996, MED SCI SPORT EXER, V28, P1247, DOI 10.1097/00005768-199610000-00007; Dehority W, 1999, AM J PHYSIOL-ENDOC M, V276, pE62; DESPLANCHES D, 1990, J APPL PHYSIOL, V68, P48, DOI 10.1152/jappl.1990.68.1.48; Erben RG, 1997, J HISTOCHEM CYTOCHEM, V45, P307, DOI 10.1177/002215549704500215; Fritton JC, 1997, ANN BIOMED ENG, V25, P831, DOI 10.1007/BF02684167; Fritton SP, 2000, J BIOMECH, V33, P317, DOI 10.1016/S0021-9290(99)00210-9; FYHRIE DP, 1986, J ORTHOPAED RES, V4, P304, DOI 10.1002/jor.1100040307; GROSS TS, 1995, J ORTHOPAED RES, V13, P708, DOI 10.1002/jor.1100130510; Gross TS, 1997, J BONE MINER RES, V12, P982, DOI 10.1359/jbmr.1997.12.6.982; Huang RP, 1999, J GERONTOL A-BIOL, V54, pB352, DOI 10.1093/gerona/54.8.B352; LeBlanc A, 1998, BONE, V22, p113S, DOI 10.1016/S8756-3282(98)00013-1; LeBlanc A., 1999, 1 BIENN SPAC BIOM IN, V1, P17; Morey-Holton E, 1981, PHYSIOLOGIST, V24, P545; OCONNOR JA, 1982, J BIOMECH, V15, P767, DOI 10.1016/0021-9290(82)90092-6; Osborn MJ, 1998, STRATEGY RES SPACE B; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Qin YX, 1998, J ORTHOPAED RES, V16, P482, DOI 10.1002/jor.1100160414; RAMBAUT PC, 1979, ACTA ASTRONAUT, V6, P1113, DOI 10.1016/0094-5765(79)90059-6; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711; RUBIN CT, 1987, J ORTHOPAED RES, V5, P300, DOI 10.1002/jor.1100050217; Ruff C, 1999, 1 BIENN SPAC BIOM IN, V1, P86; SMITH MC, 1977, PROLONGED WEIGHTLESS; SMITH ML, 1991, ASSESSMENT PROGRAMS; STUPAKOV GP, 1984, KOSM BIOL AVIAK MED+, V18, P33; Turner RT, 2000, J APPL PHYSIOL, V89, P840, DOI 10.1152/jappl.2000.89.2.840	26	223	244	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2225	2229		10.1096/fj.01-0166com	http://dx.doi.org/10.1096/fj.01-0166com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641249				2022-12-25	WOS:000171920400034
J	Temsah, RM; Kawabata, K; Chapman, D; Dhalla, NS				Temsah, RM; Kawabata, K; Chapman, D; Dhalla, NS			Modulation of cardiac sarcoplasmic reticulum gene expression by lack of oxygen and glucose	FASEB JOURNAL			English	Article						cardiac gene expression; hypoxia reoxygenation; ischemia reperfusion; intracellular Ca2+ overload	PRESSURE-OVERLOAD; CA-2+-ATPASE GENE; OXIDATIVE STRESS; RAT; CALCIUM; HEART; HYPERTROPHY; NOREPINEPHRINE; REPERFUSION; PROTEINS	Although ischemia reperfusion has been shown to depress gene expression of the sarcoplasmic reticulum (SR) proteins, such as the ryanodine receptor, Ca2+-pump ATPase, phospholamban, and calsequestrin in the heart, the mechanisms of these changes are not understood. Given the occurrence of hypoxia and the lack of glucose during the ischemic phase, we investigated the effects of these factors on the cardiac SR gene expression. Isolated rat hearts perfused in the absence of oxygen and/or glucose for 30 min showed an increase in the expression of SR genes. However, perfusion of hearts for 60 min with normal oxygenated medium after 30 min of lack of both oxygen and glucose depressed the transcript levels for the SR proteins; these changes did not occur when hearts were deprived of either oxygen or glucose. The effect of intracellular Ca2+-overload, which occurs during reperfusion, was studied by using hearts perfused for 5 min with Ca2+-free medium and then reperfused for 30 min. Ca2+-depletion/repletion induced a dramatic decrease in the transcript levels of the SR genes. These results suggest that the lack of both oxygen and glucose during ischemia are necessary for reperfusion-induced depression in SR gene expression, possibly due to the occurrence of intracellular Ca2+-overload.	St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Fac Med, Dept Physiol, Winnipeg, MB, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Dhalla, NS (corresponding author), St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, 351 Tache Ave, Winnipeg, MB R2H 2A6, Canada.	cvso@sbrc.umanitoba.ca	Dhalla, Naranjan/C-8279-2014	Dhalla, Naranjan/0000-0002-4894-4727				ALTO LE, 1981, CIRC RES, V48, P17, DOI 10.1161/01.RES.48.1.17; ALTO LE, 1979, AM J PHYSIOL, V237, pH713, DOI 10.1152/ajpheart.1979.237.6.H713; Arai M, 1996, J MOL CELL CARDIOL, V28, P1583, DOI 10.1006/jmcc.1996.0149; BOLLI R, 1992, CIRCULATION, V86, P1671, DOI 10.1161/01.CIR.86.6.1671; DELABASTIE D, 1990, CIRC RES, V66, P554, DOI 10.1161/01.RES.66.2.554; Dhalla NS, 2000, J HYPERTENS, V18, P655, DOI 10.1097/00004872-200018060-00002; Dhalla NS, 1999, CAN J CARDIOL, V15, P587; DIXON IMC, 1987, AM J PHYSIOL, V253, pH1026, DOI 10.1152/ajpheart.1987.253.5.H1026; FRASS O, 1993, CARDIOVASC RES, V27, P2037, DOI 10.1093/cvr/27.11.2037; Hashida H, 1999, CLIN SCI, V96, P387, DOI 10.1042/CS19980278; JENNINGS RB, 1991, ANNU REV MED, V42, P225, DOI 10.1146/annurev.med.42.1.225; Lai LP, 1998, J MOL CELL CARDIOL, V30, P175, DOI 10.1006/jmcc.1997.0583; LOMPRE AM, 1991, CIRC RES, V69, P1380, DOI 10.1161/01.RES.69.5.1380; MERCADIER JJ, 1990, J CLIN INVEST, V85, P305, DOI 10.1172/JCI114429; Muller A, 1997, AM J PHYSIOL-HEART C, V272, pH1876, DOI 10.1152/ajpheart.1997.272.4.H1876; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; Netticadan T, 1999, AM J PHYSIOL-CELL PH, V277, pC384, DOI 10.1152/ajpcell.1999.277.3.C384; Netticadan T, 2001, FASEB J, V15, pA891; PEGG W, 1987, AM J PHYSIOL, V252, pH22, DOI 10.1152/ajpheart.1987.252.1.H22; REIMER KA, 1986, HEART CARDIOVASCULAR, P1133; Sharikabad MN, 2000, J MOL CELL CARDIOL, V32, P441, DOI 10.1006/jmcc.1999.1092; Takeo S, 2000, MOL CELL BIOCHEM, V212, P227, DOI 10.1023/A:1007174803993; TAKEO S, 1991, J PHARMACOL EXP THER, V258, P94; TANI M, 1989, CIRC RES, V65, P1045, DOI 10.1161/01.RES.65.4.1045; Tanonaka K, 1996, JPN HEART J, V37, P105; Temsah RM, 1999, AM J PHYSIOL-HEART C, V277, pH584, DOI 10.1152/ajpheart.1999.277.2.H584; Temsah RM, 2000, J PHARMACOL EXP THER, V293, P15; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	28	15	15	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2515	+		10.1096/fj.00-0870fje	http://dx.doi.org/10.1096/fj.00-0870fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641257				2022-12-25	WOS:000171372700021
J	Robles-Flores, M; Rendon-Huerta, E; Gonzalez-Aguilar, H; Mendoza-Hernandez, G; Islas, S; Mendoza, V; Ponce-Castaneda, MV; Gonzalez-Mariscal, L; Lopez-Casillas, F				Robles-Flores, M; Rendon-Huerta, E; Gonzalez-Aguilar, H; Mendoza-Hernandez, G; Islas, S; Mendoza, V; Ponce-Castaneda, MV; Gonzalez-Mariscal, L; Lopez-Casillas, F			p32 (gC1qBP) is a general protein kinase C (PKC)-binding protein - Interaction and cellular localization of p32-PKC complexes in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL MATRIX; RNA-BINDING; ACTIVATION; RECEPTORS; CLONING; IDENTIFICATION; ASSOCIATION; EXPRESSION; SCAFFOLD; SUBUNIT	The aim of this study was to identify cellular proteins that bind protein kinase C (PKC) and may influence its activity and its localization. A 32-kDa PKC-binding protein was purified to homogeneity from the Triton X-100-insoluble fraction obtained from hepatocytes homogenates. The protein was identified by NH2-terminal amino acid sequencing as the previously described mature form of p32 (gC1qR). Recombinant p32 was expressed as a glutathione S-transferase fusion protein, affinity-purified, and tested for an in vitro interaction with PKC using an overlay assay approach. All PKC isoforms expressed in rat hepatocytes interacted in vitro with p32, but the binding dependence on PKC activators was different for each one. Whereas PKCdelta only binds to p32 in the presence of PKC activators, PKCzeta and PKCalpha increase their binding when they are in the activated form. Other PKC isoforms such as beta, epsilon, and theta bind equally well to p32 regardless of the presence of PKC activators, and PKCmu binds even better in their absence. It was also found that p32 is not a substrate for any of the PKC isoforms tested, but interestingly, its presence had a stimulatory effect (2-fold for PKCdelta) on PKC activity. We also observed in vivo interaction between PKC and p32 by immunofluorescence and confocal microscopy. A time course of phorbol ester treatment of cultured rat hepatocytes (C9 cells) showed that PKCtheta and p32 are constitutively associated in vivo, whereas PKCdelta activation is required for its association with p32. Our data also showed that phorbol ester treatment induces a transient translocation of p32 from the cytoplasm to the cell nucleus. Together, these findings suggest that p32 may be a regulator of PKC location and function.	Univ Nacl Autonoma Mexico, Fac Med, Dept Biochem, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Cellular Physiol, Mexico City 04510, DF, Mexico; CINVESTAV, Ctr Res & Adv Studies, Dept Physiol Biophys & Neurosci, Mexico City 07000, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional	Robles-Flores, M (corresponding author), Univ Nacl Autonoma Mexico, Fac Med, Dept Biochem, Mexico City 04510, DF, Mexico.	rmartha@servidor.unam.mx						BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; Garcia-Caballero A, 2001, MOL PHARMACOL, V59, P576, DOI 10.1124/mol.59.3.576; Ghebrehiwet B, 1997, J IMMUNOL, V159, P1429; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; HONORE B, 1993, GENE, V134, P283, DOI 10.1016/0378-1119(93)90108-F; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; KILEY S, 1990, J BIOL CHEM, V265, P15704; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Lynch NJ, 1997, FEBS LETT, V418, P111, DOI 10.1016/S0014-5793(97)01348-3; Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Mineo C, 1998, J CELL BIOL, V141, P601, DOI 10.1083/jcb.141.3.601; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; Muta T, 1997, J BIOL CHEM, V272, P24363, DOI 10.1074/jbc.272.39.24363; Newton AC, 1996, CURR BIOL, V6, P806, DOI 10.1016/S0960-9822(02)00600-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Petersen-Mahrt SK, 1999, EMBO J, V18, P1014, DOI 10.1093/emboj/18.4.1014; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Rendon-Huerta E, 1999, BIOCHEM J, V344, P469, DOI 10.1042/0264-6021:3440469; RoblesFlores M, 1997, PROTEIN EXPRES PURIF, V10, P32, DOI 10.1006/prep.1997.0722; ROBLESFLORES M, 1994, BIOCHEM MOL BIOL INT, V34, P465; ROBLESFLORES M, 1991, BIOCHIM BIOPHYS ACTA, V1094, P77, DOI 10.1016/0167-4889(91)90028-V; ROBLESFLORES M, 1993, BIOCHEM J, V296, P467, DOI 10.1042/bj2960467; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SMITH DB, 1990, CURRENT PROTOCOLS MO; Soltys BJ, 2000, HISTOCHEM CELL BIOL, V114, P245; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; van der Hoeven PCJ, 2000, BIOCHEM J, V347, P781, DOI 10.1042/0264-6021:3470781; Van Scoy S, 2000, VIROLOGY, V275, P145, DOI 10.1006/viro.2000.0508; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714	39	46	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5247	5255		10.1074/jbc.M109333200	http://dx.doi.org/10.1074/jbc.M109333200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11698413	hybrid			2022-12-25	WOS:000173962900090
J	Khan, KMF; Falcone, DJ; Kraemer, R				Khan, KMF; Falcone, DJ; Kraemer, R			Nerve growth factor activation of Erk-1 and Erk-2 induces matrix metalloproteinase-9 expression in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL-CHLOROFORM EXTRACTION; PROTEIN-KINASE KINASE; MOUSE GELATINASE-B; RAT CAROTID-ARTERY; SINGLE-STEP METHOD; ENZYMATIC-PROPERTIES; 92-KDA GELATINASE; RNA ISOLATION; PC12 CELLS; T-ANTIGEN	In response to vascular injury, smooth muscle cells migrate from the media into the intima, where they contribute to the development of neointimal lesions. Increased matrix metalloproteinase (MMP) expression contributes to the migratory response of smooth muscle cells by releasing them from their surrounding extracellular matrix. MMPs may also participate in the remodeling of extracellular matrix in vascular lesions that could lead to plaque weakening and subsequent rupture. Neurotrophins and their receptors, the Trk family of receptor tyrosine kinases, are expressed in neointimal lesions, where they induce smooth muscle cell migration. We now report that nerve growth factor (NGF)-induced activation of the TrkA receptor tyrosine kinase induces MMP-9 expression in both primary cultured rat aortic smooth muscle cells and in a smooth muscle cell line genetically manipulated to express TrkA. The response to NGF was specific for MMP-9 expression, as the expression of MMP-2, MMP-3, or the tissue inhibitor of metalloproteinase-2 was not changed. Activation of the Shc/mitogen-activated protein kinase pathway mediates the induction of MMP-9 in response to NGF, as this response is abrogated in cells expressing a mutant TrkA receptor that does not bind She and by pretreatment of cells with the MEK-1 inhibitor, U0126. Thus, these results indicate that the neurotrophin/Trk receptor system, by virtue of its potent chemotactic activity for smooth muscle cells and its ability to induce MMP-9 expression, is a critical mediator in the remodeling that occurs in the vascular wall in response to injury.	Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Cell Biol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Ctr Vasc Biol, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Kraemer, R (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pathol, 1300 York Ave, New York, NY 10021 USA.				NHLBI NIH HHS [P01 HL46403, HL58623] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058623, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDECK MP, 1994, CIRC RES, V75, P539, DOI 10.1161/01.RES.75.3.539; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Brown DL, 1997, AM J CARDIOL, V79, P878, DOI 10.1016/S0002-9149(97)00007-6; BROWN DL, 1995, CIRCULATION, V91, P2125, DOI 10.1161/01.CIR.91.8.2125; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Cheng L, 1998, CIRCULATION, V98, P2195, DOI 10.1161/01.CIR.98.20.2195; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DeSilva DR, 1998, J IMMUNOL, V160, P4175; DESOUZA S, 1995, J BIOL CHEM, V270, P9106, DOI 10.1074/jbc.270.16.9106; DONOVAN MJ, 1995, AM J PATHOL, V147, P309; Donovan MJ, 1996, NAT GENET, V14, P210, DOI 10.1038/ng1096-210; Donovan MJ, 2000, DEVELOPMENT, V127, P4531; Fabunmi RP, 1996, BIOCHEM J, V315, P335, DOI 10.1042/bj3150335; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Friedman WJ, 1999, EXP CELL RES, V253, P131, DOI 10.1006/excr.1999.4705; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; Khan KMF, 1997, J BIOL CHEM, V272, P8270, DOI 10.1074/jbc.272.13.8270; Khan KMF, 2000, J BIOL CHEM, V275, P4492, DOI 10.1074/jbc.275.6.4492; Kraemer R, 1999, ARTERIOSCL THROM VAS, V19, P1041, DOI 10.1161/01.ATV.19.4.1041; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LOEB DM, 1994, J BIOL CHEM, V269, P8901; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; March KL, 1999, ONCOGENE, V18, P3773, DOI 10.1038/sj.onc.1202994; Masure S, 1997, EUR J BIOCHEM, V244, P21, DOI 10.1111/j.1432-1033.1997.00021.x; MASURE S, 1993, EUR J BIOCHEM, V218, P129, DOI 10.1111/j.1432-1033.1993.tb18359.x; Newby AC, 2000, J PATHOL, V190, P300, DOI 10.1002/(SICI)1096-9896(200002)190:3<300::AID-PATH596>3.0.CO;2-I; Newby AC, 1999, CARDIOVASC RES, V41, P321; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; Pinon LGP, 1995, EUR J NEUROSCI, V7, P2397, DOI 10.1111/j.1460-9568.1995.tb01037.x; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; SANZ L, 1994, J BIOL CHEM, V269, P10044; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Webb KE, 1997, ARTERIOSCL THROM VAS, V17, P1837, DOI 10.1161/01.ATV.17.9.1837; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; ZEMPO N, 1994, J VASC SURG, V20, P209, DOI 10.1016/0741-5214(94)90008-6	47	63	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2353	2359		10.1074/jbc.M108989200	http://dx.doi.org/10.1074/jbc.M108989200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11698409	hybrid			2022-12-25	WOS:000173421300096
J	Zou, JX; Liu, YQ; Pasquale, EB; Ruoslahti, E				Zou, JX; Liu, YQ; Pasquale, EB; Ruoslahti, E			Activated Src oncogene phosphorylates R-Ras and suppresses integrin activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL-ADHESION-KINASE; V-SRC; TRANSFORMATION; LOCALIZATION; EXPRESSION; PP60C-SRC	One of the prominent effects of the Src kinase is to reduce cell adhesion. The small GTPase, R-Ras, affects cell adhesion by maintaining integrin activity, and the ability of R-Ras to do so can he regulated by phosphorylation of a tyrosine residue located in its effector domain by an Eph receptor kinase (Zou, J. X., Wang, B., Kalo, M. S., Zisch, A. H., Pasquale, E. B., and Ruoslahti, E. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 13813-13818). Here we show that Src regulates cell adhesion through R-Ras and integrins. Reduced substrate attachment of 293T cells transfected with the cDNA for an activated form of Src (v-Src) was accompanied by phosphorylation of endogenous R-Ras. v-Src also phosphorylated R-Ras in vitro. An activated form of Src similar to one that has been found in human cancers, Src527, shared with v-Src the ability to phosphorylate R-Ras. Stronger R-Ras phosphorylation was seen in Madin-Darby canine kidney cells cells transformed with temperature-sensitive v-Src at the permissive temperature than at the non-permissive temperature, and R-Ras and Src co-immunoprecipitated at the permissive temperature. Mutation analysis showed that the Src phosphorylation site in R-Ras was tyrosine 66, the position critical to the ability of R-Ras to support integrin activity. Finally, activated R-Ras in which tyrosine 66 is mutated to phenylalanine rendered cells partially resistant to the effects of Src on cell adhesion. Regulation of cell adhesion by Src through R-Ras may be at least partially responsible for the reduced adhesion and the resulting increased invasiveness of Src-transformed cells.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ruoslahti, E (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ruoslahti@burnham.org			NCI NIH HHS [CA09579, CA30199, CA82713, CA79984] Funding Source: Medline; NICHD NIH HHS [HD25938] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA079984, P30CA030199, T32CA009579, P01CA082713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; FRAME MC, 1994, MOL BIOL CELL, V5, P1177, DOI 10.1091/mbc.5.11.1177; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Hynes RO, 1990, FIBRONECTINS; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Kalo MS, 1999, CELL TISSUE RES, V298, P1, DOI 10.1007/PL00008807; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; McLean GW, 2000, J BIOL CHEM, V275, P23333, DOI 10.1074/jbc.M909322199; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	25	53	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1824	1827		10.1074/jbc.M103133200	http://dx.doi.org/10.1074/jbc.M103133200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11682467	hybrid			2022-12-25	WOS:000173421300028
J	Tsivkovskii, R; Eisses, JF; Kaplan, JH; Lutsenko, S				Tsivkovskii, R; Eisses, JF; Kaplan, JH; Lutsenko, S			Functional properties of the copper-transporting ATPase ATP7B (the Wilson's disease protein) expressed in insect cells.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; N-TERMINAL DOMAIN; MENKES-DISEASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; ASPARTYL PHOSPHATE; CANDIDATE GENE; BINDING; SITE; INTERMEDIATE	Copper-transporting ATPase ATP7B is essential for normal distribution of copper in human cells. Mutations in the ATP7B gene lead to copper accumulation in a number of tissues and to a severe multisystem disorder, known as Wilson's disease. Primary sequence analysis suggests that the copper-transporting ATPase ATP7B or the Wilson's disease protein (WNDP) belongs to the large family of cation-transporting P-type ATPases, however, the detailed characterization of its enzymatic properties has been lacking. Here, we developed a baculovirus-mediated expression system for WNDP, which permits direct and quantitative analysis of catalytic properties of this protein. Using this system, we provide experimental evidence that WNDP has functional properties characteristic of a P-type ATPase. It forms a phosphorylated intermediate, which is sensitive to hydroxylamine, basic pH, and treatments with ATP or ADP. ATP stimulates phosphorylation with an apparent K-m of 0.95 +/- 0.25 muM; ADP promotes dephosphorylation with an apparent K-m of 3.2 +/- 0.7 mum. Replacement of Asp(1027) with Ala in a conserved sequence motif DKTG abolishes phosphorylation in agreement with the proposed role of this residue as an acceptor of phosphate during the catalytic cycle. Catalytic phosphorylation of WNDP is inhibited by the copper chelator bathocuproine; copper reactivates the bathocuproine-treated WNDP in a specific and cooperative fashion confirming that copper is required for formation of the acylphosphate intermediate. These studies establish the key catalytic properties of the ATP7B copper-transporting ATPase and provide a foundation for quantitative analysis of its function in normal and diseased cells.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Lutsenko, S (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	lutsenko@ohsu.edu		Kaplan, Jack/0000-0002-7048-6574	NHLBI NIH HHS [HL30315] Funding Source: Medline; NIDDK NIH HHS [DK55719] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055719] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASTIDE F, 1973, J BIOL CHEM, V248, P8485; Bissig KD, 2001, BIOCHEM J, V357, P217, DOI 10.1042/0264-6021:3570217; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; DAME JB, 1981, J BIOL CHEM, V256, P724; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Fan B, 2001, BIOCHEM BIOPH RES CO, V286, P414, DOI 10.1006/bbrc.2001.5367; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Forbes JR, 1998, AM J HUM GENET, V63, P1663, DOI 10.1086/302163; Gatto C, 2001, AM J PHYSIOL-CELL PH, V281, pC982, DOI 10.1152/ajpcell.2001.281.3.C982; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; Hou ZJ, 2001, J BIOL CHEM, V276, P40858, DOI 10.1074/jbc.M107455200; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; Jensen PY, 1999, BBA-PROTEIN STRUCT M, V1434, P103, DOI 10.1016/S0167-4838(99)00161-2; La Fontaine S, 2001, HUM MOL GENET, V10, P361, DOI 10.1093/hmg/10.4.361; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mitra B, 2001, BIOCHEMISTRY-US, V40, P7694, DOI 10.1021/bi010576g; Okkeri J, 1999, BIOCHEMISTRY-US, V38, P14109, DOI 10.1021/bi9913956; Palmgren MG, 1998, BBA-BIOENERGETICS, V1365, P37, DOI 10.1016/S0005-2728(98)00041-3; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; POST RL, 1973, J BIOL CHEM, V248, P6993; POST RL, 1965, J BIOL CHEM, V240, P1437; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Scarborough GA, 1999, CURR OPIN CELL BIOL, V11, P517, DOI 10.1016/S0955-0674(99)80075-1; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; Sharma R, 2000, J BIOL CHEM, V275, P3873, DOI 10.1074/jbc.275.6.3873; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TSAI KJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P267, DOI 10.1006/abbi.1993.1421; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Voskoboinik I, 2001, BIOCHEM BIOPH RES CO, V281, P966, DOI 10.1006/bbrc.2001.4445; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	48	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					976	983		10.1074/jbc.M109368200	http://dx.doi.org/10.1074/jbc.M109368200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11677246	hybrid			2022-12-25	WOS:000173166800016
J	Daniels, R; De Vos, DE; Desair, J; Raedschelders, G; Luyten, E; Rosemeyer, V; Verreth, C; Schoeters, E; Vanderleyden, J; Michiels, J				Daniels, R; De Vos, DE; Desair, J; Raedschelders, G; Luyten, E; Rosemeyer, V; Verreth, C; Schoeters, E; Vanderleyden, J; Michiels, J			The cin quorum sensing locus of Rhizobium etli CNPAF512 affects growth and symbiotic nitrogen fixation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	American-Society-for-Microbiology Conference on Cell-Cell Communication in Bacteria	JUL 06-09, 2001	SNOWBIRD, UTAH	Amer Soc Microbiol			PLANT-ASSOCIATED BACTERIA; PSEUDOMONAS-AERUGINOSA; AGROBACTERIUM-TUMEFACIENS; GENE-EXPRESSION; LACTONE; LEGUMINOSARUM; MOLECULES; PROTEIN; AUTOINDUCER; NODULATION	Rhizobium etli CNPAF512 produces an autoinducer that inhibits growth of Rhizobium leguminosarum bv. viciae 248 and activates the Agrobacterium tumefaciens tra reporter system. Production of this compound in R. etli is dependent on two genes, named cinR and cinI, postulated to code for a transcriptional regulator and an autoinducer synthase, respectively. NMR analysis of the purified molecule indicates that the R. etli autoinducer produced by CinI is a saturated long chain 3-hydroxyacyl-homoserine lactone, abbreviated as 30H-(slc)-HSL. Using cin-gusA fusions, expression of cinI and cinR was shown to be growth phase-dependent. Deletion analysis of the cinI promoter region indicates that a regulatory element negatively controls cinI expression. Mutational analysis revealed that expression of the cinI gene is positively regulated by the CinR/30H-(slc)-HSL complex. Besides 30H-(slc)-HSL, R. etli produces at least six other autoinducer molecules, for which the structures have not yet been revealed, and of which the synthesis requires the previously identified rail and raiR genes. At least three different autoinducers, including a compound co-migrating with 30H-(slc)-HSL, are produced in R. etli bacteroids isolated from bean nodules. This is further substantiated by the observation that cinI and cinR are both expressed under symbiotic conditions. Acetylene reduction activity of nodules induced by the cin mutants was reduced with 60-70% compared with wild-type nodules, indicating that the R. etli 30H-(slc)HSL is involved in the symbiotic process. This was further confirmed by transmission electron microscopy of nodules induced by the wild type and the cinI mutant. Symbiosomes carrying cinI mutant bacteroids did not fully differentiate compared with wild-type symbiosomes. Finally, it was observed that the cinR gene and raiR control growth of R. etli.	Katholieke Univ Leuven, Ctr Microbial & Plant Genet, B-3001 Heverlee, Belgium; Katholieke Univ Leuven, Ctr Surface Chem & Catalysis, B-3001 Heverlee, Belgium; Katholieke Univ Leuven, Inst Zool, B-3000 Louvain, Belgium	KU Leuven; KU Leuven; KU Leuven	Vanderleyden, J (corresponding author), Katholieke Univ Leuven, Ctr Microbial & Plant Genet, Kasteelpk Arenberg 20, B-3001 Heverlee, Belgium.		Michiels, Jan/F-1601-2010	Michiels, Jan/0000-0001-5829-0897				Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; Broek AV, 1995, MOL PLANT MICROBE IN, V8, P800, DOI 10.1094/MPMI-8-0800; Cha C, 1998, MOL PLANT MICROBE IN, V11, P1119, DOI 10.1094/MPMI.1998.11.11.1119; CHILTON MD, 1974, P NATL ACAD SCI USA, V71, P3672, DOI 10.1073/pnas.71.9.3672; De Kievit T, 1999, J BACTERIOL, V181, P2175, DOI 10.1128/JB.181.7.2175-2184.1999; DHOOGHE I, 1995, MOL GEN GENET, V249, P117, DOI 10.1007/BF00290243; DIMANGO E, 1995, J CLIN INVEST, V96, P2204, DOI 10.1172/JCI118275; Dombrecht B, 2001, MOL PLANT MICROBE IN, V14, P426, DOI 10.1094/MPMI.2001.14.3.426; Fuqua C, 1998, CURR OPIN MICROBIOL, V1, P183, DOI 10.1016/S1369-5274(98)80009-X; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; Gray KM, 1996, J BACTERIOL, V178, P372, DOI 10.1128/jb.178.2.372-376.1996; Holden MTG, 1999, MOL MICROBIOL, V33, P1254, DOI 10.1046/j.1365-2958.1999.01577.x; KAPLAN HB, 1985, J BACTERIOL, V163, P1210, DOI 10.1128/JB.163.3.1210-1214.1985; Lithgow JK, 2000, MOL MICROBIOL, V37, P81, DOI 10.1046/j.1365-2958.2000.01960.x; Michiels J, 1998, J BACTERIOL, V180, P1729, DOI 10.1128/JB.180.7.1729-1740.1998; Michiels J, 1998, J BACTERIOL, V180, P3620, DOI 10.1128/JB.180.14.3620-3628.1998; Parsek MR, 1997, MOL MICROBIOL, V26, P301, DOI 10.1046/j.1365-2958.1997.5741935.x; Pearson JP, 1999, J BACTERIOL, V181, P1203, DOI 10.1128/JB.181.4.1203-1210.1999; Pesci EC, 1999, P NATL ACAD SCI USA, V96, P11229, DOI 10.1073/pnas.96.20.11229; Pierson LS, 1998, ANNU REV PHYTOPATHOL, V36, P207, DOI 10.1146/annurev.phyto.36.1.207; Rodelas B, 1999, J BACTERIOL, V181, P3816, DOI 10.1128/JB.181.12.3816-3823.1999; Rosemeyer V, 1998, J BACTERIOL, V180, P815, DOI 10.1128/JB.180.4.815-821.1998; Sambrook J., 2002, MOL CLONING LAB MANU; Schripsema J, 1996, J BACTERIOL, V178, P366, DOI 10.1128/jb.178.2.366-371.1996; Shaw PD, 1997, P NATL ACAD SCI USA, V94, P6036, DOI 10.1073/pnas.94.12.6036; SKWIERCZYNSKI RD, 1993, PHARMACEUT RES, V10, P1174, DOI 10.1023/A:1018920402644; Swift S, 1999, CELL-CELL SIGNALING IN BACTERIA, P291; Telford G, 1998, INFECT IMMUN, V66, P36, DOI 10.1128/IAI.66.1.36-42.1998; Teplitski M, 2000, MOL PLANT MICROBE IN, V13, P637, DOI 10.1094/MPMI.2000.13.6.637; VANBRUSSEL AAN, 1985, J BACTERIOL, V162, P1079, DOI 10.1128/JB.162.3.1079-1082.1985; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; von Bodman SB, 1998, P NATL ACAD SCI USA, V95, P7687, DOI 10.1073/pnas.95.13.7687; Wu H, 2000, MICROBIOL-SGM, V146, P2481, DOI 10.1099/00221287-146-10-2481; Xi CW, 2000, P NATL ACAD SCI USA, V97, P11114, DOI 10.1073/pnas.210181097; Zhu J, 1998, MOL MICROBIOL, V27, P289, DOI 10.1046/j.1365-2958.1998.00672.x	36	96	111	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					462	468		10.1074/jbc.M106655200	http://dx.doi.org/10.1074/jbc.M106655200			7	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11677232	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000173087900062
J	Eickelberg, O; Centrella, M; Reiss, M; Kashgarian, M; Wells, RG				Eickelberg, O; Centrella, M; Reiss, M; Kashgarian, M; Wells, RG			Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation - Glycosaminoglycan modifications alter betaglycan function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; PROTEOGLYCAN BETAGLYCAN; ENDOTHELIAL-CELLS; MESANGIAL CELLS; LIGAND-BINDING; EXPRESSION; ENDOGLIN; SUPERFAMILY; PROTEIN	Transforming growth factor (TGF)-beta is a multifunctional growth factor with important roles in development, cell proliferation, and matrix deposition. It signals through the sequential activation of two serine/threonine kinase receptors, the type I and type 11 receptors. A third cell surface receptor, betaglycan, serves as a co-receptor for TGF-beta in some cell types, enhancing TGF-beta-mediated signaling. We have examined the function of betaglycan in renal epithelial LLC-PK1 cells that lack endogenous betaglycan. We demonstrate that the expression of betaglycan in LLC-PK1 cells results in inhibition of TGF-beta signaling as measured by reporter gene expression, thymidine incorporation, collagen production, and phosphorylation of the downstream signaling effectors Smad2 and Smad3. In comparison, the expression of betaglycan in L6 myoblasts enhances TGF-beta signaling, which is consistent with the published literature. The effects of betaglycan in LLC-PK1 cells are not mediated by ligand sequestration or increased production of a soluble form of the receptor, which has been reported to serve as a ligand antagonist. We demonstrate instead that in LLC-PK1 cells, unlike L6 cells, expression of betaglycan prevents association between the type I and type 11 TGF-beta receptors, which is required for signaling. This is a function of the glycosaminoglycan modifications of betaglycan. Betaglycan in LLC-PK1 cells exhibits higher molecular weight glycosaminoglycan (GAG) chains than in L6 cells, and a GAG(-) betaglycan mutant does not inhibit TGF-beta signaling or type I/type II receptor association in LLC-PK1 cells. Our data indicate that betaglycan can function as a potent inhibitor of TGF-beta signaling by a novel mechanism and provide support for an essential but complex role for proteoglycan co-receptors in growth factor signaling.	Yale Univ, Sch Med, Dept Med, Sect Digest Dis, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA; Univ Med & Dent New Jersey, Canc Inst New Jersey, New Brunswick, NJ 08903 USA	Yale University; Yale University; Yale University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Wells, RG (corresponding author), Yale Univ, Sch Med, Dept Med, Sect Digest Dis, 333 Cedar St,1080 LMP, New Haven, CT 06520 USA.		Eickelberg, Oliver/A-5461-2013; Reiss, Michael/A-8314-2009	Eickelberg, Oliver/0000-0001-7170-0360; Reiss, Michael/0000-0001-8543-8092	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039201, R01AR039201] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39201] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDRES JL, 1991, J BIOL CHEM, V266, P23282; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BLOBE GC, 2001, J BIOL CHEM, V25, P25; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; Eickelberg O, 2001, FASEB J, V15, P797, DOI 10.1096/fj.00-0233com; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Fiore MM, 2001, BIOCHEM BIOPH RES CO, V284, P384, DOI 10.1006/bbrc.2001.4978; FUKUSHIMA D, 1993, J BIOL CHEM, V268, P22710; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Isono M, 2000, AM J PHYSIOL-RENAL, V278, pF830, DOI 10.1152/ajprenal.2000.278.5.F830; Ji CH, 1999, J BIOL CHEM, V274, P30487, DOI 10.1074/jbc.274.43.30487; Kaname S, 1996, BIOCHEM J, V315, P815, DOI 10.1042/bj3150815; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; Philip A, 1999, EUR J BIOCHEM, V261, P618, DOI 10.1046/j.1432-1327.1999.00298.x; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Poncelet AC, 1999, KIDNEY INT, V56, P1354, DOI 10.1046/j.1523-1755.1999.00680.x; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Rotzer D, 2001, EMBO J, V20, P480, DOI 10.1093/emboj/20.3.480; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wells RG, 1997, J BIOL CHEM, V272, P11444; Wong SH, 2000, EUR J BIOCHEM, V267, P5550, DOI 10.1046/j.1432-1327.2000.01621.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; Yan W, 2000, ONCOL RES, V12, P157; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	35	114	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					823	829		10.1074/jbc.M105110200	http://dx.doi.org/10.1074/jbc.M105110200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11668175	hybrid			2022-12-25	WOS:000173087900105
J	Kitagawa, D; Tanemura, S; Ohata, S; Shimizu, N; Seo, J; Nishitai, G; Watanabe, T; Nakagawa, K; Kishimoto, H; Wada, T; Tezuka, T; Yamamoto, T; Nishina, H; Katada, T				Kitagawa, D; Tanemura, S; Ohata, S; Shimizu, N; Seo, J; Nishitai, G; Watanabe, T; Nakagawa, K; Kishimoto, H; Wada, T; Tezuka, T; Yamamoto, T; Nishina, H; Katada, T			Activation of extracellular signal-regulated kinase by ultraviolet is mediated through Src-dependent epidermal growth factor receptor phosphorylation - Its implication in an anti-apoptotic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; STRESS; LIGHT; JNK; REQUIREMENT; CASPASE-9; PATHWAYS; DAMAGE; RAS	Ultraviolet (UV) irradiation stimulates stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/ JNK), which is a member of the mitogen-activated protein kinase (MAPK) superfamily and implicated in stress-induced apoptosis. UV also induces the activation of another MAPK member, extracellular signal-regulated kinase (ERK), which is typically involved in a growth-signaling cascade. However, the UV-induced signaling pathway leading to ERK activation, together with the physiological role, has remained unknown. Here we examined the molecular mechanism and physiological function of UV-induced ERK activation in human epidermoid carcinoma A431 cells that retain a high number of epidermal growth factor (EGF) receptors. UV-induced ERK activation was accompanied with the Tyr phosphorylation of EGF receptors, and both responses were completely abolished in the presence of a selective EGF receptor inhibitor (AG1478) or the Src inhibitor PP2 and by the expression of a kinase-dead Src mutant. On the other hand, SAPK/JNK activation by UV was partially inhibited by these inhibitors. UV stimulated Src activity in a manner similar to the ERK activation, but the Src activation was insensitive to AG1478. UV-induced cell apoptosis measured by DNA fragmentation and caspase 3 activation was enhanced by AG1478 and an ERK kinase inhibitor (U0126) but inhibited by EGF receptor stimulation by the agonist. These results indicate that UV-induced ERK activation, which provides a survival signal against stress-induced apoptosis, is mediated through Src-dependent Tyr phosphorylation of EGF receptors.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Oncol, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo	Nishina, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Ohata, Shinya/S-2320-2018	Ohata, Shinya/0000-0003-4333-4433				BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; COFFER PJ, 1995, ONCOGENE, V11, P561; DAUB H, 1997, EMBO J, V16, P7023; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Fritz G, 1999, MOL CELL BIOL, V19, P1768; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000	23	114	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					366	371		10.1074/jbc.M107110200	http://dx.doi.org/10.1074/jbc.M107110200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11694531	hybrid			2022-12-25	WOS:000173087900049
J	Peek, R; Kammerer, RA; Frank, S; Otte-Holler, I; Westphal, JR				Peek, R; Kammerer, RA; Frank, S; Otte-Holler, I; Westphal, JR			The angiopoietin-like factor cornea-derived transcript 6 is a putative morphogen for human cornea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA; MOLECULAR-CLONING; VASCULAR DENSITY; NUDE-MICE; IN-VIVO; EXPRESSION; INVITRO; PROTEIN; DEPOSITION; LIVER	The human cornea-specific protein cornea-derived transcript 6 (CDT6) is a member of the angiopoietin gene family. We report the structural and functional characterization of CDT6. We demonstrate that CDT6 is a secreted protein that folds into disulfide-linked homotetramers by coiled-coil interactions. The finding that CDT6 is expressed at high levels in the avascular corneal stromal layer suggested that the protein, similar to certain angiopoietins, acts as a negative regulator of angiogenesis. To test this hypothesis and to assay the effect of the protein on a growing tissue with high vascular density, CDT6 was expressed in a mouse xenograft model. Expression of CDT6 led to a reduction in tumor growth and aberrant blood vessel formation by inducing massive fibrosis. Interestingly, expression of CDT6 also resulted in the deposition of extracellular matrix components typical for the mature corneal stromal layer. These observations strongly suggest a role as morphogen for CDT6 in inducing a corneal phenotype in vivo.	Netherlands Ophthalm Res Inst, Dept Mol Immunol, NL-1105 BA Amsterdam, Netherlands; Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland; Univ Nijmegen, Ctr Med, Dept Pathol, NL-6500 HB Nijmegen, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Basel; Radboud University Nijmegen	Peek, R (corresponding author), Netherlands Ophthalm Res Inst, Dept Mol Immunol, POB 12141, NL-1100 AC Amsterdam, Netherlands.		Otte-Holler, Irene/N-5708-2015; Westphal, J.R./L-4754-2015; Peek, Ron/D-4041-2016	Peek, Ron/0000-0003-2134-3371; Kammerer, Richard/0000-0003-4570-5197				AYCOCK RS, 1989, CONNECT TISSUE RES, V23, P19, DOI 10.3109/03008208909103901; BIRK DE, 1990, J CELL SCI, V95, P649; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Conklin D, 1999, GENOMICS, V62, P477, DOI 10.1006/geno.1999.6041; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Fujimaki T, 1999, CORNEA, V18, P109; Kammerer RA, 1998, J BIOL CHEM, V273, P10602, DOI 10.1074/jbc.273.17.10602; Kim I, 2000, J BIOL CHEM, V275, P18550, DOI 10.1074/jbc.M910084199; Kim I, 1999, FEBS LETT, V443, P353, DOI 10.1016/S0014-5793(99)00008-3; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Klyce SD., 1988, CORNEA, P3; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MADRI JA, 1980, HUM PATHOL, V11, P353, DOI 10.1016/S0046-8177(80)80031-1; Magro Gaetano, 1997, General and Diagnostic Pathology, V143, P203; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MCLAUGHLIN JS, 1989, J CELL SCI, V94, P371; Mindan FJP, 1997, CLIN TRANSPLANT, V11, P426; Nishida K, 1996, INVEST OPHTH VIS SCI, V37, P1800; Paczek L, 1996, Ann Transplant, V1, P41; Peek R, 1998, INVEST OPHTH VIS SCI, V39, P1782; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; SCOTT JE, 1992, J ANAT, V180, P155; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Van der Laak JAWM, 1998, J PATHOL, V184, P136, DOI 10.1002/(SICI)1096-9896(199802)184:2<136::AID-PATH970>3.0.CO;2-9; VANMUIJEN GNP, 1991, INT J CANCER, V48, P85; VANMUIJEN GNP, 1991, CLIN EXP METASTAS, V9, P259, DOI 10.1007/BF01753729; VLEMING LJ, 1995, CLIN NEPHROL, V44, P211; Westphal JR, 2000, INT J CANCER, V86, P768, DOI 10.1002/(SICI)1097-0215(20000615)86:6<768::AID-IJC3>3.3.CO;2-5; Westphal JR, 1997, BRIT J CANCER, V76, P561, DOI 10.1038/bjc.1997.427	31	45	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					686	693		10.1074/jbc.M105746200	http://dx.doi.org/10.1074/jbc.M105746200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11682471	Green Published, hybrid			2022-12-25	WOS:000173087900090
J	Meadows, KN; Bryant, P; Pumiglia, K				Meadows, KN; Bryant, P; Pumiglia, K			Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL-TRANSDUCTION; TYROSINE KINASE; ACTIN REORGANIZATION; CELL-MIGRATION; RECEPTOR; PHOSPHORYLATION; IDENTIFICATION; INHIBITOR; PATHWAY	We investigated the role of Ras in vascular endothelial growth factor (VEGF)-mediated signal transduction and the promotion of angiogenic changes primary endothelial cells. We find that VEGF potently induces Ras activation and that this step is essential for the stimulation by VEGF of several cellular changes associated with angiogenesis, including proliferation, migration, and branching morphogenesis in three-dimensional culture. Inhibition of Ras signaling induced subtle changes in the actin architecture but had no effect on the phosphatidylinositol 3-kinase (PI3K) or p38 signaling pathways. In contrast, activation of ERK was largely dependent on Ras. Although inhibiting ERK activity completely suppressed cell proliferation and partially blocked in vitro differentiation, neither ERK nor PI3K activity was required for VEGF-induced migration. These data provide the first direct demonstration that inhibition of Ras signal transduction is anti-angiogenic. Interestingly, VEGF signal transduction bifurcates both upstream and downstream of Ras, with different Has-dependent signals controlling endothelial cell proliferation and migration, essential components of the angiogenic response.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Pumiglia, K (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, Mail Code 165,47 New Scotland Ave, Albany, NY 12208 USA.	pumiglk@mail.amc.edu		Pumiglia, Kevin/0000-0003-4655-0334	NATIONAL CANCER INSTITUTE [R01CA081419, R01CA090653] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-81419, R01-CA-90653, R01 CA081419] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Doanes AM, 1999, BIOCHEM BIOPH RES CO, V255, P545, DOI 10.1006/bbrc.1999.0227; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DVORAK HF, 1995, AM J PATHOL, V146, P1029; ELGJO RF, 1975, CELL TISSUE RES, V162, P49; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong TAT, 1999, CANCER RES, V59, P99; FOX PL, 1994, ONCOGENE, V9, P3519; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hegland DD, 1999, BIOCHEM BIOPH RES CO, V260, P371, DOI 10.1006/bbrc.1999.0919; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Rak J, 2001, METHOD ENZYMOL, V333, P267; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stupack DG, 2000, IMMUNOL RES, V21, P83, DOI 10.1385/IR:21:2-3:83; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	54	215	222	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49289	49298		10.1074/jbc.M108069200	http://dx.doi.org/10.1074/jbc.M108069200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11682481	hybrid			2022-12-25	WOS:000173922100088
J	Tom, S; Ranalli, TA; Podust, VN; Bambara, RA				Tom, S; Ranalli, TA; Podust, VN; Bambara, RA			Regulatory roles of p21 and apurinic/apyrimidinic endonuclease 1 in base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; DNA-POLYMERASE-DELTA; HUMAN APURINIC ENDONUCLEASE; PURIFIED HUMAN PROTEINS; HUMAN FEN1; LIGASE-I; REPLICATION; INHIBITOR; SITE; EPSILON	Many types of DNA damage induce a cellular response that inhibits replication but allows repair by up-regulating the p53 pathway and inducing p21(Cip1,) (Waf1,) (Sdil). The p21 regulatory protein can bind proliferating cell nuclear antigen (PCNA) and prohibit DNA replication. We show here that p21 also inhibits PCNA stimulation of long patch base excision repair (BER) in vitro. p21 disrupts PCNA-directed stimulation of flap endonuclease 1 (FEN1), DNA ligase I, and DNA polymerase delta. The dilemma is to understand how p21 prevents DNA replication but allows BER in vivo. Differential regulation by p21 is likely to relate to the utilization of DNA polymerase beta, which is not sensitive to p21, in the repair pathway. We have also found that apurinic/apyrimidinic endonuclease 1 (APE1) stimulates long patch BER. Furthermore, neither APE1 activity nor its ability to stimulate long patch BER is significantly affected by p21 in vitro. We propose that APE1 serves as an assembly and coordination factor for long patch BER proteins. APE1 initially cleaves the DNA and then facilitates the sequential binding and catalysis by DNA polymerase beta, DNA polymerase delta, FEN1, and DNA ligase I. This model implies that BER can be regulated differentially, based upon the assembly of relevant proteins around APE1 in the presence or absence of PCNA.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, Rochester, NY 14642 USA; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA	University of Rochester; Vanderbilt University	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	robert_bambara@urmc.rochester.edu			NIGMS NIH HHS [GM24441, GM52948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441, R01GM052948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; BLANK A, 1994, P NATL ACAD SCI USA, V91, P9047, DOI 10.1073/pnas.91.19.9047; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hindges R, 1997, BIOL CHEM, V378, P345; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; Podlutsky AJ, 2001, EMBO J, V20, P1477, DOI 10.1093/emboj/20.6.1477; Podlutsky AJ, 2001, BIOCHEMISTRY-US, V40, P809, DOI 10.1021/bi002064s; PODUST V, 1992, CHROMOSOMA, V102, pS133, DOI 10.1007/BF02451797; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Rancourt RC, 2001, AM J PHYSIOL-LUNG C, V280, pL617, DOI 10.1152/ajplung.2001.280.4.L617; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WEISER T, 1991, J BIOL CHEM, V266, P10420; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZENG XR, 1994, J BIOL CHEM, V269, P13748; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713	50	53	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48781	48789		10.1074/jbc.M109626200	http://dx.doi.org/10.1074/jbc.M109626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11641413	hybrid			2022-12-25	WOS:000173922100023
J	Myers, MP; Andersen, JN; Cheng, A; Tremblay, ML; Horvath, CM; Parisien, JP; Salmeen, A; Barford, D; Tonks, NK				Myers, MP; Andersen, JN; Cheng, A; Tremblay, ML; Horvath, CM; Parisien, JP; Salmeen, A; Barford, D; Tonks, NK			TYK2 and JAR2 are substrates of protein-tyrosine phosphatase 1B.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN SENSITIVITY; TERMINAL SEQUENCE; KINASE FAMILY; IDENTIFICATION; CLASSIFICATION; SUPERFAMILY; RECOGNITION; SPECIFICITY; ACTIVATION; RECEPTOR	The reversible tyrosine phosphorylation of proteins, modulated by the coordinated actions of protein-tyrosine kinases and protein-tyrosine phosphatases (PTPs), regulates the cellular response to a wide variety of stimuli. It is established that protein kinases possess discrete sets of substrates and that substrate recognition is often dictated by the presence of consensus phosphorylation sites. Here, we have extended this concept to the PTPs and demonstrated that (E/D)-pY-pY-(R/K) is a consensus substrate recognition motif for PTP1B. We have shown that JAK2 and TYK2 are substrates of PTP1B and that the substrate recognition site within theses kinases is similar to the site of dephosphorylation previously identified within the insulin receptor. A substrate-trapping mutant of PTP1B formed a stable interaction with JAK2 and TYK2 in response to interferon stimulation. Expression of wild type or substrate-trapping mutant PTP1B inhibited interferon-dependent transcriptional activation. Finally, mouse embryo fibroblasts deficient in PTP1B displayed subtle changes in tyrosine phosphorylation, including hyperphosphorylation of JAK2. The closely related JAK family member, JAK1, which does not match the consensus dephosphorylation site, was not recognized as a substrate. These data illustrate that PTP1B may be an important physiological regulator of cytokine signaling and that it may be possible to derive consensus substrate recognition motifs for other members of the PTP family, which may then be used to predict novel physiological substrates.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA; Univ Oxford, Lab Mol Biophys, Oxford OX2 3QU, England; Inst Canc Res, Sect Struct Biol, London SW3 6JB, England	Cold Spring Harbor Laboratory; McGill University; Icahn School of Medicine at Mount Sinai; University of Oxford; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Tonks, NK (corresponding author), Cold Spring Harbor Lab, Demerec Bldg,1 Bungtown, Cold Spring Harbor, NY 11724 USA.	tonks@cshl.org	Cheng, Alan/M-9319-2013	Cheng, Alan/0000-0001-7897-4751; Horvath, Curt/0000-0003-2449-225X	NCI NIH HHS [P30CA45508, CA53840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840, P30CA045508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN JN, 2001, IN PRESS MOL CELL BI; Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Barford D, 1995, CURR OPIN STRUC BIOL, V5, P728, DOI 10.1016/0959-440X(95)80004-2; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BOSSEMEYER D, 1995, FEBS LETT, V369, P57, DOI 10.1016/0014-5793(95)00580-3; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; Desmarais S, 1999, BIOCHEM J, V337, P219, DOI 10.1042/0264-6021:3370219; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; IHLE JN, 1994, P SOC EXP BIOL MED, V206, P268; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NEEL BG, 2001, SEMIN CELL BIOL, V4, P419; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Parisien JP, 2001, VIROLOGY, V283, P230, DOI 10.1006/viro.2001.0856; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peters GH, 2000, J BIOL CHEM, V275, P18201, DOI 10.1074/jbc.M910273199; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Stark G R, 1997, Harvey Lect, V93, P1; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	355	373	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47771	47774		10.1074/jbc.C100583200	http://dx.doi.org/10.1074/jbc.C100583200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11694501	hybrid			2022-12-25	WOS:000172927000007
J	Ward, IM; Wu, XL; Chen, JJ				Ward, IM; Wu, XL; Chen, JJ			Threonine 68 of Chk2 is phosphorylated at sites of DNA strand breaks.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; IN-VIVO; RADIATION; DAMAGE; ACTIVATION; PURIFICATION; CHECKPOINT; CELLS; ATM	The protein kinase Chk2 has been implicated in signaling DNA damage to cell cycle checkpoints. In response to ionizing radiation, Chk2 becomes rapidly phosphorylated at threonine 68 by ataxia-telangiectasia mutated (ATM). Here we show that the Thr(68)-phosphorylated form of Chk2 forms distinct nuclear foci in response to ionizing radiation. Only this activated form of Chk2 localizes at sites of DNA strand breaks. The kinase activity of Chk2 and the number of Chk2 foci formed depend on the severity of DNA damage and gradually decline correlating with the predicted value of slowly re-joining double strand breaks. These results suggest that Chk2 is regulated at the sites of DNA strand breaks in response to ionizing radiation.	Mayo Clin, Div Oncol Res, Rochester, MN 55905 USA	Mayo Clinic	Chen, JJ (corresponding author), Mayo Clin, Div Oncol Res, Guggenheim 1342,200 1st St SW, Rochester, MN 55905 USA.							Ahn JY, 2000, CANCER RES, V60, P5934; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; KODYM R, 1995, INT J RADIAT BIOL, V68, P133, DOI 10.1080/09553009514551031; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; NUNEZ MI, 1995, BRIT J CANCER, V71, P311, DOI 10.1038/bjc.1995.62; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	18	83	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47755	47758		10.1074/jbc.C100587200	http://dx.doi.org/10.1074/jbc.C100587200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11668173	hybrid			2022-12-25	WOS:000172927000003
J	Wing, MR; Houston, D; Kelley, GG; Der, CJ; Siderovski, DP; Harden, TK				Wing, MR; Houston, D; Kelley, GG; Der, CJ; Siderovski, DP; Harden, TK			Activation of phospholipase C-epsilon by heterotrimeric G protein beta gamma-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; ALPHA-SUBUNITS; RECEPTOR; BINDING; IDENTIFICATION; C-DELTA-1; INTERACTS; TERMINUS	PLC-epsilon was identified recently as a phosphoinositide-hydrolyzing phospholipase C (PLC) containing catalytic domains (X, Y, and C2) common to all PLC isozymes as well as unique CDC25- and Ras-associating domains. Novel regulation of this PLC isozyme by the Ras oncoprotein and a-subunits (G alpha (12)) of heterotrimeric G proteins was illustrated. Sequence analyses of PLC-epsilon revealed previously unrecognized PH and EF-hand domains in the amino terminus. The known interaction of G beta gamma subunits with the PH domains of other proteins led us to examine the capacity of G beta gamma to activate PLC-epsilon. Co-expression of G beta (1)gamma (2) with PLC-epsilon in COS-7 cells resulted in marked stimulation of phospholipase C activity. G beta (2) and G beta4 in combination with G gamma (1), G gamma (2), G gamma (3), or G gamma (13) also activated PLC-epsilon to levels similar to those observed with G beta (1)-containing dimers of these Gy-subunits. G beta3 in combination with the same Gy-subunits was less active, and G beta (5)-containing dimers were essentially inactive. G beta gamma -promoted activation of PLC-epsilon was blocked by cotransfection with either of two G beta gamma -interacting proteins, G alpha (i1) or the carboxyl terminus of G protein receptor kinase 2. Pharmacological inhibition of PI3-kinase-gamma had no effect on G beta (1)gamma (2)-promoted activation of PLC-epsilon. Similarly, activation of Ras in the action of G beta gamma is unlikely, because a mutation in the second RA domain of PLC-epsilon that blocks Ras activation of PLC failed to alter the stimulatory activity of G beta (1)gamma (2). Taken together, these results reveal the presence of additional functional domains in PLC-epsilon and add a new level of complexity in the regulation of this novel enzyme by heterotrimeric G proteins.	Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Neurobiol, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA; SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Harden, TK (corresponding author), Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27599 USA.	tkh@med.unc.edu	Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA42978] Funding Source: Medline; NIDDK NIH HHS [DK56294] Funding Source: Medline; NIGMS NIH HHS [GM29536, GM62338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062338, R37GM029536, R01GM029536] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baek KJ, 2001, J BIOL CHEM, V276, P5591, DOI 10.1074/jbc.M008252200; Barr AJ, 2000, BIOCHEMISTRY-US, V39, P1800, DOI 10.1021/bi992021f; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BROWN HA, 1991, MOL PHARMACOL, V40, P648; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; Carman CV, 2000, J BIOL CHEM, V275, P10443, DOI 10.1074/jbc.275.14.10443; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fushman D, 1998, J BIOL CHEM, V273, P2835, DOI 10.1074/jbc.273.5.2835; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; Siderovski DP, 2002, METHOD ENZYMOL, V344, P702; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALDO GL, 1991, J BIOL CHEM, V266, P14217; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; WU DQ, 1992, J BIOL CHEM, V267, P1811; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	39	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48257	48261		10.1074/jbc.C100574200	http://dx.doi.org/10.1074/jbc.C100574200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11641393	Green Published, hybrid			2022-12-25	WOS:000172927000070
J	Zanusso, G; Farinazzo, A; Fiorini, M; Gelati, M; Castagna, A; Righetti, PG; Rizzuto, N; Monaco, S				Zanusso, G; Farinazzo, A; Fiorini, M; Gelati, M; Castagna, A; Righetti, PG; Rizzuto, N; Monaco, S			pH-dependent prion protein conformation in classical Creutzfeldt-Jakob disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAIN VARIATION; MOLECULAR-BASIS; BIOLOGY; GENE	In transmissible spongiform encephalopathies, the cellular prion protein (PrPC) undergoes a conformational change from a prevailing a-helical structure to a beta -sheet-rich, protease-resistant isoform, termed PrPSc. PrPC has two characteristics: a high affinity for Cu2+ and a strong pH-dependent conformation. Lines of evidence indicate that PrPSc conformation is dependent on copper and that acidic conditions facilitate the conversion of PrPC --> PrPSc. In each species, PrPSc exists in multiple conformations, which are associated with different prion strains. In sporadic Creutzfeldt-Jakob disease (sCJD), different biochemical types of PrPSc have been identified according to the size of the protease-resistant fragments, patterns of glycosylation, and the metal-ion occupancy. Based on the site of cleavage produced by proteinase K, we investigated the conformational stability of PrPSc under acidic, neutral, and basic conditions in 42 sCJD subjects. Our study shows that only one type of sCJD PrPSc, associated with the classical form, shows a pH-dependent conformation, whereas two other biochemical PrPSc types, detected in distinct sCJD phenotypes, are unaffected by pH variations. This novel approach demonstrates the presence of three types of PrPSc in sCJD.	Univ Verona, Dept Neurol & Visual Sci, I-37134 Verona, Italy; Univ Verona, Dept Agr & Ind Biotechnol, I-37134 Verona, Italy	University of Verona; University of Verona	Monaco, S (corresponding author), Univ Verona, Dept Neurol & Visual Sci, Piazzale LA Scuro 10, I-37134 Verona, Italy.		Zanusso, Gianluigi/K-2823-2018; Monaco, Salvatore/K-4659-2018	Zanusso, Gianluigi/0000-0001-5199-6264; Monaco, Salvatore/0000-0003-3191-8597; Fiorini, Michele/0000-0002-5339-8716				BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; Miura T, 1996, FEBS LETT, V396, P248, DOI 10.1016/0014-5793(96)01104-0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 2000, P NATL ACAD SCI USA, V97, P10168, DOI 10.1073/pnas.97.18.10168; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; SALVATORE M, 1994, HUM GENET, V94, P375, DOI 10.1007/BF00201596; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	21	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40377	40380		10.1074/jbc.C100458200	http://dx.doi.org/10.1074/jbc.C100458200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11682490	hybrid			2022-12-25	WOS:000171925600003
J	Signorelli, P; Luberto, C; Hannun, YA				Signorelli, P; Luberto, C; Hannun, YA			Ceramide inhibition of NF-kappa B activation involves reverse translocation of classical protein kinase C (PKC) isoenzymes: requirement for kinase activity and carboxyl-terminal phosphorylation of PKC for the ceramide response	FASEB JOURNAL			English	Article						diacylglycerol; sphingolipid; glycerolipid; C(6)-ceramide	SIGNAL-TRANSDUCTION; SELECTIVE INHIBITOR; PHOSPHATIDIC-ACID; INDUCED APOPTOSIS; PHORBOL ESTER; T-LYMPHOCYTES; CELL-DEATH; TNF-ALPHA; ZETA; SPHINGOMYELINASE	Protein kinase C (PKC) is known to activate NF-kappaB whereas the lipid mediator ceramide was recently shown to inhibit activation of this transcription factor (1,2). In this study, the mechanisms by which ceramide interferes with this pathway were examined in Jurkat leukemia and MCF-7 breast cancer cells. Both exogenous and endogenous ceramide inhibited selectively PKC-mediated activation of NF-kappaB by reverting PKC translocation to the membrane. Next, confocal and immunofluorescence studies were performed to evaluate the direct effects of ceramide on PKC. These studies showed that ceramide inhibited translocation of a green fluorescent protein (GFP)-PKCb2 fusion protein in response to PMA. A mutant PKC in which autophosphorylation sites were mutated to alanine (PKC-DA) was resistant to ceramide. A kinase-inactive mutant (PKC-KR) was also resistant to ceramide action, and the results were supported using kinase inhibitors of the enzyme. Finally, overexpression of PKC-DA prevented, at least partly, the ability of ceramide to inhibit activation of NF-kappaB. Taken together, these studies show that ceramide has acute effects on translocation of PKC by inducing reverse translocation, and this reversal requires both the kinase activity of PKC and phosphorylation of the autophosphorylation sites.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 2550509, Charleston, SC 29425 USA.	hannun@musc.edu		signorelli, paola/0000-0003-2368-2393	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43707] Funding Source: Medline; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Boland MP, 1996, BIOCHEM SOC T, V24, pS1, DOI 10.1042/bst024001s; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chen CC, 1998, J IMMUNOL, V161, P6206; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Goni FM, 1999, PROG LIPID RES, V38, P1, DOI 10.1016/S0163-7827(98)00021-6; Goswami R, 2000, J NEUROSCI RES, V60, P141, DOI 10.1002/(SICI)1097-4547(20000415)60:2<141::AID-JNR2>3.0.CO;2-5; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HUANG KP, 1986, J BIOL CHEM, V261, P2134; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Kirtikara K, 1998, MOL CELL BIOCHEM, V181, P41; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kontny E, 2000, J LEUKOCYTE BIOL, V67, P249, DOI 10.1002/jlb.67.2.249; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Lee Y, 2000, ORG LETT, V2, P303, DOI 10.1021/ol9912480; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Luberto C, 1999, LIPIDS, V34, pS5, DOI 10.1007/BF02562221; Luberto C, 2000, J BIOL CHEM, V275, P14760, DOI 10.1074/jbc.275.19.14760; Manna SK, 2000, FEBS LETT, V473, P113, DOI 10.1016/S0014-5793(00)01501-5; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; Mochly-Rosen D, 1998, FASEB J, V12, P35; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Olivera A, 1997, BBA-LIPID LIPID MET, V1348, P311, DOI 10.1016/S0005-2760(97)00067-2; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Sawai H, 1997, J BIOL CHEM, V272, P2452; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; Venable ME, 1999, BBA-MOL CELL BIOL L, V1439, P291, DOI 10.1016/S1388-1981(99)00101-8; Vertegaal ACO, 2000, CELL SIGNAL, V12, P759, DOI 10.1016/S0898-6568(00)00133-9; Villalba M, 1999, J IMMUNOL, V163, P5813; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Wooten MW, 2000, MOL CELL BIOL, V20, P4494, DOI 10.1128/MCB.20.13.4494-4504.2000; Zhang P, 1997, J BIOL CHEM, V272, P9609; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	59	35	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2401	2414		10.1096/fj.01-0244com	http://dx.doi.org/10.1096/fj.01-0244com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689465				2022-12-25	WOS:000172420500010
J	Singbartl, K; Forlow, SB; Ley, K				Singbartl, K; Forlow, SB; Ley, K			Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure	FASEB JOURNAL			English	Article						neutrophils; ischemia-reperfusion; acute renal failure	ISCHEMIC-REPERFUSION INJURY; GRANULE MEMBRANE-PROTEIN; DEEP ARTERIAL INJURY; RECRUITMENT IN-VIVO; LEUKOCYTE EMIGRATION; ACTIVATED PLATELETS; ISCHEMIA/REPERFUSION; ADHESION; MICE; ANGIOPLASTY	In a neutrophil-dependent model of acute postischemic renal failure (APRF), eliminating or blocking P-selectin reduces postischemic neutrophil infiltration and preserves kidney function. This study was designed to identify the role of platelet vs. endothelial P-selectin in APRF. Using wild-type (wt) and P-selectin- deficient (P-/-) mice, we generated chimeric mice by bone marrow transplantation. Chimeric mice exclusively expressed either platelet (Plt-P) or endothelial P-selectin (EC-P). APRF was induced by bilateral renal ischemia in situ (32 min), followed by reperfusion; 48 h after reperfusion, EC-P had significantly lower creatinine concentrations (twofold over sham) than Plt-P (eightfold over sham). Compared with wt, protection from renal failure in EC-P was similar to that observed in P-/-. Plt-P and EC-P demonstrated similar overall postischemic neutrophil infiltration as measured by renal myeloperoxidase activity. However, Plt-P showed massive neutrophil infiltration into outer and inner medulla, similar to that in wt. EC-P had only patchy, more diffuse neutrophil influx. Our study identifies platelet P-selectin as crucial for postischemic neutrophil recruitment into outer and inner medulla, which is detrimental to the development of APRF. This suggests that novel therapeutic strategies for postischemic organ failure could be aimed at neutrophil-platelet interactions.	Univ Virginia, Hlth Sci Ctr, Dept Biomed Engn, Charlottesville, VA 22908 USA; Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Univ Klinikum Munster, Klin & Poliklin Anasthesiol & Operat Intens Med, Munster, Germany	University of Virginia; University of Virginia; University of Munster	Ley, K (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biomed Engn, Box 800759, Charlottesville, VA 22908 USA.	klausley@virginia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BREZIS M, 1995, NEW ENGL J MED, V332, P647, DOI 10.1056/NEJM199503093321006; BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Chiao H, 1997, J CLIN INVEST, V99, P1165, DOI 10.1172/JCI119272; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; Diacovo TG, 1996, BLOOD, V88, P146; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Gotsch U, 1997, J CELL SCI, V110, P583; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; HELLBERG POA, 1989, KIDNEY INT, V36, P555, DOI 10.1038/ki.1989.230; HIRSCH S, 1983, IMMUNOGENETICS, V18, P229, DOI 10.1007/BF00952962; Ichikawa H, 1997, CIRC RES, V81, P922; Jung U, 1998, J CLIN INVEST, V102, P1526, DOI 10.1172/JCI119893; Jung U, 1999, J IMMUNOL, V162, P6755; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kanwar S, 1998, MICROCIRCULATION, V5, P281, DOI 10.1080/713773894; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; Kogaki S, 1999, CARDIOVASC RES, V43, P968, DOI 10.1016/S0008-6363(99)00140-6; Lefer AM, 1998, CIRCULATION, V98, P1322, DOI 10.1161/01.CIR.98.13.1322; LINAS SL, 1995, KIDNEY INT, V48, P1584, DOI 10.1038/ki.1995.451; Lindner JR, 2000, CIRCULATION, V102, P2745, DOI 10.1161/01.CIR.102.22.2745; Lu HF, 1997, J CLIN INVEST, V99, P1340, DOI 10.1172/JCI119293; MASON J, 1989, MINER ELECTROL METAB, V15, P114; Massberg S, 1998, BLOOD, V92, P507, DOI 10.1182/blood.V92.2.507; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MENGER MD, 1994, MICROSURG, V15, P383, DOI 10.1002/micr.1920150605; Merhi Y, 1999, ARTERIOSCL THROM VAS, V19, P372, DOI 10.1161/01.ATV.19.2.372; MERHI Y, 1994, CIRCULATION, V90, P997, DOI 10.1161/01.CIR.90.2.997; Merhi Y, 1997, ARTERIOSCL THROM VAS, V17, P1185, DOI 10.1161/01.ATV.17.6.1185; Muller JM, 1997, J SURG RES, V71, P1, DOI 10.1006/jsre.1997.5132; MULLER WA, 1995, J LEUKOCYTE BIOL, V57, P523, DOI 10.1002/jlb.57.4.523; OLOF P, 1990, AM J PHYSIOL, V258, pF1018, DOI 10.1152/ajprenal.1990.258.4.F1018; PALLER MS, 1989, J LAB CLIN MED, V113, P379; RABB H, 1994, AM J PHYSIOL-RENAL, V267, pF1052, DOI 10.1152/ajprenal.1994.267.6.F1052; Rabb H, 1996, AM J PHYSIOL-RENAL, V271, pF408, DOI 10.1152/ajprenal.1996.271.2.F408; RABB H, 1995, BIOCHEM BIOPH RES CO, V211, P67, DOI 10.1006/bbrc.1995.1779; Rabb H, 1998, CLIN EXP PHARMACOL P, V25, P286, DOI 10.1111/j.1440-1681.1998.t01-1-.x; RACUSEN LC, 1995, ACUTE RENAL FAILURE, P1; SANDERS WE, 1992, BLOOD, V80, P795; Sawaya DE, 1999, SHOCK, V12, P227, DOI 10.1097/00024382-199909000-00010; Singbartl K, 2000, FASEB J, V14, P48, DOI 10.1096/fasebj.14.1.48; Singbartl K, 2000, CRIT CARE MED, V28, P2507, DOI 10.1097/00003246-200007000-00053; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; THORNTON MA, 1989, AM J PATHOL, V135, P509; VENKATACHALAM MA, 1978, KIDNEY INT, V14, P31, DOI 10.1038/ki.1978.87; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; WILLINGER CC, 1992, VIRCHOWS ARCH B, V62, P237, DOI 10.1007/BF02899687; YEO EL, 1994, BLOOD, V83, P2498	50	121	129	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2337	2344		10.1096/fj.01-0199com	http://dx.doi.org/10.1096/fj.01-0199com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689459				2022-12-25	WOS:000172420500004
J	Xin, H; D'Souza, S; Fang, L; Lengyel, P; Choubey, D				Xin, H; D'Souza, S; Fang, L; Lengyel, P; Choubey, D			p202, an interferon-inducible negative regulator of cell growth, is a target of the adenovirus E1A protein	ONCOGENE			English	Article						interferon-inducible p202; cell cycle; pRb; E2Fs; adenovirus E1A	E2F TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR PROTEIN; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; INHIBITION; BINDING; PRB; P53; TRANSFORMATION; PROLIFERATION	Studies have revealed that human adenovirus-encoded E1A protein promotes cell proliferation through the targeted interaction with cellular proteins that act as key negative regulators of cell growth. The targets of E1A protein include the retinoblastoma tumor suppressor protein (pRb). Because p202, an interferon (IFN)inducible murine protein (52-kDa), negatively regulates cell growth in part through the pRb/E2F pathway, we tested whether the p202 is a target of the adenovirus-encoded E1A protein for functional inactivation. Here we report that the expression of E1A protein overcame p202-mediated inhibition of cell growth and this correlated with an alleviation of p202-mediated inhibition of the transcriptional activity of E2F. Furthermore, E1A protein relieved p202-mediated inhibition of the specific DNA-binding activity of E2F complexes, including those containing the pocket proteins. Additionally, the E1A protein bound to p202 both in vitro and in vivo and a deletion of four amino acids in the conserved region 2 (CR2) of E1A protein significantly reduced the binding of E1A to p202. Interestingly, ectopic expression of p202 under reduced serum conditions significantly reduced E1A-mediated apoptosis. Taken together, our observations provide support to the idea that the p202 and adenovirus E1A protein functionally counteract each other and E1A protein targets p202 to promote cell proliferation.	Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL 60153 USA; Univ Georgia, Dept Genet, Athens, GA 30602 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Loyola University Chicago; University System of Georgia; University of Georgia; Yale University	Choubey, D (corresponding author), Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, 2160 S 1st Ave,Bldg 1, Maywood, IL 60153 USA.	dchoube@lumc.edu	Choubey, Divaker/A-4771-2008		NCI NIH HHS [CA69031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BROCKMANN D, 1995, CURR TOP MICROBIOL, V199, P81; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; Condorelli G, 1997, J CELL BIOCHEM, V67, P423, DOI 10.1002/(SICI)1097-4644(19971215)67:4<423::AID-JCB1>3.0.CO;2-U; Cress WD, 1996, CURR TOP MICROBIOL, V208, P63; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Geng Y, 2000, J BIOL REG HOMEOS AG, V14, P263; Geng YB, 2000, CELL GROWTH DIFFER, V11, P475; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; JansenDurr P, 1996, TRENDS GENET, V12, P270, DOI 10.1016/0168-9525(96)81455-7; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; Koul D, 1998, BIOCHEM BIOPH RES CO, V247, P379, DOI 10.1006/bbrc.1998.8804; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Min W, 1996, MOL CELL BIOL, V16, P359; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; NEVINS JR, 1992, SCIENCE, V258, P424; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; Sang NL, 1997, J CELL PHYSIOL, V170, P182, DOI 10.1002/(SICI)1097-4652(199702)170:2<182::AID-JCP10>3.0.CO;2-K; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; Smith K, 1996, VIROLOGY, V224, P184, DOI 10.1006/viro.1996.0520; WANG H, 2000, J BIOL CHEM, V275, P27366; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHITE E, 1995, CURR TOP MICROBIOL, V199, P33; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Yan DH, 1999, ONCOGENE, V18, P807, DOI 10.1038/sj.onc.1202369; ZANTEMA A, 1995, CURR TOP MICROBIOL, V199, P1; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	54	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6828	6839		10.1038/sj.onc.1204844	http://dx.doi.org/10.1038/sj.onc.1204844			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687962				2022-12-25	WOS:000171641000004
J	Dschietzig, T; Richter, C; Bartsch, C; Laule, M; Armbruster, FP; Baumann, G; Stangl, K				Dschietzig, T; Richter, C; Bartsch, C; Laule, M; Armbruster, FP; Baumann, G; Stangl, K			The pregnancy hormone relaxin is a player in human heart failure	FASEB JOURNAL			English	Article						RLX; congestive; endothelin 1; angiotensin II; gene expression	RAT; ENDOTHELIN; VASODILATOR; EXPRESSION; SECRETION; CELLS	Human congestive heart failure is characterized by complex neurohumoral activation associated with the up-regulation of vasoconstricting and salt-retaining mediators and the compensatory rise of counter-regulatory hormones. In the present study, we provide the first evidence that relaxin (RLX), known as a pregnancy hormone, represents a potential compensatory mediator in human heart failure: plasma concentrations of RLX and myocardial expression of the two RLX genes (H1 and H2) correlate with the severity of disease and RLX responds to therapy. The failing human heart is a relevant source of circulating RLX peptides, and myocytes as well as interstitial cells produce RLX. Elevation of ventricular filling pressure up-regulates RLX expression and the hormone acts as a potent inhibitor of endothelin 1, the most powerful vasoconstrictor in heart failure. Furthermore, RLX modulates effects of angiotensin II, another crucial mediator. Our data identify RLX as a new player in human heart failure with potential diagnostic and therapeutic relevance.	Charite, Med Klin & Poliklin S Kardiol Angiol Pulmol, D-10098 Berlin, Germany; Immundiagnost AG, D-64625 Bensheim, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stangl, K (corresponding author), Charite, Med Klin & Poliklin S Kardiol Angiol Pulmol, Campus Mitte,Schumannstr 20-21, D-10098 Berlin, Germany.	karl.stangl@charite.de	Armbruster, Franz Paul/D-7383-2014; Laule, Michael E/A-6548-2013	Laule, Michael/0000-0002-7579-295X; Dschietzig, Thomas Bernd/0000-0003-1186-8713				Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; Bortz JLG., 1990, VERTEILUNGSFREIE MET, DOI 10.1007/978-3-662-22593-6; BRYANTGREENWOOD GD, 1994, ENDOCR REV, V15, P5, DOI 10.1210/er.15.1.5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Danielson LA, 1999, J CLIN INVEST, V103, P525, DOI 10.1172/JCI5630; deBold AJ, 1996, CARDIOVASC RES, V31, P7, DOI 10.1016/S0008-6363(95)00121-2; Douglas SA, 1997, J VASC RES, V34, P152, DOI 10.1159/000159219; FIELDS PA, 1992, ENDOCRINOLOGY, V130, P2985, DOI 10.1210/en.130.5.2985; FRANGOS JA, 1988, BIOTECHNOL BIOENG, V32, P1053, DOI 10.1002/bit.260320812; GEDDES BJ, 1995, J NEUROENDOCRINOL, V7, P411, DOI 10.1111/j.1365-2826.1995.tb00777.x; Gunnersen JM, 1996, MOL CELL ENDOCRINOL, V118, P85, DOI 10.1016/0303-7207(96)03770-7; HAMOLSKY M, 1945, P SOC EXP BIOL MED, V60, P8, DOI 10.3181/00379727-60-15074P; HISAW F, 1926, P SOC EXP BIOL MED, V23, P899; HOLM S, 1979, SCAND J STAT, V6, P65; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; HUDSON P, 1981, NATURE, V291, P127, DOI 10.1038/291127a0; Lippert T. H., 1996, Clinical and Experimental Obstetrics and Gynecology, V23, P65; MARRIOTT D, 1992, MOL ENDOCRINOL, V6, P1441, DOI 10.1210/me.6.9.1441; Rossi GP, 1999, CARDIOVASC RES, V43, P300, DOI 10.1016/S0008-6363(99)00110-8; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; Stangl K, 2000, CIRCULATION, V102, P1132, DOI 10.1161/01.CIR.102.10.1132; TOO CKL, 1982, ENDOCRINOLOGY, V111, P1424, DOI 10.1210/endo-111-4-1424; Toth M, 1996, J ENDOCRINOL, V150, P487, DOI 10.1677/joe.0.1500487; Unemori EN, 1996, J CLIN INVEST, V98, P2739, DOI 10.1172/JCI119099; WEI CM, 1994, CIRCULATION, V89, P1580, DOI 10.1161/01.CIR.89.4.1580	26	170	184	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2187	2195		10.1096/fj.01-0070com	http://dx.doi.org/10.1096/fj.01-0070com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641245				2022-12-25	WOS:000171920400030
J	Fu, L; Liang, JJN				Fu, L; Liang, JJN			Detection of protein-protein interactions among lens crystallins in a mammalian two-hybrid system assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; HEAT-SHOCK-PROTEIN; DESMIN-RELATED MYOPATHY; A-CRYSTALLIN; GAMMA-CRYSTALLIN; EYE LENS; SUBUNIT EXCHANGE; 2-HYBRID SYSTEM; MISSENSE MUTATION; BETA-CRYSTALLIN	alpha-Crystallin consists of two subunits, alphaA and alphaB, and each can form an oligomer by itself or with the other. The aggregation arises from interdomain interactions. However, it is not known whether such interactions also exist among alpha-, beta-, and gamma-crystallins. This heterogeneous crystallin interaction is far weaker than the homogeneous crystallin interaction and is difficult to detect by conventional spectroscopic measurements. We used a mammalian two-hybrid system in this study. The major crystallin components, alphaA-, alphaB-, betaB2-, and -gammaC-crystallin genes, were subcloned into the DNA binding domain and transcription activation domain vectors of the two-hybrid system, and they were cotransfected along with a chloramphenicol acetyltransferase (CAT) reporter vector into HeLa cells. Chloramphenicol acetyltransferase activity indicated that there were interactions between alphaA- (or alphaB-) and betaB2- or gammaC-crystallins, but with an intensity of one-third that of alphaA-alphaB interactions. Hsp27, a member of the family of the small heat-shock proteins, showed a similar interaction property with alphaB-crystallin. Using the N- and C-terminal domain-truncated mutants, we demonstrated that both domains were important in the alphaA-crystallin self-interaction, but that only the C-terminal domain was important in the alphaB-crystallin self-interaction. These results show that the two-hybrid system can detect interactions among various crystallins and may be used in mapping interaction domains.	Harvard Univ, Sch Med, Dept Otolaryngol, Ctr Ophthalm Res, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Liang, JJN (corresponding author), Harvard Univ, Sch Med, Dept Otolaryngol, Ctr Ophthalm Res, Boston, MA 02115 USA.				NEI NIH HHS [EY05803] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Baldi P, 1999, BIOINFORMATICS, V15, P937, DOI 10.1093/bioinformatics/15.11.937; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; Bettelheim F. A., 1985, OCULAR LENS STRUCTUR, P265; Bettelheim FA, 1998, INT J BIOL MACROMOL, V22, P247, DOI 10.1016/S0141-8130(98)00022-1; BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; Boelens WC, 1998, J BIOL CHEM, V273, P28085, DOI 10.1074/jbc.273.43.28085; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; CHOU PY, 1989, PREDICTION PROTEIN S, P549; Cobb BA, 2000, BIOCHEMISTRY-US, V39, P15791, DOI 10.1021/bi001453j; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fu L, 2001, MOL VIS, V7, P178; Gill D, 2000, INVEST OPHTH VIS SCI, V41, P159; Harding J, 1991, CATARACT, P195; Heon E, 1999, AM J HUM GENET, V65, P1261, DOI 10.1086/302619; Horwitz J, 1999, EYE, V13, P403, DOI 10.1038/eye.1999.114; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; KOENIG SH, 1992, BIOPHYS J, V61, P776, DOI 10.1016/S0006-3495(92)81882-9; Koteiche HA, 1999, J MOL BIOL, V294, P561, DOI 10.1006/jmbi.1999.3242; Lampi KJ, 1997, J BIOL CHEM, V272, P2268; LAPATTO R, 1991, J MOL BIOL, V222, P1067, DOI 10.1016/0022-2836(91)90594-V; Liang JJN, 1998, BIOCHEM BIOPH RES CO, V246, P441, DOI 10.1006/bbrc.1998.8640; LIANG JN, 1991, EXP EYE RES, V53, P61, DOI 10.1016/0014-4835(91)90145-5; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; Litt M, 1997, HUM MOL GENET, V6, P665, DOI 10.1093/hmg/6.5.665; Liu CH, 1999, BIOCHEM BIOPH RES CO, V255, P256, DOI 10.1006/bbrc.1999.0174; MACH H, 1990, J BIOL CHEM, V265, P4844; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MINTON AP, 1981, BIOPOLYMERS, V20, P2093, DOI 10.1002/bip.1981.360201006; Muchowski PJ, 1999, J MOL BIOL, V289, P397, DOI 10.1006/jmbi.1999.2759; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P511; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; Sergeev YV, 2000, BIOCHEMISTRY-US, V39, P15799, DOI 10.1021/bi001882h; SIEZEN RJ, 1983, BIOPHYS CHEM, V18, P181, DOI 10.1016/0301-4622(83)80030-1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smith RS, 2000, GENOMICS, V63, P314, DOI 10.1006/geno.1999.6054; Stephan DA, 1999, P NATL ACAD SCI USA, V96, P1008, DOI 10.1073/pnas.96.3.1008; Sun TX, 1998, FEBS LETT, V430, P401, DOI 10.1016/S0014-5793(98)00707-8; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; TAKACS AM, 1993, P NATL ACAD SCI USA, V90, P10375, DOI 10.1073/pnas.90.21.10375; TARDIEU A, 1992, EUR BIOPHYS J BIOPHY, V21, P1, DOI 10.1007/BF00195438; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765	50	73	75	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4255	4260		10.1074/jbc.M110027200	http://dx.doi.org/10.1074/jbc.M110027200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11700327	hybrid			2022-12-25	WOS:000173813900063
J	Huhtinen, K; O'Byrne, J; Lindquist, PJG; Contreras, JA; Alexson, SEH				Huhtinen, K; O'Byrne, J; Lindquist, PJG; Contreras, JA; Alexson, SEH			The peroxisome proliferator-induced cytosolic type I Acyl-CoA thioesterase (CTE-I) is a serine-histidine-aspartic acid alpha/beta hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; TAURINE N-ACYLTRANSFERASE; LONG-CHAIN; RAT-LIVER; FATTY-ACIDS; MOLECULAR-CLONING; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GENE-EXPRESSION; CLOFIBRIC ACID	Long-chain acyl-CoA thioesterases hydrolyze longchain acyl-CoAs to the corresponding free fatty acid and CoASH and may therefore play important roles in regulation of lipid metabolism. We have recently cloned four members of a highly conserved acyl-CoA thioesterase multigene family expressed in cytosol (CTE-I), mitochondria (MTE-I), and peroxisomes (PTE-Ia and -Ib), all of which are regulated via the peroxisome proliferator-activated receptor a (Hunt, M. C., Nousiainen, S. E. B., Huttunen, M. K, Orii, K. E., Svensson, L. T., and Alexson, S. E. H. (1999) J. BioL Chem. 274,34317-34326). Sequence comparison revealed the presence of putative active-site serine motifs (GXSXG) in all four acyl-CoA thioesterases. In the present study we have expressed CTE-I in Escherichia coli and characterized the recombinant protein with respect to sensitivity to various amino acid reactive compounds. The recombinant CTE-I was inhibited by phenylmethylsulfonyl fluoride and diethyl pyrocarbonate, suggesting the involvement of serine and histidine residues for the activity. Extensive sequence analysis pinpointed Ser(232) ASp(324), and His(358) as the likely components of a catalytic triad, and site-directed mutagenesis verified the importance of these residues for the catalytic activity. A (SC)-C-232 mutant retained about 2% of the wild type activity and incubation with C-14-palmitoyl-CoA strongly labeled this mutant protein, in contrast to wild-type enzyme, indicating that deacylation of the acyl-enzyme intermediate becomes rate-limiting in this mutant protein. These data are discussed in relation to the structure/function of acyl-CoA thioesterases versus acyltransferases. Furthermore, kinetic characterization of recombinant CTE-I showed that this enzyme appears to be a true acyl-CoA thioesterase being highly specific for C-12-C-2, acyl-CoAs.	Huddinge Univ Hosp, Karolinska Inst, Div Clin Chem, Dept Med Lab Sci & Technol, SE-14186 Stockholm, Sweden; Lund Univ, Dept Mol & Cell Biol, SE-22100 Lund, Sweden	Karolinska Institutet; Lund University	Alexson, SEH (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Div Clin Chem, Dept Med Lab Sci & Technol, SE-14186 Stockholm, Sweden.		Huhtinen, Kaisa/AAM-3445-2020; O'Byrne, James/AAE-8182-2021	Huhtinen, Kaisa/0000-0001-9685-5246; 				Bellizzi JJ, 2000, P NATL ACAD SCI USA, V97, P4573, DOI 10.1073/pnas.080508097; Benning MM, 1998, J BIOL CHEM, V273, P33572, DOI 10.1074/jbc.273.50.33572; BERGE RK, 1987, BIOCHIM BIOPHYS ACTA, V918, P60, DOI 10.1016/0005-2760(87)90009-9; BERGE RK, 1981, FEBS LETT, V124, P43, DOI 10.1016/0014-5793(81)80050-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Branstrom R, 1998, J BIOL CHEM, V273, P31395, DOI 10.1074/jbc.273.47.31395; CZUBA B, 1986, J BIOL CHEM, V261, P6260; CZUBA B, 1980, J BIOL CHEM, V255, P5296; Das AK, 2000, J BIOL CHEM, V275, P23847, DOI 10.1074/jbc.M002758200; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; Elholm M, 2001, J BIOL CHEM, V276, P21410, DOI 10.1074/jbc.M101073200; Faergeman N J, 2000, Subcell Biochem, V34, P175; Faergeman NJ, 1997, BIOCHEM J, V323, P1; FALANY CN, 1994, J BIOL CHEM, V269, P19375; Falany CN, 1997, J LIPID RES, V38, P1139; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Hunt MC, 2000, J LIPID RES, V41, P814; HUNT MC, 2001, IN PRESS PROG LIPID; KAWASHIMA Y, 1982, BIOCHIM BIOPHYS ACTA, V712, P48; KELLEY M, 1993, J BIOCHEM TOXICOL, V8, P63, DOI 10.1002/jbt.2570080203; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; LAWSON DM, 1994, BIOCHEMISTRY-US, V33, P9382, DOI 10.1021/bi00198a003; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; Li J, 2000, NAT STRUCT BIOL, V7, P555; Li J, 1996, BIOCHEMISTRY-US, V35, P9967, DOI 10.1021/bi9605292; LIN CY, 1978, J BIOL CHEM, V253, P1954; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; MIKKELSEN J, 1987, J BIOL CHEM, V262, P1570; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; MIYAZAWA S, 1981, EUR J BIOCHEM, V117, P425, DOI 10.1111/j.1432-1033.1981.tb06356.x; Murakami K, 2001, BIOCHEM J, V353, P231, DOI 10.1042/0264-6021:3530231; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PAZIRANDEH M, 1991, J BIOL CHEM, V266, P20946; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; Svensson LT, 1998, BIOCHEM J, V329, P601, DOI 10.1042/bj3290601; TAI MH, 1993, P NATL ACAD SCI USA, V90, P1852, DOI 10.1073/pnas.90.5.1852; WAKU K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P101, DOI 10.1016/0005-2760(92)90085-A; WILCKE M, 1994, EUR J BIOCHEM, V222, P803, DOI 10.1111/j.1432-1033.1994.tb18927.x; WITKOWSKI A, 1994, J BIOL CHEM, V269, P379; WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514; WITKOWSKI A, 1992, J BIOL CHEM, V267, P18488; Wolfrum C, 2000, BIOCHEMISTRY-US, V39, P1469, DOI 10.1021/bi991638u; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; YAMADA J, 1994, ARCH BIOCHEM BIOPHYS, V308, P118, DOI 10.1006/abbi.1994.1017; Yamada J, 1997, BIOCHEM BIOPH RES CO, V232, P198, DOI 10.1006/bbrc.1997.6246	56	48	52	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3424	3432		10.1074/jbc.M109040200	http://dx.doi.org/10.1074/jbc.M109040200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11694534	hybrid			2022-12-25	WOS:000173688000050
J	Cuellar-Mata, P; Jabado, N; Liu, J; Furuya, W; Finlay, BB; Gros, P; Grinstein, S				Cuellar-Mata, P; Jabado, N; Liu, J; Furuya, W; Finlay, BB; Gros, P; Grinstein, S			Nramp1 modifies the fusion of Salmonella typhimurium-containing vacuoles with cellular endomembranes in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III SECRETION SYSTEM; MANNOSE 6-PHOSPHATE RECEPTOR; PATHOGENICITY ISLAND 2; NATURAL-RESISTANCE; INTRACELLULAR PARASITES; LYSOSOMAL MEMBRANE; MURINE MACROPHAGES; EPITHELIAL-CELLS; HOST-CELLS; LOCUS	Salmonella survive and replicate within mammalian cells by becoming secluded within specialized membrane-bound vacuoles inaccessible to the host defense mechanisms. Delayed acidification of the vacuole and its incomplete fusion with lysosomes have been implicated in intracellular Salmonella survival. Nramp1 confers to macrophages resistance to a variety of intracellular pathogens, including Salmonella, but its precise mode of action is not understood. We investigated whether Nramp1 affects the maturation and acidification of Salmonella-containing vacuoles (SCV). A mouse-derived macrophage line (RAW/Nramp1(-)) devoid of Nramp1 and therefore susceptible to infection was compared with isogenic clones stably transfected with Nramp1 (RAW/Nramp1(+)). Intravacuolar pH, measured in situ, was similar in Nramp1-expressing and -deficient cells. SCV acquired LAMP1 and fused with preloaded fluid-phase markers in both cell types. In contrast, although few vacuoles in RAW/Nramp1(-) acquired mannose 6-phosphate receptor, many more contained M6PR in RAW/Nramp1(+) cells. Shortly after closure, SCV in RAW/Nramp1(-) became inaccessible to extracellular markers, suggesting inability to fuse with newly formed endosomes. Expression of Nramp1 markedly increased the access to extracellularly added markers. We propose that Nramp1 counteracts the ability of Salmonella to become secluded in a compartment that limits access of bactericidal agents, allowing the normal degradative pathway of the macrophage to proceed.	Hosp Sick Children, Div Cell Biol, Toronto, ON M5G 1X8, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; University of Toronto; University of British Columbia	Grinstein, S (corresponding author), Hosp Sick Children, Div Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.on.ca	Jabado, Nada/AAN-4026-2020; Liu, Jun/AAC-9209-2019	Liu, Jun/0000-0002-0522-6733	NIAID NIH HHS [AI-35237] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI035237, R01AI035237] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agranoff D, 1999, J EXP MED, V190, P717, DOI 10.1084/jem.190.5.717; ARANDA CMA, 1992, P NATL ACAD SCI USA, V89, P10079, DOI 10.1073/pnas.89.21.10079; Bearson BL, 1998, J BACTERIOL, V180, P2409, DOI 10.1128/JB.180.9.2409-2417.1998; BlancPotard AB, 1997, EMBO J, V16, P5376, DOI 10.1093/emboj/16.17.5376; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; Cirillo DM, 1998, MOL MICROBIOL, V30, P175, DOI 10.1046/j.1365-2958.1998.01048.x; COLLAZO CM, 1995, MOL MICROBIOL, V15, P25, DOI 10.1111/j.1365-2958.1995.tb02218.x; Coppolino MG, 2001, J BIOL CHEM, V276, P4772, DOI 10.1074/jbc.M007792200; Demaurex N, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 3, P380; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; GARCIADELPORTILLO F, 1995, J CELL BIOL, V129, P81, DOI 10.1083/jcb.129.1.81; Govoni G, 1998, INFLAMM RES, V47, P277, DOI 10.1007/s000110050330; Govoni G, 1999, INFECT IMMUN, V67, P2225, DOI 10.1128/IAI.67.5.2225-2232.1999; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRIFFITHS G, 1990, J CELL SCI, V95, P441; Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hashim S, 2000, J BIOL CHEM, V275, P16281, DOI 10.1074/jbc.275.21.16281; Hensel M, 1998, MOL MICROBIOL, V30, P163, DOI 10.1046/j.1365-2958.1998.01047.x; Hong KH, 1998, J BACTERIOL, V180, P1793, DOI 10.1128/JB.180.7.1793-1802.1998; Jabado N, 2000, J EXP MED, V192, P1237, DOI 10.1084/jem.192.9.1237; Kehres DG, 2000, MOL MICROBIOL, V36, P1085, DOI 10.1046/j.1365-2958.2000.01922.x; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; MALUI H, 2000, MOL MICROBIOL, V35, P1065; Meresse S, 1999, EMBO J, V18, P4394, DOI 10.1093/emboj/18.16.4394; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; PANG T, 1995, TRENDS MICROBIOL, V3, P253, DOI 10.1016/S0966-842X(00)88937-4; Pfeifer CG, 1999, INFECT IMMUN, V67, P5690, DOI 10.1128/IAI.67.11.5690-5698.1999; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; Rathman M, 1996, INFECT IMMUN, V64, P2765, DOI 10.1128/IAI.64.7.2765-2773.1996; Rathman M, 1997, INFECT IMMUN, V65, P1475, DOI 10.1128/IAI.65.4.1475-1485.1997; Searle S, 1998, J CELL SCI, V111, P2855; Shea JE, 1996, P NATL ACAD SCI USA, V93, P2593, DOI 10.1073/pnas.93.6.2593; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Valdivia RH, 1996, GENE, V173, P47, DOI 10.1016/0378-1119(95)00706-7; VIDAL S, 1995, J LEUKOCYTE BIOL, V58, P382, DOI 10.1002/jlb.58.4.382; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D	41	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2258	2265		10.1074/jbc.M105508200	http://dx.doi.org/10.1074/jbc.M105508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11700301	hybrid			2022-12-25	WOS:000173421300086
J	Arion, D; Sluis-Cremer, N; Min, KL; Abram, ME; Fletcher, RS; Parniak, MA				Arion, D; Sluis-Cremer, N; Min, KL; Abram, ME; Fletcher, RS; Parniak, MA			Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase - Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANGSTROM RESOLUTION; DNA-POLYMERASE; AZIDOTHYMIDYLATE; RESISTANCE; HYDRAZONE; COMPLEX	N-(4-tert-Butylbenzoyl)-2-hydroxynaphthaidehyde hydrazone (BBNH) is a potent inhibitor of the ribonuclease H (RNase H) activity of human immunodeficiency virus (HIV)-1 reverse transcriptase (RT). Molecular modeling predicted that BBNH binds to the HIV-1 RT RNase H active site via two major interactions, coordination to the metal ion cofactor (Mg2+ or Mn2+) in the enzyme active site and aromatic ring-stacking interaction between the naphthyl ring of BBNH and amino acid Tyr-501. The latter residue equivalent is conserved in virtually all RNases H, suggesting the need for an aromatic or pi-stacking interaction in this region. To assess the importance of Tyr-501 in the binding of BBNH for the inhibition of RT RNase H activity, we used site-specific mutagenesis to generate RT with a variety of substitutions at this position. Most substitutions resulted virtually in a complete loss of RNase H activity. However, three mutants, Y501F, Y501W, and Y501R, possessed RNase H activities comparable with wild-type enzyme. Whereas BBNH inhibited Y501F RT RNase H activity with potency equivalent to wild-type RT, the Y501W mutant showed a 6-fold resistance to inhibition by BBNH, and the Y501R mutant was completely resistant to inhibition by BBNH. The replication "fitness" of HIV molecular clones with the Y501W or Y510R mutation was significantly compromised compared with wild-type virus. Importantly, BBNH was an effective inhibitor of the DNA polymerase activity of all Y501X mutants tested. Our results highlight the importance of Tyr-501 in RT RNase H activity and in N-acylhydrazone inhibitor binding and suggest that drugs that target critical residues in HIV-1 proteins may be a useful approach in new antiviral development.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Sir Mortimer B Davis Jewish Hosp, AIDS Ctr, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University	Parniak, MA (corresponding author), Univ Pittsburgh, Dept Med, Div Infect Dis, Scaife Hall Rm S818D,3550 Terrace St, Pittsburgh, PA 15261 USA.	parniakm@msx.dept-med.pitt.edu	Abram, Michael E/AEY-5248-2022	Abram, Michael E/0000-0002-6505-7281				ARTS EJ, 1994, J BIOL CHEM, V269, P14672; BAKER E, 1992, HEPATOLOGY, V15, P492, DOI 10.1002/hep.1840150323; Borkow G, 1997, BIOCHEMISTRY-US, V36, P3179, DOI 10.1021/bi9624696; Buckheit RW, 1999, ANTIVIR CHEM CHEMOTH, V10, P23, DOI 10.1177/095632029901000103; Crouch RJ, 1998, RESEARCH IN, P79; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; EDWARD JT, 1988, J CHEM ENG DATA, V33, P538, DOI 10.1021/je00054a044; FISHER AG, 1985, NATURE, V316, P262, DOI 10.1038/316262a0; Fletcher RS, 1996, PROTEIN EXPRES PURIF, V7, P27, DOI 10.1006/prep.1996.0004; Gabbara S, 1999, BIOCHEMISTRY-US, V38, P13070, DOI 10.1021/bi991085n; GOPALAKRISHNAN V, 1994, J BIOL CHEM, V269, P4110; Hnatyszyn O, 1999, PHYTOTHER RES, V13, P206, DOI 10.1002/(SICI)1099-1573(199905)13:3&lt;206::AID-PTR409&gt;3.0.CO;2-D; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lanthier CM, 1997, BIOORG MED CHEM LETT, V7, P1557, DOI 10.1016/S0960-894X(97)00267-9; Loya S, 1997, J VIROL, V71, P5668, DOI 10.1128/JVI.71.7.5668-5672.1997; LOYA S, 1990, ANTIMICROB AGENTS CH, V34, P2009, DOI 10.1128/AAC.34.10.2009; Min BS, 2000, CHEM PHARM BULL, V48, P194, DOI 10.1248/cpb.48.194; Mizuguchi K, 1998, PROTEIN SCI, V7, P2469, DOI 10.1002/pro.5560071126; MOHAN P, 1994, J MED CHEM, V37, P2513, DOI 10.1021/jm00042a004; Parniak M A, 2000, Adv Pharmacol, V49, P67; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sluis-Cremer N, 2000, CELL MOL LIFE SCI, V57, P1408, DOI 10.1007/PL00000626; TAN CK, 1991, BIOCHEMISTRY-US, V30, P4831, DOI 10.1021/bi00234a001; ZHAN XY, 1994, BIOCHEMISTRY-US, V33, P1366, DOI 10.1021/bi00172a012	25	44	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1370	1374		10.1074/jbc.M110254200	http://dx.doi.org/10.1074/jbc.M110254200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11684697	hybrid			2022-12-25	WOS:000173166800066
J	Hu, LA; Chen, W; Premont, RT; Cong, M; Lefkowitz, RJ				Hu, LA; Chen, W; Premont, RT; Cong, M; Lefkowitz, RJ			G protein-coupled receptor kinase 5 regulates beta 1-adrenergic receptor association with PSD-95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ-DOMAIN; BETA(2)-ADRENERGIC RECEPTOR; BETA(1)-ADRENERGIC RECEPTOR; INTERACTING PROTEIN; GUANYLATE KINASES; C-TERMINUS; PHOSPHORYLATION; BINDING; FAMILY; DESENSITIZATION	We previously reported that the beta(1)-adrenergic receptor (beta(1)AR) associates with PSD-95 through a PDZ domain-mediated interaction, by which PSD-95 modulates beta(1)AR function and facilitates the physical association of beta(1)AR with other synaptic proteins such as N-methyl-D-aspartate receptors. Here we demonstrate that beta(1)AR association with PSD-95 is regulated by G protein-coupled receptor kinase 5 (GRK5). When beta(1)AR and PSD-95 were coexpressed with either GRK2 or GRK5 in COS-7 cells, GRK5 alone dramatically decreased the association of beta(1)AR with PSD-95, although GRK2 and GRK5 both could be co-immunoprecipitated with beta(1)AR and both could enhance receptor phosphorylation in vivo. Increasing expression of GRK5 in the cells led to further decreased beta(1)AR association with PSD-95. Stimulation with the PAR agonist isoproterenol further decreased PSD-95 binding to beta(1)AR. In addition, GRK5 protein kinase activity was required for this regulatory effect since a kinase-inactive GRK5 mutant had no effect on PSD-95 binding to beta(1)AR. Moreover, the regulatory effect of GRK5 on beta(1)AR association with PSD-95 was observed only when GRK5 was expressed together with the receptor, but not when GRK5 was coexpressed with PSD-95. Thus, we propose that GRK5 regulates beta(1)AR association with PSD-95 through phosphorylation of beta(1)AR. Regulation of protein association through receptor phosphorylation may be a general mechanism used by G protein-coupled receptors that associate via PDZ domain-mediated protein/protein interactions.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, POB 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021	Chen, Wei/0000-0002-9934-4000; Premont, Richard/0000-0002-8053-5026	NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adey NB, 2000, CANCER RES, V60, P35; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; Chung HJ, 2000, J NEUROSCI, V20, P7258; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Cong M, 2001, J BIOL CHEM, V276, P15192, DOI 10.1074/jbc.M009130200; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dev KK, 2000, J NEUROSCI, V20, P7252; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; KIM CM, 1993, RECEPTOR, V3, P39; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; Kreienkamp HJ, 2000, J PHYSIOLOGY-PARIS, V94, P193, DOI 10.1016/S0928-4257(00)00204-7; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Leonoudakis D, 2001, J CELL SCI, V114, P987; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Matsuda S, 1999, J NEUROCHEM, V73, P1765, DOI 10.1046/j.1471-4159.1999.731765.x; Niethammer M, 1996, J NEUROSCI, V16, P2157; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Zitzer H, 1999, J BIOL CHEM, V274, P18153, DOI 10.1074/jbc.274.26.18153; Zitzer H, 1999, J BIOL CHEM, V274, P32997, DOI 10.1074/jbc.274.46.32997	41	43	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1607	1613		10.1074/jbc.M107297200	http://dx.doi.org/10.1074/jbc.M107297200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11700307	hybrid			2022-12-25	WOS:000173166800096
J	Feurle, J; Espinosa, E; Eckstein, S; Pont, F; Kunzmann, V; Fournie, JJ; Herderich, M; Wilhelm, M				Feurle, J; Espinosa, E; Eckstein, S; Pont, F; Kunzmann, V; Fournie, JJ; Herderich, M; Wilhelm, M			Escherichia coli produces phosphoantigens activating human gamma delta T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-MEVALONATE PATHWAY; 2-C-METHYL-D-ERYTHRITOL 4-PHOSPHATE; 1-DEOXY-D-XYLULOSE 5-PHOSPHATE; ISOPRENOID BIOSYNTHESIS; ANTIGENS; NANOELECTROSPRAY; STIMULATION; EXPANSION; PROTEIN; ROUTES	Human Vgamma9delta2 T lymphocytes are suggested to play an important role in the immune response to various microbial pathogens. In contrast to alphabeta T cells, gammadelta T lymphocytes recognize small, non-protein, phosphate-bearing antigens (phosphoantigens) in a major histocompatibility complex-independent manner. Four different phosphoantigens termed TUBag1 to TUBag4 with a common 3-formyl-1-butyl-pyrophosphate moiety and isopentenyl-pyrophosphate have been isolated and identified from mycobacteria. However, natural occurring gammadelta T cell ligands from other bacterial species were not characterized so far. Here, we describe the structural identification of the two compounds responsible for the gammadelta T cell-stimulating capacity of Escherichia coli as similar to the mycobacterial phosphoantigens 3-formyl-1-butylpyrophosphate and its M-r 275 homologue TUBag2. In addition, E. coli phosphoantigens exert bioactivities on gammadelta T cells with similar potencies to the mycobacterial phosphoantigens at 5-15 nm concentration. Furthermore, our results clearly prove that the deoxyxylulose 5-phophate pathway (also referred to as Rohmer metabolic route of isoprenoid biosynthesis) is essential for the biosynthesis of the phosphoantigens in E. coli. Because this pathway is absent from human cells, it proves an ideal target for focusing efficiently the antimicrobial selectivity of human gammadelta T lymphocytes.	Univ Wurzburg, Med Poliklin, D-97070 Wurzburg, Germany; CHU Purpan, INSERM U395, F-31024 Toulouse, France; CHU Purpan, IFR Claude de Preval, F-31024 Toulouse, France; Univ Wurzburg, Lehrstuhl Lebensmittelchem, D-97074 Wurzburg, Germany	University of Wurzburg; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; University of Wurzburg	Wilhelm, M (corresponding author), Univ Wurzburg, Med Poliklin, Klin Str 6-8, D-97070 Wurzburg, Germany.	wilhelm@medizin.uni-wuerzburg.de	Wilhelm, Martin/J-3964-2014; Fournie, Jean-Jacques/J-7805-2013; espinosa, eric/E-4872-2013; PONT, Frédéric/G-6289-2011	Fournie, Jean-Jacques/0000-0001-6542-6908; espinosa, eric/0000-0002-3512-0921; PONT, Frédéric/0000-0002-5493-527X				Altincicek B, 2001, J IMMUNOL, V166, P3655, DOI 10.4049/jimmunol.166.6.3655; Behr C, 1996, INFECT IMMUN, V64, P2892, DOI 10.1128/IAI.64.8.2892-2896.1996; Belman C, 1999, J BIOL CHEM, V274, P32079, DOI 10.1074/jbc.274.45.32079; Bukowski JF, 1999, IMMUNITY, V11, P57, DOI 10.1016/S1074-7613(00)80081-3; BURK MR, 1995, EUR J IMMUNOL, V25, P2052, DOI 10.1002/eji.1830250737; Cane DE, 1998, J AM CHEM SOC, V120, P1936, DOI 10.1021/ja9742085; CONSTANT P, 1995, INFECT IMMUN, V63, P4628, DOI 10.1128/IAI.63.12.4628-4633.1995; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; COOKS RG, 1991, CHEM ENG NEWS, V69, P26, DOI 10.1021/cen-v069n012.p026; Duvold T, 1997, TETRAHEDRON LETT, V38, P6181, DOI 10.1016/S0040-4039(97)01392-0; Eisenreich W, 1998, CHEM BIOL, V5, pR221, DOI 10.1016/S1074-5521(98)90002-3; Espinosa E, 2001, MICROBES INFECT, V3, P645, DOI 10.1016/S1286-4579(01)01420-4; Feurle J, 1998, J CHROMATOGR A, V803, P111, DOI 10.1016/S0021-9673(97)01214-4; Fischer S, 1996, IMMUNOL LETT, V52, P69, DOI 10.1016/0165-2478(96)02584-9; Fischer S, 1997, ANTI-CANCER DRUG, V8, pS33, DOI 10.1097/00001813-199704001-00008; HEMMI K, 1982, CHEM PHARM BULL, V30, P111; Herz S, 2000, P NATL ACAD SCI USA, V97, P2486, DOI 10.1073/pnas.040554697; Jomaa H, 1999, FEMS IMMUNOL MED MIC, V25, P371, DOI 10.1111/j.1574-695X.1999.tb01362.x; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Jonscher KR, 1997, ANAL BIOCHEM, V244, P1, DOI 10.1006/abio.1996.9877; Juraschek R, 1999, J AM SOC MASS SPECTR, V10, P300, DOI 10.1016/S1044-0305(98)00157-3; Kunzmann V, 2000, BLOOD, V96, P384; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P4509, DOI 10.1016/S0040-4039(98)00802-8; March RE, 1997, J MASS SPECTROM, V32, P351, DOI 10.1002/(SICI)1096-9888(199704)32:4<351::AID-JMS512>3.3.CO;2-P; Morita CT, 2000, SPRINGER SEMIN IMMUN, V22, P191, DOI 10.1007/s002810000042; OHLER E, 1995, SYNTHESIS-STUTTGART, V5, P539; Ottones F, 2000, IMMUNOLOGY, V100, P252, DOI 10.1046/j.1365-2567.2000.00024.x; Poquet Y, 1996, EUR J IMMUNOL, V26, P2344, DOI 10.1002/eji.1830261011; Poquet Y, 1998, INFECT IMMUN, V66, P2107, DOI 10.1128/IAI.66.5.2107-2114.1998; Poquet Y, 1996, ANAL BIOCHEM, V243, P119, DOI 10.1006/abio.1996.0489; Putra SR, 1998, FEMS MICROBIOL LETT, V164, P169; Rohdich F, 1999, P NATL ACAD SCI USA, V96, P11758, DOI 10.1073/pnas.96.21.11758; Rohmer M, 1996, J AM CHEM SOC, V118, P2564, DOI 10.1021/ja9538344; Sicard H, 2000, INFECT IMMUN, V68, P4375, DOI 10.1128/IAI.68.8.4375-4377.2000; Spenser I.D., 1997, ANGEW CHEM, V109, P1096; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; WILHELM M, 1994, SCAND J IMMUNOL, V40, P521, DOI 10.1111/j.1365-3083.1994.tb03499.x; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	38	42	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					148	154		10.1074/jbc.M106443200	http://dx.doi.org/10.1074/jbc.M106443200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11675382	hybrid			2022-12-25	WOS:000173087900021
J	Li, J; Lee, JM; Johnson, JA				Li, J; Lee, JM; Johnson, JA			Microarray analysis reveals an antioxidant responsive element-driven gene set involved in conferring protection from an oxidative stress-induced apoptosis in IMR-32 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE TOXICITY; HUMAN FIBROBLASTS; CYTOCHROME-C; INDUCTION; ACTIVATION; NRF2; ENZYMES; LINE	The present study was designed to investigate how tert-butylhydroquinone (tBHQ) prevents hydrogen peroxide-induced apoptosis in IMR-32 cells. tBHQ pretreatment (10 mum) attenuated hydrogen peroxide-induced cell death and reduced the number of TUNEL (terminal deoxynucleotidyltransferase-mediated, dUTP-incorporated nick end labeling)-positive cells. We hypothesize that tBHQ-mediated activation of the antioxidant responsive element is critical for generating this protective response. Addition of LY294002, a selective inhibitor of phosphatidylinositol 3-kinase (PI3K), 30 min prior to tBHQ treatment completely reversed the protective effect of tBHQ. Oligonucleotide microarrays were used to analyze the gene expression profile associated with tBHQ treatment in the absence and presence of LY294002. Ranking analysis using Affymetrix's difference call indicated that the expression of 137 genes changed with tBHQ treatment. Further analysis using the coefficient of variation for -fold change or average difference change reduced the list to 63 increased and 0 decreased genes. Reverse transcription-PCR for selected genes also confirmed the gene expression pattern. Many of these genes function to combat oxidative stress and increase the detoxification potential of the cells. Inhibition of PI3K significantly blocked the enhanced expression of 49 of the 63 genes induced by tBHQ. These data are the first to show a set of programmed cell life genes involved in conferring protection from an oxidative stress-induced apoptosis.	Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; Univ Wisconsin, Ctr Environm Toxicol, Madison, WI 53706 USA; Univ Wisconsin, Waisman Ctr, Madison, WI 53706 USA; Univ Wisconsin, Ctr Neurosci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Johnson, JA (corresponding author), Univ Wisconsin, Sch Pharm, 6125 Rennebohm Hall,777 Highland Ave, Madison, WI 53706 USA.			Li, Jiang/0000-0002-7006-1285	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010042, P30ES009090, R01ES008089, R29ES008089] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES09090, ES10042, ES08089] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bratton SB, 2001, TRENDS PHARMACOL SCI, V22, P306, DOI 10.1016/S0165-6147(00)01718-1; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Duffy S, 1998, J NEUROCHEM, V71, P69; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Grubb DR, 2001, ONCOGENE, V20, P4085, DOI 10.1038/sj.onc.1204545; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; Lee MH, 2001, J NEUROCHEM, V78, P32, DOI 10.1046/j.1471-4159.2001.00416.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; MURPHY TH, 1991, J NEUROCHEM, V56, P990, DOI 10.1111/j.1471-4159.1991.tb02019.x; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Peiro C, 2001, BRIT J PHARMACOL, V133, P967, DOI 10.1038/sj.bjp.0704184; Qin FZ, 2001, CARDIOVASC RES, V51, P736, DOI 10.1016/S0008-6363(01)00323-6; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; Su JYC, 1999, NEUROSCI LETT, V273, P109, DOI 10.1016/S0304-3940(99)00634-5; Sugano N, 1999, FEBS LETT, V447, P274, DOI 10.1016/S0014-5793(99)00312-9; Tretter L, 2000, J NEUROSCI, V20, P8972; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	29	157	166	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					388	394		10.1074/jbc.M109380200	http://dx.doi.org/10.1074/jbc.M109380200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11687587	hybrid			2022-12-25	WOS:000173087900052
J	Cardozo, AK; Heimberg, H; Heremans, Y; Leeman, R; Kutlu, B; Kruhoffer, M; Orntoft, T; Eizirik, DL				Cardozo, AK; Heimberg, H; Heremans, Y; Leeman, R; Kutlu, B; Kruhoffer, M; Orntoft, T; Eizirik, DL			A comprehensive analysis of cytokine-induced and nuclear factor-kappa B-dependent genes in primary rat pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-MEDIATED EXPRESSION; MESSENGER-RNA EXPRESSION; NITRIC-OXIDE SYNTHASE; REGULATORY FACTOR-I; C-MYC EXPRESSION; SUPER-REPRESSOR; TRANSGENIC MICE; TARGET GENES; APOPTOSIS; TRANSCRIPTION	Type I diabetes mellitus results from an autoimmune destruction of pancreatic beta-cells. Cytokines, such as interleukin-1beta and interferon-gamma, are putative mediators of immune-induced beta-cell death and, under in vitro conditions, cause beta-cell apoptosis. We have recently shown that interleukin-1beta + interferon-gamma modifies the expression of >200 genes in beta-cells. Several of these genes are putative targets for the transcription factor nuclear factor-kappaB (NF-kappaB), and in subsequent experiments we showed that NF-kappaB activation is mostly pro-apoptotic in beta-cells. To identify cytokine-induced and NF-kappaB-regulated genes in primary rat beta-cells, we presently combined two experimental approaches: 1) blocking of NF-kappaB activation in cytokine-exposed beta-cells by a recombinant adenovirus (AdIkappaB((SA)2)) containing an inhibitor of NF-kappaB a(IkappaBac) super-repressor (S32A/S36A) and 2) study of gene expression by microarray analysis. We identified 66 cytokine-modified and NF-kappaB-regulated genes in beta-cells. Cytokine-induced NF-kappaB activation de. creased Pdx-1 and increased c-Myc expression. This, together with NF-kappaB-dependent inhibition of Glut-2, prohormone convertase-1, and lsl-1 expression, probably contributes to the loss of differentiated beta-cell functions. NF-kappaB also regulates several genes encoding for chemokines and cytokines in beta-cells. The present data suggest that NF-kappaB is a key "switch regulator" of transcription factors and gene networks controlling cytokine-induced beta-cell dysfunction and death.	Free Univ Brussels, Gene Express Unit, Diabet Res Ctr, B-1090 Brussels, Belgium; Aarhus Univ Hosp, Dept Clin Biochem, Mol Diagnost Lab, DK-8200 Aarhus N, Denmark	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Aarhus University	Eizirik, DL (corresponding author), Free Univ Brussels, Gene Express Unit, Diabet Res Ctr, Laarbeeklaan 103, B-1090 Brussels, Belgium.	deizirik@mebo.vub.ac.be		Heimberg, Harry/0000-0003-1954-7375; Kupper Cardozo, Alessandra/0000-0001-7143-3696				Baeza N, 2001, DIABETES, V50, pS36, DOI 10.2337/diabetes.50.2007.S36; Baker MS, 2001, J SURG RES, V97, P117, DOI 10.1006/jsre.2001.6121; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Cardozo AK, 2001, DIABETES, V50, P909, DOI 10.2337/diabetes.50.5.909; Chen MC, 1999, DIABETOLOGIA, V42, P1199, DOI 10.1007/s001250051292; Chen MC, 2000, ENDOCRINOLOGY, V141, P2822, DOI 10.1210/en.141.8.2822; Chen MC, 2001, DIABETOLOGIA, V44, P325, DOI 10.1007/s001250051622; Cottet S, 2001, J BIOL CHEM, V276, P25862, DOI 10.1074/jbc.M103235200; Darville MI, 2001, DIABETES, V50, P1741, DOI 10.2337/diabetes.50.8.1741; Darville MI, 1998, DIABETOLOGIA, V41, P1101, DOI 10.1007/s001250051036; Darville MI, 2000, ENDOCRINOLOGY, V141, P153, DOI 10.1210/en.141.1.153; Delaney CA, 1997, ENDOCRINOLOGY, V138, P2610, DOI 10.1210/en.138.6.2610; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Edlund H, 2001, DIABETOLOGIA, V44, P1071, DOI 10.1007/s001250100623; EIZIRIK DL, 1993, DIABETES, V42, P738, DOI 10.2337/diabetes.42.5.738; Eizirik DL, 2001, DIABETOLOGIA, V44, P2115, DOI 10.1007/s001250100021; Eizirik DL, 2001, DIABETES, V50, pS64, DOI 10.2337/diabetes.50.2007.S64; Eizirik DL, 1996, DIABETOLOGIA, V39, P875; Eizirik DL, 1997, DIABETES METAB REV, V13, P293, DOI 10.1002/(SICI)1099-0895(199712)13:4<293::AID-DMR195>3.0.CO;2-4; Flodstrom M, 1997, ENDOCRINOLOGY, V138, P2747, DOI 10.1210/en.138.7.2747; Flodstrom M, 1999, CYTOKINE, V11, P400, DOI 10.1006/cyto.1998.0446; Giannoukakis N, 2000, J BIOL CHEM, V275, P36509, DOI 10.1074/jbc.M005943200; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gysemans CA, 2001, DIABETOLOGIA, V44, P567, DOI 10.1007/s001250051662; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heimberg H, 2001, DIABETES, V50, P2219, DOI 10.2337/diabetes.50.10.2219; Heitmeier MR, 1999, J BIOL CHEM, V274, P29266, DOI 10.1074/jbc.274.41.29266; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Hoorens A, 2001, DIABETES, V50, P551, DOI 10.2337/diabetes.50.3.551; Hostens K, 1999, J CLIN INVEST, V104, P67, DOI 10.1172/JCI6438; Jobin C, 1998, J IMMUNOL, V160, P410; John NE, 2000, DIABETES, V49, P1819, DOI 10.2337/diabetes.49.11.1819; Jonas JC, 2001, J BIOL CHEM, V276, P35375, DOI 10.1074/jbc.M105020200; Kaneto H, 2001, DIABETES, V50, pA80; Li J, 2001, J BIOL CHEM, V276, P18579, DOI 10.1074/jbc.M100846200; LING Z, 1994, DIABETOLOGIA, V37, P15; Ling ZD, 1998, ENDOCRINOLOGY, V139, P1540, DOI 10.1210/en.139.4.1540; Ling ZD, 2000, DIABETES, V49, P340, DOI 10.2337/diabetes.49.3.340; Liu DB, 2000, DIABETES, V49, P1116, DOI 10.2337/diabetes.49.7.1116; Liu DB, 2001, ENDOCRINOLOGY, V142, P2593, DOI 10.1210/en.142.6.2593; Lottmann H, 2001, J MOL MED-JMM, V79, P321, DOI 10.1007/s001090100229; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pavlovic D, 1999, EUR CYTOKINE NETW, V10, P403; Pelengaris S, 2000, CURR OPIN GENET DEV, V10, P100, DOI 10.1016/S0959-437X(99)00046-5; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; Quan N, 2001, FASEB J, V15, P1616, DOI 10.1096/fj.00-0855fje; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.0.CO;2-V; Schranz DB, 1998, DIABETES METAB REV, V14, P3, DOI 10.1002/(SICI)1099-0895(199803)14:1<3::AID-DMR206>3.0.CO;2-T; Sundstrom JB, 2001, J VIROL, V75, P6070, DOI 10.1128/JVI.75.13.6070-6085.2001; Thomas MK, 2001, J CLIN INVEST, V108, P319, DOI 10.1172/JCI200112029; Varadi A, 1996, BIOCHEM J, V319, P521, DOI 10.1042/bj3190521; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Zhou YP, 1998, J CLIN INVEST, V101, P1623, DOI 10.1172/JCI1245	60	257	269	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48879	48886		10.1074/jbc.M108658200	http://dx.doi.org/10.1074/jbc.M108658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11687580	hybrid			2022-12-25	WOS:000173922100035
J	Lee, SJ; Richardson, CC				Lee, SJ; Richardson, CC			Essential lysine residues in the RNA polymerase domain of the gene 4 primase-helicase of bacteriophage T7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PRIMASE; LAGGING-STRAND SYNTHESIS; NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; ACID REPLICATION INVITRO; NUCLEOTIDE-BINDING SITE; DNA PRIMASE; TEMPLATE RECOGNITION; CRYSTAL-STRUCTURE; DEOXYRIBONUCLEIC-ACID; PRIMER SYNTHESIS	At a replication fork DNA primase synthesizes oligoribonucleotides that serve as primers for the lagging strand DNA polymerase. In the bacteriophage T7 replication system, DNA primase is encoded by gene 4 of the phage. The 63-kDa gene 4 protein is composed of two major domains, a helicase domain and a primase domain located in the C- and N-terminal halves of the protein, respectively. T7 DNA primase recognizes the sequence 5'-NNGTC-3' via a zinc motif and catalyzes the template-directed synthesis of tetraribonucleotides pppACNN. T7 DNA primase, like other primases, shares limited homology with DNA-dependent RNA polymerases. To identify the catalytic core of the T7 DNA primase, single-point mutations were introduced into a basic region that shares sequence homology with RNA polymerases. The genetically altered gene 4 proteins were examined for their ability to support phage growth, to synthesize functional primers, and to recognize primase recognition sites. Two lysine residues, Lys-122 and Lys-128, are essential for phage growth. The two residues play a key role in the synthesis of phosphodiester bonds but are not involved in other activities mediated by the protein. The altered primases are unable to either synthesize or extend an oligoribonucleotide. However, the altered primases do recognize the primase recognition sequence, anneal an exogenous primer 5'-ACCC-3' at the site, and transfer the primer to T7 DNA polymerase. Other lysines in the vicinity are not essential for the synthesis of primers.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054397] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54397] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; Bird LE, 1997, NUCLEIC ACIDS RES, V25, P2620, DOI 10.1093/nar/25.13.2620; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; CHA TA, 1986, J BIOL CHEM, V261, P7001; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Chowdhury K, 2000, P NATL ACAD SCI USA, V97, P12469, DOI 10.1073/pnas.230448397; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; DRACHEVA S, 1995, J BIOL CHEM, V270, P14148, DOI 10.1074/jbc.270.23.14148; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Frick DN, 1999, J BIOL CHEM, V274, P35889, DOI 10.1074/jbc.274.50.35889; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; Frick DN, 1999, J BIOL CHEM, V274, P35899, DOI 10.1074/jbc.274.50.35899; Frick DN, 2001, ANNU REV BIOCHEM, V70, P39, DOI 10.1146/annurev.biochem.70.1.39; Godson GN, 2000, BIOCHEMISTRY-US, V39, P332, DOI 10.1021/bi9916628; Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303; HIASA H, 1989, GENE, V84, P9, DOI 10.1016/0378-1119(89)90133-9; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; Kato M, 2001, J BIOL CHEM, V276, P21809, DOI 10.1074/jbc.M101470200; Keck JL, 2000, SCIENCE, V287, P2482, DOI 10.1126/science.287.5462.2482; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; Kornberg A., 1992, DNA REPLICATION; Kusakabe T, 1998, EMBO J, V17, P1542, DOI 10.1093/emboj/17.5.1542; Kusakabe T, 1999, P NATL ACAD SCI USA, V96, P4295, DOI 10.1073/pnas.96.8.4295; Kusakabe T, 1997, J BIOL CHEM, V272, P12446, DOI 10.1074/jbc.272.19.12446; Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563; Kusakabe T, 1997, J BIOL CHEM, V272, P5943, DOI 10.1074/jbc.272.9.5943; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MUSTAEV AA, 1995, J BIOL CHEM, V270, P15711, DOI 10.1074/jbc.270.26.15711; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; Pan H, 2000, STRUCTURE, V8, P231, DOI 10.1016/S0969-2126(00)00101-5; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Podobnik M, 2000, J MOL BIOL, V300, P353, DOI 10.1006/jmbi.2000.3844; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; STAMFORD NPJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P17, DOI 10.1016/0167-4781(92)90047-4; STRACK B, 1992, J BIOL CHEM, V267, P13062; Sun WL, 1999, J BACTERIOL, V181, P3761, DOI 10.1128/JB.181.12.3761-3767.1999; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Urban A, 1997, NUCLEIC ACIDS RES, V25, P2227, DOI 10.1093/nar/25.11.2227; VERSALOVIC J, 1993, GENE, V136, P281, DOI 10.1016/0378-1119(93)90480-Q; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054	65	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49419	49426		10.1074/jbc.M108443200	http://dx.doi.org/10.1074/jbc.M108443200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11673465	hybrid			2022-12-25	WOS:000173922100103
J	Thoma, NH; Iakovenko, A; Goody, RS; Alexandrov, K				Thoma, NH; Iakovenko, A; Goody, RS; Alexandrov, K			Phosphoisoprenoids modulate association of Rab geranylgeranyltransferase with REP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX; PROTEINS; TRANSFERASE; GERANYLGERANYLATION; PRENYLATION; MEMBRANES; TOOLS; CELLS	Rab geranylgeranyltransferase (RabGGTase or GGTase-II) catalyzes the post-translational prenylation of Rab proteins. Rab proteins are recognized as substrates only when they are complexed to Rab Escort Protein (REP). The classical model of prenylation complex assembly assumes initial formation of the Rab.REP binary complex, which subsequently binds to RabGGTase loaded with the isoprenoid donor geranylgeranyl pyrophosphate (GGpp). We demonstrate here that REP-1 can also associate with RabGGTase in the absence of Rab protein and that this interaction is dramatically strengthened by the presence of phosphoisoprenoids such as GGpp. The GGpp-dependent interaction between RabGGTase and REP-1 was observed using affinity precipitations and gel filtration and was quantitated on the basis of fluorescence assays. In the presence of GGpp, REP-1 binds to RabGGTase with a K(d) value of similar to10 nM, while in its absence the affinity between the two proteins is in the micromolar range. We further demonstrate that binding of Rab7 to the RabGGTase.GGpp.REP-1 complex occurs without prior dissociation of REP-1. Analysis of binding and prenylation rate constants indicate that the RabGGTase.GGpp.REP-1 complex can function as a kinetically competent intermediate of the prenylation reaction. We conclude that, depending on the prevailing concentrations, binding of REP-1 to RabGGTase in the presence of GGpp may serve as an alternative pathway for the assembly of the prenylation machinery in vivo. Implications of these findings for the role of REP-1 in the prenylation reaction are discussed.	Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Dortmund, Germany	Max Planck Society	Alexandrov, K (corresponding author), Max Planck Inst Mol Physiol, Dept Phys Biochem, Otto Hanh Str 11, D-44227 Dortmund, Germany.	kirill.alexandrov@mpi-dortmund.mpg.de	Alexandrov, Kirill/A-5830-2013; Goody, Roger S/J-8845-2014	Alexandrov, Kirill/0000-0002-0957-6511; Goody, Roger S/0000-0002-0772-0444				ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; Alexandrov K, 1999, EUR J BIOCHEM, V265, P160, DOI 10.1046/j.1432-1327.1999.00699.x; Alexandrov K, 1998, FEBS LETT, V425, P460, DOI 10.1016/S0014-5793(98)00290-7; Alory C, 2000, J CELL BIOL, V150, P89, DOI 10.1083/jcb.150.1.89; Anant JS, 1998, BIOCHEMISTRY-US, V37, P12559, DOI 10.1021/bi980881a; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1995, METHOD ENZYMOL, V257, P30; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; Iakovenko A, 2000, FEBS LETT, V468, P155, DOI 10.1016/S0014-5793(00)01143-1; Owen DJ, 1999, ANGEW CHEM INT EDIT, V38, P509, DOI 10.1002/(SICI)1521-3773(19990215)38:4<509::AID-ANIE509>3.0.CO;2-3; Pereira-Leal JB, 2001, FEBS LETT, V498, P197, DOI 10.1016/S0014-5793(01)02483-8; Simon I, 1996, J BIOL CHEM, V271, P20470, DOI 10.1074/jbc.271.34.20470; SOLDATI T, 1995, METHOD ENZYMOL, V257, P253; Stenmark H, 2001, GENOME BIOL, V2; Thoma NH, 2000, BIOCHEMISTRY-US, V39, P12043, DOI 10.1021/bi000835m; Thoma NH, 2001, BIOCHEMISTRY-US, V40, P268, DOI 10.1021/bi002034p; Wilson AL, 1996, BIOCHEM J, V318, P1007, DOI 10.1042/bj3181007; Zhang H, 2000, STRUCTURE, V8, P241, DOI 10.1016/S0969-2126(00)00102-7	20	28	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48637	48643		10.1074/jbc.M108241200	http://dx.doi.org/10.1074/jbc.M108241200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11675392	hybrid			2022-12-25	WOS:000173922100006
J	Eberhardy, SR; Farnham, PJ				Eberhardy, SR; Farnham, PJ			c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE PROMOTER; NF-KAPPA-B; P-TEFB; HISTONE ACETYLATION; DNA-BINDING; TRANSCRIPTIONAL ELONGATION; GROWTH-REGULATION; GENE-EXPRESSION; TERMINAL DOMAIN; HIP1 BINDING	The c-Myc protein is a site-specific DNA-binding transcription factor that is up-regulated in a number of different cancers. We have previously shown that binding of Myc correlates with increased transcription of the cad promoter. We have now further investigated the mechanism. by which Myc mediates transcriptional activation of the cad. gene. Using a chromatin immunoprecipitation assay, we found high levels of RNA polymerase II bound to the cad promoter in quiescent NIH 3T3 cells and in differentiated U937 cells, even though the promoter is inactive. However, chromatin immunoprecipitation with an antibody that recognizes the hyperphosphorylated form of the RNA polymerase H carboxyl-terminal domain (CTD) revealed that phosphorylation of the CTD does correlate with c-Myc binding and cad transcription. We have also found that the c-Myc transactivation domain interacts with cdk9 and cyclin T1, components of the CTD kinase P-TEFb. Furthermore, activator bypass experiments have shown that direct recruitment of cyclin TI to the cad promoter can substitute for c-Myc to activate the promoter. In summary, our results suggest that c-Myc activates transcription of cad by stimulating promoter clearance and elongation, perhaps via recruitment of P-TEFb.	Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, Madison, WI 53706 USA.	farnham@oncology.wisc.edu		Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA07175, CA09135, CA45240] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045240, R29CA045240, P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blau J, 1996, MOL CELL BIOL, V16, P2044; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fry CJ, 1999, J BIOL CHEM, V274, P15883, DOI 10.1074/jbc.274.22.15883; Garber ME, 1998, COLD SPRING HARB SYM, V63, P371, DOI 10.1101/sqb.1998.63.371; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Law A, 1998, NUCLEIC ACIDS RES, V26, P919, DOI 10.1093/nar/26.4.919; Lee DH, 2000, DATA KNOWL ENG, V34, P77, DOI 10.1016/S0169-023X(00)00009-4; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Lis JT, 2000, GENE DEV, V14, P792; Luo X, 1996, MOL CELL BIOL, V16, P1367; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Pinaud S, 1998, J MOL BIOL, V280, P785, DOI 10.1006/jmbi.1998.1905; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; SANDGREN EP, 1989, ONCOGENE, V4, P715; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLANSKY JE, 1993, MOL CELL BIOL, V13, P7201; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198	66	148	153	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48562	48571		10.1074/jbc.M109014200	http://dx.doi.org/10.1074/jbc.M109014200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11673469	hybrid			2022-12-25	WOS:000172927000111
J	Ho, SY; Delgado, L; Storch, J				Ho, SY; Delgado, L; Storch, J			Monoacylglycerol metabolism in human intestinal Caco-2 cells - Evidence for metabolic compartmentation and hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID-BINDING; BRUSH-BORDER MEMBRANE; LINE CACO-2; LIPOPROTEIN SECRETION; EQUILIBRIUM-CONSTANTS; SERUM-ALBUMIN; ACYLTRANSFERASE; PLASMA; MUCOSA; ABSORPTION	Free fatty acids (FFA) and sn-2-monoacylglycerol (MG), the two major hydrolysis products of dietary triacylglycerol (TG), are absorbed from the lumen into polarized enterocytes that line the small intestine. Intensive studies regarding FFA metabolism in the intestine have been published; however, little is known regarding the metabolism of MG. In these studies, we examined the metabolism of sn-2-monoolein (sn-2-18:1) by human intestinal Caco-2 cells. To mimic the physiological presentation of MG to the enterocyte, the metabolism of [H-3]sn2-monoolein was examined by adding taurocholate-mixed sn-2-18:1 and albumin-bound sn-2-18:1 at the apical (AP) and basolateral (BL) surfaces of the Caco-2 cell, respectively. The results demonstrate that more sn-2-18:1 was incorporated into TG from A-P taurocholate-mixed sn-2-18:1, whereas more phospholipid was synthesized from BL albumin-bound sn-2-18:1. The TG: phospholipid ratio was similar to5-fold higher for AI? relative to BL MG incubation. Qualitatively similar results were observed for bovine serum albumin-bound MG added at the apical surface. It was also found that substantial sn-2-18:1 radioactivity was recovered in the FFA fraction, suggesting that sn-2-18:1 may be directly hydrolyzed within the Caco-2. We therefore used reverse transcription-PCR with primers designed from the murine MG lipase (MGL) gene, and detected the presence of MG lipase mRNA in Caco-2. The human MGL gene was cloned and found to be 83% identical to the murine MGL, and identical to a previously described lysophospholipase-like protein. Northern blot analysis showed the expression of MGL throughout Caco-2 differentiation. Thus, MG metabolism in Caco-2 cells may include not only well established anabolic processes, but also catabolic processes. Further, the observed polarity of MG metabolism suggests that, as for fatty acids, separate precursor and/or product pools of lipid may exist in the intestinal enterocyte.	Rutgers State Univ, Dept Nutrit Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Storch, J (corresponding author), Rutgers State Univ, Dept Nutrit Sci, 96 Lipman Dr, New Brunswick, NJ 08901 USA.			Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038389, R01DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38389, R01 DK038389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berk PD, 1999, MOL CELL BIOCHEM, V192, P17, DOI 10.1023/A:1006832001033; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASITUS TA, 1980, BIOCHEMISTRY-US, V19, P2763, DOI 10.1021/bi00553a035; BRASITUS TA, 1984, BIOCHIM BIOPHYS ACTA, V774, P138, DOI 10.1016/0005-2736(84)90284-0; BRINDLEY DN, 1974, BIOMEMBRANE, P621; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; DAKKA T, 1994, ENDOCRINOLOGY, V134, P603, DOI 10.1210/en.134.2.603; Darimont C, 1998, EXP CELL RES, V244, P441, DOI 10.1006/excr.1998.4186; DEJONG BJP, 1978, BIOCHIM BIOPHYS ACTA, V530, P56, DOI 10.1016/0005-2760(78)90126-1; ELMAGHRABI MR, 1978, J BIOL CHEM, V253, P974; FIELD FJ, 1988, J LIPID RES, V29, P1427; FIELDING BA, 1993, CLIN CHIM ACTA, V216, P167, DOI 10.1016/0009-8981(93)90149-X; GANGL A, 1975, J CLIN INVEST, V55, P803, DOI 10.1172/JCI107991; GANGL A, 1978, GASTROENTEROLOGY, V74, P847; Glatz JFC, 2001, CURR OPIN LIPIDOL, V12, P267, DOI 10.1097/00041433-200106000-00005; Ho SP, 2001, AM J PHYSIOL-CELL PH, V281, pC1106, DOI 10.1152/ajpcell.2001.281.4.C1106; Karlsson M, 1997, J BIOL CHEM, V272, P27218, DOI 10.1074/jbc.272.43.27218; LAMB RG, 1980, BIOCHIM BIOPHYS ACTA, V619, P385, DOI 10.1016/0005-2760(80)90086-7; LeBeyec J, 1997, EXP CELL RES, V236, P311; LEHNER R, 1995, J BIOL CHEM, V270, P13630, DOI 10.1074/jbc.270.23.13630; LEVIN MS, 1992, J LIPID RES, V33, P9; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Mahan JT, 2001, AM J PHYSIOL-GASTR L, V280, pG1187, DOI 10.1152/ajpgi.2001.280.6.G1187; MATTSON FH, 1962, J LIPID RES, V3, P281; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; OCKNER RK, 1972, GASTROENTEROLOGY, V62, P981; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; PINTO M, 1983, BIOL CELL, V47, P323; RANHEIM T, 1994, BBA-LIPID LIPID MET, V1212, P295, DOI 10.1016/0005-2760(94)90203-8; RAO RH, 1993, ARCH BIOCHEM BIOPHYS, V304, P483, DOI 10.1006/abbi.1993.1379; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; SCHULTHESS G, 1994, BIOCHEMISTRY-US, V33, P4500, DOI 10.1021/bi00181a009; Spalinger JH, 1998, BBA-LIPID LIPID MET, V1393, P119, DOI 10.1016/S0005-2760(98)00068-X; SPECTOR AA, 1971, BIOCHEMISTRY-US, V10, P3229; THOMSON ABR, 1993, CAN J PHYSIOL PHARM, V71, P531, DOI 10.1139/y93-078; Thumser AEA, 1998, J LIPID RES, V39, P1033; TRABER MG, 1987, J LIPID RES, V28, P1350; Trotter PJ, 1996, J LIPID RES, V37, P336; TROTTER PJ, 1993, J BIOL CHEM, V268, P10017; TROTTER PJ, 1991, J LIPID RES, V32, P293; TSO P, 2000, BIOCH PHYSL ASPECTS, P125; Tsujita T, 1996, J BIOL CHEM, V271, P2156, DOI 10.1074/jbc.271.4.2156; VANGREEVENBROEK MMJ, 1995, J LIPID RES, V36, P13; Wall EM, 1997, VIRUS RES, V52, P157, DOI 10.1016/S0168-1702(97)00122-6; YANG LY, 1991, J LIPID RES, V32, P1173	47	63	63	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1816	1823		10.1074/jbc.M108027200	http://dx.doi.org/10.1074/jbc.M108027200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11682480	hybrid			2022-12-25	WOS:000173421300027
J	Sousa, AD; Farah, CS				Sousa, AD; Farah, CS			Quantitative analysis of tropomyosin linear polymerization equilibrium as a function of ionic strength	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ALPHA-TROPOMYOSIN; SKELETAL-MUSCLE; STRIATED-MUSCLE; ESCHERICHIA-COLI; TROPONIN-I; F-ACTIN; NONPOLYMERIZABLE TROPOMYOSIN; CRYSTAL-STRUCTURE; TERMINAL REGIONS; AMINO TERMINUS	Tropomyosin is a coiled-coil protein that polymerizes by head-to-tail interactions in an ionic strength-dependent manner. We produced a recombinant full-length chicken a-tropomyosin containing a 5-hydroxytryptophan residue at position 269 (formerly an alanine), 15 residues from the C terminus, and show that its fluorescence intensity specifically reports tropomyosin head-to-tail interactions. We used this property to quantitatively study the monomer-polymer equilibrium in tropomyosin and to calculate the equilibrium constant of the head-to-tail interaction as a function of ionic strength. Our results show that the affinity constant changes by almost 2 orders of magnitude over an ionic strength range of 50 mm (between I = 0.045 and 0.095). We were also able to calculate the average polymer length as a function of concentration and ionic strength, which is an important parameter in the interpretation of binding isotherms of tropomyosin with other thin filament proteins such as actin and troponin.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05599970 Sao Paulo, SP, Brazil	Universidade de Sao Paulo	Farah, CS (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, CP 26-077, BR-05599970 Sao Paulo, SP, Brazil.	chsfarah@iq.usp.br	Farah, Chuck Shaker/G-5565-2012	Farah, Chuck Shaker/0000-0003-3110-6302; Sousa, Aurea/0000-0002-9153-7414				ASAI H, 1961, J BIOCHEM-TOKYO, V50, P182, DOI 10.1093/oxfordjournals.jbchem.a127432; BAILEY K, 1948, BIOCHEM J, V43, P271, DOI 10.1042/bj0430271; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CANTOR CR, 1980, BIOPHYSICAL CHEM 1, P145; CASPAR DLD, 1969, J MOL BIOL, V41, P87, DOI 10.1016/0022-2836(69)90128-4; CHO YJ, 1990, J BIOL CHEM, V265, P538; COHEN C, 1971, COLD SPRING HARB SYM, V36, P205, DOI 10.1101/SQB.1972.036.01.028; Das K, 1999, PHOTOCHEM PHOTOBIOL, V70, P719; EBASHI S, 1969, Quarterly Reviews of Biophysics, V2, P351; EBASHI S, 1965, J BIOCHEM-TOKYO, V58, P107, DOI 10.1093/oxfordjournals.jbchem.a128157; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; Farah CS, 1999, BIOCHEMISTRY-US, V38, P10543, DOI 10.1021/bi982813u; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GOODING C, 1987, NUCLEIC ACIDS RES, V15, P8105, DOI 10.1093/nar/15.19.8105; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Greenfield NJ, 1998, BIOCHEMISTRY-US, V37, P7834, DOI 10.1021/bi973167m; HANSON J, 1963, J MOL BIOL, V6, P46, DOI 10.1016/S0022-2836(63)80081-9; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HEELEY DH, 1989, J BIOL CHEM, V264, P2424; Highsmith S, 1997, BIOCHEMISTRY-US, V36, P2010, DOI 10.1021/bi961924v; HIGUCHI M, 1990, GENOMICS, V6, P65, DOI 10.1016/0888-7543(90)90448-4; Hilario E, 2001, BIOCHEM BIOPH RES CO, V284, P955, DOI 10.1006/bbrc.2001.5059; HILL LE, 1992, J BIOL CHEM, V267, P16106; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; JOHNSON P, 1977, BIOCHEMISTRY-US, V16, P2264, DOI 10.1021/bi00629a035; KAY CM, 1960, BIOCHIM BIOPHYS ACTA, V40, P149, DOI 10.1016/0006-3002(60)91325-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAK AS, 1983, J BIOL CHEM, V258, P4330; MCCUBBIN W D, 1969, Canadian Journal of Biochemistry, V47, P411; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Moraczewska J, 2000, BIOCHEMISTRY-US, V39, P6891, DOI 10.1021/bi000242b; Moraczewska J, 1999, BIOCHEMISTRY-US, V38, P15885, DOI 10.1021/bi991816j; NOLTE HJ, 1980, BIOCHEMISTRY-US, V19, P3705, DOI 10.1021/bi00557a011; Oliveira DM, 2000, J BIOL CHEM, V275, P27513; OOI T, 1962, ARCH BIOCHEM BIOPHYS, V98, P1, DOI 10.1016/0003-9861(62)90138-8; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PHILLIPS GN, 1979, NATURE, V278, P413, DOI 10.1038/278413a0; PITZER KS, 1973, J PHYS CHEM-US, V77, P2300, DOI 10.1021/j100638a009; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sano K, 2000, J BIOCHEM-TOKYO, V127, P1095; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; SODEK J, 1962, P NATL ACAD SCI USA, V62, P3800; Song XZ, 2000, BIOPHYS J, V78, P1324, DOI 10.1016/S0006-3495(00)76687-2; SOUSA AD, 2001, BIOPHYS J, V80, P91; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; STONE D, 1978, J BIOL CHEM, V253, P1137; Tobacman LS, 2000, J BIOL CHEM, V275, P27587; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TSAO TC, 1951, BIOCHEM J, V49, P27, DOI 10.1042/bj0490027; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; Whitby FG, 2000, PROTEINS, V38, P49; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	63	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2081	2088		10.1074/jbc.M109568200	http://dx.doi.org/10.1074/jbc.M109568200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11694540	hybrid			2022-12-25	WOS:000173421300064
J	Albury, MS; Affourtit, C; Crichton, PG; Moore, AL				Albury, MS; Affourtit, C; Crichton, PG; Moore, AL			Structure of the plant alternative oxidase - Site-directed mutagenesis provides new information on the active site and membrane topology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE MITOCHONDRIA; PHOTOSYNTHETIC REACTION-CENTER; CYANIDE-RESISTANT OXIDASE; FISSION YEAST; PROTEIN; OXYGEN; RESPIRATION; MECHANISM; GENE; RESOLUTION	All higher plants and many fungi contain an alternative oxidase (AOX), which branches from the cytochrome pathway at the level of the quinone pool. In an attempt, first, to distinguish between two proposed structural models of this di-iron protein, and, second, to examine the roles of two highly conserved tyrosine residues, we have expressed an array of site-specific mutants in Schizosaccharomyces pombe. Mitochondrial respiratory analysis reveals that S. pombe cells expressing AOX proteins in which Glu-217 or Glu-270 were mutated, no longer exhibit antimycin-resistant oxygen uptake, indicating that these residues are essential for AOX activity. Although such data corroborate a model that describes the AOX as an interfacial membrane protein, they are not in full agreement with the most recently proposed ligation sphere of its di-iron center. We furthermore show that upon mutation of Tyr-253 and Tyr-275 to phenylalanines, AOX activity is fully maintained or abolished, respectively. These data are discussed in reference to the importance of both residues in the catalytic cycle of the AOX.	Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England	University of Sussex	Albury, MS (corresponding author), Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England.	M.S.Albury@sussex.ac.uk	Affourtit, Charles/I-3958-2019	Affourtit, Charles/0000-0003-1776-9943; Crichton, Paul/0000-0003-3786-8359				Affourtit C, 2000, PEST MANAG SCI, V56, P31; Affourtit C, 1999, J BIOL CHEM, V274, P6212, DOI 10.1074/jbc.274.10.6212; Affourtit C, 2001, BBA-BIOENERGETICS, V1504, P58, DOI 10.1016/S0005-2728(00)00239-5; Albury MS, 1998, J BIOL CHEM, V273, P30301, DOI 10.1074/jbc.273.46.30301; Albury MS, 1996, J BIOL CHEM, V271, P17062, DOI 10.1074/jbc.271.29.17062; ALLEN JP, 1988, P NATL ACAD SCI USA, V85, P8487, DOI 10.1073/pnas.85.22.8487; Andersson ME, 1999, FEBS LETT, V449, P17, DOI 10.1016/S0014-5793(99)00376-2; Babcock GT, 1999, P NATL ACAD SCI USA, V96, P12971, DOI 10.1073/pnas.96.23.12971; Berthold DA, 2000, BBA-BIOENERGETICS, V1460, P241, DOI 10.1016/S0005-2728(00)00149-3; Berthold DA, 1998, BBA-BIOENERGETICS, V1364, P73, DOI 10.1016/S0005-2728(98)00015-2; Carol P, 1999, PLANT CELL, V11, P57, DOI 10.1105/tpc.11.1.57; Chaudhuri M, 1998, MOL BIOCHEM PARASIT, V95, P53, DOI 10.1016/S0166-6851(98)00091-7; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; ELTHON TE, 1989, PLANT PHYSIOL, V89, P1311, DOI 10.1104/pp.89.4.1311; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; Gomes CM, 2001, CHEMBIOCHEM, V2, P583, DOI 10.1002/1439-7633(20010803)2:7/8<583::AID-CBIC583>3.0.CO;2-5; Hoganson CW, 1997, SCIENCE, V277, P1953, DOI 10.1126/science.277.5334.1953; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kalman L, 1999, NATURE, V402, P696, DOI 10.1038/45300; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MOORE AL, 1992, YEAST, V8, P923, DOI 10.1002/yea.320081103; MOORE AL, 1995, J BIOENERG BIOMEMBR, V27, P367, DOI 10.1007/BF02109999; MORENO S, 1991, METHOD ENZYMOL, V194, P795; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Proshlyakov DA, 2000, SCIENCE, V290, P1588, DOI 10.1126/science.290.5496.1588; Rhoads DM, 1998, J BIOL CHEM, V273, P30750, DOI 10.1074/jbc.273.46.30750; RHOADS DM, 1991, P NATL ACAD SCI USA, V88, P2122, DOI 10.1073/pnas.88.6.2122; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIEDOW JN, 1995, FEBS LETT, V362, P10, DOI 10.1016/0014-5793(95)00196-G; Siedow JN, 2000, BBA-BIOENERGETICS, V1459, P432, DOI 10.1016/S0005-2728(00)00181-X; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; Umbach AL, 2000, ARCH BIOCHEM BIOPHYS, V378, P234, DOI 10.1006/abbi.2000.1834; Vanlerberghe GC, 1998, PLANT CELL, V10, P1551, DOI 10.1105/tpc.10.9.1551; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; Wagner AM, 1997, BIOSCIENCE REP, V17, P319, DOI 10.1023/A:1027388729586; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Wu DY, 1999, PLANT CELL, V11, P43, DOI 10.1105/tpc.11.1.43; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	41	55	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1190	1194		10.1074/jbc.M109853200	http://dx.doi.org/10.1074/jbc.M109853200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11698414	hybrid			2022-12-25	WOS:000173166800041
J	Holmes, KD; Mattar, PA; Marsh, DR; Weaver, LC; Dekaban, GA				Holmes, KD; Mattar, PA; Marsh, DR; Weaver, LC; Dekaban, GA			The N-methyl-D-aspartate receptor splice variant NR1-4 C-terminal domain - Deletion analysis and role in subcellular distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; NMDA RECEPTOR; GLUTAMATE RECEPTORS; TRANSFECTED CELLS; SUBUNIT; PSD-95; MEMBRANE; NEURONS; DENSITY; CHANNEL	The intracellular C-terminal domain of the N-methyl-D-aspartate receptor (NMDAR) subunits 1 (NR1) and 2 (NR2) are important, if not essential, to the process of NMDAR clustering and anchoring at the plasma membrane and the synapse. Eight NR1 splice variants exist, four of which arise from alternative splicing of the C-terminal exon cassettes. Alternative splice variants may display a differential ability to interact with synaptic anchoring proteins, and splicing of C-terminal exon cassettes may alter the mechanism(s) of subcellular localization and targeting. The NR1-4 isoform has a significantly different C-terminal composition than the prototypic NR1-1 isoform. Whereas the NR1-1 C terminus is composed of C0, C1, and C2 exon cassettes, the NR1-4 C terminus is composed of the C0 and C2' cassettes. In the present study, we address the importance of the NR1-4 C-terminal exon cassettes (C0C2') in subcellular localization in differentiated pheochromocytoma (PC12) cells, in organotypic cultures of dorsal root ganglia, and also in heterologous cells. NR1-4-green fluorescent protein chimeras were created with deletion of either C0, C2', or both cassettes to address their importance in subcellular distribution and cell surface expression of the NR1-4 subunit. These experiments demonstrate that the NR1-4 splice variant found predominantly in the spinal cord uses the C0 cassette, to a large degree, to organize the subcellular distribution of this receptor subunit. Although the role of the C2' subunit is less clear, it may be involved in subunit clustering. However, this clustering is not always as efficient as that attributed to C0 alone or to the natural combination of C0C2'. Finally, although an intact C-terminal domain is neither necessary for interaction with the NR2A subunit nor surface expression of the NR1-4 subunit, the C-terminal domain fragment alone blocks surface expression of native NR1-4, in a dominant negative fashion, when the two are coexpressed.	Univ Western Ontario, Gene Therapy & Mol Virol Grp, John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Neurodegenerat Res Grp, John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Dekaban, GA (corresponding author), Univ Western Ontario, Gene Therapy & Mol Virol Grp, John P Robarts Res Inst, 100 Perth Dr, London, ON N6A 5K8, Canada.		Dekaban, Gregory/L-1987-2013; Weaver, Lynne C/K-8491-2013	Dekaban, Gregory/0000-0002-3087-4660; Mattar, Pierre/0000-0002-5708-6218				Allison DW, 1998, J NEUROSCI, V18, P2423; ARP J, 1993, J GEN VIROL, V74, P211, DOI 10.1099/0022-1317-74-2-211; Bassand P, 1999, EUR J NEUROSCI, V11, P2031, DOI 10.1046/j.1460-9568.1999.00611.x; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; Ehlers MD, 1998, J NEUROSCI, V18, P720; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Holmes KD, 2000, J NEUROVIROL, V6, P33, DOI 10.3109/13550280009006380; Hsueh YP, 1998, PROG BRAIN RES, V116, P123, DOI 10.1016/S0079-6123(08)60434-3; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; Kennedy MB, 1998, BRAIN RES REV, V26, P243, DOI 10.1016/S0165-0173(97)00043-X; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; Levatte MA, 1998, NEUROSCIENCE, V86, P1321, DOI 10.1016/S0306-4522(98)00093-1; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MARHS DR, 2001, J NEUROCHEM, V76, P1; Matsuda S, 1999, NEUROSCI RES, V34, P157, DOI 10.1016/S0168-0102(99)00046-2; McIlhinney RAJ, 1996, NEUROSCIENCE, V70, P989, DOI 10.1016/0306-4522(95)00419-X; McIlhinney RAJ, 1998, NEUROPHARMACOLOGY, V37, P1355, DOI 10.1016/S0028-3908(98)00121-X; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Niethammer M, 1996, J NEUROSCI, V16, P2157; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Okabe S, 1999, J NEUROSCI, V19, P7781; Rameau GA, 2000, NEUROPHARMACOLOGY, V39, P2255, DOI 10.1016/S0028-3908(00)00066-6; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Strathdee CA, 2000, MOL THER, V1, P479, DOI 10.1006/mthe.2000.0058; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; Sun LX, 1998, FEBS LETT, V441, P392, DOI 10.1016/S0014-5793(98)01590-7; Thompson SM, 2000, CURR BIOL, V10, pR218, DOI 10.1016/S0960-9822(00)00370-5; van Rossum D, 1999, J NEUROCHEM, V72, P962, DOI 10.1046/j.1471-4159.1999.0720962.x; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0	36	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1457	1468		10.1074/jbc.M107809200	http://dx.doi.org/10.1074/jbc.M107809200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11700309	hybrid			2022-12-25	WOS:000173166800077
J	Mazerolles, F; Barbat, C; Trucy, M; Kolanus, W; Fischer, A				Mazerolles, F; Barbat, C; Trucy, M; Kolanus, W; Fischer, A			Molecular events associated with CD4-mediated down-regulation of LFA-1-dependent adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ADHESION; FC-GAMMA-RIIB; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; IMMUNE-SYSTEM; PROTEIN; RECEPTOR; BINDING; KINASE	We have previously shown that CD4 ligand binding inhibits LFA-1-dependent adhesion between CD4+ T cells and B cells in a p56(lck) - and phosphatidylinositol. 3-kinase (PI3-kinase)-dependent manner. In this work, downstream events associated with adhesion inhibition have been investigated. By using HUT78 T cell lines, CD4 ligands were shown to induce a dissociation of LFA-1 from cytohesin, a cytoplasmic protein known to bind LFA-1 and to enhance the affinity/avidity of LFA-1 for its ligand ICAM-1. A dissociation of PI3-kinase from cytohesin is also observed. In parallel, we have found that CD4 ligand binding induced a redistribution of PI3kinase and of the tyrosine phosphatase SHP-2 to the membrane and induced a transient formation of protein interactions including P13-kinase; an adaptor protein, Gab2; SHP-2; and a SH2 domain-containing inositol phosphatase, SHIP. By using antisense oligonucleotides or transfection of transdominant mutants, down-regulation of adhesion was shown to require the Gab2/PI3kinase association and the expression of SHIP and SHP-2. We therefore propose that CD4 ligands, by inducing these molecular associations, lead to sustained local high levels of D-3 phospholipids and possibly regulate the cytohesin/LFA-1 association.	Hop Necker Enfants Malad, INSERM U429, F-75743 Paris 15, France; Univ Munich, Mol Biol Lab, Gene Ctr, D-81377 Munich, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Munich	Mazerolles, F (corresponding author), Hop Necker Enfants Malad, INSERM U429, Bat Karmisson,149 Rue Sevres, F-75743 Paris 15, France.			MAZEROLLES, Fabienne/0000-0002-5991-614X				CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; Chacko GW, 1996, J IMMUNOL, V157, P2234; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; Gadina M, 2000, J BIOL CHEM, V275, P26959; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gupta N, 1999, J BIOL CHEM, V274, P7489, DOI 10.1074/jbc.274.11.7489; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P10998; Liu L, 1997, LEUKEMIA, V11, P181, DOI 10.1038/sj.leu.2400559; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; Mazerolles F, 1998, INT IMMUNOL, V10, P1897, DOI 10.1093/intimm/10.12.1897; MAZEROLLES F, 1994, J IMMUNOL, V152, P5670; MAZEROLLES F, 1988, EUR J IMMUNOL, V18, P1229, DOI 10.1002/eji.1830180813; Mazerolles F, 1996, J IMMUNOL, V157, P4844; Mazerolles F, 1996, INT IMMUNOL, V8, P267, DOI 10.1093/intimm/8.2.267; MAZEROLLES F, 1990, EUR J IMMUNOL, V20, P637, DOI 10.1002/eji.1830200326; Mazerolles F, 1997, EUR J IMMUNOL, V27, P2457, DOI 10.1002/eji.1830270946; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NAG B, 1993, J IMMUNOL, V150, P1358; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Pratt JC, 2000, J IMMUNOL, V165, P4158, DOI 10.4049/jimmunol.165.8.4158; Rey-Ladino JA, 1999, J IMMUNOL, V162, P5792; Sarmay G, 1999, IMMUNOL LETT, V68, P25, DOI 10.1016/S0165-2478(99)00026-7; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Xu FP, 2001, J BIOL CHEM, V276, P29479, DOI 10.1074/jbc.M104428200; Zhao RX, 2000, J BIOL CHEM, V275, P5453, DOI 10.1074/jbc.275.8.5453	41	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1276	1283		10.1074/jbc.M110064200	http://dx.doi.org/10.1074/jbc.M110064200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694542	hybrid			2022-12-25	WOS:000173166800054
J	Boulares, AH; Zoltoski, AJ; Contreras, FJ; Yakovlev, AG; Yoshihara, K; Smulson, ME				Boulares, AH; Zoltoski, AJ; Contreras, FJ; Yakovlev, AG; Yoshihara, K; Smulson, ME			Regulation of DNAS1L3 endonuclease activity by poly(ADP-ribosyl)ation during etoposide-induced apoptosis - Role of poly(ADP-ribose) polymerase-1 leavage in endonuclease activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTATION; ADP-RIBOSYLATION; CELL-DEATH; CLEAVAGE; THYMOCYTES; INHIBITION; MECHANISM; IDENTIFICATION; DOWNSTREAM; INDUCTION	Several endonucleases are implicated in the internucleosomal DNA fragmentation associated with apoptosis. The human Ca2+- and Mg2+-dependent endonuclease DNAS1L3 is inhibited by poly(ADP-ribosyl)ation in vitro, and its activation during apoptosis shows a time course similar to that of the cleavage of poly(ADP-ribose) polymerase-1 (PARP-1). The role of the cleavage and consequent inactivation of PARP-1 by caspase-3 in the activation of DNAS1L3 has now been investigated further both in vitro and in vivo. In an in vitro system based on purified recombinant proteins and NAD, caspase-3 prevented the inhibition of DNAS1L3 endonuclease activity by wild-type PARP-1 but not that induced by a caspase-3-resistant PARP-1 mutant. The induction by etoposide of apoptosis in human osteosarcoma cells (which were shown not to express endogenous DNAS1L3) was accompanied by internucleosomal DNA fragmentation only after transfection of the cells with a plasmid encoding DNAS1L3. This DNA fragmentation in etoposide-treated cells was blocked by 1,2-bis(2-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid, an inhibitor of intracellular Ca2+ release. Expression of the endonuclease subunit of DNA fragmentation factor (DFF40) and cleavage of its inhibitor, DFF45, were not sufficient to cause internucleosomal DNA fragmentation in osteosarcoma cells during etoposide-induced apoptosis. Coexpression of caspase-3-resistant PARP-1 mutant with DNAS1L3 in osteosarcoma cells blocked etoposide-induced internucleosomal DNA fragmentation and resulted in persistent poly(ADP-ribosyl)ation of DNAS1L3; it did not, however, prevent the activation of caspase-3 and the consequent cleavage of endogenous PARP-1. These results indicate that PARP-1 cleavage during apoptosis is not simply required to prevent excessive depletion of NAD and ATP but is also necessary to release DNAS1L3 from poly(ADP-ribosyl)ation-mediated inhibition.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Sch Med, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Dept Neurosci, Washington, DC 20007 USA; Nara Med Univ, Dept Biochem, Kashihara, Nara 6348521, Japan	Georgetown University; Georgetown University; Nara Medical University	Smulson, ME (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Sch Med, 3900 Reservoir Rd NW,Basic Sci Bldg,Rm 351, Washington, DC 20007 USA.				NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER; NCI NIH HHS [CA25344, P01CA-74175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Althaus FR, 1999, MOL CELL BIOCHEM, V193, P5, DOI 10.1023/A:1006975002262; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; ASCENSAO JL, 1981, BLOOD, V57, P170; Boulares AH, 2001, J BIOL CHEM, V276, P38185; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; BOULARES AH, 2001, IN PRESS PHARM TOXIC; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; COHEN GM, 1994, J IMMUNOL, V153, P507; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Halappanavar SS, 1999, J BIOL CHEM, V274, P37097, DOI 10.1074/jbc.274.52.37097; HASHIDA T, 1982, J BIOL CHEM, V257, P3114; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; JACOBSON MK, 1989, ADP RIBOSE TRANSFER, P81; JUAREZSALINAS H, 1982, J BIOL CHEM, V257, P607; Kawabata Y, 1999, BLOOD, V94, P3523, DOI 10.1182/blood.V94.10.3523.422k07_3523_3530; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Los M, 2000, BIOCHEMISTRY-US, V39, P7365, DOI 10.1021/bi000158w; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Rasola A, 1999, FASEB J, V13, P1711, DOI 10.1096/fasebj.13.13.1711; Ravi R, 1998, CANCER RES, V58, P882; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Robertson JD, 2000, J STRUCT BIOL, V129, P346, DOI 10.1006/jsbi.2000.4254; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Scovassi AI, 1999, MOL CELL BIOCHEM, V199, P125; SHIOKAWA D, 1994, EUR J BIOCHEM, V226, P23, DOI 10.1111/j.1432-1033.1994.tb20022.x; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Smulson ME, 1998, CANCER RES, V58, P3495; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; TANIGAWA Y, 1983, J BIOL CHEM, V258, P9184; Urbano A, 1998, J BIOL CHEM, V273, P34820, DOI 10.1074/jbc.273.52.34820; Wong E, 1997, INFLAMM RES, V46, P51, DOI 10.1007/s000110050063; Yakovlev AG, 2000, J BIOL CHEM, V275, P21302, DOI 10.1074/jbc.M001087200; Yakovlev AG, 1999, NUCLEIC ACIDS RES, V27, P1999, DOI 10.1093/nar/27.9.1999; Yin XM, 2000, J MOL MED-JMM, V78, P203, DOI 10.1007/s001090000099; YOSHIDA A, 1993, BIOCHEM BIOPH RES CO, V196, P927, DOI 10.1006/bbrc.1993.2338; Zhang JH, 1999, J BIOL CHEM, V274, P37450, DOI 10.1074/jbc.274.52.37450; Zhang JH, 2000, BIOCHEM BIOPH RES CO, V274, P225, DOI 10.1006/bbrc.2000.3122; Zhang M, 2001, APOPTOSIS, V6, P291, DOI 10.1023/A:1011387509290	48	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					372	378		10.1074/jbc.M107738200	http://dx.doi.org/10.1074/jbc.M107738200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11694507	hybrid			2022-12-25	WOS:000173087900050
J	Hegde, R; Srinivasula, SM; Zhang, ZJ; Wassell, R; Mukattash, R; Cilenti, L; DuBois, G; Lazebnik, Y; Zervos, AS; Fernandes-Alnemri, T; Alnemri, ES				Hegde, R; Srinivasula, SM; Zhang, ZJ; Wassell, R; Mukattash, R; Cilenti, L; DuBois, G; Lazebnik, Y; Zervos, AS; Fernandes-Alnemri, T; Alnemri, ES			Identification of Omi/HtrA-2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; CELL-DEATH; IAP; SMAC/DIABLO; DROSOPHILA; ACTIVATION; BINDING; GRIM; HID	To identify human proteins that bind to the Smac and caspase-9 binding pocket on the baculoviral inhibitor of apoptosis protein (IAP) repeat 3 (BIR3) domain of human XIAP, we used BIR3 as an affinity reagent, followed by elution with the BIR3 binding peptide AVPIA microsequencing, and mass spectrometry. The mature serine protease Omi (also known as HtrA2) was identified as a mitochondrial direct BIR3-binding protein and a caspase activator. Like mature Smac (also known as Diablo), mature Omi contains a conserved LAP-binding motif (AVPS) at its N terminus, which is exposed after processing of its N-terminal mitochondrial targeting sequence upon import into the mitochondria. Mature Omi is released together with mature Smac from the mitochondria into the cytosol upon disruption of the outer mitochondrial membrane during apoptosis. Finally, mature Omi can induce apoptosis in human cells in a caspase-independent manner through its protease activity and in a caspase-dependent manner via its ability to disrupt caspase-LAP interaction. Our results provide clear evidence for the involvement of a mitochondrial serine protease in the apoptotic pathway, emphasizing the critical role of the mitochondria in cell death.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Immunol & Microbiol, Philadelphia, PA 19107 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA	Jefferson University; Jefferson University; Cold Spring Harbor Laboratory; State University System of Florida; University of Central Florida	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.		Alnemri, Emad S/B-4526-2010		NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER; NCI NIH HHS [CA78890] Funding Source: Medline; NIA NIH HHS [AG13487] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HIGUCHI M, 1995, BLOOD, V86, P2248, DOI 10.1182/blood.V86.6.2248.bloodjournal8662248; Itzhaki H, 1998, J BIOL CHEM, V273, P7094, DOI 10.1074/jbc.273.12.7094; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Reed JC, 2000, CELL, V102, P545, DOI 10.1016/S0092-8674(00)00076-3; Solary E, 1998, CELL BIOL TOXICOL, V14, P121, DOI 10.1023/A:1007481921502; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012	26	577	615	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					432	438		10.1074/jbc.M109721200	http://dx.doi.org/10.1074/jbc.M109721200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11606597	hybrid, Green Published			2022-12-25	WOS:000173087900058
J	Sharma, P; Veeranna; Sharma, M; Amin, ND; Sihag, RK; Grant, P; Ahn, N; Kulkarni, AB; Pant, HC				Sharma, P; Veeranna; Sharma, M; Amin, ND; Sihag, RK; Grant, P; Ahn, N; Kulkarni, AB; Pant, HC			Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; P35; EXPRESSION; ADULT; NEURONS; DIFFERENTIATION; TRANSFORMATION; INDUCTION; DEFECTS; SUBUNIT	Cyclin-dependent protein kinase 5 (cdk5), a member of the cdk family, is active mainly in postmitotic cells and plays important roles in neuronal development and migration, neurite outgrowth, and synaptic transmission. In this study we investigated the relationship between cdk5 activity and regulation of the mitogen-activated protein (MAP) kinase pathway. We report that cdk5 phosphorylates the MAP kinase kinase-1 (MEK1) in vivo as well as the Ras-activated MEK1 in vitro. The phosphorylation of MEK1 by cdk5 resulted in inhibition of MEK1 catalytic activity and the phosphorylation of extracellular signal-regulated kinase (ERK) 1/2. In p35 (cdk5 activator) -/- mice, which lack appreciable cdk5 activity, we observed an increase in the phosphorylation of NF-M subunit of neurofilament proteins that correlated with an up-regulation of MEK1 and ERK1/2 activity. The activity of a constitutively active MEK1 with threonine 286 mutated to alanine (within a TPXK cdk5 phosphorylation motif in the proline-rich domain) was not affected by cdk5 phosphorylation, suggesting that Thr(286) might be the cdk5/p35 phosphorylation-dependent regulatory site. These findings support the hypothesis that cdk5 and the MAP kinase pathway cross-talk in the regulation of neuronal functions. Moreover, these data and the recent studies of Harada et al. (Harada, T., Morooka, T., Ogawa, S., and Nishida, E. (2001) Nat. Cell Biol. 3, 453-459) have prompted us to propose a model for feedback down-regulation of the MAP kinase signal cascade by cdk5 inactivation of MEK1.	NINCDS, Neurochem Lab, NIH, Bethesda, MD 20892 USA; Univ Colorado, Dept Biochem, Boulder, CO 80309 USA; NIDCR, Funct Genom Unit, Gene Targeting Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Colorado System; University of Colorado Boulder; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Pant, HC (corresponding author), NINCDS, Neurochem Lab, NIH, Bldg 36,Rm 4D-04, Bethesda, MD 20892 USA.	panth@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002725, Z01NS002725] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessandrini A, 1997, CELL GROWTH DIFFER, V8, P505; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Bibbb JA, 2001, J BIOL CHEM, V276, P14490, DOI 10.1074/jbc.M007197200; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; Grant P, 2001, EUR J BIOCHEM, V268, P1534, DOI 10.1046/j.1432-1033.2001.02025.x; Guidato S, 1998, J NEUROCHEM, V70, P335; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Hirooka K, 1996, J NEUROCHEM, V67, P2478; Honjyo Y, 1999, NEUROREPORT, V10, P3375, DOI 10.1097/00001756-199911080-00022; Hucho F, 1997, NATURWISSENSCHAFTEN, V84, P281, DOI 10.1007/s001140050396; Humbert S, 2000, J CELL SCI, V113, P975; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Ohshima T, 1999, J NEUROSCI, V19, P6017, DOI 10.1523/JNEUROSCI.19-14-06017.1999; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Ohshima T, 2001, P NATL ACAD SCI USA, V98, P2764, DOI 10.1073/pnas.051628498; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Rosales JL, 2000, J CELL BIOCHEM, V78, P151, DOI 10.1002/(SICI)1097-4644(20000701)78:1<151::AID-JCB14>3.0.CO;2-L; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sharma M, 1999, J NEUROCHEM, V73, P79, DOI 10.1046/j.1471-4159.1999.0730079.x; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Veeranna, 1998, J NEUROSCI, V18, P4008; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu DC, 2000, NEUROCHEM RES, V25, P923, DOI 10.1023/A:1007544106645; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAN GZ, 1995, J NEUROSCI, V15, P6200; Zheng M, 1998, J NEUROBIOL, V35, P141, DOI 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4	49	128	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					528	534		10.1074/jbc.M109324200	http://dx.doi.org/10.1074/jbc.M109324200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11684694	hybrid			2022-12-25	WOS:000173087900070
J	Wu, K; Chen, A; Tan, PL; Pan, ZQ				Wu, K; Chen, A; Tan, PL; Pan, ZQ			The Nedd8-conjugated ROC1-CUL1 core ubiquitin ligase utilizes Nedd8 charged surface residues for efficient polyubiquitin chain assembly catalyzed by Cdc34	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE GENE; CONJUGATING ENZYME; PROTEIN NEDD8; DNA-REPAIR; E2 ENZYME; COMPLEX; YEAST; SCF; DOMAIN; RBX1	Lysine 48-linked polyubiquitin chains are the principle signal for targeting proteins for degradation by the 26 S proteasome. Here we report that the conjugation of Nedd8 to ROC1-CUL1, a subcomplex of the SCF-ROC1 E3 ubiquitin ligase, selectively stimulates Cdc34-catalyzed lysine 48-linked multiubiquitin chain assembly. We have further demonstrated that separate regions within the human Cdc34 C-terminal tail are responsible for multiubiquitin chain assembly and for physical interactions with the Nedd8-conjugated ROC1-CUL1 to assemble extensive ubiquitin polymers. Structural comparisons between Nedd8 and ubiquitin reveal that six charged residues (Lys(4), Glu(12), Glu(14), Arg(25), GlU(28), and GlU(31)) are uniquely present on the surface of Nedd8. Replacement of each of the six residues with the corresponding amino acid in ubiquitin decreases the ability of Nedd8 to activate the ubiquitin ligase activity of ROC1-CUL1. Moreover, maintenance of the proper charges at amino acid positions 14 and 25 are necessary for retaining wild type levels of activity, whereas introduction of the opposite charges at these positions abolishes the Nedd8 activation function. These results suggest that Nedd8 charged surface residues mediate the activation of ROC1-CUL1 to specifically support Cdc34-catalyzed ubiquitin polymerization.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Pan, ZQ (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, 1 Gustave L Levy Pl, New York, NY 10029 USA.	zhen-qiang.pan@mssm.edu			NIGMS NIH HHS [GM55059] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE A, 1993, J BIOL CHEM, V268, P5668; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; DUTCHER SK, 1982, GENETICS, V100, P175; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; KOLMAN CJ, 1992, EMBO J, V11, P3081, DOI 10.1002/j.1460-2075.1992.tb05380.x; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; Mathias N, 1998, J BIOL CHEM, V273, P4040, DOI 10.1074/jbc.273.7.4040; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; PICKART CM, 1998, UBIQUITIN BIOL CELL, P19; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; PTAK C, 1994, J BIOL CHEM, V269, P26539; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Scheffner M., 1998, UBIQUITIN BIOL CELL, P65; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	39	73	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					516	527		10.1074/jbc.M108008200	http://dx.doi.org/10.1074/jbc.M108008200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11675391	hybrid			2022-12-25	WOS:000173087900069
J	He, W; Melia, TJ; Cowan, CW; Wensel, TG				He, W; Melia, TJ; Cowan, CW; Wensel, TG			Dependence of RGS9-1 membrane attachment on its C-terminal tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACCELERATING PROTEIN; OUTER SEGMENT MEMBRANES; CGMP PHOSPHODIESTERASE; SUBUNIT G-BETA(5); PLASMA-MEMBRANE; BETA-SUBUNIT; TRANSDUCIN; LOCALIZATION; EXPRESSION; COMPLEX	RGS9-1 is a GTPase-accelerating protein (GAP) required for rapid recovery of the light response in vertebrate rod and cone photoreceptors. Similar to its phototransduction partners transducin (G(t)) and cGMP phosphodiesterase, it is a peripheral protein of the disc membranes, but it binds membranes much more tightly. It lacks the lipid modifications found on Gt and cGMP phosphodiesterase, and the mechanism for membrane attachment is unknown. We have used limited proteolysis to generate a fragment of RGS9-1 that is readily removed from membranes under moderate salt conditions. Immunoblots reveal that this soluble fragment lacks a 3-kDa fragment from the C-terminal domain, the only domain within RGS9-1 that differs in sequence from the brain-specific isoform RGS9-2. Recombinant fragments of RGS9-1 with or without the partner subunit Gbeta(5L) were constructed with or without the C-terminal domain. Those lacking the C-terminal domain bound to photoreceptor membranes much less tightly than those containing it. Removal by urea of Gbeta(5L) from endogenous or recombinant RGS9-1 bound to rod outer segment membranes left RGS9-1 tightly membrane-bound, and recombinant RGS9-1 was urea-soluble in the absence of membranes. Thus the C-terminal domain of RGS9-1 is critical for membrane binding, whereas Gbeta(5L), does not play an important role in membrane attachment.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Grad Program Cell & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Wensel, TG (corresponding author), Baylor Coll Med, Dept Biochem, 1 Baylor Plaza, Houston, TX 77030 USA.		Cowan, Christopher W/I-2497-2014	Wensel, Theodore/0000-0003-3518-9352	NATIONAL EYE INSTITUTE [R01EY011900] Funding Source: NIH RePORTER; NEI NIH HHS [EY11900] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; DEGRIP WJ, 1982, METHOD ENZYMOL, V81, P197; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Granneman JG, 1998, MOL PHARMACOL, V54, P687; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Hu G, 2001, J BIOL CHEM, V276, P22287, DOI 10.1074/jbc.M011539200; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Rahman Z, 1999, J NEUROSCI, V19, P2016; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Skiba NP, 2000, J BIOL CHEM, V275, P32716, DOI 10.1074/jbc.C000413200; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Sowa ME, 2000, P NATL ACAD SCI USA, V97, P1483, DOI 10.1073/pnas.030409597; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Zhang JH, 2001, J BIOL CHEM, V276, P10284, DOI 10.1074/jbc.M009247200; Zhang K, 1999, GENE, V240, P23, DOI 10.1016/S0378-1119(99)00393-5; Zhou J, 2001, LIFE SCI, V68, P1457, DOI 10.1016/S0024-3205(01)00939-0	40	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48961	48966		10.1074/jbc.M107428200	http://dx.doi.org/10.1074/jbc.M107428200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11677233	hybrid			2022-12-25	WOS:000173922100046
J	Manganas, LN; Akhtar, S; Antonucci, DE; Campomanes, CR; Dolly, JO; Trimmer, JS				Manganas, LN; Akhtar, S; Antonucci, DE; Campomanes, CR; Dolly, JO; Trimmer, JS			Episodic ataxia type-1 mutations in the Kv1.1 potassium channel display distinct folding and intracellular trafficking properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; TRANSMEMBRANE CONDUCTANCE REGULATOR; BETA-SUBUNIT POLYPEPTIDES; CYSTIC-FIBROSIS; SURFACE EXPRESSION; MAMMALIAN-CELLS; ALPHA-SUBUNIT; PROTEIN STABILIZATION; KCNA1 MUTATIONS; RAT-BRAIN	Episodic ataxia type 1 (EA-1) is a neurological disorder arising from mutations in the Kv1. 1 potassium channel a-subunit. EA-1 patients exhibit substantial phenotypic variability resulting from at least 14 distinct EA-1 point mutations. We found that EA-1 missense mutations generate mutant Kv1.1 subunits with folding and intracellular trafficking properties indistinguishable from wild-type Kv1.1. However, the single identified EA-1 nonsense mutation exhibits intracellular aggregation and detergent insolubility. This phenotype can be transferred to co-assembled Kv1 alpha- and Kvbeta-subunits associated with Kv1.1 in neurons. These results suggest that as in many neurodegenerative disorders, intracellular aggregation of misfolded Kv1.1-containing channels may contribute to the pathophysiology of EA-1.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Imperial College London	Trimmer, JS (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.		Dolly, Oliver/ABH-6677-2020; Dolly, Oliver/G-1532-2012	Dolly, Oliver/0000-0002-0861-5320; Dolly, Oliver/0000-0002-0861-5320; Antonucci, Dana/0000-0001-8857-0865	NIGMS NIH HHS [T32 GM008444] Funding Source: Medline; NINDS NIH HHS [NS34383] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034383, R01NS034383] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adelman JP, 1995, NEURON, V15, P1449, DOI 10.1016/0896-6273(95)90022-5; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; BekeleArcuri Z, 1996, NEUROPHARMACOLOGY, V35, P851, DOI 10.1016/0028-3908(96)00128-1; Boland LM, 1999, NEUROSCIENCE, V91, P1557, DOI 10.1016/S0306-4522(98)00718-0; Bradbury NA, 2000, AM J PHYSIOL-CELL PH, V278, pC257, DOI 10.1152/ajpcell.2000.278.2.C257; Bretschneider F, 1999, EUR J NEUROSCI, V11, P2403, DOI 10.1046/j.1460-9568.1999.00659.x; BROWNE DL, 1995, HUM MOL GENET, V4, P1671, DOI 10.1093/hmg/4.9.1671; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; CHANDY KG, 1995, LIGAND VOLTAGE GATED, P1; Coleman SK, 1999, J NEUROCHEM, V73, P849, DOI 10.1046/j.1471-4159.1999.0730849.x; D'Adamo MC, 1998, EMBO J, V17, P1200, DOI 10.1093/emboj/17.5.1200; D'Adamo MC, 1999, FASEB J, V13, P1335, DOI 10.1096/fasebj.13.11.1335; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Dorandeu F, 1997, J NEUROSCI RES, V48, P499, DOI 10.1002/(SICI)1097-4547(19970615)48:6<499::AID-JNR2>3.0.CO;2-5; Eunson LH, 2000, ANN NEUROL, V48, P647; Felix JP, 1999, BIOCHEMISTRY-US, V38, P4922, DOI 10.1021/bi982954w; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; HALLIWELL JV, 1986, P NATL ACAD SCI USA, V83, P493, DOI 10.1073/pnas.83.2.493; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; HURST RS, 1991, MOL PHARMACOL, V40, P572; Imredy JP, 2000, J MOL BIOL, V296, P1283, DOI 10.1006/jmbi.2000.3522; Jing J, 1997, J BIOL CHEM, V272, P14021, DOI 10.1074/jbc.272.22.14021; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Koch RO, 1997, J BIOL CHEM, V272, P27577, DOI 10.1074/jbc.272.44.27577; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; Lim ST, 2000, NEURON, V25, P385, DOI 10.1016/S0896-6273(00)80902-2; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; Manganas LN, 2000, J BIOL CHEM, V275, P29685, DOI 10.1074/jbc.M005010200; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; Monaghan MM, 2001, J NEUROSCI, V21, P5973, DOI 10.1523/JNEUROSCI.21-16-05973.2001; PAULSON HL, 1990, J CELL BIOL, V110, P1705, DOI 10.1083/jcb.110.5.1705; Rasband M, 1998, J NEUROSCI, V18, P36; REA R, 2001, IN PRESS J PHYSL; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; Rhodes KJ, 1996, J NEUROSCI, V16, P4846; RHODES KJ, 1995, J NEUROSCI, V15, P5360; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SAWANO H, 1992, FEBS LETT, V303, P11, DOI 10.1016/0014-5793(92)80466-T; Scheffer H, 1998, HUM GENET, V102, P464, DOI 10.1007/s004390050722; Shamotienko O, 1999, BIOCHEMISTRY-US, V38, P16766, DOI 10.1021/bi991039n; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; SHI GY, 1994, J BIOL CHEM, V269, P23204; Shieh CC, 2000, PHARMACOL REV, V52, P557; Skach WR, 2000, KIDNEY INT, V57, P825, DOI 10.1046/j.1523-1755.2000.00921.x; Smart SL, 1998, NEURON, V20, P809, DOI 10.1016/S0896-6273(00)81018-1; Spencer RH, 1997, J BIOL CHEM, V272, P2389; Subramony SH, 1999, SEMIN NEUROL, V19, P419, DOI 10.1055/s-2008-1040856; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Trimmer JS, 1998, CURR OPIN NEUROBIOL, V8, P370, DOI 10.1016/S0959-4388(98)80063-9; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WANG H, 1994, J NEUROSCI, V14, P4588; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Zeitlin PL, 2000, RESPIRATION, V67, P351, DOI 10.1159/000029528; Zerr P, 1998, FEBS LETT, V431, P461, DOI 10.1016/S0014-5793(98)00814-X; Zerr P, 1998, J NEUROSCI, V18, P2842; Zuberi SM, 1999, BRAIN, V122, P817, DOI 10.1093/brain/122.5.817	65	55	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49427	49434		10.1074/jbc.M109325200	http://dx.doi.org/10.1074/jbc.M109325200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11679591	hybrid			2022-12-25	WOS:000173922100104
J	Takuma, K; Phuagphong, P; Lee, E; Mori, K; Baba, A; Matsuda, T				Takuma, K; Phuagphong, P; Lee, E; Mori, K; Baba, A; Matsuda, T			Anti-apoptotic effect of cGMP in cultured astrocytes - Inhibition by cGMP-dependent protein kinase of mitochondrial permeable transition pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; NITRIC-OXIDE; RAT ASTROCYTES; NA+-CA2+ EXCHANGER; REPERFUSION INJURY; CYCLOSPORINE-A; INNER MEMBRANE; PC12 CELLS; ACTIVATION	Reperfusion of cultured astrocytes with normal medium after exposure to H2O2-containing medium causes apoptosis. We have recently shown that ibudilast, which has been used for bronchial asthma and cerebrovascular disorders, attenuated the H2O2-induced apoptosis of astrocytes via the cGMP signaling pathway. This study examines the mechanism underlying the protective effect of cGMP. The membrane-permeable cGMP analog dibutyryl-cGMP attenuated the H2O2-induced decrease in cell viability, DNA ladder formation, nuclear condensation, reduction of the mitochondrial membrane potential, cytochrome c release from mitochondria, and caspase-3 activation in cultured astrocytes. These effects of dibutyryl-cGMP were almost completely inhibited by the cGMP-dependent protein kinase (PKG) inhibitor KT5823. In isolated rat brain mitochondria, cGMP in the presence of cytosolic extract from astrocytes inhibited the mitochondrial permeability transition pore (PTP) as determined by monitoring Ca2+-induced mitochondrial swelling. This ability of the cytosolic extract was inactivated by heat treatment and was mimicked by exogenous PKG. The effect of cGMP on the mitochondrial swelling was blocked by KT5823. The PTP inhibitors cyclosporin A and bongkrekic acid prevented the H2O2-induced decrease in cell viability and caspase-3 activation. These findings demonstrate that cGMP inhibits the mitochondrial PTP via the activation of PKG, and the prevention of mitochondrial dysfunction contributes to its anti-apoptotic effect.	Osaka Univ, Grad Sch Pharmaceut Sci, Lab Med Pharmacol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Lab Mol Neuropharmacol, Suita, Osaka 5650871, Japan; Kobe Gakuin Univ, Fac Pharmaceut Sci, Dept Analyt Chem, Kobe, Hyogo 6512180, Japan; Kobe Gakuin Univ, Fac Pharmaceut Sci, Dept Pharmacol, Kobe, Hyogo 6512180, Japan; Kobe Gakuin Univ, High Technol Res Ctr, Kobe, Hyogo 6512180, Japan	Osaka University; Osaka University; Kobe Gakuin University; Kobe Gakuin University; Kobe Gakuin University	Matsuda, T (corresponding author), Osaka Univ, Grad Sch Pharmaceut Sci, Lab Med Pharmacol, 1-6 Yamadaoka, Suita, Osaka 5650871, Japan.							Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; BEAUVAIS F, 1995, FEBS LETT, V361, P229, DOI 10.1016/0014-5793(95)00188-F; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Custodio JBA, 1998, TOXICOL APPL PHARM, V152, P10, DOI 10.1006/taap.1998.8510; Estevez AG, 1998, J NEUROSCI, V18, P3708; Farinelli SE, 1996, J NEUROSCI, V16, P2325; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Gu MF, 2000, J BIOL CHEM, V275, P11389, DOI 10.1074/jbc.275.15.11389; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; KRISTIAN T, 1994, BRAIN RES, V641, P295, DOI 10.1016/0006-8993(94)90158-9; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Matsuda T, 1998, J NEUROCHEM, V70, P2004; Matsuda T, 1996, EUR J NEUROSCI, V8, P951, DOI 10.1111/j.1460-9568.1996.tb01582.x; Matsuda T, 1997, JPN J PHARMACOL, V74, P1, DOI 10.1254/jjp.74.1; Moriya R, 2000, FEBS LETT, V484, P253, DOI 10.1016/S0014-5793(00)02167-0; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Sciorati C, 1997, J BIOL CHEM, V272, P23211, DOI 10.1074/jbc.272.37.23211; SIEMKOWICZ E, 1981, STROKE, V12, P236, DOI 10.1161/01.STR.12.2.236; Silberbach M, 1999, J BIOL CHEM, V274, P24858, DOI 10.1074/jbc.274.35.24858; SILVER IA, 1992, J CEREBR BLOOD F MET, V12, P759, DOI 10.1038/jcbfm.1992.107; SIMS NR, 1991, J NEUROCHEM, V56, P1836, DOI 10.1111/j.1471-4159.1991.tb03438.x; Takuma K, 2000, EUR J PHARMACOL, V399, P1, DOI 10.1016/S0014-2999(00)00334-4; Takuma K, 1999, EUR J NEUROSCI, V11, P4204, DOI 10.1046/j.1460-9568.1999.00850.x; TAKUMA K, 1994, GLIA, V12, P336, DOI 10.1002/glia.440120410; Takuma K, 1996, BRAIN RES, V735, P265, DOI 10.1016/0006-8993(96)00588-4; TAKUMA K, 1995, J NEUROCHEM, V64, P1536; Takuma K, 2000, EUR J PHARMACOL, V406, P333, DOI 10.1016/S0014-2999(00)00701-9; Takuma K, 1996, J NEUROCHEM, V67, P1840; Takuma K, 2001, BRIT J PHARMACOL, V133, P841, DOI 10.1038/sj.bjp.0704146; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; TSOU K, 1993, P NATL ACAD SCI USA, V90, P3462, DOI 10.1073/pnas.90.8.3462; Yoon HS, 2000, BIOCHEM BIOPH RES CO, V276, P151, DOI 10.1006/bbrc.2000.3445; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	44	132	136	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48093	48099		10.1074/jbc.M108622200	http://dx.doi.org/10.1074/jbc.M108622200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11677240	hybrid			2022-12-25	WOS:000172927000049
J	Stroka, DM; Burkhardt, T; Desbaillets, I; Wenger, RH; Neil, DAH; Bauer, C; Gassmann, M; Candinas, D				Stroka, DM; Burkhardt, T; Desbaillets, I; Wenger, RH; Neil, DAH; Bauer, C; Gassmann, M; Candinas, D			HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia	FASEB JOURNAL			English	Article						hypoxia-inducible factor 1; ARNT; tissue hypoxia	INDUCIBLE FACTOR 1-ALPHA; ENDOTHELIAL-GROWTH-FACTOR; TUMOR-SUPPRESSOR PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; PAS DOMAIN PROTEIN-1; TRANSCRIPTION FACTOR; FACTOR-I; RAT-BRAIN; DEGRADATION DOMAIN; VEGF EXPRESSION	Adaptation to hypoxia is regulated by hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor consisting of an oxygen-regulated alpha subunit and a constitutively expressed beta subunit. Although HIF-1 is regulated mainly by oxygen tension through the oxygen-dependent degradation of its alpha subunit, in vitro it can also be modulated by cytokines, hormones and genetic alterations. To investigate HIF-1 activation in vivo, we determined the spatial and temporal distribution of HIF-1 in healthy mice subjected to varying fractions of inspiratory oxygen. Immunohistochemical examination of brain, kidney, liver, heart, and skeletal muscle revealed that HIF-1 alpha is present in mice kept under normoxic conditions and is further increased in response to systemic hypoxia. Moreover, immunoblot analysis showed that the kinetics of HIF-1 alpha expression varies among different organs. In liver and kidney, HIF-1 alpha reaches maximal levels after 1 h and gradually decreases to baseline levels after 4 h of continuous hypoxia. In the brain, however, HIF-1 alpha is maximally expressed after 5 h and declines to basal levels by 12 h. Whereas HIF-1 beta is constitutively expressed in brain and kidney nuclear extracts, its hepatic expression increases concomitantly with HIF-1 alpha. Overall, HIF-1 alpha expression in normoxic mice suggests that HIF-1 has an important role in tissue homeostasis.	Univ Birmingham, Liver Labs, Birmingham, W Midlands, England; Univ Zurich, Inst Physiol, Zurich, Switzerland; Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany	University of Birmingham; University of Zurich; University of Lubeck	Stroka, DM (corresponding author), Queen Elizabeth Hosp, Liver Labs, Clin Res Block, Birmingham B15 2TH, W Midlands, England.	d.m.stroka@bham.ac.uk		Stroka, Deborah/0000-0002-3517-3871; Neil, Desley/0000-0001-9800-6811				Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Feldser D, 1999, CANCER RES, V59, P3915; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Jin KL, 2000, NEUROSCIENCE, V99, P577, DOI 10.1016/S0306-4522(00)00207-4; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kietzmann T, 2001, BIOCHEM J, V354, P531, DOI 10.1042/0264-6021:3540531; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; Martin C, 1998, AM J OBSTET GYNECOL, V178, P527, DOI 10.1016/S0002-9378(98)70433-8; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Royer C, 2000, BRAIN RES, V856, P119, DOI 10.1016/S0006-8993(99)02365-3; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; SCHMIDT EE, 1995, J CELL BIOL, V128, P467, DOI 10.1083/jcb.128.4.467; Smith RW, 1996, AM J PHYSIOL-REG I, V271, pR897, DOI 10.1152/ajpregu.1996.271.4.R897; Smith RW, 1999, AM J PHYSIOL-REG I, V277, pR690, DOI 10.1152/ajpregu.1999.277.3.R690; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1998, INT J MOL MED, V2, P317; Wenger RH, 1998, BLOOD, V91, P3471, DOI 10.1182/blood.V91.9.3471.3471_3471_3480; Wenger RH, 2000, J EXP BIOL, V203, P1253; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; Wenger RH, 1997, BIOL CHEM, V378, P609; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yu AY, 1998, AM J PHYSIOL-LUNG C, V275, pL818, DOI 10.1152/ajplung.1998.275.4.L818; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang X, 1997, BIOTECHNIQUES, V22, P848, DOI 10.2144/97225bm13; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 1999, CANCER RES, V59, P5830; Zundel W, 2000, GENE DEV, V14, P391	52	522	585	0	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2445	2453		10.1096/fj.01-0125com	http://dx.doi.org/10.1096/fj.01-0125com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689469	Green Published			2022-12-25	WOS:000172420500014
J	King, JG; Khalili, K				King, JG; Khalili, K			Inhibition of human brain tumor cell growth by the anti-inflammatory drug, flurbiprofen	ONCOGENE			English	Article						glioblastoma multiforme (GBM); non-steroidal anti-inflammatory drugs; COX-2; p53 induction	PRIMITIVE NEUROECTODERMAL TUMORS; COLON-CANCER CELLS; IN-VITRO; CYCLOOXYGENASE-2 EXPRESSION; R-FLURBIPROFEN; APOPTOSIS; SULINDAC; TOXICITY; MODELS; MOUSE	Despite many efforts to alter the relentlessly aggressive progression of tumors of neural origin, individuals bearing these tumors exhibit poor prognosis for longterm survival. In an attempt to find an effective treatment, we examined the efficacy of the non-steroidal anti-inflammatory drug, flurbiprofen, to suppress the growth of tumor cell lines derived from medulloblastoma and glioblastoma multiforme. Results from cell proliferation assays have revealed that flurbiprofen effectively inhibits the growth of various tumor cells in a dose-dependent manner and causes a noticeable change in the progression of cells through cell cycle stages. Treatment of tumor cells with flurbiprofen reduced the number of cells in G1 and G2, and significantly increased their numbers in S phase, suggesting that, flurbiprofen accelerates G1/S entry, and/or delays cell exit from S to G2/M stages. Results from RNase protection assay and Western blot analysis showed that while treatment of cells with flurbiprofen causes a minor change in the RNA level of different cyclins, there is a significant decrease in the level of cyclin B protein upon flurbiprofen treatment. Examination of tumor suppressors by RNase protection technique showed a subtle increase in the levels of several tumor suppressors upon flurbiprofen treatment. Interestingly, at the protein level, p53 tumor suppressor was substantially increased upon flurbiprofen treatment, yet the level of p21, a downstream target for p53 remained unchanged. Curiously, treatment of the cells with flurbiprofen enhanced the level of COX-2 expression. Results from co-immunoprecipitation showed association of COX-2 with p53 in tumor cells. These observations suggest that the interaction of COX-2 with p53 may cause p21-independent suppression of tumor cell growth upon flurbiprofen treatment.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Lab Canc Biol & Intervent, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Lab Canc Biol & Intervent, 1900 N 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.							Deininger MH, 1999, ACTA NEUROPATHOL, V98, P240, DOI 10.1007/s004010051075; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; Goldberg Y, 1996, ONCOGENE, V12, P893; Gottifredi V, 1999, J CELL SCI, V112, P2397; Grubbs CJ, 2000, CANCER RES, V60, P5599; HART MN, 1973, CANCER, V32, P890, DOI 10.1002/1097-0142(197310)32:4<890::AID-CNCR2820320421>3.0.CO;2-O; Joki T, 2000, CANCER RES, V60, P4926; Keller JJ, 1999, GUT, V45, P822, DOI 10.1136/gut.45.6.822; Kleihues P, 2000, PATHOLOGY GENETICS T; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; Matsuhashi N, 1997, GUT, V40, P344, DOI 10.1136/gut.40.3.344; MOLENAAR WM, 1994, CRIT REV ONCOL HEMAT, V17, P1, DOI 10.1016/1040-8428(94)90036-1; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Souza RF, 2000, CANCER RES, V60, P5767; Taylor MT, 2000, CANCER RES, V60, P6607; Tegeder I, 2001, FASEB J, V15, P595, DOI 10.1096/fasebj.15.3.595; von Knethen A, 1999, J IMMUNOL, V163, P2858; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Wechter WJ, 2000, CANCER RES, V60, P2203; Wechter WJ, 2000, LIFE SCI, V66, P745, DOI 10.1016/S0024-3205(99)00645-1; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 1996, AM J PHYSIOL, V270, P393; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	24	39	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6864	6870		10.1038/sj.onc.1204907	http://dx.doi.org/10.1038/sj.onc.1204907			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687965				2022-12-25	WOS:000171641000007
J	Konduri, SD; Rao, CN; Chandrasekar, N; Tasiou, A; Mohanam, S; Kin, Y; Lakka, SS; Dinh, D; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Rao, JS				Konduri, SD; Rao, CN; Chandrasekar, N; Tasiou, A; Mohanam, S; Kin, Y; Lakka, SS; Dinh, D; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Rao, JS			A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion	ONCOGENE			English	Article						TFPI-2; glioblastoma; invasion	MATRIX-DEGRADING METALLOPROTEINASE; SERINE PROTEINASE-INHIBITORS; ENDOTHELIAL GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; CELL-LINE; PROTEASE INHIBITOR; MELANOMA-CELLS; CDNA CLONING; FACTOR VIIA; IN-SITU	Human tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-type serine protease inhibitor that inhibits plasmin, trypsin, chymotrypsin, cathepsin G, and plasma kallikrein but not urokinase-type plasminogen activator, tissue plasminogen activator, or thrombin. Preliminary findings in our laboratory suggested that the expression of TFPI-2 is downregulated or lost during tumor progression in human gliomas. To investigate the role of TFPI-2 in the invasiveness of brain tumors, we stably transfected the human high-grade glioma cell line SNB19 and the human low-grade glioma cell line Hs683 with a vector capable of expressing a transcript complementary to the full-length TFPI-2 mRNA in either sense (0.7 kb) or antisense (1 kb) orientations. Parental cells and stably transfected cell lines were analysed for TFPI-2 protein by Western blotting and for TFPI-2 mRNA by Northern blotting. The levels of TFPI-2 protein and mRNA were higher in the sense clones (SNB19) and decreased in the antisense (Hs683) clones than in the corresponding parental and vector controls. In spheroid and matrigel invasion assays, the SNB19 parental cells were highly invasive, but the sense-transfected SNB-19 clones were much less invasive; the antisense-transfected Hs683 clones were more invasive than their parental and vector controls. After intracerebral injection in mice, the sense-transfected SNB19 clones were less able to form tumors than were their parental and vector controls, and the antisense-Hs683 clones but not the parental or vector controls formed small tumors. This is the first study to demonstrate that down- or upregulation of TFPI-2 plays a significant role in the invasive behavior of human gliomas.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neuropathol, Div Canc Biol, Peoria, IL 61656 USA; Zymogenet Inc, Seattle, WA 98105 USA; Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Ctr Prostate Dis Res, Rockville, MD USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; Zymogenet Inc.; University of New Mexico; University of New Mexico's Health Sciences Center	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, 1 Illini Dr, Peoria, IL 61656 USA.			Tasiou, Anastasia/0000-0002-8853-540X	NCI NIH HHS [CA-75692, CA-76350, CA-75557] Funding Source: Medline; NHLBI NIH HHS [HL-64119] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075557, R01CA076350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIZIK J, 1990, CELL REGUL, V1, P895, DOI 10.1091/mbc.1.12.895; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; DVORAK HF, 1987, HUM PATHOL, V18, P275, DOI 10.1016/S0046-8177(87)80010-2; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; Eitzman DT, 1996, BLOOD, V87, P4718; GLADSON CL, 1995, AM J PATHOL, V146, P1150; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Hembrough TA, 2001, J BIOL CHEM, V276, P12241, DOI 10.1074/jbc.M010395200; Kondraganti S, 2000, CANCER RES, V60, P6851; Konduri SD, 2001, INT J ONCOL, V18, P127; Konduri SD, 2000, CLIN EXP METASTAS, V18, P303, DOI 10.1023/A:1011085820250; KOSHIKAWA N, 1994, BIOCHEM J, V303, P187, DOI 10.1042/bj3030187; KOSHIKAWA N, 1992, CANCER RES, V52, P5046; KRAMER MD, 1994, INVAS METAST, V14, P210; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; LINO M, 1998, ARTERIOSCLER THROMB, V18, P40; LUNDJOHANSEN M, 1990, SPHEROID CULTURE CAN, P3; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Miyagi Y, 1996, DNA CELL BIOL, V15, P947, DOI 10.1089/dna.1996.15.947; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; MIYAZAKI K, 1990, CANCER RES, V50, P7758; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; Nakagawa K, 1998, SEMIN THROMB HEMOST, V24, P207, DOI 10.1055/s-2007-995843; Neaud V, 2000, J BIOL CHEM, V275, P35565, DOI 10.1074/jbc.M006101200; Ollivier V, 1998, BLOOD, V91, P2698, DOI 10.1182/blood.V91.8.2698.2698_2698_2703; PEDERSEN PH, 1993, CANCER RES, V53, P5158; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; QUAX PHA, 1991, J CELL BIOL, V115, P191, DOI 10.1083/jcb.115.1.191; Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V319, P55, DOI 10.1006/abbi.1995.1266; Rao CN, 1999, BIOCHEM BIOPH RES CO, V255, P94, DOI 10.1006/bbrc.1999.0153; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; RAO CN, 1995, J INVEST DERMATOL, V104, P379, DOI 10.1111/1523-1747.ep12665851; Rao CN, 2001, CLIN CANCER RES, V7, P570; REINARTZ J, 1993, EXP CELL RES, V208, P197, DOI 10.1006/excr.1993.1238; Ruf W, 1996, Curr Opin Hematol, V3, P379; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; Shoji M, 1998, AM J PATHOL, V152, P399; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; Taniguchi T, 1998, CANCER RES, V58, P4461; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P43; UMENISHI F, 1990, J BIOCHEM-TOKYO, V108, P537, DOI 10.1093/oxfordjournals.jbchem.a123238; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WAGNER SL, 1989, J BIOL CHEM, V264, P611; YAMAMOTO M, 1994, CANCER RES, V54, P5016; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V111, P74, DOI 10.1093/oxfordjournals.jbchem.a123721; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	58	67	79	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6938	6945		10.1038/sj.onc.1204847	http://dx.doi.org/10.1038/sj.onc.1204847			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687973				2022-12-25	WOS:000171641000015
J	Delarue, FL; Taylor, BS; Sebti, SM				Delarue, FL; Taylor, BS; Sebti, SM			Ras and RhoA suppress whereas RhoB enhances cytokine-induced transcription of nitric oxide synthase-2 in human normal liver AKN-1 cells and lung cancer A-549 cells	ONCOGENE			English	Article						NOS-2; Ras; RhoA; RhoB; Erk; cytokines	SMOOTH-MUSCLE CELLS; PRIMARY ASTROCYTES; TUMOR-GROWTH; TRANSFORMATION; PROTEIN; EXPRESSION; INDUCTION; GENE; ADENOCARCINOMA; INHIBITION	While both nitric oxide synthase-2 (NOS-2) and low molecular weight GTPases, such as Ras and Rho, have been implicated in malignant transformation, the cross talk between these important proteins is ill understood. In this study we examined the ability of H-Ras, RhoA, RhoB and Rac1 to modulate cytokine-induced NOS2. In the normal human liver AKN-1 cell line and in the human non-small cell lung carcinoma cell line, A-549, the ability of the cytokines (INF-gamma, IL-1 beta and TNF-alpha) to activate NOS-2 was blocked by activated L61-H-Ras whereas dominant negative N17-H-Ras enhanced NOS-2 activation. Consistent with this dominant negative Erk2 as well as a MEK inhibitor also enhanced cytokine activation of NOS-2. Furthermore, activated L63-RhoA blocked whereas activated V14-RhoB enhanced cytokine NOS-2 activation. Activated I115-Rac1 did not affect NOS-2 activation. These results demonstrate that the Ras/Erk and the Ras/RhoA pathways negatively regulate whereas RhoB enhances cytokine-induced NOS-2. This is the first demonstration that genes that promote malignant transformation such as Ras and RhoA inhibit, whereas genes with tumor suppresser activity such as RhoB enhance NOS2 induction.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Oncol, Tampa, FL USA; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA-67771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Baron R, 2000, P NATL ACAD SCI USA, V97, P11626, DOI 10.1073/pnas.97.21.11626; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; CURLEY SA, 1993, J LEUKOCYTE BIOL, V53, P715, DOI 10.1002/jlb.53.6.715; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; DONG ZY, 1994, CANCER RES, V54, P789; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; HER JH, 1993, MOL CELL BIOL, V19, P7519; Juang SH, 1997, CANCER BIOTHER RADIO, V12, P167, DOI 10.1089/cbr.1997.12.167; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LEPOIVRE M, 1989, CANCER RES, V49, P1970; MORDAN LJ, 1993, CARCINOGENESIS, V14, P1555, DOI 10.1093/carcin/14.8.1555; Muniyappa R, 2000, AM J PHYSIOL-HEART C, V278, pH1762, DOI 10.1152/ajpheart.2000.278.6.H1762; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; Nussler AK, 1999, IN VITRO CELL DEV-AN, V35, P190, DOI 10.1007/s11626-999-0026-4; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINI VB, 1992, EUR J PHARMACOL, V216, P379, DOI 10.1016/0014-2999(92)90434-6; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Shi Q, 2000, CANCER RES, V60, P2579; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Wang BL, 2001, CANCER RES, V61, P71; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	28	27	29	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6531	6537		10.1038/sj.onc.1204801	http://dx.doi.org/10.1038/sj.onc.1204801			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641777				2022-12-25	WOS:000171404200005
J	Sapriel, G; Wandersman, C; Delepelaire, P				Sapriel, G; Wandersman, C; Delepelaire, P			The N terminus of the HasA protein and the SecB chaperone cooperate in the efficient targeting and secretion of HasA via the ATP-binding cassette transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SERRATIA-MARCESCENS; ERWINIA-CHRYSANTHEMI; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; ABC TRANSPORTER; MEMBRANE; EXPORT; HEME; ACQUISITION	Secretion of the HasA hemophore is mediated by a C-terminal secretion signal as part of an ATP-binding cassette (ABC) pathway in the Gram-negative bacterium Serratia marcescens. We reconstituted the HasA secretion pathway in Escherichia coli. In E. coli, this pathway required three specific secretion functions and SecB, the general chaperone of the Sec pathway that recognizes HasA. The secretion of the isolated C-terminal secretion signal was not SecB-dependent. We have previously shown that intracellular folded HasA can no longer be secreted, and we proposed a step in the secretion process before the recognition of the secretion signal. Here we show that the secretion of a fully functional HasA variant, lacking the first 10 N-terminal amino acids, was less efficient than that of HasA and was SecB-independent. The N terminus of HasA was required, along with SecB, for the efficient secretion of the whole protein. We have also previously shown that HasA inhibits the secretion of metalloproteases from Erwinia chrysanthemi by their specific ABC transporter. Here we show that this abortive interaction between HasA and the E. chrysanthemi metalloprotease ABC transporter required both SecB and the N terminus of HasA. N-terminal fragments of HasA displayed this abortive interaction in vivo and also interacted specifically in vitro with the ABC protein of the Prt system. SecB also interacted specifically in vitro with the ABC protein of the Prt system. Finally, the HasA variant, lacking the first 10 N-terminal amino acids did not display this abortive interaction with the Prt system. We suggest that the N-terminal domain of HasA specifically recognizes the ABC protein in a SecB-dependent fashion, facilitating functional interaction with the C-terminal secretion signal leading to efficient secretion.	Inst Pasteur, CNRS URA 2172, Unite Membranes Bacteriennes, Dept Biotechnol, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Sapriel, G (corresponding author), Inst Pasteur, CNRS URA 2172, Unite Membranes Bacteriennes, Dept Biotechnol, 25-28 Rue Dr Roux, F-75724 Paris 15, France.	gsapriel@pasteur.fr		Delepelaire, Philippe/0000-0002-5190-7118				Arnoux P, 1999, NAT STRUCT BIOL, V6, P516; BANKAITIS VA, 1984, J BIOL CHEM, V259, P2193; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; Binet R, 1996, MOL MICROBIOL, V22, P265, DOI 10.1046/j.1365-2958.1996.00103.x; Binet R, 1997, GENE, V192, P7, DOI 10.1016/S0378-1119(96)00829-3; BINET R, 1995, EMBO J, V14, P2298, DOI 10.1002/j.1460-2075.1995.tb07224.x; COLLIER DN, 1993, ADV PROTEIN CHEM, V44, P151, DOI 10.1016/S0065-3233(08)60567-7; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; Debarbieux L, 2001, EMBO J, V20, P4657, DOI 10.1093/emboj/20.17.4657; DELEPELAIRE P, 1994, J BIOL CHEM, V269, P27952; Delepelaire P, 1998, EMBO J, V17, P936, DOI 10.1093/emboj/17.4.936; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; Ghigo JM, 1997, J BACTERIOL, V179, P3572, DOI 10.1128/jb.179.11.3572-3579.1997; GHIGO JM, 1994, J BIOL CHEM, V269, P8979; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Letoffe S, 1996, EMBO J, V15, P5804, DOI 10.1002/j.1460-2075.1996.tb00967.x; LETOFFE S, 1994, J BACTERIOL, V176, P5372; LETOFFE S, 1990, EMBO J, V9, P1375, DOI 10.1002/j.1460-2075.1990.tb08252.x; LETOFFE S, 1994, P NATL ACAD SCI USA, V91, P9876, DOI 10.1073/pnas.91.21.9876; Letoffe S, 1998, MOL MICROBIOL, V28, P1223, DOI 10.1046/j.1365-2958.1998.00885.x; Letoffe S, 2000, J BACTERIOL, V182, P4401, DOI 10.1128/JB.182.16.4401-4405.2000; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NICAUD JM, 1986, FEBS LETT, V204, P331, DOI 10.1016/0014-5793(86)80838-9; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Rossi MS, 2001, INFECT IMMUN, V69, P6707, DOI 10.1128/IAI.69.11.6707-6717.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SPRATT BG, 1986, GENE, V41, P337, DOI 10.1016/0378-1119(86)90117-4; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; WANDERSMAN C, 1987, J BACTERIOL, V169, P5046, DOI 10.1128/jb.169.11.5046-5053.1987; WANDERSMAN C, 1996, ESCHERICHIA COLI SAL, P955; Wolff N, 1997, EUR J BIOCHEM, V243, P400, DOI 10.1111/j.1432-1033.1997.0400a.x	38	21	21	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6726	6732		10.1074/jbc.M108632200	http://dx.doi.org/10.1074/jbc.M108632200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11698405	hybrid			2022-12-25	WOS:000173989200135
J	Wang, HY; Kanungo, J; Malbon, CC				Wang, HY; Kanungo, J; Malbon, CC			Expression of G alpha 13 (Q226L) induces p19 stem cells to primitive endoderm via MEKK1, 2, or 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; EMBRYONAL CARCINOMA-CELLS; RETINOIC ACID; DROSOPHILA MORPHOGENESIS; BETA-CATENIN; JNK; DIFFERENTIATION; STIMULATION	Galpha13 mediates the ability of the morphogen retinoic acid to promote primitive endoderm formation from mouse P19 embryonal carcinoma stem cells, a process that includes the obligate activation of Jun N-terminal kinase. Expression of the constitutively activated (Q226L) GTPase-deficient form of Galpha13 mimics retinoic acid and was used to investigate the signaling upstream of primitive endoderm formation. Jun N-terminal kinase 1 activity, MEK1,2, MKK4, and MEKK1 were constitutively activated in clones stably transfected to express Q226L Galpha13. Dominant negative forms of MEKK1 and MEKK4 were expressed stably in the clones harboring Q226L Galpha13. Expression of dominant negative versions of either MEKK1 or MEKK4 effectively blocks both the activation of Jun N-terminal kinase as well as the formation of primitive endoderm. Depletion of MEKK1, -2, or -4 by antisense oligodeoxynucleotides suppressed signaling from Q226L Galpha13 to JNK1 and primitive endoderm formation. We demonstrate that the signal linkage map from Galpha13 activation to primitive endoderm formation in these stem cells requires activation at three levels of the mitogen-activated protein kinase cascade: MEKK1, -2, or -4 for MAP kinase kinase kinase; MKK4 and/or MEK1 for MAP kinase kinase; and JNK1 for MAP kinase.	SUNY Stony Brook, HSC,Univ Med Ctr, Diabet & Metab Dis Res Program, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Univ Med Ctr, Diabet & Metab Dis Res Program, Dept Mol Pharmacol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Wang, HY (corresponding author), SUNY Stony Brook, HSC,Univ Med Ctr, Diabet & Metab Dis Res Program, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.		malbon, craig/ABF-3604-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK030111, DK30111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Chandler LJ, 2001, J BIOL CHEM, V276, P2627, DOI 10.1074/jbc.M003390200; Craddock BL, 2001, J BIOL CHEM, V276, P24274, DOI 10.1074/jbc.M009098200; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; Kanungo J, 2000, J BIOL CHEM, V275, P24032, DOI 10.1074/jbc.M002747200; Kawasaki M, 1999, EMBO J, V18, P3604, DOI 10.1093/emboj/18.13.3604; Lee JH, 2001, AM J PHYSIOL-LUNG C, V280, pL1019, DOI 10.1152/ajplung.2001.280.5.L1019; Magie CR, 1999, DEVELOPMENT, V126, P5353; Malbon CC, 1997, BIOCHEM PHARMACOL, V53, P1, DOI 10.1016/S0006-2952(96)00662-4; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; NAJLERAHIM A, 1993, NEUROCHEM RES, V18, P291, DOI 10.1007/BF00969085; Neo SY, 2000, BIOCHEM BIOPH RES CO, V272, P144, DOI 10.1006/bbrc.2000.2751; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Yamauchi J, 2001, J BIOL CHEM, V276, P23362, DOI 10.1074/jbc.M011752200; Yamauchi J, 2001, BIOCHEM BIOPH RES CO, V284, P1199, DOI 10.1006/bbrc.2001.5103	29	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3530	3536		10.1074/jbc.M107031200	http://dx.doi.org/10.1074/jbc.M107031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11700306	hybrid, Green Accepted			2022-12-25	WOS:000173688000063
J	Charbonnier, F; Della Gaspera, B; Armand, AS; Van der Laarse, WJ; Launay, T; Becker, C; Gallien, CL; Chanoine, C				Charbonnier, F; Della Gaspera, B; Armand, AS; Van der Laarse, WJ; Launay, T; Becker, C; Gallien, CL; Chanoine, C			Two myogenin-related genes are differentially expressed in Xenopus laevis myogenesis and differ in their ability to transactivate muscle structural genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ACTIVATION DOMAINS; PROTEIN-KINASE-C; SUCCINATE-DEHYDROGENASE; REGULATORY FACTORS; SKELETAL-MUSCLE; MESSENGER-RNAS; 2 DOMAINS; MYOD; CELLS; PHOSPHORYLATION	Among the myogenic regulatory factors, myogenin is a transcriptional activator situated at a crucial position for terminal differentiation in muscle development. It is unclear at present whether myogenin exhibits unique specificities to transactivate late muscular markers. During Xenopus development, the accumulation of myogenin mRNA is restricted to secondary myogenesis, at the onset of the appearance of adult isoforms of beta-tropomyosin and myosin heavy chain. To determine the role of myogenin in the isoform switch of these contractile proteins, we characterized and directly compared the functional properties of myogenin with other myogenic regulatory factors in Xenopus embryos. Two distinct cDNAs related to myogenin, XmyogU1 and XmyogU2, were differentially expressed during myogenesis and in adult tissues, in which they preferentially accumulated in oxidative myofibers. Animal cap assays in Xenopus embryos revealed that myogenin, but not the other myogenic regulatory factors, induced expression of embryonic/larval isoforms of the beta-tropomyosin and myosin heavy chain genes. Only XmyogU1 induced expression of the adult fast isoform of the myosin heavy chain gene. This is the first demonstration of a specific transactivation of one set of muscle structural genes by myogenin.	Univ Paris 05, Lab Biol Dev & Differenciat Musculaire EA 2507, Ctr Univ St Peres, F-75270 Paris 06, France; Free Univ Amsterdam, Physiol Lab, NL-1081 BT Amsterdam, Netherlands	UDICE-French Research Universities; Universite Paris Cite; Vrije Universiteit Amsterdam	Chanoine, C (corresponding author), Univ Paris 05, Lab Biol Dev & Differenciat Musculaire EA 2507, Ctr Univ St Peres, F-75270 Paris 06, France.			Armand, Anne-Sophie/0000-0002-0291-6421; chanoine, christophe/0000-0001-8155-2357; BECKER, Christel/0000-0002-0680-2851; della gaspera, bruno/0000-0002-0652-1822; van der Laarse, Willem J/0000-0002-8391-0354; Charbonnier, Frederic/0000-0003-4341-3246	PHS HHS [AY046532, AY046531] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bergstrom DA, 2001, MOL CELL BIOL, V21, P2404, DOI 10.1128/MCB.21.7.2404-2412.2001; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Faber J., 1994, NORMAL TABLE XENOPUS, P2; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; Gaillard C, 1999, INT J DEV BIOL, V43, P175; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; GRAF JD, 1991, METHOD CELL BIOL, V36, P19; GURDON JB, 1992, SEMIN DEV BIOL, V3, P255; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HOPWOOD ND, 1991, DEVELOPMENT, V111, P551; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; HUANG XQ, 1990, COMPUT APPL BIOSCI, V6, P373; Hughes SM, 1999, J CELL BIOL, V145, P633, DOI 10.1083/jcb.145.3.633; JENNINGS CGB, 1992, DEV BIOL, V150, P121, DOI 10.1016/0012-1606(92)90012-6; Knoepfle N, 1999, BIOCHEMISTRY-US, V38, P1582, DOI 10.1021/bi9821418; Kobiyama A, 1998, J EXP BIOL, V201, P2801; LANNERGREN J, 1966, ACTA PHYSIOL SCAND, V68, P263, DOI 10.1111/j.1748-1716.1966.tb03427.x; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Liu SH, 2000, J BIOL CHEM, V275, P41364, DOI 10.1074/jbc.M004172200; LUDOLPH DC, 1994, DEV BIOL, V166, P18, DOI 10.1006/dbio.1994.1294; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MENDELZON D, 1994, BIOCHEMISTRY-US, V33, P2568, DOI 10.1021/bi00175a028; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Myer A, 1997, DEV BIOL, V185, P127, DOI 10.1006/dbio.1997.8565; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nicolas N, 1996, DEV DYNAM, V207, P60; Nicolas N, 1998, DEV DYNAM, V213, P309, DOI 10.1002/(SICI)1097-0177(199811)213:3<309::AID-AJA7>3.0.CO;2-Z; NISHIKAWA A, 1994, DEV BIOL, V165, P86, DOI 10.1006/dbio.1994.1236; Pelpel K, 2000, FEBS LETT, V474, P233, DOI 10.1016/S0014-5793(00)01610-0; POOL CW, 1979, HISTOCHEMISTRY, V64, P251, DOI 10.1007/BF00495025; RADICE GP, 1989, DEV BIOL, V133, P562, DOI 10.1016/0012-1606(89)90058-4; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; SCALES JB, 1990, MOL CELL BIOL, V10, P1516, DOI 10.1128/MCB.10.4.1516; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; Tajbakhsh S, 2000, CURR TOP DEV BIOL, V48, P225; Talmadge RJ, 2000, MUSCLE NERVE, V23, P661, DOI 10.1002/(SICI)1097-4598(200005)23:5<661::AID-MUS3>3.0.CO;2-J; Valdez MR, 2000, DEV BIOL, V219, P287, DOI 10.1006/dbio.2000.9621; VANDERLAARSE WJ, 1989, J MUSCLE RES CELL M, V10, P221, DOI 10.1007/BF01739812; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZHOU JM, 1994, MOL CELL BIOL, V14, P6232, DOI 10.1128/MCB.14.9.6232	51	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1139	1147		10.1074/jbc.M107018200	http://dx.doi.org/10.1074/jbc.M107018200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11684685	hybrid			2022-12-25	WOS:000173166800035
J	Cliby, WA; Lewis, KA; Lilly, KK; Kaufmann, SH				Cliby, WA; Lewis, KA; Lilly, KK; Kaufmann, SH			S phase and G(2) arrests induced by topoisomerase I poisons are dependent on ATR kinase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; ATAXIA-TELANGIECTASIA CELLS; DOUBLE-STRAND BREAKS; MAMMALIAN-CELLS; REPLICATION FORKS; PROTEIN-KINASE; CAMPTOTHECIN CYTOTOXICITY; RADIOSENSITIZING AGENT; CYCLE; MECHANISMS	ATR, a human phosphatidylinositol 3-kinase-related kinase, is an important component of the cellular response to DNA damage. In the present study, we evaluated the role of ATR in modulating the response of cells to S phase-associated DNA double-stranded breaks induced by topoisomerase poisons. Prolonged exposure to low doses of the topoisomerase I poison topotecan (TPT) resulted in S phase slowing because of diminished DNA synthesis at late-firing replicons. In contrast, brief TPT exposure, as well as prolonged exposure to the topoisomerase 11 poison etoposide, resulted in subsequent G(2) arrest. These responses were associated with phosphorylation of the checkpoint kinase Chk1. The cell cycle responses and phosphorylation of Chk1 were markedly diminished by forced overexpression of a dominant negative, kinase-inactive allele of ATR. In contrast, deficiency of the related kinase ATM had no effect on these events. The loss of ATR-dependent checkpoint function sensitized GM847 human fibroblasts to the cytotoxic effects of the topoisomerase I poisons TPT and 7-ethyl-10-hydroxycamptothecin, as assessed by inhibition of colony formation, increased trypan blue uptake, and development of apoptotic morphological changes. Expression of kdATR also sensitized GM847 cells to the cytotoxic effects of prolonged low dose etoposide and doxorubicin, albeit to a smaller extent. Collectively, these results not only suggest that ATR is important in responding to the replication-associated DNA damage from topoisomerase poisons, but also support the view that ATM and ATR have unique roles in activating the downstream kinases that participate in cell cycle checkpoints.	Mayo Clin, Div Obstet & Gynecol, Rochester, MN 55905 USA; Mayo Grad Sch, Dept Mol Pharmacol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Cliby, WA (corresponding author), Mayo Clin, Div Obstet & Gynecol, 200 1st St SW, Rochester, MN 55905 USA.	cliby.william@mayo.edu		Kaufmann, Scott/0000-0002-4900-7145	NCI NIH HHS [R01 CA73709, R01 CA073709] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; Brown EJ, 2000, GENE DEV, V14, P397; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Busby EC, 2000, CANCER RES, V60, P2108; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Carr AM, 1997, CURR OPIN GENET DEV, V7, P93, DOI 10.1016/S0959-437X(97)80115-3; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen P, 1999, ONCOGENE, V18, P249, DOI 10.1038/sj.onc.1202257; Clarke DJ, 2000, BIOESSAYS, V22, P351, DOI 10.1002/(SICI)1521-1878(200004)22:4<351::AID-BIES5>3.0.CO;2-W; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; DARPA P, 1990, CANCER RES, V50, P6919; DELBINO G, 1991, EXP CELL RES, V193, P27, DOI 10.1016/0014-4827(91)90534-2; Desai SD, 2001, CANCER RES, V61, P5926; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fiorani P, 2000, ANN NY ACAD SCI, V922, P65; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; HOLM C, 1989, CANCER RES, V49, P6365; HORWITZ SB, 1973, CANCER RES, V33, P2834; HSIANG YH, 1989, CANCER RES, V49, P5077; Johnson RT, 1999, BIOCHEM BIOPH RES CO, V261, P317, DOI 10.1006/bbrc.1999.1024; KAUFMANN SH, 1991, CANCER RES, V51, P1129; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; KAUFMANN SH, 1991, CANCER RES, V51, P3534; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; LI LH, 1972, CANCER RES, V32, P2643; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Liu L F, 1992, Important Adv Oncol, P79; Liu QH, 2000, GENE DEV, V14, P1448; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mullany S, 1998, CANCER CHEMOTH PHARM, V42, P391, DOI 10.1007/s002800050835; NAEGELI H, 1994, BIOESSAYS, V16, P557, DOI 10.1002/bies.950160809; Neecke H, 1999, EMBO J, V18, P4485, DOI 10.1093/emboj/18.16.4485; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Rhind N, 2000, J CELL SCI, V113, P3889; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; SHIN CG, 1990, BIOCHEM BIOPH RES CO, V168, P135, DOI 10.1016/0006-291X(90)91684-K; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; TOBEY RA, 1972, CANCER RES, V32, P2720; TSAO YP, 1992, CANCER RES, V52, P1823; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X	59	170	178	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1599	1606		10.1074/jbc.M106287200	http://dx.doi.org/10.1074/jbc.M106287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11700302	hybrid			2022-12-25	WOS:000173166800095
J	Hellman, NE; Kono, S; Miyajima, H; Gitlin, JD				Hellman, NE; Kono, S; Miyajima, H; Gitlin, JD			Biochemical analysis of a missense mutation in aceruloplasminemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED FORM; CERULOPLASMIN GENE; COPPER; EXPRESSION; TRANSPORT; CELLS; AMPLIFICATION; BIOSYNTHESIS; MECHANISMS; REVEALS	Aceruloplasminemia is an inherited neurodegenerative disease characterized by parenchymal iron accumulation secondary to loss-of-function mutations in the ceruloplasmin gene. To elucidate the molecular pathogenesis of aceruloplasminemia, the biosynthesis of a missense mutant ceruloplasmin (P177R) occurring in an affected patient was examined. Chinese hamster ovary cells transfected with cDNAs encoding secreted and glycosylphosphatidylinositol (GPI)-linked wild-type or P177R human ceruloplasmin were examined by pulse-chase metabolic labeling. These experiments, as well as immunofluorescent analysis and N-linked glycosylation studies, indicate that both the secreted and GPI-linked forms of the P177R mutant are retained in the endoplasmic reticulum (ER). The P177R mutation resides within a novel motif, which is repeated six times in human ceruloplasmin and is conserved in the homologous proteins hephaestin and factor VIII. Analysis of additional mutations in these motifs suggests a critical role for this region in ceruloplasmin trafficking and indicates that substitution of the arginine residue is critical to the ER retention of the P177R mutant. Metabolic labeling of transfected Chinese hamster ovary cells with (CU)-C-64 indicates that the P177R mutant is retained in the ER as an apoprotein and that copper is incorporated into both secreted and GPI-linked ceruloplasmin as a late event in the secretory pathway. Taken together, these studies reveal new insights into the determinants of holoceruloplasmin biosynthesis and indicate that aceruloplasminemia can result from retention of mutant ceruloplasmin within the early secretory pathway.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 43131, Japan	Washington University (WUSTL); Hamamatsu University School of Medicine	Gitlin, JD (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, McDonnell Pediat Res Bldg,660 S Euclid Ave, St Louis, MO 63110 USA.	gitlin@kids.wustl.edu			NCI NIH HHS [CA 86307] Funding Source: Medline; NHLBI NIH HHS [HL41536] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA086307] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041536] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONARAKIS SE, 1995, HUM MUTAT, V5, P1, DOI 10.1002/humu.1380050102; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; CAMAKARIS J, 1995, HUM MOL GENET, V4, P2117, DOI 10.1093/hmg/4.11.2117; Connett JM, 1996, P NATL ACAD SCI USA, V93, P6814, DOI 10.1073/pnas.93.13.6814; De Jonghe P, 1997, J Peripher Nerv Syst, V2, P370; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Fortna RR, 1999, BIOL REPROD, V61, P1042, DOI 10.1095/biolreprod61.4.1042; Gitlin JD, 1998, PEDIATR RES, V44, P271, DOI 10.1203/00006450-199809000-00001; GITLIN JD, 1988, J BIOL CHEM, V263, P6281; GITLIN JD, 1992, BIOCHEM J, V282, P835, DOI 10.1042/bj2820835; Gow A, 1996, NAT GENET, V13, P422, DOI 10.1038/ng0896-422; Hamza I, 2001, P NATL ACAD SCI USA, V98, P6848, DOI 10.1073/pnas.111058498; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; HOLTZMAN NA, 1970, J BIOL CHEM, V245, P2350; Klomp LWJ, 1996, HUM MOL GENET, V5, P1989, DOI 10.1093/hmg/5.12.1989; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MOLLGARD K, 1988, DEV BIOL, V128, P207, DOI 10.1016/0012-1606(88)90283-7; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Patel BN, 2000, J BIOL CHEM, V275, P4305, DOI 10.1074/jbc.275.6.4305; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Salzer JL, 1998, J NEUROSCI RES, V54, P147, DOI 10.1002/(SICI)1097-4547(19981015)54:2<147::AID-JNR3>3.0.CO;2-E; SATO M, 1991, J BIOL CHEM, V266, P5128; SCHEINBERG IH, 1952, SCIENCE, V116, P484, DOI 10.1126/science.116.3018.484; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P390, DOI 10.1073/pnas.81.2.390; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	36	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1375	1380		10.1074/jbc.M109123200	http://dx.doi.org/10.1074/jbc.M109123200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11689569	hybrid			2022-12-25	WOS:000173166800067
J	Huber, MA; Denk, A; Peter, RU; Weber, L; Kraut, N; Wirth, T				Huber, MA; Denk, A; Peter, RU; Weber, L; Kraut, N; Wirth, T			The IKK-2/I kappa B alpha/NF-kappa B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts - A critical link to dermatitis in I kappa B alpha-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY EPITHELIAL-CELLS; TRANSCRIPTION FACTORS; MESSENGER-RNA; GENOMIC ORGANIZATION; ENHANCED EXPRESSION; GENE-TRANSCRIPTION; ATOPIC-DERMATITIS; INFLAMMATION; CHEMOKINE; INDUCTION	Tumor necrosis factor (TNF)-alpha-induced phosphorylation of the IkappaB proteins by the IkappaB kinase (IKK) complex containing IKK-2 and subsequent degradation of the IkappaB proteins are prerequisites for NF-kappaB activation, resulting in the stimulation of a variety of pro-inflammatory target genes. The C-C chemokine eotaxin-1 is a potent chemoattractant for eosinophils and Th2 lymphocytes, may play an important role in the pathogenesis of atopic dermatitis, and acts via binding to its receptor CCR3. To investigate the role of NF-kappaB signaling in the regulation of these genes, we stably expressed a transdominant mutant of IkappaBalpha and a constitutively active mutant of IKK-2 in mouse NIH3T3 fibroblasts. The transdominant IkappaBalpha mutant completely inhibited TNF-alpha-mediated induction of both eotaxin-1 and CCR3, whereas expression of constitutively active IKK-2 was sufficient to drive almost full expression of these two genes in the absence of TNF-alpha. Moreover, we observed elevated expression levels of CCR3 and eotaxin-l protein levels in the skin of IkappaBalpha-deficient mice characterized by a widespread dermatitis. Finally, using dermal fibroblasts derived from IkappaBalpha-deficient mice, we observed elevated basal expression, enhanced inducibility by TNF-alpha, and attenuated down-regulation upon TNF-alpha withdrawal of both CCR3 and eotaxin-1 mRNA levels. These results demonstrate that the IKK-2/IkappaBalpha/NF-kappaB pathway plays a critical role for CCR3 and eotaxin-1 expression in fibroblasts and suggests a critical link to the pathogenesis of atopic dermatitis.	Univ Ulm, Dept Dermatol, D-89081 Ulm, Germany; Univ Ulm, Dept Physiol Chem, D-89081 Ulm, Germany; Boehringer Ingelheim Austria GMBH, Dept Exploratory Res, A-1121 Vienna, Austria	Ulm University; Ulm University; Boehringer Ingelheim	Wirth, T (corresponding author), Univ Ulm, Dept Dermatol, Oberer Eselsberg 40, D-89081 Ulm, Germany.		Wirth, Thomas/X-7172-2019					Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bartels J, 1996, BIOCHEM BIOPH RES CO, V225, P1045, DOI 10.1006/bbrc.1996.1292; Barton D, 2000, EUR J IMMUNOL, V30, P2323, DOI 10.1002/1521-4141(2000)30:8<2323::AID-IMMU2323>3.0.CO;2-H; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; GarciaZepeda EA, 1997, GENOMICS, V41, P471, DOI 10.1006/geno.1997.4656; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GARINCHESA P, 1987, P NATL ACAD SCI USA, V84, P3234; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; GRIFFITHSJOHNSON DA, 1993, BIOCHEM BIOPH RES CO, V197, P1167, DOI 10.1006/bbrc.1993.2599; Grignani F, 1998, CANCER RES, V58, P14; Gutierrez-Ramos JC, 1999, IMMUNOL TODAY, V20, P500, DOI 10.1016/S0167-5699(99)01522-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hein H, 1997, BIOCHEM BIOPH RES CO, V237, P537, DOI 10.1006/bbrc.1997.7169; Huber MA, 2000, BIOCHEM BIOPH RES CO, V269, P546, DOI 10.1006/bbrc.2000.2287; Jedrzkiewicz S, 2000, AM J PHYSIOL-LUNG C, V279, pL1058, DOI 10.1152/ajplung.2000.279.6.L1058; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsukura S, 1999, J IMMUNOL, V163, P6876; Mattoli S, 1997, BIOCHEM BIOPH RES CO, V236, P299, DOI 10.1006/bbrc.1997.6958; Mochizuki M, 1998, J IMMUNOL, V160, P60; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; ROTHENBERG ME, 1995, J EXP MED, V181, P1211, DOI 10.1084/jem.181.3.1211; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739; Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Zimmermann N, 2000, BLOOD, V96, P2346	39	51	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1268	1275		10.1074/jbc.M109358200	http://dx.doi.org/10.1074/jbc.M109358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694538	hybrid			2022-12-25	WOS:000173166800053
J	Umemura, T; Matsumoto, Y; Ohnishi, K; Homma, M; Kawagishi, I				Umemura, T; Matsumoto, Y; Ohnishi, K; Homma, M; Kawagishi, I			Sensing of cytoplasmic pH by bacterial chemocreceptors involves the linker region that connects the membrane-spanning and the signal-modulating helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE SCANNING REVEALS; METHYL-ACCEPTING SITES; ESCHERICHIA-COLI; ASPARTATE RECEPTOR; KINETIC CHARACTERIZATION; COVALENT MODIFICATION; CROSS-LINKING; ALPHA-HELIX; CHEMOTAXIS; DOMAIN	The two major chemoreceptors of Escherichia coli, Tsr and Tar, mediate opposite responses to the same changes in cytoplasmic pH (pH(i)). We set out to identify residues involved in pH(i) sensing to gain insight into the general mechanisms of signaling employed by the chemoreceptors. Characterization of various chimeras of Tsr and Tar localized the pH-sensing region to Arg(259)-His(267) of Tar and Gly(261)-ASp(269) of Tsr. This region of Tar contains three charged residues (Arg(259)-Ser(261), Asp(263), and His(267)) that have counterparts of opposite charge in Tsr (Gly(261)-Glu(262), Arg(265), and Asp(269)). The replacement of all of the three charged residues in Tar or Arg(259)-Ser(260) alone by the corresponding residues of Tsr reversed the polarity of pHi response, whereas the replacement of Asp(263) or His(267) did not change the polarity but altered the time course of pHi response. These results suggest that the electrostatic properties of a short cytoplasmic region within the linker region that connects the second transmembrane helix to the first methylation helix is critical for switching the signaling state of the chemoreceptors during pH sensing. Similar conformational changes of this region in response to external ligands may be critical components of transmembrane signaling.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Marine Biotechnol Inst, Kamaishi Lab, Kamaishi, Iwate 0260001, Japan	Nagoya University	Kawagishi, I (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.		Ohnishi, Kouhei/AAN-9527-2020					BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; Bass RB, 1998, J BIOL CHEM, V273, P25006, DOI 10.1074/jbc.273.39.25006; Bass RB, 1999, STRUCT FOLD DES, V7, P829, DOI 10.1016/S0969-2126(99)80106-3; BORCZUK A, 1986, BIOCHEM BIOPH RES CO, V141, P918, DOI 10.1016/S0006-291X(86)80130-9; Butler SL, 1998, BIOCHEMISTRY-US, V37, P10746, DOI 10.1021/bi980607g; Chen XM, 1997, BIOCHEMISTRY-US, V36, P11858, DOI 10.1021/bi970911u; CONLEY MP, 1994, J BACTERIOL, V176, P3870, DOI 10.1128/JB.176.13.3870-3877.1994; DANG CV, 1986, J BACTERIOL, V166, P275, DOI 10.1128/jb.166.1.275-280.1986; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Hase CC, 1998, P NATL ACAD SCI USA, V95, P730, DOI 10.1073/pnas.95.2.730; KIHARA M, 1981, J BACTERIOL, V145, P1209, DOI 10.1128/JB.145.3.1209-1221.1981; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; KRIKOS A, 1985, P NATL ACAD SCI USA, V82, P1326, DOI 10.1073/pnas.82.5.1326; LeMoual H, 1996, J MOL BIOL, V261, P568, DOI 10.1006/jmbi.1996.0483; Levit MN, 1998, MOL MICROBIOL, V30, P459, DOI 10.1046/j.1365-2958.1998.01066.x; Li GY, 2000, CELL, V100, P357, DOI 10.1016/S0092-8674(00)80671-6; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; MADDOCK JR, 1993, SCIENCE, V259, P1717; Mayover TL, 1999, BIOCHEMISTRY-US, V38, P2259, DOI 10.1021/bi981707p; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; Nara T, 1996, J BIOL CHEM, V271, P17932, DOI 10.1074/jbc.271.30.17932; Nishiyama S, 1999, MOL MICROBIOL, V32, P357, DOI 10.1046/j.1365-2958.1999.01355.x; Nishiyama S, 1999, J MOL BIOL, V286, P1275, DOI 10.1006/jmbi.1999.2555; Nishiyama SI, 1997, J BACTERIOL, V179, P6573, DOI 10.1128/jb.179.21.6573-6580.1997; NISHIZAWA K, 1995, J BIOL CHEM, V270, P2423, DOI 10.1074/jbc.270.6.2423; Okumura H, 1998, J BACTERIOL, V180, P1862, DOI 10.1128/JB.180.7.1862-1868.1998; OOSAWA K, 1988, J BACTERIOL, V170, P2521, DOI 10.1128/jb.170.6.2521-2526.1988; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; Rebbapragada A, 1997, P NATL ACAD SCI USA, V94, P10541, DOI 10.1073/pnas.94.20.10541; REPASKE DR, 1981, J BACTERIOL, V145, P1196, DOI 10.1128/JB.145.3.1196-1208.1981; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Shimizu TS, 2000, NAT CELL BIOL, V2, P792, DOI 10.1038/35041030; Silversmith RE, 1997, BIOCHEMISTRY-US, V36, P14965, DOI 10.1021/bi9715573; SLONCZEWSKI JL, 1981, P NATL ACAD SCI-BIOL, V78, P6271, DOI 10.1073/pnas.78.10.6271; SLONCZEWSKI JL, 1982, J BACTERIOL, V152, P384; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; TATSUNO I, 1994, MOL MICROBIOL, V14, P755, DOI 10.1111/j.1365-2958.1994.tb01312.x; Taylor BL, 1998, MOL MICROBIOL, V28, P683, DOI 10.1046/j.1365-2958.1998.00835.x; Trammell MA, 1999, BIOCHEMISTRY-US, V38, P329, DOI 10.1021/bi981964u; Umemura T, 1998, J BIOL CHEM, V273, P30110, DOI 10.1074/jbc.273.46.30110; Williams SB, 1999, MOL MICROBIOL, V33, P1093, DOI 10.1046/j.1365-2958.1999.01562.x; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; YAMAMOTO K, 1990, J BACTERIOL, V172, P383, DOI 10.1128/JB.172.1.383-388.1990; Zhulin IB, 1997, BIOSCIENCE REP, V17, P335, DOI 10.1023/A:1027340813657	49	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1593	1598		10.1074/jbc.M109930200	http://dx.doi.org/10.1074/jbc.M109930200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11700325	hybrid			2022-12-25	WOS:000173166800094
J	Carmicle, S; Dai, GX; Steede, NK; Landry, SJ				Carmicle, S; Dai, GX; Steede, NK; Landry, SJ			Proteolytic sensitivity and helper T-cell epitope immunodominance associated with the mobile loop in Hsp10s	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEN EGG LYSOZYME; MYCOBACTERIUM-LEPRAE; CO-CHAPERONIN; ESCHERICHIA-COLI; ANTIGEN; GROES; SITES; DETERMINANTS; CLEAVAGE; RECOGNITION	Antigen three-dimensional structure potentially limits antigen processing and presentation to helper T-cell epitopes. The association of helper T-cell epitopes with the mobile loop in Hsp10s from mycobacteria and bacteriophage T4 suggests that the mobile loop facilitates proteolytic processing and presentation of adjacent sequences. Sites of initial proteolytic cleavage were mapped in divergent Hsp10s after treatment with a variety of proteases including cathepsin S. Each protease preferentially cleaved the Hsp10s in the mobile loop. Flexibility in the 22-residue mobile loop most probably allows it to conform to protease active sites. Three variants of the bacteriophage T4 Hsp10 were constructed with deletions in the mobile loop to test the hypothesis that shorter loops would be less sensitive to proteolysis. The two largest deletions effectively inhibited proteolysis by several proteases. Circular dichroism spectra and chemical cross-linking of the deletion variants indicate that the secondary and quaternary structures of the variants are native-like, and all three variants were more thermostable than the wild-type Hsp10. Local structural flexibility appears to be a general requirement for proteolytic sensitivity, and thus, it could be an important factor in antigen processing and helper T-cell epitope immunogenicity.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Landry, SJ (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem, 1430 Tulane Ave, New Orleans, LA 70112 USA.		Landry, Samuel/AAK-5778-2020	Landry, Samuel/0000-0002-4082-0543	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042350] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI42350] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antoniou AN, 2000, IMMUNITY, V12, P391, DOI 10.1016/S1074-7613(00)80191-0; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BENAROUDJ N, 1994, EUR J BIOCHEM, V221, P121, DOI 10.1111/j.1432-1033.1994.tb18720.x; BRAHMS S, 1977, P NATL ACAD SCI USA, V74, P3208, DOI 10.1073/pnas.74.8.3208; Castellino F, 1998, J IMMUNOL, V161, P4048; Chianese-Bullock KA, 1998, J IMMUNOL, V161, P1599; Chua-Intra B, 1998, IMMUNOLOGY, V93, P64, DOI 10.1046/j.1365-2567.1998.00400.x; Dai GX, 2002, J BIOL CHEM, V277, P161, DOI 10.1074/jbc.M102259200; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; Drakesmith H, 1998, P NATL ACAD SCI USA, V95, P14903, DOI 10.1073/pnas.95.25.14903; Farr CD, 1998, J BIOL CHEM, V273, P9744, DOI 10.1074/jbc.273.16.9744; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; Hunt JF, 1997, CELL, V90, P361, DOI 10.1016/S0092-8674(00)80343-8; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; Hussain R, 1998, CLIN EXP IMMUNOL, V114, P204; JANSSEN R, 1994, INT IMMUNOL, V6, P1187, DOI 10.1093/intimm/6.8.1187; Kim J, 1997, J IMMUNOL, V159, P335; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Landry S J, 1999, Pac Symp Biocomput, P520; Landry SJ, 1997, IMMUNOL TODAY, V18, P527, DOI 10.1016/S0167-5699(97)01152-3; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; Landry SJ, 2000, J THEOR BIOL, V203, P189, DOI 10.1006/jtbi.1999.1056; Landry SJ, 1997, BIOCHEMISTRY-US, V36, P10975, DOI 10.1021/bi971141p; Ma CL, 1999, J IMMUNOL, V163, P6413; MANCA F, 1995, J ACQ IMMUN DEF SYND, V9, P227; Moudgil KD, 1996, J AUTOIMMUN, V9, P227, DOI 10.1006/jaut.1996.0028; Nakagawa TY, 1999, IMMUNOL REV, V172, P121, DOI 10.1111/j.1600-065X.1999.tb01361.x; NOVOTNY J, 1987, FEBS LETT, V211, P185, DOI 10.1016/0014-5793(87)81433-3; Pace CN, 1998, J MOL BIOL, V279, P271, DOI 10.1006/jmbi.1998.1760; Phelps RG, 1998, J BIOL CHEM, V273, P11440, DOI 10.1074/jbc.273.19.11440; Richardson A, 1999, J BIOL CHEM, V274, P52, DOI 10.1074/jbc.274.1.52; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schneider SC, 2000, J IMMUNOL, V165, P20, DOI 10.4049/jimmunol.165.1.20; So T, 1997, J BIOL CHEM, V272, P32136, DOI 10.1074/jbc.272.51.32136; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; Vanegas RA, 1997, VACCINE, V15, P321, DOI 10.1016/S0264-410X(96)00167-3; VANNOORT JM, 1991, EUR J IMMUNOL, V21, P1989, DOI 10.1002/eji.1830210904	39	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					155	160		10.1074/jbc.M107624200	http://dx.doi.org/10.1074/jbc.M107624200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11673463	hybrid			2022-12-25	WOS:000173087900022
J	Zhang, SS; Buder, K; Burkhardt, C; Schlott, B; Gorlach, M; Grosse, F				Zhang, SS; Buder, K; Burkhardt, C; Schlott, B; Gorlach, M; Grosse, F			Nuclear DNA helicase II/RNA helicase A binds to filamentous actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PRE-MESSENGER-RNA; DOSAGE-COMPENSATION; INTERPHASE NUCLEI; MALELESS PROTEIN; LOCALIZATION; DROSOPHILA; ASSOCIATION; COMPLEX; EXPORT	Nuclear DNA helicase 11 (NDH H), also designated RNA helicase A, is a multifunctional protein involved in transcription, RNA processing, and transport. Here we report that NDH H binds to F-actin. NDH H was partially purified from HeLa nuclear extracts by ion-exchange chromatography on Bio-Rex 70 and DEAE-Sepharose. Upon gel-filtration chromatography on Sepharose 4B, partially purified NDH H resolved into two distinct peaks. The first NDH H peak, corresponding to the void volume of Sepharose 4B, displayed coelution with an abundant 42-kDa protein that was subsequently identified as actin. Several nuclear proteins such as RNA polymerase H, the U5 small nuclear ribonucleoprotein (RNP)-associated WD40 protein, and heterogeneous nuclear RNPs (hnRNPs) copurified with NDH II. However, only hnRNPs A1 and C were found together with NDH 11 and actin polymers during gel filtration. NDH II and hnRNP C from the HeLa nuclear extract coeluted with F-actin on Sepharose 4B in an RNase-resistant manner, whereas hnRNP A1 was nearly completely removed from F-actin-associated hnRNP complexes following RNA digestion. The association of NDH II and hnRNP C with F-actin was abolished by gelsolin, an F-actin-depolymerizing protein that fragments actin polymers into oligomers or monomers. Furthermore, NDH 11 co-immunoprecipitated with F-actin and hnRNP C, respectively. In vitro translated NDH 11 coeluted with F-actin on Sepharose 4B, whereas no coelution with F-actin was observed for in vitro translated hnRNP A1 or C1. Binding to F-actin requires an intact C terminus of NDH 11 and most likely a native protein conformation. Electron microscopy indicated a close spatial proximity among NDH 11, hnRNP C, and F-actin within the HeLa nucleus. These results suggest an important function of NDH 11 in mediating the attachment of hnRNP-mRPP RNP complexes to the actin nucleoskeleton for RNA processing, transport, or other actin-related processes.	Inst Mol Biotechnol, Dept Biochem, D-07745 Jena, Germany; Inst Mol Biotechnol, Dept Mol Cytol Electron Microscopy, D-07745 Jena, Germany; Inst Mol Biotechnol, Dept Mol Biophys NMR Spect, D-07745 Jena, Germany		Grosse, F (corresponding author), Inst Mol Biotechnol, Dept Biochem, Beutenbergstr 11, D-07745 Jena, Germany.							Achsel T, 1998, MOL CELL BIOL, V18, P6756, DOI 10.1128/MCB.18.11.6756; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Aratani S, 2001, MOL CELL BIOL, V21, P4460, DOI 10.1128/MCB.21.14.4460-4469.2001; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Fujii R, 2001, J BIOL CHEM, V276, P5445, DOI 10.1074/jbc.M006892200; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P2552, DOI 10.1093/nar/22.13.2552; Gonsior SM, 1999, J CELL SCI, V112, P797; GOUNON P, 1981, J CELL BIOL, V88, P410, DOI 10.1083/jcb.88.2.410; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; Hofmann W, 2001, J CELL BIOL, V152, P895, DOI 10.1083/jcb.152.5.895; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; Kageyama Y, 2001, EMBO J, V20, P2236, DOI 10.1093/emboj/20.9.2236; Kimura T, 2000, GENES CELLS, V5, P289, DOI 10.1046/j.1365-2443.2000.00326.x; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; Lallena MJ, 1998, J CELL SCI, V111, P1963; Lee CG, 1998, GENOMICS, V47, P365, DOI 10.1006/geno.1997.5139; LEE CG, 1993, J BIOL CHEM, V268, P16822; Lee CG, 1998, P NATL ACAD SCI USA, V95, P13709, DOI 10.1073/pnas.95.23.13709; LEE CG, 1992, J BIOL CHEM, V267, P4398; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; Linder P, 2001, TRENDS BIOCHEM SCI, V26, P339, DOI 10.1016/S0968-0004(01)01870-9; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; MICHAEL WM, 1995, CELL, V83, P415; MILANKOV K, 1993, EXP CELL RES, V209, P189, DOI 10.1006/excr.1993.1301; Miralles F, 2000, J CELL BIOL, V148, P271, DOI 10.1083/jcb.148.2.271; Myohanen S, 2001, J BIOL CHEM, V276, P1634, DOI 10.1074/jbc.M004481200; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NAKAYASU H, 1985, EXP CELL RES, V160, P319, DOI 10.1016/0014-4827(85)90179-X; NAKAYASU H, 1984, CELL STRUCT FUNCT, V9, P317, DOI 10.1247/csf.9.317; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Oleynikov Y, 1998, TRENDS CELL BIOL, V8, P381, DOI 10.1016/S0962-8924(98)01348-8; Pannuti A, 2000, CURR OPIN GENET DEV, V10, P644, DOI 10.1016/S0959-437X(00)00136-2; PARFENOV VN, 1995, EXP CELL RES, V217, P385, DOI 10.1006/excr.1995.1101; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Percipalle P, 2001, J CELL BIOL, V153, P229, DOI 10.1083/jcb.153.1.229; Ramos A, 2000, EMBO J, V19, P997, DOI 10.1093/emboj/19.5.997; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; Reenan RA, 2000, NEURON, V25, P139, DOI 10.1016/S0896-6273(00)80878-8; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SAHLAS DJ, 1993, J CELL SCI, V105, P347; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Story RM, 2001, P NATL ACAD SCI USA, V98, P1465, DOI 10.1073/pnas.98.4.1465; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 2000, J BIOL CHEM, V275, P32694, DOI 10.1074/jbc.M003933200; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; Waksman G, 2000, NAT STRUCT BIOL, V7, P20, DOI 10.1038/71215; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wan LL, 2001, J BIOL CHEM, V276, P7681, DOI 10.1074/jbc.M010207200; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Yang JP, 2001, J BIOL CHEM, V276, P30694, DOI 10.1074/jbc.M102809200; Zhang SS, 1999, J CELL SCI, V112, P1055; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016; ZHANG SS, 1995, J BIOL CHEM, V270, P16422, DOI 10.1074/jbc.270.27.16422; Zhang SS, 1997, J BIOL CHEM, V272, P11487; ZHANG SS, 1991, J BIOL CHEM, V266, P20483; Zhang SS, 1999, J CELL SCI, V112, P2693	60	35	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					843	853		10.1074/jbc.M109393200	http://dx.doi.org/10.1074/jbc.M109393200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11687588	hybrid			2022-12-25	WOS:000173087900108
J	Caivano, M; Gorgoni, B; Cohen, P; Poli, V				Caivano, M; Gorgoni, B; Cohen, P; Poli, V			The induction of cyclooxygenase-2 mRNA in macrophages is biphasic and requires both CCAAT enhancer-binding protein beta (C/EBP beta) and C/EBP delta transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR KAPPA-B; ENDOPEROXIDE SYNTHASE-2 GENE; NUCLEAR FACTOR; RESPONSE ELEMENT; RAW264 MACROPHAGES; KINASE CASCADES; MESSENGER-RNA; PHORBOL ESTER; FACTOR-ALPHA	Prostaglandins are important mediators of activated macrophage functions, and their inducible synthesis is mediated by cyclooxygenase-2 (COX-2). Here, we make use of the murine macrophage cells RAW264 as well as of immortalized macrophages derived from mice deficient for the transcription factor CCAAT enhancer-binding protein beta (C/EBPbeta) to explore the molecular mechanisms regulating COX-2 induction in activated macrophages. We demonstrate that lipopolysaccharide-mediated COX-2 mRNA induction is biphasic. The initial phase is independent of de novo protein synthesis, correlates with cAMP-response element-binding protein (CREB) activation, is inhibited by treatments that abolish CREB phosphorylation and reduce NF-kappaB-mediated gene activation, and requires the presence of the transcription factor C/EBPbeta. On the other hand, C/EBPdelta appears to be essential in addition to C/EBPbeta to effect the second phase of COX-2 gene transcription, which is important for maintaining the induced state and requires de novo protein synthesis. Indeed, both phases of COX-2 induction were defective in C/EBPbeta-/- macrophages. Moreover, the synthesis of C/EBPdelta was increased dramatically by treatment with lipopolysaccharide and, like COX-2 induction, repressed by combined inhibition of the MAPK and of the SAPK2/p38 cascades. Taken together, these data identify CREB, NF-kappaB, and both C/EBPbeta and -delta as key factors in coordinately orchestrating transcription from the COX-2 promoter in activated macrophages.	Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, Dundee DD1 5EH, Scotland; Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Poli, V (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, Dow St, Dundee DD1 5EH, Scotland.		Poli, Valeria/A-9215-2012	Poli, Valeria/0000-0002-3739-3966				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; Bazan HEP, 1997, INVEST OPHTH VIS SCI, V38, P2492; Berrier A, 1998, J IMMUNOL, V161, P2267; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; Caivano M, 1998, FEBS LETT, V429, P249, DOI 10.1016/S0014-5793(98)00578-X; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Everts B, 2000, CLIN RHEUMATOL, V19, P331, DOI 10.1007/s100670070024; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferreri NR, 1999, AM J PHYSIOL-RENAL, V277, pF360, DOI 10.1152/ajprenal.1999.277.3.F360; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Morisset S, 1998, J RHEUMATOL, V25, P1146; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nedelec E, 2001, BIOCHEM PHARMACOL, V61, P965, DOI 10.1016/S0006-2952(01)00559-7; Newton R, 1997, FEBS LETT, V418, P135, DOI 10.1016/S0014-5793(97)01362-8; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; NIIRO H, 1995, BLOOD, V85, P3736, DOI 10.1182/blood.V85.12.3736.bloodjournal85123736; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Patrono C, 2001, J CLIN INVEST, V108, P7, DOI 10.1172/JCI13418; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Potter S, 2000, MOL HUM REPROD, V6, P771, DOI 10.1093/molehr/6.9.771; Prescott SM, 2000, J CLIN INVEST, V105, P1511, DOI 10.1172/JCI10241; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Turchi L, 2000, EXP CELL RES, V261, P220, DOI 10.1006/excr.2000.5060; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	51	133	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48693	48701		10.1074/jbc.M108282200	http://dx.doi.org/10.1074/jbc.M108282200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11668179	hybrid			2022-12-25	WOS:000173922100012
J	Price, DL; Rhett, PM; Thorpe, SR; Baynes, JW				Price, DL; Rhett, PM; Thorpe, SR; Baynes, JW			Chelating activity of advanced glycation end-product inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; CROSS-LINKING; DIABETES-MELLITUS; PROTEIN; MECHANISM; AMINOGUANIDINE; AUTOXIDATION; TENILSETAM; ASCORBATE; COLLAGEN	The advanced glycation end-product (AGE) hypothesis proposes that accelerated chemical modification of proteins by glucose during hyperglycemia contributes to the pathogenesis of diabetic complications. The two most commonly measured AGEs, N-epsilon-(carboxymethyl)lysine and pentosidine, are glycoxidation products, formed from glucose by sequential glycation and autoxidation reactions. Although several compounds have been developed as AGE inhibitors and are being tested in animal models of diabetes and in clinical trials, the mechanism of action of these inhibitors is poorly understood. In general, they are thought to function as nucleophilic traps for reactive carbonyl intermediates in the formation of AGEs; however alternative mechanisms of actions, such as chelation, have not been rigorously examined. To distinguish between the carbonyl trapping and antioxidant activity of AGE inhibitors, we have measured the chelating activity of the inhibitors by determining the concentration required for 50% inhibition of the rate of copper-catalyzed autoxidation of ascorbic acid in phosphate buffer. All AGE inhibitors studied were chelators of copper, as measured by inhibition of metal-catalyzed autoxidation of ascorbate. Apparent binding constants for copper ranged from similar to2 mm for aminoguanidine and pyridoxamine, to 10-100 mum for carnosine, phenazinediamine, OPB-9195 and tenilsetam. The AGE-breakers, phenacylthiazolium. and phenacyldimethythiazolium bromide, and their hydrolysis products, were among the most potent inhibitors of ascorbate oxidation. We conclude that, at millimolar concentrations of AGE inhibitors used in many in vitro studies, inhibition of AGE formation results primarily from the chelating or antioxidant activity of the AGE inhibitors, rather than their carbonyl trapping activity. Further, at therapeutic concentrations, the chelating activity of AGE inhibitors and AGE-breakers may contribute to their inhibition of AGE formation and protection against development of diabetic complications.	Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Baynes, JW (corresponding author), Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.	baynes@mail.chem.sc.edu	YAMAMOTO, MASAHIRO/F-9094-2011	YAMAMOTO, MASAHIRO/0000-0003-3859-0125	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019971, R37DK019971] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19971] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alderson NA, 2001, DIABETES, V50, pA172; Baran EJ, 2000, BIOCHEMISTRY-MOSCOW+, V65, P789; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; BAYNES JW, 1999, DIABETES NEW MILLENN, P337; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; BURROWS JL, 1990, J CHROMATOGR-BIOMED, V529, P486, DOI 10.1016/S0378-4347(00)83859-1; Cameron NE, 2001, DIABETOLOGIA, V44, P621, DOI 10.1007/s001250051669; CHACE KV, 1991, ARCH BIOCHEM BIOPHYS, V288, P473, DOI 10.1016/0003-9861(91)90223-6; Coussons PJ, 1997, FREE RADICAL BIO MED, V22, P1217, DOI 10.1016/S0891-5849(96)00557-6; DEGENHARDT TP, 2001, IN PRESS KIDNEY INT; DUNN JA, 1990, BIOCHEMISTRY-US, V29, P10964, DOI 10.1021/bi00501a014; Ferguson GP, 1999, CHEM RES TOXICOL, V12, P617, DOI 10.1021/tx990007y; FU MX, 1994, DIABETES, V43, P676, DOI 10.2337/diabetes.43.5.676; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; GUSTAFSON RL, 1957, ARCH BIOCHEM BIOPHYS, V68, P485, DOI 10.1016/0003-9861(57)90379-X; Hawkins CL, 1997, BBA-MOL BASIS DIS, V1360, P84, DOI 10.1016/S0925-4439(96)00069-5; HAYAKAWA K, 1977, J NUTR SCI VITAMINOL, V23, P395; JIANG ZY, 1991, BIOCHEM PHARMACOL, V42, P1273, DOI 10.1016/0006-2952(91)90265-7; Keegan A, 1999, FREE RADICAL BIO MED, V27, P536, DOI 10.1016/S0891-5849(99)00125-2; Khalifah RG, 1999, BIOCHEM BIOPH RES CO, V257, P251, DOI 10.1006/bbrc.1999.0371; Lee KW, 1999, BBA-MOL BASIS DIS, V1453, P141, DOI 10.1016/S0925-4439(98)00097-0; Litchfield JE, 1999, INT J BIOCHEM CELL B, V31, P1297, DOI 10.1016/S1357-2725(99)00091-6; Lopes-Virella MF, 2000, ATHEROSCLEROSIS, V152, P107, DOI 10.1016/S0021-9150(99)00456-6; Miyata T, 2000, J AM SOC NEPHROL, V11, P1719, DOI 10.1681/ASN.V1191719; Miyata TR, 1998, KIDNEY INT, V54, P1290, DOI 10.1046/j.1523-1755.1998.00093.x; MUNCH G, 1994, J NEURAL TRANSM-PARK, V8, P193, DOI 10.1007/BF02260940; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; Nilsson BO, 1999, INFLAMM RES, V48, P509, DOI 10.1007/s000110050495; Onorato JM, 2000, J BIOL CHEM, V275, P21177, DOI 10.1074/jbc.M003263200; Qian MW, 2000, FREE RADICAL BIO MED, V28, P652, DOI 10.1016/S0891-5849(99)00262-2; QUINN PJ, 1992, MOL ASPECTS MED, V13, P379, DOI 10.1016/0098-2997(92)90006-L; Rahbar S, 1999, BIOCHEM BIOPH RES CO, V262, P651, DOI 10.1006/bbrc.1999.1275; RAHBAR S, 2000, CELL BIOL RES COMMUN, V3, P360; Shoda H, 1997, ENDOCRINOLOGY, V138, P1886, DOI 10.1210/en.138.5.1886; Soulis T, 1999, DIABETOLOGIA, V42, P472, DOI 10.1007/s001250051181; THORNALLEY P, 1984, BIOCHIM BIOPHYS ACTA, V797, P276, DOI 10.1016/0304-4165(84)90131-4; Thornalley PJ, 2000, BIOCHEM PHARMACOL, V60, P55, DOI 10.1016/S0006-2952(00)00287-2; Thornalley PJ, 1999, BIOCHEM PHARMACOL, V57, P303, DOI 10.1016/S0006-2952(98)00284-6; Thorpe SR, 1996, DRUG AGING, V9, P69, DOI 10.2165/00002512-199609020-00001; VANREYK DM, 1995, FREE RADICAL RES, V23, P533, DOI 10.3109/10715769509065274; Vasan S, 1996, NATURE, V382, P275, DOI 10.1038/382275a0; Weiss MF, 1999, PERITON DIALYSIS INT, V19, pS62; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; Wolffenbuttel BHR, 1998, P NATL ACAD SCI USA, V95, P4630, DOI 10.1073/pnas.95.8.4630; WOOLLARD ACS, 1990, FREE RADICAL BIO MED, V9, P299, DOI 10.1016/0891-5849(90)90004-3	47	268	276	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48967	48972		10.1074/jbc.M108196200	http://dx.doi.org/10.1074/jbc.M108196200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11677237	hybrid			2022-12-25	WOS:000173922100047
J	Santolini, J; Meade, AL; Stuehr, DJ				Santolini, J; Meade, AL; Stuehr, DJ			Differences in three kinetic parameters underpin the unique catalytic profiles of nitric-oxide synthases I, II, and III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NO COMPLEX-FORMATION; ELECTRON-TRANSFER; L-ARGININE; FEEDBACK INHIBITION; CYTOCHROME P450NOR; REDUCTASE DOMAIN; HEME REDUCTION; NITROXYL ANION; BINDING; TETRAHYDROBIOPTERIN	We previously reported the existence of a special autoregulation property of neuronal nitric-oxide synthase (NOS) based on NO near-geminate combination and partial trapping of neuronal NOS (nNOS) through a futile regenerating pathway. On this basis, we developed a kinetic simulation model that was proven to predict nNOS catalytic specificities and mutations effects (Santolini, J., Adak, S., Curran, C. M., and Stuehr, D. J. (2001) J. Biol. Chem. 276, 1233-1243; Adak, S., Santolini, J., Tikunova, S., Wang, Q., Johnson, J. D., and Stuehr, D. J. (2001) J. BioL Chem. 276,1244-1252). Here we show that the same model simulates and explains the distinct catalytic behaviors of inducible and endothelial NOS (iNOS and eNOS). Their marked differences were linked to variations in three basic parameters (rates of ferric heme reduction, ferric heme-NO dissociation, and ferrous heme-NO oxidation) that together control partitioning between futile and productive pathways and their relative rates. We also incorporated feedback inhibition into the kinetic model to account for potential rebinding of accumulated solution NO. The model accu- rately simulated the different relative impacts of both NOS-NO interactions (near-geminate combination of NO versus rebinding of solution NO) on catalytic behavior of each NOS isoform, including their speed and extent of heme-NO complex accumulation, K,, for 02, and propensity to transform NO into a higher oxide. Thus, individual catalytic behavior of any NOS can be understood through a single unified kinetic model. Because the model defines how different settings of individual kinetic parameters control regulation by two distinct NOS-NO interactions, it sheds light on mechanisms, structural features, and scope of NOS regulation and its physiologic impact.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave,Immunol NB-3, Cleveland, OH 44195 USA.	stuehrd@ccf.org		Santolini, Jerome/0000-0001-8919-112X				Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P6876, DOI 10.1021/bi010066m; Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Adak S, 1999, J BIOL CHEM, V274, P26907, DOI 10.1074/jbc.274.38.26907; Adak S, 2000, J BIOL CHEM, V275, P17434, DOI 10.1074/jbc.M000846200; Adak S, 2001, J BIOL CHEM, V276, P23246, DOI 10.1074/jbc.M102509200; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; ANDERSEN HJ, 1992, J AGR FOOD CHEM, V40, P1741, DOI 10.1021/jf00022a004; Arnold EV, 1996, METHOD ENZYMOL, V269, P41; ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; Berka V, 2000, BIOCHEMISTRY-US, V39, P9373, DOI 10.1021/bi992769y; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; FELLISCH M, 1996, METHODS NITRIC OXIDE, P455; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; Giuffre A, 1999, P NATL ACAD SCI USA, V96, P14718, DOI 10.1073/pnas.96.26.14718; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Hemmens B, 1998, METH MOL B, V100, P1; Herold S, 1999, FEBS LETT, V443, P80, DOI 10.1016/S0014-5793(98)01591-9; HEVEL JM, 1993, ADV EXP MED BIOL, V338, P285; Honeychurch MJ, 1999, FEBS LETT, V451, P351, DOI 10.1016/S0014-5793(99)00610-9; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; LINCOLN J, 1997, NITRIC OXIDE HLTH DI, P27; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; Marnett Lawrence J., 1995, P49; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; MURPHY ME, 1991, P NATL ACAD SCI USA, V88, P10860, DOI 10.1073/pnas.88.23.10860; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Presta A, 1997, NITRIC OXIDE-BIOL CH, V1, P74, DOI 10.1006/niox.1996.0110; Quaroni L, 1996, BBA-PROTEIN STRUCT M, V1296, P5, DOI 10.1016/0167-4838(96)00097-0; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Scheele JS, 1999, J BIOL CHEM, V274, P13105, DOI 10.1074/jbc.274.19.13105; Sennequier N, 1996, BIOCHEMISTRY-US, V35, P5883, DOI 10.1021/bi952844e; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; SHIRO Y, 1995, J BIOL CHEM, V270, P1617, DOI 10.1074/jbc.270.4.1617; SHIRO Y, 1995, BIOCHEMISTRY-US, V34, P9052, DOI 10.1021/bi00028a014; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1999, BIOCHIM BIOPHYS ACTA, V1411, P2146; TURK T, 1992, BIOCHEM BIOPH RES CO, V183, P983, DOI 10.1016/S0006-291X(05)80287-6; ZHAO XJ, 1995, BIOCHEM BIOPH RES CO, V212, P1054, DOI 10.1006/bbrc.1995.2076	63	110	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48887	48898		10.1074/jbc.M108666200	http://dx.doi.org/10.1074/jbc.M108666200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11684690	hybrid			2022-12-25	WOS:000173922100036
J	Fuchs, M; Hafer, A; Munch, C; Kannenberg, F; Teichmann, S; Scheibner, J; Stange, EF; Seedorf, U				Fuchs, M; Hafer, A; Munch, C; Kannenberg, F; Teichmann, S; Scheibner, J; Stange, EF; Seedorf, U			Disruption of the sterol carrier protein 2 gene in mice impairs biliary lipid and hepatic cholesterol metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-PROTEIN; DENSITY-LIPOPROTEIN CHOLESTEROL; RAT-LIVER; HUMAN-FIBROBLASTS; SMALL-INTESTINE; IN-VIVO; SR-BI; SECRETION; TRANSPORT; MEMBRANE	Hepatic up-regulation of sterol carrier protein 2 (Scp2) in mice promotes hypersecretion of cholesterol into bile and gallstone formation in response to a lithogenic diet. We hypothesized that Scp2 deficiency may alter biliary lipid secretion and hepatic cholesterol metabolism. Male gallstone-susceptible C57/BL/6 and C57BL/6(Scp2(-/-)) knockout mice were fed a standard chow or lithogenic diet. Hepatic biles were collected to determine biliary lipid secretion rates, bile flow, and bile salt pool size. Plasma lipoprotein distribution was investigated, and gene expression of cytosolic lipid-binding proteins, lipoprotein receptors, hepatic regulatory enzymes, and intestinal cholesterol absorption was measured. Compared with chow-fed wild-type animals, C57BL/6(Scp2(-/-)) mice had higher bile flow and lower bile salt secretion rates, decreased hepatic apolipoprotein expression, increased hepatic cholesterol synthesis, and up-regulation of liver fatty acid-binding protein. In addition, the bile salt pool size was reduced and intestinal cholesterol absorption was unaltered in C57BL/6(Scp(-/-)) mice. When C57BL/(6Scp2(-/-)) mice were challenged with a lithogenic diet, a smaller increase of hepatic free cholesterol failed to suppress cholesterol synthesis and biliary cholesterol secretion increased to a much smaller extent than phospholipid and bile salt secretion. Scp2 deficiency did not prevent gallstone formation and may be compensated in part by hepatic up-regulation of liver fatty acid-binding protein. These results support a role of Scp2 in hepatic cholesterol metabolism, biliary lipid secretion, and intracellular cholesterol distribution.	Med Univ Lubeck, Div Gastroenterol, Dept Med 1, D-23538 Lubeck, Germany; Univ Munster, Inst Arteriosclerosis Res, D-48129 Munster, Germany; Univ Munster, Inst Clin Chem & Lab Med, D-48129 Munster, Germany	University of Lubeck; University of Munster; University of Munster	Fuchs, M (corresponding author), Univ Ulm, Dept Med 1, Robert Koch Str 8, D-89081 Ulm, Germany.	fuchs@amedizin.uni-ulm.de						Apstein MD, 1996, EUR J CLIN INVEST, V26, P343, DOI 10.1046/j.1365-2362.1996.148287.x; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; BAUM CL, 1993, J LIPID RES, V34, P729; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; DIXON JL, 1992, SEMIN LIVER DIS, V12, P364, DOI 10.1055/s-2008-1040406; Frolov A, 1996, J LIPID RES, V37, P1862; Frolov A, 1996, J BIOL CHEM, V271, P16075, DOI 10.1074/jbc.271.27.16075; Fuchs M, 2001, HEPATOLOGY, V33, P1451, DOI 10.1053/jhep.2001.24373; Fuchs M, 1997, AM J PHYSIOL-GASTR L, V273, pG1312, DOI 10.1152/ajpgi.1997.273.6.G1312; Fuchs M, 1998, BIOCHEM J, V336, P33, DOI 10.1042/bj3360033; Gallegos AM, 2001, BIOCHEMISTRY-US, V40, P6493, DOI 10.1021/bi010217l; Gallegos AM, 2000, CHEM PHYS LIPIDS, V105, P9, DOI 10.1016/S0009-3084(99)00128-0; HOFMANN AF, 1990, HEPATOLOGY, V12, pS17; Ito T, 1996, GASTROENTEROLOGY, V110, P1619, DOI 10.1053/gast.1996.v110.pm8613070; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Kannenberg F, 1999, J BIOL CHEM, V274, P35455, DOI 10.1074/jbc.274.50.35455; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KEMPEN HJM, 1983, BIOCHEM J, V216, P511, DOI 10.1042/bj2160511; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; LANGE Y, 1989, J BIOL CHEM, V264, P3786; Mardones P, 2001, J LIPID RES, V42, P170; MAZZONE T, 1991, J LIPID RES, V32, P507; Mok KS, 1999, GASTROENTEROLOGY, V116, pA1249; MONGE JC, 1989, FEBS LETT, V243, P213, DOI 10.1016/0014-5793(89)80132-2; NEMECZ G, 1991, J BIOL CHEM, V266, P17180; OHBA T, 1995, BIOCHEMISTRY-US, V34, P10660, DOI 10.1021/bi00033a042; Puglielli L, 1996, BIOCHEM J, V317, P681, DOI 10.1042/bj3170681; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723; Rolf B, 1995, BBA-LIPID LIPID MET, V1259, P245, DOI 10.1016/0005-2760(95)00170-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHROEDER F, 1990, J BIOL CHEM, V265, P151; SCHROEDER F, 1985, J BIOL CHEM, V260, P2904; Schwarz M, 1998, J LIPID RES, V39, P1833; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; Shamburek RD, 1997, J LIPID RES, V38, P2422; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; Suzuki T, 2000, BIOTECHNIQUES, V29, P332, DOI 10.2144/00292rv02; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Thumser AEA, 1996, BIOCHEM J, V320, P729, DOI 10.1042/bj3200729; THURNHOFER H, 1991, BIOCHIM BIOPHYS ACTA, V1064, P275, DOI 10.1016/0005-2736(91)90312-V; VANAMERONGEN A, 1989, BIOCHIM BIOPHYS ACTA, V1001, P243, DOI 10.1016/0005-2760(89)90106-9; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; VERKADE HJ, 1995, HEPATOLOGY, V21, P1174; Wang DQH, 1999, J LIPID RES, V40, P2066; Wang DQH, 1999, AM J PHYSIOL-GASTR L, V276, pG751, DOI 10.1152/ajpgi.1999.276.3.G751; Wolfrum C, 1999, J LIPID RES, V40, P708; WOUTERS FS, 1995, BBA-LIPID LIPID MET, V1259, P192, DOI 10.1016/0005-2760(95)00163-7; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482; Zanlungo S, 2000, GASTROENTEROLOGY, V119, P1708, DOI 10.1053/gast.2000.20198	53	86	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48058	48065		10.1074/jbc.M106732200	http://dx.doi.org/10.1074/jbc.M106732200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11673458	hybrid			2022-12-25	WOS:000172927000045
J	Pfeiffer, S; Lass, A; Schmidt, K; Mayer, B				Pfeiffer, S; Lass, A; Schmidt, K; Mayer, B			Protein tyrosine nitration in mouse peritoneal macrophages activated in vitro and in vivo: evidence against an essential role of peroxynitrite	FASEB JOURNAL			English	Article						3-nitrotyrosine; nitric oxide; superoxide anion; activated macrophages; myeloperoxidase	NITRIC-OXIDE SYNTHASE; ACID PORPHYRIN MNTBAP; NECROSIS-FACTOR-ALPHA; SUPEROXIDE-DISMUTASE; REACTIVE NITROGEN; LEISHMANIA-MAJOR; MURINE MACROPHAGES; HYDROGEN-PEROXIDE; PHYSIOLOGICAL PH; IFN-GAMMA	Tyrosine nitration is considered a key reaction of peroxynitrite-triggered tissue injury in inflammatory diseases. We investigated the potential involvement of peroxynitrite in protein tyrosine nitration in isolated murine peritoneal macrophages activated either in vitro with interferon-gamma /lipopolysaccharide or in vivo by priming mice with Corynebacterium parvum (10 mg x kg(-1)). Both protocols led to release of NO and accumulation of nitrite accompanied by formation of protein-bound 3-nitrotyrosine. Oxidation of dihydrorhodamine 123, a measure of peroxynitrite release, remained close to basal levels upon in vitro activation of the macrophages but was increased;twofold in vivo. Tyrosine nitration in macrophages activated in vitro was inhibited by catalase and the time course of nitration correlated with nitrite accumulation, whereas superoxide (O(2)(radical anion)) and H(2)O(2) release occurred at much earlier times. To address the contribution of O(2)(radical anion) and peroxynitrite to in vivo nitration, a O(2)(radical anion) scavenger (MnTBAP; 1 mg x kg(-1)) was given to C. parvum-primed mice. MnTBAP led to almost complete inhibition of C. parvum-triggered O(2)(radical anion) and peroxynitrite release, whereas nitrite accumulation and formation of 3-nitrotyrosine were less affected (similar to 50% of controls). These results argue against an essential role of peroxynitrite in protein tyrosine nitration in vivo.	Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria	University of Graz	Mayer, B (corresponding author), Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, Univ Pl 2, A-8010 Graz, Austria.	mayer@kfunigraz.ac.at	Mayer, Bernd/B-9391-2008; Lass, Achim/C-3332-2008	Lass, Achim/0000-0002-8190-7151; Mayer, Bernd/0000-0002-2921-3494				ASSREUY J, 1994, EUR J IMMUNOL, V24, P672, DOI 10.1002/eji.1830240328; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BECKMAN JS, 1996, AM J PHYSIOL, V40, pC1424; Berlett BS, 1998, P NATL ACAD SCI USA, V95, P2784, DOI 10.1073/pnas.95.6.2784; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Crow JP, 2000, FREE RADICAL BIO MED, V28, P1487, DOI 10.1016/S0891-5849(00)00249-5; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Cuzzocrea S, 1999, BRIT J PHARMACOL, V128, P1241, DOI 10.1038/sj.bjp.0702826; Cuzzocrea S, 1999, FREE RADICAL BIO MED, V26, P25, DOI 10.1016/S0891-5849(98)00142-7; DELAHARPE J, 1985, J IMMUNOL METHODS, V78, P323, DOI 10.1016/0022-1759(85)90089-4; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1999, P NATL ACAD SCI USA, V96, P6365, DOI 10.1073/pnas.96.11.6365; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Ferrer-Sueta G, 1997, CHEM RES TOXICOL, V10, P1338, DOI 10.1021/tx970116h; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; GREEN SJ, 1990, J IMMUNOL, V145, P4290; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Hodges GR, 2000, CHEM RES TOXICOL, V13, P1287, DOI 10.1021/tx0001272; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Jourd'heuil D, 2001, J BIOL CHEM, V276, P28799, DOI 10.1074/jbc.M102341200; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lass A, 1997, J BIOL CHEM, V272, P19199, DOI 10.1074/jbc.272.31.19199; LI Y, 1992, EUR J IMMUNOL, V22, P441, DOI 10.1002/eji.1830220223; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; MILES AM, 1995, J LEUKOCYTE BIOL, V58, P616, DOI 10.1002/jlb.58.5.616; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; PAUL BB, 1973, SCIENCE, V181, P849, DOI 10.1126/science.181.4102.849; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; REES DD, 1995, BRIT J PHARMACOL, V114, P689, DOI 10.1111/j.1476-5381.1995.tb17193.x; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199; SCHMIDT K, 1997, NITRIC OXIDE PROTOCO, P101; SCHOEDON G, 1993, EUR J BIOCHEM, V213, P833, DOI 10.1111/j.1432-1033.1993.tb17826.x; Shigenaga MK, 1999, METHOD ENZYMOL, V301, P27; STRAUSS RR, 1975, NATURE, V255, P343, DOI 10.1038/255343a0; STUEHR DJ, 1987, CANCER RES, V47, P5590; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Szabo C, 1996, FEBS LETT, V381, P82, DOI 10.1016/0014-5793(96)00087-7; UEDA T, 1995, HISTOCHEM CELL BIOL, V103, P11, DOI 10.1007/BF01464470; van der Vliet A, 1998, J BIOL CHEM, V273, P30255, DOI 10.1074/jbc.273.46.30255; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; VODOVOTZ Y, 1994, J IMMUNOL, V152, P4110; Wallerath T, 1997, THROMB HAEMOSTASIS, V77, P163; Weinberg JB, 1998, MOL MED, V4, P557, DOI 10.1007/BF03401758; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; ZHANG XK, 1993, J EXP MED, V177, P511, DOI 10.1084/jem.177.2.511; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P259, DOI 10.1038/sj.bjp.0700872	58	98	102	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2355	2364		10.1096/fj.01-0295com	http://dx.doi.org/10.1096/fj.01-0295com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689461				2022-12-25	WOS:000172420500006
J	Xue, BZ; Greenberg, AG; Kraemer, FB; Zemel, MB				Xue, BZ; Greenberg, AG; Kraemer, FB; Zemel, MB			Mechanism of intracellular calcium ([Ca2+](i)) inhibition of lipolysis in human adipocytes	FASEB JOURNAL			English	Article						agouti; cAMP; hormone-sensitive lipase; phosphodiesterase	HORMONE-SENSITIVE LIPASE; CAMP-PHOSPHODIESTERASE; RAT ADIPOCYTES; ANTILIPOLYTIC ACTION; AGOUTI REGULATION; ADIPOSE-TISSUE; PHOSPHORYLATION; INSULIN; PROTEIN; IDENTIFICATION	We investigated the mechanisms responsible for the anti-lipolytic effect of intracellular Ca2+ ([Ca2+]i) in human adipocytes. Increasing [Ca2+]i inhibited lipolysis induced by beta -adrenergic receptor activation, A1 adenosine receptor inhibition, adenylate cyclase activation, and phosphodiesterase (PDE) inhibition, as well as by a hydrolyzable cAMP analog, but not by a nonhydrolyzable cAMP analog. This finding indicates that the anti-lipolytic effect of [Ca2+]i may be mediated by the activation of adipocyte PDE. Consistent with this theory, [Ca2+]i inhibition of isoproterenol-stimulated lipolysis was reversed completely by the nonselective PDE inhibitor isobutyl methylxanthine and also by the selective PDE 3B inhibitor cilostamide, but not by selective PDE 1 and 4 inhibitors. In addition, phosphatidylinositol-3 kinase inhibition with wortmannin completely prevented insulin's anti-lipolytic effect but only minimally blocked [Ca2+]i's effect, which suggests that [Ca2+]i and insulin may activate PDE 3B via different mechanisms. In contrast, the antilipolytic effect of [Ca2+]i was not affected by inhibitors of calmodulin, Ca2+/calmodulin-dependent kinase, protein phosphatase 2B, and protein kinase C. Finally, [Ca2+]i inhibited significantly isoproterenol-stimulated increases in cAMP levels and hormone-sensitive lipase phosphorylation in human adipocytes. In conclusion, increasing [Ca2+]i exerts an antilipolytic effect mainly by activation of PDE, leading to a decrease in cAMP and HSL phosphorylation and, consequently, inhibition of lipolysis.	Univ Tennessee, Dept Nutr, Knoxville, TN 37996 USA; Tufts Univ, JM USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Stanford Univ, Vet Affairs Palo Alto Hlth Care Syst, Dept Med, Div Endocrinol, Palo Alto, CA 94304 USA	University of Tennessee System; University of Tennessee Knoxville; Tufts University; United States Department of Agriculture (USDA); Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Zemel, MB (corresponding author), Univ Tennessee, Dept Nutr, 1215 W Cumberland Ave Room 229, Knoxville, TN 37996 USA.	mzemel@utk.edu	Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807; Zemel, Michael/0000-0003-4104-5750				Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; ARNER P, 1993, J LIPID RES, V34, P1737; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BEEBE SJ, 1988, METHOD ENZYMOL, V159, P531; BEEBE SJ, 1985, J BIOL CHEM, V260, P5781; BOOBIS LH, 1983, CLIN CHIM ACTA, V132, P173, DOI 10.1016/0009-8981(83)90245-0; Castan I, 1999, BIOCHEM J, V339, P281, DOI 10.1042/0264-6021:3390281; Chabardes D, 1999, CELL SIGNAL, V11, P651, DOI 10.1016/S0898-6568(99)00031-5; DERGERMAN E, 1998, METHODS COMPANION ME, V14, P43; ELKS ML, 1985, ENDOCRINOLOGY, V116, P2119, DOI 10.1210/endo-116-5-2119; ELKS ML, 1984, ENDOCRINOLOGY, V115, P1262, DOI 10.1210/endo-115-4-1262; ERIKSSON H, 1995, BBA-MOL CELL RES, V1266, P101, DOI 10.1016/0167-4889(94)00237-9; GARTON AJ, 1988, FEBS LETT, V229, P68, DOI 10.1016/0014-5793(88)80799-3; GARTON AJ, 1990, EUR J BIOCHEM, V191, P245, DOI 10.1111/j.1432-1033.1990.tb19116.x; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; GOSWAMI A, 1978, ENDOCRINOLOGY, V103, P2223, DOI 10.1210/endo-103-6-2223; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Holm C, 1997, METHOD ENZYMOL, V286, P45; Kim JH, 1997, AM J PHYSIOL-ENDOC M, V272, pE379, DOI 10.1152/ajpendo.1997.272.3.E379; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; KRAEMER FB, 1993, J LIPID RES, V34, P663; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langin D, 1996, P NUTR SOC, V55, P93, DOI 10.1079/PNS19960013; LARROUY D, 1994, EUR J PHARM-MOLEC PH, V267, P225, DOI 10.1016/0922-4106(94)90174-0; LONDOS C, 1978, P NATL ACAD SCI USA, V75, P5362, DOI 10.1073/pnas.75.11.5362; NEMECEK GM, 1978, J CYCLIC NUCL PROT, V4, P299; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; SCHMITZPEIFFER C, 1992, CELL SIGNAL, V4, P37, DOI 10.1016/0898-6568(92)90006-T; SIDDLE K, 1977, BIOCHEM SOC T, V5, P959, DOI 10.1042/bst0050959; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; STRALFORS P, 1983, J BIOL CHEM, V258, P5146; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; Tebar F, 1996, ENDOCRINOLOGY, V137, P4181, DOI 10.1210/en.137.10.4181; TEBAR F, 1993, J BIOL CHEM, V268, P17199; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391; YEN T T T, 1970, Hormone and Metabolic Research, V2, P200; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733	39	166	176	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2527	+		10.1096/fj.01-0278fje	http://dx.doi.org/10.1096/fj.01-0278fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641262				2022-12-25	WOS:000171372700018
J	Reddy, ASN; Day, IS; Narasimhulu, SB; Safadi, F; Reddy, VS; Golovkin, M; Harnly, MJ				Reddy, ASN; Day, IS; Narasimhulu, SB; Safadi, F; Reddy, VS; Golovkin, M; Harnly, MJ			Isolation and characterization of a novel calmodulin-binding protein from potato	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINESIN-LIKE PROTEIN; SOLANUM-TUBEROSUM-L; POLLEN-TUBE GROWTH; PLANT CALMODULIN; CDNA CLONES; GENE FAMILY; ARABIDOPSIS; CALCIUM; EXPRESSION; ISOFORMS	Tuberization in potato is controlled by hormonal and environmental signals. Ca2+, an important intracellular messenger, and calmodulin (CaM), one of the primary Ca2+ sensors, have been implicated in controlling diverse cellular processes in plants including tuberization. The regulation of cellular processes by CaM involves its interaction with other proteins. To understand the role of Ca2+/CaM in tuberization, we have screened an expression library prepared from developing tubers with biotinylated CaM. This screening resulted in isolation of a cDNA encoding a novel CaM-binding protein (potato calmodulin-binding protein (PCBP)). Ca2+-dependent binding of the cDNA-encoded protein to CaM is confirmed by S-35-labeled CaM. The full-length cDNA is 5 kb long and encodes a protein of 1309 amino acids. The deduced amino acid sequence showed significant similarity with a hypothetical protein from another plant, Arabidopsis. However, no homologs of PCBP are found in nonplant systems, suggesting that it is likely to be specific to plants. Using truncated versions of the protein and a synthetic peptide in CaM binding assays we mapped the CaM-binding region to a 20-amino acid stretch (residues 1216-1237). The bacterially expressed protein containing the CaM-binding domain interacted with three CaM isoforms (CaM2, CaM4, and CaM6). PCBP is encoded by a single gene and is expressed differentially in the tissues tested. The expression of CaM, PCBP, and another CaM-binding protein is similar in different tissues and organs. The predicted protein contained seven putative nuclear localization signals and several strong PEST motifs. Fusion of the N-terminaI region of the protein containing six of the seven nuclear localization signals to the reporter gene beta-glucuronidase targeted the reporter gene to the nucleus, suggesting a nuclear role for PCBP.	Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Cell & Mol Biol Program, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University	Reddy, ASN (corresponding author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.	reddy@lamar.colostate.edu	Safadi, Fayez/AAU-8699-2021	Reddy, Anireddy/0000-0002-4038-4091				Agell N, 1998, CELL CALCIUM, V23, P115, DOI 10.1016/S0143-4160(98)90109-9; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BACHS O, 1994, CELL CALCIUM, V16, P289, DOI 10.1016/0143-4160(94)90092-2; BALAMANI V, 1986, PLANT PHYSIOL, V80, P856, DOI 10.1104/pp.80.4.856; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Bibikova TN, 1997, PLANTA, V203, P495, DOI 10.1007/s004250050219; Bowser J, 1997, PLANT J, V12, P1429, DOI 10.1046/j.1365-313x.1997.12061429.x; Bunney TD, 2000, FEBS LETT, V476, P145, DOI 10.1016/S0014-5793(00)01709-9; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; Cho MJ, 1998, BIOCHEMISTRY-US, V37, P15593, DOI 10.1021/bi981497g; COX JA, 1985, J BIOL CHEM, V260, P2527; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FORDHAMSKELTON AP, 1994, PLANT MOL BIOL REP, V12, P355; Franklin-Tong VE, 1999, CURR OPIN PLANT BIOL, V2, P490, DOI 10.1016/S1369-5266(99)00017-5; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; Golovkin M, 1996, PLANT CELL, V8, P1421, DOI 10.1105/tpc.8.8.1421; Heo WD, 1999, P NATL ACAD SCI USA, V96, P766, DOI 10.1073/pnas.96.2.766; Hsieh HL, 1996, PLANT MOL BIOL, V30, P135, DOI 10.1007/BF00017808; INITIATIVE TAG, 2000, NATURE, V408, P796, DOI DOI 10.1038/35048692; Jackson SD, 1999, PLANT PHYSIOL, V119, P1, DOI 10.1104/pp.119.1.1; JENA PK, 1989, P NATL ACAD SCI USA, V86, P3644, DOI 10.1073/pnas.86.10.3644; Kao YL, 2000, BIOCHEM BIOPH RES CO, V267, P201, DOI 10.1006/bbrc.1999.1896; Knight H, 2000, INT REV CYTOL, V195, P269; KODA Y, 1983, JPN J CROP SCI, V52, P582, DOI 10.1626/jcs.52.582; Kohler C, 2000, FEBS LETT, V471, P133, DOI 10.1016/S0014-5793(00)01383-1; Krauss A., 1985, Potato physiology, P209; Krishnakumar S, 1999, DEVELOPMENT, V126, P3079; LEE SH, 1995, J BIOL CHEM, V270, P21806, DOI 10.1074/jbc.270.37.21806; Lee SH, 2000, BIOCHEM J, V350, P299, DOI 10.1042/0264-6021:3500299; Lee SH, 1999, BBA-PROTEIN STRUCT M, V1433, P56, DOI 10.1016/S0167-4838(99)00149-1; Liao BR, 1996, ARCH BIOCHEM BIOPHYS, V327, P53, DOI 10.1006/abbi.1996.0092; LING V, 1991, PLANT PHYSIOL, V96, P1196, DOI 10.1104/pp.96.4.1196; LU YT, 1994, PLANT PHYSIOL BIOCH, V32, P413; LUKAS TJ, 1987, P 5 INT S CALC BIND, P533; MENZEL CM, 1983, ANN BOT-LONDON, V52, P697, DOI 10.1093/oxfordjournals.aob.a086627; Narasimhulu SB, 1998, PLANT CELL, V10, P957, DOI 10.1105/tpc.10.6.957; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Oppenheimer DG, 1997, P NATL ACAD SCI USA, V94, P6261, DOI 10.1073/pnas.94.12.6261; Pauly N, 2000, NATURE, V405, P754, DOI 10.1038/35015671; PIERSON ES, 1994, PLANT CELL, V6, P1815, DOI 10.1105/tpc.6.12.1815; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; Poovaiah BW, 1996, J PLANT PHYSIOL, V149, P553, DOI 10.1016/S0176-1617(96)80333-6; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; Reddy ASN, 1996, PLANT J, V10, P9, DOI 10.1046/j.1365-313X.1996.10010009.x; Reddy ASN, 2000, BIOCHEM BIOPH RES CO, V279, P762, DOI 10.1006/bbrc.2000.4032; Reddy ASN, 1996, J BIOL CHEM, V271, P7052, DOI 10.1074/jbc.271.12.7052; Reddy ASN, 2001, PLANT SCI, V160, P381, DOI 10.1016/S0168-9452(00)00386-1; REDDY ASN, 1993, PLANT SCI, V94, P109, DOI 10.1016/0168-9452(93)90012-O; REDDY ASN, 2001, HDB PLANT CROP PHYSL, P697; REDDY ASN, 2001, INTL REV CYTOL CELL, V204, P98; Reddy VS, 1999, J BIOL CHEM, V274, P31727, DOI 10.1074/jbc.274.44.31727; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Safadi F, 2000, J BIOL CHEM, V275, P35457, DOI 10.1074/jbc.M002720200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schuurink RC, 1998, P NATL ACAD SCI USA, V95, P1944, DOI 10.1073/pnas.95.4.1944; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; Smirnova EA, 1998, CELL MOTIL CYTOSKEL, V41, P271, DOI 10.1002/(SICI)1097-0169(1998)41:3<271::AID-CM8>3.3.CO;2-N; Snedden WA, 1998, TRENDS PLANT SCI, V3, P299, DOI 10.1016/S1360-1385(98)01284-9; SNYDER RG, 1989, HORTSCIENCE, V24, P336; Song H, 1997, P NATL ACAD SCI USA, V94, P322, DOI 10.1073/pnas.94.1.322; Stomp A., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P103; Szymanski DB, 1996, PLANT CELL, V8, P1069, DOI 10.1105/tpc.8.6.1069; TAKEZAWA D, 1995, PLANT MOL BIOL, V27, P693, DOI 10.1007/BF00020223; TAYLOR MA, 1992, PLANT MOL BIOL, V20, P641, DOI 10.1007/BF00046449; Trewavas AJ, 1998, CURR OPIN PLANT BIOL, V1, P428, DOI 10.1016/S1369-5266(98)80268-9; van der Luit AH, 1999, PLANT PHYSIOL, V121, P705, DOI 10.1104/pp.121.3.705; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; Vos JW, 2000, PLANT CELL, V12, P979, DOI 10.1105/tpc.12.6.979; Wang W, 1996, PLANT MOL BIOL, V31, P683, DOI 10.1007/BF00042240; Warr CG, 1996, BIOCHEM J, V314, P497, DOI 10.1042/bj3140497; Yang TB, 1996, MOL GEN GENET, V252, P684, DOI 10.1007/BF02173974; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	82	33	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4206	4214		10.1074/jbc.M104595200	http://dx.doi.org/10.1074/jbc.M104595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11684678	hybrid			2022-12-25	WOS:000173813900057
J	Tran, D; Tran, PA; Tang, YQ; Yuan, J; Cole, T; Selsted, ME				Tran, D; Tran, PA; Tang, YQ; Yuan, J; Cole, T; Selsted, ME			Homodimeric theta-defensins from Rhesus macaque leukocytes - Isolation, synthesis, antimicrobial activities, and bacterial binding properties of the cyclic peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTINE-KNOT; STRUCTURAL MOTIF; INNATE IMMUNITY; ALPHA-DEFENSINS; BETA-DEFENSIN; CDNA CLONING; CIRCULIN-A; INDOLICIDIN; TACHYPLESINS; ANTIBIOTICS	Rhesus theta-defensin 1 (RTD-1) is a unique tridisulfide, cyclic antimicrobial peptide formed by the ligation of two 9-residue sequences derived from heterodimeric splicing of similar 76-amino acid, a-defensin-related precursors, termed RTD1a and RTD1b (Tang, Y. Q., Yuan, J., Osapay, G., Osapay, K., Tran, D., Miller, C. J., Ouellette, A. J., and Selsted, M. E. (1999) Science 286,498-502). The structures of RTD-2 and RTD-3 were predicted to exist if homodimeric splicing of the RTD1a and RTD1b occurs in vivo. Western blotting disclosed the presence of putative theta-defensins, distinct from RTD-1, in leukocyte extracts. Two new theta-defensins, RTD-2 and RTD-3, were purified by reverse-phase high performance liquid chromatography and characterized by amino acid analysis, matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy, and comparison to the synthetic standards. RTD-2 and RTD-3 are the predicted homodimeric splicing products of RTD1b and RTD1a, respectively. The cellular abundances of RTD-1, -2, and -3 were 29:1:2, indicating that there is a preference for the heterodimeric ligation that generates RTD-1. RTD-1, -2, and -3 had similar antimicrobial activities against Staphylococcus aureus, Candida albicans, and Cryptococcus neoformans, whereas the activity of RTD-2 against Escherichia coli was 2-3-fold less than those of RTD-1 and RTD-3. Equal amounts of each theta-defensin bound to E. coli cells, indicating that the differences in antibacterial activities are the result of post-binding processes.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Selsted, ME (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022931, R01AI022931] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22931] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Boman HG, 1998, SCAND J IMMUNOL, V48, P15; COHEN SA, 1993, ANAL BIOCHEM, V211, P279, DOI 10.1006/abio.1993.1270; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Daly NL, 2000, J BIOL CHEM, V275, P19068, DOI 10.1074/jbc.M000450200; Daly NL, 1999, J MOL BIOL, V285, P333, DOI 10.1006/jmbi.1998.2276; DELSAL G, 1992, BIOCHEM BIOPH RES CO, V187, P467, DOI 10.1016/S0006-291X(05)81517-7; Gallo RL, 1998, J INVEST DERMATOL, V111, P739, DOI 10.1046/j.1523-1747.1998.00361.x; GANZ T, 1990, EUR J HAEMATOL, V44, P1; Garcia JRC, 2001, FASEB J, V15, P1819, DOI 10.1096/fj.00-0865fje; Gennaro R, 2000, BIOPOLYMERS, V55, P31, DOI 10.1002/1097-0282(2000)55:1<31::AID-BIP40>3.3.CO;2-0; Gudmundsson GH, 1999, J IMMUNOL METHODS, V232, P45, DOI 10.1016/S0022-1759(99)00152-0; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Hecht G, 1999, AM J PHYSIOL-CELL PH, V277, pC351, DOI 10.1152/ajpcell.1999.277.3.C351; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hwang PM, 1998, BIOCHEM CELL BIOL, V76, P235, DOI 10.1139/bcb-76-2-3-235; IWANAGA S, 1994, CIBA F SYMP, V186, P160; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; Jia HP, 2001, GENE, V263, P211; JONES DE, 1992, J BIOL CHEM, V267, P23216; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; Leonova L, 2001, J LEUKOCYTE BIOL, V70, P461; Linzmeier R, 1999, GENE, V233, P205, DOI 10.1016/S0378-1119(99)00136-5; Liu L, 1998, GENE, V222, P237, DOI 10.1016/S0378-1119(98)00480-6; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; Navale V, 1999, ANAL BIOCHEM, V267, P125, DOI 10.1006/abio.1998.3003; Osapay K, 2000, J BIOL CHEM, V275, P12017, DOI 10.1074/jbc.275.16.12017; Ouellette AJ, 1999, AM J PHYSIOL-GASTR L, V277, pG257, DOI 10.1152/ajpgi.1999.277.2.G257; Schroder JM, 1999, BIOCHEM PHARMACOL, V57, P121, DOI 10.1016/S0006-2952(98)00226-3; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1985, J CLIN INVEST, V76, P1436, DOI 10.1172/JCI112121; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SELSTED ME, 1983, J BIOL CHEM, V258, P4485; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; Tang YQ, 1999, INFECT IMMUN, V67, P6139, DOI 10.1128/IAI.67.11.6139-6144.1999; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Trabi M, 2001, BIOCHEMISTRY-US, V40, P4211, DOI 10.1021/bi002028t; VANABEL RJ, 1995, INT J PEPT PROT RES, V45, P401; Wang MSC, 1997, ANAL BIOCHEM, V253, P225, DOI 10.1006/abio.1997.2347	45	174	193	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3079	3084		10.1074/jbc.M109117200	http://dx.doi.org/10.1074/jbc.M109117200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11675394	hybrid			2022-12-25	WOS:000173688000005
J	Friedrich, R; Fuentes-Prior, P; Ong, E; Coombs, G; Hunter, M; Oehler, R; Pierson, D; Gonzalez, R; Huber, R; Bode, W; Madison, EL				Friedrich, R; Fuentes-Prior, P; Ong, E; Coombs, G; Hunter, M; Oehler, R; Pierson, D; Gonzalez, R; Huber, R; Bode, W; Madison, EL			Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; FACTOR ACTIVATOR INHIBITOR; PANCREATIC TRYPSIN-INHIBITOR; PLASMINOGEN-ACTIVATOR; CRYSTAL-STRUCTURE; CRYSTALLOGRAPHIC REFINEMENT; ALPHA-CHYMOTRYPSIN; PROTEASE; COMPLEX; MATRIPTASE	The type 11 transmembrane multidomain serine proteinase MT-SP1/matriptase is highly expressed in many human cancer-derived cell lines and has been implicated in extracellular matrix re-modeling, tumor growth, and metastasis. We have expressed the catalytic domain of MT-SP1 and solved the crystal structures of complexes with benzamidine at 1.3 Angstrom and bovine pancreatic trypsin inhibitor at 2.9 Angstrom. MT-SP1 exhibits a trypsin-like serine proteinase fold, featuring a unique nine-residue 60-insertion loop that influences interactions with protein substrates. The structure discloses a trypsin-like S1 pocket, a small hydrophobic S2 subsite, and an open negatively charged S4 cavity that favors the binding of basic P3/P4 residues. A complementary charge pattern on the surface opposite the active site cleft suggests a distinct docking of the preceding low density lipoprotein receptor class A domain. The benzamidine crystals possess a freely accessible active site and are hence well suited for soaking small molecules, facilitating the improvement of inhibitors. The crystal structure of the MT-SP1 complex with bovine pancreatic trypsin inhibitor serves as a model for hepatocyte growth factor activator inhibitor 1, the physiological inhibitor of MT-SP1, and suggests determinants for the substrate specificity.	Abt Strukturforsch, Max Planck Inst Biochem, D-82152 Martinsried, Germany; Corvas Int, San Diego, CA 92121 USA	Max Planck Society	Bode, W (corresponding author), Abt Strukturforsch, Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	bode@biochem.mpg.de		Coombs, Gary/0000-0002-0711-185X; Fuentes-Prior, Pablo/0000-0002-6618-3204				Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; BIRKTOFT JJ, 1972, J MOL BIOL, V68, P187, DOI 10.1016/0022-2836(72)90210-0; BLEVINS RA, 1985, J BIOL CHEM, V260, P4264; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BODE W, 1992, PROTEIN SCI, V1, P426; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Enyedy IJ, 2001, J MED CHEM, V44, P1349, DOI 10.1021/jm000395x; EVANS R, 1990, VIA, V11, P134; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; KARSHIKOV A, 1992, PROTEIN SCI, V1, P727, DOI 10.1002/pro.5560010605; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; KITAMOTO Y, 1995, BIOCHEMISTRY-US, V34, P4562, DOI 10.1021/bi00014a008; Kute TE, 1998, BREAST CANCER RES TR, V47, P9, DOI 10.1023/A:1005882520982; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lu DS, 1999, J MOL BIOL, V292, P361, DOI 10.1006/jmbi.1999.3089; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Nienaber V, 2000, J BIOL CHEM, V275, P7239, DOI 10.1074/jbc.275.10.7239; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; Qin L, 1998, FEBS LETT, V436, P111, DOI 10.1016/S0014-5793(98)01105-3; SHI YE, 1993, CANCER RES, V53, P1409; Shimomura T, 1999, J BIOCHEM-TOKYO, V126, P821, DOI 10.1093/oxfordjournals.jbchem.a022522; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; STUBBS MT, 1995, FEBS LETT, V375, P103, DOI 10.1016/0014-5793(95)01190-P; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P131; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; TURK D, 1992, THESIS TU MUNCHEN; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977	43	104	127	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2160	2168		10.1074/jbc.M109830200	http://dx.doi.org/10.1074/jbc.M109830200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11696548	hybrid			2022-12-25	WOS:000173421300075
J	Okada, M; Itoh, M; Haraguchi, M; Okajima, T; Inoue, M; Oishi, H; Matsuda, Y; Iwamoto, T; Kawano, T; Fukumoto, S; Miyazaki, H; Furukawa, K; Aizawa, S; Furukawa, K				Okada, M; Itoh, M; Haraguchi, M; Okajima, T; Inoue, M; Oishi, H; Matsuda, Y; Iwamoto, T; Kawano, T; Fukumoto, S; Miyazaki, H; Furukawa, K; Aizawa, S; Furukawa, K			b-series ganglioside deficiency exhibits no definite changes in the neurogenesis and the sensitivity to Fas-mediated apoptosis but impairs regeneration of the lesioned hypoglossal nerve	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GD3 GANGLIOSIDE; HUMAN-MELANOMA; SYNTHASE GENE; CELL-LINES; EXPRESSION; ANTIBODY; MICE; PROLIFERATION; INTERLEUKIN-2; THYMOCYTES	The polymorphic carbohydrate structures of gangliosides play regulatory roles. In particular, b-series gangliosides, all of which contain alpha-2,8 sialic acids, have been considered to be critical in various biological events such as adhesion, toxin binding, neurite extension, cell growth, and apoptosis. To clarify the physiological functions of b-series gangliosides in vivo, we have established a gene knockout mouse of GD3 synthase. Although all b-series structures were deleted in the mutant mice, they showed an almost complete nervous tissue morphology with no apparent abnormal behavior. Moreover, no differences in Fas-mediated apoptotic reaction of lymphocytes between wild type and the mutant mice were detected. However, the mutant mice exhibited clearly reduced regeneration of axotomized hypoglossal nerves compared with the wild type, suggesting that b-series gangliosides are more important in the repair rather than in the differentiation of the nervous system and apoptotic process induced via Fas.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagasaki Univ, Sch Med, Dept Pediat, Nagasaki 852, Japan; Nagasaki Univ, Sch Med, Dept Surg 2, Nagasaki 852, Japan; Nagasaki Univ, Sch Dent, Dept Oral Surg, Nagasaki 852, Japan; Nagasaki Univ, Sch Dent, Dept Pediat Dent, Nagasaki 852, Japan; Hokkaido Univ, Grad Sch Environm Earth Sci, Div Biosci, Lab Cytogenet, Sapporo, Hokkaido 0600815, Japan; Kumamoto Univ, Dept Morphogenesis, Inst Mol Embryol & Genet, Kumamoto 8600811, Japan	Nagoya University; Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; Hokkaido University; Kumamoto University	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Iwamoto, Tsutomu/AAA-6597-2019; Okajima, Tetsuya/I-7332-2014; Iwamoto, Tsutomu/AAI-8952-2021	Iwamoto, Tsutomu/0000-0001-8472-605X; Okajima, Tetsuya/0000-0002-3677-648X; Fukumoto, Satoshi/0000-0002-5046-6891				AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; Birkle S, 1999, J NEUROCHEM, V72, P954, DOI 10.1046/j.1471-4159.1999.0720954.x; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Furukawa K, 1996, J BIOL CHEM, V271, P20836, DOI 10.1074/jbc.271.34.20836; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; Itoh M, 1999, GLYCOBIOLOGY, V9, P1247, DOI 10.1093/glycob/9.11.1247; Itoh M, 2001, GLYCOBIOLOGY, V11, P125, DOI 10.1093/glycob/11.2.125; Kawai H, 2001, J BIOL CHEM, V276, P6885, DOI 10.1074/jbc.C000847200; KING CA, 1975, J INFECT DIS, V131, P643, DOI 10.1093/infdis/131.6.643; KLEINMAN HK, 1979, P NATL ACAD SCI USA, V76, P3367, DOI 10.1073/pnas.76.7.3367; NAKAMURA K, 1995, J BIOL CHEM, V270, P3876, DOI 10.1074/jbc.270.8.3876; Nakano J, 1996, J INVEST DERMATOL, V107, P543, DOI 10.1111/1523-1747.ep12582802; Nohara K, 1998, J BIOCHEM, V124, P194, DOI 10.1093/oxfordjournals.jbchem.a022079; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P455; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; TSUJI S, 1983, J BIOCHEM-TOKYO, V94, P303, DOI 10.1093/oxfordjournals.jbchem.a134344; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; Yamamoto A, 1996, GLYCOCONJUGATE J, V13, P471, DOI 10.1007/BF00731480; Zhao JM, 1999, J BIOL CHEM, V274, P13744, DOI 10.1074/jbc.274.20.13744	24	144	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1633	1636		10.1074/jbc.C100395200	http://dx.doi.org/10.1074/jbc.C100395200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11682464	hybrid			2022-12-25	WOS:000173421300002
J	Denicola, A; Batthyany, C; Lissi, E; Freeman, BA; Rubbo, H; Radi, R				Denicola, A; Batthyany, C; Lissi, E; Freeman, BA; Rubbo, H; Radi, R			Diffusion of nitric oxide into low density lipoprotein.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZED LIPID DERIVATIVES; CORONARY HEART-DISEASE; PEROXYL RADICALS; OXIDATIVE MODIFICATION; SCAVENGER RECEPTOR; PYRENE DERIVATIVES; ENDOTHELIAL-CELLS; ALPHA-TOCOPHEROL; PEROXYNITRITE; PEROXIDATION	A key early event in the development of atherosclerosis is the oxidation of low density lipoprotein (LDL) via different mechanisms including free radical reactions with both protein and lipid components. Nitric oxide ((NO)-N-.) is capable of inhibiting LDL oxidation by scavenging radical species involved in oxidative chain propagation reactions. Herein, the diffusion of (NO)-N-. into LDL is studied by fluorescence quenching of pyrene derivatives. Selected probes 1-(pyrenyl)methyltrimethylammonium (PMTMA) and 1-(pyrenyl)-methyl-3-(9-octadecenoyloxy)-22,23-bisnor-5-cholenate (PMChO) were chosen so that they could be incorporated at different depths of the LDL particle. Indeed, PMTMA and PMChO were located in the surface and core of LDL, respectively, as indicated by changes in fluorescence spectra, fluorescence quenching studies with water-soluble quenchers and the lifetime values (To) of the excited probes. The apparent second order rate quenching constants of (NO)-N-. (k(NO)) for both probes were 2.6-3.8 x 10(10) M-1 s(-1) and 1.2 x 10(10) M-1 s(-1) in solution and native LDL, respectively, indicating that there is no significant barrier to the diffusion of (NO)-N-. to the surface and core of LDL. Nitric oxide was also capable of diffusing through oxidized LDL. Considering the preferential partitioning of (NO)-N-. in apolar milieu (6-8 for n-octanol:water) and therefore a larger (NO)-N-. concentration in LDL with respect to the aqueous phase, a corrected kNO value of similar to0.2 x 1010 M-1 s(-1) can be determined, which still is sufficiently large and consistent with a facile diffusion of .NO through LDL. Applying the Einstein-Smoluchowsky treatment, the apparent diffusion coefficient ONO) of (NO)-N-. in native LDL is on average 2 x 10(-5) cm(2) s(-1), six times larger than that previously reported for erythrocyte plasma membrane. Thus, our observations support that (NO)-N-. readily traverses the LDL surface accessing the hydrophobic lipid core of the particle and affirm a role for (NO)-N-. as a major lipophilic antioxidant in LDL.	Univ Republica, Fac Ciencias, Dept Phys Biochem, Montevideo 11400, Uruguay; Univ Republica, Fac Med, Dept Biochem, Montevideo 11800, Uruguay; Univ Santiago Chile, Dept Chem, Santiago 2, Chile; Univ Alabama, Ctr Free Rad Biol, Dept Anesthesiol, Birmingham, AL 35233 USA	Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay; Universidad de Santiago de Chile; University of Alabama System; University of Alabama Birmingham	Radi, R (corresponding author), Univ Republica, Fac Med, Dept Bioquim, Avda Gral Flores 2125, Montevideo 11800, Uruguay.		Freeman, Bruce A/H-9342-2012; Batthyany, Carlos I./A-6478-2009	Rubbo, Homero/0000-0002-7897-6551; Denicola, Ana/0000-0002-5181-9708; Batthyany, Carlos/0000-0002-0627-1982	FOGARTY INTERNATIONAL CENTER [R03TW000999] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW00999, TW001493] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Batthyany C, 2000, ARCH BIOCHEM BIOPHYS, V384, P335, DOI 10.1006/abbi.2000.2102; Boullier A, 2000, J BIOL CHEM, V275, P9163, DOI 10.1074/jbc.275.13.9163; BROWN MS, 1980, J BIOL CHEM, V255, P9344; Buerk DG, 2001, ANNU REV BIOMED ENG, V3, P109, DOI 10.1146/annurev.bioeng.3.1.109; Campos H, 2001, JAMA-J AM MED ASSOC, V286, P1468, DOI 10.1001/jama.286.12.1468; Carr AC, 2001, J BIOL CHEM, V276, P1822, DOI 10.1074/jbc.M009082200; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; Coffey MJ, 2001, P NATL ACAD SCI USA, V98, P8006, DOI 10.1073/pnas.141136098; Cominacini L, 2000, J BIOL CHEM, V275, P12633, DOI 10.1074/jbc.275.17.12633; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V328, P208, DOI 10.1006/abbi.1996.0162; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; Feelisch M., 1996, METHODS NITRIC OXIDE, P455; FIELDING CJ, 1984, J LIPID RES, V25, P1624; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1533, DOI 10.1172/JCI107331; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; Goss SPA, 1997, J BIOL CHEM, V272, P21647, DOI 10.1074/jbc.272.34.21647; GRAHAM A, 1993, FEBS LETT, V330, P181, DOI 10.1016/0014-5793(93)80269-Z; GRATZEL M, 1974, J AM CHEM SOC, V96, P7869; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Guy RA, 2001, ATHEROSCLEROSIS, V155, P19, DOI 10.1016/S0021-9150(00)00524-4; HANDELMAN GJ, 1993, BIOCHEM MOL BIOL INT, V31, P777; HOGG N, 1995, J LIPID RES, V36, P1756; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; Kenar JA, 1996, CHEM RES TOXICOL, V9, P737, DOI 10.1021/tx9600098; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; LISSI EA, 1989, J BIOENERG BIOMEMBR, V21, P375, DOI 10.1007/BF00762728; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Lopez D, 2001, AM J PHYSIOL-HEART C, V280, pH2929, DOI 10.1152/ajpheart.2001.280.6.H2929; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V194, P960, DOI 10.1006/bbrc.1993.1914; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; MALINSKI T, 1996, METHODS NITRIC OXIDE, P319; Mykkanen L, 1999, ARTERIOSCL THROM VAS, V19, P2742, DOI 10.1161/01.ATV.19.11.2742; ODonnell VB, 1997, BIOCHEMISTRY-US, V36, P15216, DOI 10.1021/bi971891z; Orlova EV, 1999, P NATL ACAD SCI USA, V96, P8420, DOI 10.1073/pnas.96.15.8420; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; PUHL H, 1994, METHOD ENZYMOL, V233, P425; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Rubbo H, 2000, J BIOL CHEM, V275, P10812, DOI 10.1074/jbc.275.15.10812; Rubbo H, 1995, ARCH BIOCHEM BIOPHYS, V324, P15, DOI 10.1006/abbi.1995.9935; SCHUSTER B, 1995, P NATL ACAD SCI USA, V92, P2509, DOI 10.1073/pnas.92.7.2509; SEPULVEDA P, 1992, J COLLOID INTERF SCI, V152, P104; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; THOMAS JP, 1994, ARCH BIOCHEM BIOPHYS, V315, P244, DOI 10.1006/abbi.1994.1496; Trostchansky A, 2001, ARCH BIOCHEM BIOPHYS, V395, P225, DOI 10.1006/abbi.2001.2583; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Warnholtz A, 1999, CIRCULATION, V99, P2027, DOI 10.1161/01.CIR.99.15.2027; Wattanapitayakul SK, 2000, FASEB J, V14, P271, DOI 10.1096/fasebj.14.2.271; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; Yang CY, 1999, BIOCHEMISTRY-US, V38, P15903, DOI 10.1021/bi991464g	53	70	77	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					932	936		10.1074/jbc.M106589200	http://dx.doi.org/10.1074/jbc.M106589200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11689557	hybrid			2022-12-25	WOS:000173166800010
J	Lowry, WE; Huang, XY				Lowry, WE; Huang, XY			G protein beta gamma subunits act on the catalytic domain to stimulate Bruton's agammaglobulinemia tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN-HOMOLOGY DOMAIN; X-LINKED AGAMMAGLOBULINEMIA; PHOSPHOLIPASE-C; MEMBRANE ASSOCIATION; ADENYLYL-CYCLASE; PHOSPHATIDYLINOSITOL 3-KINASE; ALPHA-SUBUNIT; PH DOMAIN; ACTIVATION; BINDING	G proteins are critical cellular signal transducers for a variety of cell surface receptors. Both alpha and betagamma subunits of G proteins are able to transduce receptor signals. Several direct effect molecules for Gbetagamma subunits have been reported; yet the biochemical mechanism by which Gbetagamma executes its modulatory role is not well understood. We have shown that Gbetagamma could directly increase the kinase activity of Bruton's tyrosine kinase (Btk) whose defects are responsible for X chromosome-linked agammaglobulinemia in patients. The well characterized interaction of Gbetagamma with the PH (pleckstrin homology)/TH (Tec-homology) module of Btk was proposed to be the underlying activation mechanism. Here we show that Gbetagamma also interacts with the catalytic domain of Btk leading to increased kinase activity. Furthermore, we showed that the PH/TH module is required for Gbetagamma-induced membrane translocation of Btk. The membrane anchorage is also dependent on the interaction of Btk with phosphatidylinositol 3,4,5-trisphosphate, the product of phosphoinositide 3-kinase. These data support a dual role for Gbetagamma in the activation of Btk signaling function, namely membrane translocation and direct regulation of Btk catalytic activity.	Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA	Cornell University	Huang, XY (corresponding author), Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA.							August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Lowry WE, 2001, J BIOL CHEM, V276, P45276, DOI 10.1074/jbc.M104449200; Ma YC, 1998, P NATL ACAD SCI USA, V95, P12197, DOI 10.1073/pnas.95.21.12197; Nore BF, 2000, EUR J IMMUNOL, V30, P145, DOI 10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Vihinen M, 1999, HUM MUTAT, V13, P280, DOI 10.1002/(SICI)1098-1004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2	37	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1488	1492		10.1074/jbc.M110390200	http://dx.doi.org/10.1074/jbc.M110390200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11698416	hybrid			2022-12-25	WOS:000173166800080
J	Uhlmann-Schiffler, H; Rossler, OG; Stahl, H				Uhlmann-Schiffler, H; Rossler, OG; Stahl, H			The mRNA of DEAD box protein p72 is alternatively translated into an 82-kDa RNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL RIBOSOME ENTRY; 5' UNTRANSLATED REGION; FIBROBLAST GROWTH-FACTOR; ESTROGEN-RECEPTOR-ALPHA; SECONDARY STRUCTURE; MAMMALIAN-CELLS; ESCHERICHIA-COLI; INITIATION; P68; EXPRESSION	p68 and p72 are two highly related DEAD box proteins with similar biochemical activities in the nucleus of vertebrate cells; it is unknown whether they have redundant or differential in vivo functions. We report on a third member of this subfamily that is alternatively expressed from p72 mRNA. A detailed analysis of HeLa p72 mRNA was performed. It has an overall length of more than 5 kb and contains a 0.75-kb 5'-untranslated region and a X-untranslated region of 2.5 kb. Its open reading frame extends to nucleotide -243 upstream of the first in-frame AUG (A in the AUG triplet is +1) which serves as the p72 translation initiator codon. We provide evidence that alternative translation at a non-AUG within the extra coding region of this mRNA yields an 82-kDa protein (p82). Immunological studies substantiate that p82 is a naturally existing p72 variant and that both proteins are expressed at similar concentrations. p82 purified from HeLa cells is an ATP-dependent RNA helicase with biochemical properties almost identical to those of p72.	Univ Saarland, Fachbereich Med Biochem & Mol Biol, D-66421 Homburg, Germany	Saarland University	Stahl, H (corresponding author), Univ Saarland, Fachbereich Med Biochem & Mol Biol, D-66421 Homburg, Germany.	bchsta@med-rz.uni-saarland.de						Akileswaran L, 2001, J BIOL CHEM, V276, P17448, DOI 10.1074/jbc.M101171200; BARTA I, 1995, EMBO J, V14, P3800, DOI 10.1002/j.1460-2075.1995.tb00049.x; Beyersmann D, 2000, EXS, V89, P11; BORMAN AM, 1995, NUCLEIC ACIDS RES, V23, P3656, DOI 10.1093/nar/23.18.3656; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Carter PS, 1999, ONCOGENE, V18, P4326, DOI 10.1038/sj.onc.1202890; Chen Y, 1999, GENES GENET SYST, V74, P271, DOI 10.1266/ggs.74.271; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; Day DA, 1998, J ENDOCRINOL, V157, P361, DOI 10.1677/joe.0.1570361; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Fang L, 1998, J BACTERIOL, V180, P90, DOI 10.1128/JB.180.1.90-95.1998; Galas DJ, 2001, SCIENCE, V291, P1257, DOI 10.1126/science.291.5507.1257; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HLOCH P, 1995, THESIS U KONSTANZ GE; IGGO R, 1990, NUCLEIC ACIDS RES, V18, P5413, DOI 10.1093/nar/18.18.5413; Ip FCF, 2000, NEUROREPORT, V11, P457, DOI 10.1097/00001756-200002280-00006; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Jost JP, 1999, NUCLEIC ACIDS RES, V27, P3245, DOI 10.1093/nar/27.16.3245; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamm GM, 1996, NUCLEIC ACIDS RES, V24, P3739, DOI 10.1093/nar/24.19.3739; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MEHDI H, 1990, GENE, V91, P173, DOI 10.1016/0378-1119(90)90085-6; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; op den Camp RGL, 1998, NUCLEIC ACIDS RES, V26, P2058, DOI 10.1093/nar/26.9.2058; Oumard A, 2000, MOL CELL BIOL, V20, P2755, DOI 10.1128/MCB.20.8.2755-2759.2000; Pal M, 2001, RNA, V7, P5, DOI 10.1017/S1355838201000127; PEABODY DS, 1987, J BIOL CHEM, V262, P11847; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; REIM P, 1993, THESIS U KONSTANZ GE; Rossler OG, 2001, NUCLEIC ACIDS RES, V29, P2088, DOI 10.1093/nar/29.10.2088; Rossler OG, 2000, NUCLEIC ACIDS RES, V28, P932, DOI 10.1093/nar/28.4.932; ROSSLER OG, 2000, THESIS U SAARLAND SA; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SCHNEIDER E, 1995, HYBRIDOMA, V14, P329, DOI 10.1089/hyb.1995.14.329; Seufert DW, 2000, J EXP ZOOL, V288, P193, DOI 10.1002/1097-010X(20001015)288:3<193::AID-JEZ1>3.0.CO;2-V; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; STRAKA A, 1995, THESIS U KONSTANZ GE; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307	59	41	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1066	1075		10.1074/jbc.M107535200	http://dx.doi.org/10.1074/jbc.M107535200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11675387	hybrid			2022-12-25	WOS:000173166800026
J	Blair, LA; Maggi, LB; Scarim, AL; Corbett, JA				Blair, LA; Maggi, LB; Scarim, AL; Corbett, JA			Role of interferon regulatory factor-1 in double-stranded RNA-induced iNOS expression by mouse islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE SYNTHASE EXPRESSION; NF-KAPPA-B; DEPENDENT DIABETES-MELLITUS; BETA-CELL PRODUCTION; PROTEIN-KINASE PKR; NITRIC-OXIDE; MACROPHAGE ACTIVATION; TRANSCRIPTION FACTOR; SIGNALING PATHWAYS; POTENTIAL ROLE	Environmental factors, such as viral infection, have been implicated as potential triggering events leading to the initial destruction of pancreatic 13 cells during the development of autoimmune diabetes. Double-stranded RNA (dsRNA), the active component of a viral infection that stimulates antiviral responses in infected cells, has been shown in combination with interferon-gamma (IFN-gamma) to stimulate inducible nitric oxide synthase (iNOS) expression and nitric oxide production and to inhibit P cell function. Interferon regulatory factor-1 (IRF-1), the activation of which is induced by dsRNA, viral infection, and IFN-gamma, regulates the expression of many antiviral proteins, including PKR, type I IFN, and iNOS. In this study, we show that IRF-1 is not required for dsRNA + IFN-gamma-stimulated iNOS expression and nitric oxide production by mouse islets. In contrast to islets, dsRNA + IFN-gamma fails to induce iNOS expression or nitric oxide production by macrophages isolated from IRF-1(-/-)mice; however, dsRNA + IFN-gamma induces similar levels of IL-1 release by macrophages isolated from both IRF-1(-/-)and IRF-1(+/+) mice. Importantly, we show that dsRNA- or dsRNA + IFN-gamma-stimulated IRF-1 expression by mouse islets and peritoneal macrophages is independent of PKR. These results indicate that IRF-1 is required for dsRNA + IFN-gamma-induced iNOS expression and nitric oxide production by mouse peritoneal macrophages but not by mouse islets. These findings suggest that dsRNA + IFN-gamma stimulates iNOS expression by two distinct PKR-independent mechanisms; one that is IRF-1dependent in macrophages and another that is IRF-1-independent in islets.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Corbett, JA (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	corbettj@slu.edu	Maggi, Leonard/L-5217-2019	Maggi, Leonard/0000-0003-0138-0984	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052194] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-44458] Funding Source: Medline; NIDDK NIH HHS [DK-52194] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnush M, 1998, J IMMUNOL, V160, P2684; Arnush M, 1998, J CLIN INVEST, V102, P516, DOI 10.1172/JCI844; BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; BANATVALA JE, 1985, LANCET, V1, P1409; Beck KF, 1996, FEBS LETT, V394, P263, DOI 10.1016/0014-5793(96)00966-0; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; Blair LA, 2001, DIABETES, V50, P283, DOI 10.2337/diabetes.50.2.283; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CHU SC, 1995, J BIOL CHEM, V270, P10625, DOI 10.1074/jbc.270.18.10625; Chung YH, 1997, J IMMUNOL, V159, P466; Clemens MJ, 1997, INT J BIOCHEM CELL B, V29, P945, DOI 10.1016/S1357-2725(96)00169-0; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EWEL CH, 1992, DIABETES, V41, P1016, DOI 10.2337/diabetes.41.8.1016; Flodstrom M, 1997, ENDOCRINOLOGY, V138, P2747, DOI 10.1210/en.138.7.2747; GEPTS W, 1965, DIABETES, V14, P619, DOI 10.2337/diab.14.10.619; GODAMBE SA, 1993, CYTOKINE, V5, P327, DOI 10.1016/1043-4666(93)90064-C; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gupta S, 1998, J IMMUNOL, V161, P5997; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; Heitmeier MR, 1999, J BIOL CHEM, V274, P12531, DOI 10.1074/jbc.274.18.12531; Heitmeier MR, 1998, J BIOL CHEM, V273, P15301, DOI 10.1074/jbc.273.24.15301; Heitmeier MR, 2001, J BIOL CHEM, V276, P11151, DOI 10.1074/jbc.M009159200; Hill JR, 1996, ANAL BIOCHEM, V236, P14, DOI 10.1006/abio.1996.0125; Hirasawa K, 1997, J VIROL, V71, P4024, DOI 10.1128/JVI.71.5.4024-4031.1997; Hirasawa K, 1996, J GEN VIROL, V77, P737, DOI 10.1099/0022-1317-77-4-737; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LACY PE, 1991, AM J PATHOL, V138, P1183; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KU, 1988, DIABETES, V37, P989, DOI 10.2337/diabetes.37.7.989; Maggi LB, 2000, EMBO J, V19, P3630, DOI 10.1093/emboj/19.14.3630; MANDRUPPOULSEN T, 1985, ALLERGY, V40, P424, DOI 10.1111/j.1398-9995.1985.tb02681.x; Pavlovic D, 1999, EUR CYTOKINE NETW, V10, P403; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Robertson HD, 1996, BIOCHIMIE, V78, P909, DOI 10.1016/S0300-9084(97)86712-0; Saura M, 1999, J MOL BIOL, V289, P459, DOI 10.1006/jmbi.1999.2752; Scarim AL, 2001, AM J PATHOL, V159, P273, DOI 10.1016/S0002-9440(10)61693-8; SIBLEY RK, 1985, LAB INVEST, V53, P132; SOBEL DO, 1992, DIABETES, V41, P515, DOI 10.2337/diabetes.41.4.515; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; vonHerrath MG, 1996, CURR OPIN IMMUNOL, V8, P878, DOI 10.1016/S0952-7915(96)80019-7; vonHerrath MG, 1996, IMMUNOL REV, V152, P111; WEISS EH, 1984, NATURE, V310, P650, DOI 10.1038/310650a0; Williams BRG, 1997, BIOCHEM SOC T, V25, P509, DOI 10.1042/bst0250509; XANTHOUDAKIS S, 1989, J BIOL CHEM, V264, P1139; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; YOON JW, 1995, DIABETES METAB REV, V11, P83, DOI 10.1002/dmr.5610110202	57	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					359	365		10.1074/jbc.M109819200	http://dx.doi.org/10.1074/jbc.M109819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11694524	hybrid			2022-12-25	WOS:000173087900048
J	Ju, TZ; Brewer, K; D'Souza, A; Cummings, RD; Canfield, WM				Ju, TZ; Brewer, K; D'Souza, A; Cummings, RD; Canfield, WM			Cloning and expression of human core 1 beta 1,3-galactosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGA NEPHROPATHY; TN-SYNDROME; O-GLYCANS; GALACTOSYLTRANSFERASE; ANTIGEN; PROTEIN; GLYCOSYLATION; BIOSYNTHESIS; ANTIBODY; BINDING	The common core 1 O-glycan structure Galbeta1-->3GalNAc-R is the precursor for many extended mucin-type O-glycan structures in animal cell surface and secreted glycoproteins. Core 1 is synthesized by the transfer of Gal from UDP-Gal to GalNAcalpha1-R by core 1 beta3-galactosyltransferase (core 1 beta3-Gal-T). Amino acid sequences from purified rat core 1 beta3-Gal-T (Ju, T., Cummings, R. D., and Canfield, W. M. (2002) J. Biol. Chem. 277, 169-177) were used to identify the core 1 beta3-Gal-T sequences in the human expressed sequence tag data bases. A 1794-bp human core 1 beta3-Gal-T cDNA sequence was determined by sequencing the expressed sequence tag and performing 5'-rapid amplification of cDNA ends. The core 1 beta3-Gal-T predicts a 363-amino acid type II transmembrane protein. Expression of both the full-length and epitope-tagged soluble forms of the putative enzyme in human 293T cells generated core 1 beta3-Gal-T activity that transferred galactose from UDP-Gal to GalNAcalpha1-O-phenyl, and a synthetic glycopeptide with Thr-linked GalNAc and the product was shown to have the core I structure. Northern analysis demonstrated widespread expression of core 1 beta3-Gal-T in tissues with a predominance in kidney, heart, placenta, and liver. Highly homologous cDNAs were identified and cloned from rat, mouse, Drosophila melanogaster, and Caenorhabditis elegans, suggesting that the enzyme is widely distributed in metazoans. The core 1 beta3-Gal-T sequence has minimal homology with conserved sequences found in previously described beta3-galactosyltransferases, suggesting this enzyme is only distantly related to the known beta3-galactosyltransferase family.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; W K Warren Med Res Inst, Oklahoma City, OK 73104 USA; Dept Med, Oklahoma City, OK 73104 USA; Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NE 10th ST,BRC Rm 417, Oklahoma City, OK 73104 USA.			Ju, Tongzhong/0000-0002-4429-1976	NIAID NIH HHS [R01 AI48075-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048075] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen AC, 1997, NEPHROL DIAL TRANSPL, V12, P701, DOI 10.1093/ndt/12.4.701; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; ANDRE PM, 1990, J CLIN LAB ANAL, V4, P115, DOI 10.1002/jcla.1860040208; Berger EG, 1999, BBA-MOL BASIS DIS, V1455, P255, DOI 10.1016/S0925-4439(99)00069-1; BIRD GWG, 1971, BRIT J HAEMATOL, V21, P443, DOI 10.1111/j.1365-2141.1971.tb02705.x; Brockhausen I, 1997, BIOCHEM SOC T, V25, P871, DOI 10.1042/bst0250871; Brockhausen I, 1998, GLYCOCONJUGATE J, V15, P595, DOI 10.1023/A:1006967910803; BROCKHAUSEN I, 1997, GLYCOPROTEINS HUMAN, P13; DAUSSET J, 1959, BLOOD, V14, P1079, DOI 10.1182/blood.V14.10.1079.1079; Feehally J, 1999, J NEPHROL, V12, P59; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Felner KM, 1998, BBA-MOL BASIS DIS, V1406, P115; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; INOUE M, 1994, CANCER RES, V54, P85; Ju TZ, 2002, J BIOL CHEM, V277, P169, DOI 10.1074/jbc.M109056200; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; Kokubo T, 1999, NEPHROL DIAL TRANSPL, V14, P81, DOI 10.1093/ndt/14.1.81; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; Mattu TS, 1998, J BIOL CHEM, V273, P2260, DOI 10.1074/jbc.273.4.2260; MESTECKY J, 1993, CONTRIB NEPHROL, V104, P172; PILLER V, 1990, J BIOL CHEM, V265, P9264; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; Sambrook J., 2002, MOL CLONING LAB MANU; SCHACHTER H, 1971, J BIOL CHEM, V246, P5321; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; THURNHER M, 1993, J CLIN INVEST, V91, P2103, DOI 10.1172/JCI116434; TOMANA M, 1995, ADV EXP MED BIOL, V376, P221	33	218	242	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					178	186		10.1074/jbc.M109060200	http://dx.doi.org/10.1074/jbc.M109060200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11677243	hybrid			2022-12-25	WOS:000173087900025
J	Moradpour, D; Bieck, E; Hugle, T; Wels, W; Wu, JZ; Hong, Z; Blum, HE; Bartenschlager, R				Moradpour, D; Bieck, E; Hugle, T; Wels, W; Wu, JZ; Hong, Z; Blum, HE; Bartenschlager, R			Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN ANTIBODY; DE-NOVO INITIATION; CRYSTAL-STRUCTURE; CELL-LINES; NS5B; MECHANISM; REPLICATION; IDENTIFICATION; TRANSCRIPTION	The hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp), represented by nonstructural protein 513 (NS5B), has recently emerged as a promising target for antiviral intervention. Here, we describe the isolation, functional characterization, and molecular cloning of a monoclonal antibody (mAb) inhibiting the HCV RdRp. This m)Ab, designated 5B-12B7, binds with high affinity to a conformational epitope in the palm subdomain of the HCV RdRp and recognizes native NS5B expressed in the context of the entire HCV polyprotein or subgenomic replicons. Complete inhibition of RdRp activity in vitro was observed at equimolar concentrations of NS5B and mAb 5B-12B7, whereas RdRp activities of classical swine fever virus NS5B and poliovirus 3D polymerase were not affected. mAb 5B-12B7 selectively inhibited NTP binding to HCV NS5B, whereas binding of template RNA was unaffected, thus explaining the mechanism of action at the molecular level. The mAb 5B-12B7 heavy and light chain variable domains were cloned by reverse transcription-PCR, and a single chain Fv fragment was assembled for expression in Escherichia coli and in eukaryotic cells. The mAb 5B-12B7 single chain Fv fragment bound to NS5B both in vitro and in transfected human cell lines and therefore may be potentially useful for intracellular immunization against HCV. More important, detailed knowledge of the mAb 5B-12B7 contact sites on the enzyme may facilitate the development of small molecule RdRp inhibitors as novel antiviral agents.	Univ Freiburg, Dept Med 2, D-79106 Freiburg, Germany; Georg Speyer Haus, Biomed Res Inst, D-60596 Frankfurt, Germany; Johannes Gutenberg Univ Mainz, Inst Virol, D-55131 Mainz, Germany; ICN Pharmaceut, Costa Mesa, CA 92626 USA	University of Freiburg; Octapharma; Johannes Gutenberg University of Mainz	Blum, HE (corresponding author), Univ Hosp Freiburg, Dept Med 2, Hugstetter Str 55, D-79106 Freiburg, Germany.	heblum@ukl.uni-freiburg.de	; Moradpour, Darius/G-7918-2017; Bartenschlager, Ralf/L-2582-2015	Wels, Winfried/0000-0001-9858-3643; Moradpour, Darius/0000-0003-1977-6792; Bartenschlager, Ralf/0000-0001-5601-9307				Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Baginski SG, 2000, P NATL ACAD SCI USA, V97, P7981, DOI 10.1073/pnas.140220397; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; Harlow E., 1988, ANTIBODIES LAB MANUA; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Ingravallo P, 2001, VIRUS RES, V75, P179, DOI 10.1016/S0168-1702(01)00239-8; Jia YP, 1997, J BIOL CHEM, V272, P30147, DOI 10.1074/jbc.272.48.30147; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Lavanchy D, 1999, J VIRAL HEPATITIS, V6, P35; Lesburg C A, 2000, Curr Opin Investig Drugs, V1, P289; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1999, J BIOL CHEM, V274, P10807, DOI 10.1074/jbc.274.16.10807; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; Moradpour D, 1998, HEPATOLOGY, V28, P192, DOI 10.1002/hep.510280125; Moradpour D, 2001, SWISS MED WKLY, V131, P291; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Rondon IJ, 1997, ANNU REV MICROBIOL, V51, P257, DOI 10.1146/annurev.micro.51.1.257; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schmidt-Mende J, 2001, J BIOL CHEM, V276, P44052, DOI 10.1074/jbc.M103358200; WELS W, 1995, INT J CANCER, V60, P137, DOI 10.1002/ijc.2910600120; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; Wolk B, 2000, J VIROL, V74, P2293, DOI 10.1128/JVI.74.5.2293-2304.2000; Yamamoto M, 1999, HEPATOLOGY, V30, P300, DOI 10.1002/hep.510300105; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000	36	45	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					593	601		10.1074/jbc.M108748200	http://dx.doi.org/10.1074/jbc.M108748200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11641406	hybrid			2022-12-25	WOS:000173087900078
J	Phan, J; Pesaran, T; Davis, RC; Reue, K				Phan, J; Pesaran, T; Davis, RC; Reue, K			The Diet1 locus confers protection against hypercholesterolemia through enhanced bile acid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR LXR; CHOLESTEROL 7-ALPHA-HYDROXYLASE EXPRESSION; DENSITY-LIPOPROTEIN CHOLESTEROL; BILIARY LIPID SECRETION; TRANSGENIC MICE; BIOSYNTHESIS; GENE; TRANSPORT; LIVER; HOMEOSTASIS	The C57BL,/6ByJ (B6By) mouse strain is resistant to diet-induced hypercholesterolemia and atherosclerosis, despite its near genetic identity with the atherosclerosis-susceptible C57BL/6J (B6J) strain. We previously identified a genetic locus, Diet1, which is responsible for the resistant phenotype in B6By mice. To investigate the function of Diet1, we compared mRNA expression profiles in the liver of B6By and B6J mice fed an atherogenic diet using a DNA microarray. These studies revealed elevated expression levels in B6By liver for key bile acid synthesis proteins, including cholesterol 7alpha-hydroxylase and sterol-27-hydroxylase, and the oxysterol nuclear receptor liver X receptor alpha. Expression levels for several other genes involved in bile acid metabolism were subsequently found to differ between B6By and B6J mice, including the bile acid receptor farnesoid X receptor, oxysterol 7alpha-hydroxylase, sterol-12alpha-hydroxylase, and hepatic bile acid transporters on both sinusoidal and canalicular membranes. The overall expression profile of the B6By strain suggests a higher rate of bile acid synthesis and transport in these mice. Consistent with this interpretation, fecal bile acid excretion is increased 2-fold in B6By mice, and bile acid levels in blood and urine are elevated 3- and 18-fold, respectively. Genetic analysis of serum bile acid levels revealed co-segregation with Diet1, indicating that this locus is likely responsible for both increased bile acid excretion and resistance to hypercholesterolemia in B6By mice.	Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles	Reue, K (corresponding author), Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 113,Rm 312, Los Angeles, CA 90073 USA.			Phan, Jack/0000-0001-5977-6004	NHLBI NIH HHS [HL58627, HL28481] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481, R01HL058627] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSTIN MA, 1987, AM J EPIDEMIOL, V125, P308, DOI 10.1093/oxfordjournals.aje.a114531; Bahar RJ, 1999, GASTROENTEROL CLIN N, V28, P27, DOI 10.1016/S0889-8553(05)70042-X; BIANCHINI F, 1989, J NUTR, V119, P1617, DOI 10.1093/jn/119.11.1617; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BUCHER KD, 1988, GENET EPIDEMIOL, V5, P17, DOI 10.1002/gepi.1370050103; Cohen DE, 1999, CURR OPIN LIPIDOL, V10, P295, DOI 10.1097/00041433-199908000-00002; Cohen JC, 1999, CURR OPIN LIPIDOL, V10, P303, DOI 10.1097/00041433-199908000-00003; Cohen RD, 1997, J CLIN INVEST, V99, P1906, DOI 10.1172/JCI119358; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Elferink RPJO, 2000, SEMIN LIVER DIS, V20, P293, DOI 10.1055/s-2000-9385; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; FOX RR, 1997, HDB GENETICALLY STAN; FRITJERS CM, 1997, BIOCHEM J, V321, P389; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; HEDRICK CC, 1993, J BIOL CHEM, V268, P20676; Hofmann AF, 1999, ARCH INTERN MED, V159, P2647, DOI 10.1001/archinte.159.22.2647; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; JONES MP, 1993, J LIPID RES, V34, P885; KIRK EA, 1995, J LIPID RES, V36, P1522; Kullak-Ublick GA, 2000, SEMIN LIVER DIS, V20, P273, DOI 10.1055/s-2000-9426; Lammert Frank, 1997, Hepatology, V26, p358A; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Machleder D, 1997, J CLIN INVEST, V99, P1406, DOI 10.1172/JCI119300; MAZER NA, 1984, J LIPID RES, V25, P932; Mouzeyan A, 2000, J LIPID RES, V41, P573; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PERUSSE L, 1989, ARTERIOSCLEROSIS, V9, P308, DOI 10.1161/01.ATV.9.3.308; PODREZ EA, 1993, LIPIDS, V28, P709, DOI 10.1007/BF02535991; POORMAN JA, 1993, J LIPID RES, V34, P1675; RAMIREZ MI, 1994, MOL CELL BIOL, V14, P2809, DOI 10.1128/MCB.14.4.2809; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; RICE T, 1991, HUM HERED, V41, P107, DOI 10.1159/000153987; RIEDY MC, 1995, BIOTECHNIQUES, V18, P70; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Schwarz M, 1998, CURR OPIN LIPIDOL, V9, P113, DOI 10.1097/00041433-199804000-00006; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; Spady DK, 1998, J BIOL CHEM, V273, P126, DOI 10.1074/jbc.273.1.126; Turley SD, 1998, HEPATOLOGY, V28, P1088, DOI 10.1002/hep.510280425; TWISK J, 1995, BIOCHEM J, V305, P505, DOI 10.1042/bj3050505; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Vlahcevic ZR, 1996, AM J PHYSIOL-GASTR L, V270, pG646, DOI 10.1152/ajpgi.1996.270.4.G646; Wang JP, 1998, J CLIN INVEST, V101, P1283, DOI 10.1172/JCI1343	53	21	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					469	477		10.1074/jbc.M107107200	http://dx.doi.org/10.1074/jbc.M107107200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11682476	hybrid			2022-12-25	WOS:000173087900063
J	Rutherfurd, KJ; Rutherfurd, SM; Moughan, PJ; Hendriks, WH				Rutherfurd, KJ; Rutherfurd, SM; Moughan, PJ; Hendriks, WH			Isolation and characterization of a felinine-containing peptide from the blood of the domestic cat (Felis catus)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; ACID	Felinine is a unique sulfur-containing amino acid found in the urine of domestic cats and select members of the Felidae family. Research over the past 50 years has led to the conclusion that felinine must be synthesized in the kidney, as free felinine is not present in the blood or tissues of cats. We propose that felinine is present in the blood as gamma-glutamylfelinylglycine, a glutathione conjugate. To test our hypothesis [S-35]cysteine was administered intraperitoneally to one entire male cat, and two radiolabeled fractions were isolated from the blood. We showed that the amounts of both fractions in serum were linked to the gender of the cat, with entire males expressing significantly higher levels compared with castrated males, entire females, or spayed females. Both fractions were characterized using amino acid analysis with one fraction (S18), containing an equimolar ratio of Cys, Glu, and Gly, while fraction S16 was found to contain Cys, plus free amino acids. Nanospray mass spectrometry confirmed the sequence of fraction S18 as being gamma-glutamylfelinylglycine and conclusively proving that felinine is present in the blood of cats as part of a larger molecule, thereby questioning the current theory that felinine is synthesized in the kidney.	Massey Univ, Inst Food Nutr & Human Hlth, Palmerston North, New Zealand	Massey University	Rutherfurd, KJ (corresponding author), Massey Univ, Inst Food Nutr & Human Hlth, Private Bag 11 222, Palmerston North, New Zealand.		Rutherfurd, Shane M/D-8254-2011					*ASS AM FEED CONTR, 2000, OFF PUBL ASS AM FEED; AVIZONIS PV, 1959, BIOCHIM BIOPHYS ACTA, V34, P279, DOI 10.1016/0006-3002(59)90271-9; BAILLIE TA, 1993, BIOL MASS SPECTROM, V22, P319, DOI 10.1002/bms.1200220602; BORCHERS J., 1967, DEUT TIERARZTL WOCHENSCHR, V74, P532; DATTA SP, 1951, J PHYSIOL-LONDON, V114, pP39; EGGERER H, 1962, LIEBIGS ANN CHEM, V657, P212; Griffith O., 1983, METHOD ENZYMAT AN, V8, P521; HENDRIKS W, 1995, BIOORG CHEM, V23, P89, DOI 10.1006/bioo.1995.1007; Hendriks WH, 1995, COMP BIOCHEM PHYS B, V112, P581, DOI 10.1016/0305-0491(95)00130-1; HENDRIKS WH, 1995, PHYSIOL BEHAV, V58, P467, DOI 10.1016/0031-9384(95)00084-V; Hendriks WH, 2001, COMP BIOCHEM PHYS C, V129, P211, DOI 10.1016/S1532-0456(01)00196-X; KUWAKI T, 1963, BIOCHIM BIOPHYS ACTA, V78, P553, DOI 10.1016/0006-3002(63)90924-7; MACDONALD ML, 1984, ANNU REV NUTR, V4, P521, DOI 10.1146/annurev.nu.04.070184.002513; MIZUHARA S, 1961, ARCH BIOCHEM BIOPHYS, V92, P53, DOI 10.1016/0003-9861(61)90217-X; Mutlib AE, 2000, J PHARMACOL EXP THER, V294, P735; ROBERTS RN, 1963, THESIS STATE U NEW Y; ROSS LA, 1981, AM J VET RES, V42, P1704; SHAPIRO IL, 1962, THESIS U DELAWARE NE; SIES H, 1983, GLUTATHIONE STORAGE, P63; TALLAN HH, 1954, J BIOL CHEM, V211, P927; Tarttelin MF, 1998, PHYSIOL BEHAV, V65, P83, DOI 10.1016/S0031-9384(98)00132-2; WANG TM, 1964, THESIS U DELAWARE; WESTALL RG, 1953, BIOCHEM J, V55, P244, DOI 10.1042/bj0550244; Zhu MS, 1997, J CHROMATOGR B, V688, P187, DOI 10.1016/S0378-4347(96)00277-0; 1992, CODE ETHICAL CONDUCT	25	20	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					114	119		10.1074/jbc.M107728200	http://dx.doi.org/10.1074/jbc.M107728200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11698402	hybrid			2022-12-25	WOS:000173087900016
J	Cartee, RT; Forsee, WT; Jensen, JW; Yother, J				Cartee, RT; Forsee, WT; Jensen, JW; Yother, J			Expression of the Streptococcus pneumoniae type 3 synthase in Escherichia coli - Assembly of type 3 polysaccharide on a lipid primer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULAR POLYSACCHARIDE; BIOSYNTHESIS; GLYCOSYLTRANSFERASES; MECHANISM; GLUCOSYLTRANSFERASE; PURIFICATION; STRAINS; SURFACE; ACID	Synthesis of the type 3 capsular polysaccharide of Streptococcus pneumoniae is catalyzed by the membrane-localized type 3 synthase, which utilizes UDP-Glc and UDP-GlcUA to form high molecular mass [3-beta-D-GlcUA-(1-->4)-beta-D-Glc-(1-->](n). Expression of the synthase in Escherichia coli resulted in synthesis of a 40-kDa protein that was reactive with antibody directed against the C terminus of the synthase and was the same size as the native enzyme. Membranes isolated from E. coli contained active synthase, as demonstrated by the ability to incorporate Glc and GlcUA into a high molecular mass polymer that could be degraded by type 3 polysaccharide-specific depolymerase. As in S. pneumoniae, the membrane-bound synthase from E. coli catalyzed a rapid release of enzyme-bound polysaccharide when incubated with either UDP-Glc or UDP-GlcUA alone. The recombinant enzyme expressed in E. coli was capable of releasing all of the polysaccharide from the enzyme, although the chains remained associated with the membrane. The recombinant enzyme was also able to reinitiate polysaccharide synthesis following polymer release by utilizing a lipid primer present in the membranes. At low concentrations of UDP-Gle and UDP-GlcUA (I mum in the presence of Mg2+ and 0.2 mum in Mn2+), novel glycolipids composed of repeating disaccharides with linkages consistent with type 3 polysaccharide were synthesized. As the concentration of the UDP-sugars was increased, there was a marked transition from glycolipid to polymer formation. At UDP-sugar concentrations of either 5 gm (with Mg2+,) or 1.5 mum (with Mn2+), 80% of the incorporated sugar was in polymer form, and the size of the polymer increased dramatically as the concentration of UDP-sugars was increased. These results suggest a cooperative interaction between the UDP-precursor-binding site(s) and the nascent polysaccharide-binding site, resulting in a non-processive addition of sugars at the lower UDP-sugar concentrations and a processive reaction as the substrate concentrations increase.	Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Yother, J (corresponding author), Univ Alabama Birmingham, Dept Microbiol, BBRB 661-12,845 19th St S, Birmingham, AL 35294 USA.	jyother@uab.edu			NHLBI NIH HHS [T32 HL07553] Funding Source: Medline; NIGMS NIH HHS [GM53017] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053017] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrecubieta C, 1996, J EXP MED, V184, P449, DOI 10.1084/jem.184.2.449; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bliss JM, 1996, MOL MICROBIOL, V21, P221, DOI 10.1046/j.1365-2958.1996.6461357.x; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Cartee RT, 2000, J BIOL CHEM, V275, P3907, DOI 10.1074/jbc.275.6.3907; Charnock SJ, 2001, PLANT PHYSIOL, V125, P527, DOI 10.1104/pp.125.2.527; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; Dennis EA, 1983, ENZYMES, P307; DILLARD JP, 1994, MOL MICROBIOL, V12, P959, DOI 10.1111/j.1365-2958.1994.tb01084.x; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; Forsee WT, 2000, J BIOL CHEM, V275, P25972, DOI 10.1074/jbc.M002613200; FORSEE WT, 1989, J BIOL CHEM, V264, P3869; FORSEE WT, 1981, J BIOL CHEM, V256, P7240; GOTSCHLICH EC, 1981, J BIOL CHEM, V256, P8915; Hardy GG, 2000, J BACTERIOL, V182, P1854, DOI 10.1128/JB.182.7.1854-1863.2000; HENRICHSEN J, 1995, J CLIN MICROBIOL, V33, P2759, DOI 10.1128/JCM.33.10.2759-2762.1995; IMAMURA S, 1979, J BIOCHEM, V85, P79, DOI 10.1093/oxfordjournals.jbchem.a132334; Jorasch P, 1998, MOL MICROBIOL, V29, P419, DOI 10.1046/j.1365-2958.1998.00930.x; Jorasch P, 2000, EUR J BIOCHEM, V267, P3770, DOI 10.1046/j.1432-1327.2000.01414.x; Keenleyside WJ, 1996, J BIOL CHEM, V271, P28581, DOI 10.1074/jbc.271.45.28581; KENNEDY EP, 1996, ESCHERICHIA COLI SAL, P1064; Koyama M, 1997, P NATL ACAD SCI USA, V94, P9091, DOI 10.1073/pnas.94.17.9091; KUHN HM, 1988, FEMS MICROBIOL LETT, V54, P195, DOI 10.1111/j.1574-6968.1988.tb02743.x; Magee AD, 2001, INFECT IMMUN, V69, P3755, DOI 10.1128/IAI.69.6.3755-3761.2001; Reeves RE, 1941, J BIOL CHEM, V139, P511; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SCHMIDT MA, 1982, FEMS MICROBIOL LETT, V14, P69, DOI 10.1016/0378-1097(82)90045-3; SMITH EEB, 1960, J GEN MICROBIOL, V22, P265, DOI 10.1099/00221287-22-1-265; TOLMASKY ME, 1982, J BIOL CHEM, V257, P6751; VANDAM JEG, 1990, ANTON LEEUW INT J G, V58, P1; WEISSBORN AC, 1984, J BIOL CHEM, V259, P2644; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; YOTHER J, 1994, J BACTERIOL, V176, P2976, DOI 10.1128/JB.176.10.2976-2985.1994	35	25	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48831	48839		10.1074/jbc.M106481200	http://dx.doi.org/10.1074/jbc.M106481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11684683	hybrid			2022-12-25	WOS:000173922100029
J	Kanzaki, M; Watson, RT; Khan, AH; Pessin, JE				Kanzaki, M; Watson, RT; Khan, AH; Pessin, JE			Insulin stimulates actin comet tails on intracellular GLUT4-containing compartments in differentiated 3T3L1 adipocytes.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT ADIPOCYTES; BINDING PROTEIN CDC42; GTP-GAMMA-S; GLUCOSE-TRANSPORTER; N-WASP; SHIGELLA-FLEXNERI; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; ARP2/3 COMPLEX; PHOSPHATIDYLINOSITOL 3-KINASE	Incubation of isolated GLUT4-containing vesicles with Xenopus oocyte extracts resulted in a guanosine 5'-[gamma-thio]triphosphate (GTP-gammaS) and sodium orthovanadate stimulation of actin comet tails. The in vitro actin-based GLUT4 vesicle motility was inhibited by both latrunculin B and a dominant-interfering N-WASP mutant, N-WASP/DeltaVCA. Preparations of gently sheared (broken) 3T3L1 adipocytes also displayed GTPgammaS and sodium orthovanadate stimulation of actin comet tails on GLUT4 intracellular compartments. Furthermore, insulin pretreatment of intact adipocytes prior to gently shearing also resulted in a marked increase in actin polymerization and actin comet tailing on GLUT4 vesicles. In addition, the insulin stimulation of actin comet tails was completely inhibited by Clostridum difficile toxin B, demonstrating a specific role for a Rho family member small GTP-binding protein. Expression of N-WASP/DeltaVCA in intact cells had little effect on adipo-cyte cortical actin but partially inhibited insulin-stimulated GLUT4 translocation. Taken together, these data demonstrate that insulin can induce GLUT4 vesicle actin comet tails that are necessary for the efficient translocation of GLUT4 from intracellular storage sites to the plasma membrane.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.		Kanzaki, Makoto/H-6680-2017	Kanzaki, Makoto/0000-0002-6884-2955	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK059291, R01DK033823] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59291, DK33823, DK25925] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDINI G, 1991, J BIOL CHEM, V266, P4037; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; BERNSTEIN BW, 1989, NEURON, V3, P257, DOI 10.1016/0896-6273(89)90039-1; Bogan JS, 2001, MOL CELL BIOL, V21, P4785, DOI 10.1128/MCB.21.14.4785-4806.2001; Cameron LA, 2000, NAT REV MOL CELL BIO, V1, P110, DOI 10.1038/35040061; Carlier MF, 1998, CURR OPIN CELL BIOL, V10, P45, DOI 10.1016/S0955-0674(98)80085-9; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; Fletcher LM, 2000, BIOCHEM J, V352, P267, DOI 10.1042/0264-6021:3520267; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; Gouin E, 1999, J CELL SCI, V112, P1697; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Khayat ZA, 2000, J CELL SCI, V113, P279; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Ma L, 1998, J CELL BIOL, V140, P1125; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Moreau V, 1998, FEBS LETT, V427, P353, DOI 10.1016/S0014-5793(98)00443-8; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; Olson AL, 2001, J BIOL CHEM, V276, P10706, DOI 10.1074/jbc.M007610200; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Patki V, 2001, MOL BIOL CELL, V12, P129, DOI 10.1091/mbc.12.1.129; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; SATOH S, 1993, J BIOL CHEM, V268, P17820; SHIBATA H, 1995, J BIOL CHEM, V270, P11489, DOI 10.1074/jbc.270.19.11489; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Tsakiridis T, 1998, J BIOL CHEM, V273, P28322, DOI 10.1074/jbc.273.43.28322; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YANG J, 1993, J BIOL CHEM, V268, P4600	51	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49331	49336		10.1074/jbc.M109657200	http://dx.doi.org/10.1074/jbc.M109657200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11606595	hybrid			2022-12-25	WOS:000173922100092
J	Sarkar, S; Pollack, BP; Lin, KT; Kotenko, SV; Cook, JR; Lewis, A; Pestka, S				Sarkar, S; Pollack, BP; Lin, KT; Kotenko, SV; Cook, JR; Lewis, A; Pestka, S			hTid-1, a human DnaJ protein, modulates the interferon signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAK-STAT PATHWAY; JAK/STAT PATHWAY; ARGININOSUCCINATE SYNTHETASE; ANGIOTENSIN-II; HUMAN HOMOLOG; KINASE JAK2; RECEPTOR; DROSOPHILA; ACTIVATION; GENE	The Jak family of protein-tyrosine kinases are crucial for the signaling of a large number of different polypeptide ligands, including the interferons, many cytokines, erythropoietin, and growth factors. Through their interaction with receptors, the Jaks initiate a signaling cascade resulting in the activation of gene transcription and ultimately a cellular response to various ligands. In addition to their role in cellular signaling, alteration of Jak activity has been implicated in several disease states. In identifying Jak2-interacting proteins with the yeast two-hybrid system, we cloned the human homologue of the Drosophila melanogaster tumor suppressor gene lethal (2) tumorous imaginal discs, which encodes the protein Tid56. Drosophila Tid56 and its human homologue hTid-1 represent members of the DnaJ family of molecular chaperones. The TID1 gene encodes two splice variants hTid-1(S) and hTid-1(L). We confirmed the interaction between Jak2 and hTid-1(S) or hTid-1L by immunoprecipitation from COS-1 cells expressing these proteins. The interaction between endogenous hTid-1 and Jak2 was shown in HEp2 cells. We further showed that hTid-1 interacts with the human interferon-gamma (Hu-IFN-gamma) receptor subunit rFN-gammaR2. In addition, using a chimeric construct where the extracellular domain of IFN-gammaR2 was fused to the kinase domain of Jak2, we showed that hTid-1 binds more efficiently to the chimera with an active kinase domain than to a similar construct with an inactive kinase domain. Additionally, the data demonstrate that hTid-1 isoforms as well as Jak2 interact with Hsp70/Hsc70 in vivo, and the interaction between Hsp70/Hsc70 and hTid-1 is reduced after IFN-gamma treatment. Furthermore, both hTid-1(S) and hTid-1L can modulate IFN-gamma-mediated transcriptional activity.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Pestka, S (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	pestka@waksman.rutgers.edu			NCI NIH HHS [R01-CA46465, R01-CA46465-12S1, R01-CA46465-13S1] Funding Source: Medline; NIAID NIH HHS [R01-AI43369, R01-AI36450, 2T32AI07403] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043369, R01AI036450, T32AI007403] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aringer M, 1999, LIFE SCI, V64, P2173, DOI 10.1016/S0024-3205(98)00538-4; Berhow MT, 1996, J NEUROSCI, V16, P8019; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cattaneo E, 1996, J BIOL CHEM, V271, P23374, DOI 10.1074/jbc.271.38.23374; CHAUHAN D, 1995, J EXP MED, V182, P1801, DOI 10.1084/jem.182.6.1801; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Das R, 1996, ONCOGENE, V13, P1139; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; Fuhrer DK, 1996, BIOCHEM BIOPH RES CO, V224, P289, DOI 10.1006/bbrc.1996.1023; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; HARPER JW, 1993, CELL, V75, P805; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; Hou XS, 1997, TRENDS GENET, V13, P105, DOI 10.1016/S0168-9525(97)01006-8; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; Kotenko SV, 1999, P NATL ACAD SCI USA, V96, P5007, DOI 10.1073/pnas.96.9.5007; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; KurzikDumke U, 1997, CANCER J - FRANCE, V10, P56; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lee JH, 2000, BIOCHEM BIOPH RES CO, V274, P105, DOI 10.1006/bbrc.2000.3049; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Maegawa H, 1996, BIOCHEM BIOPH RES CO, V228, P122, DOI 10.1006/bbrc.1996.1626; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Melville MW, 1997, P NATL ACAD SCI USA, V94, P97, DOI 10.1073/pnas.94.1.97; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; NUSSLER AK, 1994, J BIOL CHEM, V269, P1257; Pan J, 1997, CIRC RES, V81, P611, DOI 10.1161/01.RES.81.4.611; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; PERRIMON N, 1986, DEV BIOL, V118, P28, DOI 10.1016/0012-1606(86)90070-9; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Pestka Sidney, 1997, Cytokine and Growth Factor Reviews, V8, P189, DOI 10.1016/S1359-6101(97)00009-9; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Pollack Brian P., 1997, Journal of Interferon and Cytokine Research, V17, pS72; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; PREVARSKAYA NB, 1995, J BIOL CHEM, V270, P24292, DOI 10.1074/jbc.270.41.24292; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	59	51	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49034	49042		10.1074/jbc.M103683200	http://dx.doi.org/10.1074/jbc.M103683200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11679576	hybrid			2022-12-25	WOS:000173922100056
J	Knox, AJ; Corbett, L; Stocks, J; Holland, E; Zhu, YM; Pang, LH				Knox, AJ; Corbett, L; Stocks, J; Holland, E; Zhu, YM; Pang, LH			Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism	FASEB JOURNAL			English	Article						VEGF; BK; cyclooxygenase; PKC	NECROSIS-FACTOR-ALPHA; ASTHMATIC AIRWAYS; NASAL SECRETIONS; RELEASE; EXPRESSION; CYTOKINE; BETA(2)-AGONISTS; INHIBITION; KALLIKREIN; ICATIBANT	Bronchial vascular remodeling is an important feature of the pathology of chronic asthma, but the responsible mechanisms and main sources of angiogenic factors are unclear. Here we report that human airway smooth muscle cells express vascular endothelial growth factor (VEGF)(121, 165, 189, 206) splice variants and secrete VEGF protein constitutively. VEGF protein secretion was increased by the proinflammatory asthma mediator bradykinin through post-transcriptional mechanisms. Bradykinin-induced VEGF secretion was dependent on the B-2 bradykinin receptor, activation of protein kinase C, and generation of endogenous prostanoids. This is the first report that bradykinin can increase VEGF secretion in any biological system and the first to show that airway smooth muscle cells produce VEGF. Our results suggest a novel role for human airway smooth muscle in contributing to bronchial mucosal angiogenesis in chronic asthma by secretion of VEGF and suggest a wider role for mesenchymal cell products in mediating angiogenesis in inflammatory and allergic diseases.	City Hosp, Div Resp Med, Nottingham NG5 1PB, England	University of Nottingham	Knox, AJ (corresponding author), City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.	alan.knox@nottingham.ac.uk	Stocks, Joanne/K-4403-2019; Stocks, Joanne/A-3307-2017	Stocks, Joanne/0000-0002-7800-6002; Stocks, Joanne/0000-0002-7800-6002; Knox, Alan/0000-0002-5906-4143				Akbary AM, 1996, IMMUNOPHARMACOLOGY, V33, P238, DOI 10.1016/0162-3109(96)00065-3; Asano K, 1996, AM J PHYSIOL-LUNG C, V271, pL126, DOI 10.1152/ajplung.1996.271.1.L126; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; Berse B, 1999, CLIN EXP IMMUNOL, V115, P176; Boesiger J, 1998, J EXP MED, V188, P1135, DOI 10.1084/jem.188.6.1135; Boussat S, 2000, AM J PHYSIOL-LUNG C, V279, pL371, DOI 10.1152/ajplung.2000.279.2.L371; Carroll NG, 1997, AM J RESP CRIT CARE, V155, P689, DOI 10.1164/ajrccm.155.2.9032214; Charan NB, 1997, EUR RESPIR J, V10, P1173, DOI 10.1183/09031936.97.10051173; CHRISTIANSEN SC, 1987, J CLIN INVEST, V79, P188, DOI 10.1172/JCI112782; Elias JA, 1997, AM J PHYSIOL-LUNG C, V273, pL648, DOI 10.1152/ajplung.1997.273.3.L648; Fehrenbach H, 1999, ANAT REC, V254, P61; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933, DOI 10.1164/ajrccm.159.6.9805039; Griga T, 1999, HEPATO-GASTROENTEROL, V46, P920; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hogg JC, 1999, THORAX, V54, P283, DOI 10.1136/thx.54.4.283; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; John M, 1997, J IMMUNOL, V158, P1841; Johnson S, 1999, AM J PHYSIOL-LUNG C, V277, pL1109, DOI 10.1152/ajplung.1999.277.6.L1109; Johnson SR, 1997, TRENDS PHARMACOL SCI, V18, P288, DOI 10.1016/S0165-6147(97)01092-4; KNOX AJ, 1994, CLIN SCI, V86, P647, DOI 10.1042/cs0860647; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; NARUMIYA S, 1994, ANN NY ACAD SCI, V744, P126, DOI 10.1111/j.1749-6632.1994.tb52729.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOVERAL JP, 1994, AM J PHYSIOL-LUNG C, V267, pL761, DOI 10.1152/ajplung.1994.267.6.L761; Orsida BE, 1999, THORAX, V54, P289, DOI 10.1136/thx.54.4.289; PAEGELOW I, 1995, INFLAMM RES, V44, P306, DOI 10.1007/BF02032574; Pang LH, 1998, J IMMUNOL, V161, P2509; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; Pang LH, 1997, AM J PHYSIOL-LUNG C, V273, pL1132, DOI 10.1152/ajplung.1997.273.6.L1132; Pang LH, 2001, FASEB J, V15, P261, DOI 10.1096/fj.00-0103com; Pang LH, 2000, AM J RESP CELL MOL, V23, P79, DOI 10.1165/ajrcmb.23.1.3985; PANG LH, 2000, AM J RESP CRIT CARE, V161, pA473; PEACOCK DJ, 1992, J EXP MED, V175, P1135, DOI 10.1084/jem.175.4.1135; Peters KG, 1998, CIRC RES, V83, P342, DOI 10.1161/01.RES.83.3.342; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; *SPSS INC, 1996, SPSS BAS WIND US GUI; Turner P, 2001, J ALLERGY CLIN IMMUN, V107, P105, DOI 10.1067/mai.2001.111145; Yoshiji H, 1999, CANCER RES, V59, P4413	42	110	118	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2480	2488		10.1096/fj.01-0256com	http://dx.doi.org/10.1096/fj.01-0256com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689473				2022-12-25	WOS:000172420500018
J	Chaussade, L; Eymin, B; Brambilla, E; Gazzeri, S				Chaussade, L; Eymin, B; Brambilla, E; Gazzeri, S			Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status	ONCOGENE			English	Article						p(15INK4b); p16(INK4a); p14(ARF); expression; methylation; lung tumour	DEPENDENT KINASE INHIBITORS; CPG ISLAND METHYLATION; CELL-CYCLE ARREST; CDK INHIBITORS; BETA-TRANSCRIPT; P16(INK4) GENE; HUMAN CANCERS; TGF-BETA; INACTIVATION; SUPPRESSOR	The cell cycle inhibitor p15(INK4B) is frequently inactivated by homozygous deletions together with p16(INK4a)/14(ARF) in many tumour types. Although it is now well established that p16(INK4a) and p14(ARF) act as tumour suppressor genes, the role of p15(INK4b) remains to be well defined. In order to explore the possibility of a selective deregulation of p15(INK4b) in human lung carcinogenesis, we studied p15INK4b status in neuroendocrine (NE) lung tumours where homozygous deletions of the p16(INK4a)/p14(ARF) locus are rarely observed. Expressions of p15 and p15.5 protein isoforms were analysed in a series of eight control normal lung, 12 tumour-associated normal lung, five low grade and 15 high grade neuroendocrine (NE) lung tumours and relationship with a specific p15(INK4b) methylation status was studied. Using Western blot analysis, we showed that p15 and p15.5 isoforms displayed a high heterogeneous pattern of expression in both normal and tumour tissues. P15 and p15.5 expressions were correlated in control normal lung (P < 0.04) whereas they were not in tumours and associated normal lung. The level of p15.5 was significantly higher in associated normal lung and in tumours (P < 0.02 respectively), specially in low grade tumours (P < 0.01), than in control normal lung. Furthermore, p15.5 expression was more variable in tumours than in normal lung (P < 0.01) and in low grade than in high grade NE lung tumours (P < 0.02). Levels of p15 and p15.5 were distinct (up- or downregulated) from those observed in paired normal lung in 4/12 (33%) and 10/12 (83%) tumours respectively. Aberrant methylation at the 5 ' end of P15(INK4b) gene was observed in 15% of NE lung tumours using PCR-based assay, in a region proximal to the translation start where methylation did not occur in control and associated normal lung. However, no correlation could be assessed with protein status. MSP analysis of CpG islands proximal to the transcription start revealed methylation in all normal and tumour samples. No correlation was found between p15(INK4b) and p16(INK4a) or p14(ARF) status. These data suggest that complex deregulation of p15.5 is implicated in the carcinogenesis of human NE lung tumours independently of p16(INK4a) and p14(ARF) status.	Inst Albert Bonniot, INSERM EMI 9925, Grp Rech Canc Poumon, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, INSERM EMI 9925, Grp Rech Canc Poumon, F-38706 La Tronche, France.		Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019; gazzeri, sylvie/M-1961-2013; Brambilla, Elisabeth MP/L-8796-2013; eymin, beatrice/U-4670-2019	Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810				Aggerholm A, 1999, CANCER RES, V59, P436; Anbazhagan R, 1999, CANCER RES, V59, P5119; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dosaka-Akita H, 2000, CANCER, V88, P550, DOI 10.1002/(SICI)1097-0142(20000201)88:3<550::AID-CNCR9>3.0.CO;2-D; Fuxe J, 2000, ONCOGENE, V19, P1724, DOI 10.1038/sj.onc.1203496; Gazzeri S, 1998, CANCER RES, V58, P3926; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; GLENDENING JM, 1995, CANCER RES, V55, P5531; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GrayBablin J, 1997, CANCER RES, V57, P604; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Iravani M, 1997, ONCOGENE, V15, P2609, DOI 10.1038/sj.onc.1201428; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAKAGAWA K, 1995, ONCOGENE, V11, P1843; OKAMOTO A, 1995, CANCER RES, V55, P1448; Packenham JP, 1995, CLIN CANCER RES, V1, P687; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rusin MR, 1996, INT J CANCER, V65, P734, DOI 10.1002/(SICI)1097-0215(19960315)65:6<734::AID-IJC4>3.0.CO;2-#; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, ONCOGENE, V11, P987; TRAVIS WD, 1999, EMBO J, V18, P4280; Tsubari M, 1997, CANCER RES, V57, P2966; WASHIMI O, 1995, CANCER RES, V55, P514; XIAO S, 1995, CANCER RES, V55, P2968; Yuan JP, 1999, J PATHOL, V189, P358	44	18	20	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6587	6596		10.1038/sj.onc.1204798	http://dx.doi.org/10.1038/sj.onc.1204798			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641784				2022-12-25	WOS:000171404200012
J	Fazi, B; Cope, MJTV; Douangamath, A; Ferracuti, S; Schirwitz, K; Zucconi, A; Drubin, DG; Wilmanns, M; Cesareni, G; Castagnoli, L				Fazi, B; Cope, MJTV; Douangamath, A; Ferracuti, S; Schirwitz, K; Zucconi, A; Drubin, DG; Wilmanns, M; Cesareni, G; Castagnoli, L			Unusual binding properties of the SH3 domain of the yeast actin-binding protein Abp1 - Structural and functional analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ASSOCIATED PROTEIN; PROLINE-RICH REGION; CYTOSKELETON ORGANIZATION; BUDDING YEAST; HOMOLOGY; SRC; SPECIFICITY; LIGANDS; ADAPTER; ENDOCYTOSIS	Abp1p is an actin-binding protein that plays a central role in the organization of Saccharomyces cerevisiae actin cytoskeleton. By a combination of two-hybrid and phage-display approaches, we have identified six new ligands of the Abp1-SH3 domain. None of these SH3-mediated novel interactions was detected in recent all genome high throughput protein interaction projects. Here we show that the SH3-mediated association of Abp1p with the Ser/Thr kinases Prk1p and Ark1p is essential for their localization to actin cortical patches. The Abp1-SH3 domain has a rather unusual binding specificity, because its target peptides contain the tetrapentapeptide +XXXPXXPX+PXXL with positive charges flanking the polyproline core on both sides. Here we present the structure of the Abp1-SH3 domain solved at 1.3-A resolution. The peptide-binding pockets in the SH3 domain are flanked by two acidic residues that are uncommon at those positions in the SH3 domain family. We have shown by site-directed mutagenesis that one of these negatively charged side chains may be the key determinant for the preference for non-classical ligands.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Calif Berkeley, Berkeley, CA 94720 USA; DESY Hamburg, EMBL, D-22603 Hamburg, Germany	University of Rome Tor Vergata; University of California System; University of California Berkeley; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Castagnoli, L (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	luisa.castagnoli@uniroma2.it	Cesareni, Gianni/AAW-1382-2020	Castagnoli, Luisa/0000-0001-5283-8671; Wilmanns, Matthias/0000-0002-4643-5435; Cope, Jamie/0000-0002-6960-8271	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042759, R01GM042759, R01GM050399] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42759, GM50399] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balguerie A, 1999, J CELL SCI, V112, P2529; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Brannetti B, 2000, J MOL BIOL, V298, P313, DOI 10.1006/jmbi.2000.3670; Cesareni G, 1999, COMB CHEM HIGH T SCR, V2, P1; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; Cope MJTV, 1999, J CELL BIOL, V144, P1203, DOI 10.1083/jcb.144.6.1203; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; Freeman NL, 1996, MOL CELL BIOL, V16, P548; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Kessels MM, 2000, MOL BIOL CELL, V11, P393, DOI 10.1091/mbc.11.1.393; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ooms LM, 2000, MOL CELL BIOL, V20, P9376, DOI 10.1128/MCB.20.24.9376-9390.2000; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Sorkin A, 2000, J CELL SCI, V113, P4375; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Tang HY, 2000, MOL CELL BIOL, V20, P12, DOI 10.1128/MCB.20.1.12-25.2000; TONG AHY, 2001, IN PRESS SCIENCE; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Zeng GS, 1999, J CELL BIOL, V144, P71, DOI 10.1083/jcb.144.1.71; Zucconi A, 2001, J MOL BIOL, V307, P1329, DOI 10.1006/jmbi.2001.4572	51	83	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5290	5298		10.1074/jbc.M109848200	http://dx.doi.org/10.1074/jbc.M109848200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11668184	hybrid			2022-12-25	WOS:000173962900095
J	Lewis, DEA; Adhya, S				Lewis, DEA; Adhya, S			In vitro repression of the gal promoters by GalR and HU depends on the proper helical phasing of the two operators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; DNA; TRANSCRIPTION; PURIFICATION; REQUIREMENT; INHIBITION; ACTIVATION; DISTANCE; COMPLEX	Repression of transcription initiation from the two gal promoters, P1 and P2, requires binding of GalR protein to two Ranking operators, O-E and O-I, binding of HU to a site, hbs, located between the two operators, and supercoiled DNA template. Previous experiments suggested that repression involves the interaction of two DNA-bound GalR proteins, which generates a 113-bp DNA loop encompassing the promoter region. Interaction between two DNA-bound proteins would be allowed if the binding sites on DNA are properly aligned. To test the idea that the observed repression of gal transcription in vitro is mediated by DNA looping, we investigated the effect of changing the relative angular orientation of OE and 01 in the DNA helix. We found that repression is a periodic function of the distance between the two operator sites. Since repression recurred commensurate with DNA helical repeat, we conclude that the observed in vitro repression is mediated by DNA looping and the in vitro conditions reflect the in vivo situation.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Adhya, S (corresponding author), NCI, Mol Biol Lab, NIH, 37 Convent Dr,Rm 5138, Bethesda, MD 20892 USA.	sadhya@helix.nih.gov						ADHYA S, 1985, SEQUENCE SPECIFICITY, P245; Aki T, 1996, GENES CELLS, V1, P179, DOI 10.1046/j.1365-2443.1996.d01-236.x; Aki T, 1997, EMBO J, V16, P3666, DOI 10.1093/emboj/16.12.3666; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; CHOY HE, 1992, P NATL ACAD SCI USA, V89, P11264, DOI 10.1073/pnas.89.23.11264; Choy HE, 1997, J MOL BIOL, V272, P293, DOI 10.1006/jmbi.1997.1221; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; Geanacopoulos M, 2001, NAT STRUCT BIOL, V8, P432, DOI 10.1038/87595; GOODRICH JA, 1992, J MOL BIOL, V224, P15, DOI 10.1016/0022-2836(92)90573-3; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HAHN S, 1986, J MOL BIOL, V188, P355, DOI 10.1016/0022-2836(86)90160-9; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; IRANI MH, 1983, CELL, V32, P783, DOI 10.1016/0092-8674(83)90064-8; Kar S, 2001, GENE DEV, V15, P2273, DOI 10.1101/gad.920301; KRAMER H, 1988, EMBO J, V7, P547, DOI 10.1002/j.1460-2075.1988.tb02844.x; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; LAW SM, 1993, J MOL BIOL, V230, P161, DOI 10.1006/jmbi.1993.1133; LEE DH, 1989, P NATL ACAD SCI USA, V86, P476, DOI 10.1073/pnas.86.2.476; Lewis DEA, 1999, MOL MICROBIOL, V31, P451, DOI 10.1046/j.1365-2958.1999.01186.x; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; Lyubchenko YL, 1997, NUCLEIC ACIDS RES, V25, P873, DOI 10.1093/nar/25.4.873; MAJUMDAR A, 1987, J BIOL CHEM, V262, P2326; Muller J, 1998, J MOL BIOL, V284, P851, DOI 10.1006/jmbi.1998.2253; Muller J, 1996, J MOL BIOL, V257, P21, DOI 10.1006/jmbi.1996.0143; Perez N, 2000, NUCLEIC ACIDS RES, V28, P3600, DOI 10.1093/nar/28.18.3600; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; Roy S, 1998, J BIOL CHEM, V273, P14059, DOI 10.1074/jbc.273.23.14059; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SQUIRES C, 1981, NUCLEIC ACIDS RES, V9, P6827, DOI 10.1093/nar/9.24.6827; TOMIZAWA J, 1981, P NATL ACAD SCI-BIOL, V78, P1421, DOI 10.1073/pnas.78.3.1421; TULLIUS TD, 1985, SCIENCE, V230, P679, DOI 10.1126/science.2996145; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259	34	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2498	2504		10.1074/jbc.M108456200	http://dx.doi.org/10.1074/jbc.M108456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11700313	hybrid			2022-12-25	WOS:000173421500018
J	Holbrook, JD; Danpure, CJ				Holbrook, JD; Danpure, CJ			Molecular basis for the dual mitochondrial and cytosolic localization of Alanine: Glyoxylate aminotransferase in amphibian liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE AMINOTRANSFERASE; SINGLE-GENE; SUBCELLULAR-DISTRIBUTION; PEROXISOMAL ALANINE; TARGETING SIGNAL; HEPATIC ALANINE; PTS1 MOTIF; RAT-LIVER; EVOLUTION; SERINE	To gain further insights into the molecular basis of the evolution of alanine:glyoxylate aminotransferase (AGT) intracellular targeting in vertebrates, we have studied the molecular basis of its dual mitochondrial and cytosolic distribution in amphibian liver cells. The AGT gene in Xenopus laevis encodes a polypeptide of 415 amino acids, which includes a 24-residue N-terminal mitochondrial targeting sequence (MTS), at either end of which are located two in-frame potential translation start sites. This MTS is necessary to target Xenopus AGT and sufficient to target a green fluorescent fusion protein to mitochondria in transfected COS cells. The C-terminal tripeptide (KKM), despite being similar to the nonconsensus type 1 peroxisomal targeting sequence in human AGT (KKL), was unable to target Xenopus AGT or human AGT to peroxisomes. The Xenopus AGT gene produces two types of transcript. The longer form encodes a polypeptide that contains the MTS and is targeted to mitochondria. The shorter form encodes a polypeptide that does not contain the MTS and remains in the cytosol. These results are discussed not only in terms of the molecular evolution of AGT targeting but also in terms of the ancillary requirements for the peroxisomal targeting of human AGT.	UCL, Dept Biol, London WC1E 6BT, England	University of London; University College London	Danpure, CJ (corresponding author), UCL, Dept Biol, Gower St, London WC1E 6BT, England.	c.danpure@ucl.ac.uk						BARRATT TM, 1999, PEDIAT NEPHROLOGY, P609; Birdsey GM, 1998, BIOCHEM J, V331, P49, DOI 10.1042/bj3310049; Bulitta C, 1996, BBA-PROTEIN STRUCT M, V1293, P55, DOI 10.1016/0167-4838(95)00241-3; COOPER PJ, 1988, J HISTOCHEM CYTOCHEM, V36, P1285, DOI 10.1177/36.10.3418107; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; Danpure C. J., 2001, METABOLIC MOL BASES, V2, P3323; Danpure CJ, 1997, BIOESSAYS, V19, P317, DOI 10.1002/bies.950190409; DANPURE CJ, 1994, EUR J CELL BIOL, V64, P295; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P230, DOI 10.1016/S0962-8924(00)89016-9; Danpure CJ, 2000, UROL CLIN N AM, V27, P287, DOI 10.1016/S0094-0143(05)70258-5; DANPURE CJ, 1990, J CELL SCI, V97, P669; DANPURE CJ, 1989, J CELL BIOL, V108, P1345, DOI 10.1083/jcb.108.4.1345; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Holbrook JD, 2000, MOL BIOL EVOL, V17, P387, DOI 10.1093/oxfordjournals.molbev.a026318; Knott TG, 2000, BIOCHEM J, V352, P409, DOI 10.1042/0264-6021:3520409; Leiper JM, 1996, J CELL BIOL, V135, P939, DOI 10.1083/jcb.135.4.939; Liepman AH, 2001, PLANT J, V25, P487, DOI 10.1046/j.1365-313x.2001.00961.x; Lumb MJ, 1999, J BIOL CHEM, V274, P20587, DOI 10.1074/jbc.274.29.20587; Lumb MJ, 2000, J BIOL CHEM, V275, P36415, DOI 10.1074/jbc.M006693200; LUMB MJ, 1994, EUR J BIOCHEM, V221, P53, DOI 10.1111/j.1432-1033.1994.tb18714.x; MIYAJIMA H, 1989, J BIOCHEM-TOKYO, V105, P500, DOI 10.1093/oxfordjournals.jbchem.a122695; MOTLEY A, 1995, J CELL BIOL, V131, P95, DOI 10.1083/jcb.131.1.95; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Oatey PB, 1996, EUR J BIOCHEM, V241, P374, DOI 10.1111/j.1432-1033.1996.00374.x; Oatey PB, 1996, ANN NY ACAD SCI, V804, P652, DOI 10.1111/j.1749-6632.1996.tb18653.x; ODA T, 1982, J BIOCHEM, V91, P219, DOI 10.1093/oxfordjournals.jbchem.a133679; ODA T, 1987, EUR J BIOCHEM, V168, P537, DOI 10.1111/j.1432-1033.1987.tb13451.x; ODA T, 1990, J BIOL CHEM, V265, P7513; PURDUE PE, 1990, J CELL BIOL, V111, P2341, DOI 10.1083/jcb.111.6.2341; PURDUE PE, 1992, EUR J BIOCHEM, V207, P757, DOI 10.1111/j.1432-1033.1992.tb17106.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; TAKADA Y, 1990, BIOCHEM J, V268, P517, DOI 10.1042/bj2680517; YAMAMOTO K, 1992, J HISTOCHEM CYTOCHEM, V40, P1909, DOI 10.1177/40.12.1360481	36	20	20	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2336	2344		10.1074/jbc.M107047200	http://dx.doi.org/10.1074/jbc.M107047200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11694530	hybrid			2022-12-25	WOS:000173421300094
J	Liou, HL; Kahn, PC; Storch, J				Liou, HL; Kahn, PC; Storch, J			Role of the helical domain in fatty acid transfer from adipocyte and heart fatty acid-binding proteins to membranes - Analysis of chimeric proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-BINDING; PHOSPHOLIPID-MEMBRANES; COLLISIONAL TRANSFER; CRYSTAL-STRUCTURE; LYSINE RESIDUES; LIVER; EXPRESSION; MUSCLE; SURFACE; LIGAND	The adipocyte and heart fatty acid-binding proteins (A- and HFABP) are members of a lipid-binding protein family with a beta-barrel body capped by a small helix-turn-helix motif. Both proteins are hypothesized to transport fatty acid (FA) to phospholipid membranes through a collisional process. Previously, we suggested that the helical domain is particularly important for the electrostatic interactions involved in this transfer mechanism (Herr, F. M., Aronson, J., and Storch, J. (1996) Biochemistry 35, 1296-1303; and Liou, H.-L., and Storch, J. (2001) Biochemistry 40,6475-6485). Despite their using qualitatively similar FA transfer mechanisms, differences in absolute transfer rates as well as regulation of transfer from AFABP versus HFABP, prompted us to consider the structural determinants that underlie these functional disparities. To determine the specific elements underlying the functional differences between AFABP and HFABP in FA transfer, two pairs of chimeric proteins were generated. The first and second pairs had the entire helical domain and the first alpha-helix exchanged between A- and HFABP, respectively. The transfer rates of anthroyloxy-labeled fatty acid from proteins to small unilamellar vesicles were compared with the wild type AFABP and HFABP. The results suggest that the alphaII-helix is important in determining the absolute FA transfer rates. Furthermore, the alphaI-helix appears to be particularly important in regulating protein sensitivity to the negative charge of membranes. The alphaI-helix of HFABP and the all-helix of AFABP increased the sensitivity to anionic vesicles; the alphaI-helix of AFABP and alphaII-helix of HFABP decreased the sensitivity. The differential sensitivities to negative charge, as well as differential absolute rates of FA transfer, may help these two proteins to function uniquely in their respective cell types.	Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA; Rutgers State Univ, Dept Biochem & Microbiol, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Storch, J (corresponding author), Rutgers State Univ, Dept Nutr Sci, 96 Lipman Dr, New Brunswick, NJ 08901 USA.	storch@aesop.rutgers.edu		Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK038389, DK38393] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANATHARMAIAH G, 1993, AMPHIPATHIC HELIX, P109; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASS NM, 1986, BIOCHEM BIOPH RES CO, V137, P929, DOI 10.1016/0006-291X(86)90314-1; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Cistola DP, 1996, BIOCHEMISTRY-US, V35, P7559, DOI 10.1021/bi952912x; Corsico B, 1998, P NATL ACAD SCI USA, V95, P12174, DOI 10.1073/pnas.95.21.12174; CRAIG L, 1994, J BIOL CHEM, V269, P3311; CRISMAN TS, 1987, J MOL CELL CARDIOL, V19, P423, DOI 10.1016/S0022-2828(87)80394-2; FOURNIER NC, 1983, BIOCHEMISTRY-US, V22, P1863, DOI 10.1021/bi00277a019; Gericke A, 1997, BIOCHEMISTRY-US, V36, P8311, DOI 10.1021/bi970679s; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Herr FM, 1996, BIOCHEMISTRY-US, V35, P1296, DOI 10.1021/bi952204b; HERR FM, 1995, BIOCHEMISTRY-US, V34, P11840, DOI 10.1021/bi00037a023; HEUCKEROTH RO, 1987, J BIOL CHEM, V262, P9709; HIGUCHI RB, 1986, NUCLEIC ACIDS RES, V16, P7351; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P2278, DOI 10.1021/bi962018l; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P1450, DOI 10.1021/bi961890r; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; Huang C, 1974, Methods Enzymol, V32, P485; Kajander T, 2000, STRUCTURE, V8, P1203, DOI 10.1016/S0969-2126(00)00520-7; KIM HK, 1992, J BIOL CHEM, V267, P77; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LiCata VJ, 1998, PROTEINS, V33, P577, DOI 10.1002/(SICI)1097-0134(19981201)33:4<577::AID-PROT10>3.0.CO;2-2; Liou HL, 2001, BIOCHEMISTRY-US, V40, P6475, DOI 10.1021/bi0101042; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; Prieto J, 1997, J MOL BIOL, V274, P276, DOI 10.1006/jmbi.1997.1322; Reese-Wagoner A, 1999, BBA-MOL CELL BIOL L, V1441, P106, DOI 10.1016/S1388-1981(99)00154-7; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1988, J BIOL CHEM, V263, P5815; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCAPIN G, 1993, MOL CELL BIOCHEM, V123, P3, DOI 10.1007/BF01076469; Shen WJ, 1999, P NATL ACAD SCI USA, V96, P5528, DOI 10.1073/pnas.96.10.5528; Smith ER, 1999, J BIOL CHEM, V274, P35325, DOI 10.1074/jbc.274.50.35325; Specht B, 1996, J BIOL CHEM, V271, P19943, DOI 10.1074/jbc.271.33.19943; SPITSBERG VL, 1995, EUR J BIOCHEM, V230, P872, DOI 10.1111/j.1432-1033.1995.tb20630.x; STORCH J, 1993, MOL CELL BIOCHEM, V123, P45, DOI 10.1007/BF01076474; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; Thumser AEA, 2000, J LIPID RES, V41, P647; Vayda ME, 1998, BIOCHEM J, V330, P375; VEERKAMP JH, 1993, MOL CELL BIOCHEM, V123, P101, DOI 10.1007/BF01076480; WANG SK, 1995, J BIOL CHEM, V270, P612, DOI 10.1074/jbc.270.2.612; Woolf TB, 1998, BIOPHYS J, V74, P694, DOI 10.1016/S0006-3495(98)73995-5; Woolf TB, 1999, MOL CELL BIOCHEM, V192, P143, DOI 10.1023/A:1006818203334; WOOTAN MG, 1993, BIOCHEMISTRY-US, V32, P8622, DOI 10.1021/bi00084a033; WOOTAN MG, 1994, J BIOL CHEM, V269, P10517; WOOTAN MG, 1990, BIOCHEMISTRY-US, V29, P9305, DOI 10.1021/bi00492a001; XU ZH, 1993, J BIOL CHEM, V268, P7874; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6; Zanotti G, 1999, BBA-MOL CELL BIOL L, V1441, P94, DOI 10.1016/S1388-1981(99)00163-8; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541; ZEZULAK KM, 1985, MOL CELL BIOL, V5, P419, DOI 10.1128/MCB.5.2.419	56	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1806	1815		10.1074/jbc.M107987200	http://dx.doi.org/10.1074/jbc.M107987200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11675390	hybrid			2022-12-25	WOS:000173421300026
J	Singal, R; Wang, SZ; Sargent, T; Zhu, SZ; Ginder, GD				Singal, R; Wang, SZ; Sargent, T; Zhu, SZ; Ginder, GD			Methylation of promoter proximal-transcribed sequences of an embryonic globin gene inhibits transcription in primary erythroid cells and promotes formation of a cell type-specific methyl cytosine binding complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; DE-NOVO METHYLATION; DNA METHYLATION; CODING REGION; PROTEIN; REPRESSION; ACTIVATION; EXPRESSION; MECP2; METHYLTRANSFERASE	The methylation pattern of a 248-base pair proximal transcribed region (rho248) of the avian embryonic p-globin gene was found to correlate inversely with stage-specific expression in avian erythroid cells. In vitro methylation of the rho248 segment alone (in the absence of promoter methylation) resulted in a 5-fold inhibition of transcription in a transient transfection assay in primary erythroid cells in which the transfected gene is packaged into nucleosomal chromatin. This effect was observed if the rho248 segment was positioned adjacent to the promoter but not when it was located 2.7 kilobases downstream. Fully methylated but not unmethylated rho248 formed a novel cell type-specific methyl cytosine-binding protein complex (MeCPC) that contained methyl binding domain protein-2 (MBD-2) and histone deacetylase 1 proteins but differed from MeCP-1. The histone deacetylase inhibitor trichostatin A failed to relieve methylation-mediated repression of transcription from the p-gene promoter, supporting the notion of the dominance of methylation over histone deacetylation in silencing through CpG-rich sequences at this locus. These data demonstrate that site-specific methylation of a vertebrate gene 5'-transcribed region alone at the exact CpGs that are methylated in vivo can suppress transcription in homologous primary cells and facilitate binding to a cell type-specific MeCPC.	Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Internal Med & Human Genet, Richmond, VA 23298 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71101 USA; Overton Brooks Veta Affairs Med Ctr, Dept Med, Shreveport, LA 71101 USA	Virginia Commonwealth University; Virginia Commonwealth University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Ginder, GD (corresponding author), Massey Canc Ctr, Box 980037, Richmond, VA 23298 USA.	gdginder@hsc.vcu.edu			NCI NIH HHS [CA85159] Funding Source: Medline; NIDDK NIH HHS [DK29902] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA085159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029902, R01DK029902] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albano CR, 1998, BIOTECHNOL PROGR, V14, P351, DOI 10.1021/bp970121b; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BROTHERTON TW, 1986, BIOCHEMISTRY-US, V25, P3447, DOI 10.1021/bi00359a053; BROWN JL, 1974, J BIOL CHEM, V249, P3960; BURNS LJ, 1988, BLOOD, V72, P1536; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; Coffee B, 1999, NAT GENET, V22, P98, DOI 10.1038/8807; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GINDER GD, 1984, P NATL ACAD SCI-BIOL, V81, P3954, DOI 10.1073/pnas.81.13.3954; Ginder GD, 1998, ANN NY ACAD SCI, V850, P70, DOI 10.1111/j.1749-6632.1998.tb10464.x; GRAESSMANN A, 1994, MOL CELL BIOL, V14, P2004, DOI 10.1128/MCB.14.3.2004; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; Hohn T, 1996, P NATL ACAD SCI USA, V93, P8334, DOI 10.1073/pnas.93.16.8334; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LANDES GM, 1982, J BIOL CHEM, V257, P1002; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; MEEHAN R, 1992, J CELL SCI, P9; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Schubeler D, 2000, MOL CELL BIOL, V20, P9103, DOI 10.1128/MCB.20.24.9103-9112.2000; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2; Singal R, 2001, BLOOD, V98, P3441, DOI 10.1182/blood.V98.12.3441; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Singal R, 2001, CANCER RES, V61, P4820; Singal R, 1997, P NATL ACAD SCI USA, V94, P13724, DOI 10.1073/pnas.94.25.13724	41	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1897	1905		10.1074/jbc.M105580200	http://dx.doi.org/10.1074/jbc.M105580200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11684679	hybrid			2022-12-25	WOS:000173421300038
J	Winterbourn, CC; Peskin, AV; Parsons-Mair, HN				Winterbourn, CC; Peskin, AV; Parsons-Mair, HN			Thiol oxidase activity of copper,zinc superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; HYDROGEN-PEROXIDE GENERATION; ZINC-BINDING SITE; BIOLOGICAL CHEMISTRY; CATALYZED OXIDATION; REDUCED GLUTATHIONE; D-PENICILLAMINE; MECHANISM; CYSTEINE; AUTOXIDATION	The ability of copper,zinc superoxide dismutase (Cu,Zn-SOD) to catalyze autoxidation of cysteine and other thiols was investigated by measuring thiol loss and oxygen consumption. The reaction occurred equally well with the bovine and human enzymes and produced hydrogen peroxide and the corresponding disulfide. It did not occur with manganese SOD and is not, therefore, due to the dismutase activity of the enzyme. Cysteine and cysteamine were highly reactive: the K-m for cysteine was 1.4 mm and V-max (with 40 mug/ml SOD) 35 mum/ min; the equivalent values for cysteamine (with 20 mug/ml SOD) were 1.4 mm and 36 mum/min. With I mM thiol and 40 mug/ml SOD, rates of oxidation of other thiols (mum/min) were as follows: GSH, 1.0; dithiothreitol, 2.1; dihydrolipoic acid, 1.7; homocysteine, 1.6; cys-gly, 1.4; penicillamine, 0.6; and N-acetylcysteine, 0.1. SOD-mediated oxidation of cysteine, in the absence of chelating agents, proceeded only after a variable lag phase. The lag was decreased but not eliminated with Chelex-treated reagents and is attributed to interference by submicromolar concentrations of iron and possibly other transition metal ions. SOD-catalyzed oxidation of the other thiols was variably affected by adventitious metal ions and chelating agents. Reactions were all performed in the presence of desferrioxamine to obviate these effects. SOD-catalyzed oxidation of GSH and homocysteine was enhanced by cysteine through a thiol-disulfide exchange mechanism. This study characterizes a novel pro-oxidant thiol oxidase activity of Cu,Zn-SOD. It is a potential source of reactive oxidants and may contribute to the cytotoxicity of reactive thiols such as cysteine and cysteamine.	Christchurch Sch Med & Hlth Sci, Dept Pathol, Christchurch, New Zealand	University of Otago	Winterbourn, CC (corresponding author), Christchurch Sch Med & Hlth Sci, Dept Pathol, POB 4345, Christchurch, New Zealand.	christine.winterbourn@chmeds.ac.nz	Peskin, alexander/R-6457-2019	peskin, alexander/0000-0001-9890-6043				BEUTLER E, 1984, RED CELL METABOLISM, P134; BIAGLOW JE, 1984, RADIAT RES, V100, P298, DOI 10.2307/3576351; BIAGLOW JE, 1983, RADIAT RES, V95, P437, DOI 10.2307/3576092; CARLSSON J, 1979, APPL ENVIRON MICROB, V37, P383, DOI 10.1128/AEM.37.3.383-390.1979; CAVALLINI D, 1969, ARCH BIOCHEM BIOPHYS, V130, P354, DOI 10.1016/0003-9861(69)90044-7; Crow JP, 1997, J NEUROCHEM, V69, P1936; EHRENBERG L, 1989, ACTA CHEM SCAND, V43, P177, DOI 10.3891/acta.chem.scand.43-0177; GLATT H, 1983, SCIENCE, V220, P961, DOI 10.1126/science.6342137; Goss SPA, 1999, J BIOL CHEM, V274, P28233, DOI 10.1074/jbc.274.40.28233; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; HELD KD, 1993, RADIAT RES, V134, P375, DOI 10.2307/3578200; Held KD, 1996, RADIAT RES, V145, P542, DOI 10.2307/3579272; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; Hogg N, 1999, FREE RADICAL BIO MED, V27, P28, DOI 10.1016/S0891-5849(99)00029-5; ISSELS RD, 1984, CANCER RES, V44, P3911; JEWETT SL, 1989, EUR J BIOCHEM, V180, P569, DOI 10.1111/j.1432-1033.1989.tb14683.x; JOCELYN PC, 1995, SULFUR SULFUR AMINO, P44; Johnson MA, 2001, J BIOL CHEM, V276, P39872, DOI 10.1074/jbc.M102781200; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V361, P323, DOI 10.1006/abbi.1998.1010; Kachur AV, 1999, FREE RADICAL RES, V31, P23, DOI 10.1080/10715769900300571; Kachur AV, 1997, RADIAT RES, V147, P409, DOI 10.2307/3579496; Kachur AV, 1998, FREE RADICAL RES, V28, P259, DOI 10.3109/10715769809069278; Kato N, 1999, J INORG BIOCHEM, V75, P117, DOI 10.1016/S0162-0134(99)00044-6; Liochev SI, 2000, J BIOL CHEM, V275, P38482, DOI 10.1074/jbc.M007891200; Liochev SI, 2001, ARCH BIOCHEM BIOPHYS, V388, P281, DOI 10.1006/abbi.2001.2296; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; Lyons TJ, 1999, MET IONS BIOL SYST, V36, P125; MISRA HP, 1974, J BIOL CHEM, V249, P2151; MUNDAY R, 1989, BIOCHEM PHARMACOL, V38, P4349, DOI 10.1016/0006-2952(89)90641-2; Munday R, 1994, Adv Pharmacol, V27, P237, DOI 10.1016/S1054-3589(08)61035-2; NYBERG GK, 1979, APPL ENVIRON MICROB, V38, P29, DOI 10.1128/AEM.38.1.29-34.1979; Peskin AV, 2000, CLIN CHIM ACTA, V293, P157, DOI 10.1016/S0009-8981(99)00246-6; ROTILIO G, 1972, BIOCHEMISTRY-US, V11, P2182, DOI 10.1021/bi00761a027; SAEZ G, 1982, BIOCHIM BIOPHYS ACTA, V719, P24, DOI 10.1016/0304-4165(82)90302-6; Singh RJ, 1999, ARCH BIOCHEM BIOPHYS, V372, P8, DOI 10.1006/abbi.1999.1447; Stamler JS, 1996, NUTR REV, V54, P1; STARKEBAUM G, 1985, J IMMUNOL, V134, P3371; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; VALENTINE JS, 1979, P NATL ACAD SCI USA, V76, P4245, DOI 10.1073/pnas.76.9.4245; WINTERBOURN CC, 1994, ARCH BIOCHEM BIOPHYS, V314, P284, DOI 10.1006/abbi.1994.1444; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; YIM MB, 1993, J BIOL CHEM, V268, P4099; ZHANG N, 1991, J PHYS CHEM-US, V95, P4718, DOI 10.1021/j100165a024	45	78	79	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1906	1911		10.1074/jbc.M107256200	http://dx.doi.org/10.1074/jbc.M107256200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11698397	hybrid			2022-12-25	WOS:000173421300039
J	Nishizawa, H; Yamagata, K; Shimomura, L; Takahashi, M; Kuriyama, H; Kishida, K; Hotta, K; Nagaretani, H; Maeda, N; Matsuda, M; Kihara, S; Nakamura, T; Nishigori, H; Tomura, H; Moore, DD; Takeda, J; Funahashi, T; Matsuzawa, Y				Nishizawa, H; Yamagata, K; Shimomura, L; Takahashi, M; Kuriyama, H; Kishida, K; Hotta, K; Nagaretani, H; Maeda, N; Matsuda, M; Kihara, S; Nakamura, T; Nishigori, H; Tomura, H; Moore, DD; Takeda, J; Funahashi, T; Matsuzawa, Y			Small heterodimer partner, an orphan nuclear receptor, augments peroxisome proliferator-activated receptor gamma transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL HYPOPLASIA CONGENITA; ANTIDIABETIC AGENT CS-045; HORMONE-RECEPTOR; TRANSCRIPTION FACTOR; ESTROGEN-RECEPTORS; RETINOIC ACID; CO-REPRESSOR; DNA-BINDING; SUPERFAMILY; SHP	Small heterodimer partner (SHP, NR0B2) is an atypical orphan nuclear receptor that inhibits transcriptional activation by several other nuclear receptors. We recently reported that mutations in the SHP gene are associated with insulin resistance. In the present study, we demonstrated that the SHP gene is expressed in adipose tissues. A reporter gene assay showed that a gene product of SHP increased the transcriptional activation of peroxisome proliferator-activated receptor (PPAR) gamma. SHP-mediated activation of PPARgamma was observed both in the presence and absence of the ligand of PPARgamma. Immunoprecipitation and glutathione S-transferase pull-down assay showed that SHP directly bound to PPARgamma and competed with nuclear receptor corepressor for binding to PPARgamma. Serial deletion studies indicated that the C terminus of SHP is important for PPARgamma activation. Mutant SHP proteins, which are found in naturally occurring mutation, showed less enhancing activity for PPARgamma than wild-type SHP. Our results suggest that SHP may act as an endogenous enhancer of PPARgamma.	Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Mol Genet Lab, Dept Cell Biol, Gunma 3718512, Japan; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77401 USA	Osaka University; Gunma University; Baylor College of Medicine	Matsuzawa, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, B5,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Hotta, Kikuko/0000-0003-2427-6354				BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Day C, 1999, DIABETIC MED, V16, P179, DOI 10.1046/j.1464-5491.1999.00023.x; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; IWAMOTO Y, 1991, DIABETES CARE, V14, P1083, DOI 10.2337/diacare.14.11.1083; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim YS, 2001, J BIOL CHEM, V276, P33736, DOI 10.1074/jbc.M101977200; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lefebvre AM, 1997, ARTERIOSCL THROM VAS, V17, P1756, DOI 10.1161/01.ATV.17.9.1756; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Nishigori H, 2001, P NATL ACAD SCI USA, V98, P575, DOI 10.1073/pnas.98.2.575; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; ONATE SA, 1995, SCIENCE, V270, P1354; Owen GI, 2000, CELL MOL LIFE SCI, V57, P809, DOI 10.1007/s000180050043; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; YOUNG PW, 1995, DIABETES, V44, P1087, DOI 10.2337/diabetes.44.9.1087; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899	36	97	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1586	1592		10.1074/jbc.M104301200	http://dx.doi.org/10.1074/jbc.M104301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11696534	hybrid			2022-12-25	WOS:000173166800093
J	Parent, CA; Borleis, J; Devreotes, PN				Parent, CA; Borleis, J; Devreotes, PN			Regulation of adenylyl cyclases by a region outside the minimally functional cytoplasmic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEINS; DICTYOSTELIUM DEVELOPMENT; CATALYTIC MECHANISM; BETA-GAMMA; STIMULATION; MUTANTS; IDENTIFICATION; EXPRESSION; ACTIVATION; G(S-ALPHA)	The highly conserved topological structure of G protein-activated adenylyl cyclases seems unnecessary because the soluble cytoplasmic domains retain regulatory and catalytic properties. Yet, we previously isolated a constitutively active mutant of the Dictyostelium discoideum adenylyl cyclase harboring a single point mutation in the region linking the cytoplasmic and membrane domains (Leu-394). We show here that multiple amino acid substitutions at Leu-394 also display constitutive activity. The constitutive activity of these mutants is not dependent on G proteins or cytosolic regulators, although some of the mutants can be activated to higher levels than wild type. Combining a constitutive mutation such as L394T with K482N, a point mutation that renders the enzyme insensitive to regulators, restores an enzyme with wild type properties of low basal activity and the capacity to be activated by G proteins. Thus regions located outside the cytoplasmic loops of adenylyl cyclases are not only important in the acquisition of an activated conformation, they also have impact on other regions within the catalytic core of the enzyme.	Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Parent, CA (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, 37 Convent Dr,Bldg 37,Rm 1E24, Bethesda, MD 20892 USA.				NIGMS NIH HHS [GM57874] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cann Martin J., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P121; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; Hatley ME, 2000, J BIOL CHEM, V275, P38626, DOI 10.1074/jbc.M007148200; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LILLY PJ, 1995, J CELL BIOL, V129, P1659, DOI 10.1083/jcb.129.6.1659; PARENT CA, 1995, J BIOL CHEM, V270, P22693, DOI 10.1074/jbc.270.39.22693; Parent CA, 1996, J BIOL CHEM, V271, P18333, DOI 10.1074/jbc.271.31.18333; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PUPILLO M, 1992, MOL BIOL CELL, V3, P1229, DOI 10.1091/mbc.3.11.1229; REDDY R, 1995, J BIOL CHEM, V270, P14340, DOI 10.1074/jbc.270.24.14340; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; Scholich K, 1997, P NATL ACAD SCI USA, V94, P9602, DOI 10.1073/pnas.94.18.9602; Simonds WF, 1999, TRENDS PHARMACOL SCI, V20, P66, DOI 10.1016/S0165-6147(99)01307-3; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tan CM, 2001, BIOCHEMISTRY-US, V40, P1702, DOI 10.1021/bi0015818; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1998, CURR OPIN STRUC BIOL, V8, P713, DOI 10.1016/S0959-440X(98)80090-0; Wittpoth C, 1999, P NATL ACAD SCI USA, V96, P9551, DOI 10.1073/pnas.96.17.9551; Wu GC, 2001, J BIOL CHEM, V276, P35450, DOI 10.1074/jbc.M009704200; Yan SZ, 2001, J BIOL CHEM, V276, P8500, DOI 10.1074/jbc.M010361200; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zimmermann G, 1999, MOL PHARMACOL, V56, P895, DOI 10.1124/mol.56.5.895; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	36	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1354	1360		10.1074/jbc.M106430200	http://dx.doi.org/10.1074/jbc.M106430200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694527	hybrid			2022-12-25	WOS:000173166800064
J	de Avalos, SV; Blader, IJ; Fisher, M; Boothroyd, JC; Burleigh, BA				de Avalos, SV; Blader, IJ; Fisher, M; Boothroyd, JC; Burleigh, BA			Immediate/early response to Trypanosoma cruzi infection involves minimal modulation of host cell transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MICROARRAY ANALYSIS REVEALS; NATURAL-KILLER-CELLS; GENE-EXPRESSION; EPITHELIAL-CELLS; IFN-GAMMA; PROINFLAMMATORY CYTOKINES; LISTERIA-MONOCYTOGENES; ENDOTHELIAL-CELLS; IN-VITRO	Host cell infection by the intracellular pathogen, Trypanosoma cruzi, involves activation of signaling pathways, cytoskeletal reorganization, and targeted recruitment of host cell lysosomes. To determine the consequences of T. cruzi invasion on host cell gene expression, high density microarrays consisting of similar to27,000 human cDNAs were hybridized with fluorescent probes generated from T. cruzi-infected human fibroblasts (HFF) at early time points following infection (2-24 h). Surprisingly, no genes were induced greater than or equal to2-fold in HFF between 2 and 6 h post-infection (hpi) in repeated experiments while immediate repression of six host cell transcripts was observed. A significant increase in transcript abundance for 106 host cell genes was observed at 24 hpi. Among the most highly induced is a set of interferon-stimulated genes, indicative of a type I interferon (IFN) response to T. cruzi. In support of this, T. cruzi-infected fibroblasts begin to secrete IFNbeta at 18 hpi following the induction of IFNbeta transcripts. As compared with global transcriptional responses evoked by other intracellular pathogens, T. cruzi is a stealth parasite that elicits few changes in host cell transcription during the initiation of infection.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Harvard University; Harvard T.H. Chan School of Public Health; Stanford University	Burleigh, BA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.	bburleig@hsph.harvard.edu		Boothroyd, John C./0000-0001-9719-745X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047960, F32AI010478, R37AI021423, R01AI045057, R01AI021423] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47960, AI45057, AI21423, 1F32AI10478] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alizadeh A, 1999, COLD SPRING HARB SYM, V64, P71, DOI 10.1101/sqb.1999.64.71; Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476; ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2; Belcher CE, 2000, P NATL ACAD SCI USA, V97, P13847, DOI 10.1073/pnas.230262797; Bigger CB, 2001, J VIROL, V75, P7059, DOI 10.1128/JVI.75.15.7059-7066.2001; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Blader IJ, 2001, J BIOL CHEM, V276, P24223, DOI 10.1074/jbc.M100951200; Blohm DH, 2001, CURR OPIN BIOTECH, V12, P41, DOI 10.1016/S0958-1669(00)00175-0; Burleigh BA, 1998, CURR OPIN MICROBIOL, V1, P461, DOI 10.1016/S1369-5274(98)80066-0; Caler EV, 1998, EMBO J, V17, P4975, DOI 10.1093/emboj/17.17.4975; Camargo MM, 1997, J IMMUNOL, V158, P5890; Camargo MM, 1997, J IMMUNOL, V159, P6131; Cardillo F, 1996, INFECT IMMUN, V64, P128, DOI 10.1128/IAI.64.1.128-134.1996; Chang YJE, 2000, J VIROL, V74, P4174, DOI 10.1128/JVI.74.9.4174-4182.2000; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Cohen P, 2000, J BIOL CHEM, V275, P11181, DOI 10.1074/jbc.275.15.11181; Cummings CA, 2000, EMERG INFECT DIS, V6, P513, DOI 10.3201/eid0605.000511; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Dessus-Babus S, 2000, CELL MICROBIOL, V2, P317, DOI 10.1046/j.1462-5822.2000.00058.x; Detweiler CS, 2001, P NATL ACAD SCI USA, V98, P5850, DOI 10.1073/pnas.091110098; Diehn M, 2001, CURR OPIN MICROBIOL, V4, P95, DOI 10.1016/S1369-5274(00)00171-5; Drew PD, 1995, J NEUROIMMUNOL, V63, P157, DOI 10.1016/0165-5728(95)00140-9; DVORAK JA, 1979, J PROTOZOOL, V26, P114, DOI 10.1111/j.1550-7408.1979.tb02742.x; Eckmann L, 2000, J BIOL CHEM, V275, P14084, DOI 10.1074/jbc.275.19.14084; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Frosch S, 1996, MED MICROBIOL IMMUN, V185, P189, DOI 10.1007/s004300050030; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hall BS, 2000, INFECT IMMUN, V68, P2077, DOI 10.1128/IAI.68.4.2077-2081.2000; Huang H, 1999, INFECT IMMUN, V67, P5434, DOI 10.1128/IAI.67.10.5434-5440.1999; Hunter CA, 1997, J IMMUNOL, V158, P3311; Ichikawa JK, 2000, P NATL ACAD SCI USA, V97, P9659, DOI 10.1073/pnas.160140297; JAMES SL, 1982, INFECT IMMUN, V35, P588, DOI 10.1128/IAI.35.2.588-593.1982; Joubert BM, 2001, ORG LETT, V3, P1957, DOI 10.1021/ol0160506; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Liendo A, 1999, MOL BIOCHEM PARASIT, V104, P81, DOI 10.1016/S0166-6851(99)00129-2; Machado FS, 2000, CIRCULATION, V102, P3003, DOI 10.1161/01.CIR.102.24.3003; Manger ID, 2000, CURR OPIN IMMUNOL, V12, P215, DOI 10.1016/S0952-7915(99)00077-1; Mossman KL, 2001, J VIROL, V75, P750, DOI 10.1128/JVI.75.2.750-758.2001; MUNOZFERNANDEZ MA, 1992, IMMUNOL LETT, V33, P35, DOI 10.1016/0165-2478(92)90090-B; Rodriguez A, 1996, J CELL BIOL, V134, P349, DOI 10.1083/jcb.134.2.349; RODRIGUEZ A, 1995, J CELL BIOL, V129, P1263, DOI 10.1083/jcb.129.5.1263; Ropert C, 2000, CURR OPIN MICROBIOL, V3, P395, DOI 10.1016/S1369-5274(00)00111-9; Ropert C, 2001, J IMMUNOL, V166, P3423, DOI 10.4049/jimmunol.166.5.3423; ROTTENBERG M, 1988, SCAND J IMMUNOL, V28, P573, DOI 10.1111/j.1365-3083.1988.tb01489.x; Saavedra E, 1999, J EXP MED, V190, P1825, DOI 10.1084/jem.190.12.1825; SCHWAN WR, 1994, P NATL ACAD SCI USA, V91, P6428, DOI 10.1073/pnas.91.14.6428; Silva JS, 1998, BRAZ J MED BIOL RES, V31, P111, DOI 10.1590/S0100-879X1998000100014; Stryker GA, 1995, EXP PARASITOL, V81, P564, DOI 10.1006/expr.1995.1150; Tachado SD, 1999, PARASITE IMMUNOL, V21, P609, DOI 10.1046/j.1365-3024.1999.00268.x; Talvani A, 2000, MICROBES INFECT, V2, P851, DOI 10.1016/S1286-4579(00)00388-9; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; Taylor LA, 2000, CIRC RES, V87, P328, DOI 10.1161/01.RES.87.4.328; Todorov AG, 2000, J BIOL CHEM, V275, P32182, DOI 10.1074/jbc.M909440199; Urbina JA, 1996, SCIENCE, V273, P969, DOI 10.1126/science.273.5277.969; Urbina JA, 1999, J MOL MED-JMM, V77, P332, DOI 10.1007/s001090050359; Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470	56	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					639	644		10.1074/jbc.M109037200	http://dx.doi.org/10.1074/jbc.M109037200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11668183	hybrid			2022-12-25	WOS:000173087900084
J	Delmotte, P; Degroote, S; Lafitte, JJ; Lamblin, G; Perini, JM; Roussel, P				Delmotte, P; Degroote, S; Lafitte, JJ; Lamblin, G; Perini, JM; Roussel, P			Tumor necrosis factor alpha increases the expression of glycosyltransferases and sulfotransferases responsible for the biosynthesis of sialylated and/or sulfated Lewis x epitopes in the human bronchial mucosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS PATIENTS; AIRWAY EPITHELIAL-CELLS; RESPIRATORY-MUCUS GLYCOPROTEINS; SERUM ALPHA-1-ACID GLYCOPROTEIN; INFLAMMATION-INDUCED EXPRESSION; MUCIN CARBOHYDRATE CHAINS; NF-KAPPA-B; ALPHA(1)-ACID GLYCOPROTEIN; GENE-EXPRESSION; E-SELECTIN	There is increasing evidence that inflammation may affect glycosylation and sulfation of various glycoproteins. The present study reports the effect of tumor necrosis factor a (TNF-alpha), a proinflammatory cytokine, on the glycosyl- and sulfotransferases of the human bronchial mucosa responsible for the biosynthesis of Lewis x epitope and of its sialylated and/or sulfated derivatives, which are expressed in human bronchial mucins. Fragments of macroscopically normal human bronchial mucosa were exposed to TNF-alpha at a concentration of 20 ng/ml. TNF-alpha was shown to increase alpha1,3-fucosyltransferase activity as well as expression of the two alpha1,3-fucosyltransferase genes expressed in the human airway, FUT3 and FUT4. It had no influence on alpha1,2-fucosyltransferase activity or FUT2 expression. It also increased alpha2,3-sialyltransferase activity and the expression of ST3Gal-III and, more importantly, ST3Gal-IV and both N-acetylglucosamine 6-O-sulfotransferase and galactose 3-O-sulfotransferase. These results are consistent with the observation of oversialylation and increased expression sialyl-Lewis x epitopes on human airway mucins secreted by patients with severe lung infection such as those with cystic fibrosis, whose airways are colonized by Pseudomonas aeruginosa. However, other cytokines may also be involved in this process.	INSERM, U377, F-59045 Lille, France; Univ Lille 2, F-59045 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Roussel, P (corresponding author), INSERM, U377, Pl Verdun, F-59045 Lille, France.	proussel@univ-lille2.fr						Azuma Y, 2000, CLIN CHIM ACTA, V294, P93, DOI 10.1016/S0009-8981(99)00248-X; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BARASCH J, 1993, J CELL SCI, P229; Blander JM, 1999, J IMMUNOL, V163, P3746; BOAT TF, 1976, ARCH BIOCHEM BIOPHYS, V177, P95, DOI 10.1016/0003-9861(76)90419-7; Bonfield TL, 1999, J ALLERGY CLIN IMMUN, V104, P72, DOI 10.1016/S0091-6749(99)70116-8; BONFIELD TL, 1995, AM J RESP CRIT CARE, V152, P2111, DOI 10.1164/ajrccm.152.6.8520783; BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257, DOI 10.1165/ajrcmb.13.3.7544594; BREG J, 1987, EUR J BIOCHEM, V168, P57, DOI 10.1111/j.1432-1033.1987.tb13387.x; Brinkman-van der Linden ECM, 1998, GLYCOCONJUGATE J, V15, P177, DOI 10.1023/A:1006972307166; BrinkmanVanderLinden ECM, 1996, GLYCOCONJUGATE J, V13, P27, DOI 10.1007/BF01049676; BrinkmanVanderLinden ECM, 1996, J BIOL CHEM, V271, P14492, DOI 10.1074/jbc.271.24.14492; Casale TB, 1999, INFLAMM RES, V48, P22, DOI 10.1007/s000110050379; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Crottet P, 1996, GLYCOBIOLOGY, V6, P191, DOI 10.1093/glycob/6.2.191; Davril M, 1999, GLYCOBIOLOGY, V9, P311, DOI 10.1093/glycob/9.3.311; DEGRAAF TW, 1993, J EXP MED, V177, P657, DOI 10.1084/jem.177.3.657; Degroote S, 1997, J BIOL CHEM, V272, P29493, DOI 10.1074/jbc.272.47.29493; Degroote S, 1999, GLYCOBIOLOGY, V9, P1199, DOI 10.1093/glycob/9.11.1199; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; Emery N, 1997, GLYCOBIOLOGY, V7, P95, DOI 10.1093/glycob/7.1.95; Enss ML, 2000, INFLAMM RES, V49, P162, DOI 10.1007/s000110050576; FRATES RC, 1983, PEDIATR RES, V17, P30, DOI 10.1203/00006450-198301000-00006; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; Jorgensen HG, 1998, BIOMED CHROMATOGR, V12, P343, DOI 10.1002/(SICI)1099-0801(199811/12)12:6<343::AID-BMC760>3.0.CO;2-6; Karpati F, 2000, SCAND J INFECT DIS, V32, P75, DOI 10.1080/00365540050164263; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KLEIN A, 1993, EUR J BIOCHEM, V211, P491, DOI 10.1111/j.1432-1033.1993.tb17575.x; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; KONSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152; Krunkosky TM, 2000, AM J RESP CELL MOL, V22, P685, DOI 10.1165/ajrcmb.22.6.3925; Kuninaka S, 2000, CYTOKINE, V12, P8, DOI 10.1006/cyto.1998.0504; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Lamblin G, 1976, Mod Probl Paediatr, V19, P153; LAMBLIN G, 1984, J BIOL CHEM, V259, P9051; LAMMERS G, 1988, BIOCHEM J, V256, P623, DOI 10.1042/bj2560623; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196, DOI 10.1165/ajrcmb.12.2.7865217; Lin JH, 2000, J INFECT DIS, V182, P882, DOI 10.1086/315767; LO SK, 1994, CIRC RES, V75, P955, DOI 10.1161/01.RES.75.6.955; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; LOGUIDICE JM, 1995, J BIOL CHEM, V270, P27544, DOI 10.1074/jbc.270.46.27544; LOMBART C, 1980, BIOCHIM BIOPHYS ACTA, V629, P1, DOI 10.1016/0304-4165(80)90259-7; LUKACS NW, 1995, J IMMUNOL, V154, P5411; MACKIEWICZ A, 1995, GLYCOCONJUGATE J, V12, P241, DOI 10.1007/BF00731326; MACKIEWICZ A, 1987, J EXP MED, V166, P253, DOI 10.1084/jem.166.1.253; MACKIEWICZ A, 1990, INFLAMMATION, V14, P485, DOI 10.1007/BF00914270; MAJURI ML, 1994, EUR J IMMUNOL, V24, P3205, DOI 10.1002/eji.1830241244; MAJURI ML, 1995, INT J CANCER, V63, P551, DOI 10.1002/ijc.2910630416; Matsukura S, 1999, J IMMUNOL, V163, P6876; Orntoft TF, 1996, J BIOL CHEM, V271, P32260, DOI 10.1074/jbc.271.50.32260; Osika E, 1999, EUR RESPIR J, V14, P339, DOI 10.1034/j.1399-3003.1999.14b17.x; POS O, 1989, INFLAMMATION, V13, P415, DOI 10.1007/BF00914925; POUS C, 1992, INFLAMMATION, V16, P197, DOI 10.1007/BF00918809; Recchi MA, 1998, CANCER RES, V58, P4066; Renkonen R, 1997, GLYCOCONJUGATE J, V14, P593, DOI 10.1023/A:1018536509950; ROUSSEL P, 1975, J BIOL CHEM, V250, P2114; Roussel P, 1996, GLYCOPROTEINS DIS, P351; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Saso L, 1998, BIOCHEM MOL BIOL INT, V46, P867; Scharfman A, 1999, GLYCOBIOLOGY, V9, P757, DOI 10.1093/glycob/9.8.757; Scharfman A, 2001, INFECT IMMUN, V69, P5243, DOI 10.1128/IAI.69.9.5243-5248.2001; Smith G., 1985, Parasitology Today, V1, P76, DOI 10.1016/0169-4758(85)90047-X; Tirouvanziam R, 2000, AM J RESP CELL MOL, V23, P121, DOI 10.1165/ajrcmb.23.2.4214; TURNER GA, 1995, ADV EXP MED BIOL, V376, P231; TURNER GA, 1995, GLYCOCONJUGATE J, V12, P211, DOI 10.1007/BF00731322; Van Dijk W, 1995, ANN NY ACAD SCI, V762, P319; van Heeckeren A, 1997, J CLIN INVEST, V100, P2810, DOI 10.1172/JCI119828; VANDIJK W, 1995, GLYCOCONJUGATE J, V12, P227, DOI 10.1007/BF00731324; VANHALBEEK H, 1988, EUR J BIOCHEM, V177, P443; VANKUIK JA, 1986, EUR J BIOCHEM, V159, P297; VISHWANATH S, 1988, INFECT IMMUN, V56, P2218, DOI 10.1128/IAI.56.9.2218-2222.1988; Wagers AJ, 1998, J EXP MED, V188, P2225, DOI 10.1084/jem.188.12.2225; YAGO K, 1993, CANCER RES, V53, P5559; Zhang YL, 1995, J CLIN INVEST, V96, P2997, DOI 10.1172/JCI118372	76	102	107	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					424	431		10.1074/jbc.M109958200	http://dx.doi.org/10.1074/jbc.M109958200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11679593	hybrid			2022-12-25	WOS:000173087900057
J	Lim, EK; Doucet, CJ; Li, Y; Elias, L; Worrall, D; Spencer, SP; Ross, J; Bowles, DJ				Lim, EK; Doucet, CJ; Li, Y; Elias, L; Worrall, D; Spencer, SP; Ross, J; Bowles, DJ			The activity of Arabidopsis glycosyltransferases toward salicylic acid, 4-hydroxybenzoic acid, and other benzoates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-HYDROXYBENZOATE GLUCOSYLTRANSFERASE; L-MALATE SINAPOYLTRANSFERASE; HAIRY ROOT CULTURES; UDP-GLUCOSE; SHIKONIN BIOSYNTHESIS; BIOCHEMICAL-CHARACTERIZATION; ANTIOXIDANT ACTIVITY; CELL-CULTURES; CAFFEIC ACID; EXPRESSION	Benzoates are a class of natural products containing compounds of industrial and strategic importance. In plants, the compounds exist in free form and as conjugates to a wide range of other metabolites such as glucose, which can be attached to the carboxyl group or to specific hydroxyl groups on the benzene ring. These glucosylation reactions have been studied for many years, but to date only one gene encoding a benzoate glucosyltransferase has been cloned. A phylogenetic analysis of sequences in the Arabidopsis genome revealed a large multigene family of putative glycosyl-transferases containing a consensus sequence typically found in enzymes transferring glucose to small molecular weight compounds such as secondary metabolites. Ninety of these sequences have now been expressed as recombinant proteins in Escherichia coli, and their in vitro catalytic activities toward benzoates have been analyzed. The data show that only 14 proteins display activity toward 2-hydroxybenzoic acid, 4-hydroxybenzoic acid, and 3,4-dihydroxybenzoic acid. Of these, only two enzymes are active toward 2-hydroxybenzoic acid, suggesting they are the Arabidopsis salicylic acid glucosyltransferases. All of the enzymes forming glucose esters with the metabolites were located in Group L of the phylogenetic tree, whereas those forming O-glucosides were dispersed among five different groups. Catalytic activities were observed toward glucosylation of the 2-, 3-, or 4-hydroxyl group on the ring. To further explore their regioselectivity, the 14 enzymes were analyzed against benzoic acid, 3-hydroxybenzoic acid, 2,3-, 2,4-, 2,5-, and 2,6-dihydroxybenzoic acid. The data showed that glycosylation of specific sites could be positively or negatively influenced by the presence of additional hydroxyl groups on the ring. This study provides new tools for biotransformation reactions in vitro and a basis for engineering benzoate metabolism in plants.	Univ York, Dept Biol, Ctr Novel Agr Prod, York YO10 SDD, N Yorkshire, England	University of York - UK	Bowles, DJ (corresponding author), Univ York, Dept Biol, Ctr Novel Agr Prod, York YO10 SDD, N Yorkshire, England.	djb32@york.ac.uk						Alvarez ME, 2000, PLANT MOL BIOL, V44, P429, DOI 10.1023/A:1026561029533; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BECHTHOLD A, 1991, ARCH BIOCHEM BIOPHYS, V288, P39, DOI 10.1016/0003-9861(91)90162-C; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CHAN WS, 1995, ANTICANCER RES, V15, P703; CHIMI H, 1991, J AM OIL CHEM SOC, V68, P307, DOI 10.1007/BF02657682; DAVIS DG, 1991, PLANT SCI, V74, P73, DOI 10.1016/0168-9452(91)90257-9; Dong DW, 2001, EUR POLYM J, V37, P611, DOI 10.1016/S0014-3057(00)00123-3; Gaisser S, 1996, PHYTOCHEMISTRY, V41, P1065, DOI 10.1016/0031-9422(95)00633-8; Glazebrook J, 2001, CURR OPIN PLANT BIOL, V4, P301, DOI 10.1016/S1369-5266(00)00177-1; HEIDE L, 1989, PHYTOCHEMISTRY, V28, P1873, DOI 10.1016/S0031-9422(00)97877-4; HEURISSAT B, 2000, PLANT PHYSIOL, V124, P1515; Hollman PCH, 1997, FEBS LETT, V418, P152, DOI 10.1016/S0014-5793(97)01367-7; Hostel W., 1981, BIOCH PLANTS, V7, P725; HUGHES J, 1994, DNA SEQUENCE, V5, P41, DOI 10.3109/10425179409039703; Jackson RG, 2001, J BIOL CHEM, V276, P4350, DOI 10.1074/jbc.M006185200; Jones P, 2001, PLANTA, V213, P164, DOI 10.1007/s004250000492; KENT PW, 1959, TETRAHEDRON, V7, P252, DOI 10.1016/S0040-4020(01)93193-X; KLECZKOWSKI K, 1995, CRIT REV PLANT SCI, V14, P283, DOI 10.1080/07352689509382361; KLICK S, 1988, PHYTOCHEMISTRY, V27, P2177, DOI 10.1016/0031-9422(88)80121-3; Lee H, 1999, J BIOL CHEM, V274, P36637, DOI 10.1074/jbc.274.51.36637; Lee HI, 1998, PHYTOPATHOLOGY, V88, P692, DOI 10.1094/PHYTO.1998.88.7.692; Li SM, 1997, PHYTOCHEMISTRY, V46, P27, DOI 10.1016/S0031-9422(97)00212-4; Li Y, 2001, J BIOL CHEM, V276, P4338, DOI 10.1074/jbc.M007447200; Lim EK, 1998, J BIOL CHEM, V273, P34920, DOI 10.1074/jbc.273.52.34920; Lim EK, 2001, J BIOL CHEM, V276, P4344, DOI 10.1074/jbc.M007263200; Ma XY, 2001, CARBOHYD RES, V333, P159, DOI 10.1016/S0008-6215(01)00122-7; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MICHALCZUK L, 1982, BIOCHEM J, V207, P273, DOI 10.1042/bj2070273; Miller KD, 1999, J BIOL CHEM, V274, P34011, DOI 10.1074/jbc.274.48.34011; MOCK HP, 1993, PHYTOCHEMISTRY, V32, P575, DOI 10.1016/S0031-9422(00)95139-2; Nakamura Y, 2001, FREE RADICAL BIO MED, V30, P967, DOI 10.1016/S0891-5849(01)00481-6; NISHIMURA T, 1995, J FERMENT BIOENG, V80, P18, DOI 10.1016/0922-338X(95)98170-P; Papageorgiou VP, 1999, ANGEW CHEM INT EDIT, V38, P270, DOI 10.1002/(SICI)1521-3773(19990201)38:3<270::AID-ANIE270>3.0.CO;2-0; Rea PA, 1999, J EXP BOT, V50, P895, DOI 10.1093/jexbot/50.suppl_1.895; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; SAKUSHIMA A, 1995, PHYTOCHEMISTRY, V40, P257, DOI 10.1016/0031-9422(95)00059-G; SHARMA V, 1985, PLANTA, V163, P563, DOI 10.1007/BF00392714; Siebert M, 1996, PLANT PHYSIOL, V112, P811, DOI 10.1104/pp.112.2.811; Sommer S, 1999, PLANT MOL BIOL, V39, P683, DOI 10.1023/A:1006185806390; Sommer S, 1998, PLANT CELL PHYSIOL, V39, P1240, DOI 10.1093/oxfordjournals.pcp.a029326; STRACK D, 1982, PLANTA, V155, P31, DOI 10.1007/BF00402928; STRACK D, 1983, Z NATURFORSCH C, V38, P21; STRACK D, 1977, Z PFLANZENPHYSIOL, V84, P139, DOI 10.1016/S0044-328X(77)80186-4; Tyrakowska B, 1999, FREE RADICAL BIO MED, V27, P1427, DOI 10.1016/S0891-5849(99)00192-6; Vogt T, 1999, PLANT J, V19, P509, DOI 10.1046/j.1365-313X.1999.00540.x; WETZEL A, 1994, ARCH BIOCHEM BIOPHYS, V314, P323, DOI 10.1006/abbi.1994.1449; YAMANAKA M, 1995, PHYTOCHEMISTRY, V40, P1149, DOI 10.1016/0031-9422(95)00456-H; YAZAKI K, 1986, PHYTOCHEMISTRY, V25, P1629, DOI 10.1016/S0031-9422(00)81223-6; YAZAKI K, 1995, PHYTOCHEMISTRY, V38, P1127, DOI 10.1016/0031-9422(94)00821-A	52	206	241	3	60	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					586	592		10.1074/jbc.M109287200	http://dx.doi.org/10.1074/jbc.M109287200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11641410	hybrid			2022-12-25	WOS:000173087900077
J	Borel, A; Eichenberger, D; Farjanel, J; Kessler, E; Gleyzal, C; Hulmes, DJS; Sommer, P; Font, B				Borel, A; Eichenberger, D; Farjanel, J; Kessler, E; Gleyzal, C; Hulmes, DJS; Sommer, P; Font, B			Lysyl oxidase-like protein from bovine aorta - Isolation and maturation to an active form by bone morphogenetic protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN C-PROTEINASE; PURIFICATION; GENE; COLLAGEN; FIBROBLASTS; EXPRESSION; PRECURSOR; CHAIN; SKIN	Recently several cDNAs have been described encoding lysyl oxidase-like proteins. Their deduced amino acid sequences are characterized by a strong similarity in the C-terminal region, corresponding to the lysyl oxidase family catalytic domain, and by marked differences in the N-terminal regions. Different biological functions have been described for lysyl oxidases in addition to their traditionally assumed cross-linking role. To answer the question of whether these different functions are carried out by different lysyl oxidases, purified and active forms of these enzymes are required. At present only the classical form of lysyl oxidase has been purified and characterized. The purpose of this study was to isolate and characterize the lysyl oxidase-like protein. In view of the strong sequence homology with the C-terminal domain of other lysyl oxidases, we chose to purify the protein from bovine aorta using antibodies specific to the N-terminal domain of the proenzyme. We have isolated a 56-kDa protein identified by amino acid sequencing as the bovine lysyl oxidase-like precursor, which is cleaved at the Arg-Arg-Arg sequence at positions 89-91 by a furin-like activity, as revealed after deblocking of the N-terminal residue. The immunopurified protein was largely inactive, but further processing in vitro by bone morphogenetic protein-1 led to an enzyme that was active on elastin and collagen substrates.	Univ Lyon 1, CNRS UMR 5086, Inst Biol & Chim Prot, F-69637 Lyon 07, France; Tel Aviv Univ, Sackler Fac Med, Chaim Sheba Med Ctr, Maurice & Gabriela Goldschleger Eye Res Inst, IL-52621 Tel Hashomer, Israel	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Sommer, P (corresponding author), Univ Lyon 1, CNRS UMR 5086, Inst Biol & Chim Prot, 7 Passage du Vercors, F-69637 Lyon 07, France.			Hulmes, David/0000-0002-0651-1317				Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BUTLER E, 1987, EXP CELL RES, V173, P174, DOI 10.1016/0014-4827(87)90343-0; CRONSHAW AD, 1995, BIOCHEM J, V306, P279, DOI 10.1042/bj3060279; CRONSHAW AD, 1993, MATRIX, V13, P255, DOI 10.1016/S0934-8832(11)80009-0; Decitre M, 1998, LAB INVEST, V78, P143; Di Donato A, 1997, FEBS LETT, V419, P63, DOI 10.1016/S0014-5793(97)01420-8; FONT B, 1993, J BIOL CHEM, V268, P25015; HAJNAL A, 1993, CANCER RES, V53, P4670; HAMALAINEN ER, 1991, GENOMICS, V11, P508, DOI 10.1016/0888-7543(91)90057-L; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Ito H, 2001, J BIOL CHEM, V276, P24023, DOI 10.1074/jbc.M100861200; Jourdan-Le Saux C, 1999, J BIOL CHEM, V274, P12939; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KENYON K, 1993, J BIOL CHEM, V268, P18435; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; Kessler E, 2001, J BIOL CHEM, V276, P27051, DOI 10.1074/jbc.M102921200; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; KIM YH, 1995, J BIOL CHEM, V270, P7176, DOI 10.1074/jbc.270.13.7176; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maki JM, 2001, BIOCHEM J, V355, P381, DOI 10.1042/0264-6021:3550381; Moschcovich L, 2001, EUR J BIOCHEM, V268, P2991, DOI 10.1046/j.1432-1327.2001.02189.x; MOYER M, 1990, Journal of Protein Chemistry, V9, P282; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; ROMEROCHAPMAN N, 1991, BIOCHEM J, V275, P657, DOI 10.1042/bj2750657; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; SHACKLETON DR, 1990, ANAL BIOCHEM, V185, P359, DOI 10.1016/0003-2697(90)90308-V; Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9; SOMMER P, 1993, LAB INVEST, V69, P460; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078	35	113	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48944	48949		10.1074/jbc.M109499200	http://dx.doi.org/10.1074/jbc.M109499200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11684696	hybrid			2022-12-25	WOS:000173922100043
J	Choi, S; Kim, HJ; Ko, YS; Jeong, SW; Kim, YI; Simonds, WF; Oh, JW; Nah, SY				Choi, S; Kim, HJ; Ko, YS; Jeong, SW; Kim, YI; Simonds, WF; Oh, JW; Nah, SY			G alpha(q/11) coupled to mammalian phospholipase C beta 3-like enzyme mediates the ginsenoside effect on Ca2+-activated Cl- current in the Xenopus oocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; CA2+ CHANNELS; G-PROTEIN; CATECHOLAMINE SECRETION; ALPHA-SUBUNIT; BETA; RECEPTOR; ACTIVATION	Recently we demonstrated that ginsenosides, the active ingredients of Panax ginseng, enhanced Ca2+-activated Cl- current in the Xenopus oocyte through a signal transduction mechanism involving the activation of pertussis toxin-insensitive G protein and phospholipase C (PLC). However, it has not yet been determined precisely which G protein subunit(s) and which PLC isoform(s) participate in the ginsenoside signaling. To provide answers to these questions, we investigated the changes in ginsenoside effect on the Cl- current after intraoocyte injections of the cRNAs coding various G protein subunits, a regulator of G protein signaling (RGS2), and Gbetagamma-binding proteins. In addition, we examined which of mammalian PLCbeta1-3 antibodies injected into the oocyte inhibited the action of ginsenosides on the Cl- current. Injection of Galpha(q) or Galpha(11) cRNA increased the basal Cl- current recorded 48 h after, and it further prevented ginsenosides from enhancing the Cl- current, whereas Galpha(12) and Galpha(oA) cRNA injection had no significant effect. The changes following Galpha(q) cRNA injection were prevented when Gbeta(1)gamma(2) and Galpha(q) subunits were co-expressed by simultaneous injection of the cRNAs coding these subunits. Injection of cRNA coding Galpha(q)Q209L, a constitutively active mutant that does not bind to Gbetagamma, produced effects similar to those of Galpha(q) cRNA injection. The effects of Galpha(q)Q209L cRNA injection, however, were not prevented by co-injection of Gbeta(1)gamma(2) cRNA. Injection of the cRNA coding RGS2, which interacts most selectively with Galpha(q/11) among various identified RGS isoforms and stimulates the hydrolysis of GTP to GDP in active GTP-bound Galpha subunit, resulted in a severe attenuation of ginsenoside effect on the Cl- current. Finally, antibodies against PLCbeta3, but not -beta1 and -beta2, markedly attenuated the ginsenoside effect examined at 3-h postinjection. These results suggest that Galpha(q/11), coupled to mammalian PLC beta3-like enzyme mediates ginsenoside effect on Ca2+-activated Cl- current in the Xenopus oocyte.	Chonnam Natl Univ, Coll Vet Med, Natl Res Lab Study Ginseng Signal Transduct, Kwangju 500757, South Korea; Chonnam Natl Univ, Coll Vet Med, Dept Physiol, Kwangju 500757, South Korea; Korea Univ, Coll Med, Dept Physiol, Seoul 136701, South Korea; Korea Univ, Coll Med, Neurosci Res Inst, Seoul 136701, South Korea; Yonsei Univ, Wonju Coll Med, Dept Physiol, Seoul 136701, South Korea; NIDDK, Metab Dis Branch, Bethesda, MD 20892 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	Chonnam National University; Chonnam National University; Korea University; Korea University Medicine (KU Medicine); Korea University; Korea University Medicine (KU Medicine); Yonsei University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Alabama System; University of Alabama Birmingham	Nah, SY (corresponding author), Chonnam Natl Univ, Coll Vet Med, Natl Res Lab Study Ginseng Signal Transduct, Kwangju 500757, South Korea.			Kim, Yang/0000-0003-3420-7870	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043304, ZIADK043304] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Choi S, 2001, BRIT J PHARMACOL, V132, P641, DOI 10.1038/sj.bjp.0703856; Filtz TM, 1996, J BIOL CHEM, V271, P31121, DOI 10.1074/jbc.271.49.31121; HONG HY, 1998, J GINSENG RES, V22, P126; Ingi T, 1998, J NEUROSCI, V18, P7178; KAKU T, 1975, ARZNEIMITTEL-FORSCH, V25, P539; Kammermeier PJ, 1999, NEURON, V22, P819, DOI 10.1016/S0896-6273(00)80740-0; Kim HS, 1998, BRAIN RES BULL, V46, P245, DOI 10.1016/S0361-9230(98)00014-8; Kudo K, 1998, EUR J PHARMACOL, V341, P139, DOI 10.1016/S0014-2999(97)01350-2; LEE CH, 1992, J BIOL CHEM, V267, P16044; Li ZY, 2001, J CARDIOVASC PHARM, V37, P41, DOI 10.1097/00005344-200101000-00005; Li ZY, 2000, LIFE SCI, V67, P2983, DOI 10.1016/S0024-3205(00)00880-8; MA HW, 1993, J BIOL CHEM, V268, P19915; NABATA H, 1973, JPN J PHARMACOL, V23, P29, DOI 10.1254/jjp.23.29; NAH SY, 1994, J ETHNOPHARMACOL, V42, P45, DOI 10.1016/0378-8741(94)90022-1; NAH SY, 1995, P NATL ACAD SCI USA, V92, P8739, DOI 10.1073/pnas.92.19.8739; Nah SY, 1997, KOREAN J GINSENG SCI, V21, P1; Quick MW, 1996, J BIOL CHEM, V271, P32021, DOI 10.1074/jbc.271.50.32021; Rim KT, 1997, KOR J GINSENG SCI, V21, P19; SHIN EK, 1996, KOREAN J GINSENG SCI, V20, P159; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TACHIKAWA E, 1995, J PHARMACOL EXP THER, V273, P629; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0	23	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48797	48802		10.1074/jbc.M104346200	http://dx.doi.org/10.1074/jbc.M104346200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11673455	hybrid			2022-12-25	WOS:000173922100025
J	Brown, CR; Cui, DY; Hung, GGC; Chiang, HL				Brown, CR; Cui, DY; Hung, GGC; Chiang, HL			Cyclophilin a mediates Vid22p function in the import of fructose-1,6-bisphosphatase into vid vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PLASMA-MEMBRANE PROTEINS; SACCHAROMYCES-CEREVISIAE; CYCLOSPORINE-A; YEAST VACUOLE; SECRETORY PATHWAY; HOMOLOG NINAA; IN-VITRO; DEGRADATION; BIOGENESIS	Fructose-1,6-bisphosphatase (FBPase) is synthesized in yeast during glucose starvation but is rapidly degraded in the vacuole following the addition of glucose. FBPase trafficking to the vacuole involves two distinct steps, import into intermediate transport vesicles (Vid vesicles) and Vid vesicle trafficking to the vacuole. FBPase import into Vid vesicles requires the VID22 gene. However, VID22 affects FBPase import indirectly through a cytosolic factor. To identify the required cytosolic component, wild type cytosol was fractionated and screened for proteins that complement Delta vid22 mutant cytosol using an in vitro assay that reproduces FBPase import into Vid vesicles. Cyclophilin A (Cpr1p) was identified as a cytosolic protein that mediates Vid22p function in FBPase import. Mutants lacking Cpr1p were defective in FBPase import. Furthermore, the addition of purified Cpr1p restored FBPase import in both the Delta cpr1 and the Delta vid22 mutants. The cyclosporin A binding pocket is important for Cpr1p function, since cyclosporin A binding-deficient mutants failed to complement FBPase import in Delta cpr1 and Delta vid22 mutants. The levels of Cpr1p were reduced in the Delta vid22 mutants, implying that the expression of Cpr1p is regulated by Vid22p. Our results suggest that Cpr1p mediates Vid22p function and is directly involved in the import of FBPase into Vid vesicles.	Penn State Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Brown, CR (corresponding author), Penn State Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.				NIGMS NIH HHS [R01 GM59480] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059480] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; Brown CR, 2000, J CELL BIOL, V150, P65, DOI 10.1083/jcb.150.1.65; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; CARDENAS ME, 1995, J BIOL CHEM, V270, P20997, DOI 10.1074/jbc.270.36.20997; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; Chiang HL, 1996, J BIOL CHEM, V271, P9934, DOI 10.1074/jbc.271.17.9934; Chiang MC, 1998, J CELL BIOL, V140, P1347, DOI 10.1083/jcb.140.6.1347; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; CONIBEAR E, 1995, CELL, V83, P513, DOI 10.1016/0092-8674(95)90088-8; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; CULLEN BR, 1994, NATURE, V372, P319, DOI 10.1038/372319a0; Dietrich L, 2001, J VIROL, V75, P4721, DOI 10.1128/JVI.75.10.4721-4733.2001; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Dolinski K, 1997, MOL BIOL CELL, V8, P2267, DOI 10.1091/mbc.8.11.2267; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hoffman M, 1996, GENETICS, V143, P1555; Huang PH, 1997, J CELL BIOL, V136, P803, DOI 10.1083/jcb.136.4.803; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Jiang Y, 1998, EMBO J, V17, P6942, DOI 10.1093/emboj/17.23.6942; JONES EW, 1991, J BIOL CHEM, V266, P7963; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; Schule T, 2000, EMBO J, V19, P2161, DOI 10.1093/emboj/19.10.2161; Scott SV, 1998, CURR OPIN CELL BIOL, V10, P523, DOI 10.1016/S0955-0674(98)80068-9; Shieh HL, 1998, J BIOL CHEM, V273, P3381, DOI 10.1074/jbc.273.6.3381; Shieh HL, 2001, J BIOL CHEM, V276, P10398, DOI 10.1074/jbc.M001767200; Streblow DN, 1998, VIROLOGY, V245, P197, DOI 10.1006/viro.1998.9155; Webel R, 2000, J BIOL CHEM, V275, P24752, DOI 10.1074/jbc.M002668200; Wu XY, 2000, EMBO J, V19, P3727, DOI 10.1093/emboj/19.14.3727; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	44	52	54	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48017	48026		10.1074/jbc.M109222200	http://dx.doi.org/10.1074/jbc.M109222200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11641409	hybrid			2022-12-25	WOS:000172927000040
J	Girard, T; Cavagna, D; Padovan, E; Spagnoli, G; Urwyler, A; Zorzato, F; Treves, S				Girard, T; Cavagna, D; Padovan, E; Spagnoli, G; Urwyler, A; Zorzato, F; Treves, S			B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ RELEASE CHANNEL; NECROSIS-FACTOR-ALPHA; SARCOPLASMIC-RETICULUM; CA2+ RELEASE; MOUSE MODEL; CALCIUM; PLASMA; 4-CHLORO-M-CRESOL; PATHOGENESIS; MODULATION	Malignant hyperthemia (MH) is a pharmacogenetic disease triggered by volatile anesthetics and succinylcholine in genetically predisposed individuals. The underlying feature of MH is a hypersensitivity of the calcium release machinery of the sarcoplasmic reticulum, and in many cases this is a result of point mutations in the skeletal muscle ryanodine receptor calcium release channel (RYR1). RYR1 is mainly expressed in skeletal muscle, but a recent report demonstrated the existence of this isoform in human B-lymphocytes. As B-cells can produce a number of cytokines, including endogenous pyrogens, we investigated whether some of the symptoms seen during MH could be related to the involvement of the immune system. Our results show that (i) Epstein-Barr virus-immortalized B-cells from MH-susceptible individuals carrying the V2168M RYR1 gene mutation were more sensitive to the RYR activator 4-chloro-m-cresol and (ii) their peripheral blood leukocytes produce more interleukin (IL)-1 beta after treatment with the RYR activators caffeine and 4-chloro-m-cresol, compared with cells from healthy controls. Our result demonstrate that RYR1-mediated calcium signaling is involved in release of IL-1 beta from B-lymphocytes and suggest that some of the symptoms seen during an MH episode may be due to IL-1 beta production.	Univ Basel, Kantonsspital, Dept Anaesthesia, CH-4031 Basel, Switzerland; Univ Basel, Kantonsspital, Dept Res, CH-4031 Basel, Switzerland; Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Univ Basel, Kantonsspital, Div Res, Dept Surg, CH-4031 Basel, Switzerland	Kantonsspital Aarau AG (KSA); University of Basel; Kantonsspital Aarau AG (KSA); University of Basel; University of Ferrara; Kantonsspital Aarau AG (KSA); University of Basel	Treves, S (corresponding author), ZLF Basel Kantonsspital, Lab 408, Hebelstr 20, CH-4031 Basel, Switzerland.			Treves, Susan/0000-0002-0007-9631; Padovan, Elisabetta/0000-0002-8212-508X	Telethon [1259] Funding Source: Medline	Telethon(Fondazione Telethon)		Adnet P, 2000, BRIT J ANAESTH, V85, P129, DOI 10.1093/bja/85.1.129; Benacquista BL, 2000, BIOPHYS J, V78, P1349, DOI 10.1016/S0006-3495(00)76689-6; Cavagna D, 2000, BRIT J PHARMACOL, V131, P335, DOI 10.1038/sj.bjp.0703571; De Rossi M, 2000, INT IMMUNOL, V12, P1329, DOI 10.1093/intimm/12.9.1329; Denborough M, 1998, LANCET, V352, P1131, DOI 10.1016/S0140-6736(98)03078-5; DENBOROUGH MA, 1960, LANCET, V2, P45; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; Fischer DR, 2001, SHOCK, V15, P200, DOI 10.1097/00024382-200115030-00007; Gelfand J.A., 2001, HARRISONS PRINCIPLES, P90; GRONERT GA, 2000, ANESTHESIA, P1033; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hasko G, 1998, BRIT J PHARMACOL, V124, P1099, DOI 10.1038/sj.bjp.0701934; Helmy SAK, 2000, ANAESTHESIA, V55, P904, DOI 10.1046/j.1365-2044.2000.01472-2.x; HerrmannFrank A, 1996, BIOCHEM PHARMACOL, V52, P149, DOI 10.1016/0006-2952(96)00175-X; HerrmannFrank A, 1996, BBA-GEN SUBJECTS, V1289, P31, DOI 10.1016/0304-4165(95)00131-X; HOTCHKISS RS, 1994, P NATL ACAD SCI USA, V91, P3039, DOI 10.1073/pnas.91.8.3039; HOTCHKISS RS, 1995, SHOCK, V3, P337; IAIZZO PA, 1988, PFLUG ARCH EUR J PHY, V411, P648, DOI 10.1007/BF00580861; Jurkat-Rott K, 2000, MUSCLE NERVE, V23, P4, DOI 10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LARACH MG, 1994, ANESTHESIOLOGY, V80, P771, DOI 10.1097/00000542-199404000-00008; LASKOV R, 1990, J IMMUNOL, V144, P3424; MACK MM, 1994, J BIOL CHEM, V269, P23236; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; MCCARTHY TV, 1990, NATURE, V343, P562, DOI 10.1038/343562a0; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; PALADE P, 1987, J BIOL CHEM, V262, P6142; Paul-Pletzer K, 2001, BIOCHEMISTRY-US, V40, P531, DOI 10.1021/bi001502s; Richter M, 1997, J BIOL CHEM, V272, P5256, DOI 10.1074/jbc.272.8.5256; ROITT I, 1996, IMMUNOLOGY, P169; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Sei Y, 1999, J BIOL CHEM, V274, P5995, DOI 10.1074/jbc.274.9.5995; Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x; Struk A, 1999, J PHYSIOL-LONDON, V515, P221, DOI 10.1111/j.1469-7793.1999.221ad.x; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tong JF, 1999, J BIOL CHEM, V274, P693, DOI 10.1074/jbc.274.2.693; TREVES S, 1994, BIOCHEM J, V301, P661, DOI 10.1042/bj3010661; Wappler F, 2001, ANESTHESIOLOGY, V94, P95, DOI 10.1097/00000542-200101000-00019; WINGARD DW, 1974, LANCET, V2, P1450; Xu L, 1998, ANN NY ACAD SCI, V853, P130; YAMADA H, 1993, J EXP MED, V177, P1613, DOI 10.1084/jem.177.6.1613; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192; Zucchi R, 1997, PHARMACOL REV, V49, P1	48	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48077	48082		10.1074/jbc.M107134200	http://dx.doi.org/10.1074/jbc.M107134200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11673462	hybrid			2022-12-25	WOS:000172927000047
J	Frontini, M; Imbriano, C; diSilvio, A; Bell, B; Bogni, A; Romier, C; Moras, D; Tora, L; Davidson, I; Mantovani, R				Frontini, M; Imbriano, C; diSilvio, A; Bell, B; Bogni, A; Romier, C; Moras, D; Tora, L; Davidson, I; Mantovani, R			NF-Y recruitment of TFIID, multiple interactions with histone fold TAF(II)s	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; CLASS-II TRANSACTIVATOR; MHC CLASS-II; TRANSCRIPTIONAL ACTIVATION; TAF(II)-CONTAINING COMPLEX; NUCLEOSOME ACETYLATION; DTAF(II)110 COMPONENT; MOLECULAR-CLONING; DNA-BINDING; PROMOTER	The nuclear factor y (NF-Y) trimer and TFIID contain histone fold subunits, and their binding to the CCAAT and Initiator elements of the major histocompatibility complex class II Ea promoter is required for transcriptional activation. Using agarose-electrophoretic mobility shift assay we found that NF-Y increases the affinity of holo-TFIID for Ea in a CCAAT- and Inr-dependent manner. We began to dissect the interplay between NF-Y- and TBP-associated factors PO1II (TAF(II)s)-containing histone fold domains in protein-protein interactions and transfections. hTAF(II)20, hTAF(II)28, and hTAF(II)18-hTAF(II)28 bind to the NF-Y B-NF-YC histone fold dimer; hTAF(II)80 and hTAF(II)31-hTAF(II)80 interact with the trimer but not with the NF-YB-NF-YC dimer. The histone fold alpha2 helix of hTAF(II)80 is not required for NF-Y association, as determined by interactions with the naturally occurring splice variant hTAF(II)80delta. Expression of hTAF(II)28 and hTAF(II)18 in mouse cells significantly and specifically reduced NF-Y activation in GAL4-based experiments, whereas hTAF,120 and hTAF(II)135 increased it. These results indicate that NF-Y (i) recruits purified holo-TFIID in vitro and (ii) can associate multiple TAF(II)s, potentially accommodating different core promoter architectures.	Univ Modena & Reggio Emilia, Dipartimento Biol Anim, I-41100 Modena, Italy; Inst Genet & Biol Mol & Cellulaire, F-67404 Strasbourg, France	Universita di Modena e Reggio Emilia; Institut National de la Sante et de la Recherche Medicale (Inserm)	Mantovani, R (corresponding author), Univ Modena & Reggio Emilia, Dipartimento Biol Anim, Via Campi 213-D, I-41100 Modena, Italy.	mantor@mail.unimo.it	Imbriano, Carol/ABD-8204-2021; Tora, Laszlo/E-9999-2018; Imbriano, Carol/C-9376-2015	Imbriano, Carol/0000-0003-2864-4820; Tora, Laszlo/0000-0001-7398-2250; Imbriano, Carol/0000-0003-2864-4820; Romier, Christophe/0000-0002-3680-935X; Davidson, Irwin/0000-0001-5533-1171				Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; APONE LM, 1998, GENE DEV, V10, P2368; Bando M, 1997, J BIOCHEM-TOKYO, V121, P591; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Bell B, 2001, MOL CELL, V8, P591, DOI 10.1016/S1097-2765(01)00325-2; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Bellorini M, 1996, MOL CELL BIOL, V16, P503; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Caretti G, 1999, MOL CELL BIOL, V19, P8591; Caron C, 1997, P NATL ACAD SCI USA, V94, P3662, DOI 10.1073/pnas.94.8.3662; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; Coustry F, 1998, BIOCHEM J, V331, P291, DOI 10.1042/bj3310291; di Silvio A, 1999, NUCLEIC ACIDS RES, V27, P2578; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Duan ZJ, 2001, MOL CELL BIOL, V21, P3083, DOI 10.1128/MCB.21.9.3083-3095.2001; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Felinski EA, 1999, J BIOL CHEM, V274, P11672, DOI 10.1074/jbc.274.17.11672; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Gangloff YG, 2001, MOL CELL BIOL, V21, P1841, DOI 10.1128/MCB.21.5.1841-1853.2001; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Gusmaroli G, 2001, GENE, V264, P173, DOI 10.1016/S0378-1119(01)00323-7; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; INOSTROZA JA, 1992, CELL, V70, P477; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KRESTOVALI A, 1998, MOL CELL BIOL, V18, P6777; LANDSBERGER N, 1995, MOL CELL BIOL, V15, P6013; Lavigne AC, 1999, MOL CELL BIOL, V19, P5050; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Martin J, 1999, MOL CELL BIOL, V19, P5548; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Perletti L, 1999, J BIOL CHEM, V274, P15301, DOI 10.1074/jbc.274.22.15301; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; VIVILLE S, 1991, J IMMUNOL, V146, P3211; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Wolffe AP, 1996, TRENDS GENET, V12, P58, DOI 10.1016/0168-9525(96)81401-6; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161	72	59	60	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					5841	5848		10.1074/jbc.M103651200	http://dx.doi.org/10.1074/jbc.M103651200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11689552	hybrid, Green Published			2022-12-25	WOS:000173989200021
J	Ma, Q; Kinneer, K				Ma, Q; Kinneer, K			Chemoprotection by phenolic antioxidants - Inhibition of tumor necrosis factor alpha induction in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; BUTYLATED HYDROXYTOLUENE; INDUCIBLE EXPRESSION; OXIDATIVE STRESS; NRF2; TNF; CARCINOGENESIS; IDENTIFICATION; ELEMENTS	Phenolic antioxidants exhibit anti-inflammatory activity in protection against chemical toxicity and cancer. To investigate the molecular mechanism of anti-inflammation, we analyzed the regulation of tumor necrosis factor alpha (TNF-alpha) expression in macrophages, a key step in inflammation, by the antioxidants. Whereas lipopolysaccharide (LPS), an inflammatory inducer, stimulates rapid synthesis of TNF-alpha protein, phenolic antioxidants, exemplified by tert-butyl hydroquinone and 1,4-dihydroquinone, block LPS-induced production of TNF-alpha protein in a time- and dose-dependent manner. Inhibition of TNF-alpha induction correlates with the capacity of the antioxidants to undergo oxidation-reduction cycling, implicating oxidative signaling in the inhibition. The antioxidants blocked LPS-induced increase of the steady-state mRNA of TNF-alpha but did not affect the half-life of the mRNA. Electrophoretic mobility shift assay reveals a total inhibition of LPS-induced formation of nuclear factor kappaB(.)DNA binding complexes by phenolic antioxidants. Finally, 1,4-dihydroquinone blocks the induction of TNF-alpha target genes interleukin 1beta and interleukin 6 at both mRNA and protein levels. Our findings demonstrate that phenolic antioxidants potently inhibit signal-induced TNF-alpha transcription and suggest a mechanism of anti-inflammation by the antioxidants through control of cytokine induction during inflammation.	CDCP, NIOSH, Receptor Biol Lab,Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Ma, Q (corresponding author), CDCP, NIOSH, Receptor Biol Lab,Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Mailstop 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.	qam1@cdc.gov						Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; AHMAD S, 1995, OXIDATIVE STRESS ANT, P1; Bishop A, 1998, NUTR REV, V56, P287, DOI 10.1111/j.1753-4887.1998.tb01661.x; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; ERNSTER L, 1987, CHEM SCRIPTA, V27A, P1; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; GAREWAL HS, 1997, ANTIOXIDANTS DIS PRE, P1; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hiramoto M, 1998, J IMMUNOL, V160, P810; Hirose M, 1998, EUR J CANCER PREV, V7, P233, DOI 10.1097/00008469-199806000-00008; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Luster MI, 1998, ENVIRON HEALTH PERSP, V106, pA418, DOI 10.2307/3434211; MA Q, 1992, J BIOL CHEM, V267, P22298; NAGAKAWA J, 1993, J PHARMACOL EXP THER, V264, P496; NAGAKAWA JI, 1992, J PHARMACOL EXP THER, V262, P145; Nishizono S, 2000, BIOSCI BIOTECH BIOCH, V64, P1153, DOI 10.1271/bbb.64.1153; NUNN CJ, 1991, FOOD CHEM TOXICOL, V29, P73, DOI 10.1016/0278-6915(91)90070-N; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; Pohl LR, 1996, EUR J HAEMATOL, V57, P98; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; Prieschl EE, 1998, NUCLEIC ACIDS RES, V26, P2291, DOI 10.1093/nar/26.10.2291; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; ULLAND BM, 1973, FOOD COSMET TOXICOL, V11, P199, DOI 10.1016/S0015-6264(73)80486-9; VERHAGEN H, 1991, CHEM-BIOL INTERACT, V80, P109, DOI 10.1016/0009-2797(91)90019-4; Wagner H, 2001, IMMUNITY, V14, P499, DOI 10.1016/S1074-7613(01)00144-3; WATTENBERG LW, 1972, JNCI-J NATL CANCER I, V48, P1425; WATTENBERG LW, 1985, CANCER RES, V45, P1; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974; Ye JP, 1999, AM J PHYSIOL-LUNG C, V276, pL426, DOI 10.1152/ajplung.1999.276.3.L426	46	103	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2477	2484		10.1074/jbc.M106685200	http://dx.doi.org/10.1074/jbc.M106685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11694529	hybrid			2022-12-25	WOS:000173421500016
J	Saville, B; Poukka, H; Wormke, M; Janne, OA; Palvimo, JJ; Stoner, M; Samudio, I; Safe, S				Saville, B; Poukka, H; Wormke, M; Janne, OA; Palvimo, JJ; Stoner, M; Samudio, I; Safe, S			Cooperative coactivation of estrogen receptor alpha in ZR-75 human breast cancer cells by SNURF and TATA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTORS; PROLIFERATOR-ACTIVATED RECEPTOR; RING FINGER PROTEIN; PREGNANE-X-RECEPTOR; CATHEPSIN-D GENE; TRANSCRIPTIONAL ACTIVATION; ER-ALPHA; CHROMOSOMAL LOCALIZATION; DEPENDENT TRANSCRIPTION; COREGULATORY PROTEINS	SNURF is a small RING finger protein that binds the zinc finger region of steroid hormone receptors and enhances Sp1- and androgen receptor-mediated transcription in COS and CV-1 cells. In this study, we show that SNURF coactivates both wild-type estrogen receptor a (ERalpha) (4-fold)- and HE19 (ERalpha deletion of activation function I (AF1)) (210-fold) -mediated activation of an estrogen-responsive element promoter in ZR-75 cells. In mammalian two-hybrid assays in ZR-75 cells SNURF interactions were estrogen (E2)-dependent and were not observed with the antiestrogen ICI 182,780. ERalpha interacted with multiple regions of SNURF; SNURF interactions with ERalpha were dependent on AF2, and D538N, E542Q, and D545N mutations in helix 12 abrogated both SNURF-ERalpha binding and coactivation. Moreover, peptide fusion proteins that inhibit interactions between helix 12 of ERalpha with LXXLL box-containing proteins also blocked ERalpha coactivation by SNURF. However, cotransfection of SNURF with prototypical steroid receptor coactivators 1, 2, and 3 that contain LXXLL box motifs did not enhance E2 responsiveness, whereas TATA-binding protein (TBP) and SNURF cooperatively coactivated ERalpha-mediated transactivation. The results are consistent with a unique model for cooperative coactivation of ERalpha that requires ligand binding, repositioning of helix 12, recruitment of TBP, and interaction with SNURF, which binds both ERalpha and TBP.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Univ Helsinki, Biomedicum Helsinki, Inst Biomed Physiol, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Clin Chem, FIN-00014 Helsinki, Finland	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; University of Helsinki; University of Helsinki; University of Helsinki	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, 4466 TAMU, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu	Samudio, Ismael/D-3581-2013	Samudio, Ismael/0000-0001-8676-1035; Palvimo, Jorma/0000-0003-2373-0578	NATIONAL CANCER INSTITUTE [R01CA076636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER; NCI NIH HHS [CA76636] Funding Source: Medline; NIEHS NIH HHS [ES09106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; Edwards DP, 1999, VITAM HORM, V55, P165; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gonzalez MI, 2001, J BIOL CHEM, V276, P6420, DOI 10.1074/jbc.M008689200; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Hakli M, 2001, J BIOL CHEM, V276, P23653, DOI 10.1074/jbc.M009891200; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; Mak HY, 1999, MOL CELL BIOL, V19, P3895; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Melvin VS, 1999, STEROIDS, V64, P576, DOI 10.1016/S0039-128X(99)00036-7; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Norris JD, 1998, J BIOL CHEM, V273, P6679, DOI 10.1074/jbc.273.12.6679; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Porter W, 1996, MOL ENDOCRINOL, V10, P1371, DOI 10.1210/me.10.11.1371; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Poukka H, 2000, J BIOL CHEM, V275, P571, DOI 10.1074/jbc.275.1.571; Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Samudio I, 2001, ENDOCRINOLOGY, V142, P1000, DOI 10.1210/en.142.3.1000; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xie W, 2000, ENDOCRINOLOGY, V141, P2439, DOI 10.1210/en.141.7.2439; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZACHAREWSKI TR, 1994, CANCER RES, V54, P2707; Zhang H, 1999, ARCH BIOCHEM BIOPHYS, V368, P14, DOI 10.1006/abbi.1999.1307; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	99	33	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2485	2497		10.1074/jbc.M109021200	http://dx.doi.org/10.1074/jbc.M109021200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11696545	hybrid			2022-12-25	WOS:000173421500017
J	Ma, DQ; Xing, ZL; Liu, B; Pedigo, NG; Zimmer, SG; Bai, ZL; Postel, EH; Kaetzel, DM				Ma, DQ; Xing, ZL; Liu, B; Pedigo, NG; Zimmer, SG; Bai, ZL; Postel, EH; Kaetzel, DM			NM23-H1 and NM23-H2 repress transcriptional activities of nuclease-hypersensitive elements in the platelet-derived growth factor-A promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; CHAIN GENE-TRANSCRIPTION; B/V-SIS CONFERS; DNA-BINDING; TUMOR-METASTASIS; PDGF RECEPTORS; EXPRESSION; PROTEIN; BRCA1; MELANOMA	The platelet-derived growth factor (PDGF)-A promoter is regulated by a number of GC-rich regulatory elements that possess non-B-form DNA structures. Screening of a HeLa cDNA expression library with the C-rich strand of a PDGF-A silencer sequence (5'-S1 nuclease-hypersensitive site (SHS)) yielded three cDNA clones encoding NM23-H1, a protein implicated as a suppressor of metastasis in melanoma and breast carcinoma. Recombinant human NM23-H1 cleaved within the W-portions of both 5'-SHS strands in either single-stranded or duplex forms. In contrast, NM23-H2, known as a transcriptional activator with a DNA cleavage function, cleaved within the W-portions of both strands, revealing that NM23-H1 and NM23-H2 cleave at distinct sites of the 5'-SHS and by different mechanisms. NM23-H1 and NM23-H2 also cleaved within the PDGF-A basal promoter region, again exhibiting preferences for cleavage within the 5'- and 3'-portions of the element, respectively. Transient transfection analyses in HepG2 cells revealed that both NM23-H1 and -H2 repressed transcriptional activity driven by the PDGF-A basal promoter (-82 to +8). Activity of the negative regulatory region (-1853 to -883), which contains the 5'-SHS, was also inhibited modestly by NM23-H1 and NM23-H2. These studies demonstrate for the first time that NM23-H1 interacts both structurally and functionally with DNA. They also indicate a role for NM23 proteins in repressing transcription of a growth factor oncogene, providing a possible molecular mechanism to explain their metastasis-suppressing effects.	Univ Kentucky, Med Ctr, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Shandong Univ, Dept Dev Biol, Jinan 250100, Peoples R China	University of Kentucky; University of Kentucky; Princeton University; Shandong University	Kaetzel, DM (corresponding author), Univ Kentucky, Med Ctr, Dept Mol & Biomed Pharmacol, MS305,800 Rose St, Lexington, KY 40536 USA.	dmkaetz@pop.uky.edu		ma, deqin/0000-0002-8581-6345	NCI NIH HHS [R01-CA76496, R01-CA83237] Funding Source: Medline; NIDDK NIH HHS [R29-DK45518] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076496, R01CA083237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045518] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal R P, 1978, Methods Enzymol, V51, P376; ALBINO AP, 1991, CANCER RES, V51, P4815; Anan K, 1996, SURGERY, V119, P333, DOI 10.1016/S0039-6060(96)80120-6; BERBERICH SJ, 1995, ONCOGENE, V10, P2343; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HERMANSON M, 1992, CANCER RES, V52, P3213; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; KAETZEL DM, 1994, BIOCHEM J, V301, P321, DOI 10.1042/bj3010321; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEVEEN P, 1990, INT J CANCER, V46, P1066, DOI 10.1002/ijc.2910460620; LIN XH, 1992, J BIOL CHEM, V267, P25614; Liu B, 1996, J BIOL CHEM, V271, P26281, DOI 10.1074/jbc.271.42.26281; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Maxam A M, 1980, Methods Enzymol, V65, P499; NAKAYAMA H, 1993, JPN J CANCER RES, V84, P184, DOI 10.1111/j.1349-7006.1993.tb02853.x; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; Ogbourne S, 1998, BIOCHEM J, V331, P1; OHNEDA K, 1994, FEBS LETT, V348, P273, DOI 10.1016/0014-5793(94)00623-7; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; Parvin JD, 2001, P NATL ACAD SCI USA, V98, P5952, DOI 10.1073/pnas.121184998; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 2000, J BIOENERG BIOMEMBR, V32, P277, DOI 10.1023/A:1005541114029; Postel EH, 1999, J BIOL CHEM, V274, P22821, DOI 10.1074/jbc.274.32.22821; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; Postel EH, 2000, P NATL ACAD SCI USA, V97, P14194, DOI 10.1073/pnas.97.26.14194; Potapova O, 1996, CANCER RES, V56, P280; Potapova O, 1996, INT J CANCER, V66, P669, DOI 10.1002/(SICI)1097-0215(19960529)66:5<669::AID-IJC15>3.0.CO;2-#; ROBBINS KC, 1982, SCIENCE, V218, P1131, DOI 10.1126/science.6293053; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Schilling D, 1998, BIOCHEM J, V333, P637, DOI 10.1042/bj3330637; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SILVER BJ, 1992, BIOFACTORS, V3, P217; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STEEG PS, 1993, BREAST CANCER RES TR, V25, P175, DOI 10.1007/BF00662142; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; TAKIMOTO Y, 1953, P NATL ACAD SCI USA, V18, P123; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WATSON JD, 1953, COLD SPRING HARB SYM, V18, P123, DOI 10.1101/SQB.1953.018.01.020; WESTERMARK B, 1993, ACTA ONCOL, V32, P101, DOI 10.3109/02841869309083897; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	58	98	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1560	1567		10.1074/jbc.M108359200	http://dx.doi.org/10.1074/jbc.M108359200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694515	hybrid			2022-12-25	WOS:000173166800090
J	Wells, CD; Liu, MY; Jackson, M; Gutowski, S; Sternweis, PM; Rothstein, JD; Kozasa, T; Sternweis, PC				Wells, CD; Liu, MY; Jackson, M; Gutowski, S; Sternweis, PM; Rothstein, JD; Kozasa, T; Sternweis, PC			Mechanisms for reversible regulation between G(13) and Rho exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; HETEROTRIMERIC G-PROTEINS; ALPHA-SUBUNITS; TRANSITION-STATE; P115 RHOGEF; RGS4; G-ALPHA(13); GAIP; PURIFICATION; RECEPTOR	The heterotrimeric G proteins, G(12) and G(13), mediate signaling between G protein-coupled receptors and the monomeric GTPase, RhoA. One pathway for this modulation is direct stimulation by Galpha(13) of p115 RhoGEF, an exchange factor for RhoA. The GTPase activity of both Galpha(12) and Galpha(13) is increased by the N terminus of p115 Rho guanine nucleotide exchange factor (GEF). This region has weak homology to the RGS box sequence of the classic regulators of G protein signaling (RGS), which act as GTPase-activating proteins (GAP) for G(i) and G(q). Here, the RGS region of p115 RhoGEF is shown to be distinctly different in that sequences flanking the predicted "RGS box" region are required for both stable expression and GAP activity. Deletions in the N terminus of the protein eliminate GAP activity but retain substantial binding to Galpha(13) and activation of RhoA exchange activity by Galpha(13). In contrast, GTRAP48, a homolog of p115 RhoGEF, bound to Galpha(13) but was not stimulated by the a subunit and had very poor GAP activity. Besides binding to the N-terminal RGS region, Galpha(13) also bound to a truncated protein consisting only of the Dbl homology (DH) and pleckstrin homology (PH) domains. However, Galpha(13) did not stimulate the exchange activity of this truncated protein. A chimeric protein, which contained the RGS region of GTRAP48 in place of the endogenous N terminus of p115 RhoGEF, was activated by Galpha(13). These results suggest a mechanism for activation of the nucleotide exchange activity of p115 RhoGEF that involves direct and coordinate interaction of Galpha(13) to both its RGS and DH domains.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Hybrigen Inc, Dallas, TX 75207 USA; Johns Hopkins Univ, Dept Neurol & Neurosci, Baltimore, MD 21287 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60612 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Sternweis, PC (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		rothstein, jeffrey d/C-9470-2013		NIGMS NIH HHS [GM61454, GM31954, GM07062] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954, T32GM007062, R01GM061454] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; de Alba E, 1999, J MOL BIOL, V291, P927, DOI 10.1006/jmbi.1999.2989; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LEE BN, 1994, MOL MICROBIOL, V14, P323, DOI 10.1111/j.1365-2958.1994.tb01293.x; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Longenecker KL, 2001, STRUCTURE, V9, P559, DOI 10.1016/S0969-2126(01)00620-7; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Spink KE, 2000, EMBO J, V19, P2270, DOI 10.1093/emboj/19.10.2270; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wells C, 2002, METHOD ENZYMOL, V345, P371; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200	41	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1174	1181		10.1074/jbc.M105274200	http://dx.doi.org/10.1074/jbc.M105274200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11698392	hybrid			2022-12-25	WOS:000173166800039
J	Du, JY; Fisher, DE				Du, JY; Fisher, DE			Identification of aim-1 as the underwhite mouse mutant and its transcriptional regulation by MITF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROPHTHALMIA GENE-PRODUCT; WAARDENBURG SYNDROME; REPETITIVE ELEMENTS; TIETZ-SYNDROME; EXPRESSION; ACTIVATION; MUTATION; ALBINISM; MELANOMA; REPEATS	Animal pigmentation mutants have provided rich models for the identification of genes modulating pathways from melanocyte development to melanoma. One mouse model is the underwhite locus, alleles of which manifest altered pigmentation of both eye and fur, sometimes in an age-dependent fashion. Here we show that the mouse homolog of a recently identified gene whose mutation produces Japanese gold-colored fish, medaka b, maps to the mouse underwhite locus. We identify distinct mutations of this gene, known as Aim-1, in three underwhite mouse alleles and find that structure/function differences correlate with recessive versus dominant inheritance. The human ortholog of AIM-1 was originally identified as a melanocyte-restricted antigen that is recognized by autologous T cells from a patient with melanoma. We also provide evidence that AIM-1 is transcriptionally modulated by MITF, a melanocyte-specific transcription factor essential to pigmentation and a clinical diagnostic marker in human melanoma. Although AIM-1 appears to reside downstream of MITF, chromatin immunoprecipitations do not reveal binding of MITF to a 5'-flanking region containing histone 3 acetylation, indicating that MITF either acts indirectly on AIM-1 or it binds to a remote regulatory sequence. Nevertheless, MITF links AIM-1 expression and the underwhite phenotype to a transcriptional network central to pigmentation in mammals.	Harvard Univ, Childrens Hosp, Sch Med, Div Pediat Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NIAMS NIH HHS [AR43369] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043369] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amiel J, 1998, CLIN DYSMORPHOL, V7, P17; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Blake JA, 2001, NUCLEIC ACIDS RES, V29, P91, DOI 10.1093/nar/29.1.91; Busam KJ, 2001, AM J SURG PATHOL, V25, P197, DOI 10.1097/00000478-200102000-00007; Dickie MM, 1964, MOUSE NEWS LETT, V30, P30; Fukamachi S, 2001, NAT GENET, V28, P381, DOI 10.1038/ng584; Harada M, 2001, CANCER RES, V61, P1089; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Jurka J, 1998, CURR OPIN STRUC BIOL, V8, P333, DOI 10.1016/S0959-440X(98)80067-5; Jurka J, 1996, COMPUT CHEM, V20, P119, DOI 10.1016/S0097-8485(96)80013-1; Jurka J, 2000, TRENDS GENET, V16, P418, DOI 10.1016/S0168-9525(00)02093-X; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; KING RA, 1986, CLIN GENET, V29, P42; Koch MB, 2001, AM J SURG PATHOL, V25, P58, DOI 10.1097/00000478-200101000-00006; Lehman AL, 2000, J INVEST DERMATOL, V115, P601, DOI 10.1046/j.1523-1747.2000.00107.x; Miettinen M, 2001, AM J SURG PATHOL, V25, P205, DOI 10.1097/00000478-200102000-00008; Newton JM, 2001, AM J HUM GENET, V69, P981, DOI 10.1086/324340; Price ER, 1998, J BIOL CHEM, V273, P33042, DOI 10.1074/jbc.273.49.33042; Price ER, 2001, NEURON, V30, P15, DOI 10.1016/S0896-6273(01)00259-8; Salti GI, 2000, CANCER RES, V60, P5012; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Smith SD, 2000, J MED GENET, V37, P446, DOI 10.1136/jmg.37.6.446; Sweet HO, 1998, J HERED, V89, P546, DOI 10.1093/jhered/89.6.546; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Van Belle D, 2001, CURR OPIN CELL BIOL, V13, P389, DOI 10.1016/S0955-0674(00)00226-X; Wu M, 2000, GENE DEV, V14, P301; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058	28	75	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					402	406		10.1074/jbc.M110229200	http://dx.doi.org/10.1074/jbc.M110229200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11700328	hybrid			2022-12-25	WOS:000173087900054
J	Evdokimov, AA; Zinoviev, VV; Malygin, EG; Schlagman, SL; Hattman, S				Evdokimov, AA; Zinoviev, VV; Malygin, EG; Schlagman, SL; Hattman, S			Bacteriophage T4 Dam DNA-[N-6-adenine]methyltransferase - Kinetic evidence for a catalytically essential conformational change in the ternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; ECORV DNA METHYLTRANSFERASE; STEADY-STATE KINETICS; ESCHERICHIA-COLI; HHAI METHYLTRANSFERASE; RECOGNITION SITES; BINDING; MECHANISM; BASE; CYTOSINE	We carried out a steady state kinetic analysis of the bacteriophage T4 DNA-[N-6-adeninelmethyltransferase (T4 Dam) mediated methyl group transfer reaction from S-adenOSyl-L-Methionine (AdoMet) to Ade in the palindromic recognition sequence, GATC, of a 20-mer oligonucleotide duplex. Product inhibition patterns were consistent with a steady state-ordered bi-bi mechanism in which the order of substrate binding and product (methylated DNA, DNA(Me) and S-adenoSyl-L-homocysteine, AdoHcy) release was AdoMet down arrow DNA down arrow DNA(Me) up arrow AdoHcy up arrow . A strong reduction in the rate of methylation was observed at high concentrations of the substrate 20-mer DNA duplex. In contrast, increasing substrate AdoMet concentration led to stimulation in the reaction rate with no evidence of saturation. We propose the following model. Free T4 Dam (initially in conformational form E) randomly interacts with substrates AdoMet and DNA to form a ternary T4 Dam-AdoMet-DNA complex in which T4 Dam has isomerized to conformational state F, which is specifically adapted for catalysis. After the chemical step of methyl group transfer from AdoMet to DNA, product DNA(Me) dissociates relatively rapidly (k(off) = 1.7 s(-1)) from the complex. In contrast, dissociation of product AdoHcy proceeds relatively slowly (k(off) = 0.018 s(-1)), indicating that its release is the rate-limiting step, consistent with k(cat) = 0.015 s(-1). After AdoHcy release, the enzyme remains in the F conformational form and is able to preferentially bind AdoMet (unlike form E, which randomly binds AdoMet and DNA), and the AdoMet-F binary complex then binds DNA to start another methylation cycle. We also propose an alternative pathway in which the release of AdoHcy is coordinated with the binding of AdoMet in a single concerted event, while T4 Dam remains in the isomerized form F. The resulting AdoMet-F binary complex then binds DNA, and another methylation reaction ensues. This route is preferred at high AdoMet concentrations.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA; State Res Ctr Virol & Biotechnol, Inst Mol Biol, Novosibirsk 630559, Russia	University of Rochester; State Research Center of Virology & Biotechnology VECTOR	Hattman, S (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	modDNA@mail.rochester.edu	Ernst, Malygin/A-6741-2014; Evdokimov, Alexey/A-6485-2014		FIC NIH HHS [TW00529] Funding Source: Medline; NIGMS NIH HHS [GM29227] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams GM, 1997, BIOCHEMISTRY-US, V36, P8284, DOI 10.1021/bi961885n; Ahmad I, 1996, CRIT REV BIOCHEM MOL, V31, P361, DOI 10.3109/10409239609108722; Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074/jbc.274.46.33011; BERGERAT A, 1990, NUCLEIC ACIDS RES, V18, P4369, DOI 10.1093/nar/18.15.4369; Bhattacharya SK, 1999, J BIOL CHEM, V274, P14743, DOI 10.1074/jbc.274.21.14743; BONNICHSEN RK, 1947, ACTA CHEM SCAND, V1, P685, DOI 10.3891/acta.chem.scand.01-0685; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cal S, 1997, J BIOL CHEM, V272, P490; Cleland W W, 1979, Methods Enzymol, V63, P500; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; Dong AP, 2001, NUCLEIC ACIDS RES, V29, P439, DOI 10.1093/nar/29.2.439; Dryden D. S, 1999, BACTERIAL DNA METHYL, P283; Fatemi M, 2001, J MOL BIOL, V309, P1189, DOI 10.1006/jmbi.2001.4709; Flynn J, 1998, BIOCHEMISTRY-US, V37, P15162, DOI 10.1021/bi9810609; Friedrich T, 1998, BIOL CHEM, V379, P475, DOI 10.1515/bchm.1998.379.4-5.475; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; Gowher H, 2000, J MOL BIOL, V303, P93, DOI 10.1006/jmbi.2000.4127; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; JAVOR GT, 1983, ANTIMICROB AGENTS CH, V24, P860, DOI 10.1128/AAC.24.6.860; Jeltsch A, 1999, J MOL BIOL, V285, P1121, DOI 10.1006/jmbi.1998.2389; Klimasauskas S, 1998, EMBO J, V17, P317, DOI 10.1093/emboj/17.1.317; KOSSYKH VG, 1993, NUCLEIC ACIDS RES, V21, P4659, DOI 10.1093/nar/21.20.4659; KOSSYKH VG, 1995, J BIOL CHEM, V270, P14389, DOI 10.1074/jbc.270.24.14389; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Malygin EG, 1999, NUCLEIC ACIDS RES, V27, P1135, DOI 10.1093/nar/27.4.1135; Malygin EG, 1997, NUCLEIC ACIDS RES, V25, P4393, DOI 10.1093/nar/25.21.4393; Malygin EG, 2000, NUCLEIC ACIDS RES, V28, P4207, DOI 10.1093/nar/28.21.4207; MALYGIN EG, 1977, BIOFIZIKA+, V22, P15; Malygin EG, 2001, NUCLEIC ACIDS RES, V29, P2361, DOI 10.1093/nar/29.11.2361; O'Gara M, 1999, J MOL BIOL, V287, P201, DOI 10.1006/jmbi.1999.2608; OGARA M, 1995, GENE, V157, P135, DOI 10.1016/0378-1119(94)00669-J; OGara M, 1996, J MOL BIOL, V261, P634, DOI 10.1006/jmbi.1996.0489; OGURA Y, 1955, ARCH BIOCHEM BIOPHYS, V57, P288, DOI 10.1016/0003-9861(55)90291-5; PIEKAROWICZ A, 1980, J MOL BIOL, V144, P415, DOI 10.1016/0022-2836(80)90329-0; Posnick LM, 1999, J BACTERIOL, V181, P6756, DOI 10.1128/JB.181.21.6756-6762.1999; POWELL LM, 1995, NUCLEIC ACIDS RES, V23, P967, DOI 10.1093/nar/23.6.967; RAO DN, 1989, J MOL BIOL, V209, P599, DOI 10.1016/0022-2836(89)90597-4; REICH NO, 1993, J BIOL CHEM, V268, P9191; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Roth M, 1998, J BIOL CHEM, V273, P17333, DOI 10.1074/jbc.273.28.17333; Roth M, 2001, NUCLEIC ACIDS RES, V29, P3137, DOI 10.1093/nar/29.15.3137; Rudolph F B, 1979, Methods Enzymol, V63, P411; SCHLAGMAN SL, 1983, GENE, V22, P139, DOI 10.1016/0378-1119(83)90098-7; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10724, DOI 10.1021/bi00034a004; SZILAK L, 1993, EUR J BIOCHEM, V218, P727, DOI 10.1111/j.1432-1033.1993.tb18427.x; Thielking V, 1997, BIOL CHEM, V378, P407, DOI 10.1515/bchm.1997.378.5.407; Tran PH, 1998, STRUCT FOLD DES, V6, P1563, DOI 10.1016/S0969-2126(98)00154-3; Tuzikov FV, 1997, MOL BIOL+, V31, P73; Vertino PM, 1999, S ADENOSYLMETHIONINE, P341; Vilkaitis G, 2001, J BIOL CHEM, V276, P20924, DOI 10.1074/jbc.M101429200; WOLCKE J, 1998, THESIS U DORTMUND GE; WU JC, 1987, J BIOL CHEM, V262, P4778; Zinoviev VV, 1998, BIOL CHEM, V379, P481, DOI 10.1515/bchm.1998.379.4-5.481	60	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					279	286		10.1074/jbc.M108864200	http://dx.doi.org/10.1074/jbc.M108864200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11687585	hybrid			2022-12-25	WOS:000173087900038
J	Alvarez, I; Marti, M; Vazquez, J; Camafeita, E; Ogueta, S; de Castro, JAL				Alvarez, I; Marti, M; Vazquez, J; Camafeita, E; Ogueta, S; de Castro, JAL			The Cys-67 residue of HLA-B27 influences cell surface stability, peptide specificity, and T-cell antigen presentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HL-A 27; ANKYLOSING-SPONDYLITIS; MONOCLONAL-ANTIBODY; TRANSGENIC RATS; INFLAMMATORY DISEASE; INVITRO MUTAGENESIS; MUTANTS MIMICKING; VIRAL PEPTIDES; TARGET-CELL; BINDING	Cys-67 of HLA-B27 is located in the B pocket, which determines peptide-binding specificity. We analyzed effects of the Cys-67 --> Ser mutation on cell surface expression, peptide specificity, and T-cell recognition of HIA-B*2705. Surface expression was assessed with antibodies recognizing either native or unfolded HILA proteins. Whereas native B*2705 molecules predominated over unfolded ones, this ratio was reversed in the mutant, suggesting lower stability. Comparison of B*2705and Cys-67 --> Ser-bound peptides revealed that the mutant failed to bind similar to15% of the B*2705 ligands, while binding as many novel ones. Two peptides with Gln-2 found in both B*2705 and Cys-67 --> Ser are the first demonstration of natural 13*2705 ligands lacking Arg-2. Other effects of the mutation on peptide specificity were: 1) average molecular mass of natural ligands higher than for B*2705, 2) bias against small residues at peptide position (P) 1, and 3) increased P2 permissiveness. The results suggest that the Cys-67 --> Ser mutation weakens B pocket interactions, leading to decreased stability of the mutant-peptide complexes. This may be partially compensated by interactions involving bulky P1 residues. The effect of the mutation on allorecognition was consistent with that on peptide specificity. Our results may aid understanding of the pathogenetic role of HIA-B27 in spondyloarthropathy.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, CSIC, E-28049 Madrid, Spain; Ctr Nacl Biotecnol, Madrid 28049, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	de Castro, JAL (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, CSIC, E-28049 Madrid, Spain.		Martí, Mercè/I-2164-2015; Vazquez, Jesus/B-7697-2015; Alvarez, Iñaki/A-6684-2011	Martí, Mercè/0000-0002-1846-0043; Vazquez, Jesus/0000-0003-1461-5092; Alvarez, Iñaki/0000-0001-9484-0868				Allen RL, 1999, IMMUNOGENETICS, V50, P220, DOI 10.1007/s002510050596; Allen RL, 1999, J IMMUNOL, V162, P5045; Alvarez I, 2001, J BIOL CHEM, V276, P32729, DOI 10.1074/jbc.M104663200; APARICIO P, 1987, J EXP MED, V165, P428, DOI 10.1084/jem.165.2.428; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; Boisgerault F, 1996, J CLIN INVEST, V98, P2764, DOI 10.1172/JCI119102; BREWERTON DA, 1973, LANCET, V2, P996, DOI 10.1016/S0140-6736(73)91091-X; BREWERTON DA, 1973, LANCET, V1, P904; BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709; CALVO V, 1990, J IMMUNOL, V144, P4038; CHOO SY, 1988, HUM IMMUNOL, V21, P209; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; Colbert RA, 2000, J RHEUMATOL, V27, P1107; DAMATO M, 1995, EUR J IMMUNOL, V25, P3199, DOI 10.1002/eji.1830251133; Edwards JCW, 2000, IMMUNOL TODAY, V21, P256, DOI 10.1016/S0167-5699(00)01625-X; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; ELZAATARI FAK, 1990, J IMMUNOL, V144, P1512; Fiorillo MT, 2000, J CLIN INVEST, V106, P47, DOI 10.1172/JCI9295; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Galocha B, 1996, TISSUE ANTIGENS, V48, P509, DOI 10.1111/j.1399-0039.1996.tb02664.x; Gao XM, 1996, EUR J IMMUNOL, V26, P1443, DOI 10.1002/eji.1830260707; Griffin TA, 1997, J IMMUNOL, V159, P4887; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HERMANN E, 1993, LANCET, V342, P646, DOI 10.1016/0140-6736(93)91760-J; Kuon W, 2001, J IMMUNOL, V167, P4738, DOI 10.4049/jimmunol.167.8.4738; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LOPEZ D, 1994, J IMMUNOL, V152, P5557; LOPEZLARREA C, 1995, TISSUE ANTIGENS, V45, P169, DOI 10.1111/j.1399-0039.1995.tb02436.x; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; Marina A, 1999, J MASS SPECTROM, V34, P17, DOI 10.1002/(SICI)1096-9888(199901)34:1<17::AID-JMS746>3.3.CO;2-Y; MAZIARZ RT, 1986, IMMUNOGENETICS, V24, P206; Mear JP, 1999, J IMMUNOL, V163, P6665; Paradela A, 2000, J IMMUNOL, V164, P329, DOI 10.4049/jimmunol.164.1.329; Paradela A, 1998, J IMMUNOL, V161, P5481; PARHAM P, 1983, J BIOL CHEM, V258, P6179; PARHAM P, 1995, IMMUNOL REV, V143, P141, DOI 10.1111/j.1600-065X.1995.tb00674.x; PARHAM P, 1994, TISSUE ANTIGENS, V43, P302, DOI 10.1111/j.1399-0039.1994.tb02344.x; PARKER KC, 1994, BIOCHEMISTRY-US, V33, P7736, DOI 10.1021/bi00190a029; Reinelt S, 2001, J BIOL CHEM, V276, P18472, DOI 10.1074/jbc.M101282200; ROJO S, 1987, J IMMUNOL, V139, P3396; Simmons WA, 1997, J IMMUNOL, V159, P2750; Smith KJ, 1996, IMMUNITY, V4, P215, DOI 10.1016/S1074-7613(00)80430-6; STAM NJ, 1986, J IMMUNOL, V137, P2299; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; TAUROG JD, 1988, J CLIN INVEST, V82, P987, DOI 10.1172/JCI113708; Taurog JD, 1999, IMMUNOL REV, V169, P209; TAUROG JD, 1999, J IMMUNOL, V163, P5741; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VILCHES C, 1994, IMMUNOGENETICS, V40, P166, DOI 10.1007/BF00188185; VILLADANGOS JA, 1994, J IMMUNOL, V152, P2317; VILLADANGOS JA, 1995, EUR J IMMUNOL, V25, P2370, DOI 10.1002/eji.1830250837; WHELAN MA, 1993, EUR J IMMUNOL, V23, P3278, DOI 10.1002/eji.1830231233; Yague J, 1998, TISSUE ANTIGENS, V52, P416, DOI 10.1111/j.1399-0039.1998.tb03067.x; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941; Zhou M, 1998, J EXP MED, V188, P877, DOI 10.1084/jem.188.5.877	57	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48740	48747		10.1074/jbc.M108882200	http://dx.doi.org/10.1074/jbc.M108882200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11673468	hybrid			2022-12-25	WOS:000173922100018
J	Fatma, N; Singh, DP; Shinohara, T; Chylack, LT				Fatma, N; Singh, DP; Shinohara, T; Chylack, LT			Transcriptional regulation of the antioxidant protein 2 gene, a thiol-specific antioxidant, by lens epithelium-derived growth factor to protect cells from oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; HEAT-SHOCK; MAMMALIAN PEROXIREDOXIN; CLONING; EXPRESSION; LEDGF; P52; PURIFICATION; MECHANISM; SURVIVAL	Antioxidant protein 2 (AOP2), a member of the newly defined family of thiol-specific antioxidant proteins, has been shown to remove H2O2 and protect proteins and DNA from oxidative stress. Here we report that LEDGF is one of the regulatory factors for the AOP2 gene. We found that LEDGF bound to the heat shock element and to stress-related elements in the AOP2 promoter. It trans-activated expression of AOP2-CAT in COS-7 cells and lens epithelial cells overexpressing LEDGF. Mutations in the heat shock element and stress-related elements of the AOP2 promoter reduced LEDGF-dependent trans-activation. Lens epithelial cells showed a higher level of AOP2 mRNA in the presence of LEDGF. Cells overexpressing LEDGF exhibited a higher level of AOP2 protein, the level of which was directly related to the increase in cellular protection. Thus, LEDGF, by activating the AOP2 gene, protected and enhanced the survival of cells under oxidative stress.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Ophthalm Res,Dept Ophthalmol,Dept Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Chylack, LT (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Ophthalm Res,Dept Ophthalmol,Dept Surg, 221 Longwood Ave,LMRC 103A, Boston, MA 02115 USA.	LTCHYLACK@RICS.BWH.HARVARD.EDU		Shinohara, Toshimichi/0000-0002-7197-9039				ANDLEY U, 1999, PRINCIPLES PRACTICE, P1428; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CRAIG EA, 1992, MOL CELLULAR BIOL YE, P501; Fatma N, 2000, INVEST OPHTH VIS SCI, V41, P2648; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; ISHII T, 1993, J BIOL CHEM, V268, P18633; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kimura A, 2000, J BIOL CHEM, V275, P1152, DOI 10.1074/jbc.275.2.1152; Lim MJ, 1998, GENE, V216, P197, DOI 10.1016/S0378-1119(98)00290-X; LIM YS, 1993, BIOCHEM BIOPH RES CO, V192, P273, DOI 10.1006/bbrc.1993.1410; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; Machida S, 2001, INVEST OPHTH VIS SCI, V42, P1087; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Munz B, 1997, BIOCHEM J, V326, P579, DOI 10.1042/bj3260579; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Ofuji K, 2000, JPN J OPHTHALMOL, V44, P1, DOI 10.1016/S0021-5155(99)00168-9; Peshenko IV, 1996, FEBS LETT, V381, P12, DOI 10.1016/0014-5793(96)00071-3; Phelan SA, 1998, GENOMICS, V54, P132, DOI 10.1006/geno.1998.5568; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; PROSPERI MT, 1994, GENOMICS, V19, P236, DOI 10.1006/geno.1994.1053; Reddy VN, 1997, OPHTHALMOLOGICA, V211, P192, DOI 10.1159/000310788; RHEE SG, 1994, MOL CELLS, V4, P137; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Sharma P, 2000, BIOCHEM BIOPH RES CO, V276, P1320, DOI 10.1006/bbrc.2000.3606; SHAU HG, 1994, IMMUNOGENETICS, V40, P129; Singh DP, 2000, BIOCHEM BIOPH RES CO, V267, P373, DOI 10.1006/bbrc.1999.1979; Singh DP, 1999, INVEST OPHTH VIS SCI, V40, P1444; Singh DP, 2000, GENE, V242, P265, DOI 10.1016/S0378-1119(99)00506-5; Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441	42	119	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48899	48907		10.1074/jbc.M100733200	http://dx.doi.org/10.1074/jbc.M100733200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11677226	hybrid			2022-12-25	WOS:000173922100037
J	Huang, CC; Liang, YC; Hsu, KS				Huang, CC; Liang, YC; Hsu, KS			Characterization of the mechanism underlying the reversal of long term potentiation by low frequency stimulation at hippocampal CA1 synapses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RECEPTOR GLUR1 SUBUNIT; RAT HIPPOCAMPUS; GLUTAMATE RECEPTORS; SYNAPTIC RESPONSES; IN-VITRO; PHOSPHORYLATION SITES; PHOSPHATASE-ACTIVITY; DENTATE GYRUS; OKADAIC ACID	Reversal of long term potentiation (LTP) may function to increase the flexibility and storage capacity of neuronal circuits; however, the underlying mechanisms remain incompletely understood. We show that depotentiation induced by low frequency stimulation (LFS) (2 Hz, 10 min, 1200 pulses) was input-specific and dependent on N-methyl-D-aspartate (NMDA) receptor activation. The ability of LFS to reverse LTP was mimicked by a brief application of NMDA. This NMDA-induced depotentiation was blocked by adenosine A(1) receptor antagonist. However, the reversal of LTP by LFS was unaffected by metabotropic glutamate receptor antagonism. This LFS-induced depotentiation was specifically prevented by protein phosphatase (PP) I inhibitors, okadaic acid, and calyculin A but not by the PP2A or PP2B inhibitors. Furthermore, by using phosphorylation site-specific antibodies, we found that LFS-induced depotentiation is associated with a persistent dephosphorylation of the GluR1 subunit of amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor at serine 831, a protein kinase C and calcium/calmodulin-dependent protein kinase II (CaMKII) substrate, but not at serine 845, a substrate of cAMP-dependent protein kinase. This effect was mimicked by bath-applied adenosine or NMDA and was specifically prevented by okadaic acid. Also, the increased phosphorylation of CaMKII at threonine 286 and the decreased PP activity seen with LTP were overcome by LFS, adenosine, or NMDA application. These results suggest that LFS erases LTP through an NMDA receptor-mediated activation of PPI to dephosphorylate amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and CaMKII in the CA1 region of the hippocampus.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan	National Cheng Kung University	Hsu, KS (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 1 Ta Hsieu Rd, Tainan 701, Taiwan.		Hsu, Kuei-Sen/AAV-8386-2021					ARAI A, 1990, NEUROSCI LETT, V119, P41, DOI 10.1016/0304-3940(90)90750-4; Bahr BA, 1997, J NEUROSCI, V17, P1320; BARR DS, 1995, J NEUROSCI, V15, P5402; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BARRIONUEVO G, 1980, LIFE SCI, V27, P2385, DOI 10.1016/0024-3205(80)90509-3; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P265, DOI 10.1016/0014-2999(93)91009-C; BASHIR ZI, 1994, EXP BRAIN RES, V100, P437, DOI 10.1007/BF02738403; BASHIR ZI, 1992, EUR J NEUROSCI, V4, P485, DOI 10.1111/j.1460-9568.1992.tb00898.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burette F, 1997, J NEUROPHYSIOL, V78, P1155, DOI 10.1152/jn.1997.78.2.1155; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DUNWIDDIE T, 1978, J PHYSIOL-LONDON, V276, P353, DOI 10.1113/jphysiol.1978.sp012239; Froc DJ, 2000, J NEUROSCI, V20, P438, DOI 10.1523/JNEUROSCI.20-01-00438.2000; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; Fujii S, 1997, EUR J PHARMACOL, V331, P9, DOI 10.1016/S0014-2999(97)01024-8; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; Hastie CJ, 1998, FEBS LETT, V431, P357, DOI 10.1016/S0014-5793(98)00775-3; Hensch TK, 1998, J NEUROSCI, V18, P2108; Holscher C, 1997, EUR J PHARMACOL, V322, P155, DOI 10.1016/S0014-2999(96)01000-X; Huang CC, 1999, J PHYSIOL-LONDON, V520, P783, DOI 10.1111/j.1469-7793.1999.00783.x; Huang CC, 1999, J NEUROSCI, V19, P9728; Huang CC, 2001, REV NEUROSCIENCE, V12, P51; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; LARSON J, 1993, BRAIN RES, V600, P97, DOI 10.1016/0006-8993(93)90406-D; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; LISMAN JE, 1993, P NATL ACAD SCI USA, V86, P9574; Lu YF, 1996, BRAIN RES, V729, P142, DOI 10.1016/0006-8993(96)00568-9; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; MANZONI OJ, 1994, SCIENCE, V265, P2089; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; O'Dell T J, 1994, Learn Mem, V1, P129; OMARA SM, 1995, NEUROSCIENCE, V68, P621, DOI 10.1016/0306-4522(95)00233-9; OMARA SM, 1995, NEUROPHARMACOLOGY, V34, P983, DOI 10.1016/0028-3908(95)00062-B; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Sanes JR, 1999, NAT NEUROSCI, V2, P597, DOI 10.1038/10154; SELIG DK, 1995, J NEUROPHYSIOL, V74, P1075, DOI 10.1152/jn.1995.74.3.1075; SHINOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; STAUBLI U, 1990, BRAIN RES, V513, P113, DOI 10.1016/0006-8993(90)91096-Y; Staubli U, 1996, LEARN MEMORY, V3, P96, DOI 10.1101/lm.3.2-3.96; Staubli U, 1998, J NEUROSCI, V18, P3460; Staubli U, 1996, J NEUROSCI, V16, P853; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; WAGNER JJ, 1995, J NEUROSCI, V15, P1577; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; Zhuo M, 1999, P NATL ACAD SCI USA, V96, P4650, DOI 10.1073/pnas.96.8.4650	53	126	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48108	48117		10.1074/jbc.M106388200	http://dx.doi.org/10.1074/jbc.M106388200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11679581	hybrid			2022-12-25	WOS:000172927000051
J	Hu, ZB; Gomes, I; Horrigan, SK; Kravarusic, J; Mar, B; Arbieva, Z; Chyna, B; Fulton, N; Edassery, S; Raza, A; Westbrook, CA				Hu, ZB; Gomes, I; Horrigan, SK; Kravarusic, J; Mar, B; Arbieva, Z; Chyna, B; Fulton, N; Edassery, S; Raza, A; Westbrook, CA			A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31	ONCOGENE			English	Article						tumor suppressor; nuclear protein; 5qNCA; leukemia; zinc finger; jmjC domain	COMMONLY DELETED REGION; MOLECULAR DELINEATION; 1A LGMD1A; HAIRLESS; MYELODYSPLASIA; ABNORMALITIES; DIAGNOSIS; DELETIONS; SEQUENCE; INTERVAL	Interstitial deletion or loss of chromosome 5, del(5q) or -5, is a frequent finding in myeloid leukemias and myelodysplasias, suggesting the presence of a tumor suppressor gene within the deleted region. In our search for this gene, we identified a candidate, 5qNCA (LOC51780), which lies within a consistently-deleted segment of 5q31. 5qNCA expresses a 7.2-kb transcript with a 5286-bp open reading frame which is present at high levels in heart, skeletal muscle, kidney, placenta, and liver as well as CD34+ cells and AML cell lines. 5qNCA encodes a 191-kD nuclear protein which contains a highly-conserved C-terminus containing a zinc finger with the unique spacing Cys-X2-Cys-X7-His-X2-Cys-X2-Cys-X4-Cys-X2-Cys and a jmjC domain, which is often found in proteins that regulate chromatin remodeling. Expression of 5qNCA in a del(5q) cell line results in suppression of clonogenic growth. Preliminary sequence results in AML and MDS samples and cell lines has revealed a possible mutation in the KG-1 cell line resulting in a THR to ALA substitution that has not been found in over 100 normal alleles to date. We propose 5qNCA is a good candidate for the del(5q) tumor suppressor gene based on its predicted function and growth suppressive activities, and suggest that further mutational and functional study of this interesting gene is warranted.	Univ Illinois, Dept Med, Hematol Oncol Sect, Chicago, IL 60607 USA; Avalon Pharmaceut, Gaithersburg, MD USA; Rush Canc Inst, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University	Westbrook, CA (corresponding author), Univ Illinois, Dept Med, Hematol Oncol Sect, M-C 734,900 S Ashland, Chicago, IL 60607 USA.	cwcw@uic.edu		Mar, Brenton/0000-0002-3857-9324	NATIONAL CANCER INSTITUTE [P01CA075606, R01CA072593] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-72593, P01-CA-75606] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartoloni L, 1998, GENOMICS, V54, P250, DOI 10.1006/geno.1998.5579; Brandt JE, 1999, BLOOD, V94, P106, DOI 10.1182/blood.V94.1.106.413k01_106_113; Christiansen H, 1996, PLANT MOL BIOL, V32, P809, DOI 10.1007/BF00020479; Cichon S, 1998, HUM MOL GENET, V7, P1671, DOI 10.1093/hmg/7.11.1671; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Fairman J, 1996, BLOOD, V88, P2259, DOI 10.1182/blood.V88.6.2259.bloodjournal8862259; FAIRMAN J, 1995, P NATL ACAD SCI USA, V92, P7406, DOI 10.1073/pnas.92.16.7406; Fenaux P, 1996, SEMIN HEMATOL, V33, P127; Frazer KA, 1997, GENOME RES, V7, P495, DOI 10.1101/gr.7.5.495; FURLEY AJ, 1986, BLOOD, V68, P1101; GALLAGHER R, 1979, BLOOD, V54, P713; HOOG C, 1991, MOL REPROD DEV, V30, P173, DOI 10.1002/mrd.1080300302; Horrigan SK, 2000, BLOOD, V95, P2372, DOI 10.1182/blood.V95.7.2372.007k20_2372_2377; Horrigan SK, 1999, GENOMICS, V57, P24, DOI 10.1006/geno.1999.5765; Horrigan SK, 1996, BLOOD, V88, P2665, DOI 10.1182/blood.V88.7.2665.bloodjournal8872665; Hu ZB, 2000, BLOOD, V95, P1047, DOI 10.1182/blood.V95.3.1047.003k43_1047_1055; Lai F, 2000, GENOMICS, V70, P123, DOI 10.1006/geno.2000.6345; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LEBEAU MM, 1993, CANC SURVEYS, V15, P143; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Mao EJ, 1998, J ORAL PATHOL MED, V27, P297; NAGARAJAN L, 1995, LEUKEMIA LYMPHOMA, V17, P361, DOI 10.3109/10428199509056846; Panteleyev AA, 1998, J INVEST DERMATOL, V110, P902, DOI 10.1046/j.1523-1747.1998.00219.x; PEDERSEN B, 1993, ANTICANCER RES, V13, P1913; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; ROWLEY JD, 1981, BLOOD, V58, P759; SAMUELS BL, 1988, LEUKEMIA, V2, P79; SCHIFFER CA, 1989, BLOOD, V73, P263; Steube KG, 1997, LEUKEMIA LYMPHOMA, V25, P345, DOI 10.3109/10428199709114174; Thompson CC, 1996, J NEUROSCI, V16, P7832; Westbrook CA, 2000, BRIT J HAEMATOL, V110, P847, DOI 10.1046/j.1365-2141.2000.02285.x; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xie H, 2000, LEUKEMIA, V14, P2128, DOI 10.1038/sj.leu.2401935; Zhao ND, 1997, P NATL ACAD SCI USA, V94, P6948, DOI 10.1073/pnas.94.13.6948	34	61	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6946	6954		10.1038/sj.onc.1204850	http://dx.doi.org/10.1038/sj.onc.1204850			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687974				2022-12-25	WOS:000171641000016
J	Li, DL; Turi, TG; Schuck, A; Freedberg, IM; Khitrov, G; Blumenberg, M				Li, DL; Turi, TG; Schuck, A; Freedberg, IM; Khitrov, G; Blumenberg, M			Rays and arrays: the transcriptional program in the response of human epidermal keratinocytes to UVB illumination	FASEB JOURNAL			English	Article						aging; cornified envelope; DNA repair; IL-8; skin	NF-KAPPA-B; PROTEIN-KINASE PATHWAYS; GENE-EXPRESSION; DNA-DAMAGE; ULTRAVIOLET-LIGHT; C-JUN; GROWTH-FACTOR; HUMAN SKIN; IN-VIVO; POSTTRANSCRIPTIONAL REGULATION	The epidermis, our first line of defense from ultraviolet (UV) light, bears the majority of photodamage, which results in skin thinning, wrinkling, keratosis, and malignancy. Hypothesizing that skin has specific mechanisms to protect itself and the organism from UV damage, we used DNA arrays to follow UV-caused gene expression changes in epidermal keratinocytes. Of the 6,800 genes examined, UV regulates the expression of at least 198. Three waves of changes in gene expression can be distinguished, 0.5-2, 4-8, and 16-24 h after illumination. The first contains transcription factors, signal transducing, and cytoskeletal proteins that change cell phenotype from a normal, fast-growing cell to an activated, paused cell. The second contains secreted growth factors, cytokines, and chemokines; keratinocytes, having changed their own physiology, alert the surrounding tissues to the UV damage. The third wave contains components of the cornified envelope, as keratinocytes enhance the epidermal protective covering and, simultaneously, terminally differentiate and die, removing a carcinogenic threat. UV also induces the expression of mitochondrial proteins that provide additional energy, and the enzymes that synthesize raw materials for DNA repair. Using a novel skin organ culture model, we demonstrated that the UV-induced changes detected in keratinocyte cultures also occur in human epidermis in vivo.	NYU, Sch Med, RO Perelman Dept Dermatol, New York, NY 10016 USA; Pfizer Inc, Div Cent Res, Groton, CT 06340 USA; NYU, Sch Med, Kaplan Canc Res Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA	New York University; Pfizer; New York University; New York University; New York University	Blumenberg, M (corresponding author), NYU, Sch Med, RO Perelman Dept Dermatol, 550 1st Ave, New York, NY 10016 USA.	blumem01@med.nyu.edu						ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Alhonen L, 1998, J BIOL CHEM, V273, P1964, DOI 10.1074/jbc.273.4.1964; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Aragane Y, 1997, P NATL ACAD SCI USA, V94, P11490, DOI 10.1073/pnas.94.21.11490; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8; Beissert S, 1999, J INVEST DERM SYMP P, V4, P61, DOI 10.1038/sj.jidsp.5640183; Bernerd F, 1999, P NATL ACAD SCI USA, V96, P11329, DOI 10.1073/pnas.96.20.11329; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; De Matteis MA, 2000, J CELL SCI, V113, P2331; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fujisawa H, 1997, J INTERF CYTOK RES, V17, P347, DOI 10.1089/jir.1997.17.347; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GARMYN M, 1995, DERMATOLOGY, V190, P305, DOI 10.1159/000246722; GEISER T, 1993, J BIOL CHEM, V268, P15419; Gilchrest BA, 1995, PHOTODAMAGE; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Hanada K, 1998, J INVEST DERMATOL, V111, P582, DOI 10.1046/j.1523-1747.1998.00342.x; HERRLICH P, 1994, ADV ENZYME REGUL, V34, P381, DOI 10.1016/0065-2571(94)90024-8; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; IYER V, 1998, SCIENCE, V283, P17; JIANG CK, 1994, MOL CELL BIOL, V14, P4759, DOI 10.1128/MCB.14.7.4759; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KEMENY L, 1995, INT ARCH ALLERGY IMM, V106, P351, DOI 10.1159/000236866; Kennedy M, 1997, INVEST OPHTH VIS SCI, V38, P2483; Komine M, 2001, J INVEST DERMATOL, V116, P330, DOI 10.1046/j.1523-1747.2001.01249.x; Komine M, 2000, J BIOL CHEM, V275, P32077, DOI 10.1074/jbc.M001253200; KREIS T, 1999, GUIDEBOOK CYTSKELETA; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; MOSER B, 1993, BIOCHEM J, V294, P285, DOI 10.1042/bj2940285; Niu M, 2000, CELL ADHES COMMUN, V7, P311, DOI 10.3109/15419060009015002; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2000, CURR OPIN GENET DEV, V10, P100, DOI 10.1016/S0959-437X(99)00046-5; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; SIMON MM, 1994, J INVEST DERMATOL, V102, P422, DOI 10.1111/1523-1747.ep12372194; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARANI J, 1993, AM J PATHOL, V142, P189; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Zhang MC, 1999, MOL CELL BIOL, V19, P7314; Zhuang LH, 2000, J INTERF CYTOK RES, V20, P445, DOI 10.1089/10799900050023852	66	106	111	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2533	+		10.1096/fj.01-0172fje	http://dx.doi.org/10.1096/fj.01-0172fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641260				2022-12-25	WOS:000171372700022
J	Maillet, L; Collart, MA				Maillet, L; Collart, MA			Interaction between Not1p, a component of the Ccr4-Not complex, a global regulator of transcription, and Dhh1p, a putative RNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; DIFFERENTIALLY AFFECTS; PROTEIN; YEAST; IDENTIFICATION; PROMOTERS	The Ccr4-Not complex is a global regulator of transcription that affects genes positively and negatively and is thought to regulate transcription factor IID function. Two components of this complex, Caf1p and Ccr4p, are directly involved in mRNA deadenylation, and Caf1p is associated with Dhh1p, a putative RNA helicase thought to be a component of the decapping complex. In this work, we tried to determine whether Dhh1p, might interact with the Ccr4-Not complex. We found that, first, not mutations displayed severe synthetic phenotypes when combined with a dhh1-null mutation. Second, overexpression of Not1p was toxic in dhh1-null cells. Third, a not mutant phenotype was suppressed by deletion of DHH1 and mimicked by overexpression of DHH1. Fourth, dhh1-null mutants displayed resistance to heat shock, a phenotype observed for all mutants that affect the Ccr4-Not complex. Finally, like Caf1p and Ccr4p, Dhh1p co-immunoprecipitated with the nonessential N-terminal domain of Not1p, and the levels of Caf1p and Dhh1p were dependent upon this Not1p domain. Taken together, our results suggest that the Ccr4-Not complex, via the N-terminal region of Not1p, is necessary for the maintenance of stable cellular levels of Dhh1p and Caf1p, thus contributing to regulation of mRNA decay in addition to transcription.	Univ Geneva, Sch Med, Dept Med Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Collart, MA (corresponding author), Univ Geneva, Sch Med, Dept Med Biochem, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.		MAILLET, Laurent/K-7959-2015	MAILLET, Laurent/0000-0002-8169-060X; Collart, Martine/0000-0001-6955-1773				Badarinarayana V, 2000, GENETICS, V155, P1045; Bai YL, 1999, MOL CELL BIOL, V19, P6642; Benson JD, 1998, EMBO J, V17, P6714, DOI 10.1093/emboj/17.22.6714; Chang MP, 1999, MOL CELL BIOL, V19, P1056; COLLART MA, 1993, EMBO J, V12, P177, DOI 10.1002/j.1460-2075.1993.tb05643.x; Collart MA, 1996, MOL CELL BIOL, V16, P6668; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; de la Cruz J, 1998, EMBO J, V17, P1128, DOI 10.1093/emboj/17.4.1128; DENIS CL, 1984, GENETICS, V108, P833; DENIS CL, 1990, GENETICS, V124, P283; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; Hata H, 1998, GENETICS, V148, P571; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Lemaire M, 2000, J BIOL CHEM, V275, P26925; Liu HY, 2001, J BIOL CHEM, V276, P7541, DOI 10.1074/jbc.M009112200; Liu HY, 1997, EMBO J, V16, P5289, DOI 10.1093/emboj/16.17.5289; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Maillet L, 2000, J MOL BIOL, V303, P131, DOI 10.1006/jmbi.2000.4131; Oberholzer U, 1998, GENE, V207, P61, DOI 10.1016/S0378-1119(97)00605-7; SAKAI A, 1992, NUCLEIC ACIDS RES, V20, P6227, DOI 10.1093/nar/20.23.6227; STRAHLBOLSINGER S, 1993, YEAST, V9, P429, DOI 10.1002/yea.320090414; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009	25	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2835	2842		10.1074/jbc.M107979200	http://dx.doi.org/10.1074/jbc.M107979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11696541	Green Published, hybrid			2022-12-25	WOS:000173421500062
J	Hogan, BP; Hartsch, T; Erie, DA				Hogan, BP; Hartsch, T; Erie, DA			Transcript cleavage by Thermus thermophilus RNA polymerase. Effects of GreA and anti-GreA factors.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TERNARY COMPLEXES; ELONGATION-FACTOR; II ELONGATION; CHAIN ELONGATION; GENOME SEQUENCE; DNA HYBRID; DISTINCT; PROTEIN; STABILITY	All known multisubunit RNA polymerases possess the ability to endonucleolytically degrade the nascent RNA transcript. To gain further insight into the conformational changes that govern transcript cleavage, we have examined the effects of certain anions on the intrinsic transcript cleavage activity of Thermus thermophilus RNA polymerase. Our results indicate that the conformational transitions involved in transcript cleavage, and therefore backtracking, are anion-dependent. In addition to characterizing the intrinsic cleavage activity of T. thermophilus RNA polymerase, we have identified, cloned, and expressed a homolog of the prokaryotic transcript cleavage factor GreA from the extreme thermophiles, T. thermophilus and Thermus aquaticus. The thermostable GreA factors contact the 3'-end of RNA, stimulate the intrinsic cleavage activity of T. thermophilus :RNA polymerase, and increase the k(app) of the cleavage reaction 25-fold. In addition, we have identified a novel transcription factor in T. thermophilus and T. aquaticus that shares a high degree of sequence similarity with GreA, but has several residues that are not conserved with the N-terminal "basic patch" region of GreA. This protein, Gfh1, functions as an anti-GreA factor in vitro by reducing intrinsic cleavage and competing with GreA for a binding site on the polymerase.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Inst Microbiol & Genet, Gottingen Genom Lab, D-37077 Gottingen, Germany	University of North Carolina; University of North Carolina Chapel Hill	Erie, DA (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.				NIGMS NIH HHS [R29 GM54136] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054136] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Chan CL, 1997, J MOL BIOL, V268, P37, DOI 10.1006/jmbi.1997.0934; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; KATO R, 1993, J BIOCHEM-TOKYO, V114, P926, DOI 10.1093/oxfordjournals.jbchem.a124278; Kireeva ML, 2000, J BIOL CHEM, V275, P6530, DOI 10.1074/jbc.275.9.6530; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Koulich D, 1998, J MOL BIOL, V276, P379, DOI 10.1006/jmbi.1997.1545; Koulich D, 1997, J BIOL CHEM, V272, P7201, DOI 10.1074/jbc.272.11.7201; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; Kulish D, 2000, J BIOL CHEM, V275, P12789, DOI 10.1074/jbc.275.17.12789; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; Loizos N, 1999, J BIOL CHEM, V274, P23378, DOI 10.1074/jbc.274.33.23378; Marr MT, 2000, MOL CELL, V6, P1275, DOI 10.1016/S1097-2765(00)00126-X; Minakhin L, 2001, J BACTERIOL, V183, P71, DOI 10.1128/JB.183.1.71-76.2001; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; Nolling J, 2001, J BACTERIOL, V183, P4823, DOI 10.1128/JB.183.16.4823-4838.2001; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Palangat M, 2001, J MOL BIOL, V311, P265, DOI 10.1006/jmbi.2001.4842; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINES D, 1992, J BIOL CHEM, V267, P3795; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; Toulme F, 2000, EMBO J, V19, P6853, DOI 10.1093/emboj/19.24.6853; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; WNENDT S, 1990, EUR J BIOCHEM, V191, P467, DOI 10.1111/j.1432-1033.1990.tb19145.x; Xue Y, 2000, BIOCHEMISTRY-US, V39, P14356, DOI 10.1021/bi0012538; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	37	32	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					967	975		10.1074/jbc.M108737200	http://dx.doi.org/10.1074/jbc.M108737200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11606592	hybrid			2022-12-25	WOS:000173166800015
J	Kang, HY; Schneider, H; Rudd, CE				Kang, HY; Schneider, H; Rudd, CE			Phosphatidylinositol 3-kinase p85 adaptor function in T-cells. Co-stimulation and regulation of cytokine transcription independent of associated p110.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHOINOSITIDE 3-KINASE; DISTINCT ROLES; PI 3-KINASE; CD28; ACTIVATION; BINDING; WORTMANNIN; PATHWAYS; MEMBRANE	Phosphatidylinositol 3-kinase (PI3K) is a key regulator of a variety of cellular functions from cytoskeletal organization, vesicular trafficking, and cell proliferation to apoptosis. The enzyme complex is comprised of an 85-kDa adaptor (p85) coupled to a 110-kDa catalytic subunit (p110). While the function of PI3K has been largely attributed to the generation of D-3 lipids, an unanswered question has been whether p85 with a number of motifs (SH2, SH3, Bell homology (1311) region) can generate independent intracellular signals. In this study, we demonstrate that p85 lacking p110 (Deltap85) can activate NFAT transcription in T-cell hybridomas and normal splenocytes. This up-regulatory effect was unaffected by inhibition of PI 3-kinase, and cooperated specifically with Rac1, but not related family members. Stimulation correlated with Rac1 binding and was lost with the deletion of the BH domain. Lastly, the CD28-Deltap85 chimera also cooperated with TcR/CD3 to provide co-signals that enhanced IL-2 transcription. Our findings identify for the first time p85 as an adaptor that operates independently of the classic PI 3-kinase catalytic pathway and further shows that this pathway can provide co-signals in the regulation of T-cell function.	Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Haematol, London W12 0NN, England	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Imperial College London	Rudd, CE (corresponding author), Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.	c.rudd@ic.ac.uk	Rudd, Christopher E/ABF-7259-2021; Rudd, Christopher E/GOH-2021-2022	Rudd, Christopher E/0000-0001-5295-9019				Beeton C A, 1999, Mol Cell Biol Res Commun, V1, P153, DOI 10.1006/mcbr.1999.0124; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; CAI YC, 1995, IMMUNITY, V3, P417, DOI 10.1016/1074-7613(95)90171-X; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; Cefai D, 1996, INT IMMUNOL, V8, P1609, DOI 10.1093/intimm/8.10.1609; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Courjal F, 1997, GENOMICS, V44, P242, DOI 10.1006/geno.1997.4871; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; EXLEY M, 1994, J BIOL CHEM, V269, P15140; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; Gold MR, 2000, IMMUNOL REV, V176, P47; Gringhuis SI, 1998, MOL CELL BIOL, V18, P1725, DOI 10.1128/MCB.18.3.1725; Harada Y, 2001, J IMMUNOL, V166, P3797, DOI 10.4049/jimmunol.166.6.3797; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; HUTCHCROFT JE, 1994, P NATL ACAD SCI USA, V91, P3260, DOI 10.1073/pnas.91.8.3260; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Lafont V, 2000, FEBS LETT, V486, P38, DOI 10.1016/S0014-5793(00)02235-3; LINSLEY PS, 1995, J EXP MED, V182, P289, DOI 10.1084/jem.182.2.289; LU YL, 1995, EUR J IMMUNOL, V25, P533, DOI 10.1002/eji.1830250234; Marshall AJ, 2000, IMMUNOL REV, V176, P30; Nolte RT, 1996, NAT STRUCT BIOL, V3, P364, DOI 10.1038/nsb0496-364; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Okkenhaug K, 2001, NAT IMMUNOL, V2, P325, DOI 10.1038/86327; Pages F, 1996, J BIOL CHEM, V271, P9403, DOI 10.1074/jbc.271.16.9403; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Reif K, 1997, CURR BIOL, V7, P285, DOI 10.1016/S0960-9822(06)00151-5; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rudd CE, 1996, IMMUNITY, V4, P527, DOI 10.1016/S1074-7613(00)80479-3; Schneider H, 2001, EUR J IMMUNOL, V31, P2042, DOI 10.1002/1521-4141(200107)31:7<2042::AID-IMMU2042>3.0.CO;2-D; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; THOMPSON CB, 1995, CELL, V81, P979, DOI 10.1016/S0092-8674(05)80001-7; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; TRUITT KE, 1995, J IMMUNOL, V155, P4702; UEDA Y, 1995, INT IMMUNOL, V7, P957, DOI 10.1093/intimm/7.6.957; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WARD SG, 1995, EUR J IMMUNOL, V25, P526, DOI 10.1002/eji.1830250233; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	65	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					912	921		10.1074/jbc.M107648200	http://dx.doi.org/10.1074/jbc.M107648200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11679587	hybrid			2022-12-25	WOS:000173166800008
J	Mengerink, KJ; Moy, GW; Vacquier, VD				Mengerink, KJ; Moy, GW; Vacquier, VD			suREJ3, a polycystin-1 protein, is cleaved at the GPS domain and localizes to the acrosomal region of sea urchin sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY-DISEASE GENE; ALPHA-LATROTOXIN; POLYACRYLAMIDE GELS; COUPLED RECEPTORS; MEMBRANE-PROTEIN; PKD1; EXOCYTOSIS; SEQUENCE; CHANNEL; FAMILY	The sea urchin sperm acrosome reaction (AR) is a prerequisite for sperm-egg fusion. This report identifies sea urchin sperm receptor for egg jelly-3 (suREJ3) as a new member of the polycystin-1 family (the protein mutated in autosomal dominant polycystic kidney disease). suREJ3 is a multidomain, 2,681-amino acid, heavily glycosylated orphan receptor with 11 putative transmembrane segments (TMS) that localize to the plasma membrane covering the sperm acrosomal vesicle. Like the latrophilins and other members of the secretin family of G-protein-coupled receptors, suREJ3 is cleaved at the consensus GPS (G-protein-coupled receptor proteolytic site) domain. Antibodies to the extracellular 1,455-residue NH2-terminal portion identify a band at 250 kDa that shifts in electrophoretic mobility to 180 kDa upon glycosidase digestion. Antibodies to the 1,226-residue COOH-terminal portion identify a band at 150 kDa that shifts to 140 kDa after glycosidase treatment. Antibodies to both portions of suREJ3 localize exclusively to the plasma membrane over the acrosomal vesicle. Immunoprecipitation shows that both portions of suREJ3 are associated in detergent extracts. This is the first report showing that a polycystin family member is cleaved at the GPS domain. Localization of suREJ3 to the acrosomal region provides the first suggestion for the role of a polycystin-1 protein (components of nonselective cation channels) in a specific cellular process.	Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Mengerink, KJ (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA.				NICHD NIH HHS [HD12986] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012986, R01HD012986] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Alves AP, 1998, GLYCOBIOLOGY, V8, P939, DOI 10.1093/glycob/8.9.939; Barr MM, 1999, NATURE, V401, P386, DOI 10.1038/43916; Barr MM, 2001, CURR BIOL, V11, P1341, DOI 10.1016/S0960-9822(01)00423-7; Bateman A, 1999, CURR BIOL, V9, pR588, DOI 10.1016/S0960-9822(99)80380-7; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; Calvet JP, 2001, SEMIN NEPHROL, V21, P107, DOI 10.1053/snep.2001.20929; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; CUELLARMATA P, 1995, DEV GROWTH DIFFER, V37, P173; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Gray JX, 1996, J IMMUNOL, V157, P5438; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Harris PC, 1999, HUM MOL GENET, V8, P1861, DOI 10.1093/hmg/8.10.1861; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hlubek MD, 2000, MOL PHARMACOL, V57, P519, DOI 10.1124/mol.57.3.519; Hosono M, 1999, BBA-GEN SUBJECTS, V1472, P668, DOI 10.1016/S0304-4165(99)00185-3; Hughes J, 1999, HUM MOL GENET, V8, P543, DOI 10.1093/hmg/8.3.543; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; KELLER SH, 1994, DEV GROWTH DIFFER, V36, P551; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; Matsushita H, 1999, FEBS LETT, V443, P348, DOI 10.1016/S0014-5793(99)00005-8; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OZEKI Y, 1991, BIOCHEMISTRY-US, V30, P2391, DOI 10.1021/bi00223a014; Ponting CP, 1999, CURR BIOL, V9, pR585, DOI 10.1016/S0960-9822(99)80379-0; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Sandford R, 1997, HUM MOL GENET, V6, P1483, DOI 10.1093/hmg/6.9.1483; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Schulz JR, 1997, DEV BIOL, V191, P80, DOI 10.1006/dbio.1997.8712; Schulz JR, 1998, J BIOL CHEM, V273, P24355, DOI 10.1074/jbc.273.38.24355; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Tateno H, 1998, J BIOL CHEM, V273, P19190, DOI 10.1074/jbc.273.30.19190; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; Vacquier VD, 1997, DEV BIOL, V192, P125, DOI 10.1006/dbio.1997.8729; VACQUIER VD, 1986, METHOD CELL BIOL, V27, P15, DOI 10.1016/S0091-679X(08)60340-4; WARD CJ, 1994, CELL, V77, P881	52	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					943	948		10.1074/jbc.M109673200	http://dx.doi.org/10.1074/jbc.M109673200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11696547	hybrid			2022-12-25	WOS:000173166800012
J	Stemmer, C; Schwander, A; Bauw, G; Fojan, P; Grasser, KD				Stemmer, C; Schwander, A; Bauw, G; Fojan, P; Grasser, KD			Protein kinase CK2 differentially phosphorylates maize chromosomal high mobility group B (HMGB) proteins modulating their stability and DNA interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; ARCHITECTURAL ELEMENTS; REGIONS FLANKING; ACIDIC TAIL; BINDING; DOMAIN; CHROMATIN; ARABIDOPSIS; RECOGNITION; EXPRESSION	The high mobility group (HMG) proteins of the HMGB family are architectural factors in eukaryotic chromatin, which are involved in the regulation of various DNA-dependent processes. We have examined the post-translational modifications of five HMGB proteins from maize suspension cultured cells, revealing that HMGB1 and HMGB2/3, but not HMGB4 and HMGB5, are phosphorylated by protein kinase CK2. The phosphorylation sites have been mapped to the acidic C-terminal domains by analysis of tryptic peptides derive in HMGB1 and HMGB2/3 using nanospray ion trap mass spectrometry. In native HMGB1, Ser(149) is constitutively phosphorylated, whereas Ser(133) and Ser(136) are differentially phosphorylated. The functional significance of the CK2-mediated phosphorylation of HMGB proteins was analyzed by circular dichroism measurements showing that the phosphorylation increases the thermal stability of the HMGB proteins. Electrophoretic mobility shift assays demonstrate that the phosphorylation reduces the affinity of the HMGB proteins for linear DNA. The specific recognition of DNA minicircles is not affected by the phosphorylation, but a different pattern of protein-DNA complexes is formed. Collectively, these findings show that phosphorylation of residues within the acidic C-terminal domain of the HMGB proteins can modulate protein stability and the DNA binding properties of the HMGB proteins.	Univ Aalborg, Dept Life Sci, DK-9000 Aalborg, Denmark; Univ Freiburg, Inst Biol 3, D-79104 Freiburg, Germany	Aalborg University; University of Freiburg	Grasser, KD (corresponding author), Univ Aalborg, Dept Life Sci, Sohngaardsholmsvej 49, DK-9000 Aalborg, Denmark.			Fojan, Peter/0000-0002-0626-4766				ALONSO JC, 1995, J BIOL CHEM, V270, P2938, DOI 10.1074/jbc.270.7.2938; BOLDYREFF B, 1993, BIOCHIM BIOPHYS ACTA, V1173, P32, DOI 10.1016/0167-4781(93)90239-A; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Creighton T. E., 1993, PROTEINS STRUCTURES; DOBROWOLSKA G, 1992, EUR J BIOCHEM, V204, P299, DOI 10.1111/j.1432-1033.1992.tb16637.x; EINCK L, 1985, EXP CELL RES, V156, P295, DOI 10.1016/0014-4827(85)90539-7; GRASSER KD, 1989, BIOCHEM BIOPH RES CO, V162, P456, DOI 10.1016/0006-291X(89)92019-6; Grasser KD, 1998, TRENDS PLANT SCI, V3, P260, DOI 10.1016/S1360-1385(98)01259-X; Grasser KD, 1996, J BIOL CHEM, V271, P32900, DOI 10.1074/jbc.271.51.32900; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; Hidalgo P, 2001, PLANT PHYSIOL, V125, P396, DOI 10.1104/pp.125.1.396; KLIMCZAK LJ, 1994, PLANT PHYSIOL, V105, P911, DOI 10.1104/pp.105.3.911; Lee KB, 2000, J MOL BIOL, V304, P135, DOI 10.1006/jmbi.2000.4206; Lee Y, 1999, PLANT PHYSIOL, V119, P989, DOI 10.1104/pp.119.3.989; Lichota J, 2001, BIOCHEMISTRY-US, V40, P7860, DOI 10.1021/bi010548y; Ogueta S, 2000, J MASS SPECTROM, V35, P556; OLIVEBERG M, 1994, BIOCHEMISTRY-US, V33, P8826, DOI 10.1021/bi00195a026; Payet D, 1997, J MOL BIOL, V266, P66, DOI 10.1006/jmbi.1996.0782; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Riera M, 2001, PLANT J, V25, P365, DOI 10.1046/j.1365-313x.2001.00973.x; Ritt C, 1998, BIOCHEMISTRY-US, V37, P2673, DOI 10.1021/bi972620r; Ritt C, 1998, PLANT J, V14, P623, DOI 10.1046/j.1365-313X.1998.00154.x; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; Sickmann A, 2001, ELECTROPHORESIS, V22, P1669, DOI 10.1002/1522-2683(200105)22:9<1669::AID-ELPS1669>3.0.CO;2-7; Stemmer C, 1999, PLANT MOL BIOL, V41, P351, DOI 10.1023/A:1006311121717; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; Sugano S, 1999, P NATL ACAD SCI USA, V96, P12362, DOI 10.1073/pnas.96.22.12362; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Travers A, 2000, CURR OPIN STRUC BIOL, V10, P102, DOI 10.1016/S0959-440X(99)00056-1; van Holde KE., 1989, SPRINGER SERIES MOL; Webb M, 2001, J MOL BIOL, V309, P79, DOI 10.1006/jmbi.2001.4667; Wisniewski JR, 1999, J BIOL CHEM, V274, P20116; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; WISNIEWSKI JR, 1994, EUR J BIOCHEM, V225, P687, DOI 10.1111/j.1432-1033.1994.00687.x; Yen YM, 1998, J BIOL CHEM, V273, P4424, DOI 10.1074/jbc.273.8.4424; Yoshioka K, 1999, BIOCHEMISTRY-US, V38, P589, DOI 10.1021/bi981834l	38	76	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1092	1098		10.1074/jbc.M109503200	http://dx.doi.org/10.1074/jbc.M109503200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694523	hybrid			2022-12-25	WOS:000173166800029
J	daCosta, CJB; Ogrel, AA; McCardy, EA; Blanton, MP; Baenziger, JE				daCosta, CJB; Ogrel, AA; McCardy, EA; Blanton, MP; Baenziger, JE			Lipid-protein interactions at the nicotinic acetylcholine receptor - A functional coupling between nicotinic receptors and phosphatidic acid-containing lipid bilayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED DIFFERENCE SPECTROSCOPY; EXCHANGE-RESISTANT CORE; SECONDARY STRUCTURE; RECONSTITUTED MEMBRANES; NONCOMPETITIVE ANTAGONIST; ION-CHANNEL; CHOLESTEROL; PHOSPHOLIPIDS; DYNAMICS; STATES	The structural and functional properties of reconstituted nicotinic acetylcholine receptor membranes composed of phosphatidyl choline either with or without cholesterol and/or phosphatidic acid have been examined to test the hypothesis that receptor conformational equilibria are modulated by the physical properties of the surrounding lipid environment. Spectroscopic and chemical labeling data indicate that the receptor in phosphatidylcholine alone is stabilized in a desensitized-like state, whereas the presence of either cholesterol or phosphatidic acid favors a resting-like conformation. Membranes that effectively stabilize a resting-like state exhibit a relatively large proportion of non-hydrogen-bonded lipid ester carbonyls, suggesting a relatively tight packing of the lipid head groups and thus a well ordered membrane. Functional reconstituted membranes also exhibit gel-to-liquid crystal phase transition temperatures that are higher than those of nonfunctional reconstituted membranes composed of phosphatidylcholine alone. Significantly, incorporation of the receptor into phosphatidic acid-containing membranes leads to a dramatic increase in both the lateral packing densities and the gel-to-liquid crystal phase transition temperatures of the reconstituted lipid bilayers. These results suggest a functional link between the nicotinic acetylcholine receptor and the physical properties of phosphatidic acid-containing membranes that could underlie the mechanism by which this lipid preferentially enhances receptor function.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Texas Tech Univ, Hlth Sci Ctr, Dept Anesthesiol, Lubbock, TX 79430 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol, Lubbock, TX 79430 USA	University of Ottawa; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Baenziger, JE (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.			Baenziger, John/0000-0002-2888-5328	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035786] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35786] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUGER M, 1990, J AM CHEM SOC, V112, P1373, DOI 10.1021/ja00160a013; Baenziger JE, 1999, BIOCHEMISTRY-US, V38, P4905, DOI 10.1021/bi990181l; Baenziger JE, 2000, J BIOL CHEM, V275, P777, DOI 10.1074/jbc.275.2.777; BAENZIGER JE, 1992, BIOPHYS J, V61, P983, DOI 10.1016/S0006-3495(92)81905-7; BAENZIGER JE, 1992, BIOCHEMISTRY-US, V31, P3377, DOI 10.1021/bi00128a011; BAENZIGER JE, 1995, J BIOL CHEM, V270, P29129, DOI 10.1074/jbc.270.49.29129; BARRANTES FJ, 1989, CRIT REV BIOCHEM MOL, V24, P437, DOI 10.3109/10409238909086961; BHUSHAN A, 1993, BIOPHYS J, V64, P716, DOI 10.1016/S0006-3495(93)81431-0; Blanton MP, 2000, J BIOL CHEM, V275, P3469, DOI 10.1074/jbc.275.5.3469; BLUME A, 1988, BIOCHEMISTRY-US, V27, P8239, DOI 10.1021/bi00421a038; BUTLER DH, 1993, BIOCHIM BIOPHYS ACTA, V1150, P17, DOI 10.1016/0005-2736(93)90116-H; Chiara DC, 2001, BIOCHEMISTRY-US, V40, P296, DOI 10.1021/bi0021481; CRIADO M, 1982, BIOCHEMISTRY-US, V21, P3622, DOI 10.1021/bi00258a015; CRIADO M, 1984, J BIOL CHEM, V259, P9188; ELLENA JF, 1983, BIOCHEMISTRY-US, V22, P5523, DOI 10.1021/bi00293a012; FERNANDEZBALLESTER G, 1994, BIOCHEMISTRY-US, V33, P4065, DOI 10.1021/bi00179a035; FONG TM, 1987, BIOCHEMISTRY-US, V26, P3871, DOI 10.1021/bi00387a020; FONG TM, 1986, BIOCHEMISTRY-US, V25, P830, DOI 10.1021/bi00352a015; Gil T, 1998, BBA-REV BIOMEMBRANES, V1376, P245, DOI 10.1016/S0304-4157(98)00022-7; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; HUBNER W, 1991, BIOPHYS J, V59, P1261, DOI 10.1016/S0006-3495(91)82341-4; MARSH D, 1978, P NATL ACAD SCI USA, V75, P4329, DOI 10.1073/pnas.75.9.4329; MCCARTHY MP, 1992, J BIOL CHEM, V267, P7655; McNamee M., 1988, LIPID DOMAINS RELATI, P43; Mendelson R., 1986, PROGR PROTEIN LIPID, V2, P103; METHOT N, 1995, BIOCHEMISTRY-US, V34, P15142, DOI 10.1021/bi00046a021; Methot N, 1998, BIOCHEMISTRY-US, V37, P14815, DOI 10.1021/bi980848o; METHOT N, 1994, BIOCHEMISTRY-US, V33, P7709, DOI 10.1021/bi00190a026; Rankin SE, 1997, BIOPHYS J, V73, P2446, DOI 10.1016/S0006-3495(97)78273-0; Reid SE, 1996, SPECTROCHIM ACTA A, V52, P1347, DOI 10.1016/0584-8539(96)01718-7; Ryan SE, 1996, J BIOL CHEM, V271, P24590, DOI 10.1074/jbc.271.40.24590; Ryan SE, 1999, MOL PHARMACOL, V55, P348, DOI 10.1124/mol.55.2.348; SEELIG J, 1978, BIOCHEMISTRY-US, V17, P3310, DOI 10.1021/bi00609a021; SUNSHINE C, 1994, BBA-BIOMEMBRANES, V1191, P59, DOI 10.1016/0005-2736(94)90233-X; WHITE BH, 1992, J BIOL CHEM, V267, P15770	35	95	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					201	208		10.1074/jbc.M108341200	http://dx.doi.org/10.1074/jbc.M108341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11682482	hybrid			2022-12-25	WOS:000173087900028
J	Guibal, FC; Moog-Lutz, C; Smolewski, P; Di Gioia, Y; Darzynkiewicz, Z; Lutz, PG; Cayre, YE				Guibal, FC; Moog-Lutz, C; Smolewski, P; Di Gioia, Y; Darzynkiewicz, Z; Lutz, PG; Cayre, YE			ASB-2 inhibits growth and promotes commitment in myeloid leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; PML-RAR-ALPHA; LASER-SCANNING CYTOMETRY; INDUCED DIFFERENTIATION; MOLECULAR PATHOGENESIS; HISTONE DEACETYLASE; HL-60 CELLS; STEM-CELLS; PROTEIN	In acute promyelocytic leukemia (APL) cells harboring the promyelocytic leukemia retinoic acid receptor alpha (PML-RARalpha) chimeric protein, retinoic acid (RA)-induced differentiation is triggered through a PML-RARa signaling resulting in activation of critical target genes. Induced differentiation of APL cells is always preceded by withdrawal from the cell cycle and commitment events leading to terminal differentiation. Here we have identified the human ankyrin repeat-containing protein with a suppressor of cytokine signaling box-2 (ASB-2) cDNA, as a novel RA-induced gene in APL cells. PML/RARalpha strongly enhanced RA-induced ASB-2 mRNA expression. In myeloid leukemia cells, ASB-2 expression induced growth inhibition and chromatin condensation recapitulating early events critical to RA-induced differentiation of APL cells.	Hop St Antoine, Unite INSERM U417, F-75012 Paris, France; New York Med Coll, Brander Canc Res Inst, Hawthorne, NY 10532 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Immunol Microbiol, Philadelphia, PA 19107 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; New York Medical College; Jefferson University	Cayre, YE (corresponding author), Hop St Antoine, Unite INSERM U417, 184 Rue Faubourg St Antoine, F-75012 Paris, France.		MOOG-LUTZ, Christel/F-1975-2011; Lutz, Pierre/B-8822-2009	Lutz, Pierre/0000-0003-0590-9101; Smolewski, Piotr/0000-0003-2700-3343; Darzynkiewicz, Zbigniew/0000-0002-2040-7081	NCI NIH HHS [R01 CA028704, R01 CA028704-25] Funding Source: Medline; PHS HHS [R0-128704] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bedner E, 1997, CYTOMETRY, V29, P191, DOI 10.1002/(SICI)1097-0320(19971101)29:3<191::AID-CYTO1>3.3.CO;2-3; Begley CG, 1999, BLOOD, V93, P1443, DOI 10.1182/blood.V93.5.1443.405a31_1443_1447; Botling J, 1997, J BIOL CHEM, V272, P9443; Brooks SC, 1997, EXP CELL RES, V234, P259, DOI 10.1006/excr.1997.3620; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHOMIENNE C, 1990, BLOOD, V76, P1710; COLE RD, 1987, INT J PEPT PROT RES, V30, P433; Cook DM, 1996, ONCOGENE, V13, P1789; Darzynkiewicz Z, 1999, EXP CELL RES, V249, P1, DOI 10.1006/excr.1999.4477; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; DERMIME S, 1993, BLOOD, V82, P1573; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; GORCZYCA W, 1992, INT J ONCOL, V1, P639; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Juan G, 1998, EXP CELL RES, V244, P83, DOI 10.1006/excr.1998.4165; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kastner P, 2001, BLOOD, V97, P1314, DOI 10.1182/blood.V97.5.1314; Kile BT, 2000, GENE, V258, P31, DOI 10.1016/S0378-1119(00)00402-9; LANOTTE M, 1991, BLOOD, V77, P1080; Li X, 2000, EXP CELL RES, V255, P125, DOI 10.1006/excr.1999.4796; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LOWENBERG B, 1993, BLOOD, V81, P281; Lutz PG, 2001, BLOOD, V97, P2449, DOI 10.1182/blood.V97.8.2449; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; Miyauchi J, 1997, BLOOD, V90, P803, DOI 10.1182/blood.V90.2.803.803_803_813; Moog-Lutz C, 2001, J BIOL CHEM, V276, P22375, DOI 10.1074/jbc.M011683200; Reddy GPV, 1997, BLOOD, V90, P2293; SOKOLOSKI JA, 1991, LEUKEMIA RES, V15, P1051, DOI 10.1016/0145-2126(91)90111-6; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSIFTSOGLOU AS, 1985, CANCER RES, V45, P2334; TUCKER KA, 1987, BLOOD, V70, P372; TURHAN AG, 1995, BLOOD, V85, P2154, DOI 10.1182/blood.V85.8.2154.bloodjournal8582154; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	47	69	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					218	224		10.1074/jbc.M108476200	http://dx.doi.org/10.1074/jbc.M108476200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11682484	Green Published, hybrid			2022-12-25	WOS:000173087900030
J	Kwon, K; Stivers, JT				Kwon, K; Stivers, JT			Fluorescence spectroscopy studies of vaccinia type IB DNA topoisomerase - Closing of the enzyme clamp is faster than DNA cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETIC-ANALYSIS; ABASIC SITES; DUPLEX DNA; MECHANISM; 2-AMINOPURINE; LIGATION; CONTACTS; BASE	The prototypic type IB topoisomerase isolated from vaccinia virus cleaves the phosphodiester backbone of duplex DNA at the sequence 5'-(C/T)CCTT, forming a covalent 3'-phosphotyrosyl adduct. A precleavage conformational change in which the enzyme clamps circumferentially around the DNA has been implicated on the basis of structural and biochemical studies. However, no direct measurements to elucidate this key step have been obtained to date. To address this shortcoming we have developed two new fluorescence assays that allow detection of conformational changes in both the enzyme and substrate DNA, and allow determination of the thermodynamic and kinetic mechanism for noncovalent DNA binding and phosphodiester cleavage. The results indicate that clamp closing occurs in a rapid step (>25 s(-1)) that is at least 14-fold faster than the maximal rate of DNA cleavage. Opening of the clamp to release the noncovalently bound substrate is also 5-8-fold more rapid than DNA cleavage. We propose a model in which DNA cleavage and religation are connected through a single high energy transition state involving covalent bond breaking. Alternative models that involve a slow precleavage conformational step are not easily reconciled with the available data.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University	Stivers, JT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.							Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; Cheng CH, 2000, NUCLEIC ACIDS RES, V28, P1893, DOI 10.1093/nar/28.9.1893; Hwang Y, 1999, VIROLOGY, V262, P479, DOI 10.1006/viro.1999.9920; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P61; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Kwon K, 2002, J BIOL CHEM, V277, P353, DOI 10.1074/jbc.M109450200; Law SM, 1996, BIOCHEMISTRY-US, V35, P12329, DOI 10.1021/bi9614545; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Petersen BO, 1996, J MOL BIOL, V263, P181, DOI 10.1006/jmbi.1996.0568; Petersen BO, 1997, NUCLEIC ACIDS RES, V25, P2091, DOI 10.1093/nar/25.11.2091; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P946, DOI 10.1021/bi001664o; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P957, DOI 10.1021/bi001665g; SEKIGUCHI J, 1994, NUCLEIC ACIDS RES, V22, P5360, DOI 10.1093/nar/22.24.5360; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; Sekiguchi J, 1997, J BIOL CHEM, V272, P15721, DOI 10.1074/jbc.272.25.15721; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P29760; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; Stivers JT, 1998, NUCLEIC ACIDS RES, V26, P3837, DOI 10.1093/nar/26.16.3837; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Stivers JT, 1997, BIOCHEMISTRY-US, V36, P5212, DOI 10.1021/bi962880t; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001	27	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					345	352		10.1074/jbc.M109449200	http://dx.doi.org/10.1074/jbc.M109449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11689572	hybrid			2022-12-25	WOS:000173087900046
J	Visser, F; Vickers, MF; Ng, AML; Baldwin, SA; Young, JD; Cass, CE				Visser, F; Vickers, MF; Ng, AML; Baldwin, SA; Young, JD; Cass, CE			Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NITROBENZYLTHIOINOSINE BINDING; FUNCTIONAL EXPRESSION; SPECIES-DIFFERENCES; MOLECULAR-CLONING; INTRACELLULAR MEMBRANES; CULTURED-CELLS; XENOPUS-LAEVIS; HIGH-AFFINITY; ADENOSINE	Human equilibrative nucleoside transporters (hENT) I and 2 differ in that hENT1 is inhibited by nanomolar concentrations of dipyridamole and dilazep, whereas hENT2 is 2 and 3 orders of magnitude less sensitive, respectively. When a yeast expression plasmid containing the hENT1 cDNA was randomly mutated and screened by phenotypic complementation in Saccharomyces cerevisiae to identify mutants with reduced sensitivity to dilazep, clones with a point mutation that converted Met(33) to Ile (hENT1-M33I) were obtained. Characterization of the mutant protein in S. cerevisiae and Xenopus laevis oocytes revealed that the mutant had less than one-tenth the sensitivity to dilazep and dipyridamole than wild type hENT1, with no change in nitrobenzylmercaptopurine ribonucleoside (NBMPR) sensitivity or apparent uridine affinity. To determine whether the reciprocal mutation in hENT2 (Ile 33 to Met) also altered sensitivity to dilazep and dipyridamole, hENT2-I33M was created by site-directed mutagenesis. Although the resulting mutant (hENT2-I33M) displayed >10-fold higher dilazep and dipyridamole sensitivity and >13-fold higher uridine affinity compared with wild type hENT2, it retained insensitivity to NBMPR These data established that mutation of residue 33 (Met versus Ile) of hENT1 and hENT2 altered the dilazep, and dipyridamole sensitivities in both proteins, suggesting that a common region of inhibitor interaction has been identified.	Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol Biol Membrane Prot, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Membrane Transport Grp, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Physiol, Edmonton, AB T6G 1Z2, Canada; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Leeds	Cass, CE (corresponding author), Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.		Cass, Carol E/F-5861-2010					Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; BRUNELLI JP, 1993, YEAST, V9, P1309, DOI 10.1002/yea.320091204; CASS CE, 1999, MEMBRANE TRANSPORTER, V12, P313; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; GATI WP, 1989, MOL PHARMACOL, V36, P134; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HAMMOND JR, 1991, MOL PHARMACOL, V39, P771; Hammond JR, 2000, N-S ARCH PHARMACOL, V361, P373, DOI 10.1007/s002100000214; HARLEY ER, 1982, CANCER RES, V42, P1289; HOGUE DL, 1990, BIOCHEM CELL BIOL, V68, P199, DOI 10.1139/o90-026; Hogue DL, 1996, J BIOL CHEM, V271, P9801, DOI 10.1074/jbc.271.16.9801; Hogue DL, 1997, BIOCHEM BIOPH RES CO, V238, P811, DOI 10.1006/bbrc.1997.7400; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; JARVIS SM, 1982, BIOCHEM J, V208, P83, DOI 10.1042/bj2080083; JARVIS SM, 1982, J PHYSIOL-LONDON, V324, P31, DOI 10.1113/jphysiol.1982.sp014099; JARVIS SM, 1986, MOL PHARMACOL, V30, P659; JARVIS SM, 1983, BIOCHEM J, V216, P661, DOI 10.1042/bj2160661; Jennings LL, 1998, DRUG DEVELOP RES, V45, P277, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<277::AID-DDR26>3.0.CO;2-7; Kiss A, 2000, BIOCHEM J, V352, P363, DOI 10.1042/0264-6021:3520363; KOREN R, 1983, BIOCHEM J, V216, P299, DOI 10.1042/bj2160299; Mackey JR, 1998, DRUG RESIST UPDATE, V1, P310, DOI 10.1016/S1368-7646(98)80047-2; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Osses N, 1996, BIOCHEM J, V317, P843, DOI 10.1042/bj3170843; PATERSON ARP, 1980, MOL PHARMACOL, V18, P40; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V969, P1, DOI 10.1016/0167-4889(88)90081-X; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; Ritzel MWL, 1998, MOL MEMBR BIOL, V15, P203; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHI MM, 1986, BIOCHEM J, V240, P879, DOI 10.1042/bj2400879; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; Sundaram M, 2001, BIOCHEMISTRY-US, V40, P8146, DOI 10.1021/bi0101805; VANBELLE H, 1993, CARDIOVASC RES, V27, P68; Vickers MF, 2000, J BIOL CHEM, V275, P25931, DOI 10.1074/jbc.M000239200; Vickers MF, 1999, BIOCHEM J, V339, P21, DOI 10.1042/0264-6021:3390021; VICKERS MF, 2000, EMERGING THERAPEUTIC, V4, P515; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 2001, MOL MEMBR BIOL, V18, P161, DOI 10.1080/09687680110048318; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	48	112	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					395	401		10.1074/jbc.M105324200	http://dx.doi.org/10.1074/jbc.M105324200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11689555	hybrid			2022-12-25	WOS:000173087900053
J	Deng, H; Callender, R; Howell, E				Deng, H; Callender, R; Howell, E			Vibrational structure of dihydrofolate bound to R67 dihydrofolate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE EVIDENCE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ACTIVE-SITE; MECHANISM; PROTEIN; SPECTROSCOPY; CONSTRUCTION; SUBSTRATE; CATALYSIS	R67 is a Type H dihydrofolate reductase (DHFR) that catalyzes the reduction of dihydrofolate (DHF) to tetrahydrofolate by facilitating the addition of a proton to N5 of DHF and the transfer of a hydride ion from NADPH to C6. Because this enzyme is a plasmid-encoded DHFR from trimethoprim-resistant bacteria, extensive studies on R67 with various methods have been performed to elucidate its reaction mechanism. Here, Raman difference measurements, conducted on the ternary complex of R67(.)NADP(+.)DHF believed to be an accurate mimic of the productive DHFR(.)NADPH(.)DHF complex, show that the pK(alpha), of N5 in the complex is less than 4. This is in clear contrast to the behavior observed in Escherichia coli DHFR, a substantially more efficient enzyme, where the pK(alpha), of bound DHF at N5 is increased to 6.5 compared with its solution value of 2.6. A comparison of the ternary complexes in R67 and E. coli DHFRs suggests that enzymic raising of the pK(alpha). at N5 can significantly increase the catalytic efficiency of the hydride transfer step. However, R67 shows that even without such a strategy an effective DHFR can still be designed.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Univ Tennessee, Dept Biochem Mol & Cell Biol, Knoxville, TN 37966 USA	Yeshiva University; Albert Einstein College of Medicine; University of Tennessee System; University of Tennessee Knoxville	Deng, H (corresponding author), Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA.			Howell, Elizabeth/0000-0001-6157-433X	NIGMS NIH HHS [GM35183] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035183] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blakley R L, 1995, Adv Enzymol Relat Areas Mol Biol, V70, P23; BLAKLEY RL, 1993, ARCH BIOCHEM BIOPHYS, V306, P501, DOI 10.1006/abbi.1993.1543; Bradrick TD, 1996, BIOCHEMISTRY-US, V35, P11414, DOI 10.1021/bi960205d; CALLENDER R, 1994, ANNU REV BIOPH BIOM, V23, P215, DOI 10.1146/annurev.bb.23.060194.001243; Cannon WR, 1997, J AM CHEM SOC, V119, P2386, DOI 10.1021/ja962621r; CHEN YQ, 1994, BIOCHEMISTRY-US, V33, P7021, DOI 10.1021/bi00189a001; Deng H, 1998, J AM CHEM SOC, V120, P7730, DOI 10.1021/ja9814974; Deng H, 2000, J BIOL CHEM, V275, P30139, DOI 10.1074/jbc.M004464200; DionSchultz A, 1997, PROTEIN ENG, V10, P263, DOI 10.1093/protein/10.3.263; FIERKE CA, 1987, BIOCHEMISTRY-US, V26, P4085, DOI 10.1021/bi00387a052; GREADY JE, 1985, BIOCHEMISTRY-US, V24, P4761, DOI 10.1021/bi00339a008; Hennig M, 1998, NAT STRUCT BIOL, V5, P357, DOI 10.1038/nsb0598-357; HOWELL EE, 1986, SCIENCE, V231, P1123, DOI 10.1126/science.3511529; HUENNEKENS F. M., 1964, P355; KRAUT J, 1987, BIOL MACROMOL ASSEM, V3, P1; Li DW, 2001, BIOCHEMISTRY-US, V40, P4242, DOI 10.1021/bi0026425; MAHARAJ G, 1990, BIOCHEMISTRY-US, V29, P4554, DOI 10.1021/bi00471a008; MATTHEWS DA, 1986, BIOCHEMISTRY-US, V25, P4194, DOI 10.1021/bi00363a005; MORRISON JF, 1988, BIOCHEMISTRY-US, V27, P5499, DOI 10.1021/bi00415a017; NARAYANA N, 1995, NAT STRUCT BIOL, V2, P1018, DOI 10.1038/nsb1195-1018; NICHOLS R, 1993, BIOCHEMISTRY-US, V32, P1695, DOI 10.1021/bi00058a002; Park HY, 1997, J BIOL CHEM, V272, P2252; REECE LJ, 1991, BIOCHEMISTRY-US, V30, P10895, DOI 10.1021/bi00109a013; SELINSKY BS, 1990, BIOCHEMISTRY-US, V29, P1290, DOI 10.1021/bi00457a026	24	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48956	48960		10.1074/jbc.M105107200	http://dx.doi.org/10.1074/jbc.M105107200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11679579	hybrid			2022-12-25	WOS:000173922100045
J	Escuyer, VE; Lety, MA; Torrelles, JB; Khoo, KH; Tang, JB; Rithner, CD; Frehel, C; McNeil, MR; Brennan, PJ; Chatterjee, D				Escuyer, VE; Lety, MA; Torrelles, JB; Khoo, KH; Tang, JB; Rithner, CD; Frehel, C; McNeil, MR; Brennan, PJ; Chatterjee, D			The role of the embA and embB gene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL; ARABINAN BIOSYNTHESIS; MASS-SPECTROMETRY; STRUCTURAL FEATURES; ETHAMBUTOL; TUBERCULOSIS; LIPOARABINOMANNAN; RESISTANCE; TRANSFORMATION; RHODOCOCCUS	The emb genes are conserved among different mycobacteria. In Mycobacterium smegmatis and Mycobacterium tuberculosis, they belong to an operon comprising three genes, embC, embA, and embB. The EmbB protein has been proposed to be the target of ethambutol, a drug which is known to inhibit the synthesis of the arabinan portion of the mycobacterial cell wall arabinogalactan (AG). To further define the role of EmbB protein in arabinan biosynthesis, embA, -B, and -C genes were inactivated individually by homologous recombination in M. smegmatis. All three mutants were viable, and among the three, the slowest growing embB(-) mutant encountered profound morphological changes and exhibited a higher sensitivity to hydrophobic drugs and detergents, presumably due to an increase in cell wall permeability. Furthermore, chemical analyses showed that there was a diminution in the arabinose content of arabinogalactan from the embA(-) and embB- mutants. Specific-ally, in comparison with the wild-type strain, the crucial terminal hexaarabinofuranosyl motif, which is a template for mycolylation, was altered in both embA- and embB-mutants. Detailed nuclear magnetic resonance studies coupled with enzyme digestion, chromatography, and mass spectrometry analyses revealed that the disaccharide beta-D-Ara(f)(1-->2)-alpha-D-Ara(f) extension from the 3-position of the 3,5-linked alpha-D-Ara(f) residue is markedly diminished. As a consequence, a linear terminal beta-D-Ara(f)(1-->2)-alpha-D-Ara(f)-(1-->5)-alpha-D-Ara(f)-(1-->5)-alpha-D-Ara(f) is formed, a motif which is a recognized, nonreducing terminal feature of lipoarabinomannan but not of normal AG. Upon complementation with the embB and embA wild-type genes, the phenotype of the mutants reverted to wildtype, in that normal AG was resynthesized. Our results clearly show that both EmbA and EmbB proteins are involved in the formation of the proper terminal hexaarabinofuranoside motif in AG, thus paving the way for future studies to identify the complete array of arabinosyltransferases involved in the synthesis of mycobacterial cell wall arabinan.	Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; INSERM U411, F-75723 Paris 15, France	Colorado State University; Colorado State University; Academia Sinica - Taiwan; Institut National de la Sante et de la Recherche Medicale (Inserm)	Escuyer, VE (corresponding author), Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA.	escuyer@sri.org; delphi@lamar.colostate.edu	Khoo, Kay-Hooi/E-1989-2019; Torrelles, Jordi/E-4204-2011; McNeil, Michael/G-3325-2019	Khoo, Kay-Hooi/0000-0003-2906-406X; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033706, R21AI037139, R01AI037139, P01AI046393, R01AI018357, R22AI018357, R37AI018357] Funding Source: NIH RePORTER; NIAID NIH HHS [P0I AI-46393, AI-37139, AI-33706, AI-18357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; CHATTERJEE D, 1992, INFECT IMMUN, V60, P1249, DOI 10.1128/IAI.60.3.1249-1253.1992; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DAFFE M, 1993, CARBOHYD RES, V249, P383, DOI 10.1016/0008-6215(93)84102-C; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; DELL A, 1994, METHOD ENZYMOL, V230, P108; DENG LY, 1995, ANTIMICROB AGENTS CH, V39, P694, DOI 10.1128/AAC.39.3.694; FREHEL C, 1987, J BACTERIOL, V169, P210, DOI 10.1128/jb.169.1.210-217.1987; GARBE TR, 1994, MICROBIOL-SGM, V140, P133, DOI 10.1099/13500872-140-1-133; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Khoo HH, 2001, J BIOL CHEM, V276, P3863, DOI 10.1074/jbc.M004010200; Khoo KH, 1996, J BIOL CHEM, V271, P28682, DOI 10.1074/jbc.271.45.28682; Lee RE, 1997, GLYCOBIOLOGY, V7, P1121, DOI 10.1093/glycob/7.8.1121; Lety MA, 1997, ANTIMICROB AGENTS CH, V41, P2629, DOI 10.1128/AAC.41.12.2629; Marienfeld S, 1997, ANTON LEEUW INT J G, V72, P291, DOI 10.1023/A:1000578811089; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; McNeil M, 1999, GENETICS OF BACTERIALS POLYSACCHARIDES, P207; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; MCNEIL MR, 1994, GLYCOBIOLOGY, V4, P165, DOI 10.1093/glycob/4.2.165; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; Nair S, 1999, MOL MICROBIOL, V31, P185, DOI 10.1046/j.1365-2958.1999.01159.x; Pelicic V, 1997, P NATL ACAD SCI USA, V94, P10955, DOI 10.1073/pnas.94.20.10955; Puech V, 2001, MICROBIOL-SGM, V147, P1365, DOI 10.1099/00221287-147-5-1365; Ramaswamy SV, 2000, ANTIMICROB AGENTS CH, V44, P326, DOI 10.1128/AAC.44.2.326-336.2000; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; Sambrook J., 1989, MOL CLONING, pA1; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Sreevatsan S, 1997, ANTIMICROB AGENTS CH, V41, P1677, DOI 10.1128/AAC.41.8.1677; Sutcliffe IC, 1997, VET MICROBIOL, V56, P287, DOI 10.1016/S0378-1135(97)00097-7; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; Telenti A, 1997, NAT MED, V3, P567, DOI 10.1038/nm0597-567; THIERY JP, 1967, J MICROSC-PARIS, V6, P987; TRIEUCUOT P, 1985, EMBO J, V4, P3583, DOI 10.1002/j.1460-2075.1985.tb04120.x; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328	37	138	148	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48854	48862		10.1074/jbc.M102272200	http://dx.doi.org/10.1074/jbc.M102272200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11677227	hybrid			2022-12-25	WOS:000173922100032
J	Song, MS; McHenry, CS				Song, MS; McHenry, CS			Carboxyl-terminal domain III of the delta ' subunit of DNA polymerase III holoenzyme binds DnaX and supports cooperative DnaX complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; ESCHERICHIA-COLI; ACCESSORY PROTEINS; CRYSTAL-STRUCTURE; SLIDING CLAMPS; GAMMA-SUBUNIT; IDENTIFICATION; LOADER; TAU; PURIFICATION	The delta' subunit of the DNA polymerase-Ill holoenzyme is a key component of the DnaX complex; it is required for loading the 13, processivity factor onto a primed template. The x-ray crystal structure of delta' indicates a three domain C-shaped structure (Guenther, B., Onrust, R., Sali, A., O'Donnell, M., and Kuriyan, J. (1997) Cell 91, 335-345). In this study, we localized the DnaX-binding domain of delta' to its carboxyl-terminal domain III by quantifying protein-protein interactions using a series of delta' fusion proteins lacking specific domains. The fusion protein corresponding to domain III of delta' bound to DnaX with an affinity approaching that of full-length delta'. In contrast, a construct bearing delta' domains I-II did not bind DnaX at detectable levels. The presence of 5 and chipsi strengthened the interaction of DnaX with full-length delta' and delta' domain III. Thus, domain III of delta' not only contains the DnaX-binding site, but also contains the elements required for positive cooperative assembly of the DnaX complex. A domain III-specific anti-delta' monoclonal antibody interfered with DnaX complex formation and abolished the replication activity of DNA polymerase III holoenzyme.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McHenry, CS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.				NIGMS NIH HHS [GM35695] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gao DX, 2001, J BIOL CHEM, V276, P4447, DOI 10.1074/jbc.M009827200; Gao DX, 2001, J BIOL CHEM, V276, P4433, DOI 10.1074/jbc.M009828200; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; Glover BP, 2001, J BIOL CHEM, V276, P35842, DOI 10.1074/jbc.M103719200; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; GUENTHER BD, 1996, THESIS ROCKEFELLER U; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim DR, 1996, J BIOL CHEM, V271, P20699, DOI 10.1074/jbc.271.34.20699; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCHENRY CS, 1989, MOL MECH DNA REPLICA, P115; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Neuwald AF, 1999, GENOME RES, V9, P27; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Song MS, 2001, J BIOL CHEM, V276, P40668, DOI 10.1074/jbc.M106373200; Song MS, 2001, J BIOL CHEM, V276, P35165, DOI 10.1074/jbc.M100389200; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; Uhlmann F, 1997, J BIOL CHEM, V272, P10065; Uhlmann F, 1997, J BIOL CHEM, V272, P10058	31	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48709	48715		10.1074/jbc.M107936200	http://dx.doi.org/10.1074/jbc.M107936200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11606586	hybrid			2022-12-25	WOS:000173922100014
J	Zhang, WJ; Frei, B				Zhang, WJ; Frei, B			alpha-lipoic acid inhibits TNF-alpha-induced NF-kappa B activation and adhesion molecule expression in human aortic endothelial cells	FASEB JOURNAL			English	Article						antioxidants; adhesion molecules; endothelium; nuclear factor kappa B	TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; E-SELECTIN; SIGNAL-TRANSDUCTION; LIPID-PEROXIDATION; DIHYDROLIPOIC ACID; ICAM-1 EXPRESSION; MONOCYTE ADHESION; REDOX REGULATION; CYTOKINE	Endothelial activation and monocyte adhesion are initiating steps in atherogenesis thought to be caused in part by oxidative stress. The metabolic thiol antioxidant alpha -lipoic acid has been suggested to be of therapeutic value in pathologies associated with redox imbalances. We investigated the role of (R)-alpha -lipoic acid (LA) vs. glutathione and ascorbic acid in tumor necrosis factor alpha (TNF-alpha)-induced adhesion molecule expression and nuclear factor kappaB (NF-kappaB) signaling in human aortic endothelial cells (HAEC). Preincubation of HAEC for 48 h with LA (0.05-1 mmol/l) dose-dependently inhibited TNF-alpha (10 U/ml) -induced adhesion of human monocytic THP-1 cells, as well as mRNA and protein expression of E-selectin, vascular cell adhesion molecule 1 and intercellular adhesion molecule 1. LA also strongly inhibited TNF-alpha -induced mRNA expression of monocyte chemoattractant protein-1 but did not affect expression of TNF-alpha receptor 1. Furthermore, LA dose-dependently inhibited TNF-alpha -induced I kappaB kinase activation, subsequent degradation of I kappaB, the cytoplasmic NF-kappaB inhibitor, and nuclear translocation of NF-kappaB. In contrast, TNF-alpha -induced NF-kappaB activation and adhesion molecule expression were not affected by ascorbic acid or by manipulating cellular glutathione status with L-2-oxo-4-thiazolidinecarboxylic acid, N-acetyl-L-cysteine, or D,L-buthionine-S,R-sulfoximine. Our data show that clinically relevant concentrations of LA, but neither vitamin C nor glutathione, inhibit adhesion molecule expression in HAEC and monocyte adhesion by inhibiting the I kappaB/NF-kappaB signaling pathway at the level, or upstream, of I kappaB kinase.	Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA	Oregon State University	Frei, B (corresponding author), Oregon State Univ, Linus Pauling Inst, 571 Weniger Hall, Corvallis, OR 97331 USA.	Balz.frei@orst.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060886, R01HL056170] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-60886, HL-56170] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Aoki T, 1996, AM J RESP CELL MOL, V15, P319, DOI 10.1165/ajrcmb.15.3.8810635; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BAST A, 1988, BIOCHIM BIOPHYS ACTA, V963, P558, DOI 10.1016/0005-2760(88)90326-8; BEVILACQUA MP, 1994, ANNU REV MED, V45, P361, DOI 10.1146/annurev.med.45.1.361; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; BRADLEY JR, 1993, AM J PATHOL, V142, P1598; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; CARLOS TM, 1994, BLOOD, V84, P2068; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DE CR, 1995, J CLIN INVEST, V96, P60; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIENER AM, 1985, J IMMUNOL, V135, P537; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; Friedrichs B, 1998, ARTERIOSCL THROM VAS, V18, P1829, DOI 10.1161/01.ATV.18.12.1829; HANDELMAN GJ, 1994, BIOCHEM PHARMACOL, V47, P1725, DOI 10.1016/0006-2952(94)90298-4; Haramaki N, 1997, FREE RADICAL BIO MED, V22, P535, DOI 10.1016/S0891-5849(96)00400-5; Hoare GS, 1999, AM J PHYSIOL-HEART C, V277, pH1975, DOI 10.1152/ajpheart.1999.277.5.H1975; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KAWAI M, 1995, J IMMUNOL, V154, P2333; Knowles JW, 2000, ARTERIOSCL THROM VAS, V20, P2336, DOI 10.1161/01.ATV.20.11.2336; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Lodge JK, 1998, FREE RADICAL BIO MED, V25, P287, DOI 10.1016/S0891-5849(98)00048-3; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MEYER GA, 1993, YELLOWSTONE SCI, V2, P2; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OU PM, 1995, BIOCHEM PHARMACOL, V50, P123, DOI 10.1016/0006-2952(95)00116-H; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; PETER G, 1995, ARZNEIMITTELFORSCH, V45-1, P293; POSTON RN, 1992, AM J PATHOL, V140, P665; RICHARDSON M, 1994, ARTERIOSCLER THROMB, V14, P760, DOI 10.1161/01.ATV.14.5.760; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Roy S, 1998, FREE RADICAL BIO MED, V25, P229, DOI 10.1016/S0891-5849(98)00062-8; ROYALL JA, 1992, ARCH BIOCHEM BIOPHYS, V294, P686, DOI 10.1016/0003-9861(92)90742-F; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHOLICH H, 1989, BIOCHIM BIOPHYS ACTA, V1001, P256, DOI 10.1016/0005-2760(89)90108-2; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, BIOCHEM BIOPH RES CO, V218, P148, DOI 10.1006/bbrc.1996.0026; SEN CK, 1996, OXIDATIVE STRESS CAN, P251; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAAL FJT, 1995, METHOD ENZYMOL, V252, P168; Suzuki YJ, 1995, BIOCHEM MOL BIOL INT, V36, P241; SUZUKI YJ, 1992, BIOCHEM BIOPH RES CO, V189, P1709, DOI 10.1016/0006-291X(92)90275-P; SUZUKI YJ, 1991, FREE RADICAL RES COM, V15, P255, DOI 10.3109/10715769109105221; SUZUKI YJ, 1995, BIOCHEM BIOPH RES CO, V210, P537, DOI 10.1006/bbrc.1995.1693; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; True AL, 2000, AM J PHYSIOL-LUNG C, V279, pL302, DOI 10.1152/ajplung.2000.279.2.L302; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WEBER C, 1994, ARTERIOSCLER THROMB, V14, P1665, DOI 10.1161/01.ATV.14.10.1665; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; Zhang WJ, 1997, ARTERIOSCL THROM VAS, V17, P465, DOI 10.1161/01.ATV.17.3.465; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	61	198	216	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2423	2432		10.1096/fj.01-0260com	http://dx.doi.org/10.1096/fj.01-0260com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689467				2022-12-25	WOS:000172420500012
J	von der Thusen, JH; Kuiper, J; Fekkes, ML; de Vos, P; van Berkel, TJC; Biessen, EAL				von der Thusen, JH; Kuiper, J; Fekkes, ML; de Vos, P; van Berkel, TJC; Biessen, EAL			Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr - /- Mice	FASEB JOURNAL			English	Article						adenoviral gene transfer; atherosclerosis; anti-inflammatory therapy; transgenic mice	TUMOR-NECROSIS-FACTOR; HUMORAL IMMUNE-RESPONSES; ATHEROSCLEROTIC PLAQUES; IL-10; EXPRESSION; ENDOTOXIN; RECEPTOR; CELL; INFLAMMATION; CHOLESTEROL	In view of its multifaceted anti-inflammatory properties, interleukin-10 (IL-10) has been deemed to be potentially anti-atherogenic. We have evaluated the capacity of adenoviral gene transfer of IL-10 for the modulation of de novo atherosclerotic lesion formation by systemic and by local overexpression. Atherogenesis was initiated in the carotid arteries of low-density lipoprotein receptor deficient mice by perivascular placement of silastic collars. One week after collar placement, mice were injected intravenously with 1 x 10(9) plaque-forming units (pfu's) of IL-10 (Ad.IL-10) or control adenovirus (Ad.empty). Administration of Ad.IL-10 resulted in extended systemic expression of IL-10 (peak serum level 3.0 +/- 1.1 ng/ml) and a reduction in atherosclerotic lumen stenosis by 62.2% (P<0.02). This finding was accompanied by monocyte deactivation and lowering of serum cholesterol levels (maximum decrease 44%). In a second experiment, collared arteries were transfected locally by transluminal instillation of adenovirus (titer 1.5x10(10) pfu/ml). Systemic parameters remained unchanged following local transfection, but the degree of stenosis was, nonetheless, decreased by 44.9% (P<0.05). We conclude that a marked inhibition of atherogenesis can be achieved by systemic overexpression of Ad.IL-10, owing to its metabolic and immunomodulatory effects. Local IL-10 transfer is virtually equipotent, however, and it may represent a valuable addition to the armory of antiatherosclerotic therapies.	Leiden Univ, Sylvius Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Biessen, EAL (corresponding author), Leiden Univ, Sylvius Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Wassenaarseweg 72,POB 9503, NL-2300 RA Leiden, Netherlands.	biessen@lacdr.leidenuniv.nl	Van Berkel, Theo/ABD-7677-2021	von der Thusen, Jan/0000-0001-9699-4860				Apostolopoulos J, 1996, ARTERIOSCL THROM VAS, V16, P1007, DOI 10.1161/01.ATV.16.8.1007; BARATH P, 1990, AM J CARDIOL, V65, P297, DOI 10.1016/0002-9149(90)90291-8; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; CLINTON SK, 1991, AM J PATHOL, V138, P1005; Feingold KR, 1996, J LIPID RES, V37, P223; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792; Gudmundsson G, 1998, AM J RESP CELL MOL, V19, P812, DOI 10.1165/ajrcmb.19.5.3153; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; Lalani I, 1997, ANN ALLERG ASTHMA IM, V79, P469, DOI 10.1016/S1081-1206(10)63052-9; Lee TS, 1999, ARTERIOSCL THROM VAS, V19, P734, DOI 10.1161/01.ATV.19.3.734; Lindner H, 1997, TRANSPLANTATION, V64, P1370, DOI 10.1097/00007890-199711150-00023; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1991, J EXP MED, V174, P915; Mallat Z, 1999, CIRC RES, V85, pE17, DOI 10.1161/01.RES.85.8.e17; Mallat Z, 1999, ARTERIOSCL THROM VAS, V19, P611, DOI 10.1161/01.ATV.19.3.611; MEMON RA, 1993, ENDOCRINOLOGY, V132, P2246, DOI 10.1210/en.132.5.2246; Minter RM, 2000, J IMMUNOL, V164, P443, DOI 10.4049/jimmunol.164.1.443; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; MOSMANN TR, 1994, ADV IMMUNOL, V56, P1, DOI 10.1016/S0065-2776(08)60449-6; Oslund LJP, 1999, ARTERIOSCL THROM VAS, V19, P2847, DOI 10.1161/01.ATV.19.12.2847; Reape TJ, 1999, ATHEROSCLEROSIS, V147, P213, DOI 10.1016/S0021-9150(99)00346-9; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SANDSTROM LP, 1993, ALCOHOL, V10, P303, DOI 10.1016/0741-8329(93)90010-L; Schieffer B, 2000, CIRCULATION, V101, P1372, DOI 10.1161/01.CIR.101.12.1372; Schreiber S, 2000, GASTROENTEROLOGY, V119, P1461, DOI 10.1053/gast.2000.20196; SEINO Y, 1994, CYTOKINE, V6, P87, DOI 10.1016/1043-4666(94)90013-2; Smith EM, 1999, J NEUROIMMUNOL, V100, P140, DOI 10.1016/S0165-5728(99)00206-4; Song S, 1997, BLOOD, V89, P4461, DOI 10.1182/blood.V89.12.4461; 't Hoen PAC, 2000, BIOCHEM PHARMACOL, V60, P1509; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; Terkeltaub RA, 1999, ARTERIOSCL THROM VAS, V19, P2823, DOI 10.1161/01.ATV.19.12.2823; Uyemura K, 1996, J CLIN INVEST, V97, P2130, DOI 10.1172/JCI118650; von der Thusen JH, 2001, CIRCULATION, V103, P1164, DOI 10.1161/01.CIR.103.8.1164; Werner W, 1971, Quad Sclavo Diagn, V7, P232; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995	38	138	140	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2730	+		10.1096/fj.01-0483fje	http://dx.doi.org/10.1096/fj.01-0483fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11687507				2022-12-25	WOS:000171920400002
J	Taimor, G; Rakow, A; Piper, HM				Taimor, G; Rakow, A; Piper, HM			Transcription activator protein 1 (AP-1) mediates NO-induced apoptosis of adult cardiomyocytes	FASEB JOURNAL			English	Article						c-Jun amino-terminal kinase; decoy-oligonucleotides; extracellular signal-regulated kinase	CARDIAC MYOCYTES; NITRIC-OXIDE; VENTRICULAR MYOCYTES; KINASE PATHWAY; P53 PROMOTER; CELL-DEATH; GENE; JUN; P38; PHOSPHORYLATION	Release of nitric oxide (NO) during inflammation can induce apoptosis in the heart. Here we analyzed the involvement of members of the mitogen-activated protein kinase (MAPK) family and their downstream target, the transcription factor AP-1, in induction of apoptosis by NO in isolated adult cardiomyocytes of rat. The NO-donor (+/-)- S-nitroso-N-acetylpenicillamine (100 muM SNAP)- induced apoptosis in 10.5 +/- 0.7% of cardiomyocytes and activated the transcription activator protein AP-1 by 333.6 +/- 122.3%. Intracellular scavenging of AP-1 with decoyoligonucleotides blocked NO-induced apoptosis to control levels (3.8 +/- 0.5% apoptotic cells). Activation of AP-1 with a c-Jun amino-terminal kinase (JNK) activator (Ro318220, 10 muM) provoked apoptosis in 18.7 +/- 1.2% cardiomyocytes, which was again blocked by intracellular scavenging of AP-1. NO activated JNK by 87.0 +/- 27.3% and extracellular signal-regulated kinase (ERK) by 35 +/- 3%. Inhibition of ERK by the mitogen-activated protein kinase kinase (MEK1) inhibitor PD98059 (10 muM) abolished AP-1 activation and apoptosis induction with SNAP. Evidence that p38 MAPK plays a role in NO-induced apoptosis was not found. These results clearly demonstrate the involvement of the transcription factor AP-1 in NO-induced apoptosis in cardiomyocytes. The activation of AP-1 is mediated by the two MAP kinases JNK and ERK.	Univ Giessen, Inst Physiol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Taimor, G (corresponding author), Univ Giessen, Inst Physiol, Aulweg 129, D-35392 Giessen, Germany.	Gerhild.Taimor@physiologie.med.uni-giessen.de						Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Andreka P, 2001, CIRC RES, V88, P305, DOI 10.1161/01.RES.88.3.305; Babu GJ, 2000, J MOL CELL CARDIOL, V32, P1447, DOI 10.1006/jmcc.2000.1185; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Ing DJ, 1999, CIRC RES, V84, P21; Ishikawa Y, 1999, BIOCHEM BIOPH RES CO, V264, P696, DOI 10.1006/bbrc.1999.1542; Jiang K, 1998, BIOCHEM BIOPH RES CO, V246, P192, DOI 10.1006/bbrc.1998.8591; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kankaanranta H, 1999, J PHARMACOL EXP THER, V290, P621; KIA Z, 1995, SCIENCE, V270, P1326; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Kirshenbaum LA, 1997, CIRCULATION, V96, P1580, DOI 10.1161/01.CIR.96.5.1580; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Leppa S, 2001, MOL CELL BIOL, V21, P4369, DOI 10.1128/MCB.21.13.4369-4378.2001; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; Mandal M, 2001, GASTROENTEROLOGY, V120, P71, DOI 10.1053/gast.2001.20897; Maulik N, 2000, FEBS LETT, V485, P7, DOI 10.1016/S0014-5793(00)02174-8; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Park YG, 1999, J BIOL CHEM, V274, P1573, DOI 10.1074/jbc.274.3.1573; PIPER HM, 1982, J MOL CELL CARDIOL, V14, P397, DOI 10.1016/0022-2828(82)90171-7; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; *SAS STAT, 1993, US GUID, V2, P946; Schluter KD, 1999, AM J PHYSIOL-HEART C, V276, pH1655, DOI 10.1152/ajpheart.1999.276.5.H1655; Taimor G, 2000, CARDIOVASC RES, V45, P588, DOI 10.1016/S0008-6363(99)00272-2; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743	33	54	56	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					2518	+		10.1096/fj.01-0353fje	http://dx.doi.org/10.1096/fj.01-0353fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641266				2022-12-25	WOS:000171372700020
J	Gilbert, GE; Kaufman, RJ; Arena, AA; Miao, HZ; Pipe, SW				Gilbert, GE; Kaufman, RJ; Arena, AA; Miao, HZ; Pipe, SW			Four hydrophobic amino acids of the factor VIIIC2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-V; PHOSPHATIDYL-L-SERINE; C-TYPE DOMAIN; PHOSPHOLIPID-VESICLES; VONWILLEBRAND-FACTOR; BLOOD-COAGULATION; MAMMALIAN-CELLS; MOLECULAR-BASIS; FACTORS-IXA; FACTOR-X	Factor VIII binds to phospholipid membranes and to von Willebrand factor (vWf) via its second C domain, which has lectin homology. The crystal structure of the C2 domain has prompted a model in which membrane binding is mediated by two hydrophobic spikes, each composed of a pair of residues displayed on a beta-hairpin turn, and also by net positive charge and specific interactions with phospho-L-serine. To test this model, we prepared 16 factor VIII mutants in which single or multiple amino acids were changed to alanine. Mutants at Arg(2215), Arg(2220), Lys(2227), Lys(2249), Gln(2213), Asn(2217), and Phe(2196)/Thr(2197) had specific activities that were >70% of the wild type. Mutants at Arg(2209), Lys(2227), Trp(2313), and Arg(2320) were degraded within the cell. Hydrophobic spike mutants at Met(2199)/Phe(2200), Leu(2251)/Leu(2252), and Met(2199)/Phe(2200)/Leu(2251)/Leu(22520) (4-Ala) exhibited 43, 59, and 91% reduction in specific activity in the activated partial thromboplastin time assay. In a phospholipid-limiting factor Xa activation assay, these mutants had a 65, 85, and 96% reduction in specific activity. Equilibrium binding of fluorescent, sonicated phospholipid vesicles to mutants immobilized on Superose beads was measured by flow cytometry. The affinities for phospholipid were reduced similar to20-, 30-, and >35-fold for 2199/2200, 2251/2252, and 4-Ala, respectively. A dimeric form of mature vWf bound to immobilized factor VIII and the same mutants, but the affinities of the mutants were reduced similar to5-, 10-, and >20-fold, respectively. In a competition, solution phase enzyme-linked immunosorbent assay, plasma vWf bound factor VIII and the same mutants with the affinities for the mutants reduced >5-, >5-, and >50-fold, respectively. We conclude that the two hydrophobic spikes are constituents of both the phospholipid-binding and vWf-binding motifs. In plasma, vWf apparently binds the inherently sticky membrane-binding motif, preventing nonspecific interactions.	Brigham & Womens Hosp, Vet Affairs Boston Healthcare Syst, W Roxbury, MA 02132 USA; Harvard Univ, Sch Med, W Roxbury, MA 02132 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System; Harvard University; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Gilbert, GE (corresponding author), VA Boston Healthcare Syst, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.	ggilbert@rics.bwh.harvard.edu	Pipe, Steven W./ABC-3843-2020	Pipe, Steven W./0000-0003-2558-2089	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173, P01HL042443] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BARTLES JR, 1982, BIOCHIM BIOPHYS ACTA, V687, P129, DOI 10.1016/0005-2736(82)90538-7; BEALS JM, 1986, BIOCHEM J, V236, P861, DOI 10.1042/bj2360861; Bendetowicz AV, 1998, BLOOD, V92, P529, DOI 10.1182/blood.V92.2.529.414k31_529_538; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1995, J BIOL CHEM, V270, P18500, DOI 10.1074/jbc.270.31.18500; GILBERT GE, 1992, J BIOL CHEM, V267, P15861; Gilbert GE, 1996, J BIOL CHEM, V271, P11120, DOI 10.1074/jbc.271.19.11120; GILBERT GE, 1995, BIOCHEMISTRY-US, V34, P3022, DOI 10.1021/bi00009a033; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; Gilbert GE, 1998, BIOCHEMISTRY-US, V37, P13526, DOI 10.1021/bi972944f; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; Jacquemin MG, 1998, BLOOD, V92, P496, DOI 10.1182/blood.V92.2.496.414k16_496_506; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KANE WH, 1988, BLOOD, V71, P539; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Kim SW, 1999, BIOCHEMISTRY-US, V38, P11448, DOI 10.1021/bi991275y; Kim SW, 2000, BIOCHEMISTRY-US, V39, P1951, DOI 10.1021/bi992256r; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; Kuwabara I, 1999, J IMMUNOL METHODS, V224, P89, DOI 10.1016/S0022-1759(99)00012-5; LOLLAR P, 1991, MAYO CLIN PROC, V66, P524, DOI 10.1016/S0025-6196(12)62395-7; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; MANN KG, 1990, BLOOD, V76, P1; MERTENS K, 1984, BIOCHEM J, V223, P599, DOI 10.1042/bj2230599; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; Pellequer JL, 1998, BLOOD CELL MOL DIS, V24, P448, DOI 10.1006/bcmd.1998.0214; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Saenko EL, 1996, J BIOL CHEM, V271, P27424, DOI 10.1074/jbc.271.44.27424; Spiegel PC, 2001, BLOOD, V98, P13, DOI 10.1182/blood.V98.1.13; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; Vlot AJ, 1996, BLOOD, V87, P1809; WISE RJ, 1991, J BIOL CHEM, V266, P21948	47	98	108	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6374	6381		10.1074/jbc.M104732200	http://dx.doi.org/10.1074/jbc.M104732200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11698391	hybrid			2022-12-25	WOS:000173989200090
J	Rauscher, L; Expert, D; Matzanke, BF; Trautwein, AX				Rauscher, L; Expert, D; Matzanke, BF; Trautwein, AX			Chrysobactin-dependent iron acquisition in Erwinia chrysanthemi - Functional study of a homolog of the Escherichia coli ferric enterobactin esterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC-HYDROLYSIS; NUCLEOTIDE-SEQUENCE; TRANSPORT-SYSTEM; PROMOTER REGION; GENE-EXPRESSION; SIDEROPHORE; ENTEROCHELIN; FUR; FES; RELEASE	Under iron limitation, the plant pathogen Erwinia chrysanthemi produces the catechol-type siderophore chrysobactin, which acts as a virulence factor. It can also use enterobactin as a xenosiderophore. We began this work by sequencing the 5'-upstream region of the fct-cbsCEBA operon, which encodes the ferric chrysobactin receptor and proteins involved in synthesis of the catechol moiety. We identified a new iron-regulated gene (cbsH) transcribed divergently relative to the fct gene, the translated sequence of which is 45.6% identical to that of Escherichia coli ferric enterobactin esterase. Insertions within this gene interrupt the chrysobactin biosynthetic pathway by exerting a polar effect on a downstream gene with some sequence identity to the E. coli enterobactin synthase gene. These mutations had no effect on the ability of the bacterium to obtain iron from enterobactin, showing that a functional cbsH gene is not required for iron removal from ferric enterobactin in E. chrysanthemi. The cbsH-negative mutants were less able to utilize ferric chrysobactin, and this effect was not caused by a defect in transport per se. In a nonpolar cbsH-negative mutant, chrysobactin accumulated intracellularly. These defects were rescued by the cbsH gene supplied on a plasmid. The amino acid sequence of the CbsH protein revealed characteristics of the S9 prolyl oligopeptidase family. Ferric chrysobactin hydrolysis was detected in cell extracts from a cbsH-positive strain that was inhibited by diisopropyl fluorophosphate. These data are consistent with the fact that chrysobactin is a D-lysyl-L-serine derivative. Mossbauer spectroscopy of whole cells at various states of Fe-57-labeled chrysobactin uptake showed that this enzyme is not required for iron removal from chrysobactin in vivo. The CbsH protein may therefore be regarded as a peptidase that prevents the bacterial cells from being intracellularly iron-depleted by chrysobactin.	Univ Paris 06, Inst Natl Agron Paris Grignon, INRA, Lab Pathol Vegetale,UMR 217, F-75231 Paris 05, France; Med Univ Lubeck, D-23538 Lubeck, Germany; Inst Phys, D-23538 Lubeck, Germany; Isotope Lab, D-23538 Lubeck, Germany	AgroParisTech; INRAE; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; University of Lubeck	Expert, D (corresponding author), Univ Paris 06, Inst Natl Agron Paris Grignon, INRA, Lab Pathol Vegetale,UMR 217, 16 Claude Bernard, F-75231 Paris 05, France.	expert@inapg.inra.fr						ARMSTRONG SK, 1990, J BIOL CHEM, V265, P14536; Arnow LE, 1937, J BIOL CHEM, V118, P531; Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; BAUMINGER ER, 1980, BIOCHIM BIOPHYS ACTA, V623, P237, DOI 10.1016/0005-2795(80)90252-4; BOHNKE R, 1995, BIOMETALS, V8, P223; Braun V, 1998, MET IONS BIOL SYST, V35, P67; BRICKMAN TJ, 1992, J BIOL CHEM, V267, P12350; BUTTERTON JR, 1994, J BACTERIOL, V176, P5631, DOI 10.1128/JB.176.18.5631-5638.1994; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; CODERRE PE, 1989, J GEN MICROBIOL, V135, P3043; Cohen SM, 1998, J AM CHEM SOC, V120, P6277, DOI 10.1021/ja973442s; COOPER SR, 1978, P NATL ACAD SCI USA, V75, P3551, DOI 10.1073/pnas.75.8.3551; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; DELORENZO V, 1988, J MOL BIOL, V203, P875, DOI 10.1016/0022-2836(88)90113-1; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; Earhart C.F., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1075; Enard C, 2000, MICROBIOL-UK, V146, P2051, DOI 10.1099/00221287-146-8-2051; ENARD C, 1988, J BACTERIOL, V170, P2419, DOI 10.1128/jb.170.6.2419-2426.1988; ENARD C, 1991, PLANT SOIL, V130, P263, DOI 10.1007/BF00011882; Escolar L, 1999, J BACTERIOL, V181, P6223, DOI 10.1128/JB.181.20.6223-6229.1999; EXPERT D, 1992, MOL MICROBIOL, V6, P2009, DOI 10.1111/j.1365-2958.1992.tb01373.x; Expert D, 1999, ANNU REV PHYTOPATHOL, V37, P307, DOI 10.1146/annurev.phyto.37.1.307; FISCHER E, 1990, ARCH MICROBIOL, V153, P329, DOI 10.1007/BF00249001; FONTECAVE M, 1994, BIOMETALS, V7, P3; Franza T, 1999, MOL PLANT MICROBE IN, V12, P119, DOI 10.1094/MPMI.1999.12.2.119; FRANZA T, 1991, J BACTERIOL, V173, P6874, DOI 10.1128/jb.173.21.6874-6881.1991; FRANZA T, 1991, MOL MICROBIOL, V5, P1319, DOI 10.1111/j.1365-2958.1991.tb00778.x; FROLOW F, 1994, NAT STRUCT BIOL, V1, P453, DOI 10.1038/nsb0794-453; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P2648, DOI 10.1021/bi9726584; GREENWOOD KT, 1978, BIOCHIM BIOPHYS ACTA, V525, P209, DOI 10.1016/0005-2744(78)90216-4; HALLE F, 1992, EUR J BIOCHEM, V209, P621, DOI 10.1111/j.1432-1033.1992.tb17328.x; HEIDINGER S, 1983, J BACTERIOL, V153, P109, DOI 10.1128/JB.153.1.109-115.1983; HOLLIFIELD WC, 1978, BIOCHEMISTRY-US, V17, P1922, DOI 10.1021/bi00603a019; HUGOUVIEUXCOTTEPATTAT N, 1985, J BACTERIOL, V162, P248, DOI 10.1128/JB.162.1.248-255.1985; HUNT MD, 1994, J BACTERIOL, V176, P3944, DOI 10.1128/JB.176.13.3944-3955.1994; LANGMAN L, 1972, J BACTERIOL, V112, P1142, DOI 10.1128/JB.112.3.1142-1149.1972; LEBRUN NE, 1995, BIOCHEM J, V312, P385, DOI 10.1042/bj3120385; LODGE JS, 1980, BIOCHEM BIOPH RES CO, V97, P1291, DOI 10.1016/S0006-291X(80)80006-4; Lu C, 1996, BIOMETALS, V9, P377, DOI 10.1007/BF00140607; LUNDRIGAN MD, 1986, J BIOL CHEM, V261, P797; MAHE B, 1995, MOL MICROBIOL, V18, P33, DOI 10.1111/j.1365-2958.1995.mmi_18010033.x; MASCLAUX C, 1995, PLANT J, V7, P121, DOI 10.1046/j.1365-313X.1995.07010121.x; Matzanke B.F., 1991, HDB MICROBIAL IRON C, P15; Matzanke BF, 1997, TRANSITION METALS IN MICROBIAL METABOLISM, P117; MATZANKE BF, 1987, IRON TRANSPORT MICRO, P251; MATZANKE BF, 1989, IRON CARRIERS IRON P, V5, P89; Matzanke BF, 1994, ENCY INORGANIC CHEM, V4, P1915; MENARD R, 1993, J BACTERIOL, V175, P5899; Miller J. H., 1972, EXPT MOL GENETICS, P431; Munzinger M, 2000, Z NATURFORSCH C, V55, P328; OBRIEN IG, 1970, BIOCHIM BIOPHYS ACTA, V215, P393, DOI 10.1016/0304-4165(70)90038-3; PERSMARK M, 1992, BIOMETALS, V5, P29, DOI 10.1007/BF01079695; PERSMARK M, 1989, J BIOL CHEM, V264, P3187; PERSMARK M, 1992, J BACTERIOL, V174, P4783, DOI 10.1128/JB.174.14.4783-4789.1992; PETTIS GS, 1988, J BIOL CHEM, V263, P18857; PETTIS GS, 1987, J BACTERIOL, V169, P4154, DOI 10.1128/jb.169.9.4154-4162.1987; PORRA RJ, 1972, ARCH BIOCHEM BIOPHYS, V153, P74, DOI 10.1016/0003-9861(72)90422-5; Postle K, 1999, NAT STRUCT BIOL, V6, P3, DOI 10.1038/4869; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; RESIBOIS A, 1984, VIROLOGY, V137, P102, DOI 10.1016/0042-6822(84)90013-8; RUSNAK F, 1991, BIOCHEMISTRY-US, V30, P2916, DOI 10.1021/bi00225a027; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sauvage C, 1996, J BACTERIOL, V178, P1227, DOI 10.1128/jb.178.4.1227-1231.1996; Schubert S, 1999, J BACTERIOL, V181, P6387, DOI 10.1128/JB.181.20.6387-6395.1999; SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9; SIMON R, 1989, GENE, V80, P161, DOI 10.1016/0378-1119(89)90262-X; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WALSH C, 1979, ENZYMATIC REACTION M, P94; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; WINKELMANN G, 1994, BIOMETALS, V7, P149; WINKLER H, 1994, HYPERFINE INTERACT, V91, P841, DOI 10.1007/BF02064616; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YARIV J, 1983, BIOCHEM J, V211, P527, DOI 10.1042/bj2110527	73	24	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2385	2395		10.1074/jbc.M107530200	http://dx.doi.org/10.1074/jbc.M107530200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11694506	hybrid			2022-12-25	WOS:000173421500005
J	Baert, JL; Beaudoin, C; Coutte, L; de Launoit, Y				Baert, JL; Beaudoin, C; Coutte, L; de Launoit, Y			ERM transactivation is up-regulated by the repression of DNA binding after the PKA phosphorylation of a consensus site at the edge of the ETS domain.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ELK-1; FAMILY MEMBER ERM; NF-KAPPA-B; MAP KINASE; GENE-EXPRESSION; MOLECULAR CHARACTERIZATION; ONCOGENE FAMILY; FACTOR ER81; FACTOR PEA3; PROTEIN	The final step of the transduction pathway is the activation of gene transcription, which is driven by kinase cascades leading to changes in the activity of many transcription factors. Among these latter, PEA3/E1AF, ER81/ETV1, and ERM, members of the well conserved PEAS group from the Ets family are involved in these processes. We show here that protein kinase A (PKA) increases the transcriptional activity of human ERM and human ETV1, through a Ser residue situated at the edge of the ETS DNA-binding domain. PKA phosphorylation does not directly affect the ERM transactivation domains but does affect DNA binding activity. Unphosphorylated wild-type ERM bound DNA avidly, whereas after PKA phosphorylation it did so very weakly. Interestingly, S367A mutation significantly reduced the ERM-mediated transcription in the presence of the kinase, and the DNA binding of this mutant, although similar to that of unphosphorylated wild-type protein, was insensitive to PKA treatment. Mutations, which may mimic a phosphorylated serine, converted ERM from an efficient DNA-binding protein to a poor DNA binding one, with inefficiency of PKA phosphorylation. The present data clearly demonstrate a close correlation between the capacity of PKA to increase the transactivation of ERM and the drastic down-regulation of the binding of the ETS domain to the targeted DNA. What we thus demonstrate here is a relatively rare transcription activation mechanism through a decrease in DNA binding, probably by the shift of a non-active form of an Ets protein to a PKA-phosphorylated active one, which should be in a conformation permitting a transactivation domain to be active.	Inst Pasteur, UMR 8526 CNRS, Inst Biol Lille, F-59021 Lille, France; Free Univ Brussels, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite Libre de Bruxelles; Vrije Universiteit Brussel	de Launoit, Y (corresponding author), Inst Pasteur, UMR 8526 CNRS, Inst Biol Lille, BP 447,1 Rue Calmette, F-59021 Lille, France.			coutte, laurent/0000-0002-0031-4742				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Brown LA, 1998, ONCOGENE, V17, P93, DOI 10.1038/sj.onc.1201911; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Buttice G, 1996, ONCOGENE, V13, P2297; CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Coutte L, 1999, ONCOGENE, V18, P6278, DOI 10.1038/sj.onc.1203020; Cowley DO, 2000, GENE DEV, V14, P366; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; FISHER RJ, 1994, PROTEIN SCI, V3, P257; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Hodge DR, 1996, ONCOGENE, V12, P11; Janknecht R, 1996, ONCOGENE, V13, P1745; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JANKNECHT R, 1996, MOL CELL BIOL, V16, P1551; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; JEON IS, 1995, ONCOGENE, V10, P1229; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Laget MP, 1996, ONCOGENE, V12, P1325; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Li JX, 1998, J BIOL CHEM, V273, P4592, DOI 10.1074/jbc.273.8.4592; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Menetski JP, 2000, J BIOL CHEM, V275, P7619, DOI 10.1074/jbc.275.11.7619; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; OHagan RC, 1996, ONCOGENE, V13, P1323; Ouyang W, 1999, P NATL ACAD SCI USA, V96, P3888, DOI 10.1073/pnas.96.7.3888; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHARROCKS AD, 1995, FEBS LETT, V368, P77, DOI 10.1016/0014-5793(95)00604-8; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Szymczyna BR, 2000, J BIOL CHEM, V275, P28363, DOI 10.1074/jbc.M004294200; Taylor JM, 1997, MOL CELL BIOL, V17, P5550, DOI 10.1128/MCB.17.9.5550; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	59	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1002	1012		10.1074/jbc.M107139200	http://dx.doi.org/10.1074/jbc.M107139200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11682477	hybrid			2022-12-25	WOS:000173166800019
J	Boras, K; Hamel, PA				Boras, K; Hamel, PA			Alx4 binding to LEF-1 regulates N-CAM promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR LEF-1; EPITHELIAL-MESENCHYMAL INTERACTIONS; HAIR FOLLICLE MORPHOGENESIS; ALPHA ENHANCER FUNCTION; BETA-CATENIN; HOMEODOMAIN PROTEINS; HMG DOMAIN; CELL-DIFFERENTIATION; ADHESION MOLECULES; DNA	During murine embryogenesis, expression of the paired-like homeodomain protein Alx4 is restricted to tissues whose development depends on the expression of lymphoid enhancer factor-1 (LEF-1). Given the defects seen in hair follicle development in both LEF-1 and Alx4 knockout and mutant animals and the overlapping expression patterns, we predicted that LEF-1 and Alx4 might form physical complexes. We demonstrate here the interaction between LEF-1 and Alx4. This interaction is mediated through a specific proline-rich domain in the N-terminal region of Alx4 and requires the DNA-binding domain (HMG-box) of LEF-1. We also demonstrate that LEF-1 and Alx4 can bind simultaneously to adjacent sites on the neural cell adhesion molecule (NCAM) promoter and that this binding alters N-CAM promoter activity. Furthermore, when expressed in primary mammary stromal cells, Alx4 decreases the expression of endogenous N-CAM protein. These results reveal a potential mechanism that gives rise to mesenchymal-specific activities of LEF-1.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada	University of Toronto	Hamel, PA (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Rm 6318,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.							Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Botchkarev VA, 1999, NAT CELL BIOL, V1, P158, DOI 10.1038/11078; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo R, 1997, CURR OPIN GENET DEV, V7, P459, DOI 10.1016/S0959-437X(97)80071-8; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; CHAN DC, 1995, DEVELOPMENT, V121, P1971; Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; Chuong CM, 1996, J INVEST DERMATOL, V107, P639, DOI 10.1111/1523-1747.ep12584254; Combates NJ, 1997, J INVEST DERMATOL, V109, P672, DOI 10.1111/1523-1747.ep12337725; CUNHA GR, 1994, CANCER, V74, P1030, DOI 10.1002/1097-0142(19940801)74:3+<1030::AID-CNCR2820741510>3.0.CO;2-Q; Fadel MP, 2001, J BIOL CHEM, V276, P27083, DOI 10.1074/jbc.M101676200; FORSTHOEFEL PF, 1972, TERATOLOGY, V6, P5, DOI 10.1002/tera.1420060103; FORSTHOEFEL PF, 1966, J MORPHOL, V118, P565, DOI 10.1002/jmor.1051180409; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; Hardy MH, 1996, ACTA ANAT, V157, P169; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Hudson R, 1998, DEV DYNAM, V213, P159, DOI 10.1002/(SICI)1097-0177(199810)213:2<159::AID-AJA1>3.0.CO;2-F; Iseki S, 1996, BIOCHEM BIOPH RES CO, V218, P688, DOI 10.1006/bbrc.1996.0123; Jiang TX, 1999, DEVELOPMENT, V126, P4997; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; MILATOVICH A, 1991, GENOMICS, V11, P1040, DOI 10.1016/0888-7543(91)90030-I; Millar SE, 1999, DEV BIOL, V207, P133, DOI 10.1006/dbio.1998.9140; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Muller-Rover S, 1998, J HISTOCHEM CYTOCHEM, V46, P1401; Okamura RM, 1998, IMMUNITY, V8, P11, DOI 10.1016/S1074-7613(00)80454-9; Qu SM, 1997, DEVELOPMENT, V124, P3999; Qu SM, 1999, DEVELOPMENT, V126, P359; Qu SM, 1998, DEVELOPMENT, V125, P2711; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rosenquist TA, 1996, DEV DYNAM, V205, P379, DOI 10.1002/(SICI)1097-0177(199604)205:4<379::AID-AJA2>3.0.CO;2-F; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Thesleff I, 1996, CURR OPIN CELL BIOL, V8, P844, DOI 10.1016/S0955-0674(96)80086-X; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; Tucker SC, 1999, J BIOL CHEM, V274, P32325, DOI 10.1074/jbc.274.45.32325; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang YB, 1996, P NATL ACAD SCI USA, V93, P1892, DOI 10.1073/pnas.93.5.1892; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WILSON DS, 1995, CURR BIOL, V5, P32, DOI 10.1016/S0960-9822(95)00010-8; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	60	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1120	1127		10.1074/jbc.M109912200	http://dx.doi.org/10.1074/jbc.M109912200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11696550	hybrid			2022-12-25	WOS:000173166800033
J	Fraser, JA; Saunders, RDC; McLellan, LI				Fraser, JA; Saunders, RDC; McLellan, LI			Drosophila melanogaster glutamate-cysteine ligase activity is regulated by a modifier subunit with a mechanism of action similar to that of the mammalian form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; AMINO-ACID-SEQUENCE; GLUTATHIONE SYNTHESIS; MOLECULAR-CLONING; ESCHERICHIA-COLI; GENE-EXPRESSION; GENOME PROJECT; PURIFICATION; YEAST; INACTIVATION	Glutamate-cysteine ligase (GCL) plays an important role in regulating glutathione homeostasis. In mammals, it comprises a catalytic (GCLC) and modifier (GCLM) subunit. The existence of a modifier subunit in invertebrates has not been described to date. We now demonstrate that GCL from Drosophila melanogaster has a functional modifier subunit (DmGCLM). A putative DmGCLM was obtained as an expressed sequence tag with 27% identity to human GCLM at the amino acid level. D. melanogaster GCLC (DmGCLC) and the candidate DmGCLM were expressed separately in Escherichia coli, purified, mixed, and then subjected to gel filtration, where they eluted as an similar to140-kDa complex. DmGCLC co-immunoprecipitated with DmGCLM from S2 cell extracts, suggesting that they also associate in vivo. Enzyme kinetic analyses showed that DmGCLC has a K-m for glutamate of 2.88 mm, but when complexed with DmGCLM, the K-m for glutamate is 0.45 mm. Inhibition of DmGCLC activity by glutathione was found to be competitive with respect to glutamate (K-i = 0.03 mm), whereas inhibition of the GCL complex was mixed (K-i = 0.67 mm), suggesting allosteric effects. In accordance with this, DmGCLC and DmGCLM have the ability to form reversible intermolecular disulfide bridges. A further mechanism for control of D. melanogaster GCL was found to be induction of DmGCLC by tert-butylhydroquinone in S2 cells. DmGCLM levels were, however, unaffected by tert-butylhydroquinone.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Open Univ, Dept Biol Sci, Milton Keynes MK7 6AA, Bucks, England	University of Dundee; Open University - UK	McLellan, LI (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.			Fraser, Jennifer/0000-0001-5546-3916				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brekken DL, 1998, J BIOL CHEM, V273, P26317, DOI 10.1074/jbc.273.41.26317; Cleland W W, 1979, Methods Enzymol, V63, P103; COBLENZ A, 1995, YEAST, V11, P1171, DOI 10.1002/yea.320111207; Dalton TP, 2000, BIOCHEM BIOPH RES CO, V279, P324, DOI 10.1006/bbrc.2000.3930; DAVIS JS, 1973, BIOCHEM J, V133, P667, DOI 10.1042/bj1330667; EASTERBY JS, 1996, HYPER; EASTERBY JS, 1996, HYPER VERSION 1 1S; Fenton MJ, 2000, NAT IMMUNOL, V1, P279, DOI 10.1038/79719; Galloway DC, 1999, BBA-GENE STRUCT EXPR, V1446, P47, DOI 10.1016/S0167-4781(99)00073-1; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; HUSSEIN AS, 1995, MOL BIOCHEM PARASIT, V72, P57, DOI 10.1016/0166-6851(94)00064-T; Kockel L, 2001, ONCOGENE, V20, P2347, DOI 10.1038/sj.onc.1204300; LEBO RV, 1978, J BIOL CHEM, V253, P2615; Lueder DV, 1996, J BIOL CHEM, V271, P17485, DOI 10.1074/jbc.271.29.17485; Luersen K, 1999, MOL BIOCHEM PARASIT, V98, P131, DOI 10.1016/S0166-6851(98)00161-3; Luersen K, 2000, MOL BIOCHEM PARASIT, V111, P243, DOI 10.1016/S0166-6851(00)00325-X; May MJ, 1998, P NATL ACAD SCI USA, V95, P12049, DOI 10.1073/pnas.95.20.12049; MAY MJ, 1994, P NATL ACAD SCI USA, V91, P10059, DOI 10.1073/pnas.91.21.10059; Misra I, 1998, PROTEIN EXPRES PURIF, V13, P268, DOI 10.1006/prep.1998.0897; OHTAKE Y, 1991, YEAST, V7, P953, DOI 10.1002/yea.320070907; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Saunders RDC, 2000, FEBS LETT, V467, P337, DOI 10.1016/S0014-5793(00)01148-0; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; SEELIG GF, 1984, J BIOL CHEM, V259, P3534; SEELIG GF, 1982, J BIOL CHEM, V257, P5092; SEKURA R, 1977, J BIOL CHEM, V252, P2599; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; Soltaninassab SR, 2000, J CELL PHYSIOL, V182, P163, DOI 10.1002/(SICI)1097-4652(200002)182:2<163::AID-JCP4>3.0.CO;2-1; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Spradling AC, 1999, GENETICS, V153, P135; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsuchiya K, 1995, GENOMICS, V30, P630, DOI 10.1006/geno.1995.1293; Tu ZH, 1998, ARCH BIOCHEM BIOPHYS, V354, P247, DOI 10.1006/abbi.1998.0676; WATANABE K, 1986, NUCLEIC ACIDS RES, V14, P4393, DOI 10.1093/nar/14.11.4393; Wild AC, 2000, FREE RADICAL RES, V32, P281, DOI 10.1080/10715760000300291; YAN N, 1990, J BIOL CHEM, V265, P1588	43	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1158	1165		10.1074/jbc.M106683200	http://dx.doi.org/10.1074/jbc.M106683200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11698394	hybrid, Green Published, Green Accepted			2022-12-25	WOS:000173166800037
J	Kelly, AA; Dormann, P				Kelly, AA; Dormann, P			DGD2, an Arabidopsis gene encoding a UDP-galactose-dependent digalactosyldiacylglycerol synthase is expressed during growth under phosphate-limiting conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST ENVELOPES; LIPID-COMPOSITION; OUTER-MEMBRANE; BIOSYNTHESIS; THALIANA; MUTANT; DEFICIENT; MONOGALACTOSYLDIACYLGLYCEROL; GLYCOSYLTRANSFERASES; SIMILARITIES	The galactolipid digalactosyldiacylglycerol (DGDG), one of the main chloroplast lipids in higher plants, is believed to be synthesized by the galactolipid:galactolipid galactosyltransferase, which transfers a galactose moiety from one molecule of monogalactosyldiacylglycerol (MGDG) to another. Here, we report that Arabidopsis as well as other plant species contain two genes, DGD1 and DGD2, encoding enzymes with DGDG synthase activity. Using MGDG and UDP-galactose as substrates for in vitro assays with DGD2 we could for the first time measure DGDG synthase activity of a heterologously expressed plant cDNA. UDP-galactose, but not MGDG, serves as the galactose donor for DGDG synthesis catalyzed by DGD2, providing clear evidence for the existence of a UDP-galactose-dependent DGDG synthase in higher plants. In in vitro assays, DGD2 was capable of galactosylating DGDG, resulting in the synthesis of an oligogalactolipid tentatively identified as trigalactosyldiacylglycerol. DGD2 mRNA expression in leaves was very low but was strongly induced during growth under phosphate-limiting conditions. This induction correlates with the previously described increase in DGDG during phosphate deprivation. Therefore, in contrast to DGD1, which is responsible for the synthesis of the bulk of DGDG found in chloroplasts, DGD2 apparently is involved in the synthesis of DGDG under specific growth conditions.	Max Planck Inst Mol Plant Physiol, Dept Mol Physiol, D-14476 Golm, Germany	Max Planck Society	Dormann, P (corresponding author), Max Planck Inst Mol Plant Physiol, Dept Mol Physiol, Muhlenberg 1, D-14476 Golm, Germany.							AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; Awai K, 2001, P NATL ACAD SCI USA, V98, P10960, DOI 10.1073/pnas.181331498; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWSE J, 1986, BIOCHEM J, V235, P25, DOI 10.1042/bj2350025; BROWSE J, 1988, PLANT SCI, V56, P15, DOI 10.1016/0168-9452(88)90179-3; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CARTER HE, 1956, J AM CHEM SOC, V78, P3735, DOI 10.1021/ja01596a051; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLINE K, 1983, PLANT PHYSIOL, V71, P366, DOI 10.1104/pp.71.2.366; Dormann P, 1999, SCIENCE, V284, P2181, DOI 10.1126/science.284.5423.2181; DORMANN P, 1995, PLANT CELL, V7, P1801, DOI 10.1105/tpc.7.11.1801; DORNE AJ, 1982, FEBS LETT, V145, P30, DOI 10.1016/0014-5793(82)81200-3; Douce, 1987, BIOCH PLANTS, P215, DOI 10.1016/B978-0-12-675409-4.50015-0; Essigmann B, 1998, P NATL ACAD SCI USA, V95, P1950, DOI 10.1073/pnas.95.4.1950; ESTELLE MA, 1987, MOL GEN GENET, V206, P200, DOI 10.1007/BF00333575; Fitzpatrick LM, 2001, PLANT J, V27, P59, DOI 10.1046/j.0960-7412.2001.01061.x; Froehlich JE, 2001, J BIOL CHEM, V276, P31806, DOI 10.1074/jbc.M104652200; Hartel H, 2000, P NATL ACAD SCI USA, V97, P10649, DOI 10.1073/pnas.180320497; Hartel H, 1997, PLANT PHYSIOL, V115, P1175, DOI 10.1104/pp.115.3.1175; HEEMSKERK JWM, 1990, PLANT PHYSIOL, V93, P1286, DOI 10.1104/pp.93.4.1286; HEEMSKERK JWM, 1988, PLANT PHYSIOL, V86, P971, DOI 10.1104/pp.86.3.971; HEINZ E, 1983, PLANT PHYSIOL, V72, P273, DOI 10.1104/pp.72.2.273; Henrissat B, 2000, PLANT PHYSIOL, V124, P1515, DOI 10.1104/pp.124.4.1515; Jarvis P, 2000, P NATL ACAD SCI USA, V97, P8175, DOI 10.1073/pnas.100132197; Jorasch P, 1998, MOL MICROBIOL, V29, P419, DOI 10.1046/j.1365-2958.1998.00930.x; Jorasch P, 2000, EUR J BIOCHEM, V267, P3770, DOI 10.1046/j.1432-1327.2000.01414.x; Jorasch P, 1999, TRENDS PLANT SCI, V4, P469, DOI 10.1016/S1360-1385(99)01505-8; Joyard Jacques, 1993, P231; KOJIMA M, 1990, BIOCHEM CELL BIOL, V68, P59; KUNST L, 1988, P NATL ACAD SCI USA, V85, P4143, DOI 10.1073/pnas.85.12.4143; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; Marechal E, 1997, PHYSIOL PLANTARUM, V100, P65, DOI 10.1034/j.1399-3054.1997.1000106.x; Miege C, 1999, EUR J BIOCHEM, V265, P990, DOI 10.1046/j.1432-1327.1999.00801.x; NEUFELD EF, 1964, BIOCHEM BIOPH RES CO, V14, P503, DOI 10.1016/0006-291X(64)90259-1; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; ONGUN A, 1968, J BIOL CHEM, V243, P1558; POIRIER Y, 1991, PLANT PHYSIOL, V97, P1087, DOI 10.1104/pp.97.3.1087; Reifarth F, 1997, BIOCHEMISTRY-US, V36, P11769, DOI 10.1021/bi9709654; Sambrook J., 2002, MOL CLONING LAB MANU; Shimojima M, 1997, P NATL ACAD SCI USA, V94, P333, DOI 10.1073/pnas.94.1.333; SIEBERTZ M, 1977, H-S Z PHYSIOL CHEM, V358, P27, DOI 10.1515/bchm2.1977.358.1.27; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; TAKAKAZU K, 1997, PLANT CELL PHYSL, V38, P1171; Uwer U, 1998, PLANT CELL, V10, P1277, DOI 10.1105/tpc.10.8.1277; VANBESOUW A, 1978, BIOCHIM BIOPHYS ACTA, V529, P44, DOI 10.1016/0005-2760(78)90102-9; Vijayan P., 1998, LIPIDS PHOTOSYNTHESI, P263	47	144	153	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1166	1173		10.1074/jbc.M110066200	http://dx.doi.org/10.1074/jbc.M110066200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11696551	hybrid			2022-12-25	WOS:000173166800038
J	Russo, K; Ragone, R; Facchiano, AM; Capogrossi, MC; Facchiano, A				Russo, K; Ragone, R; Facchiano, AM; Capogrossi, MC; Facchiano, A			Platelet-derived growth factor-BB and basic fibroblast growth factor directly interact in vitro with high affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SURFACE-PLASMON RESONANCE; PDGF-A-CHAIN; MONOCLONAL-ANTIBODIES; EXTRACELLULAR REGION; INTIMAL HYPERPLASIA; LIMITED PROTEOLYSIS; BETA-DYSTROGLYCAN; DOMAIN-STRUCTURES; RECEPTOR-BINDING	Platelet-derived growth factor-BB (PDGF-BB) and basic fibroblast growth factor (bFGF) are potent growth factors active on many cell types. The present study indicates that they directly interact in vitro. The interaction was investigated with overlay experiments, surface plasmon resonance experiments, and solid-phase immunoassays by immobilizing one factor or the other and by steady-state fluorescence analysis. The interaction observed was specific, dose-dependent, and saturable, and the bFGF/PDGF-BB binding stoichiometry was found to be 2:1. K-D1 for the first step equilibrium and the overall K-D values were found to be in the nanomolar and in the picomolar range, respectively. Basic FGF/ PDGF-BB interaction was strongly reduced as a function of time of PDGF-BB proteolysis. Furthermore, docking analysis suggested that the PDGF-BB region interacting with bFGF may overlap, at least in part, with the PDGF-BB receptor-binding site. This hypothesis was supported by surface plasmon resonance experiments showing that an anti-PDGF-BB antibody, known to inhibit PDGF-BB binding with its receptor, strongly reduced bFGF/PDGF-BB interaction, whereas a control antibody was ineffective. According to these data, the observed bFGF(.)PDGF-BB complex formation might explain, at least in part, previous observations showing that PDGF-BB chemotactic and mitogenic activity on smooth muscle cells are strongly inhibited in the presence of bFGF.	Ist Dermopat Immacolata, Lab Patol Vascolare, I-00167 Rome, Italy; Univ Naples 2, Dipartimento Biochim & Biofis, I-80138 Naples, Italy; CNR, Ist Sci Alimentaz, I-83100 Avellino, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR)	Facchiano, A (corresponding author), Ist Dermopat Immacolata, Lab Patol Vascolare, Via Monti Creta 104, I-00167 Rome, Italy.	a.facchiano@idi.it	Facchiano, Antonio/J-4744-2012; Facchiano, Angelo/K-3375-2012; Facchiano, Antonio/K-5984-2016	Facchiano, Antonio/0000-0002-4243-2392; Facchiano, Angelo/0000-0002-7077-4912; Facchiano, Antonio/0000-0002-4243-2392; Russo, Katia/0000-0002-8355-6869				Akyurek LM, 1996, TRANSPLANTATION, V62, P1526; ANDERSSON M, 1995, GROWTH FACTORS, V12, P159, DOI 10.3109/08977199509028962; AVIVI A, 1992, ONCOGENE, V7, P1957; Bailly S, 1997, J BIOL CHEM, V272, P16329, DOI 10.1074/jbc.272.26.16329; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; Bono F, 1997, BIOCHEM J, V326, P661, DOI 10.1042/bj3260661; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; CROWLEY ST, 1995, AM J PHYSIOL-HEART C, V269, pH1641, DOI 10.1152/ajpheart.1995.269.5.H1641; DEMARCHIS F, 2002, IN PRESS BLOOD; Di Stasio E, 1999, BIOCHEM BIOPH RES CO, V266, P274, DOI 10.1006/bbrc.1999.1803; Drubaix I, 1998, GERONTOLOGY, V44, P9, DOI 10.1159/000021976; Facchiano A, 2000, J CELL SCI, V113, P2855; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; Faries PL, 1996, J VASC SURG, V24, P463, DOI 10.1016/S0741-5214(96)70203-3; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; Hajitou A, 2001, CANCER RES, V61, P3450; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Herzog A, 2000, FEBS LETT, V472, P73, DOI 10.1016/S0014-5793(00)01431-9; HUANG CY, 1982, METHOD ENZYMOL, V87, P509; Job P, 1928, ANN CHIM FRANCE, V9, P113; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; Krufka A, 1996, BIOCHEMISTRY-US, V35, P11131, DOI 10.1021/bi960125+; LAROCHELLE WJ, 1992, J BIOL CHEM, V267, P17074; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; LIU HM, 1994, ACTA NEUROPATHOL, V88, P143; Lokker NA, 1997, J BIOL CHEM, V272, P33037, DOI 10.1074/jbc.272.52.33037; MALEK AM, 1993, J CLIN INVEST, V92, P2013, DOI 10.1172/JCI116796; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; MOSES MA, 1991, BIO-TECHNOL, V9, P630, DOI 10.1038/nbt0791-630; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Nawratil P, 1996, J BIOL CHEM, V271, P31735, DOI 10.1074/jbc.271.49.31735; Nemoto T, 1997, J BIOL CHEM, V272, P26179, DOI 10.1074/jbc.272.42.26179; Newbell BJ, 1997, BIOCHEMISTRY-US, V36, P1295, DOI 10.1021/bi962452n; Nishimura T, 2000, BBA-GENE STRUCT EXPR, V1492, P203, DOI 10.1016/S0167-4781(00)00067-1; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Pye DA, 1999, J BIOL CHEM, V274, P13456, DOI 10.1074/jbc.274.19.13456; RAINES EW, 1982, J BIOL CHEM, V257, P5154; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REIDY MA, 1992, CIRCULATION, V86, P43; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; Rusnati M, 1999, MOL BIOL CELL, V10, P313, DOI 10.1091/mbc.10.2.313; Russo K, 2000, BIOCHEM BIOPH RES CO, V274, P93, DOI 10.1006/bbrc.2000.3103; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SJOLUND M, 1988, J CELL BIOL, V106, P403, DOI 10.1083/jcb.106.2.403; STERLIKOVA AV, 1995, ZH NAUCH PRIKL FOTOG, V40, P14; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; Taraboletti G, 1997, CELL GROWTH DIFFER, V8, P471; THYBERG J, 1990, J CELL SCI, V97, P219; Toda S, 1999, J PATHOL, V188, P415, DOI 10.1002/(SICI)1096-9896(199908)188:4<415::AID-PATH380>3.0.CO;2-H; Tripathi RC, 1997, EXP EYE RES, V64, P335, DOI 10.1006/exer.1996.0215; Uchida K, 1996, ATHEROSCLEROSIS, V124, P9, DOI 10.1016/0021-9150(95)05742-0; UENO H, 1993, J BIOL CHEM, V268, P22814; Vakser IA, 1996, PROTEIN ENG, V9, P37, DOI 10.1093/protein/9.1.37; Volpert OV, 2000, CANCER METAST REV, V19, P87, DOI 10.1023/A:1026560618302; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; Westphal JR, 2000, INT J CANCER, V86, P768, DOI 10.1002/(SICI)1097-0215(20000615)86:6<768::AID-IJC3>3.3.CO;2-5; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YEH HJ, 1987, P NATL ACAD SCI USA, V84, P2317, DOI 10.1073/pnas.84.8.2317; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	82	23	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1284	1291		10.1074/jbc.M108858200	http://dx.doi.org/10.1074/jbc.M108858200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694520	hybrid			2022-12-25	WOS:000173166800055
J	Steen, H; Kuster, B; Fernandez, M; Pandey, A; Mann, M				Steen, H; Kuster, B; Fernandez, M; Pandey, A; Mann, M			Tyrosine phosphorylation mapping of the epidermal growth factor receptor signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCING ADAPTER MOLECULE; MASS-SPECTROMETRY; AUTOPHOSPHORYLATION SITES; PROTEIN-PHOSPHORYLATION; IDENTIFICATION; DOMAIN; SHC; CBL; PHOSPHOPEPTIDES; CHROMATOGRAPHY	Phosphorylation is one of the most common forms of protein modification. The most frequent targets for protein phosphorylation in eukaryotes are serine and threonine residues, although tyrosine residues also undergo phosphorylation. Many of the currently applied methods for the detection and localization of protein phosphorylation sites are mass spectrometry-based and are biased against the analysis of tyrosine-phosphorylated residues because of the stability and low reactivity of phosphotyrosines. To overcome this lack of sensitive methods for the detection of phosphotyrosine-containing peptides, we have recently developed a method that is not affected by the more predominant threonine or serine phosphorylation within cells. It is based on the specific detection of immonium ion of phosphotyrosine at 216.043 Da and does not require prior knowledge of the protein sequence. In this report, we describe the first application of this new method in a proteomic strategy. Using anti-phosphotyrosine antibodies for immuno-precipitation and one-dimensional gel electrophoresis, we have identified 10 proteins in the epidermal growth factor receptor signaling pathway, of which 8 have been shown previously to be involved in epidermal growth factor signaling. Most importantly, in addition to several known tyrosine phosphorylation sites, we have identified five novel sites on SHIP-2, Hrs, Cbl, STAM, and STAM2, most of which were not predicted to be phosphorylated. Because of its sensitivity and selectivity, this approach will be useful in proteomic approaches to study tyrosine phosphorylation in a number of signal transduction pathways.	Univ So Denmark, Ctr Expt Bioinformat, Dept Biochem & Mol Biol, Prot Interact Lab, DK-5230 Odense M, Denmark; MDS Prote AS, DK-5230 Odense M, Denmark	University of Southern Denmark	Mann, M (corresponding author), Univ So Denmark, Ctr Expt Bioinformat, Dept Biochem & Mol Biol, Prot Interact Lab, Campusvej 55, DK-5230 Odense M, Denmark.	mann@bmb.sdu.dk	Kuster, Bernhard/Q-6031-2016; Mann, Matthias/A-3454-2013; Pandey, Akhilesh/B-4127-2009	Kuster, Bernhard/0000-0002-9094-1677; Mann, Matthias/0000-0003-1292-4799; Pandey, Akhilesh/0000-0001-9943-6127; Steen, Hanno/0000-0003-0179-6648	NATIONAL CANCER INSTITUTE [K01CA075447] Funding Source: NIH RePORTER; NCI NIH HHS [CA75447] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Annan RS, 2001, ANAL CHEM, V73, P393, DOI 10.1021/ac001130t; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; BLAKE TJ, 1991, ONCOGENE, V6, P653; COCHET C, 1988, J BIOL CHEM, V263, P3290; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Egerton M, 1996, BIOCHEM BIOPH RES CO, V224, P666, DOI 10.1006/bbrc.1996.1082; Endo K, 2000, FEBS LETT, V477, P55, DOI 10.1016/S0014-5793(00)01760-9; GOLD MR, 1994, ELECTROPHORESIS, V15, P441, DOI 10.1002/elps.1150150161; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; HUDDLESTON MJ, 1993, J AM SOC MASS SPECTR, V4, P710, DOI 10.1016/1044-0305(93)80049-5; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Ishihara H, 1999, BIOCHEM BIOPH RES CO, V260, P265, DOI 10.1006/bbrc.1999.0888; KNOWLTON AA, 2000, AM J PHYSIOL, V278, pH1214; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Kussmann M, 1997, J MASS SPECTROM, V32, P593; Love PE, 2000, IMMUNITY, V12, P591, DOI 10.1016/S1074-7613(00)80210-1; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; Morio T, 1999, IMMUNITY, V11, P339, DOI 10.1016/S1074-7613(00)80109-0; Neubauer G, 1999, ANAL CHEM, V71, P235, DOI 10.1021/ac9804902; Pandey A, 2000, J BIOL CHEM, V275, P38633, DOI 10.1074/jbc.M007849200; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Schlosser A, 2001, ANAL CHEM, V73, P170, DOI 10.1021/ac000826j; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Soskic V, 1999, BIOCHEMISTRY-US, V38, P1757, DOI 10.1021/bi982093r; Steen H, 2001, J MASS SPECTROM, V36, P782, DOI 10.1002/jms.174; Steen H, 2001, ANAL CHEM, V73, P1440, DOI 10.1021/ac001318c; Stensballe A, 2001, PROTEOMICS, V1, P207, DOI 10.1002/1615-9861(200102)1:2<207::AID-PROT207>3.3.CO;2-V; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; van Leeuwen JEM, 1999, J BIOL CHEM, V274, P5153, DOI 10.1074/jbc.274.8.5153; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yan JX, 1998, J CHROMATOGR A, V808, P23, DOI 10.1016/S0021-9673(98)00115-0	40	174	184	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1031	1039		10.1074/jbc.M109992200	http://dx.doi.org/10.1074/jbc.M109992200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11687594	hybrid			2022-12-25	WOS:000173166800022
J	Carosa, E; Kozmik, Z; Rall, JE; Piatigorsky, J				Carosa, E; Kozmik, Z; Rall, JE; Piatigorsky, J			Structure and expression of the scallop Omega-crystallin gene - Evidence for convergent evolution of promoter sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS-SPECIFIC EXPRESSION; ALDEHYDE DEHYDROGENASE GENE; GLUTATHIONE S-TRANSFERASES; TRANSGENIC MICE; RETINOIC-ACID; ARGININOSUCCINATE LYASE; DELTA-CRYSTALLIN; ALPHA-CRYSTALLIN; B-CRYSTALLIN; DUCK LENS	Omega-Crystallin of the scallop lens is an inactive aldehyde dehydrogenase (1A9). Here we have cloned the scallop Omega-crystallin gene. Except for an extra novel first exon, its 14-exon structure agrees well with that of mammalian aldehyde dehydrogenases 1, 2, and 6. The -2120/+63, -714/+63, and -156/+63 Omega-crystallin promoter fragments drive the luciferase reporter gene in transfected alphaTN4-1 lens cells and L929 fibroblasts but not in Cos7 cells. Putative binding sequences for cAMP-responsive element-binding protein (CREB)/Jun, alphaACRYBP1, AP-1, and PAX-6 in the Omega-crystallin promoter are surprisingly similar to the cis-elements used for lens promoter activity of the mouse and chicken alphaA-crystallin genes, which encode proteins homologous to small heat shock proteins. Site-specific mutations in the overlapping CREB/Jun and Pax-6 sites abolished activity of the Omega-crystallin promoter in transfected cells. Gel shift experiments utilizing extracts from the alphaTN4-1, L929, and Cos7 cells and the scallop stomach and oligonucleotides derived from the putative binding sites of the Omega-crystallin promoter showed complex formation. Gel shift experiments showed binding of recombinant Pax-6 and CREB to their respective sites. Our data suggest convergent evolutionary adaptations that underlie the preferential expression of crystallin genes in the lens of vertebrates and invertebrates.	NEI, Lab Mol & Dev Biol, Bethesda, MD 20892 USA; NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Piatigorsky, J (corresponding author), NEI, Lab Mol & Dev Biol, 6 Ctr Dr,Bldg 6-Rm 201, Bethesda, MD 20892 USA.		Kozmik, Zbynek/G-3581-2014; Kozmik, Zbynek/I-8807-2014	Kozmik, Zbynek/0000-0002-5850-2105; CAROSA, Eleonora/0000-0002-6593-6833				ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; BARBOSA P, 1991, J BIOL CHEM, V266, P22319; Behrens M, 1998, GENE, V216, P319, DOI 10.1016/S0378-1119(98)00346-1; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; CHEPELINSKY AB, 1985, P NATL ACAD SCI USA, V82, P2334, DOI 10.1073/pnas.82.8.2334; CHIOU SH, 1988, FEBS LETT, V241, P261, DOI 10.1016/0014-5793(88)81073-1; COOPER DL, 1991, GENE, V98, P201, DOI 10.1016/0378-1119(91)90174-A; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; CVEKL A, 1995, MOL CELL BIOL, V15, P653; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; Duncan MK, 1996, MECH DEVELOP, V57, P79, DOI 10.1016/0925-4773(96)00533-3; Duncan MK, 1998, MOL CELL BIOL, V18, P5579, DOI 10.1128/MCB.18.9.5579; EAKIN RM, 1979, AM ZOOL, V19, P647; Earle WR, 1943, J NATL CANCER I, V4, P165; Gehring WJ, 1999, TRENDS GENET, V15, P371, DOI 10.1016/S0168-9525(99)01776-X; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GopalSrivastava R, 1996, J BIOL CHEM, V271, P23029, DOI 10.1074/jbc.271.38.23029; GOPALSRIVASTAVA R, 1994, NUCLEIC ACIDS RES, V22, P1281, DOI 10.1093/nar/22.7.1281; Graham C, 1996, J BIOL CHEM, V271, P15623, DOI 10.1074/jbc.271.26.15623; Haynes JI, 1996, DEV DYNAM, V207, P75, DOI 10.1002/(SICI)1097-0177(199609)207:1<75::AID-AJA8>3.3.CO;2-O; HEJTMANCIK JF, 2001, METABOLIC MOL BASIS, P6033; HENDRIKS W, 1988, P NATL ACAD SCI USA, V85, P7114, DOI 10.1073/pnas.85.19.7114; Hickson RE, 2000, MOL BIOL EVOL, V17, P530, DOI 10.1093/oxfordjournals.molbev.a026333; Hsu LC, 1999, BIOCHEM J, V339, P387, DOI 10.1042/0264-6021:3390387; HSU LC, 1994, GENOMICS, V24, P333, DOI 10.1006/geno.1994.1624; HSU LC, 1989, GENOMICS, V5, P857, DOI 10.1016/0888-7543(89)90127-4; Hsu LC, 1988, GENOMICS, V2, P57, DOI 10.1016/0888-7543(88)90109-7; Ilagan JG, 1999, J BIOL CHEM, V274, P19973, DOI 10.1074/jbc.274.28.19973; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JAWORSKI CJ, 1991, J MOL EVOL, V33, P495, DOI 10.1007/BF02102802; Kamachi Y, 2001, GENE DEV, V15, P1272, DOI 10.1101/gad.887101; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; KLEMENT JF, 1989, J BIOL CHEM, V264, P19837; Klok EJ, 1998, J BIOL CHEM, V273, P17206, DOI 10.1074/jbc.273.27.17206; KONDOH H, 1987, DEV BIOL, V120, P177, DOI 10.1016/0012-1606(87)90116-3; KONDOH H, 1991, GENE, V99, P267, DOI 10.1016/0378-1119(91)90137-Z; Kostrouch Z, 1998, P NATL ACAD SCI USA, V95, P13442, DOI 10.1073/pnas.95.23.13442; Kozmik Z, 1997, EMBO J, V16, P6793, DOI 10.1093/emboj/16.22.6793; Li X, 1997, DEV GENET, V20, P258; MATSUO I, 1992, NUCLEIC ACIDS RES, V20, P3701, DOI 10.1093/nar/20.14.3701; McDermott JB, 1996, BIOCHEM BIOPH RES CO, V221, P559, DOI 10.1006/bbrc.1996.0635; MONTGOMERY MK, 1992, J BIOL CHEM, V267, P2099; Nishiguchi S, 1998, GENE DEV, V12, P776, DOI 10.1101/gad.12.6.776; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; Papanikolaou NA, 2000, J BIOL CHEM, V275, P26683; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; Piatigorsky J, 2000, J BIOL CHEM, V275, P41064, DOI 10.1074/jbc.M005625200; PIATIGORSKY J, 1992, ADV DEV BIOCH, V1, P211; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RICHARDSON J, 1995, P NATL ACAD SCI USA, V92, P4676, DOI 10.1073/pnas.92.10.4676; ROSS J, 1974, J MOL BIOL, V87, P697, DOI 10.1016/0022-2836(74)90079-5; SALVINIPLAWEN LV, 1977, EVOLUTIONARY BIOL, V10, P207; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SAX CM, 1993, NUCLEIC ACIDS RES, V21, P2633, DOI 10.1093/nar/21.11.2633; SIEZEN RJ, 1982, BIOCHIM BIOPHYS ACTA, V704, P304, DOI 10.1016/0167-4838(82)90160-1; THOMPSON MA, 1987, GENE, V56, P173, DOI 10.1016/0378-1119(87)90135-1; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; TOMAREV SI, 1994, J MOL EVOL, V39, P134; TOMAREV SI, 1993, J BIOL CHEM, V268, P4534; TOMAREV SI, 1992, J BIOL CHEM, V267, P8604; TOMAREV SI, 1988, NATURE, V336, P86, DOI 10.1038/336086a0; Tomarev SI, 1997, P NATL ACAD SCI USA, V94, P2421, DOI 10.1073/pnas.94.6.2421; Tomarev SI, 1996, EUR J BIOCHEM, V235, P449, DOI 10.1111/j.1432-1033.1996.00449.x; WAWROUSEK EF, 1990, DEV BIOL, V137, P68, DOI 10.1016/0012-1606(90)90008-7; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749; WISTOW GJ, 1990, GENE, V96, P263, DOI 10.1016/0378-1119(90)90262-P; WISTOW GJ, 1988, J CELL BIOL, V107, P2729, DOI 10.1083/jcb.107.6.2729; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052; Yokoyama S, 2000, PROG RETIN EYE RES, V19, P385, DOI 10.1016/S1350-9462(00)00002-1; Yoshida A, 1998, EUR J BIOCHEM, V251, P549, DOI 10.1046/j.1432-1327.1998.2510549.x; ZINOVIEVA RD, 1993, J BIOL CHEM, V268, P11449	83	29	29	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					656	664		10.1074/jbc.M107004200	http://dx.doi.org/10.1074/jbc.M107004200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11682475	hybrid			2022-12-25	WOS:000173087900086
J	Lee, HJ; Choi, C; Lee, SJ				Lee, HJ; Choi, C; Lee, SJ			Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; LEWY BODY DISEASE; A-BETA COMPONENT; PARKINSONS-DISEASE; IN-VITRO; CYTOPLASMIC INCLUSIONS; PRESYNAPTIC PROTEIN; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; FATTY-ACIDS	alpha-Synuclein exists as at least two structural isoforms: a helix-rich, membrane-bound form and a disordered, cytosolic form. Here, we investigated the role of membrane-bound alpha-synuclein in the aggregation process. In a cell-free system consisting of isolated brain fractions, spontaneous and progressive aggregation of alpha-synuclein was observed in membranes starting at day 1, whereas no aggregation was observed in the cytosolic fraction in a 3-day period. The addition of antioxidants reduced the aggregation in the membrane fraction, implicating the role of oxidative modifications. When excess cytosolic alpha-synuclein was added to brain membranes, the rate of aggregation was increased, while the lag time was unaffected. Incorporation of cytosolic alpha-synuclein into membrane-associated aggregates was demonstrated by fractionation and co-immunoprecipitation experiments. In our recent study, we showed that mitochondrial inhibitors such as rotenone, induced alpha-synuclein aggregation in cells. In the present study using rotenone-treated cells, the earliest appearance of alpha-synuclein oligomeric species was observed in membranous compartments. Furthermore, alpha-synuclein-positive inclusions were co-stained with DiI, a membrane-partitioning fluorescent dye, confirming the presence of lipid components in alpha-synuclein aggregates. These results suggest that membrane-bound alpha-synuclein can generate nuclei that seed the aggregation of the more abundant cytosolic form.	Parkinsons Inst, Sunnyvale, CA 94089 USA; Chonnam Natl Univ, Med Sch, Dept Pathol, Kwangju 501190, South Korea	Chonnam National University	Lee, SJ (corresponding author), Parkinsons Inst, 1170 Morse Ave, Sunnyvale, CA 94089 USA.	slee@parkinsonsinstitute.org		Lee, Seung-Jae/0000-0002-5155-5335				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Arima K, 1998, ACTA NEUROPATHOL, V96, P439, DOI 10.1007/s004010050917; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; Baba M, 1998, AM J PATHOL, V152, P879; Braak E, 2001, ACTA NEUROPATHOL, V101, P195; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DEHAAN JB, 1992, MOL BRAIN RES, V13, P179, DOI 10.1016/0169-328X(92)90025-7; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fezoui Y, 2000, NAT STRUCT BIOL, V7, P1095, DOI 10.1038/81937; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Gai WP, 1999, J NEUROCHEM, V73, P2093; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; GEREMIA E, 1990, NEUROCHEM RES, V15, P719, DOI 10.1007/BF00973653; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Koppaka V, 2000, BIOCHEMISTRY-US, V39, P10011, DOI 10.1021/bi000619d; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Matsuoka Y, 2001, NEUROBIOL DIS, V8, P535, DOI 10.1006/nbdi.2001.0392; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Papadimitriou A, 1999, NEUROLOGY, V52, P651, DOI 10.1212/WNL.52.3.651; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Schmidt A, 1998, METHODS, V16, P160, DOI 10.1006/meth.1998.0663; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; VOLLES MJ, 1918, BIOCHEMISTRY-US, V40, P7812; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X	66	351	372	1	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					671	678		10.1074/jbc.M107045200	http://dx.doi.org/10.1074/jbc.M107045200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11679584	hybrid			2022-12-25	WOS:000173087900088
J	Miyazaki, K; Yano, T; Schmidt, DJ; Tokui, T; Shibata, M; Lifshitz, LM; Kimura, S; Tuft, RA; Ikebe, M				Miyazaki, K; Yano, T; Schmidt, DJ; Tokui, T; Shibata, M; Lifshitz, LM; Kimura, S; Tuft, RA; Ikebe, M			Rho-dependent agonist-induced spatio-temporal change in myosin phosphorylation in smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; GUANINE-NUCLEOTIDE EXCHANGE; BOVINE BRAIN MEMBRANES; GTP-BINDING PROTEIN; CALCIUM SENSITIZATION; CA2+ SENSITIZATION; TRANSLOCATION; PURIFICATION; INHIBITION; GENE	Agonist-induced translocation of RhoA and the spatio-temporal change in myosin regulatory light chain (MLC20) phosphorylation in smooth muscle was clarified at the single cell level. We expressed green fluorescent protein-tagged RhoA in the differentiated tracheal smooth muscle cells and visualized the translocation of RhoA in a living cell with three-dimensional digital imaging analysis. The stimulation of the cells by carbachol initiated the translocation of green fluorescent protein-tagged wild type RhoA to the plasma membrane within a minute. The change in MLC20 phosphorylation level after carbachol stimulation was monitored by using phospho-Ser-19-specific antibody recognizing the phosphorylated MLC20 in single cells. Cells expressing the dominant negative form (T19N) of RhoA significantly suppressed sustained MLC20 phosphorylation during the prolonged phase (>300 s), whereas the maximum phosphorylation level (reached at 10 s after stimulation) of these cells was not significantly different from the control cells. The kinetics of RhoA translocation was consistent with that of sustained myosin phosphorylation, suggesting the involvement of a RhoA pathway. Carbachol stimulation increased myosin phosphorylation within a minute both at the cortical and the central region. On the other hand, during prolonged phase, myosin phosphorylation was sustained at the cortical region of the cells but not at the central fibers. A myosin light chain kinase-specific inhibitor, ML-9, diminished myosin phosphorylation at the central region of the cells after the stimulation but not at the cortical area. On the other hand, Y-27632, a Rho kinase-specific inhibitor, diminished myosin phosphorylation at the cortical region but not the central region. The results clearly show that the myosin light chain kinase pathway and the Rho pathway distinctly change myosin phosphorylation in smooth muscle cells in both a temporal and spatial manner.	Univ Massachusetts, Med Sch, Dept Physiol, Worcester, MA 01655 USA; Univ Massachusetts, Med Sch, Dept Biomed Imaging Grp, Worcester, MA 01655 USA; Med & Biol Labs, Ina, Nagano 396, Japan; Univ Tokyo, Dept Internal Med, Bunkyo Ku, Tokyo 113, Japan	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Tokyo	Ikebe, M (corresponding author), Univ Massachusetts, Med Sch, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	Mitsuo.Ikebe@umassmed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061426, R01HL060831] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60831, HL61426] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; ANDERSON PS, 1987, MOL CELL BIOL, V7, P3620, DOI 10.1128/MCB.7.10.3620; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CARRINGTON WA, 1990, NONINVASIVE TECHNIQU, P53; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; Drummond RM, 1999, J PHYSIOL-LONDON, V516, P139, DOI 10.1111/j.1469-7793.1999.139aa.x; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Feng JH, 1999, J BIOL CHEM, V274, P3744, DOI 10.1074/jbc.274.6.3744; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fujihara H, 1997, MOL BIOL CELL, V8, P2437, DOI 10.1091/mbc.8.12.2437; Gong MC, 2001, AM J PHYSIOL-CELL PH, V281, pC257, DOI 10.1152/ajpcell.2001.281.1.C257; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Gong MC, 1997, J BIOL CHEM, V272, P10704; Halayko AJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1040, DOI 10.1152/ajplung.1996.270.6.L1040; Halayko AJ, 1999, AM J PHYSIOL-LUNG C, V276, pL197, DOI 10.1152/ajplung.1999.276.1.L197; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; Katoh K, 2001, J CELL BIOL, V153, P569, DOI 10.1083/jcb.153.3.569; Katoh K, 2001, AM J PHYSIOL-CELL PH, V280, pC1669, DOI 10.1152/ajpcell.2001.280.6.C1669; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Komatsu S, 2000, J BIOL CHEM, V275, P34512, DOI 10.1074/jbc.M003019200; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Lin PJ, 1999, J BIOL CHEM, V274, P5987, DOI 10.1074/jbc.274.9.5987; Lin PJ, 1997, J BIOL CHEM, V272, P7412, DOI 10.1074/jbc.272.11.7412; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; NISHIMURA J, 1992, CIRC RES, V71, P951, DOI 10.1161/01.RES.71.4.951; NODA M, 1995, FEBS LETT, V367, P246, DOI 10.1016/0014-5793(95)00573-R; Poperechnaya A, 2000, J CELL BIOL, V151, P697, DOI 10.1083/jcb.151.3.697; ROBERTSON D, 1995, J HISTOCHEM CYTOCHEM, V43, P471, DOI 10.1177/43.5.7537292; SASAKI T, 1993, J BIOL CHEM, V268, P23959; Somlyo A P, 1999, Rev Physiol Biochem Pharmacol, V134, P201; Somlyo AP, 1998, ACTA PHYSIOL SCAND, V164, P437; Strassheim D, 2000, J BIOL CHEM, V275, P6699, DOI 10.1074/jbc.275.10.6699; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016	42	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					725	734		10.1074/jbc.M108568200	http://dx.doi.org/10.1074/jbc.M108568200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11673466	hybrid			2022-12-25	WOS:000173087900095
J	Denmat-Ouisse, LA; Phebidias, C; Honkavaara, P; Robin, P; Geny, B; Min, DS; Bourgoin, S; Frohman, MA; Raymond, MN				Denmat-Ouisse, LA; Phebidias, C; Honkavaara, P; Robin, P; Geny, B; Min, DS; Bourgoin, S; Frohman, MA; Raymond, MN			Regulation of constitutive protein transit by phospholipase D in HT29-cl19A cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDIC-ACID; EPITHELIAL-CELLS; PLASMA-MEMBRANE; SECRETORY VESICLES; GOLGI NETWORK; D ACTIVATION; GENE FAMILY; MDCK CELLS; N-GLYCANS; D DEFINES	Phospholipase D (PLD) plays a central role in the control of vesicle budding and protein transit. We previously showed that in resting epithelial HT29-cl19A cells, PLD is implicated in the control of constitutive protein transit, from the trans-Golgi network to the plasma membrane, and that phorbol ester stimulation of protein transit is correlated with PLD activation (Auger, R., Robin, P., Camier, B., Vial, G., Rossignol, B., Tenu, J.-P., and Raymond, M.-N. (1999) J. Biol. Chem. 274, 28652-28659). In this paper we demonstrate that: 1) PLD is not implicated in the earliest phases of protein transit; 2) PLD controls apical but not basolateral protein transit; 3) HT29-cl19A cells express PLD1b and PLD2a mRNAs and proteins; 4) the expression of a catalytically inactive mutant of PLD2 (mPLD2-K758R) significantly inhibited apical constitutive protein transit whereas expression of a catalytically inactive mutant of PLD1 (hPLD1b-K898R) prevented increases in the rate of apical transit as triggered by phorbol esters; 5) PLD2 appears to be located in a perinuclear region containing the Golgi whereas PLD1, which is scattered in the cyto. plasm in resting cells, is translocated to the plasma membrane after phorbol ester stimulation. Taken together, these data lead to the conclusion that in HT29cl19A cells, both PLDs regulate protein transit between the trans-Golgi network and the apical plasma membrane, but that they do so at different steps in the pathway.	Univ Paris 11, CNRS, UMR 8619, Lab Biochim Transport Cellulaires, F-91405 Orsay, France; SUNY Stony Brook, Ctr Dev Genet, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Univ Laval, Quebec City, PQ G1V 4G2, Canada; CHUL, Fac Med, Dept Anat Physiol, Quebec City, PQ G1V 4G2, Canada; Catholic Univ Korea, Coll Med, Dept Physiol, Seoul 137701, South Korea; INSERM, U332, ICGM, F-75014 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Laval University; Laval University; Catholic University of Korea; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Raymond, MN (corresponding author), Univ Paris 11, CNRS, UMR 8619, Lab Biochim Transport Cellulaires, Bat 430, F-91405 Orsay, France.			Bourgoin, Sylvain/0000-0001-9779-0368				Auger R, 1999, J BIOL CHEM, V274, P28652, DOI 10.1074/jbc.274.40.28652; AUGERON C, 1984, CANCER RES, V44, P3961; Battu S, 1998, FEBS LETT, V437, P49, DOI 10.1016/S0014-5793(98)01196-X; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; Boisgard R, 2000, BBA-MOL CELL RES, V1495, P281, DOI 10.1016/S0167-4889(99)00167-6; Brandsch C, 1998, SCAND J GASTROENTERO, V33, P833; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Czarny M, 2000, FEBS LETT, V467, P326, DOI 10.1016/S0014-5793(00)01174-1; Freyberg Z, 2001, MOL BIOL CELL, V12, P943, DOI 10.1091/mbc.12.4.943; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Jilling T, 1996, J BIOL CHEM, V271, P4381; Kim Y, 1999, BBA-MOL CELL BIOL L, V1436, P319, DOI 10.1016/S0005-2760(98)00120-9; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Larsen JE, 1999, FEBS LETT, V451, P19, DOI 10.1016/S0014-5793(99)00526-8; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Londono I, 1999, KIDNEY INT, V55, P1407, DOI 10.1046/j.1523-1755.1999.00365.x; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Marcil J, 1997, J BIOL CHEM, V272, P20660, DOI 10.1074/jbc.272.33.20660; MEGA T, 1980, J BIOL CHEM, V255, P4057; Millar CA, 1999, BIOCHEM BIOPH RES CO, V254, P734, DOI 10.1006/bbrc.1998.0110; Min DS, 2000, J NEUROCHEM, V75, P274, DOI 10.1046/j.1471-4159.2000.0750274.x; Morash SC, 2000, BBA-MOL CELL BIOL L, V1487, P177, DOI 10.1016/S1388-1981(00)00094-9; Morgan CP, 1997, BIOCHEM J, V325, P581, DOI 10.1042/bj3250581; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Shome K, 2000, ENDOCRINOLOGY, V141, P2200, DOI 10.1210/en.141.6.2200; Siddhanta A, 1998, J BIOL CHEM, V273, P17995, DOI 10.1074/jbc.273.29.17995; Siddhanta A, 2000, J BIOL CHEM, V275, P12023, DOI 10.1074/jbc.275.16.12023; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; Toda K, 1999, FEBS LETT, V442, P221, DOI 10.1016/S0014-5793(98)01646-9; Tuscher O, 1997, FEBS LETT, V419, P271, DOI 10.1016/S0014-5793(97)01471-3; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Vogel LK, 2000, FEBS LETT, V473, P297, DOI 10.1016/S0014-5793(00)01548-9; Way G, 2000, BIOCHEM J, V346, P63, DOI 10.1042/0264-6021:3460063; Williger BT, 1999, J BIOL CHEM, V274, P735, DOI 10.1074/jbc.274.2.735	43	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48840	48846		10.1074/jbc.M104276200	http://dx.doi.org/10.1074/jbc.M104276200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11687572	hybrid			2022-12-25	WOS:000173922100030
J	McGee, MP; Liang, J				McGee, MP; Liang, J			Regulation of glycosaminoglycan function by osmotic potentials. Measurement of water transfer during antithrombin activation by heparin.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERPIN-PROTEINASE COMPLEX; REACTIVE CENTER LOOP; BINDING-SITE; FACTOR-XA; ALLOSTERIC REGULATION; EXCLUDED VOLUME; MECHANISM; HYDRATION; KINETICS; IDENTIFICATION	The sulfated glycosaminoglycan heparin is an important anticoagulant, widely used to treat and to prevent arterial thrombosis. Heparin triggers conformational changes in, and the functional activation of, the serine proteinase inhibitor antithrombin. We investigated water-transfer reactions during the activation process to explore the possibility that functional interaction between antithrombin and sulfated glycosaminoglycans can be regulated by osmotic potentials. Volume of water transferred upon heparin binding was measured from differences in free energy change, Delta(DeltaG), with osmotic stress, pi. Osmotic stress was induced with chemically inert probes that are geometrically excluded from the water-permeable spaces of antithrombin and from intermolecular spaces formed during the association reaction. The free energy change, DeltaG, for the antithrombin/heparin interaction was calculated from the dissociation constant, determined by functional titrations of heparin with antithrombin at fixed concentrations of the coagulation protease factor Xa. The effect of osmotic stress was independent of the chemical nature of osmotic probes but correlated with their radius up to radius >17Angstrom. In mixtures including a large and a small probe, the effect of the large probe was not modified by the small probe added at a large molar excess. With an osmotic probe of 4-Angstrom radius, the Delta(DeltaG)/pi slope corresponds to a transfer of 119 +/- 25 water molecules to bulk solution on formation of the complex. Analytical characterization of water-permeable volumes in x-ray-derived bound and free antithrombin structures revealed complex surfaces with smaller hydration volumes in the bound relative to the free conformation. The residue distribution in, and atomic composition of, the pockets containing atoms from residues implicated in heparin binding were distinct in the bound versus free conformer. The results demonstrate that the heparin/antithrombin interaction is linked to net water transfer and, therefore, can be regulated in biological gels by osmotic potentials.	Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA	Wake Forest University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	McGee, MP (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	mmcgec@wfubmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057936] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57936] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAKAWA T, 1985, BIOCHEMISTRY-US, V24, P6756, DOI 10.1021/bi00345a005; ATHA DH, 1981, J BIOL CHEM, V256, P2108; Beauchamp NJ, 1998, BLOOD, V92, P2696, DOI 10.1182/blood.V92.8.2696.420a43_2696_2706; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; COLOMBO MF, 1992, SCIENCE, V256, P655, DOI 10.1126/science.1585178; Colombo MF, 1996, J BIOL CHEM, V271, P4895; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; Desai UR, 1998, BIOCHEMISTRY-US, V37, P13033, DOI 10.1021/bi981426h; DOUZOU P, 1994, P NATL ACAD SCI USA, V91, P1657, DOI 10.1073/pnas.91.5.1657; DZINGELESKI GD, 1993, BIOCHEMISTRY-US, V32, P9143, DOI 10.1021/bi00086a020; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; Futamura A, 2000, J BIOL CHEM, V275, P4092, DOI 10.1074/jbc.275.6.4092; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; GLASSTONE S, 1941, THEORY RATE PROCESSE; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JOOS G, 1986, THEORETICAL PHYSICS, P543; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KNOLL D, 1983, J BIOL CHEM, V258, P5710; KUGA S, 1981, J CHROMATOGR, V206, P449, DOI 10.1016/S0021-9673(00)88914-1; LANE DA, 1992, BLOOD COAGUL FIBRIN, V3, P315, DOI 10.1097/00001721-199206000-00012; Lawrence DA, 1997, NAT STRUCT BIOL, V4, P339, DOI 10.1038/nsb0597-339; Lee KN, 1998, J BIOL CHEM, V273, P2509, DOI 10.1074/jbc.273.5.2509; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Liang J, 1998, PROTEINS, V33, P1; Liang J, 1998, BIOPHYS J, V75, P573, DOI 10.1016/S0006-3495(98)77548-4; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; MAROUDAS A, 1991, BIOCHIM BIOPHYS ACTA, V1073, P285, DOI 10.1016/0304-4165(91)90133-2; MCGEE MP, 1991, J BIOL CHEM, V266, P8079; MCGEE MP, 1995, J BIOL CHEM, V270, P15170, DOI 10.1074/jbc.270.25.15170; Meagher JL, 1998, J BIOL CHEM, V273, P23283, DOI 10.1074/jbc.273.36.23283; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Parsegian VA, 2000, P NATL ACAD SCI USA, V97, P3987, DOI 10.1073/pnas.97.8.3987; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; PARSEGIAN VA, 1986, METHOD ENZYMOL, V227, P401; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; RAND RP, 1992, SCIENCE, V256, P618, DOI 10.1126/science.256.5057.618; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; TANAKA T, 1981, SCI AM, V244, P110; WANNIER GH, 1987, STAT PHYSICS, P336	45	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49275	49282		10.1074/jbc.M104413200	http://dx.doi.org/10.1074/jbc.M104413200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11677228	hybrid			2022-12-25	WOS:000173922100086
J	Shen, WJ; Liang, Y; Hong, R; Patel, S; Natu, V; Sridhar, K; Jenkins, A; Bernlohr, DA; Kraemer, FB				Shen, WJ; Liang, Y; Hong, R; Patel, S; Natu, V; Sridhar, K; Jenkins, A; Bernlohr, DA; Kraemer, FB			Characterization of the functional interaction of adipocyte lipid-binding protein with hormone-sensitive lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-TISSUE; SEQUENCE SIMILARITY; THERMOSTABLE ESTERASE; LIPOLYTIC STIMULATION; TARGETED DISRUPTION; FATTY-ACID; TRANSLOCATION; PURIFICATION; EXPRESSION; GENE	Hormone-sensitive lipase (HSL) is an intracellular lipase that plays an important role in the hydrolysis of triacylglycerol in adipose tissue. HSL has been shown to interact with adipocyte lipid-binding protein (ALBP), a member of the family of intracellular lipid-binding proteins that bind fatty acids and other hydrophobic ligands. The current studies have addressed the functional significance of the association and mapped the site of interaction between HSL and ALBP. Incubation of homogeneous ALBP with purified, recombinant HSL in vitro resulted in a 2-fold increase in substrate hydrolysis. Moreover, the ability of oleate to inhibit HSL hydrolytic activity was attenuated by co-incubation with ALBP. Co-transfection of Chinese hamster ovary cells with HSL and ALBP resulted in greater hydrolytic activity than transfection of cells with HSL and vector alone. Deletional mutations of HSL localized the region of HSL that interacts with ALBP to amino acids 192-200, and site-directed mutagenesis of individual amino acids in this region identified His-194 and Glu-199 as critical for mediating the interaction of HSL with ALBP. Interestingly, HSL mutants H194L and E199A, each of which retained normal basal hydrolytic activity, failed to display an increase in hydrolytic activity when co-transfected with wild type ALBP. Therefore, ALBP increases the hydrolytic activity of HSL through its ability to bind and sequester fatty acids and via specific protein-protein interaction. Thus, HSL and ALBP constitute a functionally important lipolytic complex.	Stanford Univ, Div Endocrinol, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Minnesota System; University of Minnesota Twin Cities	Kraemer, FB (corresponding author), Stanford Univ, Div Endocrinol, Dept Med, S-005, Stanford, CA 94305 USA.	fbk@stanford.edu	Kraemer, Fredric/AAC-3633-2019	Shen, Wen-Jun/0000-0001-5150-1698; Kraemer, Fredric/0000-0003-2468-7807	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007217, R01DK053189, R01DK046942] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53189, DK 46942, DK 07217] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Bernlohr D. A., 2000, Adipocyte biology and hormone signaling., P31; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; BERTOLINI MC, 1995, EUR J BIOCHEM, V228, P863, DOI 10.1111/j.1432-1033.1995.0863m.x; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; Choo DW, 1998, APPL ENVIRON MICROB, V64, P486; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; Coe NR, 1999, J LIPID RES, V40, P967; Contreras JA, 1996, J BIOL CHEM, V271, P31426, DOI 10.1074/jbc.271.49.31426; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; FREDRIKSON G, 1986, BIOCHIM BIOPHYS ACTA, V876, P288, DOI 10.1016/0005-2760(86)90286-9; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; GORDON RS, 1956, J CLIN INVEST, V35, P206, DOI 10.1172/JCI103265; HEMILA H, 1994, BBA-LIPID LIPID MET, V1210, P249, DOI 10.1016/0005-2760(94)90129-5; HUTTUNEN JK, 1970, P NATL ACAD SCI USA, V67, P290, DOI 10.1073/pnas.67.1.290; JEPSON CA, 1992, FEBS LETT, V310, P197, DOI 10.1016/0014-5793(92)81328-J; Kanaya S, 1998, BIOCHEM J, V332, P75, DOI 10.1042/bj3320075; KRAEMER FB, 1993, J LIPID RES, V34, P663; Manco G, 2000, ARCH BIOCHEM BIOPHYS, V373, P182, DOI 10.1006/abbi.1999.1497; Manco G, 1998, BIOCHEM J, V332, P203, DOI 10.1042/bj3320203; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Scheja L, 1999, DIABETES, V48, P1987, DOI 10.2337/diabetes.48.10.1987; SHA RS, 1993, J BIOL CHEM, V268, P7885; Shen WJ, 2000, BIOCHEMISTRY-US, V39, P2392, DOI 10.1021/bi992283h; Shen WJ, 1999, P NATL ACAD SCI USA, V96, P5528, DOI 10.1073/pnas.96.10.5528; Shen WJ, 1998, BIOCHEMISTRY-US, V37, P8973, DOI 10.1021/bi980545u; XU ZH, 1993, J BIOL CHEM, V268, P7874; XU ZH, 1991, J BIOL CHEM, V266, P14367	29	70	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49443	49448		10.1074/jbc.M104095200	http://dx.doi.org/10.1074/jbc.M104095200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11682468	hybrid			2022-12-25	WOS:000173922100106
J	Shamay, M; Agami, R; Shaul, Y				Shamay, M; Agami, R; Shaul, Y			HBV integrants of hepatocellular carcinoma cell lines contain an active enhancer	ONCOGENE			English	Article						HBV enhancer; in vivo footprinting; onco-DNA; fetoprotein transcription factor (FTF)	HEPATITIS-B-VIRUS; COMPARATIVE GENOMIC HYBRIDIZATION; TRANSCRIPTION FACTORS; NUCLEAR RECEPTOR; GENE PROMOTER; ACTIVATION; SEQUENCES; DNA; ELEMENT; ABERRATIONS	Hepatitis B virus (HBV) infection is a major risk factor worldwide for the development of hepatocellular carcinoma (HCC). Integrated HBV DNA fragments, often highly rearranged, are frequently detected in HCC. In woodchuck, the viral enhancer plays a central role in hepatocarcinogenesis, but in humans the mechanism of HBV oncogenesis has not been established. In this study we investigated the status of the viral enhancer in two human HCC cell lines, Hep3B and PLC/PRF/5 each containing one or more integrated HBV DNA fragments. Active enhancer was defined by virtue of its protein occupancy as determined by genomic in vivo DMS footprinting. In PLC/ PRF/5 cells, the HBV DNA was integrated in a cellular gene at chromosome 11q13, at a locus reported to be amplified in many tumors. We show here that in both cell lines, the integrated HBV DNA fragments contain an active enhancer-I. In particular, the occupation of the two previously defined basic enhancer elements, E and EP, was prominent. While in both cell lines the same protein binds to the EP elements, the E element, however, is occupied in a cell-line specific manner. In PLC/PRF/5 but not Hep3B, the prominent binding of an undefined protein was detected. Our data suggest that this protein is likely to be the fetoprotein transcription factor (FTF). The finding that enhancer sequences are conserved and functional in different cell lines suggests a selection pressure for their long-term maintenance. We therefore propose that the HBV enhancer-I might play a role in hepatocellular carcinogenesis.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		agami, reuven/GOG-8289-2022	Agami, Reuven/0000-0002-2848-2473				BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; BERGER I, 1987, J VIROL, V61, P1180, DOI 10.1128/JVI.61.4.1180-1186.1987; Blake M, 1996, J VIROL, V70, P6060, DOI 10.1128/JVI.70.9.6060-6066.1996; Bossard P, 1997, METHODS, V11, P180, DOI 10.1006/meth.1996.0404; BULLA GA, 1988, J VIROL, V62, P1437, DOI 10.1128/JVI.62.4.1437-1441.1988; Butel JS, 1996, TRENDS MICROBIOL, V4, P119, DOI 10.1016/0966-842X(96)81529-0; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; CHANG HK, 1987, NUCLEIC ACIDS RES, V15, P2261, DOI 10.1093/nar/15.5.2261; CHEN JY, 1994, INTERVIROLOGY, V37, P41, DOI 10.1159/000150355; Datta S, 2000, J VIROL, V74, P8277, DOI 10.1128/JVI.74.18.8277-8285.2000; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P4427, DOI 10.1128/MCB.10.8.4427; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3682; Doitsh G, 1999, ONCOGENE, V18, P7506, DOI 10.1038/sj.onc.1203209; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FAKTOR O, 1988, VIROLOGY, V162, P362, DOI 10.1016/0042-6822(88)90476-X; Flajolet M, 1998, J VIROL, V72, P6175, DOI 10.1128/JVI.72.7.6175-6180.1998; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; Gilbert S, 2000, J VIROL, V74, P5032, DOI 10.1128/JVI.74.11.5032-5039.2000; GRAEF E, 1994, ONCOGENE, V9, P81; Greenblatt MS, 1997, CANCER RES, V57, P426; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; Hershkovitz M, 1997, METHODS, V11, P253, DOI 10.1006/meth.1996.0412; Hildt E, 1998, RECENT RES CANCER, V154, P315; Ishida H, 2000, J VIROL, V74, P1241, DOI 10.1128/JVI.74.3.1241-1251.2000; Kairat A, 1999, INTERVIROLOGY, V42, P228, DOI 10.1159/000024982; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; Kosovsky MJ, 1999, VIROLOGY, V259, P60, DOI 10.1006/viro.1999.9776; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Li M, 1998, J BIOL CHEM, V273, P29022, DOI 10.1074/jbc.273.44.29022; Miyaki M, 2000, INT J CANCER, V85, P518, DOI 10.1002/(SICI)1097-0215(20000215)85:4<518::AID-IJC12>3.0.CO;2-7; ORI A, 1995, VIROLOGY, V207, P98, DOI 10.1006/viro.1995.1055; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; OU JH, 1987, NUCLEIC ACIDS RES, V15, P8919, DOI 10.1093/nar/15.21.8919; Paran N, 2000, MOL CELL BIOL, V20, P834, DOI 10.1128/MCB.20.3.834-841.2000; Rivkina M, 1996, CARCINOGENESIS, V17, P2689, DOI 10.1093/carcin/17.12.2689; Sakakura C, 1999, BRIT J CANCER, V80, P2034, DOI 10.1038/sj.bjc.6690638; SHAUL Y, 1986, J VIROL, V59, P731, DOI 10.1128/JVI.59.3.731-734.1986; SHAUL Y, 1984, J VIROL, V51, P776, DOI 10.1128/JVI.51.3.776-787.1984; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; Shuster MI, 2000, GENE CHROMOSOME CANC, V28, P153, DOI 10.1002/(SICI)1098-2264(200006)28:2<153::AID-GCC4>3.0.CO;2-9; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; Wang PC, 2001, J VIROL METHODS, V92, P83, DOI 10.1016/S0166-0934(00)00278-0; Wong N, 2000, CLIN CANCER RES, V6, P4000; ZHOU DX, 1990, J BIOL CHEM, V265, P20731; ZIEMER M, 1985, J VIROL, V53, P885, DOI 10.1128/JVI.53.3.885-892.1985	49	34	37	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6811	6819		10.1038/sj.onc.1204879	http://dx.doi.org/10.1038/sj.onc.1204879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687960				2022-12-25	WOS:000171641000002
J	Bifulco, M; Laezza, C; Portella, G; Vitale, M; Orlando, P; De Petrocellis, L; Di Marzo, V				Bifulco, M; Laezza, C; Portella, G; Vitale, M; Orlando, P; De Petrocellis, L; Di Marzo, V			Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth	FASEB JOURNAL			English	Article						anandamide; CB1 receptor; K-ras oncogene; thyroid cell; cancer	HUMAN BREAST-CANCER; THYROID EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; ENDOCANNABINOIDS; ANANDAMIDE; CB1; TRANSFORMATION; PROLIFERATION; INVOLVEMENT; INHIBITION	We investigated the effect of 2-methyl-arachidonyl-2'-fluoro-ethylamide (Met-F-AEA), a stable analog of the endocannabinoid anandamide, on a rat thyroid epithelial cell line (FRTL-5) transformed by the K-ras oncogene, and on epithelial tumors derived from these cells. Met-F-AEA effect in vivo was evaluated in a nude mouse xenograft model, where K-ras-transformed (KiMol) cells were implanted subcutaneously. Met-F-AEA (0.5 mg/kg/dose) induced a drastic reduction in tumor volume. This effect was inhibited by the CB1 receptor antagonist SR141716A (0.7 mg/kg/dose) and was accompanied by a strong reduction of K-ras activity. Accordingly, KiMol cells and tumors express CB1 receptors. Met-F-AEA inhibited (IC50 similar to5 muM) the proliferation in vitro and the transition to the S phase of KiMol cells and it reduced K-ras activity; these effects were antagonized by SR141716A. Met-F-AEA cytostatic action was significantly smaller in nontransformed FRTL-5 cells than in KiMol cells. Met-F-AEA treatment exerted opposite effects on the expression of CB1 receptors in KiMol and FRTL-5 cells, with a strong up-regulation in the former case and a suppression in nontransformed cells. The data suggest that: 1) Met-F-AEA inhibits ras oncogene-dependent tumor growth in vivo through CB1 cannabinoid receptors; and 2) responsiveness of FRTL-5 cells to endocannabinoids depends on whether or not they are transformed by K-ras.	CNR, Ctr Endocrinol & Oncol Sperimentale, Endocannabinoid Res Grp, I-80078 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, I-80078 Naples, Italy; Univ Catanzaro, Dipartimento Med Sperimentale & Clin G Salvatore, I-80078 Naples, Italy; CNR, Ist Biochim Prot & Enzimol, I-80078 Naples, Italy; CNR, Ist Cibernet, I-80078 Naples, Italy; CNR, Ist Chim Biomol, I-80078 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR)	Bifulco, M (corresponding author), CNR, Ctr Endocrinol & Oncol Sperimentale, Endocannabinoid Res Grp, Via Campi Flegrei 34,Comprensorio Olivetti,Fabbr, I-80078 Naples, Italy.	maubiful@unina.it; vdimarzo@icmib.na.cnr.it	Di Marzo, Vincenzo/AAD-7742-2019; laez, chi/AAW-4437-2020; Portella, Giuseppe/AFU-6826-2022	Di Marzo, Vincenzo/0000-0002-1490-3070; PORTELLA, Giuseppe/0000-0001-8276-9769; Bifulco, Maurizio/0000-0002-1771-4531				Aceto MD, 1998, J PHARMACOL EXP THER, V287, P598; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIFULCO M, 1993, J CELL PHYSIOL, V155, P340, DOI 10.1002/jcp.1041550215; Bisogno T, 1998, EUR J BIOCHEM, V254, P634, DOI 10.1046/j.1432-1327.1998.2540634.x; BOS JL, 1989, CANCER RES, V49, P4682; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; Derkinderen P, 2001, J NEUROCHEM, V77, P957, DOI 10.1046/j.1471-4159.2001.00333.x; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Di Marzo V, 1998, BBA-LIPID LIPID MET, V1392, P153, DOI 10.1016/S0005-2760(98)00042-3; FOULDS L, 1969, NEOPLASTIC DEV, V1; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Guzman M, 2001, TRENDS PHARMACOL SCI, V22, P19, DOI 10.1016/S0165-6147(00)01586-8; Guzman M, 2001, J MOL MED-JMM, V78, P613, DOI 10.1007/s001090000177; Kobayashi Y, 2001, J BIOCHEM-TOKYO, V129, P665, DOI 10.1093/oxfordjournals.jbchem.a002904; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; Laezza C, 1998, P NATL ACAD SCI USA, V95, P13646, DOI 10.1073/pnas.95.23.13646; Martin BR, 1999, LIFE SCI, V65, P573, DOI 10.1016/S0024-3205(99)00281-7; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; Melck D, 2000, ENDOCRINOLOGY, V141, P118, DOI 10.1210/en.141.1.118; Melck D, 1999, FEBS LETT, V463, P235, DOI 10.1016/S0014-5793(99)01639-7; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814; Sanchez C, 2001, CANCER RES, V61, P5784; Sanchez C, 1998, FEBS LETT, V436, P6, DOI 10.1016/S0014-5793(98)01085-0; SCHWAB G, 1994, P NATL ACAD SCI USA, V91, P10460, DOI 10.1073/pnas.91.22.10460; SUAREZ HG, 1988, ONCOGENE, V2, P403	31	114	119	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2745	+		10.1096/fj.01-0320fje	http://dx.doi.org/10.1096/fj.01-0320fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11687506				2022-12-25	WOS:000171920400006
J	Rabbitts, TH				Rabbitts, TH			Chromosomal translocation master genes, mouse models and experimental therapeutics	ONCOGENE			English	Article						cancer; therapy; chromosomal translocation; cytogenetics; leukaemia; sarcoma	T-CELL LEUKEMIA; LIM-PROTEIN RBTN2; C-MYC GENE; TRANSCRIPTION FACTORS; BURKITT-LYMPHOMA; HOMEOBOX GENE; CRE-LOXP; LMO2; FUSION; DOMAIN	Molecular biologists have elucidated general principles about chromosomal translocations by cloning oncogenes or fusion genes at chromosomal translocation junctions. These genes invariably encode intracellular proteins and in acute cancers, often involve transcription and developmental regulators, which are master regulators of cell fate (e.g. LMO2 which is involved in acute leukaemia). Chromosomal translocations are usually associated with specific cell types. The reason for this close association is under investigation using mouse models. We are trying to emulate the cell-specific consequences of chromosomal translocations in mice using homologous recombination in embryonic stem cells to generate de novo chromosomal translocations or to mimic the consequence of these translocations. In addition, chromosomal translocation genes and their products are important targets for therapy. We have designed new therapeutic strategies which include antigen-specific recruitment of endogenous cellular pathways to affect cellular viability and a novel structured form of antisense to ablate the function of fusion mRNAs. We will evaluate these procedures in the mouse models of chromosomal translocations and the long term aim is to perfect rapid procedures for characterizing patient-specific chromosomal translocations to tailor therapy to individual patients.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	thr@mrc-lmb.cam.ac.uk	Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Bemark M, 2000, ONCOGENE, V19, P3404, DOI 10.1038/sj.onc.1203686; BENTLEY DL, 1981, CELL, V24, P613, DOI 10.1016/0092-8674(81)90088-X; BERNHEIM A, 1981, CANCER GENET CYTOGEN, V3, P307, DOI 10.1016/0165-4608(81)90039-X; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CROCE CM, 1979, P NATL ACAD SCI USA, V76, P3416, DOI 10.1073/pnas.76.7.3416; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Delassus S, 1999, BLOOD, V94, P1495, DOI 10.1182/blood.V94.5.1495.417a08_1495_1503; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; DRYNAN LF, 2001, IN PRESS ONCOGENE; DUBE ID, 1991, BLOOD, V78, P2996; FISCH P, 1992, ONCOGENE, V7, P2389; Fischer A, 1998, SCIENCE, V280, P237, DOI 10.1126/science.280.5361.237; Grutz GG, 1998, EMBO J, V17, P4594, DOI 10.1093/emboj/17.16.4594; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; HOBART MJ, 1981, ANN HUM GENET, V45, P331, DOI 10.1111/j.1469-1809.1981.tb00346.x; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; Klein G, 1981, NATURE, V294, P313, DOI 10.1038/294313a0; KOVACS G, 1987, INT J CANCER, V40, P171, DOI 10.1002/ijc.2910400208; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LARSON RC, 1994, ONCOGENE, V9, P3675; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; MALCOLM S, 1982, P NATL ACAD SCI-BIOL, V79, P4957, DOI 10.1073/pnas.79.16.4957; Martineau P, 1998, J MOL BIOL, V280, P117, DOI 10.1006/jmbi.1998.1840; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RABBITTS TH, 1983, BIOCHEM SOC T, V11, P119, DOI 10.1042/bst0110119; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Rabbitts TH, 1999, CANCER RES, V59, p1794S; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RABBITTS TH, 1985, EMBO J, V4, P1461, DOI 10.1002/j.1460-2075.1985.tb03803.x; ROYERPOKORA B, 1995, ONCOGENE, V10, P1353; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SANCHEZGARCIA I, 1991, ONCOGENE, V6, P577; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Stocks MR, 2000, EMBO REP, V1, P59, DOI 10.1093/embo-reports/kvd003; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TAVLADORAKI P, 1993, NATURE, V366, P469, DOI 10.1038/366469a0; Tse E, 2000, P NATL ACAD SCI USA, V97, P12266, DOI 10.1073/pnas.97.22.12266; TSE E, 2001, IN PRESS METHDOS MOL; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VAN DJ, 1995, P NATL ACAD SCI USA, V92, P7376; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wagner RW, 1997, MOL MED TODAY, V3, P31, DOI 10.1016/S1357-4310(96)10053-8; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320; 2001, NATURE	73	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5763	5777		10.1038/sj.onc.1204597	http://dx.doi.org/10.1038/sj.onc.1204597			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607826				2022-12-25	WOS:000170887500017
J	Iwasaki, H; Chiba, K; Uchiyama, T; Yoshikawa, F; Suzuki, F; Ikeda, M; Furuichi, T; Mikoshiba, K				Iwasaki, H; Chiba, K; Uchiyama, T; Yoshikawa, F; Suzuki, F; Ikeda, M; Furuichi, T; Mikoshiba, K			Molecular characterization of the starfish inositol 1,4,5-trisphosphate receptor and its role during oocyte maturation and fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; AMP-DEPENDENT PHOSPHORYLATION; LIGAND-BINDING SITE; INDUCED CALCIUM-RELEASE; MEIOTIC MATURATION; ENDOPLASMIC-RETICULUM; XENOPUS-LAEVIS; CA-2+ RELEASE; HAMSTER EGGS; CA2+ RELEASE	The release of calcium ions (Ca2+) from their intracellular stores is essential for the fertilization of oocytes of various species. The calcium pools can be induced to release Ca2+ via two main types of calcium channel receptor: the inositol 1,4,5-trisphosphate receptor (IP3R) and the ryanodine receptor. Starfish oocytes have often been used to study intracellular calcium mobilization during oocyte maturation and fertilization, but how the intracellular calcium channels contribute to intracellular calcium mobilization has never been understood fully, because these molecules have not been identified and no specific inhibitors of these channels have ever been found. In this study, we utilized a novel IP3R antagonist, the "IP3 sponge," to investigate the role of IP3 during fertilization of the starfish oocyte. The IP3 sponge strongly and specifically competed with endogenous IP3R for binding to IP3. By injecting IP3 sponge into starfish oocyte, the increase in intracellular calcium and formation of the fertilization envelope were both dramatically blocked, although oocyte maturation was not blocked. To investigate the role of IP3R in the starfish oocyte more precisely, we cloned IP3R from the ovary of starfish, and the predicted amino acid sequence indicated that the starfish IP3R has 58-68% identity to mammalian IP3R types 1, 2, and 3. We then raised antibodies that recognize starfish IP3R, and use of the antibodies to perform immunoblot analysis revealed that the level of expression of IP3R remained unchanged throughout oocyte maturation. An immunocytochemical study, however, revealed that the distribution of starfish IP3R changes during oocyte maturation.	RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Minato Ku, Tokyo 1088039, Japan; Ochanomizu Univ, Dept Biol, Bunkyo Ku, Tokyo 1128610, Japan; RIKEN, Brain Sci Inst, Lab Mol Neurogenesis, Wako, Saitama 3510198, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biosci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	RIKEN; University of Tokyo; Ochanomizu University; RIKEN; Tokyo Institute of Technology	Iwasaki, H (corresponding author), RIKEN, Brain Sci Inst, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Furuichi, Teiichi/B-5086-2014; Mikoshiba, Katsuhiko/N-7943-2015	Furuichi, Teiichi/0000-0002-9676-1888; Iwasaki, Hirohide/0000-0002-7432-5938				Baylis HA, 1999, J MOL BIOL, V294, P467, DOI 10.1006/jmbi.1999.3229; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUCK WR, 1992, EXP CELL RES, V202, P59, DOI 10.1016/0014-4827(92)90404-V; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; Carroll DJ, 1997, J CELL BIOL, V138, P1303, DOI 10.1083/jcb.138.6.1303; CHIBA K, 1992, EUR J BIOCHEM, V207, P833, DOI 10.1111/j.1432-1033.1992.tb17114.x; CHIBA K, 1990, DEV BIOL, V140, P300, DOI 10.1016/0012-1606(90)90080-3; CIAPA B, 1992, DEVELOPMENT, V115, P187; CIAPA B, 1986, FEBS LETT, V195, P347, DOI 10.1016/0014-5793(86)80191-0; EHLICH BE, 1988, NATURE, V336, P583; ENOUF J, 1987, BIOCHIM BIOPHYS ACTA, V928, P76, DOI 10.1016/0167-4889(87)90087-5; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2232; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; JAFFE LA, 1994, DEV BIOL, V164, P579, DOI 10.1006/dbio.1994.1225; KAMEL LC, 1985, LIPIDS, V20, P350, DOI 10.1007/BF02534201; KANATANI H, 1969, NATURE, V221, P273, DOI 10.1038/221273a0; KIEHART DP, 1982, METHOD CELL BIOL, V25, P13, DOI 10.1016/S0091-679X(08)61418-1; KISHIMOTO T, 1986, METHOD CELL BIOL, V27, P379, DOI 10.1016/S0091-679X(08)60359-3; KLINE JT, 1994, BIOL REPROD, V50, P193, DOI 10.1095/biolreprod50.1.193; KOGA T, 1994, J BIOL CHEM, V269, P11640; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; MAEDA N, 1991, J BIOL CHEM, V266, P1109; Mehlmann LM, 1996, DEV BIOL, V180, P489, DOI 10.1006/dbio.1996.0322; MEIJER L, 1987, DEV BIOL, V121, P306, DOI 10.1016/0012-1606(87)90166-7; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAZAKI S, 1995, CURR OPIN CELL BIOL, V7, P190, DOI 10.1016/0955-0674(95)80027-1; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; NAKADE S, 1994, J BIOL CHEM, V269, P6735; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NUCITELLI R, 1993, DEV BIOL, V158, P200; PICARD A, 1985, FEBS LETT, V182, P446, DOI 10.1016/0014-5793(85)80351-3; QUINTON TM, 1992, BIOCHEM BIOPH RES CO, V184, P893, DOI 10.1016/0006-291X(92)90675-B; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; Santella L, 1999, EXP CELL RES, V248, P567, DOI 10.1006/excr.1999.4425; SANTELLA L, 1994, BIOCHEM BIOPH RES CO, V203, P674, DOI 10.1006/bbrc.1994.2235; SARDET C, 1992, DEVELOPMENT, V115, P221; SHEN SS, 1993, DEV BIOL, V157, P157, DOI 10.1006/dbio.1993.1120; Stapleton G, 1998, DEV BIOL, V193, P36, DOI 10.1006/dbio.1997.8791; STITH BJ, 1993, MOL BIOL CELL, V4, P435, DOI 10.1091/mbc.4.4.435; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; STRICKER SA, 1995, DEV BIOL, V170, P496, DOI 10.1006/dbio.1995.1232; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TERASAKI M, 1991, J CELL BIOL, V115, P1031, DOI 10.1083/jcb.115.4.1031; TERASAKI M, 1994, J CELL SCI, V107, P1797; Terasaki M, 1996, DEV BIOL, V179, P320, DOI 10.1006/dbio.1996.0263; Terasaki M, 2001, MOL BIOL CELL, V12, P1103, DOI 10.1091/mbc.12.4.1103; TURNER PR, 1984, NATURE, V310, P414, DOI 10.1038/310414a0; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WITCHEL HJ, 1990, DEV BIOL, V141, P393, DOI 10.1016/0012-1606(90)90393-W; XU Z, 1993, DEV GENET, V14, P424, DOI 10.1002/dvg.1020140604; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; Yoshikawa F, 1999, J BIOL CHEM, V274, P328, DOI 10.1074/jbc.274.1.328; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498; YOSHIKAWA F, 1996, J BIOL CHEM, V271, P18227; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613	65	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2763	2772		10.1074/jbc.M108839200	http://dx.doi.org/10.1074/jbc.M108839200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11687583	hybrid			2022-12-25	WOS:000173421500052
J	Ahmed, MM; Alcock, A; Chendil, D; Dey, S; Das, A; Venkatasubbarao, K; Mohiuddin, M; Sun, LZ; Strodel, WE; Freeman, JW				Ahmed, MM; Alcock, A; Chendil, D; Dey, S; Das, A; Venkatasubbarao, K; Mohiuddin, M; Sun, LZ; Strodel, WE; Freeman, JW			Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; II RECEPTOR GENE; RADIATION-INDUCED APOPTOSIS; COLON-CARCINOMA CELLS; HUMAN HEPATOMA-CELLS; BCL-X-L; TGF-BETA; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; CYTOCHROME-C	In this study, we investigated whether lack of transforming growth factor beta (TGF-beta) type II receptor (RII) expression and loss of TGF-beta signaling played a role in radiation resistance of pancreatic cancer cells MIA PaCa-2 that possess a mutated p53 gene. Transfection of this cell line with a RII cDNA led to a stimulation of the transcriptional activity of p3TP-Lux, a TGF-beta-responsive reporter construct. The RII transfectants (MIA PaCa-2/RII) showed a significant increase in sensitivity to radiation when compared with MIA PaCa-2/vector cells. The increase in sensitivity to radiation was reversed by neutralizing antibodies to TGF-beta, indicating that these changes were dependent on TGF-beta signaling. Compared with MIA PaCa-2/vector cells, MIA PaCa-2/RII cells showed a greater than 3-fold increase in apoptosis after radiation. Enhanced radiation sensitivity of MIA PaCa-2/RII cells was associated with an induction of Bax mRNA and protein that was followed by a release of cytochrome c and activation of caspase-3 and poly(ADPribose) polymerase cleavage after radiation exposure. Overexpression of Bcl-x(L) or treatment with antisense oligodeoxynucleotides targeted against Bax significantly inhibited radiation-induced apoptosis in MIA PaCa-2/RII but not in MIA PaCa-2/Vector cells, suggesting that Bax induction is necessary for radiation-induced TGF-beta signaling-mediated apoptosis. Thus, restoration of TGF-beta signaling sensitized these cells to ionizing radiation, although these cells possess a mutated p53 gene. In addition, disruption of RII function by dominant negative mutant of RII inhibited the radiation-induced TGF-beta signaling and apoptosis in primary cultures of mouse embryonic fibroblasts. Together these observations imply that RII is an important component of radiation-induced TGF-beta signaling, and loss of function of RII may enhance resistance to radiation-induced apoptosis.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA; Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA	University of Texas System; University of Texas Health San Antonio; University of Kentucky; University of Kentucky	Freeman, JW (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.		, LuZhe/AAW-4095-2021; Ahmed, Mansoor/AAK-5988-2020; Das, Anindita/K-8003-2013	Das, Anindita/0000-0003-4422-7277	NCI NIH HHS [CA96122] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Arnold SF, 1999, RADIAT RES, V152, P487, DOI 10.2307/3580144; BERROZPE G, 1994, INT J CANCER, V58, P185, DOI 10.1002/ijc.2910580207; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chang EH, 1997, ARCH OTOLARYNGOL, V123, P507; Chiarugi V, 1998, TUMORI, V84, P517, DOI 10.1177/030089169808400501; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; CORYO R, 1996, RADIOL MED TORINO, V92, P298; Das A, 2001, J BIOL CHEM, V276, P3279, DOI 10.1074/jbc.M008454200; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; GEISER AG, 1992, J BIOL CHEM, V267, P2588; Goggins M, 1998, CANCER RES, V58, P5329; Grau AM, 1997, CANCER RES, V57, P3929; Guo YP, 1999, CANCER RES, V59, P1366; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HOWELL GM, 1993, CANCER METAST REV, V12, P275, DOI 10.1007/BF00665958; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; Hu YX, 1998, CLIN CANCER RES, V4, P1147; Huang YL, 1998, J BIOMED SCI, V5, P185; Hunt KK, 1998, CANCER RES, V58, P5656; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KASTAN MB, 1991, CANCER RES, V51, P6304; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kyprianou N, 1998, ANTICANCER RES, V18, P897; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee J, 1999, EXP MOL MED, V31, P126, DOI 10.1038/emm.1999.21; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; Malcomson RDG, 1997, J PATHOL, V181, P166; Manfredini R, 1998, ANTISENSE NUCLEIC A, V8, P341, DOI 10.1089/oli.1.1998.8.341; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIYASHITA T, 1995, CELL, V80, P293; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Motyl T, 1998, EUR J CELL BIOL, V75, P367, DOI 10.1016/S0171-9335(98)80070-8; Motyl T, 2000, CELL MOL BIOL, V46, P175; MYEROFF LL, 1995, CANCER RES, V55, P5545; Ohmori T, 1998, EXP CELL RES, V245, P350, DOI 10.1006/excr.1998.4261; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; PERSICO MG, 1986, NUCLEIC ACIDS RES, V14, P2511, DOI 10.1093/nar/14.6.2511; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; Rozenblum E, 1997, CANCER RES, V57, P1731; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Sato Y, 1997, ANTICANCER RES, V17, P2779; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Schutte M, 1996, CANCER RES, V56, P2527; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Suardet L, 1996, INT J CANCER, V68, P126, DOI 10.1002/(SICI)1097-0215(19960927)68:1<126::AID-IJC22>3.0.CO;2-8; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Venkatasubbarao K, 1998, GENE CHROMOSOME CANC, V22, P138, DOI 10.1002/(SICI)1098-2264(199806)22:2<138::AID-GCC8>3.0.CO;2-Y; Venkatasubbarao K, 2000, ANTICANCER RES, V20, P43; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Ye SC, 1999, CANCER RES, V59, P4725; YUNIS AA, 1977, INT J CANCER, V19, P218; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	72	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2234	2246		10.1074/jbc.M110168200	http://dx.doi.org/10.1074/jbc.M110168200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11694525	hybrid			2022-12-25	WOS:000173421300084
J	Dornan, S; Sebestyen, Z; Gamble, J; Nagy, P; Bodnar, A; Alldridge, L; Doe, S; Holmes, N; Goff, LK; Beverley, P; Szollosi, J; Alexander, DR				Dornan, S; Sebestyen, Z; Gamble, J; Nagy, P; Bodnar, A; Alldridge, L; Doe, S; Holmes, N; Goff, LK; Beverley, P; Szollosi, J; Alexander, DR			Differential association of CD45 Isoforms with CD4 and CD8 regulates the actions of specific pools of p56(lck) tyrosine kinase in T cell antigen receptor signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE COMMON ANTIGENS; PHOSPHATASE CD45; MONOCLONAL-ANTIBODIES; THYMOCYTE DEVELOPMENT; NEGATIVE REGULATOR; INHIBITORY WEDGE; ENERGY-TRANSFER; PROTEIN-KINASE; DEFICIENT MICE; EXPRESSION	An investigation into the role of CD45 isoforms in T cell antigen receptor signal transduction was carried out by transfecting CD45-negative CD4(+)CD8(+) HPB-ALL T cells with the CD45RO, CD45RBC, and CD45RABC isoforms. Fluorescence resonance energy transfer analysis showed that the CD45R0 isoform, but not the CD45RBC or CD45RABC isoforms, was found as homodimers and also preferentially associated with CD4 and CD8 at the cell-surface. A comparison was therefore made of T cell antigen receptor signaling between sub-clones expressing either CD45RO or CD45RBC. Under basal conditions CD4-associated p56(lck) tyrosine kinase activity and cellular protein tyrosine phosphorylation levels were higher in the CD45R0(+) than in the CD45RBC(+) sub-clones. Upon CD3-CD4 ligation, TCR-zeta phosphorylation, ZAP-70 recruitment to the p21/p23 TCR-zeta phosphoisomers, ZAP-70 phosphorylation, as well as p56(lck), c-Cb1 and Slp-76 phosphorylation, were all markedly increased in CD45R0(+) compared with CD45RBC+ cells. T cell antigen receptor (TCR) stimulation alone also promoted c-Cbl phosphorylation in CD45R0(+) but not in CD45RBC(+) cells. Our results are consistent with a model in which association of CD45RO with CD4 generates a more active pool of CD4-associated p56(lck) kinase molecules. Upon CD3-CD4 co-ligation, the active p56(lck) increases the intensity of T cell antigen receptor signal transduction coupling by promoting TCR-zeta chain phosphorylation and ZAP-70 recruitment.	Babraham Inst, Lab Lymphocyte Signalling & Dev, Programme Mol Immunol, Cambridge CB2 4AT, England; Edward Jenner Inst, Newbury RG20 7NN, Berks, England; St Bartholomews Hosp, Imperial Canc Res Fund, Med Oncol Unit, London EC1M 6BQ, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Univ Debrecen, Dept Biophys & Cell Biol, H-4012 Debrecen, Hungary	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Cancer Research UK; University of London; Queen Mary University London; University of Cambridge; University of Debrecen	Alexander, DR (corresponding author), Babraham Inst, Lab Lymphocyte Signalling & Dev, Programme Mol Immunol, Cambridge CB2 4AT, England.	Denis.Alexander@BBSRC.AC.UK	Bodnar, Andrea/A-9286-2011; Nagy, Peter/D-2188-2013	Nagy, Peter/0000-0002-7466-805X; Beverley, Peter/0000-0003-0481-2180				AKBAR AN, 1988, J IMMUNOL, V140, P2171; Alexander DR, 2000, SEMIN IMMUNOL, V12, P349, DOI 10.1006/smim.2000.0218; ALEXANDER DR, 1997, LYMPHOCYTE SIGNALLIN, P107; Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; Baker M, 2000, EMBO J, V19, P4644, DOI 10.1093/emboj/19.17.4644; BIFFEN M, 1994, EMBO J, V13, P1920, DOI 10.1002/j.1460-2075.1994.tb06461.x; Bonnard M, 1997, CELL IMMUNOL, V175, P1, DOI 10.1006/cimm.1996.1044; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; D'Oro U, 1999, J IMMUNOL, V162, P1879; Damjanovich S, 1997, Q REV BIOPHYS, V30, P67, DOI 10.1017/S0033583596003307; Ding I, 1999, EUR J IMMUNOL, V29, P3956, DOI 10.1002/(SICI)1521-4141(199912)29:12<3956::AID-IMMU3956>3.3.CO;2-7; Hederer RA, 2000, INT IMMUNOL, V12, P505, DOI 10.1093/intimm/12.4.505; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; Kirsch KH, 2001, J BIOL CHEM, V276, P4957, DOI 10.1074/jbc.M005784200; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; Krummel MF, 2000, SCIENCE, V289, P1349, DOI 10.1126/science.289.5483.1349; Leitenberg D, 1996, J EXP MED, V183, P249, DOI 10.1084/jem.183.1.249; Leitenberg D, 1999, IMMUNITY, V10, P701, DOI 10.1016/S1074-7613(00)80069-2; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Majeti R, 2000, CELL, V103, P1059, DOI 10.1016/S0092-8674(00)00209-9; MCCALL MN, 1992, IMMUNOLOGY, V76, P310; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MCKENNEY DW, 1995, J BIOL CHEM, V270, P24949, DOI 10.1074/jbc.270.42.24949; MITTLER RS, 1991, J IMMUNOL, V147, P3434; NOVAK TJ, 1994, IMMUNITY, V1, P109, DOI 10.1016/1074-7613(94)90104-X; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; Pingel S, 1999, EUR J IMMUNOL, V29, P2376; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; ROGERS PR, 1992, J IMMUNOL, V148, P4054; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; Seavitt JR, 1999, MOL CELL BIOL, V19, P4200; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; Stone JD, 1997, J IMMUNOL, V158, P5773; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J IMMUNOL, V141, P3910; SZOLLOSI J, 1984, CYTOMETRY, V5, P210, DOI 10.1002/cyto.990050216; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; TRON L, 1984, BIOPHYS J, V45, P939, DOI 10.1016/S0006-3495(84)84240-X; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; YOKOUCHI M, 2001, J BIOL CHEM, V11, P11	46	81	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1912	1918		10.1074/jbc.M108386200	http://dx.doi.org/10.1074/jbc.M108386200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11694532	hybrid, Green Published			2022-12-25	WOS:000173421300040
J	Fagerholm, S; Morrice, N; Gahmberg, CG; Cohen, P				Fagerholm, S; Morrice, N; Gahmberg, CG; Cohen, P			Phosphorylation of the cytoplasmic domain of the integrin CD18 chain by protein kinase C isoforms in leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; T-CELL ADHESION; BETA-SUBUNIT; LYMPHOCYTES-T; CYTOSKELETAL INTERACTIONS; ALPHA-ACTININ; LFA-1; BINDING; ACTIVATION; ASSOCIATION	The CD11/CD18 (beta(2)) integrins are leukocyte-specific adhesion receptors, and their ability to bind ligands on other cells can be activated by extracellular stimuli. During cell activation, the CD18 chain is known to become phosphorylated on serine and functionally important threonine residues located in the intracellular C-terminal tail. Here, we identify catalytic domain fragments of protein kinase C (PKC) delta and PKCbetaI/II as the major protein kinases in leukocyte extracts that phosphorylate a peptide corresponding to the cytoplasmic tail of the integrin CD18 chain. The sites phosphorylated in vitro were identified as Ser-745 and Thr-758. PKCalpha and PKCeta also phosphorylated these residues, and PKCalpha additionally phosphorylated Thr-760. Ser-745, a novel site, was shown to become phosphorylated in T cells in response to phorbol ester stimulation. Ser-756, a residue not phosphorylated by PKC isoforms, also became phosphorylated in T cells after phorbol ester stimulation. When leukocyte extracts were subjected to affinity chromatography on agarose to which residues 751-761 of the CD18 chain phosphorylated at Thr-758 were bound covalently, the only proteins that bound specifically were identified as isoforms of 14-3-3 proteins. Thus, PKC-mediated phosphorylation of CD18 after cell stimulation could lead to the recruitment of 14-3-3 proteins to the activated integrin, which may play a role in regulating its adhesive state or ability to signal.	Univ Helsinki, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland; Univ Dundee, MRC Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	University of Helsinki; University of Dundee	Gahmberg, CG (corresponding author), Univ Helsinki, Dept Biosci, Div Biochem, POB 56,Viikinkaari 5, FIN-00014 Helsinki, Finland.	susanna.fagerholm@helsinki.fi	Gahmberg, Carl/AAE-1876-2019	Gahmberg, Carl/0000-0001-9892-9296				AXELSSON B, 1988, J IMMUNOL, V141, P2912; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Bleijs DA, 2001, J BIOL CHEM, V276, P10338, DOI 10.1074/jbc.M008967200; BUYON JP, 1990, J IMMUNOL, V144, P191; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; Cowan KJ, 2000, J BIOL CHEM, V275, P36423, DOI 10.1074/jbc.M004068200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Fagerholm SC, 2001, FEBS LETT, V491, P131, DOI 10.1016/S0014-5793(01)02182-2; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; Haller H, 1998, CIRC RES, V82, P157; Han DC, 2001, ONCOGENE, V20, P346, DOI 10.1038/sj.onc.1204068; HARA T, 1985, LEUKOCYTE TYPING 2, V3, P77; HARLOW E, 1988, ANTIBODIES LABORATOR, P82; HEDMAN H, 1992, J IMMUNOL, V149, P2295; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; KANTOR C, 1988, EUR J BIOCHEM, V170, P653, DOI 10.1111/j.1432-1033.1988.tb13747.x; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; KEIZER GD, 1988, J IMMUNOL, V140, P1393; Kirk RI, 2000, J BIOL CHEM, V275, P30901, DOI 10.1074/jbc.M001908200; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KOOPMAN G, 1990, J IMMUNOL, V145, P3589; Kotovuori A, 1999, J IMMUNOL, V162, P6613; KUPFER A, 1990, J MOL CELL IMMUNOL, V4, P317; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; LI R, 1993, J BIOL CHEM, V268, P21474; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; NORTAMO P, 1988, SCAND J IMMUNOL, V28, P537, DOI 10.1111/j.1365-3083.1988.tb01485.x; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; PARDI R, 1992, J CELL BIOL, V116, P1211, DOI 10.1083/jcb.116.5.1211; PATARROYO M, 1985, SCAND J IMMUNOL, V22, P171, DOI 10.1111/j.1365-3083.1985.tb01869.x; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; PONTREMOLI S, 1989, RBC-CELL BIOL REV, V20, P161; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; ROURKE AM, 1998, J IMMUNOL, V161, P5800; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stewart MP, 1996, J IMMUNOL, V156, P1810; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; VALMU L, 1991, EUR J IMMUNOL, V21, P2857, DOI 10.1002/eji.1830211130; Valmu L, 1999, BIOCHEM J, V339, P119, DOI 10.1042/0264-6021:3390119; Valmu L, 1999, EUR J IMMUNOL, V29, P2107, DOI 10.1002/(SICI)1521-4141(199907)29:07<2107::AID-IMMU2107>3.0.CO;2-T; VALMU L, 1995, J IMMUNOL, V155, P1175; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WOODS LY, 2001, BIOCHEM J, V355, P597; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	69	85	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1728	1738		10.1074/jbc.M106856200	http://dx.doi.org/10.1074/jbc.M106856200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11700305	hybrid			2022-12-25	WOS:000173421300016
J	Lyon, M; Deakin, JA; Gallagher, JT				Lyon, M; Deakin, JA; Gallagher, JT			The mode of action of heparan and dermatan sulfates in the regulation of hepatocyte growth factor/scatter factor.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; C-MET RECEPTOR; CRYSTAL-STRUCTURE; BINDING-SITE; NK1 FRAGMENT; LIGAND; OLIGOSACCHARIDES; IDENTIFICATION; PHOSPHORYLATION; PROTEOGLYCANS	Hepatocyte growth factor/scatter factor, in addition to binding to its specific signal-transducing receptor, Met, also interacts with both heparan and dermatan sulfates with high affinity. We have investigated the comparative role of these two glycosaminoglycans in the activation of Met by hepatocyte growth factor/scatter factor. Using glycosaminoglycan-deficient CHO pgsA-745 cells we have shown that growth factor activity is critically dependent upon glycosaminoglycans, and that heparan sulfate and dermatan sulfate are equally potent as co-receptors. Cross-linked 1:1 conjugates of growth factor and either heparan or dermatan sulfate do not dimerize under physiological conditions and are biologically active. This implies that a ternary signaling complex with Met forms in vivo. Native Met isolated from CHO pgsA-745 cells shows only very weak intrinsic affinity for heparin in vitro. Also, a heparin-derived hexasaccharide, which is the minimal size for high affinity binding to the growth factor alone, is sufficient to induce biological activity, Together these observations imply that the role of these glycosaminoglycan may be primarily to effect a conformational change in hepatocyte growth factor/scatter factor, rather than to induce a necessary growth factor dimerization, or to stabilize a ternary complex by additionally interacting with Met.	Univ Manchester, Christie Hosp NHS Trust, Christie CRC Res Ctr, Dept Med Oncol, Manchester M20 4BX, Lancs, England; Canc Res Campaign, Manchester M20 4BX, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Lyon, M (corresponding author), Univ Manchester, Christie Hosp NHS Trust, Christie CRC Res Ctr, Dept Med Oncol, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	MLyon@pier.man.ac.uk		Lyon, Malcolm/0000-0001-9575-6879				ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOCK GR, 1997, CIBA FDN S, V212; BOCK GR, 1997, PLASMINOGEN RELATED, V212; Chirgadze DY, 1999, NAT STRUCT BIOL, V6, P72; Chirgadze DY, 1998, FEBS LETT, V430, P126, DOI 10.1016/S0014-5793(98)00558-4; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Deakin JA, 1999, J CELL SCI, V112, P1999; Delehedde M, 2001, EUR J BIOCHEM, V268, P4423, DOI 10.1046/j.1432-1327.2001.02363.x; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Gallagher JT, 2000, PROTEOGLYCANS STRUCT, P27; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hartmann G, 1998, CURR BIOL, V8, P125, DOI 10.1016/S0960-9822(98)70059-4; ISHIHARA M, 1995, J BIOCHEM-TOKYO, V118, P1255, DOI 10.1093/oxfordjournals.jbchem.a125015; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MARK MR, 1992, J BIOL CHEM, V267, P26166; Matsumoto K, 2001, KIDNEY INT, V59, P2023, DOI 10.1046/j.1523-1755.2001.00717.x; Matsumoto K, 1998, J BIOL CHEM, V273, P22913, DOI 10.1074/jbc.273.36.22913; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; Miller M, 1998, FEBS LETT, V429, P1, DOI 10.1016/S0014-5793(98)00533-X; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Pye DA, 1999, J BIOL CHEM, V274, P13456, DOI 10.1074/jbc.274.19.13456; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; Sakata H, 1997, J BIOL CHEM, V272, P9457; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; Sergeant N, 2000, J BIOL CHEM, V275, P17094, DOI 10.1074/jbc.M000237200; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Trusolino L, 1998, FASEB J, V12, P1267, DOI 10.1096/fasebj.12.13.1267; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Ultsch M, 1998, STRUCT FOLD DES, V6, P1383, DOI 10.1016/S0969-2126(98)00138-5; Vacherot F, 1999, J BIOL CHEM, V274, P7741, DOI 10.1074/jbc.274.12.7741; van der Voort R, 1999, J BIOL CHEM, V274, P6499, DOI 10.1074/jbc.274.10.6499; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P3658, DOI 10.1073/pnas.96.7.3658; WALKER A, 1994, J BIOL CHEM, V269, P931; Zhou HJ, 1999, BIOCHEMISTRY-US, V38, P14793, DOI 10.1021/bi9908641; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	51	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1040	1046		10.1074/jbc.M107506200	http://dx.doi.org/10.1074/jbc.M107506200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11689562	hybrid			2022-12-25	WOS:000173166800023
J	Kumar-Sinha, C; Varambally, S; Sreekumar, A; Chinnaiyan, AM				Kumar-Sinha, C; Varambally, S; Sreekumar, A; Chinnaiyan, AM			Molecular cross-talk between the TRAIL and interferon signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING LIGAND; DEPENDENT PROTEIN-KINASE; NECROSIS-FACTOR RECEPTOR; T-CELL PROLIFERATION; VITAMIN-D-RECEPTOR; IFN-GAMMA; CANCER-CELLS; MEDIATED APOPTOSIS; CD95 FAS/APO-1; CASPASE 8	TRAIL/APO-2L, induces apoptosis in a variety of transformed cells and has potential as an anti-cancer therapeutic. The physiologic role of TRAIL is presumably more complex than merely activating caspase-mediated cell death. To shed light into TRAIL-mediated signaling, we used DNA microarrays to profile gene expression mediated by TRAIL in breast carcinoma cells. Primary response genes induced by TRAIL included a number of known NF-kappaB-dependent genes such as cIAP2, A20, and E-selectin. Remarkably, global transcriptome analysis revealed that TRAIL also induced a cohort of genes related to the interferon-signaling pathway. Assessing interferon-induced gene expression suggested various points of interaction with the TRAIL signaling pathway. Interestingly, while we observed interferon-mediated up-regulation of TRAIL, we also demonstrated a concomitant TRAIL-mediated induction of interferon-beta. Combining TRAIL and interferon in vitro, synergistically induced apoptosis and caspase activation in breast cancer cells. Together, these data indicate multiple levels of molecular cross-talk between the two diverse cytokines with anti-tumor properties.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Chinnaiyan, AM (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd,MSI Rm 4237, Ann Arbor, MI 48109 USA.	arul@umich.edu		Kumar, Chandan/0000-0002-8696-3400; Varambally, Sooryanarayana/0000-0002-2277-1127	NATIONAL CANCER INSTITUTE [P50CA069568] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA69568] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi Y, 1999, INT J ONCOL, V15, P1191; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Ahmad M, 2000, ONCOGENE, V19, P3363, DOI 10.1038/sj.onc.1203679; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bogdan S, 2001, MECH DEVELOP, V103, P61, DOI 10.1016/S0925-4773(01)00332-X; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bonavida B, 1999, INT J ONCOL, V15, P793; Bortoff KD, 1997, ENDOCRINE, V7, P199, DOI 10.1007/BF02778142; Bradbury J, 2001, LANCET, V357, P1770, DOI 10.1016/S0140-6736(00)04939-4; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Chinnaiyan AM, 2001, AM J PATHOL, V159, P1199, DOI 10.1016/S0002-9440(10)62505-9; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Dunican AL, 2000, SHOCK, V13, P244, DOI 10.1097/00024382-200003000-00012; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fearon DT, 2001, SCIENCE, V293, P248, DOI 10.1126/science.1062589; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; Gores GJ, 2001, HEPATOLOGY, V34, P3, DOI 10.1053/jhep.2001.25173; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harashima S, 2001, J IMMUNOL, V166, P130, DOI 10.4049/jimmunol.166.1.130; Harvey KF, 1998, J BIOL CHEM, V273, P13524, DOI 10.1074/jbc.273.22.13524; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HURWITZ AA, 1992, J EXP MED, V176, P1631, DOI 10.1084/jem.176.6.1631; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu SX, 2001, J IMMUNOL, V166, P5407, DOI 10.4049/jimmunol.166.9.5407; Manos EJ, 2001, CANCER RES, V61, P433; Masuelli L, 1996, MOL CELL BIOL, V16, P5466; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; Moses H, 1999, NEUROLOGY, V52, P1729, DOI 10.1212/WNL.52.9.1729; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Nakamura Y, 2000, LEUKEMIA LYMPHOMA, V38, P505, DOI 10.3109/10428190009059269; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Ozoren N, 2000, CANCER RES, V60, P6259; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Qin JZ, 2001, NAT MED, V7, P385, DOI 10.1038/86401; Rathbun RK, 2000, BLOOD, V96, P4204; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SARMA V, 1992, J IMMUNOL, V148, P3302; Sasagawa T, 2000, BIOCHEM BIOPH RES CO, V272, P674, DOI 10.1006/bbrc.2000.2835; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwab BL, 1998, EXP CELL RES, V238, P415, DOI 10.1006/excr.1997.3850; Sedger LM, 1999, J IMMUNOL, V163, P920; Shin EC, 2001, INT J CANCER, V93, P262, DOI 10.1002/ijc.1310; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Takayama M, 2000, FEBS LETT, V477, P43, DOI 10.1016/S0014-5793(00)01756-7; Taniguchi T, 2001, NAT REV MOL CELL BIO, V2, P378, DOI 10.1038/35073080; van Golen KL, 2000, NEOPLASIA, V2, P418, DOI 10.1038/sj.neo.7900115; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wagner KD, 2001, J AM SOC NEPHROL, V12, P1188, DOI 10.1681/ASN.V1261188; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Wu M, 2000, J NEUROSCI RES, V61, P464, DOI 10.1002/1097-4547(20000815)61:4<464::AID-JNR14>3.0.CO;2-G; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	88	86	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					575	585		10.1074/jbc.M107795200	http://dx.doi.org/10.1074/jbc.M107795200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11677236	hybrid			2022-12-25	WOS:000173087900076
J	Leon, J; Royo, J; Vancanneyt, G; Sanz, C; Silkowski, H; Griffiths, G; Sanchez-Serrano, JJ				Leon, J; Royo, J; Vancanneyt, G; Sanz, C; Silkowski, H; Griffiths, G; Sanchez-Serrano, JJ			Lipoxygenase H1 gene silencing reveals a specific role in supplying fatty acid hydroperoxides for aliphatic aldehyde production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL JASMONATE; TOMATO LEAVES; PATHWAY; PLANTS; ARABIDOPSIS; EXPRESSION; BIOSYNTHESIS; POTATO; DEFENSE; PROMOTER	Lipoxygenases catalyze the formation of fatty acid hydroperoxide precursors of an array of compounds involved in the regulation of plant development and responses to stress. To elucidate the function of the potato 13-lipoxygenase 111 (LOX HI), we have generated transgenic potato plants with reduced expression of the LOX H1 gene as a consequence of co-suppression-mediated gene silencing. Three independent LOX H1-silenced transgenic lines were obtained, having less than 1% of the LOX H1 protein present in wild-type plants. This depletion of LOX HI has no effect on the basal or wound-induced levels of jasmonates derived from 13-hydroperoxylinolenic acid. However, LOX H1 depletion results in a marked reduction in the production of volatile aliphatic C6 aldehydes. These compounds are involved in plant defense responses, acting as either signaling molecules for wound-induced gene expression or as antimicrobial substances. LOX H1 protein was localized to the chloroplast and the protein, expressed in Escherichia coli, showed activity toward unesterified linoleic and linolenic acids and plastidic phosphatidylglycerol. The results demonstrate that LOX H1 is a specific isoform involved in the generation of volatile defense and signaling compounds through the HPL branch of the octadecanoid pathway.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; CSIC, Inst Grasa, Seville 41012, Spain; Hort Res Int, Warwick 35CV 9EF, England	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de la Grasa (IG)	Sanchez-Serrano, JJ (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Campus Cantoblanco,Colmenar Viejo Km 15500, E-28049 Madrid, Spain.		Serrano, Jose J Sanchez/H-6955-2015; Sanz, Carlos/K-1743-2014; Vancanneyt, Guy/P-3809-2015; León, José/C-4756-2016; Royo, Joaquin/L-4855-2015	Serrano, Jose J Sanchez/0000-0002-4489-4785; Sanz, Carlos/0000-0002-7387-3393; Vancanneyt, Guy/0000-0003-2557-0723; León, José/0000-0002-7332-1572; Royo, Joaquin/0000-0002-8245-5791				BANAS A, 1992, PLANT SCI, V84, P137, DOI 10.1016/0168-9452(92)90127-8; Bate NJ, 1998, PLANT J, V16, P561, DOI 10.1046/j.1365-313x.1998.00324.x; BELL E, 1993, PLANT PHYSIOL, V103, P1133, DOI 10.1104/pp.103.4.1133; BELL E, 1991, MOL GEN GENET, V230, P456, DOI 10.1007/BF00280303; BELL E, 1995, P NATL ACAD SCI USA, V92, P8675, DOI 10.1073/pnas.92.19.8675; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BLECHERT S, 1995, P NATL ACAD SCI USA, V92, P4099, DOI 10.1073/pnas.92.10.4099; Blee E, 1996, PLANT PHYSIOL, V110, P445, DOI 10.1104/pp.110.2.445; Blee E, 1998, PROG LIPID RES, V37, P33, DOI 10.1016/S0163-7827(98)00004-6; Christie W.W., 2003, LIPID ANAL; Clouse SD, 1996, PLANT PHYSIOL, V111, P671, DOI 10.1104/pp.111.3.671; Conconi A, 1996, PLANT PHYSIOL, V111, P797, DOI 10.1104/pp.111.3.797; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; CROFT KPC, 1993, PLANT PHYSIOL, V101, P13, DOI 10.1104/pp.101.1.13; Dammann C, 1997, PLANT J, V11, P773, DOI 10.1046/j.1365-313X.1997.11040773.x; DENG WL, 1993, J AGR FOOD CHEM, V41, P506, DOI 10.1021/jf00027a030; FARMER EE, 1992, PLANT PHYSIOL, V98, P995, DOI 10.1104/pp.98.3.995; Gardner HW, 1996, J AGR FOOD CHEM, V44, P882, DOI 10.1021/jf950509r; GEERTS A, 1994, PLANT PHYSIOL, V105, P269, DOI 10.1104/pp.105.1.269; Griffiths G, 2000, J EXP BOT, V51, P1363, DOI 10.1093/jexbot/51.349.1363; Gundlach H, 1998, PHYTOCHEMISTRY, V47, P527, DOI 10.1016/S0031-9422(97)00572-4; Hamberg M, 1999, LIPIDS, V34, P1131, DOI 10.1007/s11745-999-0464-7; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; Heitz T, 1997, PLANT PHYSIOL, V114, P1085, DOI 10.1104/pp.114.3.1085; HILDEBRAND DF, 1993, J CHEM ECOL, V19, P1875, DOI 10.1007/BF00983793; KEIL M, 1989, EMBO J, V8, P1323, DOI 10.1002/j.1460-2075.1989.tb03512.x; Kohlmann M, 1999, EUR J BIOCHEM, V260, P885, DOI 10.1046/j.1432-1327.1999.00231.x; Kunz C, 1996, PLANT J, V10, P437, DOI 10.1046/j.1365-313X.1996.10030437.x; Leon J, 1999, PLANT PHYSIOL BIOCH, V37, P373, DOI 10.1016/S0981-9428(99)80043-6; McConn M, 1997, P NATL ACAD SCI USA, V94, P5473, DOI 10.1073/pnas.94.10.5473; McKenzie MJ, 1998, PLANT PHYSIOL, V116, P969, DOI 10.1104/pp.116.3.969; Napoli CA, 1999, CURR TOP DEV BIOL, V44, P127; Narvaez-Vasquez J, 1999, PLANT CELL, V11, P2249, DOI 10.1105/tpc.11.11.2249; NEUHUBER F, 1994, MOL GEN GENET, V244, P230, DOI 10.1007/BF00285450; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; Orozco-Cardenas ML, 2001, PLANT CELL, V13, P179, DOI 10.1105/tpc.13.1.179; Rance I, 1998, P NATL ACAD SCI USA, V95, P6554, DOI 10.1073/pnas.95.11.6554; Rosahl S, 1996, Z NATURFORSCH C, V51, P123; Royo J, 1999, P NATL ACAD SCI USA, V96, P1146, DOI 10.1073/pnas.96.3.1146; Royo J, 1996, J BIOL CHEM, V271, P21012, DOI 10.1074/jbc.271.35.21012; Ruegger M, 1997, PLANT CELL, V9, P745, DOI 10.1105/tpc.9.5.745; Schweizer P, 1998, PLANT J, V14, P475, DOI 10.1046/j.1365-313X.1998.00141.x; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045; STAM M, 1999, DEVELOPMENT, V126, P4763; Vancanneyt G, 2001, P NATL ACAD SCI USA, V98, P8139, DOI 10.1073/pnas.141079498; VAUGHN SF, 1993, J CHEM ECOL, V19, P2337, DOI 10.1007/BF00979668; Vick Brady A., 1993, P167; Vijayan P, 1998, P NATL ACAD SCI USA, V95, P7209, DOI 10.1073/pnas.95.12.7209; Weber H, 1997, P NATL ACAD SCI USA, V94, P10473, DOI 10.1073/pnas.94.19.10473	50	73	88	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					416	423		10.1074/jbc.M107763200	http://dx.doi.org/10.1074/jbc.M107763200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11675388	hybrid			2022-12-25	WOS:000173087900056
J	Roy, D; Belsham, DD				Roy, D; Belsham, DD			Melatonin receptor activation regulates GnRH gene expression and secretion in GT1-7 GnRH neurons - Signal transduction mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GONADOTROPIN-RELEASING-HORMONE; PROTEIN-KINASE-C; OVINE PARS-TUBERALIS; BREAST-CANCER CELLS; WHITE-FOOTED MOUSE; RAT LEYDIG-CELLS; ADENYLATE-CYCLASE; COUPLED RECEPTORS; INDUCED INCREASE; MESSENGER-RNA	Melatonin plays a significant role in the control of the hypothalamic-pituitary-gonadal axis. Using the GT1-7 cell line, an in vitro model of GnRH-secreting neurons of the hypothalamus, we examined the potential signal transduction pathways activated by melatonin directly at the level of the GT1-7 neuron. We found that melatonin inhibits forskolin-stimulated adenosine 3'-, 5'-cyclic monophosphate accumulation in GT1-7 cells through an inhibitory G protein. Melatonin induced protein kinase C activity by 1.65-fold over basal levels, increased the phosphorylation of extracellular signal-regulated kinase I and 2 proteins, and activated c-fos and junB mRNA expression in GT1-7 cells. Using the protein kinase A inhibitor H-89, the protein kinase C inhibitor bisindolylmaleimide, and the mitogen-activated protein kinase kinase inhibitor PD98059, we found that the melatonin-mediated cyclical regulation of GnRH mRNA expression may involve the protein kinase C and the extracellular signal-regulated kinase I and 2 pathways, but not the protein kinase A pathway. We found that melatonin suppresses GnRH secretion by similar to45% in the GT1-7 neurons. However, in the presence of the inhibitors H-89, bisindolylmaleimide, and PD98059 melatonin was unable to suppress GnRH secretion. These results provide insights into the potential signal transduction mechanisms involved in the control of GnRH gene expression and secretion by melatonin.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Univ Hlth Network, Div Cell & Mol Biol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Belsham, DD (corresponding author), Univ Toronto, Dept Physiol, Med Sci Bldg,Rm 3247A,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	d.belsham@utoronto.ca	Roy, Deboleena/X-7059-2018	Roy, Deboleena/0000-0003-3571-169X				ADELMAN JP, 1986, P NATL ACAD SCI USA, V83, P179, DOI 10.1073/pnas.83.1.179; Aleandri V, 1996, HUM REPROD UPDATE, V2, P225, DOI 10.1093/humupd/2.3.225; ANTONTAY F, 1969, NATURE, V221, P474, DOI 10.1038/221474a0; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Barrett P, 1996, MOL ENDOCRINOL, V10, P892, DOI 10.1210/me.10.7.892; Barrett P, 1998, ENDOCRINOLOGY, V139, P163, DOI 10.1210/en.139.1.163; Bettahi I, 1998, J PINEAL RES, V25, P34, DOI 10.1111/j.1600-079X.1998.tb00383.x; Bokoch GM, 1996, FASEB J, V10, P1290, DOI 10.1096/fasebj.10.11.8836042; BRUDER JM, 1992, ENDOCRINOLOGY, V131, P2552, DOI 10.1210/en.131.6.2552; Brydon L, 1999, MOL ENDOCRINOL, V13, P2025, DOI 10.1210/me.13.12.2025; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1987, ONCOGENE, V2, P79; DELAESCALERA GM, 1992, ENDOCRINOLOGY, V131, P1397; DELAESCALERA GM, 1992, ENDOCRINOLOGY, V131, P2965; DUBOCOVICH ML, 1988, J PHARMACOL EXP THER, V246, P902; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Gilad E, 1997, ENDOCRINOLOGY, V138, P4255, DOI 10.1210/en.138.10.4255; GLASS JD, 1987, NEUROENDOCRINOLOGY, V46, P48, DOI 10.1159/000124795; Godson C, 1997, ENDOCRINOLOGY, V138, P397, DOI 10.1210/endo.138.1.4824; Guerrero HY, 2000, NEUROENDOCRINOLOGY, V71, P163, DOI 10.1159/000054533; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Hazlerigg DG, 1996, ENDOCRINOLOGY, V137, P210, DOI 10.1210/en.137.1.210; KAO LWL, 1977, ENDOCRINOLOGY, V100, P1723; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KAWAKAMI Z, 1992, NUCL ACIDS RES, V20; KENNAWAY DJ, 1995, J REPROD FERTIL, P423; KILDUFF TS, 1992, MOL BRAIN RES, V16, P47, DOI 10.1016/0169-328X(92)90192-E; Krsmanovic LZ, 1998, ENDOCRINOLOGY, V139, P4037, DOI 10.1210/en.139.10.4037; Kumar V, 1997, MOL BRAIN RES, V52, P242, DOI 10.1016/S0169-328X(97)00260-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LEI ZM, 1995, MOL CELL ENDOCRINOL, V109, P151, DOI 10.1016/0303-7207(95)03497-U; Li L, 1998, J PINEAL RES, V25, P219, DOI 10.1111/j.1600-079X.1998.tb00391.x; Malpaux B, 1999, REPROD NUTR DEV, V39, P355, DOI 10.1051/rnd:19990308; Maniatis T., 1982, MOL CLONING LAB MANU; McArthur AJ, 1997, ENDOCRINOLOGY, V138, P627, DOI 10.1210/en.138.2.627; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MILENKOVIC I, 1994, P NATL ACAD SCI USA, V91, P1244, DOI 10.1073/pnas.91.4.1244; MOLIS TM, 1994, MOL ENDOCRINOL, V8, P1681, DOI 10.1210/me.8.12.1681; MORETTO M, 1993, ENDOCRINOLOGY, V133, P2399, DOI 10.1210/en.133.5.2399; MORGAN PJ, 1990, J NEUROENDOCRINOL, V2, P773, DOI 10.1111/j.1365-2826.1990.tb00639.x; Petit L, 1999, BIOCHEM PHARMACOL, V58, P633, DOI 10.1016/S0006-2952(99)00134-3; PETTERBORG LJ, 1984, J PINEAL RES, V1, P371, DOI 10.1111/j.1600-079X.1984.tb00227.x; Ram PT, 1998, MOL CELL ENDOCRINOL, V141, P53, DOI 10.1016/S0303-7207(98)00095-1; RASMUSSEN DD, 1993, J ENDOCRINOL INVEST, V16, P1; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; ROSEN H, 1988, ENDOCRINOLOGY, V122, P2873, DOI 10.1210/endo-122-6-2873; Ross AW, 1998, ENDOCRINOLOGY, V139, P1723, DOI 10.1210/en.139.4.1723; Ross AW, 1996, MOL CELL ENDOCRINOL, V123, P71, DOI 10.1016/0303-7207(96)03897-X; Roy D, 2001, ENDOCRINOLOGY, V142, P4711, DOI 10.1210/en.142.11.4711; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Sakakibara H, 1998, NEUROENDOCRINOLOGY, V68, P365, DOI 10.1159/000054386; Shi B, 1998, NEUROENDOCRINOLOGY, V67, P209, DOI 10.1159/000054316; Shiu SYW, 2000, BIOL SIGNAL RECEPT, V9, P172; SIROTKIN AV, 1994, J PINEAL RES, V17, P112, DOI 10.1111/j.1600-079X.1994.tb00121.x; Sumova A, 1997, J NEUROENDOCRINOL, V9, P135; Tamura H, 1998, J PINEAL RES, V25, P135, DOI 10.1111/j.1600-079X.1998.tb00551.x; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Valenti S, 1997, EUR J ENDOCRINOL, V136, P633, DOI 10.1530/eje.0.1360633; Valenti S, 1999, J MOL ENDOCRINOL, V23, P299, DOI 10.1677/jme.0.0230299; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vanecek J, 1998, PHYSIOL REV, V78, P687, DOI 10.1152/physrev.1998.78.3.687; VANECEK J, 1990, NEUROSCI LETT, V110, P199, DOI 10.1016/0304-3940(90)90811-M; VANECEK J, 1988, J NEUROCHEM, V51, P1436, DOI 10.1111/j.1471-4159.1988.tb01108.x; Vitalis EA, 2000, P NATL ACAD SCI USA, V97, P1861, DOI 10.1073/pnas.040545197; WEAVER DR, 1989, J NEUROSCI, V9, P2581; Weaver DR, 1996, NEUROREPORT, V8, P109, DOI 10.1097/00001756-199612200-00022; WETSEL WC, 1995, CELL MOL NEUROBIOL, V15, P43, DOI 10.1007/BF02069558; WETSEL WC, 1993, ENDOCRINOLOGY, V132, P2360, DOI 10.1210/en.132.6.2360; WIERMAN ME, 1995, CELL MOL NEUROBIOL, V15, P79, DOI 10.1007/BF02069559; Witt-Enderby PA, 2000, CELL MOTIL CYTOSKEL, V46, P28, DOI 10.1002/(SICI)1097-0169(200005)46:1<28::AID-CM4>3.0.CO;2-5	72	99	105	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					251	258		10.1074/jbc.M108890200	http://dx.doi.org/10.1074/jbc.M108890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11684691	hybrid			2022-12-25	WOS:000173087900034
J	Lee, SE; Chung, WJ; Kwak, HB; Chung, CH; Kwack, K; Lee, ZH; Kim, HH				Lee, SE; Chung, WJ; Kwak, HB; Chung, CH; Kwack, K; Lee, ZH; Kim, HH			Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COLONY-STIMULATING FACTOR; FACTOR RECEPTOR; BONE-RESORPTION; OSTEOBLASTIC CELLS; TERMINAL KINASE; TNF RECEPTOR; TRAF FAMILY; IN-VITRO; C-SRC	Differentiated osteoclasts have a short life span. We tested various cytokines and growth factors for the effects on the survival of purified mature osteoclasts. In the absence of any added factors, osteoclasts exhibited the survival rate of less than 25% after a 24-h incubation. Among the tested factors, tumor necrosis factor-a (TNF-alpha) was found to increase the survival rate to similar to80%. The TNF-alpha-enhanced survival of osteoclasts appeared to be associated with reduction in apoptosis and suppression of caspase activation. The antiapoptotic signaling pathways involved in the TNF-alpha-induced osteoclast survival were investigated. TNF-a treatment increased the phosphorylation of Akt in osteoclasts, which was suppressed by a phosphatidylinositol 3-kinase inhibitor LY294002 and an Sre family kinase-selective inhibitor PP1. These inhibitors also attenuated the TNF-a stimulation of osteoclast survival. In addition an increase in the phosphorylation of ERK was observed upon TNF-a stimulation. PD98059, a specific inhibitor of the ERK-activating kinase MEK-1, abolished the TNF-alpha-induced ERK phosphorylation and osteoclast survival, and in these responses the involvement of Grb2 and ceramide was observed. These results suggest that TNF-alpha promotes the survival of osteoclasts by engaging the phosphatidylinositol 3-kinase Akt and MEK/ERK signaling pathways.	Chosun Univ, Sch Dent, Dong Gu, Kwangju 501759, South Korea; Chosun Univ, Natl Res Lab Bone Metab, Dong Gu, Kwangju 501759, South Korea; Chosun Univ, Res Ctr Proteinaceous Mat, Dong Gu, Kwangju 501759, South Korea; Univ Ulsan, Immunomodulat Res Ctr, Ulsan 680749, South Korea	Chosun University; Chosun University; Chosun University; University of Ulsan	Kim, HH (corresponding author), Chosun Univ, Sch Dent, Dong Gu, 375 Seosuk Dong, Kwangju 501759, South Korea.	hhkim@mail.chosun.ac.kr						Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Assuma R, 1998, J IMMUNOL, V160, P403; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Hildt E, 1999, J EXP MED, V189, P1707, DOI 10.1084/jem.189.11.1707; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Jimi E, 1999, J IMMUNOL, V163, P434; JIMI E, 1995, ENDOCRINOLOGY, V136, P808, DOI 10.1210/en.136.2.808; Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489; Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014-5793(98)01731-1; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Lee ZH, 2000, MOL PHARMACOL, V58, P1536, DOI 10.1124/mol.58.6.1536; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002-9440(10)65266-2; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723; Ozes ON, 1999, NATURE, V401, P82; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Selander KS, 1996, MOL CELL ENDOCRINOL, V122, P119, DOI 10.1016/0303-7207(96)03870-1; Suda T, 1997, METHOD ENZYMOL, V282, P223; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; THOMSON BM, 1987, J IMMUNOL, V138, P775; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200	50	78	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49343	49349		10.1074/jbc.M103642200	http://dx.doi.org/10.1074/jbc.M103642200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11675379	hybrid			2022-12-25	WOS:000173922100094
J	Marchese, A; Benovic, JL				Marchese, A; Benovic, JL			Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; CLATHRIN ADAPTER; DOWN-REGULATION; BETA-ARRESTIN; INTERNALIZATION; ENDOCYTOSIS; TRAFFICKING; PHOSPHORYLATION; REPLICATION; TAIL	Ligand-induced trafficking plays an important role in the physiologic regulation of many G protein-coupled receptors (GPCRs). Although numerous GPCRs are sorted to a degradative pathway upon prolonged stimulation, the molecular events leading to degradation are poorly understood. Here we report that the human immunodeficiency virus co-receptor CXCR4 undergoes rapid agonist-promoted degradation by a process involving endocytosis via clathrin-coated pits and subsequent sorting to lysosomes. Studies analyzing the sorting of various CXCR4 mutants revealed the presence of a degradation motif (SSLKILSKGK) in the carboxyl terminus of CXCR4. The first two serines as well as the dileucine motif were critical for agonist-induced endocytosis, whereas all three serines but not the dileucine were important in mediating degradation. Mutation of the three lysine residues had no effect on CXCR4 endocytosis yet completely inhibited receptor degradation. Because lysine residues represent potential sites of ubiquitination, we also examined the ubiquitination of CXCR4. Interestingly, CXCR4 was shown to undergo rapid agonist-promoted ubiquitination that was attenuated by mutation of the lysine residues within the degradation motif. These studies implicate a specific role for ubiquitination in sorting endocytosed GPCRs to lysosomes.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.				NIGMS NIH HHS [GM47417] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047417, R01GM047417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Di Salvo J, 2000, EUR J PHARMACOL, V409, P143, DOI 10.1016/S0014-2999(00)00846-3; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Forster R, 1998, J IMMUNOL, V160, P1522; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Pelchen-Matthews A, 1999, IMMUNOL REV, V168, P33, DOI 10.1111/j.1600-065X.1999.tb01281.x; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Tarasova NI, 1998, J BIOL CHEM, V273, P15883, DOI 10.1074/jbc.273.26.15883; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9	27	374	379	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45509	45512		10.1074/jbc.C100527200	http://dx.doi.org/10.1074/jbc.C100527200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11641392	hybrid			2022-12-25	WOS:000172573100004
J	Enshell-Seijffers, D; Smelyanski, L; Vardinon, N; Yust, I; Gershoni, JM				Enshell-Seijffers, D; Smelyanski, L; Vardinon, N; Yust, I; Gershoni, JM			Dissection of the humoral immune response toward an immunodominant epitope of HIV: a model for the analysis of antibody diversity in HIV plus individuals	FASEB JOURNAL			English	Article						AIDS; phage display; humoral response; peptides	HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODIES; RANDOM PEPTIDE LIBRARIES; NEUTRALIZING ANTIBODIES; TRANSMEMBRANE GLYCOPROTEIN; PASSIVE-IMMUNIZATION; PROTECTIVE IMMUNITY; AFFINITY MATURATION; GLOBULIN THERAPY; HUMAN SERA	Understanding the dynamics of the humoral immune response to HIV epitopes in the presence of genetic drift and antigenic variation of the virus may reveal critical elements of protective immunity against HIV. Analysis of antibody maturation and diversity is difficult to study at the molecular level in humans. We used a combinatorial phage display peptide library to elucidate antibody diversity in HIV-infected individuals to a single immunodominant epitope in gp41. A serum sample derived from an HIV+ individual was used to screen a phage display a 12 mer cysteine-constrained loop peptide library. In doing so, we isolated mimotope-presenting phages corresponding to the immunodominant gp41 epitope CSGKLIC (residues 603-609). The mimotopes and control phages expressing epitope variants were reacted with a panel of 30 HIV+ sera. The patients showed distinct and variable recognition patterns compared with one another. Subfractions of the polyclonal sera were affinity purified and analyzed for epitope specificities. These analyses illustrated that epitope variants can be used to decipher antibody diversity. Elucidation of the plasticity of the humoral response and its polyclonality toward discrete epitopes contributes to our understanding of the antibody maturation process in individuals infected with viruses such as HIV.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Tel Aviv Sourasky Med Ctr, Dept Clin Immunol, IL-64239 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Gershoni, JM (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.	gershoni@post.tau.ac.il		Enshell-Seijffers, David/0000-0002-8228-2659				ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; ARENDRUP M, 1993, J GEN VIROL, V74, P855, DOI 10.1099/0022-1317-74-5-855; ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303; Arvin AM, 1996, CLIN MICROBIOL REV, V9, P361, DOI 10.1128/CMR.9.3.361; BACHMANN MF, 1994, J IMMUNOL, V152, P4235; BANAPOUR B, 1987, J IMMUNOL, V139, P4027; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; Borrebaeck CAK, 1998, IMMUNOL TODAY, V19, P524, DOI 10.1016/S0167-5699(98)01329-2; BUGGE TH, 1990, J VIROL, V64, P4123, DOI 10.1128/JVI.64.9.4123-4129.1990; Burton DR, 1998, NAT MED, V4, P495, DOI 10.1038/nm0598supp-495; Burton DR, 1997, AIDS, V11, pS87; Cole KS, 1997, J VIROL, V71, P5069, DOI 10.1128/JVI.71.7.5069-5079.1997; Conley AJ, 1996, J VIROL, V70, P6751, DOI 10.1128/JVI.70.10.6751-6758.1996; CORTESE R, 1994, TRENDS BIOTECHNOL, V12, P262, DOI 10.1016/0167-7799(94)90137-6; Cortese Riccardo, 1995, Current Opinion in Biotechnology, V6, P73, DOI 10.1016/0958-1669(95)80012-3; Cotropia J, 1996, J ACQ IMMUN DEF SYND, V12, P221, DOI 10.1097/00042560-199607000-00002; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Delmastro P, 1997, VACCINE, V15, P1276, DOI 10.1016/S0264-410X(97)00072-8; DENISOVA G, 1995, FASEB J, V9, P127, DOI 10.1096/fasebj.9.1.7529735; Denisova GF, 2000, MOL IMMUNOL, V37, P53, DOI 10.1016/S0161-5890(00)00022-5; EATON AM, 1994, AIDS RES HUM RETROV, V10, P13, DOI 10.1089/aid.1994.10.13; EICHBERG JW, 1992, AIDS RES HUM RETROV, V8, P1515, DOI 10.1089/aid.1992.8.1515; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; FOLGORI A, 1994, EMBO J, V13, P2236, DOI 10.1002/j.1460-2075.1994.tb06501.x; GNANN JW, 1987, J INFECT DIS, V156, P261, DOI 10.1093/infdis/156.2.261; Gonzalez-Fernandez A, 1998, IMMUNOLOGY, V93, P149; GORNY MK, 1989, P NATL ACAD SCI USA, V86, P1624, DOI 10.1073/pnas.86.5.1624; GOUDSMIT J, 1990, INTERVIROLOGY, V31, P327, DOI 10.1159/000150169; GOUDSMIT J, 1991, FASEB J, V5, P2427, DOI 10.1096/fasebj.5.10.2065891; Haigwood N L, 1998, AIDS, V12 Suppl A, pS121; Haigwood NL, 1996, IMMUNOL LETT, V51, P107, DOI 10.1016/0165-2478(96)02563-1; HAIGWOOD NL, 1995, VACCINES, P149; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HORAL P, 1991, J VIROL, V65, P2718, DOI 10.1128/JVI.65.5.2718-2723.1991; Kalinke U, 1996, IMMUNITY, V5, P639, DOI 10.1016/S1074-7613(00)80277-0; KELLER PM, 1993, VIROLOGY, V193, P709, DOI 10.1006/viro.1993.1179; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LANE DP, 1993, CURR OPIN IMMUNOL, V5, P268, DOI 10.1016/0952-7915(93)90016-L; PAL R, 1992, INTERVIROLOGY, V86, P86; POLLOCK BJ, 1989, CLIN EXP IMMUNOL, V78, P323; Prezzi C, 1996, J IMMUNOL, V156, P4504; PRIGENT S, 1990, AIDS, V4, P11, DOI 10.1097/00002030-199001000-00002; PRINCE AM, 1991, AIDS RES HUM RETROV, V7, P971, DOI 10.1089/aid.1991.7.971; Puntoriero G, 1998, EMBO J, V17, P3521, DOI 10.1093/emboj/17.13.3521; ROBERTGUROFF M, 1988, AIDS RES HUM RETROV, V4, P343, DOI 10.1089/aid.1988.4.343; Scala G, 1999, J IMMUNOL, V162, P6155; SCHRIER RD, 1988, J VIROL, V62, P2531, DOI 10.1128/JVI.62.8.2531-2536.1988; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; TEEUWSEN VJP, 1990, AIDS RES HUM RETROV, V6, P381, DOI 10.1089/aid.1990.6.381; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; TYLER DS, 1990, J IMMUNOL, V145, P3276; UGEN KE, 1992, J CLIN INVEST, V89, P1923, DOI 10.1172/JCI115798; Urbanelli L, 2000, J IMMUNOL METHODS, V236, P167, DOI 10.1016/S0022-1759(99)00238-0; VANINI S, 1993, AIDS, V7, P164; XU JY, 1991, J VIROL, V65, P4832, DOI 10.1128/JVI.65.9.4832-4838.1991; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	57	37	39	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2112	2120		10.1096/fj.00-0898com	http://dx.doi.org/10.1096/fj.00-0898com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641237				2022-12-25	WOS:000171920400022
J	Kallio, MJ; Nieminen, M; Eriksson, JE				Kallio, MJ; Nieminen, M; Eriksson, JE			Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit	FASEB JOURNAL			English	Article						survivin; mitosis; spindle checkpoint	ANAPHASE-PROMOTING COMPLEX; SPINDLE CHECKPOINT; CELL-DIVISION; AURORA-LIKE; KINASE; MAD2; KINETOCHORE; ANTIBODY; MITOSIS; ONSET	A signaling cascade termed the "spindle checkpoint" monitors interactions between the kinetochores of chromosomes and spindle microtubules to prevent precocious separation of sister chromatids. We have investigated the role of human inhibitor of apoptosis protein (IAP) survivin in regulation of cell division. We demonstrate that HeLa and PtK1 cells transfected or microinjected with survivin anti-sense oligonucleotides produce significantly more polyploid and micronucleated progeny cells and show abortive mitosis when treated with spindle poisons. Furthermore, perturbation of survivin function in HeLa and PtK1 cells with anti-survivin antibodies at the beginning of mitosis affects the normal timing of separation of sister chromatids and disturbs the 3F3/2 phosphoepitope-recognized tension sensing mechanism of the spindle checkpoint. This leads to premature separation of sister chromatids, which results in an uneven distribution of chromosomes between the newly formed progeny cells-an event associated with tumor formation in many cell types. Finally, cells injected with anti-survivin antibody exit mitotic block induced with microtubule drugs. Our data suggest that survivin protein may function within the spindle checkpoint pathway.	Univ Oklahoma, Hlth Sci Ctr, Ctr Biomed Res, Dept Cell Biol, Oklahoma City, OK 73104 USA; Univ Turku, Turku Ctr Biotechnol, FIN-20521 Turku, Finland; Abo Akad Univ, FIN-20521 Turku, Finland; Univ Turku, Dept Biol, FIN-20014 Turku, Finland	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Turku; Abo Akademi University; University of Turku	Kallio, MJ (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Ctr Biomed Res, Dept Cell Biol, 975 NE 10th St,Room 266, Oklahoma City, OK 73104 USA.	Marko-Kallio@ouhsc.edu		Kallio, Marko/0000-0002-6345-1680				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Daum JR, 2000, CURR BIOL, V10, pR850, DOI 10.1016/S0960-9822(00)00836-8; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Gorbsky GJ, 1999, FASEB J, V13, pS231, DOI 10.1096/fasebj.13.9002.S231; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; JORDAN MA, 1992, J CELL SCI, V102, P401; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Page AM, 1997, CANCER SURV, V29, P133; Peters JM, 1999, EXP CELL RES, V248, P339, DOI 10.1006/excr.1999.4443; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Tatsuka M, 1998, CANCER RES, V58, P4811; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Zhao J, 2000, J CELL SCI, V113, P4363	30	58	63	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2721	+		10.1096/fj.01-0280fje	http://dx.doi.org/10.1096/fj.01-0280fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11687505				2022-12-25	WOS:000171920400005
J	Zhou, GS; Mihindukulasuriya, KA; MacCorkle-Chosnek, RA; Van Hooser, A; Hu, MCT; Brinkley, BR; Tan, TH				Zhou, GS; Mihindukulasuriya, KA; MacCorkle-Chosnek, RA; Van Hooser, A; Hu, MCT; Brinkley, BR; Tan, TH			Protein phosphatase 4 is involved in tumor necrosis factor-alpha-induced activation of c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR KINASE-1; DUAL-SPECIFICITY PHOSPHATASES; MAP KINASE; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; INDUCED APOPTOSIS; GENE FAMILY; CELL-GROWTH; 2A; CENTROSOME	Protein phosphatase 4 (PP4, previously named protein phosphatase X (PPX)), a PP2A-related serine/threonine phosphatase, has been shown to be involved in essential cellular processes, such as microtubule growth and nuclear factor kappaB activation. We provide evidence that PP4 is involved in tumor necrosis factor (TNF)-alpha signaling in human embryonic kidney 293T (HEK293T) cells. Treatment of HEK293T cells with TNF-alpha resulted in time-dependent activation of endogenous PP4, peaking at 10 min, as well as increased serine and threonine phosphorylation of PP4. We also found that PP4 is involved in relaying the TNF-alpha signal to c-Jun N-terminal kinase (JNK) as indicated by the ability of PP4-RL, a dominant-negative PP4 mutant, to block TNF-alpha-induced JNK activation. Moreover, the response of JNK to TNF-alpha was inhibited in HEK293 cells stably expressing PP4-RL in comparison to parental HEK293 cells. The involvement of PP4 in JNK signaling was further demonstrated by the specific activation of JNK, but not p38 and ERK2, by PP4 in transient transfection assays. However, no direct PP4-JNK interaction was detected, suggesting that PP4 exerts its positive regulatory effect on JNK in an indirect manner. Taken together, these data indicate that PP4 is a signaling component of the JNK cascade and involved in relaying the TNF-alpha signal to the JNK pathway.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Tan, TH (corresponding author), Baylor Coll Med, Dept Immunol, M929,1 Baylor Plaza, Houston, TX 77030 USA.	ttan@bcm.tmc.edu	Hall, Rebecca/L-3432-2019; Hall, Rebecca/G-4929-2012; Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021	Hall, Rebecca/0000-0002-5460-0090; Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Mihindukulasuriya, Kathie/0000-0001-9372-3758	NATIONAL CANCER INSTITUTE [R37CA041424, R01CA041424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532, R01AI038649, R56AI042532] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; BREWIS ND, 1992, BIOCHIM BIOPHYS ACTA, V1171, P231, DOI 10.1016/0167-4781(92)90129-N; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; CHEN J, 1994, J BIOL CHEM, V269, P7957; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Evans DRH, 1998, NATURE, V394, P23, DOI 10.1038/27782; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Guo DQ, 2000, J BIOL CHEM, V275, P11216, DOI 10.1074/jbc.275.15.11216; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Hastie CJ, 2000, BIOCHEM J, V347, P845, DOI 10.1042/0264-6021:3470845; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hu MCT, 1998, J BIOL CHEM, V273, P33561, DOI 10.1074/jbc.273.50.33561; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JaramilloBabb VL, 1996, J BIOL CHEM, V271, P5988, DOI 10.1074/jbc.271.11.5988; Kantrow SP, 2000, FEBS LETT, V483, P119, DOI 10.1016/S0014-5793(00)02083-4; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kloeker S, 1997, BIOCHEM J, V327, P481, DOI 10.1042/bj3270481; Kloeker S, 1999, J BIOL CHEM, V274, P5339, DOI 10.1074/jbc.274.9.5339; Ling P, 1999, MOL CELL BIOL, V19, P1359; LIU XH, 1995, EUR J CANCER, V31A, P953, DOI 10.1016/0959-8049(95)00050-X; Mack GJ, 1998, ARTHRITIS RHEUM, V41, P551; Menegay HJ, 2000, J CELL SCI, V113, P3241; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Nanahoshi M, 1999, FEBS LETT, V446, P108, DOI 10.1016/S0014-5793(99)00189-1; Parsons Ramon, 1998, Current Opinion in Oncology, V10, P88, DOI 10.1097/00001622-199801000-00014; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Shapiro PS, 1998, J BIOL CHEM, V273, P1788, DOI 10.1074/jbc.273.3.1788; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Uh ST, 2000, J BIOL CHEM, V275, P793, DOI 10.1074/jbc.275.2.793; Van Hooser A, 1999, METHOD CELL BIOL, V61, P57; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wigley WC, 1999, J CELL BIOL, V145, P481; WRIGHT SC, 1993, J CELL BIOCHEM, V53, P222, DOI 10.1002/jcb.240530307; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	55	61	66	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6391	6398		10.1074/jbc.M107014200	http://dx.doi.org/10.1074/jbc.M107014200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11698396	hybrid			2022-12-25	WOS:000173989200092
J	Shearwin, KE; Dodd, IB; Egan, JB				Shearwin, KE; Dodd, IB; Egan, JB			The helix-turn-helix motif of the coliphage 186 immunity repressor binds to two distinct recognition sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR CONTROL REGION; DNA-BINDING; ESCHERICHIA-COLI; GENE-EXPRESSION; PROTEIN; LAMBDA; LYSOGENY; SINGLE; SITE; PURIFICATION	The CI protein of coliphage 186 is responsible for maintaining the stable lysogenic state. To do this CI must recognize two distinct DNA sequences, termed A type sites and B type sites. Here we investigate whether CI contains two separate DNA binding motifs or whether CI has one motif that recognizes two different operator sequences. Sequence alignment with 186-like repressors predicts an N-terminal helix-turn-helix (HTH) motif, albeit with poor homology to a large master set of such motifs. The domain structure of CI was investigated by linker insertion mutagenesis and limited proteolysis. Cl consists of an N-terminal domain, which weakly dimerizes and binds both A and B type sequences, and a C-terminal domain, which associates to octamers but is unable to bind DNA. A fusion protein consisting of the 186 N-terminal domain and the phage lambda oligomerization domain binds A and B type sequences more efficiently than the isolated 186 CI N-terminal domain, hence the 186 C-terminal domain likely mediates oligomerization and cooperativity. Site-directed mutation of the putative 186 HTH motif eliminates binding to both A and B type sites, supporting the idea that binding to the two distinct DNA sequences is mediated by a variant HTH motif.	Univ Adelaide, Dept Mol Biosci, Adelaide, SA 5005, Australia	University of Adelaide	Shearwin, KE (corresponding author), Univ Adelaide, Dept Mol Biosci, North Terrace, Adelaide, SA 5005, Australia.		Shearwin, Keith/AAS-1247-2021	Shearwin, Keith/0000-0002-7736-2742; Dodd, Ian/0000-0003-2969-6841				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bell CE, 2000, CELL, V101, P801, DOI 10.1016/S0092-8674(00)80891-0; Biery MC, 2000, NUCLEIC ACIDS RES, V28, P1067, DOI 10.1093/nar/28.5.1067; Bipatnath M, 1998, J BACTERIOL, V180, P265, DOI 10.1128/JB.180.2.265-273.1998; Brumby AM, 1996, VIROLOGY, V219, P105, DOI 10.1006/viro.1996.0227; CARLSON NG, 1993, J MOL BIOL, V230, P1108, DOI 10.1006/jmbi.1993.1229; CARLSON PA, 1994, J BACTERIOL, V176, P6907, DOI 10.1128/JB.176.22.6907-6914.1994; Dodd IB, 1996, J BIOL CHEM, V271, P11532, DOI 10.1074/jbc.271.19.11532; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; DODD IB, 1993, MOL MICROBIOL, V10, P1139, DOI 10.1111/j.1365-2958.1993.tb00983.x; DODD IB, 1990, J MOL BIOL, V214, P27, DOI 10.1016/0022-2836(90)90144-B; Esposito D, 1996, NUCLEIC ACIDS RES, V24, P2360, DOI 10.1093/nar/24.12.2360; EUSTANCE RJ, 1994, J MOL BIOL, V242, P330; Friedman DI, 2001, CURR OPIN MICROBIOL, V4, P201, DOI 10.1016/S1369-5274(00)00189-2; GAO Y, 1999, P 6 SPIRE C, P63; GOFF SP, 1991, METHOD ENZYMOL, V208, P586; Henikoff JG, 1999, NUCLEIC ACIDS RES, V27, P226, DOI 10.1093/nar/27.1.226; HSU MY, 1990, P NATL ACAD SCI USA, V87, P9454, DOI 10.1073/pnas.87.23.9454; KALININ NL, 1995, ANAL BIOCHEM, V228, P238, DOI 10.1006/abio.1995.1345; KALIONIS B, 1986, J MOL BIOL, V191, P199, DOI 10.1016/0022-2836(86)90257-3; LAMONT I, 1989, P NATL ACAD SCI USA, V86, P5492, DOI 10.1073/pnas.86.14.5492; Miller J.H., 1972, EXPT MOL GENETICS; Nesper J, 1999, J BACTERIOL, V181, P2902, DOI 10.1128/JB.181.9.2902-2913.1999; Neufing PJ, 1996, MOL MICROBIOL, V21, P751, DOI 10.1046/j.1365-2958.1996.351394.x; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; OGAWA T, 1988, J MOL BIOL, V202, P537, DOI 10.1016/0022-2836(88)90284-7; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; POWELL BS, 1994, NUCLEIC ACIDS RES, V22, P5765, DOI 10.1093/nar/22.25.5765; Ptashne M, 1986, GENETIC SWITCH; Revet B, 1999, CURR BIOL, V9, P151, DOI 10.1016/S0960-9822(99)80069-4; Rhee S, 1998, P NATL ACAD SCI USA, V95, P10413, DOI 10.1073/pnas.95.18.10413; ROBERTS JW, 1977, P NATL ACAD SCI USA, V74, P2283, DOI 10.1073/pnas.74.6.2283; Sarkar D, 2001, EMBO J, V20, P1203, DOI 10.1093/emboj/20.5.1203; SAUER RT, 1982, J BIOL CHEM, V257, P4458; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P268; SCHUPP JM, 1995, BIOTECHNIQUES, V19, P18; Senear DF, 1998, METHODS, V16, P3, DOI 10.1006/meth.1998.0641; SENEAR DF, 1993, BIOCHEMISTRY-US, V32, P6179, DOI 10.1021/bi00075a010; Shearwin KE, 1996, J BIOL CHEM, V271, P11525, DOI 10.1074/jbc.271.19.11525; Shearwin KE, 1998, J BIOL CHEM, V273, P5708, DOI 10.1074/jbc.273.10.5708; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Skowronek K, 1997, GENE, V196, P139, DOI 10.1016/S0378-1119(97)00219-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60	45	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3186	3194		10.1074/jbc.M107740200	http://dx.doi.org/10.1074/jbc.M107740200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11700308	hybrid			2022-12-25	WOS:000173688000018
J	Brown, BJ; Hyun, JW; Duvvuri, S; Karplus, PA; Massey, V				Brown, BJ; Hyun, JW; Duvvuri, S; Karplus, PA; Massey, V			The role of glutamine 114 in Old Yellow Enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTAERYTHRITOL TETRANITRATE REDUCTASE; SACCHAROMYCES-GENOME-DATABASE; ENTEROBACTER-CLOACAE PB2; ARABIDOPSIS-THALIANA; MORPHINONE REDUCTASE; MOLECULAR-CLONING; SEQUENCE; EXPRESSION; PROTEIN; FLAVIN	Glutamine 114 of OYE1 is a well conserved residue in the active site of the Old Yellow Enzyme family. It forms hydrogen bonds to the 02 and N3 of the flavoprotein prosthetic group, FMN. Glutamine 114 was mutated to asparagine, introducing an R-group that is one methylene group shorter. The resultant enzyme was characterized to determine the effect of the mutation on the mechanistic behavior of the enzyme, and the crystal structure was solved to determine the effect of the mutation on the structure of the protein. The Q114N mutation results in little change in the protein structure, moving the amide group of residue 114 out of H-bonding distance, allowing repositioning of the FAIN prosthetic group to form new interactions that replace the lost H-bonds. The mutation decreases the ability to bind ligands, as all dissociation constants for substituted phenols are larger than for the wild type enzyme. The rate constant for the reductive half-reaction with beta-NADPH is slightly greater, whereas that for the oxidative half-reaction with 2-cyclohexenone is smaller than for the wild type enzyme. Oxidation with molecular oxygen is biphasic and involves formation and reaction with O-2, a phenomenon that is more pronounced with this mutation than with wild type enzyme. When superoxide dismutase is added to the reaction, we observe a single-phase reaction typical of the wild type enzyme. Turnover reactions using beta-NADPH with 2-cyclohexenone and molecular oxygen were studied to further characterize the mutant enzyme.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	University of Michigan System; University of Michigan; Oregon State University	Massey, V (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	massey@umich.edu		Karplus, Paul/0000-0001-8725-6292	NIGMS NIH HHS [GM11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5321; ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; Biesgen C, 1999, PLANTA, V208, P155, DOI 10.1007/s004250050545; Blehert DS, 1999, J BACTERIOL, V181, P6254, DOI 10.1128/JB.181.20.6254-6263.1999; Brown BJ, 1998, J BIOL CHEM, V273, P32753, DOI 10.1074/jbc.273.49.32753; Brown BJ, 1994, FLAVINS AND FLAVOPROTEINS 1993, P391; BROWN BJ, 1999, FLAVINS FLAVOPROTEIN, P659; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; Chervitz SA, 1999, NUCLEIC ACIDS RES, V27, P74, DOI 10.1093/nar/27.1.74; Craig DH, 1998, BIOCHEMISTRY-US, V37, P7598, DOI 10.1021/bi980345i; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; Fox KM, 1999, J BIOL CHEM, V274, P9357, DOI 10.1074/jbc.274.14.9357; French CE, 1995, BIOCHEM J, V312, P671, DOI 10.1042/bj3120671; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; HORECKER BL, 1948, J BIOL CHEM, V175, P385; Iuchi S, 1996, PLANT CELL PHYSIOL, V37, P1073, DOI 10.1093/oxfordjournals.pcp.a029056; KEMAL C, 1977, J AM CHEM SOC, V99, P7272, DOI 10.1021/ja00464a030; Kohli RM, 1998, J BIOL CHEM, V273, P32763, DOI 10.1074/jbc.273.49.32763; MADANI ND, 1994, P NATL ACAD SCI USA, V91, P922, DOI 10.1073/pnas.91.3.922; MASSEY V, 1969, BIOCHEM BIOPH RES CO, V36, P891, DOI 10.1016/0006-291X(69)90287-3; MASSEY V, 1986, J BIOL CHEM, V261, P1215; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; Massey V, 1994, FLAVINS AND FLAVOPROTEINS 1993, P371; Massey V., 1973, OXIDASES RELATED RED, P25; Massey V., 1984, FLAVINS FLAVOPROTEIN, P191; MATTHEWS RG, 1969, J BIOL CHEM, V244, P1779; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MIRANDA M, 1995, YEAST, V11, P459, DOI 10.1002/yea.320110509; Miura K, 1997, BIOL PHARM BULL, V20, P110; Moody PCE, 1998, ACTA CRYSTALLOGR D, V54, P675, DOI 10.1107/S0907444997017836; NIINO YS, 1995, J BIOL CHEM, V270, P1983, DOI 10.1074/jbc.270.5.1983; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rohde BH, 1999, J BACTERIOL, V181, P814, DOI 10.1128/JB.181.3.814-822.1999; SAITO K, 1991, J BIOL CHEM, V266, P20720; Schaller F, 1998, PLANT PHYSIOL, V118, P1345, DOI 10.1104/pp.118.4.1345; Schaller F, 1997, J BIOL CHEM, V272, P28066, DOI 10.1074/jbc.272.44.28066; SCHOPFER LM, 1990, STUDY ENZYMES, P247; Snape JR, 1997, J BACTERIOL, V179, P7796, DOI 10.1128/jb.179.24.7796-7802.1997; STEWART RC, 1985, J BIOL CHEM, V260, P3639; STOTT K, 1993, J BIOL CHEM, V268, P6097; Strassner J, 1999, J BIOL CHEM, V274, P35067, DOI 10.1074/jbc.274.49.35067; Theorell H, 1935, BIOCHEM Z, V275, P344; THEORELL H, 1956, ARCH BIOCHEM BIOPHYS, V65, P439, DOI 10.1016/0003-9861(56)90204-1; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; Warburg O, 1933, BIOCHEM Z, V266, P377; Warburg O, 1932, NATURWISSENSCHAFTEN, V20, P980, DOI 10.1007/BF01504728; Xu D, 1999, P NATL ACAD SCI USA, V96, P3556, DOI 10.1073/pnas.96.7.3556	50	37	39	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2138	2145		10.1074/jbc.M108453200	http://dx.doi.org/10.1074/jbc.M108453200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11668181	hybrid			2022-12-25	WOS:000173421300072
J	Jegalian, AG; Wu, H				Jegalian, AG; Wu, H			Regulation of socs gene expression by the proto-oncoprotein GFI-1B - Two routes for STAT5 target gene induction by erythropoietin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; MICE LACKING SUPPRESSOR; TRANSCRIPTIONAL REPRESSOR; TRANSLATIONAL REPRESSION; TYROSINE RESIDUES; CYTOKINE; ACTIVATION; INHIBITOR; DOMAIN; CIS	SOCS proteins take part in a classical negative feedback loop to attenuate cytokine signaling. Although STAT family members positively modulate Socs gene expression, little else is known about Socs gene regulation. Here, we identify functional binding sites for GFI-1B, a proto-oncogenic transcriptional repressor, in the promoters of murine Socs1 and Socs3. Thus, mutating these sites relieved transcriptional repression, as determined by luciferase reporter assays of transiently transfected erythropoietin-responsive 32D-EpoR and HCD57 cells. Furthermore, cotransfection of Gfi-1B expression plasmid repressed reporter activity of wild-type (but not mutagenized) Socs1 and Socs3 promoters, strongly suggestive of direct GFI-1B binding to these promoters. In addition, overexpression of Gfi-1B resulted in reduced transcript levels of Socs1 and Socs3, but not Socs2 or Cis. Upon stimulation with erythropoietin, Socs transcripts were rapidly induced, whereas Gfi-1B mRNA was down-regulated. Interestingly, the latter effect appears to rely on STAT5 activity, but not on phosphoinositide 3-kinase or MAPK pathways. Thus, cytokine-mediated STAT5 activation allows relief of direct repression by GFI-1B of the Socs1 and Socs3 promoters, but apparently not of the Socs2 and Cis promoters. This constitutes a previously undescribed mode of controlling cytokine responsiveness, through the direct repression of a tumor suppressor (SOCS1) by a proto-oncoprotein (GFI-1B).	Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Wu, H (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, 650 Charles Young Dr,23-234 CHS,POB 951735, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08042] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Bergelson S, 1998, J BIOL CHEM, V273, P2396, DOI 10.1074/jbc.273.4.2396; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Feng Q, 2001, GENE DEV, V15, P827; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Gregorieff A, 2000, J BIOL CHEM, V275, P21596, DOI 10.1074/jbc.M910087199; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; Krebs DL, 2000, J CELL SCI, V113, P2813; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nagai H, 2001, J HEPATOL, V34, P416, DOI 10.1016/S0168-8278(00)00038-6; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Schluter G, 2000, BIOCHEM BIOPH RES CO, V268, P255, DOI 10.1006/bbrc.2000.2109; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; SPIVAK JL, 1991, BLOOD, V77, P1228; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	38	73	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2345	2352		10.1074/jbc.M105575200	http://dx.doi.org/10.1074/jbc.M105575200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11696536	hybrid			2022-12-25	WOS:000173421300095
J	Jez, JM; Noel, JP				Jez, JM; Noel, JP			Reaction mechanism of chalcone isomerase - pH dependence, diffusion control, and product binding differences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTITUTED 2-HYDROXYCHALCONES; CHEMICAL-MODIFICATION; CYCLIZATION; PURIFICATION; ENZYME; PEROXIDASE; CATALYSIS; VISCOSITY; INSIGHTS; PETUNIA	Chalcone isomerase (CHI) catalyzes the intramolecular cyclization of bicyclic chalcones into tricyclic (S)- flavanones. The activity of CHI is essential for the biosynthesis of flavanone precursors of floral pigments and phenylpropanoid plant defense compounds. We have examined the spontaneous and CHI-catalyzed cyclization reactions of 4,2',4',6'-tetrahydroxychalcone, 4,2',4'-trihydroxychalcone, 2',4'-dihydroxychalcone, and 4,2'-dihydroxychalcone into the corresponding flavanones. The pH dependence of flavanone formation indicates that both the non-enzymatic and enzymatic reactions first require the bulk phase ionization of the substrate 2'-hydroxyl group and subsequently on the reactivity of the newly formed 2'-oxyanion during C-ring formation. Solvent viscosity experiments demonstrate that at pH 7.5 the CHI-catalyzed cyclization reactions of 4,2',4',6'tetrahydroxychalcone, 4,2',4'-trihydroxychalcone, and 2',4'-dihydroxychalcone are similar to90% diffusion-controlled, whereas cyclization of 4,2'-dihydroxychalcone is limited by a chemical step that likely reflects the higher pK(alpha) of the 2'-hydroxyl group. At pH 6.0, the reactions with 4,2',4',6'tetrahydroxychalcone and 4,2',4'-trihydroxychalcone are similar to50% diffusion-limited, whereas the reactions of both dihy-droxychalcones are limited by chemical steps. Comparisons of the 2.1-2.3 Angstrom resolution crystal structures of CHI complexed with the products 7,4'-dihydroxyflavanone, 7-hydroxyflavanone, and 4'-hydroxyflavanone show that the 7-hydroxyflavanones all share a common binding mode, whereas 4'-hydroxyflavanone binds in an altered orientation at the active site. Our functional and structural studies support the proposal that CHI accelerates the stereochemically defined intramolecular cyclization of chalcones into biologically active (2S)-flavanones by selectively binding an ionized chalcone in a conformation conducive to ring closure in a diffusion-controlled reaction.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Noel, JP (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	noel@sbl.salk.edu	Noel, Joseph P/A-9459-2009					ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5631, DOI 10.1021/bi00670a032; BEDNAR RA, 1988, J BIOL CHEM, V263, P9582; BEDNAR RA, 1989, J BIOL CHEM, V264, P14272; BEDNAR RA, 1990, ARCH BIOCHEM BIOPHYS, V282, P393, DOI 10.1016/0003-9861(90)90134-K; BEDNAR RA, 1990, BIOCHEMISTRY-US, V29, P3684, DOI 10.1021/bi00467a014; BENDAR RA, 1991, BIOCONJUGATE CHEM, V2, P211; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P1158, DOI 10.1021/bi00404a013; BOLAND MJ, 1979, BIOORG CHEM, V8, P1, DOI 10.1016/0045-2068(79)90030-0; Boyer P.D., 1990, ENZYMES, V19, P99; BROUWER AC, 1982, BIOCHEMISTRY-US, V21, P1302, DOI 10.1021/bi00535a030; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cleland W W, 1979, Methods Enzymol, V63, P103; DIXON RA, 1988, PHYTOCHEMISTRY, V27, P2801, DOI 10.1016/0031-9422(88)80666-6; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; Dixon RA, 1999, TRENDS PLANT SCI, V4, P394, DOI 10.1016/S1360-1385(99)01471-5; DIXON RA, 1982, BIOCHIM BIOPHYS ACTA, V715, P25, DOI 10.1016/0304-4165(82)90045-9; DOONER HK, 1991, ANNU REV GENET, V25, P173, DOI 10.1146/annurev.ge.25.120191.001133; DUNFORD HB, 1977, BIOCHEMISTRY-US, V16, P2949, DOI 10.1021/bi00632a023; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Fersht A., 1999, STRUCTURE MECH PROTE, P169; FURLONG JJP, 1988, J CHEM SOC PERK T 2, P1213, DOI 10.1039/p29880001213; FURLONG JJP, 1985, J CHEM SOC PERK T 2, P633, DOI 10.1039/p29850000633; Grace MR, 1997, BIOCHEMISTRY-US, V36, P1874, DOI 10.1021/bi962138t; GRAY JV, 1990, BIOCHEMISTRY-US, V29, P8872, DOI 10.1021/bi00489a051; HAHLBROCK K, 1970, EUR J BIOCHEM, V15, P13, DOI 10.1111/j.1432-1033.1970.tb00969.x; Jez JM, 1998, BIOCHEMISTRY-US, V37, P9695, DOI 10.1021/bi980294p; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; JONES PG, 1993, ACTA CRYSTALLOGR C, V49, P1148, DOI 10.1107/S0108270192012484; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURZ LC, 1987, BIOCHEMISTRY-US, V26, P3027, DOI 10.1021/bi00385a012; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE AY, 1995, J AM CHEM SOC, V117, P3627, DOI 10.1021/ja00117a038; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; LOO S, 1977, BIOCHIM BIOPHYS ACTA, V481, P279, DOI 10.1016/0005-2744(77)90159-0; MCKHANN HI, 1994, PLANT MOL BIOL, V24, P767, DOI 10.1007/BF00029858; MILES CO, 1985, J CHEM SOC PERK T 2, P1639, DOI 10.1039/p29850001639; MOUSTAFA E, 1967, PHYTOCHEMISTRY, V6, P625, DOI 10.1016/S0031-9422(00)86001-X; Muir SR, 2001, NAT BIOTECHNOL, V19, P470, DOI 10.1038/88150; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; Setchell KDR, 1999, J NUTR, V129, p758S, DOI 10.1093/jn/129.3.758S; SIMOPOULOS TT, 1994, BIOCHEMISTRY-US, V33, P10375, DOI 10.1021/bi00200a018; VANTUNEN AJ, 1991, PLANT CELL, V3, P39, DOI 10.1105/tpc.3.1.39	46	117	130	4	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1361	1369		10.1074/jbc.M109224200	http://dx.doi.org/10.1074/jbc.M109224200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11698411	hybrid			2022-12-25	WOS:000173166800065
J	Kim, SJ; Ju, JW; Oh, CD; Yoon, YM; Song, WK; Kim, JH; Yoo, YJ; Bang, OS; Kang, SS; Chun, JS				Kim, SJ; Ju, JW; Oh, CD; Yoon, YM; Song, WK; Kim, JH; Yoo, YJ; Bang, OS; Kang, SS; Chun, JS			ERK-1/2 and p38 kinase oppositely regulate nitric oxide-induced apoptosis of chondrocytes in association with p53, caspase-3, and differentiation status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CYTOCHROME-C; INDUCED PHOSPHORYLATION; ARTICULAR CHONDROCYTES; CARTILAGE DEGRADATION; UV-RADIATION; IN-VIVO; OSTEOARTHRITIS; RELEASE; BAX	Nitric oxide regulates cartilage destruction by causing dedifferentiation and apoptosis of chondrocytes. We investigated the role of the mitogen-activated protein kinase subtypes, extracellular signal-regulated protein kinase (ERK)-1/2, and p38 kinase in NO-induced apoptosis of rabbit articular chondrocytes and their involvement in dedifferentiation. Generation of NO with sodium nitroprusside (SNP) caused dedifferentiation, as indicated by the inhibition of type II collagen expression and proteoglycan synthesis. NO additionally caused apoptosis, accompanied by p53 accumulation and caspase-3 activation. SNP treatment stimulated activation of ERK-1/2 and p38 kinase. Inhibition of ERK-1/2 with PD98059 rescued SNP-induced dedifferentiation but enhanced apoptosis up to 2-fold, whereas inhibition of p38 kinase with SB203580 enhanced dedifferentiation, with significant blockage of apoptosis. The stimulation of apoptosis by ERK inhibition was accompanied by increased p53 accumulation and caspase-3 activity, whereas the inhibitory effect of p38 kinase blockade was associated with reduced p53 accumulation and caspase-3 activity. Our results indicate that NO-induced p38 kinase functions as an induction signal for apoptosis and in the maintenance of chondrocyte phenotype, whereas ERK activity causes dedifferentiation and operates as an anti-apoptotic signal. NO generation is less proapoptotic in chondrocytes that are dedifferentiated by serial monolayer culture or phorbol ester treatment. NO-induced p38 kinase activity is low in dedifferentiated cells compared with that in differentiated chondrocytes, with lower levels of p53 accumulation and caspase-3 activity. Our findings collectively suggest that ERK-1/2 and p38 kinase oppositely regulate NO-induced apoptosis of chondrocytes, in association with p53 accumulation, caspase-3 activation, and differentiation status.	Kwangju Inst Sci & Technol, Dept Life Sci, Natl Res Lab, Kwangju 500712, South Korea; Kyungpook Natl Univ, Dept Biol, Taegu 702701, South Korea	Gwangju Institute of Science & Technology (GIST); Kyungpook National University	Chun, JS (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Natl Res Lab, Kwangju 500712, South Korea.	jschun@kjist.ac.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208; Oh, Chundo/0000-0002-5419-8011				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018; Anderson CNG, 1999, J NEUROSCI, V19, P664; BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9; Blanco FJ, 1998, ARTHRITIS RHEUM, V41, P284, DOI 10.1002/1529-0131(199802)41:2<284::AID-ART12>3.0.CO;2-T; BLANCO FJ, 1995, J IMMUNOL, V154, P4018; BLANCO FJ, 1995, AM J PATHOL, V146, P75; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Callsen D, 1999, BIOCHEMISTRY-US, V38, P2279, DOI 10.1021/bi982292a; Cao M, 1997, BIOCHEM J, V324, P305, DOI 10.1042/bj3240305; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DENKO CW, 1999, FRONT BIOSCI, V4, P686; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; FINER MH, 1985, MOL CELL BIOL, V5, P1415, DOI 10.1128/MCB.5.6.1415; Frenkel SR, 1999, FRONT BIOSCI-LANDMRK, V4, P671, DOI 10.2741/frenkel; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Grabowski PS, 1997, BRIT J RHEUMATOL, V36, P651; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1632, DOI 10.1002/1529-0131(199809)41:9<1632::AID-ART14>3.0.CO;2-A; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Keller D, 1999, BIOCHEM BIOPH RES CO, V261, P464, DOI 10.1006/bbrc.1999.1023; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Martel-Pelletier J, 1999, FRONT BIOSCI, V4, pD694; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McInnes LB, 1996, J EXP MED, V184, P1519, DOI 10.1084/jem.184.4.1519; MURRELL GAC, 1995, BIOCHEM BIOPH RES CO, V206, P15, DOI 10.1006/bbrc.1995.1003; Notoya K, 2000, J IMMUNOL, V165, P3402, DOI 10.4049/jimmunol.165.6.3402; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Pelletier JP, 1996, OSTEOARTHR CARTILAGE, V4, P77, DOI 10.1016/S1063-4584(96)80009-4; Pelletier JP, 1998, ARTHRITIS RHEUM-US, V41, P1275, DOI 10.1002/1529-0131(199807)41:7<1275::AID-ART19>3.0.CO;2-T; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Poole AR, 1999, FRONT BIOSCI, V4, P662; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sandell L., 1999, FRONT BIOSCI-LANDMRK, V4, P731; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Shakibaei M, 2001, J BIOL CHEM, V276, P13289, DOI 10.1074/jbc.M010859200; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SMITH RL, 1999, FRONT BIOSCI, V4, P704; STADLER J, 1991, J IMMUNOL, V147, P3915; TASKIRAN D, 1994, BIOCHEM BIOPH RES CO, V200, P142, DOI 10.1006/bbrc.1994.1426; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang H, 1998, J NEUROSCI, V18, P1363; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yatsugi N, 2000, J Orthop Sci, V5, P150, DOI 10.1007/s007760050142; Yoon YM, 2000, J BIOL CHEM, V275, P12353, DOI 10.1074/jbc.275.16.12353	58	209	222	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1332	1339		10.1074/jbc.M107231200	http://dx.doi.org/10.1074/jbc.M107231200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11689560	hybrid			2022-12-25	WOS:000173166800061
J	Yamamoto, T; Ikemoto, N				Yamamoto, T; Ikemoto, N			T-tubule depolarization-induced local events in the ryanodine receptor, as monitored with the fluorescent conformational probe incorporated by mediation of peptide A.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-III-LOOP; MUSCLE DIHYDROPYRIDINE RECEPTOR; JUNCTIONAL FOOT PROTEIN; CA2+ RELEASE CHANNEL; SKELETAL-MUSCLE; CALCIUM-RELEASE; SARCOPLASMIC-RETICULUM; ACTIVATION; SEQUENCE; DOMAINS	There is a considerable controversy about the postulated role of the Thrg(671)-Leu(690) (peptide A) region of the dihydropyridine (DHP) receptor alpha1 II-III loop. Here we report that peptide A introduced the fluorescence probe methyl coumarin acetamido (MCA) in a well defined region of the ryanodine receptor (RyR), A-site, in a specific manner. Depolarization of the T-tubule moiety of the triad induced a rapid increase of the fluorescence intensity of the MCA attached to the A-site. Other RyR agonists, which activate the RyR without mediation of the DHP receptor (e.g. caffeine, polylysine, and peptide A), induced Ca2+ release without producing such an MCA fluorescence increase. Both magnitudes of the fluorescence change and Ca2+ release increased with the increase in the degree of T-tubule depolarization. MCA fluorescence increase at the A-site and subsequent sarcoplasmic reticulum Ca2+ release were blocked by blocking of the DHP receptor-to-RyR communication. These results may be accounted for by two alternative models as follows. (a) Upon T-tubule depolarization a portion of the DHP receptor comes close to the RyR, forming a hydrophobic interface (within such an interface the A-site is located), or (b) T-tubule depolarization may produce a local conformational change in the A-site-containing region of the RyR that is not necessarily within the DHP receptor/RyR junction.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School	Ikemoto, N (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	ikemoto@bbri.org			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016922] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR16922] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahern CA, 2001, P NATL ACAD SCI USA, V98, P6935, DOI 10.1073/pnas.111001898; Casarotto MG, 2000, J BIOL CHEM, V275, P11631, DOI 10.1074/jbc.275.16.11631; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P15634, DOI 10.1074/jbc.270.26.15634; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; IKEMOTO N, 1994, BIOCHEMISTRY-US, V33, P10961, DOI 10.1021/bi00202a015; IKEMOTO N, 1988, METHOD ENZYMOL, V157, P469; Ikemoto N, 1998, ADV EXP MED BIOL, V453, P199; KANG JJ, 1992, BIOCHEMISTRY-US, V31, P3288, DOI 10.1021/bi00127a034; Lamb GD, 2000, AM J PHYSIOL-CELL PH, V279, pC891, DOI 10.1152/ajpcell.2000.279.4.C891; LAMB GD, 1990, J PHYSIOL-LONDON, V423, P495, DOI 10.1113/jphysiol.1990.sp018036; Leong P, 1998, J BIOL CHEM, V273, P29958, DOI 10.1074/jbc.273.45.29958; LU X, 1995, BIOPHYS J, V68, P372; LU XY, 1994, J BIOL CHEM, V269, P6511; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; NAKAJIMA Y, 1973, NATURE-NEW BIOL, V246, P216, DOI 10.1038/newbio246216a0; Proenza C, 2000, J BIOL CHEM, V275, P29935, DOI 10.1074/jbc.C000464200; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; Saiki Y, 1999, J BIOL CHEM, V274, P7825, DOI 10.1074/jbc.274.12.7825; Stange M, 2001, BIOPHYS J, V81, P1419, DOI 10.1016/S0006-3495(01)75797-9; STEPHENSON EW, 1981, AM J PHYSIOL, V240, pC1, DOI 10.1152/ajpcell.1981.240.1.C1; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Wang JP, 1996, J BIOL CHEM, V271, P8387, DOI 10.1074/jbc.271.14.8387; Wilkens CM, 2001, P NATL ACAD SCI USA, V98, P5892, DOI 10.1073/pnas.101618098; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; YAMAMOTO T, 2000, BIOPHYS J, V79, P428; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; YANO M, 1995, J BIOL CHEM, V270, P3017, DOI 10.1074/jbc.270.7.3017; Yoshikawa F, 1999, J BIOL CHEM, V274, P328, DOI 10.1074/jbc.274.1.328; Zhu XS, 1999, FEBS LETT, V450, P221, DOI 10.1016/S0014-5793(99)00496-2	35	6	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					984	992		10.1074/jbc.M102347200	http://dx.doi.org/10.1074/jbc.M102347200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11682466	hybrid			2022-12-25	WOS:000173166800017
J	Zhang, H; Joseph, J; Gurney, M; Beckert, D; Kalyanaraman, B				Zhang, H; Joseph, J; Gurney, M; Beckert, D; Kalyanaraman, B			Bicarbonate enhances peroxidase activity of Cu,Zn-superoxide dismutase. Role of carbonate anion radical and scavenging of carbonate anion radical by metalloporphyrin antioxidant enzyme mimetics.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ERYTHROCYTE SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; DEPENDENT APOPTOSIS; OXIDATIVE STRESS; NITRIC-OXIDE; PEROXYNITRITE; HYDROXYL; DIOXIDE; ADDUCTS	Much evidence exists for the increased peroxidase activity of copper, zinc superoxide dismutase (SOD1) in oxidant-induced diseases. In this study, we measured the peroxidase activity of SOD1 by monitoring the oxidation of dichlorodihydrofluorescein (DCFH) to dichlorofluorescein (DCF). Bicarbonate dramatically enhanced DCFH oxidation to DCF in a SOD1/H2O2/DCFH system. Peroxidase activity could be measured at a lower 11202 concentration (similar to1 mum). We propose that DCFH oxidation to DCF is a sensitive index for measuring the peroxidase activity of SOD1 and familial amyotrophic lateral sclerosis SOD1 mutants and that the carbonate radical anion (CO3.) is responsible for oxidation of DCFH to DCF in the SOD1/H2O2/bicarbonate system. Bicarbonate enhanced H2O2-dependent oxidation of DCFH to DCF by spinal cord extracts of transgenic mice expressing SOD1(G93A). The SOD1/H2O2/HCO3-. dependent oxidation was mimicked by photolysis of an inorganic cobalt carbonato complex that generates CO3.. Metalloporphyrin antioxidants that are usually considered as SOD1 mimetic or peroxynitrite dismutase effectively scavenged the CO3 radical. Implications of this reaction as a plausible protective mechanism in inflammatory cellular damage induced by peroxynitrite are discussed.	Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Radical Res Ctr, Milwaukee, WI 53226 USA; DeCODE Genet, Reykjavik, Iceland; Florida Int Univ, Dept Chem, Miami, FL USA	Medical College of Wisconsin; Medical College of Wisconsin; State University System of Florida; Florida International University	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Biophys Res Inst, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.				NCRR NIH HHS [RR01008] Funding Source: Medline; NHLBI NIH HHS [HL63119] Funding Source: Medline; NINDS NIH HHS [NS40494] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040494] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; BASOLO F, 1953, INORG SYN, V4, P171, DOI 10.1002/9780470132357.ch56; BECKMAN JS, 2000, SCIENCE, V288, P399; BEHAR D, 1970, J PHYS CHEM-US, V74, P2206, DOI 10.1021/j100909a029; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; CHEN SN, 1973, RADIAT RES, V56, P40, DOI 10.2307/3573789; Ciriolo MR, 2000, J BIOL CHEM, V275, P5065, DOI 10.1074/jbc.275.7.5065; COPE VW, 1973, J AM CHEM SOC, V95, P3116, DOI 10.1021/ja00791a005; CROW J, 2001, 3 INT C PER REACT NI; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FEIX JB, 1991, ARCH BIOCHEM BIOPHYS, V291, P43, DOI 10.1016/0003-9861(91)90103-P; Ferrer-Sueta G, 1999, CHEM RES TOXICOL, V12, P442, DOI 10.1021/tx980245d; FLOYD RA, 1981, BIOCHEM BIOPH RES CO, V99, P1209, DOI 10.1016/0006-291X(81)90748-8; Goss SPA, 1999, J BIOL CHEM, V274, P28233, DOI 10.1074/jbc.274.40.28233; GRONER Y, 1994, BIOMED PHARMACOTHER, V48, P231, DOI 10.1016/0753-3322(94)90138-4; Gurney ME, 1998, J INHERIT METAB DIS, V21, P587, DOI 10.1023/A:1005475206997; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; HUIE RE, 1991, RADIAT PHYS CHEM, V38, P477; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; KALYANARAMAN B, 1985, J BIOL CHEM, V260, P4003; KALYANARAMAN B, 2000, FREE RADIC BIOL MED, V29, P127; Kang JH, 2000, BBA-GEN SUBJECTS, V1524, P162, DOI 10.1016/S0304-4165(00)00153-7; KOTAKE Y, 1991, J AM CHEM SOC, V113, P9503, DOI 10.1021/ja00025a013; Lee JB, 1998, J AM CHEM SOC, V120, P6053, DOI 10.1021/ja9801036; Liochev SI, 1999, FREE RADICAL BIO MED, V27, P1444, DOI 10.1016/S0891-5849(99)00190-2; Liochev SI, 1998, ARCH BIOCHEM BIOPHYS, V352, P237, DOI 10.1006/abbi.1998.0616; Liochev SI, 2001, J BIOL CHEM, V276, P35253, DOI 10.1074/jbc.M104237200; Liu RG, 1998, ANN NEUROL, V44, P763, DOI 10.1002/ana.410440510; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; Misko TP, 1998, J BIOL CHEM, V273, P15646, DOI 10.1074/jbc.273.25.15646; MOTTLEY C, 1986, BIOCHEM BIOPH RES CO, V141, P622, DOI 10.1016/S0006-291X(86)80218-2; POPP JL, 1990, BIOCHEMISTRY-US, V29, P10475, DOI 10.1021/bi00498a008; REDPATH JL, 1973, INT J RADIAT BIOL, V23, P51, DOI 10.1080/09553007314550051; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Sampson JB, 2001, ARCH BIOCHEM BIOPHYS, V392, P8, DOI 10.1006/abbi.2001.2418; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Williamson T L, 2000, Science, V288, P399; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709; Zhang H, 2000, J BIOL CHEM, V275, P14038, DOI 10.1074/jbc.275.19.14038	47	36	36	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1013	1020		10.1074/jbc.M108585200	http://dx.doi.org/10.1074/jbc.M108585200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11682485	hybrid			2022-12-25	WOS:000173166800020
J	Downer, R; Roche, F; Park, PW; Mecham, RP; Foster, TJ				Downer, R; Roche, F; Park, PW; Mecham, RP; Foster, TJ			The elastin-binding protein of Staphylococcus aureus (EbpS) is expressed at the cell surface as an integral membrane protein and not as a cell wall-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLUMPING FACTOR; GENETIC-ANALYSIS; RECEPTOR; VECTORS; IDENTIFICATION; MECHANISM; ADHERENCE; MUTANTS; DOMAINS; CLONING	The elastin-binding proteins EbpS of Staphylococcus aureus strains Cowan and 8325-4 were predicted from sequence analysis to comprise 486 residues. Specific antibodies were raised against an N-terminal domain (residues 1-267) and a C-terminal domain (residues 343-486) expressed as recombinant proteins in Escherichia coli. Western blotting of lysates of wild-type 8325-4 and Newman and the corresponding ebpS mutants showed that EbpS migrated with an apparent molecular mass of 83 kDa. The protein was found exclusively in cytoplasmic membrane fractions purified from protoplasts or lysed cells, in contrast to the clumping factor CIfA, which was cell-wall-associated. EbpS was predicted to have three hydrophobic domains H1-(205-224), H2(265-280), and H3-(315-342). A series of hybrid proteins was formed between EbpS at the N terminus and either alkaline phosphatase or beta-galactosidase at the C terminus (EbpS-PhoA, EbpS-LacZ). PhoA and LacZ were fused to EbpS between hydrophobic domains H1-H2 and H2-H3, and distal to H3. Expression of enzymatic activity in E. coli showed that EbpS is an integral membrane protein with two membrane-spanning domains H1 and H3. N-terminal residues 1-205 and C-terminal residues 343-486 were predicted to be exposed on the outer face of the cytoplasmic membrane. The ligand-binding domain of EbpS is known from previous studies to be present in the N terminus between residues 14-34 and probing whole cells with anti-EbpS1-267 antibodies indicated that this region is exposed on the surface of intact cells. This was also confirmed by the observation that wildtype S. aureus Newman cells bound labeled tropooelastin whereas the ebpS mutant bound 72% less. In contrast, the C terminus, which carries a putative LysM peptidoglycan-binding domain, is not exposed on the surface of intact cells and presumably remains buried within the peptidoglycan. Finally, expression of EbpS was correlated with the ability of cells to grow to a higher density in liquid culture, suggesting that EbpS may have a role in regulating cell growth.	Univ Dublin Trinity Coll, Dept Microbiol, Moyne Inst Prevent Med, Dublin 2, Ireland; Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Trinity College Dublin; Baylor College of Medicine; Washington University (WUSTL)	Foster, TJ (corresponding author), Univ Dublin Trinity Coll, Dept Microbiol, Moyne Inst Prevent Med, Dublin 2, Ireland.	tfoster@tcd.ie		Park, Pyong Woo/0000-0002-7979-4979				AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; AUGUSTIN J, 1992, EUR J BIOCHEM, V204, P1149, DOI 10.1111/j.1432-1033.1992.tb16740.x; BODEN MK, 1989, INFECT IMMUN, V57, P2358; Bohach GA, 2000, GRAM-POSITIVE PATHOGENS, P367; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; CROSSLEY KB, 1997, STAPHYLOCOCCI HUMAN; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; ELLS HA, 1959, ARCH BIOCHEM BIOPHYS, V85, P561, DOI 10.1016/0003-9861(59)90527-2; Foster TJ, 1998, METHOD MICROBIOL, V27, P433; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Fulkerson JF, 2000, J BACTERIOL, V182, P1722, DOI 10.1128/JB.182.6.1722-1730.2000; GREENE C, 1995, MOL MICROBIOL, V17, P1143, DOI 10.1111/j.1365-2958.1995.mmi_17061143.x; Hartleib J, 2000, BLOOD, V96, P2149; HOOK M, 1999, GRAM POSITIVE BACTER, P386; HORINOUCHI S, 1982, J BACTERIOL, V150, P804, DOI 10.1128/JB.150.2.804-814.1982; HUSSAIN M, 1991, J MED MICROBIOL, V34, P143, DOI 10.1099/00222615-34-3-143; INDIK Z, 1990, ARCH BIOCHEM BIOPHYS, V280, P80, DOI 10.1016/0003-9861(90)90521-Y; Jonquieres R, 1999, MOL MICROBIOL, V34, P902, DOI 10.1046/j.1365-2958.1999.01652.x; JONSSON K, 1995, J BIOL CHEM, V270, P21457, DOI 10.1074/jbc.270.37.21457; JORIS B, 1992, FEMS MICROBIOL LETT, V91, P257; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; KUBAK BM, 1982, BIOCHIM BIOPHYS ACTA, V687, P238, DOI 10.1016/0005-2736(82)90552-1; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CY, 1991, GENE, V103, P101, DOI 10.1016/0378-1119(91)90399-V; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; Mazmanian SK, 2001, MOL MICROBIOL, V40, P1049, DOI 10.1046/j.1365-2958.2001.02411.x; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; O'Connell DP, 1998, J BIOL CHEM, V273, P6821, DOI 10.1074/jbc.273.12.6821; OWEN P, 1985, ENTEROBACTERIAL SURF, P237; Palma M, 1999, J BACTERIOL, V181, P2840, DOI 10.1128/JB.181.9.2840-2845.1999; Park PW, 1996, J BIOL CHEM, V271, P15803, DOI 10.1074/jbc.271.26.15803; Park PW, 1999, J BIOL CHEM, V274, P2845, DOI 10.1074/jbc.274.5.2845; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; POTEMPA J, 1988, J BIOL CHEM, V263, P2664; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDBERG LB, 1981, NEW ENGL J MED, V304, P566, DOI 10.1056/NEJM198103053041004; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; SWITALSKI LM, 1989, J BIOL CHEM, V264, P21080; TIEDEMAN AA, 1988, NUCLEIC ACIDS RES, V16, P3587, DOI 10.1093/nar/16.8.3587; VARGA Z, 1989, FEBS LETT, V258, P5, DOI 10.1016/0014-5793(89)81602-3; WRENN DS, 1986, BIOCHEMISTRY-US, V25, P5172, DOI 10.1021/bi00366a028; Xie G, 1999, Microb Comp Genomics, V4, P5, DOI 10.1089/omi.1.1999.4.5; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	50	98	110	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					243	250		10.1074/jbc.M107621200	http://dx.doi.org/10.1074/jbc.M107621200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11684686	Green Published, hybrid			2022-12-25	WOS:000173087900033
J	Shibata, Y; Nakamura, T				Shibata, Y; Nakamura, T			Defective flap endonuclease 1 activity in mammalian cells is associated with impaired DNA repair and prolonged S phase delay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; STRAND BREAKS; DAMAGE; REPLICATION; PATHWAY; FEN-1; RECONSTITUTION; METABOLISM; PROTEINS; PCNA	Flap endonuclease I (FEN-1) is a 5'-3' flap exo-/endonuclease that plays an important role in Okazaki fragment maturation, nonhomologous end joining of double-stranded DNA breaks, and long patch base excision repair. Here, we demonstrate that the wild type FEN-1 binds tightly to chromatin in conjunction with proliferating cell nuclear antigen (PCNA) recruitment after MMS treatment, and the nuclease-defective FEN-1 increased the sensitivity of the cells to methylmethane sulfonate (MMS) and to UV light but not to ionizing radiation. In contrast, the cells expressing the nuclease-defective and PCNA binding-defective double mutant FEN-1 exhibited sensitivities similar to those in the cells expressing the wild type FEN-1. AMS treatment caused a prolonged delay of S phase progression and impairment in colony-forming activity of cells expressing nuclease-defective FEN-1. A comet assay demonstrated that DNA repair after AMS or UV treatment was impaired in the cells expressing nuclease-deficient FEN-1 but not in the cells with double-mutated FEN-1. Taken together, these findings suggest that FEN-1 plays an essential role in the DNA repair processes in mammalian cells and that this activity of FEN-1 is PCNA-dependent.	Nagasaki Univ, Sch Dent, Dept Radiol & Canc Biol, Nagasaki 8528588, Japan	Nagasaki University	Nakamura, T (corresponding author), Nagasaki Univ, Sch Dent, Dept Radiol & Canc Biol, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.							Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bibikova M, 1998, J BIOL CHEM, V273, P34222, DOI 10.1074/jbc.273.51.34222; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Frank G, 2001, J BIOL CHEM, V276, P36295, DOI 10.1074/jbc.M103397200; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gary R, 1999, MOL CELL BIOL, V19, P5373; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; Kim CY, 1999, J BIOL CHEM, V274, P1233, DOI 10.1074/jbc.274.3.1233; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; NOCENTINI S, 1995, RADIAT RES, V144, P170, DOI 10.2307/3579256; Okano S, 2000, J BIOL CHEM, V275, P32635, DOI 10.1074/jbc.M004085200; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Qiu JZ, 2001, J BIOL CHEM, V276, P4901, DOI 10.1074/jbc.M007825200; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBINS P, 1994, J BIOL CHEM, V269, P28535; Savio M, 1998, CARCINOGENESIS, V19, P591, DOI 10.1093/carcin/19.4.591; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; WAGA S, 1994, J BIOL CHEM, V269, P10923; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Yoon JH, 1999, BIOCHEMISTRY-US, V38, P4809, DOI 10.1021/bi990105i; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	33	40	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					746	754		10.1074/jbc.M109461200	http://dx.doi.org/10.1074/jbc.M109461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11687589	hybrid			2022-12-25	WOS:000173087900097
J	Guo, J; Casolaro, V; Seto, E; Yang, WM; Chang, C; Seminario, MC; Keen, J; Georas, SN				Guo, J; Casolaro, V; Seto, E; Yang, WM; Chang, C; Seminario, MC; Keen, J; Georas, SN			Yin-yang 1 activates interleukin-4 gene expression in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IL-4 PROMOTER; TRANSCRIPTION FACTOR GATA-3; NUCLEAR FACTOR; RESPONSIVE ELEMENT; ADENOVIRUS E1A; FACTOR YY1; TH2 CELLS; TRANSACTIVATION DOMAIN; BINDING PROTEIN; IN-VIVO	Interleukin-4 (IL-4) is a multifunctional cytokine that plays an important role in immune and inflammatory responses. Expression of the IL-4 gene is tightly controlled at the level of gene transcription by both positive and negative regulatory elements in the IL-4 promoter. Several constitutive nuclear factors have been identified that can interact with IL-4 promoter elements in DNA binding assays. Here we report that the zinc-finger protein YY-1 (Yin-Yang 1) can bind to multiple elements within the human IL-4 promoter. Cotransfection of Jurkat T cells with different IL-4 promoter/reporter constructs together with expression vectors encoding antisense, wild-type, or zinc finger-deleted mutant YY-1 suggested that YY-1 enhanced IL-4 promoter activity in a DNA-binding domain-dependent manner. Site-directed mutagenesis revealed that a proximal YY-1-binding site, termed Y0 ((-59)TCATTTT(-53)) was essential for YY-1-driven IL-4 promoter activity. In addition, cotransfected YY-1 enhanced both IL-4 promoter activity and endogenous IL-4 gene expression in nontransformed peripheral blood T cells. Thus, YY-1 positively regulates IL-4 gene expression in lymphocytes.	Johns Hopkins Asthma & Allergy Ctr, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA; Johns Hopkins Asthma & Allergy Ctr, Div Allergy & Clin Immunol, Baltimore, MD 21224 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Georas, SN (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Pulm & Crit Care Med, Rm 4B41,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	sgeoras@jhmi.edu	Casolaro, Vincenzo/E-9144-2010; Yang, Wusheng/G-5970-2011	Casolaro, Vincenzo/0000-0001-9810-0488; Yang, Wen-Ming/0000-0002-5871-5979	NHLBI NIH HHS [HLAI61875] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061875] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Agarwal S, 1999, J ALLERGY CLIN IMMUN, V103, P990, DOI 10.1016/S0091-6749(99)70168-5; Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; Bovolenta C, 1999, J IMMUNOL, V163, P6892; Breslin MB, 1998, J STEROID BIOCHEM, V67, P369, DOI 10.1016/S0960-0760(98)00138-1; Brown MA, 1997, CRIT REV IMMUNOL, V17, P1; Burke TF, 2000, BIOCHEM BIOPH RES CO, V270, P1016, DOI 10.1006/bbrc.2000.2508; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; Bushmeyer SM, 1998, J CELL BIOCHEM, V68, P484, DOI 10.1002/(SICI)1097-4644(19980315)68:4<484::AID-JCB8>3.3.CO;2-F; CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; Casolaro V, 1996, CURR OPIN IMMUNOL, V8, P796, DOI 10.1016/S0952-7915(96)80007-0; Casolaro V, 2000, J BIOL CHEM, V275, P36605, DOI 10.1074/jbc.M007086200; Chen RB, 2000, J IMMUNOL, V164, P825, DOI 10.4049/jimmunol.164.2.825; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; Coull JJ, 2000, J VIROL, V74, P6790, DOI 10.1128/JVI.74.15.6790-6799.2000; Cron RQ, 1997, J IMMUNOL METHODS, V205, P145, DOI 10.1016/S0022-1759(97)00065-3; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Gallichan WS, 1999, J IMMUNOL, V163, P1696; Georas S, 2000, LEUKEMIA, V14, P629, DOI 10.1038/sj.leu.2401712; Georas SN, 1998, BLOOD, V92, P4529, DOI 10.1182/blood.V92.12.4529.424k39_4529_4538; Grogan JL, 2001, IMMUNITY, V14, P205, DOI 10.1016/S1074-7613(01)00103-0; HENKEL G, 1992, J IMMUNOL, V149, P3239; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; HODGE MR, 1995, J IMMUNOL, V154, P6397; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kelso A, 1999, INT IMMUNOL, V11, P617, DOI 10.1093/intimm/11.4.617; Lee GR, 2001, IMMUNITY, V14, P447, DOI 10.1016/S1074-7613(01)00125-X; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Li-Weber M, 1998, J IMMUNOL, V161, P1380; LIWEBER M, 1994, J IMMUNOL, V153, P4122; LIWEBER M, 1993, J IMMUNOL, V151, P1371; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; MIN LW, 1992, J IMMUNOL, V148, P1913; Mordvinov VA, 1999, J ALLERGY CLIN IMMUN, V103, P1125, DOI 10.1016/S0091-6749(99)70188-0; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; Paliogianni F, 1996, CELL IMMUNOL, V168, P33, DOI 10.1006/cimm.1996.0046; Petkova V, 2001, J BIOL CHEM, V276, P7932, DOI 10.1074/jbc.M007411200; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Sweetser MT, 1998, J BIOL CHEM, V273, P34775, DOI 10.1074/jbc.273.52.34775; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; Szabo SJ, 1997, CURR OPIN IMMUNOL, V9, P776, DOI 10.1016/S0952-7915(97)80177-X; Takemoto N, 1997, INT IMMUNOL, V9, P1329, DOI 10.1093/intimm/9.9.1329; Takemoto N, 1998, INT IMMUNOL, V10, P1981, DOI 10.1093/intimm/10.12.1981; TARA D, 1993, J IMMUNOL, V151, P3617; TARA D, 1995, J IMMUNOL, V154, P4592; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; Walowitz JL, 1998, J BIOL CHEM, V273, P6656, DOI 10.1074/jbc.273.12.6656; Wenner CA, 1997, J IMMUNOL, V158, P765; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 2001, EMBO J, V20, P4814, DOI 10.1093/emboj/20.17.4814; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Zhang DH, 1998, J IMMUNOL, V161, P3817; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995	70	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48871	48878		10.1074/jbc.M101592200	http://dx.doi.org/10.1074/jbc.M101592200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11687571	hybrid			2022-12-25	WOS:000173922100034
J	El-Gazzar, MA; Maeda, K; Nomiyama, H; Nakao, M; Kuwahara, K; Sakaguchi, N				El-Gazzar, MA; Maeda, K; Nomiyama, H; Nakao, M; Kuwahara, K; Sakaguchi, N			PU.1 is involved in the regulation of B lineage-associated and developmental stage-dependent expression of the germinal center-associated DNA primase GANP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PU.1; RNA POLYMERASE-II; J-CHAIN GENE; SOMATIC HYPERMUTATION; CELL DIFFERENTIATION; ENHANCER ACTIVITY; NUCLEAR FACTOR; PROTEIN; REPLICATION; PROMOTER	Germinal center-associated DNA primase (GANP) associated with MCM3 of the DNA replication complex is up-regulated selectively in germinal center B cells. We studied promoter activity of the 5' region involved in the developmental stage-dependent expression in B lineage cells by luciferase reporter assay. Selective regulation of ganp expression was observed in the -737-bp promoter region in B and plasma cell lines but was significantly low in pre-B and T cell lines. The deletion constructs displayed a gap decrease after shortening the region from -134 to -108 bp. Further narrowing suggested the involvement of the PU.1 consensus sequence at -126 bp by electrophoretic. mobility shift assay. The protein component PU.1 complex is not inhibited with mutated probes at the consensus site but is inhibited with the known PU.1 probe of CD72 and with anti-PU.1 antibody. Moreover, introduction of PU.1 cDNA enhanced the reporter gene activity in a dose-dependent manner in B cells, whereas the reporter construct with the mutated PU.1 site did not respond. Anti-CD40 stimulation induced the reporter activity with a 100% increase, which is not observed with the PU.1-mutated reporter construct. These results demonstrate that the germinal center-associated DNA primase expression is partly regulated by the transcription factor PU.1 expressed in B lineage cells.	Kumamoto Univ, Sch Med, Dept Immunol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Biochem, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan	Kumamoto University; Kumamoto University; Kumamoto University	Sakaguchi, N (corresponding author), Kumamoto Univ, Sch Med, Dept Immunol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Nomiyama, Hisayuki/F-2840-2013	Nomiyama, Hisayuki/0000-0002-2716-4043				Abe E, 2000, GENE, V255, P219, DOI 10.1016/S0378-1119(00)00336-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157; HAGMAN J, 1991, EMBO J, V10, P3409, DOI 10.1002/j.1460-2075.1991.tb04905.x; Himmelmann A, 1996, BLOOD, V87, P1036, DOI 10.1182/blood.V87.3.1036.bloodjournal8731036; Igarashi H, 2001, BLOOD, V97, P2680, DOI 10.1182/blood.V97.9.2680; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KELSOE G, 1995, IMMUNOL TODAY, V16, P324, DOI 10.1016/0167-5699(95)80146-4; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; Kuwahara K, 2000, BLOOD, V95, P2321, DOI 10.1182/blood.V95.7.2321.007k33_2321_2328; Kuwahara K, 2001, P NATL ACAD SCI USA, V98, P10279, DOI 10.1073/pnas.181335698; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Linderson Y, 2001, GENE, V262, P107, DOI 10.1016/S0378-1119(00)00546-1; Liu YJ, 1997, IMMUNOL REV, V156, P111, DOI 10.1111/j.1600-065X.1997.tb00963.x; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MacLennan ICM, 1997, IMMUNOL REV, V156, P53, DOI 10.1111/j.1600-065X.1997.tb00958.x; Maeda K, 1998, GENE, V210, P287, DOI 10.1016/S0378-1119(98)00079-1; Maitra S, 2000, MOL CELL BIOL, V20, P1911, DOI 10.1128/MCB.20.6.1911-1922.2000; Mitsuyoshi S, 1997, BIOCHEM BIOPH RES CO, V235, P191, DOI 10.1006/bbrc.1997.6759; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Rinkenberger JL, 1996, IMMUNITY, V5, P377, DOI 10.1016/S1074-7613(00)80263-0; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Shinall SM, 2000, J IMMUNOL, V164, P5729, DOI 10.4049/jimmunol.164.11.5729; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; Storb U, 1996, CURR OPIN IMMUNOL, V8, P206, DOI 10.1016/S0952-7915(96)80059-8; Su GH, 1997, EMBO J, V16, P7118, DOI 10.1093/emboj/16.23.7118; Takei Y, 1998, J BIOL CHEM, V273, P22177, DOI 10.1074/jbc.273.35.22177; Takei Y, 2001, EMBO REP, V2, P119, DOI 10.1093/embo-reports/kve026; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; UBANEK P, 1994, CELL, V79, P901; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200; Wang Y, 2000, EUR J IMMUNOL, V30, P2226, DOI 10.1002/1521-4141(2000)30:18<2226::AID-IMMU2226>3.0.CO;2-M; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; Winter DB, 2000, MOL IMMUNOL, V37, P125, DOI 10.1016/S0161-5890(00)00040-7; Ying H, 1998, J IMMUNOL, V160, P2287; Zan H, 1999, J IMMUNOL, V162, P3437	50	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48000	48008		10.1074/jbc.M106696200	http://dx.doi.org/10.1074/jbc.M106696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11641399	hybrid			2022-12-25	WOS:000172927000038
J	Li, BR; Zhang, W; Chan, G; Jancso-Radek, A; Liu, SH; Weiss, MA				Li, BR; Zhang, W; Chan, G; Jancso-Radek, A; Liu, SH; Weiss, MA			Human sex reversal due to impaired nuclear localization of SRY - A clinical correlation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTIS-DETERMINING GENE; DNA-BINDING PROPERTIES; HMG BOX REGION; CAMPOMELIC DYSPLASIA; POINT MUTATIONS; MOLECULAR-BASIS; 46,XY FEMALE; Y-CHROMOSOME; PROTEIN; SEQUENCE	SRY, an architectural transcription factor encoded by the sex-determining region of the Y chromosome, initiates testicular differentiation in mammalian embryogenesis. The protein contains a high-mobility group (HMG) box, a DNA-bending motif conserved among a broad class of nuclear proteins. Mutations causing human sex reversal (46, XY pure gonadal dysgenesis) are clustered in this domain. Basic N- and C-terminal regions of the HMG box are each proposed to provide nuclear localization signals. The significance of the C-terminal basic cluster (SRY residues 130-134) is uncertain, however, as its activity in cell culture varies with assay conditions. To test its importance, we have investigated a C-terminal sex-reversal mutation (R133W, position 78 of the HMG box). This de novo mutation impairs nuclear localization but not specific DNA binding or sharp DNA bending. Correlation between these proper ties and the phenotype of the patient suggests that nuclear localization of SRY is required for testicular differentiation and directed in part by the C-terminal basic cluster. To our knowledge, these results provide the first example of impaired organogenesis due to a nuclear localization signal mutation.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Weiss, MA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	weiss@biochemistry.cwru.edu	zhang, wei/A-7015-2011	Li, Biaoru/0000-0002-5626-9557				AFFARA NA, 1993, HUM MOL GENET, V2, P785, DOI 10.1093/hmg/2.6.785; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Brown S, 1998, AM J HUM GENET, V62, P189, DOI 10.1086/301684; BURKE GT, 1984, INT J PEPT PROT RES, V23, P394; CHAN SJ, 1987, P NATL ACAD SCI USA, V84, P2194, DOI 10.1073/pnas.84.8.2194; COHEN DR, 1994, P NATL ACAD SCI USA, V91, P4372, DOI 10.1073/pnas.91.10.4372; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Deckert J, 1999, NUCLEIC ACIDS RES, V27, P3518, DOI 10.1093/nar/27.17.3518; Domenice S, 1998, HUM GENET, V102, P213, DOI 10.1007/s004390050680; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Garcia-Higuera I, 1999, Curr Opin Hematol, V6, P83, DOI 10.1097/00062752-199903000-00005; Giese K, 1997, P NATL ACAD SCI USA, V94, P12845, DOI 10.1073/pnas.94.24.12845; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gu JJ, 2001, CANCER RES, V61, P1741; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Hanley NA, 2000, MECH DEVELOP, V91, P403, DOI 10.1016/S0925-4773(99)00307-X; HAQQ CM, 1993, P NATL ACAD SCI USA, V90, P1097, DOI 10.1073/pnas.90.3.1097; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HAWKINS JR, 1992, HUM GENET, V88, P471, DOI 10.1007/BF00215684; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Imai A, 1999, ENDOCR J, V46, P735, DOI 10.1507/endocrj.46.735; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; Koopman P, 2001, EXS, V91, P25; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; LnenicekAllen M, 1996, NUCLEIC ACIDS RES, V24, P1047, DOI 10.1093/nar/24.6.1047; Lorenz M, 1999, BIOCHEMISTRY-US, V38, P12150, DOI 10.1021/bi990459+; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; LOVELLBADGE R, 1993, PHILOS T R SOC B, V339, P159, DOI 10.1098/rstb.1993.0012; Naf D, 1998, MOL CELL BIOL, V18, P5952; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; NER S S, 1992, Current Biology, V2, P208, DOI 10.1016/0960-9822(92)90541-H; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; PONTIGGIA A, 1995, GENE, V154, P277, DOI 10.1016/0378-1119(94)00853-K; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; Preiss S, 2001, J BIOL CHEM, V276, P27864, DOI 10.1074/jbc.M101278200; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Salas-Cortes L, 1999, INT J DEV BIOL, V43, P135; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Soutar AK, 1998, CURR OPIN LIPIDOL, V9, P141, DOI 10.1097/00041433-199804000-00011; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; TAJIMA T, 1994, HUM MOL GENET, V3, P1187, DOI 10.1093/hmg/3.7.1187; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; Ukiyama E, 2001, MOL ENDOCRINOL, V15, P363, DOI 10.1210/me.15.3.363; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; Veitia R, 1997, HUM GENET, V99, P648, DOI 10.1007/s004390050422; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WERNER MH, 1995, BIOCHEMISTRY-US, V34, P11998, DOI 10.1021/bi00037a042	61	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46480	46484		10.1074/jbc.C100388200	http://dx.doi.org/10.1074/jbc.C100388200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11641389	hybrid			2022-12-25	WOS:000172573100133
J	Schrauwen, P; Saris, WHM; Hesselink, MKC				Schrauwen, P; Saris, WHM; Hesselink, MKC			An alternative function for human uncoupling protein 3: protection of mitochondria against accumulation of nonesterified fatty acids inside the mitochondrial matrix	FASEB JOURNAL			English	Article						UCP3; fatty acid metabolism; fatty acid transport	MESSENGER-RNA EXPRESSION; HUMAN SKELETAL-MUSCLE; GENE-EXPRESSION; ENERGY-EXPENDITURE; UP-REGULATION; WEIGHT-REDUCTION; THYROID-HORMONE; UCP3; EXERCISE; OBESITY	The physiological function of the human uncoupling protein 3 UCP3, which was discovered in 1997, is unknown. Here we evaluate the available data on human UCP3 expression and show that UCP3 is up-regulated in situations where fatty acid delivery to the mitochondria exceeds oxidative capacity, whereas down-regulation of UCP3 is observed when oxidative capacity is enhanced. With a surplus of fatty acid delivery, accumulation of nonesterified fatty acids in the cytoplasm is likely to occur. Although the inner mitochondrial membrane provides a barrier for nonesterified fatty acids, neutral nonesterified fatty acids can partition into the phospholipid bilayer and flip-flop to the other side of the membrane, where they can be released into the mitochondrial matrix. Due to pH differences, these nonesterified fatty acids will be protonated. Because fatty acid anions can neither be metabolized inside the matrix or cross the inner mitochondrial membrane, accumulation of nonesterified fatty acids inside the matrix might occur. Therefore, we postulate that UCP3 is required for the outward translocation of fatty acids from the mitochondrial matrix. In this way, UCP3 is involved in the protection of mitochondria against accumulation of nonesterified fatty acids inside the mitochondrial matrix.	Maastricht Univ, Dept Human Biol, NUTRIM, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Dept Movement Sci, NL-6200 MD Maastricht, Netherlands	Maastricht University; Maastricht University	Schrauwen, P (corresponding author), Maastricht Univ, Dept Human Biol, NUTRIM, POB 616, NL-6200 MD Maastricht, Netherlands.	p.schrauwen@hb.unimaas.nl		schrauwen, patrick/0000-0002-0973-847X				Barbe P, 2001, FASEB J, V15, P13; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; Bouchard C, 1997, HUM MOL GENET, V6, P1887, DOI 10.1093/hmg/6.11.1887; Buemann B, 2001, INT J OBESITY, V25, P467, DOI 10.1038/sj.ijo.0801564; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Cortright RN, 1999, AM J PHYSIOL-ENDOC M, V276, pE217, DOI 10.1152/ajpendo.1999.276.1.E217; Emilsson V, 2000, METABOLISM, V49, P1610, DOI 10.1053/meta.2000.18692; Esterbauer H, 1999, DIABETOLOGIA, V42, P302, DOI 10.1007/s001250051155; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FREAKE HC, 1995, ANNU REV NUTR, V15, P263, DOI 10.1146/annurev.nu.15.070195.001403; GARDNER AW, 1989, HUM BIOL, V61, P559; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; GISSLINGER H, 1991, CLIN EXP RHEUMATOL, V9, P383; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; Keys A, 1950, BIOL HUMAN STARVATIO; Khalfallah Y, 2000, DIABETES, V49, P25, DOI 10.2337/diabetes.49.1.25; Klannemark M, 1998, EUR J ENDOCRINOL, V139, P217, DOI 10.1530/eje.0.1390217; Klingenberg M, 1999, INT J OBESITY, V23, pS24, DOI 10.1038/sj.ijo.0800939; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Matsuda J, 1997, FEBS LETT, V418, P200, DOI 10.1016/S0014-5793(97)01381-1; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Samec S, 1999, PFLUG ARCH EUR J PHY, V438, P452, DOI 10.1007/s004240051061; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Schrauwen P, 2000, DIABETOLOGIA, V43, P1408, DOI 10.1007/s001250051547; Schrauwen P, 1999, INT J OBESITY, V23, P966, DOI 10.1038/sj.ijo.0801026; Schrauwen P, 1999, OBES RES, V7, P97, DOI 10.1002/j.1550-8528.1999.tb00396.x; Schrauwen P, 2001, FASEB J, V15, P2497, DOI 10.1096/fj.01-0400hyp; Schrauwen P, 1999, DIABETES, V48, P146, DOI 10.2337/diabetes.48.1.146; Schrauwen P, 2001, INT J OBESITY, V25, P449, DOI 10.1038/sj.ijo.0801566; Schrauwen P, 1997, AM J CLIN NUTR, V66, P276, DOI 10.1093/ajcn/66.2.276; SCHRAUWEN P, 2001, IN PRESS AM J PHYSL; Tsuboyama-Kasaoka N, 1998, BIOCHEM BIOPH RES CO, V247, P498, DOI 10.1006/bbrc.1998.8818; Vidal-Puig A, 1999, OBES RES, V7, P133, DOI 10.1002/j.1550-8528.1999.tb00694.x; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Walder K, 1998, HUM MOL GENET, V7, P1431, DOI 10.1093/hmg/7.9.1431; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE622, DOI 10.1152/ajpendo.2000.279.3.E622	46	157	159	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2497	2502		10.1096/fj.01-0400hyp	http://dx.doi.org/10.1096/fj.01-0400hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689475	Green Submitted			2022-12-25	WOS:000172420500020
J	Forus, A; D'Angelo, A; Henriksen, J; Merla, G; Maelandsmo, GM; Florenes, VA; Olivieri, S; Bjerkehagen, B; Meza-Zepeda, LA; Blanco, FD; Muller, C; Sanvito, F; Kononen, J; Nesland, JM; Fodstad, O; Reymond, A; Kallioniemi, OP; Arrigoni, G; Ballabio, A; Myklebost, O; Zollo, M				Forus, A; D'Angelo, A; Henriksen, J; Merla, G; Maelandsmo, GM; Florenes, VA; Olivieri, S; Bjerkehagen, B; Meza-Zepeda, LA; Blanco, FD; Muller, C; Sanvito, F; Kononen, J; Nesland, JM; Fodstad, O; Reymond, A; Kallioniemi, OP; Arrigoni, G; Ballabio, A; Myklebost, O; Zollo, M			Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas - a possible mechanism for altering the nm23-H1 activity	ONCOGENE			English	Article						PRUNE; nm23; sarcoma; breast	COMPARATIVE GENOMIC HYBRIDIZATION; NUCLEOSIDE DIPHOSPHATE KINASE; HUMAN HEPATOCELLULAR-CARCINOMA; CELL-LINES; MOLECULAR CHARACTERIZATION; TISSUE MICROARRAYS; PROTEIN EXPRESSION; TUMOR PROGRESSION; GENE-EXPRESSION; DROSOPHILA	PRUNE, the human homologue of the Drosophila gene, is located in 1q21.3, a region highly amplified in human sarcomas, malignant tumours of mesenchymal origin. Prune protein interacts with the metastasis suppressor nm23-H1, but shows impaired affinity towards the nm23-H1 S120G mutant associated with advanced neuroblastoma. Based on these observations, we previously suggested that prune may act as a negative regulator of nm23-H1 activity. We found amplification of PRUNE in aggressive sarcoma subtypes, such as leiomyosarcomas and malignant fibrous histiocytomas (NIFH) as well as in the less malignant liposarcomas. PRUNE amplification was generally accompanied by high mRNA and moderate to high protein levels. The sarcoma samples expressed nm23-H1 mostly at low or moderate levels, whereas mRNA and protein levels were moderate to high in breast carcinomas. For the more aggressive sarcoma subtypes, 9/13 patients with PRUNE amplification developed metastases. A similar situation was observed in all breast carcinomas with amplification of PRUNE. Infection of NIH3T3 cells with a PRUNE recombinant retrovirus increased cell proliferation. Possibly, amplification and overexpression of PRUNE has the same effect in the tumours. We suggest that amplification and overexpression of PRUNE could be a mechanism for inhibition of nm23-H1 activity that affect the development or progression of these tumours.	Telethon Inst Genet & Med, I-80131 Naples, Italy; Norwegian Radium Hosp, Dept Tumor Biol, Oslo, Norway; Norwegian Radium Hosp, Dept Pathol, Oslo, Norway; HSR Biomed Sci Pk, Dept Pathol, Milan, Italy; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Tampere, Inst Med Technol, Canc Genet Lab, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland; Univ Geneva, Sch Med, Div Med Genet, CH-1211 Geneva, Switzerland	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Oslo; University of Oslo; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Tampere University; Tampere University; Tampere University Hospital; University of Geneva	Zollo, M (corresponding author), Telethon Inst Genet & Med, Via Pietro Castellino 111, I-80131 Naples, Italy.	zollo@tigem.it	Kutalik, Zoltan/HHZ-5697-2022; Myklebost, Ola/E-9335-2010; merla, giuseppe/K-4627-2012; BALLABIO, Andrea/AAL-2672-2020; Kallioniemi, Olli P/H-5111-2011; Meza-Zepeda, Leonardo Andres/CAG-5229-2022	Kutalik, Zoltan/0000-0001-8285-7523; Myklebost, Ola/0000-0002-2866-3223; merla, giuseppe/0000-0001-5078-928X; BALLABIO, Andrea/0000-0003-1381-4604; Kallioniemi, Olli P/0000-0002-3231-0332; Meza-Zepeda, Leonardo Andres/0000-0003-3056-212X; Reymond, Alexandre/0000-0003-1030-8327; Kononen, Juha/0000-0002-0157-2137	Telethon [TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; Berner JM, 1997, ONCOGENE, V14, P2935, DOI 10.1038/sj.onc.1201135; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; Caligo MA, 1997, INT J CANCER, V74, P102, DOI 10.1002/(SICI)1097-0215(19970220)74:1<102::AID-IJC18>3.0.CO;2-H; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; Cipollini G, 1997, INT J CANCER, V73, P297, DOI 10.1002/(SICI)1097-0215(19971009)73:2<297::AID-IJC22>3.0.CO;2-B; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; Enzinger FM, 1995, SOFT TISSUE TUMORS, V3rd; FLORENES VA, 1992, CANCER RES, V52, P6088; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; Forus A, 1998, BRIT J CANCER, V78, P495, DOI 10.1038/bjc.1998.521; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; Forus A, 2001, CANCER GENET CYTOGEN, V125, P100, DOI 10.1016/S0165-4608(00)00369-1; Gronwald J, 1997, CANCER RES, V57, P481; Hartsough MT, 2001, CANCER RES, V61, P2320; HE J, 1995, CANCER RES, V55, P4833; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; Hirai M, 1999, GENE CHROMOSOME CANC, V25, P261, DOI 10.1002/(SICI)1098-2264(199907)25:3<261::AID-GCC8>3.0.CO;2-#; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kudoh K, 1999, CLIN CANCER RES, V5, P2526; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P855; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Marenholz I, 1996, GENOMICS, V37, P295, DOI 10.1006/geno.1996.0563; MARTINEZ JA, 1995, GUT, V37, P712, DOI 10.1136/gut.37.5.712; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller W, 1998, CANCER-AM CANCER SOC, V83, P2481, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2481::AID-CNCR11>3.0.CO;2-P; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREVI N, 1975, MUTAT RES, V33, P193, DOI 10.1016/0027-5107(75)90195-5; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pedeutour F, 1999, GENE CHROMOSOME CANC, V24, P30, DOI 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P; Pilotti S, 1998, J PATHOL, V185, P188; Qin LX, 1999, CANCER RES, V59, P5662; Reymond A, 1999, ONCOGENE, V18, P7244, DOI 10.1038/sj.onc.1203140; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; Royds JA, 1997, BRIT J CANCER, V75, P1195, DOI 10.1038/bjc.1997.204; Roymans D, 2001, EXP CELL RES, V262, P145, DOI 10.1006/excr.2000.5087; Russell RL, 1998, BRIT J CANCER, V78, P710, DOI 10.1038/bjc.1998.566; SANTORO M, 1994, ONCOGENE, V9, P509; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Simons A, 2000, CANCER GENET CYTOGEN, V118, P89, DOI 10.1016/S0165-4608(99)00178-8; Srivatsa PJ, 1996, GYNECOL ONCOL, V60, P363, DOI 10.1006/gyno.1996.0056; Subramanian C, 2001, NAT MED, V7, P350, DOI 10.1038/85499; Szymanska J, 1996, GENE CHROMOSOME CANC, V15, P89, DOI 10.1002/(SICI)1098-2264(199602)15:2<89::AID-GCC2>3.0.CO;2-#; Tapper J, 1998, CANCER RES, V58, P2715; Tarkkanen M, 1999, INT J CANCER, V84, P114, DOI 10.1002/(SICI)1097-0215(19990420)84:2<114::AID-IJC4>3.0.CO;2-Q; Timmons L, 1996, GENETICS, V144, P1589; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Tseng YH, 2001, CANCER RES, V61, P2071; Volorio S, 1998, DNA SEQUENCE, V9, P307, DOI 10.3109/10425179809008469; Weiss SW, 1994, WHO HISTOLOGICAL CLA, V2nd; WHITE CJ, 1899, J CUTAN GENITOURIN, V17, P1; Wong N, 1999, AM J PATHOL, V154, P37, DOI 10.1016/S0002-9440(10)65248-0; Zimonjic DB, 1999, HEPATOLOGY, V29, P1208, DOI 10.1002/hep.510290410	61	48	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6881	6890		10.1038/sj.onc.1204874	http://dx.doi.org/10.1038/sj.onc.1204874			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687967				2022-12-25	WOS:000171641000009
J	Mazurek, S; Zwerschke, W; Jansen-Durr, P; Eigenbrodt, E				Mazurek, S; Zwerschke, W; Jansen-Durr, P; Eigenbrodt, E			Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7	ONCOGENE			English	Article						metabolome; glycolysis; glutaminolysis; M2-PK; adenylate kinase; nucleotides	HUMAN-PAPILLOMAVIRUS TYPE-16; ROUS-SARCOMA VIRUS; PYRUVATE-KINASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; SACCHAROMYCES-CEREVISIAE; MALIGNANT TRANSFORMATION; MELANOMA-CELLS; C-MYC; PROLIFERATION; CYCLE	The metabolism of tumor cells (tumor metabolome) is characterized by a high concentration of glycolytic enzymes including pyruvate kinase isoenzyme type M2 (M2-PK), a high glutaminolytic capacity, high fructose 1,6-bisphosphate (FBP) levels and a low (ATP + GTP):(CTP+UTP) ratio. The sequence of events required for the establishment of the tumor metabolome is presently unknown. In non-transformed rat kidney (NRK) cells we observed a high glutaminolytic flux rate and a low (ATP + GTP):(CTP + UTP) ratio, whereas FBP levels and M2-PK activity are still extremely low. After stable expression of oncogenic ras in NRK cells a strong upregulation of FBP levels and of M2-PK activity was observed. Elevated FBP levels induce a tetramerization of M2-PK and its migration into the glycolytic enzyme complex. AMP levels increase whereas UTP and CTP levels strongly decrease. Thus, ras expression completes the glycolytic part of tumor metabolism leading to the inhibition of nucleic acid synthesis and cell proliferation. The HPV-16 E7 oncoprotein, which cooperates with ras in cell transformation, directly binds to M2-PK, induces its dimerization and restores nucleic acid synthesis as well as cell proliferation. Apparently, the combination of the different metabolic effects of ras and E7 constructs the perfect tumor metabolome as generally found in tumor cells.	Univ Giessen, Fac Vet, Inst Biochem & Endocrinol, D-35392 Giessen, Germany; Austrian Acad Sci, Inst Biomed Ageing Res, A-6020 Innsbruck, Austria; Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria	Justus Liebig University Giessen; Austrian Academy of Sciences; University of Innsbruck	Mazurek, S (corresponding author), Univ Giessen, Fac Vet, Inst Biochem & Endocrinol, Frankfurter Str 100, D-35392 Giessen, Germany.		Jansen-Dürr, Pidder/ABG-2466-2020; Mazurek, Sybille/ABH-2089-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Zwerschke, Werner/0000-0003-1137-2953				AON MA, 1995, EXP CELL RES, V217, P42, DOI 10.1006/excr.1995.1061; BEDELL MA, 1987, J VIROL, V61, P3635, DOI 10.1128/JVI.61.11.3635-3640.1987; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; Boros LG, 1997, CANCER RES, V57, P4242; Boros LG, 2000, CANCER RES, V60, P1183; Brazill DT, 1997, J BACTERIOL, V179, P4415, DOI 10.1128/jb.179.13.4415-4418.1997; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cascante M, 2000, NUTR CANCER, V36, P150, DOI 10.1207/S15327914NC3602_2; Chopade BA, 1997, J BACTERIOL, V179, P2181, DOI 10.1128/jb.179.7.2181-2188.1997; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Downes CS, 2000, J CELL SCI, V113, P1089; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; Eigenbrodt E., 1992, Critical Reviews in Oncogenesis, V3, P91; Eigenbrodt E, 1998, ANTICANCER RES, V18, P3267; EIGENBRODT E, 1998, CELL GROWTH ONCOGENE, P15; EIGENBRODT E, 1985, REGULATION CARBOHYDR, P141; Glass-Marmor L, 1999, EUR J PHARMACOL, V370, P195, DOI 10.1016/S0014-2999(99)00155-7; GLOSSMANN H, 1981, MOL CELL ENDOCRINOL, V23, P49, DOI 10.1016/0303-7207(81)90116-7; GREGORY SH, 1976, ARCH BIOCHEM BIOPHYS, V175, P644, DOI 10.1016/0003-9861(76)90555-5; HENDERSON JF, 1981, PHARMACOL THERAPEUT, V8, P539; HUNTING D, 1981, CAN J BIOCHEM CELL B, V59, P821, DOI 10.1139/o81-114; Inouye S, 1999, BIOCHEM BIOPH RES CO, V254, P618, DOI 10.1006/bbrc.1998.0116; JACKSON RC, 1980, CANCER RES, V40, P1286; Kim CY, 1997, CANCER RES, V57, P4200; Kohler C, 1999, FEBS LETT, V447, P10, DOI 10.1016/S0014-5793(99)00251-3; KOLE HK, 1991, ARCH BIOCHEM BIOPHYS, V286, P586, DOI 10.1016/0003-9861(91)90084-V; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Mazurek S, 1996, J CELL PHYSIOL, V167, P238, DOI 10.1002/(SICI)1097-4652(199605)167:2<238::AID-JCP7>3.0.CO;2-Q; Mazurek S, 1997, J BIOENERG BIOMEMBR, V29, P315, DOI 10.1023/A:1022490512705; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; Mazurek S, 1998, ANTICANCER RES, V18, P3275; Mazurek S, 1997, J BIOL CHEM, V272, P4941, DOI 10.1074/jbc.272.8.4941; Mazurek S, 1999, J CELL PHYSIOL, V181, P136; MAZUREK S, 2001, IN PRESS BR J NUTR; MOYER JD, 1982, CANCER RES, V42, P4525; Nagy E, 2000, BIOCHEM BIOPH RES CO, V275, P253, DOI 10.1006/bbrc.2000.3246; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; Noma T, 1999, BIOCHEM BIOPH RES CO, V264, P990, DOI 10.1006/bbrc.1999.1616; Penso J, 1998, EUR J PHARMACOL, V342, P113, DOI 10.1016/S0014-2999(97)01507-0; PRESEK P, 1988, FEBS LETT, V242, P194, DOI 10.1016/0014-5793(88)81014-7; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; RYLL T, 1992, BIOTECHNOL BIOENG, V40, P934, DOI 10.1002/bit.260400810; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Thomas S, 1998, EUR J BIOCHEM, V258, P956, DOI 10.1046/j.1432-1327.1998.2580956.x; WEBER G, 1971, CANCER RES, V31, P2177; Zwerschke W, 2000, ADV CANCER RES, V78, P1; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291	51	91	99	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6891	6898		10.1038/sj.onc.1204792	http://dx.doi.org/10.1038/sj.onc.1204792			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687968				2022-12-25	WOS:000171641000010
J	Lambert, S; Lopez, BS				Lambert, S; Lopez, BS			Role of RAD51 in sister-chromatid exchanges in mammalian cells	ONCOGENE			English	Article						homologous recombination; SCE; RAD51; mammalian cells; alkylating agent	DOUBLE-STRAND BREAK; HOMOLOGY-DIRECTED REPAIR; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; VERTEBRATE CELLS; GENE CONVERSION; DNA; RECOMBINATION; DISRUPTION; PROMOTES	To measure the impact of the RAD51 pathway on Sister-Chromatid Exchanges (SCE), we used hamster cells expressing either the wild-type MmRAD51, which stimulates, or the dominant negative SMRAD51, which inhibits, gene conversion without affecting cell viability of untreated as well as T-rays irradiated cells. We show that MmRAD51 did not affect the rate of spontaneous SCE while it strongly stimulated spontaneous recombination between tandem repeats. No spontaneous recombinant was detected when expressing SMRAD51 while spontaneous SCE were only slightly diminished. After treatment by an alkylating agent (MNU), MmRAD51 stimulated MNU-induced recombination whereas no recombinant was detected when expressing SMRAD51. MNU induced SCE in all cell lines, even in the SMRAD51 expressing lines, but the induction of SCE was slightly more efficient in lines expressing MmRAD51 and less efficient in lines expressing SMRAD51. Thus, in mammalian cells, the RAD51-dependent gene conversion pathway drastically affects recombination between intrachromosomal tandem repeats, whereas it only partially participates in SCE formation, measured at a chromosomal level. These results show that RAD51-gene conversion can participate in induced SCE but that alternative pathways should exist.	CEA, UMR 217 CNRS, Direct Sci Vivant, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, UMR 217 CNRS, Direct Sci Vivant, Dept Radiobiol & Radiopathol, 60-68 Ave Gen Leclerc, F-92265 Fontenay Aux Roses, France.		Lopez, Bernard S/O-7308-2017; lambert, sarah/K-7750-2017	Lopez, Bernard S/0000-0001-5088-0155; lambert, sarah/0000-0002-1403-3204				BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CONNELL JR, 1982, CARCINOGENESIS, V3, P385, DOI 10.1093/carcin/3.4.385; DILLEHAY LE, 1989, MUTAT RES, V215, P15, DOI 10.1016/0027-5107(89)90213-3; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; FABRE F, 1984, MOL GEN GENET, V195, P139, DOI 10.1007/BF00332736; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; KADYK LC, 1992, GENETICS, V132, P387; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Zhang H, 1996, CARCINOGENESIS, V17, P2229, DOI 10.1093/carcin/17.10.2229	19	42	44	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6627	6631		10.1038/sj.onc.1204813	http://dx.doi.org/10.1038/sj.onc.1204813			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641788				2022-12-25	WOS:000171404200016
J	Hoffmann, KF; McCarty, TC; Segal, DH; Chiaramonte, M; Hesse, M; Davis, EM; Cheever, AW; Meltzer, PS; Morse, HC; Wynn, TA				Hoffmann, KF; McCarty, TC; Segal, DH; Chiaramonte, M; Hesse, M; Davis, EM; Cheever, AW; Meltzer, PS; Morse, HC; Wynn, TA			Disease fingerprinting with cDNA microarrays reveals distinct gene expression profiles in lethal type-1 and type-2 cytokine-mediated inflammatory reactions	FASEB JOURNAL			English	Article						schistosomiasis; Th1/Th2; liver; mice; fibrosis	SCHISTOSOMA-MANSONI EGGS; GRANULOMA-FORMATION; HEPATIC-FIBROSIS; TNF-ALPHA; MURINE SCHISTOSOMIASIS; INHIBITS APOPTOSIS; LIVER PATHOLOGY; DEFICIENT MICE; INFECTED MICE; IFN-GAMMA	Development of polarized immune responses controls resistance and susceptibility to many microorganisms. However, studies of several infectious, allergic, and autoimmune diseases have shown that chronic type-1 and type-2 cytokine responses can also cause significant morbidity and mortality if left unchecked. We used mouse cDNA microarrays to molecularly phenotype the gene expression patterns that characterize two disparate but equally lethal forms of liver pathology that develop in Schistosoma mansoni infected mice polarized for type-1 and type-2 cytokine responses. Hierarchical clustering analysis identified at least three groups of genes associated with a polarized type-2 response and two linked with an extreme type-1 cytokine phenotype. Predictions about liver fibrosis, apoptosis, and granulocyte recruitment and activation generated by the microarray studies were confirmed later by traditional biological assays. The data show that cDNA microarrays are useful not only for determining coordinated gene expression profiles but are also highly effective for molecularly "fingerprinting" diseased tissues. Moreover, they illustrate the potential of genome-wide approaches for generating comprehensive views on the molecular and biochemical mechanisms regulating infectious disease pathogenesis.	NIAID, Immunobiol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; NIAID, Immunopathol Lab, NIH, Bethesda, MD 20892 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Biomed Res Inst, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Wynn, TA (corresponding author), NIAID, Immunobiol Sect, Parasit Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	twynn@niaid.nih.gov	Wynn, Thomas A/AAO-3523-2021; McCarty, Tom/ABG-6003-2020; Wynn, Thomas A/C-2797-2011; McCarty, Thomas/GVU-0812-2022	Wynn, Thomas A/0000-0002-7244-8731; McCarty, Tom/0000-0001-5815-2531; McCarty, Thomas/0000-0001-5815-2531; Hoffmann, Karl/0000-0002-3932-5502; Morse, Herbert/0000-0002-9331-3705	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000465, Z01AI000829, ZIAAI000829] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVDI NJ, 2000, J BIOL CHEM; Ayala A, 1998, J SURG RES, V76, P165, DOI 10.1006/jsre.1998.5314; Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; Bergquist NR, 1998, PARASITOL TODAY, V14, P99, DOI 10.1016/S0169-4758(97)01207-6; Brunet LR, 1999, J IMMUNOL, V163, P4976; Brunet LR, 1997, J IMMUNOL, V159, P777; Cheever AW, 1999, INFECT IMMUN, V67, P2201, DOI 10.1128/IAI.67.5.2201-2208.1999; CHEEVER AW, 1993, AM J TROP MED HYG, V48, P496, DOI 10.4269/ajtmh.1993.48.496; CHEEVER AW, 1994, J IMMUNOL, V153, P753; CHENSUE SW, 1994, CLIN EXP IMMUNOL, V98, P395, DOI 10.1111/j.1365-2249.1994.tb05503.x; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Chiaramonte MG, 1999, J IMMUNOL, V162, P920; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; CZAJA MJ, 1989, HEPATOLOGY, V10, P795, DOI 10.1002/hep.1840100508; Dallaporta B, 2000, CELL DEATH DIFFER, V7, P368, DOI 10.1038/sj.cdd.4400661; Decitre M, 1998, LAB INVEST, V78, P143; DeRisi J, 1996, NAT GENET, V14, P457; DOY TG, 1984, RES VET SCI, V37, P219, DOI 10.1016/S0034-5288(18)31908-8; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fallon PG, 2000, J IMMUNOL, V164, P2585, DOI 10.4049/jimmunol.164.5.2585; Fallon PG, 2000, EUR J IMMUNOL, V30, P470, DOI 10.1002/1521-4141(200002)30:2&lt;470::AID-IMMU470&gt;3.0.CO;2-T; GIBODA M, 1992, ANN TROP MED PARASIT, V86, P631, DOI 10.1080/00034983.1992.11812719; GRIMAUD JA, 1987, AM J TROP MED HYG, V37, P335, DOI 10.4269/ajtmh.1987.37.335; HARRIS AW, 2000, ATLAS MOUSE HEMATOPA, V1, P21; Hoffmann KF, 1999, J IMMUNOL, V163, P927; Hoffmann KF, 1998, J IMMUNOL, V161, P4201; Hoffmann KF, 2000, J IMMUNOL, V164, P6406, DOI 10.4049/jimmunol.164.12.6406; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Jankovic D, 1998, J EXP MED, V187, P619, DOI 10.1084/jem.187.4.619; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Khan J, 1998, CANCER RES, V58, P5009; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kristensen DB, 2000, HEPATOLOGY, V32, P268; Louis H, 1998, HEPATOLOGY, V28, P1607, DOI 10.1002/hep.510280621; Lundy SK, 2001, INFECT IMMUN, V69, P271, DOI 10.1128/IAI.69.1.271-280.2001; Mahidhara R, 2000, CRIT CARE MED, V28, pN105, DOI 10.1097/00003246-200004001-00013; Matesic LE, 2000, FASEB J, V14, P2247, DOI 10.1096/fj.99-1051com; Musashi M, 2000, INT J HEMATOL, V72, P12; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NODES BR, 1987, J BIOL CHEM, V262, P5422; Ortiz LA, 1998, AM J PHYSIOL-LUNG C, V275, pL1208, DOI 10.1152/ajplung.1998.275.6.L1208; Pearce EJ, 1998, ADV EXP MED BIOL, V452, P67; Perks B, 2000, AM J RESP CRIT CARE, V162, P1767, DOI 10.1164/ajrccm.162.5.9908107; Phimister B, 1999, NAT GENET, V21, P1, DOI 10.1038/4423; Robinson MJ, 2000, BIOCHEM BIOPH RES CO, V275, P865, DOI 10.1006/bbrc.2000.3407; Rodriguez I, 1997, DEV BIOL, V184, P115, DOI 10.1006/dbio.1997.8522; SABIN EA, 1995, J IMMUNOL, V155, P4844; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SHER A, 1991, J IMMUNOL, V147, P2713; Smelt SC, 2000, J IMMUNOL, V164, P3681, DOI 10.4049/jimmunol.164.7.3681; SVETIC A, 1991, J IMMUNOL, V147, P2391; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; Tsamandas AC, 1996, MODERN PATHOL, V9, P767; Wang J, 2000, J CELL SCI, V113, P753; WU CH, 1982, HEPATOLOGY, V2, P366; WYNN TA, 1995, CURR OPIN IMMUNOL, V7, P505, DOI 10.1016/0952-7915(95)80095-6; WYNN TA, 1993, J IMMUNOL, V151, P1430; Wynn TA, 1996, ANN NY ACAD SCI, V797, P191, DOI 10.1111/j.1749-6632.1996.tb52960.x; WYNN TA, 1995, NATURE, V376, P594, DOI 10.1038/376594a0; ZWINGENBERGER K, 1991, SCAND J IMMUNOL, V34, P243, DOI 10.1111/j.1365-3083.1991.tb01543.x	62	78	82	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					2545	+		10.1096/fj.01-0306fje	http://dx.doi.org/10.1096/fj.01-0306fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641263				2022-12-25	WOS:000171372700027
J	Wang, HB; Kazanietz, MG				Wang, HB; Kazanietz, MG			Chimaerins, novel non-protein kinase C phorbol ester receptors, associate with Tmp21-I (p23) - Evidence for a novel anchoring mechanism involving the chimaerin C1 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; N-CHIMAERIN; REGULATORY DOMAIN; GOLGI-APPARATUS; TUMOR PROMOTERS; BINDING; DIACYLGLYCEROL; CELLS; RAC; BETA-2-CHIMAERIN	The regulation and function of chimaerins, a family of "non-protein kinase C" (PKC) phorbol ester/diacylglycerol receptors with Rac-GAP activity, is largely unknown. In a search for chimaerin-interacting proteins, we isolated Tmp21-I (p23), a protein localized at the perinuclear Golgi area. Remarkably,, phorbol esters translocate beta2-chimaerin to the perinuclear region and promote its association with Tmp21-I in a PKC-independent manner. A deletional analysis revealed that the C1 domain in chimaerins is required for the interaction with Tmp21-I, thereby implying a novel function for this domain in protein-protein associations in addition to its role in lipid and phorbol ester binding. Our results support the emerging concept that multiple pathways transduce signaling by phorbol esters and revealed that, like PKC isozymes, chimaerins are subject to a positional regulation. In this setting, Tmp21-I serves as an anchoring protein that determines the intracellular localization of these novel phorbol ester receptors.	Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Kazanietz, MG (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, 816 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		wang, hongbin/E-5541-2011		NCI NIH HHS [R01-CA74197-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED S, 1993, J BIOL CHEM, V268, P10709; Alonso M, 1998, EUR J CELL BIOL, V76, P93, DOI 10.1016/S0171-9335(98)80021-6; ARECES LB, 1994, J BIOL CHEM, V269, P19553; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; Blum R, 1999, J CELL SCI, V112, P537; BOGI K, CANC RES, V58, P1523; Caloca MJ, 1999, P NATL ACAD SCI USA, V96, P11854, DOI 10.1073/pnas.96.21.11854; Caloca MJ, 1997, J BIOL CHEM, V272, P26488, DOI 10.1074/jbc.272.42.26488; Caloca MJ, 2001, J BIOL CHEM, V276, P18303, DOI 10.1074/jbc.M011368200; Cavalli V, 2001, FEBS LETT, V498, P190, DOI 10.1016/S0014-5793(01)02484-X; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Estrada L, 2001, HUM MOL GENET, V10, P485, DOI 10.1093/hmg/10.5.485; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; HALL C, 1993, MOL CELL BIOL, V13, P4986, DOI 10.1128/MCB.13.8.4986; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEUNG T, 1994, J BIOL CHEM, V269, P12888; LEUNG T, 1993, J BIOL CHEM, V268, P3813; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Miller J.H., 1972, EXPT MOL GENETICS; Mochly-Rosen D, 1998, FASEB J, V12, P35; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nickel W, 1997, P NATL ACAD SCI USA, V94, P11393, DOI 10.1073/pnas.94.21.11393; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; Radhakrishna H, 1999, J CELL SCI, V112, P855; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rojo M, 2000, J CELL SCI, V113, P1043; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Simon JP, 1996, J CELL BIOL, V135, P355, DOI 10.1083/jcb.135.2.355; Song Y, 1999, MOL BIOL CELL, V10, P1609, DOI 10.1091/mbc.10.5.1609; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Zeidman R, 1999, J CELL BIOL, V145, P713, DOI 10.1083/jcb.145.4.713	48	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					4541	4550		10.1074/jbc.M107150200	http://dx.doi.org/10.1074/jbc.M107150200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11689559	hybrid			2022-12-25	WOS:000173813900098
J	Yusoff, P; Lao, DH; Ong, SH; Wong, ESM; Lim, J; Lo, TL; Leong, HF; Fong, CW; Guy, GR				Yusoff, P; Lao, DH; Ong, SH; Wong, ESM; Lim, J; Lo, TL; Leong, HF; Fong, CW; Guy, GR			Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of raf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; INTRACELLULAR SIGNALING PATHWAYS; REQUIRES PHOSPHORYLATION; DROSOPHILA SPROUTY; FACTOR RECEPTOR; PROTEIN; DIFFERENTIATION; EXPRESSION; RESIDUES; HOMOLOG	Several genetic studies in Drosophila have shown that the dSprouty (dSpry) protein inhibits the Ras/mitogen-activated protein (MAP) kinase pathway induced by various activated receptor tyrosine kinase receptors, most notably those of the epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor (FGFR). Currently, the mode of action of dSpry is unknown, and the point of inhibition remains controversial. There are at least four mammalian Spry isoforms that have been shown to co-express preferentially with FGFRs as compared with EGFRs. In this study, we investigated the effects of the various mammalian Spry isoforms on the Ras/MAP kinase pathway in cells over-expressing constitutively active FGFR1. hSpry2 was significantly more potent than mSpry1 or mSpry4 in inhibiting the Ras/MAP kinase pathway. Additional experiments indicated that full-length hSpry2 was required for its full potency. hSpry2 had no inhibitory effect on either the JNK or the p38 pathway and displayed no inhibition of FRS2 phosphorylation, Akt activation, and Ras activation. Constitutively active mutants of Ras, Raf, and Mek were employed to locate the prospective point of inhibition of hSpry2 downstream of activated Ras. Results from this study indicated that hSpry2 exerted its inhibitory effect at the level of Raf, which was verified in a Raf activation assay in an FGF signaling context.	Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Guy, GR (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, 30 Med Dr, Singapore 117609, Singapore.		Lim, Jormay/A-7257-2011	Lim, Jormay/0000-0001-7191-545X				BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Glienke J, 2000, MECH DEVELOP, V96, P91, DOI 10.1016/S0925-4773(00)00378-6; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Lim YP, 1999, J BIOL CHEM, V274, P19025, DOI 10.1074/jbc.274.27.19025; Low BC, 1999, J BIOL CHEM, V274, P33123, DOI 10.1074/jbc.274.46.33123; Marais R, 1996, CANCER SURV, V27, P101; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Minowada G, 1999, DEVELOPMENT, V126, P4465; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Reich A, 1999, DEVELOPMENT, V126, P4139; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wong ESM, 2001, J BIOL CHEM, V276, P5866, DOI 10.1074/jbc.M006945200; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	31	183	187	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3195	3201		10.1074/jbc.M108368200	http://dx.doi.org/10.1074/jbc.M108368200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11698404	hybrid			2022-12-25	WOS:000173688000019
J	Xie, T; Yu, L; Bader, MW; Bardwell, JCA; Yu, CA				Xie, T; Yu, L; Bader, MW; Bardwell, JCA; Yu, CA			Identification of the ubiquinone-binding domain in the disulfide catalyst disulfide bond protein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RESPIRATORY-CHAIN; DSBA; PATHWAY; ISOMERASE; REDUCTASE; OXIDIZES	Disulfide bond (Dsb) formation is catalyzed in the periplasm of prokaryotes by the Dsb proteins. DsbB, a key enzyme in this process, generates disulfides de novo by using the oxidizing power of quinones. To explore the mechanism of this newly described enzymatic activity, we decided to study the ubiquinone-protein interaction and identify the ubiquinone-binding domain in DsbB by cross-linking to photoactivatable quinone analogues. When purified Escherichia coli DsbB was incubated with an azidoubiquinone derivative, 3-azido-2-methyl-5-[H-3]methoxy-6-decyl-1,4-benzoquinone ([H-3]azido-Q), and illuminated with long wavelength UV light, the decrease in enzymatic activity correlated with the amount of 3-azido-2-methyl-5-methoxy-6-decyl-1,4-benzoquinone (azido-Q) incorporated into the protein. One azido-Q-linked peptide with a retention time of 33.5 min was obtained by high performance liquid chromatography of the V8 digest of [H-3]azido-Q-labeled DsbB. This peptide has a partial NH2-terminal amino acid sequence of NH2-HTMLQLY corresponding to residues 91-97. This sequence occurs in the second periplasmic domain of the inner membrane protein DsbB in a loop connecting transmembrane helices 3 and 4. We propose that the quinone-binding site is within or very near to this sequence.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA	Oklahoma State University System; Oklahoma State University - Stillwater; University of Michigan System; University of Michigan	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	cayuq@okstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057039, R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57039, GM30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Debarbieux L, 1999, CELL, V99, P117, DOI 10.1016/S0092-8674(00)81642-6; Faig M, 2000, P NATL ACAD SCI USA, V97, P3177, DOI 10.1073/pnas.050585797; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Glockshuber R, 1999, NATURE, V401, P30, DOI 10.1038/43344; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; Kadokura H, 2000, P NATL ACAD SCI USA, V97, P10884, DOI 10.1073/pnas.97.20.10884; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; YU L, 1985, J BIOL CHEM, V260, P963; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	23	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1649	1652		10.1074/jbc.M108697200	http://dx.doi.org/10.1074/jbc.M108697200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11698406	hybrid			2022-12-25	WOS:000173421300006
J	Gonzalez-Garcia, A; Garrido, E; Hernandez, C; Alvarez, B; Jimenez, C; Cantrell, DA; Pullen, N; Carrera, AC				Gonzalez-Garcia, A; Garrido, E; Hernandez, C; Alvarez, B; Jimenez, C; Cantrell, DA; Pullen, N; Carrera, AC			A new role for the p85-phosphatidylinositol 3-kinase regulatory subunit linking FRAP to p70 S6 kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; C-ZETA; PHOSPHORYLATION SITE; MAMMALIAN TARGET; CELL-GROWTH; RAPAMYCIN; P70(S6K); TRANSLATION	The serine/threonine kinase p70 S6 kinase (p70S6K) phosphorylates the 40 S ribosomal protein S6, modulating the translation of an mRNA subset that encodes ribosomal proteins and translation elongation factors. p70S6K is activated in response to mitogenic stimuli and is required for progression through the G, phase of the cell cycle and for cell growth. Activation of p70S6K is regulated by phosphorylation of seven different residues distributed throughout the protein, a subset of which depends on the activity of p85/p110 phosphatidylinositol 3-kinase (PI3K); in fact, the phosphorylation status of Thr(229) and Thr(389) is intimately linked to PI3K activity. In the full-length enzyme, however, these sites are also acutely sensitive to the action of FKBP 12-rapa-mycin-associated protein (FRAP). The mechanism by which PI3K and FRAP cooperate to induce p70S6K activation remains unclear. Here we show that the p85 regulatory subunit of PI3K also controls p70S6K activation by mediating formation of a ternary complex with p70S6K and FRAP. The p85 C-terminal SH2 domain is responsible for p85 coupling to p70S6K and FRAP, because deletion of the C-terminal SH2 domain inhibits complex formation and impairs p70S6K activation by PI3K Formation of this complex is not required for activation of a FRAP-independent form of p70S6K, however, underscoring the role of p85 in regulating FRAP-dependent p70S6K activation. These studies thus show that, in addition to the contribution of PI3K activity, the p85 regulatory subunit plays a critical role in p70S6K activation.	CSIC, Dept Immunol & Oncol, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Imperial Canc Res Fund, London WC2A 3PX, England; Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Cancer Research UK; Friedrich Miescher Institute for Biomedical Research	Carrera, AC (corresponding author), CSIC, Dept Immunol & Oncol, Ctr Nacl Biotecnol, Carretera Colmenar Km 15, E-28049 Madrid, Spain.		Gonzalez-Garcia, Ana/D-9736-2014	Jimenez, Maria Concepcion/0000-0002-7011-9328; Cantrell, Doreen/0000-0001-7525-3350; Pullen, Nicholas/0000-0002-4014-9278; Gonzalez-Garcia, Ana/0000-0002-6669-1735; Carrera, Ana/0000-0002-3999-5434				Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CARRERA AC, 1997, METHOD IMMUNOL, P1164; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dufner A, 1999, MOL CELL BIOL, V19, P4525; FERRARI S, 1993, J BIOL CHEM, V268, P16091; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; LANE HA, 1991, METHOD ENZYMOL, V200, P268; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Templeton DJ, 2001, CURR BIOL, V11, pR596, DOI 10.1016/S0960-9822(01)00361-X; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; TOKER A, 1994, J BIOL CHEM, V269, P32358; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; WENG QP, 1995, MOL CELL BIOL, V15, P2333; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Yao R, 1996, ONCOGENE, V13, P343; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	60	40	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1500	1508		10.1074/jbc.M103808200	http://dx.doi.org/10.1074/jbc.M103808200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11684675	hybrid			2022-12-25	WOS:000173166800082
J	Schneider, M; Boffa, M; Stewart, R; Rahman, M; Koschinsky, M; Nesheim, M				Schneider, M; Boffa, M; Stewart, R; Rahman, M; Koschinsky, M; Nesheim, M			Two naturally occurring variants of TAFI (Thr-325 and Il-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVABLE FIBRINOLYSIS INHIBITOR; PLASMA PROCARBOXYPEPTIDASE B; 3-DIMENSIONAL STRUCTURE; ACTIVATION; CARBOXYPEPTIDASE; INSTABILITY; INTACT; GENE	Thrombin-activable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like zymogen that is activated to TAFIa by plasmin, thrombin, or the thrombin-thrombomodulin complex. The enzyme TAFIa attenuates clot lysis by removing lysine residues from a fibrin clot. Screening of nine human cDNA libraries indicated a common variation in TAFI at position 325 (Ile-325 or Thr-325). This is in addition to the variation at amino acid position 147 (Ala-147 or Thr-147) characterized previously. Thus, four variants of TAFI having either Ala or Thr at position 147 and either Thr or Ile at position 325 were stably expressed in baby hamster kidney cells and purified to homogeneity. The kinetics of activation of TAFI by thrombin/thrombomodulin were identical for all four variants; however, Ile at position 325 extended the half-life of TAFIa from 8 to 15 min at 37 degreesC, regardless of the residue at position 147. In clot lysis assays with thrombomodulin and the TAFI variants, or with pre-activated TAFI variants, the Ile-325 variants exhibited an antifibrinolytic effect that was 60% greater than the Thr-325 variants. Similarly, in the absence of thrombomodulin, the Ile-325 variants exhibited an antifibrinolytic effect that was 30-50% greater than the Thr-325 variants. In contrast, the variation at position 147 had little if any effect on the antifibrinolytic potential of TAFIa. The increased antifibrinolytic potential of the Ile-325-containing TAFI variants reflects the fact that these variants have an increased ability to mediate the release of lysine from partially degraded fibrin and suppress plasminogen activation. These findings imply that individuals homozygous for the Ile-325 variant of TAFI would likely have a longer lived and more potent TAFIa enzyme than those homozygous for the Thr-325 variant.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Nesheim, M (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	nesheimm@post.queen.su.ca	Boffa, Michael/N-6539-2019; Rahman, Mona/GRF-6475-2022	Boffa, Michael/0000-0003-1211-3064; Koschinsky, Marlys/0000-0002-2643-2288; Rahman, Mona Naeema/0000-0002-9782-0173				Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; Boffa MB, 1999, BIOCHEMISTRY-US, V38, P6547, DOI 10.1021/bi990229v; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; Brouwers GJ, 2001, BLOOD, V98, P1992, DOI 10.1182/blood.V98.6.1992; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLL M, 1991, EMBO J, V10, P1; EATON DL, 1991, J BIOL CHEM, V266, P21833; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2176; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; Mao SS, 1999, J BIOL CHEM, V274, P35046, DOI 10.1074/jbc.274.49.35046; Marx PF, 2000, J BIOL CHEM, V275, P12410, DOI 10.1074/jbc.275.17.12410; Mock WL, 1999, BIOORG MED CHEM LETT, V9, P187, DOI 10.1016/S0960-894X(98)00715-X; Mosnier LO, 1998, THROMB HAEMOSTASIS, V80, P829; Schatteman KA, 2000, CLIN CHIM ACTA, V292, P25, DOI 10.1016/S0009-8981(99)00205-3; Stromqvist M, 2001, THROMB HAEMOSTASIS, V85, P12, DOI 10.1055/s-0037-1612656; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; Thorsen Sixtus, 1992, V667, P52; Walker JB, 1999, J BIOL CHEM, V274, P5201, DOI 10.1074/jbc.274.8.5201; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WANG W, 1994, J BIOL CHEM, V269, P15937; Zhao L, 1998, THROMB HAEMOSTASIS, V80, P949	27	147	158	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1021	1030		10.1074/jbc.M104444200	http://dx.doi.org/10.1074/jbc.M104444200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11684677	hybrid			2022-12-25	WOS:000173166800021
J	Gerbal-Chaloin, S; Daujat, M; Pascussi, JM; Pichard-Garcia, L; Vilarem, MJ; Maurel, P				Gerbal-Chaloin, S; Daujat, M; Pascussi, JM; Pichard-Garcia, L; Vilarem, MJ; Maurel, P			Transcriptional regulation of CYP2C9 gene - Role of glucocorticoid receptor and constitutive androstane receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; NUCLEAR RECEPTOR; HUMAN HEPATOCYTES; RAT-LIVER; PHENOBARBITAL INDUCTION; RESPONSIVE ENHANCER; ACTIVATED RECEPTOR; SIGNALING PATHWAY; ALPHA EXPRESSION; DRUG-METABOLISM	Although cytochrome P450 2C9 (CYP2C9) is a major CYP expressed in the adult human liver, its mechanism of regulation is poorly known. In previous work, we have shown that CYP2C9 is inducible in primary human hepatocytes by xenobiotics including dexamethasone, rifampicin, and phenobarbital. The aim of this work was to investigate the molecular mechanism(s) controlling the inducible expression of CYP2C9. Deletional analysis of CYP2C9 regulatory region (+21 to -2088) in the presence of various hormone nuclear receptors suggested the presence of two functional response elements, a glucocorticoid receptor-responsive element (-1648/-1684) and a constitutive androstane receptor-responsive element (CAR, - 1783/-1856). Each of these were characterized by co-transfection experiments, directed mutagenesis, gel shift assays, and response to specific antagonists RU486 and androstanol. By these experiments we located a glucocorticoid-responsive element imperfect palindrome at -1662/-1676, and a DR4 motif at -1803/-1818 recognized and transactivated by human glucocorticoid receptor and by hCAR and pregnane X receptor, respectively. Identification of these functional elements provides rational mechanistic basis for CYP2C9 induction by dexamethasone (submicromolar concentrations), and by phenobarbital and rifampicin, respectively. CYP2C9 appears therefore to be a primary glucocorticoid-responsive gene, which in addition, may be induced by xenobiotics through CAR/pregnane X receptor activation.	INSERM U128, IFR24, F-34293 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Maurel, P (corresponding author), INSERM U128, IFR24, Campus CNRS,1919 Route Mende, F-34293 Montpellier, France.		Daujat-Chavanieu, Martine/AAU-2908-2020; pascussi, jean marc/F-9311-2013; GERBAL-CHALOIN, sabine/M-8783-2017; Daujat-Chavanieu, Martine/T-5155-2018	Daujat-Chavanieu, Martine/0000-0001-5560-1610; pascussi, jean marc/0000-0002-5168-5383; GERBAL-CHALOIN, sabine/0000-0002-2549-7899; Daujat-Chavanieu, Martine/0000-0001-5560-1610				Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; DEMORAIS SMF, 1993, BIOCHEM BIOPH RES CO, V194, P194, DOI 10.1006/bbrc.1993.1803; Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242; GOLDSTEIN JA, 1994, PHARMACOGENETICS, V4, P285, DOI 10.1097/00008571-199412000-00001; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1998, BIOCHEM J, V330, P889, DOI 10.1042/bj3300889; IBEANU GC, 1995, BIOCHEMISTRY-US, V34, P8028, DOI 10.1021/bi00025a008; Jarukamjorn K, 1999, ARCH BIOCHEM BIOPHYS, V369, P89, DOI 10.1006/abbi.1999.1342; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kim J, 1997, J BIOL CHEM, V272, P29423, DOI 10.1074/jbc.272.47.29423; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Miners JO, 1998, BRIT J CLIN PHARMACO, V45, P525, DOI 10.1046/j.1365-2125.1998.00721.x; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; PALLISGAARD N, 1994, GENE, V138, P115, DOI 10.1016/0378-1119(94)90791-9; Park YK, 1996, J BIOL CHEM, V271, P23725, DOI 10.1074/jbc.271.39.23725; Parmentier JH, 1997, BIOCHEM PHARMACOL, V54, P889, DOI 10.1016/S0006-2952(97)00256-6; Pascussi JM, 2000, MOL PHARMACOL, V58, P361, DOI 10.1124/mol.58.2.361; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; Pascussi JM, 2000, BIOCHEM BIOPH RES CO, V274, P707, DOI 10.1006/bbrc.2000.3219; Pereira TM, 1998, DNA CELL BIOL, V17, P39, DOI 10.1089/dna.1998.17.39; SCHMID E, 1987, EUR J BIOCHEM, V165, P499, DOI 10.1111/j.1432-1033.1987.tb11467.x; Schuetz EG, 2000, DRUG METAB DISPOS, V28, P268; SCHUETZ EG, 1984, J BIOL CHEM, V259, P2007; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; SIDHU JS, 1995, PHARMACOGENETICS, V5, P24, DOI 10.1097/00008571-199502000-00003; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; WAXMAN DJ, 1990, BIOCHEM J, V271, P113, DOI 10.1042/bj2710113; Wright MC, 1996, MOL PHARMACOL, V50, P856; Zelko I, 2000, BIOCHEM BIOPH RES CO, V277, P1, DOI 10.1006/bbrc.2000.3557; ZILLY W, 1977, EUR J CLIN PHARMACOL, V11, P287, DOI 10.1007/BF00607679	37	218	223	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					209	217		10.1074/jbc.M107228200	http://dx.doi.org/10.1074/jbc.M107228200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11679585	hybrid			2022-12-25	WOS:000173087900029
J	Hamazaki, Y; Itoh, M; Sasaki, H; Furuse, M; Tsukita, S				Hamazaki, Y; Itoh, M; Sasaki, H; Furuse, M; Tsukita, S			Multi-PDZ domain protein 1 (MUPP1) is concentrated at tight junctions through its possible interaction with claudin-1 and junctional adhesion molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; GUANYLATE KINASE; EPITHELIAL-CELLS; DIRECT BINDING; ZO-1; OCCLUDIN; STRANDS; IDENTIFICATION; PERMEABILITY; POLYPEPTIDE	Claudins, most of which end in valine at their COOH termini, constitute tight junction (TJ) strands, suggesting that TJ strands strongly attract PDZ-containing proteins. Indeed, ZO-1, -2, and -3, each of which contains three PDZ domains, were shown to directly bind to claudins. Using the yeast two-hybrid system, we identified ZO-1 and MUPP1 (multi-PDZ domain protein 1) as binding partners for the COOH terminus of claudin-1. MUPP1 has been identified as a protein that contains 13 PDZ domains, but it has not been well characterized. In vitro binding assays with recombinant MUPP1 confirmed the interaction between MUPP1 and claudin-1 and identified PDZ10 as the responsible domain for this interaction. A polyclonal antibody specific for MUPP1 was then generated. Immunofluorescence confocal microscopy as well as immunoelectron microscopy with this antibody revealed that in polarized epithelial cells MUPP1 was exclusively concentrated at TJs. Furthermore, in vitro binding and transfection experiments showed that junctional adhesion molecule, another TJ adhesion molecule, also bound to the PDZ9 domain of MUPP1. These findings suggested that MUPP1. is concentrated at TJs in epithelial cells through its binding to claudin and junctional adhesion molecule and that it may function as a multivalent scaffold protein that recruits various proteins to TJs.	Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan; KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008317, Japan	Kyoto University; KAN Research Institute	Tsukita, S (corresponding author), Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan.	htsukita@mfour.med.kyoto-u.ac.jp	Hamazaki, Y*/Q-3076-2019	Hamazaki, Y*/0000-0001-5866-7340; Furuse, Mikio/0000-0003-2847-8156; Sasaki, Hiroyuki/0000-0002-5358-5853				ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Bazzoni G, 2000, J BIOL CHEM, V275, P30970, DOI 10.1074/jbc.M003946200; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Mancini A, 2000, FEBS LETT, V482, P54, DOI 10.1016/S0014-5793(00)02036-6; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; McCarthy KM, 1996, J CELL SCI, V109, P2287; Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Morita K, 1999, J CELL BIOL, V145, P579, DOI 10.1083/jcb.145.3.579; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; SCHNEEBERGER EE, 1992, AM J PHYSIOL, V262, pL647, DOI 10.1152/ajplung.1992.262.6.L647; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Simpson EH, 1999, GENOMICS, V59, P102, DOI 10.1006/geno.1999.5853; STAEHELIN LA, 1973, J CELL SCI, V13, P763; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 2000, J CELL BIOL, V149, P13, DOI 10.1083/jcb.149.1.13; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	55	285	298	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					455	461		10.1074/jbc.M109005200	http://dx.doi.org/10.1074/jbc.M109005200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11689568	hybrid, Green Submitted			2022-12-25	WOS:000173087900061
J	Kao, HY; Lee, CH; Komarov, A; Han, CC; Evans, RM				Kao, HY; Lee, CH; Komarov, A; Han, CC; Evans, RM			Isolation and characterization of mammalian HDAC10, a novel histone deacetylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCYTE ENHANCER FACTOR-2; MEF2 TRANSCRIPTION FACTOR; N-COR; COREPRESSOR COMPLEX; NUCLEAR EXPORT; RECEPTOR; CHROMATIN; REPRESSION; BINDING; SMRT	Acetylation of histone core particles plays an important role in modulating chromatin structure and gene expression. The acetylation status of the histone tails is determined by two opposing enzymatic activities, histone acetyltransferases and histone deacetylases (HDACs). Here: we describe the isolation and characterization of HDAC10, a novel class 11 histone deacetylase. Molecular cloning and Northern blot analyses reveal that the HDAC10 transcript is widely expressed and subjected to alternative splicing. HDAC10 is both nuclear and cytoplasmic, a feature reminiscent of HDACs 4, 5, and 7. Distinct from other family members, HDAC10 harbors an amino-terminal catalytic domain and a carboxyl pseudo-repeat that shares significant homology with its catalytic domain. Mutational analysis reveals that transcriptional repression by HDAC10 requires its intrinsic historic deacetylase activity. Taken together, HDAC10 represents a distinct HDAC that may play a role in transcription regulation.	Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA; UHC, Cleveland, OH 44106 USA; CWRU, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Howard Hughes Medical Institute; Salk Institute; Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University	Kao, HY (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hxk43@po.cwruu.edu; evans@salk.edu	Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027183] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27183] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bodmer R, 1998, DEV GENET, V22, P181, DOI 10.1002/(SICI)1520-6408(1998)22:3<181::AID-DVG1>3.0.CO;2-2; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; El-Osta A, 2000, GENE EXPRESSION, V9, P63; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guarente L, 2000, GENE DEV, V14, P1021; Guenther MG, 2000, GENE DEV, V14, P1048; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang EY, 2000, GENE DEV, V14, P45; Kao HY, 2000, GENE DEV, V14, P55; Khochbin S, 2001, FEBS LETT, V494, P141, DOI 10.1016/S0014-5793(01)02327-4; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	52	153	167	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					187	193		10.1074/jbc.M108931200	http://dx.doi.org/10.1074/jbc.M108931200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11677242	hybrid			2022-12-25	WOS:000173087900026
J	Bian, X; McAllister-Lucas, LM; Shao, F; Schumacher, KR; Feng, ZW; Porter, AG; Castle, VP; Opipari, AW				Bian, X; McAllister-Lucas, LM; Shao, F; Schumacher, KR; Feng, ZW; Porter, AG; Castle, VP; Opipari, AW			NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CISPLATIN-INDUCED APOPTOSIS; BCL-2; TRANSCRIPTION; INHIBITION; EXPRESSION; INDUCTION; THERAPY; PROTEIN; FAS; DIFFERENTIATION	Neuroblastoma is the most common extracranial solid tumor of childhood. N-type neuroblastoma cells (represented by SH-SY5Y and IMR32 cell lines) are characterized by a neuronal phenotype. N-type cell lines are generally N-myc amplified, express the anti-apoptotic protein Bcl-2, and do not express caspase-8. The present study was designed to determine the mechanism by which N-type cells die in response to specific cytotoxic agents (such as cisplatin and doxorubicin) commonly used to treat this disease. We found that N-type cells were equally sensitive to cisplatin and doxorubicin. Yet death induced by cisplatin was inhibited by the nonselective caspase inhibitor z-Val-Ala-Asp-fluoromethylketone or the specific caspase-9 inhibitor N-acetyl-Leu-Glu-His-Asp-aldehyde, whereas in contrast, caspase inhibition did not prevent doxorubicin-induced death. Neither the reactive oxygen species nor the mitochondrial permeability transition appears to play an important role in this process. Doxorubicin induced NF-kappaB transcriptional activation in association with I-kappaBalpha degradation prior to loss of cell viability. Surprisingly, the antioxidant and NF-kappaB inhibitor pyrrolidine dithiocarbamate blocked doxorubicin-induced NF-kappaB transcriptional activation and provided profound protection against doxorubicin killing. Moreover, SH-SY5Y cells expressing a super-repressor form of I-kappaB were completely resistant to doxorubicin killing. Together these findings show that NF-kappaB activation mediates doxorubicin-induced cell death without evidence of caspase function and suggest that cisplatin and doxorubicin engage different death pathways to kill neuroblastoma cells.	Univ Michigan, Ctr Comprehens Canc, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Castle, VP (corresponding author), Univ Michigan, Ctr Comprehens Canc, Sch Med, Dept Pediat, Rm 4302,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	vcastle@umich.edu			NCI NIH HHS [CA69276-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069276] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambros IM, 2000, NEUROBLASTOMA, P229; Aoki M, 2001, HYPERTENSION, V38, P48, DOI 10.1161/01.HYP.38.1.48; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Asselin E, 2001, CANCER RES, V61, P1862; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; Boland MP, 2000, J BIOL CHEM, V275, P25231, DOI 10.1074/jbc.275.33.25231; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Decaudin D, 1997, CANCER RES, V57, P62; Di Bartolomeo S, 2000, J NEUROCHEM, V75, P532, DOI 10.1046/j.1471-4159.2000.0750532.x; DOLE M, 1994, CANCER RES, V54, P3253; DOLE MG, 1995, CANCER RES, V55, P2576; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Feng ZW, 1999, J BIOL CHEM, V274, P30341, DOI 10.1074/jbc.274.43.30341; Frappaz D, 2000, J CLIN ONCOL, V18, P468, DOI 10.1200/JCO.2000.18.3.468; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Horky M, 2001, J CELL SCI, V114, P663; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; KOTOULA V, 1997, P AM ASSOC CANC RES, V38, P194; Kuwahara D, 2000, CANCER LETT, V148, P65, DOI 10.1016/S0304-3835(99)00315-8; LASORELLA A, 1995, CANCER RES, V55, P4711; Lopez E, 2000, MOL BRAIN RES, V85, P61, DOI 10.1016/S0169-328X(00)00235-7; LOWN JW, 1982, BIOCHEM PHARMACOL, V31, P575; MACHIN GA, 1982, NEUROBLASTOMA CLIN B, P195; Maestre N, 2001, CANCER RES, V61, P2558; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; ORMEROD MG, 1994, BRIT J CANCER, V69, P93, DOI 10.1038/bjc.1994.14; Panet H, 2001, J NEUROCHEM, V77, P391, DOI 10.1046/j.1471-4159.2001.00213.x; Posmantur R, 1997, J NEUROCHEM, V68, P2328; Poulaki V, 2001, CANCER RES, V61, P4864; ROSS RA, 1983, J NATL CANCER I, V71, P741; ROSS RA, 1980, ADV NEUROBLASTOMA RE, P151; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SAXEN L, 1960, CANCER, V13, P899, DOI 10.1002/1097-0142(196009/10)13:5<899::AID-CNCR2820130506>3.0.CO;2-U; Schmidt ML, 2000, J CLIN ONCOL, V18, P1260, DOI 10.1200/JCO.2000.18.6.1260; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tietze MK, 2000, CANCER GENE THER, V7, P1315, DOI 10.1038/sj.cgt.0241; Tieu K, 1999, J NEUROSCI RES, V58, P426, DOI 10.1002/(SICI)1097-4547(19991101)58:3<426::AID-JNR8>3.3.CO;2-6; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914	61	134	137	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48921	48929		10.1074/jbc.M108674200	http://dx.doi.org/10.1074/jbc.M108674200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11679590	hybrid			2022-12-25	WOS:000173922100040
J	Grimaud, R; Ezraty, B; Mitchell, JK; Lafitte, D; Briand, C; Derrick, PJ; Barras, F				Grimaud, R; Ezraty, B; Mitchell, JK; Lafitte, D; Briand, C; Derrick, PJ; Barras, F			Repair of oxidized proteins - Identification of a new methionine sulfoxide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC REDUCTION; CATALYTIC MECHANISM; GENE; EXPRESSION; OXIDATION; MUTAGENESIS; CALMODULIN; SITE; RESIDUES; CLONING	Oxidation of methionine residues to methionine sulfoxide can lead to inactivation of proteins. Methionine sulfoxide reductase (MsrA) has been known for a long time, and its repairing function well characterized. Here we identify a new methionine sulfoxide reductase, which we referred to as MsrB, the gene of which is present in genomes of eubacteria, archaebacteria, and eucaryotes. The msrA and msrB genes exhibit no sequence similarity and, in some genomes, are fused. The Escherichia coli MsrB protein (currently predicted to be encoded by an open reading frame of unknown function named yeaA) was used for genetic, enzymatic, and mass spectrometric investigations. Our in vivo study revealed that msrB is required for cadmium resistance of E. coli, a carcinogenic compound that induces oxidative stress. Our in vitro studies, showed that (i) MsrB and MsrA enzymes reduce free methionine sulfoxide with turnover rates of 0.6 min(-1) and 20 min(-1), respectively, (ii) MsrA and MsrB act on oxidized calmodulin, each by repairing four to six of the eight methionine sulfoxide residues initially present, and (iii) simultaneous action of both MsrA and MsrB allowed full reduction of oxidized calmodulin. A possibility is that these two ubiquitous methionine sulfoxide reductases exhibit different substrate specificity.	CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, F-13402 Marseille 20, France; Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England; Fac Pharm Marseille, F-3005 Marseille, France	Centre National de la Recherche Scientifique (CNRS); University of Warwick	Barras, F (corresponding author), CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	barras@ibsm.cnrs-mrs.fr	Grimaud, Régis/AAA-1730-2021	Grimaud, Régis/0000-0002-5017-7571; Ezraty, Benjamin/0000-0003-3818-6907; lafitte, daniel/0000-0001-9921-7522				ABRAMS WR, 1981, P NATL ACAD SCI-BIOL, V78, P7483, DOI 10.1073/pnas.78.12.7483; Balasubramanian S, 2000, NUCLEIC ACIDS RES, V28, P3075, DOI 10.1093/nar/28.16.3075; Boschi-Muller S, 2000, J BIOL CHEM, V275, P35908, DOI 10.1074/jbc.M006137200; BROT N, 1981, P NATL ACAD SCI-BIOL, V78, P2155, DOI 10.1073/pnas.78.4.2155; Brot N, 2000, BIOPOLYMERS, V55, P288, DOI 10.1002/1097-0282(2000)55:4<288::AID-BIP1002>3.0.CO;2-M; CRAIG TA, 1987, J BIOL CHEM, V262, P3278; Davis DA, 2000, BIOCHEM J, V346, P305, DOI 10.1042/0264-6021:3460305; El Hassouni M, 1999, P NATL ACAD SCI USA, V96, P887, DOI 10.1073/pnas.96.3.887; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; Gabbita SP, 1999, J NEUROCHEM, V73, P1660, DOI 10.1046/j.1471-4159.1999.0731660.x; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Laplace JM, 2000, APPL MICROBIOL BIOT, V53, P685, DOI 10.1007/s002530000350; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; Lowther WT, 2000, BIOCHEMISTRY-US, V39, P13307, DOI 10.1021/bi0020269; Lowther WT, 2000, P NATL ACAD SCI USA, V97, P6463, DOI 10.1073/pnas.97.12.6463; MENARD R, 1993, J BACTERIOL, V175, P5899; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P2095, DOI 10.1073/pnas.93.5.2095; Moskovitz J, 2000, J BIOL CHEM, V275, P14167, DOI 10.1074/jbc.275.19.14167; MOSKOVITZ J, 1995, J BACTERIOL, V177, P502, DOI 10.1128/jb.177.3.502-507.1995; Murphy KC, 1998, J BACTERIOL, V180, P2063, DOI 10.1128/JB.180.8.2063-2071.1998; Palmblad M, 2000, EUR J MASS SPECTROM, V6, P267, DOI 10.1255/ejms.348; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; ROBERTS DM, 1985, BIOCHEMISTRY-US, V24, P5090, DOI 10.1021/bi00340a020; Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1; Sharov VS, 2000, FREE RADICAL BIO MED, V29, P986, DOI 10.1016/S0891-5849(00)00400-7; Squier TC, 2000, FRONT BIOSCI-LANDMRK, V5, pD504, DOI 10.2741/Squier; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Sun HY, 1999, BIOCHEMISTRY-US, V38, P105, DOI 10.1021/bi981295k; Tete-Favier F, 2000, STRUCTURE, V8, P1167, DOI 10.1016/S0969-2126(00)00526-8; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; Wizemann TM, 1996, P NATL ACAD SCI USA, V93, P7985, DOI 10.1073/pnas.93.15.7985	32	289	299	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48915	48920		10.1074/jbc.M105509200	http://dx.doi.org/10.1074/jbc.M105509200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11677230	hybrid, Green Published			2022-12-25	WOS:000173922100039
J	Jacovina, AT; Zhong, FM; Khazanova, E; Lev, E; Deora, AB; Hajjar, KA				Jacovina, AT; Zhong, FM; Khazanova, E; Lev, E; Deora, AB; Hajjar, KA			Neuritogenesis and the nerve growth factor-induced differentiation of PC-12 cells requires annexin II-mediated plasmin generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOREBRAIN CHOLINERGIC NEURONS; HUMAN-ENDOTHELIAL CELLS; NEURITE OUTGROWTH; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; ACTIVATOR INHIBITOR; BINDING-SITES; MESSENGER-RNA; PC12 CELLS; T-PA	One of the key morphological changes associated with the nerve growth factor (NGF)-induced differentiation of rat adrenal pheochromocytoma (PC-12) cells is the growth of axon-like processes called neurites. A growing body of evidence suggests that this process may be dependent upon plasmin, a serine protease generated from plasminogen (Plg) by either urokinase Plg activator (u-PA) or tissue Plg activator (t-PA). Prior work in our laboratory has identified annexin II (Ann-II) as a co-receptor for Plg and t-PA that promotes and localizes plasmin generation near the cell surface. In the present study, we report a 3-9-fold increase in Ann-II protein and message levels in NGF-treated PC-12 cells. Message stability and nuclear run-on assays suggest that this induction occurs at the level of gene transcription. Neurite outgrowth assays on and within a three-dimensional matrix demonstrate the inhibition of NGF-induced PC-12 cell differentiation by polyclonal and monoclonal antibodies directed against Ann-H as well as by the overexpression of antisense Ann-II mRNA. Neuritogenesis is also impaired by alpha(2)-plasmin inhibitor, antibodies directed against t-PA and u-PA, and E-aminocaproic acid, a lysine analog that inhibits Plg activation and the binding of Plg to Ann-II. Plasmin generation assays reveal a 2-fold increase in plasmin production on NGF-treated PC-12 cells, which can be blocked by a polyclonal antibody directed against the tail region of Ann-H. From these data, we conclude that Ann-II is transcriptionally up-regulated by NGF and that Ann-II-mediated plasmin generation may play an important role during neurite development in the differentiating PC-12 cell.	Cornell Univ, Weill Med Coll, Dept Pediat, Div Hematol Oncol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA	Cornell University; Cornell University	Hajjar, KA (corresponding author), Cornell Univ, Weill Med Coll, Dept Pediat, Div Hematol Oncol, 1300 York Ave,Box 45, New York, NY 10021 USA.				NHLBI NIH HHS [HL 67839, T32 HL 07423, HL 42493, HL 46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007423, P01HL067839, P01HL046403, R01HL042493] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKJAERSIG N, 1959, J BIOL CHEM, V234, P832; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Broer S, 1995, BIOCHEM J, V312, P863, DOI 10.1042/bj3120863; BURGOYNE RD, 1989, J MOL NEUROSCI, V1, P47, DOI 10.1007/BF02918890; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; Chacko G, 1998, J BIOL CHEM, V273, P19840, DOI 10.1074/jbc.273.31.19840; Chen KS, 1997, J NEUROSCI, V17, P7288; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DENT MAR, 1993, EUR J NEUROSCI, V5, P633, DOI 10.1111/j.1460-9568.1993.tb00529.x; FOX MT, 1991, BIOCHEM BIOPH RES CO, V177, P1188, DOI 10.1016/0006-291X(91)90666-U; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; HAJJAR KA, 1987, J CLIN INVEST, V80, P1712, DOI 10.1172/JCI113262; HAJJAR KA, 1990, J BIOL CHEM, V265, P2908; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; Hajjar KA, 1999, TRENDS CARDIOVAS MED, V9, P128, DOI 10.1016/S1050-1738(99)00020-1; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; HAJJAR KA, 1997, HEMATOLOGY INFANCY C, P1557; HAMRE KM, 1995, J COMP NEUROL, V352, P421, DOI 10.1002/cne.903520308; Herbert CB, 1996, J COMP NEUROL, V365, P380, DOI 10.1002/(SICI)1096-9861(19960212)365:3<380::AID-CNE4>3.0.CO;2-0; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; LEPRINCE P, 1991, J NEUROCHEM, V57, P665, DOI 10.1111/j.1471-4159.1991.tb03798.x; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MASIAKOWSKI P, 1990, J NEUROSCI RES, V27, P264, DOI 10.1002/jnr.490270304; Menell JS, 1999, NEW ENGL J MED, V340, P994, DOI 10.1056/NEJM199904013401303; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MUIR D, 1994, EXP CELL RES, V210, P243, DOI 10.1006/excr.1994.1036; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagase H, 1997, BIOL CHEM, V378, P151; NORDSTROM LA, 1995, MOL CELL NEUROSCI, V6, P56, DOI 10.1006/mcne.1995.1006; PITTMAN RN, 1995, J NEUROCHEM, V64, P566; PITTMAN RN, 1989, DEV NEUROSCI-BASEL, V11, P41, DOI 10.1159/000111884; PITTMAN RN, 1989, J NEUROSCI, V9, P4269; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; Seeds N W, 1990, Adv Exp Med Biol, V265, P169; Seeds NW, 1997, CELL TISSUE RES, V290, P367, DOI 10.1007/s004410050942; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; SINGER RH, 1972, NATURE, V240, P100, DOI 10.1038/240100a0; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SUMI Y, 1992, DEVELOPMENT, V116, P625; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TALIAN JC, 1991, DEV BIOL, V143, P68, DOI 10.1016/0012-1606(91)90055-8; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; WEBER K, 1992, ANNEXINS, P61; YE RD, 1987, J BIOL CHEM, V262, P3718	52	91	97	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49350	49358		10.1074/jbc.M106289200	http://dx.doi.org/10.1074/jbc.M106289200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11679580	hybrid			2022-12-25	WOS:000173922100095
J	Keire, DA; Anton, P; Faull, KF; Ruth, E; Walsh, JH; Chew, P; Quisimoro, D; Territo, M; Reeve, JR				Keire, DA; Anton, P; Faull, KF; Ruth, E; Walsh, JH; Chew, P; Quisimoro, D; Territo, M; Reeve, JR			Diethyl phthalate, a chemotactic factor secreted by Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DI(2-ETHYLHEXYL) PHTHALATE; GASTRIC-CARCINOMA; PROTEIN-1 MCP-1; INFECTION; METABOLITES; CHEMOKINES; LEUKOCYTES; MUCOSA; IDENTIFICATION; HEMODIALYSIS	The structure of a small-molecule, non-peptide chemotactic factor has been determined from activity purified to apparent homogeneity from Helicobacter pylori supernatants. H. pylori was grown in brucella broth media until one liter of solution had 0.9 absorbance units. The culture was centrifuged, and the bacteria re-suspended in physiological saline and incubated at 37 degreesC for 4 h. A monocyte migration bioassay revealed the presence of a single active chemotactic factor in the supernatant from this incubation. The chemotactic factor was concentrated by solid phase chromatography and purified by reverse phase high pressure liquid chromatography. The factor was shown to be indistinguishable from diethyl phthalate (DEP) on the basis of multiple criteria including nuclear magnetic resonance spectroscopy, electron impact mass spectroscopy, UV visible absorption spectrometry, GC and high pressure liquid chromatography retention times, and chemotactic activity toward monocytes. Control experiments with incubated culture media without detectable bacteria did not yield detectable DEP, suggesting it is bacterially derived. It is not known if the bacteria produce diethyl phthalate de novo or if it is a metabolic product of a precursor molecule present in culture media. DEP produced by H. pylori in addition to DEP present in man-made products may contribute to the high levels of DEP metabolites observed in human urine. DEP represents a new class of chemotactic factor.	Vet Affairs Greater Los Angeles Hlth Care Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Civil & Environm Engn, Environm Engn Analyt Chem Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA; City Hope Res Inst, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; Univ Calif Los Angeles, Sch Med, Div Digest Dis, Los Angeles, CA 90024 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; City of Hope; Beckman Research Institute of City of Hope; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Reeve, JR (corresponding author), Vet Affairs Greater Los Angeles Hlth Care Syst, CURE Digest Dis Res Ctr, Bldg 115,Rm 115,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.		Reeve, James/GYI-8415-2022; Keire, David/AAN-8378-2020	Keire, David/0000-0002-7767-7904	NCI NIH HHS [CA3572] Funding Source: Medline; NIAID NIH HHS [K-24 AI 01610, AI 28697] Funding Source: Medline; NIDDK NIH HHS [DK-41301] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI001610, P30AI028697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRO PW, 1973, J CHROMATOGR, V76, P321, DOI 10.1016/S0021-9673(01)96915-8; ALBRO PW, 1989, TOXICOL APPL PHARM, V100, P193, DOI 10.1016/0041-008X(89)90305-0; AMADE P, 1994, J ANTIBIOT, V47, P201, DOI 10.7164/antibiotics.47.201; ANTON PA, 1994, HELICOBACTER PYLORI, P198; BAKER RWR, 1978, TOXICOLOGY, V9, P319, DOI 10.1016/0300-483X(78)90015-X; BEDFORD DJ, 1995, J BACTERIOL, V177, P4544, DOI 10.1128/jb.177.15.4544-4548.1995; Blaser MJ, 1998, BRIT MED J, V316, P1507, DOI 10.1136/bmj.316.7143.1507; Blount BC, 2000, ANAL CHEM, V72, P4127, DOI 10.1021/ac000422r; Blount BC, 2000, ENVIRON HEALTH PERSP, V108, P979, DOI 10.2307/3435058; CRABTREE JE, 1991, GUT, V32, P1473, DOI 10.1136/gut.32.12.1473; Crabtree JE, 1996, ALIMENT PHARM THER, V10, P29, DOI 10.1046/j.1365-2036.1996.22164003.x; CRAIG PM, 1992, GUT, V33, P1020, DOI 10.1136/gut.33.8.1020; DAVIS MT, 1992, PROTEIN SCI, V1, P935, DOI 10.1002/pro.5560010712; DeVries ME, 1999, SEMIN IMMUNOL, V11, P95, DOI 10.1006/smim.1999.0165; DIMROTH P, 1970, EUR J BIOCHEM, V13, P98, DOI 10.1111/j.1432-1033.1970.tb00904.x; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FORMAN D, 1993, LANCET, V341, P359; FUKUDA T, 1990, J CLIN GASTROENTEROL, V12, pS131, DOI 10.1097/00004836-199001001-00022; George KM, 1999, SCIENCE, V283, P854, DOI 10.1126/science.283.5403.854; GRANHOLM T, 1992, J REPROD IMMUNOL, V21, P1, DOI 10.1016/0165-0378(92)90036-4; Gray LE, 1999, TOXICOL IND HEALTH, V15, P94, DOI 10.1191/074823399678846664; HAZELL SL, 1986, J INFECT DIS, V153, P658, DOI 10.1093/infdis/153.4.658; Hellwig J, 1997, FOOD CHEM TOXICOL, V35, P501, DOI 10.1016/S0278-6915(97)00008-2; HORUK R, 1996, CHEMOATTRACTANT LIGA; KOZOL R, 1993, DIGEST DIS SCI, V38, P137, DOI 10.1007/BF01296786; LAKE BG, 1977, TOXICOL APPL PHARM, V39, P239, DOI 10.1016/0041-008X(77)90157-0; LAMB J, 1997, ENV HLTH PERSPECT, V105, P245; MacDermott RP, 1999, J CLIN IMMUNOL, V19, P266, DOI 10.1023/A:1020583306627; MAI UEH, 1992, J EXP MED, V175, P517, DOI 10.1084/jem.175.2.517; MARSHALL BJ, 1984, LANCET, V1, P1311; MITCHELL AM, 1985, TOXICOL APPL PHARM, V80, P23, DOI 10.1016/0041-008X(85)90097-3; MOONEY C, 1991, GUT, V32, P853, DOI 10.1136/gut.32.8.853; NIELSEN H, 1992, GUT, V33, P738, DOI 10.1136/gut.33.6.738; NIELSEN H, 1992, GASTROENTEROLOGY, V103, P1747, DOI 10.1016/0016-5085(92)91430-C; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; PANEL NCD, 1994, JAMA-J AM MED ASSOC, V272, P65; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PEREZ HD, 1996, CHEMOATTRACTANT LIGA, P261; POLLACK GM, 1985, TOXICOL APPL PHARM, V79, P257, DOI 10.1016/0041-008X(85)90347-3; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REYMUNDE A, 1993, DIGEST DIS SCI, V38, P1697, DOI 10.1007/BF01303180; ROSS JS, 1992, AM J PATHOL, V141, P721; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; SHARON P, 1984, GASTROENTEROLOGY, V86, P453; Shimada T, 1998, J GASTROENTEROL, V33, P613, DOI 10.1007/s005350050146; SIMON L, 2000, IMMUNOL CELL REV, V78, P415; Takahashi S, 1998, DIGEST DIS SCI, V43, P754, DOI 10.1023/A:1018861930068; TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788; Tekstra J, 1999, CLIN EXP IMMUNOL, V117, P489; TUFANO MA, 1994, INFECT IMMUN, V62, P1392, DOI 10.1128/IAI.62.4.1392-1399.1994	52	20	27	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48847	48853		10.1074/jbc.M109811200	http://dx.doi.org/10.1074/jbc.M109811200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11677249	hybrid			2022-12-25	WOS:000173922100031
J	Schubert, W; Frank, PG; Razani, B; Park, DS; Chow, CW; Lisanti, MP				Schubert, W; Frank, PG; Razani, B; Park, DS; Chow, CW; Lisanti, MP			Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; ONCOGENICALLY TRANSFORMED-CELLS; RICH MEMBRANE DOMAINS; PLASMA-MEMBRANE; CAPILLARY ENDOTHELIUM; GENE FAMILY; MUSCLE CAPILLARIES; PROTEIN-COMPONENT; IN-VIVO; VESICLES	The role of endothelial cell caveolae in the uptake and transport of macromolecules from the blood-space to the tissue-space remains controversial. To address this issue directly, we employed caveolin-1 gene knock-out mice that lack caveolin-1 protein expression and caveolae organelles. Here, we show that endothelial cell caveolae are required for the efficient uptake and transport of a known caveolar ligand, i.e. albumin, in vivo. Caveolin-1-null mice were perfused with 5-nm gold-conjugated albumin, and its uptake was followed by transmission electron microscopy. Our results indicate that gold-conjugated albumin is not endocytosed by Cav-1-deficient lung endothelial cells and remains in the blood vessel lumen; in contrast, gold-conjugated albumin was concentrated and internalized by lung endothelial cell caveolae in wild-type mice, as expected. To quantitate this defect in uptake, we next studied the endocytosis of radioiodinated albumin using aortic ring segments from wild-type and Cav-1-null mice. Interestingly, little or no uptake of radioiodinated albumin was observed in the aortic segments from Cav-1-deficient mice, whereas aortic segments from wild-type mice showed robust uptake that was time. and temperature-dependent and competed by unlabeled albumin. We conclude that endothelial cell caveolae are required for the efficient uptake and transport of albumin from the blood to the interstitium.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Div Hormone Dependent Tumor Biol, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Albert Einstein Comprehens Canc Ctr, 1300 Morris Pk Ave,Rm 202,Golding Bldg, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael/B-6131-2018; Eckhardt, Erik/G-1567-2010; Lisanti, Michael P/C-6866-2013; Frank, Philippe G/A-3463-2011	Lisanti, Michael/0000-0003-2034-1382; Frank, Philippe G/0000-0003-4857-5279; Razani, Babak/0000-0002-7172-9240	NATIONAL CANCER INSTITUTE [T32CA009475] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09475, TG-CA09475] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRETSCHER MS, 1977, J ULTRA MOL STRUCT R, V61, P215, DOI 10.1016/S0022-5320(77)80088-9; BUCHANAN R, 1988, MICROVASC RES, V36, P191, DOI 10.1016/0026-2862(88)90020-9; BUNDGAARD M, 1983, MICROVASC RES, V25, P358, DOI 10.1016/0026-2862(83)90025-0; BUNDGAARD M, 1983, FED PROC, V42, P2425; BUNDGAARD M, 1979, P NATL ACAD SCI USA, V76, P6439, DOI 10.1073/pnas.76.12.6439; Christ GJ, 1999, AM J PHYSIOL-HEART C, V276, pH1911, DOI 10.1152/ajpheart.1999.276.6.H1911; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAN JY, 1983, J CELL SCI, V61, P219; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; FROKJAERJENSEN J, 1984, TISSUE CELL, V16, P31, DOI 10.1016/0040-8166(84)90016-8; FROKJAERJENSEN J, 1991, J ELECTRON MICR TECH, V19, P291, DOI 10.1002/jemt.1060190305; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; GALIS Z, 1988, EUR J CELL BIOL, V47, P358; GHINEA N, 1988, J CELL BIOL, V107, P231, DOI 10.1083/jcb.107.1.231; GHITESCU L, 1992, J CELL BIOL, V117, P745, DOI 10.1083/jcb.117.4.745; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; PREDESCU D, 1993, AM J PHYSIOL, V265, pH725, DOI 10.1152/ajpheart.1993.265.2.H725; Predescu SA, 1997, AM J PHYSIOL-HEART C, V272, pH937, DOI 10.1152/ajpheart.1997.272.2.H937; Razani B, 2001, J BIOL CHEM, V276, P38121; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SEVERS NJ, 1988, J CELL SCI, V90, P341; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SIMIONESCU N, 1983, PHYSIOL REV, V63, P1536, DOI 10.1152/physrev.1983.63.4.1536; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tiruppathi C, 1997, J BIOL CHEM, V272, P25968, DOI 10.1074/jbc.272.41.25968; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	54	261	266	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48619	48622		10.1074/jbc.C100613200	http://dx.doi.org/10.1074/jbc.C100613200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11689550	hybrid			2022-12-25	WOS:000173922100002
J	Siehler, S; Wang, YR; Fan, XM; Windh, RT; Manning, DR				Siehler, S; Wang, YR; Fan, XM; Windh, RT; Manning, DR			Sphingosine 1-phosphate activates nuclear factor-kappa B through Edg receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; HETEROTRIMERIC G-PROTEINS; SERUM RESPONSE FACTOR; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAYS; NEURITE RETRACTION; GENE-EXPRESSION; INTRACELLULAR CALCIUM; TRANSCRIPTION FACTOR; MOLECULAR-CLONING	Sphingosine I-phosphate (SIP) exerts a variety of actions as a second messenger or as an agonist that binds to one or more members of the Edg family of G protein-coupled receptors. By using human embryonic kidney 293 cells, we show that SIP activates nuclear factor-kappaB (NF-kappaB) in a receptor-dependent fashion. Edg-3 and Edg-5, which are coupled to G(i), G(q), and G(13), affect activation of NF-kappaB, whereas Edg-1, which is coupled to Gi alone, does not. We find that the activation of NF-kappaB requires protein kinase C and Ca2+, probably downstream of Gq, but that the activation of Rho alone by SIP, whether through Gq or G13, does not translate into the activation of NF-kappaB. GOT has little effect of its own but potentiates the activation of NF-kappaB achieved through other G proteins. We conclude that the activation of NF-kappaB by SIP is a receptor-mediated process that relies primarily on the activation of a phospholipase C by Gq and secondarily on effector regulation through other G proteins.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Manning, DR (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.				NIGMS NIH HHS [GM55196] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; An SZ, 1999, MOL PHARMACOL, V55, P787; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cowen DS, 1997, MOL PHARMACOL, V52, P221, DOI 10.1124/mol.52.2.221; Dumais N, 1998, J BIOL CHEM, V273, P27306, DOI 10.1074/jbc.273.42.27306; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Heringdorf DMZ, 2001, EUR J PHARMACOL, V414, P145, DOI 10.1016/S0014-2999(01)00789-0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HLA T, 1990, J BIOL CHEM, V265, P9308; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Malek RL, 2001, J BIOL CHEM, V276, P5692, DOI 10.1074/jbc.M003964200; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MARI B, 1994, J BIOL CHEM, V269, P8517; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PAN Z, 1995, J BIOL CHEM, P7787; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pan ZXK, 1998, J IMMUNOL, V160, P3038; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rumenapp U, 2001, J BIOL CHEM, V276, P2474, DOI 10.1074/jbc.M004957200; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Shatrov VA, 1997, BIOCHEM BIOPH RES CO, V234, P121, DOI 10.1006/bbrc.1997.6598; Shi CS, 2001, J BIOL CHEM, V276, P31845, DOI 10.1074/jbc.M101043200; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; Todisco A, 1999, BIOCHEM BIOPH RES CO, V261, P877, DOI 10.1006/bbrc.1999.1141; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Vancurova I, 2001, J BIOL CHEM, V276, P19746, DOI 10.1074/jbc.M100234200; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wess J, 1997, LIFE SCI, V60, P1007, DOI 10.1016/S0024-3205(97)00041-6; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	66	66	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48733	48739		10.1074/jbc.M011072200	http://dx.doi.org/10.1074/jbc.M011072200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11673450	hybrid			2022-12-25	WOS:000173922100017
J	Ward, IM; Chen, JJ				Ward, IM; Chen, JJ			Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DNA; PROTEIN; BRCA1; FRAGMENTATION; CHECKPOINTS; DISRUPTION; 53BP1; LEADS	H2AX, a member of the histone H2A family, is rapidly phosphorylated in response to ionizing radiation. This phosphorylation, at an evolutionary conserved C-terminal phosphatidylinositol 3-OH-kinase-related kinase (PI3KK) motif, is thought to be critical for recognition and repair of DNA double strand breaks. Here we report that inhibition of DNA replication by hydroxyurea or ultraviolet irradiation also induces phosphorylation and foci formation of H2AX. These phospho-H2AX foci colocalize with proliferating cell nuclear antigen (PCNA), BRCA1, and 53BP1 at the arrested replication fork in S phase cells. This response is ATR-dependent but does not require ATM or Hus1. Our findings suggest that, in addition to its role in the recognition and repair of double strand breaks, H2AX also participates in the surveillance of DNA replication.	Mayo Clin, Div Oncol Res, Rochester, MN 55905 USA	Mayo Clinic	Chen, JJ (corresponding author), Mayo Clin, Div Oncol Res, Guggenheim 1342,200 1st St SW, Rochester, MN 55905 USA.	Chen.junjie@mayo.edu						ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Brown EJ, 2000, GENE DEV, V14, P397; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Chen JJ, 2000, CANCER RES, V60, P5037; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; NAEGELI H, 1994, BIOESSAYS, V16, P557, DOI 10.1002/bies.950160809; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Weiss RS, 2000, GENE DEV, V14, P1886; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	20	874	925	1	58	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47759	47762		10.1074/jbc.C100569200	http://dx.doi.org/10.1074/jbc.C100569200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11673449	hybrid			2022-12-25	WOS:000172927000004
J	Wang, SC; Makino, K; Xia, WY; Kim, JS; Im, SA; Peng, H; Mok, SC; Singletary, SE; Hung, MC				Wang, SC; Makino, K; Xia, WY; Kim, JS; Im, SA; Peng, H; Mok, SC; Singletary, SE; Hung, MC			DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway	ONCOGENE			English	Article						ILK; DOC-2/hDab-2; anoikis; breast cancer; HER-2; neu	INTEGRIN-LINKED KINASE; EPITHELIAL OVARIAN-CANCER; PHOSPHOINOSITIDE-3-OH KINASE; ACTIVATION; EXPRESSION; CLONING; DOMAIN; B/AKT; GENE	DOC-2/hDab-2 was identified due to the loss of its expression in primary ovarian cancer cells. It is believed that loss of DOC-2/hDab-2 expression is one of the early events of ovarian malignancy. These results suggest a function of DOC-2/hDab-2 as a tumor suppressor. However, it is not clear how DOC-2/hDab-2 negatively regulates cancer cell growth. In this report, we demonstrate that DOC-2/hDab-2 expression in breast cancer cells resulted in sensitivity to suspension-induced cell death (anoikis). This event was associated with the down-regulation of the integrin-linked kinase (ILK) activity. Since ILK is a key factor in regulating the cellular signaling in responding to the extracellular signals through adhesion molecules like integrins, our results indicate that DOC-2/hDab-2 may prevent tumor growth and invasion by modulating the anti-apoptotic ILK pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Brigham & Womens Hosp, Dana Farber Harvard Canc Ctr, Div Gynecol Oncol, Lab Gynecol Oncol, Houston, TX USA; Brigham & Womens Hosp, Dana Farber Harvard Canc Ctr, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.		Wang, Shao-Chun/P-9904-2019; Hung, Mien-Chie/ABD-5911-2021	Wang, Shao-Chun/0000-0002-5477-1682; Hung, Mien-Chie/0000-0003-4317-4740				Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; YU DH, 1991, ONCOGENE, V6, P1991; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200	14	40	42	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6960	6964		10.1038/sj.onc.1204873	http://dx.doi.org/10.1038/sj.onc.1204873			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687976				2022-12-25	WOS:000171641000018
J	Fernandez-Patron, C; Zouki, C; Whittal, R; Chan, JSD; Davidge, ST; Filep, JG				Fernandez-Patron, C; Zouki, C; Whittal, R; Chan, JSD; Davidge, ST; Filep, JG			Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1[1-32]	FASEB JOURNAL			English	Article						gelatinases; ETA receptor; L-selectin; CD11b/CD18; leukocyte trafficking; endothelium; inflammation	ACTIVATED PROTEIN-KINASE; C-REACTIVE PROTEIN; BIG ENDOTHELIN-1; L-SELECTIN; LEUCYL-PHENYLALANINE; ISCHEMIA-REPERFUSION; LEUKOCYTE ADHESION; NITRIC-OXIDE; IN-VITRO; EXPRESSION	We recently reported that matrix metalloproteinase 2 (MMP-2, gelatinase A) cleaves big endothelin 1 (ET-1), yielding the vasoactive peptide ET-1[1-32]. We tested whether ET-1[1-32] could affect the adhesion of human neutrophils to coronary artery endothelial cells (HCAEC). ET-1[1-32] rapidly downregulated the expression of L-selectin and up-regulated expression of CD11b/CD18 on the neutrophil surface, with EC50 values of 1-3 nM. These actions of ET-1[1-32] were mediated via ETA receptors and did not require conversion of ET-1[1-32] into ET-1 by neutrophil proteases, as revealed by liquid chromatography and mass spectroscopy. Moreover, ET-1[1-32] evoked release of neutrophil gelatinase B, which cleaved big ET-1 to yield ET-1[1-32], thus revealing a positive feedback loop for ET-1[1-32] generation. Up-regulation of CD11b/CD18 expression and gelatinase release was tightly associated with activation of extracellular signal-regulated kinase (Erk). Stimulation of Erk activity was due to activation of Ras, Raf-1, and MEK (MAPK kinase). ET-1[1-32] also produced slight increases in the expression of ICAM-1 and E-selectin on HCAEC, and markedly enhanced beta (2) integrin-dependent adhesion of neutrophils to activated HCAEC. These results are the first indication that gelatinolytic MMPs via cleavage of big ET-1 to yield ET-1[1-32] activate neutrophils and promote leukocyte-endothelial cell adhesion and, consequently, neutrophil trafficking into inflamed tissues.	Univ Montreal, Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ H1T 2M4, Canada; Univ Montreal, Dept Med, Montreal, PQ H1T 2M4, Canada; Univ Alberta, Perinatal Res Ctr, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Chem, Lab Mass Spectrometry, Edmonton, AB T6G 2S2, Canada	Universite de Montreal; Universite de Montreal; University of Alberta; University of Alberta	Filep, JG (corresponding author), Univ Montreal, Maisonneuve Rosemont Hosp, Res Ctr, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.	janos.g.filep@umontreal.ca		Whittal, Randy/0000-0003-1174-8172				AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARAMORI I, 1993, MOL PHARMACOL, V43, P127; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Boros M, 1998, GASTROENTEROLOGY, V114, P103, DOI 10.1016/S0016-5085(98)70638-9; BORREGAARD N, 1987, SCIENCE, V237, P1204, DOI 10.1126/science.3629236; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Espinosa G, 1996, KIDNEY INT, V50, P776, DOI 10.1038/ki.1996.376; FARRE AL, 1993, CIRCULATION, V88, P1166, DOI 10.1161/01.CIR.88.3.1166; Fernandez-Patron C, 2000, CIRC RES, V87, P670, DOI 10.1161/01.RES.87.8.670; Fernandez-Patron C, 1999, CIRC RES, V85, P906; Fernandez-Patron C, 1999, THROMB HAEMOSTASIS, V82, P1353; FILEP J, 1989, LIFE SCI, V44, P517, DOI 10.1016/0024-3205(89)90613-9; FILEP JG, 1995, BRIT J PHARMACOL, V115, P227, DOI 10.1111/j.1476-5381.1995.tb15868.x; Filep JG, 1997, CIRCULATION, V96, P295; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GOMEZGARRE D, 1992, EUR J PHARMACOL, V224, P167, DOI 10.1016/0014-2999(92)90801-A; HALIM A, 1995, THROMB RES, V77, P321, DOI 10.1016/0049-3848(95)93835-N; Hayasaki Y, 1996, BIOCHEM BIOPH RES CO, V229, P817, DOI 10.1006/bbrc.1996.1886; Helset E, 1996, AM J PHYSIOL-LUNG C, V271, pL538, DOI 10.1152/ajplung.1996.271.4.L538; ISHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P496, DOI 10.1016/S0006-291X(05)80061-0; ISHIKAWA K, 1994, P NATL ACAD SCI USA, V91, P4892, DOI 10.1073/pnas.91.11.4892; Jenkins GM, 1998, CIRCULATION, V97, P82, DOI 10.1161/01.CIR.97.1.82; KAW S, 1992, P NATL ACAD SCI USA, V89, P6886, DOI 10.1073/pnas.89.15.6886; Khimenko PL, 1996, J APPL PHYSIOL, V80, P203, DOI 10.1152/jappl.1996.80.1.203; LEFER AM, 1993, ANNU REV PHARMACOL, V33, P71, DOI 10.1146/annurev.pa.33.040193.000443; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; LOPEZFARRE A, 1995, CIRCULATION, V91, P2080, DOI 10.1161/01.CIR.91.7.2080; MCCARRON RM, 1993, NEUROSCI LETT, V156, P31, DOI 10.1016/0304-3940(93)90432-K; MIYAUCHI T, 1989, LANCET, V2, P53, DOI 10.1016/S0140-6736(89)90303-6; Murohara T, 1996, BLOOD, V88, P3894, DOI 10.1182/blood.V88.10.3894.bloodjournal88103894; Nakano A, 1997, J IMMUNOL, V159, P1987; NEWBY AC, 1994, BASIC RES CARDIOL, V89, P59; Parks WC, 1998, BIOL EXTRAC, P263; Pillinger MH, 1996, J BIOL CHEM, V271, P12049, DOI 10.1074/jbc.271.20.12049; Sanz MJ, 1999, AM J PHYSIOL-HEART C, V277, pH1823, DOI 10.1152/ajpheart.1999.277.5.H1823; Sawicki G, 1997, NATURE, V386, P616, DOI 10.1038/386616a0; SPERTINI O, 1991, J IMMUNOL, V147, P2565; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; WATANABE T, 1991, CIRC RES, V69, P370, DOI 10.1161/01.RES.69.2.370; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YU H, 1995, J BIOL CHEM, V270, P15719, DOI 10.1074/jbc.270.26.15719; Zouki C, 1997, J CLIN INVEST, V100, P522, DOI 10.1172/JCI119561; Zouki C, 1999, BRIT J PHARMACOL, V127, P969, DOI 10.1038/sj.bjp.0702593; ZOUKI C, 2000, FASEB J         1109	51	106	110	3	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2230	2240		10.1096/fj.01-0178com	http://dx.doi.org/10.1096/fj.01-0178com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641250				2022-12-25	WOS:000171920400035
J	Tchougounova, E; Pejler, G				Tchougounova, E; Pejler, G			Regulation of extravascular coagulation and fibrinolysis by heparin-dependent mast cell chymase	FASEB JOURNAL			English	Article						heparin proteoglycan; plasmin; thrombin	MOLECULAR-CLONING; HYPERSENSITIVITY REACTIONS; MIGRATION-INHIBITION; GRANULE CHYMASE; MICE LACKING; IN-VIVO; MOUSE; TRYPTASE; GENE; DEFICIENT	We recently characterized a heparin-deficient mouse strain generated by targeting the gene for N-deacetylase/N-sulfotransferase-2 (NDST-2). The NDST-2(-/-) mice show severe defects in their organization of mast cell (MC) secretory granules, with an almost total absence of the various heparin-binding MC proteases. In the present report we have studied the consequences of heparin/MC protease deficiency for extravascular coagulation and fibrinolysis. Addition of prothrombin to peritoneal cells-a mixture of macrophages, lymphocytes, and MCs-resulted in formation of thrombin but the accumulation of thrombin occurred faster in the NDST-2(-/-) cells than in normal controls. Further, the generated thrombin was subsequently inactivated in the NDST-2(+/+) cell cultures but not in the NDST-2(-/-) cells. Plasminogen was activated to plasmin at an apparently higher rate in peritoneal cells from NDST-2 null mice than in the normal controls. Similar to thrombin, the generated plasmin was inactivated by NDST-2(+/+) but not by the NDST-2(-/-) cells. Subsequent experiments with normal cells showed that cell surface-associated MC chymase, in a strongly heparin-dependent manner, was responsible for both the thrombinin-activating- and plasmin-inactivating activities. These results show that MC chymase-heparin complexes have the potential to regulate extravascular coagulation processes, as well as the plasminogen activator/plasmin system.	Swedish Univ Agr Sci, Ctr Biomed, Dept Vet Med Chem, S-75123 Uppsala, Sweden	Swedish University of Agricultural Sciences	Pejler, G (corresponding author), Swedish Univ Agr Sci, Ctr Biomed, Dept Vet Med Chem, Box 575, S-75123 Uppsala, Sweden.	Gunnar.Pejler@vmk.slu.se						Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BAUER PI, 1983, INT J BIOCHEM, V15, P871, DOI 10.1016/0020-711X(83)90161-1; Bugge TH, 1997, BLOOD, V90, P4522; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ENERBACK L, 1985, BIOCHEM J, V227, P661, DOI 10.1042/bj2270661; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; GECZY CL, 1981, J IMMUNOL, V126, P1059; GERVASONI JE, 1986, J IMMUNOL, V136, P285; Gotis-Graham I, 1998, ANN RHEUM DIS, V57, P664, DOI 10.1136/ard.57.11.664; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; He SH, 1997, J IMMUNOL, V159, P6216; He SH, 1998, BRIT J PHARMACOL, V125, P1491, DOI 10.1038/sj.bjp.0702223; He SH, 1998, EUR J PHARMACOL, V352, P91, DOI 10.1016/S0014-2999(98)00343-4; HOPPER KE, 1981, J IMMUNOL, V126, P1052; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J IMMUNOL, V160, P1910; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Knight PA, 2000, J EXP MED, V192, P1849, DOI 10.1084/jem.192.12.1849; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1989, ARCH BIOCHEM BIOPHYS, V273, P180, DOI 10.1016/0003-9861(89)90177-X; Majima M, 1989, Adv Exp Med Biol, V247A, P487; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; Molinari JF, 1995, J APPL PHYSIOL, V79, P1966, DOI 10.1152/jappl.1995.79.6.1966; Molinari JF, 1996, AM J RESP CRIT CARE, V154, P649, DOI 10.1164/ajrccm.154.3.8810600; Pejler G, 1999, BIOCHEMISTRY-US, V38, P12187, DOI 10.1021/bi991046b; PEJLER G, 1995, EUR J BIOCHEM, V233, P192, DOI 10.1111/j.1432-1033.1995.192_1.x; PEJLER G, 1993, J BIOL CHEM, V268, P11817; PEJLER G, 1995, EUR J BIOCHEM, V227, P102, DOI 10.1111/j.1432-1033.1995.tb20364.x; PEJLER G, 1994, BIOCHEM J, V299, P507, DOI 10.1042/bj2990507; Pejler G, 1999, INFLAMM RES, V48, P344, DOI 10.1007/s000110050470; Pejler G, 2000, THROMB HAEMOSTASIS, V84, P429; PEJLER G, 1994, J BIOL CHEM, V269, P14451; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; Sabapathy KT, 1997, J CELL BIOL, V137, P953, DOI 10.1083/jcb.137.4.953; SCHECHTER NM, 1995, BIOCHEMISTRY-US, V34, P10628, DOI 10.1021/bi00033a038; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; Shapiro RL, 1996, CANCER RES, V56, P3597; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; Sommerhoff CP, 2000, BBA-PROTEIN STRUCT M, V1477, P75, DOI 10.1016/S0167-4838(99)00265-4; STERK AR, 1982, J IMMUNOL, V128, P838; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; Tchougounova E, 2001, J BIOL CHEM, V276, P3772, DOI 10.1074/jbc.M008434200; Trautmann A, 2000, J PATHOL, V190, P100, DOI 10.1002/(SICI)1096-9896(200001)190:1<100::AID-PATH496>3.0.CO;2-Q; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X	60	40	41	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2763	+		10.1096/fj.01-0486fje	http://dx.doi.org/10.1096/fj.01-0486fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11687508				2022-12-25	WOS:000171920400003
J	Haapa-Paananen, S; Rita, H; Savilahti, H				Haapa-Paananen, S; Rita, H; Savilahti, H			DNA transposition of bacteriophage Mu - A quantitative analysis of target site selection in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TN10 INSERTION SPECIFICITY; PHAGE-MU; CONSENSUS SEQUENCE; STRAND TRANSFER; B-PROTEIN; IN-VITRO; RECOGNITION; TN7; RECOMBINATION; TRANSPOSOSOME	The Mu transpositional DNA recombination machinery selects target sites by assembling a protein-DNA complex that interacts with the target DNA and reacts whenever it locates a favorable sequence composition. Splicing of a transposon into the target generates a 5-bp duplication that reflects the original target site. Preferential usage of different target pentamers was examined with a minimal Mu in vitro system and quantitatively compiled consensus sequences for the most preferred and the least preferred sites were generated. When analyzed as base steps, preferences toward certain steps along the 5-bp target site were detected. We further show that insertion sites can be predicted on the basis of additively calculated base step values. Also surrounding sequences influence the preference of a given pentamer; a symmetrical structural component was revealed, suggesting potential hinges at and around the target site.	Univ Helsinki, Viikki Bioctr, Inst Biotechnol, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Systemat & Ecol, Div Populat Biol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Savilahti, H (corresponding author), Univ Helsinki, Viikki Bioctr, Inst Biotechnol, Program Cellular Biotechnol, POB 56,Viikinkaari 9, FIN-00014 Helsinki, Finland.		Haapa-Paananen, Saija/D-3075-2012	Savilahti, Harri/0000-0002-6246-2572				ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Allemann RK, 1997, CHEM BIOL, V4, P643, DOI 10.1016/S1074-5521(97)90218-0; ALLET B, 1979, CELL, V16, P123, DOI 10.1016/0092-8674(79)90193-4; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BENDER J, 1992, P NATL ACAD SCI USA, V89, P7996, DOI 10.1073/pnas.89.17.7996; Berg DE, 1989, MOBILE DNA; Boeke JD, 1998, CELL, V93, P1087, DOI 10.1016/S0092-8674(00)81450-6; BRUKNER I, 1995, EMBO J, V14, P1812, DOI 10.1002/j.1460-2075.1995.tb07169.x; BUKHARI AI, 1972, NATURE-NEW BIOL, V236, P240, DOI 10.1038/newbio236240a0; CASTILHO BA, 1991, J BACTERIOL, V173, P1339, DOI 10.1128/jb.173.3.1339-1343.1991; Chaconas G, 1996, CURR BIOL, V6, P817, DOI 10.1016/S0960-9822(02)00603-6; COUTURIER M, 1976, CELL, V7, P155, DOI 10.1016/0092-8674(76)90015-5; Craig NL, 1996, CURR TOP MICROBIOL, V204, P27; CRAIG NL, 1991, MOL MICROBIOL, V5, P2569, DOI 10.1111/j.1365-2958.1991.tb01964.x; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; Craig NL, 1997, ANNU REV BIOCHEM, V66, P437, DOI 10.1146/annurev.biochem.66.1.437; DANIELL E, 1972, J MOL BIOL, V69, P1, DOI 10.1016/0022-2836(72)90019-8; DAVIES CJ, 1995, NUCLEIC ACIDS RES, V23, P507, DOI 10.1093/nar/23.3.507; ElHassan MA, 1996, J MOL BIOL, V259, P95, DOI 10.1006/jmbi.1996.0304; EMR SD, 1980, J MOL BIOL, V141, P63, DOI 10.1016/S0022-2836(80)80029-5; GORIN AA, 1995, J MOL BIOL, V247, P34, DOI 10.1006/jmbi.1994.0120; Goryshin IY, 1998, P NATL ACAD SCI USA, V95, P10716, DOI 10.1073/pnas.95.18.10716; Haapa S, 1999, NUCLEIC ACIDS RES, V27, P2777, DOI 10.1093/nar/27.13.2777; Haapa S, 1999, GENOME RES, V9, P308; HALLET B, 1994, MOL MICROBIOL, V14, P131, DOI 10.1111/j.1365-2958.1994.tb01273.x; HALLING SM, 1982, CELL, V28, P155, DOI 10.1016/0092-8674(82)90385-3; Haren L, 1999, ANNU REV MICROBIOL, V53, P245, DOI 10.1146/annurev.micro.53.1.245; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Hu WY, 2001, J MOL BIOL, V306, P403, DOI 10.1006/jmbi.2000.4421; IVANOV VI, 1994, MOL BIOL+, V28, P780; KAHMANN R, 1979, NATURE, V280, P247, DOI 10.1038/280247a0; KAMP D, 1980, COLD SPRING HARB SYM, V45, P329; Katz RA, 1998, J BIOL CHEM, V273, P24190, DOI 10.1074/jbc.273.37.24190; Kennedy AK, 2000, CELL, V101, P295, DOI 10.1016/S0092-8674(00)80839-9; Ketting RF, 1997, NUCLEIC ACIDS RES, V25, P4041, DOI 10.1093/nar/25.20.4041; KUBO KM, 1990, J BACTERIOL, V172, P2774, DOI 10.1128/jb.172.5.2774-2778.1990; Kuduvalli PN, 2001, EMBO J, V20, P924, DOI 10.1093/emboj/20.4.924; Liao GC, 2000, P NATL ACAD SCI USA, V97, P3347, DOI 10.1073/pnas.050017397; Lilley D. M. J., 1995, DNA PROTEIN STRUCTUR; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; Mizuuchi K, 1997, GENES CELLS, V2, P1, DOI 10.1046/j.1365-2443.1997.970297.x; MIZUUCHI M, 1993, COLD SPRING HARB SYM, V58, P515, DOI 10.1101/SQB.1993.058.01.058; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; Olson WK, 1998, P NATL ACAD SCI USA, V95, P11163, DOI 10.1073/pnas.95.19.11163; Peters JE, 2000, MOL CELL, V6, P573, DOI 10.1016/S1097-2765(00)00056-3; Pribil PA, 2000, J MOL BIOL, V303, P145, DOI 10.1006/jmbi.2000.4135; RAIBAUD O, 1979, MOL GEN GENET, V179, P241; Rao JE, 2000, P NATL ACAD SCI USA, V97, P3936, DOI 10.1073/pnas.080061497; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; SAEDLER H, 1996, CURR TOP MICROBIOL I, V204; Sambrook J., 2002, MOL CLONING LAB MANU; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SHERRAT DJ, 1995, MOBILE GENETIC ELEME; SILHAVY TJ, 1979, MOL GEN GENET, V174, P249, DOI 10.1007/BF00267797; VANLUENEN HGAM, 1994, NUCLEIC ACIDS RES, V22, P262, DOI 10.1093/nar/22.3.262; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; WANG XH, 1994, MOL MICROBIOL, V12, P665, DOI 10.1111/j.1365-2958.1994.tb01054.x; Williams TL, 1999, GENE DEV, V13, P2725, DOI 10.1101/gad.13.20.2725	61	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2843	2851		10.1074/jbc.M108044200	http://dx.doi.org/10.1074/jbc.M108044200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11700310	hybrid			2022-12-25	WOS:000173421500063
J	Park, KM; Kramers, C; Vayssier-Taussat, M; Chen, A; Bonventre, JV				Park, KM; Kramers, C; Vayssier-Taussat, M; Chen, A; Bonventre, JV			Prevention of kidney ischemia/reperfusion-induced functional injury, MAPK and MAPK kinase activation, and inflammation by remote transient ureteral obstruction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; OXIDATIVE STRESS; CELL INJURY; MONOCLONAL-ANTIBODIES; PROXIMAL TUBULES; ISCHEMIA; ALPHA; PHOSPHORYLATION; HSP27; CYTORESISTANCE	Protection against ischemic kidney injury is afforded by 24 h of ureteral obstruction (UO) applied 6 or 8 days prior to the ischemia. Uremia or humoral factors are not responsible for the protection, since unilateral UO confers protection on that kidney but not the contralateral kidney. Prior UO results in reduced postischemic outer medullary congestion and leukocyte infiltration. Prior UO results in reduced postischemic phosphorylation of c-Jun N-terminal stress-activated protein kinase 1/2 (JNK1/2), p38, mitogen-activated protein kinase (MAPK) kinase 4 (MKK4), and MKK3/6. Very few cells stain positively for proliferating cell nuclear antigen after obstruction, indicating that subsequent protection against ischemia is not related to proliferation with increased numbers of newly formed daughter cells more resistant to injury. UO increases the expression of heat shock protein (HSP)-25 and HSP-72. The increased HSP-25 expression persists for 6 or 8 days, whereas HSP-72 does not. HSP-25 expression is increased in the proximal tubule cells in the outer stripe of the outer medulla post-obstruction, prior to, and 24 h after ischemia. In LLC-PK1 renal epithelial cells, adenovirus-expressed human HSP-27 confers resistance to chemical anoxia and oxidative stress. Increased HSP-27 expression in LLC-PK1 cells results in reduced H2O2-induced phosphorylation of JNK1/2 and p38. In conclusion, prior transient UO renders the kidney resistant to ischemia. This resistance to functional consequences of ischemia is associated with reduced postischemic activation of JNK, p38 ALAP kinases, and their upstream MAPK kinases. The persistent increase in HSP-25 that occurs as a result of UO may contribute to the reduction in phosphorylation of MAPKs that have been implicated in adhesion molecule up-regulation and cell death.	Massachusetts Gen Hosp E, Med Serv, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; Harvard Univ, MIT, Div Hlth Sci & Technol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT)	Bonventre, JV (corresponding author), Massachusetts Gen Hosp E, Med Serv, 149 13th St,Suite 4002, Charlestown, MA 02129 USA.	joseph_bonventre@hms.harvard.edu	Kramers, C./L-4458-2015		NIDDK NIH HHS [DK 39773, DK 38452] Funding Source: Medline; NINDS NIH HHS [NS 10828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039773, R01DK039773, P01DK038452] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS010828, P01NS010828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBATE M, 1994, AM J PHYSIOL-RENAL, V267, pF971, DOI 10.1152/ajprenal.1994.267.6.F971; Armstrong SC, 2000, J MOL CELL CARDIOL, V32, P1301, DOI 10.1006/jmcc.2000.1164; Arystarkhova E, 1996, J BIOL CHEM, V271, P23407, DOI 10.1074/jbc.271.38.23407; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BHAN AK, 1985, LAB INVEST, V53, P421; Borkan SC, 1997, AM J PHYSIOL-RENAL, V272, pF347, DOI 10.1152/ajprenal.1997.272.3.F347; DeMeester SL, 2001, FASEB J, V15, P270, DOI 10.1096/fj.00-0170hyp; Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000; Hu YH, 1997, J BIOL CHEM, V272, P9113; Huot J, 1996, CANCER RES, V56, P273; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; JOANNIDIS M, 1995, KIDNEY INT, V47, P1752, DOI 10.1038/ki.1995.242; KELLERMAN PS, 1990, AM J PHYSIOL, V259, pF279, DOI 10.1152/ajprenal.1990.259.2.F279; KELLERMAN PS, 1992, KIDNEY INT, V42, P896, DOI 10.1038/ki.1992.366; Kelly KJ, 2001, KIDNEY INT, V59, P1798, DOI 10.1046/j.1523-1755.2001.0590051798.x; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; Lewis SE, 1999, J NEUROSCI, V19, P8945, DOI 10.1523/JNEUROSCI.19-20-08945.1999; Liu LX, 1998, AM J PHYSIOL-REG I, V275, pR315, DOI 10.1152/ajpregu.1998.275.1.R315; LOVIS C, 1994, RENAL FAILURE, V16, P179, DOI 10.3109/08860229409044859; Martin JL, 1997, CIRCULATION, V96, P4343; Maulik N, 1998, AM J PHYSIOL-HEART C, V275, pH1857, DOI 10.1152/ajpheart.1998.275.5.H1857; Meng XZ, 1999, ANN NY ACAD SCI, V874, P69, DOI 10.1111/j.1749-6632.1999.tb09226.x; MOLITORIS BA, 1988, J MEMBRANE BIOL, V106, P233, DOI 10.1007/BF01872161; MOLITORIS BA, 1985, J CLIN INVEST, V76, P2097, DOI 10.1172/JCI112214; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NAGLE RB, 1976, LAB INVEST, V35, P18; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; POLLA BS, 1988, J CELL BIOL, V107, P373, DOI 10.1083/jcb.107.1.373; POMBO CM, 1994, J BIOL CHEM, V269, P26546; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; Rucker M, 2001, SURGERY, V129, P292, DOI 10.1067/msy.2001.111079; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; Safirstein R, 1998, SEMIN NEPHROL, V18, P519; SCHOTT RJ, 1990, CIRC RES, V66, P1133, DOI 10.1161/01.RES.66.4.1133; Schwartz N, 1999, AM J PHYSIOL-RENAL, V276, pF544, DOI 10.1152/ajprenal.1999.276.4.F544; Sheridan AM, 2000, CURR OPIN NEPHROL HY, V9, P427, DOI 10.1097/00041552-200007000-00015; Smoyer WE, 2000, J AM SOC NEPHROL, V11, P211, DOI 10.1681/ASN.V112211; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; Terajima H, 2000, HEPATOLOGY, V31, P407, DOI 10.1002/hep.510310221; Tian W, 2000, AM J PHYSIOL-RENAL, V279, pF593, DOI 10.1152/ajprenal.2000.279.4.F593; Turman MA, 1999, KIDNEY INT, V55, P189, DOI 10.1046/j.1523-1755.1999.00251.x; Wang YH, 1996, AM J PHYSIOL-RENAL, V270, pF1057, DOI 10.1152/ajprenal.1996.270.6.F1057; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yoo CG, 2000, J IMMUNOL, V164, P5416, DOI 10.4049/jimmunol.164.10.5416; ZAGER RA, 1994, KIDNEY INT, V45, P1760, DOI 10.1038/ki.1994.229; ZAGER RA, 1995, KIDNEY INT, V47, P628, DOI 10.1038/ki.1995.80; ZAGER RA, 1995, LAB INVEST, V72, P592; Zager RA, 1999, KIDNEY INT, V56, P1788, DOI 10.1046/j.1523-1755.1999.00745.x; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001	51	135	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2040	2049		10.1074/jbc.M107525200	http://dx.doi.org/10.1074/jbc.M107525200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11696540	hybrid, Green Published			2022-12-25	WOS:000173421300059
J	Hofmann, A; Grella, M; Botos, I; Filipowicz, W; Wlodawer, A				Hofmann, A; Grella, M; Botos, I; Filipowicz, W; Wlodawer, A			Crystal structures of the semireduced and inhibitor-bound forms of cyclic nucleotide phosphodiesterase from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSE 1'',2''-CYCLIC PHOSPHATE; ELECTRON-DENSITY MAPS; DISULFIDE BONDS; RIBONUCLEASE-A; WHEAT-GERM; PROTEIN; PURIFICATION; DIFFRACTION; METABOLISM; MOLSCRIPT	The crystal structure of the semireduced form of cyclic nucleotide phosphodiesterase (CPDase) from Arabidopsis thaliana has been solved by molecular replacement and refined at the resolution of 1.8 Angstrom. We have previously reported the crystal structure of the native form of this enzyme, whose main target is ADP-ribose 1",2"-cyclic phosphate, a product of the tRNA splicing reaction. CPDase possesses six cysteine residues, four of which are involved in forming two intra-molecular disulfide bridges. One of these bridges, between Cys-104 and Cys-110, is opened in the semireduced CPDase, whereas the other remains intact. This change of the redox state leads to a conformational rearrangement in the loop covering the active site of the protein. While the native structure shows this partially disordered loop in a coil conformation, in the semireduced enzyme the N-terminal lobe of this loop winds up and elongates the preceding alpha-helix. The semireduced state of CPDase also enabled co-crystallization with a putative inhibitor of its enzymatic activity, 2',3'-cyclic uridine vanadate. The ligand is bound within the active site, and the mode of binding is in agreement with the previously proposed enzymatic mechanism. Selected biophysical properties of the oxidized and the semireduced CPDase are also discussed.	NCI, Macromol Crystallog Lab, NIH, Frederick, MD 21702 USA; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Friedrich Miescher Institute for Biomedical Research	Hofmann, A (corresponding author), NCI, Macromol Crystallog Lab, NIH, Frederick, MD 21702 USA.		Hofmann, Andreas/B-9515-2008; Hofmann, Andreas/M-9870-2019	Hofmann, Andreas/0000-0003-4408-5467; Hofmann, Andreas/0000-0003-4408-5467; Botos, Istvan/0000-0002-7702-6749				BOHM G, 1997, CDNN CD SPECTRA DECO; BORAH B, 1985, BIOCHEMISTRY-US, V24, P2058, DOI 10.1021/bi00329a038; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; CULVER GM, 1994, J BIOL CHEM, V269, P24928; CULVER GM, 1993, SCIENCE, V261, P206, DOI 10.1126/science.8392224; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Genschik P, 1997, J BIOL CHEM, V272, P13211, DOI 10.1074/jbc.272.20.13211; Hofmann A, 2000, EMBO J, V19, P6207, DOI 10.1093/emboj/19.22.6207; HOFMANN A, 2002, IN PRESS BIOINFORMAT; Hohoff C, 1999, BIOCHEMISTRY-US, V38, P12229, DOI 10.1021/bi990305u; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; Klink TA, 2000, EUR J BIOCHEM, V267, P566, DOI 10.1046/j.1432-1327.2000.01037.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUWAJIMA K, 1990, BIOCHEMISTRY-US, V29, P8240, DOI 10.1021/bi00488a007; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu Y, 1997, BIOCHEMISTRY-US, V36, P5323, DOI 10.1021/bi962423c; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; *MOL SIM INC, INS 2 VERS 2000; Nasr F, 2000, NUCLEIC ACIDS RES, V28, P1676, DOI 10.1093/nar/28.8.1676; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pace CN, 1995, METHOD ENZYMOL, V259, P538; *PERS VIS DEV TEAM, 1999, POVRAY; STEWART JJP, 1990, J COMPUT AID MOL DES, V4, P1, DOI 10.1007/BF00128336; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; TYC K, 1987, J BIOL CHEM, V262, P12994; ZHANG T, 1994, NAT STRUCT BIOL, V1, P434, DOI 10.1038/nsb0794-434; ZILLMANN M, 1991, MOL CELL BIOL, V11, P5410, DOI 10.1128/MCB.11.11.5410; ZILLMANN M, 1992, J BIOL CHEM, V267, P10289	33	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1419	1425		10.1074/jbc.M107889200	http://dx.doi.org/10.1074/jbc.M107889200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694509	hybrid			2022-12-25	WOS:000173166800072
J	Jiang, ZY; Chawla, A; Bose, A; Way, M; Czech, MP				Jiang, ZY; Chawla, A; Bose, A; Way, M; Czech, MP			A phosphatidylinositol 3-kinase-independent insulin signaling pathway to N-WASP/Arp2/3/F-actin required for GLUT4 glucose transporter recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASE; N-WASP; 3T3-L1 ADIPOCYTES; 3-KINASE ACTIVATION; ACTIN CYTOSKELETON; RAT ADIPOCYTES; TRANSLOCATION; STIMULATION; PROTEIN; MECHANISMS	Recruitment of intracellular glucose transporter 4 (GLUT4) to the plasma membrane of fat and muscle cells in response to insulin requires phosphatidylinositol (PI) 3-kinase as well as a proposed PI 3-kinase-independent pathway leading to activation of the small GTPase TC10. Here we show that in cultured adipocytes insulin causes acute cortical localization of the actin-regulatory neural Wiskott-Aldrich syndrome protein (N-WASP) and F-actin related protein-3 (Arp3) as well as cortical F-actin polymerization by a mechanism that is insensitive to the PI 3-kinase inhibitor wortmannin. Expression of the dominant inhibitory N-WASP-DeltaWA protein lacking the Arp and actin binding regions attenuates the cortical F-actin rearrangements by insulin in these cells. Remarkably, the N-WASP-DeltaWA protein also inhibits insulin action on GLUT4 translocation, indicating dependence of GLUT4 recycling on N-WASP-directed cortical F-actin assembly. TC10 exhibits sequence similarity to Cdc42 and has been reported to bind N-WASP. We show the inhibitory TC10 (T31N) mutant, which abrogates insulin-stimulated GLUT4 translocation and glucose transport, also inhibits both cortical localization of N-WASP and F-actin formation in response to insulin. These findings reveal that N-WASP likely functions downstream of TC10 in a PI 3-kinase-independent insulin signaling pathway to mobilize cortical F-actin, which in turn promotes GLUT4 responsiveness to insulin.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	University of Massachusetts System; University of Massachusetts Worcester; European Molecular Biology Laboratory (EMBL)	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.			Way, Michael/0000-0001-7207-2722	NIDDK NIH HHS [DK30898] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030898, R37DK030898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asahi Yoshihiko, 1999, Journal of Medical Investigation, V46, P192; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; Fletcher LM, 2000, BIOCHEM J, V352, P267, DOI 10.1042/0264-6021:3520267; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Imagawa M, 1999, BIOCHEM BIOPH RES CO, V254, P299, DOI 10.1006/bbrc.1998.9937; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Kamal A, 2000, CURR OPIN CELL BIOL, V12, P503, DOI 10.1016/S0955-0674(00)00123-X; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; Kennedy JW, 1999, DIABETES, V48, P1192, DOI 10.2337/diabetes.48.5.1192; Khayat ZA, 2000, J CELL SCI, V113, P279; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Lawrence JTR, 2001, MOL CELL BIOL, V21, P5276, DOI 10.1128/MCB.21.15.5276-5285.2001; MARCUSOHN J, 1995, CURR BIOL, V5, P1296, DOI 10.1016/S0960-9822(95)00256-9; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; Murphy GA, 2001, CELL GROWTH DIFFER, V12, P157; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Olson AL, 2001, J BIOL CHEM, V276, P10706, DOI 10.1074/jbc.M007610200; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Patki V, 2001, MOL BIOL CELL, V12, P129, DOI 10.1091/mbc.12.1.129; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Takenawa T, 2001, J CELL SCI, V114, P1801; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Valentijn JA, 2000, P NATL ACAD SCI USA, V97, P1091, DOI 10.1073/pnas.97.3.1091; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619	47	121	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					509	515		10.1074/jbc.M108280200	http://dx.doi.org/10.1074/jbc.M108280200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11694514	hybrid			2022-12-25	WOS:000173087900068
J	Seachrist, JL; Laporte, SA; Dale, LB; Babwah, AV; Caron, MG; Anborgh, PH; Ferguson, SSG				Seachrist, JL; Laporte, SA; Dale, LB; Babwah, AV; Caron, MG; Anborgh, PH; Ferguson, SSG			Rab5 association with the angiotensin II type 1A receptor promotes Rab5 GTP binding and vesicular fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED ENDOCYTOSIS; CLATHRIN ADAPTER; GTPASES; RESENSITIZATION; INTERNALIZATION; TRAFFICKING; IDENTIFICATION; SEQUESTRATION	Previous studies have demonstrated that the internalization of the angiotensin 11 type 1A receptor (AT(1A)R) may be mediated by both beta-arrestin-sensitive and -insensitive mechanisms. Therefore, we have used the AT(1A)R carboxyl-terminal tail to screen a rat brain yeast two-hybrid expression library for novel AT(1A)R-interacting proteins that might contribute to the regulation of AT(1A)R internalization. We have identified Rab5a as an AT(1A)R-binding protein that selectively associates with the AT(1A)R and not with the beta(2)-adrenergic receptor. A Rab5a-S34N mutant defective in GTP binding does not prevent the internalization of the AT(1A)R but does prevent the trafficking of the AT(1A)R into larger hollow cored vesicular structures. Agonist activation of the AT(1A)R promotes both the formation of Rab5a-AT(1A)R protein complexes and Rab5a GTP binding. Rab5a interactions with the AT(1A)R are mediated in part by the last 10 amino acid residues of the AT(1A)R carboxyl-terminal tail, and although a mutant receptor lacking these residues internalizes normally, it does not redistribute into larger hollow vesicles. Our data suggest that AT(1A)R activation modulates Rab5a activity leading to the homotypic fusion of endocytic vesicles. These observations suggest that vesicular cargo proteins, such as the AT(1A)R, may control their targeting between intracellular compartments by directly regulating the activity of components of the intracellular trafficking machinery such as Rab5a.	Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Physiol & Med, London, ON N6A 5K8, Canada; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Duke University; Howard Hughes Medical Institute	Ferguson, SSG (corresponding author), Robarts Res Inst, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.		Laporte, Stephane/ABC-4228-2021; Laporte, Stephane A/F-3282-2012	Laporte, Stephane/0000-0002-0633-543X; 				Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Bai C, 1997, METHOD ENZYMOL, V283, P141; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Carroll KS, 2001, SCIENCE, V292, P1373, DOI 10.1126/science.1056791; CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; Gaborik Z, 2001, MOL PHARMACOL, V59, P239, DOI 10.1124/mol.59.2.239; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GUARENTE L, 1993, P NATL ACAD SCI USA, V90, P1639, DOI 10.1073/pnas.90.5.1639; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Jedd G, 1997, J CELL BIOL, V137, P563, DOI 10.1083/jcb.137.3.563; Krueger KM, 1997, J BIOL CHEM, V272, P5; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Rodman JS, 2000, J CELL SCI, V113, P183; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Schmidlin F, 2001, J BIOL CHEM, V276, P25427, DOI 10.1074/jbc.M101688200; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Touyz RM, 2000, PHARMACOL REV, V52, P639; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	42	104	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					679	685		10.1074/jbc.M109022200	http://dx.doi.org/10.1074/jbc.M109022200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11682489	hybrid			2022-12-25	WOS:000173087900089
J	Duyndam, MCA; Hulscher, TM; Fontijn, D; Pinedo, HM; Boven, E				Duyndam, MCA; Hulscher, TM; Fontijn, D; Pinedo, HM; Boven, E			Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1 alpha protein by the oxidative stressor arsenite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED TRANSCRIPTIONAL ACTIVATION; UBIQUITIN-PROTEASOME PATHWAY; SMOOTH-MUSCLE CELLS; FACTOR GENE; NITRIC-OXIDE; INDUCED APOPTOSIS; GLIOMA-CELLS; FACTOR-ALPHA; DNA-BINDING; GLUTATHIONE	Recent evidence suggests that vascular endothelial growth factor (VEGF) expression is up-regulated by oxidative stressors through activation of hypoxia-inducible Factor I (HIF-1). To investigate whether this is a general phenomenon, we studied the effects of the sulfhydryl reagent arsenite on VEGF expression in human ovarian cancer cells. Arsenite potently induces the production of reactive oxygen species (ROS) in several cell systems and directly interacts with sulfhydryl groups of cellular thiols. We report that arsenite induces VEGF mRNA and protein levels in normoxic H134 and OVCAR-3 cells. Arsenite also increases HIF-1 alpha protein levels, suggesting a role for HIF-1 in the induction of VEGF expression. Pretreatment with the ROS inhibitors catalase and mannitol attenuated arsenite-induced ROS production, but did not affect induction of VEGF mRNA and HIF-1 alpha protein. In contrast, pretreatment with the thiol antioxidants glutathione or N-acetylcysteine completely abrogated both effects, whereas a potentiation was observed by depletion of intracellular glutathione. These results demonstrate that arsenite-induced VEGF mRNA and HIF-1 alpha protein expression is independent of increased ROS production but critically regulated by the cellular reduced glutathione content. In addition, these data suggest the involvement of a thiol-sensitive mechanism in the regulation of VEGF mRNA expression and HIF-1 alpha protein in human ovarian cancer cells.	Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Duyndam, MCA (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.							Brauchle M, 1996, J BIOL CHEM, V271, P21793, DOI 10.1074/jbc.271.36.21793; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419; DUYNDAM MCA, 2002, IN PRESS AM J PATHOL; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Giaccone G, 1995, BBA-GENE STRUCT EXPR, V1264, P337, DOI 10.1016/0167-4781(95)00171-9; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Haddad JJE, 2000, J BIOL CHEM, V275, P21130, DOI 10.1074/jbc.M000737200; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; Hossain MA, 2000, J BIOL CHEM, V275, P27874; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; HUANG H, 1993, TOXICOLOGY, V79, P195, DOI 10.1016/0300-483X(93)90211-A; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; KLEMPERER NS, 1989, J BIOL CHEM, V264, P19245; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lin HL, 2000, CANCER-AM CANCER SOC, V89, P983, DOI 10.1002/1097-0142(20000901)89:5<983::AID-CNCR7>3.3.CO;2-7; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Lynn S, 2000, CIRC RES, V86, P514, DOI 10.1161/01.RES.86.5.514; Lynn S, 1998, FREE RADICAL BIO MED, V24, P442, DOI 10.1016/S0891-5849(97)00279-7; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McDowell HE, 1997, EUR J BIOCHEM, V247, P306, DOI 10.1111/j.1432-1033.1997.00306.x; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Muller I, 1998, INT J MOL MED, V1, P491; Murgo AJ, 2001, ONCOLOGIST, V6, P22, DOI 10.1634/theoncologist.6-suppl_2-22; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Richard DE, 1999, BIOCHEM BIOPH RES CO, V266, P718, DOI 10.1006/bbrc.1999.1889; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Robinson CJ, 2001, J CELL SCI, V114, P853; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salnikow K, 2000, CANCER RES, V60, P3375; SCOTT N, 1993, CHEM RES TOXICOL, V6, P102, DOI 10.1021/tx00031a016; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; Sodhi A, 2000, CANCER RES, V60, P4873; Sowter HM, 1997, LAB INVEST, V77, P607; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Uslu R, 2000, CLIN CANCER RES, V6, P4957; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WINSKI SL, 1995, J TOXICOL ENV HEALTH, V46, P379, DOI 10.1080/15287399509532043; Yamamoto S, 1997, BRIT J CANCER, V76, P1221, DOI 10.1038/bjc.1997.537; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541	65	100	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48066	48076		10.1074/jbc.M106282200	http://dx.doi.org/10.1074/jbc.M106282200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11641398	hybrid			2022-12-25	WOS:000172927000046
J	Joseph, TD; Look, DC				Joseph, TD; Look, DC			Specific inhibition of interferon signal transduction pathways by adenoviral infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-GAMMA RECEPTOR; INTERCELLULAR-ADHESION MOLECULE-1; EPITHELIAL-CELLS; IN-VIVO; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTORS; TARGETED DISRUPTION; ICAM-1 EXPRESSION; GENE-EXPRESSION; IMMUNE EVASION	Adenoviral evolution has generated strategies to resist host cell antiviral systems, but molecular mechanisms for evasion of interferon (IFN) effects by adenoviruses during late-phase infection are poorly defined. In this study, we examined adenovirus type 5 (AdV) effects on IFN-gamma -dependent gene expression and Janus family kinase-signal transducer and activator of transcription signaling components in human tracheobronchial epithelial cells. We found that AdV infection specifically inhibited. IFN-gamma -dependent gene expression in airway epithelial cells without evidence of epithelial cell injury or generation of a soluble extracellular inhibitor. Furthermore, infection with AdV for 18-24 h blocked phosphorylation/activation of the Stat1 transcription factor that regulates IFN-gamma -dependent genes. Although AdV also inhibited IFN-alpha -dependent phosphorylation of Stat1 and Stat2, interleukin-4-dependent phosphorylation of the related transcription factor Stat6 was not affected, indicating that the virus selectively affected specific signaling pathways. Our results indicate that AdV inhibition of the IFN-gamma signal transduction cascade occurs through loss of ligand-induced receptor complex assembly and consequent component phosphorylation and suggest that lack of complex assembly is due to decreased expression of the IFN-gamma R2 chain of the IFN-gamma receptor. rFN-gamma R2 is required at an early step in Janus family kinase-signal transducer and activator of transcription pathway activation and is expressed at low levels in airway epithelial cells, supporting the concept that adenoviral down-regulation of the level of this IFN-gamma receptor component allows for persistent modulation of IFN-y-dependent gene expression.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Look, DC (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, C33-GH,200 Hawkins Dr, Iowa City, IA 52242 USA.							Abendroth A, 2000, J VIROL, V74, P1900, DOI 10.1128/JVI.74.4.1900-1907.2000; ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; BACH EA, 1995, SCIENCE, V270, P1215, DOI 10.1126/science.270.5239.1215; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bach EA, 1996, MOL CELL BIOL, V16, P3214; Blanchette J, 1999, EUR J IMMUNOL, V29, P3737, DOI 10.1002/(SICI)1521-4141(199911)29:11&lt;3737::AID-IMMU3737&gt;3.0.CO;2-S; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Doffinger R, 2000, J INFECT DIS, V181, P379, DOI 10.1086/315197; Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Frick AG, 2000, J IMMUNOL, V164, P4185, DOI 10.4049/jimmunol.164.8.4185; Fujii N, 1999, VIRUS RES, V65, P175, DOI 10.1016/S0168-1702(99)00114-8; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; Geginat G, 1997, J IMMUNOL, V158, P3303; GINSBERG HS, 1994, INFECT AGENT DIS, V3, P1; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; GIRDLESTONE J, 1993, P NATL ACAD SCI USA, V90, P11568, DOI 10.1073/pnas.90.24.11568; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Guerette B, 1997, J LEUKOCYTE BIOL, V61, P533, DOI 10.1002/jlb.61.4.533; Hogg JC, 1999, AM J RESP CRIT CARE, V160, pS26, DOI 10.1164/ajrccm.160.5.8; HOLTZMAN MJ, 1995, AM J RESP CELL MOL, V12, P127, DOI 10.1165/ajrcmb.12.2.7865211; Holtzman MJ, 1998, P ASSOC AM PHYSICIAN, V110, P1; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; Hussain S, 1999, J IMMUNOL, V163, P2041; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KIERSZENBAUM F, 1995, PARASITE IMMUNOL, V17, P207, DOI 10.1111/j.1365-3024.1995.tb00890.x; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; Leonard GT, 1996, VIROLOGY, V224, P25, DOI 10.1006/viro.1996.0503; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Look DC, 1999, AM J RESP CELL MOL, V20, P1103, DOI 10.1165/ajrcmb.20.6.f150; LOOK DC, 1992, AM J PHYSIOL, V263, pL79, DOI 10.1152/ajplung.1992.263.1.L79; LOOK DC, 1994, J BIOL CHEM, V269, P8952; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; MACEK V, 1994, AM J RESP CRIT CARE, V150, P7, DOI 10.1164/ajrccm.150.1.8025775; Mahr JA, 1999, IMMUNOL REV, V168, P121, DOI 10.1111/j.1600-065X.1999.tb01287.x; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Miller DM, 1998, J EXP MED, V187, P675, DOI 10.1084/jem.187.5.675; Min W, 1996, J IMMUNOL, V156, P3174; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nicolis E, 1998, GENE THER, V5, P131, DOI 10.1038/sj.gt.3300558; Novelli F, 1996, J IMMUNOL, V157, P1935; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Ray M, 2000, J INFECT DIS, V181, P1121, DOI 10.1086/315330; Rieger D, 1997, ANAL BIOCHEM, V246, P67, DOI 10.1006/abio.1996.9978; Rodel J, 1998, INFECT IMMUN, V66, P4491; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; Ting LM, 1999, J IMMUNOL, V163, P3898; Walter MJ, 1997, J BIOL CHEM, V272, P28582, DOI 10.1074/jbc.272.45.28582; Wold William S. M., 1994, Trends in Microbiology, V2, P437, DOI 10.1016/0966-842X(94)90801-X; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1995, P NATL ACAD SCI USA, V92, P7257, DOI 10.1073/pnas.92.16.7257; Zar JH., 1999, BIOSTAT ANAL	67	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47136	47142		10.1074/jbc.M102030200	http://dx.doi.org/10.1074/jbc.M102030200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11668174	hybrid			2022-12-25	WOS:000172768500063
J	Villalobos, C; Nunez, L; Chamero, P; Alonso, MT; Garcia-Sancho, J				Villalobos, C; Nunez, L; Chamero, P; Alonso, MT; Garcia-Sancho, J			Mitochondrial [Ca2+] oscillations driven by local high [Ca2+] domains generated by spontaneous electric activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; PITUITARY-CELLS; ENDOPLASMIC-RETICULUM; CALCIUM OSCILLATIONS; CYTOSOLIC CA2+; AEQUORIN; MICRODOMAINS; RELEASE; TOOLS	Mitochondria take up calcium during cell activation thus shaping Ca2+ signaling and exocytosis. In turn, Ca2+ uptake by mitochondria increases respiration and ATP synthesis. Targeted aequorins are excellent Ca2+ probes for subcellular analysis, but single-cell imaging has proven difficult. Here we combine virus-based expression of targeted aequorins with photon-counting imaging to resolve dynamics of the cytosolic, mitochondrial, and nuclear Ca2+ signals at the single-cell level in anterior pituitary cells. These cells exhibit spontaneous electric activity and cytosolic Ca2+ oscillations that are responsible for basal secretion of pituitary hormones and are modulated by hypophysiotrophic factors. Aequorin reported spontaneous [Ca2+] oscillations in all the three compartments, bulk cytosol, nucleus, and mitochondria. Interestingly, a fraction of mitochondria underwent much larger [Ca2+] oscillations, which were driven by local high [Ca2+] domains generated by the spontaneous electric activity. These oscillations were large enough to stimulate respiration, providing the basis for local tune-up of mitochondrial function by the Ca2+ signal.	Univ Valladolid, Fac Med, Dept Fisiol, Inst Biol & Genet Mol, E-47005 Valladolid, Spain; CSIC, Fac Med, Dept Bioquim & Fisiol, E-47005 Valladolid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Consejo Superior de Investigaciones Cientificas (CSIC)	Garcia-Sancho, J (corresponding author), Univ Valladolid, Fac Med, Dept Fisiol, Inst Biol & Genet Mol, E-47005 Valladolid, Spain.	jgsancho@ibgm.uva.es	Villalobos, Carlos/M-9839-2017; nunez, lucia/AAG-8018-2019; Alonso Alonso, Maria Teresa/K-5003-2014; Garcia-Sancho, Javier/K-2975-2014	Villalobos, Carlos/0000-0002-0429-3846; Chamero, Pablo/0000-0002-4305-1073; Nunez, Lucia/0000-0002-9638-5747; Garcia-Sancho, Javier/0000-0003-4573-7930				Alonso MT, 1998, CELL CALCIUM, V24, P87, DOI 10.1016/S0143-4160(98)90076-8; Alonso MT, 1999, J CELL BIOL, V144, P241, DOI 10.1083/jcb.144.2.241; Alvarez J, 1999, NEWS PHYSIOL SCI, V14, P161; Alvarez Javier, 2001, P147; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; FRAWLEY LS, 1994, ENDOCRINOLOGY, V135, P468, DOI 10.1210/en.135.1.468; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hajnoczky G, 2000, J PHYSIOL-LONDON, V529, P69, DOI 10.1111/j.1469-7793.2000.00069.x; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Kaftan EJ, 2000, J BIOL CHEM, V275, P25465, DOI 10.1074/jbc.M000903200; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; Maechler P, 2000, J PHYSIOL-LONDON, V529, P49, DOI 10.1111/j.1469-7793.2000.00049.x; Mollard P, 1996, TRENDS ENDOCRIN MET, V7, P361, DOI 10.1016/S1043-2760(96)00186-5; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; PRALONG WF, 1992, P NATL ACAD SCI USA, V89, P132, DOI 10.1073/pnas.89.1.132; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; Villalobos C, 1996, PFLUG ARCH EUR J PHY, V431, P371, DOI 10.1007/BF02207274; Villalobos C, 1996, FASEB J, V10, P654, DOI 10.1096/fasebj.10.5.8621065; WINIGER BP, 1988, BIOCHEM J, V255, P161, DOI 10.1042/bj2550161	31	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40293	40297		10.1074/jbc.C100465200	http://dx.doi.org/10.1074/jbc.C100465200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11668185	Green Published, hybrid			2022-12-25	WOS:000171789200105
J	Noda, T; Iwakiri, R; Fujimoto, K; Aw, TY				Noda, T; Iwakiri, R; Fujimoto, K; Aw, TY			Induction of mild intracellular redox imbalance inhibits proliferation of CaCo-2 cells	FASEB JOURNAL			English	Article						cellular redox; GSH : GSSG ratio; cell cycle arrest; intestinal cell turnover; EGF	OXIDATIVE STRESS; GLUTATHIONE SYNTHESIS; GROWTH-FACTOR; ORNITHINE DECARBOXYLASE; BUTHIONINE SULFOXIMINE; CELLULAR PROLIFERATION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; GENE-EXPRESSION; DNA-SYNTHESIS	Intracellular redox status plays a critical role in cell function, such as proliferation. Oxidative stress, which elicits redox imbalance, also affects cell growth. Therefore, it is often difficult to distinguish the effects of redox imbalance from those of oxidative stress. The objective of this study was to determine the role of redox imbalance independent of reactive oxygen species (ROS) production, in proliferation of human colonic CaCo-2 cells. Low concentrations of diamide plus 1,3-bis(2 chloroethyl)-1-nitrosourea (BCNU) increased intracellular GSSG and decreased GSH and the GSH: GSSG ratio. These changes occurred within 30 min, which preceded a decrease in thymidine incorporation at 6 and 24 h. ROS formation was not detected under these conditions. This suppression of cell proliferative activity was attenuated by N-acetyl cysteine, in parallel with restoration of the intracellular GSH redox status. DL-buthionine-[S, R]-sulfoximine (BSO) decreased intracellular GSH level, but did not change the GSH: GSSG ratio. BSO alone had no effect on cell proliferation, but its presence exaggerated the suppressive effect of diamide plus BCNU. Flow cytometric analysis showed that cells were arrested at G(1)-to-S transition and G(2)/M phase. Collectively, this study shows that mild intracellular redox imbalance inhibited cell proliferation independent of ROS generation. Moreover, cells with compromised cellular GSH were susceptible to redox imbalance-induced inhibition of proliferation.	Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA; Saga Med Sch, Dept Internal Med, Saga, Japan	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Saga University	Aw, TY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, 1501 Kings Highway, Shreveport, LA 71130 USA.	taw@lsuhsc.edu			NIDDK NIH HHS [R01 DK044510, DK 44510, R01 DK044510-08] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044510] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; Aw TY, 1999, AM J CLIN NUTR, V70, P557; BILL CA, 1988, CANCER RES, V48, P3389; BISHOP WP, 1995, GASTROENTEROLOGY, V109, P1882, DOI 10.1016/0016-5085(95)90755-6; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Brigellius R., 1985, OXIDATIVE STRESS, P243; BURDON RH, 1994, FREE RADICAL RES, V21, P121, DOI 10.3109/10715769409056564; Chang WK, 1999, CLIN EXP IMMUNOL, V117, P482, DOI 10.1046/j.1365-2249.1999.01009.x; CLARK S, 1993, BIOCHEM J, V292, P17; COSTA LG, 1986, BIOCHEM PHARMACOL, V35, P3383, DOI 10.1016/0006-2952(86)90439-9; DAGOSTINO L, 1989, GASTROENTEROLOGY, V97, P888, DOI 10.1016/0016-5085(89)91493-5; Davis MA, 2000, TOXICOL SCI, V53, P48, DOI 10.1093/toxsci/53.1.48; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Engler JA, 1999, DIGEST DIS SCI, V44, P1902, DOI 10.1023/A:1018815327769; Esposito F, 2000, FEBS LETT, V470, P211, DOI 10.1016/S0014-5793(00)01318-1; Flattery-O'Brien JA, 1998, J BIOL CHEM, V273, P8564, DOI 10.1074/jbc.273.15.8564; FRISCHER H, 1977, J LAB CLIN MED, V89, P1080; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GRIMM LM, 1985, BIOCHIM BIOPHYS ACTA, V844, P50, DOI 10.1016/0167-4889(85)90232-0; Hutter DE, 1997, EXP CELL RES, V232, P435, DOI 10.1006/excr.1997.3527; Iantomasi T, 1999, BBA-MOL CELL RES, V1452, P303, DOI 10.1016/S0167-4889(99)00142-1; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; Jonas CR, 1999, J NUTR, V129, P1278, DOI 10.1093/jn/129.7.1278; KANG YJ, 1994, J CELL PHYSIOL, V161, P589, DOI 10.1002/jcp.1041610323; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MOLDEUS P, 1994, METHOD ENZYMOL, V234, P482; NOELLE RJ, 1981, BIOCHEM J, V198, P571, DOI 10.1042/bj1980571; Obrador E, 1997, BIOCHEM J, V325, P183, DOI 10.1042/bj3250183; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; SHAW JP, 1986, J CELL PHYSIOL, V129, P193, DOI 10.1002/jcp.1041290210; Smith J, 2000, P NATL ACAD SCI USA, V97, P10032, DOI 10.1073/pnas.170209797; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TABATA K, 1986, AM J PHYSIOL, V251, pG370, DOI 10.1152/ajpgi.1986.251.3.G370; TERRADEZ P, 1993, BIOCHEM J, V292, P477, DOI 10.1042/bj2920477; Voehringer DW, 1999, FREE RADICAL BIO MED, V27, P945, DOI 10.1016/S0891-5849(99)00174-4; Wang TG, 2000, FASEB J, V14, P1567, DOI 10.1096/fj.14.11.1567; WHITE AC, 1992, AM J RESP CELL MOL, V6, P364, DOI 10.1165/ajrcmb/6.4.364	44	82	84	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2131	2139		10.1096/fj.01-0131com	http://dx.doi.org/10.1096/fj.01-0131com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641239				2022-12-25	WOS:000171920400024
J	Cherepanov, AV; de Vries, S				Cherepanov, AV; de Vries, S			Kinetic mechanism of the Mg2+-dependent nucleotidyl transfer catalyzed by T4 DNA and RNA ligases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DINUCLEOSIDE POLYPHOSPHATES; ADENYLATE INTERMEDIATE; ADENOSINE-TRIPHOSPHATE; POLYNUCLEOTIDE LIGASE; DEOXYRIBONUCLEIC-ACID; ENZYMATIC BREAKAGE; ATP; COMPLEX; MAGNESIUM	The Mg2+-dependent adenylylation of the T4 DNA and RNA ligases was studied in the absence of a DNA substrate using transient optical absorbance and fluorescence spectroscopy. The concentrations of Mg2+, ATP, and pyrophosphate were systematically varied, and the results led to the conclusion that the nucleotidyl transfer proceeds according to a two-metal ion mechanism. According to this mechanism, only the di-magnesium-coordinated form Mg(2)ATP(0) reacts with the enzyme forming the covalent complex E-AMP. The reverse reaction (ATP synthesis) occurs between the mono-magnesium-coordinated pyrophosphate form MgP2O72- and the enzyme(.)MgAMP complex. The nucleotide binding rate decreases in the sequence ATP(4-) > MgATP(2-) > Mg(2)ATP(0), indicating that the formation of the non-covalent enzyme-nucleotide complex is driven by electrostatic interactions. T4 DNA ligase shows notably higher rates of ATP binding and of subsequent adenylylation compared with RNA ligase, in part because it decreases the K-d of Mg2+ for the enzyme-bound Mg(2)ATP(0) more than 10-fold. To elucidate the role of Mg2+ in the nucleotidyl transfer catalyzed by T4 DNA and RNA ligases, we propose a transition state configuration, in which the catalytic Mg2+ ion coordinates to both reacting nucleophiles: the lysyl moiety of the enzyme that forms the phosphoramidate bond and the alpha-beta-bridging oxygen of ATP.	Delft Univ Technol, Kluyver Dept Biotechnol, NL-2628 BC Delft, Netherlands	Delft University of Technology	de Vries, S (corresponding author), Delft Univ Technol, Kluyver Dept Biotechnol, Julianalaan 67, NL-2628 BC Delft, Netherlands.	S.deVries@tnw.tudelft.nl						Arabshahi A, 1999, J BIOL CHEM, V274, P8586, DOI 10.1074/jbc.274.13.8586; Atencia EA, 1999, EUR J BIOCHEM, V261, P802, DOI 10.1046/j.1432-1327.1999.00338.x; Atencia EA, 2000, EUR J BIOCHEM, V267, P1707, DOI 10.1046/j.1432-1327.2000.01165.x; Boyer P.D., 1982, ENZYMES, P31; Cherepanov AV, 2001, BIOPHYS J, V81, P3545, DOI 10.1016/S0006-3495(01)75985-1; COLE FX, 1970, BIOCHEMISTRY-US, V9, P3143, DOI 10.1021/bi00818a005; Conyers GB, 2000, BIOCHEMISTRY-US, V39, P2347, DOI 10.1021/bi992458n; Cowan JA., 1995, BIOL CHEM MAGNESIUM; CRANSTON JW, 1974, J BIOL CHEM, V249, P7447; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Doherty AJ, 1996, J BIOL CHEM, V271, P11083, DOI 10.1074/jbc.271.19.11083; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; ELDER RH, 1992, EUR J BIOCHEM, V203, P53, DOI 10.1111/j.1432-1033.1992.tb19826.x; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FISCHER BE, 1979, EUR J BIOCHEM, V94, P523, DOI 10.1111/j.1432-1033.1979.tb12921.x; FREY CM, 1972, J AM CHEM SOC, V94, P9198, DOI 10.1021/ja00781a035; GUMPORT RI, 1971, P NATL ACAD SCI USA, V68, P2559, DOI 10.1073/pnas.68.10.2559; Hakansson K, 1998, P NATL ACAD SCI USA, V95, P1505, DOI 10.1073/pnas.95.4.1505; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Heikinheimo P, 2001, P NATL ACAD SCI USA, V98, P3121, DOI 10.1073/pnas.061612498; HUANG SL, 1982, BIOCHEMISTRY-US, V21, P951, DOI 10.1021/bi00534a021; Iuodka B A, 1979, Biokhimiia, V44, P599; Iuodka B A, 1991, Biokhimiia, V56, P798; Kack H, 1998, P NATL ACAD SCI USA, V95, P5495, DOI 10.1073/pnas.95.10.5495; KAIM W, 1994, BIOINORGANIC CHEM IN, P286; Larsen TM, 1998, BIOCHEMISTRY-US, V37, P6247, DOI 10.1021/bi980243s; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; LEHMAN IR, 1974, SCIENCE, V186, P790; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; Madrid O, 1998, FEBS LETT, V433, P283, DOI 10.1016/S0014-5793(98)00932-6; Matsuda S, 1996, EUR J BIOCHEM, V237, P691, DOI 10.1111/j.1432-1033.1996.0691p.x; MILDVAN AS, 1987, MAGNESIUM, V6, P28; MOE OA, 1972, J BIOL CHEM, V247, P7308; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PORSCHKE D, 1985, BIOPHYS CHEM, V22, P237, DOI 10.1016/0301-4622(85)80046-6; RAAE AJ, 1975, EUR J BIOCHEM, V60, P437, DOI 10.1111/j.1432-1033.1975.tb21021.x; RAMIREZ F, 1974, TETRAHEDRON, V30, P371, DOI 10.1016/S0040-4020(01)97009-7; Rossi R, 1997, NUCLEIC ACIDS RES, V25, P2106, DOI 10.1093/nar/25.11.2106; SIGEL H, 1990, COORDIN CHEM REV, V100, P453, DOI 10.1016/0010-8545(90)85018-N; Sillero A, 2000, PHARMACOL THERAPEUT, V87, P91, DOI 10.1016/S0163-7258(00)00047-4; Smith D. J. H., 1979, COMPREHENSIVE ORGANI, V2, P1233; Smith R. M., 1989, CRITICAL STABILITY C, V6; Sriskanda V, 1999, NUCLEIC ACIDS RES, V27, P3953, DOI 10.1093/nar/27.20.3953; Sriskanda V, 2000, NUCLEIC ACIDS RES, V28, P2221, DOI 10.1093/nar/28.11.2221; Sriskanda V, 2001, J BIOL CHEM, V276, P36100, DOI 10.1074/jbc.M105643200; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Timson DJ, 2000, MUTAT RES-DNA REPAIR, V460, P301, DOI 10.1016/S0921-8777(00)00033-1; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Verri A, 1999, BIOCHEM J, V337, P585, DOI 10.1042/0264-6021:3370585; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; WEISS B, 1968, J BIOL CHEM, V243, P4543; WEISS B, 1968, J BIOL CHEM, V243, P4556; ZAGREBEL'NYI S N, 1984, Molekulyarnaya Biologiya (Moscow), V18, P227; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	57	31	33	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1695	1704		10.1074/jbc.M109616200	http://dx.doi.org/10.1074/jbc.M109616200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11687591	hybrid			2022-12-25	WOS:000173421300012
J	Petit, F; Arnoult, D; Lelievre, JD; Moutouh-de Parseval, L; Hance, AJ; Schneider, P; Corbeil, J; Ameisen, JC; Estaquier, J				Petit, F; Arnoult, D; Lelievre, JD; Moutouh-de Parseval, L; Hance, AJ; Schneider, P; Corbeil, J; Ameisen, JC; Estaquier, J			Productive HIV-1 infection of primary CD4+T cells induces mitochondrial membrane permeabilization leading to a caspase-independent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD4(+) T-CELLS; CYTOCHROME-C RELEASE; INDUCED APOPTOSIS; IMMUNE ACTIVATION; SIGNALING COMPLEX; LYMPH-NODES; FAS LIGAND; WILD-TYPE; VIRUS; PROTEASE	We have explored in vitro the mechanism by which human immunodeficiency virus, type 1 (HIV-1) induces cell death of primary CD4+ T cells in conditions of productive infection. Although HIV-1 infection primed phytohemagglutinin-activated CD4+ T cells for death induced by anti-CD95 antibody, T cell death was not prevented by a CD95-Fc decoy receptor, nor by decoy receptors of other members of the TNFR family (TNFR1/R2, TRAILR1/R2/OPG, TRAMP) or by various blocking antibodies, suggesting that triggering of death receptors by their cognate ligands is not involved in HIV-induced CD4+ T cell death. HIV-1 induced CD4+ T cell shrinkage, cell surface exposure of phosphatidylserine, loss of mitochondrial membrane potential (Deltapsim), and mitochondrial release of cytochrome c and apoptosis-inducing factor. A typical apoptotic phenotype (nuclear chromatin condensation and fragmentation) only occurred in around half of the dying cells. Treatment with benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone, a broad spectrum caspase inhibitor, prevented nuclear chromatin condensation and fragmentation in HIV-infected CD4+ T cells and in a cell-free system (in which nuclei were incubated with cytoplasmic extracts from the HIV-infected CD4+ T cells). Nevertheless, benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone did not prevent mitochondrial membrane potential loss and cell death, suggesting that caspases are dispensable for HIV-mediated cell death. Our findings suggest a major role of the mitochondria in the process of CD4+ T cell death induced by HIV, in which targeting of Bax to the mitochondria may be involved.	Univ Paris 07, INSERM EMI U9922, CHU Bichat, F-75018 Paris, France; INSERM, IMEA, U552, F-75018 Paris, France; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Diego; University of California System; University of California San Diego; University of Lausanne	Estaquier, J (corresponding author), Univ Paris 07, INSERM EMI U9922, 16 Rue Henri Huchard, F-75018 Paris, France.		Corbeil, Jacques/AAW-9739-2020; Arnoult, Damien/R-2032-2018; , ESTAQUIER/AAR-7799-2020; , Lelievre/AAB-1398-2020	Corbeil, Jacques/0000-0002-9973-2740; , ESTAQUIER/0000-0002-9432-8044; Schneider, Pascal/0000-0003-0677-9409; Lelievre, Jean-Daniel/0000-0002-8182-3628	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029164, R37AI029164, U01AI038858, U01AI027670, P30AI036214] Funding Source: NIH RePORTER; NIAID NIH HHS [5 P30 AI 36214, AI 29164, AI 36214, AI 38858, AI 27670] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Baumler CB, 1996, BLOOD, V88, P1741; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; Bossi G, 1999, NAT MED, V5, P90, DOI 10.1038/4779; Buzyn A, 1999, BLOOD, V94, P3135, DOI 10.1182/blood.V94.9.3135.421k37_3135_3140; Chinnaiyan AM, 1997, NAT MED, V3, P333, DOI 10.1038/nm0397-333; Conti L, 1998, J EXP MED, V187, P403, DOI 10.1084/jem.187.3.403; Corbeil J, 1996, J EXP MED, V183, P39, DOI 10.1084/jem.183.1.39; CORBEIL J, 1995, J GEN VIROL, V76, P681, DOI 10.1099/0022-1317-76-3-681; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dumont C, 2000, BLOOD, V96, P1030, DOI 10.1182/blood.V96.3.1030.015k21_1030_1038; ESTAQUIER J, 1994, P NATL ACAD SCI USA, V91, P9431, DOI 10.1073/pnas.91.20.9431; ESTAQUIER J, 1995, J EXP MED, V182, P1759, DOI 10.1084/jem.182.6.1759; Estaquier J, 1996, BLOOD, V87, P4959, DOI 10.1182/blood.V87.12.4959.bloodjournal87124959; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gandhi RT, 1998, J EXP MED, V187, P1113, DOI 10.1084/jem.187.7.1113; Genini D, 2001, FASEB J, V15, P5; Glynn JM, 1996, J IMMUNOL, V157, P2754; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P553, DOI 10.1089/aid.1993.9.553; Gougeon ML, 1997, J IMMUNOL, V158, P2964; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Holler N, 2000, J IMMUNOL METHODS, V237, P159, DOI 10.1016/S0022-1759(99)00239-2; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KATSIKIS PD, 1995, J EXP MED, V181, P2029, DOI 10.1084/jem.181.6.2029; Katsikis PD, 1997, J EXP MED, V186, P1365, DOI 10.1084/jem.186.8.1365; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAURENTCRAWFORD AG, 1995, RES VIROLOGY, V146, P5, DOI 10.1016/0923-2516(96)80585-1; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LAURENTCRAWFORD AG, 1993, AIDS RES HUM RETROV, V9, P761, DOI 10.1089/aid.1993.9.761; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LEWIS DE, 1994, J IMMUNOL, V153, P412; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Macreadie IG, 1997, FEBS LETT, V410, P145, DOI 10.1016/S0014-5793(97)00542-5; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Moutouh L, 1998, J VIROL, V72, P8061, DOI 10.1128/JVI.72.10.8061-8072.1998; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OYAIZU N, 1993, BLOOD, V82, P3392; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Piller SC, 1998, P NATL ACAD SCI USA, V95, P4595, DOI 10.1073/pnas.95.8.4595; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rapaport E, 1998, VIROLOGY, V252, P407, DOI 10.1006/viro.1998.9459; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rennert P, 2000, J EXP MED, V192, P1677, DOI 10.1084/jem.192.11.1677; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 2000, METHOD ENZYMOL, V322, P325; Sloand EM, 1997, BLOOD, V89, P1357, DOI 10.1182/blood.V89.4.1357; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571; SU L, 1995, IMMUNITY, V2, P25, DOI 10.1016/1074-7613(95)90076-4; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VEREAMMEN D, 1998, J EXP MED, V188, P919; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yao XJ, 1998, J VIROL, V72, P4686, DOI 10.1128/JVI.72.6.4686-4693.1998; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Zhou GY, 2000, J VIROL, V74, P9048, DOI 10.1128/JVI.74.19.9048-9053.2000	80	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1477	1487		10.1074/jbc.M102671200	http://dx.doi.org/10.1074/jbc.M102671200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11689551	Green Published, hybrid			2022-12-25	WOS:000173166800079
J	Zhang, T; Johnson, EN; Gu, YS; Morissette, MR; Sah, VP; Gigena, MS; Belke, DD; Dillmann, WH; Rogers, TB; Schulman, H; Ross, J; Brown, JH				Zhang, T; Johnson, EN; Gu, YS; Morissette, MR; Sah, VP; Gigena, MS; Belke, DD; Dillmann, WH; Rogers, TB; Schulman, H; Ross, J; Brown, JH			The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; SARCOPLASMIC-RETICULUM; CAM KINASE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CALMODULIN; PHOSPHORYLATION; TRANSCRIPTION; PHOSPHOLAMBAN; ACTIVATION	The delta isoform of Ca2+/calmodulin-dependent protein kinase H (CaMKII) predominates in the heart. To investigate the role of CaMKII in cardiac function, we made transgenic (TG) mice that express the nuclear delta(B) isoform of CaMKII The expressed CaMKIIdelta(B) transgene was restricted to the myocardium and highly concentrated in the nucleus. Cardiac hypertrophy was evidenced by an increased left ventricle to body weight ratio and up-regulation of embryonic and contractile protein genes including atrial natriuretic factor, beta-myosin heavy chain, and a-skeletal actin. Echocardiography revealed ventricular dilation and decreased cardiac function, which was also observed in hemodynamic measurements from CaMKIIdelta(B) TG mice. Surprisingly, phosphorylation of phospholamban at both Thr(17) and Ser(16) was significantly decreased in the basal state as well as upon adrenergic stimulation. This was associated with diminished sarcoplasmic reticulum Ca2+ uptake in vitro and altered relaxation properties in vivo. The activity and expression of protein phosphatase 2A were both found to be increased in CaMKII TG mice, and immunoprecipitation studies indicated that protein phosphatase 2A directly associates with CaMKII. Our findings are the first to demonstrate that CaMRII can induce hypertrophy and dilation in vivo and indicate that compensatory increases in phosphatase activity contribute to the resultant phenotype.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Stanford Univ, Dept Neurobiol, Sch Med, Stanford, CA 94305 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Maryland; University of Maryland Baltimore; Stanford University	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jhbrown@ucsd.edu	gu, yu/GSD-4507-2022		NHLBI NIH HHS [HL-46345, HL-28143] Funding Source: Medline; NIA NIH HHS [AG-14637] Funding Source: Medline; NIGMS NIH HHS [GM-40600] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028143, P01HL046345, R37HL028143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014637] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams JW, 1998, CIRC RES, V83, P167, DOI 10.1161/01.RES.83.2.167; ANDERSON ME, 1994, CIRC RES, V75, P854, DOI 10.1161/01.RES.75.5.854; BALTAS LG, 1995, FEBS LETT, V373, P71, DOI 10.1016/0014-5793(95)00981-E; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Brewis N, 2000, AM J PHYSIOL-HEART C, V279, pH1307, DOI 10.1152/ajpheart.2000.279.3.H1307; Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1; Colomer JM, 2000, MOL ENDOCRINOL, V14, P1125, DOI 10.1210/me.14.8.1125; DUBELL WH, 2001, AM J PHYSIOL, V282, pH38; EDMAN CF, 1994, BBA-MOL CELL RES, V1221, P89, DOI 10.1016/0167-4889(94)90221-6; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; Hajjar RJ, 1998, J MOL MED-JMM, V76, P747, DOI 10.1007/s001090050276; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; Harjai KJ, 1999, ANN INTERN MED, V131, P376, DOI 10.7326/0003-4819-131-5-199909070-00009; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Huang BY, 1999, CIRC RES, V85, P848, DOI 10.1161/01.RES.85.9.848; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; Karczewski P, 1997, BASIC RES CARDIOL, V92, P37, DOI 10.1007/BF00794066; Katz A M, 1998, J Card Fail, V4, P67, DOI 10.1016/S1071-9164(98)90509-7; LINDEMANN JP, 1985, J BIOL CHEM, V260, P4516; MACDOUGALL LK, 1991, EUR J BIOCHEM, V196, P725, DOI 10.1111/j.1432-1033.1991.tb15871.x; Mascareno E, 1998, P NATL ACAD SCI USA, V95, P5590, DOI 10.1073/pnas.95.10.5590; MAYER P, 1995, BASIC RES CARDIOL, V90, P372, DOI 10.1007/BF00788498; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MIYANO O, 1992, J BIOL CHEM, V267, P1198; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Neumann J, 1999, J PHARMACOL EXP THER, V289, P188; Olson EN, 1999, CIRC RES, V84, P623, DOI 10.1161/01.RES.84.6.623; PAGANI ED, 1984, METHOD PHARMACOL, V5, P49; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Sah VP, 1999, J CLIN INVEST, V103, P1627, DOI 10.1172/JCI6842; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SOLEM M, 1995, J NEUROSCI, V15, P5966; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; STEENAART NAE, 1992, ARCH BIOCHEM BIOPHYS, V293, P17, DOI 10.1016/0003-9861(92)90359-5; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Szymanska G, 1999, PFLUG ARCH EUR J PHY, V439, P1, DOI 10.1007/s004240051121; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; XU A, 1993, J BIOL CHEM, V268, P8394; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429; Zhu WD, 2000, J BIOL CHEM, V275, P15239, DOI 10.1074/jbc.275.20.15239	45	197	206	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1261	1267		10.1074/jbc.M108525200	http://dx.doi.org/10.1074/jbc.M108525200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694533	hybrid			2022-12-25	WOS:000173166800052
J	Hausmann, S; Vivares, CP; Shuman, S				Hausmann, S; Vivares, CP; Shuman, S			Characterization of the mRNA capping apparatus of the microsporidian parasite Encephalitozoon cuniculi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP METHYLTRANSFERASE; GUANYLYLTRANSFERASE COMPONENT; SCHIZOSACCHAROMYCES-POMBE; TRIPHOSPHATASE COMPONENT; MUTATIONAL ANALYSIS; IN-VIVO; YEAST; POLYMERASE; MECHANISM; ENZYMES	A scheme of eukaryotic phylogeny has been suggested based on the structure and physical linkage of the enzymes that catalyze mRNA cap formation. Here we show that the intracellular parasite Encephatitozoon cuniculi encodes a complete mRNA capping apparatus consisting of separate triphosphatase (EcCet1), guanylyltransferase (EcCeg1), and methyltransferase (Ecm1) enzymes, which we characterize biochemically and genetically. The triphosphatase EcCetl belongs to a metal-dependent phosphohydrolase family that includes the triphosphatase components of the capping apparatus of fungi, DNA viruses, and the malaria parasite Plasmodium falciparum. These enzymes are structurally and mechanistically unrelated to the metal-independent cysteine phosphatase-type RNA tri-phosphatases found in metazoans and plants. Our findings support the proposed evolutionary connection between microsporidia and fungi, and they place fungi and protozoa in a common lineage distinct from that of metazoans and plants. RNA triphosphatase presents an attractive target for antiprotozoal/antifungal drug development.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Univ Clermont Ferrand, F-63177 Clermont Ferrand, France	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bisaillon M, 2001, J BIOL CHEM, V276, P17261, DOI 10.1074/jbc.M100980200; Bujnicki JM, 2001, BMC BIOINFORMATICS, V2, DOI 10.1186/1471-2105-2-2; Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Douglas S, 2001, NATURE, V410, P1091, DOI 10.1038/35074092; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Hausmann S, 2001, J BIOL CHEM, V276, P36116, DOI 10.1074/jbc.M105856200; Hirt RP, 1999, P NATL ACAD SCI USA, V96, P580, DOI 10.1073/pnas.96.2.580; Ho CK, 2001, P NATL ACAD SCI USA, V98, P3050, DOI 10.1073/pnas.061636198; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 2001, J VIROL, V75, P1744, DOI 10.1128/JVI.75.4.1744-1750.2001; Ho CK, 2000, J VIROL, V74, P5486, DOI 10.1128/JVI.74.12.5486-5494.2000; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; Katinka MD, 2001, NATURE, V414, P450, DOI 10.1038/35106579; Lehman K, 2001, J BIOL CHEM, V276, P14996, DOI 10.1074/jbc.M100588200; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; Mao XD, 1996, MOL CELL BIOL, V16, P475; Metenier G, 2001, MICROBES INFECT, V3, P407, DOI 10.1016/S1286-4579(01)01398-3; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Pei Y, 2000, NUCLEIC ACIDS RES, V28, P1885, DOI 10.1093/nar/28.9.1885; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; Schwer B, 2001, J BIOL CHEM, V276, P1857, DOI 10.1074/jbc.M006072200; Schwer B, 2000, GENETICS, V155, P1561; Shuman S, 1997, P NATL ACAD SCI USA, V94, P12758, DOI 10.1073/pnas.94.24.12758; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; Van de Peer Y, 2000, GENE, V246, P1, DOI 10.1016/S0378-1119(00)00063-9; Vivares CP, 2001, BIOESSAYS, V23, P194, DOI 10.1002/1521-1878(200102)23:2&lt;194::AID-BIES1027&gt;3.0.CO;2-D; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683	32	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					96	103		10.1074/jbc.M109649200	http://dx.doi.org/10.1074/jbc.M109649200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11687593	hybrid			2022-12-25	WOS:000173087900014
J	Mohammad-Panah, R; Ackerley, C; Rommens, J; Choudhury, M; Wang, YC; Bear, CE				Mohammad-Panah, R; Ackerley, C; Rommens, J; Choudhury, M; Wang, YC; Bear, CE			The chloride channel ClC-4 co-localizes with cystic fibrosis transmembrane conductance regulator and may mediate chloride flux across the apical membrane of intestinal epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTS-DISEASE; DEFECTIVE REGULATION; CFTR; EXPRESSION; KIDNEY; PROTEIN; CELLS; MICE; ENDOCYTOSIS; MECHANISM	Cystic fibrosis (CF) causing mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) lead to mislocalization of CFTR protein from the brush border membrane of epithelial tissues and/or its dysfunction as a chloride channel. In initial reports, it was proposed that certain channels from the CIC family of chloride channels may provide compensatory or alternative pathways for epithelial chloride secretion in tissues from cystic fibrosis patients. In the present work, we provide the first evidence that CIC-4 protein is functionally expressed on the surface of the intestinal epithelium and hence, is appropriately localized to act as a therapeutic target in this CF-affected tissue. We show using confocal and electron microscopy that CIC-4 colocalizes with CFTR in the brush border membrane of the epithelium lining intestinal crypts in mouse and human tissues. In Caco-2 cells, a cell line thought to model human enterocytes, CIC-4 protein is expressed on the cell surface and also partially co-localizes with EEA1 and transferrin, marker molecules of early and recycling endosomes, respectively. Hence, like CFTR, CIC-4 may cycle between the plasma membrane and endosomal compartment. Furthermore, we show that CIC-4 functions as a chloride channel on the surface of these epithelial cells as antisense CIC-4 cDNA expression reduced the amplitude of endogenous chloride currents by 50%. These studies provide the first evidence that CIC-4 is endogenously expressed and may be functional in the brush border membrane of enterocytes and hence should be considered as a candidate channel to provide an alternative pathway for chloride secretion in the gastrointestinal tract of CF patients.	Hosp Sick Children, Res Inst, Program Struct Biol, Toronto, ON M5S 1G8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Bear, CE (corresponding author), Hosp Sick Children, Res Inst, Program Struct Biol, 555 Univ Ave, Toronto, ON M5S 1G8, Canada.							Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Adler DA, 1997, P NATL ACAD SCI USA, V94, P9244, DOI 10.1073/pnas.94.17.9244; Bosl MR, 2001, EMBO J, V20, P1289, DOI 10.1093/emboj/20.6.1289; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLARKE LL, 1994, P NATL ACAD SCI USA, V91, P479, DOI 10.1073/pnas.91.2.479; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Gyomorey K, 2000, AM J PHYSIOL-CELL PH, V279, pC1787, DOI 10.1152/ajpcell.2000.279.6.C1787; Gyomorey K, 2001, PFLUG ARCH EUR J PHY, V443, pS103, DOI 10.1007/s004240100654; Gyomorey K, 2000, PEDIATR RES, V48, P731; HAAGSMAN HP, 1991, BIOCHEM J, V275, P273, DOI 10.1042/bj2750273; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Lloyd SE, 1997, HUM MOL GENET, V6, P1233, DOI 10.1093/hmg/6.8.1233; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Mohammad-Panah R, 2001, J BIOL CHEM, V276, P8306, DOI 10.1074/jbc.M006764200; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; Rozmahel R, 1996, NAT GENET, V12, P280, DOI 10.1038/ng0396-280; Schwake M, 2001, J BIOL CHEM, V276, P12049, DOI 10.1074/jbc.M010642200; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Shimada K, 2000, AM J PHYSIOL-GASTR L, V279, pG268, DOI 10.1152/ajpgi.2000.279.2.G268; SOOD R, 1992, EMBO J, V11, P2487, DOI 10.1002/j.1460-2075.1992.tb05313.x; Staub O, 1997, AM J PHYSIOL-CELL PH, V272, pC1871, DOI 10.1152/ajpcell.1997.272.6.C1871; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Uchida S, 2000, AM J PHYSIOL-RENAL, V279, pF802, DOI 10.1152/ajprenal.2000.279.5.F802; Vandewalle A, 2001, AM J PHYSIOL-CELL PH, V280, pC373, DOI 10.1152/ajpcell.2001.280.2.C373; VANSLEGTENHORST MA, 1994, HUM MOL GENET, V3, P547; Waldegger S, 2000, J AM SOC NEPHROL, V11, P1331, DOI 10.1681/ASN.V1171331; Wang SS, 2000, HUM MOL GENET, V9, P2937, DOI 10.1093/hmg/9.20.2937; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wilson JM, 2000, MOL BIOL CELL, V11, P2657, DOI 10.1091/mbc.11.8.2657	42	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					566	574		10.1074/jbc.M106968200	http://dx.doi.org/10.1074/jbc.M106968200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11675385	hybrid			2022-12-25	WOS:000173087900075
J	Jankowski, A; Kim, JH; Collins, RF; Daneman, R; Walton, P; Grinstein, S				Jankowski, A; Kim, JH; Collins, RF; Daneman, R; Walton, P; Grinstein, S			In situ measurements of the pH of mammalian peroxisomes using the fluorescent protein pHluorin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROINJECTED PROTEINS; TARGETING SIGNAL; LIPID-METABOLISM; BETA-OXIDATION; RAT-LIVER; YEASTS; IMPORT; MEMBRANE; ATPASE; CELLS	Peroxisomes are metabolically active organelles that participate in the oxidation of long-chain fatty acids and in the biosynthesis of bile acids, cholesterol, and ether phospholipids. Even though maintenance of a stable acid-base milieu is essential for proper peroxisomal function, the determination of the peroxisomal pH (pHP) remains inconclusive, and little is known about its regulation. To measure the pH of intact peroxisomes in situ, we used the peroxisome-specific carboxyl-terminal targeting sequence, SKL, to deliver a pH-sensitive mutant of the green fluorescent protein (pHluorin-SKL) selectively into peroxisomes. Proper targeting was verified by colocalization with the peroxisomal marker catalase. Peroxisomes were visualized by imaging fluorescence microscopy, and ratiometric measurements were combined with calibration using ionophores or a null-point method to estimate pH(p). The pH(p) was between 6.9 and 7.1, resembling the cytosolic pH. Manipulation of the cytosolic pH in intact cells or after permeabilization of the plasmalemma with streptolysin O revealed that pHP changed in parallel, suggesting that the peroxisomal membrane is highly permeable to H+ (equivalents). We conclude that peroxisomes do not regulate their pH independently, but instead their large H+ permeability effectively connects them with the buffer reservoir of the cytoplasm and with the homeostatic mechanisms that control cytosolic pH.	Hosp Sick Children, Cell Biol Program, Inst Res, Toronto, ON M5G 1X8, Canada; Univ Western Ontario, Dept Anat & Cell Biol, London, ON N5X 2Y8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Western University (University of Western Ontario)	Grinstein, S (corresponding author), Hosp Sick Children, Cell Biol Program, Inst Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							Dansen TB, 2000, NAT CELL BIOL, V2, P51, DOI 10.1038/71375; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; DOUMA AC, 1990, YEAST, V6, P45, DOI 10.1002/yea.320060105; DOUMA AC, 1987, ARCH MICROBIOL, V147, P42, DOI 10.1007/BF00492903; EISNER DA, 1989, PFLUG ARCH EUR J PHY, V413, P553, DOI 10.1007/BF00594188; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HARRISON JE, 1983, BIOCHEM MED METAB B, V29, P149, DOI 10.1016/0006-2944(83)90035-2; HILL PE, 1995, J CELL SCI, V108, P1469; IMANAKA T, 1993, BIOCHEM BIOPH RES CO, V195, P1027, DOI 10.1006/bbrc.1993.2147; MASTERS CJ, 1995, MECH AGEING DEV, V80, P69, DOI 10.1016/0047-6374(94)01563-2; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; MUROI M, 1993, CELL STRUCT FUNCT, V18, P139, DOI 10.1247/csf.18.139; NICOLAY K, 1987, ARCH MICROBIOL, V147, P37, DOI 10.1007/BF00492902; OSUMI T, 1978, BIOCHEM BIOPH RES CO, V83, P479, DOI 10.1016/0006-291X(78)91015-X; PARISH RW, 1975, ARCH MICROBIOL, V105, P187, DOI 10.1007/BF00447136; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; SANTOS MJ, 1985, EXP CELL RES, V161, P189, DOI 10.1016/0014-4827(85)90503-8; Schapiro FB, 2000, J BIOL CHEM, V275, P21025, DOI 10.1074/jbc.M002386200; SCHULZ I, 1990, METHOD ENZYMOL, V192, P280; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANVELDHOVEN P, 1983, BIOCHEM J, V210, P685, DOI 10.1042/bj2100685; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; WALTON PA, 1992, MOL CELL BIOL, V12, P531, DOI 10.1128/MCB.12.2.531; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675; Wanders RJA, 2000, BIOCHEM SOC T, V28, P141, DOI 10.1042/bst0280141; WATERHAM HR, 1990, FEBS LETT, V262, P17, DOI 10.1016/0014-5793(90)80142-6	28	63	65	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48748	48753		10.1074/jbc.M109003200	http://dx.doi.org/10.1074/jbc.M109003200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11641408	hybrid			2022-12-25	WOS:000173922100019
J	Miyazaki, E; Sakaguchi, M; Wakabayashi, S; Shigekawa, M; Mihara, K				Miyazaki, E; Sakaguchi, M; Wakabayashi, S; Shigekawa, M; Mihara, K			NHE6 protein possesses a signal peptide destined for endoplasmic reticulum membrane and localizes in secretory organelles of the cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; NA+/H+ EXCHANGER; STRUCTURAL REQUIREMENTS; PREPROTEIN TRANSLOCASE; QUALITY-CONTROL; SEQUENCE; IDENTIFICATION; TOPOGENESIS; RECEPTOR; TOM20	The NHE6 protein is a unique Na+/H+ exchanger isoform believed to localize in mitochondria. It possesses a hydrophilic N-terminal portion that is rich in positively charged residues and many hydrophobic segments. In the present study, signal sequences in the NHE6 molecule were examined for organelle localization and membrane topogenesis. When the full-length protein was expressed in COS7 cells, it localized in the endoplasmic reticulum and on the cell surface. Furthermore, the protein was fully N-glycosylated, When green fluorescent protein was fused after the second (H2) or third (H3) hydrophobic segment, the fusion proteins were targeted to the endoplasmic reticulum (ER) membrane. The localization pattern was the same as that of fusion proteins in which green fluorescent protein was fused after H2 of NHE1 In an in vitro system, H1 behaved as a signal peptide that directs the translocation of the following polypeptide chain and is then processed off. The next hydrophobic segment (H2) halted translocation and eventually became a transmembrane segment. The N-terminal hydrophobic segment (H1) of NHE1 also behaved as a signal peptide. Cell fractionation studies using antibodies against the 15 C-terminal residues indicated that NHE6 protein localized in the microsomal membranes of rat liver cells. All of the NHE6 molecules in liver tissue possess an endoglycosidase H-resistant sugar chain. These findings indicate that NHE6 protein is targeted to the ER membrane via the N-terminal signal peptide and is sorted to organelle membranes derived from the ER membrane.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Suita, Osaka 5658565, Japan	Kyushu University; National Cerebral & Cardiovascular Center - Japan	Sakaguchi, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; BEDWELL DM, 1989, MOL CELL BIOL, V9, P1014, DOI 10.1128/MCB.9.3.1014; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; ISHIHARA N, 1995, J BIOCHEM-TOKYO, V118, P397, DOI 10.1093/oxfordjournals.jbchem.a124920; ISHIHARA S, 1990, J BIOCHEM-TOKYO, V108, P899, DOI 10.1093/oxfordjournals.jbchem.a123310; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; Kato Y, 2001, P NATL ACAD SCI USA, V98, P6488, DOI 10.1073/pnas.101556598; Kida Y, 2000, J CELL BIOL, V150, P719, DOI 10.1083/jcb.150.4.719; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; Kuroiwa T, 1996, J BIOL CHEM, V271, P6423, DOI 10.1074/jbc.271.11.6423; KUROIWA T, 1990, J BIOCHEM, V108, P829, DOI 10.1093/oxfordjournals.jbchem.a123288; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; Saeki K, 2000, J BIOL CHEM, V275, P31996, DOI 10.1074/jbc.M004794200; SAKAGUCHI M, 1992, J BIOCHEM, V112, P243, DOI 10.1093/oxfordjournals.jbchem.a123884; Sakaguchi M, 1997, CURR OPIN BIOTECH, V8, P595, DOI 10.1016/S0958-1669(97)80035-3; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; TSE CM, 1994, BIOCHEMISTRY-US, V33, P12954, DOI 10.1021/bi00248a003; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Zizak M, 2000, BIOCHEMISTRY-US, V39, P8102, DOI 10.1021/bi000870t	38	78	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49221	49227		10.1074/jbc.M106267200	http://dx.doi.org/10.1074/jbc.M106267200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11641397	hybrid			2022-12-25	WOS:000173922100079
J	Chen, YH; Layne, MD; Watanabe, M; Yet, SF; Perrella, MA				Chen, YH; Layne, MD; Watanabe, M; Yet, SF; Perrella, MA			Upstream stimulatory factors regulate aortic preferentially expressed gene-1 expression in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL CREST; PROMOTER; DIFFERENTIATION; TRANSCRIPTION; ACTIVATION; ELEMENTS; BINDING; RAT; IDENTIFICATION; PROTEIN	The phenotypic modulation of vascular smooth muscle cells (VSMC) plays a central role in the pathogenesis of arteriosclerosis. Aortic preferentially expressed gene-1 (APEG-1), a VSMC-specific gene, is expressed highly in differentiated but not in dedifferentiated VSMC. Previously, we identified an E-box element in the mouse APEG-1 proximal promoter, which is essential for VSMC reporter activity. In this study, we investigated the role of upstream stimulatory factors (USF) in the regulation of APEG-1 transcription via this E-box element. By electrophoretic mobility shift assays, recombinant USF1 and USF2 homo- and heterodimers bound specifically to the APEG-1 E-box. Nuclear extracts prepared from primary cultures of rat aortic smooth muscle cells exhibited specific USF1 and USF2 binding to the APEG-1 E-box. To investigate the binding properties of USF during VSMC differentiation, nuclear extracts were prepared from the neural crest cell line, MONC-1, which differentiates into VSMC in culture. Maximal USF1 and USF2 protein levels and binding to the APEG-1 E-box occurred 3 h after the differentiation of MONC-1 cells was initiated. Co-transfection experiments demonstrated that dominant negative USF repressed APEG-1 promoter activity, and USF1, but not USF2, transactivated the APEG-1 promoter. Our studies demonstrate that USF factors contribute to the regulation of APEG-1 expression and may influence the differentiation of VSMC.	Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Kaohsiung Med Univ, Dept Internal Med, Div Infect Dis, Kaohsiung 807, Taiwan	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Kaohsiung Medical University	Perrella, MA (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care, 75 Francis St,TH1133A, Boston, MA 02115 USA.		Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010; Chen, Yen-Hsu/D-5484-2009	Layne, Matthew/0000-0003-0007-4870; Yet, Shaw-Fang/0000-0001-9097-3962; Chen, Yen-hsu/0000-0002-8667-4844	NHLBI NIH HHS [HL-10113, HL-57977, HL-65639] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010113, R01HL065639, R01HL057977] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APONE S, 1995, J BIOL CHEM, V270, P21420, DOI 10.1074/jbc.270.36.21420; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; ATCHLEY WR, 1995, P NATL ACAD SCI USA, V92, P10217, DOI 10.1073/pnas.92.22.10217; BLANK RS, 1992, J BIOL CHEM, V267, P984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Heckert LL, 2000, MOL ENDOCRINOL, V14, P1836, DOI 10.1210/me.14.11.1836; Hsieh CM, 1999, J BIOL CHEM, V274, P14344, DOI 10.1074/jbc.274.20.14344; Hsieh CM, 1996, J BIOL CHEM, V271, P17354, DOI 10.1074/jbc.271.29.17354; Jain MK, 1998, J BIOL CHEM, V273, P5993, DOI 10.1074/jbc.273.11.5993; Johnson AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1420, DOI 10.1152/ajpcell.1999.276.6.C1420; KATOH Y, 1994, J BIOL CHEM, V269, P30538; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; Kiermaier A, 1999, ONCOGENE, V18, P7200, DOI 10.1038/sj.onc.1203166; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; Lanigan TM, 1997, J BIOL CHEM, V272, P18316, DOI 10.1074/jbc.272.29.18316; Layne MD, 1998, J BIOL CHEM, V273, P15654, DOI 10.1074/jbc.273.25.15654; Moore AW, 2000, P NATL ACAD SCI USA, V97, P10436, DOI 10.1073/pnas.170301897; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; OSBOURN JK, 1995, GENE, V154, P249, DOI 10.1016/0378-1119(94)00847-L; Owens GK, 1998, ACTA PHYSIOL SCAND, V164, P623, DOI 10.1111/j.1365-201X.1998.tb10706.x; OWENS GK, 1995, PHYSIOL REV, V75, P487; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Rao MS, 1997, J NEUROBIOL, V32, P722, DOI 10.1002/(SICI)1097-4695(19970620)32:7<722::AID-NEU7>3.0.CO;2-6; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Samoylenko A, 2001, BLOOD, V97, P2657, DOI 10.1182/blood.V97.9.2657; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; THANOS PK, 1995, J RECONSTR MICROSURG, V11, P423, DOI 10.1055/s-2007-1006556; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	31	30	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47658	47663		10.1074/jbc.M108678200	http://dx.doi.org/10.1074/jbc.M108678200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11606591	hybrid			2022-12-25	WOS:000172768500127
J	Lafarge, S; Sylvain, V; Ferrara, M; Bignon, YJ				Lafarge, S; Sylvain, V; Ferrara, M; Bignon, YJ			Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway	ONCOGENE			English	Article						BRCA1; microtubule-interfering agents; JNK; ribozyme	DNA-DAMAGE RESPONSE; CELL-CYCLE; TUMOR-SUPPRESSOR; CANCER-CELLS; SELF-CLEAVAGE; RNA; EXPRESSION; APOPTOSIS; PROTEIN; PHOSPHORYLATION	We have developed ribozymes (Rz) that inhibit BRCA1 expression in order to study the role of this gene in chemosensitivity. Two Rz, targeting positions 358 or 5282 of the BRCA1 mRNA, were cloned into the retroviral vector LXSN and lipofected into the breast cancer cell-line HBL100. We obtained 79-99% inhibition of BRCA1 expression, as determined by real-time quantitative PCR and by Western blotting. Decreased expression of BRCA1 led to sensitivity to the DNA damaging agents cisplatin and etoposide, resistance to the microtubule-interfering agents (MIA) taxol and vincristine. The molecular mechanism of resistance to MIA was investigated further by determining the status of the JNK pathway. We found that JNK1 expression was elevated, while JNK2 expression was decreased in Rz-expressing clones compared to controls. We have quantified the mRNA levels of BRCA1, JNK1, 2, MEK-4, -7 and c-jun after treatment with MIA. Vincristine treatment of control cells resulted in transcriptional repression of BRCA1, while the JNK1, 2, MEK-4, -7 and c-jun genes were induced. In Rz-treated cells, only JNK1 and MEK-4 were expressed and none was induced after MIA treatment. We then studied the phosphorylation of c-jun, a downstream effector of the JNK pathway. We observed a strong increase in phosphorylated c-jun after MIA treatment of the control cells but not in BRCA1-Rz treated cells, suggesting inhibition of the JNK pathway. These results show that the BRCA1-JNK pathway is involved in the cytotoxic response to MIA treatment, and inhibition of BRCA1 leads to transcriptional modifications of the JNK pathway.	Ctr Jean Perrin, Oncol Mol Lab, F-63011 Clermont Ferrand 1, France; INRA, UNCM, F-63122 St Genes Champanelle, France	UNICANCER; Centre Jean Perrin; INRAE	Bignon, YJ (corresponding author), Ctr Jean Perrin, Oncol Mol Lab, BP 392, F-63011 Clermont Ferrand 1, France.	Yves-Jean.Bignon@cjp.u-clermont1.fr	, bignon/Y-3243-2019					Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 2000, CANCER RES, V60, P5037; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen JJ, 1999, CANCER RES, V59, p1752S; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; Fromes Y, 1996, J PROTEIN CHEM, V15, P377, DOI 10.1007/BF01886864; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Husain A, 1998, CANCER RES, V58, P1120; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rao VN, 1996, ONCOGENE, V12, P523; Rossi JJ, 1999, CHEM BIOL, V6, pR33, DOI 10.1016/S1074-5521(99)80001-5; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Tomlinson GE, 1998, CANCER RES, V58, P3237; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; Vaish NK, 1998, NUCLEIC ACIDS RES, V26, P5237, DOI 10.1093/nar/26.23.5237; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang CC, 1999, CANCER RES, V59, P3663; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	47	152	163	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6597	6606		10.1038/sj.onc.1204812	http://dx.doi.org/10.1038/sj.onc.1204812			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641785				2022-12-25	WOS:000171404200013
J	Nitz, M; Ling, CC; Otter, A; Cutler, JE; Bundle, DR				Nitz, M; Ling, CC; Otter, A; Cutler, JE; Bundle, DR			The unique solution structure and immunochemistry of the Candida albicans beta-1,2-mannopyranan cell wall antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS CAPSULAR POLYSACCHARIDE; BRUCELLA A-ANTIGEN; NIH B-792 STRAIN; CONFORMATIONAL-ANALYSIS; MOLECULAR-DYNAMICS; MANNOSE RESIDUES; SEROTYPE-A; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURES; ANTIBODY-BINDING	Synthetic oligomers of the antigenic Candida albicans (1-->2)-beta-mannopyranans adopt a compact solution conformation that leads to numerous inter-residue nuclear Overhauser effects, including unprecedented nuclear Overhauser effects between n and n + 3 residues. In excellent agreement with experimentally determined distances, unrestrained molecular dynamics point to a single family of conformations that approximate a compact helical motif with a three-residue repeat for this unique homopolymer. When the synthetic di- to hexasaccharides were employed as inhibitors of monoclonal antibodies, which protect mice against a lethal dose of the yeast pathogen, a novel pattern of inhibitor activity was observed. Instead of the paradigm first reported by Kabat (Kabat, E. A. (1962) Fed. Proc. 21, 694-701; Kabat, E. A. (1966) J. Immunol. 97, 1-11), wherein homo-oligosaccharides exhibit increasing inhibitory activity with increasing size, here the maximum activity is reached for di- and trisaccharides and diminishes significantly for tetra-, penta-, and hexasaccharides. These immuno-chemical data correlate with the ordered conformation of the beta-1,2-linked mannopyranan and imply that a uniquely small antigenic determinant has potential as a component of synthetic conjugate vaccines against Candida albicans.	Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada; Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA	University of Alberta; Montana State University System; Montana State University Bozeman	Bundle, DR (corresponding author), Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI037194, R01AI024912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013982] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI24912, P01 AI37194] Funding Source: Medline; NIDCR NIH HHS [R01 DE13982] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANUILERA B, 1998, CARBOHYD RES, V308, P19; Babcook DM, 1996, MAGN RESON CHEM, V34, P851, DOI 10.1002/(SICI)1097-458X(199611)34:11<851::AID-OMR988>3.0.CO;2-6; BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247; BOCK K, 1984, CARBOHYD RES, V130, P35, DOI 10.1016/0008-6215(84)85268-4; BOCK K, 1994, CARBOHYD RES, V253, P51, DOI 10.1016/0008-6215(94)80055-3; BRISSON JR, 1992, BIOCHEMISTRY-US, V31, P4996, DOI 10.1021/bi00136a012; Brisson JR, 1997, BIOCHEMISTRY-US, V36, P3278, DOI 10.1021/bi961819l; Bundle D. R, 1998, CARBOHYDRATES, P370; CAROFF M, 1984, INFECT IMMUN, V46, P384, DOI 10.1128/IAI.46.2.384-388.1984; Casadevall A, 1998, MED MYCOL, V36, P95; Crich D, 2001, J AM CHEM SOC, V123, P5826, DOI 10.1021/ja015985e; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; EVANS SV, 1995, BIOCHEMISTRY-US, V34, P6737, DOI 10.1021/bi00020a019; FAILLE C, 1992, CARBOHYD RES, V236, P17, DOI 10.1016/0008-6215(92)85004-J; Geyer A, 1996, CHEM-EUR J, V2, P981, DOI 10.1002/chem.19960020813; GLAUDEMANS CPJ, 1991, CHEM REV, V91, P25, DOI 10.1021/cr00001a002; Goins TL, 2000, J CLIN MICROBIOL, V38, P2862, DOI 10.1128/JCM.38.8.2862-2869.2000; Han Y, 1997, INFECT IMMUN, V65, P4100, DOI 10.1128/IAI.65.10.4100-4107.1997; Han Y, 1999, J INFECT DIS, V179, P1477, DOI 10.1086/314779; Han Y, 2000, INFECT IMMUN, V68, P1649, DOI 10.1128/IAI.68.3.1649-1654.2000; HAN YM, 1995, INFECT IMMUN, V63, P2714, DOI 10.1128/IAI.63.7.2714-2719.1995; Han YM, 1997, J INFECT DIS, V175, P1169, DOI 10.1086/516455; Han YM, 2001, J IMMUNOL, V167, P1550, DOI 10.4049/jimmunol.167.3.1550; HOMANS SW, 1990, BIOCHEMISTRY-US, V29, P9110, DOI 10.1021/bi00491a003; HURD RE, 1990, J MAGN RESON, V87, P422, DOI 10.1016/0022-2364(90)90021-Z; HWANG TL, 1992, J AM CHEM SOC, V114, P3157, DOI 10.1021/ja00034a083; JEFFREY GA, 1977, ACTA CRYSTALLOGR B, V33, P728, DOI 10.1107/S0567740877004567; JEFFREY PD, 1995, NAT STRUCT BIOL, V2, P466, DOI 10.1038/nsb0695-466; Jouault T, 1997, CLIN DIAGN LAB IMMUN, V4, P328, DOI 10.1128/CDLI.4.3.328-333.1997; KABAT EA, 1966, J IMMUNOL, V97, P1; KABAT EA, 1962, FED PROC, V21, P694; KANBE T, 1993, INFECT IMMUN, V61, P2578, DOI 10.1128/IAI.61.6.2578-2584.1993; KIHLBERG J, 1991, CARBOHYD RES, V216, P67, DOI 10.1016/0008-6215(92)84151-H; LEMIEUX RU, 1980, CAN J CHEM, V58, P631, DOI 10.1139/v80-098; LEVITZ SM, 1992, CLIN INFECT DIS   S1, V14, P37; MAKELA O, 1984, SCAND J IMMUNOL, V19, P541, DOI 10.1111/j.1365-3083.1984.tb00965.x; MAKELA O, 1985, EUR J BIOCHEM, V15, P827; MICHON F, 1987, BIOCHEMISTRY-US, V26, P8399, DOI 10.1021/bi00399a055; Milton MJ, 1998, J AM CHEM SOC, V120, P10547, DOI 10.1021/ja982263n; Montero E, 2000, EUR J ORG CHEM, V2000, P1945; Montero E, 1998, FEBS LETT, V421, P243, DOI 10.1016/S0014-5793(97)01571-8; Nilsson U, 1996, CHEM-EUR J, V2, P295, DOI 10.1002/chem.19960020310; Nitz M, 2001, J ORG CHEM, V66, P8411, DOI 10.1021/jo010570x; Nitz M, 2000, ORG LETT, V2, P2939, DOI 10.1021/ol0061743; Odds FC, 1996, INT J ANTIMICROB AG, V6, P145, DOI 10.1016/0924-8579(95)00048-8; OGAWA T, 1982, CARBOHYD RES, V104, P271, DOI 10.1016/S0008-6215(00)82588-4; OGAWA T, 1983, CARBOHYD RES, V123, pC16, DOI 10.1016/0008-6215(83)88400-6; OTTER A, 1995, CARBOHYD RES, V275, P381, DOI 10.1016/0008-6215(95)00163-N; Otter A, 1999, EUR J BIOCHEM, V259, P295, DOI 10.1046/j.1432-1327.1999.00036.x; PETERS T, 1990, CAN J CHEM, V68, P979, DOI 10.1139/v90-154; POZSGAY V, 1995, CARBOHYD RES, V277, P51, DOI 10.1016/0008-6215(95)00199-4; Pozsgay V, 1999, P NATL ACAD SCI USA, V96, P5194, DOI 10.1073/pnas.96.9.5194; POZSGAY V, 1980, ADV CARBOHYD CHEM BI, V56, P1553; REES DA, 1971, J CHEM SOC B, P469, DOI 10.1039/j29710000469; ROSE DR, 1993, PROTEIN SCI, V2, P1106, DOI 10.1002/pro.5560020705; RUTHERFORD TJ, 1994, GLYCOBIOLOGY, V4, P59, DOI 10.1093/glycob/4.1.59; SHIBATA N, 1993, ARCH BIOCHEM BIOPHYS, V302, P113, DOI 10.1006/abbi.1993.1188; SHIBATA N, 1992, BIOCHEMISTRY-US, V31, P5680, DOI 10.1021/bi00139a036; SHIBATA N, 1989, CARBOHYD RES, V187, P239, DOI 10.1016/0008-6215(89)80006-0; SHIBATA N, 1986, ARCH BIOCHEM BIOPHYS, V251, P697, DOI 10.1016/0003-9861(86)90379-6; Sugiyama H, 2000, CARBOHYD RES, V325, P177, DOI 10.1016/S0008-6215(99)00310-9; Trinel PA, 1997, FEBS LETT, V416, P203, DOI 10.1016/S0014-5793(97)01205-2; Trinel PA, 1999, J BIOL CHEM, V274, P30520, DOI 10.1074/jbc.274.43.30520; Villeneuve S, 2000, P NATL ACAD SCI USA, V97, P8433, DOI 10.1073/pnas.060022997; VYAS MN, 1993, J MOL BIOL, V231, P133, DOI 10.1006/jmbi.1993.1262; WESSELS MR, 1987, P NATL ACAD SCI USA, V84, P9170, DOI 10.1073/pnas.84.24.9170; Zou W, 1999, J IMMUNOL, V163, P820	67	79	83	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3440	3446		10.1074/jbc.M109274200	http://dx.doi.org/10.1074/jbc.M109274200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11700318	hybrid			2022-12-25	WOS:000173688000052
J	Tomoda, K; Kubota, Y; Arata, Y; Mori, S; Maeda, M; Tanaka, T; Yoshida, M; Yoneda-Kato, N; Kato, JY				Tomoda, K; Kubota, Y; Arata, Y; Mori, S; Maeda, M; Tanaka, T; Yoshida, M; Yoneda-Kato, N; Kato, JY			The cytoplasmic shuttling and subsequent degradation of p27(Kip1) mediated by Jab1/CSN5 and the COP9 signalosome complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27(KIP1); NUCLEAR EXPORT SIGNALS; CELL-CYCLE; S-PHASE; DEPENDENT DEGRADATION; TARGETED DISRUPTION; HORMONE-RECEPTOR; BREAST-CANCER; PROTEIN; P27	The fifth component of the COP9 signalosome complex, Jab1/CSN5, directly binds to and induces specific down-regulation of the cyclin-dependent kinase inhibitor p27 (P27(Kip1)). Nuclear-cytoplasmic translocation plays an important role because leptomycin B (LMB), a chemical inhibitor of CRM1-dependent nuclear export, prevents p27 degradation mediated by Jab1/CSN5. Here we show that Jab1/CSN5 functions as an adaptor between p27 and CRM1 to induce nuclear export and subsequent degradation. Jab1/CSN5, but not p27, contains a typical leucine-rich nuclear export signal (NES) sequence conserved among different species, through which CRM1 bound to Jab1/CSN5 in an LMB-sensitive manner. Alteration of conserved leucine residues to alanine within Jab1/CSN5-NES abolished the interaction with CRM1 in vitro and impaired LMB-sensitive nuclear export and the ability to induce p27 breakdown in cultured cells. A Jab1/CSN5 truncation mutant lacking NES reversed p27 down-regulation induced by the full-length Jab1/CSN5, indicating that this mutant functions as a dominant negative (DN-Jab1). Introduction of DN-Jab1 into proliferating fibroblasts increased the level of p27 protein, thereby inducing growth arrest of the cells. Random mutagenesis analysis revealed that specific aspartic acid, leucine, and asparagine residues contained in the Jab1/CSN5-binding domain of p27 were required for interaction with Jab1/CSN5 and for down-regulation of p27. Glycerol gradient and cell fractionation experiments showed that at least two different forms of Jab1/CSN5-containing complexes existed within the cell. One is the conventional 450-kDa COP9 signalosome (CSN) complex located in the nucleus, and the other is much smaller (around 100-kDa), containing only a subset of CSN components (CSN4-8 but not CSN1-3), and mainly located in the cytoplasm. Treatment of cells with LMB greatly reduced the level of the smaller complex, suggesting that it originated from the CSN complex by nuclear export. Besides Jab1/CSN5, CSN3, -6, -7, and -8 were capable of inducing p27 down-regulation, when ectopically expressed. These results indicate that cytoplasmic shuttling regulated by Jab1/CSN5 and other CSN components may be a new pathway to control the intracellular abundance of the key cell cycle regulator.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Univ Tokyo, Dept Biotechnol, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan	Nara Institute of Science & Technology; University of Tokyo	Kato, JY (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.	jkata@bs.aist-nara.ac.jp	Yoshida, Minoru/C-8049-2014; Tanaka, Toshiaki/C-5567-2013; Arata, Yukinobu/AAE-3467-2019	Yoshida, Minoru/0000-0002-4376-5674; Tanaka, Toshiaki/0000-0002-9448-1452; 				Akamatsu E, 1998, J BIOL CHEM, V273, P16494, DOI 10.1074/jbc.273.26.16494; Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; CADWELL RC, 1994, PCR METH APPL, V3, pS136; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Deng XW, 2000, TRENDS GENET, V16, P202, DOI 10.1016/S0168-9525(00)01982-X; Dressel U, 1999, MOL CELL BIOL, V19, P3383; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Elsea SH, 1999, AM J MED GENET, V87, P342, DOI 10.1002/(SICI)1096-8628(19991203)87:4<342::AID-AJMG12>3.3.CO;2-1; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freilich S, 1999, CURR BIOL, V9, P1187, DOI 10.1016/S0960-9822(00)80023-8; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; KATO J, 1993, GENE DEV, V7, P331; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Kwok SF, 1998, PLANT CELL, V10, P1779, DOI 10.1105/tpc.10.11.1779; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Mahalingam S, 1998, P NATL ACAD SCI USA, V95, P3419, DOI 10.1073/pnas.95.7.3419; Muller D, 2000, EMBO J, V19, P2168, DOI 10.1093/emboj/19.10.2168; Mundt KE, 1999, CURR BIOL, V9, P1427, DOI 10.1016/S0960-9822(00)80091-3; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Smitherman M, 2000, MOL CELL BIOL, V20, P5631, DOI 10.1128/MCB.20.15.5631-5642.2000; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x	54	251	271	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2302	2310		10.1074/jbc.M104431200	http://dx.doi.org/10.1074/jbc.M104431200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11704659	hybrid			2022-12-25	WOS:000173421300090
J	Eichenmuller, B; Everley, P; Palange, J; Lepley, D; Suprenant, KA				Eichenmuller, B; Everley, P; Palange, J; Lepley, D; Suprenant, KA			The human EMAP-like protein-70 (ELP70) is a microtubule destabilizer that localizes to the mitotic apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIC INSTABILITY; WD-REPEAT; MOLECULAR CHARACTERIZATION; INDIVIDUAL MICROTUBULES; GTP HYDROLYSIS; ONCOPROTEIN 18; IN-VIVO; TUBULIN; IDENTIFICATION; PURIFICATION	In this report, we show that the echinoderm (m) under bar icrotubule (MT)(a) under bar ssociated protein (EMAP) and related (E) under bar MAP-(l) under bar ike (p) under bar roteins (ELPs) share a similar domain organization with a highly conserved (h) under bar ydrophobic (ELP) under bar (HELP) domain and a large tryptophan-aspartic acid (WD) repeat domain. To determine the function of mammalian ELPs, we generated antibodies against a 70-kDa human ELP and showed that ELP70 coassembled with Mrs in HeLa cell extracts and colocalized with MTs in the mitotic apparatus. To determine whether ELP70 bound to MTs directly, human ELP70 was expressed and purified to homogeneity from baculovirus-infected Sf9 cells. Purified ELP70 bound to purified MTs with a stoichiometry of 0.40 +/- 0.04 mol of ELP70/mol of tubulin dimer and with an intrinsic dissociation constant of 0.44 +/- 0.13 mum. Using a nucleated assembly assay and video-enhanced differential interference contrast microscopy, we demonstrated that ELP70 reduced seeded nucleation, reduced the growth rate, and promoted MT catastrophes in a concentration-dependent manner. As a result, ELP70-containing MTs were significantly shorter than MTs assembled from tubulin alone. These data indicate that ELP70 is a novel MT destabilizer. A lateral destabilization model is presented to describe ELP70's effects on microtubules.	Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA	University of Kansas	Suprenant, KA (corresponding author), Univ Kansas, Dept Mol Biosci, 1200 Sunnyside Ave, Lawrence, KS 66045 USA.	ksupre@ukans.edu						ALGAIER J, 1988, BIOCHIM BIOPHYS ACTA, V954, P235, DOI 10.1016/0167-4838(88)90078-7; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Arnal I, 2000, J CELL BIOL, V149, P767, DOI 10.1083/jcb.149.4.767; BARRONG SD, 1992, ARCH OPHTHALMOL-CHIC, V110, P706, DOI 10.1001/archopht.1992.01080170128040; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BLOOM GS, 1985, CELL MOTIL CYTOSKEL, V5, P431, DOI 10.1002/cm.970050602; Brisch E, 1996, J CELL SCI, V109, P2885; BULINSKI JC, 1979, P NATL ACAD SCI USA, V76, P293, DOI 10.1073/pnas.76.1.293; BULINSKI JC, 1994, J CELL SCI, V107, P2839; BULINSKI JC, 1991, BIOESSAYS, V13, P285, DOI 10.1002/bies.950130605; Bulinski Jeannette Chloe, 1994, V13, P167; CARLIER MF, 1989, BIOCHEMISTRY-US, V28, P1783, DOI 10.1021/bi00430a054; CASSIMERIS L, 1993, CELL MOTIL CYTOSKEL, V26, P275, DOI 10.1002/cm.970260402; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Detrich HW, 2000, J BIOL CHEM, V275, P37038, DOI 10.1074/jbc.M005699200; Eichenmuller B, 2001, CELL MOTIL CYTOSKEL, V50, P161, DOI 10.1002/cm.10002; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; ERICKSON HP, 1974, J CELL BIOL, V60, P153, DOI 10.1083/jcb.60.1.153; Eudy JD, 1997, GENOMICS, V43, P104, DOI 10.1006/geno.1997.4779; Field CM, 1998, METHOD ENZYMOL, V298, P525, DOI 10.1016/S0076-6879(98)98043-0; Hamill DR, 1998, J BIOL CHEM, V273, P9285, DOI 10.1074/jbc.273.15.9285; Hartman JJ, 1998, CELL, V93, P277, DOI 10.1016/S0092-8674(00)81578-0; Heidebrecht HJ, 2000, GENOMICS, V68, P348, DOI 10.1006/geno.2000.6301; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Hueston JL, 2000, MOL BIOL CELL, V11, p198A; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; KELLER TCS, 1982, J CELL BIOL, V93, P788, DOI 10.1083/jcb.93.3.788; Kirschner M W, 1978, Int Rev Cytol, V54, P1, DOI 10.1016/S0074-7696(08)60164-3; KIRSCHNER MW, 1975, J MOL BIOL, V99, P263, DOI 10.1016/S0022-2836(75)80144-6; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; Lepley DM, 1999, GENE, V237, P343, DOI 10.1016/S0378-1119(99)00335-2; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LI QW, 1994, J BIOL CHEM, V269, P31777; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; Margolis RL, 1998, BIOESSAYS, V20, P830, DOI 10.1002/(SICI)1521-1878(199810)20:10<830::AID-BIES8>3.0.CO;2-N; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MASSON D, 1993, J CELL BIOL, V123, P357, DOI 10.1083/jcb.123.2.357; McNally FJ, 1998, MOL BIOL CELL, V9, P1847, DOI 10.1091/mbc.9.7.1847; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; MELKI R, 1989, BIOCHEMISTRY-US, V28, P9143, DOI 10.1021/bi00449a028; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; OLSON KR, 1995, J CELL BIOL, V130, P639, DOI 10.1083/jcb.130.3.639; REIJO RA, 1994, MOL BIOL CELL, V5, P29, DOI 10.1091/mbc.5.1.29; Rusan NM, 2001, MOL BIOL CELL, V12, P971, DOI 10.1091/mbc.12.4.971; Saunders W, 1997, J CELL BIOL, V137, P417, DOI 10.1083/jcb.137.2.417; SHELDEN E, 1993, J CELL BIOL, V120, P935, DOI 10.1083/jcb.120.4.935; SIMON JR, 1990, J CELL SCI, V96, P571; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUPRENANT KA, 1987, J CELL SCI, V87, P71; Suprenant KA, 2000, DEV GENES EVOL, V210, P2, DOI 10.1007/PL00008183; SUPRENANT KA, 1993, J CELL SCI, V104, P445; TIWARI SC, 1993, ANAL BIOCHEM, V215, P96, DOI 10.1006/abio.1993.1560; Towbin H, 1992, Biotechnology, V24, P145; Tran PT, 1997, J CELL BIOL, V138, P105, DOI 10.1083/jcb.138.1.105; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VALLEE RB, 1986, METHOD ENZYMOL, V134, P116; VALLEE RB, 1983, P NATL ACAD SCI-BIOL, V80, P6259, DOI 10.1073/pnas.80.20.6259; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; Wadsworth P, 1999, CELL MOTIL CYTOSKEL, V42, P48, DOI 10.1002/(SICI)1097-0169(1999)42:1<48::AID-CM5>3.3.CO;2-#; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WEATHERBEE JA, 1980, BIOCHEMISTRY-US, V19, P4116, DOI 10.1021/bi00558a033; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WEST RR, 1991, J BIOL CHEM, V266, P21886; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201; ZHAI Y, 1994, J CELL SCI, V107, P881	73	51	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1301	1309		10.1074/jbc.M106628200	http://dx.doi.org/10.1074/jbc.M106628200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694528	hybrid			2022-12-25	WOS:000173166800057
J	Hunt, MC; Solaas, K; Kase, BF; Alexson, SEH				Hunt, MC; Solaas, K; Kase, BF; Alexson, SEH			Characterization of an acyl-CoA thioesterase that functions as a major regulator of peroxisomal lipid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; RAT-LIVER PEROXISOMES; COENZYME-A; FATTY-ACID; BETA-OXIDATION; ESCHERICHIA-COLI; 3-ALPHA,7-ALPHA,12-ALPHA-TRIHYDROXY-5-BETA-CHOLESTANOIC ACID; ADAPTIVE RESPONSE; CHOLIC-ACID; HIV-1 NEF	Peroxisomes function in beta-oxidation of very long and long-chain fatty acids, dicarboxylic fatty acids, bile acid intermediates, prostaglandins, leukotrienes, thromboxanes, pristanic acid, and xenobiotic carboxylic acids. These lipids are mainly chain-shortened for excretion as the carboxylic acids or transported to mitochondria for further metabolism. Several of these carboxylic acids are slowly oxidized and may therefore sequester coenzyme A (CoASH). To prevent CoASH sequestration and to facilitate excretion of chain-shortened carboxylic acids, acyl-CoA thioesterases, which catalyze the hydrolysis of acyl-CoAs to the free acid and CoASH, may play important roles. Here we have cloned and characterized a peroxisomal acyl-CoA thioesterase from mouse, named PTE-2 (peroxisomal acyl-CoA thioesterase 2). PTE-2 is ubiquitously expressed and induced at mRNA level by treatment with the peroxisome proliferator WY-14,643 and fasting. Induction seen by these treatments was dependent on the peroxisome proliferator-activated receptor alpha. Recombinant PTE-2 showed a broad chain length specificity with acyl-CoAs from short- and medium-, to long-chain acyl-CoAs, and other substrates including trihydroxycoprostanoyl-CoA, hydroxymethylglutaryl-CoA, and branched chain acyl-CoAs, all of which are present in peroxisomes. Highest activities were found with the CoA esters of primary bile acids choloyl-CoA and chenodeoxycholoyl-CoA as substrates. PTE-2 activity is inhibited by free CoASH, suggesting that intraperoxisomal free CoASH levels regulate the activity of this enzyme. The acyl-CoA specificity of recombinant PTE-2 closely resembles that of purified mouse liver peroxisomes, suggesting that PTE-2 is the major acyl-CoA thioesterase in peroxisomes. Addition of recombinant PTE-2 to incubations containing isolated mouse liver peroxisomes strongly inhibited bile acid-CoA:amino acid N-acyltransferase activity, suggesting that this thioesterase can interfere with CoASH-dependent pathways. We propose that PTE-2 functions as a key regulator of peroxisomal lipid metabolism.	Huddinge Univ Hosp, Dept Med Lab Sci & Technol, Div Clin Chem C1 74, Karolinska Inst, SE-14186 Stockholm, Sweden; Natl Hosp Norway, Dept Pediat Res, NO-0027 Oslo, Norway	Karolinska Institutet; University of Oslo; National Hospital Norway	Hunt, MC (corresponding author), Huddinge Univ Hosp, Dept Med Lab Sci & Technol, Div Clin Chem C1 74, Karolinska Inst, SE-14186 Stockholm, Sweden.	mary.hunt@chemlab.hs.sll.se		Hunt, Mary/0000-0001-6415-2992				ALEXSON SEH, 1989, BIOCHEM J, V262, P41, DOI 10.1042/bj2620041; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; BERGE RK, 1984, EUR J BIOCHEM, V141, P637, DOI 10.1111/j.1432-1033.1984.tb08239.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASS EP, 1994, CHEM-BIOL INTERACT, V90, P203, DOI 10.1016/0009-2797(94)90010-8; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Cohen GB, 2000, J BIOL CHEM, V275, P23097, DOI 10.1074/jbc.M000536200; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; DICZFALUSY U, 1994, PROG LIPID RES, V33, P403, DOI 10.1016/0163-7827(94)90025-6; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gargiulo CE, 1999, J LIPID RES, V40, P881; Gasmi L, 2001, BIOCHEM J, V357, P33, DOI 10.1042/0264-6021:3570033; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hertz R, 2001, BIOCHEM PHARMACOL, V61, P1057, DOI 10.1016/S0006-2952(01)00578-0; HORIE S, 1986, J BIOCHEM, V99, P1345, DOI 10.1093/oxfordjournals.jbchem.a135602; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Hunt MC, 2000, J LIPID RES, V41, P814; Hunt MC, 2000, J BIOL CHEM, V275, P28947, DOI 10.1074/jbc.M002782200; HUNT MC, 2001, IN PRESS PROG LIPID; Jones JM, 2000, BIOCHEM BIOPH RES CO, V275, P233, DOI 10.1006/bbrc.2000.3285; Jones JM, 1999, J BIOL CHEM, V274, P9216, DOI 10.1074/jbc.274.14.9216; KASE F, 1983, J LIPID RES, V24, P1560; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEIGHTON F, 1989, J BIOL CHEM, V264, P10347; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Li J, 2000, NAT STRUCT BIOL, V7, P555; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; Liu LX, 2000, J VIROL, V74, P5310, DOI 10.1128/JVI.74.11.5310-5319.2000; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; NEMALI MR, 1988, CANCER RES, V48, P5316; Olivier LM, 2000, J LIPID RES, V41, P1921; OSMUNDSEN H, 1980, INT J BIOCHEM, V12, P625, DOI 10.1016/0020-711X(80)90015-4; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; PEDERSEN JI, 1980, FEBS LETT, V121, P345, DOI 10.1016/0014-5793(80)80377-2; PRYDZ K, 1986, J LIPID RES, V27, P622; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; RUSNAK N, 1987, BIOCHEM BIOPH RES CO, V148, P890, DOI 10.1016/0006-291X(87)90959-4; SHAH PP, 1968, STEROIDS, V12, P571, DOI 10.1016/S0039-128X(68)80034-0; Solaas K, 2000, SCAND J CLIN LAB INV, V60, P91, DOI 10.1080/00365510050184903; Solaas K, 2000, J LIPID RES, V41, P1154; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; Van Veldhoven PP, 1999, ADV EXP MED BIOL, V466, P261; VANBROEKHOVEN A, 1981, BIOCHEM BIOPH RES CO, V100, P305, DOI 10.1016/S0006-291X(81)80097-6; VANVELDHOVEN PP, 1986, BIOCHEM BIOPH RES CO, V139, P1195, DOI 10.1016/S0006-291X(86)80304-7; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Watanabe W, 1997, BIOCHEM BIOPH RES CO, V238, P234, DOI 10.1006/bbrc.1997.7217; WILCKE M, 1994, EUR J BIOCHEM, V222, P803, DOI 10.1111/j.1432-1033.1994.tb18927.x; YAMADA J, 1987, BIOCHIM BIOPHYS ACTA, V921, P292; YAMADA J, 1986, BIOCHEM PHARMACOL, V35, P4363, DOI 10.1016/0006-2952(86)90749-5	62	120	144	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1128	1138		10.1074/jbc.M106458200	http://dx.doi.org/10.1074/jbc.M106458200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11673457	hybrid, Green Submitted			2022-12-25	WOS:000173166800034
J	Blasko, E; Glaser, CB; Devlin, JJ; Xia, W; Feldman, RI; Polokoff, MA; Phillips, GB; Whitlow, M; Auld, DS; McMillan, K; Ghosh, S; Stuehr, DJ; Parkinson, JF				Blasko, E; Glaser, CB; Devlin, JJ; Xia, W; Feldman, RI; Polokoff, MA; Phillips, GB; Whitlow, M; Auld, DS; McMillan, K; Ghosh, S; Stuehr, DJ; Parkinson, JF			Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE NO SYNTHASE; L-ARGININE; SUBUNIT DIMERIZATION; CATALYTIC ACTIVITY; ELECTRON-TRANSFER; OXYGENASE DOMAIN; ESCHERICHIA-COLI; DIMERIC ENZYME; IN-VITRO; HEME	A series of potent and selective inducible nitric-oxide synthase (iNOS) inhibitors was shown to prevent iNOS dimerization in cells and inhibit iNOS in vivo. These inhibitors are now shown to block dimerization of purified human iNOS monomers. A H-3-labeled inhibitor bound to full-length human iNOS monomer with apparent K(d)similar to1.8 nm and had a slow off rate, 1.2 x 10(-4) s(-1). Inhibitors also bound with high affinity to both murine full-length and murine oxygenase domain iNOS monomers. Spectroscopy and competition binding with imidazole confirmed an inhibitor-heme interaction. Inhibitor affinity in the binding assay (apparent K-d values from 330 pm to 27 nm) correlated with potency in a cell-based iNOS assay (IC50 values from 290 pm to 270 nm). Inhibitor potency in cells was not prevented by medium supplementation with L-arginine or sepiapterin, but inhibition decreased with time of addition after cytokine stimulation. The results are consistent with a mechanism whereby inhibitors bind to a heme-containing iNOS monomer species to form an inactive iNOS monomer-heme-inhibitor complex in a pterin- and L-arginine-independent manner. The selectivity for inhibiting dimerization of iNOS versus endothelial and neuronal NOS suggests that the energetics and kinetics of monomer-dimer equilibria are substantially different for the mammalian NOS isoforms. These inhibitors provide new research tools to explore these processes.	Berlex Biosci, Dept Immunol, Richmond, CA 94804 USA; Berlex Biosci, Dept Cardiovasc Res, Richmond, CA 94804 USA; Berlex Biosci, Dept Canc Res, Richmond, CA 94804 USA; Berlex Biosci, Prot Express & Cell Sci Dept, Richmond, CA 94804 USA; Berlex Biosci, Discovery Res Dept, Richmond, CA 94804 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Pharmacopeia Inc, Princeton, NJ 08512 USA	Cleveland Clinic Foundation	Parkinson, JF (corresponding author), Berlex Biosci, Dept Immunol, 15049 San Pablo Ave, Richmond, CA 94804 USA.	john_parkinson@berlex.com		Ghosh, Sanjay/0000-0001-8624-1494	NCI NIH HHS [CA53914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bender AT, 2000, J BIOL CHEM, V275, P17407, DOI 10.1074/jbc.M000155200; Bender AT, 2000, J BIOL CHEM, V275, P26018, DOI 10.1074/jbc.275.34.26018; Berka V, 2000, BIOCHEMISTRY-US, V39, P9373, DOI 10.1021/bi992769y; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHEN PF, 1994, J BIOL CHEM, V269, P25062; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; Felley-Bosco E, 2000, P NATL ACAD SCI USA, V97, P14334, DOI 10.1073/pnas.250406797; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; McMillan K, 2000, P NATL ACAD SCI USA, V97, P1506, DOI 10.1073/pnas.97.4.1506; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Musial A, 2001, J BIOL CHEM, V276, P24268, DOI 10.1074/jbc.M100725200; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; Panda Koustubh, 2000, Nitric Oxide, V4, P222; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; RIVEROSMORENO V, 1995, EUR J BIOCHEM, V230, P52; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Sari MA, 1996, BIOCHEMISTRY-US, V35, P7204, DOI 10.1021/bi960087u; Sennequier N, 1999, J BIOL CHEM, V274, P930, DOI 10.1074/jbc.274.2.930; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425	46	84	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					295	302		10.1074/jbc.M105691200	http://dx.doi.org/10.1074/jbc.M105691200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11689556	hybrid			2022-12-25	WOS:000173087900040
J	Mosammaparast, N; Guo, YR; Shabanowitz, J; Hunt, DF; Pemberton, LF				Mosammaparast, N; Guo, YR; Shabanowitz, J; Hunt, DF; Pemberton, LF			Pathways mediating the nuclear import of histones H3 and H4 in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN L25; AMINO-ACID-SEQUENCES; TATA-BINDING PROTEIN; MAMMALIAN-CELLS; TRANSPORT; NUCLEOSOME; ACETYLTRANSFERASE; PEPTIDES; DATABASE; PARTICLE	The correct assembly of chromatin is necessary for the maintenance of genomic stability in eukaryotic cells. A critical step in the assembly of new chromatin is the cell cycle-regulated synthesis and nuclear import of core histones. Here we demonstrate that the nuclear import pathway of histones H3 and H4 is mediated by at least two karyopherinstimportins, Kap123p and Kap121p. Cytosolic H4 is found associated with Kap123p and H3. Kap121p is also present in the H4-PrA-associated fractions, albeit in lesser amounts than Kap123p, suggesting that this Kap serves as an additional import receptor. We further demonstrate that cytosolic Kap123p, is associated with acetylated H3 and H4. H3 and H4 each contain a nuclear localization signal (NLS) in their aminoterminal domains. These amino-terminal domains were found to be essential for the nuclear accumulation of H3 and H4-green fluorescent protein reporters. Each NLS mediated direct binding to Kap123p and Kap121p, and decreased nuclear accumulation of H3 and H4 NLS-green fluorescent protein reporters was observed in specific kap mutant strains. H3 and H4 are the first histones to be assembled onto DNA, and these results show that their import is mediated by at least two import pathways.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Pemberton, LF (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Ctr Cell Signaling, POB 800577, Charlottesville, VA 22908 USA.		Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368	NIGMS NIH HHS [GM-37537] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Albertini M, 1998, J CELL BIOL, V143, P1447, DOI 10.1083/jcb.143.6.1447; Baake M, 2001, J CELL BIOCHEM, V81, P333, DOI 10.1002/1097-4644(20010501)81:2<333::AID-JCB1048>3.3.CO;2-4; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gharahdaghi F, 1996, ANAL BIOCHEM, V233, P94, DOI 10.1006/abio.1996.0012; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Langer T, 2000, HISTOCHEM CELL BIOL, V113, P455; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Morehouse H, 1999, P NATL ACAD SCI USA, V96, P12542, DOI 10.1073/pnas.96.22.12542; Mosammaparast N, 2001, J CELL BIOL, V153, P251, DOI 10.1083/jcb.153.2.251; Muhlhausser P, 2001, EMBO REP, V2, P690, DOI 10.1093/embo-reports/kve168; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pemberton LF, 1999, J CELL BIOL, V145, P1407, DOI 10.1083/jcb.145.7.1407; Pemberton LF, 1997, J CELL BIOL, V139, P1645, DOI 10.1083/jcb.139.7.1645; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rosenblum JS, 1997, J CELL BIOL, V139, P1655, DOI 10.1083/jcb.139.7.1655; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Ruiz-Garcia AB, 1998, J BIOL CHEM, V273, P12599, DOI 10.1074/jbc.273.20.12599; SCHAAP PJ, 1991, J MOL BIOL, V221, P225; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Sherman F., 1986, METHODS YEAST GENETI; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Verreault A, 2000, GENE DEV, V14, P1430; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Yoshida K, 2001, J CELL BIOL, V152, P729, DOI 10.1083/jcb.152.4.729	37	120	123	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					862	868		10.1074/jbc.M106845200	http://dx.doi.org/10.1074/jbc.M106845200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11694505	hybrid			2022-12-25	WOS:000173087900110
J	Snyder, PM; Olson, DR; Thomas, BC				Snyder, PM; Olson, DR; Thomas, BC			Serum and glucocorticoid-regulated kinase modulates Nedd4-2-mediated inhibition of the epithelial Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIDDLES-SYNDROME; SODIUM-CHANNELS; PLASMA-MEMBRANE; PROTEIN-KINASE; BLOOD-PRESSURE; PY MOTIF; NEDD4; SGK; SUBUNITS; DOMAINS	The epithelial Na+ channel (ENaC) forms the pathway for Na+ absorption across epithelia, including the kidney collecting duct, where it plays a critical role in Na+ homeostasis and blood pressure control. Na+ absorption is regulated in part by mechanisms that control the expression of ENaC at the apical cell surface. Nedd4 family members (e.g. Nedd4, Nedd4-2) bind to the channel and decrease its surface expression by catalyzing its ubiquitination and degradation. Conversely, serum and glucocorticoid-regulated kinase (SGK), a downstream mediator of aldosterone, increases the expression of ENaC at the cell surface. Here we show that SGK and human Nedd4-2 (hNedd4-2) converge in a common pathway to regulate epithelial Na+ absorption. Consistent with this model, we found that SGK bound to hNedd4-2 and hNedd4. A PY motif in SGK mediated the interaction and was required for SGK to stimulate ENaC. SGK phosphorylated hNedd4-2 (but not hNedd4), altering hNedd4-2 function; phosphorylation reduced the binding of hNedd4-2 to alphaENaC, and hence, the hNedd4-2-mediated inhibition of Na+ absorption. These data suggest that SGK regulates epithelial Na+ absorption in part by modulating the function of hNedd4-2.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Snyder, PM (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA.	psnyder@blue.weeg.uiowa.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058812, R01HL061781, P50HL055006, R29HL058812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK052617] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55006, HL61781, HL03575, HL58812] Funding Source: Medline; NIDDK NIH HHS [DK52617] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Diviani D, 2001, J CELL SCI, V114, P1431; Espanel X, 1999, J BIOL CHEM, V274, P17284, DOI 10.1074/jbc.274.24.17284; Farr TJ, 2000, BIOCHEM J, V345, P503, DOI 10.1042/0264-6021:3450503; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Snyder PM, 2001, J BIOL CHEM, V276, P28321, DOI 10.1074/jbc.M011487200; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; SNYDER PM, 2001, IN PRESS ENDOCR REV; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, AM J PHYSIOL-CELL PH, V272, pC1871, DOI 10.1152/ajpcell.1997.272.6.C1871; Stokes JB, 1999, KIDNEY INT, V56, P2318, DOI 10.1046/j.1523-1755.1999.00803.x; Wang J, 2001, AM J PHYSIOL-RENAL, V280, pF303, DOI 10.1152/ajprenal.2001.280.2.F303	31	356	368	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					5	8		10.1074/jbc.C100623200	http://dx.doi.org/10.1074/jbc.C100623200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11696533	hybrid			2022-12-25	WOS:000173087900002
J	Protchenko, O; Ferea, T; Rashford, J; Tiedeman, J; Brown, PO; Botstein, D; Philpott, CC				Protchenko, O; Ferea, T; Rashford, J; Tiedeman, J; Brown, PO; Botstein, D; Philpott, CC			Three cell wall mannoproteins facilitate the uptake of iron in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; TRANSCRIPTIONAL CONTROL; FERRIC REDUCTASE; FET3 GENE; YEAST; TRANSPORT; COPPER; IDENTIFICATION; SIDEROPHORES; PROTEIN	Analysis of iron-regulated gene expression in Saccharomyces cerevisiae using cDNA microarrays has identified three putative cell wall proteins that are directly regulated by Aft1p, the major iron-dependent transcription factor in yeast. FIT1, FIT2, and FIT3 (for facilitator of iron transport) were more highly expressed in strains grown in low concentrations of iron and in strains in which AFT1-1(up), a constitutively active allele of AFT1, was expressed. Northern blot analysis confirmed that FIT1, FIT2, and FIT3 mRNA transcript levels were increased 60-230-fold in response to iron deprivation in an Aft1p-dependent manner. Fit1p was localized exclusively to the cell wall by indirect immunofluorescence. Deletion of the FIT genes, individually or in combination, resulted in diminished uptake of iron bound to the siderophores ferrioxamine B and ferrichrome, without diminishing the uptake of ferric iron salts, or the siderophores triacetylfusarinine C and enterobactin. FIT-deletion strains exhibited increased expression of Aft1p target genes as measured by a FET3-lacZ reporter gene or by Arn1p Western blotting, indicating that cells respond to the absence of FIT genes by up-regulating systems of iron uptake. Aft1p activation in FIT-deleted strains occurred when either ferrichrome or ferric salts were used as sources of iron during growth, suggesting that the FIT genes enhance uptake of iron from both sources. Enzymatic digestion of the cell wall resulted in the release of significant amounts of iron from cells, and the relative quantity of iron released was reduced in FIT-deletion strains. Fit1p, Fit2p, and Fit3p may function by increasing the amount of iron associated with the cell wall and periplasmic space.	NIDDK, Liver Dis Sect, NIH, Bethesda, MD 20892 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Howard Hughes Med Inst, Stanford, CA 94305 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Stanford University; Stanford University; Howard Hughes Medical Institute	Philpott, CC (corresponding author), NIDDK, Liver Dis Sect, NIH, Bldg 10,Rm 9B16,10 Ctr Dr, Bethesda, MD 20892 USA.	carolinep@intra.niddk.nih.gov	Protchenko, Olga/AAU-9237-2021	Protchenko, Olga/0000-0002-4688-4214	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK054507, Z01DK054507] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams Alison, 1997, P123; Albrecht-Gary AM, 1998, MET IONS BIOL SYST, V35, P239; Andrews NC, 2000, CURR OPIN PEDIATR, V12, P596, DOI 10.1097/00008480-200012000-00015; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1998, J BIOL CHEM, V273, P22415, DOI 10.1074/jbc.273.35.22415; Bacon BR, 2001, GASTROENTEROLOGY, V120, P718, DOI 10.1053/gast.2001.21913; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Cabib E, 1997, BIOCHEM SOC T, V25, P200, DOI 10.1042/bst0250200; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Goldman RC, 1999, CURR PHARM DESIGN, V5, P473; Hamada K, 1999, J BACTERIOL, V181, P3886, DOI 10.1128/JB.181.13.3886-3889.1999; Hamada K, 1998, MOL GEN GENET, V258, P53, DOI 10.1007/s004380050706; Heymann P, 2000, BIOMETALS, V13, P65, DOI 10.1023/A:1009250017785; Heymann P, 1999, BIOMETALS, V12, P301, DOI 10.1023/A:1009252118050; Heymann P, 2000, FEMS MICROBIOL LETT, V186, P221, DOI 10.1016/S0378-1097(00)00152-X; Kapteyn JC, 1999, BBA-GEN SUBJECTS, V1426, P373, DOI 10.1016/S0304-4165(98)00137-8; Leong SA, 1998, MET IONS BIOL SYST, V35, P147; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; LIN CM, 1993, J GEN MICROBIOL, V139, P1605, DOI 10.1099/00221287-139-7-1605; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Orlean P., 1997, MOL CELLULAR BIOL YE, P229; Philpott CC, 1998, EMBO J, V17, P5026, DOI 10.1093/emboj/17.17.5026; Schneider BL, 1996, YEAST, V12, P129, DOI 10.1002/(SICI)1097-0061(199602)12:2<129::AID-YEA891>3.0.CO;2-O; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SCOTT JH, 1980, J BACTERIOL, V142, P414, DOI 10.1128/JB.142.2.414-423.1980; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Stearman R, 1998, GENE, V212, P197, DOI 10.1016/S0378-1119(98)00179-6; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Van der Helm D., 1994, METAL IONS FUNGI, V11, P39; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709; Yun CW, 2001, J BIOL CHEM, V276, P10218, DOI 10.1074/jbc.M010065200	44	125	133	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49244	49250		10.1074/jbc.M109220200	http://dx.doi.org/10.1074/jbc.M109220200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11673473	hybrid			2022-12-25	WOS:000173922100082
J	Sun, JM; Chen, HY; Davie, JR				Sun, JM; Chen, HY; Davie, JR			Effect of estradiol on histone acetylation dynamics in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEINS; ESTROGEN-RECEPTOR-ALPHA; NUCLEAR MATRIX; TRANSCRIPTION FACTORS; CHICKEN ERYTHROCYTES; DEACETYLATION; TRAFFICKING; ACTIVATION; RATES; DNA	Histone acetylation plays an important role in remodeling chromatin structure, facilitating nuclear processes such as transcription. We investigated the effect of estradiol on global histone acetylation in hormone-responsive human breast cancer cells. Pulse-chase experiments and immunoblot analyses of dynamically acetylated histones show that estradiol rapidly increases histone acetylation in estrogen receptor (ER)positive, hormone-dependent T5, but not in ER-negative, hormone-independent MDA MB 231 breast cancer cells. The effect of estradiol on the rates of histone acetylation and deacetylation in T5 cells was determined. We found that estradiol increased the level of acetylated histories by reducing the rate of histone deacetylation, whereas the rate of histone acetylation was not altered. Enzymatic assays and immunoblot analyses of cell fractions showed that estradiol did not affect the level, sub-nuclear distribution, or activity of class I and II histone deacetylases. However, estradiol did alter the intranuclear distribution of ER and histone acetyltransferases, with both becoming tightly bound in the nucleus and associated with the nuclear matrix. We propose that, following the association of ER with nuclear matrix sites, ER alters the balance of historic acetyltransferases and histone deacetylases at these sites and the dynamics of acetylation of histories associated with transcriptionally active and competent chromatin.	Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada		Davie, JR (corresponding author), Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	davie@cc.umanitoba.ca		Davie, James/0000-0002-0420-6888				Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Coutts AS, 1996, J CELL BIOCHEM, V63, P174, DOI 10.1002/(SICI)1097-4644(19961101)63:2<174::AID-JCB5>3.0.CO;2-V; COVAULT J, 1980, J BIOL CHEM, V255, P9110; Davie JR, 1999, J CELL BIOCHEM, P141; Davie JR, 2000, CRIT REV EUKAR GENE, V10, P303; ECKERT RL, 1984, ENDOCRINOLOGY, V114, P629, DOI 10.1210/endo-114-2-629; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; HENDZEL MJ, 1994, J BIOL CHEM, V269, P22894; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HORIUCHI K, 1981, CANCER RES, V41, P1488; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; PASQUALINI JR, 1989, BREAST CANCER RES TR, V14, P101, DOI 10.1007/BF01805980; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Samudio I, 2001, ENDOCRINOLOGY, V142, P1000, DOI 10.1210/en.142.3.1000; Samuel SK, 1998, CANCER RES, V58, P3004; Schiltz RL, 2000, BBA-REV CANCER, V1470, pM37, DOI 10.1016/S0304-419X(99)00037-2; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Spencer VA, 1998, J BIOL CHEM, V273, P29093, DOI 10.1074/jbc.273.44.29093; Spencer VA, 2001, J BIOL CHEM, V276, P34810, DOI 10.1074/jbc.M104886200; Stein GS, 2000, J CELL SCI, V113, P2527; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Sun JM, 1999, BIOCHEMISTRY-US, V38, P5939, DOI 10.1021/bi982633k; SUN JM, 2001, IN PRESS J CELL BIOC; THORBURN A, 1993, BIOCHEM BIOPH RES CO, V191, P308, DOI 10.1006/bbrc.1993.1218; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; ZHANG DE, 1988, BIOCHEM J, V250, P241, DOI 10.1042/bj2500241; ZHANG DE, 1988, BIOCHEM J, V250, P233, DOI 10.1042/bj2500233	31	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49435	49442		10.1074/jbc.M108364200	http://dx.doi.org/10.1074/jbc.M108364200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11682483	hybrid			2022-12-25	WOS:000173922100105
J	Swiderska, A; Berndtson, AK; Cha, MR; Li, L; Beaudoin, GMJ; Zhu, J; Fuqua, C				Swiderska, A; Berndtson, AK; Cha, MR; Li, L; Beaudoin, GMJ; Zhu, J; Fuqua, C			Inhibition of the Agrobacterium tumefaciens TraR quorum-sensing regulator - Interactions with the tram anti-activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID CONJUGAL TRANSFER; TI-PLASMID; BACILLUS-SUBTILIS; RNA-POLYMERASE; TRANSCRIPTIONAL ACTIVATOR; HOMOSERINE LACTONES; AUTOINDUCER-BINDING; ANTIACTIVATOR TRAM; TERMINAL REGION; GENE-REGULATION	The Agrobacterium tumefaciens quorum-sensing transcriptional regulator TraR and its inducing ligand 3-oxo-octanoyl-L-homoserine lactone control conjugal transfer of the tumor-inducing plasmid, the primary virulence factor responsible for crown gall disease of plants. This regulatory system enables A tumefaciens to express its conjugal transfer regulon preferentially at high population densities. TraR activity is antagonized by a second tumor-inducing plasmid-encoded protein designated TraM. TraM and TraR are thought to form an anti-activation complex that prevents TraR from recognizing its target DNA-binding sites. The formation and inhibitory function of the TraM-TraR anti-activation complex was analyzed using several different assays for protein-protein interaction, including surface plasmon resonance. The TraR-TraM complex forms readily in solution and is extremely stable (K-D of 1-4 x 10(-9) m). Directed mutational analysis of TraM identified a number of amino acids that play important roles in the inhibition of TraR, clustering in two regions of the protein. Interestingly, several mutants were identified that proficiently bound TraR but were unable to inhibit its activity. This observation suggests a mechanistic separation between the initial assembly of the complex and conversion of TraR to an inactive form.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Cornell Univ, Microbiol Sect, Ithaca, NY 14853 USA	Indiana University System; Indiana University Bloomington; Cornell University	Fuqua, C (corresponding author), Indiana Univ, Dept Biol, Jordan Hall 142,1001 E 3rd St, Bloomington, IN 47405 USA.		Zhu, Jun/A-1324-2007	Beaudoin, Gerard/0000-0002-4217-4370	NIGMS NIH HHS [GM42893] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042893, R01GM042893] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL F, 1997, SHORT PROTOCOLS MOL, P3; BAI U, 1993, GENE DEV, V7, P139, DOI 10.1101/gad.7.1.139; BENSON AK, 1993, P NATL ACAD SCI USA, V90, P2330, DOI 10.1073/pnas.90.6.2330; BROWN KL, 1995, MOL MICROBIOL, V16, P397, DOI 10.1111/j.1365-2958.1995.tb02405.x; Chadsey MS, 1998, GENE DEV, V12, P3123, DOI 10.1101/gad.12.19.3123; Chai Y, 2001, MOL MICROBIOL, V40, P414, DOI 10.1046/j.1365-2958.2001.02385.x; CHEN CY, 1991, J BACTERIOL, V173, P1139, DOI 10.1128/jb.173.3.1139-1144.1991; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; Egland KA, 2000, J BACTERIOL, V182, P805, DOI 10.1128/JB.182.3.805-811.2000; Farrand S. K, 1998, RHIZOBIACEAE MOL BIO, P199, DOI DOI 10.1007/978-94-011-5060-6; Freiberg C, 1997, NATURE, V387, P394, DOI 10.1038/387394a0; Fuqua C, 1996, MOL MICROBIOL, V20, P1199, DOI 10.1111/j.1365-2958.1996.tb02640.x; Fuqua C, 1998, CURR OPIN MICROBIOL, V1, P183, DOI 10.1016/S1369-5274(98)80009-X; Fuqua C, 1996, J BACTERIOL, V178, P435, DOI 10.1128/jb.178.2.435-440.1996; FUQUA C, 1995, J BACTERIOL, V177, P1367, DOI 10.1128/jb.177.5.1367-1373.1995; Fuqua C, 1999, CELL-CELL SIGNALING IN BACTERIA, P211; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; FUQUA WC, 1994, J BACTERIOL, V176, P2796, DOI 10.1128/JB.176.10.2796-2806.1994; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HANZELKA BL, 1995, J BACTERIOL, V177, P815, DOI 10.1128/jb.177.3.815-817.1995; HEINZEL T, 1990, J BIOL CHEM, V265, P17928; Hwang IY, 1999, MOL MICROBIOL, V34, P282, DOI 10.1046/j.1365-2958.1999.01595.x; HWANG IY, 1994, P NATL ACAD SCI USA, V91, P4639, DOI 10.1073/pnas.91.11.4639; HWANG IY, 1995, J BACTERIOL, V177, P449, DOI 10.1128/jb.177.2.449-458.1995; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Li PL, 2000, J BACTERIOL, V182, P179, DOI 10.1128/JB.182.1.179-188.2000; Luo ZQ, 2000, J BIOL CHEM, V275, P7713, DOI 10.1074/jbc.275.11.7713; Luo ZQ, 1999, P NATL ACAD SCI USA, V96, P9009, DOI 10.1073/pnas.96.16.9009; Luo ZQ, 2001, MOL PLANT MICROBE IN, V14, P98, DOI 10.1094/MPMI.2001.14.1.98; MERSEREAU M, 1990, GENE, V90, P149, DOI 10.1016/0378-1119(90)90452-W; More MI, 1996, SCIENCE, V272, P1655, DOI 10.1126/science.272.5268.1655; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Newman JR, 1999, GENE, V227, P197, DOI 10.1016/S0378-1119(98)00601-5; Oger P, 1998, MOL MICROBIOL, V27, P277, DOI 10.1046/j.1365-2958.1998.00671.x; Panagiotidis CH, 1998, MOL MICROBIOL, V30, P535, DOI 10.1046/j.1365-2958.1998.01084.x; Piper KR, 2000, J BACTERIOL, V182, P1080, DOI 10.1128/JB.182.4.1080-1088.2000; PIPER KR, 1993, NATURE, V362, P448, DOI 10.1038/362448a0; Qin YP, 2000, EMBO J, V19, P5212, DOI 10.1093/emboj/19.19.5212; Schreiber V, 2000, MOL MICROBIOL, V35, P765, DOI 10.1046/j.1365-2958.2000.01747.x; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Scott DJ, 1999, J MOL BIOL, V293, P997, DOI 10.1006/jmbi.1999.3221; SUSSKIND M, 1983, LAMBDA, P234; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TEMPE J, 1977, P NATL ACAD SCI USA, V74, P2848, DOI 10.1073/pnas.74.7.2848; Turgay K, 1998, EMBO J, V17, P6730; Winans SC, 1999, CELL-CELL SIGNALING IN BACTERIA, P117; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0; Zhu J, 1998, MOL MICROBIOL, V27, P289, DOI 10.1046/j.1365-2958.1998.00672.x; Zhu J, 1999, P NATL ACAD SCI USA, V96, P4832, DOI 10.1073/pnas.96.9.4832; Zhu J, 1998, J BACTERIOL, V180, P5398, DOI 10.1128/JB.180.20.5398-5405.1998; Zhu J, 2001, P NATL ACAD SCI USA, V98, P1507, DOI 10.1073/pnas.98.4.1507	52	51	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49449	49458		10.1074/jbc.M107881200	http://dx.doi.org/10.1074/jbc.M107881200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11687576	hybrid			2022-12-25	WOS:000173922100107
J	Voice, JK; Dorsam, G; Lee, H; Kong, Y; Goetzl, EJ				Voice, JK; Dorsam, G; Lee, H; Kong, Y; Goetzl, EJ			Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor	FASEB JOURNAL			English	Article						neuropeptide; IgE; cytokines; eosinophils; hypersensitivity	MESSENGER-RNA; CHROMOSOMAL LOCALIZATION; MURINE SCHISTOSOMIASIS; LYMPHOCYTES; VIP; POLYPEPTIDE; MODEL; MOUSE; GENE	Vasoactive intestinal peptide (VIP) and its G-protein-coupled receptors (VPAC1 and VPAC2 Rs) are prominent in the immune system. In T cells, VPAC1 R is expressed constitutively whereas VPAC2 R is induced only after stimulation of the T cell receptor (TCR) or exposure to some cytokines. VPAC1 R and VPAC2 R also transduce different effects of VIP on T cells. Constitutive expression of VPAC2 R selectively in CD4(+) T cells (helper-inducer Th cells) of transgenic (TG) C57BL/6 mice directed by the lck tyrosine kinase promoter is now shown to evoke production of more Th2-type interleukins 4 and 5, and less Th1-type interferon gamma after TCR activation. VPAC2 R TG mice consequently have significant elevations of blood IgE, IgG1, and eosinophils. VPAC2 R TG mice also show increased IgE antibody responses, which mediate heightened cutaneous allergic reactions, and have depressed delayed-type hypersensitivity. VIP enhancement of the ratio of Th2 cell to Th1 cell cytokines thus evokes an allergic state in normally nonallergic mice, which suggests the possibility of neuropeptide contributions to immune phenotypic alterations in human hypersensitivity diseases.	Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Ctr, Dept Microbiol Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Med, UB8B,Box 0711,533 Parnassus & 4th, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu	Dorsam, Glenn/GYD-8815-2022	Lee, Hsinyu/0000-0002-1477-0183	NIAID NIH HHS [AI 29912] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029912, R37AI029912] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; Bellinger DL, 1996, ADV NEUROIMMUNOL, V6, P5, DOI 10.1016/S0960-5428(96)00008-3; Delgado M, 1999, NEUROIMMUNOMODULAT, V6, P97, DOI 10.1159/000026369; Delgado M, 1996, J NEUROIMMUNOL, V68, P27, DOI 10.1016/0165-5728(96)00063-X; DORSAM G, 2001, ANN NY ACAD SCI, V952, P79; Fujieda S, 1996, J CLIN INVEST, V98, P1527, DOI 10.1172/JCI118944; Ganea D, 1996, ADV NEUROIMMUNOL, V6, P61, DOI 10.1016/S0960-5428(96)00007-1; Goetzl EJ, 1996, J IMMUNOL, V156, P1; GOETZL EJ, 1994, MOL CELL NEUROSCI, V5, P145, DOI 10.1006/mcne.1994.1016; GOETZL EJ, 2001, IN PRESS P NATL ACAD; GOMARIZ RP, 1994, REGUL PEPTIDES, V50, P177, DOI 10.1016/0167-0115(94)90033-7; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Harmar AJ, 1998, PHARMACOL REV, V50, P265; HASSNER A, 1993, J ALLERGY CLIN IMMUN, V92, P891, DOI 10.1016/0091-6749(93)90067-P; Hernanz A, 1996, J NEUROIMMUNOL, V71, P25, DOI 10.1016/S0165-5728(96)00118-X; Jabrane-Ferrat N, 2000, BIOCHEMISTRY-US, V39, P9771, DOI 10.1021/bi0008783; JOHNSTON JA, 1994, J IMMUNOL, V153, P1762; Kaltreider HB, 1997, AM J RESP CELL MOL, V16, P133, DOI 10.1165/ajrcmb.16.2.9032120; Lara-Marquez ML, 2001, J IMMUNOL, V166, P2522, DOI 10.4049/jimmunol.166.4.2522; Mackay M, 1996, GENOMICS, V37, P345, DOI 10.1006/geno.1996.0569; Martinez C, 1996, J IMMUNOL, V156, P4128; MATHEW RC, 1992, J IMMUNOL, V148, P3572; Metwali A, 2000, FASEB J, V14, P948, DOI 10.1096/fasebj.14.7.948; Pankhaniya R, 1998, FASEB J, V12, P119, DOI 10.1096/fasebj.12.1.119; SAID SI, 1988, ANN NY ACAD SCI, V527, P1; SREEDHARAN SP, 1994, BIOCHEM BIOPH RES CO, V203, P141, DOI 10.1006/bbrc.1994.2160; SREEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939, DOI 10.1073/pnas.92.7.2939; SUN L, 1993, J NEUROIMMUNOL, V48, P59, DOI 10.1016/0165-5728(93)90059-8; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629; Xia MH, 1996, J IMMUNOL, V156, P160	30	72	73	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2489	2496		10.1096/fj.01-0671com	http://dx.doi.org/10.1096/fj.01-0671com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689474				2022-12-25	WOS:000172420500019
J	Zou, CP; Youssef, EM; Zou, CC; Carey, TE; Lotan, R				Zou, CP; Youssef, EM; Zou, CC; Carey, TE; Lotan, R			Differential effects of chromosome 3p deletion on the expression of the putative tumor suppressor RAR beta and on retinoid resistance in human squamous carcinoma cells	ONCOGENE			English	Article						chromosome 3p; retinoic acid receptor beta; retinoic acid; growth inhibition; head and neck cancer	ACID RECEPTOR-BETA; HUMAN HEAD; RESPONSIVE ELEMENT; BREAST-CANCER; GROWTH; GENE; METHYLATION; PROMOTER; OVEREXPRESSION; KERATINIZATION	Retinoids' effects on cell growth and differentiation are mediated by nuclear retinoid receptors, which are ligand-activated transcription enhancing factors. Because the expression of the retinoic acid receptor beta (RAR beta) gene, which is located on chromosome 3p24, is diminished in premalignant and malignant tissues it has been proposed that it acts as a tumor suppressor. To test the hypothesis that RAR beta loss leads to retinoid resistance, we studied several karyotyped head and neck squamous carcinoma (HNSCC) cell lines (UMSCC-17A, -17B, -22A, -22B, and -38) with deletion of one chromosome 3p arm. RAR beta mRNA was neither detected nor induced by retinoic acid in these cells, whereas it was expressed and induced by retinoic acid in two other HNSCC cell lines (1483 and 183) without 3p deletion. Methylation of the RAR beta gene promoter was detected in the 17B and 22B cells that failed to express RAR beta but no methylation was found in 183A cells that did express RAR beta mRNA. Responsiveness of HNSCC cells to several retinoids in assays of growth inhibition and colony formation, was rank ordered as: 22B > 1483 > 38 > 183 > 17B. Additionally, retinoid response elements were transactivated in 22B more efficiently than in 17B cells. These results indicate that loss of RAR beta expression does not necessarily lead to loss of growth inhibition by retinoids or to a block of retinoid signaling.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Obstet Gynecol & Reprod Sci, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; Univ Michigan, Ctr Canc, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System; UTMD Anderson Cancer Center; University of Michigan System; University of Michigan	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.	rlotan@mdanderson.org		Carey, Thomas/0000-0002-5202-7518	NCI NIH HHS [P01 CA52051, R25 CA57730] Funding Source: Medline; NIDCR NIH HHS [P50 DE11906] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA057730, P01CA052051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ausubel FM, 1998, CURRENT PROTOCOLS MO; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Buchhagen DL, 1996, HEAD NECK-J SCI SPEC, V18, P529; Burge-Bottenbley A, 1983, Nutr Cancer, V5, P121, DOI 10.1080/01635588309513788; CAREY TE, 1989, CANCER RES, V49, P6098; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; CROWE DL, 1991, DIFFERENTIATION, V48, P199, DOI 10.1111/j.1432-0436.1991.tb00258.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FERRARI N, 1994, EXP CELL RES, V211, P121, DOI 10.1006/excr.1994.1067; GEBERT JF, 1991, ONCOGENE, V6, P1859; GRENMAN R, 1991, CANCER, V67, P2741, DOI 10.1002/1097-0142(19910601)67:11<2741::AID-CNCR2820671105>3.0.CO;2-S; Hayashi K, 2000, CANCER LETT, V151, P199, DOI 10.1016/S0304-3835(99)00422-X; Hayashi K, 2001, JPN J CANCER RES, V92, P42, DOI 10.1111/j.1349-7006.2001.tb01046.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KRAUSE CJ, 1981, ARCH OTOLARYNGOL, V107, P703; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LATIF F, 1992, CANCER RES, V52, P1451; Le Q, 2000, ONCOGENE, V19, P1457, DOI 10.1038/sj.onc.1203436; LOTAN R, 1994, CANCER RES, V54, pS1987; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LOTAN R, 1991, METHODS ENZYMOLOGY R, P100; MAESTRO R, 1993, CANCER RES, V53, P5775; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MATTEI MG, 1988, HUM GENET, V80, P189, DOI 10.1007/BF00702867; McGregor F, 1997, CANCER RES, V57, P3886; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; Oridate N, 1996, ONCOGENE, V12, P2019; Oridate N, 1996, IN VITRO CELL DEV-AN, V32, P192; Picard E, 1999, J NATL CANCER I, V91, P1059, DOI 10.1093/jnci/91.12.1059; SACKS PG, 1988, CANCER RES, V48, P2858; SCHWARTZ J L, 1985, Nutrition and Cancer, V7, P77; SHALINSKY DR, 1995, CANCER RES, V55, P3183; Shalinsky DR, 1997, CANCER RES, V57, P162; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sun SY, 2000, CLIN CANCER RES, V6, P1563; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANDYKE DL, 1994, GENE CHROMOSOME CANC, V9, P192, DOI 10.1002/gcc.2870090308; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wan HS, 1999, CANCER RES, V59, P3518; Wan HS, 1998, J BIOL CHEM, V273, P26915, DOI 10.1074/jbc.273.41.26915; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; XU XC, 1994, CANCER RES, V54, P3580; Youssef Emile M., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P550; ZOU CP, 1994, CANCER RES, V54, P5479; Zou CP, 1999, DIFFERENTIATION, V64, P123, DOI 10.1046/j.1432-0436.1999.6420123.x	55	30	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6820	6827		10.1038/sj.onc.1204846	http://dx.doi.org/10.1038/sj.onc.1204846			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687961				2022-12-25	WOS:000171641000003
J	Burek, C; Roth, J; Koch, HG; Harzer, K; Los, M; Schulze-Osthoff, K				Burek, C; Roth, J; Koch, HG; Harzer, K; Los, M; Schulze-Osthoff, K			The role of ceramide in receptor- and stress-induced apoptosis studied in acidic ceramidase-deficient Farber disease cells	ONCOGENE			English	Article						apoptosis; ceramide; ceramidase; CD95; Farber disease	NIEMANN-PICK-DISEASE; GD3 GANGLIOSIDE; SPHINGOMYELINASE; DEATH; CD95; MICE; FAS; ACTIVATION; CASPASE-3; ABSENCE	The activation of sphingomyelinases leading to the generation of ceramide has been implicated in various apoptotic pathways. However, the role of ceramide as an essential death mediator remains highly controversial. In the present study, we investigated the functional relevance of ceramide in a genetic model by using primary cells from a Farber disease patient. These cells accumulate ceramide as the result of an inherited deficiency of acidic ceramidase. We demonstrate that Farber disease lymphocytes and fibroblasts underwent apoptosis induced by various stress stimuli, including staurosporine, anticancer drugs and gamma -irradiation, equally as normal control cells. In addition, caspase activation by these proapoptotic agents occurred rather similarly in Farber disease and control fibroblasts. Interestingly, Farber disease lymphoid cells underwent apoptosis induced by the CD95 death receptor more rapidly than control cells. Our data therefore suggest that ceramide does not play an essential role as a second messenger in stress-induced apoptosis. However, in accordance with a role in lipid-rich microdomains, ceramide by altering membrane composition may function as an amplifier in CD95-mediated apoptosis.	Univ Munich, Dept Immunol & Cell Biol, D-48149 Munster, Germany; Univ Munster, Dept Pediat, D-4400 Munster, Germany; Univ Tubingen, Neurochem Lab, Tubingen, Germany	University of Munich; University of Munster; Eberhard Karls University of Tubingen	Schulze-Osthoff, K (corresponding author), Univ Munich, Dept Immunol & Cell Biol, Rontgenstr 21, D-48149 Munster, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Los, Marek/0000-0001-9518-1411				Bezombes C, 2001, FASEB J, V15, P297; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; Chatelut M, 1996, CLIN CHIM ACTA, V245, P61, DOI 10.1016/0009-8981(95)06173-8; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Farina F, 2000, J HISTOCHEM CYTOCHEM, V48, P57, DOI 10.1177/002215540004800106; FUJIWAKI T, 1992, Acta Paediatrica Japonica, V34, P72; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Gulbins E, 2000, AM J PHYSIOL-RENAL, V279, pF605, DOI 10.1152/ajprenal.2000.279.4.F605; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Hsu SC, 1998, BLOOD, V91, P2658, DOI 10.1182/blood.V91.8.2658.2658_2658_2663; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kolodny EH, 2000, CURR OPIN HEMATOL, V7, P48, DOI 10.1097/00062752-200001000-00009; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Los M, 2000, BIOCHEMISTRY-US, V39, P7365, DOI 10.1021/bi000158w; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; MOSER HW, 1969, AM J MED, V47, P869, DOI 10.1016/0002-9343(69)90202-2; Nishioka K, 1998, ARTHRITIS RHEUM, V41, P1; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; Qualman S J, 1987, Am J Med Genet Suppl, V3, P233; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; Segui B, 2000, FASEB J, V14, P36, DOI 10.1096/fasebj.14.1.36; Spinedi A, 1999, BIOCHEM BIOPH RES CO, V255, P456, DOI 10.1006/bbrc.1999.0230; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; SUGITA M, 1972, SCIENCE, V178, P1100, DOI 10.1126/science.178.4065.1100; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	49	37	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6493	6502		10.1038/sj.onc.1204841	http://dx.doi.org/10.1038/sj.onc.1204841			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641773	Green Published			2022-12-25	WOS:000171404200001
J	Butz, K; Denk, C; Fitscher, B; Crnkovic-Mertens, I; Ullmann, A; Schroder, CH; Hoppe-Seyler, F				Butz, K; Denk, C; Fitscher, B; Crnkovic-Mertens, I; Ullmann, A; Schroder, CH; Hoppe-Seyler, F			Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity	ONCOGENE			English	Article						liver cancer; Hepatitis B virus; peptide aptamers; therapy; virus replication	TRANSIENT EXPRESSION; DNA; INHIBITION; PARTICLES; SELECTION; MUTANTS; CANCER; IDENTIFICATION; REPLICATION; 2-HYBRID	A substantial proportion of the worldwide liver cancer incidence is associated with chronic hepatitis B virus (HBV) infection. The therapeutic management of HBV infections is still problematic and novel antiviral strategies are urgently required. Using the peptide aptamer screening system, we aimed to isolate new molecules, which can block viral replication by interfering with capsid formation. Eight peptide aptamers were isolated from a randomized expression library, which specifically bound to the HBV core protein under intracellular conditions. One of them, named C1-1, efficiently inhibited viral capsid formation and, consequently, HBV replication and virion production. Hence, C1-1 is a novel model compound for inhibiting HBV replication by blocking capsid formation and provides a new basis for the development of therapeutic molecules with specific antiviral potential against HBV infections.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	hoppe-seyler@dkfz-heidelberg.de		Hoppe-Seyler, Felix/0000-0002-1864-300X				Allen MI, 1998, HEPATOLOGY, V27, P1670, DOI 10.1002/hep.510270628; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; Bottcher B, 1998, EMBO J, V17, P6839, DOI 10.1093/emboj/17.23.6839; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; BUTZ K, 1995, ONCOGENE, V10, P927; CALVERT J, 1994, J VIROL, V68, P2084, DOI 10.1128/JVI.68.4.2084-2090.1994; CHANG CM, 1987, EMBO J, V6, P675, DOI 10.1002/j.1460-2075.1987.tb04807.x; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Colas P, 2000, CURR OPIN CHEM BIOL, V4, P54, DOI 10.1016/S1367-5931(99)00051-4; Conway JF, 1997, NATURE, V386, P91, DOI 10.1038/386091a0; CROWTHER RA, 1994, CELL, V77, P943, DOI 10.1016/0092-8674(94)90142-2; Cunningham BC, 1997, CURR OPIN STRUC BIOL, V7, P457, DOI 10.1016/S0959-440X(97)80107-8; Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702; DYSON MR, 1995, P NATL ACAD SCI USA, V92, P2194, DOI 10.1073/pnas.92.6.2194; Elliott G, 1999, GENE THER, V6, P149, DOI 10.1038/sj.gt.3300850; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; GANEM D, 1996, VIROLOGY, P2703; HARLOW E, 1999, USING ANTIBODIES LAB, P221; Hoppe-Seyler F, 2000, J MOL MED, V78, P426, DOI 10.1007/s001090000140; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; Konig S, 1998, J VIROL, V72, P4997; LADNER RC, 1995, TRENDS BIOTECHNOL, V13, P426, DOI 10.1016/S0167-7799(00)88997-0; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; LAMBERTS C, 1993, J VIROL, V67, P3756, DOI 10.1128/JVI.67.7.3756-3762.1993; Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; ROBINSON WS, 1994, ANNU REV MED, V45, P297; ROINGEARD P, 1990, HEPATOLOGY, V11, P277, DOI 10.1002/hep.1840110219; Scaglioni P, 1996, HEPATOLOGY, V24, P1010; SCAGLIONI PP, 1994, VIROLOGY, V205, P112, DOI 10.1006/viro.1994.1625; Seifer M, 1995, INTERVIROLOGY, V38, P47, DOI 10.1159/000150414; SUMMERS J, 1990, J VIROL, V64, P2819, DOI 10.1128/JVI.64.6.2819-2824.1990; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; SUREAU C, 1986, CELL, V47, P37, DOI 10.1016/0092-8674(86)90364-8; TUTTLEMAN JS, 1986, CELL, V47, P451, DOI 10.1016/0092-8674(86)90602-1; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; von Weizsacker F, 1999, HEPATOLOGY, V30, P308, DOI 10.1002/hep.510300139; vonWeizsacker F, 1996, HEPATOLOGY, V24, P294; vonWeizsacker F, 1997, HEPATOLOGY, V26, P251, DOI 10.1002/hep.510260237; WRIGHT TL, 1993, LANCET, V342, P1340, DOI 10.1016/0140-6736(93)92250-W; WU TT, 1990, VIROLOGY, V175, P255, DOI 10.1016/0042-6822(90)90206-7; Wynne SA, 1999, MOL CELL, V3, P771, DOI 10.1016/S1097-2765(01)80009-5; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; ZHOU S, 1992, P NATL ACAD SCI USA, V89, P10046, DOI 10.1073/pnas.89.21.10046	50	71	81	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6579	6586		10.1038/sj.onc.1204805	http://dx.doi.org/10.1038/sj.onc.1204805			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641783				2022-12-25	WOS:000171404200011
J	Meuwissen, R; Linn, SC; van der Valk, M; Mooi, WJ; Berns, A				Meuwissen, R; Linn, SC; van der Valk, M; Mooi, WJ; Berns, A			Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene	ONCOGENE			English	Article						somatic activation; Cre-lox; conditional K-Ras allele; lung epithelial tissue; lung tumors; non-small cell lung cancer	TRANSCRIPTION FACTOR-I; SURFACTANT PROTEIN-B; TRANSGENIC MICE; PULMONARY ADENOCARCINOMA; CLINICAL-SIGNIFICANCE; PROGNOSTIC MARKER; CELL CARCINOMAS; GENE-TRANSFER; CANCER; EXPRESSION	The onset of human lung cancer occurs through sequential mutations in oncogenes and tumor suppressor genes. Mutations in K-Ras play a prominent role in human non-small cell lung cancer. We have developed a mouse lung tumor model in which K-Ras can be sporadically activated through Cre-lox mediated somatic recombination. Adenoviral mediated delivery of Cre recombinase in lung epithelial cells gave rise to rapid onset of tumorigenesis, yielding pulmonary adenocarcinomas with 100% incidence after a short latency. The lung tumor lesions shared many features with human non-small cell lung cancer. Our data show that sporadic expression of the K-Ras oncogene is sufficient to elicit lung tumorigenesis. Therefore this model has many advantages over conventional transgenic models used thus far.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Expt Anim Pathol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Diagnost Oncol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	tberns@nki.nl						Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BOS JL, 1989, CANCER RES, V49, P4682; CAREY FA, 1992, THORAX, V47, P1041, DOI 10.1136/thx.47.12.1041; CHAN GL, 1992, THER DRUG MONIT, V14, P42, DOI 10.1097/00007691-199202000-00007; Contag CH, 2000, NEOPLASIA, V2, P41, DOI 10.1038/sj.neo.7900079; Cooper CA, 1997, J PATHOL, V181, P401, DOI 10.1002/(SICI)1096-9896(199704)181:4<401::AID-PATH799>3.0.CO;2-Y; EDWARDS CW, 1987, J CLIN PATHOL, V40, P125, DOI 10.1136/jcp.40.2.125; FIJNEMAN RJA, 1995, IMMUNOGENETICS, V41, P106, DOI 10.1007/BF00182320; Garcia SB, 1999, J PATHOL, V187, P61, DOI 10.1002/(SICI)1096-9896(199901)187:1<61::AID-PATH247>3.0.CO;2-I; GAZDAR AF, 1994, ANTICANCER RES, V14, P261; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Howell JM, 1998, HUM GENE THER, V9, P629, DOI 10.1089/hum.1998.9.5-629; Huncharek M, 1999, CARCINOGENESIS, V20, P1507, DOI 10.1093/carcin/20.8.1507; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kaufmann O, 2000, HISTOPATHOLOGY, V36, P8; KHOOR A, 1994, J HISTOCHEM CYTOCHEM, V42, P1187, DOI 10.1177/42.9.8064126; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Malkinson AM, 1998, EXP LUNG RES, V24, P541, DOI 10.3109/01902149809087385; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MARONPOT RR, 1991, EXP LUNG RES, V17, P305, DOI 10.3109/01902149109064420; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MILLS NE, 1995, CANCER RES, V55, P1444; Omer CA, 2000, CANCER RES, V60, P2680; OOMEN LCJM, 1991, EXP LUNG RES, V17, P283, DOI 10.3109/01902149109064419; Ordonez NG, 2000, ADV ANAT PATHOL, V7, P123, DOI 10.1097/00125480-200007020-00007; Otake K, 1998, HUM GENE THER, V9, P2207, DOI 10.1089/hum.1998.9.15-2207; OUDEJANS JJ, 1991, INT J CANCER, V49, P875, DOI 10.1002/ijc.2910490613; Park JY, 2000, LUNG CANCER-J IASLC, V30, P83, DOI 10.1016/S0169-5002(00)00189-6; PELLEGATA NS, 1994, CANCER RES, V54, P1556; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; Rom WN, 2000, AM J RESP CRIT CARE, V161, P1355, DOI 10.1164/ajrccm.161.4.9908012; SAITOH A, 1990, ONCOGENE, V5, P1195; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schmidt EE, 2000, P NATL ACAD SCI USA, V97, P13702, DOI 10.1073/pnas.240471297; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shimkin M B, 1975, Adv Cancer Res, V21, P1, DOI 10.1016/S0065-230X(08)60970-7; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; SOZZI G, 1995, CANCER RES, V55, P135; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TenHaveOpbroek AAW, 1997, HISTOL HISTOPATHOL, V12, P319; TSUCHIYA E, 1995, J CANCER RES CLIN, V121, P577, DOI 10.1007/BF01197773; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; WHITSETT JA, 1995, PHYSIOL REV, V75, P749, DOI 10.1152/physrev.1995.75.4.749; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675; World Health Organization, 1981, HIST TYP LUNG TUM; ZSENGELLER ZK, 1995, HUM GENE THER, V6, P457, DOI 10.1089/hum.1995.6.4-457	52	150	159	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6551	6558		10.1038/sj.onc.1204837	http://dx.doi.org/10.1038/sj.onc.1204837			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641780				2022-12-25	WOS:000171404200008
J	Koduri, RS; Gronroos, JO; Laine, VJO; Le Calvez, C; Lambeau, G; Nevalainen, TJ; Gelb, MH				Koduri, RS; Gronroos, JO; Laine, VJO; Le Calvez, C; Lambeau, G; Nevalainen, TJ; Gelb, MH			Bactericidal properties of human and murine groups I, II, V, X, and XII secreted phospholipases A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; INFLAMMATORY DISEASES; ARACHIDONIC-ACID; MAST-CELLS; DETERMINANTS; EXPRESSION; FLUID; GENE	Group IIA secreted phospholipase A(2) (sPLA2) is known to display potent Gram-positive bactericidal activity in vitro and in vivo. We have analyzed the bactericidal activity of the full set of recombinant murine and human groups I, II, V, X, and XII sPLA2s on Listeria monocytogenes, Staphylococcus aureus, and Escherichia coli. The rank order potency among human sPLA2s against Gram-positive bacteria is group IIA > X > V >XII > IIE > IB, IIF (for murine sPLA2s: IIA > IID > V > IIE > IIC, X > IB, IIF), and only human group XII displays detectable bactericidal activity against the Gram-negative bacterium E. coli. These studies show that highly basic sPLA2s display potent bactericidal activity with the exception of the ability of the acidic human group X sPLA2 to kill Gram-positive bacteria. By studying the Bacillus subtilis and S. aureus bactericidal potencies of a large panel of human group IIA mutants in which basic residues were mutated to acidic residues, it was found that: 1) the overall positive charge of the sPLA2 is the dominant factor in dictating bactericidal potency; 2) basic residues on the putative membrane binding surface of the sPLA2 are modestly more important for bactericidal activity than are other basic residues; 3) relative bactericidal potency tracks well with the ability of these mutants to degrade phospholipids in the bacterial membrane; and 4) exposure of the bacterial membrane of Gram-positive bacteria by disruption of the cell wall dramatically reduces the negative effect of charge reversal mutagenesis on bactericidal potency.	CNRS, UPR 411, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Turku Univ Hosp, Turku 20520, Finland; Univ Turku, Dept Pathol, Turku 20520, Finland; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Turku; University of Turku; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Nevalainen, TJ (corresponding author), CNRS, UPR 411, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	timo.nevalainen@utu.fi; gelb@chem.washington.edu	Lambeau, Gerard/GRJ-5624-2022	gelb, michael/0000-0001-7000-5219; Lambeau, Gerard/0000-0002-9239-518X				Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1484, P195, DOI 10.1016/S1388-1981(00)00018-4; CROWL RM, 1991, J BIOL CHEM, V266, P2647; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Elsbach P, 1997, PROG SURG, V24, P17, DOI 10.1159/000075479; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Foreman-Wykert AK, 1999, J CLIN INVEST, V103, P715, DOI 10.1172/JCI5468; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Gronroos JO, 2001, J IMMUNOL, V166, P4029, DOI 10.4049/jimmunol.166.6.4029; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; Ho IC, 2001, J BIOL CHEM, V276, P18321, DOI 10.1074/jbc.M008837200; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V117, P217; Laine VJO, 1999, J IMMUNOL, V162, P7402; Laine VJO, 2000, INFECT IMMUN, V68, P87, DOI 10.1128/IAI.68.1.87-92.2000; Madsen LM, 1996, INFECT IMMUN, V64, P2425, DOI 10.1128/IAI.64.7.2425-2430.1996; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; Nevalainen TJ, 2000, BBA-MOL CELL BIOL L, V1488, P83, DOI 10.1016/S1388-1981(00)00112-8; NEVALAINEN TJ, 1993, CLIN CHEM, V39, P2453; Othman R, 1996, BBA-LIPID LIPID MET, V1303, P92, DOI 10.1016/0005-2760(96)00083-5; Paramo L, 1998, EUR J BIOCHEM, V253, P452, DOI 10.1046/j.1432-1327.1998.2530452.x; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Richmond BL, 2001, GASTROENTEROLOGY, V120, P1193, DOI 10.1053/gast.2001.23254; RUBINSTEIN E, 1985, GASTROENTEROLOGY, V88, P927, DOI 10.1016/S0016-5085(85)80009-3; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, BIOCHEM BIOPH RES CO, V279, P223, DOI 10.1006/bbrc.2000.3908; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Weinrauch Y, 1996, J CLIN INVEST, V97, P250, DOI 10.1172/JCI118399; Weinrauch Y, 1998, J CLIN INVEST, V102, P633, DOI 10.1172/JCI3121; WEISS J, 1991, J BIOL CHEM, V266, P4162; WEISS J, 1994, J BIOL CHEM, V269, P26331	39	204	211	1	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					5849	5857		10.1074/jbc.M109699200	http://dx.doi.org/10.1074/jbc.M109699200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11694541	hybrid			2022-12-25	WOS:000173989200022
J	Wang, H; McIntosh, LP; Graves, BJ				Wang, H; McIntosh, LP; Graves, BJ			Inhibitory module of Ets-1 allosterically regulates DNA binding through a dipole-facilitated phosphate contact	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; MURINE ETS-1; INDIRECT READOUT; AUTO-INHIBITION; FACTORS ELK-1; ALPHA-HELIX; DOMAIN; PROTEINS; COMPLEX; RECOGNITION	DNA binding of the transcription factor Ets-1 is negatively regulated by three inhibitory helices that lie near the ETS domain. The current model suggests that this negative regulation, termed autoinhibition, is caused by the energetic expense of a DNA-induced structural transition that includes the unfolding of one inhibitory helix. This report investigates the role of helix H1 of the ETS domain in the autoinhibition mechanism. Previous structural studies modeled the inhibitory helices packing together and connecting with helix H1, suggesting a role of this helix in the configuration of an inhibitory module. Recently, high-resolution structures of the ETS domain-DNA interface indicate that the N terminus of helix H1 directly contacts DNA. The contact, which is augmented by the macrodipole of helix H1, consists of a hydrogen bond between the amide NH of leucine 337 in helix HI and the oxygen of a corresponding phosphate. We propose that this hydrogen bond positions helix H1 to be a link between autoinhibition and DNA binding. Four independent approaches tested this hypothesis. First, the hydrogen bond was disrupted by removal of the phosphate in a missing phosphate analysis. Second, base pairs that surround the helix HI-contacting phosphate and appear to dictate DNA backbone conformation were mutated. Next, a hydrophobic residue in helix H1 that is expected to position the N terminus of the helix was altered. Finally, a residue on the surface of helix 111 that may contact the inhibitory elements was changed. In each case DNA binding and autoinhibition was affected. Taken together, the results demonstrate the role of the dipole-facilitated phosphate contact in DNA binding. Furthermore, the findings support a model in which helix H1 links the inhibitory elements to the ETS domain. We speculate that this helix, which is conserved in all Ets proteins, provides a common route to regulation.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of British Columbia; University of British Columbia	Graves, BJ (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, 200 Circle Hope, Salt Lake City, UT 84112 USA.				NCI NIH HHS [CA24014] Funding Source: Medline; NIGMS NIH HHS [GM38663, R01 GM038663] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038663, R29GM038663] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYMAMI J, 1990, P NATL ACAD SCI USA, V87, P2526, DOI 10.1073/pnas.87.7.2526; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Cowley DO, 2000, GENE DEV, V14, P366; COWLEY DO, 2000, THESIS U UTAH SALT L; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; Garvie CW, 2000, STRUCTURE, V8, P905, DOI 10.1016/S0969-2126(00)00182-9; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILLESPIE ME, 1998, THESIS U UTAH SALT L; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Graves BJ, 1998, COLD SPRING HARB SYM, V63, P621, DOI 10.1101/sqb.1998.63.621; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GREENALL A, 2001, J BIOL CHEM, V17, P17; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; Hassler M, 2001, EMBO J, V20, P3018, DOI 10.1093/emboj/20.12.3018; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; JONSEN M, 1999, THESIS U UTAH SALT L; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; Laget MP, 1996, ONCOGENE, V12, P1325; Lane MJ, 1997, NUCLEIC ACIDS RES, V25, P611, DOI 10.1093/nar/25.3.611; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Mo Y, 2000, NAT STRUCT BIOL, V7, P292; Mohibullah N, 1999, NUCLEIC ACIDS RES, V27, P2760, DOI 10.1093/nar/27.13.2760; Myszka DG, 1998, ANAL BIOCHEM, V265, P326, DOI 10.1006/abio.1998.2937; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PIETERS JML, 1989, NUCLEIC ACIDS RES, V17, P4551, DOI 10.1093/nar/17.12.4551; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAYGALLET D, 1995, ONCOGENE, V11, P303; Roll C, 1998, BIOCHEMISTRY-US, V37, P4059, DOI 10.1021/bi972377w; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Singh S, 1997, BIOCHEMISTRY-US, V36, P13214, DOI 10.1021/bi970819y; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; SNOWDENIFFT EA, 1990, BIOCHEMISTRY-US, V29, P6017, DOI 10.1021/bi00477a020; Szymczyna BR, 2000, J BIOL CHEM, V275, P28363, DOI 10.1074/jbc.M004294200; Wenz C, 1996, J BIOL CHEM, V271, P5565, DOI 10.1074/jbc.271.10.5565; Werner MH, 1997, J BIOMOL NMR, V10, P317, DOI 10.1023/A:1018399711996; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666	50	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2225	2233		10.1074/jbc.M109430200	http://dx.doi.org/10.1074/jbc.M109430200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11689571	hybrid			2022-12-25	WOS:000173421300083
J	Pearce, D; Naray-Fejes-Toth, A; Fejes-Toth, G				Pearce, D; Naray-Fejes-Toth, A; Fejes-Toth, G			Determinants of subnuclear organization of mineralocorticoid receptor characterized through analysis of wild type and mutant receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; HUMAN GLUCOCORTICOID RECEPTOR; LIVING CELLS; GENE-EXPRESSION; TRANSCRIPTIONAL SYNERGY; STEROID-RECEPTORS; ANDROGEN RECEPTOR; HORMONE RECEPTORS; BINDING DOMAIN; DNA-BINDING	The mineralocorticoid receptor (MR) is a hormone-dependent regulator of gene transcription that in the absence of ligand resides both in the cytoplasm and the nucleus. Agonists but not antagonists increase the number of MRs residing in the nucleus and cause aggregation of MRs into distinct clusters. To identify the functional determinants of MR nuclear organization, we examined the localization pattern of wild type MR and a series of mutants in the presence and absence of ligands using fluorescent protein chimeras in living cells. Our data show that although AM DNA binding is not necessary to mediate nuclear localization, it is absolutely required for wild type cluster formation as is an intact N-terminal or C-terminal activation function. In contrast, destabilization of a dimerization motif within the DNA-binding domain has no effect on subnuclear receptor architecture. These data suggest that normal AM cluster formation is dependent on both DNA binding and intact transcriptional activation functions but not on DNA-dependent receptor dimerization. Because dimer mutants bind with high affinity to hormone response element DNA multimers but not to single palindromic DNA sites, we suggest that clusters represent MR aggregates bound to DNA response element multimers in the vicinity of regulated genes.	Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Nephrol, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Dartmouth Coll Sch Med, Dept Physiol, Lebanon, NH 03756 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Dartmouth College	Pearce, D (corresponding author), Univ Calif San Francisco, Dept Med, Div Nephrol, Box 0532, San Francisco, CA 94143 USA.				NIDDK NIH HHS [DK51151, DK55845, DK54376] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051151, R56DK051151, R01DK055845, R01DK054376, R01DK051151] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; Chen SX, 1998, SCI CHINA SER A, V41, P39, DOI 10.1007/BF02900770; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; DeFranco Donald B., 1999, Cell Biochemistry and Biophysics, V30, P1, DOI 10.1007/BF02737882; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; Geller DS, 2000, SCIENCE, V289, P119, DOI 10.1126/science.289.5476.119; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; Govindan MV, 1998, J BIOL CHEM, V273, P24439, DOI 10.1074/jbc.273.38.24439; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KASPAR F, 1993, MOL CELL BIOL, V13, P7850, DOI 10.1128/MCB.13.12.7850; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; Liu WH, 1996, MOL ENDOCRINOL, V10, P1399, DOI 10.1210/me.10.11.1399; Llopis J, 2000, P NATL ACAD SCI USA, V97, P4363, DOI 10.1073/pnas.97.8.4363; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Meijer OC, 2000, J NEUROENDOCRINOL, V12, P245; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; Pearce D, 1998, J BIOL CHEM, V273, P30081, DOI 10.1074/jbc.273.46.30081; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x; ZHANG XK, 1991, J BIOL CHEM, V266, P8248; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	40	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1451	1456		10.1074/jbc.M105966200	http://dx.doi.org/10.1074/jbc.M105966200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11677231	hybrid			2022-12-25	WOS:000173166800076
J	Skorvaga, M; Theis, K; Mandavilli, BS; Kisker, C; Van Houten, B				Skorvaga, M; Theis, K; Mandavilli, BS; Kisker, C; Van Houten, B			The beta-hairpin motif of UvrB is essential for DNA binding, damage processing, and UvrC-mediated incisions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; ESCHERICHIA-COLI UVRAB; CRYSTAL-STRUCTURE; PROTEIN COMPLEX; PREINCISION COMPLEX; POLYMERASE-I; HELICASE-II; THERMUS-THERMOPHILUS; (A)BC EXCINUCLEASE; NUCLEASE	UvrB plays a major role in recognition and processing of DNA lesions during nucleotide excision repair. The crystal structure of UvrB revealed a similar fold as found in monomeric DNA helicases. Homology modeling suggested that the beta-hairpin motif of UvrB might be involved in DNA binding (Theis, K., Chen, P. J., Skorvaga, M., Van Houten, B., and Kisker, C. (1999) EMBO J. 18, 6899-6907). To determine a role of the beta-hairpin of Bacillus caldotenax UvrB, we have constructed a deletion mutant, Deltabetah UvrB, which lacks residues Gln-97-Asp-112 of the beta-hairpin. Deltabetah UvrB does not form a stable UvrB-DNA pre-incision complex and is inactive in UvrABC-mediated incision. However, Deltabetah UvrB is able to bind to UvrA and form a complex with UvrA and damaged DNA, competing with wild type UvrB. In addition, Deltabetah UvrB shows wild type-like ATPase activity in complex with UvrA that is stimulated by damaged DNA. In contrast to wild type UvrB, the ATPase activity of mutant UvrB does not lead to a destabilization of the damaged duplex. These results indicate that the conserved beta-hairpin motif is a major factor in DNA binding.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; Slovak Acad Sci, Canc Res Inst, Dept Mol Genet, Bratislava 83391, Slovakia; SUNY Stony Brook, Dept Pharmacol Sci, Ctr Struct Biol, Stony Brook, NY 11794 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Slovak Academy of Sciences; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Van Houten, B (corresponding author), NIEHS, Mol Genet Lab, NIH, POB 12233,MD D3-01,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	vanhout1@niehs.nih.gov	Skorvaga, Milan/AAO-2360-2021; Van Houten, Bennett/K-2284-2019; Kisker, Caroline/T-1724-2019	Kisker, Caroline/0000-0002-0216-6026; Theis, Karsten/0000-0003-2697-6143				CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10891, DOI 10.1093/nar/16.22.10891; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GOOSEN N, 1998, NUCL ACID M, V12, P103; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Gordienko I, 1997, EMBO J, V16, P889, DOI 10.1093/emboj/16.4.889; GROSSMAN L, 1998, NUCLEOTIDE EXCISION, V1, P11; HSU DS, 1995, J BIOL CHEM, V270, P8319, DOI 10.1074/jbc.270.14.8319; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6824, DOI 10.1073/pnas.88.15.6824; LLOYD RS, 1995, DNA REPAIR MECH IMPA, P25; Machius M, 1999, P NATL ACAD SCI USA, V96, P11717, DOI 10.1073/pnas.96.21.11717; Moolenaar GF, 2000, J BIOL CHEM, V275, P8044, DOI 10.1074/jbc.275.11.8044; Moolenaar GF, 2000, J BIOL CHEM, V275, P8038, DOI 10.1074/jbc.275.11.8038; Moolenaar GF, 1997, MUTAT RES-DNA REPAIR, V385, P195, DOI 10.1016/S0921-8777(97)00042-6; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; Nakagawa N, 1999, J BIOCHEM, V126, P986, DOI 10.1093/oxfordjournals.jbchem.a022566; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1992, J BIOL CHEM, V267, P780; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Sohi M, 2000, FEBS LETT, V465, P161, DOI 10.1016/S0014-5793(99)01690-7; Soultanas P, 1999, J MOL BIOL, V290, P137, DOI 10.1006/jmbi.1999.2873; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Theis K, 2000, MUTAT RES-DNA REPAIR, V460, P277, DOI 10.1016/S0921-8777(00)00032-X; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; Verhoeven EEA, 2000, J BIOL CHEM, V275, P5120, DOI 10.1074/jbc.275.7.5120; Yamagata A, 2000, J BIOL CHEM, V275, P13235, DOI 10.1074/jbc.275.18.13235; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889; ZOU Y, 1995, BIOCHEMISTRY-US, V34, P13582, DOI 10.1021/bi00041a038	38	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1553	1559		10.1074/jbc.M108847200	http://dx.doi.org/10.1074/jbc.M108847200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11687584	hybrid			2022-12-25	WOS:000173166800089
J	Zaghini, I; Landrier, JF; Grober, J; Krief, S; Jones, SA; Monnot, MC; Lefrere, I; Watson, MA; Collins, JL; Fujii, H; Besnard, P				Zaghini, I; Landrier, JF; Grober, J; Krief, S; Jones, SA; Monnot, MC; Lefrere, I; Watson, MA; Collins, JL; Fujii, H; Besnard, P			Sterol regulatory element-binding protein-1c is responsible for cholesterol regulation of ileal bile acid-binding protein gene in vivo - Possible involvement of liver-X-receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; ADIPOCYTE DETERMINATION; MOLECULAR-CLONING; TRANSPORTER GENE; EXPRESSION; IDENTIFICATION; TRANSCRIPTION; ABSORPTION; 1C; METABOLISM	Real bile acid-binding protein (I-BAEP) is a cytosolic protein that binds bile acid (BA) specifically. In the ileum, it is thought to be implied in their enterohepatic circulation. Because the fecal excretion of BA represents the main physiological way of elimination for cholesterol (CS), the I-BABP gene could have a major function in CS homeostasis. Therefore, the I-BABP gene expression might be controlled by CS. I-BABP mRNA levels were significatively increased when the human enterocyte-like CaCo-2 cells were CS-deprived and repressed when CS were added to the medium. A highly conserved sterol regularory element-like sequence (SRE) and a putative GC box were found in human BABP gene promoter. Different constructs of human IBABP promoter, cloned upstream of a chloramphenicol acetyltransferase (CAT) reporter gene, have been used in transfections studies. CAT activity of the wild type promoter was increased in presence of CS-deprived medium, and conversely, decreased by a CS-supplemented medium. The inductive effect of CS depletion was fully abolished when the putative SRE sequence and/or GC box were mutated or deleted. Co-transfections experiments with the mature isoforms of human sterol responsive element-binding proteins (SREBPs) and Sp1 demonstrate that the CS-mediated regulation of I-BABP gene was dependent of these transcriptional factors. Paradoxically, mice subjected to a standard chow supplemented with 2% CS for 14 days exhibited a significant rise in both I-BABP and SREBP1c mRNA levels. We show that in vivo, this up-regulation could be explained by a recently described regulatory pathway involving a positive regulation of SREBP1c by liver-X-receptor following a high CS diet.	Univ Bourgogne, FRE 2049 CNRS, ENSBANA, F-21000 Dijon, France; Bioprojet Biotech, F-35760 St Gregoire, France; GlaxoSmithKline Res & Dev Ltd, Syst Res, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline Res & Dev Ltd, Med Chem, Res Triangle Pk, NC 27709 USA; Niigata Univ, Sch Med, Dept Biochem, Niigata 951, Japan	Institut Agro; AgroSup Dijon; Universite de Bourgogne; GlaxoSmithKline; GlaxoSmithKline; Niigata University	Besnard, P (corresponding author), Univ Bourgogne, FRE 2049 CNRS, ENSBANA, 1 Esplanade Erasme, F-21000 Dijon, France.	pbesnard@u-bourgogne.fr	Landrier, Jean-Francois/AAH-2757-2019	Landrier, Jean-Francois/0000-0002-8690-8014; Krief, Stephane/0000-0002-5543-731X				Alpini G, 1997, GASTROENTEROLOGY, V113, P1734, DOI 10.1053/gast.1997.v113.pm9352879; AMANO O, 1992, ANAT REC, V234, P215, DOI 10.1002/ar.1092340208; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; Duane WC, 2000, J LIPID RES, V41, P1384; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Field FJ, 2001, J LIPID RES, V42, P1687; Field FJ, 2001, J LIPID RES, V42, P1; FUJITA M, 1995, EUR J BIOCHEM, V233, P406, DOI 10.1111/j.1432-1033.1995.406_2.x; GONG YZ, 1994, P NATL ACAD SCI USA, V91, P4741, DOI 10.1073/pnas.91.11.4741; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Kanda T, 1996, FEBS LETT, V384, P131, DOI 10.1016/0014-5793(96)00291-8; Kanda T, 1998, BIOCHEM J, V330, P261, DOI 10.1042/bj3300261; KRAMER W, 1993, J BIOL CHEM, V268, P18035; KRAMER W, 1995, BBA-LIPID LIPID MET, V1257, P230, DOI 10.1016/0005-2760(95)00075-N; Kramer W, 1998, BIOCHEM J, V333, P335, DOI 10.1042/bj3330335; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Lucke C, 2000, EUR J BIOCHEM, V267, P2929, DOI 10.1046/j.1432-1327.2000.01307.x; Lucke C, 1996, STRUCTURE, V4, P785, DOI 10.1016/S0969-2126(96)00086-X; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MALLORDY A, 1995, EUR J BIOCHEM, V227, P801, DOI 10.1111/j.1432-1033.1995.tb20204.x; Oelkers P, 1997, J CLIN INVEST, V99, P1880, DOI 10.1172/JCI119355; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; SACCHETTINI JC, 1990, J BIOL CHEM, V265, P19199; Schoonjans K, 2000, BBA-MOL CELL BIOL L, V1529, P114, DOI 10.1016/S1388-1981(00)00141-4; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Whitney KD, 2001, J BIOL CHEM, V276, P43509, DOI 10.1074/jbc.M106155200; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	46	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1324	1331		10.1074/jbc.M106375200	http://dx.doi.org/10.1074/jbc.M106375200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11684682	hybrid			2022-12-25	WOS:000173166800060
J	Morotami-Yano, K; Yano, K; Saito, H; Sun, Z; Iwama, A; Miki, Y				Morotami-Yano, K; Yano, K; Saito, H; Sun, Z; Iwama, A; Miki, Y			Human regulatory factor X 4 (RFX4) is a testis-specific dimeric DNA-binding protein that cooperates with other human RFX members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II DEFICIENCY; TRANSCRIPTION FACTORS; DIMERIZATION DOMAIN; REPRESSION DOMAINS; GENE; ACTIVATION; COMPLEX; FAMILY; LOCALIZATION; PROMOTER	Regulatory factor X (RFX) members are evolutionarily conserved transcription factors that share a highly conserved winged helix DNA-binding domain. Human RFX4 has been isolated from breast cancer as a partial cDNA encoding a short RFX-type DNA-binding domain fused to the estrogen receptor, but the entire structure of RFX4 has been unknown. Here, we report the molecular cloning and characterization of human RFX4. RFX4 contains evolutionarily conserved regions, including a RFX-type DNA-binding domain, a dimerization domain, and other conserved regions, and is closely related to RFX1, RFX2, and RFX3 in structure. The expression of RFX4 is restricted to testis. In vitro synthesized RFX4 protein bound to typical RFX binding sites in a sequence-dependent manner. Immunoprecipitation analyses showed that RFX4 interacts physically with RFX2, RFX3, and RFX4 itself but not with RFX1. In contrast to other mammalian RFX members that form dimers, RFX4 is revealed to have no distinct transcriptional activation domains. By using a chimeric protein of RFX1 an R the C-terminal domain of RFX4 was shown to be a possible transcriptional repression domain. Taken together, these results indicate that RFX4 is the first mammalian member of RFX family without transcriptional activation capacity and might function through selective interactions with other RFX members in transcriptional regulation.	Japanese Fdn Canc Res, Inst Canc, Dept Mol Diag, Toshima Ku, Tokyo 1708455, Japan; Stanford Univ, Sch Med, Liem Sioe Liong Mol Biol Lab, Dept Surg & Genet, Stanford, CA 94305 USA; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan	Japanese Foundation for Cancer Research; Stanford University; University of Tsukuba	Miki, Y (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Mol Diag, Toshima Ku, 1-37-1 Kamiikebukuro, Tokyo 1708455, Japan.				NCI NIH HHS [R01 CA070297] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen L, 2000, J BIOL CHEM, V275, P32227, DOI 10.1074/jbc.M002645200; DOTZLAW H, 1992, MOL ENDOCRINOL, V6, P773, DOI 10.1210/me.6.5.773; Doyle J, 1996, GENOMICS, V35, P227, DOI 10.1006/geno.1996.0343; Durand B, 2000, GENE, V246, P285, DOI 10.1016/S0378-1119(00)00093-7; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Iwama A, 1999, MOL CELL BIOL, V19, P3940; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; Katan-Khaykovich Y, 1998, J BIOL CHEM, V273, P24504, DOI 10.1074/jbc.273.38.24504; Katan-Khaykovich Y, 1999, J MOL BIOL, V294, P121, DOI 10.1006/jmbi.1999.3245; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu MS, 1999, J BIOL CHEM, V274, P15433, DOI 10.1074/jbc.274.22.15433; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; MENASCE LP, 1993, GENOMICS, V17, P263, DOI 10.1006/geno.1993.1320; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; SAMBROOK J, 1989, MOL CLONING LAB MANU, V18, P47; Schmitt EK, 2000, J BIOL CHEM, V275, P9348, DOI 10.1074/jbc.275.13.9348; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; SUN ZJ, 1995, J BIOL CHEM, V270, P1462, DOI 10.1074/jbc.270.3.1462; Swoboda P, 2000, MOL CELL, V5, P411, DOI 10.1016/S1097-2765(00)80436-0; Villard J, 2000, MOL CELL BIOL, V20, P3364, DOI 10.1128/MCB.20.10.3364-3376.2000; Villard J, 1997, HUM MUTAT, V10, P430; WU SY, 1995, MOL CELL BIOL, V15, P1479; Yano K, 2000, BIOCHEM BIOPH RES CO, V270, P171, DOI 10.1006/bbrc.2000.2392; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253	31	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					836	842		10.1074/jbc.M108638200	http://dx.doi.org/10.1074/jbc.M108638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11682486	hybrid			2022-12-25	WOS:000173087900107
J	Peterbauer, T; Mucha, J; Mach, L; Richter, A				Peterbauer, T; Mucha, J; Mach, L; Richter, A			Chain elongation of raffinose in pea seeds - Isolation, charcterization, and molecular cloning of a multifunctional enzyme catalyzing the synthesis of stachyose and verbascose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AJUGA-REPTANS L; FAMILY OLIGOSACCHARIDES; ALPHA-GALACTOSIDASE; PURIFICATION; LEAVES; BIOSYNTHESIS; MYOINOSITOL; METABOLISM; COFACTOR; DATABASE	Raffinose oligosaccharides are major soluble carbohydrates in seeds and other tissues of plants. Their biosynthesis proceeds by stepwise addition of galactose units to sucrose, which are provided by the unusual donor galactinol (O-alpha-D-galactopyranosyl-(1-->1)-L-myo-inositol). Chain elongation may also proceed by transfer of galactose units between raffinose oligosaccharides. We here report on the purification, characterization, and heterologous expression of a multifunctional stachyose synthase (EC 2.4.1.67) from developing pea (Pisum sativum L.) seeds. The protein, a member of family 36 of glycoside hydrolases, catalyzes the synthesis of stachyose, the tetrasaccharide of the raffinose series, by galactosyl transfer from galactinol to raffinose. It also mediates the synthesis of the pentasaccharide verbascose by galactosyl transfer from galactinol to stachyose as well as by self-transfer of the terminal galactose residue from one stachyose molecule to another. These activities show optima at pH 7.0. The enzyme also catalyzes hydrolysis of the terminal galactose residue of its substrates, but is unable to initiate the synthesis of raffinose oligosaccharides by galactosyl transfer from galactinol to sucrose. A minimum reaction mechanism which accounts for the broad substrate specificity and the steady-state kinetic properties of the protein is presented.	Univ Vienna, Inst Ecol, A-1090 Vienna, Austria; Univ Bodenkultur Wien, Ctr Appl Genet, A-1190 Vienna, Austria	University of Vienna; University of Natural Resources & Life Sciences, Vienna	Richter, A (corresponding author), Univ Vienna, Inst Ecol, Althanstr 14, A-1090 Vienna, Austria.	Andreas.Richter@univie.ac.at	Richter, Andreas/D-8483-2012; Peterbauer, Thomas/A-8001-2008	Richter, Andreas/0000-0003-3282-4808; Peterbauer, Thomas/0000-0002-2362-5711; Mach, Lukas/0000-0001-9013-5408				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BACHMANN M, 1994, PLANT PHYSIOL, V105, P1335, DOI 10.1104/pp.105.4.1335; BACHMANN M, 1995, PLANT PHYSIOL, V109, P991, DOI 10.1104/pp.109.3.991; Braun R, 2000, AUST J PLANT PHYSIOL, V27, P743, DOI 10.1071/PP99165; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; Fersht AR., 1977, ENZYME STRUCTURE MEC; Fischer S, 2001, ANN THORAC SURG, V71, P1140, DOI 10.1016/S0003-4975(01)02426-2; GAUDREAULT PR, 1981, PHYTOCHEMISTRY, V20, P2629, DOI 10.1016/0031-9422(81)85257-0; Gilmour SJ, 2000, PLANT PHYSIOL, V124, P1854, DOI 10.1104/pp.124.4.1854; Hart DO, 2000, BIOCHEMISTRY-US, V39, P9826, DOI 10.1021/bi0008074; Henikoff JG, 2000, NUCLEIC ACIDS RES, V28, P228, DOI 10.1093/nar/28.1.228; Henrissat B, 2001, PLANT MOL BIOL, V47, P55, DOI 10.1023/A:1010667012056; Hoch G, 1999, ARCH BIOCHEM BIOPHYS, V366, P75, DOI 10.1006/abbi.1999.1212; Hoekstra FA, 2001, TRENDS PLANT SCI, V6, P431, DOI 10.1016/S1360-1385(01)02052-0; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HOLTHAUS U, 1991, PLANTA, V184, P525, DOI 10.1007/BF00197902; Horbowicz M, 1994, SEED SCI RES, V4, P385, DOI 10.1017/S0960258500002440; Kandler O., 1982, Encyclopedia of plant physiology. New series. Volume 13 A. Plant carbohydrates.I. Intracellular carbohydrates [Loewus, R.A.; Tanner, W. (Editors)], P348; LEHLE L, 1970, H-S Z PHYSIOL CHEM, V351, P1494, DOI 10.1515/bchm2.1970.351.2.1494; Leiter H, 1999, J BIOL CHEM, V274, P21830, DOI 10.1074/jbc.274.31.21830; Ly HD, 2000, CARBOHYD RES, V329, P539, DOI 10.1016/S0008-6215(00)00214-7; Muzquiz M, 1999, IND CROP PROD, V9, P183, DOI 10.1016/S0926-6690(98)00030-2; Peterbauer T, 1998, PLANT CELL PHYSIOL, V39, P334, DOI 10.1093/oxfordjournals.pcp.a029374; Peterbauer T, 2001, SEED SCI RES, V11, P185; Peterbauer T, 1998, PLANT PHYSIOL, V117, P165, DOI 10.1104/pp.117.1.165; Peterbauer T, 1999, PLANT J, V20, P509, DOI 10.1046/j.1365-313X.1999.00618.x; PETERBAUER T, 2001, IN PRESS PLANT PHYSL; Puchart V, 2000, BBA-GEN SUBJECTS, V1524, P27, DOI 10.1016/S0304-4165(00)00138-0; Richter A, 1997, J NAT PROD, V60, P749, DOI 10.1021/np970212i; Sprenger N, 2000, PLANT J, V21, P249, DOI 10.1046/j.1365-313x.2000.00671.x; TANNER W, 1967, BIOCHEM BIOPH RES CO, V29, P166, DOI 10.1016/0006-291X(67)90581-5; TANNER W, 1968, EUR J BIOCHEM, V4, P233, DOI 10.1111/j.1432-1033.1968.tb00199.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tortuero F, 1997, NUTR RES, V17, P41, DOI 10.1016/S0271-5317(96)00231-X; Travert S, 1997, PLANT PHYSIOL, V114, P1433, DOI 10.1104/pp.114.4.1433; Van Laere KMJ, 1999, APPL MICROBIOL BIOT, V52, P681, DOI 10.1007/s002530051579; WHISTLER RL, 1950, J AM CHEM SOC, V72, P677, DOI 10.1021/ja01158a009; YASUI T, 1985, BOT MAG TOKYO, V98, P75, DOI 10.1007/BF02488908	39	74	77	5	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					194	200		10.1074/jbc.M109734200	http://dx.doi.org/10.1074/jbc.M109734200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11675396	hybrid			2022-12-25	WOS:000173087900027
J	Samuel, W; Nagineni, CN; Kutty, RK; Parks, WT; Gordon, JS; Prouty, SM; Hooks, JJ; Wiggert, B				Samuel, W; Nagineni, CN; Kutty, RK; Parks, WT; Gordon, JS; Prouty, SM; Hooks, JJ; Wiggert, B			Transforming growth factor-beta regulates stearoyl coenzyme A desaturase expression through a smad signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIAL-CELLS; COA DESATURASE; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; MESSENGER-RNA; TUMOR-CELLS; FATTY-ACIDS; RECEPTOR; PROTEIN; PROMOTER	The regulation of stearoyl-CoA desaturase (SCD), a rate-limiting enzyme in the synthesis of unsaturated fatty acids, is physiologically important because the ratio of saturated to unsaturated fatty acids is thought to control cellular functions by modulating the structural integrity and fluidity of cell membranes. Transforming growth factor-beta (TGF-beta), a multifunctional cytokine, increased SCD mRNA expression in cultured human retinal pigment epithelial cells. This response was elicited by all three TGF-beta isoforms, beta1, beta2, and beta3. However, SCD mRNA expression was not increased either by other members of the TGF-beta family or by other growth factors or cytokines. TGF-beta also increased SCD mRNA expression in several other cell lines tested. The increase in SCD mRNA expression was preceded by a marked increase in Smad2 phosphorylation in TGF-beta-treated human retinal pigment epithelial cells. TGF-beta did not induce SCD mRNA expression in a Smad4-deficient cell line. However, Smad4 overexpression restored the TGF-beta effect in this cell line. Moreover, TGF-beta-induced SCD mRNA expression was effectively blocked by the overexpression of Smad7, an inhibitory Smad. Thus, a TGF-beta signal transduction pathway involving Smad proteins appears to regulate the cellular expression of the SCD gene, and this regulation may play an important role in lipid metabolism.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20878 USA; NEI, Biochem Sect, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20878 USA; NEI, Immunol & Virol Sect, Immunol Lab, NIH, Bethesda, MD 20878 USA; Johnson & Johnson, Consumer Prod World Wide, Skin Biol Tech Resource Ctr, Skillman, NJ 08558 USA; RW Johnson Pharmaceut Res Inst, Drug Discovery, Spring House, PA 19477 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Johnson & Johnson; Johnson & Johnson USA; Johnson & Johnson; Johnson & Johnson USA	Samuel, W (corresponding author), NEI, LRCMB, NIH, Rm 338,6 Ctr Dr, Bethesda, MD 20892 USA.	william@helix.nih.gov			NATIONAL EYE INSTITUTE [ZIAEY000233, Z01EY000070, Z01EY000233] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Albi E, 1997, CELL BIOCHEM FUNCT, V15, P181; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Bene H, 2001, BIOCHEM BIOPH RES CO, V284, P1194, DOI 10.1006/bbrc.2001.5102; BOK D, 1993, J CELL SCI, P189; Casimir DA, 1996, J BIOL CHEM, V271, P29847, DOI 10.1074/jbc.271.47.29847; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; deVries JE, 1997, J LIPID RES, V38, P1384; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; FALK LA, 1991, BLOOD, V77, P1248; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; Hayashi A, 1996, CURR EYE RES, V15, P487, DOI 10.3109/02713689609000760; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Helliwell PA, 2000, BIOCHEM J, V350, P163, DOI 10.1042/0264-6021:3500163; HICKS D, 1991, PROG RETIN RES, V11, P333, DOI 10.1016/0278-4327(91)90033-X; Hill-Kapturczak N, 2000, J BIOL CHEM, V275, P40904, DOI 10.1074/jbc.M006621200; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KASTURI R, 1982, J BIOL CHEM, V257, P2224; Kates M., 1984, MEMBRANE FLUIDITY, P379; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154; Kurebayashi S, 1997, DIABETES, V46, P2115, DOI 10.2337/diabetes.46.12.2115; KUTTY RK, 1994, J CELL PHYSIOL, V159, P371; KUTTY RK, 1995, BIOCHEM BIOPH RES CO, V215, P386, DOI 10.1006/bbrc.1995.2477; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; LEIKIN AI, 1988, BIOCHIM BIOPHYS ACTA, V963, P311, DOI 10.1016/0005-2760(88)90296-2; LI J, 1994, INT J CANCER, V57, P348, DOI 10.1002/ijc.2910570310; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MIHARA K, 1990, J BIOCHEM-TOKYO, V108, P1022, DOI 10.1093/oxfordjournals.jbchem.a123301; Miller CW, 1996, P NATL ACAD SCI USA, V93, P9443, DOI 10.1073/pnas.93.18.9443; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; NAGINENI CN, 1994, CLIN DIAGN LAB IMMUN, V1, P569, DOI 10.1128/CDLI.1.5.569-577.1994; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Ntambi JM, 1996, BIOCHEM BIOPH RES CO, V220, P990, DOI 10.1006/bbrc.1996.0520; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; ROBERTS AB, 1992, CANCER SURV, V14, P205; Samuel W, 2001, J BIOL CHEM, V276, P28744, DOI 10.1074/jbc.M103587200; Sporn M.B., 1994, RETINOIDS BIOL CHEM; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; Taylor LM, 2000, J BIOL CHEM, V275, P16709, DOI 10.1074/jbc.275.22.16709; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Waters KM, 1997, BIOCHEM BIOPH RES CO, V233, P838, DOI 10.1006/bbrc.1997.6550; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu GX, 2001, J CELL PHYSIOL, V187, P315, DOI 10.1002/jcp.1078; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang L, 1999, BIOCHEM J, V340, P255, DOI 10.1042/0264-6021:3400255; Zhang L, 2001, BIOCHEM J, V357, P183, DOI 10.1042/0264-6021:3570183; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhao JS, 2000, J BIOL CHEM, V275, P23992, DOI 10.1074/jbc.M002433200; Zheng Y, 2001, GENOMICS, V71, P182, DOI 10.1006/geno.2000.6429	67	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					59	66		10.1074/jbc.M108730200	http://dx.doi.org/10.1074/jbc.M108730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11677241	hybrid			2022-12-25	WOS:000173087900010
J	Sanada, K; Okano, T; Fukada, Y				Sanada, K; Okano, T; Fukada, Y			Mitogen-activated protein kinase phosphorylates and negatively regulates basic helix-loop-helix-PAS transcription factor BMAL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPRACHIASMATIC NUCLEI; CIRCADIAN RHYTHMICITY; OSCILLATOR; MECHANISMS; SEQUENCE; GENE	In vertebrates, mitogen-activated protein kinase (MAPK) exhibits circadian activation in several clock structures and likely participates in the timekeeping mechanism of the circadian clock. Here we show that MAPK associates with a basic helix-loop-helix-PAS transcription factor BMAL1, a positive regulator for the autoregulatory feedback loop of the circadian oscillator. MAPK phosphorylates BMAL1 at multiple sites, including Ser-527, Thr-534, and Ser-599, in vitro, and BMAL1: CLOCK-induced transactivation from the E-box element is inhibited by expression of a constitutive active form of MAPK kinase in 293 cells. The inhibitory effect is reversed by coexpression of the kinase-dead mutant of MAPK or by mutation of BMAL1 at Thr-534. These results indicate that BMAL1:CLOCK-induced transcription is negatively regulated by MAPK-mediated phosphorylation of BMAL1 at Thr-534 and suggest a molecular link between circadian-activated MAPK and the clock oscillator.	Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol, Core Res Engn Sci & Technol, Tokyo 1130033, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Fukada, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		吉孝, 深田/G-5090-2014; SANADA, YOSHIKADO/G-5014-2014	Okano, Toshiyuki/0000-0001-6740-6265; Sanada, Kamon/0000-0002-0280-8957				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; CAHILL GM, 1995, PROG RETIN EYE RES, V14, P267, DOI 10.1016/1350-9462(94)00001-Y; Cermakian N, 2000, P NATL ACAD SCI USA, V97, P4339, DOI 10.1073/pnas.97.8.4339; Chang DC, 2001, NEURON, V29, P555, DOI 10.1016/S0896-6273(01)00230-6; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DEGUCHI T, 1979, SCIENCE, V203, P1245, DOI 10.1126/science.424750; Dunlap J, 1998, SCIENCE, V280, P1548, DOI 10.1126/science.280.5369.1548; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Harada Y, 2000, J BIOL CHEM, V275, P37078, DOI 10.1074/jbc.M004706200; Hogenesch JB, 2000, J NEUROSCI, V20, part. no.; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Ko GYP, 2001, NEURON, V29, P255, DOI 10.1016/S0896-6273(01)00195-7; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; Obrietan K, 1999, J BIOL CHEM, V274, P17748, DOI 10.1074/jbc.274.25.17748; Okano T, 2001, GENES CELLS, V6, P825, DOI 10.1046/j.1365-2443.2001.00462.x; Okano T, 2001, NEUROSCI LETT, V300, P111, DOI 10.1016/S0304-3940(01)01581-6; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Sanada K, 2000, J NEUROSCI, V20, P986, DOI 10.1523/JNEUROSCI.20-03-00986.2000; SANADA K, 1995, J BIOL CHEM, V270, P15459, DOI 10.1074/jbc.270.26.15459; Takahata S, 2000, GENES CELLS, V5, P739, DOI 10.1046/j.1365-2443.2000.00363.x; Takayama M, 1999, J Biomol Tech, V10, P194; Yamaguchi S, 2000, CURR BIOL, V10, P873, DOI 10.1016/S0960-9822(00)00602-3; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yokota S, 2001, J NEUROCHEM, V77, P618, DOI 10.1046/j.1471-4159.2001.00270.x	27	115	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					267	271		10.1074/jbc.M107850200	http://dx.doi.org/10.1074/jbc.M107850200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11687575	hybrid			2022-12-25	WOS:000173087900036
J	Yamaguchi, A; Taniguchi, M; Hori, O; Ogawa, S; Tojo, N; Matsuoka, N; Miyake, S; Kasai, K; Sugimoto, H; Tamatani, M; Yamashita, T; Tohyama, M				Yamaguchi, A; Taniguchi, M; Hori, O; Ogawa, S; Tojo, N; Matsuoka, N; Miyake, S; Kasai, K; Sugimoto, H; Tamatani, M; Yamashita, T; Tohyama, M			Peg3/Pw1 is involved in p53-mediated cell death pathway in brain ischemia/hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRAL-ARTERY OCCLUSION; HYPOXIA-INDUCED APOPTOSIS; KAPPA-B ACTIVATION; IMPRINTED GENE; MESSENGER-RNA; HUMAN HOMOLOG; P53; EXPRESSION; INDUCTION; GROWTH	Emerging evidence has shown that tumor suppressor p53 expression is enhanced in response to brain ischemia/hypoxia and that p53 plays a critical role in the cell death pathway in such an acute neurological insult. However the mechanism remains unclear. Recently it was reported that Peg3/Pw1, originally identified as a paternally expressed gene, plays a pivotal role in the p53-mediated cell death pathway in mouse fibroblast cell lines. In this study, we found that Peg3/Pw1 expression is enhanced in peri-ischemic neurons in rat stroke model by in situ hybridization analysis, where p53 expression was also induced by immunohistochemical analysis. Moreover, we found that p53 was co-localized with Peg3/Pw1 in brain ischemia/hypoxia by double staining analysis. In human neuroblastoma-derived SK-N-SH cells, Peg3/Pw1 mRNA expression is enhanced remarkably at 24 h post-hypoxia, when p53 protein expression was also enhanced at high levels. Subcellular localization of Peg3/Pw1 was observed in the nucleus. Adenovirus-mediated high dose p53 overexpression induced Peg3/Pw1 mRNA expression. Overexpression of Peg3/Pw1 reduced cell viability under hypoxic conditions, whereas that of the C-terminal-deleted mutant and anti-sense Peg3/Pw1 inhibited hypoxia-induced cell death. These results suggest that Peg3/Pw1 is involved in the p53-mediated cell death pathway as a downstream effector of p53 in brain ischemia/hypoxia.	Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Emergency Med, Suita, Osaka 5650871, Japan; Kanazawa Univ, Sch Med, Dept Anat, Kanazawa, Ishikawa 2908640, Japan; Fujisawa Pharmaceut Co Ltd, Med Biol Res Labs, Osaka 5328514, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 105, Japan	Osaka University; Osaka University; Kanazawa University; Astellas Pharmaceuticals; Japan Science & Technology Agency (JST)	Yamaguchi, A (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Taniguchi, Masateru/G-3185-2017	Yamashita, Toshihide/0000-0003-4559-7018				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; Brink R, 1998, J BIOL CHEM, V273, P4129, DOI 10.1074/jbc.273.7.4129; CHOPP M, 1992, BIOCHEM BIOPH RES CO, V182, P1201, DOI 10.1016/0006-291X(92)91859-O; Cregan SP, 1999, J NEUROSCI, V19, P7860; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; GIACCIA AJ, 1992, INT J RADIAT ONCOL, V23, P891, DOI 10.1016/0360-3016(92)90667-7; Hori O, 1996, J NEUROCHEM, V66, P973; Hu G, 1999, MOL CELL BIOL, V19, P724; Jordan J, 1997, J NEUROSCI, V17, P1397; Kim J, 1997, GENOME RES, V7, P532, DOI 10.1101/gr.7.5.532; Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186; Li LL, 1999, SCIENCE, V284, P330, DOI 10.1126/science.284.5412.330; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Min W, 1998, J IMMUNOL, V161, P319; MIYASHITA T, 1995, CELL, V80, P293; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; Relaix F, 1996, DEV BIOL, V177, P383, DOI 10.1006/dbio.1996.0172; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; Stempien-Otero A, 1999, J BIOL CHEM, V274, P8039, DOI 10.1074/jbc.274.12.8039; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; Xiang H, 1996, J NEUROSCI, V16, P6753; Yamaguchi A, 1999, J CELL BIOL, V147, P1195, DOI 10.1083/jcb.147.6.1195; Yamashita T, 1996, J CEREBR BLOOD F MET, V16, P1203, DOI 10.1097/00004647-199611000-00014; ZHANG WW, 1994, CANCER GENE THER, V1, P5	33	52	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					623	629		10.1074/jbc.M107435200	http://dx.doi.org/10.1074/jbc.M107435200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11679586	hybrid			2022-12-25	WOS:000173087900082
J	Chigaev, A; Blenc, AM; Braaten, JV; Kumaraswamy, N; Kepley, CL; Andrews, RP; Oliver, JM; Edwards, BS; Prossnitz, ER; Larson, RS; Sklar, LA				Chigaev, A; Blenc, AM; Braaten, JV; Kumaraswamy, N; Kepley, CL; Andrews, RP; Oliver, JM; Edwards, BS; Prossnitz, ER; Larson, RS; Sklar, LA			Real time analysis of the affinity regulation of alpha(4)-integrin - The physiologically activated receptor is intermediate in affinity between resting and Mn2+ or antibody activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; P-SELECTIN; INTEGRIN; VCAM-1; VLA-4; EXPRESSION; BINDING; PROTEIN; STATES; SYK	This work examines the affinity of alpha(4)beta(1)-integrin and whether affinity regulation by G protein-coupled receptor (GPCR) and chemokines receptors is compatible with cell adhesion mediated between alpha(4)-integrin and vascular cell adhesion molecule-1. We used flow cytometry to examine the binding of a fluorescent derivative of an LDV peptide (Chen, L. L., Whitty, A., Lobb, R. R., Adams, S. P., and Pepinsky, R. B. (1999) J. Biol. Chem. 274, 13167-13175) to several cell lines and leukocytes with alpha4-integrin ranging from about 2,000 to 100,000 sites/cell. The results support the idea that alpha-integrins exhibit multiple affinities and that affinity changes are regulated by the dissociation rate and conformation. The affinity varies by 3 orders of magnitude with the affinity induced by binding mAb TS2/16 plus Mn2+ > Mn-2+ ' TS2/16 > activation because of occupancy of GPCR or chemokines receptor > resting receptors. A significant fraction of the receptors respond to the activating process. The change in alpha4-integrin affinity and the corresponding change in off rates mediated by GPCR receptor activation are rapid and transient, and their duration depends on GPCR desensitization. The affinity changes mediated by IgE receptor or interleukin-5 receptor persist longer. It appears that the physiologically active state of the alpha4-integrin, determined by inside-out signaling, has similar affinity in several cell types.	Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Ctr Canc, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Commonwealth Biotechnol Inc, Richmond, VA 23235 USA; Los Alamos Natl Lab, Natl Flow Cytometry Resource, Los Alamos, NM 87545 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; United States Department of Energy (DOE); Los Alamos National Laboratory	Sklar, LA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Pathol, CRF 219, Albuquerque, NM 87131 USA.	lsklar@salud.unm.edu	Prossnitz, Eric R./B-4543-2008; Chigaev, Alexandre/A-3103-2010; Prossnitz, Eric/I-4599-2019	Chigaev, Alexandre/0000-0002-7726-638X; Prossnitz, Eric/0000-0001-9190-8302	NATIONAL CANCER INSTITUTE [R24CA088339] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR014175, P41RR001315] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056384] Funding Source: NIH RePORTER; NCI NIH HHS [CA88339] Funding Source: Medline; NCRR NIH HHS [RR01315, RR14175] Funding Source: Medline; NHLBI NIH HHS [HL56384] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chan JR, 2000, J IMMUNOL, V164, P746, DOI 10.4049/jimmunol.164.2.746; Chen C, 1999, J IMMUNOL, V162, P1084; Chen LL, 1999, J BIOL CHEM, V274, P13167, DOI 10.1074/jbc.274.19.13167; Edwards BS, 2000, J IMMUNOL, V165, P404, DOI 10.4049/jimmunol.165.1.404; Evangelista V, 1999, BLOOD, V93, P876, DOI 10.1182/blood.V93.3.876.403k25_876_885; FAULL RJ, 1995, STEM CELLS, V13, P38, DOI 10.1002/stem.5530130106; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Kepley CL, 2000, J IMMUNOL, V165, P5913, DOI 10.4049/jimmunol.165.10.5913; Kepley CL, 1998, J ALLERGY CLIN IMMUN, V102, P304, DOI 10.1016/S0091-6749(98)70100-9; Kew RR, 1997, J LEUKOCYTE BIOL, V61, P329, DOI 10.1002/jlb.61.3.329; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Loftus JC, 1997, J CLIN INVEST, V100, pS77; LYNAM EB, 1994, BLOOD, V83, P3303; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; Nolan John P., 1998, P19; Nolan JP, 1998, NAT BIOTECHNOL, V16, P633, DOI 10.1038/nbt0798-633; NOLAN JP, 1995, CYTOMETRY, V21, P223, DOI 10.1002/cyto.990210302; Oi V.T., 1980, SELECTED METHODS CEL, P351; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P10686, DOI 10.1074/jbc.270.18.10686; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; SANCHEZMATEOS P, 1993, J IMMUNOL, V151, P3817; Sanz-Rodriguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346; Seamer L, 2001, METHOD CELL BIOL, V63, P169; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	29	109	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48670	48678		10.1074/jbc.M103194200	http://dx.doi.org/10.1074/jbc.M103194200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11641394	hybrid			2022-12-25	WOS:000173922100010
J	Kuraoka, I; Robins, P; Masutani, C; Hanaoka, F; Gasparutto, D; Cadet, J; Wood, RD; Lindahl, T				Kuraoka, I; Robins, P; Masutani, C; Hanaoka, F; Gasparutto, D; Cadet, J; Wood, RD; Lindahl, T			Oxygen free radical damage to DNA. Translesion synthesis by human DNA polymerase eta and resistance to exonuclease action at cyclopurine deoxynuelcoside residues.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; RADIATION-INDUCED DAMAGE; I-COMPOUNDS; GENE; IDENTIFICATION; EFFICIENT; PATHWAY; BYPASS; LESION	Cyclopurine deoxynucleosides are common DNA lesions generated by exposure to reactive oxygen species under hypoxic conditions. The S and R diastereoisomers of cyclodeoxyadenosine on DNA were investigated separately for their ability to block 3' to 5' exonucleases. The mammalian DNA-editing enzyme DNase III (TREX1) was blocked by both diastereoisomers, whereas only the S diastereoisomer was highly efficient in preventing digestion by the exonuclease function of T4 DNA polymerase. Digestion in both cases was frequently blocked one residue before the modified base. Oligodeoxyribonucleotides containing a cyclodeoxyadenosine residue were further employed as templates for synthesis by human DNA polymerase eta (pol eta) . pol eta could catalyze translesion synthesis on the R diastereoisomer of cyclodeoxyadenosine. On the S diastereoisomer, pol eta could catalyze the incorporation of one nucleotide opposite the lesion but could not continue elongation. Although pol eta preferentially incorporated dAMP opposite the R diastereoisomer, elongation continued only when dTMP was incorporated, suggesting bypass of this lesion by pol eta with reasonable fidelity. With the S diastereoisomer, pol eta mainly incorporated dAMP or dTMP opposite the lesion but could not elongate even after incorporating a correct nucleotide. These data suggest that the S diastereoisomer may be a more cytotoxic DNA lesion than the R diastereoisomer.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; CEA, Serv Chim Inorgan & Biol, Lab Les Acides Nucl, F-38054 Grenoble 9, France; CEA, Dept Rech Fondamentale Mat Condensee, UMR 5046, F-38054 Grenoble 9, France	Osaka University; CEA; CEA	Wood, RD (corresponding author), Univ Pittsburgh, Inst Canc, S867 Scaife Hall,Box 100, Pittsburgh, PA 15261 USA.	rdwood@pitt.edu	Masutani, Chikahide/I-6160-2014; Cadet, Jean/M-2971-2018; Wood, Richard/M-6319-2018	Cadet, Jean/0000-0003-2594-9485; Masutani, Chikahide/0000-0002-8600-8227; Kuraoka, Isao/0000-0001-6391-3411; Wood, Richard/0000-0002-9495-6892				Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; Cadet J, 1999, MUTAT RES-FUND MOL M, V424, P9, DOI 10.1016/S0027-5107(99)00004-4; DIZDAROGLU M, 1992, INT J RADIAT BIOL, V61, P175, DOI 10.1080/09553009214550791; Dizdaroglu M, 2001, FREE RADICAL BIO MED, V30, P774, DOI 10.1016/S0891-5849(01)00464-6; DIZDAROGLU M, 1987, BIOCHEM J, V241, P929, DOI 10.1042/bj2410929; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Mazur DJ, 2001, J BIOL CHEM, V276, P17022, DOI 10.1074/jbc.M100623200; MIASKIEWICZ K, 1995, NUCLEIC ACIDS RES, V23, P515, DOI 10.1093/nar/23.3.515; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; RAMPINO NJ, 1994, P NATL ACAD SCI USA, V91, P10977, DOI 10.1073/pnas.91.23.10977; Randerath K, 2001, J BIOL CHEM, V276, P36051, DOI 10.1074/jbc.M105472200; Randerath K, 1999, MUTAT RES-FUND MOL M, V424, P183, DOI 10.1016/S0027-5107(99)00018-4; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Romieu A, 1999, CHEM RES TOXICOL, V12, P412, DOI 10.1021/tx9802668; Romieu A, 1998, J ORG CHEM, V63, P5245, DOI 10.1021/jo980083q; SCHRODER E, 1995, INT J RADIAT BIOL, V68, P509, DOI 10.1080/09553009514551501; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919	26	106	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49283	49288		10.1074/jbc.M107779200	http://dx.doi.org/10.1074/jbc.M107779200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11677235	hybrid			2022-12-25	WOS:000173922100087
J	Martin-Belmonte, F; Arvan, P; Alonso, MA				Martin-Belmonte, F; Arvan, P; Alonso, MA			MAL mediates apical transport of secretory proteins in polarized epithelial Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; RAFT-ASSOCIATED PROTEIN; MDCK CELLS; N-GLYCANS; SORTING SIGNALS; SURFACE TRANSPORT; MEMBRANE-PROTEINS; PATHWAY; CHOLESTEROL	The MAL proteolipid is an integral membrane protein identified as a component of the raft machinery for apical sorting of membrane proteins in Madin-Darby canine kidney (MDCK) cells. Previous studies have implicated lipid rafts in the transport of exogenous thyroglobulin (Tg), the predominant secretory protein of thyroid epithelial cells, to the apical surface in MDCK cells. We have examined the secretion of recombinant Tg and gp80/clusterin, a major endogenous secretory protein not detected in Triton X-100 insoluble rafts, for the investigation of the involvement of MAL in the constitutive apical secretory pathway of MDCK cells. We show that MAL depletion impairs apical secretion of Tg and causes its accumulation in the Golgi. Cholesterol sequestration, which blocks apical secretion of Tg, did not alter the levels of ALAL in rafts but created a block proximal to Tg entrance into rafts. Apical secretion of gp80/ clusterin was also inhibited by elimination of endogenous NUL. Our results suggest a role for MAL in the transport of both endogenously and exogenously expressed apical secretory proteins in MDCK cells.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; CSIC, E-28049 Madrid, Spain; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Div Endocrinol, Bronx, NY 10461 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC); Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Alonso, MA (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Alonso, Miguel A/J-3945-2016	Alonso, Miguel A/0000-0002-7001-8826; Martin-Belmonte, Fernando/0000-0002-2564-4430				ALONSO MA, 1987, P NATL ACAD SCI USA, V84, P1997, DOI 10.1073/pnas.84.7.1997; Alonso MA, 1997, J BIOL CHEM, V272, P30748, DOI 10.1074/jbc.272.49.30748; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Bravo-Zehnder M, 2000, P NATL ACAD SCI USA, V97, P13114, DOI 10.1073/pnas.240455697; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cheong KH, 1999, P NATL ACAD SCI USA, V96, P6241, DOI 10.1073/pnas.96.11.6241; Dhanvantari S, 2000, J BIOL CHEM, V275, P29887, DOI 10.1074/jbc.M005364200; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Graichen R, 1996, J BIOL CHEM, V271, P15854, DOI 10.1074/jbc.271.27.15854; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Larsen JE, 1999, FEBS LETT, V451, P19, DOI 10.1016/S0014-5793(99)00526-8; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Lipardi C, 2000, MOL BIOL CELL, V11, P531, DOI 10.1091/mbc.11.2.531; LISANTI MP, 1990, P NATL ACAD SCI USA, V87, P7419, DOI 10.1073/pnas.87.19.7419; Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P3248, DOI 10.1073/pnas.070049497; Martin-Belmonte F, 2000, J BIOL CHEM, V275, P41074, DOI 10.1074/jbc.M005429200; Martin-Belmonte F, 1998, ENDOCRINOLOGY, V139, P2077, DOI 10.1210/en.139.4.2077; Martin-Belmonte F, 2000, MOL BIOL CELL, V11, P2033, DOI 10.1091/mbc.11.6.2033; Marzolo MP, 1997, P NATL ACAD SCI USA, V94, P1834, DOI 10.1073/pnas.94.5.1834; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Meerson NR, 2000, J CELL SCI, V113, P4193; Millan J, 1997, BIOCHEM BIOPH RES CO, V233, P707, DOI 10.1006/bbrc.1997.6530; Muresan Z, 1997, J BIOL CHEM, V272, P26095, DOI 10.1074/jbc.272.42.26095; Puertollano R, 1997, J BIOL CHEM, V272, P18311, DOI 10.1074/jbc.272.29.18311; Puertollano R, 1999, J CELL BIOL, V145, P141, DOI 10.1083/jcb.145.1.141; Puertollano R, 2001, MOL BIOL CELL, V12, P1869, DOI 10.1091/mbc.12.6.1869; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Schmidt K, 2001, J BIOL CHEM, V276, P14315, DOI 10.1074/jbc.M006221200; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Zacchetti D, 1995, FEBS LETT, V377, P465, DOI 10.1016/0014-5793(95)01396-2; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	40	50	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49337	49342		10.1074/jbc.M106882200	http://dx.doi.org/10.1074/jbc.M106882200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11673461	hybrid			2022-12-25	WOS:000173922100093
J	Morton, HC; Howard, CJ; Storset, AK; Brandtzaeg, P				Morton, HC; Howard, CJ; Storset, AK; Brandtzaeg, P			Identification of residues within the extracellular domain 1 of bovine Fe gamma 2R essential for binding bovine IgG2.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; FC-GAMMA-RECEPTOR; EPSILON-RI-ALPHA; CRYSTAL-STRUCTURE; INHIBITORY RECEPTOR; IMMUNOGLOBULIN; IGA; NEUTROPHILS; CD89; ORGANIZATION	Neutrophils and monocytes in cattle express a novel class of immunoglobulin Fc receptor, specific for bovine IgG2 (bIgG2), termed bFc gamma 2R. In cows, the ability of neutrophils to kill immunoglobulin-opsonized microorganisms appears to depend largely on this subclass, whose interaction with bFc gamma 2R initiates the killing process. bFc gamma 2R is a transmembrane glycoprotein consisting of two extracellular immunoglobulin-like domains, followed by a 19-amino acid membrane-spanning region and a short cytoplasmic tail. Although related to other mammalian Fc gamma Rs, bFc gamma 2R belongs to a novel gene family that includes the human killer cell inhibitory receptor and Fc alpha RI (CD89) proteins. We have shown previously (Morton, H. C., van Zandbergen, G., van Kooten, C., Howard, C. J., van de Winkel, J. G., and Brandtzaeg, P. (1999) J. Exp. Med. 189, 1715-1722) that like these proteins (and unlike other Fc gamma Rs), bFc gamma 2R binds bIgG2 via the membrane-distal extracellular domain 1 (EC1). In this present study, we introduced mutations into the predicted loop regions of the EC1 domain and assayed the resulting bFc gamma 2R mutants for their ability to bind hIgG2. Our results indicated that the bIgG2 binding site lies within the predicted F-G loop region of the EC1 domain. Furthermore, single amino acid mutational analysis of this region identified Phe-82 and Trp-87 as being critical for bIgG2 binding.	Univ Oslo, Rikshosp, Inst Pathol, LIIPAT, N-0027 Oslo, Norway; Inst Anim Hlth, Div Immunol & Pathol, Newbury RG20 7NN, Berks, England; Norwegian Sch Vet Sci, Dept Pharmacol Microbiol & Food Hyg, N-0033 Oslo, Norway	University of Oslo; National Hospital Norway; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Norwegian University of Life Sciences	Morton, HC (corresponding author), Univ Oslo, Rikshosp, Inst Pathol, LIIPAT, N-0027 Oslo, Norway.		Morton, H. Craig/H-8600-2012	Morton, H. Craig/0000-0002-9440-5759				Bianchi A, 1996, VET IMMUNOL IMMUNOP, V54, P25, DOI 10.1016/S0165-2427(96)05671-1; Boehm MK, 1999, J MOL BIOL, V286, P1421, DOI 10.1006/jmbi.1998.2556; BUTLER JE, 1983, VET IMMUNOL IMMUNOP, V4, P43, DOI 10.1016/0165-2427(83)90056-9; BUTLER JE, 1987, IMMUNOL LETT, V16, P31, DOI 10.1016/0165-2478(87)90057-5; Butler JE, 1998, REV SCI TECH OIE, V17, P43, DOI 10.20506/rst.17.1.1096; Carayannopoulos L, 1996, J EXP MED, V183, P1579, DOI 10.1084/jem.183.4.1579; Chapman TL, 2000, IMMUNITY, V13, P727, DOI 10.1016/S1074-7613(00)00071-6; Clarkson C. A., 1993, Molecular Immunology, V30, P1195, DOI 10.1016/0161-5890(93)90138-2; Collins RA, 1997, IMMUNOGENETICS, V45, P440, DOI 10.1007/s002510050228; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dennis G, 2000, P NATL ACAD SCI USA, V97, P13245, DOI 10.1073/pnas.230442897; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; Garman SC, 1999, ANNU REV IMMUNOL, V17, P973, DOI 10.1146/annurev.immunol.17.1.973; HOWARD CJ, 1980, RES VET SCI, V29, P128, DOI 10.1016/S0034-5288(18)32705-X; HOWARD CJ, 1979, RES VET SCI, V27, P388, DOI 10.1016/S0034-5288(18)32815-7; HOWARD CJ, 1984, VET IMMUNOL IMMUNOP, V6, P321, DOI 10.1016/0165-2427(84)90057-6; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; Kacskovics I, 2000, J IMMUNOL, V164, P1889, DOI 10.4049/jimmunol.164.4.1889; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; Klungland H, 1997, MAMM GENOME, V8, P300, DOI 10.1007/s003359900425; KNIGHT KL, 1988, J IMMUNOL, V140, P3654; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; MAZENGERA RL, 1990, BIOCHEM J, V272, P159, DOI 10.1042/bj2720159; Morton HC, 1999, J EXP MED, V189, P1715; Pleass RJ, 1999, J BIOL CHEM, V274, P23508, DOI 10.1074/jbc.274.33.23508; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; SYMONS DBA, 1989, MOL IMMUNOL, V26, P841, DOI 10.1016/0161-5890(89)90140-5; SYMONS DBA, 1992, MOL IMMUNOL, V29, P1407, DOI 10.1016/0161-5890(92)90178-Z; Wagtmann N, 1997, CURR BIOL, V7, P615, DOI 10.1016/S0960-9822(06)00263-6; Wende H, 1999, MAMM GENOME, V10, P154, DOI 10.1007/s003359900961; Wines BD, 1999, J IMMUNOL, V162, P2146; Wines BD, 2001, J IMMUNOL, V166, P1781, DOI 10.4049/jimmunol.166.3.1781; Winter CC, 1997, J IMMUNOL, V158, P4026; ZHANG GP, 1994, IMMUNOGENETICS, V39, P423, DOI 10.1007/BF00176160; ZHANG GP, 1995, J IMMUNOL, V155, P1534; Zhang YH, 2000, IMMUNITY, V13, P387, DOI 10.1016/S1074-7613(00)00038-8	39	8	10	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47794	47800		10.1074/jbc.M104066200	http://dx.doi.org/10.1074/jbc.M104066200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11641395	hybrid			2022-12-25	WOS:000172927000010
J	Siu, F; Chen, C; Zhong, C; Kilberg, MS				Siu, F; Chen, C; Zhong, C; Kilberg, MS			CCAAT/enhancer-binding protein-beta is a mediator of the nutrient-sensing response pathway that activates the human asparagine synthetase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID REGULATION; TRANSCRIPTIONAL ACTIVATOR; EXPRESSION; CHOP; RNA; LAP; INHIBITOR; ELEMENTS; CELLS; LIVER	Transcription from the human asparagine synthetase (AS) gene is increased in response to either amino acid (amino acid response) or glucose (unfolded protein response) deprivation. These two independent pathways converge on the same set of genomic cis-elements within the AS promoter, which are referred to as nutrient-sensing response element (NSRE)-1 and -2, both of which are absolutely necessary for gene activation. The NSRE-1 sequence was used to identify the corresponding transcription factor by yeast one-hybrid screening. Based on those results, electrophoretic mobility shift assays for individual CCAAT/enhancer-binding protein-beta (C/EBP) family members were performed to test for supershifting of complexes by specific antibodies. The results indicated that of all the family members, C/EBP beta bound to the NSRE-1 sequence to the greatest extent and that the absolute amount of this complex was increased when extracts from amino acid- or glucose-deprived cells were tested. Using electrophoretic mobility shift assays, mutation of the NSRE-1 sequence completely prevented formation of the C/EBP beta -containing complexes. In contrast, mutation of the NSRE-2 sequence did not block C/EBP beta binding. Overexpression in HepG2 hepatoma cells of the activating isoform of C/EBP beta increased AS promoter-driven transcription, whereas the inhibitory dominant-negative isoform of C/EBP beta blocked enhanced transcription following amino acid or glucose deprivation. Collectively, the results provide both in vitro and in vivo evidence for a role of C/EBP beta in the transcriptional activation of the AS gene in response to nutrient deprivation.	Univ Florida, Coll Med, Ctr Mammalian Genet, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Ctr Nutrit Sci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Ctr Mammalian Genet, Dept Biochem & Mol Biol, POB 100245, Gainesville, FL 32610 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amylon MD, 1999, LEUKEMIA, V13, P335, DOI 10.1038/sj.leu.2401310; ANDRULIS IL, 1979, J BIOL CHEM, V254, P629; ARFIN SM, 1977, P NATL ACAD SCI USA, V74, P2367, DOI 10.1073/pnas.74.6.2367; Aslanian AM, 2001, BIOCHEM J, V357, P321, DOI 10.1042/0264-6021:3570321; Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HOFFER LJ, 1993, CAN J PHYSIOL PHARM, V71, P633, DOI 10.1139/y93-092; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Hutson RG, 1996, CLIN NUTR, V15, P327, DOI 10.1016/S0261-5614(96)80009-4; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; Jefferson LS, 2001, J NUTR, V131, p2460S, DOI 10.1093/jn/131.9.2460S; Jousse C, 1999, Curr Opin Clin Nutr Metab Care, V2, P297, DOI 10.1097/00075197-199907000-00008; Jousse C, 2000, J NUTR, V130, P1555, DOI 10.1093/jn/130.6.1555; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; KERRIGAN LA, 1994, CURRENT PROTOCOLS MO; Laine RO, 1996, PROG NUCLEIC ACID RE, V53, P219, DOI 10.1016/S0079-6603(08)60146-4; Lie-Venema H, 1998, PROG NUCLEIC ACID RE, V61, P243, DOI 10.1016/S0079-6603(08)60829-6; Mizock BA, 1999, NUTRITION, V15, P220, DOI 10.1016/S0899-9007(98)00191-9; MORGANE PJ, 1993, NEUROSCI BIOBEHAV R, V17, P91, DOI 10.1016/S0149-7634(05)80234-9; ROEDIGER WEW, 1995, J PEDIATR GASTR NUTR, V21, P130, DOI 10.1097/00005176-199508000-00002; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sood R, 2000, GENETICS, V154, P787; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000	34	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48100	48107		10.1074/jbc.M109533200	http://dx.doi.org/10.1074/jbc.M109533200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11677247	hybrid			2022-12-25	WOS:000172927000050
J	Tavazzi, B; Amorini, AM; Fazzina, G; Di Pierro, D; Tuttobene, M; Giardina, B; Lazzarino, G				Tavazzi, B; Amorini, AM; Fazzina, G; Di Pierro, D; Tuttobene, M; Giardina, B; Lazzarino, G			Oxidative stress induces impairment of human erythrocyte energy metabolism through the oxygen radical-mediated direct activation of AMP-deaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; LIPID-PEROXIDATION; VITAMIN-E; INACTIVATION; CATABOLISM; ISCHEMIA; AGE; ANTIOXIDANTS; DERIVATIVES; MECHANISMS	The effect of oxidative stress on human red blood cell AMP-deaminase activity was studied by incubating either fresh erythrocytes or hemolysates with H2O2 (0.5, 1, 2, 4, 6, 8, and 10 mm) or NaNO2 (1, 5,10, 20, and 50 mm), for 15 min at 37 degreesC. AMP-deaminase tremendously increased by increasing H2O2 or NaNO2 at up to 4 and 20 nim, respectively (maximal effect for both oxidants was 9.5 and 6.5 times higher enzymatic activity than control erythrocytes or hemolysates, respectively). The incubation of hemolysates with iodoacetate (5-100 mm), N-ethylmaleimide (0.1-10 mm), or p-hydroxymercuribenzoate (0.1-5 mm) mimicked the effect of oxidative stress on AMP-deaminase, indicating that sulfhydryl group modification is involved in the enzyme activation. In comparison with control hemolysates, changes of the kinetic properties of AMP-deaminase (decrease of AMP concentration necessary for half-maximal activation, increase of V-max, modification of the curve shape of V-o versus [S], Hill plots, and coefficients) were recorded with 4 nim H2O2- and 1 mm N-ethylmaleimide-treated hemolysates. Data obtained using 90% purified enzyme, incubated with Fenton reagents (Fe2+ + H2O2) or -SH-modifying compounds, demonstrated that (i) reactive oxygen species are directly responsible for AMP-deaminase activation; (ii) this phenomenon occurs through sulfhydryl group modification; and (iii) the activation does not involve the loss of the tetrameric protein structure. Results of experiments conducted with glucose-6-phosphate dehydrogenase-deficient erythrocytes, challenged with increasing doses of the anti-malarial drug qui nine hydro. chloride and showing dramatic AMP-deaminase activation, suggest relevant physiopathological implications of this enzymatic activation in conditions of increased oxidative stress. To the best of our knowledge, this is the first example of an enzyme, fundamental for the maintenance of the correct red blood cell energy metabolism, that is activated (rather than inhibited) by the interaction with reactive oxygen species.	Univ Catania, Biochem Lab, Dept Chem Sci, I-95125 Catania, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00135 Rome, Italy; Garibaldi Hosp, Transfus Ctr, I-95100 Catania, Italy; Univ Cattolica Sacro Cuore, Inst Chem & Clin Chem, I-00168 Rome, Italy; Univ Cattolica Sacro Cuore, CNR, Ctr Studio Chim Recettori, I-00168 Rome, Italy	University of Catania; University of Rome Tor Vergata; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR)	Lazzarino, G (corresponding author), Univ Catania, Biochem Lab, Dept Chem Sci, Viale A Doria 6, I-95125 Catania, Italy.		TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	TAVAZZI, BARBARA/0000-0001-8743-0895; lazzarino, giuseppe/0000-0002-5917-7279; AMORINI, Angela Maria/0000-0003-3525-9955				ALMARAZ L, 1988, J PHYSIOL-LONDON, V407, P557, DOI 10.1113/jphysiol.1988.sp017431; ALMARAZ L, 1989, FEBS LETT, V244, P417, DOI 10.1016/0014-5793(89)80575-7; Beutler E., 1971, RED CELL METABOLISM, P103; BONTEMPS F, 1989, CANCER RES, V49, P4983; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; Ciolino HP, 1997, FREE RADICAL BIO MED, V22, P1277, DOI 10.1016/S0891-5849(96)00495-9; DALE GL, 1989, BLOOD, V74, P2157; DAVIES KJA, 1987, J BIOL CHEM, V262, P8220; DeFlora S, 1996, MUTAT RES-REV GENET, V366, P197, DOI 10.1016/S0165-1110(96)00043-7; Engstrom I, 1996, SCAND J CLIN LAB INV, V56, P345, DOI 10.3109/00365519609090586; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; JANERO DR, 1995, BIOCHEM J, V306, P421, DOI 10.1042/bj3060421; LAUTIER D, 1994, BBA-MOL CELL RES, V1221, P215, DOI 10.1016/0167-4889(94)90243-7; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; Miura T, 1997, CHEM-BIOL INTERACT, V107, P173, DOI 10.1016/S0009-2797(97)00085-9; Miyazawa T, 1996, MECH AGEING DEV, V86, P145, DOI 10.1016/0047-6374(95)01687-2; MORDENTE A, 1994, J BIOL CHEM, V44, P27394; Murakami K, 1997, BIOCHEM MOL BIOL INT, V42, P1063; Nakano T, 1997, P NATL ACAD SCI USA, V94, P202, DOI 10.1073/pnas.94.1.202; Nathans G R, 1978, Methods Enzymol, V51, P497; OUWERKERK R, 1989, EUR J HAEMATOL, V43, P441; PAGLIA DE, 1986, BLOOD, V67, P988; PAGLIA DE, 1989, BLOOD, V74, P2161; RAVINDRANATH V, 1990, BIOCHEM BIOPH RES CO, V169, P1075, DOI 10.1016/0006-291X(90)92004-J; Rego AC, 1999, FREE RADICAL BIO MED, V26, P1405, DOI 10.1016/S0891-5849(98)00337-2; SNYDER LM, 1988, BIOCHIM BIOPHYS ACTA, V937, P229, DOI 10.1016/0005-2736(88)90245-3; STOCCHI V, 1994, ARCH BIOCHEM BIOPHYS, V311, P160, DOI 10.1006/abbi.1994.1221; Tavazzi B, 1998, FREE RADICAL RES, V28, P25, DOI 10.3109/10715769809097873; Tavazzi B, 2000, EUR J BIOCHEM, V267, P684, DOI 10.1046/j.1432-1327.2000.01042.x; Thabrew MI, 1999, ANN CLIN BIOCHEM, V36, P216, DOI 10.1177/000456329903600214; Vagnozzi R, 1997, EXP BRAIN RES, V117, P411, DOI 10.1007/s002210050235; VANDENBERGHE G, 1990, BIOMED BIOCHIM ACTA, V49, pS117; Watson BD, 1996, NEUROCHEM INT, V29, P173, DOI 10.1016/0197-0186(95)00118-2	35	55	59	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48083	48092		10.1074/jbc.M101715200	http://dx.doi.org/10.1074/jbc.M101715200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11675377	hybrid			2022-12-25	WOS:000172927000048
J	Widlak, P; Li, LY; Wang, XD; Garrard, WT				Widlak, P; Li, LY; Wang, XD; Garrard, WT			Action of recombinant human apoptotic endonuclease G on naked DNA and chromatin substrates - Cooperation with exonuclease and DNase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-ACTIVATED DNASE; HEAT-SHOCK LOCUS; TOPOISOMERASE-II; CYTOCHROME-C; FRAGMENTATION; NUCLEASE; INHIBITOR; CLEAVAGE; PROTEIN; DEATH	Endonuclease G (endoG) is released from mitochondria during apoptosis and is in part responsible for internucleosomal DNA cleavage. Here we report the action of the purified human recombinant form of this endonuclease on naked DNA and chromatin substrates. The addition of the protein to isolated nuclei from nonapoptotic cells first induces higher order chromatin cleavage into DNA fragments greater than or equal to 50 kb in length, followed by inter- and intranucleosomal DNA cleavages with products possessing significant internal single-stranded nicks spaced at nucleosomal (similar to 190 bases) and subnucleosomal (similar to 10 bases) periodicities. We demonstrate that both exonucleases and DNase I stimulate the ability of endoG to generate double-stranded DNA cleavage products at physiological ionic strengths, suggesting that these activities work in concert with endoG in apoptotic cells to ensure efficient DNA breakdown.	Univ Texas, SW Med Ctr, Dept Mol Biol, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garrard, WT (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Widlak, Piotr/AAL-8075-2021	Widlak, Piotr/0000-0001-5099-4726	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059809] Funding Source: NIH RePORTER; NIGMS NIH HHS [GMR01-17158, GMR01-59809] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonifer C, 2000, TRENDS GENET, V16, P310, DOI 10.1016/S0168-9525(00)02029-1; COTE J, 1993, SCIENCE, V261, P765, DOI 10.1126/science.7688144; COTE J, 1989, J BIOL CHEM, V264, P3301; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GERSCHENSON M, 1995, NUCLEIC ACIDS RES, V23, P88, DOI 10.1093/nar/23.1.88; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Ikeda S, 1997, BIOCHEM BIOPH RES CO, V235, P291, DOI 10.1006/bbrc.1997.6786; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; LUTTER LC, 1979, NUCLEIC ACIDS RES, V6, P41, DOI 10.1093/nar/6.1.41; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Oliveri M, 2001, EUR J IMMUNOL, V31, P743, DOI 10.1002/1521-4141(200103)31:3<743::AID-IMMU743>3.0.CO;2-9; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; RUIZCARRILLO A, 1987, EMBO J, V6, P401, DOI 10.1002/j.1460-2075.1987.tb04769.x; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; UDVARDY A, 1993, MOL CELL BIOL, V13, P7522, DOI 10.1128/MCB.13.12.7522; VANHOLDE KE, 1988, CHROMATIN, P27; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Widlak P, 2000, CELL MOL BIOL LETT, V5, P373; Widlak P, 1997, J BIOL CHEM, V272, P17654, DOI 10.1074/jbc.272.28.17654; Widlak P, 2000, J BIOL CHEM, V275, P8226, DOI 10.1074/jbc.275.11.8226; Widlak P, 2001, MOL CELL BIOCHEM, V218, P125, DOI 10.1023/A:1007231822086; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYLLIE AH, 1984, J PATHOL, V142, P66; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZASSENHAUS HP, 1988, NUCLEIC ACIDS RES, V16, P3283, DOI 10.1093/nar/16.8.3283; Zhang JH, 2000, BIOCHEM BIOPH RES CO, V274, P225, DOI 10.1006/bbrc.2000.3122; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	39	135	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48404	48409		10.1074/jbc.M108461200	http://dx.doi.org/10.1074/jbc.M108461200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606588	hybrid			2022-12-25	WOS:000172927000091
J	Sauer, H; Klimm, B; Hescheler, J; Wartenberg, M				Sauer, H; Klimm, B; Hescheler, J; Wartenberg, M			Activation of p90RSK and growth stimulation of multicellular tumor spheroids are dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP	FASEB JOURNAL			English	Article						mitogen-activated protein kinase; suramin; radical scavengers	CYTOSOLIC PHOSPHOLIPASE A(2); SMOOTH-MUSCLE CELLS; RIBOSOMAL S6 KINASE; PROTEIN-KINASE; EXTRACELLULAR ATP; HYDROGEN-PEROXIDE; FREE-RADICALS; SIGNAL-TRANSDUCTION; REDOX-REGULATION; MESANGIAL CELLS	Mitogenic stimulation by growth factors may be mediated through intracellular reactive oxygen species (ROS) acting as signaling molecules. Incubation of multicellular prostate tumor spheroids with adenosine 5' triphosphate (ATP) dose-dependently stimulated tumor growth. ATP, uridine 5'-triphosphate (UTP), adenosine 5'-diphosphate (ADP), and 2-methylthio-ATP (2-MeS-ATP) increased intracellular ROS levels significantly. ROS generation by ATP was inhibited by the P-2 receptor antagonist suramin, by the reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitors diphenylene iodonium chloride (DPI) and 4-(2-aminoethyl) benzenesulfonylfluoride (AEBSF), as well as by the Ca2+-dependent phospholipase A(2) (PLA(2)) inhibitors indomethacin and methyl arachidonyl fluorophosphonate (MAFP). The generation of ROS was dependent on the intracellular Ca2+ response evoked by ATP. Exogenous ATP activated the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) pathway, which was blunted by the MAPK/ERK kinase 1/2 (MEK1/2) antagonist PD98059. The radical scavengers vitamin E, dimethyl thiourea (DMTU), and N-acetyl cysteine (NAC) failed to inhibit ERK1/2 activation but abolished p90 ribosomal S6 kinase (p90RSK) activation downstream of ERK1/2, as well as the growth stimulation of tumor spheroids. Our data indicate that p90RSK downstream of ERK1/2 is the molecular target for ROS generated through stimulation of purinergic receptors by ATP.	Univ Cologne, Dept Neurophysiol, D-50931 Cologne, Germany	University of Cologne	Wartenberg, M (corresponding author), Univ Cologne, Dept Neurophysiol, Robert Koch Str 39, D-50931 Cologne, Germany.	mw@physiologie.uni-koeln.de						Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bestilny LJ, 2000, EXP CELL RES, V256, P264, DOI 10.1006/excr.2000.4821; BURDON RH, 1989, FREE RADICAL RES COM, V6, P345, DOI 10.3109/10715768909087918; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; Dichmann S, 2000, BLOOD, V95, P973, DOI 10.1182/blood.V95.3.973.003k47_973_978; Dixon CJ, 1997, BRIT J CANCER, V75, P34, DOI 10.1038/bjc.1997.6; Dixon CJ, 1999, BRIT J PHARMACOL, V127, P1680, DOI 10.1038/sj.bjp.0702653; Erlinge D, 1998, GEN PHARMACOL-VASC S, V31, P1, DOI 10.1016/S0306-3623(97)00420-5; FANG WG, 1992, J CLIN INVEST, V89, P191, DOI 10.1172/JCI115562; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; FRENKEL K, 1991, FREE RADICAL RES COM, V12-3, P783, DOI 10.3109/10715769109145860; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; Harada H, 2000, KIDNEY INT, V57, P949, DOI 10.1046/j.1523-1755.2000.00911.x; Harper S, 1998, BRIT J PHARMACOL, V124, P703, DOI 10.1038/sj.bjp.0701895; Hazan I, 1997, BIOCHEM J, V326, P867, DOI 10.1042/bj3260867; Janssens R, 2001, BRIT J PHARMACOL, V132, P536, DOI 10.1038/sj.bjp.0703833; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; Nakamura E, 2000, AM J PHYSIOL-CELL PH, V279, pC510, DOI 10.1152/ajpcell.2000.279.2.C510; Neary JT, 1999, J NEUROSCI, V19, P4211, DOI 10.1523/jneurosci.19-11-04211.1999; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Ruiz-Gines JA, 2000, J CARDIOVASC PHARM, V35, P109, DOI 10.1097/00005344-200001000-00014; Sauer H, 1997, FEBS LETT, V419, P201, DOI 10.1016/S0014-5793(97)01456-7; Sauer H, 2000, AM J PHYSIOL-CELL PH, V279, pC295, DOI 10.1152/ajpcell.2000.279.2.C295; Sauer H, 1999, FREE RADICAL BIO MED, V27, P1276, DOI 10.1016/S0891-5849(99)00164-1; SCHULZELOHOFF E, 1992, AM J PHYSIOL, V263, pF374, DOI 10.1152/ajprenal.1992.263.3.F374; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tu MT, 2000, BRIT J PHARMACOL, V129, P1481, DOI 10.1038/sj.bjp.0703182; Wagstaff SC, 2000, CARCINOGENESIS, V21, P2175, DOI 10.1093/carcin/21.12.2175; Wartenberg M, 1999, J BIOL CHEM, V274, P27759, DOI 10.1074/jbc.274.39.27759; Wartenberg M, 2000, INT J CANCER, V85, P267, DOI 10.1002/(SICI)1097-0215(20000115)85:2<267::AID-IJC19>3.0.CO;2-H; Wartenberg M, 2001, J BIOL CHEM, V276, P17420, DOI 10.1074/jbc.M100141200; Wever RMF, 1997, BIOCHEM BIOPH RES CO, V237, P340, DOI 10.1006/bbrc.1997.7069; Wilden PA, 1998, AM J PHYSIOL-HEART C, V275, pH1209, DOI 10.1152/ajpheart.1998.275.4.H1209; Yu SM, 1996, MOL PHARMACOL, V50, P1000; Zafari AM, 1999, ANTIOXID REDOX SIGN, V1, P167, DOI 10.1089/ars.1999.1.2-167	42	52	53	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2539	+		10.1096/fj.01-0360fje	http://dx.doi.org/10.1096/fj.01-0360fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641267				2022-12-25	WOS:000171372700028
J	Lopez-Rovira, T; Chalaux, E; Massague, J; Rosa, JL; Ventura, F				Lopez-Rovira, T; Chalaux, E; Massague, J; Rosa, JL; Ventura, F			Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; LOOP-HELIX GENES; FUNCTIONAL COOPERATION; DNA-BINDING; MYOGENIC DIFFERENTIATION; SIGNAL-TRANSDUCTION; JUNB PROMOTER; TARGET; CELLS; EXPRESSION	Bone morphogenetic proteins (BMPs) are potent inhibitors of myoblast differentiation and inducers of bone formation both in vivo and in vitro. Expression of Id1, a negative regulator of basic helix-loop-helix transcription factors, is up-regulated by BMPs and contributes to the antimyogenic effects of this family of cytokines. In this report, we have identified a specific BMP-2 immediate early response enhancer in the human Id1 gene. Transcriptional activation of the enhancer was increased by overexpression of BMP-responsive Smads, and Smad4 and was completely abrogated in Smad4-deficient cells. Deletion analysis demonstrates that the responsive region is composed of two separate DNA binding elements, a set of overlapping GC boxes, which bind BMP-regulated Smads upon BMP stimulation, and three repeats of CAGAC boxes. Gel shift and oligonucleotide pull-down assays demonstrated that these two types of motifs were capable of binding their corresponding Smads. However, deletion or mutation of either DNA binding element was nonadditive, since disruption of either GC or CAGAC boxes resulted in complete or severe loss of BMP-2 responsiveness. These data suggest the simultaneous requirement of two independent DNA binding elements to allow functional co-operativity of BMP-regulated Smads and Smad4 in BNIP-activated gene promoters.	Univ Barcelona, Dept Ciencies Fisiol 2, Lhospitalet De Llobregat 08907, Spain; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	University of Barcelona; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Ventura, F (corresponding author), Univ Barcelona, Unitat Bioquim, Campus Bellvitge,Feixa Llarga S-N, Lhospitalet De Llobregat 08907, Spain.		Rosa, Jose Luis/K-6685-2014; Ventura, Francesc/K-9700-2014; Ventura, Francesc/ABG-2285-2020	Rosa, Jose Luis/0000-0002-6161-5688; Ventura, Francesc/0000-0001-9673-9405; Ventura, Francesc/0000-0001-9673-9405; Massague, Joan/0000-0001-9324-8408				Ausubel FM, 1992, CURRENT PROTOCOLS MO; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; Cai L, 2000, DEVELOPMENT, V127, P3021; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Hullinger TG, 2001, EXP CELL RES, V262, P69, DOI 10.1006/excr.2000.5074; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Katagiri T, 1997, EXP CELL RES, V230, P342, DOI 10.1006/excr.1996.3432; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Kusanagi K, 2001, J BIOL CHEM, V276, P28155, DOI 10.1074/jbc.M103371200; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MELKINOVA IN, 1999, EXP CELL RES, V247, P94; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Raftery LA, 1999, DEV BIOL, V210, P251, DOI 10.1006/dbio.1999.9282; Rawls A, 1997, CELL, V89, P5, DOI 10.1016/S0092-8674(00)80175-0; Rodan GA, 1997, CELL, V89, P677, DOI 10.1016/S0092-8674(00)80249-4; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spits H, 2000, J EXP MED, V192, P1775, DOI 10.1084/jem.192.12.1775; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; Tang SJ, 1998, DEVELOPMENT, V125, P1877; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tournay O, 1996, MOL CELL BIOL, V16, P2418; URIST MR, 1983, SCIENCE, V220, P680, DOI 10.1126/science.6403986; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	58	244	256	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3176	3185		10.1074/jbc.M106826200	http://dx.doi.org/10.1074/jbc.M106826200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11700304	Green Published, hybrid			2022-12-25	WOS:000173688000017
J	Alim, MA; Hossain, MS; Arima, K; Takeda, K; Izumiyama, Y; Nakamura, M; Kaji, H; Shinoda, T; Hisanaga, S; Ueda, K				Alim, MA; Hossain, MS; Arima, K; Takeda, K; Izumiyama, Y; Nakamura, M; Kaji, H; Shinoda, T; Hisanaga, S; Ueda, K			Tubulin seeds alpha-synuclein fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; GLIAL CYTOPLASMIC INCLUSIONS; LEWY BODIES; NACP/ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; NEURODEGENERATIVE DISEASES; IN-VITRO; PROTEIN; COMPONENT; DEMENTIA	Increasing evidence suggests that a-synuclein is a common pathogenic molecule in several neurodegenerative diseases, particularly in Parkinson's disease. To understand alpha-synuclein pathology, we investigated molecules that interact with alpha-synuclein in human and rat brains and identified tubulin as an a-synuclein binding/associated protein. Tubulin co-localized with alpha-synuelein in Lewy bodies and other alpha-synuclein-positive pathological structures. Tubulin initiated and promoted alpha-synuclein fibril formation under physiological conditions in vitro. These findings suggest that an interaction between tubulin and alpha-synuclein might accelerate alpha-synuclein aggregation in diseased brains, leading to the formation of Lewy bodies.	Tokyo Inst Psychiat, Dept Neural Plast, Setagaya Ku, Tokyo 1568585, Japan; Tokyo Inst Psychiat, Dept Ultrastruct & Histochem, Setagaya Ku, Tokyo 1568585, Japan; Tokyo Inst Psychiat, Electron Microscopy Ctr, Setagaya Ku, Tokyo 1568585, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Chem, Hachioji, Tokyo 1920364, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Biol, Hachioji, Tokyo 1920364, Japan	Tokyo Institute of Psychiatry; Tokyo Institute of Psychiatry; Tokyo Institute of Psychiatry; Tokyo Metropolitan University; Tokyo Metropolitan University	Ueda, K (corresponding author), Tokyo Inst Psychiat, Dept Neural Plast, Setagaya Ku, 2-1-8 Kmaikitazawa, Tokyo 1568585, Japan.		Kaji, Hiroyuki/L-7122-2018	Kaji, Hiroyuki/0000-0002-0910-9999				Arima K, 1998, ACTA NEUROPATHOL, V96, P439, DOI 10.1007/s004010050917; Arima K, 2000, NEUROLOGY, V54, P1787, DOI 10.1212/WNL.54.9.1787; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; HOSSAIN MS, 2001, IN PRESS J ALZHEIMER; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; Mukaetova-Ladinska EB, 2000, J NEUROPATH EXP NEUR, V59, P408, DOI 10.1093/jnen/59.5.408; POOYMEROPOULOS MH, 1997, SCIENCE, V276, P2045; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takeda A, 1998, AM J PATHOL, V152, P367; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Xia Y, 2001, J ALZHEIMERS DIS, V3, P485, DOI 10.3233/JAD-2001-3508	31	156	164	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2112	2117		10.1074/jbc.M102981200	http://dx.doi.org/10.1074/jbc.M102981200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11698390	hybrid			2022-12-25	WOS:000173421300068
J	Chen, M; Costa, FK; Lindvay, CR; Han, YP; Woodley, DT				Chen, M; Costa, FK; Lindvay, CR; Han, YP; Woodley, DT			The recombinant expression of full-length type VII collagen and characterization of molecular mechanisms underlying dystrophic epidermolysis bullosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORING FIBRILS; HUMAN-SKIN; DERMAL FIBROBLASTS; TISSUE FORM; NC1 DOMAIN; GENE; PROCOLLAGEN; MUTATIONS; COL7A1; ACQUISITA	Type VII collagen is a major component of anchoring fibrils, attachment structures that mediate dermal-epidermal adherence in human skin. Dystrophic epidermolysis bullosa (DEB) is an inherited mechano-bullous disorder caused by mutations in the type VII collagen gene and perturbations in anchoring fibrils. In this study, we produced recombinant human type VII collagen in stably transfected human 293 cell clones and purified large quantities of the recombinant protein from culture media. The recombinant type VII collagen was secreted as a correctly folded, disulfide-bonded, helical trimer resistant to protease degradation. Purified type VII collagen bound to fibronectin, laminin-5, type I collagen, and type IV collagen and also supported human dermal fibroblast adhesion. In an attempt to establish genotype-phenotype relationships, we generated two individual substitution mutations that have been associated with recessive DEB, R2008G and G2749R, and purified the recombinant mutant proteins. The G2749R mutation resulted in mutant type VII collagen with increased sensitivity to protease degradation and decreased ability to form trimers. The R2008G mutation caused the intracellular accumulation of type VII collagen. We conclude that structural and functional studies of in vitro generated type VII collagen mutant proteins will aid in correlating genetic mutations with the clinical phenotypes of DEB patients.	Univ So Calif, Div Dermatol, Dept Med, Div Plast & Reconstruct Surg, Los Angeles, CA 90033 USA	University of Southern California	Woodley, DT (corresponding author), Univ So Calif, Div Dermatol, Dept Med, Div Plast & Reconstruct Surg, CRL 2040 1301 Miss Rd, Los Angeles, CA 90033 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033625, R01AR047981] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR33625, R01 AR47981] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; Bruckner-Tuderman L, 1999, MATRIX BIOL, V18, P43, DOI 10.1016/S0945-053X(98)00007-9; BRUCKNERTUDERMAN L, 1987, EUR J BIOCHEM, V165, P607, DOI 10.1111/j.1432-1033.1987.tb11483.x; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; Chen M, 1999, EXP CELL RES, V249, P231, DOI 10.1006/excr.1999.4473; Chen M, 2001, J BIOL CHEM, V276, P21649, DOI 10.1074/jbc.M100180200; Chen M, 1997, J BIOL CHEM, V272, P14516, DOI 10.1074/jbc.272.23.14516; Chen M, 1997, J INVEST DERMATOL, V108, P125, DOI 10.1111/1523-1747.ep12332300; Chen M, 2000, J BIOL CHEM, V275, P24429, DOI 10.1074/jbc.M003440200; CHRISTIANO AM, 1994, J BIOL CHEM, V269, P20256; Christiano AM, 1996, AM J HUM GENET, V58, P671; CHRISTIANO AM, 1994, GENOMICS, V21, P160, DOI 10.1006/geno.1994.1238; CHRISTIANO AM, 1996, CURR OPIN DERMATOL, V3, P225; Gayraud B, 1997, J BIOL CHEM, V272, P9531; Hammami-Hauasli N, 1998, J BIOL CHEM, V273, P19228, DOI 10.1074/jbc.273.30.19228; Han YP, 2001, J CELL SCI, V114, P131; Hovnanian A, 1997, AM J HUM GENET, V61, P599, DOI 10.1086/515495; HOVNANIAN A, 1992, J CLIN INVEST, V90, P1032, DOI 10.1172/JCI115916; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; LAPIERE JC, 1994, J INVEST DERMATOL, V94, P637; Lin AN, 1992, EPIDERMOLYSIS BULLOS; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; LUNSTRUM GP, 1987, J BIOL CHEM, V262, P13706; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; NIEBOER C, 1980, BRIT J DERMATOL, V102, P383, DOI 10.1111/j.1365-2133.1980.tb06550.x; OKEEFE EJ, 1984, J INVEST DERMATOL, V82, P150, DOI 10.1111/1523-1747.ep12259708; PARENTE MG, 1991, P NATL ACAD SCI USA, V88, P6931, DOI 10.1073/pnas.88.16.6931; PETERSEN MJ, 1987, J BIOL CHEM, V262, P835; SELTZER JL, 1989, J BIOL CHEM, V264, P3822; TIDMAN MJ, 1985, J INVEST DERMATOL, V84, P373; UITTO J, 1993, SEMIN DERMATOL, V12, P191; UITTO J, 1995, P ASSOC AM PHYSICIAN, V107, P245; UITTO J, 1994, ARCH DERMATOL RES, V287, P16, DOI 10.1007/BF00370713; UITTO J, 1992, EXP DERMATOL, P12; UITTO J, 1992, J INVEST DERMATOL, V38, P391; WOODLEY DT, 1983, BIOCHIM BIOPHYS ACTA, V761, P278, DOI 10.1016/0304-4165(83)90077-6; WOODLEY DT, 1984, NEW ENGL J MED, V310, P1007, DOI 10.1056/NEJM198404193101602; WOODLEY DT, 1988, J CLIN INVEST, V81, P683, DOI 10.1172/JCI113373	40	59	67	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2118	2124		10.1074/jbc.M108779200	http://dx.doi.org/10.1074/jbc.M108779200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11698408	hybrid			2022-12-25	WOS:000173421300069
J	Gu, YP; Fujioka, H; Mishra, RS; Li, RL; Singh, N				Gu, YP; Fujioka, H; Mishra, RS; Li, RL; Singh, N			Prion peptide 106-126 modulates the aggregation of cellular prion protein and induces the synthesis of potentially neurotoxic transmembrane PrP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONGIFORM ENCEPHALOPATHY; SCRAPIE ISOFORM; DISEASE; CELLS; CONFORMATIONS; ACCUMULATION; PATHOGENESIS; DEGRADATION; INHIBITION; FORMS	In infectious and familial prion disorders, neurodegeneration is often seen without obvious deposits of the scrapie prion protein (PrPSc), the principal cause of neuronal death in prion disorders. In such cases, neurotoxicity must be mediated by alternative pathways of cell death. One such pathway is through a transmembrane form of PrP. We have investigated the relationship between intracellular accumulation of prion protein aggregates and the consequent up-regulation of transmembrane prion protein in a cell model. Here, we report that exposure of neuroblastoma cells to the prion peptide 106-126 catalyzes the aggregation of cellular prion protein to a weakly proteinase K-resistant form and induces the synthesis of transmembrane prion protein, the proposed mediator of neurotoxicity in certain prion disorders. The N terminus of newly synthesized transmembrane prion protein is cleaved spontaneously on the cytosolic face of the endoplasmic reticulum, and the truncated C-terminal fragment accumulates on the cell surface. Our results suggest that neurotoxicity in prion disorders is mediated by a complex pathway involving transmembrane prion protein and not by deposits of aggregated and proteinase K-resistant PrP alone.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Singh, N (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.				NINDS NIH HHS [NS39089, NS35962] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035962, R29NS035962, R01NS039089] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brown DR, 2000, BIOCHEM J, V352, P511, DOI 10.1042/0264-6021:3520511; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; Chabry J, 1998, J BIOL CHEM, V273, P13203, DOI 10.1074/jbc.273.21.13203; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Doh-Ura K, 2000, J VIROL, V74, P4894, DOI 10.1128/JVI.74.10.4894-4897.2000; Ettaiche M, 2000, J BIOL CHEM, V275, P36487, DOI 10.1074/jbc.C000579200; Grigoriev V, 1999, NEUROSCI LETT, V264, P57, DOI 10.1016/S0304-3940(99)00146-9; Gu YP, 2001, J ALZHEIMERS DIS, V3, P169; Haik S, 2000, NEUROBIOL DIS, V7, P644, DOI 10.1006/nbdi.2000.0316; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Holscher C, 1998, J VIROL, V72, P1153; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kaneko K, 2000, J MOL BIOL, V295, P997, DOI 10.1006/jmbi.1999.3386; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; LASZLO L, 1992, J PATHOL, V166, P333, DOI 10.1002/path.1711660404; Manson JC, 1999, EMBO J, V18, P6855, DOI 10.1093/emboj/18.23.6855; Mizuno T, 1999, J BIOL CHEM, V274, P15110, DOI 10.1074/jbc.274.21.15110; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rymer DL, 2000, J NEUROCHEM, V75, P2536, DOI 10.1046/j.1471-4159.2000.0752536.x; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TATEISHI J, 1995, BRAIN PATHOL, V5, P53, DOI 10.1111/j.1750-3639.1995.tb00577.x; TATEISHI J, 1990, NEUROLOGY, V40, P1578, DOI 10.1212/WNL.40.10.1578; Tuo WB, 2001, J BIOL CHEM, V276, P18229, DOI 10.1074/jbc.M008887200; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	38	81	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2275	2286		10.1074/jbc.M104345200	http://dx.doi.org/10.1074/jbc.M104345200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11682469	hybrid			2022-12-25	WOS:000173421300088
J	Qin, KF; Yang, Y; Mastrangelo, P; Westaway, D				Qin, KF; Yang, Y; Mastrangelo, P; Westaway, D			Mapping Cu(II) binding sites in prion proteins by diethyl pyrocarbonate modification and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometric footprinting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; COPPER-BINDING; SCRAPIE PRION; CHEMICAL MODIFICATION; SECONDARY STRUCTURE; CELLULAR PRP; N-TERMINUS; IDENTIFICATION; RECOMBINANT; PEPTIDES	Although Cu(II) ions bind to the prion protein (PrP), there have been conflicting findings concerning the number and location of binding sites. We have combined diethyl pyrocarbonate (DEPC)-mediated carbethoxylation, protease digestion, and mass spectrometric analysis of apo-PrP and copper-coordinated mouse PrP23-231 to "footprint" histidine-dependent Cu(II) coordination sites within this molecule. At pH 7.4 Cu(II) protected five histidine residues from DEPC modification. No protection was afforded by Ca(II), Mn(II), or Mg(II) ions, and only one or two residues were protected by Zn(II) or MUD ions. Post-source decay mapping of DEPC-modified histidines pinpointed residues 60, 68, 76, and 84 within the four PHGGG/SWGQ octarepeat units and residue 95 within the related sequence GGGTHNQ. Besides defining a copper site within the protease-resistant core of PrP, our findings suggest application of DEPC foot-printing methodologies to probe copper occupancy and pathogenesis-associated conformational changes in PrP purified from tissue samples.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Mol Med Res Ctr, Toronto, ON M5S 3H2, Canada; Univ Toronto, Mass Spectrometry Lab, Mol Med Res Ctr, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto	Westaway, D (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Neurosci Bldg,6 Queens Pk,Crescent W, Toronto, ON M5S 3H2, Canada.	david.westaway@utoronto.ca						Aronoff-Spencer E, 2000, BIOCHEMISTRY-US, V39, P13760, DOI 10.1021/bi001472t; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BAZAN JF, 1987, PROTEIN ENG, V1, P125, DOI 10.1093/protein/1.2.125; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BIEMANN K, 1987, SCIENCE, V237, P992, DOI 10.1126/science.3303336; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Cereghetti GM, 2001, BIOPHYS J, V81, P516, DOI 10.1016/S0006-3495(01)75718-9; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; FUKUDA H, 1988, COMP BIOCHEM PHYS B, V91, P285, DOI 10.1016/0305-0491(88)90144-7; Glocker MO, 1996, BIOCHEMISTRY-US, V35, P14625, DOI 10.1021/bi961199o; Hasnain SS, 2001, J MOL BIOL, V311, P467, DOI 10.1006/jmbi.2001.4795; Hilditch-Maguire P, 2000, HUM MOL GENET, V9, P2789, DOI 10.1093/hmg/9.19.2789; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Kalkum M, 1998, BIOCONJUGATE CHEM, V9, P226, DOI 10.1021/bc970162t; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KINTNER M, 2000, COLLISIONALLY INDUCE; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LI CW, 1993, J INORG BIOCHEM, V51, P727, DOI 10.1016/0162-0134(93)85005-S; LIPPARD SJ, 1977, BIOCHEMISTRY-US, V16, P1136, DOI 10.1021/bi00625a017; Loo JA, 1997, MASS SPECTROM REV, V16, P1; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MCKINLEY MP, 1981, SCIENCE, V214, P1259, DOI 10.1126/science.6795721; Miles E W, 1977, Methods Enzymol, V47, P431; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Rogers JT, 1999, J BIOL CHEM, V274, P6421, DOI 10.1074/jbc.274.10.6421; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Salih B, 1998, J MASS SPECTROM, V33, P994, DOI 10.1002/(SICI)1096-9888(1998100)33:10<994::AID-JMS714>3.0.CO;2-#; Silverman GL, 2000, J BIOL CHEM, V275, P26834; Simonic T, 2000, FEBS LETT, V469, P33, DOI 10.1016/S0014-5793(00)01232-1; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; TITHALL RW, 1990, FEMS MICROBIOL LETT, V56, P261; Tsubaki M, 2000, BIOCHEMISTRY-US, V39, P3276, DOI 10.1021/bi991883d; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; Whittal RM, 2000, PROTEIN SCI, V9, P332; Williamson RA, 1996, P NATL ACAD SCI USA, V93, P7279, DOI 10.1073/pnas.93.14.7279	59	143	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1981	1990		10.1074/jbc.M108744200	http://dx.doi.org/10.1074/jbc.M108744200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11698407	hybrid			2022-12-25	WOS:000173421300051
J	Thomas, R; Patenaude, SI; MacKenzie, CR; To, R; Hirama, T; Young, NM; Evans, SV				Thomas, R; Patenaude, SI; MacKenzie, CR; To, R; Hirama, T; Young, NM; Evans, SV			Structure of an anti-blood group A Fv and improvement of its binding affinity without loss of specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPROVED CARBOHYDRATE-BINDING; SINGLE-CHAIN FV; COMBINING SITE; GROUP-A; SATURATION MUTAGENESIS; SOMATIC HYPERMUTATION; MUTATIONAL ANALYSIS; PHAGE DISPLAY; ANTIBODIES; SELECTION	The specificity of antibody recognition of the ABO blood group trisaccharide antigens has been explored by crystal structure analysis and mutation methods. The crystal structure of the Fv corresponding to the anti-blood group A antibody AC1001 has been determined to 2.2-Angstrom resolution and reveals a binding pocket that is complementary to the blood group A-trisaccharide antigen. The effect of mutating specific residues lining this pocket on binding to the A and B blood group oligosaccharide antigens was investigated through a panel of single point mutations and through a phage library of mutations in complementarity determining region H3. Both approaches gave several mutants with improved affinity for antigen. Surface plasmon resonance indicated up to 8-fold enhancement in affinity for the A-pentasaccharide with no observable binding to the blood group B antigen. This is the first example of single point mutations in a carbohydrate-binding antibody resulting in significant increases in binding affinity without loss of specificity.	Univ Ottawa, Dept Biochem, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Ottawa; University of Ottawa; National Research Council Canada	Evans, SV (corresponding author), Univ Ottawa, Dept Biochem, Ottawa, ON K1H 8M5, Canada.			Evans, Stephen/0000-0002-0366-4027				[Anonymous], 1994, ACTA CRYSTALLOGR SEC, VD50, P760; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; Brorson K, 1999, J IMMUNOL, V163, P6694; BRUMMELL DA, 1993, BIOCHEMISTRY-US, V32, P1180, DOI 10.1021/bi00055a024; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Burks EA, 1997, P NATL ACAD SCI USA, V94, P412, DOI 10.1073/pnas.94.2.412; Casset F, 1996, EUR J BIOCHEM, V239, P710, DOI 10.1111/j.1432-1033.1996.0710u.x; Chen G, 1999, PROTEIN ENG, V12, P349, DOI 10.1093/protein/12.4.349; CHEN HT, 1987, J BIOL CHEM, V262, P13579; CONNOLLY ML, 1981, QUANTUM CHEM PROGRAM, V1, P75; DENG SJ, 1995, P NATL ACAD SCI USA, V92, P4992, DOI 10.1073/pnas.92.11.4992; DENG SJ, 1994, J BIOL CHEM, V269, P9533; England P, 1999, J IMMUNOL, V162, P2129; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EVANS SV, 1994, J MOL BIOL, V241, P691, DOI 10.1006/jmbi.1994.1544; Harrison JL, 1996, METHOD ENZYMOL, V267, P83; HAWKINS RE, 1993, J MOL BIOL, V234, P958, DOI 10.1006/jmbi.1993.1650; Ignatovich O, 1997, J MOL BIOL, V268, P69, DOI 10.1006/jmbi.1997.0956; JEFFREY PD, 1995, NAT STRUCT BIOL, V2, P466, DOI 10.1038/nsb0695-466; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKENZIE CR, 1994, BIO-TECHNOL, V12, P390, DOI 10.1038/nbt0494-390; MacKenzie R, 1998, J IMMUNOL METHODS, V220, P39, DOI 10.1016/S0022-1759(98)00143-4; Manivel V, 2000, IMMUNITY, V13, P611, DOI 10.1016/S1074-7613(00)00061-3; Patenaude SI, 1998, ACTA CRYSTALLOGR D, V54, P1456, DOI 10.1107/S0907444998005824; Sambrook J., 2002, MOL CLONING LAB MANU; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; SEYMOUR GJ, 1995, IMMUNOLOGY INTRO HLT, P109; Sharp KA, 1998, PROTEINS, V33, P39, DOI 10.1002/(SICI)1097-0134(19981001)33:1<39::AID-PROT4>3.3.CO;2-K; Tomlinson IM, 1996, J MOL BIOL, V256, P813, DOI 10.1006/jmbi.1996.0127; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; Yang PL, 1999, J MOL BIOL, V294, P1191, DOI 10.1006/jmbi.1999.3197; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626; YELTON DE, 1995, J IMMUNOL, V155, P1994	35	27	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2059	2064		10.1074/jbc.M104364200	http://dx.doi.org/10.1074/jbc.M104364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11679577	hybrid			2022-12-25	WOS:000173421300061
J	Ryden, M; Dicker, A; van Hermelen, V; Hauner, H; Brunnberg, M; Perbeck, L; Lonnqvist, F; Arner, P				Ryden, M; Dicker, A; van Hermelen, V; Hauner, H; Brunnberg, M; Perbeck, L; Lonnqvist, F; Arner, P			Mapping of early signaling events in tumor necrosis factor-alpha-mediated lipolysis in human fat cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-RESISTANCE; TNF-ALPHA; METABOLIC-RESPONSE; LIPID-METABOLISM; RECEPTOR; ACTIVATION; ADIPOCYTES; DIFFERENTIATION; TRANSDUCTION; SPECIFICITY	Tumor necrosis factor-alpha (TNF-alpha) is a pleiotropic cytokine with a proposed role in obesity-related insulin resistance. This could be mediated by increased lipolysis in adipose tissue resulting in elevated free fatty acid levels. The early intracellular signals entailed in TNF-alpha-mediated lipolysis are unknown but may involve members of the mitogen-activated protein kinase (MAPK) family. We investigated the possible contribution of MAPK in TNF-alpha-induced lipolysis in human preadipocytes. TNF-alpha activated the three mammalian MAPK, p44/ 42, JNK, and p38, in a distinct time- and concentration-dependent manner. TNF-alpha also induced a concentration-dependent stimulation of lipolysis with a more than 3-fold increase at the maximal dose. Lipolysis was completely inhibited by blockers specific for p44/42 (PD98059) and JNK (dimetylaminopurine) but was not affected by the p38 blocker SB203580. Use of receptor-specific TNF-alpha mutants showed that activation of MAPK is entirely mediated by the TNFR1 receptor. The results in human preadipocytes differed from those obtained in murine 3T3-L1 adipocytes in which all three MAPK were constitutively active. Thus, studies of intracellular signaling pathways obtained in different cellular contexts should be interpreted with caution. In conclusion, although TNF-alpha activates all three known MAPK in human preadipocytes, only p44/42 and JNK appear to be involved in the regulation of lipolysis.	Huddinge Univ Hosp, Ctr Metab & Endocrinol, Lipidlab, Dept Med & Surg,Karolinska Inst, S-14186 Huddinge, Sweden; Univ Dusseldorf, German Diabet Res Inst, D-40225 Dusseldorf, Germany	Karolinska Institutet; Deutsches Diabetes-Zentrum (DDZ); Heinrich Heine University Dusseldorf	Arner, P (corresponding author), Huddinge Univ Hosp, Ctr Metab & Endocrinol, Lipidlab, Dept Med & Surg,Karolinska Inst, M61, S-14186 Huddinge, Sweden.	peter.arner@med-hs.ki.se		van Harmelen, Vanessa/0000-0003-0111-9858; Arner, Peter/0000-0002-6208-6220				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; De Cesaris P, 1998, J BIOL CHEM, V273, P7566, DOI 10.1074/jbc.273.13.7566; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; EVANS RD, 1992, CLIN SCI, V82, P205, DOI 10.1042/cs0820205; Gasic S, 1999, J BIOL CHEM, V274, P6770, DOI 10.1074/jbc.274.10.6770; GREEN A, 1994, ENDOCRINOLOGY, V134, P2581, DOI 10.1210/en.134.6.2581; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; HAUNER H, 1995, DIABETOLOGIA, V38, P764, DOI 10.1007/s001250050350; HELLMER J, 1989, ANAL BIOCHEM, V177, P132, DOI 10.1016/0003-2697(89)90027-4; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Jain RG, 1999, J CELL PHYSIOL, V179, P58, DOI 10.1002/(SICI)1097-4652(199904)179:1<58::AID-JCP8>3.0.CO;2-1; KISSEBAH AH, 1998, HDB OBESITY, P601; Kyriakis JM, 1999, GENE EXPRESSION, V7, P217; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; LopezSoriano J, 1997, MOL CELL ENDOCRINOL, V132, P93, DOI 10.1016/S0303-7207(97)00125-1; Marino MW, 1996, J BIOL CHEM, V271, P28624, DOI 10.1074/jbc.271.45.28624; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miles PDG, 1997, DIABETES, V46, P1678, DOI 10.2337/diabetes.46.11.1678; Orlinick JR, 1998, CELL SIGNAL, V10, P543, DOI 10.1016/S0898-6568(98)00018-7; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; Prins JB, 1997, DIABETES, V46, P1939, DOI 10.2337/diabetes.46.12.1939; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Samad F, 1997, THROMB HAEMOSTASIS, V78, P652; Sethi JK, 1999, SEMIN CELL DEV BIOL, V10, P19, DOI 10.1006/scdb.1998.0273; Sethi JK, 2000, FEBS LETT, V469, P77, DOI 10.1016/S0014-5793(00)01250-3; Shimizu M, 1996, PHARMACOL TOXICOL, V78, P254, DOI 10.1111/j.1600-0773.1996.tb00214.x; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; STARNES HF, 1988, J CLIN INVEST, V82, P1321, DOI 10.1172/JCI113733; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Tisdale MJ, 1999, J NUTR, V129, p243S, DOI 10.1093/jn/129.1.243S; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; VANDERPOLL T, 1991, AM J PHYSIOL, V261, pE457, DOI 10.1152/ajpendo.1991.261.4.E457; Ventre J, 1997, DIABETES, V46, P1526, DOI 10.2337/diabetes.46.9.1526	39	186	202	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1085	1091		10.1074/jbc.M109498200	http://dx.doi.org/10.1074/jbc.M109498200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694522	hybrid			2022-12-25	WOS:000173166800028
J	Uchimura, K; Kadomatsu, K; Nishimura, H; Muramatsu, H; Nakamura, E; Kurosawa, N; Habuchi, O; El-Fasakhany, FM; Yoshikai, Y; Muramatsu, T				Uchimura, K; Kadomatsu, K; Nishimura, H; Muramatsu, H; Nakamura, E; Kurosawa, N; Habuchi, O; El-Fasakhany, FM; Yoshikai, Y; Muramatsu, T			Functional analysis of the chondroitin 6-sulfotransferase gene in relation to lymphocyte subpopulations, brain development, and oversulfated chondroitin sulfates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH ENDOTHELIAL VENULES; BINDING GROWTH-FACTOR; MOLECULAR-CLONING; NEURITE OUTGROWTH; FACTOR MIDKINE; L-SELECTIN; EXPRESSION; PROTEOGLYCANS; CARTILAGE; 6-O-SULFOTRANSFERASE	Chondroitin 6-sulfotransferase (C6ST) catalyzes the transfer of sulfate to position 6 of the N-acetylgalactosamine residue of chondroitin. To obtain direct evidence regarding the function of C6ST and its product, chondroitin 6-sulfate, in vivo, we isolated the mouse C6ST gene (C6st) and generated mice deficient in this gene (C6st(-/-)) by embryonic stem cell technology. C6st(-/-) mice were born at approximately the expected frequency and were viable through adulthood. In the spleen of C6st(-/-) mice, the level of chondroitin 6-sulfate became almost undetectable. Analyses of these knockout mice provided insights into the biosynthesis of oversulfated chondroitin sulfates in mice; chondroitin sulfate D in the brain of null mice and the cartilage and telencephalon of null embryos disappeared, whereas the chondroitin sulfate E level in the spleen and brain of the null mice was unchanged. Despite the disappearance of chondroitin sulfate D structure, brain development was normal in the C6st(-/-) mice. Further analysis revealed that the number of CD62L(+)CD44(low) T lymphocytes corresponding to naive T lymphocytes in the spleen of 5-6-week-old C6st(-/-) mice was significantly decreased, whereas those in other secondary lymphoid organs were unchanged. This finding suggested that chondroitin 6-sulfate plays a role in the maintenance of naive T lymphocytes in the spleen of young mice.	Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Lab Host Def & Germfree Life, Res Inst Dis Mechanism & Control,Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 4488542, Japan	Nagoya University; Nagoya University; Nagoya University; Aichi University Education	Muramatsu, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		NAKAMURA, EIICHI/G-5041-2014; Kadomatsu, Kenji/G-8083-2012; Uchimura, Kenji/AFV-1802-2022; Uchimura, Kenji/C-9635-2014; ELFASAKHANY, Fathy/ABD-2927-2021	Uchimura, Kenji/0000-0003-3009-248X; Uchimura, Kenji/0000-0003-3009-248X; Kurosawa, Nobuyuki/0000-0002-1548-4541				Bayliss MT, 1999, J BIOL CHEM, V274, P15892, DOI 10.1074/jbc.274.22.15892; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Derry CJ, 1999, EUR J IMMUNOL, V29, P419, DOI 10.1002/(SICI)1521-4141(199902)29:02<419::AID-IMMU419>3.0.CO;2-A; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1998, BBA-GENE STRUCT EXPR, V1399, P57, DOI 10.1016/S0167-4781(98)00089-X; Garwood J, 1999, J NEUROSCI, V19, P3888; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Habuchi O, 1996, GLYCOBIOLOGY, V6, P51, DOI 10.1093/glycob/6.1.51; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; Habuchi O, 1997, GLYCOBIOLOGY, V7, P405, DOI 10.1093/glycob/7.3.405; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; Igakura T, 1998, DEV BIOL, V194, P152, DOI 10.1006/dbio.1997.8819; Ito Y, 2000, J BIOL CHEM, V275, P34728, DOI 10.1074/jbc.M909633199; Kitagawa H, 2000, J BIOL CHEM, V275, P21075, DOI 10.1074/jbc.M002101200; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Nakano H, 1998, BLOOD, V91, P2886, DOI 10.1182/blood.V91.8.2886.2886_2886_2895; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; Powell EM, 1997, CELL TISSUE RES, V290, P385, DOI 10.1007/s004410050945; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; ROSEN SD, 1989, J IMMUNOL, V142, P1895; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Uchimura K, 2000, BIOCHEM BIOPH RES CO, V274, P291, DOI 10.1006/bbrc.2000.3141; Uchimura K, 1998, GLYCOBIOLOGY, V8, P489, DOI 10.1093/glycob/8.5.489; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x	36	61	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1443	1450		10.1074/jbc.M104719200	http://dx.doi.org/10.1074/jbc.M104719200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11696535	hybrid			2022-12-25	WOS:000173166800075
J	Volodin, AA; Camerini-Otero, RD				Volodin, AA; Camerini-Otero, RD			Influence of DNA sequence on the positioning of RecA monomers in RecA-DNA cofilaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GENOME; PAIRING SEQUENCES; LOW FIDELITY; CHI-SITES; PROTEIN; RECOMBINATION; COMPLEXES; ISLANDS; RECOGNITION; SELECTION	We show that certain DNA sequences have the ability to influence the positioning of RecA monomers in RecA-DNA complexes. A tendency for RecA monomers to be phased was observed in RecA protein complexes with several oligonucleotides containing a recombinational hotspot sequence, the chi-site from Escherichia coli. This influence was observed in both the 5' to 3' and 3' to 5' directions with respect to chi. A 5'-end phosphate group and probably some other features in DNA also influence the phasing of RecA monomers. We conclude that natural DNAs contain a number of features that influence the positioning of RecA monomers. The ability of specific DNA sequences to influence the positioning of RecA monomers demonstrates some specificity in the binding of individual bases at different sites within a RecA monomer and, most likely, reflects the stereochemical non-equivalence of these sites. The possible biological implications of the phasing of RecA monomers in presynaptic DNA-protein cofilaments are discussed.	NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Russian Academy of Sciences	Camerini-Otero, RD (corresponding author), NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA.		Volodin, Alexander/B-9656-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052008] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Biaudet V, 1998, MOL MICROBIOL, V29, P666, DOI 10.1046/j.1365-2958.1998.00949.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CameriniOtero RD, 1995, ANNU REV GENET, V29, P509, DOI 10.1146/annurev.genet.29.1.509; Colbert T, 1998, TRENDS GENET, V14, P485, DOI 10.1016/S0168-9525(98)01606-0; COX MM, 1981, J BIOL CHEM, V256, P4676; DICAPUA E, 1987, EMBO J, V6, P2493, DOI 10.1002/j.1460-2075.1987.tb02531.x; JOHNSRUD L, 1978, P NATL ACAD SCI USA, V75, P5314, DOI 10.1073/pnas.75.11.5314; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; LAM ST, 1974, GENETICS, V77, P425; Malkov VA, 1998, J MOL BIOL, V278, P317, DOI 10.1006/jmbi.1998.1706; Malkov VA, 1997, J MOL BIOL, V271, P168, DOI 10.1006/jmbi.1997.1164; SAMBROOK J, 1989, MOL CLONING LAB MANU, P1123; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; Tracy RB, 1996, GENE DEV, V10, P1890, DOI 10.1101/gad.10.15.1890; Tracy RB, 1997, CELL, V90, P205, DOI 10.1016/S0092-8674(00)80328-1; Volodin AA, 1997, FEBS LETT, V407, P325, DOI 10.1016/S0014-5793(97)00367-0; ZLOTNICK A, 1990, J BIOL CHEM, V265, P17050	19	11	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1614	1618		10.1074/jbc.M108871200	http://dx.doi.org/10.1074/jbc.M108871200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11700314	hybrid			2022-12-25	WOS:000173166800097
J	Wagner, TC; Velichko, S; Vogel, D; Rani, MRS; Leung, S; Ransohoff, RM; Stark, GR; Perez, HD; Croze, E				Wagner, TC; Velichko, S; Vogel, D; Rani, MRS; Leung, S; Ransohoff, RM; Stark, GR; Perez, HD; Croze, E			Interferon signaling is dependent on specific tyrosines located within the intracellular domain of IFNAR2c - Expression of IFNAR2c tyrosine muants in U5A cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BETA RECEPTOR; ACTIVATION; PHOSPHATASE; CHAIN; PHOSPHORYLATION; SUBUNIT; SH2; TRANSCRIPTION; DIMERIZATION; RECRUITMENT	Type I interferons (IFNs) are cytokines that play a central role in mediating antiviral, antiproliferative, and immunomodulatory activities in virtually all cells. These activities are entirely dependent on the interaction of IFNs with their particular cell surface receptor. In this report, we identify two specific tyrosine residues located within the cytoplasmic domain of IFNAR2c that are obligatory for IFN-dependent signaling. Various IFNAR2c tyrosine mutants were expressed in a human lung fibroscarcoma cell line lacking IFNAR2c (U5A). Stable clones expressing these mutants were analyzed for their ability to induce STAT1 and STAT2 activation, ISGF3 transcriptional complex formation, gene expression, and cell growth regulation in response to stimulation with type I IFNs. The replacement of all seven cytoplasmic tyrosine residues of IFNAR2c with phenylalanine resulted in a receptor unable to respond to IFN stimulation. Substitution of single tyrosines at amino acid residue 269, 316, 318, 337, or 512 with phenylalanine had no effect on IFN-dependent signaling, suggesting that no single tyrosine is essential for IFN receptor-mediated signaling. In addition, IFNAR2c retaining five proximal tyrosines residues (269,306,316,318, and 337) or either two distal tyrosine residues (411 or 512) continued to be responsive to IFN stimulation. Surprisingly, the presence of only a single tyrosine at either position 337 or 512 was sufficient to restore a complete IFN response. These results indicate that IFN-dependent signaling proceeds through the redundant usage of two tyrosine residues in the cytoplasmic domain of IFNAR2c.	Berlex Biosci Inc, Dept Immunol, Richmond, CA 94804 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Croze, E (corresponding author), Berlex Biosci Inc, Dept Immunol, 15049 San Pablo Ave, Richmond, CA 94804 USA.	ed_croze@berlex.com			PHS HHS [P0I 62220] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022-1759(94)90396-4; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Croze E, 1996, J BIOL CHEM, V271, P33165, DOI 10.1074/jbc.271.52.33165; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Farrar JD, 2000, J BIOL CHEM, V275, P2693, DOI 10.1074/jbc.275.4.2693; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Gibbs VC, 1996, J BIOL CHEM, V271, P28710, DOI 10.1074/jbc.271.45.28710; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kotenko SV, 1999, P NATL ACAD SCI USA, V96, P5007, DOI 10.1073/pnas.96.9.5007; Krishnan K, 1996, ONCOGENE, V13, P125; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; Mason JM, 2000, J BIOL CHEM, V275, P4398, DOI 10.1074/jbc.275.6.4398; Mulcahy L, 2001, SEMIN ONCOL, V28, P19, DOI 10.1053/sonc.2001.25394; Nadeau OW, 1999, J BIOL CHEM, V274, P4045, DOI 10.1074/jbc.274.7.4045; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Pattyn E, 1999, J BIOL CHEM, V274, P34838, DOI 10.1074/jbc.274.49.34838; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Russell-Harde D, 2000, J BIOL CHEM, V275, P23981, DOI 10.1074/jbc.M002518200; SANDHYA R, 1996, J BIOL CHEM, V271, P22878; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STARK RG, 1999, ANNU REV BIOCHEM, V67, P227; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; XIAOXIA L, 1997, MOL CELL BIOL, V17, P2048; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	37	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1493	1499		10.1074/jbc.M108928200	http://dx.doi.org/10.1074/jbc.M108928200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11682488	hybrid			2022-12-25	WOS:000173166800081
J	Caro, AA; Cederbaum, AI				Caro, AA; Cederbaum, AI			Role of calcium and calcium-activated proteases in CYP2E1-dependent toxicity in HEPG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; TERT-BUTYL HYDROPEROXIDE; HUMAN CYTOCHROME P4502E1; OXIDATIVE STRESS; CULTURED-HEPATOCYTES; ION CONCENTRATION; G2 CELLS; IN-SITU; INJURY; CYTOTOXICITY	The objective of this work was to investigate whether CYP2E1- and oxidative stress-dependent toxicity in HepG2 cells is mediated by an increase of cytosolic Ca2+ and activation of Ca2+-modulated processes. HepG2 cells expressing CYP2E1 (E47 cells) or control cells not expressing CYP2E1 (C34 cells) were preloaded with arachidonic acid (AA, up to 10 pm) and, after washing, incubated with iron-nitrilotriacetic acid (up to 100 mum) for variable periods (up to 12 h). Toxicity was greater in E47 cells than in C34 cells at all times and combinations of iron/AA tested. Cytosolic calcium increased with incubation time in both cell lines, but the increase was higher in E47 cells than in C34 cells. The rise in calcium was an early event and preceded the developing toxicity. Toxicity in E47 cells and the increase in Ca2+ were inhibited by omission of Ca2+ from the extracellular medium, and toxicity was restored by reincorporation of Ca2+. An inhibitor of Ca2+ release from intracellular stores did not prevent the toxicity or the increase in Ca2+, reflecting a role for the influx of extracellular Ca2+ in the toxicity. Reactive oxygen production was similar in media with or without calcium, indicating that calcium was not modulating CYP2E1-dependent oxidative stress. Toxicity, lipid peroxidation, and the increase of Ca2+ in E47 cells exposed to iron-AA were inhibited by a-tocopherol. E47 cells (but not C34 cells) exposed to iron-AA showed increased calpain activity in situ (40-fold). The toxicity in E47 cells mirrorred calpain activation and was inhibited by calpeptin, suggesting that calpain activation plays a causal role in toxicity. These results suggest that CYP2E1-dependent toxicity in this model depends on the activation of lipid peroxidation, followed by an increased influx of extracellular Ca2+ and activation of Ca2+-dependent proteases.	CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Cederbaum, AI (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1603,1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006610, R37AA006610] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06610] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aguilar HI, 1996, GASTROENTEROLOGY, V110, P558, DOI 10.1053/gast.1996.v110.pm8566604; ALBANO E, 1991, BIOCHIM BIOPHYS ACTA, V1091, P310, DOI 10.1016/0167-4889(91)90194-3; Anghileri LJ, 1999, IN VIVO, V13, P13; Auld A, 2000, BBA-MOL CELL RES, V1497, P11, DOI 10.1016/S0167-4889(00)00045-8; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Barros LF, 2001, HEPATOLOGY, V33, P114, DOI 10.1053/jhep.2001.20530; Caro AA, 2001, MOL PHARMACOL, V60, P742; Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; DAI Y, 1993, BIOCHEMISTRY-US, V32, P6928, DOI 10.1021/bi00078a017; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FARBER JL, 1990, ENVIRON HEALTH PERSP, V84, P107, DOI 10.2307/3430711; GLENDE EA, 1991, RES COMMUN CHEM PATH, V73, P41; Guttmann RP, 1998, J BIOL CHEM, V273, P13331, DOI 10.1074/jbc.273.21.13331; Guttmann RP, 2000, METH MOL B, V144, P143; Kass GEN, 1999, ENVIRON HEALTH PERSP, V107, P25, DOI 10.2307/3434469; Kim JA, 2000, FREE RADICAL RES, V33, P267, DOI 10.1080/10715760000301431; Kohli V, 1999, GASTROENTEROLOGY, V116, P168, DOI 10.1016/S0016-5085(99)70241-6; LANDON EJ, 1986, BIOCHEM PHARMACOL, V35, P697, DOI 10.1016/0006-2952(86)90369-2; Lenz T, 1997, AM J PHYSIOL-CELL PH, V273, pC1526, DOI 10.1152/ajpcell.1997.273.5.C1526; Lomonosova EE, 1998, FREE RADICAL BIO MED, V25, P493, DOI 10.1016/S0891-5849(98)00080-X; MAK IT, 1994, METHOD ENZYMOL, V234, P620; MCCONKEY DJ, 1988, TOXICOL LETT, V42, P123, DOI 10.1016/0378-4274(88)90069-0; Miyoshi H, 1996, GASTROENTEROLOGY, V110, P1897, DOI 10.1053/gast.1996.v110.pm8964416; OLLINGER K, 1995, FREE RADICAL BIO MED, V19, P565, DOI 10.1016/0891-5849(95)00062-3; Orrenius S, 1996, ADV NEUROL, V71, P137; RAGHAV N, 1993, INDIAN J MED RES-B, V98, P188; ROSSER BG, 1995, GASTROENTEROLOGY, V108, P252, DOI 10.1016/0016-5085(95)90032-2; SAKAIDA I, 1991, J BIOL CHEM, V266, P717; Sakurai K, 1998, MOL PHARMACOL, V54, P1024, DOI 10.1124/mol.54.6.1024; Sarvazyan N, 1998, ARCH BIOCHEM BIOPHYS, V350, P132, DOI 10.1006/abbi.1997.0518; Schafer FQ, 2000, CELL MOL BIOL, V46, P657; STARKE PE, 1986, J BIOL CHEM, V261, P3006; STRUBELT O, 1987, TOXICOLOGY, V45, P213, DOI 10.1016/0300-483X(87)90107-7; Thomas D, 2000, CELL CALCIUM, V28, P213, DOI 10.1054/ceca.2000.0152; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; Tsukamoto H, 2000, Hepatology, V32, P154; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wu DF, 1996, J BIOL CHEM, V271, P23914, DOI 10.1074/jbc.271.39.23914; YAMAMOTO K, 1984, JPN J PHARMACOL, V35, P253, DOI 10.1254/jjp.35.253; Yang CF, 2000, ARCH BIOCHEM BIOPHYS, V380, P319, DOI 10.1006/abbi.2000.1939; Zhang BH, 1997, GASTROENTEROLOGY, V113, P641, DOI 10.1053/gast.1997.v113.pm9247486	44	33	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					104	113		10.1074/jbc.M107864200	http://dx.doi.org/10.1074/jbc.M107864200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11689564	hybrid			2022-12-25	WOS:000173087900015
J	Stern, N; Hochman, A; Zemach, N; Weizman, N; Hammel, I; Shiloh, Y; Rotman, G; Barzilai, A				Stern, N; Hochman, A; Zemach, N; Weizman, N; Hammel, I; Shiloh, Y; Rotman, G; Barzilai, A			Accumulation of DNA damage and reduced levels of nicotine adenine dinucleotide in the brains of Atm-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA GENE; PYRIDINE-NUCLEOTIDES; POLY(ADP-RIBOSE) POLYMERASE-1; OXIDATIVE STRESS; PROTEIN; SUPEROXIDE; DEFECTS; SIR2	Ataxia-telangiectasia (A-T) is a human genetic disorder caused by mutational inactivation of the ATM gene. A-T patients display a pleiotropic phenotype, in which a major neurological feature is progressive ataxia due to degeneration of cerebellar Purkinje and granule neurons. Disruption of the mouse Atm locus creates a murine model of A-T that exhibits most of the clinical and cellular features of the human disease, but the neurological phenotype is barely expressed. We present evidence for the accumulation of DNA strand breaks in the brains of Atm(-/-), supporting the notion that ATM plays a major role in maintaining genomic stability. We also show a perturbation of the steady state levels of pyridine nucleotides. There is a significant decrease in both the reduced and the oxidized forms of NAD and in the total levels of NADP(T) and NADP(+) in the brains of Atm(-/-) mice. The changes in NAD(T), NADH, NAD(+), NADPT, and NADP(+) were progressive and observed primarily in the cerebellum of 4-month-old Atm(-/-) mice. Higher rates of mitochondrial respiration were also recorded in 4-month-old Atm(-/-) cerebella. Taken together, our findings support the hypothesis that absence of functional ATM results in continuous stress, which may be an important cause of the degeneration of cerebellar neurons in A-T.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Barzilai, A (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	barzilai@post.tau.ac.il			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS-31763] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen DR, 2001, GENE DEV, V15, P554, DOI 10.1101/gad.869001; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BERNOFSKY C, 1973, ANAL BIOCHEM, V53, P452, DOI 10.1016/0003-2697(73)90094-8; Borghesani PR, 2000, P NATL ACAD SCI USA, V97, P3336, DOI 10.1073/pnas.050584897; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Hageman GJ, 2001, MUTAT RES-FUND MOL M, V475, P45, DOI 10.1016/S0027-5107(01)00078-1; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hoffschir F, 1998, FREE RADICAL BIO MED, V24, P809, DOI 10.1016/S0891-5849(97)00350-X; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KALIDMAN LK, 2001, BIOPHYS BIOCH ACTA, V1525, P136; Kamsler A, 2001, CANCER RES, V61, P1849; KAPLAN NO, 1985, CURR TOP CELL REGUL, V26, P371; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee Y, 2000, GENE DEV, V14, P2576, DOI 10.1101/gad.837100; LEHNINGER AL, 1993, PRINCIPLES BIOCH, P446; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; NISSELBA.JS, 1969, ANAL BIOCHEM, V27, P212, DOI 10.1016/0003-2697(69)90025-6; Quick KL, 2001, ANN NEUROL, V49, P627, DOI 10.1002/ana.1005; RADI R, 1991, J BIOL CHEM, V266, P4244; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Rolig RL, 2000, TRENDS NEUROSCI, V23, P417, DOI 10.1016/S0166-2236(00)01625-8; ROSENTHAL RE, 1987, J CEREBR BLOOD F MET, V7, P752, DOI 10.1038/jcbfm.1987.130; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Su JH, 1997, BRAIN RES, V774, P193, DOI 10.1016/S0006-8993(97)81703-9; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; VINOGRADOV AD, 1993, J BIOENERG BIOMEMBR, V25, P367, DOI 10.1007/BF00762462; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	44	78	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					602	608		10.1074/jbc.M106798200	http://dx.doi.org/10.1074/jbc.M106798200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11679583	hybrid			2022-12-25	WOS:000173087900079
J	Banik, U; Beechem, JM; Klebanow, E; Schroeder, S; Weil, PA				Banik, U; Beechem, JM; Klebanow, E; Schroeder, S; Weil, PA			Fluorescence-based analyses of the effects of full-length recombinant TAF130p on the interaction of TATA box-binding protein with TATA box DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; YEAST TFIIA/TBP/DNA COMPLEX; BASAL TRANSCRIPTION FACTOR; CORE PROMOTER ELEMENT; SACCHAROMYCES-CEREVISIAE; IN-VIVO; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; GENE-TRANSCRIPTION; GLOBAL REPRESSOR	We have used a combination of fluorescence anisotropy spectroscopy and fluorescence-based native gel electrophoresis methods to examine the effects of the transcription factor IID-specific subunit TAF130p (TAF145p) upon the TATA box DNA binding properties of TATA box-binding protein (TBP). Purified full-length recombinant TAF130p decreases TBP-TATA DNA complex formation at equilibrium by competing directly with DNA for binding to TBP. Interestingly, we have found that full-length TAF130p is capable of binding multiple molecules of TBP with nanomolar binding affinity. The biological implications of these findings are discussed.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Weil, PA (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.	tony.weil@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM052461, R01GM052461] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM5858, GM52461] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; BECKMANN H, 1995, SCIENCE, V270, P1506, DOI 10.1126/science.270.5241.1506; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1998, CELL, V94, P551, DOI 10.1016/S0092-8674(00)81596-2; Campbell KM, 2000, BIOCHEMISTRY-US, V39, P2633, DOI 10.1021/bi9922998; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Coleman RA, 1997, P NATL ACAD SCI USA, V94, P7221, DOI 10.1073/pnas.94.14.7221; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; Daugherty MA, 2000, BIOCHEMISTRY-US, V39, P4869, DOI 10.1021/bi992423n; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Forget D, 1997, P NATL ACAD SCI USA, V94, P7150, DOI 10.1073/pnas.94.14.7150; Furukawa T, 2000, J BIOL CHEM, V275, P29847, DOI 10.1074/jbc.M002989200; Galasinski SK, 2000, MOL CELL BIOL, V20, P1923, DOI 10.1128/MCB.20.6.1923-1930.2000; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Geisberg JV, 2001, MOL CELL BIOL, V21, P2736, DOI 10.1128/MCB.21.8.2736-2742.2001; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hoopes BC, 1998, J MOL BIOL, V277, P1015, DOI 10.1006/jmbi.1998.1651; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; Huet J, 1997, J BIOL CHEM, V272, P18341, DOI 10.1074/jbc.272.29.18341; INOSTROZA JA, 1992, CELL, V70, P477; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Lee DH, 2000, DATA KNOWL ENG, V34, P77, DOI 10.1016/S0169-023X(00)00009-4; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Librizzi MD, 1998, J BIOL CHEM, V273, P4563, DOI 10.1074/jbc.273.8.4563; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Matangkasombut O, 2000, GENE DEV, V14, P951; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; Mencia M, 2001, MOL CELL BIOL, V21, P1145, DOI 10.1128/MCB.21.4.1145-1154.2001; Mitsiou DJ, 2000, MOL CELL, V6, P527, DOI 10.1016/S1097-2765(00)00052-6; Mittal V, 1999, GENE DEV, V13, P1807, DOI 10.1101/gad.13.14.1807; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; O'Brien T, 1998, MOL CELL, V1, P905, DOI 10.1016/S1097-2765(00)80089-1; Ozer J, 1998, J BIOL CHEM, V273, P14293, DOI 10.1074/jbc.273.23.14293; Parkhurst KM, 1999, J MOL BIOL, V289, P1327, DOI 10.1006/jmbi.1999.2835; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PETRI V, 1995, BIOCHEMISTRY-US, V34, P9977, DOI 10.1021/bi00031a020; Petri V, 1998, BIOCHEMISTRY-US, V37, P15842, DOI 10.1021/bi981072u; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; POON D, 1993, J BIOL CHEM, V268, P15325; POON D, 1994, J BIOL CHEM, V269, P23135; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; POON D, 1993, J BIOL CHEM, V268, P5005; POWELL RM, 2001, J BIOL CHEM, V31, P31; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Sanders SL, 2000, J BIOL CHEM, V275, P13895, DOI 10.1074/jbc.275.18.13895; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SCHROEDER SC, 1994, J BIOL CHEM, V269, P28335; Schroeder SC, 1998, NUCLEIC ACIDS RES, V26, P4186, DOI 10.1093/nar/26.18.4186; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; Tsukihashi Y, 2000, MOL CELL BIOL, V20, P2385, DOI 10.1128/MCB.20.7.2385-2399.2000; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; Willy PJ, 2000, SCIENCE, V290, P982, DOI 10.1126/science.290.5493.982	89	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49100	49109		10.1074/jbc.M109246200	http://dx.doi.org/10.1074/jbc.M109246200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11677244	hybrid			2022-12-25	WOS:000173922100064
J	Gan, XD; Kaplan, R; Menke, JG; MacNaul, K; Chen, YL; Sparrow, CP; Zhou, GH; Wright, SD; Cai, TQ				Gan, XD; Kaplan, R; Menke, JG; MacNaul, K; Chen, YL; Sparrow, CP; Zhou, GH; Wright, SD; Cai, TQ			Dual mechanisms of ABCA1 regulation by geranylgeranyl pyrophosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE TRANSPORTER 1; TANGIER-DISEASE; CHOLESTEROL EFFLUX; PLASMA-MEMBRANE; APOA-I; BINDING; GENE; ACTIVATION; GTPASES; INTERLEUKIN-8	ATP-binding cassette transporter A1 (ABCA1) mediates an active efflux of cholesterol and phospholipids and is mutated in patients with Tangier disease. Expression of ABCA1 may be increased by certain oxysterols such as 22(R)-hydroxycholesterol via activation of the nuclear hormone receptor liver X receptor (LXR). In searching for potential modulators of ABCA1 expression, we have studied the effects of various mevalonate metabolites on the expression of ABCA1 in two human cell lines, THP-1 and Caco-2 cells. Most of the tested metabolites, including mevalonate, geranyl pyrophosphate, farnesyl pyrophosphate, and ubiquinone, failed to significantly change the expression levels of ABCA1 However, treatment with geranylgeranyl pyrophosphate resulted in a dose- and time-dependent reduction of ABCA1 expression. Geranylgeranyl pyrophosphate appears to reduce ABCA1 expression via two different mechanisms. One of these mechanisms is by acting directly as an antagonist of LXR since it reduces the interaction between LXRalpha or -beta with nuclear coactivator SRC-1. Another mechanism appears to involve activation of the Rho GTP-binding proteins since treatment of Caco-2 cells with inhibitors of geranylgeranyl transferase or the Rho proteins significantly increased the expression and promoter activity of ABCA1. Further studies showed that mutations in the DR4 element of the ABCA1 promoter completely eliminate the inducible activities of these inhibitors. These data indicate that activation of the Rho proteins may change the activation status of LXR.	Merck Res Labs, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Mol Endocrinol, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Cai, TQ (corresponding author), Merck Res Labs, Dept Atherosclerosis & Endocrinol, RY80W-250,126 E Lincoln Ave, Rahway, NJ 07065 USA.	tianquan_cai@merck.com						ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; ASSMANN G, 1995, METABOLIC BASIS INHE, P20553; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Costet P, 2000, J BIOL CHEM, V275, P28240; DEAN M, 1995, CURR OPIN GENET DEV, V5, P779, DOI 10.1016/0959-437X(95)80011-S; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; FREDRICKSON DS, 1964, J CLIN INVEST, V43, P228, DOI 10.1172/JCI104907; GENEST JJ, 1991, AM J CARDIOL, V67, P1185, DOI 10.1016/0002-9149(91)90924-A; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HUBER HE, 2000, P AM ASSOC CANC RES, V41, P446; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Kwiterovich PO, 1998, AM J CARDIOL, V82, p13Q; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; ONATE SA, 1995, SCIENCE, V270, P1354; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Schwiebert EM, 1999, AM J PHYSIOL-CELL PH, V276, pC1, DOI 10.1152/ajpcell.1999.276.1.C1; Shu H, 2000, BIOCHEM BIOPH RES CO, V267, P345, DOI 10.1006/bbrc.1999.1968; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; VAN AL, 1997, GENE DEV, V11, P2295; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	41	85	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48702	48708		10.1074/jbc.M109402200	http://dx.doi.org/10.1074/jbc.M109402200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11641412	hybrid			2022-12-25	WOS:000173922100013
J	Czjzek, M; Bolam, DN; Mosbah, A; Allouch, J; Fontes, CMGA; Ferreira, LMA; Bornet, O; Zamboni, V; Darbon, H; Smith, NL; Black, GW; Henrissat, B; Gilbert, HJ				Czjzek, M; Bolam, DN; Mosbah, A; Allouch, J; Fontes, CMGA; Ferreira, LMA; Bornet, O; Zamboni, V; Darbon, H; Smith, NL; Black, GW; Henrissat, B; Gilbert, HJ			The location of the ligand-binding site of carbohydrate-binding modules that have evolved from a common sequence is not conserved	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOMONAS-FIMI CENC; CLOSTRIDIUM-THERMOCELLUM; IMPROVED SENSITIVITY; MANNAN-BINDING; DOMAIN; XYLANASE; SPECIFICITY; PROTEIN; POLYSACCHARIDES; SPECTROSCOPY	Polysaccharide-degrading enzymes are generally modular proteins that contain non-catalytic carbohydrate-binding modules (CBMs), which potentiate the activity of the catalytic module. CBMs have been grouped into sequence-based families, and three-dimensional structural data are available for half of these families. Clostridium thermocellum xylanase 11A is a modular enzyme that contains a CBM from family 6 (CBM6), for which no structural data are available. We have determined the crystal structure of this module to a resolution of 2.1 Angstrom. The protein is a beta -sandwich that contains two potential ligand-binding clefts designated cleft A and B. The CBM interacts primarily with xylan, and NMR spectroscopy coupled with site-directed mutagenesis identified cleft A, containing Trp-92, Tyr-34, and Asn-120, as the ligand-binding site. The overall fold of CBM6 is similar to proteins in CBM families 4 and 22, although surprisingly the ligand-binding site in CBM4 and CBM22 is equivalent to cleft B in CBM6. These structural data define a superfamily of CBMs, comprising CBM4, CBM6, and CBM22, and demonstrate that, although CBMs have evolved from a relatively small number of ancestors, the structural elements involved in ligand recognition have been assembled at different locations on the ancestral scaffold.	CNRS, Lab Architecture & Fonct Macromol Biol, IBSM, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; Univ Newcastle Upon Tyne, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Fac Med Vet, CIISA, P-1199 Lisbon, Portugal; Northumbria Univ, Sch Appl & Mol Sci, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Newcastle University - UK; Universidade de Lisboa; Northumbria University	Czjzek, M (corresponding author), CNRS, Lab Architecture & Fonct Macromol Biol, IBSM, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	czjzek@afmb.cnrs-mrs.fr	Henrissat, Bernard/J-2475-2012	Henrissat, Bernard/0000-0002-3434-8588; Ferreira, Luis/0000-0002-3543-9166; Black, Gary/0000-0003-3697-0714; Bolam, David/0000-0003-0314-3122; Fontes, Carlos/0000-0002-1219-9753				Abou Hachem M, 2000, BIOCHEM J, V345, P53, DOI 10.1042/0264-6021:3450053; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BAX A, 1991, Journal of Biomolecular NMR, V1, P99, DOI 10.1007/BF01874573; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P6240, DOI 10.1021/bi0101695; BORASTON AB, 2001, IN PRESS MOL MICROBI; Brun E, 2000, BIOCHEMISTRY-US, V39, P2445, DOI 10.1021/bi992079u; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; Coutinho PM, 1999, ROY SOC CH, P3; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; Creagh AL, 1996, P NATL ACAD SCI USA, V93, P12229, DOI 10.1073/pnas.93.22.12229; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Fernandes AC, 1999, BIOCHEM J, V342, P105, DOI 10.1042/0264-6021:3420105; FERREIRA LMA, 1990, BIOCHEM J, V269, P261, DOI 10.1042/bj2690261; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; Johnson PE, 1996, BIOCHEMISTRY-US, V35, P14381, DOI 10.1021/bi961612s; KAY LE, 1993, J MAGN RESON SER B, V101, P33; KELLETT LE, 1990, BIOCHEM J, V272, P369, DOI 10.1042/bj2720369; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raghothama S, 2000, BIOCHEMISTRY-US, V39, P978, DOI 10.1021/bi992163+; Ravelli RBG, 1997, J APPL CRYSTALLOGR, V30, P551, DOI 10.1107/S0021889897003543; ROUSSEL A, 1991, TURBO FRODO GEOMETRY; Shoham Y, 1999, TRENDS MICROBIOL, V7, P275, DOI 10.1016/S0966-842X(99)01533-4; Simpson PJ, 1999, STRUCTURE, V7, P853, DOI 10.1016/S0969-2126(99)80108-7; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; Sorimachi K, 1997, STRUCTURE, V5, P647, DOI 10.1016/S0969-2126(97)00220-7; Spurway TD, 1997, J BIOL CHEM, V272, P17523, DOI 10.1074/jbc.272.28.17523; Stoll D, 2000, FEMS MICROBIOL LETT, V183, P265, DOI 10.1111/j.1574-6968.2000.tb08969.x; Sunna A, 2001, BIOCHEM J, V356, P791, DOI 10.1042/0264-6021:3560791; SZABO L, 2001, IN PRESS J BIOL CHEM, V276; TAKEO K, 1984, ELECTROPHORESIS, V5, P187, DOI 10.1002/elps.1150050402; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tomme P, 1996, BIOCHEMISTRY-US, V35, P13885, DOI 10.1021/bi961185i; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xie HF, 2001, BIOCHEMISTRY-US, V40, P9167, DOI 10.1021/bi0106742; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	47	99	102	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48580	48587		10.1074/jbc.M109142200	http://dx.doi.org/10.1074/jbc.M109142200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11673472	hybrid, Green Accepted			2022-12-25	WOS:000172927000113
J	Wang, J; Boja, ES; Tan, WH; Tekle, E; Fales, HM; English, S; Mieyal, JJ; Chock, PB				Wang, J; Boja, ES; Tan, WH; Tekle, E; Fales, HM; English, S; Mieyal, JJ; Chock, PB			Reversible glutathionylation regulates actin polymerization in A431 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN THIOLTRANSFERASE GLUTAREDOXIN; TYROSINE-PHOSPHATASE 1B; SIGNAL-TRANSDUCTION; S-THIOLATION; DISULFIDE; PHOSPHORYLATION; GENERATION; FILAMENTS; RECEPTOR	In response to growth factor stimulation, many mammalian cells transiently generate reactive oxygen species (ROS) that lead to the elevation of tyrosine-phosphorylated and glutathionylated proteins. While investigating EGF-induced glutathionylation in A431 cells, paradoxically we found deglutathionylation of a major 42-kDa protein identified as actin. Mass spectrometric analysis revealed that the glutathionylation site is Cys-374. Deglutathionylation of the G-actin leads to about a 6-fold increase in the rate of polymerization. In vivo studies revealed a 12% increase in F-actin content 15 min after EGF treatment, and F-actin was found in the cell periphery suggesting that in response to growth factor, actin polymerization in vivo is regulated by a reversible glutathionylation mechanism. Deglutathionylation is most likely catalyzed by glutaredoxin (thioltranferase), because Cd(II), an inhibitor of glutaredoxin, inhibits intracellular actin deglutathionylation at 2 muM, comparable with its IC50 in vitro. Moreover, mass spectral analysis showed efficient transfer of GSH from immobilized S-glutathionylated actin to glutaredoxin. Overall, this study revealed a novel physiological relevance of actin polymerization regulated by reversible glutathionylation of the penultimate cysteine mediated by growth factor stimulation.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Case Western Reserve University	Chock, PB (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 50,Rm 2134,50 South Dr,MSC-8012, Bethesda, MD 20892 USA.				NIA NIH HHS [AG15885] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000202, Z01HL001003, ZIAHL000202, ZIAHL001003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKTORIES K, 1990, J MUSCLE RES CELL M, V11, P95, DOI 10.1007/BF01766487; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; CHRESTENSEN CA, 1995, FEBS LETT, V374, P25, DOI 10.1016/0014-5793(95)01066-N; COOPER AJL, 1997, MOL GENETIC BASIS NE, P1195; DREWES G, 1993, EUR J BIOCHEM, V212, P247, DOI 10.1111/j.1432-1033.1993.tb17656.x; DREWES G, 1990, J BIOL CHEM, V265, P3017; ELZINGA M, 1975, J BIOL CHEM, V250, P5897; ENHENEGOUWEN PMPV, 1992, EXP CELL RES, V199, P90, DOI 10.1016/0014-4827(92)90465-K; Gravina Mieyal S.A, 1995, BIOTHIOLS HLTH DIS, P305; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HINSHAW DB, 1991, ARCH BIOCHEM BIOPHYS, V288, P311, DOI 10.1016/0003-9861(91)90200-3; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1992, ANNU REV BIOPH BIOM, V21, P49, DOI 10.1146/annurev.biophys.21.1.49; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LIU DF, 1990, BIOCHEM J, V266, P453, DOI 10.1042/bj2660453; RIJKEN PJ, 1991, J CELL SCI, V100, P491; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; SASAKI Y, 1994, J BIOCHEM-TOKYO, V116, P236, DOI 10.1093/oxfordjournals.jbchem.a124511; SHETERLINE P, 1996, ACTINS, P1; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; STOURNARAS C, 1990, ANTICANCER RES, V10, P1651; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; VANDELFT S, 1995, FEBS LETT, V357, P251, DOI 10.1016/0014-5793(94)01359-9; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504	30	257	265	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47763	47766		10.1074/jbc.C100415200	http://dx.doi.org/10.1074/jbc.C100415200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11684673	hybrid			2022-12-25	WOS:000172927000005
J	Drotschmann, K; Yang, W; Brownewell, FE; Kool, ET; Kunkel, TA				Drotschmann, K; Yang, W; Brownewell, FE; Kool, ET; Kunkel, TA			Asymmetric recognition of DNA local distortion - Structure-based functional studies of eukaryotic Msh2-Msh6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR PROTEIN MUTS; MISMATCH REPAIR; HMUTS-ALPHA; ATPASE ACTIVITY; BINDING; HMSH6; COMPLEXES; MUTATION; SUBUNIT; MSH6	Crystal structures of bacterial MutS homodimers bound to mismatched DNA reveal asymmetric interactions of the two subunits with DNA. A phenylalanine and glutamate of one subunit make mismatched base-specific interactions, and residues of both subunits contact the DNA backbone surrounding the mismatched base, but asymmetrically. A number of amino acids in MutS that contact the DNA are conserved in the eukaryotic Msh2-Msh6 heterodimer. We report here that yeast strains with amino acids substituted for residues inferred to interact with the DNA backbone or mismatched base have elevated spontaneous mutation rates consistent with defective mismatch repair. Purified Msh2-Msh6 with substitutions in the conserved Phe(337) and Glu(339) in Msh6 thought to stack or hydrogen bond, respectively, with the mismatched base do have reduced DNA binding affinity but normal ATPase activity. Moreover, wild-type Msh2-Msh6 binds with lower affinity to mismatches with thymine replaced by difluorotoluene, which lacks the ability to hydrogen bond. The results suggest that yeast Msh2-Msh6 interacts asymmetrically with the DNA through base-specific stacking and hydrogen bonding interactions and backbone contacts. The importance of these contacts decreases with increasing distance from the mismatch, implying that interactions at and near the mismatch are important for binding in a kinked DNA conformation.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Stanford University	Kunkel, TA (corresponding author), NIEHS, Struct Biol Lab, NIH, 111 TW Alexander Dr,POB 12233, Res Triangle Pk, NC 27709 USA.		Yang, Wei/ABB-4785-2020; Yang, Wei/D-4926-2011; Kunkel, Thomas A./D-5088-2019	Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195; Kunkel, Thomas A./0000-0002-9900-1788; Kool, Eric/0000-0002-7310-2935; Brownewell, Floyd/0000-0002-9304-1690	NIGMS NIH HHS [GM52956] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK036119, Z01DK036119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052956] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Biswas I, 2001, J MOL BIOL, V305, P805, DOI 10.1006/jmbi.2000.4367; Bowers J, 1999, J BIOL CHEM, V274, P16115, DOI 10.1074/jbc.274.23.16115; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Clark AB, 1999, NUCLEIC ACIDS RES, V27, P736, DOI 10.1093/nar/27.3.736; Das Gupta R, 2000, NAT GENET, V24, P53, DOI 10.1038/71684; Drotschmann K, 1999, P NATL ACAD SCI USA, V96, P2970, DOI 10.1073/pnas.96.6.2970; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Dufner P, 2000, J BIOL CHEM, V275, P36550, DOI 10.1074/jbc.M005987200; Guckian KM, 1998, NAT STRUCT BIOL, V5, P954, DOI 10.1038/2930; Hall MC, 2001, J MOL BIOL, V312, P637, DOI 10.1006/jmbi.2001.4958; Harfe BD, 2000, MUTAT RES-FUND MOL M, V451, P151, DOI 10.1016/S0027-5107(00)00047-6; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kool ET, 1998, BIOPOLYMERS, V48, P3, DOI 10.1002/(SICI)1097-0282(1998)48:1<3::AID-BIP2>3.0.CO;2-7; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Schofield MJ, 2001, J BIOL CHEM, V276, P45505, DOI 10.1074/jbc.C100449200; Studamire B, 1998, MOL CELL BIOL, V18, P7590, DOI 10.1128/MCB.18.12.7590; Yamamoto A, 2000, NUCLEIC ACIDS RES, V28, P3564, DOI 10.1093/nar/28.18.3564	29	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46225	46229		10.1074/jbc.C100450200	http://dx.doi.org/10.1074/jbc.C100450200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11641390	hybrid			2022-12-25	WOS:000172573100100
J	Lin, H; Bhatia, R; Lal, R				Lin, H; Bhatia, R; Lal, R			Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology	FASEB JOURNAL			English	Article						atomic force microscope; A beta P; calcium uptake; AD	RAPID CELLULAR DEGENERATION; INSULIN-DEGRADING ENZYME; BLOOD-BRAIN-BARRIER; ZN2+-SENSITIVE CHANNEL; BILAYER-MEMBRANES; PC12 CELLS; IN-VITRO; PEPTIDE; CALCIUM; NEURONS	Amyloid beta protein (A betaP) is the major constituent of senile plaques associated with Alzheimer's disease (AD). However, its mechanistic role in AD pathogenesis is poorly understood. Globular and nonfibrillar A beta Ps are continuously released during normal metabolism. Using techniques of atomic force microscopy, laser confocal microscopy, electrical recording, and biochemical assays, we have examined the molecular conformations of reconstituted globular A beta Ps as well as their real-time and acute effects on neuritic degeneration. Atomic force microscopy (AFM) of A betaP(1-42) shows globular structures that do not form fibers in physiological-buffered solution for up to 8 h of continuous imaging. AFM of A betaP(1-42) reconstituted in a planar lipid bilayer reveals multimeric channel-like structures. Consistent with these AFM resolved channel-like structures, biochemical analysis demonstrates that predominantly monomeric A beta Ps in solution form stable tetramers and hexamers after incorporation into lipid membranes. Electrophysiological recordings demonstrate the presence of multiple single channel currents of different sizes. At the cellular level, A betaP(1-42) allows calcium uptake and induces neuritic abnormality in a dose- and time-dependent fashion. At physiological nanomolar concentrations, rapid neuritic degeneration was observed within minutes; at micromolar concentrations, neuronal death was observed within 3-4 h. These effects are prevented by zinc (an A betaP channel blocker) and by the removal of extracellular calcium, but are not prevented by antagonists of putative AbP cell surface receptors. Thus, A betaP channels may provide a direct pathway for calcium-dependent A betaP toxicity in AD.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Lal, R (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.	lal@lifesci.ucsb.edu						Anderton BH, 1998, PROG NEUROBIOL, V55, P595, DOI 10.1016/S0301-0082(98)00022-7; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Arispe N, 1996, P NATL ACAD SCI USA, V93, P1710, DOI 10.1073/pnas.93.4.1710; Bhatia R, 2000, FASEB J, V14, P1233, DOI 10.1096/fasebj.14.9.1233; Biere AL, 1996, J BIOL CHEM, V271, P32916, DOI 10.1074/jbc.271.51.32916; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Cummings JL, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.1_Suppl_1.S2; DURELL SR, 1994, BIOPHYS J, V67, P2137, DOI 10.1016/S0006-3495(94)80717-9; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; GhersiEgea JF, 1996, J NEUROCHEM, V67, P880; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Harkany T, 1999, NEUROBIOL DIS, V6, P109, DOI 10.1006/nbdi.1998.0230; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hirakura Y, 1999, J NEUROSCI RES, V57, P458, DOI 10.1002/(SICI)1097-4547(19990815)57:4<458::AID-JNR5>3.0.CO;2-4; Huang HM, 2000, LIFE SCI, V66, P1525, DOI 10.1016/S0024-3205(00)00470-7; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jensen M, 1999, ANN NEUROL, V45, P504, DOI 10.1002/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9; Kawahara M, 2000, BRAIN RES BULL, V53, P389, DOI 10.1016/S0361-9230(00)00370-1; Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2; Kourie JI, 2000, AM J PHYSIOL-CELL PH, V278, pC1063, DOI 10.1152/ajpcell.2000.278.6.C1063; Kuo YM, 1996, J BIOL CHEM, V271, P4077; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; LAL R, 1994, AM J PHYSIOL, V266, pC1, DOI 10.1152/ajpcell.1994.266.1.C1; Lane NJ, 1998, J NEUROCYTOL, V27, P707, DOI 10.1023/A:1006976400227; Lin H, 1999, BIOCHEMISTRY-US, V38, P11189, DOI 10.1021/bi982997c; Mason RP, 1999, J BIOL CHEM, V274, P18801, DOI 10.1074/jbc.274.26.18801; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; MIRZABEKOV T, 1998, METH ENZ, V294, P67; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; Mou JX, 1996, BIOCHEMISTRY-US, V35, P3222, DOI 10.1021/bi9520242; NAIDU A, 1995, J BIOL CHEM, V270, P1369, DOI 10.1074/jbc.270.3.1369; Pallitto MM, 1999, BIOCHEMISTRY-US, V38, P3570, DOI 10.1021/bi982119e; PARBHU A, 2001, IN PRESS PEPTIDES; Pillot T, 1999, J NEUROCHEM, V73, P1626, DOI 10.1046/j.1471-4159.1999.0731626.x; Poduslo JF, 1999, NEUROBIOL DIS, V6, P190, DOI 10.1006/nbdi.1999.0238; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Rhee SK, 1998, J BIOL CHEM, V273, P13379, DOI 10.1074/jbc.273.22.13379; Sanderson KL, 1997, BRAIN RES, V744, P7, DOI 10.1016/S0006-8993(96)01060-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMMONS MA, 1993, NEUROSCI LETT, V150, P133, DOI 10.1016/0304-3940(93)90519-Q; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Torp R, 2000, PROG NEURO-PSYCHOPH, V24, P801, DOI 10.1016/S0278-5846(00)00107-X; Tseng BP, 1999, BIOCHEMISTRY-US, V38, P10424, DOI 10.1021/bi990718v; Vargas J, 2000, BIOPHYS J, V79, P934, DOI 10.1016/S0006-3495(00)76348-X; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; WHITSON JS, 1995, NEUROBIOL AGING, V16, P5, DOI 10.1016/0197-4580(95)80002-9; Yamin R, 1999, J BIOL CHEM, V274, P18777, DOI 10.1074/jbc.274.26.18777; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244; ZLOKOVIC BV, 1993, BIOCHEM BIOPH RES CO, V197, P1034, DOI 10.1006/bbrc.1993.2582	53	525	550	2	133	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2433	2444		10.1096/fj.01-0377com	http://dx.doi.org/10.1096/fj.01-0377com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689468				2022-12-25	WOS:000172420500013
J	Steinman, RA; Lu, YL; Yaroslavskiy, B; Stehle, C				Steinman, RA; Lu, YL; Yaroslavskiy, B; Stehle, C			Cell cycle-independent upregulation of p27Kip1 by p21Waf1 in K562 cells	ONCOGENE			English	Article						p21Waf1; p27Kip1; differentiation; cell cycle	DEPENDENT-KINASE INHIBITOR; CDK-INHIBITOR; MYELOID CELLS; IN-VITRO; P27(KIP1); P27; DIFFERENTIATION; PHOSPHORYLATION; P21(WAF1/CIP1); EXPRESSION	Cellular differentiation frequently involves sequential peaks in the expression of cyclin-dependent kinase inhibitors (cdki's). For example, an increase in levels of the cdki p27Kip1 follows upregulation of p21Waf1 in several cell types induced to differentiate by diverse stimuli. In this study, we have investigated whether p21Waf1 expression itself, rather than the differentiating agent, could be increasing p27Kip1 protein levels. We used an inducible p21Waf1 expression vector in a K562 leukemic cell model which we had previously shown to initiate differentiation following p21Waf1 upregulation. The current study reports that p21Waf1 upregulated p27Kip1 protein without altering p27Kip1 mRNA levels. This effect did not depend on Gl-phase arrest-the increase in p27Kip1 occurred at all phases of the cell cycle. p21Waf1-expressing extracts inhibited phosphorylation of p27Kip1 on threonine-187, leading to decreased ubiquitination and decreased proteasomal destruction of p27Kip1. In K562 cells, upregulation of p27Kip1 by p21Waf1 during differentiation facilitated an ordered transition between these two cdki's, each of which may distinctly influence the differentiation process.	Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Steinman, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, E1052 BST,200 Lothrop St, Pittsburgh, PA 15213 USA.	Steinman@imap.pitt.edu						Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Chen YJ, 1999, EUR J CELL BIOL, V78, P824, DOI 10.1016/S0171-9335(99)80033-8; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Ghiani CA, 1999, DEVELOPMENT, V126, P1077; Harvat BL, 1998, J CELL SCI, V111, P1185; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Huss R, 1999, BRIT J CANCER, V81, P808, DOI 10.1038/sj.bjc.6690768; Kawa S, 1997, BRIT J CANCER, V76, P884, DOI 10.1038/bjc.1997.479; Liu JB, 2000, ONCOGENE, V19, P661, DOI 10.1038/sj.onc.1203373; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Muto A, 1999, BLOOD, V93, P2225, DOI 10.1182/blood.V93.7.2225.407a05_2225_2233; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Steinman RA, 1998, BLOOD, V91, P4531, DOI 10.1182/blood.V91.12.4531.412k10_4531_4542; Steinman RA, 2000, LEUKEMIA RES, V24, P601, DOI 10.1016/S0145-2126(00)00020-5; Tam S. W., 1997, Leukemia (Basingstoke), V11, P363; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Tian JQ, 1999, AM J PHYSIOL-CELL PH, V276, pC1245, DOI 10.1152/ajpcell.1999.276.6.C1245; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Urashima M, 1997, BLOOD, V90, P279; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Wagner EF, 1998, J IMMUNOL, V161, P1123; Xu X, 1999, BIOCHEMISTRY-US, V38, P8713; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	46	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6524	6530		10.1038/sj.onc.1204800	http://dx.doi.org/10.1038/sj.onc.1204800			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641776				2022-12-25	WOS:000171404200004
J	Berdyshev, EV; Schmid, PC; Krebsbach, RJ; Schmid, HHO				Berdyshev, EV; Schmid, PC; Krebsbach, RJ; Schmid, HHO			Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells	FASEB JOURNAL			English	Article						anandamide; platelet-activating factor; macrophages; human platelets	CANNABINOID CB1 RECEPTOR; RAT KUPFFER CELLS; NF-KAPPA-B; PLATELET-AGGREGATION; GENE-EXPRESSION; NUCLEAR FACTOR; T-CELLS; ANANDAMIDE; ACID; ACYLETHANOLAMINES	The endocannabinoid signaling system is believed to play a down-regulatory role in the control of cell functions. However, little is known about the factors activating endocannabinoid synthesis and which of two known endocannabinoids, 2-arachidonoylglycerol (2-AG) or N-arachidonoylethanolamine (20:4n-6 NAE, anandamide), is of physiological importance. We approached these questions by studying a possible link between cell activation with 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor, PAF) and the generation of 2-AG and anandamide in human platelets and mouse P388D1 macrophages. Human platelets responded to stimulation with the production of various 1- and 2-monoacylglycerols, including 2-AG, whereas stimulation of P388D1 macrophages induced the rapid and selective generation of 2-AG, which was immediately released into the medium. The effect of PAF was receptor mediated, as PAF receptor antagonist BN52021 blocked the effect. The treatment did not change the content of anandamide in either macrophages or platelet-rich plasma. The inhibitors of PI- and PC-specific phospholipases C (U73122 and D609) as well as PI3-kinase inhibitor (wortmannin) attenuated PAF-induced 2-AG production in macrophages. These data suggest a direct role for the endocannabinoid system in controlling immune cell activation status and indicate that 2-AG rather than anandamide is the endocannabinoid rapidly produced in response to proinflammatory stimulation of immune cells.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Berdyshev, EV (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	eberdyshev@hotmail.com			NIGMS NIH HHS [GM45741] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045741] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ben-Shabat S, 1998, EUR J PHARMACOL, V353, P23, DOI 10.1016/S0014-2999(98)00392-6; Berdyshev E, 1998, LIFE SCI, V63, pPL125, DOI 10.1016/S0024-3205(98)00324-5; Berdyshev EV, 2000, BIOCHEM J, V346, P369, DOI 10.1042/0264-6021:3460369; Berdyshev EV, 1997, EUR J PHARMACOL, V330, P231, DOI 10.1016/S0014-2999(97)01007-8; Berdyshev EV, 2000, CHEM PHYS LIPIDS, V108, P169, DOI 10.1016/S0009-3084(00)00195-X; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONAVIDA B, 1994, CLIN REV ALLERG, V12, P381; BOTTECCHIA D, 1984, SCAND J HAEMATOL, V32, P33; Boulay F, 1997, ANN NY ACAD SCI, V832, P69, DOI 10.1111/j.1749-6632.1997.tb46238.x; BRAQUET P, 1991, MED RES REV, V11, P295, DOI 10.1002/med.2610110303; CATTANEO M, 1985, THROMB HAEMOSTASIS, V53, P221; Condie R, 1996, J BIOL CHEM, V271, P13175, DOI 10.1074/jbc.271.22.13175; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1999, EUR J BIOCHEM, V264, P258, DOI 10.1046/j.1432-1327.1999.00631.x; DUDLEY DT, 1986, BIOCHEM J, V236, P235, DOI 10.1042/bj2360235; ElBawab S, 1996, J LIPID RES, V37, P2098; Gallily R, 2000, EUR J PHARMACOL, V406, pR5, DOI 10.1016/S0014-2999(00)00653-1; GANDHI CR, 1991, LIPIDS, V26, P1038, DOI 10.1007/BF02536498; GANDHI CR, 1990, J BIOL CHEM, V265, P18234; Gonsiorek W, 2000, MOL PHARMACOL, V57, P1045; HANAHAN DJ, 1985, METHOD BIOCHEM ANAL, V31, P195, DOI 10.1002/9780470110522.ch4; Kaminski NE, 1998, J NEUROIMMUNOL, V83, P124, DOI 10.1016/S0165-5728(97)00228-2; Kaminski NE, 1996, BIOCHEM PHARMACOL, V52, P1133, DOI 10.1016/0006-2952(96)00480-7; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; Klein TW, 1998, IMMUNOL TODAY, V19, P373, DOI 10.1016/S0167-5699(98)01300-0; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lauener RW, 1999, BBA-MOL CELL RES, V1452, P197, DOI 10.1016/S0167-4889(99)00125-1; LEE M, 1995, J PHARMACOL EXP THER, V275, P529; Maccarrone M, 2001, EUR J BIOCHEM, V268, P819, DOI 10.1046/j.1432-1327.2001.01942.x; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 1998, EUR J PHARMACOL, V362, pR1, DOI 10.1016/S0014-2999(98)00777-8; MUTOH H, 1994, BIOCHEM BIOPH RES CO, V205, P1137, DOI 10.1006/bbrc.1994.2784; Ouyang YL, 1998, MOL PHARMACOL, V53, P676, DOI 10.1124/mol.53.4.676; Pestonjamasp VK, 1998, BBA-LIPID LIPID MET, V1394, P249, DOI 10.1016/S0005-2760(98)00110-6; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, P71, DOI 10.1016/S0009-3084(00)00188-2; Schmid PC, 1997, CHEM PHYS LIPIDS, V87, P103, DOI 10.1016/S0009-3084(97)00032-7; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; Schmid PC, 2000, CHEM PHYS LIPIDS, V104, P185, DOI 10.1016/S0009-3084(99)00124-3; SEBALDT RJ, 1992, BIOCHEM J, V284, P367, DOI 10.1042/bj2840367; SHUKLA SD, 1991, LIPIDS, V26, P1028, DOI 10.1007/BF02536496; SOLOWIJ N, 1999, HLTH EFFECTS CANNABI, P195; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 2000, CHEM PHYS LIPIDS, V108, P89, DOI 10.1016/S0009-3084(00)00189-4; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; Sugiura T, 1998, BIOCHEM BIOPH RES CO, V243, P838, DOI 10.1006/bbrc.1998.8187; Varga K, 1998, FASEB J, V12, P1035, DOI 10.1096/fasebj.12.11.1035; Wagner JA, 1997, NATURE, V390, P518, DOI 10.1038/37371; Yea SS, 2000, J PHARMACOL EXP THER, V292, P597	52	77	80	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2171	2178		10.1096/fj.01-0181com	http://dx.doi.org/10.1096/fj.01-0181com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641243				2022-12-25	WOS:000171920400028
J	Forteza, R; Lieb, T; Aoki, T; Savani, RC; Conner, GE; Salathe, M				Forteza, R; Lieb, T; Aoki, T; Savani, RC; Conner, GE; Salathe, M			Hyaluronan serves a novel role in airway mucosal host defense	FASEB JOURNAL			English	Article						kallikrein; lactoperoxidase; cilia; epithelium; airway	IMMUNOREACTIVE TISSUE KALLIKREIN; LOWER RESPIRATORY-TRACT; CILIARY BEAT FREQUENCY; BRONCHOALVEOLAR LAVAGE; ASTHMATIC SUBJECTS; EPITHELIAL-CELLS; BINDING-PROTEIN; RECEPTOR RHAMM; SPERM MOTILITY; GUINEA-PIG	Enzymes secreted onto epithelial surfaces play a vital role in innate mucosal defense, but are believed to be steadily removed from the surface by mechanical actions. Thus, the amount and availability of enzymes on the surface are thought to be maintained by secretion. In contrast to this paradigm, we show here that enzymes are retained at the apical surface of the airway epithelium by binding to surface-associated hyaluronan, providing an apical enzyme pool 'ready for use' and protected from ciliary clearance. We have studied lactoperoxidase, which prevents bacterial colonization of the airway, and kallikrein, which mediates allergic bronchoconstriction that limits the inhalation of noxious substances. Binding to hyaluronan inhibits kallikrein, which is needed only in certain situations, whereas lactoperoxidase, useful at all times, does not change its activity. Hyaluronan itself interacts with the receptor for hyaluronic acid-mediated motility (RHAMM or CD168) that is expressed at the apex of ciliated airway epithelial cells. Functionally, hyaluronan binding to RHAMM stimulates ciliary beating. Thus, hyaluronan plays a previously unrecognized pivotal role in mucosal host defense by stimulating ciliary clearance of foreign material while simultaneously retaining enzymes important for homeostasis at the apical surface so that they cannot be removed by ciliary action.	Univ Miami, Sch Med, Div Pulm & Crit Care Med R47, Miami, FL 33136 USA; Univ Penn, Sch Med, Div Neonatol, Philadelphia, PA 19104 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA	University of Miami; University of Pennsylvania; University of Miami	Salathe, M (corresponding author), Univ Miami, Sch Med, Div Pulm & Crit Care Med R47, 1600 NW 10th Ave,RMSB 7063, Miami, FL 33136 USA.	msalathe@miami.edu	Conner, Gregory/AAI-1285-2021; Rashmin C. Savani, MBChB/AAG-2041-2021	Conner, Gregory/0000-0003-2217-2252; Rashmin C. Savani, MBChB/0000-0002-9533-5422; Salathe, Matthias/0000-0001-9092-4861	PHS HHS [R01-62472, K01-03534, R01-60644] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BASBAUM CB, 1987, BIORHEOLOGY, V24, P585; BJERMER L, 1992, EUR RESPIR J, V5, P785; BRAY BA, 1994, EXP LUNG RES, V20, P317, DOI 10.3109/01902149409064390; CHRISTENSEN TG, 1984, SURV SYN PATHOL RES, V3, P201; CHRISTENSEN TG, 1981, CELL TISSUE RES, V214, P407; CHRISTIANSEN SC, 1992, AM REV RESPIR DIS, V145, P900, DOI 10.1164/ajrccm/145.4_Pt_1.900; Cole AM, 1999, INFECT IMMUN, V67, P3267, DOI 10.1128/IAI.67.7.3267-3275.1999; Forteza R, 1999, AM J RESP CELL MOL, V21, P666, DOI 10.1165/ajrcmb.21.6.3651; FRESCURA M, 1994, BIOCHEM SOC T, V22, pS228; Gerson C, 2000, AM J RESP CELL MOL, V22, P665, DOI 10.1165/ajrcmb.22.6.3980; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HARLOW E, 1988, ANTIBODIES LAB MAN; HUBBARD RC, 1989, P NATL ACAD SCI USA, V86, P680, DOI 10.1073/pnas.86.2.680; HUSZAR G, 1990, FERTIL STERIL, V54, P1127; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Korngreen A, 1996, J PHYSIOL-LONDON, V497, P53, DOI 10.1113/jphysiol.1996.sp021749; KORNOVSKI BS, 1994, FERTIL STERIL, V61, P935; Lackie PM, 1997, AM J RESP CELL MOL, V16, P14, DOI 10.1165/ajrcmb.16.1.8998074; LARSSON K, 1992, CHEST, V101, P109, DOI 10.1378/chest.101.1.109; Lieb T, 2000, J AEROSOL MED, V13, P231, DOI 10.1089/jam.2000.13.231; Lin WQ, 1997, J HISTOCHEM CYTOCHEM, V45, P1157, DOI 10.1177/002215549704500813; LONGAKER MT, 1990, J PEDIATR SURG, V25, P430, DOI 10.1016/0022-3468(90)90387-O; NILSSON K, 1990, INT J RADIAT BIOL, V58, P519, DOI 10.1080/09553009014551861; PAUL A, 1988, ARCH BIOCHEM BIOPHYS, V260, P75, DOI 10.1016/0003-9861(88)90426-2; POBLETE MT, 1993, HISTOCHEM J, V25, P834; PROUD D, 1993, AM J RESP CELL MOL, V8, P16, DOI 10.1165/ajrcmb/8.1.16; Salathe M, 1997, AM J RESP CELL MOL, V17, P97, DOI 10.1165/ajrcmb.17.1.2719; SALATHE M, 1995, J CELL SCI, V108, P431; Salathe M, 1999, J PHYSIOL-LONDON, V520, P851, DOI 10.1111/j.1469-7793.1999.00851.x; Salathe M, 1997, AM J PHYSIOL-LUNG C, V272, pL301, DOI 10.1152/ajplung.1997.272.2.L301; SAVANI RC, 1995, J CLIN INVEST, V95, P1158, DOI 10.1172/JCI117764; SAVANI RC, 1995, P W PHARMACOL SOC, V38, P131; Sbracia M, 1997, HUM REPROD, V12, P1949, DOI 10.1093/humrep/12.9.1949; SCOTT JE, 1998, SCI HYALURONAN TODAY; Turley E., 1999, SCI HYALURONAN TODAY; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; Uzlaner N, 1999, J PHYSIOL-LONDON, V516, P179, DOI 10.1111/j.1469-7793.1999.179aa.x; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; WEISSMANN B, 1954, J AM CHEM SOC, V76, P1753, DOI 10.1021/ja01636a010; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YOSHITSUGU M, 1993, ACTA OTO-LARYNGOL, V113, P655, DOI 10.3109/00016489309135880	46	100	100	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2179	2186		10.1096/fj.01-0036com	http://dx.doi.org/10.1096/fj.01-0036com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641244				2022-12-25	WOS:000171920400029
J	Lee, YK; Moore, DD				Lee, YK; Moore, DD			Dual mechanisms for repression of the monomeric orphan receptor liver receptor homologous protein-1 by the orphan small heterodimer partner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL HYPOPLASIA CONGENITA; DNA-BINDING DOMAIN; HEPATITIS-B VIRUS; NUCLEAR RECEPTOR; STEROIDOGENIC FACTOR-1; TRANSCRIPTION FACTOR; ESTROGEN-RECEPTORS; GENE-EXPRESSION; DAX-1; SHP	The orphan nuclear hormone receptor liver receptor homologous protein-1 (LRH-1; NR5A2, also known as FTF), an unusual receptor that binds DNA as a monomer, is an essential regulator of expression of a rate-limiting enzyme in bile acid formation, cholesterol 7-alpha-hydroxylase. In a classic negative feedback loop that is a crucial component of the complex regulation of cholesterol metabolism, cholesterol 7-alpha-hydroxylase expression is decreased when bile acid levels are high. This repression is thought to be based on the bile acid-dependent induction of expression of the orphan receptor small heterodimer partner (SHP) NR0B2, which inhibits the activity of LRH-1. We have explored the molecular basis for this important regulatory effect by characterizing the mechanisms by which mouse and human SHP inhibit LRH-1-mediated transactivation. Both SHP proteins specifically interact with the AF-2 transactivation domain of LRH-1 both in vivo and in vitro. This domain is a common target for coactivator interaction, and the SHP proteins can compete with p160 coactivators for binding to LRH-1. In addition to the N-terminal receptor interaction domain, SHP includes a C-terminal domain with autonomous repression function. Neither a deletion nor a point mutation specifically affecting this domain blocked the ability to interact with LRH-1 to compete for coactivator binding or to repress LRH-1 transactivation. However, the relative ability of these mutants to inhibit LRH-1-mediated transactivation was markedly decreased. We conclude that the proposed central role of SHP in cholesterol metabolism is based on a two-step mechanism that is dependent on both coactivator competition and direct transcriptional repression.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Moore, DD (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	moore@bcm.tmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK057743] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK57743] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altincicek B, 2000, J BIOL CHEM, V275, P7662, DOI 10.1074/jbc.275.11.7662; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; Gilbert S, 2000, J VIROL, V74, P5032, DOI 10.1128/JVI.74.11.5032-5039.2000; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Lalli E, 1997, MOL ENDOCRINOL, V11, P1950, DOI 10.1210/me.11.13.1950; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lee YK, 1999, J BIOL CHEM, V274, P20869, DOI 10.1074/jbc.274.30.20869; Li M, 1998, J BIOL CHEM, V273, P29022, DOI 10.1074/jbc.273.44.29022; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Masuda N, 1997, BBA-GENE STRUCT EXPR, V1350, P27, DOI 10.1016/S0167-4781(96)00196-0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Nishigori H, 2001, P NATL ACAD SCI USA, V98, P575, DOI 10.1073/pnas.98.2.575; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; Zhang H, 2000, J BIOL CHEM, V275, P39855, DOI 10.1074/jbc.C000567200	25	135	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2463	2467		10.1074/jbc.M105161200	http://dx.doi.org/10.1074/jbc.M105161200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11668176	hybrid			2022-12-25	WOS:000173421500014
J	Baglia, FA; Badellino, KO; Li, CQ; Lopez, JA; Walsh, PN				Baglia, FA; Badellino, KO; Li, CQ; Lopez, JA; Walsh, PN			RETRACTED: Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin (Retracted Article. See vol 282, pg 29067, 2007)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							MOLECULAR-WEIGHT KININOGEN; COAGULATION-FACTOR-XI; BERNARD-SOULIER PLATELETS; HUMAN-BLOOD PLATELETS; VON-WILLEBRAND-FACTOR; VONWILLEBRAND-FACTOR; MONOCLONAL-ANTIBODY; ALPHA-THROMBIN; HEAVY-CHAIN; SITE	Factor XI binds to high affinity sites on the surface of stimulated platelets where it is efficiently activated by thrombin. Here, we provide evidence that the factor XI binding site on platelets is in the glycoprotein (GP) Ibalpha subunit of the GP Ib-IX-V complex as follows. 1) Bernard-Soulier platelets, lacking the complex, are deficient in factor XI binding; 2) two GP Ibalpha ligands, SZ-2 (a monoclonal antibody) and bovine von Willebrand factor, inhibit factor XI binding to platelets; 3) by surface plasmon resonance, factor XI bound specifically to glycocalicin (the extracellular domain of GP Iba) in Zn2+-dependent fashion (K-d app similar to 52 nm). We then investigated whether glycocalicin could promote factor XI activation by thrombin, another GP Ibalpha ligand. In the presence of high molecular weight kininogen (45 nm), Zn2+ and Ca2+ ions, thrombin activated factor XI in the presence of glycocalicin at rates comparable with those seen in the presence of dextran sulfate (1 mug/ml). With higher high molecular weight kininogen concentrations (360 nm), the rate of thrombin-catalyzed factor XI activation in the presence of glycocalicin was comparable with that on activated platelets. Thus, factor XI binds to the GP Ib-IX-V complex, promoting its activation by thrombin.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX 77030 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.	pnw@astro.temple.edu			NHLBI NIH HHS [HL46213, HL64943, HL64796, HL56914, HL54218] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064943, R01HL046213, P01HL056914, R01HL054218, R01HL064796] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; Baglia FA, 2000, J BIOL CHEM, V275, P31954, DOI 10.1074/jbc.M005465200; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BINDER B, 1975, THROMB DIATH HAEMOST, V34, P354; Bradford HN, 1997, BLOOD, V90, P1508, DOI 10.1182/blood.V90.4.1508.1508_1508_1515; BRUNNEE T, 1993, BLOOD, V81, P580; COLLER BS, 1983, BLOOD, V61, P99; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dong JF, 2001, BLOOD, V97, P162, DOI 10.1182/blood.V97.1.162; DU XP, 1987, BLOOD, V69, P1524; FOX JEB, 1987, J BIOL CHEM, V262, P12627; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; Furman MI, 2000, THROMB HAEMOSTASIS, V84, P897, DOI 10.1055/s-0037-1614134; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAILANI D, 1993, SEMIN THROMB HEMOST, V19, P396, DOI 10.1055/s-2007-993291; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; HARMON JT, 1988, BIOCHEMISTRY-US, V27, P2151, DOI 10.1021/bi00406a050; Ho DH, 2000, J BIOL CHEM, V275, P25139, DOI 10.1074/jbc.M001890200; Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; Joseph K, 1999, MOL MED, V5, P555, DOI 10.1007/BF03401982; Kaplan A P, 1981, Ann N Y Acad Sci, V370, P253, DOI 10.1111/j.1749-6632.1981.tb29738.x; KUNICKI TJ, 1978, J CLIN INVEST, V62, P716, DOI 10.1172/JCI109181; LI CY, 1995, BLOOD, V86, P3805, DOI 10.1182/blood.V86.10.3805.bloodjournal86103805; Lopez J A, 1997, Curr Opin Hematol, V4, P323; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MELONI FJ, 1992, BLOOD, V79, P1233; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; MURATA M, 1991, J BIOL CHEM, V266, P15474; Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803; RUAN CG, 1987, BLOOD, V69, P570; RUGGERI ZM, 1987, BLOOD, V70, P895; THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862; van Zanten GH, 1998, BLOOD, V91, P2353, DOI 10.1182/blood.V91.7.2353.2353_2353_2359; WALSH PN, 1975, BRIT J HAEMATOL, V29, P639, DOI 10.1111/j.1365-2141.1975.tb02750.x; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; WEISS HJ, 1974, AM J MED, V57, P920, DOI 10.1016/0002-9343(74)90170-3; WHITE JG, 1984, BLOOD, V63, P1249; WICKI AN, 1987, EUR J BIOCHEM, V163, P43, DOI 10.1111/j.1432-1033.1987.tb10734.x	44	81	87	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1662	1668		10.1074/jbc.M108319200	http://dx.doi.org/10.1074/jbc.M108319200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11696542	hybrid			2022-12-25	WOS:000173421300008
J	Balasubramanian, S; Efimova, T; Eckert, RL				Balasubramanian, S; Efimova, T; Eckert, RL			Green tea Polyphenol stimulates a Ras, MEKK1, MEK3, and p38 cascade to increase activator protein 1 factor-dependent involucrin gene expression in normal human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; MAP KINASE; CROSS-LINKING; (-)-EPIGALLOCATECHIN GALLATE; EPIDERMAL KERATINOCYTE; SELECTIVE ACTIVATION; MOUSE KERATINOCYTES; PROMOTER ACTIVITY; BINDING-PROTEINS; CANCER-CELLS	(-)-Epigallocatechin-3-gallate (EGCG) is an important bioactive constituent of green tea that efficiently reduces epidermal cancer cell proliferation. This inhibition is associated with a reduction in activator protein I (AP1) transcription factor level and activity. However, its effects on AP1 function in normal epidermal cells have not been extensively explored. Our present studies show that EGCG regulates normal keratinocyte function. To understand the mechanism of action, we examined the effects of EGCG on AP1 factor activity, MAPK signal transduction, and expression of the AP1 factor-regulated human involucrin (hINV) gene. EGCG increases hINV promoter activity in a concentration-dependent manner that requires the presence of an intact hINV promoter AP1 factor binding site. This response appears to be physiologic, as endogenous hINV gene expression is also increased. Fra-1, Fra-2, FosB, JunB, JunD, c-Jun, and c-Fos levels are increased by EGCG treatment, as is AP1 factor binding to hINV promoter AP1 site. Gel mobility shift studies show that this complex contains Fra-1 and JunD. Signal transduction analysis indicates that the EGCG response requires Ras, MEKK1, MEK3, and p38 kinases. Kinase assays and inhibitor studies suggest that p385 is the p38 isoform responsible for the regulation. These changes are also associated with a cessation of cell proliferation and enhanced cornified envelope formation. These studies show that in normal human keratinocytes EGCG markedly increases, via a MAPK signaling mechanism, AP1 factor-associated responses.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 2109 Adelbert Rd, Cleveland, OH 44106 USA.			Efimova, Tatiana/0000-0002-9869-1545	NCI NIH HHS [P30 CA134274] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA134274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agarwal C, 1999, J BIOL CHEM, V274, P6190, DOI 10.1074/jbc.274.10.6190; AGARWAL C, 1991, CANCER RES, V51, P3982; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Barthelman M, 1998, CARCINOGENESIS, V19, P2201, DOI 10.1093/carcin/19.12.2201; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; Chen WX, 1999, MOL CARCINOGEN, V24, P79, DOI 10.1002/(SICI)1098-2744(199902)24:2<79::AID-MC1>3.0.CO;2-E; Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6; Chung JY, 1999, CANCER RES, V59, P4610; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Dashti SR, 2001, J BIOL CHEM, V276, P27214, DOI 10.1074/jbc.M100465200; Dashti SR, 2001, J BIOL CHEM, V276, P8059, DOI 10.1074/jbc.C000862200; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dong ZG, 1997, CANCER RES, V57, P4414; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; GORODESKI GI, 1989, DIFFERENTIATION, V42, P75, DOI 10.1111/j.1432-0436.1989.tb00609.x; Green H, 1980, Harvey Lect, V74, P101; Guo WT, 1999, INT J ONCOL, V15, P817; Hanley K, 1998, J INVEST DERMATOL, V110, P368, DOI 10.1046/j.1523-1747.1998.00139.x; ITIN PH, 1994, ENDOCRINOLOGY, V135, P1793, DOI 10.1210/en.135.5.1793; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Kuroda Y, 1999, MUTAT RES-REV MUTAT, V436, P69, DOI 10.1016/S1383-5742(98)00019-2; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin JK, 1999, BIOCHEM PHARMACOL, V58, P911, DOI 10.1016/S0006-2952(99)00112-4; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Mukhtar H, 2000, AM J CLIN NUTR, V71, p1698S, DOI 10.1093/ajcn/71.6.1698S; Mukhtar H, 1999, TOXICOL SCI, V52, P111, DOI 10.1093/toxsci/52.2.111; Nomura M, 2000, MOL CARCINOGEN, V28, P148, DOI 10.1002/1098-2744(200007)28:3<148::AID-MC3>3.0.CO;2-Q; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; REDNER RL, 1992, ONCOGENE, V7, P43; Ren FG, 2000, ONCOGENE, V19, P1924, DOI 10.1038/sj.onc.1203511; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Rutberg SE, 1996, ONCOGENE, V13, P167; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Steinert P M, 1995, Cell Death Differ, V2, P33; Suganuma M, 1996, CANCER RES, V56, P3711; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; WANG HL, 1994, P NATL ACAD SCI USA, V91, P4649, DOI 10.1073/pnas.91.11.4649; Wang HL, 1996, J CELL BIOL, V135, P1151, DOI 10.1083/jcb.135.4.1151; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; Yu R, 1997, CARCINOGENESIS, V18, P451, DOI 10.1093/carcin/18.2.451	67	120	128	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1828	1836		10.1074/jbc.M110376200	http://dx.doi.org/10.1074/jbc.M110376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11698415	hybrid			2022-12-25	WOS:000173421300029
J	Bruce, JIE; Shuttleworth, TJ; Giovannucci, DR; Yule, DI				Bruce, JIE; Shuttleworth, TJ; Giovannucci, DR; Yule, DI			Phosphorylation of inositol 1,4,5-trisphosphate receptors in parotid acinar cells - A mechanism for the synergistic effects of cAMP on Ca2+ signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RECONSTITUTED LIPID VESICLES; CALCIUM-RELEASE CHANNEL; CYCLIC-AMP; RYANODINE RECEPTOR; SKELETAL-MUSCLE; ENDOPLASMIC-RETICULUM; SALIVARY SECRETION; WAVE-PROPAGATION; AMYLASE RELEASE	Acetylcholine-evoked secretion from the parotid gland is substantially potentiated by cAMP-raising agonists. A potential locus for the action of cAMP is the intracellular signaling pathway resulting in elevated cytosolic calcium levels ([Ca2+](i)). This hypothesis was tested in mouse parotid acinar cells. Forskolin dramatically potentiated the carbachol-evoked increase in [Ca2+](i), converted oscillatory [Ca2+](i) changes into a sustained [Ca2+](i) increase, and caused subthreshold concentrations of carbachol to increase [Ca2+]i measurably. This potentiation was found to be independent of Ca2+ entry and inositol 1,4,5-trisphosphate (InSP3) production, suggesting that cAMP-mediated effects on Ca2+ release was the major underlying mechanism. Consistent with this hypothesis, dibutyryl cAAEP dramatically potentiated InsP(3)-evoked Ca2+ release from streptolysin-O-permeabilized cells. Furthermore, type II InSP3 receptors (InsP(3)R) were shown to be directly phosphorylated by a protein kinase A (PKA)-mediated mechanism after treatment with forskolin. In contrast, no evidence was obtained to support direct PKA-mediated activation of ryanodine receptors (RyRs). However, inhibition of RyRs in intact cells, demonstrated a role for RyRs in propagating Ca2+ oscillations and amplifying potentiated Ca2+ release from InsP(3)Rs. These data indicate that potentiation of Ca2+ release is primarily the result of PKA-mediated phosphorylation of InsP(3)Rs, and may largely explain the synergistic relationship between cAMP-raising agonists and acetylcholine-evoked secretion in the parotid. In addition, this report supports the emerging consensus that phosphorylation at the level of the Ca2+ release machinery is a broadly important mechanism by which cells can regulate Ca2+-mediated processes.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Bruce, JIE (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Physiol & Pharmacol, 601 Elmwood Ave, Rochester, NY 14642 USA.	jason_bruce@urmc.rochester.edu	Giovannucci, David R/A-5657-2018		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK054568, R01DK054568] Funding Source: NIH RePORTER; NIDCR NIH HHS [DEO 13539] Funding Source: Medline; NIDDK NIH HHS [DK54568] Funding Source: Medline; NIGMS NIH HHS [GM 40457] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDYSWALIGORSKA A, 1987, BIOCHIM BIOPHYS ACTA, V929, P190, DOI 10.1016/0167-4889(87)90175-3; BAUM B J, 1987, P123; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOBYOCK E, 1989, J DENT RES, V68, P1489, DOI 10.1177/00220345890680110401; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; Bugrim AE, 1999, CELL CALCIUM, V25, P219, DOI 10.1054/ceca.1999.0027; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DiJulio DH, 1997, J BIOL CHEM, V272, P15687, DOI 10.1074/jbc.272.25.15687; Evans RL, 1999, J BIOL CHEM, V274, P29025, DOI 10.1074/jbc.274.41.29025; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Fujita-Yoshigaki J, 1998, CELL SIGNAL, V10, P371, DOI 10.1016/S0898-6568(97)00178-2; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; Giovannucci DR, 2000, J BIOL CHEM, V275, P33704, DOI 10.1074/jbc.M004278200; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; Hyrc KB, 2000, CELL CALCIUM, V27, P75, DOI 10.1054/ceca.1999.0092; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Kraus-Friedmann N, 2000, CELL CALCIUM, V27, P127, DOI 10.1054/ceca.2000.0109; LARSSON O, 1989, ACTA PHYSIOL SCAND, V137, P231, DOI 10.1111/j.1748-1716.1989.tb08743.x; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Li GD, 1996, CELL CALCIUM, V19, P535, DOI 10.1016/S0143-4160(96)90063-9; Martinez JR, 1998, EUR J MORPHOL, V36, P190; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MCKINNEY JS, 1989, AM J PHYSIOL, V257, pC651, DOI 10.1152/ajpcell.1989.257.4.C651; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NAKADE S, 1994, J BIOL CHEM, V269, P6735; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Ozawa T, 1998, BIOCHEM BIOPH RES CO, V246, P422, DOI 10.1006/bbrc.1998.8636; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PENNER R, 1988, J EXP BIOL, V139, P329; PETERSEN OH, 1988, ANNU REV PHYSIOL, V50, P65; PITTNER RA, 1989, BIOCHEM J, V257, P455, DOI 10.1042/bj2570455; Putney JW, 1998, SCIENCE, V279, P191, DOI 10.1126/science.279.5348.191; PUTNEY JW, 1986, ANNU REV PHYSIOL, V48, P75, DOI 10.1146/annurev.ph.48.030186.000451; RUBIN RP, 1994, J PHARMACOL EXP THER, V268, P600; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Sei Y, 1999, J BIOL CHEM, V274, P5995, DOI 10.1074/jbc.274.9.5995; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Shuttleworth TJ, 1999, CELL CALCIUM, V25, P237, DOI 10.1054/ceca.1999.0022; Sonnleitner A, 1998, EMBO J, V17, P2790, DOI 10.1093/emboj/17.10.2790; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; SUPPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747; Takemura H, 1999, BIOCHEM BIOPH RES CO, V259, P656, DOI 10.1006/bbrc.1999.0818; Tanimura A, 1999, AM J PHYSIOL-CELL PH, V276, pC1282, DOI 10.1152/ajpcell.1999.276.6.C1282; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; Tojyo Y, 1998, EUR J PHARMACOL, V360, P73, DOI 10.1016/S0014-2999(98)00651-7; Tojyo Y, 1997, BIOCHEM BIOPH RES CO, V240, P189, DOI 10.1006/bbrc.1997.7584; Tojyo Y, 1997, CELL CALCIUM, V22, P455, DOI 10.1016/S0143-4160(97)90073-7; vandePut FHMM, 1997, J BIOL CHEM, V272, P27764, DOI 10.1074/jbc.272.44.27764; vandePut FHMM, 1996, J BIOL CHEM, V271, P4999; Verma V, 1996, BIOCHEM J, V319, P449, DOI 10.1042/bj3190449; VOLPE P, 1990, AM J PHYSIOL, V258, pC1086, DOI 10.1152/ajpcell.1990.258.6.C1086; Westerblad H, 1998, CELL CALCIUM, V24, P105, DOI 10.1016/S0143-4160(98)90078-1; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; Yoshimura K, 1998, BBA-MOL CELL RES, V1402, P171, DOI 10.1016/S0167-4889(98)00007-X; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8; Zhang XJ, 1999, BIOCHEM J, V340, P519, DOI 10.1042/0264-6021:3400519; Zhang XJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1306, DOI 10.1152/ajpcell.1997.273.4.C1306; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192; Zucchi R, 1997, PHARMACOL REV, V49, P1	72	121	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1340	1348		10.1074/jbc.M106609200	http://dx.doi.org/10.1074/jbc.M106609200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694504	hybrid			2022-12-25	WOS:000173166800062
J	Hirohashi, N; Vacquier, VD				Hirohashi, N; Vacquier, VD			High molecular mass egg fucose sulfate polymer is required for opening both Ca2+ channels involved in triggering the sea urchin sperm acrosome reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN ANTAGONISTS; ANTICOAGULANT ACTIVITY; JELLY COAT; CALCIUM; PROTEIN; GENETICS; INCREASE; INHIBIT; FUCANS; BINDS	A linear fucose sulfate polymer (FSP), > 10(6) daltons, is a major component of sea urchin egg jelly. FSP induces the sperm acrosome reaction (AR), an exocytotic process required for animal fertilization. Two Ca2+ channels activate during AR induction, the first opens 1 s after FSP addition, and the second opens 5 s after the first. Mild acid hydrolysis of FSP results in a linear decrease in polymer size. The ability of FSP to induce the AR and activate sperm Ca2+ channels decreases with increasing time of hydrolysis. Hydrolyzed FSP of similar to60 kDa blocks intact FSP from inducing the AR. At 44 mug/ml hydrolyzed FSP, Ca2+ entry into sperm is almost equal to that occurring in 3.8 mug/ml intact FSP; however the AR is not induced. The shape of the [Ca2+](i) increase curve and use of the Ca2+ channel blockers nifidipine and Ni2+ indicate that hydrolyzed FSP opens the second Ca2+ channel, but not the first, and thus does not induce the AR. The giant size of intact FSP is required to open both Ca2+ channels involved in triggering the AR.	Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Hirohashi, N (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA.	nhirohashi@ucsd.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012986, R37HD012986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057325] Funding Source: NIH RePORTER; NICHD NIH HHS [HD12986] Funding Source: Medline; NIDDK NIH HHS [1P50DK57325] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alves AP, 1997, J BIOL CHEM, V272, P6965, DOI 10.1074/jbc.272.11.6965; Alves AP, 1998, GLYCOBIOLOGY, V8, P939, DOI 10.1093/glycob/8.9.939; Arnaout MA, 2001, ANNU REV MED, V52, P93, DOI 10.1146/annurev.med.52.1.93; BELTRAN C, 1994, FEBS LETT, V338, P23, DOI 10.1016/0014-5793(94)80109-6; BENOFF S, 1998, FRONT BIOSCI, V3, P1220; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; DEANGELIS PL, 1987, J BIOL CHEM, V262, P13946; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Farias WRL, 2000, J BIOL CHEM, V275, P29299, DOI 10.1074/jbc.M002422200; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Gonzalez-Martinez MT, 2001, DEV BIOL, V236, P220, DOI 10.1006/dbio.2001.0323; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; GUERRERO A, 1989, BIOCHIM BIOPHYS ACTA, V980, P109, DOI 10.1016/0005-2736(89)90206-X; GUERRERO A, 1989, J BIOL CHEM, V264, P19593; Guerrero A, 1998, BBA-MOL CELL RES, V1401, P329, DOI 10.1016/S0167-4889(97)00127-4; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; KAZAZOGLOU T, 1985, P NATL ACAD SCI USA, V82, P1460, DOI 10.1073/pnas.82.5.1460; KELLER SH, 1994, DEV BIOL, V162, P304, DOI 10.1006/dbio.1994.1087; Koyota S, 1997, J BIOL CHEM, V272, P10372; Lopez-Gonzalez I, 2001, DEV BIOL, V236, P210, DOI 10.1006/dbio.2001.0314; Mengerink KJ, 2001, GLYCOBIOLOGY, V11, p37R, DOI 10.1093/glycob/11.4.37R; MORRIS SJ, 1994, METHOD CELL BIOL, V40, P183; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; PARK JT, 1949, J BIOL CHEM, V181, P149; Pereira MS, 1999, J BIOL CHEM, V274, P7656, DOI 10.1074/jbc.274.12.7656; Publicover SJ, 1999, HUM REPROD, V14, P873, DOI 10.1093/humrep/14.4.873; SCHACKMANN RW, 1981, DEV BIOL, V81, P145, DOI 10.1016/0012-1606(81)90357-2; SEGALL GK, 1979, DEV BIOL, V71, P33, DOI 10.1016/0012-1606(79)90080-0; TERHO TT, 1971, ANAL BIOCHEM, V41, P471, DOI 10.1016/0003-2697(71)90167-9; TRIMMER JS, 1987, J CELL BIOL, V105, P1121, DOI 10.1083/jcb.105.3.1121; TRIMMER JS, 1986, P NATL ACAD SCI USA, V83, P9055, DOI 10.1073/pnas.83.23.9055; Vacquier VD, 1997, DEV BIOL, V192, P125, DOI 10.1006/dbio.1997.8729; Vacquier VD, 1998, SCIENCE, V281, P1995, DOI 10.1126/science.281.5385.1995; VACQUIER VD, 1995, DEV GROWTH DIFFER, V37, P1; VACQUIER VD, 1986, METHOD CELL BIOL, V27, P15, DOI 10.1016/S0091-679X(08)60340-4; Vilela-Silva ACES, 1999, GLYCOBIOLOGY, V9, P927, DOI 10.1093/glycob/9.9.927; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Weston BS, 2001, BBA-MOL BASIS DIS, V1536, P161, DOI 10.1016/S0925-4439(01)00046-1; Wu GQ, 2000, MOL GENET METAB, V69, P1, DOI 10.1006/mgme.1999.2943	40	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1182	1189		10.1074/jbc.M108046200	http://dx.doi.org/10.1074/jbc.M108046200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11700311	hybrid			2022-12-25	WOS:000173166800040
J	Mizushina, Y; Kamisuki, S; Kasai, N; Shimazaki, N; Takemura, M; Asahara, H; Linn, S; Yoshida, S; Matsukage, A; Koiwai, O; Sugawara, F; Yoshida, H; Sakaguchi, K				Mizushina, Y; Kamisuki, S; Kasai, N; Shimazaki, N; Takemura, M; Asahara, H; Linn, S; Yoshida, S; Matsukage, A; Koiwai, O; Sugawara, F; Yoshida, H; Sakaguchi, K			A plant phytotoxin, solanapyrone A, is an inhibitor of DNA polymerase beta and lambda	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL 8-KDA DOMAIN; BASE-EXCISION-REPAIR; STRUCTURAL BASIS; DIFFERENTIAL INHIBITION; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; LITHOCHOLIC ACID; FOMITELLIC ACIDS; HUMAN TELOMERASE	Solanapyrone A, a phytotoxin and enzyme inhibitor isolated from a fungus (SUT 01B1-2) selectively inhibits the activities of mammalian DNA polymerase beta and lambda (pol beta and lambda) in vitro. The IC50 values of the compound were 30 mum for pol beta and 37 mum for pol lambda. Because pol beta and lambda are in a family and their three-dimensional structures are thought to be highly similar to each other, we used pol beta to analyze the biochemical relationship with solanapyrone A. On pol beta, solanapyrone A antagonistically competed with both the DNA template and the nucleotide substrate. BIAcore analysis demonstrated that solanapyrone A bound selectively to the N-terminal 8-kDa domain of pol beta. This domain is known to bind single-stranded DNA, provide 5'-phosphate recognition of gapped DNA, and cleave the sugar-phosphate bond 3' to an intact apurinic/apyrimidinic (AP) site (i.e. AP lyase activity) including 5'-deoxyribose phosphate lyase activity. Solanapyrone A inhibited the single-stranded DNA-binding activity but did not influence the activities of the 5'-phosphate recognition in gapped DNA structures and the AP lyase. Based on these results, the inhibitory mechanism of solanapyrone A is discussed.	Kobe Gakuin Univ, Lab Food & Nutr Sci, Dept Nutr Sci, Nishi Ku, Kobe, Hyogo 6512180, Japan; Kobe Gakuin Univ, High Technol Res Ctr, Nishi Ku, Kobe, Hyogo 6512180, Japan; Sci Univ Tokyo, Dept Appl Biol Sci, Noda, Chiba 2788510, Japan; Nagoya Univ, Sch Med, Res Inst Dis Mech & Control, Lab Canc Cell Biol, Nagoya, Aichi 4668550, Japan; Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Japan Womens Univ, Dept Chem & Biol Sci, Bunkyo Ku, Tokyo 1128681, Japan	Kobe Gakuin University; Kobe Gakuin University; Tokyo University of Science; Nagoya University; University of California System; University of California Berkeley; Japan Womens University	Mizushina, Y (corresponding author), Kobe Gakuin Univ, Lab Food & Nutr Sci, Dept Nutr Sci, Nishi Ku, Kobe, Hyogo 6512180, Japan.							Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Beard WA, 2000, MUTAT RES-DNA REPAIR, V460, P231, DOI 10.1016/S0921-8777(00)00029-X; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; Chui GSJ, 1995, METHOD ENZYMOL, V262, P93; DATE T, 1988, BIOCHEMISTRY-US, V27, P2983, DOI 10.1021/bi00408a048; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; Deng JZ, 2000, BIOORGAN MED CHEM, V8, P247, DOI 10.1016/S0968-0896(99)00276-X; Deng JZ, 2000, J NAT PROD, V63, P1356, DOI 10.1021/np000129m; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Esposito G, 2000, P NATL ACAD SCI USA, V97, P1166, DOI 10.1073/pnas.97.3.1166; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Hanashima S, 2000, JPN J CANCER RES, V91, P1073, DOI 10.1111/j.1349-7006.2000.tb00887.x; HIROSE F, 1989, EXP CELL RES, V181, P169, DOI 10.1016/0014-4827(89)90191-2; Horie T, 1998, INT J MOL MED, V1, P83; ICHIHARA A, 1983, TETRAHEDRON LETT, V24, P5373, DOI 10.1016/S0040-4039(00)87872-7; ICHIHARA A, 1985, TETRAHEDRON LETT, V26, P2453, DOI 10.1016/S0040-4039(00)94851-2; IZUTA S, 1991, BIOCHEM BIOPH RES CO, V179, P776, DOI 10.1016/0006-291X(91)91884-F; Katayama K, 1998, BBA-PROTEIN STRUCT M, V1384, P387, DOI 10.1016/S0167-4838(98)00040-5; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOIZUMI KT, 1997, BIOCHEM MOL BIOL INT, V41, P1179; KORNBERG A, 1992, DNA REPLICATION, P197; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; Kurinov IV, 1999, PROTEIN SCI, V8, P1765, DOI 10.1110/ps.8.9.1765; Lawrence CW, 1996, CANCER SURV, V28, P21; LIU DJ, 1994, BIOCHEMISTRY-US, V33, P9537, DOI 10.1021/bi00198a020; Liu DJ, 1996, BIOCHEMISTRY-US, V35, P6188, DOI 10.1021/bi952656o; LU BC, 1991, J BIOL CHEM, V266, P21060; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Mizushina Y, 2000, BBA-GEN SUBJECTS, V1523, P172, DOI 10.1016/S0304-4165(00)00119-7; Mizushina Y, 2000, BIOCHEMISTRY-US, V39, P12606, DOI 10.1021/bi001276m; Mizushina Y, 2000, J BIOL CHEM, V275, P33957, DOI 10.1074/jbc.M006096200; Mizushina Y, 1998, BBA-MOL CELL RES, V1403, P5, DOI 10.1016/S0167-4889(98)00027-5; Mizushina Y, 1999, J BIOL CHEM, V274, P25599, DOI 10.1074/jbc.274.36.25599; Mizushina Y, 1998, BIOCHEM J, V330, P1325, DOI 10.1042/bj3301325; Mizushina Y, 1998, BIOCHEM PHARMACOL, V55, P537, DOI 10.1016/S0006-2952(97)00536-4; Mizushina Y, 1997, BBA-GEN SUBJECTS, V1336, P509, DOI 10.1016/S0304-4165(97)00067-6; Mizushina Y, 1996, BBA-GENE STRUCT EXPR, V1308, P256, DOI 10.1016/0167-4781(96)00121-2; MIZUSHINA Y, 1998, J BIOCHEM-TOKYO, V126, P430; MULLEN GP, 1997, BASE EXCISION REPAIR, P121; MURAKAMIMUROFUSHI K, 1992, J BIOL CHEM, V267, P21512; MUROFUSHI KM, 1995, BIOCHIM BIOPHYS ACTA, V1258, P57; NAKAYAMA C, 1985, J BIOCHEM-TOKYO, V97, P1385, DOI 10.1093/oxfordjournals.jbchem.a135192; Ogawa A, 1998, JPN J CANCER RES, V89, P1154, DOI 10.1111/j.1349-7006.1998.tb00510.x; Ohashi E, 2000, GENE DEV, V14, P1589; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONO K, 1988, EUR J BIOCHEM, V176, P305, DOI 10.1111/j.1432-1033.1988.tb14282.x; ONO K, 1988, EUR J BIOCHEM, V172, P349, DOI 10.1111/j.1432-1033.1988.tb13893.x; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12778, DOI 10.1021/bi960790i; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; PRASAD R, 1993, J BIOL CHEM, V268, P22746; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; SAKAGUCHI K, 1980, CELL STRUCT FUNCT, V5, P323, DOI 10.1247/csf.5.323; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; Sharief FS, 1999, GENOMICS, V59, P90, DOI 10.1006/geno.1999.5843; SHOJIKAWAGUCHI M, 1995, J BIOCHEM-TOKYO, V117, P1095, DOI 10.1093/oxfordjournals.jbchem.a124812; SIMBULAN CMG, 1994, BBA-PROTEIN STRUCT M, V1205, P68, DOI 10.1016/0167-4838(94)90093-0; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SOLTIS DA, 1982, J BIOL CHEM, V257, P1332; Sugo N, 2000, EMBO J, V19, P1397, DOI 10.1093/emboj/19.6.1397; Sun DA, 1999, J AM CHEM SOC, V121, P6120, DOI 10.1021/ja990208o; TAMAI K, 1988, BIOCHIM BIOPHYS ACTA, V950, P263, DOI 10.1016/0167-4781(88)90122-4; Tanaka N, 1998, J NAT PROD, V61, P193, DOI 10.1021/np970127a; Ueno T, 2000, BIOCHEMISTRY-US, V39, P5995, DOI 10.1021/bi992661i; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199	75	63	65	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					630	638		10.1074/jbc.M105144200	http://dx.doi.org/10.1074/jbc.M105144200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11677229	hybrid			2022-12-25	WOS:000173087900083
J	Moir, RD; Puglia, KV; Willis, IM				Moir, RD; Puglia, KV; Willis, IM			Autoinhibition of TFIIIB70 binding by the tetratricopeptide repeat-containing subunit of TFIIIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TARGETING SIGNAL-1 RECOGNITION; TRANSCRIPTION FACTOR; YEAST TFIIIB; PROTEIN PHOSPHATASE-5; CRYSTAL-STRUCTURE; TPR DOMAIN; COMPLEX; RECRUITMENT; COMPONENT	An important step in the assembly of RNA polymerase (pol) III transcription complexes on tRNA and 5 S genes is the interaction between the tetratricopeptide repeat (TPR)-containing subunit of TFIIIC (TFIIIC131) and the TFIIB-related subunit of TFIIIB (TFIIIB70/Brf1). A fragment of TFIIIC131 that contains the hydrophilic amino terminus and two TPR arrays, with five and four repeats, respectively (Nt-TPR9), is sufficient to support an interaction with TFIIIB70. Here we evaluate the contribution of each TPR array to TFIIIB70 binding. Both TPR arrays bind independently to TFIIIB70 with TPR6-9 having a 4-fold higher apparent affinity than TPR1-5. However, the TPR arrays are not sufficient for a high affinity interaction with TFIIIB70. The addition of amino-terminal sequences increases the affinity of TPR1-5 18-fold to create a high affinity TFIIIB70 binding site (Nt-TPR5, 44 +/- 6 nm). Although the Nt-TPR5 and TPR6-9 fragments are contained entirely within the Nt-TPR9 fragment, the affinity of the latter is significantly lower than either of these smaller fragments. The results demonstrate that the TFIIIB70 binding sites in TFIIIC131 are subject to autoinhibition. We propose that the binding of TFIIIB70 to these sites within the TFIIIC complex may proceed in an ordered fashion.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Willis, IM (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Willis, Ian/0000-0001-6599-2395	NIGMS NIH HHS [GM42728] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042728] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Cloutier TE, 2001, P NATL ACAD SCI USA, V98, P9581, DOI 10.1073/pnas.161292298; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dumay H, 1999, J BIOL CHEM, V274, P33462, DOI 10.1074/jbc.274.47.33462; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gatto GJ, 2000, PROTEINS, V38, P241, DOI 10.1002/(SICI)1097-0134(20000215)38:3<241::AID-PROT1>3.0.CO;2-1; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Grove A, 1999, J MOL BIOL, V285, P1429, DOI 10.1006/jmbi.1998.2347; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Huang Y, 2001, NUCLEIC ACIDS RES, V29, P2675, DOI 10.1093/nar/29.13.2675; Huet J, 1997, J BIOL CHEM, V272, P18341, DOI 10.1074/jbc.272.29.18341; HUET J, 1994, NUCLEIC ACIDS RES, V22, P2282, DOI 10.1093/nar/22.12.2282; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; Kassavetis GA, 1998, MOL CELL BIOL, V18, P5587, DOI 10.1128/MCB.18.9.5587; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; Kumar A, 2001, J MOL BIOL, V307, P271, DOI 10.1006/jmbi.2000.4465; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; Moir RD, 1997, MOL CELL BIOL, V17, P7119, DOI 10.1128/MCB.17.12.7119; Moir RD, 2000, J BIOL CHEM, V275, P26591, DOI 10.1074/jbc.M003991200; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Ponting CCP, 1996, BIOCHEM J, V314, P1053, DOI 10.1042/bj3141053; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; Sethy-Coraci I, 1998, NUCLEIC ACIDS RES, V26, P2344, DOI 10.1093/nar/26.10.2344; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Sinclair C, 1999, J BIOL CHEM, V274, P23666, DOI 10.1074/jbc.274.33.23666; Taylor P, 2001, STRUCTURE, V9, P431, DOI 10.1016/S0969-2126(01)00603-7; WHITE RJ, 1998, RNA POLYMERASE, V3, P131; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	41	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					694	701		10.1074/jbc.M108924200	http://dx.doi.org/10.1074/jbc.M108924200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11684692	hybrid			2022-12-25	WOS:000173087900091
J	Soldatenkov, VA; Chasovskikh, S; Potaman, VN; Trofimova, I; Smulson, ME; Dritschilo, A				Soldatenkov, VA; Chasovskikh, S; Potaman, VN; Trofimova, I; Smulson, ME; Dritschilo, A			Transcriptional repression by binding of poly(ADP-ribose) polymerase to promoter sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; DEPENDENT TRANSCRIPTION; DNA BREAKS; GENE; COACTIVATOR; REPAIR; SPECIFICITY; RECOGNITION; ACTIVATION; ENHANCER	Poly(ADP-ribose) polymerase (PARP) is a DNA-binding enzyme that plays roles in response to DNA damage, apoptosis, and genetic stability. Recent evidence has implicated PARP in transcription of eukaryotic genes. However, the existing paradigm tying PARP function to the presence of DNA strand breaks does not provide a mechanism by which it may be recruited to gene-regulating domains in the absence of DNA damage. Here we report that PARP can bind to the DNA secondary structures (hairpins) in heteroduplex DNA in a DNA end-independent fashion and that automodification of PARP in the presence of NAD(+) inhibited its hairpin binding activity. Atomic force microscopic images show that in vitro PARP protein has a preference for the promoter region of the PARP gene in superhelical DNA where the dyad symmetry elements likely form hairpins according to DNase probing. Using a chromatin cross-linking and immunoprecipitation assay we show that PARP protein binds to the chromosomal PARP promoter in vivo. Reporter gene assays have revealed that the transcriptional activity of the PARP promoter is 4-5-fold greater in PARP knockout cells than in wild type fibroblasts. Reintroduction of vectors expressing full-length PARP protein or its truncated mutant (DNA-binding domain retained but lacking catalytic activity) into PARP(-/-) cells has conferred transcriptional down-regulation of the PARP gene promoter. These data provide support for PARP protein as a potent regulator of transcription including down-regulation of its own promoter.	Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Texas A&M Univ System, Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA	Georgetown University; Georgetown University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Dritschilo, A (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Res Bldg E202A-B,3970 Reservoir NW, Washington, DC 20007 USA.							ACKERMAN SL, 1993, P NATL ACAD SCI USA, V90, P11865, DOI 10.1073/pnas.90.24.11865; Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; ALTHAUS FR, 1987, ADP RIBOSYLATION PRO; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; BOWATER R, 1992, METHOD ENZYMOL, V212, P105; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P1724; Engel A, 1999, TRENDS CELL BIOL, V9, P77, DOI 10.1016/S0962-8924(98)01415-9; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; GlucksmannKuis MA, 1996, CELL, V84, P147, DOI 10.1016/S0092-8674(00)81001-6; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HANKE JH, 1995, J MOL BIOL, V246, P63, DOI 10.1006/jmbi.1994.0066; HORWITZ MSZ, 1988, SCIENCE, V241, P703, DOI 10.1126/science.2456617; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; OGURA T, 1990, BIOCHEM BIOPH RES CO, V167, P701, DOI 10.1016/0006-291X(90)92082-B; Oussatcheva EA, 1999, J MOL BIOL, V292, P75, DOI 10.1006/jmbi.1999.3043; Pietrasanta LI, 1999, P NATL ACAD SCI USA, V96, P3757, DOI 10.1073/pnas.96.7.3757; Plaza S, 1999, ONCOGENE, V18, P1041, DOI 10.1038/sj.onc.1202406; Potaman VN, 1998, BIOCHEMISTRY-US, V37, P12952, DOI 10.1021/bi972510k; Potaman VN, 1996, J BIOL CHEM, V271, P13441, DOI 10.1074/jbc.271.23.13441; Rawling JM, 1997, BIOCHEM J, V324, P249, DOI 10.1042/bj3240249; Rosenthal DS, 1997, NUCLEIC ACIDS RES, V25, P1437, DOI 10.1093/nar/25.7.1437; SASTRY SS, 1990, BIOCHEM BIOPH RES CO, V167, P842, DOI 10.1016/0006-291X(90)92102-6; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHWEIGER M, 1992, ADP RIBOSYLATION REA, P20; Sinden R.R., 1994, DNA STRUCTURE FUNCTI, P95; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; SMULSON ME, 1998, CANCER RES, V58, P3405; Soldatenkov VA, 1999, ONCOGENE, V18, P3954, DOI 10.1038/sj.onc.1202778; Spiro C, 1997, J BIOL CHEM, V272, P33145, DOI 10.1074/jbc.272.52.33145; STEVNSNER T, 1995, NUCLEIC ACIDS RES, V22, P4620; Vispe S, 2000, P NATL ACAD SCI USA, V97, P9886, DOI 10.1073/pnas.170280397; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509	45	100	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					665	670		10.1074/jbc.M108551200	http://dx.doi.org/10.1074/jbc.M108551200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11684688	hybrid			2022-12-25	WOS:000173087900087
J	Suzuki, N; Kojima, H; Urano, Y; Kikuchi, K; Hirata, Y; Nagano, T				Suzuki, N; Kojima, H; Urano, Y; Kikuchi, K; Hirata, Y; Nagano, T			Orthogonality of calcium concentration and ability of 4,5-diaminofluorescein to detect NO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE PRODUCTION; FLUORESCENT INDICATORS; SIGNALING PATHWAY; CELLS; ACTIVATION; CA2+; CHROMOPHORE; SYNTHASE	We have developed diaminofluoresceins (DAFs) and diaminorhodamines as fluorescent indicators for NO based on the specific reaction of the aromatic vicinal diamines with NO. Among them, 4,5-diaminofluorescein (DAF-2) is widely used for real-time biological imaging of NO in cultured cells or tissues by many researchers. Contrary to a recent report of divalent cation sensitivity and photoactivation of DAF-2 (Broillet, M. C., Randin, O., and Chatton, J. Y. (2001) FEBS Lett. 491, 227-232), our study using NO gas itself reveals that the reaction of DAF-2 and NO is completely independent of Ca2+ and Mg2+ at physiological concentrations. Ca2+ enhances not the conversion of DAF-2 into its fluorescent product (DAF-2 triazole) but the release of NO from NO donors. Therefore it is concluded that DAF-2 can provide reliable information on NO production in biological systems regardless of the dynamic changes of Ca2+ concentration.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Dept Internal Med 2, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Nagano, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.		Kikuchi, Kazuya/D-2370-2009; Urano, Yasuteru/H-1380-2012	Suzuki, Noriyuki/0000-0002-9345-6335				Berkels R, 2000, CELL CALCIUM, V27, P281, DOI 10.1054/ceca.2000.0119; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Broillet MC, 2001, FEBS LETT, V491, P227, DOI 10.1016/S0014-5793(01)02206-2; Brown LA, 1999, J NEUROSCI METH, V92, P101, DOI 10.1016/S0165-0270(99)00098-9; Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; Gorbunov NV, 2000, RADIAT RES, V154, P73, DOI 10.1667/0033-7587(2000)154[0073:AOTNOS]2.0.CO;2; GUNASEKAR PG, 1995, J NEUROSCI METH, V61, P15, DOI 10.1016/0165-0270(95)00018-P; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Igarashi J, 1999, P NATL ACAD SCI USA, V96, P12583, DOI 10.1073/pnas.96.22.12583; Kojima H, 2001, J NEUROCHEM, V76, P1404, DOI 10.1046/j.1471-4159.2001.00161.x; Kojima H, 2001, ANAL CHEM, V73, P1967, DOI 10.1021/ac001136i; Kojima H, 1998, CHEM PHARM BULL, V46, P373; Kojima H, 1999, ANGEW CHEM INT EDIT, V38, P3209, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3209::AID-ANIE3209>3.0.CO;2-6; Kojima H, 2000, TETRAHEDRON LETT, V41, P69, DOI 10.1016/S0040-4039(99)02002-X; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Kuo RK, 2000, NATURE, V406, P633, DOI 10.1038/35020577; Li DC, 2000, AM J RESP CELL MOL, V23, P175, DOI 10.1165/ajrcmb.23.2.4022; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; Noble DR, 2001, J CHEM SOC PERK T 2, P13, DOI 10.1039/b008112o; PACKER L, 1996, METHODS ENZYMOLOGY, V269; SINGH RJ, 1995, FEBS LETT, V360, P47, DOI 10.1016/0014-5793(95)00065-H; Willmott NJ, 2000, J NEUROSCI, V20, P1767; Yoshioka T, 2000, BRIT J PHARMACOL, V129, P1530, DOI 10.1038/sj.bjp.0703241	24	69	71	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					47	49		10.1074/jbc.M108195200	http://dx.doi.org/10.1074/jbc.M108195200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11641405	hybrid			2022-12-25	WOS:000173087900008
J	Tai, LJ; McFall, SM; Huang, K; Demeler, B; Fox, SG; Brubaker, K; Radhakrishnan, I; Morimoto, RI				Tai, LJ; McFall, SM; Huang, K; Demeler, B; Fox, SG; Brubaker, K; Radhakrishnan, I; Morimoto, RI			Structure-function analysis of the heat shock factor-binding protein reveals a protein composed solely of a highly conserved and dynamic coiled-coil trimerization domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN4 LEUCINE-ZIPPER; SEDIMENTATION-VELOCITY EXPERIMENTS; TRANSCRIPTIONAL ACTIVATOR GCN4; AMINO-ACID SUBSTITUTIONS; OLIGOMERIZATION-STATE; HYDROPHOBIC CORE; NMR EXPERIMENTS; DNA-BINDING; MOLECULAR-PARAMETERS; CIRCULAR-DICHROISM	Heat shock factor-binding protein (HSBP) I is a small, evolutionarily conserved protein originally identified in a yeast two-hybrid screen using the trimerization domain of heat shock factor (HSF) I as the bait. Similar in size to HSF1 trimerization domain, human HSBP1 contains two arrays of hydrophobic heptad repeats (designated HR-N and HR-C) characteristic of coiled-coil proteins. Proteins of the HSBP family are relatively small (< 100 residues), comprising solely a putative coiled-coil oligomerization domain without any other readily recognizable structural or functional motif. Our biophysical and biochemical characterization of human HSBP1 reveals a cooperatively folded protein with high a-helical content and moderate stability. NMR analyses reveal a single continuous helix encompassing both HR-N and HR-C in the highly conserved central region, whereas the less conserved carboxyl terminus is unstructured and accessible to proteases. Unlike previously characterized coiled-coils, backbone N-15 relaxation measurements implicate motional processes on the millisecond time scale in the coiled-coil region. Analytical ultracentrifugation and native PAGE studies indicate that HSBP1 is predominantly trimeric over a wide concentration range. NMR analyses suggest a rotationally symmetric trimer. Because the highly conserved hydrophobic heptad repeats extend over 60% of HSBP1, we propose that HSBP most likely regulates the function of other proteins through coiled-coil interactions.	Northwestern Univ, Dept Biochem, Evanston, IL 60208 USA; Northwestern Univ, Dept Mol Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Rice Inst Biomed Res, Evanston, IL 60208 USA; Northwestern Univ, Struct Biol NMR Facil, Evanston, IL 60208 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; University of Texas System; University of Texas Health San Antonio	Radhakrishnan, I (corresponding author), Northwestern Univ, Dept Biochem, Evanston, IL 60208 USA.	i-radhakrishnan@northwestern.edu; r-morimoto@northwestern.edu	Radhakrishnan, Ishwar/AHA-7392-2022; Radhakrishnan, Ishwar/R-8442-2018	Radhakrishnan, Ishwar/0000-0002-0195-9710; Radhakrishnan, Ishwar/0000-0002-0195-9710; McFall, Sally/0000-0001-5554-6615; Demeler, Borries/0000-0002-2414-9518	NCI NIH HHS [5T32CA70085-03] Funding Source: Medline; NIGMS NIH HHS [F32 GM20246-01, GM38109, R37 GM038109, GM08152] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA070085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038109, F32GM020246, R37GM038109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, V2; AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, V4; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; Bracken C, 1999, J MOL BIOL, V285, P2133, DOI 10.1006/jmbi.1998.2429; Brown JH, 1996, PROTEINS, V26, P134; Cai ML, 1998, J BIOMOL NMR, V11, P97, DOI 10.1023/A:1008222131470; CANTAU B, 1980, J RECEPTOR RES, V1, P137, DOI 10.3109/10799898009044096; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2; Carruthers LM, 2000, METHOD ENZYMOL, V321, P66; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Deleage G, 1997, BIOCHIMIE, V79, P681, DOI 10.1016/S0300-9084(97)83524-9; Demeler B, 1998, BIOPHYS J, V74, P444, DOI 10.1016/S0006-3495(98)77802-6; Demeler B, 1997, BIOPHYS J, V72, P397, DOI 10.1016/S0006-3495(97)78680-6; Demeler B, 2000, METHOD ENZYMOL, V321, P38; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; GEISLER N, 1982, CELL, V30, P277, DOI 10.1016/0092-8674(82)90033-2; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P1002, DOI 10.1038/nsb1296-1002; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P1011, DOI 10.1038/nsb1296-1011; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; KING L, 1995, BIOCHEMISTRY-US, V34, P6770, DOI 10.1021/bi00020a023; KOHN WD, 1995, J BIOL CHEM, V270, P25495, DOI 10.1074/jbc.270.43.25495; Kohn WD, 1998, J MOL BIOL, V283, P993, DOI 10.1006/jmbi.1998.2125; LAUE TM, 1990, METHOD ENZYMOL, V182, P566; Loria JP, 1999, J BIOMOL NMR, V15, P151, DOI 10.1023/A:1008355631073; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; LUMB KJ, 1994, BIOCHEMISTRY-US, V33, P7361, DOI 10.1021/bi00189a042; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Miller JH., 1972, EXPT MOL GENETICS; Monera OD, 1996, PROTEIN ENG, V9, P353, DOI 10.1093/protein/9.4.353; MONERA OD, 1993, J BIOL CHEM, V268, P19218; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Nautiyal S, 1999, PROTEIN SCI, V8, P84; Ogihara NL, 1997, PROTEIN SCI, V6, P80; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PATEL LR, 1994, P NATL ACAD SCI USA, V91, P7360, DOI 10.1073/pnas.91.15.7360; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; POTEKHIN SA, 1994, PROTEIN ENG, V7, P1097, DOI 10.1093/protein/7.9.1097; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Radhakrishnan I, 1999, J MOL BIOL, V287, P859, DOI 10.1006/jmbi.1999.2658; RALSTON GB, 1993, INTRO ANAL ULTRACENT, P21; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; Steinmetz MO, 1998, EMBO J, V17, P1883, DOI 10.1093/emboj/17.7.1883; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Venters RA, 1996, J MOL BIOL, V264, P1101, DOI 10.1006/jmbi.1996.0699; Wagschal K, 1999, J MOL BIOL, V285, P785, DOI 10.1006/jmbi.1998.2284; Wagschal K, 1999, PROTEIN SCI, V8, P2312; Weigelt J, 1998, J AM CHEM SOC, V120, P10778, DOI 10.1021/ja982649y; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; Yang PK, 1999, BIOPOLYMERS, V50, P667, DOI 10.1002/(SICI)1097-0282(199911)50:6<667::AID-BIP11>3.0.CO;2-2; Zeng X, 1997, P NATL ACAD SCI USA, V94, P3673, DOI 10.1073/pnas.94.8.3673; Zhu G, 1999, J BIOMOL NMR, V13, P77, DOI 10.1023/A:1008398227519; Zolkiewski M, 1997, BIOCHEMISTRY-US, V36, P7876, DOI 10.1021/bi962947c	71	34	39	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					735	745		10.1074/jbc.M108604200	http://dx.doi.org/10.1074/jbc.M108604200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11679589	hybrid			2022-12-25	WOS:000173087900096
J	Rey, O; Sinnett-Smith, J; Zhukova, E; Rozengurt, E				Rey, O; Sinnett-Smith, J; Zhukova, E; Rozengurt, E			Regulated nucleocytoplasmic transport of protein kinase D in response to G protein-coupled receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; PLECKSTRIN HOMOLOGY DOMAIN; CYSTEINE-RICH MOTIFS; C-MU; MAP KINASE; PHORBOL ESTERS; CELL-NUCLEUS; PKC-MU; TRANSDUCTION PATHWAY; MITOGENIC RESPONSE	Protein kinase D (PKD)/protein kinase Cmu is a serine/ threonine protein kinase activated by growth factors, antigen-receptor engagement, and G protein-coupled receptor (GPCR) agonists via a phosphorylation-dependent mechanism that requires protein kinase C (PKC) activity. In order to investigate the dynamic mechanisms associated with GPCR signaling, the intracellular distribution of PKD was analyzed in live cells by imaging fluorescent protein-tagged PKD and in fixed cells by immunocytochemistry. We found that PKD shuttled between the cytoplasm and the nucleus in both fibroblasts and epithelial cells. Cell stimulation with mitogenic GPCR agonists that activate PKD induced a transient nuclear accumulation of PKD that was prevented by inhibiting PKC activity. The nuclear import of PKD requires its cys2 domain in conjunction with a nuclear import receptor, while its nuclear export requires its pleckstrin homology domain and a competent Crm1-dependent nuclear export pathway. This study thus characterizes the regulated nuclear transport of a signaling molecule in response to mitogenic GPCR agonists and positions PKD as a serine kinase whose kinase activity and intracellular localization is coordinated by PKC.	Univ Calif Los Angeles, Sch Med,Dept Med,Div Digest Dis, Unit Signal Transduct & Gastrointestinal Canc, CURE,Digest Dis Res Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med,Dept Med,Div Digest Dis, Unit Signal Transduct & Gastrointestinal Canc, CURE,Digest Dis Res Ctr, 900 Vet Ave,Warren Hall Rm 11-124, Los Angeles, CA 90095 USA.			Rey, Osvaldo/0000-0003-1575-9864	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, R37DK017294, R01DK017294] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 17294, DK56930, DK 55003, DK-55003-01S1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Buchner K, 2000, J CANCER RES CLIN, V126, P1, DOI 10.1007/PL00008458; CELIS JE, 1994, CELL BIOL LAB HDB, P79; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chiu T, 2001, AM J PHYSIOL-CELL PH, V280, pC929, DOI 10.1152/ajpcell.2001.280.4.C929; Chiu T, 2001, FEBS LETT, V489, P101, DOI 10.1016/S0014-5793(01)02076-2; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; FELDHERR C, 1992, NUCL TRAFFICKING, P137; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gama-Carvalho M, 2001, FEBS LETT, V498, P157, DOI 10.1016/S0014-5793(01)02487-5; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Mohamed AJ, 2000, J BIOL CHEM, V275, P40614, DOI 10.1074/jbc.M006952200; Moriguchi T, 1996, Adv Pharmacol, V36, P121, DOI 10.1016/S1054-3589(08)60579-7; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Paolucci L, 1999, CANCER RES, V59, P572; Perander M, 2001, J BIOL CHEM, V276, P13015, DOI 10.1074/jbc.M010356200; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rey O, 2001, BIOCHEM BIOPH RES CO, V287, P21, DOI 10.1006/bbrc.2001.5530; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yamaga M, 1999, J BIOL CHEM, V274, P28537, DOI 10.1074/jbc.274.40.28537; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	77	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49228	49235		10.1074/jbc.M109395200	http://dx.doi.org/10.1074/jbc.M109395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11641411	hybrid			2022-12-25	WOS:000173922100080
J	Kyritsis, C; Gorbulev, S; Hutschenreiter, S; Pawlitschko, K; Abele, R; Tampe, R				Kyritsis, C; Gorbulev, S; Hutschenreiter, S; Pawlitschko, K; Abele, R; Tampe, R			Molecular mechanism and structural aspects of transporter associated with antigen processing inhibition by the cytomegalovirus protein US6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; PEPTIDE BINDING; NUCLEOTIDE-BINDING; ENDOPLASMIC-RETICULUM; TAP TRANSPORTER; ACTIVE DOMAIN; HEAVY-CHAINS; ICP47; TRANSLOCATION; RECOGNITION	The human cytomegalovirus (HCMV) has evolved a set of elegant strategies to evade host immunity. The HCMV-encoded type I glycoprotein US6 inhibits peptide trafficking from the cytosol into the endoplasmic reticulum and subsequent peptide loading of major histocompatibility complex I molecules by blocking the transporter associated with antigen processing (TAP). We studied the molecular mechanism of TAP inhibition by US6 in vitro. By using purified US6 and human TAP co-reconstituted in proteoliposomes, we demonstrate that the isolated endoplasmic reticulum (ER)-luminal domain of US6 is essential and sufficient to block TAP-dependent peptide transport. Neither the overall amount of bound peptides nor the peptide affinity of TAP is affected by US6. Interestingly, US6 causes a specific arrest of the peptide-stimulated ATPase activity of TAP by preventing binding of ATP but not ADP. The affinity of the US6-TAP interaction was determined to 1 muM. The ER-luminal domain of US6 is monomeric in solution and consists of 19% alpha -helices, 25% beta -sheets, and 27% beta -turns. All eight cysteine residues are involved in forming a stabilizing network of four intramolecular disulfide bridges. Glycosylation of US6 is not required for function. These findings point to fascinating mechanistic and structural properties, by which specific binding of US6 at the ER-luminal loops of TA-P signals across the membrane to the nucleotide-binding domains to prevent ATP hydrolysis of TAP.	Univ Marburg, Inst Physiol Chem, D-35033 Marburg, Germany	Philipps University Marburg	Tampe, R (corresponding author), Univ Frankfurt, Inst Biochem, Bioctr, Marie Curie Str 9, D-60439 Frankfurt, Germany.		Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Abele R, 1999, BBA-BIOMEMBRANES, V1461, P405, DOI 10.1016/S0005-2736(99)00171-6; Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; Alberts P, 2001, CURR BIOL, V11, P242, DOI 10.1016/S0960-9822(01)00073-2; Beinert D, 1997, BIOCHEMISTRY-US, V36, P4694, DOI 10.1021/bi962940v; Cresswell P, 2000, TRAFFIC, V1, P301, DOI 10.1034/j.1600-0854.2000.010402.x; ELLMAN GL, 1967, J LAB CLIN MED, V70, P518; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; Gewurz BE, 2001, P NATL ACAD SCI USA, V98, P6794, DOI 10.1073/pnas.121172898; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; Hengel H, 1997, CURR OPIN IMMUNOL, V9, P470, DOI 10.1016/S0952-7915(97)80097-0; Hengel H, 1997, IMMUNITY, V6, P623, DOI 10.1016/S1074-7613(00)80350-7; Hewitt EW, 2001, EMBO J, V20, P387, DOI 10.1093/emboj/20.3.387; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; Jones TR, 1996, P NATL ACAD SCI USA, V93, P11327, DOI 10.1073/pnas.93.21.11327; Karttunen JT, 2001, P NATL ACAD SCI USA, V98, P7431, DOI 10.1073/pnas.121180198; Knittler MR, 1999, CURR BIOL, V9, P999, DOI 10.1016/S0960-9822(99)80448-5; Lapinski PE, 2001, J BIOL CHEM, V276, P7526, DOI 10.1074/jbc.M009448200; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MULLER KM, 1994, J BIOL CHEM, V269, P14032; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Neumann L, 1997, J MOL BIOL, V272, P484, DOI 10.1006/jmbi.1997.1282; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Pfander R, 1999, BIOCHEMISTRY-US, V38, P13692, DOI 10.1021/bi9909647; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; RUSS G, 1995, J BIOL CHEM, V270, P21312, DOI 10.1074/jbc.270.36.21312; Saveanu L, 2001, J BIOL CHEM, V276, P22107, DOI 10.1074/jbc.M011221200; Sweet C, 1999, FEMS MICROBIOL REV, V23, P457, DOI 10.1111/j.1574-6976.1999.tb00408.x; Tomazin R, 1996, EMBO J, V15, P3256, DOI 10.1002/j.1460-2075.1996.tb00690.x; Uebel S, 1997, P NATL ACAD SCI USA, V94, P8976, DOI 10.1073/pnas.94.17.8976; Uebel S, 1999, CURR OPIN IMMUNOL, V11, P203, DOI 10.1016/S0952-7915(99)80034-X; UEBEL S, 1995, J BIOL CHEM, V270, P18512, DOI 10.1074/jbc.270.31.18512; Uebel S, 1997, FEBS LETT, V416, P359, DOI 10.1016/S0014-5793(97)01222-2; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	38	80	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48031	48039		10.1074/jbc.M108528200	http://dx.doi.org/10.1074/jbc.M108528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606590	hybrid			2022-12-25	WOS:000172927000042
J	Bhandari, P; Shashidhara, LS				Bhandari, P; Shashidhara, LS			Studies on human colon cancer gene APC by targeted expression in Drosophila	ONCOGENE			English	Article						colorectal cancer; APC; beta-catenin; drug screening; transgenic Drosophila	LONG-RANGE ACTION; BETA-CATENIN; ADENOMATOUS POLYPOSIS; MORPHOGENETIC FURROW; ADULT ABDOMEN; CELL FATES; WINGLESS; EYE; PROTEIN; ARMADILLO	Mutations in human Adenomatous Polyposis Coli (APC) gene are associated with both familial and sporadic colorectal tumors. APC is known to down regulate beta -catenin levels, a transducer of Wnt signaling. The aim of this study is to provide transgenic Drosophila expressing either full-length or truncated forms of human APC (hAPC) protein and methods for using them in functional,genomics and drug screening. Consistent with its biochemical properties, targeted expression of either full-length hAPC or its beta -catenin binding domain alone negatively regulated the function of the beta -catenin homologue, Armadillo (Arm) and thereby, inhibited Wnt/Wg signaling during fly development. hAPC inhibited Arm function even in the absence of GSK-3 beta activity, although the latter was required to mediate the degradation of Arm. Consistent with this, hAPC suppressed the phenotypes induced by the over-expression of degradation-resistant forms of Arm. Subsequently, using hAPC-induced eye phenotypes as the assay in a suppressor-enhancer screen, we have identified two new loci in Drosophila, which modulate Wnt/Wg signaling. In addition, an anti-colon cancer drug, indomethacin, specifically enhanced hAPC-induced phenotypes.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Shashidhara, LS (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	shashi@gene.ccmbindia.org						Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; Deshpande N, 1997, J BIOL CHEM, V272, P10664; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fossgreen A, 1998, P NATL ACAD SCI USA, V95, P13703, DOI 10.1073/pnas.95.23.13703; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Friedl W, 1996, HUM GENET, V97, P579; GHYSEN A, 1989, DEVELOPMENT, V105, P35; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; Hazelett DJ, 1998, DEVELOPMENT, V125, P3741; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HELD LI, 1994, ROUX ARCH DEV BIOL, V203, P310, DOI 10.1007/BF00457802; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kopp A, 1999, DEVELOPMENT, V126, P3495; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARDON G, 1994, DEVELOPMENT, V120, P3473; Morimura S, 1996, DEV BIOL, V177, P136, DOI 10.1006/dbio.1996.0151; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Pai LM, 1997, DEVELOPMENT, V124, P2255; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Pignoni F, 1997, DEVELOPMENT, V124, P271; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Rao Y, 1998, P NATL ACAD SCI USA, V95, P2077, DOI 10.1073/pnas.95.5.2077; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Scott RJ, 1996, HUM MOL GENET, V5, P1921, DOI 10.1093/hmg/5.12.1921; Shashidhara LS, 1999, DEV BIOL, V212, P491, DOI 10.1006/dbio.1999.9341; Shih IM, 2000, CANCER RES, V60, P1671; Shirras AD, 1996, DEV BIOL, V175, P24, DOI 10.1006/dbio.1996.0092; SIMMONDS AJ, 1995, NATURE, V376, P424, DOI 10.1038/376424a0; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Steitz MC, 1998, DEV BIOL, V197, P218, DOI 10.1006/dbio.1998.8884; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thomas BI, 1999, TRENDS GENET, V15, P184, DOI 10.1016/S0168-9525(99)01720-5; TREISMAN JE, 1995, DEVELOPMENT, V121, P3519; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu J, 1999, DEVELOPMENT, V126, P109; Yamaguchi M, 1999, ONCOGENE, V18, P6767, DOI 10.1038/sj.onc.1203113; YOFFE KB, 1995, DEV BIOL, V170, P636, DOI 10.1006/dbio.1995.1243; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	57	16	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6871	6880		10.1038/sj.onc.1204849	http://dx.doi.org/10.1038/sj.onc.1204849			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687966				2022-12-25	WOS:000171641000008
J	Atamna, H; Robinson, C; Ingersoll, R; Elliott, H; Ames, BN				Atamna, H; Robinson, C; Ingersoll, R; Elliott, H; Ames, BN			N-t-butyl hydroxylamine is an antioxidant that reverses age-related changes in mitochondria in vivo and in vitro	FASEB JOURNAL			English	Article						NtBHA; senescence; proteasome; growth factors	FLOW CYTOMETRIC ANALYSIS; OLD HUMAN-FIBROBLASTS; ACETYL-L-CARNITINE; OXIDATIVE DAMAGE; CALORIC RESTRICTION; PROTEIN OXIDATION; ACRIDINE-ORANGE; THYROID-HORMONE; RAT HEPATOCYTES; NITRIC-OXIDE	N-t-butyl hydroxylamine (NtBHA) delays senescence-dependent changes in human lung fibroblasts (IMR90) (Atamna et al., J. Biol. Chem. 275, 6741-6748). The current study examines the effect of NtBHA on mitochondria in old and young rats and human primary fibroblasts (IMR90). In NtBHA-treated rats, the age-dependent decline in food consumption and ambulatory activity was reversed without affecting body weight. The respiratory control ratio of mitochondria from liver of old rats improved after feeding NtBHA. These findings suggest that NtBHA improved mitochondrial function in vivo. The age-dependent increase in proteins with thiol-mixed disulfides was significantly lower in old rats treated with NtBHA. NtBHA was effective only in old rats; no significant effect was observed in young rats. In IMR90 cells, NtBHA delayed senescence-associated changes in mitochondria and cellular senescence induced by maintaining the cells under suboptimal levels of growth factors. Proteasomal activity was also higher in cells treated with NtBHA than in untreated cells. NtBHA accumulates in cells 10- to 15-fold the extracellular concentration and is maintained by mitochondrial NADH. NtBHA is an antioxidant that is recycled by mitochondrial electron transport chain and prevents radical-induced toxicity to mitochondria.	Univ Calif Berkeley, CHORI, Dept Mol & Cell Biol, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California Berkeley	Ames, BN (corresponding author), Univ Calif Berkeley, CHORI, Dept Mol & Cell Biol, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	bnames@uclink4.berkeley.edu			NIA NIH HHS [AG17140] Funding Source: Medline; NIEHS NIH HHS [ES01896] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017140] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Atamna H, 2000, J BIOL CHEM, V275, P6741, DOI 10.1074/jbc.275.10.6741; Atamna H, 2000, P NATL ACAD SCI USA, V97, P686, DOI 10.1073/pnas.97.2.686; Barja G, 1998, ANN NY ACAD SCI, V854, P224, DOI 10.1111/j.1749-6632.1998.tb09905.x; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Beckman KB, 1998, ANN NY ACAD SCI, V854, P118, DOI 10.1111/j.1749-6632.1998.tb09897.x; BENEL L, 1989, BASIC APPL HISTOCHEM, V33, P71; BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; CHAMULITRAT W, 1995, FREE RADICAL RES, V23, P1, DOI 10.3109/10715769509064014; CHAMULITRAT W, 1993, J BIOL CHEM, V268, P11520; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; DARZYNKIEWICZ Z, 1981, P NATL ACAD SCI-BIOL, V78, P2383, DOI 10.1073/pnas.78.4.2383; de Grey ADNJ, 2000, ARCH BIOCHEM BIOPHYS, V373, P295, DOI 10.1006/abbi.1999.1509; DEALMEIDA AF, 1989, INT J BIOCHEM, V21, P937, DOI 10.1016/0020-711X(89)90295-4; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; Dikalov SI, 1999, J BIOL CHEM, V274, P9392, DOI 10.1074/jbc.274.14.9392; DJOUADI F, 1994, AM J PHYSIOL, V267, pC245, DOI 10.1152/ajpcell.1994.267.1.C245; DUMAS M, 1995, CR ACAD SCI III-VIE, V318, P191; FEUERS RJ, 1989, MECH AGEING DEV, V48, P179, DOI 10.1016/0047-6374(89)90049-3; FISHER HF, 1985, METHOD ENZYMOL, V113, P16; Gabbita SP, 1997, FREE RADICAL BIO MED, V23, P191, DOI 10.1016/S0891-5849(97)00043-9; GORDON MN, 1988, ENDOCRINOLOGY, V122, P726, DOI 10.1210/endo-122-2-726; Hack V, 1998, BLOOD, V92, P59, DOI 10.1182/blood.V92.1.59.413a05_59_67; Hagen TM, 1998, ANN NY ACAD SCI, V854, P214, DOI 10.1111/j.1749-6632.1998.tb09904.x; Hagen TM, 1999, FASEB J, V13, P411, DOI 10.1096/fasebj.13.2.411; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hagen TM, 1998, P NATL ACAD SCI USA, V95, P9562, DOI 10.1073/pnas.95.16.9562; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; HARDY L, 1991, BIOCHEM J, V274, P133, DOI 10.1042/bj2740133; Harman D, 1998, ANN NY ACAD SCI, V854, P1, DOI 10.1111/j.1749-6632.1998.tb09886.x; Harman D, 1998, J Int Fed Clin Chem, V10, P24; Kotake Y, 1999, ANTIOXID REDOX SIGN, V1, P481, DOI 10.1089/ars.1999.1.4-481; LAGERCRANTZ C, 1991, FREE RADICAL RES COM, V14, P395, DOI 10.3109/10715769109093428; LEE CY, 1982, METHOD ENZYMOL, V89, P252; LEQUOC D, 1989, ARCH BIOCHEM BIOPHYS, V273, P466, DOI 10.1016/0003-9861(89)90506-7; LIZARD G, 1990, CYTOTECHNOLOGY, V3, P179, DOI 10.1007/BF00143680; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P247, DOI 10.1111/j.1432-1033.1992.tb17044.x; Lykkesfeldt J, 1998, FASEB J, V12, P1183, DOI 10.1096/fasebj.12.12.1183; MARTINEZ AO, 1987, MECH AGEING DEV, V39, P1, DOI 10.1016/0047-6374(87)90081-9; MARTINEZ AO, 1991, GROWTH DEVELOP AGING, V55, P185; Nakahara H, 1998, FREE RADICAL BIO MED, V24, P85, DOI 10.1016/S0891-5849(97)00164-0; NELSON BD, 1995, BBA-MOL BASIS DIS, V1271, P85, DOI 10.1016/0925-4439(95)00014-U; PACKER L, 1994, ANN NY ACAD SCI, V738, P257; PARADIES FMR, 1993, B MOL BIOL MED, V18, P89; Prieur B, 1998, EUR J BIOCHEM, V252, P194, DOI 10.1046/j.1432-1327.1998.2520194.x; Raha S, 2000, FREE RADICAL BIO MED, V29, P170, DOI 10.1016/S0891-5849(00)00338-5; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; Sastre J, 2000, FREE RADICAL RES, V32, P189, DOI 10.1080/10715760000300201; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SHUKLA SP, 1968, EXP GERONTOL, V3, P31, DOI 10.1016/0531-5565(68)90053-3; SIES H, 1977, EUR J BIOCHEM, V72, P301, DOI 10.1111/j.1432-1033.1977.tb11253.x; Sitte N, 2000, FREE RADICAL BIO MED, V28, P701, DOI 10.1016/S0891-5849(99)00279-8; Stadtman ER, 1997, CHEM RES TOXICOL, V10, P485, DOI 10.1021/tx960133r; STIO M, 1994, BIOCHEM CELL BIOL, V72, P58, DOI 10.1139/o94-010; TORII K, 1992, AM J RESP CELL MOL, V6, P88, DOI 10.1165/ajrcmb/6.1.88; TYLER DD, 1992, RESP ENZYME SYSTEMS; WILKINSON RF, 1993, ART SCI TISSUE CULTU, V12, P1; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; WULF JH, 1975, EXP GERONTOL, V10, P101, DOI 10.1016/0531-5565(75)90040-6; Zhou ZX, 2000, J HISTOCHEM CYTOCHEM, V48, P585, DOI 10.1177/002215540004800502	64	41	42	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2196	2204		10.1096/fj.01-0134com	http://dx.doi.org/10.1096/fj.01-0134com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641246				2022-12-25	WOS:000171920400031
J	You, KR; Wen, J; Lee, ST; Kim, DG				You, KR; Wen, J; Lee, ST; Kim, DG			Cytochrome c oxidase subunit III - A molecular marker for N-(4-hydroxyphenyl)retinamide-induced oxidative stress in hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERVICAL-CARCINOMA CELLS; RETINOIC ACID; GENE-EXPRESSION; MESSENGER-RNA; APOPTOSIS; MITOCHONDRIA; RETINAMIDE; INDUCTION; CANCER; CONSTRUCTION	N-(4-hydroxyphenyl)retinamide (4HPR), a chemopreventive and chemotherapeutic retinoid, induces apoptosis in various types of cells. Currently, oxidative mitochondrial damage is thought to cause 4HPR-induced apoptosis, although the exact mechanism has not yet been clarified. 4HPR effectively induces apoptosis in hepatoma cells although the susceptibility differs in a cell-specific manner. Hep-3B and PLC/PRF/5 cells were more susceptible to 4HPR than were Hep-G2 and SK-HEP-1 cells, and the resistance to 4HPR seems to be related to growth inhibition (G(1) arrest). We further observed that 4HPR specifically down-regulates cytochrome c oxidase subunit III (CO III) transcript levels through destabilization of its mRNA and thus decreases the activity of cytochrome c oxidase (complex IV). To explore the mechanism whereby the CO III transcript was decreased by 4HPR, we used adenine nucleotide translocator (ANT) ligands, which modulate mitochondrial transmembrane potential (Deltapsi(m)) without altering CO III transcription. Intriguingly, bongkrekic acid, a specific ANT inhibitor, enhanced 4HPR-induced Deltapsi(m). disruption, which in turn decreased the level of CO III transcripts, which was accompanied by increases in the generation of reactive oxygen species and in apoptosis. In contrast, atractyloside, an activator of ANT, inhibited those 4HPR-induced effects. Taken together, these results indicate that down-regulation of CO III, a molecular marker of oxidative stress, may result from upstream Deltapsi(m) disruption and that ligands of ANT may be capable of modulating 4HPR-induced oxidative stress and apoptosis.	Chonbuk Natl Univ, Med Sch & Hosp, Dept Internal Med, Div Gastroenterol & Hepatol Dukjin Ku Inst Mol Bi, Chonju 561712, South Korea	Jeonbuk National University	Kim, DG (corresponding author), Chonbuk Natl Univ, Med Sch & Hosp, Dept Internal Med,Inst Mol Biol, Div Gastroenterol & Hepatol, Dukjin Ku, Chonju 561712, South Korea.							ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; BAE IS, 1995, CANCER RES, V55, P2387; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CHOI SS, 1995, MAMM GENOME, V6, P653, DOI 10.1007/BF00352374; Crompton M, 1999, BIOCHEM SOC SYMP, V66, P167, DOI 10.1042/bss0660167; DELIA D, 1993, CANCER RES, V53, P6036; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; Doerner A, 1997, FEBS LETT, V414, P258, DOI 10.1016/S0014-5793(97)01000-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Elliot RM, 1999, FREE RADICAL BIO MED, V26, P646, DOI 10.1016/S0891-5849(98)00235-4; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; HEERDT BG, 1991, J BIOL CHEM, V266, P19120; KADENBACH B, 1981, FEBS LETT, V135, P1, DOI 10.1016/0014-5793(81)80932-5; KADOWAKI T, 1991, EXP CELL RES, V192, P243, DOI 10.1016/0014-4827(91)90182-T; Kim DG, 1996, CANCER LETT, V107, P149, DOI 10.1016/0304-3835(96)04407-2; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lippman SC, 2000, J NUTR, V130, p479S, DOI 10.1093/jn/130.2.479S; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MONTOYA J, 1981, NATURE, V290, P465, DOI 10.1038/290465a0; MOON RC, 1979, CANCER RES, V39, P1339; MORIN PE, 1991, BIOCHEMISTRY-US, V30, P8494, DOI 10.1021/bi00098a030; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; PAPADOPOULOU LC, 1993, CANCER RES, V53, P1072; Papadopoulou LC, 1996, BIOCHEM PHARMACOL, V52, P713, DOI 10.1016/0006-2952(96)00349-8; Papadopoulou LC, 1999, BIOCHEM PHARMACOL, V57, P481, DOI 10.1016/S0006-2952(98)00305-0; PENG YM, 1989, INT J CANCER, V43, P22, DOI 10.1002/ijc.2910430106; PERLMAN R, 1970, NATURE, V227, P133; PONZONI M, 1995, CANCER RES, V55, P853; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; Seidl J, 2001, INT J CANCER, V92, P671, DOI 10.1002/1097-0215(20010601)92:5<671::AID-IJC1240>3.0.CO;2-P; Sun SY, 1999, MOL PHARMACOL, V55, P403; Sun SY, 1999, CANCER RES, V59, P2493; Supino R, 1996, INT J CANCER, V65, P491, DOI 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; SZABO I, 1993, FEBS LETT, V330, P206, DOI 10.1016/0014-5793(93)80274-X; Tamura K, 1997, CARCINOGENESIS, V18, P2133, DOI 10.1093/carcin/18.11.2133; VINCI AD, 1994, INT J CANCER, V59, P422; Weinberg JM, 2000, P NATL ACAD SCI USA, V97, P2826, DOI 10.1073/pnas.97.6.2826; WILSON KS, 1990, ARCH BIOCHEM BIOPHYS, V282, P413, DOI 10.1016/0003-9861(90)90137-N; Wu SL, 1995, BIOCHEMISTRY-US, V34, P16298, DOI 10.1021/bi00050a009; YANG J, 1997, SCIENCE, V275, P1081; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; Zheng Y, 1997, CARCINOGENESIS, V18, P2119, DOI 10.1093/carcin/18.11.2119	53	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 8	2002	277	6					3870	3877		10.1074/jbc.M109284200	http://dx.doi.org/10.1074/jbc.M109284200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	520ZP	11698412	hybrid			2022-12-25	WOS:000173813900012
J	Roussel, A; Miled, N; Berti-Dupuis, L; Riviere, M; Spinelli, S; Berna, P; Gruber, V; Verger, R; Cambillau, C				Roussel, A; Miled, N; Berti-Dupuis, L; Riviere, M; Spinelli, S; Berna, P; Gruber, V; Verger, R; Cambillau, C			Crystal structure of the open form of dog gastric lipase in complex with a phosphonate inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFACIAL ACTIVATION; LIPOLYTIC ENZYME; TRIAD FORMS; PROTEIN; PURIFICATION; CUTINASE; MODEL; SITE	Fat digestion in humans and some mammals such as dogs requires the successive intervention of two lipases: gastric lipase, which is stable and active despite the highly acidic stomach environment, followed by the classical pancreatic lipase secreted into the duodenum. We previously solved the structure of recombinant human gastric lipase (HGL) at 3.0-Angstrom resolution in its closed form; this was the first structure to be described within the mammalian acid lipase family. Here we report on the open structure of the recombinant dog gastric lipase (r-DGL) at 2.7-Angstrom resolution in complex with the undecylbutyl (C11Y4) phosphonate inhibitor. HGL and r-DGL show 85.7% amino acid sequence identity, which makes it relevant to compare the forms from two different species. The open r-DGL structure confirms the previous description of the HGL catalytic triad (Ser(153), His(353), and Asp(324)) with the catalytic serine buried and an oxy-anion hole (NH groups of Gln(154) and Leu(67)). In r-DGL, the binding of the C11Y4 phosphonate inhibitor induces part of the cap domain, the lid, to roll over the enzyme surface and to expose a catalytic crevice measuring similar to20 x 20 x 7 Angstrom(3). The C11Y4 phosphonate fits into this crevice, and a molecule of beta-octyl glucoside fills up the crevice. The C11Y4 phosphonate inhibitor and the detergent molecule suggest a possible binding mode for the natural substrates, the triglyceride molecules.	CNRS, UMR 6098, AFMB, F-13402 Marseille 20, France; CNRS, UPR 9025, Lab Lipolyse Enzymat, F-13402 Marseille 20, France; Parke Davis & Co, Inst Rech Jouveinal, Dept Biochem & Enzymol, F-94265 Fresnes, France; Meristem Therapeut, ZI Brezet, F-63100 Clermont Ferrand, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Pfizer	Verger, R (corresponding author), CNRS, UMR 6098, AFMB, 31 Chem Joseph Aiguier, F-13402 Marseille 20, France.	verger@ibsm.cnrs-mrs.fr; cambillau@afmb.cnrs-mrs.fr	Miled, Nabil/ABC-6773-2020; berti, liliane/F-5878-2011	Miled, Nabil/0000-0001-7445-6324; 				Armstrong C. L., 1991, Maize Genetics Cooperation News Letter, P92; BENICOURT C, 1993, INT CONGR SER, V1034, P291; BLANCHARD C, 1994, Patent No. 9413816; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BRUNGER AT, 1996, X PLOR VERSION 3 843; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; Campanacci V, 2001, J BIOL CHEM, V276, P20078, DOI 10.1074/jbc.M100713200; CARRIERE F, 1991, EUR J BIOCHEM, V202, P75, DOI 10.1111/j.1432-1033.1991.tb16346.x; CARRIERE P, 1994, LIPASES THEIR STRUCT, P181; Cavalier JF, 1999, CHEM PHYS LIPIDS, V100, P3, DOI 10.1016/S0009-3084(99)00028-6; CYGLER M, 1994, J AM CHEM SOC, V116, P3180, DOI 10.1021/ja00087a002; DEPICKER A, 1982, Journal of Molecular and Applied Genetics, V1, P561; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; EGLOFF MP, 1995, BIOCHEMISTRY-US, V34, P2751, DOI 10.1021/bi00009a003; GARGOURI Y, 1986, GASTROENTEROLOGY, V91, P919, DOI 10.1016/0016-5085(86)90695-5; GARGOURI Y, 1988, J BIOL CHEM, V263, P2159; GROCHULSKI P, 1994, BIOCHEMISTRY-US, V33, P3494, DOI 10.1021/bi00178a005; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; Gruber V, 2001, MOL BREEDING, V7, P329, DOI 10.1023/A:1011653220724; HAMOSH M, 1994, PHYSL GASTROINTESTIN, V1, P1239; Joliff G, 1998, BIOTECHNOL LETT, V20, P697, DOI 10.1023/A:1005330826017; JUNIEN JL, 1991, Patent No. 0261016; JUNIEN JL, 1993, Patent No. 5075231; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; MARGUET F, 1994, BBA-LIPID LIPID MET, V1210, P157, DOI 10.1016/0005-2760(94)90116-3; MARTINEZ C, 1994, BIOCHEMISTRY-US, V33, P83, DOI 10.1021/bi00167a011; MARTINEZ C, 1992, NATURE, V356, P615, DOI 10.1038/356615a0; MCELROY D, 1991, MOL GEN GENET, V231, P150, DOI 10.1007/BF00293832; MOREAU H, 1988, BIOCHIM BIOPHYS ACTA, V959, P247, DOI 10.1016/0005-2760(88)90197-X; MOREAU H, 1988, FEBS LETT, V236, P383, DOI 10.1016/0014-5793(88)80061-9; MOREAU H, 1988, BIOCHIM BIOPHYS ACTA, V960, P286, DOI 10.1016/0005-2760(88)90036-7; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOBLE MEM, 1993, FEBS LETT, V331, P123, DOI 10.1016/0014-5793(93)80310-Q; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REINA M, 1990, NUCLEIC ACIDS RES, V18, P6426, DOI 10.1093/nar/18.21.6426; Roussel A, 1999, J BIOL CHEM, V274, P16995, DOI 10.1074/jbc.274.24.16995; Roussel A, 1991, SILICON GRAPHICS GEO, P86; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THOMPSON CJ, 1987, EMBO J, V6, P2519, DOI 10.1002/j.1460-2075.1987.tb02538.x; Tomes D. T., 1995, P197; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	47	101	106	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2266	2274		10.1074/jbc.M109484200	http://dx.doi.org/10.1074/jbc.M109484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11689574	hybrid			2022-12-25	WOS:000173421300087
J	Walters, MR; Dutertre, M; Smith, CL				Walters, MR; Dutertre, M; Smith, CL			SKF-82958 is a subtype-selective estrogen receptor-alpha (ER alpha) agonist that induces functional interactions between ER alpha and AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDEPENDENT ACTIVATION; CHICKEN PROGESTERONE-RECEPTOR; DEPENDENT TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; CHROMOSOMAL LOCALIZATION; MEDIATED TRANSCRIPTION; CONFORMATIONAL-CHANGES; BINDING-PROTEIN; KINASE PATHWAY; PHOSPHORYLATION	The transcriptional activity of estrogen receptors (ERs) can be regulated by ligands as well as agents such as dopamine, which stimulate intracellular signaling pathways able to communicate with these receptors. We examined the ability of SKF-82958 (SKIP), a previously characterized full dopamine D1 receptor agonist, to stimulate the transcriptional activity of ERalpha and ERbeta. Treatment of HeLa cells with SKF-82958 stimulated robust ERalpha-dependent transcription from an estrogen-response element-E1b-CAT reporter in the absence of estrogen, and this was accompanied by increased receptor phosphorylation. However, induction of ERbeta-directed gene expression under the same conditions was negligible. In our cell model, SKIP treatment did not elevate cAMP levels nor enhance transcription from a cAMP-response element-linked reporter. Control studies revealed that SKF-82958, but not dopamine, competes with 17beta-estradiol for binding to ERalpha or ERbeta with comparable relative binding affinities. Therefore, SKF-82958 is an ERalpha-selective agonist. Transcriptional activation of ERalpha by SKIP was more potent than expected from its relative binding activity, and further examination revealed that this synthetic compound induced expression of an AP-1 target gene in a tetradecanoylphorbol-13-acetate-response element (TRE)-dependent manner. A putative TRE site upstream of the estrogen-response element and the amino-terminal domain of the receptor contributed to, but were not required for, SKF-induced expression of an ERalpha-dependent reporter gene. Overexpression of the AP-1 protein c-Jun, but not c-Fos, strongly enhanced SKF-induced ERalpha target gene expression but only when the TRE was present. These studies provide information on the ability of a ligand that weakly stimulates ERalpha to yield strong stimulation of ERalpha-dependent gene expression through cross-talk with other intracellular signaling pathways producing a robust combinatorial response within the cell.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Tulane Univ, Sch Med, Dept Physiol, New Orleans, LA 70112 USA	Baylor College of Medicine; Tulane University	Smith, CL (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	carolyns@bcm.tmc.edu	DUTERTRE, Martin/Q-1815-2019; Dutertre, Martin/N-7060-2017	DUTERTRE, Martin/0000-0003-0278-4120; Dutertre, Martin/0000-0003-0278-4120	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053002] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53002] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Anstead GM, 1997, STEROIDS, V62, P268, DOI 10.1016/S0039-128X(96)00242-5; Apostolakis EM, 1996, J NEUROSCI, V16, P4823; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Asghar M, 2001, EUR J PHARMACOL, V411, P61, DOI 10.1016/S0014-2999(00)00896-7; BAI WL, 1994, MOL ENDOCRINOL, V8, P1465, DOI 10.1210/me.8.11.1465; Bai WL, 1997, J BIOL CHEM, V272, P10457; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P2122, DOI 10.1073/pnas.90.6.2122; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Delaunay F, 2000, MOL PHARMACOL, V58, P584, DOI 10.1124/mol.58.3.584; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Gaido KW, 1999, ENDOCRINOLOGY, V140, P5746, DOI 10.1210/en.140.12.5746; Gangolli EA, 1997, J STEROID BIOCHEM, V61, P1, DOI 10.1016/S0960-0760(97)00003-4; Gorelova NA, 2000, J NEUROPHYSIOL, V84, P75, DOI 10.1152/jn.2000.84.1.75; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JENNER P, 1995, NEUROLOGY, V45, P6; JORDAN VC, 1984, PHARMACOL REV, V36, P245; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katz JL, 1999, J PHARMACOL EXP THER, V291, P265; Kraichely DM, 2000, ENDOCRINOLOGY, V141, P3534, DOI 10.1210/en.141.10.3534; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KURTEN RC, 1989, ENDOCRINOLOGY, V125, P1345, DOI 10.1210/endo-125-3-1345; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Larrea F, 2001, ENDOCRINOLOGY, V142, P3791, DOI 10.1210/en.142.9.3791; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; MANI SK, 1994, SCIENCE, V265, P1246, DOI 10.1126/science.7915049; Mani SK, 1996, MOL ENDOCRINOL, V10, P1728, DOI 10.1210/me.10.12.1728; MATKOVITS T, 1995, MOL ENDOCRINOL, V9, P232, DOI 10.1210/me.9.2.232; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MURRAY AM, 1989, EUR J PHARMACOL, V160, P377, DOI 10.1016/0014-2999(89)90093-9; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; OBOYLE KM, 1989, NEUROPHARMACOLOGY, V28, P401, DOI 10.1016/0028-3908(89)90036-1; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Patrone C, 1996, MOL ENDOCRINOL, V10, P499, DOI 10.1210/me.10.5.499; PHAM TA, 1991, P NATL ACAD SCI USA, V88, P3125, DOI 10.1073/pnas.88.8.3125; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Riby JE, 2000, BIOCHEM PHARMACOL, V60, P167, DOI 10.1016/S0006-2952(00)00307-5; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; Sun J, 1999, ENDOCRINOLOGY, V140, P800, DOI 10.1210/en.140.2.800; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tremblay A, 2001, J STEROID BIOCHEM, V77, P19, DOI 10.1016/S0960-0760(01)00031-0; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; Xing WR, 1998, MOL ENDOCRINOL, V12, P1310, DOI 10.1210/me.12.9.1310	88	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1669	1679		10.1074/jbc.M109320200	http://dx.doi.org/10.1074/jbc.M109320200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11700319	hybrid			2022-12-25	WOS:000173421300009
J	Yoshikawa, T; Shimano, H; Yahagi, N; Ide, T; Amemiya-Kudo, M; Matsuzaka, T; Nakakuki, M; Tomita, S; Okazaki, H; Tamura, Y; Iizuka, Y; Ohashi, K; Takahashi, A; Sone, H; Osuga, J; Gotoda, T; Ishibashi, S; Yamada, N				Yoshikawa, T; Shimano, H; Yahagi, N; Ide, T; Amemiya-Kudo, M; Matsuzaka, T; Nakakuki, M; Tomita, S; Okazaki, H; Tamura, Y; Iizuka, Y; Ohashi, K; Takahashi, A; Sone, H; Osuga, J; Gotoda, T; Ishibashi, S; Yamada, N			Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; TRANSCRIPTION FACTOR; TRANSGENIC MICE; GENE-EXPRESSION; MESSENGER-RNAS; CHOLESTEROL; ALPHA; MOUSE; PATHWAY; MECHANISM	Previous studies have demonstrated that polyunsaturated fatty acids (PUFAs) suppress sterol regulatory element-binding protein 1c (SREBP-1c) expression and, thus, lipogenesis. In the current study, the molecular mechanism for this suppressive effect was investigated with luciferase reporter gene assays using the SREBP-1c promoter in HEK293 cells. Consistent with previous data, the addition of PUFAs to the medium in the assays robustly inhibited the SREBP-1c promoter activity. Deletion and mutation of the two liver X receptor (LXR)-responsive elements (LXREs) in the SREBP-1c promoter region eliminated this suppressive effect, indicating that both LXREs are important PUFA-suppressive elements. The luciferase activities of both SREBP-1c promoter and LXRE enhancer constructs induced by co-expression of LXRalpha or -beta were strongly suppressed by the addition of various PUFAs (arachidonic acid > eicosapentaenoic acid > docosahexaenoic acid > linoleic acid), whereas saturated or mono-unsaturated fatty acids had minimal effects. Gel shift mobility and ligand binding domain activation assays demonstrated that PUFA suppression of SREBP-1c expression is mediated through its competition with LXR ligand in the activation of the ligand binding domain of LXR, thereby inhibiting binding of LXP/retinoid X receptor heterodimer to the LXREs in the SREBP-le promoter. These data suggest that PUFAs could be deeply involved in nutritional regulation of cellular fatty acid levels by inhibiting an LXR-SREBP-1c system crucial for lipogenesis.	Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tokyo, Fac Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan	University of Tsukuba; University of Tokyo	Shimano, H (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Internal Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.		Yahagi, Naoya/D-2360-2014; Sone, Hirohito/ABC-9346-2021; Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020	Yahagi, Naoya/0000-0002-1823-1865; Sone, Hirohito/0000-0003-1263-2817; Shimano, Hitoshi/0000-0002-5562-5572; 				Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	38	296	309	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1705	1711		10.1074/jbc.M105711200	http://dx.doi.org/10.1074/jbc.M105711200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11694526	hybrid			2022-12-25	WOS:000173421300013
J	Linder, MD; Morkunaite-Haimi, S; Kinnumen, PKJ; Bernardi, P; Eriksson, O				Linder, MD; Morkunaite-Haimi, S; Kinnumen, PKJ; Bernardi, P; Eriksson, O			Ligand-selective modulation of the permeability transition pore by arginine modification. Opposing effects of p-hydroxyphenylglyoxal and phenylglyoxal.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; ADP/ATP CARRIER; MEMBRANE; CHANNEL; MITOCHONDRIA; INHIBITION; SITE; CYCLOPHILIN; TRANSPORT; CA2+	Chemical modification of mitochondria with the arginine-specific reagents phenylglyoxal (PGO) and 2,3-butanedione (BAD) decreases the Ca2+ sensitivity of the permeability transition pore (PTP) and stabilizes it in the closed conformation (Eriksson, O., Fontaine, E., and Bernardi, P. (1998) J Biof,. Chem. 273,12669-12674). Unexpectedly, modification of mitochondria with the arginine-specific reagent p-hydroxyphenylglyoxal (OH- PGO) resulted instead in PTP opening. Sequential modification with OH-PGO and PGO (or BAD) revealed that the effects on the PTP depended on the order of the additions. PTP opening was observed when OH-PGO preceded, and PTP closing was observed when OH-PGO followed, the addition of PGO (or BAD). The differential effects of OH-PGO and PGO on the PTP open probability (i) were not modified by the conformation-specific ligands of the adenine nucleotide translocase bongkrekate and atractylate; and (ii) were also observed in deenergized mitochondria, indicating that the effect is exerted directly on the PTP. OH-PGO dramatically sensitized PTP opening, which was triggered by depolarization even in the presence of EGTA. These data show that arginine modification modulates the PTP conformation in a ligand-selective fashion and suggest that the effects of OH-PGO, PGO, and BAD are mediated by the same arginine residues. We analyzed the structure of the arginine adducts by matrix-assisted laser desorption ionization and time-of-flight mass spectrometry using a test peptide and N-acetylarginine. The results indicate that both OH-PGO and PGO react with arginine at a stoichiometry of 2:1 and form stable adducts that may be feasible to identify the PTP at the molecular level.	Univ Helsinki, Inst Biomed Biochem, Helsinki Biophys & Biomembrane Grp, FIN-00014 Helsinki, Finland; Univ Padua, Dept Biomed Sci, I-35131 Padua, Italy	University of Helsinki; University of Padua	Eriksson, O (corresponding author), Univ Helsinki, Inst Biomed Biochem, Helsinki Biophys & Biomembrane Grp, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.		Bernardi, Paolo/C-3656-2008; Eriksson-Rosenberg, Ove/GVU-6692-2022	Bernardi, Paolo/0000-0001-9187-3736; 				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; BOGNER W, 1986, EUR J BIOCHEM, V161, P611, DOI 10.1111/j.1432-1033.1986.tb10485.x; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; COLL KE, 1982, J BIOL CHEM, V257, P8696; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Eriksson O, 2001, BIOPHYS J, V80, p238A; Eriksson O, 1997, FEBS LETT, V409, P361, DOI 10.1016/S0014-5793(97)00549-8; Eriksson O, 1998, J BIOL CHEM, V273, P12669, DOI 10.1074/jbc.273.20.12669; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961; LEQUOC D, 1989, ARCH BIOCHEM BIOPHYS, V273, P466, DOI 10.1016/0003-9861(89)90506-7; MAJIMA E, 1994, BIOCHEMISTRY-US, V33, P9530, DOI 10.1021/bi00198a019; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Walter L, 2000, J BIOL CHEM, V275, P29521, DOI 10.1074/jbc.M004128200; YAMASAKI RB, 1980, ANAL BIOCHEM, V109, P32, DOI 10.1016/0003-2697(80)90006-8	25	31	31	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					937	942		10.1074/jbc.M107610200	http://dx.doi.org/10.1074/jbc.M107610200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11698400	hybrid			2022-12-25	WOS:000173166800011
J	Reusch, JEB; Klemm, DJ				Reusch, JEB; Klemm, DJ			Inhibition of cAMP-response element-binding protein activity decreases protein kinase B/Akt expression in 3T3-L1 adipocytes and induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; CELL-SURVIVAL; FACTOR-I; INSULIN; CREB; DIFFERENTIATION; ADIPOGENESIS; ACTIVATION; OBESITY; DEATH	White adipose tissue mass is governed by competing processes that control lipid synthesis and storage, the development of new adipocytes, and their survival. We have shown that the transcription factor cAMP-response element-binding protein (CREB) participates in adipogenesis, with constitutively active forms of CREB inducing adipocyte differentiation and dominant negative forms of CREB blocking this process. In other cell types, CREB and related factors have been shown to play important roles in survival and apoptosis. Here we demonstrate that reduction of CREB activity by ectopic expression of the dominant negative CREB, KCREB, induces apoptosis of mature 3T3-L1 adipocytes in culture. Death by apoptosis was confirmed by increased nuclear condensation, changes in membrane morphology, and increased DNA fragmentation. Gene microarray analysis indicated that KCREB expression increased expression of several pro-apoptotic genes like Interleukin Converting Enzyme and decreased the expression of the anti-apoptotic signaling molecule, Akt/protein kinase B. Finally, introduction of constitutively active CREB, CREB-DIEDML, blocked death of mature adipocytes treated with TNF-alpha. The data indicate that CREB plays a central role in adipocyte survival, perhaps by regulating the expression of certain pro- and anti-apoptotic genes. These results not only extend the role of CREB in adipocyte biology but also highlight the general developmental and survival role of this factor in numerous cell and tissue types.	Vet Affairs Med Ctr, Pulm & Crit Care Sect, Denver, CO 80220 USA; Vet Affairs Med Ctr, Endocrinol Sect, Denver, CO 80220 USA; Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Endocrinol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Cardiovasc Pulm Res Lab, Denver, CO 80262 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Klemm, DJ (corresponding author), Vet Affairs Med Ctr, Pulm & Crit Care Sect, 1055 Clermont St, Denver, CO 80220 USA.	Dwight.Klemm@UCHSC.edu		Reusch, Jane/0000-0001-8620-1003	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053969, K08DK002351] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK53969, K08-DK02351] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Domingo P, 1999, AIDS, V13, P2261, DOI 10.1097/00002030-199911120-00008; Dowell P, 2000, J BIOL CHEM, V275, P41325, DOI 10.1074/jbc.M006474200; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Francois F, 2000, FEBS LETT, V486, P281, DOI 10.1016/S0014-5793(00)02316-4; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gagnon A, 1999, DIABETES, V48, P691, DOI 10.2337/diabetes.48.4.691; Gagnon A, 2001, ENDOCRINOLOGY, V142, P205, DOI 10.1210/en.142.1.205; Ganda OP, 2000, ANN INTERN MED, V133, P304, DOI 10.7326/0003-4819-133-4-200008150-00017; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; Hegele R A, 2000, Curr Atheroscler Rep, V2, P397, DOI 10.1007/s11883-000-0078-0; HIRSCH J, 1969, J LIPID RES, V10, P77; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Klemm DJ, 2001, J BIOL CHEM, V276, P28430, DOI 10.1074/jbc.M103382200; Klemm DJ, 1998, J BIOL CHEM, V273, P917, DOI 10.1074/jbc.273.2.917; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; Lenhard JM, 2000, ANTIVIR RES, V47, P121, DOI 10.1016/S0166-3542(00)00102-9; McIntyre AM, 1998, J ROY SOC HEALTH, V118, P76, DOI 10.1177/146642409811800207; Murao S, 1998, INTERNAL MED, V37, P1031, DOI 10.2169/internalmedicine.37.1031; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pi-Sunyer FX, 1999, J CLIN ENDOCR METAB, V84, P3, DOI 10.1210/jc.84.1.3; PRINS JB, 1994, BIOCHEM BIOPH RES CO, V205, P625, DOI 10.1006/bbrc.1994.2711; PRINS JB, 1994, BIOCHEM BIOPH RES CO, V201, P500, DOI 10.1006/bbrc.1994.1730; Prins JB, 1997, DIABETES, V46, P1939, DOI 10.2337/diabetes.46.12.1939; Prins JB, 1997, CLIN SCI, V92, P3, DOI 10.1042/cs0920003; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Qian H, 1998, ENDOCRINOLOGY, V139, P791, DOI 10.1210/en.139.2.791; Qian H, 2001, BIOCHEM BIOPH RES CO, V284, P1176, DOI 10.1006/bbrc.2001.5100; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; REUSCH JEB, 1994, ENDOCRINOLOGY, V135, P2418, DOI 10.1210/en.135.6.2418; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; RONCARI DAK, 1981, METABOLISM, V30, P425, DOI 10.1016/0026-0495(81)90174-8; Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945; Scobey MJ, 2001, ENDOCRINOLOGY, V142, P948, DOI 10.1210/en.142.2.948; Shimomura A, 1998, J NEUROCHEM, V70, P1029; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Sung JY, 2001, J BIOL CHEM, V276, P13858, DOI 10.1074/jbc.M010610200; Urso B, 2001, CELL SIGNAL, V13, P279, DOI 10.1016/S0898-6568(01)00130-9; *US DEP HHS, 1998, NAT HLTH NUTR SURV, V3; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Walton M, 1999, J NEUROCHEM, V73, P1836; Xia XM, 1999, J CELL PHYSIOL, V178, P9, DOI 10.1002/(SICI)1097-4652(199901)178:1<9::AID-JCP2>3.0.CO;2-#; Zauli G, 2001, FASEB J, V15, P483, DOI 10.1096/fj.00-0354com	47	69	71	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1426	1432		10.1074/jbc.M107923200	http://dx.doi.org/10.1074/jbc.M107923200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11694510	hybrid			2022-12-25	WOS:000173166800073
J	Rudberg, PC; Tholander, F; Thunnissen, MMGM; Haeggstrom, JZ				Rudberg, PC; Tholander, F; Thunnissen, MMGM; Haeggstrom, JZ			Leukotriene A(4) hydrolase/aminopeptidase - Glutamate 271 is a catalytic residue with specific roles in two distinct enzyme mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A(4) HYDROLASE; BIFUNCTIONAL ENZYME; SITE; B-4; AMINOPEPTIDASE; 5-LIPOXYGENASE; MUTATION; RECEPTOR; POTENT	Leukotriene A(4) hydrolase/aminopeptidase is a bifunctional zinc metalloenzyme that converts the fatty acid epoxide leukotriene A(4) into leukotriene 134, a potent chemoattractant and immune-modulating lipid mediator. Recently, the structure of leukotriene A4 hydrolase revealed that Glu-271, which belongs to a conserved GXMEN motif in the M1 family of zinc peptidases, and Gln-136 are located at the active site. Here we report that mutagenetic replacements of Glu-271, but not Gln-136, abrogate both catalytic activities of leukotriene 4 hydrolase. Furthermore, the 2.1 Angstrom crystal structure of [E271Q]Ieukotriene A(4) hydrolase revealed minimal conformational changes that could not explain the loss of enzyme function. We propose that the carboxylate of Glu-271 participates in an acid-induced opening of the epoxide moiety of leukotriene A(4) and formation of a carbocation intermediate. Moreover, Glu-271 appears to act as an N-terminal recognition site and may potentially stabilize the transition-state during turnover of peptides, a property that most likely pertains to all members of the M1 family of zinc aminopeptidases. Hence, Glu-271 is a unique example of an amino acid, which has dual and separate functions in two different catalytic reactions, involving lipid and peptide substrates, respectively.	Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 2, S-17177 Stockholm, Sweden; Univ Stockholm, Dept Biochem, Arrhenius Labs A4, S-10691 Stockholm, Sweden	Karolinska Institutet; Stockholm University	Haeggstrom, JZ (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 2, S-17177 Stockholm, Sweden.	jesper.haeggstrom@mbb.ki.se	Thunnissen, Marjolein MGM/B-9366-2011					ARAND M, 1994, FEBS LETT, V338, P251, DOI 10.1016/0014-5793(94)80278-5; Arand M, 1996, J BIOL CHEM, V271, P4223; Argiriadi MA, 1999, P NATL ACAD SCI USA, V96, P10637, DOI 10.1073/pnas.96.19.10637; Bailie MB, 1996, J IMMUNOL, V157, P5221; BARRET AJ, 1998, HDB PROTEOLYTIC ENZY, P994; BLOMSTER M, 1995, EUR J BIOCHEM, V231, P528, DOI 10.1111/j.1432-1033.1995.tb20728.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Byrum RS, 1999, J IMMUNOL, V163, P6810; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Griffiths RJ, 1997, J EXP MED, V185, P1123, DOI 10.1084/jem.185.6.1123; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAEGGSTROM J, 1986, J BIOL CHEM, V261, P6332; Haeggstrom JZ, 2000, AM J RESP CRIT CARE, V161, pS25, DOI 10.1164/ajrccm.161.supplement_1.ltta-6; Hogg JH, 1998, CHEM-EUR J, V4, P1698, DOI 10.1002/(SICI)1521-3765(19980904)4:9<1698::AID-CHEM1698>3.3.CO;2-A; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; Jager C, 1999, J NON-CRYST SOLIDS, V258, P161, DOI 10.1016/S0022-3093(99)00436-6; Laustsen PG, 2001, EUR J BIOCHEM, V268, P98, DOI 10.1046/j.1432-1327.2001.01848.x; Luciani N, 1998, BIOCHEMISTRY-US, V37, P686, DOI 10.1021/bi971705p; Mancuso P, 2001, INFECT IMMUN, V69, P2011, DOI 10.1128/IAI.69.4.2011-2016.2001; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MEDINA JF, 1991, P NATL ACAD SCI USA, V88, P7620, DOI 10.1073/pnas.88.17.7620; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; MUELLER MJ, 1995, P NATL ACAD SCI USA, V92, P8383, DOI 10.1073/pnas.92.18.8383; Mueller MJ, 1996, P NATL ACAD SCI USA, V93, P5931, DOI 10.1073/pnas.93.12.5931; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ORNING L, 1994, J BIOL CHEM, V269, P11269; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STEWART JJP, 1990, J COMPUT AID MOL DES, V4, P1, DOI 10.1007/BF00128336; Thunnissen MMGM, 2001, NAT STRUCT BIOL, V8, P131, DOI 10.1038/84117; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Vazeux G, 1998, BIOCHEM J, V334, P407, DOI 10.1042/bj3340407; WETTERHOLM A, 1995, J PHARMACOL EXP THER, V275, P31; WETTERHOLM A, 1992, P NATL ACAD SCI USA, V89, P9141, DOI 10.1073/pnas.89.19.9141; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zou JY, 2000, STRUCTURE, V8, P111, DOI 10.1016/S0969-2126(00)00087-3	41	67	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1398	1404		10.1074/jbc.M106577200	http://dx.doi.org/10.1074/jbc.M106577200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11675384	hybrid			2022-12-25	WOS:000173166800070
J	Wang, J; Whitman, MC; Natarajan, K; Tormo, J; Mariuzza, RA; Margulies, DH				Wang, J; Whitman, MC; Natarajan, K; Tormo, J; Mariuzza, RA; Margulies, DH			Binding of the natural killer cell inhibitory receptor Ly49A to its major histocompatibility complex class I ligand - Crucial contacts include both H-2D(d) and beta(2)-microglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; LY-49A RECOGNIZES; HYDROGEN-BOND; MHC; PEPTIDE; NK; MOLECULES; MURINE; SPECIFICITY	Ly49A, an inhibitory C-type lectin-like mouse natural killer cell receptor, functions through interaction with the major histocompatibility complex class I molecule, H-2D(d). The x-ray crystal structure of the Ly49A(.)H-2D(d) complex revealed that homodimeric Ly49A interacts at two distinct sites of H-2Dd: Site 1, spanning one side of the alpha1 and alpha2 helices, and Site 2, involving the alpha1, alpha2, alpha3, and beta(2)m domains. Mutants of Ly49A, H-2D(d), and beta(2)-microglobulin at intermolecular contacts and the Ly49A dimer interface were examined for binding affinity and kinetics. Although mutations at Site 1 had little affect, several at Site 2 and at the dimer interface hampered the Ly49A(.)H-2D(d) interaction, with no effect on gross structure or T cell receptor interaction. The region surrounding the most critical residues (in H-2D(d), Asp(122); in Ly49A, Asp(229), Ser(236), Thr(238), Arg(231), and Asp(241); and in beta(2)-microglobulin, Gln(29) and Lys(58)) of the Ly49A(.)H-2D(d) interface at Site 2 includes a network of water molecules, suggesting a molecular basis for allelic specificity in natural killer cell recognition.	NIH, LI NIAID, Mol Biol Sect, Bethesda, MD 20892 USA; Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Margulies, DH (corresponding author), NIH, LI NIAID, Mol Biol Sect, Bldg 10,Rm 11N311, Bethesda, MD 20892 USA.		Whitman, Mary/AAQ-1938-2020; Whitman, Mary/AAM-7286-2020	Whitman, Mary/0000-0001-6297-7499; Margulies, David/0000-0001-8530-7375	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047900, ZIAAI000394, Z01AI000622, Z01AI000394, ZIAAI000622] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47900] Funding Source: Medline; NIGMS NIH HHS [GM52801] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Brennan J, 1996, J EXP MED, V183, P1553, DOI 10.1084/jem.183.4.1553; BRENNAN J, 1994, J EXP MED, V180, P2287, DOI 10.1084/jem.180.6.2287; Ceman S, 1998, J EXP MED, V188, P2139, DOI 10.1084/jem.188.11.2139; Chung DH, 1999, J IMMUNOL, V163, P3699; Chung DH, 2000, J IMMUNOL, V165, P6922, DOI 10.4049/jimmunol.165.12.6922; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; CORR M, 1993, J EXP MED, V178, P1877, DOI 10.1084/jem.178.6.1877; CORREA I, 1995, IMMUNITY, V2, P61, DOI 10.1016/1074-7613(95)90079-9; DANIELS BF, 1994, J EXP MED, V180, P687, DOI 10.1084/jem.180.2.687; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Gurlo T, 1999, IMMUNOL LETT, V70, P139; Hanke T, 1999, IMMUNITY, V11, P67, DOI 10.1016/S1074-7613(00)80082-5; KANE KP, 1994, J EXP MED, V179, P1011, DOI 10.1084/jem.179.3.1011; Karre K, 1997, IMMUNOL REV, V155, P5, DOI 10.1111/j.1600-065X.1997.tb00935.x; KOZLOWSKI S, 1992, J EXP MED, V175, P1417, DOI 10.1084/jem.175.6.1417; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Ladbury JE, 1996, CHEM BIOL, V3, P973, DOI 10.1016/S1074-5521(96)90164-7; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Li HM, 1998, J MOL BIOL, V283, P179, DOI 10.1006/jmbi.1998.2091; Lian RH, 1999, J IMMUNOL, V162, P7271; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MARGULIES DH, 1983, J IMMUNOL, V130, P463; MASON LH, 1995, J EXP MED, V182, P293, DOI 10.1084/jem.182.2.293; Matsumoto N, 1998, IMMUNITY, V8, P245, DOI 10.1016/S1074-7613(00)80476-8; Matsumoto N, 2001, J IMMUNOL, V166, P4422, DOI 10.4049/jimmunol.166.7.4422; Matsumoto N, 2001, INT IMMUNOL, V13, P615, DOI 10.1093/intimm/13.5.615; Matsumoto N, 2001, J EXP MED, V193, P147, DOI 10.1084/jem.193.2.147; McFarland BJ, 1999, J IMMUNOL, V163, P3567; Mehta IK, 2001, CELL IMMUNOL, V209, P29, DOI 10.1006/cimm.2001.1786; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Michaelsson J, 2001, J IMMUNOL, V166, P7327, DOI 10.4049/jimmunol.166.12.7327; NAGASAWA R, 1987, J IMMUNOL, V138, P815; Natarajan K, 1999, IMMUNITY, V11, P591, DOI 10.1016/S1074-7613(00)80134-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Orihuela M, 1996, P NATL ACAD SCI USA, V93, P11792, DOI 10.1073/pnas.93.21.11792; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; Plaksin D, 1997, J IMMUNOL, V158, P2218; Polakova K, 2000, J IMMUNOL, V165, P5703, DOI 10.4049/jimmunol.165.10.5703; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; RIBAUDO RK, 1995, J IMMUNOL, V155, P3481; ROLAND J, 1992, INT IMMUNOL, V4, P699, DOI 10.1093/intimm/4.6.699; Rudolph MG, 2001, IMMUNITY, V14, P231, DOI 10.1016/S1074-7613(01)00105-4; Sawicki MW, 2001, IMMUNOL REV, V181, P52, DOI 10.1034/j.1600-065X.2001.1810104.x; SENTMAN CL, 1989, J EXP MED, V170, P191, DOI 10.1084/jem.170.1.191; Shields MJ, 1998, MOL IMMUNOL, V35, P919, DOI 10.1016/S0161-5890(98)00083-2; STONEMAN ER, 1995, J EXP MED, V182, P305, DOI 10.1084/jem.182.2.305; Sundback J, 1998, J IMMUNOL, V160, P5971; TAKEI F, 1983, J IMMUNOL, V130, P2794; Takei F, 1997, IMMUNOL REV, V155, P67, DOI 10.1111/j.1600-065X.1997.tb00940.x; TAKESHITA T, 1995, J IMMUNOL, V154, P1973; Tormo J, 1999, NATURE, V402, P623, DOI 10.1038/45170; Waldenstrom M, 1998, EUR J IMMUNOL, V28, P2872, DOI 10.1002/(SICI)1521-4141(199809)28:09<2872::AID-IMMU2872>3.0.CO;2-3; Wilson N, 2001, IMMUNITY, V14, P513, DOI 10.1016/S1074-7613(01)00140-6; Yokoyama W. M., 1999, FUNDAMENTAL IMMUNOLO, P575; YOKOYAMA WM, 1989, J IMMUNOL, V143, P1379	56	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1433	1442		10.1074/jbc.M110316200	http://dx.doi.org/10.1074/jbc.M110316200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11696552	hybrid			2022-12-25	WOS:000173166800074
J	Wang, Y; Lynch, AS; Chen, SJ; Wang, JC				Wang, Y; Lynch, AS; Chen, SJ; Wang, JC			On the molecular basis of the thermal sensitivity of an Escherichia coli topA mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-I; SITE-DIRECTED MUTAGENESIS; CHROMOSOME SEGREGATION; BACTERIAL ADAPTATION; OSMOTIC REGULATION; MUTATIONS; GENE; EXPRESSION; TRANSCRIPTION; SUPPRESSION	Studies of two temperature-sensitive Escherichia coli topA strains AS17 and BR83, both of which were supposed to carry a topA amber mutation and a temperature-sensitive supD43,74 amber-suppressor, led to conflicting results regarding the essentiality of DNA topoisomerase I in cells grown in media of low osmolarity. We have therefore reexamined the molecular basis of the temperature sensitivity of strain AS17. We find that the supD allele in this strain had lost its temperature sensitivity. The temperature sensitivity of the strain, in media of all osmolarity, results from the synthesis of a mutant DNA topoisomerase I that is itself temperature-sensitive. Nucleotide sequencing of the AS17 topA allele and studies of its expected cellular product show that the mutant enzyme is not as active as its wild-type parent even at 30degreesC, a permissive temperature for the strain, and its activity relative to the wildtype enzyme is further reduced at 42degreesC, a nonpermissive temperature. Our results thus implicate an indispensable role of DNA topoisomerase I in E. coli cells grown in media of any osmolarity.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Wang, JC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	jcwang@fas.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024544, R01GM024544] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24544] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN SJ, 1992, J BACTERIOL, V174, P5190, DOI 10.1128/JB.174.16.5190-5195.1992; BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; Broccoli S, 2000, MOL MICROBIOL, V35, P58, DOI 10.1046/j.1365-2958.2000.01671.x; Chandler MS, 1996, GENE, V169, P25, DOI 10.1016/0378-1119(95)00777-6; Changela A, 2001, NATURE, V411, P1077, DOI 10.1038/35082615; Chen SJ, 1998, J BIOL CHEM, V273, P6050, DOI 10.1074/jbc.273.11.6050; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DORMAN CJ, 1989, MOL MICROBIOL, V3, P531, DOI 10.1111/j.1365-2958.1989.tb00199.x; Dorman CJ, 1996, TRENDS MICROBIOL, V4, P214, DOI 10.1016/0966-842X(96)30015-2; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DROLET M, 1995, P NATL ACAD SCI USA, V92, P3526, DOI 10.1073/pnas.92.8.3526; FERNANDEZBEROS ME, 1992, J BACTERIOL, V174, P7059, DOI 10.1128/JB.174.21.7059-7062.1992; GRAEMECOOK KA, 1989, MOL MICROBIOL, V3, P1287, DOI 10.1111/j.1365-2958.1989.tb00279.x; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KIRKEGAARD K, 1984, COLD SPRING HARB SYM, V49, P411, DOI 10.1101/SQB.1984.049.01.047; Li ZY, 1997, J BIOL CHEM, V272, P19582, DOI 10.1074/jbc.272.31.19582; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LYNCH AS, 1993, J BACTERIOL, V175, P1645, DOI 10.1128/JB.175.6.1645-1655.1993; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; Masse E, 1999, J BIOL CHEM, V274, P16654, DOI 10.1074/jbc.274.23.16654; MCNAIRN E, 1995, MOL MICROBIOL, V15, P507, DOI 10.1111/j.1365-2958.1995.tb02264.x; MILLER CA, 1990, CELL, V62, P127, DOI 10.1016/0092-8674(90)90246-B; Mondragon A, 1999, STRUCTURE, V7, P1373, DOI 10.1016/S0969-2126(00)80027-1; NIBHRIAIN N, 1993, MOL MICROBIOL, V7, P351; OESCHGER MP, 1976, CELL, V7, P205, DOI 10.1016/0092-8674(76)90019-2; OVERBYE KM, 1982, COLD SPRING HARB SYM, V47, P785; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; RAJI A, 1985, J BACTERIOL, V162, P1173, DOI 10.1128/JB.162.3.1173-1179.1985; Reddy M, 2000, J BACTERIOL, V182, P1978, DOI 10.1128/JB.182.7.1978-1986.2000; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; Sawitzke JA, 2000, P NATL ACAD SCI USA, V97, P1671, DOI 10.1073/pnas.030528397; SMITH CM, 1992, ENVIRON MOL MUTAGEN, V19, P185, DOI 10.1002/em.2850190302; STERNGLANZ R, 1981, P NATL ACAD SCI-BIOL, V78, P2747, DOI 10.1073/pnas.78.5.2747; TRUCKSIS M, 1981, P NATL ACAD SCI-BIOL, V78, P2164, DOI 10.1073/pnas.78.4.2164; Tse-Dinh YC, 1998, BBA-GENE STRUCT EXPR, V1400, P19, DOI 10.1016/S0167-4781(98)00125-0; Tse-Dinh YC, 2000, J BACTERIOL, V182, P829, DOI 10.1128/JB.182.3.829-832.2000; TseDinh YC, 1997, TRENDS MICROBIOL, V5, P323, DOI 10.1016/S0966-842X(97)01080-9; TSEDINH YC, 1986, J MOL BIOL, V191, P321, DOI 10.1016/0022-2836(86)90129-4; WANG JC, 1984, J CELL SCI, P21; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1983, NUCLEIC ACIDS RES, V11, P1773, DOI 10.1093/nar/11.6.1773; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Weinstein-Fischer D, 2000, MOL MICROBIOL, V35, P1413, DOI 10.1046/j.1365-2958.2000.01805.x; ZENGEL JM, 1981, J BACTERIOL, V145, P459, DOI 10.1128/JB.145.1.459-465.1981; ZHU CX, 1995, J MOL BIOL, V250, P609, DOI 10.1006/jmbi.1995.0402; Zhu CX, 1998, J BIOL CHEM, V273, P8783, DOI 10.1074/jbc.273.15.8783; Zhu Q, 2001, P NATL ACAD SCI USA, V98, P9766, DOI 10.1073/pnas.171579898; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	52	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1203	1209		10.1074/jbc.M109436200	http://dx.doi.org/10.1074/jbc.M109436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11700321	hybrid			2022-12-25	WOS:000173166800043
J	Budovskaya, YV; Hama, H; DeWald, DB; Herman, PK				Budovskaya, YV; Hama, H; DeWald, DB; Herman, PK			The C terminus of the Vps34p phosphoinositide 3-kinase is necessary and sufficient for the interaction with the Vps15p protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOME-LIKE VACUOLE; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 3-KINASE; MEMBRANE TRAFFICKING; SIGNAL-TRANSDUCTION; CARBOXYPEPTIDASE-Y; SECRETORY PATHWAY; SHUTTLE VECTORS; HEAT REPEATS; FYVE DOMAIN	Vps34p is a phosphatidylinositol 3-kinase that is part of a membrane-associated complex with the Vps15p protein kinase. This kinase complex is required for the delivery of soluble proteins to the lysosomal/vacuolar compartment of eukaryotic cells. This study examined the Vps34p-Vpsl5p association and identified the domains within each protein that were important for this interaction. Using several different approaches, the interaction domain within Vps34p was mapped to a 28-amino acid element near its C terminus. This Vps34p motif was both necessary and sufficient for the interaction with Vps15p. Two-hybrid mapping experiments indicated that two separate regions of Vpsl5p were required for the association with Vps34p; they are the N-terminal protein kinase domain and a set of three tandem repeats of about 39 amino acids each. Neither domain alone was sufficient for the interaction. These Vpsl5p repeat elements are similar in sequence to the HEAT motifs that have been implicated in protein interactions in other proteins, including the Huntingtin protein. Finally, these studies identified a novel motif at the very C terminus of Vps34p that was required for phosphatidylinositol 3-kinase activity. This domain is highly conserved specifically in all Vps34p-like phosphatidylinositol 3-kinases but is not required for the interaction with Vpsl5p. This study thus represents a first step toward a better understanding of how this Vps15p.Vps34p kinase complex is assembled and regulated in vivo.	Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Utah State Univ, Dept Biol, Logan, UT 84322 USA	University System of Ohio; Ohio State University; Medical University of South Carolina; Utah System of Higher Education; Utah State University	Herman, PK (corresponding author), Ohio State Univ, Dept Mol Genet, 484 W 12th Ave,Rm 984, Columbus, OH 43210 USA.	herman.81@osu.edu	Budovskaya, Yelena/D-2254-2011	Budovskaya, Yelena/0000-0002-1047-693X				ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Chang YW, 2001, GENETICS, V157, P17; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; HARLOW E, 1999, USING ANTIBODIES LAB, P74; HASILIK A, 1978, EUR J BIOCHEM, V85, P599, DOI 10.1111/j.1432-1033.1978.tb12275.x; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Herman PK, 1997, EMBO J, V16, P6171, DOI 10.1093/emboj/16.20.6171; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; James P, 1996, GENETICS, V144, P1425; JONES EW, 1977, GENETICS, V85, P23; Kaiser C., 1994, METHODS YEAST GENETI; KESSLER SW, 1975, J IMMUNOL, V115, P1617; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; KLEKAMP MS, 1982, J BIOL CHEM, V257, P8432; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Moore DD, 1995, GLOB MOB SURV; Mullins C, 2001, BIOESSAYS, V23, P333, DOI 10.1002/bies.1048; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Stack JH, 1995, COLD SPRING HARB SYM, V60, P157, DOI 10.1101/SQB.1995.060.01.019; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; VIDA TA, 1993, J CELL BIOL, V121, P1245, DOI 10.1083/jcb.121.6.1245; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129	59	43	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					287	294		10.1074/jbc.M109263200	http://dx.doi.org/10.1074/jbc.M109263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11689570	hybrid			2022-12-25	WOS:000173087900039
J	D'Alonzo, RC; Selvamurugan, N; Karsenty, G; Partridge, NC				D'Alonzo, RC; Selvamurugan, N; Karsenty, G; Partridge, NC			Physical interaction of the activator protein-1 factors c-Fos and c-Jun with Cbfa1 for collagenase-3 promoter activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE; TRANSCRIPTIONAL REGULATION; GENE; AP-1; ENHANCER; COMPLEX; TRANSACTIVATION; OSTEOBLASTS; EXPRESSION; CELLS	Previously, we determined that the activator protein-1 (AP-1)-binding site and the runt domain (RD)binding site and their binding proteins, c-Fos-c-Jun and Cbfa, regulate the collagenase-3 promoter in parathyroid hormone-treated and differentiating osteoblasts. Here we show that Cbfa1 and c-Fos-c-Jun appear to cooperatively bind the RD- and AP-1-binding sites and form ternary structures in vitro. Both in vitro and in vivo co-immunoprecipitation and yeast two-hybrid studies further demonstrate interaction between Cbfa1 with c-Fos and c-Jun in the absence of phosphorylation and without binding to DNA. Additionally, only the runt domain of Cbfa1 was required for interaction with c-Jun and c-Fos. In mammalian cells, overexpression of Cbfa1 enhanced c-Jun activation of AP-1-binding site promoter activity, demonstrating functional interaction. Finally, insertion of base pairs that disrupted the helical phasing between the AP-1- and RD-binding sites also inhibited collagenase-3 promoter activation. Thus, we provide direct evidence that Cbfa1 and c-Fos-c-Jun physically interact and cooperatively bind the AP-1- and RD-binding sites in the collagenase-3 promoter. Moreover, the AP-1- and RD-binding sites appear to be organized in a specific required helical arrangement that facilitates transcription factor interaction and enables promoter activation.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Baylor College of Medicine	Partridge, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Ln, Piscataway, NJ 08854 USA.	partrinc@umdnj.edu	Selvamurugan, Nagarajan/P-7894-2016	Selvamurugan, Nagarajan/0000-0003-3713-1920; Partridge, Nicola/0000-0002-5406-4814	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047420, R56DK047420, R01DK048109] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47420, R01 DK047420, DK48109] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; CURRAN T, 1987, ONCOGENE, V2, P79; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; DELAISSE JM, 1988, ENDOCRINOLOGY, V123, P264, DOI 10.1210/endo-123-1-264; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Golling G, 1996, MOL CELL BIOL, V16, P932; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Javed A, 2000, J CELL SCI, V113, P2221; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kern BE, 1999, J BONE MINER RES, V14, pS164; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Ning YM, 1999, J BIOL CHEM, V274, P30624, DOI 10.1074/jbc.274.43.30624; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; PARTRIDGE NC, 1993, FRONTIERS OF OSTEOSARCOMA RESEARCH, P269; Partridge NC, 1996, CRIT REV EUKAR GENE, V6, P15, DOI 10.1615/CritRevEukarGeneExpr.v6.i1.20; Partridge Nicola C., 1996, P207; Porte D, 1999, ONCOGENE, V18, P667, DOI 10.1038/sj.onc.1202333; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Selvamurugan Nagarajan, 2000, Molecular Cell Biology Research Communications, V3, P218, DOI 10.1006/mcbr.2000.0215; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; WIJMENGA C, 1995, GENOMICS, V26, P611, DOI 10.1016/0888-7543(95)80185-O; Winchester SK, 2000, J BIOL CHEM, V275, P23310, DOI 10.1074/jbc.M003004200; Yamagiwa H, 1999, BONE, V25, P197, DOI 10.1016/S8756-3282(99)00157-X; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276	49	130	135	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					816	822		10.1074/jbc.M107082200	http://dx.doi.org/10.1074/jbc.M107082200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11641401	hybrid			2022-12-25	WOS:000173087900104
J	Kwon, K; Jiang, YL; Song, FH; Stivers, JT				Kwon, K; Jiang, YL; Song, FH; Stivers, JT			F-19 NMR studies of vaccinia type IB topoisomerase - Conformational dynamics of the bound DNA substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; COMPLEXES; MECHANISM; COVALENT	The site-specific DNA cleavage and religation activities of the vaccinia virus type IB topoisomerase at (C/T)CCTT+1X-1 sites in duplex DNA have allowed detailed investigations of the chemical and conformational steps on the reaction pathway of this enzyme (see accompanying article (Kwon, K., and Stivers, J. T. (2002) J. BioL Chem. 277, 345-352)). To extend these studies to the DNA substrate, we have performed F-19 NMR experiments using substrates in which the + 1 T has been replaced with the NMR-sensitive thymidine base analogue 5-fluoro-2'-deoxyuridine (5-F-dUrd). Substitution of 5-F-dUrd has little effect on the binding affinity of topoisomerase I for DNA, results in small changes in the cleavage and religation rate constants, and produces a net 3-fold decrease in the cleavage equilibrium constant as compared with the CCCTT consensus DNA. One-dimensional 19F NMR experiments show that the +1 5-FdUrd is in a dynamic equilibrium between a stacked and unstacked state in both the noncovalent complex and the covalent phosphotyrosine complex. These NMR observations are supported by the selective sensitivity of the + 1 T and + 1 5-F-dUrd to KMnO4 oxidation. A role for localized DNA distortion in the topoisomerase I mechanism is suggested.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Univ Maryland, Inst Biotechnol, Rockville, MD 20850 USA; Natl Inst Stand & Technol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; National Institute of Standards & Technology (NIST) - USA	Stivers, JT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.	jstivers@jhmi.edu						BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; GERIG JT, 1989, METHOD ENZYMOL, V177, P3; Hard T, 1999, Q REV BIOPHYS, V32, P57, DOI 10.1017/S0033583599003509; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HORE PJ, 1995, NUCL MAGNETIC RESONA, P44; Hwang Y, 1999, VIROLOGY, V262, P479, DOI 10.1006/viro.1999.9920; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; KIMBER BJ, 1978, NATURE, V271, P184, DOI 10.1038/271184a0; Klimasauskas S, 1998, EMBO J, V17, P317, DOI 10.1093/emboj/17.1.317; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Kwon K, 2002, J BIOL CHEM, V277, P345, DOI 10.1074/jbc.M109449200; MAG M, 1991, NUCLEIC ACIDS RES, V19, P1437, DOI 10.1093/nar/19.7.1437; MILLETT F, 1972, BIOCHEM BIOPH RES CO, V47, P625, DOI 10.1016/0006-291X(72)90924-2; Rastinejad F, 1995, METHOD ENZYMOL, V261, P560; Redinbo MR, 1999, J MOL BIOL, V292, P685, DOI 10.1006/jmbi.1999.3065; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; Sekiguchi J, 1996, J BIOL CHEM, V271, P19436, DOI 10.1074/jbc.271.32.19436; Stivers JT, 1997, BIOCHEMISTRY-US, V36, P5212, DOI 10.1021/bi962880t	20	19	19	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					353	358		10.1074/jbc.M109450200	http://dx.doi.org/10.1074/jbc.M109450200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11689573	hybrid			2022-12-25	WOS:000173087900047
J	Tang, XW; Batty, IH; Downes, CP				Tang, XW; Batty, IH; Downes, CP			Muscarinic receptors mediate phospholipase C-dependent activation of protein kinase B via Ca2+, ErbB3, and phosphoinositide 3-kinase in 1321N1 astrocytoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 3-KINASE; COUPLED RECEPTORS; SIGNALING PATHWAYS; PHORBOL ESTER; EPITHELIAL-CELLS; GENE-EXPRESSION; DNA-SYNTHESIS	In 1321N1 astrocytoma cells, heterotrimeric G-protein-coupled receptors that activate phosphoinositide-specific phospholipase Cbeta (PLCbeta) isoforms via G(q), induced a prolonged activation of protein kinase B (PKB) after a short delay. For example, the effect of carbachol acting on M-3 muscarinic receptors is blocked by wortmannin, suggesting it is mediated via a phosphoinositide 3-kinase (PI 3-kinase). In support of this, carbachol increased PI 3-kinase activity in PI 3-kinase (p85) immunoprecipitates. The pathway linking PLC-coupled receptors to PI 3-kinase was deduced to involve phosphoinositide hydrolysis and Ca2+-dependent ErbB3 transactivation but not protein kinase C on the basis of the following evidence: (i) inhibition of carbachol stimulated PLC by pretreatment with the phorbol ester phorbol 12-myristate 13-acetate concomitantly reduced PKB activity, whereas stimulation of other PLC-coupled receptors also activated PKB; (ii) Ca2+ ionophores and thapsigargin stimulated PKB activity in a wortmannin-sensitive manner, whereas bis(2-aminophenoxy)ethaneN,N,N',N'-tetraacetic acid blocked carbachol-stimulated PKB activity; (iii) phorbol 12-myristate 13-acetate alone did not activate PKB, whereas a protein kinase C inhibitor did not prevent the activation of PKB by carbachol; and (iv) carbachol stimulated ErbB3-tyrosine phosphorylation and association with p85, and both these and PKB activity were blocked by tyrphostin AG1478, an epidermal growth factor receptor-tyrosine kinase inhibitor. These experiments define a novel pathway linking G(q)-coupled G-protein-coupled receptors to the activation of PI 3-kinase and PKB.	Univ Dundee, Sch Life Sci, Div Cell Signalling, Dundee DD1 5EH, Scotland	University of Dundee	Tang, XW (corresponding author), Univ Dundee, Sch Life Sci, Div Cell Signalling, Dundee DD1 5EH, Scotland.			tang, xiuwen/0000-0002-6601-1234				ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; ASHKENAZI A, 1989, COLD SPRING HARB SYM, V53, P263; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Batty IH, 1997, BIOCHEM SOC T, V25, P1132, DOI 10.1042/bst0251132; Batty IH, 1996, BIOCHEM J, V317, P347, DOI 10.1042/bj3170347; BATTY IH, 1994, BIOCHEM J, V297, P529, DOI 10.1042/bj2970529; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Coffer PJ, 1998, BIOCHEM J, V335, P1; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; del Pulgar T, 2000, BIOCHEM J, V347, P369, DOI 10.1042/bj3470369; Eguchi S, 1999, J BIOL CHEM, V274, P36843, DOI 10.1074/jbc.274.52.36843; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HARDEN TK, 1979, J BIOL CHEM, V254, P4416; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Kurita M, 2000, CLIN EXP PHARMACOL P, V27, P208, DOI 10.1046/j.1440-1681.2000.03227.x; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Liebmann C, 2000, CURR MED CHEM, V7, P911, DOI 10.2174/0929867003374589; Maloney JA, 1999, AM J PHYSIOL-CELL PH, V276, pC221, DOI 10.1152/ajpcell.1999.276.1.C221; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; NAKAHATA N, 1987, BIOCHEM J, V241, P337, DOI 10.1042/bj2410337; NAKAHATA N, 1986, MOL PHARMACOL, V29, P188; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; Tang XW, 2000, J BIOL CHEM, V275, P13142, DOI 10.1074/jbc.275.17.13142; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WALKER KS, 1998, BIOCHEM J, V275, P13377; ZHENG WH, 2000, J BIOL CHEM, V331, P299; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	51	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					338	344		10.1074/jbc.M108927200	http://dx.doi.org/10.1074/jbc.M108927200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11694521	hybrid			2022-12-25	WOS:000173087900045
J	Hara, T; Kamura, T; Nakayama, K; Oshikawa, K; Hatakeyama, S; Nakayama, KI				Hara, T; Kamura, T; Nakayama, K; Oshikawa, K; Hatakeyama, S; Nakayama, KI			Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT-KINASE INHIBITOR; F-BOX PROTEIN; CELL-CYCLE; CDK INHIBITORS; BREAST-CANCER; MICE LACKING; S-PHASE; P27; EXPRESSION; COMPLEX	Targeting of the cyclin-dependent kinase inhibitor p27(Kip1) for proteolysis has been thought to be mediated by Skp2, the F-box protein component of an SCF ubiquitin ligase complex. Degradation of p27(Kip1) at the Go-G, transition of the cell cycle has now been shown to proceed normally in Shp2(-/-) lymphocytes, whereas p27(Kip1) proteolysis during S-G(2) phases is impaired in these Skp2-deficient cells. Degradation of p27(Kip1) at the G,-G(1), transition was blocked by lactacystin, a specific proteasome inhibitor, suggesting that it is mediated by the ubiquitin-proteasome pathway. The first cell cycle of stimulated Shp2(-/-) lymphocytes appeared normal, but the second cycle was markedly inhibited, presumably as a result of P27(Kip1) accumulation during S-G, phases of the first cell cycle. Polyubiquitination of p27(Kip1) in the nucleus is dependent on Skp2 and phosphorylation of P27(Kip1) on threonine 187. However, polyubiquitination activity was also detected in the cytoplasm of Shp2(-/-) cells, even with a threonine 187 --> alanine mutant of P27(Kip1) as substrate. These results suggest that a polyubiquitination activity in the cytoplasm contributes to the early phase of p27(Kip1) degradation in a Skp2-independent manner, thereby promoting cell cycle progression from Go to G,.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Kyushu University; Japan Science & Technology Agency (JST)	Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		高, 雨莉/HGU-8187-2022; Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Miura M, 1999, GENOMICS, V62, P50, DOI 10.1006/geno.1999.5965; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weiss RA, 2000, EMBO REP, V1, P2, DOI 10.1093/embo-reports/kvd017; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	42	190	195	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48937	48943		10.1074/jbc.M107274200	http://dx.doi.org/10.1074/jbc.M107274200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11682478	hybrid			2022-12-25	WOS:000173922100042
J	Isel, C; Ehresmann, C; Walter, P; Ehresmann, B; Marquet, R				Isel, C; Ehresmann, C; Walter, P; Ehresmann, B; Marquet, R			The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; DNA POLYMERIZATION; PRIMER; INITIATION; MUTATION; SENSITIVITY; STAVUDINE; RNA; ELONGATION	Nucleoside reverse transcriptase inhibitors (NRTIs) represent one of the main drug families used against AIDS. Once incorporated in DNA, they act as chain terminators, due to the lack of a 3'-hydroxyl group. As for the other anti-human immunodeficiency virus type 1 drugs, their efficiency is limited by the emergence of resistant viral strains. Unexpectedly, previous studies indicated that resistance toward NRTIs is achieved via two distinct and generally exclusive mechanisms. Resistance mutations either decrease the efficiency of NRTIs incorporation or increase their excision from the extended primer. To understand the emergence of different resistance mechanisms toward a single inhibitor class, we compared the incorporation and the pyrophosphorolysis of several NRTIs using wild type reverse transcriptase (WT RT). We found that the efficiency of discrimination or excision by pyrophosphorolysis in the presence of nucleotides of a given NRTI is a key determinant in the emergence of one or the other resistance pathway. Indeed, our results suggest that the pathway by which RT become resistant toward a given NRTI can be predicted by studying the inhibition of WT RT, because the resistance mutations do not confer new properties to the mutant enzyme, but rather exacerbate preexisting properties of the WT enzyme. They also help to understand the low cross-resistance toward d4T observed with the 3'-azido-3'-deoxythymidine (AZT or zidovudine) -resistant RT.	CNRS, UPR9002, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Isel, C (corresponding author), CNRS, UPR9002, Inst Biol Mol & Cellulaire, 15 Rue Rene Descartes, F-67084 Strasbourg, France.		Isel, Catherine/AAH-2174-2020; Isel, Catherine/B-9406-2015	Isel, Catherine/0000-0002-8014-7525; Isel, Catherine/0000-0001-7258-869X; Marquet, Roland/0000-0002-4209-3976				Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Arion D, 2000, J BIOL CHEM, V275, P9251, DOI 10.1074/jbc.275.13.9251; Arts EJ, 1996, J VIROL, V70, P712, DOI 10.1128/JVI.70.2.712-720.1996; BARSHOP BA, 1991, ANAL BIOCHEM, V197, P266, DOI 10.1016/0003-2697(91)90387-9; Benas P, 2000, RNA, V6, P1347, DOI 10.1017/S1355838200000911; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Canard B, 1998, J BIOL CHEM, V273, P14596, DOI 10.1074/jbc.273.23.14596; CARROLL SS, 1994, BIOCHEMISTRY-US, V33, P2113, DOI 10.1021/bi00174a018; Coakley EP, 2000, AIDS, V14, pF9, DOI 10.1097/00002030-200001280-00002; Feng JY, 1999, BIOCHEMISTRY-US, V38, P55, DOI 10.1021/bi982340r; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gao HQ, 2000, J MOL BIOL, V300, P403, DOI 10.1006/jmbi.2000.3823; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P1390, DOI 10.1128/AAC.37.6.1390; Gotte M, 2000, J VIROL, V74, P3579, DOI 10.1128/JVI.74.8.3579-3585.2000; GU ZX, 1995, P NATL ACAD SCI USA, V92, P2760, DOI 10.1073/pnas.92.7.2760; Gu ZX, 1995, J BIOL CHEM, V270, P31046, DOI 10.1074/jbc.270.52.31046; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; GUEDJ R, 1999, VIROLOGIE, V3, P17; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; ISEL C, 1993, J BIOL CHEM, V268, P25269; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; Katlama C, 1998, ANN INTERN MED, V129, P525, DOI 10.7326/0003-4819-129-7-199810010-00003; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; LIN PF, 1994, J INFECT DIS, V170, P1157, DOI 10.1093/infdis/170.5.1157; Lin PF, 1999, ANTIVIR THER, V4, P21; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; MARTIN JL, 1993, P NATL ACAD SCI USA, V90, P6135, DOI 10.1073/pnas.90.13.6135; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 2000, ANTIMICROB AGENTS CH, V44, P3465, DOI 10.1128/AAC.44.12.3465-3472.2000; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; REARDON JE, 1993, J BIOL CHEM, V268, P8743; Rigourd M, 2000, J BIOL CHEM, V275, P26944; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Schinazi R.F., 2000, INT ANTIVIRAL NEWS, V8, P65; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; Selmi B, 2001, J BIOL CHEM, V276, P13965, DOI 10.1074/jbc.M009837200; SKALKA A, 1993, REVERSE TRANSCRIPTAS; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; Tong WJ, 1997, BIOCHEMISTRY-US, V36, P5749, DOI 10.1021/bi962410z; Ueno T, 1997, BIOCHEMISTRY-US, V36, P1092, DOI 10.1021/bi962393d; Vaccaro JA, 1998, BIOCHEMISTRY-US, V37, P14189, DOI 10.1021/bi9810353; Vaccaro JA, 2000, ANTIMICROB AGENTS CH, V44, P217, DOI 10.1128/AAC.44.1.217-221.2000; Wilson JE, 1996, J BIOL CHEM, V271, P13656, DOI 10.1074/jbc.271.23.13656; ZHANG D, 1994, ANTIMICROB AGENTS CH, V38, P282, DOI 10.1128/AAC.38.2.282	49	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48725	48732		10.1074/jbc.M108352200	http://dx.doi.org/10.1074/jbc.M108352200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11668180	hybrid			2022-12-25	WOS:000173922100016
J	Pfannstiel, J; Cyrklaff, M; Habermann, A; Stoeva, S; Griffiths, G; Shoeman, R; Faulstich, H				Pfannstiel, J; Cyrklaff, M; Habermann, A; Stoeva, S; Griffiths, G; Shoeman, R; Faulstich, H			Human cofilin forms oligomers exhibiting actin bundling activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPOLYMERIZING FACTOR COFILIN; F-ACTIN; FILAMENT TURNOVER; BINDING-PROTEINS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ACANTHAMOEBA ACTOPHORIN; CROSS-LINKING; PHOSPHORYLATION; DYNAMICS; ADF	Human cofilin possesses the tendency for self-association, as indicated by the rapid formation of dimers and oligomers when reacted with water-soluble carbodiimide, Ellman's reagent, or glutathione disulfide. Intermolecular disulfide bonds involve Cys(39) and probably Cys(147) of two adjacent cofilin units. The disulfide-linked dimers and oligomers exhibit a biological activity distinct from the monomer. While monomeric cofilin decreased viscosity and light-scattering of F-actin solutions, dimers and oligomers caused an increase in viscosity and light scattering. Electron microscopy revealed that cofilin oligomers induce the formation of highly ordered actin bundles with occasionally blunt ends similar to actin-cofilin rods observed in cells under oxidative stress. Bundling activity of the disulfide-linked oligomers could be completely reversed into severing activity by dithiothreitol. Formation of cofilin oligomers occurred also in the presence of actin at pH 8, but not at pH 6.6, and was significantly enhanced in the presence of phosphatidylinositol 4,5-bisphosphate. Our data are consistent with the idea that cofilin exists in two forms in vivo also: as monomers exhibiting the known severing activity and as oligomers exhibiting actin bundling activity. However, stabilization of cofilin oligomers in cytoplasm is probably achieved not by disulfide bonds but by a local increase in cofilin concentration and/or binding of regulatory proteins.	Max Planck Inst Cell Biol, D-68526 Ladenburg, Germany; Max Planck Inst Med Res, D-69120 Heidelberg, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Tubingen, Inst Physiol Chem, D-72076 Tubingen, Germany	Max Planck Society; Max Planck Society; European Molecular Biology Laboratory (EMBL); Eberhard Karls University of Tubingen	Pfannstiel, J (corresponding author), Max Planck Inst Cell Biol, Schriesheimer Str 101, D-68526 Ladenburg, Germany.			Habermann, Anja/0000-0003-3686-9050				ABE H, 1989, J BIOCHEM-TOKYO, V106, P696, DOI 10.1093/oxfordjournals.jbchem.a122919; Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Aizawa H, 1999, GENES CELLS, V4, P311, DOI 10.1046/j.1365-2443.1999.00262.x; Aizawa H, 1996, J CELL BIOL, V132, P335, DOI 10.1083/jcb.132.3.335; AIZAWA H, 1995, J BIOL CHEM, V270, P10923, DOI 10.1074/jbc.270.18.10923; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; BAMBURG JR, 1987, J CELL BIOL, V105, P2817, DOI 10.1083/jcb.105.6.2817; BERNSTEIN BW, 1982, CELL MOTIL CYTOSKEL, V2, P1, DOI 10.1002/cm.970020102; Blanchoin L, 1999, J BIOL CHEM, V274, P15538, DOI 10.1074/jbc.274.22.15538; Blanchoin L, 2000, J MOL BIOL, V295, P203, DOI 10.1006/jmbi.1999.3336; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Fedorov AA, 1997, NAT STRUCT BIOL, V4, P366, DOI 10.1038/nsb0597-366; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; IIDA K, 1993, GENE, V124, P115; Iida K, 1999, GENES CELLS, V4, P21, DOI 10.1046/j.1365-2443.1999.00235.x; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Jiang CJ, 1997, P NATL ACAD SCI USA, V94, P9973, DOI 10.1073/pnas.94.18.9973; Kliche W, 1999, BIOCHEMISTRY-US, V38, P10307, DOI 10.1021/bi990615c; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MACIVER SK, 1991, J CELL BIOL, V115, P1621, DOI 10.1083/jcb.115.6.1621; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; Maciver SK, 1998, EUR J BIOCHEM, V256, P388, DOI 10.1046/j.1432-1327.1998.2560388.x; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MCKIM KS, 1994, MOL GEN GENET, V242, P346, DOI 10.1007/BF00280425; Minamide LS, 2000, NAT CELL BIOL, V2, P628, DOI 10.1038/35023579; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; NAGAOKA R, 1995, J CELL SCI, V108, P581; NAGAOKA R, 1995, CELL MOTIL CYTOSKEL, V30, P1, DOI 10.1002/cm.970300102; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; OHATA Y, 1989, J BIOL CHEM, V264, P16143; Okada K, 1999, J CELL SCI, V112, P1553; Ono S, 1999, J CELL BIOL, V145, P491, DOI 10.1083/jcb.145.3.491; Ono S, 2001, J BIOL CHEM, V276, P5952, DOI 10.1074/jbc.M007563200; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PETERS K, 1977, ANNU REV BIOCHEM, V46, P523, DOI 10.1146/annurev.bi.46.070177.002515; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Pope BJ, 2000, J MOL BIOL, V298, P649, DOI 10.1006/jmbi.2000.3688; Reichert A, 1996, J BIOL CHEM, V271, P1301, DOI 10.1074/jbc.271.3.1301; Ressad F, 1998, J BIOL CHEM, V273, P20894, DOI 10.1074/jbc.273.33.20894; Rodal AA, 1999, J CELL BIOL, V145, P1251, DOI 10.1083/jcb.145.6.1251; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P102, DOI 10.1021/bi00427a015; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Tang JX, 1996, J BIOL CHEM, V271, P8556, DOI 10.1074/jbc.271.15.8556; Theriot JA, 1997, J CELL BIOL, V136, P1165, DOI 10.1083/jcb.136.6.1165; Van Troys M, 2000, BIOCHEMISTRY-US, V39, P12181, DOI 10.1021/bi000816c; Wriggers W, 1998, J MOL BIOL, V282, P921, DOI 10.1006/jmbi.1998.2048; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YONEZAWA N, 1987, CELL STRUCT FUNCT, V12, P443, DOI 10.1247/csf.12.443; YONEZAWA N, 1991, J BIOL CHEM, V266, P10485; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; ZIGMOND SH, 1993, CELL MOTIL CYTOSKEL, V25, P309, DOI 10.1002/cm.970250402	73	55	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49476	49484		10.1074/jbc.M104760200	http://dx.doi.org/10.1074/jbc.M104760200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11679578	hybrid			2022-12-25	WOS:000173922100110
J	Shann, YJ; Hsu, MT				Shann, YJ; Hsu, MT			Cloning and characterization of liver-specific isoform of Chk1 gene from rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; CELL-CYCLE CHECKPOINT; INTACT YEAST-CELLS; PROMOTER REGIONS; PROTEIN-KINASE; PHOSPHORYLATION; PLOIDY; CDC25; ATR; TRANSFORMATION	We have isolated and characterized an isoform of protein kinase Chk1 gene from rat liver and a rat liver cDNA library by 5'-rapid amplification of cDNA ends. The gene (Cil) contains the C-terminal region of the Chk1 gene, but the 5'-end is derived from a sequence in the intron of Chk1 preceding the C-terminal domain by differential RNA splicing. The kinase domain of Chk1 gene is absent in this isoform. Tissue RNA and protein blot analyses indicated that Cil was specifically expressed only in rat liver, and its expression increased with liver development. Expression of Cil was found to be reduced in three rat hepatoma. cell lines examined. A promoter trap experiment suggested that a promoter was located in the intron preceding the C-terminal domain of Chk1, and transcription from this novel promoter generated the new 5' noncoding exon of Cil. Thus Cil was generated by both alternate promoter usage and differential RNA splicing. UV irradiation induced caffeine-sensitive phosphorylation of both Chk1 and Cil at Ser-345 in Chk1 and its equivalent site in Cil, implying a role for ATR kinase in the phosphorylation of both proteins. We demonstrated the interaction between the kinase domain of Chk1 and Cil using a yeast two-hybrid assay and pull-down technique. In contrast to the effect of Chk1, Cil was found to decrease the transactivating function of p53, and the S63A mutation of Cil abolished this effect. These results suggest that Cil may serve as a dominant negative competitor of Chk1 as suggested previously.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Hsu, MT (corresponding author), Natl Yang Ming Univ, Inst Biochem, 155 Li Nong St, Taipei 112, Taiwan.							ANATSKAYA OV, 1994, J THEOR BIOL, V168, P191, DOI 10.1006/jtbi.1994.1098; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Clarke DJ, 2000, BIOESSAYS, V22, P351, DOI 10.1002/(SICI)1521-1878(200004)22:4<351::AID-BIES5>3.0.CO;2-W; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Galgoczy P, 2001, GENE, V271, P93, DOI 10.1016/S0378-1119(01)00492-9; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Liu QH, 2000, GENE DEV, V14, P1448; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; Rhind N, 2000, J CELL SCI, V113, P3889; SAETER G, 1988, JNCI-J NATL CANCER I, V80, P1480, DOI 10.1093/jnci/80.18.1480; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanz N, 1996, BBA-MOL BASIS DIS, V1315, P123, DOI 10.1016/0925-4439(95)00113-1; Sarkaria JN, 1999, CANCER RES, V59, P4375; Seglen PO, 1997, CELL BIOL TOXICOL, V13, P301, DOI 10.1023/A:1007487425047; SEGLEN PO, 1990, ENVIRON HEALTH PERSP, V88, P197, DOI 10.2307/3431075; Shieh SY, 2000, GENE DEV, V14, P289; SIGAL SH, 1995, DIFFERENTIATION, V59, P35, DOI 10.1046/j.1432-0436.1995.5910035.x; Takai H, 2000, GENE DEV, V14, P1439; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 2001, CURR OPIN GENET DEV, V11, P78, DOI 10.1016/S0959-437X(00)00160-X; Yin MB, 2000, MOL PHARMACOL, V57, P453, DOI 10.1124/mol.57.3.453; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	41	12	14	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48863	48870		10.1074/jbc.M108253200	http://dx.doi.org/10.1074/jbc.M108253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11687578	hybrid			2022-12-25	WOS:000173922100033
J	Gross, SD; Lewellyn, AL; Maller, JL				Gross, SD; Lewellyn, AL; Maller, JL			A constitutively active form of the protein kinase p90(Rsk1) is sufficient to trigger the G(2)/M transition in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL S6 KINASE; GLYCOGEN-SYNTHASE KINASE-3; MAP KINASE; MEIOTIC MATURATION; BETA-CATENIN; CELL-CYCLE; IN-VIVO; ACTIVATION; CASCADE; RSK	The protein kinase p90(Rsk) has previously been implicated as a key target of the MAPK pathway during M phase of meiosis II in Xenopus oocytes. To determine whether Rsk is a mediator of MAPK for stimulation of the G(2)/M transition early in meiosis I, we sought to generate a form of Rsk that would be constitutively active in resting, G(2) phase oocytes. Initial studies revealed that an N-terminal truncation of 43 amino acids conferred enhanced specific activity on the enzyme in G2 phase, and stability was highest if the C terminus was not truncated. The full-length enzyme is known to be activated by phosphorylation at five sites. Two of these sites and flanking residues were replaced with either aspartic or glutamic acid, and Tyr(699) was mutated to alanine. The resulting construct, termed fully activated (FA) Rsk, had constitutive activity in G2 phase, with a specific activity equivalent to that of wild type Rsk in M phase. In eight independent experiments similar to 45% of oocytes expressing FA-Rsk underwent germinal vesicle breakdown (GVBD, the G(2)/M transition) in the absence of progesterone, and this effect could be observed even in the presence of the MAPK kinase inhibitor U0126. Moreover, the specific activity of FA-Rsk in vivo was unaffected by U0126. In oocytes that did not undergo GVBD with FA-Rsk expression, subsequent treatment with progesterone resulted in a very rapid rate of GVBD even in the presence of U0126 to inhibit the endogenous MAPK/Rsk pathway. These results indicate that Rsk is the mediator of MAPK effects for the G(2/)M transition in meiosis I and in a subpopulation of oocytes Rsk is sufficient to trigger the G(2)/M transition.	Univ Colorado, Sch Med, Dept Pharmacol, Howard Hughes Med Inst, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Dept Pharmacol, Howard Hughes Med Inst, 4200 E 9th Ave, Denver, CO 80262 USA.			Gross, Stefan/0000-0002-5645-7304	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28353-20] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSANDRINI A, 1996, BIOL CHEM, V27, P31612; Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Fisher DL, 1999, DEVELOPMENT, V126, P567; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gotoh Y, 1995, Prog Cell Cycle Res, V1, P287; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MASUI Y, 1971, J EXP ZOOL, V177, P1229; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; Palmer A, 2000, Prog Cell Cycle Res, V4, P131; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Roy LM, 1996, ONCOGENE, V12, P2203; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; SAGATA N, 1988, NATURE, V335, P19; Schwab MS, 2001, CURR BIOL, V11, P141, DOI 10.1016/S0960-9822(01)00045-8; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SPIVACK JG, 1984, MOL CELL BIOL, V4, P1631, DOI 10.1128/MCB.4.8.1631; Taieb FE, 2001, CURR BIOL, V11, P508, DOI 10.1016/S0960-9822(01)00145-2; Tian JD, 2000, P NATL ACAD SCI USA, V97, P14358, DOI 10.1073/pnas.250492197; Torres MA, 1999, MOL CELL BIOL, V19, P1427; VANRENTERGHEM B, 1993, J BIOL CHEM, V268, P19935; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	41	39	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46099	46103		10.1074/jbc.C100496200	http://dx.doi.org/10.1074/jbc.C100496200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11641391	hybrid			2022-12-25	WOS:000172573100083
J	Kroncke, KD				Kroncke, KD			Cysteine-Zn(2+) complexes: unique molecular switches for inducible nitric oxide synthase-derived NO	FASEB JOURNAL			English	Article						chaperone; cysteine switch; metalloproteinase; nitric oxide; transcription; zinc	FINGER TRANSCRIPTION FACTORS; ZINC-SULFUR CLUSTERS; CHAPERONE; METALLOTHIONEIN; INHIBITION; RELEASE; DOMAIN; DNAJ; MECHANISM; BINDING	Nitric oxide (NO) in the low nanomolar range acts as a transcellular messenger molecule to initiate regulatory and physiological responses in nearby target cells via binding to the soluble guanylate cyclase heme moiety. Higher NO concentrations, as synthesized by the inducible NO synthase (iNOS) during inflammatory processes, show additional effects: NO may react with O(2), yielding nitrogen oxides like N(2)O(3) that are able to nitrosate thiols. A variety of proteins involved in very different functions of the cell contain cysteine-Zn(2+) complexes. Effects of NO on different proteins containing cysteine-Zn(2+) domains and playing essential roles during transcription, protein folding, and proteolysis are discussed. It is suggested that iNOS-derived NO acts as a signal molecule targeting cysteine-Zn(2+) linkages, thus enabling cells to react toward nitrosative stress.	Univ Dusseldorf, Dept Med, MED, Res Grp Immunobiol 23 12, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Kroncke, KD (corresponding author), Univ Dusseldorf, Dept Med, MED, Res Grp Immunobiol 23 12, Moorenstr 5, D-40225 Dusseldorf, Germany.	kroencke@uni-duessel-dorf.de						Aravindakumar CT, 1999, BIOCHEM J, V344, P253, DOI 10.1042/0264-6021:3440253; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; Barbirz S, 2000, J BIOL CHEM, V275, P18759, DOI 10.1074/jbc.M001089200; Berendji D, 1999, MOL MED, V5, P721, DOI 10.1007/BF03402096; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Gergel D, 1996, BIOCHEMISTRY-US, V35, P16186, DOI 10.1021/bi962043r; Graumann J, 2001, STRUCTURE, V9, P377, DOI 10.1016/S0969-2126(01)00599-8; Grishin NV, 2001, NUCLEIC ACIDS RES, V29, P1703, DOI 10.1093/nar/29.8.1703; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Kim SJ, 2001, NAT STRUCT BIOL, V8, P459, DOI 10.1038/87639; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Kroncke KD, 2000, FASEB J, V14, P166; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; Kroncke KD, 2001, NITRIC OXIDE-BIOL CH, V5, P289, DOI 10.1006/niox.2001.0354; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; KRONCKE KD, 1998, BIOL CHEM, V379, pS92; Liu SX, 2001, BIOCHEM J, V354, P397, DOI 10.1042/0264-6021:3540397; Maeda H, 1998, BIOL CHEM, V379, P193, DOI 10.1515/bchm.1998.379.2.193; Martinez-Yamout M, 2000, J MOL BIOL, V300, P805, DOI 10.1006/jmbi.2000.3923; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Montoliu C, 2000, J NEUROCHEM, V75, P266, DOI 10.1046/j.1471-4159.2000.0750266.x; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wang SB, 1999, J BIOL CHEM, V274, P33190, DOI 10.1074/jbc.274.47.33190; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Zhang ZL, 2000, J BIOL CHEM, V275, P15839, DOI 10.1074/jbc.M000604200	27	29	30	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2503	2507		10.1096/fj.01-0240hyp	http://dx.doi.org/10.1096/fj.01-0240hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689476				2022-12-25	WOS:000172420500021
J	Lee, NS; Sun, BH; Williamson, R; Gunkel, N; Salvaterra, PM; Rossi, JJ				Lee, NS; Sun, BH; Williamson, R; Gunkel, N; Salvaterra, PM; Rossi, JJ			Functional colocalization of ribozymes and target mRNAs in Drosophila oocytes	FASEB JOURNAL			English	Article						3 ' UTR; RNA localization; hammerhead ribozyme; Drosophila bicoid and oskar mRNAs	MESSENGER-RNA LOCALIZATION; DOUBLE-STRANDED-RNA; ANTEROPOSTERIOR POLARITY; THERAPEUTIC AGENTS; DEPENDENT MANNER; CELL-EXTRACTS; BICOID RNA; PROTEIN; OSKAR; ACTIN	The effectiveness of catalytic RNAs (ribozymes) should be increased when they are colocalized to the same intracellular compartment as their RNA targets. We colocalized ribozymes with their mRNA targets in an animal model by using the discrete RNA localization signals present in the 3' untranslated regions (UTRs) of Drosophila bicoid and oskar mRNAs. These signals have been fused to a lacZ mRNA target and hammerhead ribozymes targeted against lacZ. Ribozyme efficacy was first assessed by an oligodeoxyribonucleotide-based assay to identify the most accessible sites for ribozyme interaction on native lacZ transcripts in ovary extracts. The most accessible sequence was used for the design and in vivo testing of a hammerhead ribozyme. When the ribozyme and target with synonymous 3' UTRs were expressed in the same ovaries, colocalization could be indirectly demonstrated by in situ hybridization. Colocalized ribozyme and target mRNAs resulted in a two- to threefold enhancement of ribozyme function compared with noncolocalized transcripts. This study provides the first demonstration of functional ribozyme target colocalization in an animal model.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Biol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA; Aventis Crop Sci, Forsch Biochem, D-65926 Frankfurt, Germany	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Rossi, JJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Biol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	jrossi@coh.org	Gunkel, Nikolas/AAR-8220-2021		NIAID NIH HHS [AI46030, AI29329] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029329, R01AI029329, P01AI046030] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; BURGIN KE, 1990, J NEUROSCI, V10, P1788; Caplen NJ, 2000, GENE, V252, P95, DOI 10.1016/S0378-1119(00)00224-9; CHRISTOFFERSEN RE, 1995, J MED CHEM, V38, P2023, DOI 10.1021/jm00012a001; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; Gunkel N, 1998, GENE DEV, V12, P1652, DOI 10.1101/gad.12.11.1652; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HILL MA, 1993, J CELL BIOL, V122, P825, DOI 10.1083/jcb.122.4.825; JEFFERY WR, 1983, DEV BIOL, V99, P408, DOI 10.1016/0012-1606(83)90290-7; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Kim-Ha Jeongsil, 1993, Development (Cambridge), V119, P169; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; Lee NS, 1999, RNA, V5, P1200, DOI 10.1017/S1355838299990246; LIEBHABER SA, 1992, J MOL BIOL, V226, P609, DOI 10.1016/0022-2836(92)90619-U; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; RONGO C, 1995, DEVELOPMENT, V121, P2737; ROSSI JJ, 1982, J BIOL CHEM, V257, P9226; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; Scherr M, 2000, NUCLEIC ACIDS RES, V28, P2455, DOI 10.1093/nar/28.13.2455; Scherr M, 2000, MOL THER, V2, P26, DOI 10.1006/mthe.2000.0091; Scherr M, 1998, NUCLEIC ACIDS RES, V26, P5079, DOI 10.1093/nar/26.22.5079; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TIEDGE H, 1991, P NATL ACAD SCI USA, V88, P2093, DOI 10.1073/pnas.88.6.2093; UHLENBECK OC, 1995, NAT STRUCT BIOL, V2, P610, DOI 10.1038/nsb0895-610; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; Wilhelm JE, 2000, J CELL BIOL, V148, P427, DOI 10.1083/jcb.148.3.427	45	6	10	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2390	2400		10.1096/fj.01-0116com	http://dx.doi.org/10.1096/fj.01-0116com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689464				2022-12-25	WOS:000172420500009
J	Ramamurthy, B; Hook, P; Jones, AD; Larsson, L				Ramamurthy, B; Hook, P; Jones, AD; Larsson, L			Changes in myosin structure and function in response to glycation	FASEB JOURNAL			English	Article						skeletal muscle; myosin; glucose; soleus muscle; MALDI; mass spectrometry	SKELETAL-MUSCLE-FIBERS; UNLOADED SHORTENING VELOCITY; VITRO MOTILITY ASSAY; ALKALI LIGHT-CHAIN; IN-VITRO; HEAVY-CHAIN; NONENZYMATIC GLYCOSYLATION; ISOFORM COMPOSITION; CONTRACTILE PROPERTIES; MYOFIBRILLAR PROTEINS	Nonenzymatic glycosylation (glycation) is recognized as an important post-translational modification underlying alterations of structure and function of extracellular proteins. The effect of glycation on intracellular proteins is, on the other hand, less well known despite the vital importance of intracellular proteins for cell, tissue, and organ function. The aim of this study was to explore the effects of glycation on the structure and function of skeletal muscle myosin. Myosin was incubated for up to 30 min with glucose and subsequently tested for structural and functional modifications by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry and a single-fiber in vitro motility assay, respectively. MALDI spectra revealed glycation-related structural alterations as evidenced by the disappearance of specific Lys-C proteolysis products and the appearance of higher mass peaks that are attributed to cross-linking by glucose. This change was paralleled by a significant reduction in the in vitro motility speed, suggesting a structure-related decline in myosin mechanics in response to glucose exposure. Further evidence that early glycation products form in the regulatory regions of the myosin molecule is derived from the fact that there is complete reversal of motility speed after reaction with the Schiff base-cleaving agent hydroxylamine hydrochloride. Thus, glycation of skeletal muscle myosin has a significant effect on both the structural and functional properties of the protein, a finding that is important in understanding the mechanisms underlying the impairment in muscle function associated with aging and diabetes.	Penn State Univ, Noll Physiol Res Ctr 111, University Pk, PA 16802 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Karolinska Institutet	Larsson, L (corresponding author), Penn State Univ, Noll Physiol Res Ctr 111, University Pk, PA 16802 USA.	lg15@psu.edu	Larsson, Lars/AAY-1347-2021; Jones, Arthur D/C-2670-2013	Larsson, Lars/0000-0003-3722-035X; Jones, A. Daniel/0000-0002-7408-6690	NCRR NIH HHS [RR11318] Funding Source: Medline; NIAMS NIH HHS [AR45627] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045627] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Avigad G, 1996, BIOCHEM MOL BIOL INT, V40, P273; Balagopal P, 1997, AM J PHYSIOL-ENDOC M, V273, pE790, DOI 10.1152/ajpendo.1997.273.4.E790; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V478, P341, DOI 10.1113/jphysiol.1994.sp020254; BROWN MR, 1992, BIOCHEM CELL BIOL, V70, P617, DOI 10.1139/o92-095; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; Degens H, 1998, ACTA PHYSIOL SCAND, V163, P33, DOI 10.1046/j.1365-201x.1998.00329.x; ELSALEH SC, 1984, J BIOL CHEM, V259, P1014; ELSALEH SC, 1986, J BIOL CHEM, V261, P4646; Frontera WR, 1997, MUSCLE NERVE, V20, P948, DOI 10.1002/(SICI)1097-4598(199708)20:8<948::AID-MUS3>3.0.CO;2-6; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; Hook P, 1999, J PHYSIOL-LONDON, V520, P463, DOI 10.1111/j.1469-7793.1999.00463.x; Hook P, 2001, AM J PHYSIOL-CELL PH, V280, pC782, DOI 10.1152/ajpcell.2001.280.4.C782; Hook P, 2000, J MUSCLE RES CELL M, V21, P357, DOI 10.1023/A:1005614212575; Kay J, 1978, BIOCHEM SOC T, V6, P789, DOI 10.1042/bst0060789; KRAFT R, 1989, NUCLEIC ACIDS RES, V17, P7529, DOI 10.1093/nar/17.18.7529; Lal GBS, 1996, MOL CELL BIOCHEM, V154, P95; Lapolla A, 2000, MASS SPECTROM REV, V19, P279; LARSSON L, 1993, J PHYSIOL-LONDON, V472, P595, DOI 10.1113/jphysiol.1993.sp019964; Larsson L, 1997, AM J PHYSIOL-CELL PH, V272, pC638, DOI 10.1152/ajpcell.1997.272.2.C638; Larsson L, 1999, ITAL J NEUROL SCI, V20, P413; Li XP, 1996, AM J PHYSIOL-CELL PH, V270, pC352, DOI 10.1152/ajpcell.1996.270.1.C352; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORADIAN AD, 1991, J AM GERIATR SOC, V39, P717, DOI 10.1111/j.1532-5415.1991.tb03628.x; Nicolau DV, 1999, BIOPHYS J, V77, P1126, DOI 10.1016/S0006-3495(99)76963-8; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Patterson MF, 2000, PFLUG ARCH EUR J PHY, V439, P845, DOI 10.1007/s004240051013; Ramamurthy B, 2000, J AGING PHYS ACTIV, V8, P289; Ramamurthy B, 1999, FASEB J, V13, pA413; Reggiani C, 1997, J PHYSIOL-LONDON, V502, P449, DOI 10.1111/j.1469-7793.1997.449bk.x; Shrager JB, 2000, J MUSCLE RES CELL M, V21, P345, DOI 10.1023/A:1005635030494; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; Svensson C, 1997, J CELL BIOCHEM, V67, P241, DOI 10.1002/(SICI)1097-4644(19971101)67:2<241::AID-JCB9>3.0.CO;2-X; SWEENEY HL, 1988, J BIOL CHEM, V263, P9034; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; SYROVY I, 1992, GEN PHYSIOL BIOPHYS, V11, P301; SYROVY I, 1993, INT J BIOCHEM, V25, P941, DOI 10.1016/0020-711X(93)90251-9; Thompson LV, 1999, J APPL PHYSIOL, V86, P881, DOI 10.1152/jappl.1999.86.3.881; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WATANABE H, 1992, BIOSCI BIOTECH BIOCH, V56, P1109, DOI 10.1271/bbb.56.1109; Yu FS, 1998, PFLUG ARCH EUR J PHY, V437, P21, DOI 10.1007/s004240050741; YUDKIN JS, 1988, DIABETIC MED, V5, P338, DOI 10.1111/j.1464-5491.1988.tb01001.x	45	104	108	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2415	2422		10.1096/fj.01-0183com	http://dx.doi.org/10.1096/fj.01-0183com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689466				2022-12-25	WOS:000172420500011
J	Dohn, M; Jiang, JY; Chen, XB				Dohn, M; Jiang, JY; Chen, XB			Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis	ONCOGENE			English	Article						EphA2; apoptosis; p53; p73; p63	FOCAL-ADHESION-KINASE; TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL ACTIVITIES; P53-RELATED PROTEIN; NEURAL DEVELOPMENT; MAMMALIAN-CELLS; HUMAN CANCERS; P73; GENE; EPHRINS	The p53 tumor suppressor protein is mutated in more than 50% of all human cancers, which makes the study of its functions and activities critical for the understanding and management of cancer. In response to cellular stresses, p53 is activated and can mediate cell cycle arrest and/or apoptosis via the upregulation of numerous target genes. Here, we have identified EphA2 as a target gene of the p53 family, that is, p53, p73, and p63. We also found that an increase of EphA2 transcript levels correlated with an increase of EphA2 protein expression, and induction of EphA2 in response to DNA damage corresponded with p53 activation. Furthermore, we identified a p53 response element located within the EphA2 promoter that is responsive to wild-type p53, p73, and p63, but not mutant p53. Interestingly, the ligand for EphA2, ephrin-A1, is also regulated by p53. EphA2 and ephrin-A1 are members of the Eph family of receptor tyrosine kinases and ligands, which are implicated in a number of developmental processes. To analyse the role of EphA2 in p53-mediated tumor suppression, we generated stable cell lines capable of expressing exogenous EphA2 in a tetracycline-repressible system. We found that EphA2 expression resulted in an increase in apoptosis. Thus, we hypothesize that the activated EphA2 may serve to impair anti-apoptotic signaling, perhaps by disrupting focal adhesions and thereby sensitize cells to pro-apoptotic stimuli.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.				NCI NIH HHS [R01 CA81237, R29 CA76069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081237, R29CA076069] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARPER JW, 1993, CELL, V75, P805; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holder N, 1999, DEVELOPMENT, V126, P2033; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; MIYASHITA T, 1995, CELL, V80, P293; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ozaki T, 1999, CANCER RES, V59, P5902; Prives C, 1999, J PATHOL, V187, P112; Rodriguez-Fernandez JL, 1999, BIOESSAYS, V21, P1069, DOI 10.1002/(SICI)1521-1878(199912)22:1<1069::AID-BIES13>3.0.CO;2-C; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Shimada A, 1999, CANCER RES, V59, P2781; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zaika AI, 1999, CANCER RES, V59, P3257; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1998, CANCER RES, V58, P5061; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	64	118	130	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6503	6515		10.1038/sj.onc.1204816	http://dx.doi.org/10.1038/sj.onc.1204816			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641774				2022-12-25	WOS:000171404200002
J	Liang, Y; Yan, CH; Schor, NF				Liang, Y; Yan, CH; Schor, NF			Apoptosis in the absence of caspase 3	ONCOGENE			English	Article						breast cancer; programmed cell death; caspases	CYTOCHROME-C; CELL-DEATH; NEUROBLASTOMA-CELLS; DNA FRAGMENTATION; PROTEASE CASCADE; GRANZYME-B; BCL-2; ACTIVATION; RELEASE; MITOCHONDRIA	MCF-7 human breast cancer cells do not express caspase 3, thought by some to be a critical component of the apoptosis cascade. Nonetheless, both mock- and bcl-2-transfected MCF-7 cells undergo apoptosis after treatment with a variety of stimuli, including the DNA-cleaving antimitotic agent, neocarzinostatin (NCS). Transfection with bcl-2 shifts the concentration-response curve to NCS but does not change the phenomenology of apoptosis when it occurs. In both cases, NCS treatment results in condensation and fragmentation of MCF-7 cell nuclei and release of cytochrome c from the mitochondria to the cytosol. This apoptosis is accompanied by decreased levels of Bcl-2 and increased levels of Bax. Using a series of caspase inhibitors with overlapping specificities, enzyme-specific chromogenic substrates, and an antibody specific for activated caspase 7, we have determined that apoptosis in MCF-7 cells proceeds via sequential activation of caspases 9, 7 and 6. P21 is detected only after activation of caspase 7, and P53 is neither expressed at baseline nor upregulated with apoptosis induction. This pathway bypasses the need for activated caspase 3 in these cells.	Childrens Hosp Pittsburgh, Pediat Ctr Neurosci, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schor, NF (corresponding author), Childrens Hosp Pittsburgh, Range Res Ctr, 3460 5th Ave, Pittsburgh, PA 15213 USA.			Schor, Nina/0000-0002-3817-7376	NCI NIH HHS [R01-CA74289] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cortazzo M, 1996, CANCER RES, V56, P1199; Eck-Enriquez K, 2000, BREAST CANCER RES TR, V61, P229, DOI 10.1023/A:1006442017658; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; Hartsell TL, 1996, J PHARMACOL EXP THER, V277, P1158; HARTSELL TL, 1995, J PHARMACOL EXP THER, V275, P479; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lecoeur H, 1996, J IMMUNOL METHODS, V198, P87, DOI 10.1016/0022-1759(96)00148-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang Ye, 2001, Pediatric Research, V49, p211A; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PARK J, 2001, BIOCHEM BIOPH RES CO, V199, P93; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samali A, 1999, CELL DEATH DIFFER, V6, P495, DOI 10.1038/sj.cdd.4400520; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHOR NF, 1992, J CLIN INVEST, V89, P774, DOI 10.1172/JCI115655; Schor NF, 2000, ONCOGENE, V19, P472, DOI 10.1038/sj.onc.1203324; Shimizu S, 1996, ONCOGENE, V12, P2251; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	190	198	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6570	6578		10.1038/sj.onc.1204815	http://dx.doi.org/10.1038/sj.onc.1204815			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641782				2022-12-25	WOS:000171404200010
J	Yang, XL; Li, DM; Chen, WL; Xu, T				Yang, XL; Li, DM; Chen, WL; Xu, T			Human homologue of Drosophila lats, LATS1, negatively regulate growth by inducing G(2)/M arrest or apoptosis	ONCOGENE			English	Article						Lats1 tumor suppressor; growth inhibition; regulation of G(2)/M	CELL-CYCLE CHECKPOINTS; TUMOR-SUPPRESSOR GENE; POTENTIAL MEDIATOR; CANCER-CELLS; DNA-DAMAGE; P53; EXPRESSION; PROTEIN; 14-3-3-SIGMA; GADD45	The lats gene encodes a family of proteins conserved from insects to humans. Drosophila carrying lats mutant cells or mice deficient for Lats1 develop tumors in various tissues. The mammalian LATS1 protein was previously shown to bind to CDC2, suggesting that LATS1 may modulate G(2)/M cell cycle progression by affecting CDC2 activity. In this study, we introduced human LATS1 into LATS(-/-) MEF cells by adenovirus-mediated gene transfer. Overexpression of LATS1 causes G(2)/M arrest through inhibition of CDC2 kinase activity. Furthermore, overexpression of LATS1 significantly suppressed the human tumor cell growth in vitro and tumorigenicity in vivo by inducing either cell cycle arrest in G(2)/M or apoptosis. These observations suggest that LATS1 is a potent growth suppressor and, like other tumor suppressors, it suppresses growth by inducing cell cycle arrest or apoptosis.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet,Howard Hughes Med Inst, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University	Xu, T (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet,Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06536 USA.	tian.xu@yale.edu						AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; He LS, 1998, CANCER RES, V58, P4238; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; QUELLE DE, 1995, ONCOGENE, V11, P635; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wechsler DS, 1997, CANCER RES, V57, P4905; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yang XL, 1996, INT J CANCER, V65, P338, DOI 10.1002/(SICI)1097-0215(19960126)65:3<338::AID-IJC11>3.0.CO;2-6; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yang XL, 2000, EXP CELL RES, V256, P491, DOI 10.1006/excr.2000.4829; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	24	106	113	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6516	6523		10.1038/sj.onc.1204817	http://dx.doi.org/10.1038/sj.onc.1204817			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641775				2022-12-25	WOS:000171404200003
J	La, M; D'Amico, M; Bandiera, S; Di Filippo, C; Oliani, SM; Gavins, FNE; Flower, RJ; Perretti, M				La, M; D'Amico, M; Bandiera, S; Di Filippo, C; Oliani, SM; Gavins, FNE; Flower, RJ; Perretti, M			Annexin 1 peptides protect against experimental myocardial ischemia-reperfusion: analysis of their mechanism of action	FASEB JOURNAL			English	Article						lipocortin 1; receptor; neutrophil; FPR; fMLP	LIPOCORTIN 1; NITRIC-OXIDE; CLINICAL-IMPLICATIONS; NEUTROPHIL DEPLETION; MONOCLONAL-ANTIBODY; BINDING PROTEINS; HUMAN-LEUKOCYTES; INFARCT SIZE; IN-VIVO; INJURY	Myocardial reperfusion injury is associated with the infiltration of blood-borne polymorphonuclear leukocytes. We have previous described the protection afforded by annexin 1 (ANXA1) in an experimental model of rat myocardial ischemia-reperfusion (IR) injury. We examined the 1) amino acid region of ANXA1 that retained the protective effect in a model of rat heart IR; 2) changes in endogenous ANXA1 in relation to the IR induced damage and after pharmacological modulation; and 3) potential involvement of the formyl peptide receptor (FPR) in the protective action displayed by ANXA1 peptides. Administration of peptide Ac2-26 at 0, 30, and 60 min postreperfusion produced a significant protection against IR injury, and this was associated with reduced myeloperoxidase activity and IL-1 beta levels in the infarcted heart. Western blotting and electron microscopy analyses showed that IR heart had increased ANXA1 expression in the injured tissue, associated mainly with the infiltrated leukocytes. Finally, an antagonist to the FPR receptor selectively inhibited the protective action of peptide ANXA1 and its derived peptides against IR injury. Altogether, these data provide further insight into the protective effect of ANXA1 and its mimetics and a rationale for a clinical use for drugs developed from this line of research.	Univ London St Bartholomews Hosp Med Coll, Coll Med, William Harvey Res Inst, Dept Biochem Pharmacol, London EC1M 6BQ, England; Univ Naples 2, Dept Expt Med, Sect Pharmacol L Donatelli, I-80138 Naples, Italy; UNESP, IBILCE, Dept Biol, Sao Jose Do Rio Preto, SP, Brazil	University of London; Queen Mary University London; Universita della Campania Vanvitelli; Universidade Estadual Paulista	La, M (corresponding author), Univ London St Bartholomews Hosp Med Coll, Coll Med, William Harvey Res Inst, Dept Biochem Pharmacol, Charterhouse Sq, London EC1M 6BQ, England.	m.la@mds.qmw.ac.uk	Gavins, Felicity N. E./AAU-6010-2020; Oliani, Sonia Maria/E-3476-2012	Gavins, Felicity N. E./0000-0001-7008-5423; Oliani, Sonia Maria/0000-0003-0918-2130; d'amico, michele/0000-0002-6899-0595				ABOUMOHAMED G, 1995, J PHARMACOL EXP THER, V275, P584; Ambrosio G, 1999, AM HEART J, V138, pS69, DOI 10.1016/S0002-8703(99)70323-6; BALLER D, 1981, BASIC RES CARDIOL, V76, P163, DOI 10.1007/BF01907955; Becker EL, 1998, CELL TISSUE RES, V292, P129, DOI 10.1007/s004410051042; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIRINO G, 1989, P NATL ACAD SCI USA, V86, P3428, DOI 10.1073/pnas.86.9.3428; Cuzzocrea S, 1997, J IMMUNOL, V159, P5089; D'Amico M, 2000, FASEB J, V14, P1867; Dreier R, 1998, HISTOCHEM CELL BIOL, V110, P137, DOI 10.1007/s004180050275; Euzger HS, 1999, MEDIAT INFLAMM, V8, P53, DOI 10.1080/09629359990720; Getting SJ, 1997, BRIT J PHARMACOL, V120, P1075, DOI 10.1038/sj.bjp.0701029; Goulding NJ, 1996, BIOCHEM J, V316, P593, DOI 10.1042/bj3160593; HANSEN PR, 1995, CIRCULATION, V91, P1872, DOI 10.1161/01.CIR.91.6.1872; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; KLONER RA, 1991, CIRCULATION, V84, P1758, DOI 10.1161/01.CIR.84.4.1758; KUBES P, 1995, J CLIN INVEST, V95, P2510, DOI 10.1172/JCI117952; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; LITT MR, 1989, CIRCULATION, V80, P1816, DOI 10.1161/01.CIR.80.6.1816; Ma XL, 1999, P NATL ACAD SCI USA, V96, P14617, DOI 10.1073/pnas.96.25.14617; McCafferty DM, 2000, EUR J IMMUNOL, V30, P2362, DOI 10.1002/1521-4141(2000)30:8<2362::AID-IMMU2362>3.0.CO;2-F; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Oliani SM, 2001, AM J PATHOL, V158, P603, DOI 10.1016/S0002-9440(10)64002-3; PEPINSKY RB, 1990, FEBS LETT, V261, P247, DOI 10.1016/0014-5793(90)80564-Y; PERRETTI M, 1993, BIOCHEM BIOPH RES CO, V192, P345, DOI 10.1006/bbrc.1993.1421; Perretti M, 2001, AM J PATHOL, V158, P1969, DOI 10.1016/S0002-9440(10)64667-6; PERRETTI M, 1995, BIOCHEM PHARMACOL, V50, P1037, DOI 10.1016/0006-2952(95)00238-U; PERRETTI M, 1993, J IMMUNOL, V151, P4306; Perretti M, 1997, TRENDS PHARMACOL SCI, V18, P418; PERRETTI M, 1995, AGENT ACTION SUPPL, V46, P131; PERRETTI M, 1993, J IMMUNOL, V150, P992; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Perretti M, 2000, CELL BIOL INT, V24, P163, DOI 10.1006/cbir.1999.0468; Poon BY, 2001, J CELL BIOL, V152, P857, DOI 10.1083/jcb.152.5.857; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; Schioth HB, 1997, NEUROPEPTIDES, V31, P565, DOI 10.1016/S0143-4179(97)90002-0; SMITH SF, 1990, ENVIRON HEALTH PERSP, V85, P135, DOI 10.2307/3430676; Solito E, 2000, J IMMUNOL, V165, P1573, DOI 10.4049/jimmunol.165.3.1573; Srikrishna G, 2001, J IMMUNOL, V166, P4678, DOI 10.4049/jimmunol.166.7.4678; Strausbaugh HJ, 2001, J IMMUNOL, V166, P6294, DOI 10.4049/jimmunol.166.10.6294; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; VERGNOLLE N, 1995, EUR J BIOCHEM, V232, P603, DOI 10.1111/j.1432-1033.1995.603zz.x; Vermeiren GLJ, 2000, RESUSCITATION, V45, P35, DOI 10.1016/S0300-9572(00)00168-4; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; Yang YH, 1998, CLIN EXP IMMUNOL, V111, P117; Zhao ZQ, 1997, J LEUKOCYTE BIOL, V62, P292, DOI 10.1002/jlb.62.3.292; Zouki C, 2000, FASEB J, V14, P572, DOI 10.1096/fasebj.14.3.572	50	106	116	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2247	2256		10.1096/fj.01-0196com	http://dx.doi.org/10.1096/fj.01-0196com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641252				2022-12-25	WOS:000171920400037
